	
The	O
psychiatric	B
symptoms	I
in	O
the	O
vast	O
majority	O
of	O
patients	O
in	O
both	O
controlled	O
and	O
open-label	O
trials	O
resolved	O
within	O
7	O
days	O
of	O
discontinuation	O
of	O
POTIGA	O
.	O
	
Chickenpox	B
and	O
measles	B
,	O
for	O
example	O
,	O
can	O
have	O
a	O
more	O
serious	O
or	O
even	O
fatal	B
course	O
in	O
susceptible	O
children	O
or	O
adults	O
using	O
corticosteroids	O
.	O
	
Approximately	O
60	O
%	O
of	O
the	O
treated	O
patients	O
were	O
male	O
,	O
with	O
a	O
mean	O
age	O
of	O
55.1	O
years	O
.	O
	
The	O
table	O
below	O
lists	O
the	O
adverse	O
drug	O
reactions	O
that	O
occurred	O
in	O
at	O
least	O
1	O
%	O
of	O
patients	O
treated	O
with	O
Ferriprox	O
in	O
clinical	O
trials	O
.	O
	
(	O
5.3	O
)	O
*	O
High	B
blood	I
pressure	I
:	O
Do	O
not	O
prescribe	O
Natazia	O
for	O
women	O
with	O
uncontrolled	O
hypertension	O
or	O
hypertension	O
with	O
vascular	O
disease	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Measure	O
the	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
before	O
starting	O
Ferriprox	O
therapy	O
and	O
monitor	O
the	O
ANC	O
weekly	O
on	O
therapy	O
.	O
	
5.9	O
Progressive	O
Multifocal	O
Leukoencephalopathy	O
JC	B
virus	I
infection	I
resulting	O
in	O
PML	B
and	O
death	B
has	O
been	O
reported	O
in	O
ADCETRIS-treated	O
patients	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
pulmonary	O
toxicity	O
,	O
including	O
cough	O
and	O
dyspnea	O
.	O
	
The	O
risk	O
of	O
thromboembolic	B
disease	I
due	O
to	O
oral	O
contraceptives	O
gradually	O
disappears	O
after	O
COC	O
use	O
is	O
discontinued	O
.	O
	
If	O
a	O
patient	O
develops	O
skin	O
discoloration	O
,	O
serious	O
consideration	O
should	O
be	O
given	O
to	O
changing	O
to	O
an	O
alternate	O
medication	O
.	O
	
During	O
periods	O
of	O
stress	O
,	O
a	O
severe	O
COPD	O
exacerbation	O
,	O
or	O
a	O
severe	O
asthma	O
attack	O
,	O
patients	O
who	O
have	O
been	O
withdrawn	O
from	O
systemic	O
corticosteroids	O
should	O
be	O
instructed	O
to	O
resume	O
oral	O
corticosteroids	O
(	O
in	O
large	O
doses	O
)	O
immediately	O
and	O
to	O
contact	O
their	O
physicians	O
for	O
further	O
instruction	O
.	O
	
fFatal	O
bleed	B
:	O
Adjudicated	O
major	O
bleed	B
as	O
defined	O
above	O
with	O
investigator	O
reported	O
fatal	B
outcome	O
and	O
adjudicated	O
death	B
with	O
primary	O
cause	O
from	O
bleeding	B
.	O
	
5.8	O
Hepatotoxicity	O
Serious	O
cases	O
of	O
hepatotoxicity	B
,	O
including	O
fatal	B
outcomes	O
,	O
have	O
occurred	O
in	O
patients	O
receiving	O
ADCETRIS	O
.	O
	
The	O
treatment	O
cycle	O
was	O
repeated	O
at	O
approximately	O
6-week	O
intervals	O
up	O
to	O
three	O
additional	O
times	O
,	O
for	O
a	O
maximum	O
of	O
8	O
total	O
injection	O
procedures	O
and	O
4	O
total	O
modeling	O
procedures	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
b	O
includes	O
neuropathy	B
peripheral	I
,	O
neuropathy	B
,	O
peripheral	B
motor	I
neuropathy	I
,	O
polyneuropathy	B
,	O
peripheral	B
sensoryneuropathy	I
,	O
and	O
paraesthesia	B
.	O
	
Grade	O
3-4	O
cardiac	B
failure	I
occurred	O
in	O
1.6	O
%	O
of	O
patients	O
taking	O
ZYTIGA	O
and	O
led	O
to	O
5	O
treatment	O
discontinuations	O
and	O
2	O
deaths	B
.	O
	
5.3	O
Hypoglycemia	O
with	O
Concomitant	O
Use	O
of	O
Insulin	O
Secretagogues	O
or	O
Insulin	O
The	O
risk	O
of	O
hypoglycemia	B
is	O
increased	O
when	O
TRULICITY	O
is	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylureas	O
)	O
or	O
insulin	O
.	O
	
Monitor	O
liver	O
laboratory	O
tests	O
at	O
least	O
monthly	O
.	O
	
*	O
Tissue	O
inflammation	O
as	O
well	O
as	O
prostatic	O
hyperplasia	O
have	O
been	O
associated	O
with	O
false	O
positive	O
11	O
C-choline	O
PET	O
images	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
for	O
MTC	O
with	O
the	O
use	O
of	O
TRULICITY	O
and	O
inform	O
them	O
of	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g	O
.	O
	
XIAFLEX	O
was	O
not	O
associated	O
with	O
shortening	B
of	I
penile	I
length	I
in	O
clinical	O
trials	O
in	O
the	O
treatment	O
of	O
Peyronie	O
's	O
disease	O
.	O
	
Myocardial	B
ischemia	I
or	O
myocardial	B
infarction	I
led	O
to	O
death	B
in	O
3	O
patients	O
in	O
the	O
placebo	O
arms	O
and	O
2	O
deaths	B
in	O
the	O
ZYTIGA	O
arms	O
.	O
	
Interrupt	O
or	O
discontinue	O
Zydelig	O
as	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
The	O
effect	O
that	O
symptomatic	O
suppression	O
has	O
upon	O
the	O
long-term	O
course	O
of	O
the	O
syndrome	O
is	O
unknown	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
923	O
patients	O
to	O
TANZEUM	O
and	O
a	O
mean	O
duration	O
of	O
exposure	O
to	O
TANZEUM	O
of	O
93	O
weeks	O
.	O
	
In	O
addition	O
,	O
beta-agonists	O
have	O
been	O
reported	O
to	O
produce	O
electrocardiographic	B
changes	I
,	O
such	O
as	O
flattening	B
of	I
the	I
T	I
wave	I
,	O
prolongation	B
of	I
the	I
QTc	I
interval	I
,	O
and	O
ST	B
segment	I
depression	I
,	O
although	O
the	O
clinical	O
significance	O
of	O
these	O
findings	O
is	O
unknown	O
.	O
	
Approximately	O
one	O
third	O
of	O
the	O
patients	O
who	O
had	O
eye	O
examinations	O
performed	O
after	O
approximately	O
4	O
years	O
of	O
treatment	O
were	O
found	O
to	O
have	O
retinal	B
pigmentary	I
abnormalities	I
.	O
	
Samples	O
from	O
6	O
patients	O
with	O
confirmed	O
binding	O
activity	O
to	O
the	O
modified	O
cytotoxic	O
T-lymphocyte-associated	O
antigen	O
4	O
(	O
CTLA-4	O
)	O
region	O
of	O
the	O
belatacept	O
molecule	O
were	O
assessed	O
by	O
an	O
in	O
vitro	O
bioassay	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
.	O
	
Interrupt	O
BLINCYTO	O
if	O
prolonged	O
neutropenia	O
occurs	O
.	O
	
Table	O
2	O
:	O
Severe	O
to	O
Fatal	B
Immune-mediated	B
Adverse	I
Reactions	I
in	O
Study	O
1	O
a	O
Including	O
fatal	B
outcome	O
.	O
	
Increased	B
levels	I
of	I
thyroid	I
stimulating	I
hormone	I
(	O
TSH	O
)	O
were	O
observed	O
in	O
57	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
after	O
the	O
first	O
dose	O
compared	O
to	O
19	O
%	O
of	O
patients	O
receiving	O
placebo	O
(	O
regardless	O
of	O
baseline	O
value	O
)	O
.	O
	
Consider	O
other	O
antidiabetic	O
therapies	O
in	O
patients	O
with	O
history	O
of	O
pancreatitis	O
(	O
5.2	O
)	O
.	O
	
(	O
5.1	O
)	O
item	O
{	O
Cataracts-	O
Use	O
of	O
corticosteroids	O
may	O
result	O
in	O
posterior	B
subcapsular	I
cataract	I
formation	O
.	O
	
5.4	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
(	O
TLS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
has	O
been	O
observed	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
*	O
Hepatic	B
toxicity	I
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.5	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
The	O
decrease	B
in	I
serum	I
potassium	I
is	O
usually	O
transient	O
,	O
not	O
requiring	O
supplementation	O
.	O
	
The	O
adverse	O
reactions	O
reported	O
in	O
more	O
than	O
one	O
subject	O
within	O
the	O
studies	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
Because	O
FANAPT	O
was	O
not	O
marketed	O
at	O
the	O
time	O
these	O
studies	O
were	O
performed	O
,	O
it	O
is	O
not	O
known	O
if	O
FANAPT	O
is	O
associated	O
with	O
this	O
increased	O
risk	O
.	O
	
(	O
N	O
for	O
females	O
:	O
Placebo=677	O
,	O
FARXIGA	O
5	O
mg=581	O
,	O
FARXIGA	O
10	O
mg=598	O
)	O
.	O
	
Patients	O
received	O
GILOTRIF	O
40	O
mg	O
daily	O
until	O
documented	O
disease	O
progression	O
or	O
intolerance	O
to	O
the	O
therapy	O
.	O
	
TRULICITY	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
severe	O
gastrointestinal	O
disease	O
,	O
including	O
severe	O
gastroparesis	O
,	O
and	O
is	O
therefore	O
not	O
recommended	O
in	O
these	O
patients	O
.	O
	
Hemorrhage	B
:	O
Severe	O
,	O
sometimes	O
fatal	B
,	O
hemorrhage	B
including	O
hemoptysis	B
and	O
gastrointestinal	B
hemorrhage	I
occurred	O
in	O
3	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
5.8	O
Contact	O
Lens	O
Wear	O
DUREZOL	O
should	O
not	O
be	O
instilled	O
while	O
wearing	O
contact	O
lenses	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Tendon	B
rupture	I
or	O
serious	O
injury	B
to	I
the	I
injected	I
finger	I
:	O
Avoid	O
injecting	O
XIAFLEX	O
into	O
tendons	O
,	O
nerves	O
,	O
blood	O
vessels	O
,	O
or	O
other	O
collagen-containing	O
structure	O
of	O
the	O
hand	O
.	O
	
The	O
most	O
frequent	O
reactions	O
were	O
hypotension	B
and	O
hypertension	B
.	O
	
5.2	O
Corporal	O
Rupture	O
(	O
Penile	O
Fracture	O
)	O
or	O
Other	O
Serious	O
Injury	O
to	O
the	O
Penis	O
in	O
the	O
Treatment	O
of	O
Peyronie	O
's	O
Disease	O
Corporal	B
rupture	I
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
after	O
XIAFLEX	O
injections	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX	O
treated	O
patients	O
in	O
the	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials	O
in	O
Peyronie	O
's	O
disease	O
.	O
	
Sinus	B
tachycardia	I
was	O
reported	O
in	O
3.0	O
%	O
,	O
2.8	O
%	O
,	O
and	O
5.6	O
%	O
of	O
patient	O
treated	O
with	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
.	O
	
(	O
5.1	O
)	O
*	O
Hemorrhage	B
:	O
Severe	O
,	O
sometimes	O
fatal	B
,	O
hemorrhage	B
including	O
hemoptysis	B
and	O
gastrointestinal	B
hemorrhage	I
occurred	O
in	O
3	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
of	O
Volume	B
DepletionVolume	O
depletion	B
includes	O
reports	O
of	O
dehydration	B
,	O
hypovolemia	B
,	O
orthostatic	B
hypotension	I
,	O
or	O
hypotension	B
.	O
	
Eye	O
disorders	O
:	O
Optic	B
neuritis	I
,	O
retinal	B
hemorrhage	I
,	O
and	O
uveitis	B
.	O
	
In	O
these	O
patients	O
,	O
a	O
comprehensive	O
evaluation	O
of	O
urologic	O
symptoms	O
prior	O
to	O
and	O
during	O
treatment	O
with	O
POTIGA	O
may	O
be	O
appropriate	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
elevations	B
in	I
triglycerides	I
>	O
=200	O
mg/dL	O
(	O
at	O
Endpoint	O
)	O
was	O
13.2	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
10.5	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
The	O
placebo-adjusted	O
change	O
at	O
the	O
distal	O
forearm	O
for	O
patients	O
randomized	O
to	O
INVOKANA	O
100	O
mg	O
was	O
0	O
%	O
.	O
	
Restart	O
treatment	O
based	O
on	O
ANC	O
and	O
platelet	O
count	O
recovery	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Suicidal	B
Behavior	I
:	O
Monitor	O
for	O
suicidal	O
thoughts	O
or	O
behavior	O
.	O
	
(	O
5.4	O
)	O
*	O
Skin	B
Reactions	I
:	O
Discontinue	O
for	O
severe	O
skin	O
reactions	O
.	O
	
To	O
adjust	O
for	O
normal	O
growth	O
,	O
z-scores	O
were	O
derived	O
(	O
measured	O
in	O
standard	O
deviations	O
[	O
SD	O
]	O
)	O
,	O
which	O
normalize	O
for	O
the	O
natural	O
growth	O
of	O
pediatric	O
patients	O
by	O
comparisons	O
to	O
age-	O
and	O
sex-matched	O
population	O
standards	O
.	O
	
5.4	O
Hypoglycemia	O
with	O
Concomitant	O
Use	O
with	O
Insulin	O
and	O
Insulin	O
Secretagogues	O
Insulin	O
and	O
insulin	O
secretagogues	O
are	O
known	O
to	O
cause	O
hypoglycemia	O
.	O
	
Allopurinol	O
has	O
also	O
been	O
used	O
during	O
the	O
beginning	O
of	O
TREANDA	O
therapy	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
Vimizim	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Patients	O
with	O
MCL	O
who	O
develop	O
lymphocytosis	O
greater	O
than	O
400,000/mcL	O
have	O
developed	O
intracranial	O
hemorrhage	O
,	O
lethargy	O
,	O
gait	O
instability	O
,	O
and	O
headache	O
.	O
	
Most	O
patients	O
(	O
87	O
%	O
)	O
were	O
less	O
than	O
65	O
years	O
of	O
age	O
;	O
58.4	O
%	O
were	O
women	O
.	O
	
The	O
incidence	O
of	O
GI	B
events	I
was	O
higher	O
early	O
in	O
the	O
course	O
of	O
treatment	O
(	O
primarily	O
in	O
month	O
1	O
)	O
and	O
usually	O
decreased	O
over	O
time	O
in	O
patients	O
treated	O
with	O
TECFIDERA	O
compared	O
with	O
placebo	O
.	O
	
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
58	O
patients	O
(	O
34	O
%	O
)	O
treated	O
with	O
XALKORI	O
.	O
	
Monitor	O
patients	O
with	O
skin	O
reactions	O
closely	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
treated	O
with	O
DALVANCE	O
was	O
47	O
years	O
,	O
ranging	O
between	O
16	O
and	O
93	O
years	O
old	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
.	O
	
Genital	O
Mycotic	O
Infections	O
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
clinical	O
trials	O
,	O
female	B
genital	I
mycotic	I
infections	I
(	O
e.g.	O
,	O
vulvovaginal	B
mycotic	I
infection	I
,	O
vulvovaginal	B
candidiasis	I
,	O
and	O
vulvovaginitis	B
)	O
occurred	O
in	O
3.2	O
%	O
,	O
10.4	O
%	O
,	O
and	O
11.4	O
%	O
of	O
females	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
The	O
increased	O
risk	O
of	O
asthma-related	O
death	B
is	O
considered	O
a	O
class	O
effect	O
of	O
the	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonists	O
,	O
including	O
ARCAPTA	O
NEOHALER	O
.	O
	
*	O
140	O
patients	O
with	O
advanced	O
phase	O
CML	O
including	O
76	O
patients	O
with	O
AP	O
CML	O
and	O
64	O
patients	O
with	O
BP	O
CML	O
.	O
	
Transient	O
increases	B
in	I
pain	I
were	O
commonly	O
observed	O
on	O
the	O
day	O
of	O
treatment	O
in	O
patients	O
treated	O
with	O
Qutenza	O
.	O
	
Dose	O
should	O
be	O
reduced	O
for	O
patients	O
with	O
mild	O
(	O
total	O
bilirubin	O
>	O
1	O
to	O
<	O
=	O
1.5	O
*	O
ULN	O
or	O
AST	O
>	O
1.5	O
*	O
ULN	O
)	O
and	O
moderate	O
(	O
total	O
bilirubin	O
>	O
1.5	O
to	O
<	O
=	O
3.0	O
*	O
ULN	O
and	O
any	O
AST	O
)	O
hepatic	O
impairment	O
,	O
based	O
on	O
tolerability	O
data	O
in	O
these	O
patients	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
Fractures	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
However	O
,	O
some	O
patients	O
may	O
require	O
treatment	O
with	O
SAPHRIS	O
despite	O
the	O
presence	O
of	O
the	O
syndrome	O
.	O
	
The	O
incidence	O
of	O
opportunistic	B
infections	I
was	O
similar	O
to	O
that	O
reported	O
with	O
placebo	O
.	O
	
(	O
2.4	O
,	O
5.2	O
)	O
*	O
Hepatic	B
Toxicity	I
:	O
Monitor	O
liver	O
enzymes	O
at	O
least	O
monthly	O
for	O
the	O
first	O
three	O
months	O
and	O
as	O
needed	O
.	O
	
Adult	O
Patients	O
:	O
Pooled	O
data	O
from	O
the	O
short-term	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
Therefore	O
,	O
the	O
combination	O
of	O
TNF-blockers	O
including	O
SIMPONI	O
ARIA	O
and	O
abatacept	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Cervical	O
Dystonia	O
About	O
3	O
%	O
of	O
subjects	O
developed	O
antibodies	O
(	O
binding	O
or	O
neutralizing	O
)	O
over	O
time	O
with	O
DYSPORT	O
(	O
r	O
)	O
treatment	O
.	O
	
Monotherapy	O
in	O
Adult	O
Patients	O
with	O
Bipolar	O
Mania	O
:	O
The	O
following	O
findings	O
are	O
based	O
on	O
the	O
short-term	O
placebo-controlled	O
trials	O
for	O
bipolar	O
mania	O
(	O
a	O
pool	O
of	O
two	O
3-week	O
flexible-dose	O
trials	O
)	O
in	O
which	O
sublingual	O
SAPHRIS	O
was	O
administered	O
in	O
doses	O
of	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
.	O
	
(	O
6.2	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Janssen	O
Products	O
,	O
LP	O
at	O
1-800-JANSSEN	O
(	O
1-800-526-7736	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormality	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
was	O
neutropenia	B
.	O
	
*	O
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
DOTAREM	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
from	O
the	O
body	O
prior	O
to	O
any	O
re-administration	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Extrapyramidal	B
symptoms	I
included	O
dystonia	B
,	O
oculogyration	B
,	O
dyskinesia	B
,	O
tardive	B
dyskinesia	I
,	O
muscle	B
rigidity	I
,	O
parkinsonism	B
,	O
tremor	B
,	O
and	O
extrapyramidal	B
disorder	I
(	O
excluding	O
akathisia	B
)	O
.	O
	
Among	O
those	O
17	O
subjects	O
,	O
10	O
subjects	O
developed	O
neutralizing	O
antibodies	O
.	O
	
Adjust	O
total	O
fluid	O
intake	O
as	O
clinically	O
appropriate	O
in	O
patients	O
with	O
baseline	O
cardiac	O
failure	O
or	O
who	O
are	O
at	O
risk	O
for	O
cardiac	O
failure	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
The	O
ovaries	O
normally	O
stop	O
making	O
estrogens	O
when	O
a	O
woman	O
is	O
between	O
45	O
and	O
55	O
years	O
old	O
.	O
	
The	O
safety	O
of	O
conjugated	O
estrogens/bazedoxifene	O
was	O
evaluated	O
in	O
four	O
Phase	O
3	O
clinical	O
trials	O
ranging	O
from	O
12	O
weeks	O
to	O
24	O
months	O
in	O
duration	O
and	O
enrolling	O
6,210	O
postmenopausal	O
women	O
age	O
40	O
to	O
75	O
years	O
(	O
mean	O
age	O
55	O
years	O
)	O
.	O
	
5.2	O
Malignancies	O
Malignancies	O
in	O
Pediatric	O
Patients	O
Malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
among	O
children	O
,	O
adolescents	O
,	O
and	O
young	O
adults	O
who	O
received	O
treatment	O
with	O
TNF-blocking	O
agents	O
(	O
initiation	O
of	O
therapy	O
<	O
=	O
18	O
years	O
of	O
age	O
)	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
.	O
	
Of	O
the	O
patients	O
in	O
those	O
trials	O
,	O
95	O
%	O
were	O
between	O
18	O
and	O
65	O
years	O
old	O
;	O
48	O
%	O
were	O
male	O
,	O
and	O
84	O
%	O
were	O
Caucasian	O
.	O
	
If	O
patients	O
taking	O
FANAPT	O
experience	O
symptoms	O
that	O
could	O
indicate	O
the	O
occurrence	O
of	O
cardiac	O
arrhythmias	O
,	O
e.g.	O
,	O
dizziness	O
,	O
palpitations	O
,	O
or	O
syncope	O
,	O
the	O
prescriber	O
should	O
initiate	O
further	O
evaluation	O
,	O
including	O
cardiac	O
monitoring	O
.	O
	
Serious	O
,	O
life-threatening	O
events	O
of	O
herpes	B
simplex	I
infections	I
,	O
including	O
cases	O
of	O
encephalitis	B
and	O
multiorgan	B
failure	I
,	O
have	O
occurred	O
with	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
Overall	O
,	O
6	O
pediatric	O
patients	O
(	O
4.3	O
%	O
)	O
reported	O
at	O
least	O
one	O
adverse	O
reaction	O
following	O
DOTAREM	O
administration	O
.	O
	
In	O
general	O
,	O
limiting	O
the	O
dose	O
injected	O
into	O
the	O
sternocleidomastoid	O
muscle	O
may	O
decrease	O
the	O
occurrence	O
of	O
dysphagia	O
.	O
	
Females	O
of	O
reproductive	O
potential	O
should	O
avoid	O
becoming	O
pregnant	O
while	O
being	O
treated	O
.	O
	
Use	O
of	O
SIMPONI	O
ARIA	O
in	O
patients	O
under	O
18	O
years	O
of	O
age	O
has	O
not	O
been	O
established	O
.	O
	
There	O
have	O
been	O
post-marketing	O
reports	O
of	O
serious	O
breathing	B
difficulties	I
,	O
including	O
respiratory	B
failure	I
.	O
	
6.2	O
Clinical	O
Trials	O
Experience	O
in	O
Asthma	O
BREO	O
ELLIPTA	O
for	O
the	O
treatment	O
of	O
asthma	O
was	O
studied	O
in	O
18	O
double-blind	O
,	O
parallel-group	O
,	O
controlled	O
trials	O
(	O
11	O
with	O
placebo	O
)	O
of	O
4	O
to	O
76	O
weeks	O
'	O
duration	O
,	O
which	O
enrolled	O
9,969	O
subjects	O
with	O
asthma	O
.	O
	
Before	O
using	O
OTEZLA	O
in	O
patients	O
with	O
a	O
history	O
of	O
depression	O
and/or	O
suicidal	O
thoughts	O
or	O
behavior	O
prescribers	O
should	O
carefully	O
weigh	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
OTEZLA	O
in	O
such	O
patients	O
.	O
	
Other	O
adverse	O
reactions	O
reported	O
included	O
rash	B
,	O
nausea	B
,	O
and	O
headache	B
in	O
patients	O
exposed	O
to	O
FIRAZYR	O
.	O
	
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
and	O
at	O
least	O
2	O
times	O
the	O
rate	O
of	O
placebo	O
)	O
in	O
these	O
trials	O
for	O
the	O
600	O
mg	O
dose	O
of	O
HORIZANT	O
were	O
somnolence/sedation	O
and	O
dizziness	B
(	O
see	O
Table	O
4	O
)	O
.	O
	
Females	O
of	O
reproductive	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
becoming	O
pregnant	O
while	O
being	O
treated	O
with	O
Kyprolis	O
.	O
	
5.3	O
Interstitial	O
Lung	O
Disease	O
(	O
ILD	O
)	O
ILD	B
or	O
ILD-like	B
adverse	I
reactions	I
(	O
e.g.	O
,	O
lung	B
infiltration	I
,	O
pneumonitis	B
,	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
or	O
alveolitis	B
allergic	I
)	O
occurred	O
in	O
1.5	O
%	O
of	O
the	O
3865	O
patients	O
who	O
received	O
GILOTRIF	O
across	O
clinical	O
trials	O
;	O
of	O
these	O
,	O
0.4	O
%	O
were	O
fatal	B
.	O
	
The	O
clinical	O
relevance	O
of	O
the	O
presence	O
of	O
anti-belimumab	O
antibodies	O
is	O
not	O
known	O
.	O
	
Renal	B
impairment	I
(	O
including	O
the	O
terms	O
renal	B
impairment	I
,	O
renal	B
failure	I
,	O
and	O
renal	B
failure	I
acute	I
)	O
led	O
to	O
discontinuation	O
of	O
treatment	O
in	O
5/1015	O
(	O
0.5	O
%	O
)	O
subjects	O
receiving	O
ZERBAXA	O
and	O
none	O
in	O
the	O
comparator	O
arms	O
.	O
	
Table	O
2	O
:	O
Monitored	O
Adverse	O
Reactions	O
-	O
Application	O
Site	O
Symptoms	O
Event	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
Vehicle	O
Application	B
site	I
Irritation	I
2	O
%	O
(	O
11/478	O
)	O
1	O
%	O
(	O
2/336	O
)	O
Application	B
site	I
anesthesia	I
2	O
%	O
(	O
10/478	O
)	O
0	O
%	O
(	O
0/336	O
)	O
Pain	B
1	O
%	O
(	O
5/478	O
)	O
0	O
%	O
(	O
1/336	O
)	O
The	O
subset	O
of	O
subjects	O
who	O
did	O
not	O
have	O
pruritus	O
,	O
erythema	O
,	O
edema	O
or	O
pyoderma	O
of	O
skin	O
and	O
scalp	O
,	O
or	O
ocular	O
irritation	O
prior	O
to	O
treatment	O
were	O
assessed	O
for	O
these	O
signs	O
and	O
symptoms	O
after	O
treatment	O
;	O
the	O
results	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
Immediate	O
gentle	O
pressure	O
at	O
the	O
injection	O
site	O
can	O
limit	O
that	O
risk	O
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
associated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
is	O
shown	O
in	O
Table	O
2	O
.	O
	
5.5	O
Pre-existing	O
Neuromuscular	O
Disorders	O
Individuals	O
with	O
peripheral	O
motor	O
neuropathic	O
diseases	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
or	O
neuromuscular	O
junction	O
disorders	O
(	O
e.g.	O
,	O
myasthenia	O
gravis	O
or	O
Lambert-Eaton	O
syndrome	O
)	O
should	O
be	O
monitored	O
particularly	O
closely	O
when	O
given	O
botulinum	O
toxin	O
.	O
	
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
.	O
	
In	O
some	O
cases	O
the	O
elevations	B
in	I
transaminases	I
were	O
consistent	O
with	O
immune	B
reconstitution	I
syndrome	I
or	O
hepatitis	B
B	I
reactivation	I
particularly	O
in	O
the	O
setting	O
where	O
anti-hepatitis	O
therapy	O
was	O
withdrawn	O
.	O
	
Fifty	O
percent	O
(	O
50	O
%	O
)	O
of	O
the	O
population	O
was	O
male	O
and	O
72	O
%	O
were	O
Caucasian	O
,	O
12	O
%	O
were	O
Asian	O
,	O
and	O
5	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
Table	O
2	O
Adverse	O
Drug	O
ReactionsFrequencies	O
of	O
adverse	O
reactions	O
are	O
based	O
on	O
all	O
treatment-emergent	O
adverse	O
events	O
,	O
attributed	O
to	O
study	O
drugs	O
.	O
	
Laboratory	O
abnormalities	O
are	O
described	O
separately	O
in	O
Table	O
9	O
.	O
	
These	O
metabolic	B
changes	I
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
weight	B
gain	I
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
POST-TRANSPLANT	B
LYMPHOPROLIFERATIVE	I
DISORDER	I
,	O
OTHER	O
MALIGNANCIES	B
,	O
AND	O
SERIOUS	O
INFECTIONS	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Pulmonary	B
embolism	I
was	O
fatal	B
in	O
2	O
%	O
(	O
1/55	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
No	O
apparent	O
correlation	O
of	O
antibody	O
development	O
to	O
clinical	O
response	O
or	O
adverse	O
events	O
was	O
observed	O
.	O
	
(	O
5.1	O
)	O
*	O
Administer	O
a	O
thyroid-blocking	O
agent	O
before	O
DaTscan	O
administration	O
.	O
	
Tuberculosis	O
Cases	O
of	O
reactivation	B
of	I
tuberculosis	I
or	O
new	B
tuberculosis	I
infections	I
have	O
been	O
observed	O
in	O
patients	O
receiving	O
TNF-blockers	O
,	O
including	O
patients	O
who	O
have	O
previously	O
received	O
treatment	O
for	O
latent	O
or	O
active	O
tuberculosis	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=10	O
%	O
and	O
>	O
=2	O
%	O
more	O
than	O
placebo	O
)	O
for	O
TECFIDERA	O
were	O
flushing	B
,	O
abdominal	B
pain	I
,	O
diarrhea	B
,	O
and	O
nausea	B
.	O
	
5.5	O
Beta-Blocker	O
Withdrawal	O
Cleviprex	O
is	O
not	O
a	O
beta-blocker	O
,	O
does	O
not	O
reduce	O
heart	O
rate	O
,	O
and	O
gives	O
no	O
protection	O
against	O
the	O
effects	O
of	O
abrupt	O
beta-blocker	O
withdrawal	O
.	O
	
In	O
some	O
instances	O
,	O
HBV	B
reactivation	I
occurring	O
in	O
conjunction	O
with	O
TNF-blocker	O
therapy	O
has	O
been	O
fatal	B
.	O
	
The	O
type	O
and	O
frequency	O
of	O
adverse	O
drug	O
reactions	O
appeared	O
to	O
be	O
consistent	O
over	O
time	O
.	O
	
Polyoma	B
virus-associated	I
nephropathy	I
can	O
lead	O
to	O
kidney	B
graft	I
loss	I
;	O
consider	O
reduction	O
in	O
immunosuppression	O
.	O
	
Bleeding	B
results	O
from	O
the	O
AMPLIFY-EXT	O
study	O
are	O
summarized	O
in	O
Table	O
7	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
cardiomyopathy	B
in	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
was	O
86	O
days	O
(	O
range	O
:	O
27	O
to	O
253	O
days	O
)	O
.	O
	
Symptoms	O
associated	O
with	O
these	O
reactions	O
have	O
included	O
chest	B
discomfort	I
,	O
flushing	B
,	O
pharyngeal	B
edema	I
,	O
pruritus	B
,	O
rhinorrhea	B
,	O
sneezing	B
,	O
nasal	B
congestion	I
,	O
throat	B
irritation	I
,	O
urticaria	B
,	O
wheezing	B
,	O
and	O
hypotension	B
.	O
	
No	O
serious	O
adverse	O
reactions	O
related	O
to	O
Neuraceq	O
administration	O
have	O
been	O
reported	O
.	O
	
Caution	O
is	O
recommended	O
in	O
patients	O
with	O
hemoglobin	O
<	O
10	O
g/dl	O
.	O
	
Apprise	O
women	O
of	O
potential	O
harm	O
to	O
the	O
fetus	O
.	O
	
Primary	O
prophylaxis	O
with	O
G-CSF	O
should	O
be	O
considered	O
in	O
patients	O
with	O
high-risk	O
clinical	O
features	O
.	O
	
Some	O
of	O
these	O
abnormalities	O
were	O
considered	O
potentially	O
clinically	O
significant	O
.	O
	
The	O
etiology	O
of	O
hepatocellular	B
injury	I
was	O
possibly	O
related	O
to	O
TANZEUM	O
but	O
direct	O
attribution	O
to	O
TANZEUM	O
was	O
confounded	O
by	O
the	O
presence	O
of	O
gallstone	O
disease	O
diagnosed	O
on	O
ultrasound	O
3	O
weeks	O
after	O
the	O
event	O
.	O
	
Doses	O
ranged	O
from	O
18	O
to	O
98	O
Units/kg	O
,	O
with	O
a	O
median	O
dose	O
of	O
49	O
Units/kg	O
.	O
	
Therefore	O
,	O
a	O
lower	O
dose	O
of	O
the	O
insulin	O
secretagogue	O
or	O
insulin	O
may	O
be	O
required	O
to	O
reduce	O
the	O
risk	O
of	O
hypoglycemia	O
when	O
used	O
in	O
combination	O
with	O
JARDIANCE	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
}	O
}	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Amgen	O
Inc.	O
at	O
1-800-77-AMGEN	O
(	O
1-800-772-6436	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
A	O
total	O
of	O
9	O
serious	O
adverse	O
reactions	O
were	O
reported	O
for	O
CAPS	O
patients	O
.	O
	
For	O
ULORIC	O
40	O
mg	O
,	O
559	O
patients	O
were	O
treated	O
for	O
>	O
=6	O
months	O
.	O
	
The	O
most	O
common	O
related	O
adverse	O
reactions	O
that	O
were	O
not	O
hematologic	O
,	O
hepatic	O
or	O
renal	O
events	O
were	O
paresthesia	B
,	O
flushing	B
,	O
and	O
nausea	B
and/or	O
vomiting	B
,	O
which	O
each	O
occurred	O
in	O
2	O
%	O
of	O
patients	O
(	O
Table	O
1	O
)	O
.	O
	
At	O
the	O
end	O
of	O
treatment	O
,	O
0.6	O
%	O
,	O
2.7	O
%	O
,	O
and	O
3.5	O
%	O
of	O
patients	O
with	O
hematocrits	O
initially	O
within	O
the	O
reference	O
range	O
had	O
values	O
above	O
the	O
upper	O
limit	O
of	O
the	O
reference	O
range	O
with	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
.	O
	
Administration	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
is	O
not	O
recommended	O
until	O
skin	O
is	O
healed	O
from	O
any	O
previous	O
drug	O
or	O
surgical	O
treatment	O
.	O
	
ADCETRIS-induced	O
peripheral	B
neuropathy	I
is	O
cumulative	O
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
with	O
neutrophil	O
counts	O
of	O
<	O
=1,500	O
cells/mm	O
3	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Analyses	O
of	O
patients	O
in	O
PRISTIQ	O
pre-marketing	O
short-term	O
controlled	O
studies	O
who	O
met	O
criteria	O
for	O
sustained	O
hypertension	B
revealed	O
a	O
consistent	O
increase	O
in	O
the	O
proportion	O
of	O
patients	O
who	O
developed	O
sustained	O
hypertension	B
.	O
	
(	O
5.1	O
)	O
*	O
Infections	B
:	O
Increased	O
risk	O
of	O
infections	B
,	O
some	O
fatal	B
.	O
	
T-cell-depleting	O
therapies	O
to	O
treat	O
acute	O
rejection	O
should	O
be	O
used	O
cautiously	O
.	O
	
Serum	O
parathyroid	O
hormone	O
levels	O
and	O
1.25	O
Vitamin	O
D	O
levels	O
were	O
also	O
higher	O
in	O
subjects	O
receiving	O
tenofovir	O
DF	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
received	O
a	O
transfusion	O
for	O
the	O
management	O
of	O
anemia	O
was	O
3	O
%	O
of	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
less	O
than	O
1	O
%	O
in	O
subjects	O
who	O
received	O
PegIntron/REBETOL	O
alone	O
.	O
	
There	O
is	O
insufficient	O
information	O
to	O
characterize	O
the	O
risks	O
of	O
resumption	O
of	O
XALKORI	O
in	O
patients	O
with	O
a	O
severe	O
visual	O
loss	O
;	O
a	O
decision	O
to	O
resume	O
XALKORI	O
should	O
consider	O
the	O
potential	O
benefits	O
to	O
the	O
patient	O
.	O
	
If	O
pulmonary	O
toxicity	O
is	O
confirmed	O
,	O
MULTAQ	O
should	O
be	O
discontinued	O
.	O
	
Monitor	O
patients	O
closely	O
during	O
and	O
after	O
administration	O
of	O
Gadavist	O
(	O
5.2	O
)	O
5.1	O
Nephrogenic	O
Systemic	O
Fibrosis	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
nephrogenic	B
systemic	I
fibrosis	I
(	O
NSF	B
)	O
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
There	O
were	O
no	O
reported	O
thromboembolic	B
events	I
in	O
the	O
patients	O
treated	O
with	O
EYLEA	O
in	O
the	O
first	O
six	O
months	O
of	O
the	O
RVO	O
studies	O
.	O
	
Follow	O
the	O
dose	O
adjustment	O
guidelines	O
to	O
achieve	O
and	O
maintain	O
target	O
platelet	O
counts	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
,	O
2.2	O
,	O
2.3	O
)	O
]	O
.	O
	
If	O
anaphylaxis	O
occurs	O
,	O
immediately	O
discontinue	O
the	O
infusion	O
(	O
5.2	O
)	O
.	O
	
d	O
Includes	O
squamous	B
cell	I
carcinoma	I
of	I
the	I
skin	I
and	O
keratoacanthoma	B
.	O
	
Neither	O
clinical	O
studies	O
nor	O
epidemiologic	O
studies	O
conducted	O
to	O
date	O
have	O
shown	O
an	O
association	O
between	O
chronic	O
administration	O
of	O
this	O
class	O
of	O
drugs	O
and	O
tumorigenesis	B
in	O
humans	O
,	O
but	O
the	O
available	O
evidence	O
is	O
too	O
limited	O
to	O
be	O
conclusive	O
.	O
	
*	O
Perform	O
test	O
for	O
latent	O
TB	O
;	O
if	O
positive	O
,	O
start	O
treatment	O
for	O
TB	O
prior	O
to	O
starting	O
SIMPONI	O
ARIA	O
(	O
5.1	O
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
*	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=	O
5	O
%	O
)	O
in	O
clinical	O
trials	O
were	O
hypersensitivity	B
reactions	I
and	O
included	O
:	O
anaphylaxis	B
,	O
rash	B
,	O
pyrexia	B
,	O
flushing/feeling	O
hot	B
,	O
urticaria	B
,	O
headache	B
,	O
hyperhidrosis	B
,	O
nausea	B
,	O
cough	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
tachycardia	B
,	O
tachypnea	B
,	O
chest	B
discomfort	I
,	O
dizziness	B
,	O
muscle	B
twitching	I
,	O
agitation	B
,	O
cyanosis	B
,	O
erythema	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
pallor	B
,	O
rigors	B
,	O
tremor	B
,	O
vomiting	B
,	O
fatigue	B
,	O
and	O
myalgia	B
(	O
6.1	O
)	O
.	O
	
5.2	O
Concomitant	O
Use	O
of	O
CYP3A4	O
Inhibitors	O
STENDRA	O
metabolism	O
is	O
principally	O
mediated	O
by	O
the	O
CYP450	O
isoform	O
3A4	O
(	O
CYP3A4	O
)	O
.	O
	
*	O
viral	B
,	I
and	I
other	I
infections	I
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Endophthalmitis	B
and	O
retinal	B
detachments	I
may	O
occur	O
following	O
intravitreal	O
injections	O
.	O
	
In	O
Trial	O
2	O
,	O
13	O
%	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
experienced	O
adverse	O
reactions	O
resulting	O
in	O
permanent	O
discontinuation	O
of	O
trial	O
medication	O
(	O
s	O
)	O
.	O
	
No	O
patients	O
treated	O
with	O
SAPHRIS	O
experienced	O
QTc	B
increases	I
>	O
=60	O
msec	O
from	O
baseline	O
measurements	O
,	O
nor	O
did	O
any	O
patient	O
experience	O
a	O
QTc	B
of	I
>	I
=500	I
msec	I
.	O
	
This	O
product	O
's	O
label	O
may	O
have	O
been	O
updated	O
.	O
	
In	O
most	O
cases	O
,	O
these	O
effects	O
appear	O
to	O
be	O
reversible	O
upon	O
drug	O
discontinuation	O
and	O
with	O
appropriate	O
medical	O
treatment	O
.	O
	
Autoimmune	B
disorders	I
(	O
such	O
as	O
Graves	B
'	I
disease	I
,	O
polymyositis	B
,	O
and	O
Guillain-Barre	B
syndrome	I
)	O
have	O
also	O
been	O
reported	O
to	O
occur	O
in	O
the	O
setting	O
of	O
immune	O
reconstitution	O
,	O
however	O
,	O
the	O
time	O
to	O
onset	O
is	O
more	O
variable	O
,	O
and	O
can	O
occur	O
many	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O
	
In	O
this	O
trial	O
,	O
use	O
of	O
ESAs	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
thromboembolic	O
events	O
including	O
pulmonary	O
embolism	O
,	O
acute	O
myocardial	O
infarction	O
,	O
cerebrovascular	O
accident	O
,	O
and	O
deep	O
vein	O
thrombosis	O
compared	O
to	O
ribavirin	O
dose	O
reduction	O
alone	O
.	O
	
Gastrointestinal	B
(	I
GI	I
)	I
hemorrhage	I
,	O
ileus	B
,	O
enterocolitis	B
,	O
neutropenic	B
enterocolitis	I
,	O
including	O
fatal	B
outcome	O
,	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
JEVTANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
*	O
Increased	O
risk	O
of	O
serious	O
infections	B
leading	O
to	O
hospitalization	O
or	O
death	B
including	O
tuberculosis	B
(	O
TB	B
)	O
,	O
bacterial	B
sepsis	I
,	O
invasive	B
fungal	I
infections	I
(	O
such	O
as	O
histoplasmosis	B
)	O
,	O
and	O
infections	B
due	I
to	I
other	I
opportunistic	I
pathogens	I
(	O
5.1	O
)	O
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
alopecia	B
,	O
angio-edema	B
,	O
dermatitis	B
,	O
dermographism	B
,	O
ecchymosis	B
,	O
eczema	B
,	O
hair	B
color	I
changes	I
,	O
hair	B
growth	I
abnormal	I
,	O
hyperhidrosis	B
,	O
peeling	B
skin	I
,	O
petechiae	B
,	O
photosensitivity	B
,	O
pruritus	B
,	O
purpura	B
,	O
skin	B
discoloration	I
,	O
skin	B
lesion	I
,	O
skin	B
odor	I
abnormal	I
,	O
urticaria	B
.	O
	
Many	O
of	O
the	O
drugs	O
metabolized	O
by	O
CYP2D6	O
can	O
prolong	O
the	O
QT	O
interval	O
and	O
should	O
not	O
be	O
administered	O
with	O
Coartem	O
Tablets	O
due	O
to	O
the	O
potential	O
additive	O
effect	O
on	O
the	O
QT	O
interval	O
(	O
e.g.	O
,	O
flecainide	O
,	O
imipramine	O
,	O
amitriptyline	O
,	O
clomipramine	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.6	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
5.5	O
Immediate	O
Hypersensitivity	O
Reactions	O
Immediate	B
hypersensitivity	I
reactions	I
,	O
including	O
anaphylaxis	B
,	O
angioedema	B
(	O
including	O
swelling	B
of	I
the	I
lips	I
)	O
,	O
urticaria	B
,	O
rash	B
,	O
bronchospasm	B
,	O
or	O
itching	B
,	O
have	O
occurred	O
after	O
administration	O
of	O
TUDORZA	O
PRESSAIR	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
experienced	O
by	O
patients	O
with	O
sALCL	O
were	O
septic	B
shock	I
(	O
3	O
%	O
)	O
,	O
supraventricular	B
arrhythmia	I
(	O
3	O
%	O
)	O
,	O
pain	B
in	I
extremity	I
(	O
3	O
%	O
)	O
,	O
and	O
urinary	B
tract	I
infection	I
(	O
3	O
%	O
)	O
.	O
	
Measure	O
serum	O
ALT	O
,	O
AST	O
,	O
and	O
bilirubin	O
prior	O
to	O
initiation	O
of	O
PROMACTA	O
,	O
every	O
2	O
weeks	O
during	O
the	O
dose	O
adjustment	O
phase	O
,	O
and	O
monthly	O
following	O
establishment	O
of	O
a	O
stable	O
dose	O
.	O
	
Call	O
your	O
doctor	O
for	O
medical	O
advice	O
about	O
side	O
effects	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
PROMACTA	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
narrow-angle	O
glaucoma	O
and	O
instruct	O
patients	O
to	O
consult	O
a	O
physician	O
immediately	O
if	O
this	O
occurs	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
In	O
addition	O
,	O
one	O
DALVANCE-treated	O
subject	O
in	O
a	O
Phase	O
1	O
trial	O
had	O
post-baseline	O
ALT	B
elevations	I
greater	O
than	O
20	O
times	O
ULN	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
CIMZIA	O
should	O
be	O
carefully	O
considered	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
with	O
chronic	O
or	O
recurrent	O
infection	O
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
arthritis	B
,	O
joint	B
stiffness	I
,	O
joint	B
swelling	I
,	O
muscle	B
spasms	I
,	O
musculoskeletal	B
pain	I
,	O
myalgia	B
.	O
	
Complete	O
blood	O
counts	O
(	O
with	O
white	O
blood	O
cell	O
differential	O
counts	O
)	O
should	O
be	O
obtained	O
at	O
pretreatment	O
,	O
and	O
at	O
Treatment	O
Weeks	O
2	O
,	O
4	O
,	O
8	O
,	O
and	O
12	O
,	O
and	O
should	O
be	O
monitored	O
closely	O
at	O
other	O
time	O
points	O
,	O
as	O
clinically	O
appropriate	O
.	O
	
5.3	O
Gastrointestinal	O
Adverse	O
Reactions	O
Nausea	B
,	O
vomiting	B
and	O
severe	O
diarrhea	B
,	O
at	O
times	O
,	O
may	O
occur	O
.	O
	
(	O
5.3	O
)	O
*	O
Worsening	B
of	I
urinary	I
retention	I
may	O
occur	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
the	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Adverse	O
reactions	O
that	O
led	O
to	O
dose	O
delays	O
in	O
more	O
than	O
5	O
%	O
of	O
ADCETRIS-treated	O
patients	O
in	O
Study	O
3	O
were	O
neutropenia	B
(	O
22	O
%	O
)	O
,	O
peripheral	B
sensory	I
neuropathy	I
(	O
16	O
%	O
)	O
,	O
upper	B
respiratory	I
tract	I
infection	I
(	O
6	O
%	O
)	O
,	O
and	O
peripheral	B
motor	I
neuropathy	I
(	O
6	O
%	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
,	O
dizziness	B
,	O
rash	B
,	O
pruritis	B
,	O
flushing	B
,	O
headache	B
,	O
and	O
injection	B
site	I
hemorrhage	I
occurred	O
in	O
<	O
1.3	O
%	O
of	O
patients	O
.	O
	
Death	B
related	O
to	O
diarrhea	B
and	O
electrolyte	B
imbalance	I
occurred	O
in	O
the	O
randomized	O
clinical	O
trial	O
.	O
	
Decreases	O
in	O
neutrophil	O
counts	O
may	O
require	O
dose	O
reduction	O
or	O
discontinuation	O
of	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
Metabolism	O
and	O
Nutrition	O
Disorders	O
:	O
anorexia	B
,	O
appetite	B
decreased	I
,	O
dehydration	B
,	O
diabetes	B
mellitus	I
,	O
hypercholesterolemia	B
,	O
hyperglycemia	B
,	O
hyperlipidemia	B
,	O
hypertriglyceridemia	B
,	O
hypokalemia	B
,	O
weight	B
decreased	I
.	O
	
*	O
viral	B
and	I
other	I
infections	I
.	O
	
Eight	O
of	O
12	O
patients	O
treated	O
with	O
DALVANCE	O
and	O
one	O
comparator	O
patient	O
had	O
underlying	O
conditions	O
which	O
could	O
affect	O
liver	O
enzymes	O
,	O
including	O
chronic	O
viral	O
hepatitis	O
and	O
a	O
history	O
of	O
alcohol	O
abuse	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
(	O
5.1	O
)	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Janssen	O
Biotech	O
,	O
Inc.	O
at	O
1-800-526-7736	O
(	O
1-800-JANSSEN	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
SERIOUS	O
INFECTIONS	B
AND	O
MALIGNANCY	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
The	O
risk	O
appears	O
lower	O
for	O
patients	O
with	O
chronic	O
,	O
moderate	O
kidney	O
disease	O
(	O
GFR	O
30	O
to	O
59	O
mL/min/1.73m	O
2	O
)	O
and	O
little	O
,	O
if	O
any	O
,	O
for	O
patients	O
with	O
chronic	O
,	O
mild	O
kidney	O
disease	O
(	O
GFR	O
60	O
to	O
89	O
mL/min/1.73m	O
2	O
)	O
.	O
	
You	O
may	O
report	O
side	O
effects	O
to	O
FDA	O
at	O
1-800-FDA-1088	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
experienced	O
by	O
patients	O
with	O
classical	O
HL	O
include	O
peripheral	B
motor	I
neuropathy	I
(	O
4	O
%	O
)	O
,	O
abdominal	B
pain	I
(	O
3	O
%	O
)	O
,	O
pulmonary	B
embolism	I
(	O
2	O
%	O
)	O
,	O
pneumonitis	B
(	O
2	O
%	O
)	O
,	O
pneumothorax	B
(	O
2	O
%	O
)	O
,	O
pyelonephritis	B
(	O
2	O
%	O
)	O
,	O
and	O
pyrexia	B
(	O
2	O
%	O
)	O
.	O
	
If	O
such	O
a	O
reaction	O
occurs	O
,	O
therapy	O
with	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
stopped	O
at	O
once	O
and	O
alternative	O
treatments	O
should	O
be	O
considered	O
.	O
	
5.4	O
Drug	O
Interactions	O
with	O
CYP2D6	O
Administration	O
of	O
Coartem	O
Tablets	O
with	O
drugs	O
that	O
are	O
metabolized	O
by	O
CYP2D6	O
may	O
significantly	O
increase	O
plasma	O
concentrations	O
of	O
the	O
coadministered	O
drug	O
and	O
increase	O
the	O
risk	O
of	O
adverse	O
effects	O
.	O
	
Table	O
1	O
presents	O
the	O
adverse	O
reactions	O
reported	O
when	O
STENDRA	O
was	O
taken	O
as	O
recommended	O
(	O
on	O
an	O
as-needed	O
basis	O
)	O
from	O
these	O
3	O
clinical	O
trials	O
.	O
	
For	O
current	O
full	O
prescribing	O
information	O
,	O
please	O
visit	O
www.pfizer.com	O
.	O
	
At	O
these	O
doses	O
,	O
SAPHRIS	O
was	O
associated	O
with	O
increases	B
in	I
QTc	I
interval	I
ranging	O
from	O
2	O
to	O
5	O
msec	O
compared	O
to	O
placebo	O
.	O
	
There	O
were	O
no	O
differences	O
in	O
efficacy	O
or	O
safety	O
between	O
patients	O
with	O
or	O
without	O
immunoreactivity	O
.	O
	
While	O
this	O
normally	O
would	O
be	O
expected	O
to	O
be	O
of	O
little	O
consequence	O
in	O
most	O
patients	O
,	O
prior	O
to	O
prescribing	O
STENDRA	O
,	O
physicians	O
should	O
carefully	O
consider	O
whether	O
patients	O
with	O
underlying	O
cardiovascular	O
disease	O
could	O
be	O
affected	O
adversely	O
by	O
such	O
vasodilatory	O
effects	O
,	O
especially	O
in	O
combination	O
with	O
sexual	O
activity	O
.	O
	
Consider	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
SIMPONI	O
ARIA	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
with	O
chronic	O
or	O
recurrent	O
infection	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Risk	O
of	O
Thyroid	O
C-cell	O
Tumors	O
Carcinogenicity	O
of	O
albiglutide	O
could	O
not	O
be	O
assessed	O
in	O
rodents	O
due	O
to	O
the	O
rapid	O
development	O
of	O
drug-clearing	O
,	O
anti-drug	O
antibodies	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
5.3	O
Spinal/Epidural	O
Anesthesia	O
or	O
Puncture	O
When	O
neuraxial	O
anesthesia	O
(	O
spinal/epidural	O
anesthesia	O
)	O
or	O
spinal/epidural	O
puncture	O
is	O
employed	O
,	O
patients	O
treated	O
with	O
antithrombotic	O
agents	O
for	O
prevention	O
of	O
thromboembolic	O
complications	O
are	O
at	O
risk	O
of	O
developing	O
an	O
spinal	B
hematoma	I
which	O
can	O
result	O
in	O
permanent	B
paralysis	I
.	O
	
Higher	O
than	O
recommended	O
dosing	O
or	O
repeated	O
dosing	O
appears	O
to	O
increase	O
the	O
risk	O
(	O
5.1	O
)	O
*	O
hypersensitivity	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
,	O
including	O
death	B
,	O
have	O
occurred	O
.	O
	
Onset	O
of	O
dyspnea	O
or	O
non-productive	O
cough	O
may	O
be	O
related	O
to	O
pulmonary	O
toxicity	O
and	O
patients	O
should	O
be	O
carefully	O
evaluated	O
clinically	O
.	O
	
Perform	O
an	O
ophthalmological	O
evaluation	O
consisting	O
of	O
best	O
corrected	O
visual	O
acuity	O
,	O
retinal	O
photographs	O
,	O
visual	O
fields	O
,	O
optical	O
coherence	O
tomography	O
(	O
OCT	O
)	O
and	O
other	O
evaluations	O
as	O
appropriate	O
for	O
new	O
onset	O
of	O
severe	O
visual	O
loss	O
.	O
	
Thromboembolic	O
events	O
have	O
been	O
associated	O
with	O
ESA	O
use	O
in	O
other	O
disease	O
states	O
;	O
and	O
have	O
also	O
been	O
reported	O
with	O
peginterferon	O
alfa	O
use	O
in	O
hepatitis	O
C	O
patients	O
.	O
	
For	O
additional	O
information	O
,	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
consult	O
the	O
VIREAD	O
prescribing	O
information	O
.	O
	
If	O
ELIQUIS	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
andClinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
*	O
Monitor	O
all	O
patients	O
for	O
active	O
TB	O
during	O
treatment	O
,	O
even	O
if	O
initial	O
latent	O
TB	O
test	O
is	O
negative	O
(	O
5.1	O
)	O
.	O
	
c	O
Includes	O
skin	B
papilloma	I
and	O
papilloma	B
.	O
	
*	O
Anaphylaxis	B
and	O
infusion	B
reactions	I
:	O
If	O
an	O
infusion	O
reaction	O
occurs	O
,	O
interrupt	O
the	O
infusion	O
.	O
	
In	O
a	O
controlled	O
trial	O
in	O
patients	O
with	O
chronic	O
liver	O
disease	O
and	O
thrombocytopenia	O
not	O
related	O
to	O
ITP	O
undergoing	O
elective	O
invasive	O
procedures	O
(	O
N	O
=	O
292	O
)	O
,	O
the	O
risk	O
of	O
thrombotic	B
events	I
was	O
increased	O
in	O
patients	O
treated	O
with	O
75	O
mg	O
of	O
PROMACTA	O
once	O
daily	O
.	O
	
The	O
incidence	O
in	O
the	O
DME	O
studies	O
from	O
baseline	O
to	O
week	O
52	O
was	O
3.3	O
%	O
(	O
19	O
out	O
of	O
578	O
)	O
in	O
the	O
combined	O
group	O
of	O
patients	O
treated	O
with	O
EYLEA	O
compared	O
with	O
2.8	O
%	O
(	O
8	O
out	O
of	O
287	O
)	O
in	O
the	O
control	O
group	O
;	O
from	O
baseline	O
to	O
week	O
100	O
,	O
the	O
incidence	O
was	O
6.4	O
%	O
(	O
37	O
out	O
of	O
578	O
)	O
in	O
the	O
combined	O
group	O
of	O
patients	O
treated	O
with	O
EYLEA	O
compared	O
with	O
4.2	O
%	O
(	O
12	O
out	O
of	O
287	O
)	O
in	O
the	O
control	O
group	O
.	O
	
Increase	B
in	I
Hematocrit	I
In	O
a	O
pool	O
of	O
four	O
placebo-controlled	O
studies	O
,	O
median	O
hematocrit	B
decreased	I
by	O
2.8	O
%	O
in	O
JARDIANCE	O
10	O
mg	O
and	O
2.8	O
%	O
in	O
JARDIANCE	O
25	O
mg	O
treated	O
patients	O
.	O
	
Table	O
1	O
:	O
Per	O
Patient	O
Incidence	O
of	O
Grade	O
1	O
and	O
2	O
Adverse	O
Reactions	O
Assessed	O
as	O
Possibly	O
,	O
Probably	O
,	O
or	O
Definitely	O
Related	O
to	O
VORAXAZE	O
Excluding	O
Hematologic	O
,	O
Hepatic	O
,	O
or	O
Renal	O
Adverse	O
Reactions	O
1	O
This	O
incidence	O
includes	O
the	O
following	O
terms	O
:	O
flushing	B
,	O
feeling	B
hot	I
,	O
burning	B
sensation	I
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
of	O
MTC	O
and	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
4.1	O
,	O
5.1	O
)	O
.	O
	
A	O
total	O
of	O
2757	O
subjects	O
with	O
hyperuricemia	O
and	O
gout	O
were	O
treated	O
with	O
ULORIC	O
40	O
mg	O
or	O
80	O
mg	O
daily	O
in	O
clinical	O
studies	O
.	O
	
Sixty-two	O
patients	O
were	O
exposed	O
to	O
ILARIS	O
for	O
at	O
least	O
6	O
months	O
,	O
56	O
for	O
at	O
least	O
1	O
year	O
and	O
4	O
for	O
at	O
least	O
3	O
years	O
.	O
	
Other	O
Risk	O
Factors	O
Other	O
known	O
risk	O
factors	O
for	O
PTLD	O
include	O
cytomegalovirus	O
(	O
CMV	O
)	O
infection	O
and	O
T-cell-depleting	O
therapy	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
,	O
and	O
treat	O
promptly	O
.	O
	
This	O
was	O
seen	O
at	O
all	O
doses	O
with	O
a	O
suggestion	O
of	O
a	O
higher	O
rate	O
at	O
400	O
mg	O
per	O
day	O
.	O
	
In	O
order	O
to	O
monitor	O
the	O
occurrence	O
of	O
neutropenia	O
,	O
frequent	O
blood	O
cell	O
counts	O
should	O
be	O
performed	O
on	O
all	O
patients	O
receiving	O
JEVTANA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Bone	B
marrow	I
suppression	I
(	O
particularly	O
neutropenia	B
)	O
and	O
its	O
clinical	O
consequences	O
(	O
febrile	B
neutropenia	I
,	O
neutropenic	B
infections	I
)	O
:	O
Monitor	O
blood	O
counts	O
frequently	O
to	O
determine	O
if	O
dosage	O
modification	O
or	O
initiation	O
of	O
G-CSF	O
is	O
needed	O
.	O
	
(	O
5.12	O
,	O
8.1	O
)	O
5.1	O
Non-infectious	O
Pneumonitis	O
Non-infectious	B
pneumonitis	I
is	O
a	O
class	O
effect	O
of	O
rapamycin	O
derivatives	O
,	O
including	O
AFINITOR	O
.	O
	
The	O
risk	O
of	O
hypoglycemia	B
is	O
increased	O
when	O
JARDIANCE	O
is	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylurea	O
)	O
or	O
insulin	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Gamma	O
Glutamyltransferase	O
(	O
GGT	O
)	O
Increase	O
In	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
,	O
the	O
adverse	O
event	O
of	O
increased	B
GGT	I
occurred	O
more	O
frequently	O
in	O
the	O
group	O
treated	O
with	O
TANZEUM	O
(	O
0.9	O
%	O
and	O
1.5	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
.	O
	
Study	O
2	O
is	O
an	O
ongoing	O
expanded	O
access	O
program	O
.	O
	
*	O
Serious	O
dermatologic	B
reactions	I
:	O
Discontinue	O
if	O
Stevens-Johnson	O
syndrome	O
or	O
toxic	O
epidermal	O
necrolysis	O
occurs	O
(	O
5.10	O
)	O
.	O
	
Hepatitis	O
B	O
Virus	O
Reactivation	O
The	O
use	O
of	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
reactivation	B
of	I
hepatitis	I
B	I
virus	I
)	O
in	O
patients	O
who	O
are	O
chronic	O
hepatitis	O
B	O
carriers	O
(	O
i.e.	O
,	O
surface	O
antigen	O
positive	O
)	O
.	O
	
Adverse	O
Reactions	O
in	O
Placebo-Controlled	O
Trials	O
In	O
the	O
two	O
well-controlled	O
studies	O
demonstrating	O
effectiveness	O
,	O
1529	O
patients	O
received	O
TECFIDERA	O
with	O
an	O
overall	O
exposure	O
of	O
2244	O
person-years	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
with	O
neutrophils	O
<	O
=	O
1,500/mm	O
3	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
The	O
overall	O
safety	O
profile	O
of	O
Neuraceq	O
is	O
based	O
on	O
data	O
from	O
978	O
administrations	O
of	O
Neuraceq	O
to	O
872	O
subjects	O
and	O
12	O
subjects	O
who	O
received	O
vehicle	O
only	O
.	O
	
Some	O
infections	B
were	O
fatal	B
.	O
	
CRNM	O
=	O
clinically	O
relevant	O
nonmajor	O
.	O
	
Use	O
in	O
liver	O
transplant	O
patients	O
is	O
not	O
recommended	O
due	O
to	O
an	O
increased	O
risk	O
of	O
graft	O
loss	O
and	O
death	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Most	O
commonly	O
reported	O
adverse	O
reactions	O
were	O
flushing	B
(	O
2	O
%	O
)	O
,	O
headache	B
(	O
1	O
%	O
)	O
,	O
increased	B
blood	I
pressure	I
(	O
2	O
%	O
)	O
,	O
nausea	B
(	O
1	O
%	O
)	O
,	O
and	O
dizziness	B
(	O
1	O
%	O
)	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
DaTscan	O
administration	O
.	O
	
No	O
neutralizing	O
antibodies	O
were	O
detected	O
.	O
	
Patients	O
were	O
between	O
the	O
ages	O
of	O
18	O
and	O
69	O
on	O
the	O
date	O
of	O
the	O
first	O
dose	O
of	O
CERDELGA	O
,	O
and	O
included	O
87	O
females	O
and	O
72	O
males	O
.	O
	
Table	O
8	O
compares	O
the	O
incidence	O
of	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
occurring	O
more	O
frequently	O
with	O
AFINITOR	O
than	O
with	O
placebo	O
.	O
	
(	O
5.5	O
)	O
*	O
Seizures	B
:	O
Use	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
conditions	O
that	O
lower	O
seizure	O
threshold	O
.	O
	
No	O
Grade	O
4	O
laboratory	O
abnormalities	O
were	O
reported	O
.	O
	
Table	O
2	O
displays	O
the	O
frequency	O
of	O
adverse	O
drug	O
reactions	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
of	O
subjects	O
in	O
any	O
treatment	O
arm	O
.	O
	
At	O
baseline	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
7.3	O
years	O
,	O
had	O
a	O
mean	O
HbA1C	O
of	O
8.0	O
%	O
and	O
20	O
%	O
had	O
established	O
microvascular	O
complications	O
of	O
diabetes	O
.	O
	
FANAPT	O
is	O
not	O
approved	O
for	O
use	O
in	O
patients	O
with	O
dementia-related	O
psychosis	O
.	O
	
c	O
Includes	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
lung	B
infiltration	I
,	O
pulmonary	B
alveolar	I
hemorrhage	I
,	O
pulmonary	B
toxicity	I
,	O
and	O
alveolitis	B
.	O
	
Psoriasis	O
Clinical	O
Trials	O
The	O
safety	O
of	O
OTEZLA	O
(	O
r	O
)	O
was	O
assessed	O
in	O
1426	O
subjects	O
in	O
3	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
in	O
adult	O
subjects	O
with	O
moderate	O
to	O
severe	O
plaque	O
psoriasis	O
who	O
were	O
candidates	O
for	O
phototherapy	O
or	O
systemic	O
therapy	O
.	O
	
5.7	O
Risk	O
of	O
Ptosis	O
in	O
Patients	O
Treated	O
with	O
XEOMIN	O
for	O
Glabellar	O
Lines	O
Do	O
not	O
exceed	O
the	O
recommended	O
dosage	O
and	O
frequency	O
of	O
administration	O
of	O
XEOMIN	O
.	O
	
Table	O
3	O
:	O
Monitored	O
Adverse	O
Reactions	O
-	O
Pruritus	B
,	O
Erythema	B
,	O
Pyoderma	B
and	O
Ocular	B
Irritation	I
with	O
Onset	O
After	O
Treatment	O
Signs/Symptoms	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
Vehicle	O
Pruritus	B
12	O
%	O
(	O
14/116	O
)	O
4	O
%	O
(	O
3/67	O
)	O
Erythema	B
10	O
%	O
(	O
32/309	O
)	O
9	O
%	O
(	O
19/217	O
)	O
Pyoderma	B
7	O
%	O
(	O
22/308	O
)	O
4	O
%	O
(	O
10/230	O
)	O
Ocular	B
irritation	I
6	O
%	O
(	O
26/428	O
)	O
1	O
%	O
(	O
3/313	O
)	O
Other	O
less	O
common	O
reactions	O
(	O
less	O
than	O
1	O
%	O
but	O
more	O
than	O
0.1	O
%	O
)	O
were	O
,	O
in	O
decreasing	O
order	O
of	O
incidence	O
:	O
application	B
site	I
dryness	I
,	O
application	B
site	I
excoriation	I
,	O
paraesthesia	B
,	O
application	B
site	I
dermatitis	I
,	O
excoriation	B
,	O
thermal	B
burn	I
,	O
dandruff	B
,	O
erythema	B
,	O
rash	B
,	O
and	O
skin	B
exfoliation	I
.	O
	
*	O
No	O
dosing	O
adjustments	O
are	O
recommended	O
in	O
the	O
presence	O
of	O
moderate	O
CYP3A4	O
inhibitors	O
(	O
e.g.	O
,	O
erythromycin	O
,	O
fluconazole	O
,	O
diltiazem	O
,	O
verapamil	O
and	O
grapefruit	O
juice	O
)	O
.	O
	
Increased	O
Mortality	O
In	O
the	O
cIAI	O
trials	O
(	O
Phase	O
2	O
and	O
3	O
)	O
,	O
death	B
occurred	O
in	O
2.5	O
%	O
(	O
14/564	O
)	O
of	O
patients	O
receiving	O
ZERBAXA	O
and	O
in	O
1.5	O
%	O
(	O
8/536	O
)	O
of	O
patients	O
receiving	O
meropenem	O
.	O
	
Elevating	O
the	O
head	O
of	O
the	O
bed	O
lessens	O
the	O
risk	O
of	O
supine	O
hypertension	O
,	O
and	O
blood	O
pressure	O
should	O
be	O
measured	O
in	O
this	O
position	O
.	O
	
The	O
incidence	O
of	O
ILD	B
appeared	O
to	O
be	O
higher	O
in	O
patients	O
of	O
Asian	O
ethnicity	O
(	O
2.1	O
%	O
)	O
as	O
compared	O
to	O
non-Asians	O
(	O
1.2	O
%	O
)	O
.	O
	
In	O
clinical	O
trials	O
,	O
subjects	O
who	O
received	O
a	O
higher	O
dose	O
of	O
DYSPORT	O
(	O
r	O
)	O
had	O
an	O
increased	O
incidence	O
of	O
eyelid	B
ptosis	I
.	O
	
In	O
addition	O
to	O
the	O
reactions	O
shown	O
in	O
Table	O
1	O
,	O
adverse	O
reactions	O
occurring	O
in	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
of	O
the	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
(	O
n	O
=	O
806	O
)	O
for	O
12	O
months	O
included	O
back	B
pain	I
,	O
pneumonia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
,	O
bronchitis	B
,	O
sinusitis	B
,	O
cough	B
,	O
oropharyngeal	B
pain	I
,	O
arthralgia	B
,	O
influenza	B
,	O
pharyngitis	B
,	O
and	O
pyrexia	B
.	O
	
Monitor	O
patients	O
during	O
and	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
after	O
administration	O
of	O
BENLYSTA	O
.	O
	
The	O
safety	O
of	O
self-administration	O
was	O
evaluated	O
in	O
a	O
separate	O
,	O
open-label	O
trial	O
in	O
56	O
patients	O
with	O
HAE	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
at	O
risk	O
for	O
gastrointestinal	O
perforation	O
or	O
fistula	O
.	O
	
Patients	O
with	O
smaller	O
neck	O
muscle	O
mass	O
and	O
patients	O
who	O
require	O
bilateral	O
injections	O
into	O
the	O
sternocleidomastoid	O
muscles	O
have	O
been	O
reported	O
to	O
be	O
at	O
greater	O
risk	O
of	O
dysphagia	B
.	O
	
at	O
1-800-678-1605	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
In	O
both	O
cases	O
,	O
the	O
patients	O
were	O
taking	O
a	O
1.25	O
mg	O
dose	O
of	O
fingolimod	O
(	O
higher	O
than	O
the	O
recommended	O
0.5	O
mg	O
dose	O
)	O
and	O
had	O
received	O
high-dose	O
corticosteroid	O
therapy	O
to	O
treat	O
suspected	O
MS	O
relapses	O
.	O
	
Adverse	O
Reactions	O
in	O
Pediatric	O
Patients	O
During	O
clinical	O
trials	O
,	O
141	O
pediatric	O
patients	O
(	O
7	O
aged	O
<	O
24	O
months	O
,	O
33	O
aged	O
2	O
-	O
5	O
years	O
,	O
58	O
aged	O
6	O
-	O
11	O
years	O
and	O
43	O
aged	O
12	O
-	O
17	O
)	O
received	O
DOTAREM	O
.	O
	
These	O
cases	O
were	O
reported	O
post-marketing	O
and	O
are	O
derived	O
from	O
a	O
variety	O
of	O
sources	O
,	O
including	O
registries	O
and	O
spontaneous	O
post-marketing	O
reports	O
.	O
	
(	O
5.14	O
,	O
8.1	O
)	O
5.1	O
Cardiac	O
Toxicities	O
worsening	B
of	I
pre-existing	I
cardiac	I
failure	I
(	O
e.g.	O
,	O
congestive	B
heart	I
failure	I
,	O
pulmonary	B
edema	I
,	O
decreased	B
ejection	I
fraction	I
)	O
,	O
restrictive	B
cardiomyopathy	I
,	O
myocardial	B
ischemia	I
,	O
and	O
myocardial	B
infarction	I
including	O
fatalities	B
have	O
occurred	O
following	O
administration	O
of	O
Kyprolis	O
.	O
	
FANAPT	O
should	O
be	O
discontinued	O
in	O
patients	O
who	O
are	O
found	O
to	O
have	O
persistent	O
QTc	O
measurements	O
>	O
500	O
msec	O
.	O
	
In	O
monotherapy	O
trials	O
in	O
patients	O
with	O
partial-onset	O
seizures	O
[	O
Study	O
1	O
and	O
Study	O
2	O
,	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
,	O
365	O
patients	O
received	O
APTIOM	O
,	O
of	O
whom	O
225	O
were	O
treated	O
for	O
longer	O
than	O
12	O
months	O
and	O
134	O
for	O
longer	O
than	O
24	O
months	O
.	O
	
Therefore	O
,	O
prescribers	O
should	O
exercise	O
caution	O
when	O
considering	O
resumption	O
of	O
TNF-blockers	O
in	O
this	O
situation	O
and	O
monitor	O
patients	O
closely	O
.	O
	
5.2	O
Lack	O
of	O
Interchangeability	O
between	O
Botulinum	O
Toxin	O
Products	O
The	O
potency	O
Units	O
of	O
XEOMIN	O
are	O
specific	O
to	O
the	O
preparation	O
and	O
assay	O
method	O
utilized	O
.	O
	
Table	O
8	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
2	O
%	O
or	O
More	O
of	O
Adult	O
Patients	O
in	O
Any	O
SAPHRIS	O
Dose	O
Group	O
and	O
Which	O
Occurred	O
at	O
Greater	O
Incidence	O
Than	O
in	O
the	O
Placebo	O
Group	O
in	O
6-Week	O
Schizophrenia	O
Trials	O
*	O
Akathisia	B
includes	O
:	O
akathisia	B
and	O
hyperkinesia	B
.	O
	
In	O
MS	O
placebo-controlled	O
trials	O
,	O
the	O
overall	O
rate	O
of	O
infections	B
(	O
72	O
%	O
)	O
with	O
GILENYA	O
was	O
similar	O
to	O
placebo	O
.	O
	
age	O
>	O
60	O
years	O
,	O
hypertension	O
,	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
(	O
5.1	O
)	O
.	O
	
Table	O
2	O
presents	O
the	O
most	O
common	O
laboratory	O
abnormalities	O
reported	O
in	O
>	O
=10	O
%	O
patients	O
who	O
received	O
INLYTA	O
or	O
sorafenib	O
.	O
	
DUAVEE	O
is	O
used	O
after	O
menopause	O
for	O
women	O
with	O
a	O
uterus	O
to	O
:	O
*	O
reduce	O
moderate	O
to	O
severe	O
hot	O
flushesEstrogens	O
are	O
hormones	O
made	O
by	O
a	O
woman	O
's	O
ovaries	O
.	O
	
An	O
additional	O
51	O
subjects	O
from	O
a	O
separate	O
repeat	O
dose	O
study	O
were	O
tested	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
only	O
.	O
	
Glabellar	O
Lines	O
Testing	O
for	O
antibodies	O
to	O
DYSPORT	O
(	O
r	O
)	O
was	O
performed	O
for	O
1554	O
subjects	O
who	O
had	O
up	O
to	O
nine	O
cycles	O
of	O
treatment	O
.	O
	
This	O
information	O
does	O
not	O
take	O
the	O
place	O
of	O
talking	O
to	O
your	O
healthcare	O
provider	O
about	O
your	O
medical	O
condition	O
or	O
your	O
treatment	O
.	O
	
This	O
risk	O
was	O
greater	O
in	O
patients	O
with	O
a	O
baseline	O
reduced	O
estimated	O
creatinine	O
clearance	O
(	O
calculated	O
using	O
Cockcroft	O
and	O
Gault	O
equation	O
)	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
:	O
Adults	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
The	O
Study	O
2	O
population	O
included	O
patients	O
with	O
a	O
median	O
age	O
of	O
7	O
years	O
(	O
1	O
to	O
17	O
years	O
)	O
;	O
63	O
%	O
were	O
male	O
,	O
27	O
%	O
were	O
Hispanic	O
or	O
Latino	O
,	O
83	O
%	O
were	O
White	O
,	O
3	O
%	O
were	O
Black/African	O
American	O
,	O
7	O
%	O
were	O
Asian	O
,	O
and	O
7	O
%	O
were	O
other	O
(	O
American	O
Indian	O
,	O
Alaska	O
Native	O
or	O
Indian	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
7	O
15	O
13	O
13	O
Psychiatric	O
disorders	O
Insomnia	B
13	O
16	O
15	O
15	O
Vascular	O
disorders	O
Hypertension	B
2	O
2	O
3	O
2	O
Dose-Related	O
Adverse	O
Reactions	O
:	O
In	O
the	O
short	O
term	O
schizophrenia	O
trials	O
the	O
incidence	O
of	O
akathisia	B
appeared	O
to	O
be	O
dose-related	O
(	O
seeTable	O
8	O
)	O
.	O
	
In	O
some	O
cases	O
,	O
hyperglycemia	O
has	O
resolved	O
when	O
the	O
atypical	O
antipsychotic	O
was	O
discontinued	O
;	O
however	O
,	O
some	O
patients	O
required	O
continuation	O
of	O
anti-diabetic	O
treatment	O
despite	O
discontinuation	O
of	O
the	O
antipsychotic	O
drug	O
.	O
	
The	O
nadir	O
in	O
serum	O
calcium	O
level	O
occurs	O
at	O
approximately	O
day	O
10	O
after	O
Prolia	O
dosing	O
in	O
subjects	O
with	O
normal	O
renal	O
function	O
.	O
	
Dermatologic	O
Reactions	O
A	O
significantly	O
higher	O
number	O
of	O
patients	O
treated	O
with	O
Prolia	O
developed	O
dermal	B
adverse	I
events	I
(	O
such	O
as	O
dermatitis	B
,	O
eczema	B
,	O
and	O
rashes	B
)	O
,	O
with	O
these	O
events	O
reported	O
in	O
8.2	O
%	O
of	O
the	O
placebo	O
and	O
10.8	O
%	O
of	O
the	O
Prolia	O
groups	O
(	O
p	O
<	O
0.0001	O
)	O
.	O
	
Patients	O
with	O
unstable	O
or	O
poorly	O
controlled	O
hypertension	O
,	O
a	O
recent	O
history	O
of	O
cardiovascular	O
or	O
cerebrovascular	O
events	O
may	O
be	O
at	O
an	O
increased	O
risk	O
of	O
adverse	B
cardiovascular	I
effects	I
.	O
	
The	O
majority	O
of	O
application	B
site	I
reactions	I
were	O
transient	O
and	O
self-limited	O
.	O
	
EXCERPT	O
:	O
*	O
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=3	O
%	O
of	O
KALBITOR-treated	O
patients	O
and	O
greater	O
than	O
placebo	O
are	O
headache	B
,	O
nausea	B
,	O
diarrhea	B
,	O
pyrexia	B
,	O
injection	B
site	I
reactions	I
,	O
and	O
nasopharyngitis	B
.	O
	
(	O
5.1	O
)	O
*	O
This	O
finding	O
of	O
an	O
increased	O
risk	O
of	O
asthma-related	O
death	B
with	O
salmeterol	O
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
,	O
including	O
indacaterol	O
,	O
the	O
active	O
ingredient	O
in	O
ARCAPTA	O
NEOHALER	O
.	O
	
In	O
the	O
patients	O
with	O
AP	O
CML	O
and	O
BP	O
CML	O
,	O
the	O
median	O
duration	O
of	O
BOSULIF	O
treatment	O
was	O
10	O
months	O
and	O
3	O
months	O
,	O
respectively	O
.	O
	
Assure	O
good	O
venous	O
access	O
prior	O
to	O
starting	O
TREANDA	O
infusion	O
and	O
monitor	O
the	O
intravenous	O
infusion	O
site	O
for	O
redness	O
,	O
swelling	O
,	O
pain	O
,	O
infection	O
,	O
and	O
necrosis	O
during	O
and	O
after	O
administration	O
of	O
TREANDA	O
.	O
	
If	O
signs	O
and	O
symptoms	O
of	O
TD	O
appear	O
in	O
a	O
patient	O
on	O
SAPHRIS	O
,	O
drug	O
discontinuation	O
should	O
be	O
considered	O
.	O
	
Administration	O
of	O
cabazitaxel	O
to	O
patients	O
with	O
mild	O
and	O
moderate	O
hepatic	O
impairment	O
should	O
be	O
undertaken	O
with	O
caution	O
and	O
close	O
monitoring	O
of	O
safety	O
.	O
	
In	O
the	O
pooled	O
analysis	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
,	O
the	O
incidence	O
of	O
renal-related	B
adverse	I
reactions	I
was	O
3.7	O
%	O
with	O
placebo	O
,	O
8.9	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
9.3	O
%	O
with	O
INVOKANA	O
300	O
mg.	O
Discontinuations	O
due	O
to	O
renal-related	B
adverse	I
events	I
occurred	O
in	O
1.0	O
%	O
with	O
placebo	O
,	O
1.2	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
1.6	O
%	O
with	O
INVOKANA	O
300	O
mg	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Females	O
of	O
childbearing	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
becoming	O
pregnant	O
during	O
treatment	O
with	O
JEVTANA	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Patients	O
treated	O
with	O
DALVANCE	O
were	O
predominantly	O
male	O
(	O
60	O
%	O
)	O
and	O
Caucasian	O
(	O
78	O
%	O
)	O
.	O
	
Where	O
skin	B
reactions	I
occur	O
,	O
they	O
may	O
be	O
progressive	O
and	O
increase	O
in	O
severity	O
with	O
further	O
treatment	O
.	O
	
Patients	O
with	O
acute	O
respiratory	O
illness	O
may	O
be	O
at	O
risk	O
of	O
serious	O
acute	O
exacerbation	O
of	O
their	O
respiratory	O
compromise	O
due	O
to	O
hypersensitivity	O
reactions	O
,	O
and	O
require	O
additional	O
monitoring	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Four	O
percent	O
(	O
4	O
%	O
)	O
of	O
patients	O
treated	O
with	O
TECFIDERA	O
and	O
less	O
than	O
1	O
%	O
of	O
placebo	O
patients	O
discontinued	O
due	O
to	O
gastrointestinal	B
events	I
.	O
	
The	O
population	O
was	O
almost	O
entirely	O
Caucasian	O
(	O
99	O
%	O
)	O
with	O
a	O
median	O
age	O
of	O
51	O
years	O
(	O
range	O
18-82	O
years	O
)	O
.	O
	
Adverse	O
reactions	O
leading	O
to	O
dose	O
reduction	O
occurred	O
in	O
14	O
%	O
of	O
patients	O
.	O
	
However	O
,	O
there	O
may	O
be	O
an	O
increased	O
risk	O
of	O
severe	O
skin	B
toxicity	I
when	O
TREANDA	O
and	O
allopurinol	O
are	O
administered	O
concomitantly	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Local	B
skin	I
reactions	I
were	O
assessed	O
within	O
the	O
selected	O
treatment	O
area	O
and	O
graded	O
by	O
the	O
investigator	O
on	O
a	O
scale	O
of	O
0	O
to	O
4	O
.	O
	
INVOKANA	O
can	O
increase	O
the	O
risk	O
of	O
hypoglycemia	B
when	O
combined	O
with	O
insulin	O
or	O
an	O
insulin	O
secretagogue	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
distance	O
of	O
a	O
z-score	O
from	O
0	O
represents	O
the	O
distance	O
of	O
a	O
percentile	O
from	O
the	O
median	O
,	O
measured	O
in	O
standard	O
deviations	O
(	O
SD	O
)	O
.	O
	
Although	O
there	O
were	O
few	O
non-Caucasian	O
patients	O
,	O
no	O
differences	O
in	O
the	O
incidences	O
of	O
adverse	O
reactions	O
compared	O
to	O
Caucasian	O
patients	O
were	O
observed	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypotension	B
:	O
Before	O
initiating	O
INVOKANA	O
,	O
assess	O
volume	O
status	O
and	O
correct	O
hypovolemia	O
in	O
patients	O
with	O
renal	O
impairment	O
,	O
the	O
elderly	O
,	O
in	O
patients	O
with	O
low	O
systolic	O
blood	O
pressure	O
,	O
or	O
if	O
on	O
diuretics	O
,	O
ACEi	O
,	O
or	O
ARB	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
trials	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
total	B
cholesterol	I
elevations	I
>	O
=240	O
mg/dL	O
(	O
at	O
Endpoint	O
)	O
was	O
8.7	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
8.6	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Table	O
1	O
.	O
	
If	O
intolerable	O
symptoms	O
occur	O
following	O
a	O
decrease	O
in	O
the	O
dose	O
or	O
upon	O
discontinuation	O
of	O
treatment	O
,	O
then	O
resuming	O
the	O
previously	O
prescribed	O
dose	O
may	O
be	O
considered	O
.	O
	
Signs	O
or	O
symptoms	O
that	O
may	O
reflect	O
serious	O
injury	O
to	O
the	O
injected	O
finger/hand	O
should	O
be	O
promptly	O
evaluated	O
because	O
surgical	O
intervention	O
may	O
be	O
required	O
.	O
	
No	O
serious	O
events	O
were	O
reported	O
through	O
Year	O
3	O
.	O
	
5.3	O
Skin	O
Discoloration	O
POTIGA	O
can	O
cause	O
skin	B
discoloration	I
.	O
	
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
:	O
Bleeding	B
and	O
injection	B
site	I
reactions	I
.	O
	
Table	O
6	O
:	O
Change	O
in	O
Body	O
Weight	O
FANAPT	O
FANAPT	O
Placebo	O
10-16	O
mg/day	O
20-24	O
mg/day	O
n=576	O
n=481	O
n=391	O
Weight	O
(	O
kg	O
)	O
Change	O
from	O
Baseline	O
-0.1	O
2.0	O
2.7	O
Weight	O
Gain	O
>	O
=7	O
%	O
increase	O
from	O
Baseline	O
4	O
%	O
12	O
%	O
18	O
%	O
5.6	O
Seizures	O
In	O
short-term	O
placebo-controlled	O
trials	O
(	O
4-	O
to	O
6-weeks	O
)	O
,	O
seizures	B
occurred	O
in	O
0.1	O
%	O
(	O
1/1344	O
)	O
of	O
patients	O
treated	O
with	O
FANAPT	O
compared	O
to	O
0.3	O
%	O
(	O
2/587	O
)	O
on	O
placebo	O
.	O
	
5.7	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TRULICITY	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Controlled	O
Study	O
The	O
data	O
in	O
Tables	O
1	O
and	O
2	O
below	O
reflect	O
exposure	O
of	O
229	O
EGFR-TKI	O
naive	O
GILOTRIF-treated	O
patients	O
with	O
EGFR	O
mutation-positive	O
,	O
metastatic	O
,	O
non-squamous	O
,	O
NSCLC	O
enrolled	O
in	O
a	O
randomized	O
,	O
multicenter	O
,	O
open-label	O
trial	O
(	O
Study	O
1	O
)	O
.	O
	
*	O
XIAFLEX	O
is	O
available	O
for	O
the	O
treatment	O
of	O
Peyronie	O
's	O
disease	O
only	O
through	O
a	O
restricted	O
program	O
called	O
the	O
XIAFLEX	O
REMS	O
Program	O
(	O
5.3	O
)	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
bleeding	O
.	O
	
Amylase	O
and	O
Lipase	O
Increase	O
Patients	O
exposed	O
to	O
TRULICITY	O
had	O
mean	O
increases	B
from	I
baseline	I
in	I
lipase	I
of	O
14	O
%	O
to	O
20	O
%	O
,	O
while	O
placebo-treated	O
patients	O
had	O
mean	O
increases	O
of	O
up	O
to	O
3	O
%	O
.	O
	
5.10	O
Interstitial	O
Lung	O
Disease	O
and	O
Eosinophilic	O
Pneumonia	O
Interstitial	B
lung	I
disease	I
and	O
eosinophilic	B
pneumonia	I
associated	O
with	O
venlafaxine	O
(	O
the	O
parent	O
drug	O
of	O
PRISTIQ	O
)	O
therapy	O
have	O
been	O
rarely	O
reported	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
YERVOY	O
.	O
	
Appropriate	O
prophylactic	O
measures	O
,	O
including	O
pretreatment	O
nontoxic	O
cytoreduction	O
and	O
on-treatment	O
hydration	O
,	O
should	O
be	O
used	O
for	O
the	O
prevention	O
of	O
TLS	O
during	O
BLINCYTO	O
treatment	O
.	O
	
Immunogenicity	O
Antibodies	O
directed	O
against	O
the	O
belatacept	O
molecule	O
were	O
assessed	O
in	O
398	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
in	O
Studies	O
1	O
and	O
2	O
(	O
212	O
of	O
these	O
patients	O
were	O
treated	O
for	O
at	O
least	O
2	O
years	O
)	O
.	O
	
If	O
this	O
product	O
is	O
used	O
for	O
10	O
days	O
or	O
longer	O
,	O
IOP	O
should	O
be	O
monitored	O
.	O
	
Patients	O
with	O
an	O
established	O
diagnosis	O
of	O
diabetes	O
mellitus	O
who	O
are	O
started	O
on	O
atypical	O
antipsychotics	O
should	O
be	O
monitored	O
regularly	O
for	O
worsening	O
of	O
glucose	O
control	O
.	O
	
(	O
5.5	O
)	O
*	O
QT	B
prolongation	I
:	O
QT	O
interval	O
should	O
be	O
monitored	O
in	O
patients	O
taking	O
concomitant	O
medications	O
known	O
to	O
increase	O
the	O
QT	O
interval	O
or	O
with	O
certain	O
heart	O
conditions	O
.	O
	
Beta-agonist	O
medications	O
may	O
produce	O
transient	O
hyperglycemia	B
in	O
some	O
patients	O
.	O
	
Amyvid	O
caused	O
no	O
serious	O
adverse	O
reactions	O
in	O
the	O
studies	O
and	O
the	O
reported	O
adverse	O
reactions	O
were	O
predominantly	O
mild	O
to	O
moderate	O
in	O
severity	O
.	O
	
*	O
Myelosuppression	B
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
However	O
,	O
an	O
earlier	O
onset	O
can	O
not	O
be	O
ruled	O
out	O
,	O
and	O
it	O
is	O
possible	O
that	O
retinal	B
abnormalities	I
were	O
present	O
earlier	O
in	O
the	O
course	O
of	O
exposure	O
to	O
POTIGA	O
.	O
	
Fatalities	B
have	O
been	O
reported	O
in	O
association	O
with	O
excessive	O
use	O
of	O
inhaled	O
sympathomimetic	O
drugs	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
from	O
NORTHERA	O
were	O
hypertension	B
or	O
increased	B
blood	I
pressure	I
and	O
nausea	B
.	O
	
Given	O
these	O
considerations	O
,	O
FANAPT	O
should	O
be	O
prescribed	O
in	O
a	O
manner	O
that	O
is	O
most	O
likely	O
to	O
minimize	O
the	O
occurrence	O
of	O
tardive	O
dyskinesia	O
.	O
	
Do	O
not	O
restart	O
if	O
pancreatitis	O
is	O
confirmed	O
.	O
	
Percentage	O
(	O
%	O
)	O
of	O
Patientsa	O
YERVOY3	O
mg/kgn=131	O
YERVOY3	O
mg/kg+gp100n=380	O
gp100n=132	O
System	O
Organ	O
Class/Preferred	O
Term	O
AnyGrade	O
Grade3-5	O
AnyGrade	O
Grade3-5	O
AnyGrade	O
Grade3-5	O
Gastrointestinal	O
Disorders	O
Diarrhea	B
32	O
5	O
37	O
4	O
20	O
1	O
Colitis	B
8	O
5	O
5	O
3	O
2	O
0	O
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
Pruritus	B
31	O
0	O
21	O
<	O
1	O
11	O
0	O
Rash	B
29	O
2	O
25	O
2	O
8	O
0	O
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
Fatigue	B
41	O
7	O
34	O
5	O
31	O
3	O
Table	O
2	O
presents	O
the	O
per-patient	O
incidence	O
of	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
immune-mediated	B
adverse	I
reactions	I
from	O
Study	O
1	O
.	O
	
5.6	O
Effects	O
on	O
Ability	O
to	O
Drive	O
and	O
Use	O
Machines	O
Due	O
to	O
the	O
potential	O
for	O
neurologic	B
events	I
,	O
including	O
seizures	B
,	O
patients	O
receiving	O
BLINCYTO	O
are	O
at	O
risk	O
for	O
loss	B
of	I
consciousness	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Anti-belatacept	O
antibody	O
development	O
was	O
not	O
associated	O
with	O
altered	O
clearance	O
of	O
belatacept	O
.	O
	
There	O
were	O
7	O
(	O
0.5	O
%	O
)	O
deaths	B
due	O
to	O
cardiorespiratory	B
arrest	I
in	O
the	O
ZYTIGA	O
arms	O
and	O
3	O
(	O
0.3	O
%	O
)	O
deaths	B
in	O
the	O
placebo	O
arms	O
.	O
	
6.3	O
Immunogenicity	O
During	O
clinical	O
studies	O
in	O
Dupuytren	O
's	O
contracture	O
and	O
Peyronie	O
's	O
disease	O
,	O
patients	O
were	O
tested	O
at	O
multiple	O
time	O
points	O
for	O
antibodies	O
to	O
the	O
protein	O
components	O
of	O
XIAFLEX	O
(	O
AUX-I	O
and	O
AUX-II	O
)	O
.	O
	
a	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
persistent	O
hoarseness	O
)	O
.	O
	
*	O
Concomitant	O
colchicine	O
or	O
androgen-deprivation	O
therapeutic	O
drugs	O
(	O
such	O
as	O
luteinizing	O
hormone-releasing	O
analogs	O
and	O
anti-androgen	O
drugs	O
)	O
may	O
interfere	O
with	O
11	O
C-choline	O
PET	O
imaging	O
.	O
	
(	O
6.1	O
)	O
*	O
In	O
patients	O
with	O
chronic	O
hepatitis	O
C-associated	O
thrombocytopenia	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
:	O
anemia	B
,	O
pyrexia	B
,	O
fatigue	B
,	O
headache	B
,	O
nausea	B
,	O
diarrhea	B
,	O
decreased	B
appetite	I
,	O
influenza-like	B
illness	I
,	O
asthenia	B
,	O
insomnia	B
,	O
cough	B
,	O
pruritus	B
,	O
chills	B
,	O
myalgia	B
,	O
alopecia	B
,	O
and	O
peripheral	B
edema	I
.	O
	
5.5	O
Imaging	O
Errors	O
due	O
to	O
Conditions	O
that	O
Affect	O
the	O
Sympathetic	O
Nervous	O
System	O
Individuals	O
with	O
conditions	O
that	O
affect	O
the	O
sympathetic	O
nervous	O
system	O
,	O
e.g.	O
,	O
Parkinsonian	O
syndromes	O
such	O
as	O
Parkinson	O
's	O
disease	O
or	O
multiple	O
system	O
atrophy	O
,	O
may	O
show	O
decreased	O
cardiac	O
uptake	O
of	O
AdreView	O
independent	O
of	O
heart	O
disease	O
.	O
	
Withhold	O
then	O
dose	O
reduce	O
,	O
or	O
permanently	O
discontinue	O
ZYKADIA	O
.	O
	
Patients	O
may	O
require	O
a	O
lower	O
dose	O
of	O
sulfonylurea	O
or	O
insulin	O
to	O
reduce	O
the	O
risk	O
of	O
hypoglycemia	O
in	O
this	O
setting	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
*	O
Fatal	B
and/or	O
serious	O
and	O
severe	O
diarrhea	B
or	O
colitis	B
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
.	O
	
Table	O
4	O
:	O
Laboratory	O
Abnormalities	O
in	O
>	O
15	O
%	O
of	O
Patients	O
in	O
the	O
ZYTIGA	O
Arm	O
of	O
Study	O
2	O
Abiraterone	O
(	O
N=542	O
)	O
Placebo	O
(	O
N=540	O
)	O
Laboratory	O
Abnormality	O
Grade	O
1-4	O
%	O
Grade	O
3-4	O
%	O
Grade	O
1-4	O
%	O
Grade	O
3-4	O
%	O
Hematology	O
Lymphopenia	B
38.2	O
8.7	O
31.7	O
7.4	O
Chemistry	O
Hyperglycemia	B
56.6	O
6.5	O
50.9	O
5.2	O
High	B
ALT	I
41.9	O
6.1	O
29.1	O
0.7	O
High	B
AST	I
37.3	O
3.1	O
28.7	O
1.1	O
Hypernatremia	B
32.8	O
0.4	O
25.0	O
0.2	O
Hypokalemia	B
17.2	O
2.8	O
10.2	O
1.7	O
Cardiovascular	O
Adverse	O
Reactions	O
:	O
In	O
the	O
combined	O
data	O
for	O
studies	O
1	O
and	O
2	O
,	O
cardiac	B
failure	I
occurred	O
more	O
commonly	O
in	O
patients	O
treated	O
with	O
ZYTIGA	O
compared	O
to	O
patients	O
on	O
the	O
placebo	O
arm	O
(	O
2.1	O
%	O
versus	O
0.7	O
%	O
)	O
.	O
	
The	O
majority	O
of	O
Peyronie	O
's	O
patients	O
experienced	O
at	O
least	O
one	O
adverse	O
reaction	O
(	O
92	O
%	O
XIAFLEX-treated	O
patients	O
,	O
61	O
%	O
placebo-treated	O
)	O
.	O
	
Use	O
of	O
COCs	O
also	O
increases	O
the	O
risk	O
of	O
arterial	B
thromboses	I
such	O
as	O
strokes	B
and	O
myocardial	B
infarctions	I
,	O
especially	O
in	O
women	O
with	O
other	O
risk	O
factors	O
for	O
these	O
events	O
.	O
	
In	O
the	O
event	O
of	O
new	O
or	O
worsening	O
pulmonary	O
symptoms	O
,	O
hold	O
ADCETRIS	O
dosing	O
during	O
evaluation	O
and	O
until	O
symptomatic	O
improvement	O
.	O
	
Psychiatric	O
disorders	O
:	O
bruxism	B
,	O
depression	B
,	O
obsessive-compulsive	B
disorder	I
.	O
	
Since	O
the	O
protein	O
components	O
in	O
XIAFLEX	O
(	O
AUX-I	O
and	O
AUX-II	O
)	O
have	O
some	O
sequence	O
homology	O
with	O
human	O
matrix	O
metalloproteinases	O
(	O
MMPs	O
)	O
,	O
anti-product	O
antibodies	O
could	O
theoretically	O
interfere	O
with	O
human	O
MMPs	O
.	O
	
The	O
possibility	O
of	O
more	O
extensive	O
systemic	O
involvement	O
has	O
not	O
been	O
excluded	O
.	O
	
3-Month	O
and	O
6-Month	O
Trials	O
TUDORZA	O
PRESSAIR	O
was	O
studied	O
in	O
two	O
3-month	O
(	O
Trials	O
B	O
and	O
C	O
)	O
and	O
one	O
6-month	O
(	O
Trial	O
D	O
)	O
placebo-controlled	O
trials	O
in	O
patients	O
with	O
COPD	O
.	O
	
5.6	O
Immunosuppression	O
Persons	O
who	O
are	O
using	O
drugs	O
that	O
suppress	O
the	O
immune	O
system	O
are	O
more	O
susceptible	O
to	O
infections	B
than	O
healthy	O
individuals	O
.	O
	
Approximately	O
two-thirds	O
of	O
patients	O
with	O
psychosis	B
in	O
controlled	O
trials	O
had	O
no	O
prior	O
psychiatric	O
history	O
.	O
	
The	O
most	O
common	O
reasons	O
for	O
interruption	O
or	O
discontinuations	O
were	O
diarrhea	B
(	O
11	O
%	O
)	O
,	O
pneumonia	B
(	O
11	O
%	O
)	O
,	O
and	O
elevated	B
transaminases	I
(	O
10	O
%	O
)	O
.	O
	
First	O
onset	O
of	O
symptoms	O
occurred	O
at	O
various	O
times	O
from	O
initiation	O
of	O
ADCETRIS	O
therapy	O
,	O
with	O
some	O
cases	O
occurring	O
within	O
3	O
months	O
of	O
initial	O
exposure	O
.	O
	
Neutropenia	B
may	O
precede	O
the	O
development	O
of	O
agranulocytosis	B
.	O
	
(	O
2.2	O
,	O
5.4	O
)	O
*	O
Hyperglycemia	B
:	O
ZYKADIA	O
can	O
cause	O
hyperglycemia	B
.	O
	
(	O
5.1	O
)	O
*	O
Liver	B
disease	I
:	O
Discontinue	O
Natazia	O
if	O
jaundice	O
occurs	O
.	O
	
Among	O
patients	O
in	O
whom	O
the	O
status	O
of	O
both	O
mucous	B
membrane	I
discoloration	I
and	O
retinal	B
pigmentary	I
abnormalities	I
are	O
reported	O
,	O
approximately	O
a	O
quarter	O
of	O
those	O
with	O
mucous	B
membrane	I
discoloration	I
had	O
concurrent	O
retinal	B
pigmentary	I
abnormalities	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Patients	O
who	O
have	O
been	O
previously	O
maintained	O
on	O
20	O
mg	O
or	O
more	O
of	O
prednisone	O
(	O
or	O
its	O
equivalent	O
)	O
may	O
be	O
most	O
susceptible	O
,	O
particularly	O
when	O
their	O
systemic	O
corticosteroids	O
have	O
been	O
almost	O
completely	O
withdrawn	O
.	O
	
If	O
SJS	O
or	O
TEN	O
occurs	O
,	O
discontinue	O
ADCETRIS	O
and	O
administer	O
appropriate	O
medical	O
therapy	O
.	O
	
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
:	O
myositis	B
,	O
chondropathy	B
,	O
trismus	B
.	O
	
Serious	O
Adverse	O
Reactions	O
and	O
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
In	O
the	O
four	O
pooled	O
Phase	O
3	O
clinical	O
trials	O
,	O
serious	O
adverse	O
reactions	O
(	O
SARs	O
)	O
occurred	O
in	O
98/1300	O
(	O
7.5	O
%	O
)	O
of	O
patients	O
receiving	O
Teflaro	O
and	O
100/1297	O
(	O
7.7	O
%	O
)	O
of	O
patients	O
receiving	O
comparator	O
drugs	O
.	O
	
Monitor	O
lipase	O
and	O
amylase	O
prior	O
to	O
treatment	O
and	O
periodically	O
thereafter	O
as	O
clinically	O
indicated	O
.	O
	
Stop	O
Natazia	O
at	O
least	O
4	O
weeks	O
before	O
and	O
through	O
2	O
weeks	O
after	O
major	O
surgery	O
.	O
	
Initiate	O
or	O
optimize	O
anti-hyperglycemic	O
medications	O
as	O
indicated	O
.	O
	
Consider	O
the	O
diagnosis	O
of	O
PML	O
in	O
any	O
patient	O
presenting	O
with	O
new-onset	O
signs	O
and	O
symptoms	O
of	O
central	O
nervous	O
system	O
abnormalities	O
.	O
	
Vascular	O
disorders	O
:	O
hypotension	B
,	O
hypertension	B
.	O
	
Liver	O
Function	O
Test	O
Abnormalities	O
:	O
Among	O
patients	O
with	O
Grade	O
0	O
or	O
1	O
ALT	O
levels	O
at	O
baseline	O
,	O
18	O
%	O
of	O
HALAVEN-treated	O
patients	O
experienced	O
Grade	O
2	O
or	O
greater	O
ALT	B
elevation	I
.	O
	
These	O
effects	O
were	O
dose-related	O
and	O
generally	O
appeared	O
within	O
the	O
first	O
8	O
weeks	O
of	O
treatment	O
.	O
	
RE-COVER	O
and	O
RE-COVER	O
II	O
studies	O
compared	O
PRADAXA	O
150	O
mg	O
twice	O
daily	O
and	O
warfarin	O
for	O
the	O
treatment	O
of	O
deep	O
vein	O
thrombosis	O
and	O
pulmonary	O
embolism	O
.	O
	
There	O
was	O
no	O
fatal	B
pneumonia	B
in	O
subjects	O
receiving	O
vilanterol	O
or	O
fluticasone	O
furoate/vilanterol	O
50	O
mcg/25	O
mcg	O
.	O
	
The	O
population	O
had	O
a	O
mean	O
age	O
of	O
64	O
years	O
(	O
ranging	O
from	O
40	O
to	O
89	O
years	O
)	O
,	O
with	O
58	O
%	O
males	O
,	O
94	O
%	O
Caucasian	O
,	O
and	O
had	O
COPD	O
with	O
a	O
mean	O
pre-bronchodilator	O
forced	O
expiratory	O
volume	O
in	O
one	O
second	O
(	O
FEV1	O
)	O
percent	O
predicted	O
of	O
48	O
%	O
.	O
	
Clinical	O
status	O
including	O
liver	O
transaminases	O
should	O
be	O
monitored	O
and	O
appropriate	O
therapy	O
initiated	O
.	O
	
Because	O
of	O
the	O
possibility	O
of	O
significant	O
systemic	O
absorption	O
of	O
inhaled	O
corticosteroids	O
in	O
sensitive	O
patients	O
,	O
patients	O
treated	O
with	O
BREO	O
ELLIPTA	O
should	O
be	O
observed	O
carefully	O
for	O
any	O
evidence	O
of	O
systemic	O
corticosteroid	O
effects	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactionsare	O
discussed	O
elsewhere	O
in	O
the	O
labeling	O
:	O
*	O
Nephrogenic	B
systemic	I
fibrosis	I
(	O
NSF	B
)	O
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Hypersensitivity	B
reactions	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
0.5	O
%	O
)	O
are	O
nausea	B
,	O
headache	B
,	O
feeling	B
hot	I
,	O
dizziness	B
,	O
and	O
back	B
pain	I
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bayer	O
HealthCare	O
Pharmaceuticals	O
Inc.	O
at	O
1-888-84-BAYER	O
(	O
1-888-842-2937	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
*	O
Blood	O
PSA	O
levels	O
<	O
2	O
ng/mL	O
have	O
been	O
associated	O
with	O
poor	O
performance	O
of	O
11	O
C-choline	O
PET	O
imaging	O
(	O
higher	O
numbers	O
of	O
false	O
positive	O
and	O
false	O
negative	O
results	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
After	O
the	O
fourth	O
injection	O
of	O
XIAFLEX	O
,	O
every	O
XIAFLEX-treated	O
patient	O
developed	O
high	O
titers	O
of	O
antibodies	O
to	O
both	O
AUX-I	O
and	O
AUX-II	O
.	O
	
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
:	O
chills	B
,	O
pyrexia	B
,	O
edema	B
peripheral	I
,	O
multi-organ	B
failure	I
.	O
	
In	O
Study	O
1	O
and	O
2	O
,	O
the	O
majority	O
of	O
arrhythmias	B
were	O
grade	O
1	O
or	O
2	O
.	O
	
The	O
median	O
duration	O
of	O
exposure	O
was	O
118	O
days	O
for	O
patients	O
receiving	O
HALAVEN	O
and	O
63	O
days	O
for	O
patients	O
receiving	O
control	O
therapy	O
.	O
	
Interrupt	O
and	O
then	O
reduce	O
or	O
discontinue	O
Zydelig	O
as	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	O
Trials	O
(	O
N=555	O
patients	O
)	O
a	O
Includes	O
the	O
terms	O
blood	B
pressure	I
increased	I
and	O
hypertension	B
.	O
	
5.17	O
Effect	O
on	O
Growth	O
Orally	O
inhaled	O
corticosteroids	O
may	O
cause	O
a	O
reduction	B
in	I
growth	I
velocity	I
when	O
administered	O
to	O
children	O
and	O
adolescents	O
.	O
	
(	O
5.7	O
)	O
5.1	O
Retinal	O
Abnormalities	O
and	O
Potential	O
Vision	O
Loss	O
POTIGA	O
can	O
cause	O
abnormalities	B
of	I
the	I
retina	I
.	O
	
Any	O
patient	O
treated	O
with	O
atypical	O
antipsychotics	O
should	O
be	O
monitored	O
for	O
symptoms	O
of	O
hyperglycemia	O
including	O
polydipsia	O
,	O
polyuria	O
,	O
polyphagia	O
,	O
and	O
weakness	O
.	O
	
1.7	O
2.9	O
3.8	O
Male	O
genital	O
mycotic	O
infectionsGenital	O
mycotic	B
infections	I
include	I
the	I
following	I
adverse	I
reactions	I
,	I
listed	I
in	I
order	I
of	I
frequency	I
reported	I
for	I
males	I
:	O
balanitis	B
,	O
fungal	B
genital	I
infection	I
,	O
balanitis	B
candida	I
,	O
genital	B
candidiasis	I
,	O
genital	B
infection	I
male	I
,	O
penile	B
infection	I
,	O
balanoposthitis	B
,	O
balanoposthitis	B
infective	I
,	O
genital	B
infection	I
,	O
posthitis	B
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
infection	O
and	O
treat	O
appropriately	O
.	O
	
Monitor	O
laboratory	O
parameters	O
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
white	O
blood	O
cell	O
count	O
and	O
absolute	O
neutrophil	O
count	O
)	O
during	O
BLINCYTO	O
infusion	O
.	O
	
Three	O
of	O
these	O
6	O
patients	O
tested	O
positive	O
for	O
neutralizing	O
antibodies	O
.	O
	
Table	O
1	O
presents	O
selected	O
adverse	O
reactions	O
from	O
Study	O
1	O
,	O
which	O
occurred	O
in	O
at	O
least	O
5	O
%	O
of	O
patients	O
in	O
the	O
YERVOY-containing	O
arms	O
and	O
with	O
at	O
least	O
5	O
%	O
increased	O
incidence	O
over	O
the	O
control	O
gp100	O
arm	O
for	O
all-grade	O
events	O
and	O
at	O
least	O
1	O
%	O
incidence	O
over	O
the	O
control	O
group	O
for	O
Grade	O
3-5	O
events	O
.	O
	
Case	O
reports	O
and	O
epidemiological	O
studies	O
(	O
case-control	O
and	O
cohort	O
design	O
)	O
have	O
demonstrated	O
an	O
association	O
between	O
use	O
of	O
drugs	O
that	O
interfere	O
with	O
serotonin	O
reuptake	O
and	O
the	O
occurrence	O
of	O
gastrointestinal	B
bleeding	I
.	O
	
The	O
mean	O
age	O
of	O
participants	O
was	O
55	O
years	O
,	O
1	O
%	O
of	O
participants	O
were	O
75	O
years	O
or	O
older	O
and	O
53	O
%	O
of	O
participants	O
were	O
male	O
.	O
	
(	O
5.1	O
)	O
	
In	O
patients	O
who	O
do	O
require	O
chronic	O
treatment	O
,	O
the	O
smallest	O
dose	O
and	O
the	O
shortest	O
duration	O
of	O
treatment	O
producing	O
a	O
satisfactory	O
clinical	O
response	O
should	O
be	O
sought	O
.	O
	
In	O
the	O
placebo-controlled	O
studies	O
,	O
a	O
total	O
of	O
485	O
patients	O
with	O
Parkinson	O
's	O
disease	O
,	O
multiple	O
system	O
atrophy	O
,	O
pure	O
autonomic	O
failure	O
,	O
dopamine	O
beta-hydroxylase	O
deficiency	O
,	O
or	O
non-diabetic	O
autonomic	O
neuropathy	O
were	O
randomized	O
and	O
treated	O
,	O
245	O
with	O
NORTHERA	O
and	O
240	O
with	O
placebo	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Approximately	O
15	O
%	O
of	O
patients	O
with	O
retinal	B
pigmentary	I
abnormalities	I
had	O
no	O
such	O
discoloration	B
.	O
	
Immune	O
system	O
disorders	O
:	O
Alopecia	B
totalis	I
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
any	O
neurological	O
toxicity	O
was	O
7	O
days	O
.	O
	
In	O
a	O
historically	O
controlled	O
post-marketing	O
trial	O
,	O
the	O
incidence	O
of	O
skin	B
laceration	I
(	O
22	O
%	O
)	O
was	O
higher	O
for	O
subjects	O
treated	O
with	O
two	O
concurrent	O
injections	O
of	O
XIAFLEX	O
compared	O
with	O
subjects	O
treated	O
with	O
up	O
to	O
three	O
single	O
injections	O
in	O
the	O
placebo-controlled	O
premarketing	O
trials	O
(	O
9	O
%	O
)	O
.	O
	
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Thrombotic	B
Events	I
:	O
Discontinue	O
COMETRIQ	O
for	O
myocardial	O
infarction	O
,	O
cerebral	O
infarction	O
,	O
or	O
other	O
serious	O
arterial	O
thromboembolic	O
events	O
.	O
	
Persistence	B
of	I
sinus	I
tachycardia	I
(	O
reported	O
at	O
more	O
than	O
2	O
visits	O
)	O
was	O
reported	O
in	O
0.2	O
%	O
,	O
0.4	O
%	O
and	O
1.6	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
.	O
	
Signs	O
and	O
symptoms	O
of	O
hyponatremia	B
include	O
headache	B
,	O
difficulty	B
concentrating	I
,	O
memory	B
impairment	I
,	O
confusion	B
,	O
weakness	B
,	O
and	O
unsteadiness	B
,	O
which	O
can	O
lead	O
to	O
falls	B
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
PERFORATIONS	B
AND	O
FISTULAS	B
,	O
andHEMORRHAGE	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
It	O
is	O
unknown	O
whether	O
TRULICITY	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
as	O
human	O
relevance	O
of	O
dulaglutide-induced	O
rodent	O
thyroid	B
C-cell	I
tumors	I
has	O
not	O
been	O
determined	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
Exposure	O
to	O
YERVOY	O
3	O
mg/kg	O
for	O
4	O
doses	O
given	O
by	O
intravenous	O
infusion	O
in	O
previously	O
treated	O
patients	O
with	O
unresectable	O
or	O
metastatic	O
melanoma	O
was	O
assessed	O
in	O
a	O
randomized	O
,	O
double-blind	O
clinical	O
study	O
(	O
Study	O
1	O
)	O
.	O
	
A	O
total	O
of	O
111	O
patients	O
were	O
treated	O
with	O
pemetrexed/cisplatin	O
.	O
	
5.6	O
Severe	O
Gastrointestinal	O
Disease	O
Use	O
of	O
TRULICITY	O
may	O
be	O
associated	O
with	O
gastrointestinal	B
adverse	I
reactions	I
,	O
sometimes	O
severe	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
5.6	O
)	O
*	O
Extravasation	B
:	O
Assure	O
good	O
venous	O
access	O
and	O
monitor	O
infusion	O
site	O
during	O
and	O
after	O
administration	O
.	O
	
Table	O
6	O
:	O
Weight	O
Change	O
Results	O
Categorized	O
by	O
BMI	O
at	O
Baseline	O
:	O
Comparator-Controlled	O
52-Week	O
Study	O
in	O
Adults	O
with	O
Schizophrenia	O
BMI	O
<	O
23	O
SAPHRIS	O
N=295	O
BMI	O
23	O
-	O
<	O
=27	O
SAPHRIS	O
N=290	O
BMI	O
>	O
27	O
SAPHRIS	O
N=302	O
Mean	O
change	O
from	O
Baseline	O
(	O
kg	O
)	O
1.7	O
1	O
0	O
%	O
with	O
>	O
=7	O
%	O
increase	B
in	I
body	I
weight	I
22	O
%	O
13	O
%	O
9	O
%	O
Pediatric	O
Patients	O
:	O
Data	O
on	O
mean	O
changes	B
in	I
body	I
weight	I
and	O
the	O
proportion	O
of	O
pediatric	O
patients	O
meeting	O
a	O
weight	B
gain	I
criterion	O
of	O
>	O
=7	O
%	O
of	O
body	O
weight	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
trial	O
are	O
presented	O
in	O
Table	O
7	O
.	O
	
5.5	O
Genital	O
Mycotic	O
Infections	O
INVOKANA	O
increases	O
the	O
risk	O
of	O
genital	B
mycotic	I
infections	I
.	O
	
Table	O
1	O
Investigator	O
Assessment	O
of	O
Maximal	O
Local	B
Skin	I
Reactions	I
in	O
the	O
Treatment	O
Area	O
during	O
the	O
57	O
Days	O
Post	O
Treatment	O
Period	O
(	O
face/scalp	O
trials	O
)	O
Face	O
and	O
Scalp	O
(	O
n=545	O
)	O
Picato	O
(	O
r	O
)	O
gel	O
,	O
0.015	O
%	O
once	O
daily	O
for	O
3	O
days	O
Skin	B
reactions	I
Any	I
Gradea	I
>	I
Baseline	I
Grade	I
4	I
87	O
(	O
32	O
%	O
)	O
3	O
(	O
1	O
%	O
)	O
1	O
(	O
0	O
%	O
)	O
0	O
(	O
0	O
%	O
)	O
a	O
Mild	O
(	O
grade	O
1	O
)	O
,	O
Moderate	O
(	O
grade	O
2-3	O
)	O
or	O
Severe	O
(	O
grade	O
4	O
)	O
.	O
	
All	O
patients	O
treated	O
with	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
in	O
the	O
placebo-controlled	O
trial	O
developed	O
anti-drug	O
antibodies	O
by	O
Week	O
4	O
.	O
	
Hypersensitivity	O
Reactions	O
In	O
a	O
pooled	O
analysis	O
,	O
the	O
overall	O
incidence	O
of	O
hypersensitivity	B
reactions	I
was	O
0.6	O
%	O
with	O
NESINA	O
25	O
mg	O
compared	O
to	O
0.8	O
%	O
with	O
all	O
comparators	O
.	O
	
*	O
Infections	B
:	O
Monitor	O
patients	O
for	O
fever	O
and	O
infections	O
and	O
evaluate	O
promptly	O
(	O
5.2	O
)	O
.	O
	
Dose	O
modifications	O
or	O
temporary	O
delay	O
of	O
treatment	O
due	O
to	O
an	O
adverse	O
reaction	O
occurred	O
in	O
199/359	O
patients	O
(	O
55	O
%	O
)	O
receiving	O
INLYTA	O
and	O
220/355	O
patients	O
(	O
62	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
(	O
5.2	O
)	O
*	O
Anaphylaxis	B
and	O
Infusion	B
Reactions	I
:	O
Severe	O
and	O
anaphylactic	B
reactions	I
have	O
occurred	O
;	O
monitor	O
clinically	O
and	O
discontinue	O
TREANDA	O
.	O
	
In	O
the	O
MS	O
placebo	O
controlled	O
trials	O
,	O
mean	O
lymphocyte	B
counts	I
decreased	I
by	O
approximately	O
30	O
%	O
during	O
the	O
first	O
year	O
of	O
treatment	O
with	O
TECFIDERA	O
and	O
then	O
remained	O
stable	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
in	O
Study	O
1	O
and	O
2	O
reported	O
for	O
TECFIDERA	O
240	O
mg	O
BID	O
at	O
>	O
=	O
2	O
%	O
higher	O
incidence	O
than	O
placebo	O
TECFIDERA	O
N=769	O
%	O
Placebo	O
N=771	O
%	O
Flushing	B
40	O
6	O
Abdominal	B
pain	I
18	O
10	O
Diarrhea	B
14	O
11	O
Nausea	B
12	O
9	O
Vomiting	B
9	O
5	O
Pruritus	B
8	O
4	O
Rash	B
8	O
3	O
Albumin	B
urine	I
present	I
6	O
4	O
Erythema	B
5	O
1	O
Dyspepsia	B
5	O
3	O
Aspartate	B
aminotransferase	I
increased	I
4	O
2	O
Lymphopenia	B
2	O
<	O
1	O
Gastrointestinal	O
TECFIDERA	O
caused	O
GI	B
events	I
(	O
e.g.	O
,	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
abdominal	B
pain	I
,	O
and	O
dyspepsia	B
)	O
.	O
	
Closely	O
observe	O
patients	O
during	O
and	O
after	O
Vimizim	O
administration	O
and	O
be	O
prepared	O
to	O
manage	O
anaphylaxis	O
.	O
	
Adverse	O
reactions	O
from	O
the	O
MCL	O
trial	O
(	O
N=111	O
)	O
using	O
single	O
agent	O
IMBRUVICA	O
560	O
mg	O
daily	O
occurring	O
at	O
a	O
rate	O
of	O
>	O
=	O
10	O
%	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
Therefore	O
,	O
the	O
possibility	O
of	O
an	O
association	O
between	O
neutralizing	O
antibody	O
titer	O
and	O
treatment	O
effect	O
can	O
not	O
be	O
assessed	O
.	O
	
The	O
median	O
daily	O
dose	O
of	O
TAFINLAR	O
was	O
300	O
mg	O
(	O
range	O
:	O
118	O
to	O
300	O
mg	O
)	O
.	O
	
JEVTANA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
In	O
individual	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
episodes	O
of	O
hypoglycemia	B
occurred	O
at	O
a	O
higher	O
rate	O
when	O
INVOKANA	O
was	O
co-administered	O
with	O
insulin	O
or	O
sulfonylureas	O
(	O
Table	O
4	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
5.5	O
Metabolic	O
Changes	O
Atypical	O
antipsychotic	O
drugs	O
have	O
been	O
associated	O
with	O
metabolic	B
changes	I
that	O
may	O
increase	B
cardiovascular/cerebrovascular	I
risk	I
.	O
	
The	O
association	O
with	O
TREANDA	O
therapy	O
has	O
not	O
been	O
determined	O
.	O
	
(	O
5.2	O
)	O
*	O
Hepatotoxicity	B
may	O
occur	O
with	O
use	O
of	O
SIRTURO	O
.	O
	
Table	O
3	O
identifies	O
adverse	O
reactions	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
for	O
all	O
grades	O
and	O
grades	O
3	O
or	O
4	O
for	O
the	O
Phase	O
1/2	O
CML	O
safety	O
population	O
.	O
	
Pain	B
increases	I
occurring	O
during	O
patch	O
application	O
usually	O
began	O
to	O
resolve	O
after	O
patch	O
removal	O
.	O
	
*	O
A	O
28-week	O
,	O
placebo-controlled	O
US	O
study	O
comparing	O
the	O
safety	O
of	O
another	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonist	O
(	O
salmeterol	O
)	O
with	O
placebo	O
,	O
each	O
added	O
to	O
usual	O
asthma	O
therapy	O
,	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
patients	O
receiving	O
salmeterol	O
(	O
13/13,176	O
in	O
patients	O
treated	O
with	O
salmeterol	O
vs.	O
3/13,179	O
in	O
patients	O
treated	O
with	O
placebo	O
;	O
RR	O
4.37	O
,	O
95	O
%	O
CI	O
1.25	O
,	O
15.34	O
)	O
.	O
	
A	O
total	O
of	O
62	O
%	O
of	O
patients	O
were	O
female	O
and	O
46	O
%	O
were	O
Asian	O
.	O
	
Cases	O
of	O
Stevens-Johnson	B
syndrome	I
(	O
SJS	B
)	O
and	O
TEN	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
when	O
TREANDA	O
was	O
administered	O
concomitantly	O
with	O
allopurinol	O
and	O
other	O
medications	O
known	O
to	O
cause	O
these	O
syndromes	O
.	O
	
In	O
a	O
pooled	O
population	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
(	O
N=1085	O
)	O
with	O
baseline	O
eGFR	O
of	O
30	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
(	O
mean	O
baseline	O
eGFR	O
48	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
the	O
overall	O
incidence	O
of	O
these	O
events	O
was	O
lower	O
than	O
in	O
the	O
dedicated	O
trial	O
but	O
a	O
dose-dependent	O
increase	O
in	O
incident	O
episodes	O
of	O
significant	O
renal	B
function	I
decline	I
compared	O
to	O
placebo	O
was	O
still	O
observed	O
.	O
	
5.4	O
Tardive	O
Dyskinesia	O
A	O
syndrome	O
of	O
potentially	O
irreversible	O
,	O
involuntary	B
,	I
dyskinetic	I
movements	I
can	O
develop	O
in	O
patients	O
treated	O
with	O
antipsychotic	O
drugs	O
.	O
	
Increases	O
in	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
(	O
LDL-C	O
)	O
and	O
non-High-Density	O
Lipoprotein	O
Cholesterol	O
(	O
non-HDL-C	O
)	O
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
trials	O
,	O
dose-related	O
increases	B
in	I
LDL-C	I
with	O
INVOKANA	O
were	O
observed	O
.	O
	
Of	O
these	O
patients	O
,	O
352	O
pediatric	O
patients	O
were	O
treated	O
with	O
SAPHRIS	O
for	O
at	O
least	O
180	O
days	O
and	O
58	O
pediatric	O
patients	O
treated	O
with	O
SAPHRIS	O
had	O
at	O
least	O
1	O
year	O
of	O
exposure	O
.	O
	
Osteonecrosis	B
of	I
the	I
Jaw	I
ONJ	B
has	O
been	O
reported	O
in	O
the	O
osteoporosis	O
clinical	O
trial	O
program	O
in	O
patients	O
treated	O
with	O
Prolia	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Upper	O
Limb	O
Spasticity	O
From	O
230	O
subjects	O
treated	O
with	O
DYSPORT	O
(	O
r	O
)	O
and	O
tested	O
for	O
the	O
presence	O
of	O
binding	O
antibodies	O
,	O
5	O
subjects	O
were	O
positive	O
at	O
baseline	O
and	O
17	O
developed	O
antibodies	O
after	O
treatment	O
.	O
	
These	O
patients	O
may	O
be	O
at	O
greater	O
risk	O
for	O
cardiac	O
complications	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8	O
)	O
]	O
.	O
	
DUAVEE	O
is	O
a	O
prescription	O
medicine	O
that	O
contains	O
a	O
mixture	O
of	O
estrogens	O
and	O
bazedoxifene	O
.	O
	
*	O
Use	O
with	O
caution	O
in	O
patients	O
with	O
compromised	O
respiratory	O
function	O
or	O
dysphagia	O
(	O
5.4	O
)	O
.	O
	
All	O
other	O
chemotherapy	O
was	O
continued	O
according	O
to	O
the	O
patient	O
's	O
prescribed	O
treatment	O
regimen	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.Study	O
2	O
enrolled	O
30	O
patients	O
[	O
29	O
were	O
being	O
treated	O
for	O
ALL	O
and	O
one	O
for	O
lymphoblastic	O
lymphoma	O
(	O
LBL	O
)	O
]	O
following	O
allergy	O
to	O
native	O
E.	O
coli	O
asparaginase	O
or	O
pegaspargase	O
.	O
	
In	O
these	O
pooled	O
trials	O
,	O
the	O
median	O
exposure	O
for	O
subjects	O
in	O
the	O
INTELENCE	O
(	O
r	O
)	O
arm	O
and	O
placebo	O
arm	O
was	O
52.3	O
and	O
51.0	O
weeks	O
,	O
respectively	O
.	O
	
Reduce	O
or	O
withhold	O
dose	O
as	O
appropriate	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
In	O
clinical	O
trials	O
(	O
Studies	O
1	O
,	O
2	O
,	O
and	O
3	O
)	O
,	O
a	O
total	O
of	O
1212	O
patients	O
with	O
relapsing	O
forms	O
of	O
multiple	O
sclerosis	O
received	O
GILENYA	O
0.5	O
mg	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merck	O
Sharp	O
&	O
Dohme	O
Corp.	O
,	O
a	O
subsidiary	O
of	O
Merck	O
&	O
Co.	O
,	O
Inc.	O
,	O
at	O
1-877-888-4231	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
risk	O
of	O
developing	O
tardive	O
dyskinesia	O
and	O
the	O
likelihood	O
that	O
it	O
will	O
become	O
irreversible	O
are	O
believed	O
to	O
increase	O
as	O
the	O
duration	O
of	O
treatment	O
and	O
the	O
total	O
cumulative	O
dose	O
of	O
antipsychotic	O
administered	O
increases	O
.	O
	
One	O
of	O
these	O
events	O
was	O
fatal	B
.	O
	
Discontinue	O
ERWINAZE	O
for	O
severe	O
or	O
hemorrhagic	O
pancreatitis	O
manifested	O
by	O
abdominal	O
pain	O
>	O
72	O
hours	O
and	O
amylase	O
elevation	O
>	O
=	O
2.0	O
x	O
ULN	O
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
and	O
adults	O
,	O
and	O
in	O
approved	O
indications	O
,	O
symptoms	O
consistent	O
with	O
spread	B
of	I
toxin	I
effect	I
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
or	O
lower	O
than	O
doses	O
used	O
to	O
treat	O
cervical	O
dystonia	O
.	O
	
Varicella	O
Zoster	O
Virus	O
Antibody	O
Testing/Vaccination	O
Patients	O
without	O
a	O
healthcare	O
professional	O
confirmed	O
history	O
of	O
chickenpox	O
or	O
without	O
documentation	O
of	O
a	O
full	O
course	O
of	O
vaccination	O
against	O
varicella	O
zoster	O
virus	O
(	O
VZV	O
)	O
should	O
be	O
tested	O
for	O
antibodies	O
to	O
VZV	O
before	O
initiating	O
GILENYA	O
.	O
	
Approximately	O
half	O
the	O
cases	O
were	O
lymphomas	B
,	O
including	O
non-Hodgkin	B
's	I
lymphoma	I
.	O
	
When	O
distant	O
effects	O
occur	O
,	O
additional	O
respiratory	O
muscles	O
may	O
be	O
involved	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
5.3	O
Neuroleptic	O
Malignant	O
Syndrome	O
(	O
NMS	O
)	O
A	O
potentially	O
fatal	O
symptom	O
complex	O
sometimes	O
referred	O
to	O
as	O
Neuroleptic	B
Malignant	I
Syndrome	I
(	O
NMS	B
)	O
has	O
been	O
reported	O
in	O
association	O
with	O
administration	O
of	O
antipsychotic	O
drugs	O
,	O
including	O
FANAPT	O
.	O
	
Across	O
controlled	O
and	O
uncontrolled	O
trials	O
in	O
patients	O
receiving	O
adjunctive	O
therapy	O
for	O
partial-onset	O
seizures	O
,	O
1195	O
patients	O
received	O
APTIOM	O
,	O
of	O
whom	O
586	O
were	O
treated	O
for	O
longer	O
than	O
6	O
months	O
and	O
462	O
for	O
longer	O
than	O
12	O
months	O
.	O
	
Some	O
patients	O
who	O
were	O
pre-treated	O
with	O
antihistamines	O
,	O
antipyretics	O
and/or	O
corticosteroids	O
still	O
experienced	O
hypersensitivity	B
reactions	I
.	O
	
5.2	O
QT	O
Prolongation	O
In	O
an	O
open-label	O
QTc	O
study	O
in	O
patients	O
with	O
schizophrenia	O
or	O
schizoaffective	O
disorder	O
(	O
n=160	O
)	O
,	O
FANAPT	O
was	O
associated	O
with	O
QTc	B
prolongation	I
of	O
9	O
msec	O
at	O
an	O
iloperidone	O
dose	O
of	O
12	O
mg	O
twice	O
daily	O
.	O
	
Patients	O
with	O
neuromuscular	O
disorders	O
may	O
be	O
at	O
increased	O
risk	O
of	O
clinically	O
significant	O
effects	O
including	O
severe	O
dysphagia	B
and	O
respiratory	B
compromise	I
from	O
typical	O
doses	O
of	O
DYSPORT	O
(	O
r	O
)	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Withhold	O
GILOTRIF	O
during	O
evaluation	O
of	O
patients	O
with	O
suspected	O
ILD	O
,	O
and	O
discontinue	O
GILOTRIF	O
in	O
patients	O
with	O
confirmed	O
ILD	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
commonly	O
reported	O
adverse	O
events	O
were	O
falls	B
(	O
24	O
%	O
)	O
,	O
urinary	B
tract	I
infections	I
(	O
15	O
%	O
)	O
,	O
headache	B
(	O
13	O
%	O
)	O
,	O
syncope	B
(	O
13	O
%	O
)	O
,	O
and	O
dizziness	B
(	O
10	O
%	O
)	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
belimumab	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
cimetidine	O
)	O
was	O
not	O
examined	O
by	O
clinical	O
study	O
,	O
some	O
pharmacokinetic	O
interaction	O
is	O
expected	O
,	O
albeit	O
less	O
than	O
that	O
observed	O
with	O
moderate	O
CYP3A4	O
inhibitors	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
and	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
The	O
median	O
duration	O
of	O
blinded	O
study	O
treatment	O
was	O
141	O
days	O
(	O
range	O
19-451	O
days	O
)	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
60	O
days	O
(	O
range	O
21-295	O
days	O
)	O
for	O
those	O
receiving	O
placebo	O
.	O
	
5.14	O
Embryo-fetal	O
Toxicity	O
Kyprolis	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
based	O
on	O
its	O
mechanism	O
of	O
action	O
and	O
findings	O
in	O
animals	O
.	O
	
Eleven	O
out	O
of	O
163	O
(	O
7	O
%	O
)	O
patients	O
treated	O
with	O
600	O
mg	O
of	O
HORIZANT	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
compared	O
with	O
10	O
of	O
the	O
245	O
(	O
4	O
%	O
)	O
patients	O
who	O
received	O
placebo	O
.	O
	
6.2	O
Immunogenicity	O
Across	O
repeated	O
treatment	O
in	O
the	O
controlled	O
trials	O
,	O
4	O
patients	O
tested	O
positive	O
for	O
anti-icatibant	O
antibodies	O
.	O
	
In	O
addition	O
,	O
the	O
incidence	O
of	O
Grade	O
1-3	O
palmar-plantar	B
erythrodysesthesia	I
syndrome	I
was	O
7	O
%	O
.	O
	
Two	O
percent	O
(	O
4	O
of	O
183	O
)	O
of	O
subjects	O
had	O
a	O
Grade	O
3	O
to	O
4	O
treatment-emergent	O
hematology	O
laboratory	O
abnormality	O
,	O
with	O
neutropenia	B
(	O
2	O
%	O
[	O
3	O
of	O
183	O
]	O
)	O
being	O
the	O
most	O
frequently	O
reported	O
.	O
	
No	O
Grade	O
3	O
or	O
4	O
ADRs	O
were	O
reported	O
.	O
	
5.9	O
Infusion	O
Reactions	O
Infusion	B
reactions	I
,	O
including	O
life-threatening	O
reactions	O
,	O
have	O
occurred	O
in	O
patients	O
receiving	O
Kyprolis	O
.	O
	
(	O
5.5	O
)	O
Metabolic	B
Changes	I
:	O
Atypical	O
antipsychotic	O
drugs	O
have	O
been	O
associated	O
with	O
metabolic	O
changes	O
that	O
may	O
increase	O
cerebrovascular	B
risk	I
.	O
	
Dose	O
adjustments	O
(	O
interruptions	O
or	O
reductions	O
)	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
52	O
%	O
of	O
AFINITOR-treated	O
patients	O
.	O
	
Patients	O
taking	O
HORIZANT	O
should	O
not	O
drive	O
until	O
they	O
have	O
gained	O
sufficient	O
experience	O
to	O
assess	O
whether	O
HORIZANT	O
impairs	O
their	O
ability	O
to	O
drive	O
.	O
	
Kyprolis	O
can	O
cause	O
increased	B
serum	I
transaminases	I
.	O
	
Table	O
6	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
at	O
Least	O
10	O
%	O
of	O
Patients	O
with	O
RCC	O
and	O
at	O
a	O
Higher	O
Rate	O
in	O
the	O
AFINITOR	O
Arm	O
than	O
in	O
the	O
Placebo	O
Arm	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Stomatitis	B
(	O
including	O
aphthous	B
stomatitis	I
)	O
,	O
and	O
tongue	B
ulceration	I
.	O
	
Subjects	O
received	O
1	O
inhalation	O
once	O
daily	O
of	O
the	O
following	O
:	O
BREO	O
ELLIPTA	O
100/25	O
,	O
BREO	O
ELLIPTA	O
200/25	O
,	O
fluticasone	O
furoate/vilanterol	O
50	O
mcg/25	O
mcg	O
,	O
fluticasone	O
furoate	O
100	O
mcg	O
,	O
fluticasone	O
furoate	O
200	O
mcg	O
,	O
vilanterol	O
25	O
mcg	O
,	O
or	O
placebo	O
.	O
	
Serious	O
adverse	O
reactions	O
related	O
to	O
asthma	B
exacerbation	I
were	O
reported	O
for	O
2	O
patients	O
in	O
the	O
indacaterol	O
300	O
mcg	O
group	O
,	O
3	O
patients	O
in	O
the	O
indacaterol	O
600	O
mcg	O
group	O
,	O
and	O
no	O
patients	O
in	O
the	O
salmeterol	O
active	O
control	O
group	O
.	O
	
Some	O
IgG-positive	O
patients	O
in	O
clinical	O
trials	O
who	O
were	O
retrospectively	O
evaluated	O
for	O
the	O
presence	O
of	O
inhibitory	O
antibodies	O
tested	O
positive	O
for	O
inhibition	O
of	O
enzyme	O
activity	O
and/or	O
uptake	O
in	O
in	O
vitro	O
assays	O
.	O
	
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
INCREASED	O
MORTALITY	B
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
5.2	O
Effects	O
on	O
Serum	O
Liver	O
Biochemistries	O
in	O
Patients	O
with	O
Hepatitis	O
B	O
or	O
C	O
Co-infection	O
Patients	O
with	O
underlying	O
hepatitis	O
B	O
or	O
C	O
may	O
be	O
at	O
increased	O
risk	O
for	O
worsening	O
or	O
development	O
of	O
transaminase	B
elevations	I
with	O
use	O
of	O
TIVICAY	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
A	O
total	O
of	O
701	O
subjects	O
received	O
STRIBILD	O
once	O
daily	O
in	O
these	O
two	O
studies	O
.	O
	
(	O
6	O
)	O
SJIA	O
:	O
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
greater	O
than	O
10	O
%	O
reported	O
by	O
patients	O
with	O
SJIA	O
treated	O
with	O
ILARIS	O
are	O
infections	B
(	O
nasopharyngitis	B
and	O
upper	B
respiratory	I
tract	I
infections	I
)	O
,	O
abdominal	B
pain	I
and	O
injection	B
site	I
reactions	I
.	O
	
The	O
most	O
frequently	O
observed	O
adverse	O
drug	O
reactions	O
in	O
subjects	O
receiving	O
Neuraceq	O
were	O
injection	B
site	I
reactions	I
.	O
	
For	O
the	O
subgroup	O
of	O
187	O
patients	O
treated	O
with	O
subcutaneous	O
KALBITOR	O
,	O
5	O
patients	O
(	O
3	O
%	O
)	O
experienced	O
anaphylaxis	B
.	O
	
Table	O
6	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=1	O
%	O
of	O
Patients	O
Treated	O
for	O
DVT	O
and	O
PE	O
in	O
the	O
AMPLIFY	O
Study	O
ELIQUISN=2676n	O
(	O
%	O
)	O
Enoxaparin/WarfarinN=2689n	O
(	O
%	O
)	O
Epistaxis	B
77	O
(	O
2.9	O
)	O
146	O
(	O
5.4	O
)	O
Contusion	B
49	O
(	O
1.8	O
)	O
97	O
(	O
3.6	O
)	O
Hematuria	B
46	O
(	O
1.7	O
)	O
102	O
(	O
3.8	O
)	O
Menorrhagia	B
38	O
(	O
1.4	O
)	O
30	O
(	O
1.1	O
)	O
Hematoma	B
35	O
(	O
1.3	O
)	O
76	O
(	O
2.8	O
)	O
Hemoptysis	B
32	O
(	O
1.2	O
)	O
31	O
(	O
1.2	O
)	O
Rectal	B
hemorrhage	I
26	O
(	O
1.0	O
)	O
39	O
(	O
1.5	O
)	O
Gingival	B
bleeding	I
26	O
(	O
1.0	O
)	O
50	O
(	O
1.9	O
)	O
AMPLIFY-EXT	O
Study	O
The	O
mean	O
duration	O
of	O
exposure	O
to	O
ELIQUIS	O
was	O
approximately	O
330	O
days	O
and	O
to	O
placebo	O
was	O
312	O
days	O
in	O
the	O
AMPLIFY-EXT	O
study	O
.	O
	
In	O
Trial	O
2	O
,	O
cardiomyopathy	B
occurred	O
in	O
9	O
%	O
(	O
5/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
in	O
none	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
For	O
these	O
patients	O
,	O
a	O
reduction	O
in	O
the	O
quantity	O
of	O
concurrently	O
administered	O
lipids	O
may	O
be	O
necessary	O
to	O
compensate	O
for	O
the	O
amount	O
of	O
lipid	O
infused	O
as	O
part	O
of	O
the	O
Cleviprex	O
formulation	O
.	O
	
The	O
majority	O
of	O
these	O
reports	O
have	O
occurred	O
in	O
patients	O
who	O
received	O
concomitant	O
immunosuppressants	O
.	O
	
Injection	B
site	I
pain	I
has	O
also	O
been	O
reported	O
.	O
	
Evaluate	O
patients	O
for	O
tuberculosis	O
risk	O
factors	O
and	O
test	O
for	O
latent	O
infection	O
prior	O
to	O
initiating	O
SIMPONI	O
ARIA	O
and	O
periodically	O
during	O
therapy	O
.	O
	
(	O
6	O
)	O
6.1	O
Clinical	O
Trials	O
Experience	O
Clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
and	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
Vizamyl	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Some	O
patients	O
with	O
hypersensitivity	B
reactions	I
also	O
reported	O
a	O
history	O
of	O
allergy	O
to	O
other	O
macrolides	O
.	O
	
For	O
cases	O
of	O
Grade	O
3	O
non-infectious	O
pneumonitis	O
interrupt	O
AFINITOR	O
until	O
resolution	O
to	O
less	O
than	O
or	O
equal	O
to	O
Grade	O
1	O
.	O
	
*	O
Increased	O
risk	O
for	O
developing	O
post-transplant	B
lymphoproliferative	I
disorder	I
(	O
PTLD	B
)	O
,	O
predominantly	O
involving	O
the	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
.	O
	
In	O
Trial	O
2	O
,	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
resulted	O
in	O
an	O
increased	O
incidence	O
of	O
deep	B
venous	I
thrombosis	I
(	O
DVT	B
)	O
and	O
pulmonary	B
embolism	I
(	O
PE	B
)	O
:	O
7	O
%	O
(	O
4/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
none	O
of	O
the	O
53	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
KALBITOR	O
should	O
not	O
be	O
administered	O
to	O
any	O
patients	O
with	O
known	O
clinical	O
hypersensitivity	O
to	O
KALBITOR	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Manage	O
by	O
dose	O
reduction	O
or	O
discontinuation	O
until	O
symptoms	O
resolve	O
,	O
and	O
consider	O
use	O
of	O
corticosteroids	O
.	O
	
WARNING	O
:	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
ELIQUIS	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	B
EVENTS	I
(	O
B	O
)	O
EPIDURAL	B
HEMATOMA	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
For	O
ULORIC	O
80	O
mg	O
,	O
1377	O
subjects	O
were	O
treated	O
for	O
>	O
=6	O
months	O
,	O
674	O
patients	O
were	O
treated	O
for	O
>	O
=1	O
year	O
and	O
515	O
patients	O
were	O
treated	O
for	O
>	O
=2	O
years	O
.	O
	
Adverse	O
Reaction	O
N=	O
290n	O
(	O
%	O
)	O
Paresthesias	B
7	O
(	O
2	O
%	O
)	O
Flushing	B
1,2	O
5	O
(	O
2	O
%	O
)	O
Nausea/Vomiting	O
5	O
(	O
2	O
%	O
)	O
Headache	B
2	O
(	O
1	O
%	O
)	O
Hypotension	B
2	O
(	O
1	O
%	O
)	O
Blurred	B
Vision	I
1	O
(	O
<	O
1	O
%	O
)	O
Diarrhea	B
1	O
(	O
<	O
1	O
%	O
)	O
Hypersensitivity	B
1	O
(	O
<	O
1	O
%	O
)	O
Hypertension	B
1	O
(	O
<	O
1	O
%	O
)	O
Rash	B
1	O
(	O
<	O
1	O
%	O
)	O
Throat	B
irritation/Throat	O
tightness	B
1	O
(	O
<	O
1	O
%	O
)	O
Tremor	B
1	O
(	O
<	O
1	O
%	O
)	O
6.2	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
potential	O
for	O
immunogenicity	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypotension	B
:	O
Before	O
initiating	O
JARDIANCE	O
assess	O
and	O
correct	O
volume	O
status	O
in	O
patients	O
with	O
renal	O
impairment	O
,	O
the	O
elderly	O
,	O
in	O
patients	O
with	O
low	O
systolic	O
blood	O
pressure	O
,	O
and	O
in	O
patients	O
on	O
diuretics	O
.	O
	
Patients	O
in	O
the	O
XALKORI	O
arm	O
(	O
n=171	O
)	O
received	O
XALKORI	O
250	O
mg	O
orally	O
twice	O
daily	O
until	O
documented	O
disease	O
progression	O
,	O
intolerance	O
to	O
therapy	O
,	O
or	O
the	O
investigator	O
determined	O
that	O
the	O
patient	O
was	O
no	O
longer	O
experiencing	O
clinical	O
benefit	O
.	O
	
Cases	O
of	O
peripheral	B
motor	I
neuropathy	I
have	O
also	O
been	O
reported	O
.	O
	
(	O
5.1	O
)	O
*	O
Eye	B
irritation	I
:	O
Avoid	O
eye	O
exposure	O
.	O
	
*	O
Hepatotoxicity	B
:	O
Monitor	O
liver	O
enzymes	O
and	O
bilirubin	O
(	O
5.8	O
)	O
.	O
	
(	O
5.11	O
)	O
*	O
Embryo-fetal	B
toxicity	I
:	O
Fetal	B
harm	I
can	O
occur	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
In	O
Trial	O
1	O
,	O
the	O
incidence	O
of	O
fever	B
(	O
serious	O
and	O
non-serious	O
)	O
was	O
28	O
%	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
and	O
10	O
%	O
in	O
patients	O
treated	O
with	O
dacarbazine	O
.	O
	
Lipids	O
Elevations	B
in	I
fasting	I
serum	I
total	I
cholesterol	I
occurred	O
in	O
the	O
controlled	O
studies	O
.	O
	
Monitor	O
renal	O
function	O
periodically	O
.	O
	
5.2	O
Infusion-Related	O
Reactions	O
DALVANCE	O
is	O
administered	O
via	O
intravenous	O
infusion	O
,	O
using	O
a	O
total	O
infusion	O
time	O
of	O
30	O
minutes	O
to	O
minimize	O
the	O
risk	O
of	O
infusion-related	O
reactions	O
.	O
	
Indwelling	O
epidural	O
or	O
intrathecal	O
catheters	O
should	O
not	O
be	O
removed	O
earlier	O
than	O
24	O
hours	O
after	O
the	O
last	O
administration	O
of	O
ELIQUIS	O
.	O
	
During	O
the	O
initial	O
phase	O
of	O
combination	O
antiretroviral	O
treatment	O
,	O
patients	O
whose	O
immune	O
system	O
responds	O
may	O
develop	O
an	O
inflammatory	O
response	O
to	O
indolent	O
or	O
residual	B
opportunistic	I
infections	I
[	O
such	O
as	O
Mycobacterium	B
avium	I
infection	I
,	O
cytomegalovirus	B
,	O
Pneumocystis	B
jirovecii	I
pneumonia	I
(	O
PCP	B
)	O
,	O
or	O
tuberculosis	B
]	O
,	O
which	O
may	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
Invasive	O
Fungal	O
Infections	O
For	O
patients	O
who	O
reside	O
or	O
travel	O
in	O
regions	O
where	O
mycoses	O
are	O
endemic	O
,	O
invasive	O
fungal	O
infection	O
should	O
be	O
suspected	O
if	O
they	O
develop	O
a	O
serious	O
systemic	O
illness	O
.	O
	
Consider	O
empiric	O
anti-fungal	O
therapy	O
in	O
patients	O
at	O
risk	O
for	O
invasive	O
fungal	O
infections	O
who	O
develop	O
severe	O
systemic	O
illness	O
.	O
	
Patients	O
should	O
be	O
instructed	O
to	O
report	O
any	O
symptoms	O
suggestive	O
of	O
endophthalmitis	O
or	O
retinal	O
detachment	O
without	O
delay	O
and	O
should	O
be	O
managed	O
appropriately	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
resulting	O
in	O
permanent	O
discontinuation	O
was	O
pyrexia	B
(	O
4	O
%	O
)	O
.	O
	
5.9	O
QT	O
Prolongation	O
The	O
effects	O
of	O
SAPHRIS	O
on	O
the	O
QT/QTc	O
interval	O
were	O
evaluated	O
in	O
a	O
dedicated	O
adult	O
QT	O
study	O
.	O
	
e	O
Cases	O
of	O
cutaneous	B
squamous	I
cell	I
carcinoma	I
were	O
required	O
to	O
be	O
reported	O
as	O
Grade	O
3	O
per	O
protocol	O
.	O
	
*	O
Discontinue	O
SIMPONI	O
ARIA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
or	O
sepsis	O
(	O
5.1	O
)	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Genzyme	O
at	O
1-800-745-4447	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
.	O
	
5.7	O
Hypokalemia	O
and	O
Hypomagnesemia	O
with	O
Potassium-Depleting	O
Diuretics	O
Hypokalemia	B
or	O
hypomagnesemia	B
may	O
occur	O
with	O
concomitant	O
administration	O
of	O
potassium-depleting	O
diuretics	O
.	O
	
Selected	O
Adverse	O
Reactions	O
in	O
Phase	O
2/3	O
Trials	O
(	O
Number	O
(	O
%	O
)	O
of	O
Patients	O
)	O
Dalbavancin	O
Comparator*	O
(	O
N	O
=	O
1778	O
)	O
(	O
N	O
=	O
1224	O
)	O
Nausea	B
98	O
(	O
5.5	O
)	O
78	O
(	O
6.4	O
)	O
Vomiting	B
50	O
(	O
2.8	O
)	O
37	O
(	O
3	O
)	O
Diarrhea	B
79	O
(	O
4.4	O
)	O
72	O
(	O
5.9	O
)	O
Headache	B
83	O
(	O
4.7	O
)	O
59	O
(	O
4.8	O
)	O
Rash	B
48	O
(	O
2.7	O
)	O
30	O
(	O
2.4	O
)	O
Pruritus	B
38	O
(	O
2.1	O
)	O
41	O
(	O
3.3	O
)	O
*	O
Comparators	O
included	O
linezolid	O
,	O
cefazolin	O
,	O
cephalexin	O
,	O
and	O
vancomycin	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
are	O
fatigue	B
,	O
joint	B
swelling	I
,	O
edema	B
,	O
hot	B
flush	I
,	O
diarrhea	B
,	O
vomiting	B
,	O
cough	B
,	O
hypertension	B
,	O
dyspnea	B
,	O
urinary	B
tract	I
infection	I
and	O
contusion	B
.	O
	
Antigen	O
and	O
antibody	O
testing	O
for	O
histoplasmosis	O
may	O
be	O
negative	O
in	O
some	O
patients	O
with	O
active	O
infection	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
peginterferon	O
alfa	O
and	O
ribavirin	O
for	O
additional	O
information	O
regarding	O
dose	O
reduction	O
or	O
discontinuation	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
)	O
include	O
headache	B
,	O
flushing	B
,	O
nasal	B
congestion	I
,	O
nasopharyngitis	B
,	O
and	O
back	B
pain	I
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
1-877-663-0412	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
FOR	O
HEPATIC	B
DECOMPENSATION	I
IN	O
PATIENTS	O
WITH	O
CHRONIC	O
HEPATITIS	O
C	O
WARNING	O
:	O
RISK	O
FOR	O
HEPATIC	B
DECOMPENSATION	I
IN	O
PATIENTS	O
WITH	O
CHRONIC	O
HEPATITIS	O
C	O
In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
PROMACTA	O
(	O
r	O
)	O
in	O
combination	O
with	O
interferon	O
and	O
ribavirin	O
may	O
increase	O
the	O
risk	O
of	O
hepatic	B
decompensation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
that	O
led	O
to	O
treatment	O
discontinuation	O
in	O
2	O
or	O
more	O
patients	O
with	O
classical	O
HL	O
or	O
sALCL	O
were	O
peripheral	B
sensory	I
neuropathy	I
(	O
8	O
%	O
)	O
and	O
peripheral	B
motor	I
neuropathy	I
(	O
3	O
%	O
)	O
.	O
	
Do	O
not	O
give	O
DUAVEE	O
to	O
other	O
people	O
,	O
even	O
if	O
they	O
have	O
the	O
same	O
symptoms	O
you	O
have	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
greater	O
than	O
35	O
%	O
of	O
subjects	O
)	O
in	O
clinical	O
trials	O
in	O
adult	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron	O
and	O
REBETOL	O
were	O
fatigue	B
,	O
anemia	B
,	O
nausea	B
,	O
headache	B
and	O
dysgeusia	B
.	O
	
Evaluate	O
abnormal	O
serum	O
liver	O
tests	O
with	O
repeat	O
testing	O
within	O
3	O
to	O
5	O
days	O
.	O
	
Other	O
important	O
serious	O
adverse	O
reactions	O
reported	O
include	O
PML	B
,	O
Stevens-Johnson	B
syndrome	I
,	O
and	O
tumor	B
lysis	I
syndrome	I
.	O
	
In	O
a	O
3-week	O
,	O
bipolar	O
mania	O
pediatric	O
trial	O
,	O
syncope	B
was	O
reported	O
in	O
1	O
%	O
(	O
1/104	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
1	O
%	O
(	O
1/99	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
0	O
%	O
(	O
0/99	O
)	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
compared	O
to	O
0	O
%	O
(	O
0/101	O
)	O
for	O
patients	O
treated	O
with	O
placebo	O
.	O
	
*	O
Talk	O
with	O
your	O
healthcare	O
provider	O
regularly	O
about	O
whether	O
you	O
should	O
continue	O
taking	O
DUAVEE	O
.	O
	
Ribavirin	O
dose	O
reduction	O
is	O
recommended	O
for	O
the	O
initial	O
management	O
of	O
anemia	O
.	O
	
MALIGNANCY	O
Lymphoma	B
and	O
other	O
malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
in	O
children	O
and	O
adolescent	O
patients	O
treated	O
with	O
TNF	O
blockers	O
,	O
of	O
which	O
CIMZIA	O
is	O
a	O
member	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
What	O
can	O
I	O
do	O
to	O
lower	O
my	O
chances	O
of	O
a	O
serious	O
side	O
effect	O
with	O
DUAVEE	O
?	O
	
Patients	O
should	O
be	O
instructed	O
about	O
non-pharmacologic	O
interventions	O
that	O
help	O
to	O
reduce	O
the	O
occurrence	O
of	O
orthostatic	O
hypotension	O
(	O
e.g.	O
,	O
sitting	O
on	O
the	O
edge	O
of	O
the	O
bed	O
for	O
several	O
minutes	O
before	O
attempting	O
to	O
stand	O
in	O
the	O
morning	O
and	O
slowly	O
rising	O
from	O
a	O
seated	O
position	O
)	O
.	O
	
If	O
bilirubin	O
is	O
elevated	O
,	O
perform	O
fractionation	O
.	O
	
Prescribers	O
and	O
patients	O
should	O
be	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
prostatic	O
hyperplasia	O
or	O
bladder-neck	O
obstruction	O
(	O
e.g.	O
,	O
difficulty	O
passing	O
urine	O
,	O
painful	O
urination	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merck	O
Sharp	O
&	O
Dohme	O
Corp.	O
,	O
a	O
subsidiary	O
of	O
Merck	O
&	O
Co.	O
,	O
Inc.	O
,	O
at	O
1-877-888-4231	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Among	O
the	O
712	O
patients	O
who	O
participated	O
in	O
this	O
open-label	O
extension	O
study	O
,	O
the	O
mean	O
age	O
of	O
the	O
population	O
was	O
56.4	O
years	O
(	O
range	O
from	O
23	O
to	O
88	O
years	O
)	O
.	O
	
Laboratory	O
Parameters	O
:	O
activated	B
partial	I
thromboplastin	I
time	I
prolonged	I
,	O
creatine	B
increased	I
,	O
bicarbonate	B
decreased	I
,	O
sodium	B
increased	I
,	O
EEG	B
abnormal	I
,	O
glucose	B
increased	I
,	O
cholesterol	B
increased	I
,	O
triglycerides	B
increased	I
,	O
amylase	B
increased	I
,	O
potassium	B
increased	I
,	O
TSH	B
increased	I
,	O
platelet	B
count	I
decreased	I
,	O
hematocrit	B
decreased	I
,	O
hemoglobin	B
decreased	I
,	O
MCV	B
increased	I
,	O
RBC	B
decreased	I
,	O
creatinine	B
increased	I
,	O
blood	B
urea	I
increased	I
,	O
BUN/creatinine	B
ratio	I
increased	I
,	O
CPK	B
)	I
increased	I
,	O
alkaline	B
phosphatase	I
increased	I
,	O
LDH	B
increased	I
,	O
PSA	B
increased	I
,	O
urine	B
output	I
increased	I
,	O
lymphocyte	B
count	I
decreased	I
,	O
neutrophil	B
count	I
decreased	I
,	O
WBC	B
increased	I
,	O
coagulation	B
test	I
abnormal	I
,	O
LDL	B
)	I
increased	I
,	O
prothrombin	B
time	I
prolonged	I
,	O
urinary	B
casts	I
,	O
urine	B
positive	I
for	I
white	I
blood	I
cells	I
.	O
	
CIMZIA	O
is	O
not	O
indicated	O
for	O
use	O
in	O
pediatric	O
patients	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
need	O
of	O
emergency	O
cardiorespiratory	O
support	O
(	O
5.2	O
)	O
5.1	O
Nephrogenic	O
Systemic	O
Fibrosis	O
(	O
NSF	O
)	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
nephrogenic	B
systemic	I
fibrosis	I
(	O
NSF	B
)	O
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
*	O
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
Gadavist	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
from	O
the	O
body	O
prior	O
to	O
any	O
re-administration	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Treat	O
patients	O
with	O
rehydration	O
,	O
anti-diarrheal	O
or	O
anti-emetic	O
medications	O
as	O
needed	O
.	O
	
The	O
transfusion	O
rate	O
was	O
4	O
%	O
in	O
subjects	O
randomized	O
to	O
receive	O
ribavirin	O
dose	O
reduction	O
and	O
2	O
%	O
in	O
subjects	O
randomized	O
to	O
receive	O
ESA	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Serious	O
hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
AdreView	O
administration	O
.	O
	
Severe	O
hypersensitivity	B
reactions	I
require	O
immediate	O
discontinuation	O
of	O
the	O
JEVTANA	O
infusion	O
and	O
appropriate	O
therapy	O
.	O
	
If	O
peginterferon	O
alfa	O
and	O
ribavirin	O
are	O
permanently	O
discontinued	O
,	O
then	O
VICTRELIS	O
must	O
also	O
be	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Empiric	O
anti-fungal	O
therapy	O
should	O
be	O
considered	O
in	O
patients	O
at	O
risk	O
for	O
invasive	O
fungal	O
infections	O
who	O
develop	O
severe	O
systemic	O
illness	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
20	O
%	O
)	O
are	O
anemia	B
,	O
elevated	B
alkaline	I
phosphatase	I
,	O
hypertriglyceridemia	B
,	O
lymphopenia	B
,	O
hypercholesterolemia	B
,	O
hyperglycemia	B
,	O
elevated	B
AST	I
,	O
hypophosphatemia	B
,	O
elevated	B
ALT	I
and	O
hypokalemia	B
.	O
	
(	O
5.1	O
)	O
*	O
Paradoxical	B
bronchospasm	I
:	O
Discontinue	O
TUDORZA	O
PRESSAIR	O
and	O
consider	O
other	O
treatments	O
if	O
paradoxical	O
bronchospasm	O
occurs	O
.	O
	
Stop	O
SIMPONI	O
ARIA	O
if	O
new	O
or	O
worsening	O
symptoms	O
occur	O
(	O
5.3	O
)	O
.	O
	
Do	O
not	O
use	O
DUAVEE	O
for	O
a	O
condition	O
for	O
which	O
it	O
was	O
not	O
prescribed	O
.	O
	
Adverse	O
reactions	O
led	O
to	O
treatment	O
discontinuation	O
in	O
32	O
%	O
of	O
ADCETRIS-treated	O
patients	O
in	O
Study	O
3	O
.	O
	
Vascular	O
Disorders	O
:	O
Thrombotic	B
microangiopathy	I
with	O
acute	B
renal	I
failure	I
.	O
	
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
:	O
*	O
Anaphylaxis	O
and	O
hypersensitivity	O
reactions	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
In	O
a	O
3-week	O
,	O
bipolar	O
mania	O
pediatric	O
trial	O
,	O
the	O
incidence	O
of	O
adverse	O
events	O
related	O
to	O
abnormal	B
prolactin	I
levels	I
were	O
0	O
%	O
in	O
the	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
treatment	O
group	O
,	O
2	O
%	O
in	O
the	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
treatment	O
group	O
,	O
and	O
1	O
%	O
in	O
the	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
treatment	O
group	O
versus	O
to	O
1	O
%	O
for	O
patients	O
treated	O
with	O
placebo	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
f	O
NA	O
=	O
not	O
applicable	O
.	O
	
Potassium	O
levels	O
should	O
be	O
within	O
the	O
normal	O
range	O
prior	O
to	O
administration	O
of	O
MULTAQ	O
and	O
maintained	O
in	O
the	O
normal	O
range	O
during	O
administration	O
of	O
MULTAQ	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
has	O
occurred	O
in	O
patients	O
with	O
impaired	O
elimination	O
of	O
GBCAs	O
.	O
	
In	O
animal	O
reproduction	O
studies	O
,	O
oral	O
administration	O
of	O
crizotinib	O
in	O
pregnant	O
rats	O
during	O
organogenesis	O
at	O
exposures	O
similar	O
to	O
those	O
observed	O
with	O
the	O
maximum	O
recommended	O
human	O
dose	O
resulted	O
in	O
embryotoxicity	B
and	O
fetotoxicity	B
.	O
	
Consider	O
the	O
potential	O
for	O
drug	O
interactions	O
prior	O
to	O
and	O
during	O
STRIBILD	O
therapy	O
;	O
review	O
concomitant	O
medications	O
during	O
STRIBILD	O
therapy	O
;	O
and	O
monitor	O
for	O
the	O
adverse	O
reactions	O
associated	O
with	O
the	O
concomitant	O
drugs	O
.	O
	
5.2	O
Bleeding	O
ELIQUIS	O
increases	O
the	O
risk	O
of	O
bleeding	B
and	O
can	O
cause	O
serious	O
,	O
potentially	O
fatal	B
,	O
bleeding	B
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
andAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.3	O
Hypoglycemia	O
with	O
Concomitant	O
Use	O
of	O
Insulin	O
Secretagogues	O
or	O
Insulin	O
The	O
risk	O
of	O
hypoglycemia	B
is	O
increased	O
when	O
TANZEUM	O
is	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylureas	O
)	O
or	O
insulin	O
.	O
	
5.8	O
Immune	O
Reconstitution	O
Syndrome	O
Immune	B
reconstitution	I
syndrome	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
,	O
including	O
STRIBILD	O
.	O
	
Appropriate	O
empiric	O
antifungal	O
therapy	O
should	O
be	O
considered	O
while	O
a	O
diagnostic	O
workup	O
is	O
being	O
performed	O
.	O
	
The	O
risk	O
of	O
these	O
events	O
may	O
be	O
increased	O
by	O
the	O
postoperative	O
use	O
of	O
indwelling	O
epidural	O
catheters	O
or	O
the	O
concomitant	O
use	O
of	O
medicinal	O
products	O
affecting	O
hemostasis	O
.	O
	
*	O
The	O
risk	O
for	O
NSF	B
appears	O
highest	O
among	O
patients	O
with	O
:	O
oChronic	O
,	O
severe	O
kidney	O
disease	O
(	O
GFR	O
<	O
30	O
mL/min/1.73m2	O
)	O
,	O
oroAcute	O
kidney	O
injury	O
.	O
	
Rapid	O
intravenous	O
infusions	O
of	O
DALVANCE	O
can	O
cause	O
reactions	O
that	O
resemble	O
``	O
Red-Man	B
Syndrome	I
,	O
''	O
including	O
flushing	B
of	I
the	I
upper	I
body	I
,	O
urticaria	B
,	O
pruritus	B
,	O
and/or	O
rash	B
.	O
	
Small	O
increases	B
in	I
creatinine	I
levels	I
(	O
about	O
0.1	O
mg/dL	O
)	O
following	O
dronedarone	O
treatment	O
initiation	O
have	O
been	O
shown	O
to	O
be	O
a	O
result	O
of	O
inhibition	O
of	O
creatinine	O
's	O
tubular	O
secretion	O
.	O
	
This	O
trial	O
involved	O
SAPHRIS	O
doses	O
of	O
5	O
mg	O
,	O
10	O
mg	O
,	O
15	O
mg	O
,	O
and	O
20	O
mg	O
twice	O
daily	O
,	O
and	O
placebo	O
,	O
and	O
was	O
conducted	O
in	O
151	O
clinically	O
stable	O
patients	O
with	O
schizophrenia	O
,	O
with	O
electrocardiographic	O
assessments	O
throughout	O
the	O
dosing	O
interval	O
at	O
baseline	O
and	O
steady	O
state	O
.	O
	
(	O
5.1	O
)	O
*	O
Increases	B
in	I
intraocular	I
pressure	I
have	O
been	O
seen	O
within	O
60	O
minutes	O
of	O
an	O
intravitreal	O
injection	O
.	O
	
At	O
the	O
time	O
of	O
data	O
cut-off	O
,	O
243	O
patients	O
were	O
enrolled	O
and	O
safety	O
data	O
was	O
available	O
for	O
141	O
patients	O
.	O
	
In	O
one	O
case	O
,	O
insufficient	O
information	O
was	O
obtained	O
to	O
establish	O
or	O
refute	O
a	O
drug-related	O
causality	O
.	O
	
*	O
Tumor	B
lysis	I
syndrome	I
:	O
Closely	O
monitor	O
patients	O
with	O
rapidly	O
proliferating	O
tumor	O
or	O
high	O
tumor	O
burden	O
(	O
5.5	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Neonatal	B
toxicity	I
:	O
Risk	O
of	O
gasping	B
syndrome	I
if	O
benzyl	O
alcohol	O
is	O
used	O
in	O
neonates	O
.	O
	
Laboratory	O
,	O
ECG	O
and	O
vital	O
sign	O
changes	O
observed	O
in	O
MDD	O
clinical	O
studies	O
The	O
following	O
changes	O
were	O
observed	O
in	O
pre-marketing	O
placebo-controlled	O
,	O
short-term	O
MDD	O
studies	O
with	O
PRISTIQ	O
.	O
	
(	O
2.2	O
)	O
(	O
4	O
)	O
(	O
5.1	O
)	O
*	O
Hypersensitivity	B
:	O
Severe	O
hypersensitivity	B
reactions	I
can	O
occur	O
.	O
	
The	O
incidence	O
and	O
severity	O
of	O
pyrexia	B
are	O
increased	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
5.8	O
)	O
*	O
Vaccinations	O
:	O
Avoid	O
live	O
vaccines	O
and	O
close	O
contact	O
with	O
those	O
who	O
have	O
received	O
live	O
vaccines	O
.	O
	
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
ELIQUIS	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	B
EVENTS	I
:	O
Premature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
ELIQUIS	O
,	O
increases	O
the	O
risk	O
of	O
thrombotic	B
events	I
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Non-infectious	B
pneumonitis	I
:	O
Monitor	O
for	O
clinical	O
symptoms	O
or	O
radiological	O
changes	O
;	O
fatal	B
cases	O
have	O
occurred	O
.	O
	
Table	O
5	O
:	O
Incidence	O
(	O
%	O
)	O
of	O
Patients	O
with	O
Proteinuria	B
in	O
the	O
Fixed-dose	O
Clinical	O
Studies	O
PRISTIQ	O
Placebo	O
50	O
mg	O
100	O
mg	O
200	O
mg	O
400	O
mg	O
Proteinuria	B
4	O
6	O
8	O
5	O
7	O
Vital	O
sign	O
changes	O
Table	O
6	O
summarizes	O
the	O
changes	O
that	O
were	O
observed	O
in	O
placebo-controlled	O
,	O
short-term	O
,	O
pre-marketing	O
studies	O
with	O
PRISTIQ	O
in	O
patients	O
with	O
MDD	O
(	O
doses	O
50	O
to	O
400	O
mg	O
)	O
.	O
	
Severe	O
hypersensitivity	B
reactions	I
require	O
immediate	O
discontinuation	O
of	O
the	O
JEVTANA	O
infusion	O
and	O
administration	O
of	O
appropriate	O
therapy	O
.	O
	
5.1	O
Peripheral	O
Neuropathy	O
ADCETRIS	O
treatment	O
causes	O
a	O
peripheral	B
neuropathy	I
.	O
	
A	O
total	O
of	O
169	O
patients	O
in	O
the	O
chemotherapy	O
arm	O
received	O
pemetrexed	O
500	O
mg/m	O
2	O
in	O
combination	O
with	O
cisplatin	O
75	O
mg/m	O
2	O
(	O
n=91	O
)	O
or	O
carboplatin	O
at	O
a	O
dose	O
calculated	O
to	O
produce	O
an	O
area	O
under	O
the	O
concentration-time	O
curve	O
(	O
AUC	O
)	O
of	O
5	O
or	O
6	O
mg	O
?	O
min/mL	O
(	O
n=78	O
)	O
.	O
	
Eye	B
disorders	I
,	O
including	O
severe	O
eye	B
pain	I
,	O
chemical	B
conjunctivitis	I
,	O
corneal	B
burn	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
periorbital	B
edema	I
can	O
occur	O
after	O
exposure	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
2	O
One	O
of	O
these	O
reactions	O
was	O
classified	O
as	O
Grade	O
3	O
in	O
severity	O
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
associated	O
with	O
ILARIS	O
treatment	O
in	O
the	O
CAPS	O
patients	O
were	O
nasopharyngitis	B
,	O
diarrhea	B
,	O
influenza	B
,	O
headache	B
,	O
and	O
nausea	B
.	O
	
6	O
.	O
	
Most	O
Common	O
Adverse	O
Reactions	O
In	O
three	O
randomized	O
,	O
controlled	O
clinical	O
studies	O
(	O
Studies	O
1	O
,	O
2	O
and	O
3	O
)	O
,	O
which	O
were	O
six	O
to	O
12	O
months	O
in	O
duration	O
,	O
the	O
following	O
adverse	O
reactions	O
were	O
reported	O
by	O
the	O
treating	O
physician	O
as	O
related	O
to	O
study	O
drug	O
.	O
	
Treatment	O
of	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
therapy	O
with	O
TNF-blockers	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
tuberculosis	O
reactivation	O
during	O
therapy	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
DaTscan	O
administration	O
.	O
	
Events	O
and	O
event	O
rates	O
include	O
one	O
enoxaparin-treated	O
patient	O
in	O
ADVANCE-1	O
who	O
also	O
had	O
intracranial	B
hemorrhage	I
.	O
	
5.4	O
Venous	O
Thromboembolism	O
Venous	B
thromboembolism	I
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Given	O
the	O
similarity	O
in	O
hypersensitivity	O
symptoms	O
and	O
acute	O
HAE	O
symptoms	O
,	O
patients	O
should	O
be	O
monitored	O
closely	O
in	O
the	O
event	O
of	O
a	O
hypersensitivity	O
reaction	O
.	O
	
AFINITOR	O
may	O
be	O
reintroduced	O
at	O
a	O
daily	O
dose	O
approximately	O
50	O
%	O
lower	O
than	O
the	O
dose	O
previously	O
administered	O
[	O
see	O
Table	O
1	O
in	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Nervous	O
system	O
disorders	O
-	O
Syncope	B
,	O
convulsion	B
,	O
dystonia	B
.	O
	
If	O
a	O
severe	O
hypersensitivity	O
reaction	O
occurs	O
,	O
DIFICID	O
(	O
r	O
)	O
should	O
be	O
discontinued	O
and	O
appropriate	O
therapy	O
should	O
be	O
instituted	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GE	O
Healthcare	O
at	O
1-800-654-0118	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
In	O
255	O
HAE	O
patients	O
treated	O
with	O
intravenous	O
or	O
subcutaneous	O
KALBITOR	O
in	O
clinical	O
studies	O
,	O
10	O
patients	O
(	O
4	O
%	O
)	O
experienced	O
anaphylaxis	B
.	O
	
5.5	O
Cardiomyopathy	O
Cardiomyopathy	B
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
and	O
with	O
trametinib	O
as	O
a	O
single	O
agent	O
[	O
refer	O
to	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
]	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
bleeding	B
occurred	O
in	O
219	O
(	O
13.3	O
%	O
)	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
72	O
(	O
8.7	O
%	O
)	O
placebo-treated	O
patients	O
.	O
	
All	O
adverse	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
of	O
short	O
duration	O
.	O
	
Cytomegalovirus	O
and	O
pneumocystis	O
prophylaxis	O
are	O
recommended	O
after	O
transplantation	O
.	O
	
EXCERPT	O
:	O
CAPS	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
greater	O
than	O
10	O
%	O
reported	O
by	O
patients	O
with	O
CAPS	O
treated	O
with	O
ILARIS	O
are	O
nasopharyngitis	B
,	O
diarrhea	B
,	O
influenza	B
,	O
headache	B
and	O
nausea	B
.	O
	
All	O
patients	O
should	O
be	O
tested	O
for	O
HBV	O
infection	O
before	O
initiating	O
TNF-blocker	O
therapy	O
.	O
	
Appendicitis	O
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
serious	O
events	O
of	O
appendicitis	B
occurred	O
in	O
0.3	O
%	O
of	O
patients	O
treated	O
with	O
TANZEUM	O
compared	O
with	O
0	O
%	O
among	O
all	O
comparators	O
.	O
	
Subjects	O
were	O
randomized	O
to	O
receive	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
or	O
placebo	O
twice	O
daily	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
treatment	O
with	O
STRIBILD	O
(	O
elvitegravir	O
150	O
mg/cobicistat	O
150	O
mg/emtricitabine	O
200	O
mg/tenofovir	O
DF	O
300	O
mg	O
)	O
;	O
ATRIPLA	O
(	O
efavirenz	O
600	O
mg/emtricitabine	O
200	O
mg/tenofovir	O
DF	O
300	O
mg	O
)	O
;	O
or	O
atazanavir	O
(	O
ATV	O
)	O
+	O
ritonavir	O
(	O
RTV	O
)	O
+	O
TRUVADA	O
(	O
emtricitabine	O
200	O
mg/tenofovir	O
DF	O
300	O
mg	O
)	O
due	O
to	O
adverse	O
events	O
,	O
regardless	O
of	O
severity	O
,	O
was	O
6.0	O
%	O
,	O
7.4	O
%	O
and	O
8.5	O
%	O
,	O
respectively	O
.	O
	
TIVICAY	O
is	O
contraindicated	O
in	O
patients	O
who	O
have	O
experienced	O
a	O
previous	O
hypersensitivity	O
reaction	O
to	O
dolutegravir	O
.	O
	
FANAPT	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
Dementia-Related	O
Psychosis	O
.	O
	
There	O
is	O
evidence	O
to	O
suggest	O
that	O
some	O
patients	O
who	O
develop	O
high	O
sustained	O
titers	O
of	O
anti-alglucosidase	O
alfa	O
antibodies	O
may	O
experience	O
reduced	O
clinical	O
efficacy	O
to	O
alglucosidase	O
alfa	O
treatment	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
There	O
were	O
no	O
deaths	B
in	O
the	O
ARCAPTA	O
NEOHALER	O
600	O
mcg	O
dose	O
group	O
or	O
in	O
the	O
salmeterol	O
active	O
control	O
group	O
.	O
	
Monitor	O
weight	O
.	O
	
Symptoms	O
include	O
fever	B
,	O
chills	B
,	O
arthralgia	B
,	O
myalgia	B
,	O
facial	B
flushing	I
,	O
facial	B
edema	I
,	O
vomiting	B
,	O
weakness	B
,	O
shortness	B
of	I
breath	I
,	O
hypotension	B
,	O
syncope	B
,	O
chest	B
tightness	I
,	O
or	O
angina	B
.	O
	
Grade	O
2	O
ADRs	O
reported	O
in	O
at	O
least	O
1	O
subject	O
were	O
rash	B
(	O
n	O
=	O
1	O
)	O
,	O
abdominal	B
pain	I
(	O
n	O
=	O
1	O
)	O
,	O
and	O
diarrhea	B
(	O
n	O
=	O
1	O
)	O
.	O
	
Table	O
1	O
presents	O
the	O
profile	O
from	O
the	O
9-month	O
double-blind	O
,	O
randomized	O
,	O
placebo-controlled	O
trial	O
of	O
40	O
treatment-naive	O
patients	O
(	O
Trial	O
1	O
)	O
.	O
	
Monitor	O
liver	O
enzymes	O
regularly	O
.	O
	
The	O
duration	O
of	O
driving	B
impairment	I
after	O
starting	O
therapy	O
with	O
HORIZANT	O
is	O
unknown	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
AFINITOR	O
dose	O
adjustment	O
was	O
stomatitis	B
.	O
	
(	O
2.2	O
,	O
5.4	O
)	O
*	O
Depression	B
:	O
Depression	B
and	O
suicidality	B
have	O
been	O
reported	O
in	O
trials	O
with	O
BENLYSTA	O
.	O
	
In	O
Study	O
1	O
,	O
the	O
overall	O
incidence	O
of	O
cutaneous	B
reactions	I
consisting	O
of	O
rash	B
,	O
erythema	B
,	O
and	O
acneiform	B
rash	I
was	O
90	O
%	O
,	O
and	O
the	O
incidence	O
of	O
Grade	O
3	O
cutaneous	B
reactions	I
was	O
16	O
%	O
.	O
	
The	O
600-mg	O
dose	O
was	O
studied	O
in	O
2	O
of	O
the	O
3	O
studies	O
.	O
	
In	O
this	O
trial	O
,	O
the	O
safety	O
profile	O
of	O
FIRAZYR	O
in	O
patients	O
who	O
self-administered	O
FIRAZYR	O
was	O
similar	O
in	O
nature	O
and	O
frequency	O
to	O
that	O
of	O
patients	O
whose	O
therapy	O
was	O
administered	O
by	O
healthcare	O
professionals	O
.	O
	
Subjects	O
received	O
1	O
inhalation	O
once	O
daily	O
of	O
the	O
following	O
:	O
BREO	O
ELLIPTA	O
100/25	O
,	O
BREO	O
ELLIPTA	O
200/25	O
,	O
fluticasone	O
furoate/vilanterol	O
50	O
mcg/25	O
mcg	O
,	O
or	O
vilanterol	O
25	O
mcg	O
.	O
	
These	O
reactions	O
can	O
occur	O
within	O
hours	O
to	O
weeks	O
after	O
injection	O
with	O
botulinum	O
toxin	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
,	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Treatment-experienced	O
,	O
Integrase	O
Strand	O
Transfer	O
Inhibitor-experienced	O
Subjects	O
:	O
The	O
most	O
common	O
treatment-emergent	O
laboratory	O
abnormalities	O
(	O
greater	O
than	O
5	O
%	O
for	O
Grades	O
2	O
to	O
4	O
combined	O
)	O
observed	O
in	O
VIKING-3	O
at	O
Week	O
48	O
were	O
elevated	B
ALT	I
(	O
10	O
%	O
)	O
.	O
	
No	O
additional	O
postmarketing	O
adverse	O
reactions	O
specific	O
for	O
emtricitabine	O
have	O
been	O
identified	O
.	O
	
5.6	O
Human	O
Albumin	O
This	O
product	O
contains	O
albumin	O
,	O
a	O
derivative	O
of	O
human	O
blood	O
.	O
	
These	O
reactions	O
were	O
more	O
likely	O
to	O
occur	O
with	O
higher	O
infusion	O
rates	O
.	O
	
12-Week	O
Trials	O
Trial	O
1	O
was	O
a	O
12-week	O
trial	O
that	O
evaluated	O
the	O
efficacy	O
of	O
BREO	O
ELLIPTA	O
100/25	O
in	O
adolescent	O
and	O
adult	O
subjects	O
with	O
asthma	O
compared	O
with	O
fluticasone	O
furoate	O
100	O
mcg	O
and	O
placebo	O
.	O
	
5.9	O
Myasthenia	O
Gravis	O
Toviaz	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
,	O
a	O
disease	O
characterized	O
by	O
decreased	O
cholinergic	O
activity	O
at	O
the	O
neuromuscular	O
junction	O
.	O
	
Macular	O
Edema	O
in	O
Patients	O
with	O
History	O
of	O
Uveitis	O
or	O
Diabetes	O
Mellitus	O
Patients	O
with	O
a	O
history	O
of	O
uveitis	O
and	O
patients	O
with	O
diabetes	O
mellitus	O
are	O
at	O
increased	O
risk	O
of	O
macular	B
edema	I
during	O
GILENYA	O
therapy	O
.	O
	
Table	O
5	O
lists	O
adverse	O
reactions	O
occurring	O
in	O
1	O
%	O
or	O
greater	O
of	O
patients	O
receiving	O
ZERBAXA	O
in	O
Phase	O
3	O
clinical	O
trials	O
.	O
	
The	O
observed	O
incidence	O
of	O
antibody	O
positivity	O
in	O
an	O
assay	O
is	O
highly	O
dependent	O
on	O
several	O
factors	O
,	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
In	O
Study	O
1	O
,	O
the	O
incidence	O
of	O
Grade	O
>	O
=3	O
ILD	B
was	O
1.3	O
%	O
and	O
resulted	O
in	O
death	B
in	O
1	O
%	O
of	O
GILOTRIF-treated	O
patients	O
.	O
	
VZV	O
vaccination	O
of	O
antibody-negative	O
patients	O
is	O
recommended	O
prior	O
to	O
commencing	O
treatment	O
with	O
GILENYA	O
,	O
following	O
which	O
initiation	O
of	O
treatment	O
with	O
GILENYA	O
should	O
be	O
postponed	O
for	O
1	O
month	O
to	O
allow	O
the	O
full	O
effect	O
of	O
vaccination	O
to	O
occur	O
.	O
	
Patients	O
or	O
caregivers	O
should	O
be	O
advised	O
to	O
seek	O
immediate	O
medical	O
care	O
if	O
swallowing	O
,	O
speech	O
,	O
or	O
respiratory	O
disorders	O
occur	O
.	O
	
In	O
the	O
placebo	O
controlled	O
adjunctive	O
therapy	O
trials	O
in	O
patients	O
with	O
partial-onset	O
seizures	O
(	O
Study	O
3	O
,	O
Study	O
4	O
and	O
Study	O
5	O
)	O
,	O
1021	O
patients	O
received	O
APTIOM	O
.	O
	
Clinical	O
manifestations	O
include	O
hyperpyrexia	B
,	O
muscle	B
rigidity	I
,	O
altered	B
mental	I
status	I
(	O
including	O
catatonic	B
signs	I
)	O
and	O
evidence	O
of	O
autonomic	B
instability	I
(	O
irregular	B
pulse	I
,	O
tachycardia	B
,	O
diaphoresis	B
,	O
and	O
cardiac	B
dysrhythmia	I
)	O
.	O
	
The	O
other	O
cases	O
represented	O
a	O
variety	O
of	O
malignancies	B
,	O
including	O
rare	B
malignancies	I
that	O
are	O
usually	O
associated	O
with	O
immunosuppression	B
,	O
and	O
malignancies	O
that	O
are	O
not	O
usually	O
observed	O
in	O
children	O
and	O
adolescents	O
.	O
	
In	O
the	O
controlled	O
portions	O
of	O
clinical	O
trials	O
of	O
TNF-blockers	O
including	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
more	O
cases	O
of	O
lymphoma	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
anti-TNF	O
treatment	O
compared	O
with	O
patients	O
in	O
the	O
control	O
groups	O
.	O
	
There	O
have	O
been	O
post-marketing	O
reports	O
of	O
serious	O
breathing	B
difficulties	I
,	O
including	O
respiratory	B
failure	I
,	O
in	O
patients	O
with	O
cervical	O
dystonia	O
treated	O
with	O
botulinum	O
toxin	O
products	O
.	O
	
Evaluate	O
patients	O
with	O
symptoms	O
compatible	O
with	O
pancreatitis	O
to	O
establish	O
a	O
diagnosis	O
.	O
	
Most	O
adverse	O
events	O
were	O
mild	O
in	O
severity	O
and	O
transient	O
in	O
nature	O
,	O
and	O
all	O
patients	O
recovered	O
without	O
treatment	O
.	O
	
Include	O
disseminated	O
herpetic	O
infections	O
in	O
the	O
differential	O
diagnosis	O
of	O
patients	O
who	O
are	O
receiving	O
GILENYA	O
and	O
present	O
with	O
an	O
atypical	O
MS	O
relapse	O
or	O
multiorgan	O
failure	O
.	O
	
Fourteen	O
(	O
24	O
%	O
)	O
patients	O
stopped	O
therapy	O
prior	O
to	O
completion	O
;	O
seven	O
due	O
to	O
allergic	B
reactions	I
,	O
five	O
due	O
to	O
physician	O
or	O
patient	O
choice	O
,	O
one	O
due	O
to	O
disease	O
progression	O
,	O
and	O
one	O
due	O
to	O
discontinuation	O
during	O
frontline	O
protocol	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
associated	O
with	O
discontinuation	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
(	O
rates	O
at	O
least	O
1	O
%	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
)	O
were	O
anxiety	B
(	O
1.1	O
%	O
)	O
and	O
oral	B
hypoesthesia	I
(	O
1.1	O
%	O
)	O
compared	O
to	O
placebo	O
(	O
0	O
%	O
)	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
also	O
may	O
not	O
reflect	O
rates	O
observed	O
in	O
practice	O
.	O
	
There	O
may	O
be	O
new	O
information	O
.	O
	
Monitor	O
renal	O
function	O
with	O
regular	O
measurement	O
of	O
the	O
serum	O
creatinine	O
and/or	O
estimated	O
creatinine	O
clearance	O
.	O
	
Patients	O
with	O
New	O
York	O
Heart	O
Association	O
Class	O
III	O
and	O
IV	O
heart	O
failure	O
,	O
recent	O
myocardial	O
infarction	O
,	O
and	O
conduction	O
abnormalities	O
uncontrolled	O
by	O
medications	O
were	O
not	O
eligible	O
for	O
the	O
clinical	O
trials	O
.	O
	
None	O
of	O
the	O
subjects	O
tested	O
positive	O
for	O
neutralizing	O
antibodies	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypertension	B
including	O
hypertensive	B
crisis	I
has	O
been	O
observed	O
.	O
	
*	O
Concomitant	O
neuromuscular	O
disorders	O
may	O
exacerbate	O
clinical	O
effects	O
of	O
treatment	O
(	O
5.5	O
)	O
.	O
	
Patients	O
in	O
the	O
XALKORI	O
arm	O
(	O
n=172	O
)	O
received	O
XALKORI	O
250	O
mg	O
orally	O
twice	O
daily	O
until	O
documented	O
disease	O
progression	O
,	O
intolerance	O
to	O
therapy	O
,	O
or	O
the	O
investigator	O
determined	O
that	O
the	O
patient	O
was	O
no	O
longer	O
experiencing	O
clinical	O
benefit	O
.	O
	
Most	O
of	O
these	O
events	O
were	O
not	O
specific	O
to	O
the	O
injection	O
site	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
Mean	O
changes	B
(	I
percent	I
changes	I
)	I
from	I
baseline	I
in	I
LDL-C	I
relative	O
to	O
placebo	O
were	O
4.4	O
mg/dL	O
(	O
4.5	O
%	O
)	O
and	O
8.2	O
mg/dL	O
(	O
8.0	O
%	O
)	O
with	O
INVOKANA	O
100	O
mg	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
In	O
clinical	O
studies	O
,	O
subjects	O
with	O
impaired	O
renal	O
function	O
were	O
more	O
likely	O
to	O
have	O
greater	O
reductions	O
in	O
serum	O
calcium	O
levels	O
compared	O
to	O
subjects	O
with	O
normal	O
renal	O
function	O
.	O
	
Data	O
are	O
not	O
available	O
to	O
determine	O
whether	O
the	O
rate	O
of	O
death	O
in	O
patients	O
with	O
COPD	O
is	O
increased	O
by	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonists	O
.	O
	
Although	O
the	O
prevalence	O
of	O
the	O
syndrome	O
appears	O
to	O
be	O
highest	O
among	O
the	O
elderly	O
,	O
especially	O
elderly	O
women	O
,	O
it	O
is	O
impossible	O
to	O
rely	O
upon	O
prevalence	O
estimates	O
to	O
predict	O
,	O
at	O
the	O
inception	O
of	O
antipsychotic	O
treatment	O
,	O
which	O
patients	O
are	O
likely	O
to	O
develop	O
the	O
syndrome	O
.	O
	
6.1	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
Adverse	O
reactions	O
were	O
evaluated	O
for	O
1778	O
patients	O
treated	O
with	O
DALVANCE	O
and	O
1224	O
patients	O
treated	O
with	O
comparator	O
antibacterial	O
drugs	O
in	O
seven	O
Phase	O
2	O
and	O
Phase	O
3	O
clinical	O
trials	O
.	O
	
The	O
relationship	O
to	O
TREANDA	O
can	O
not	O
be	O
determined	O
.	O
	
Across	O
the	O
340	O
patients	O
who	O
were	O
treated	O
in	O
Study	O
1	O
,	O
the	O
median	O
age	O
was	O
53	O
years	O
;	O
16	O
%	O
of	O
patients	O
were	O
older	O
than	O
65	O
years	O
.	O
	
5.7	O
Extravasation	O
Injury	O
TREANDA	O
extravasations	B
have	O
been	O
reported	O
in	O
post	O
marketing	O
resulting	O
in	O
hospitalizations	O
from	O
erythema	B
,	O
marked	O
swelling	B
,	O
and	O
pain	B
.	O
	
These	O
metabolic	B
changes	I
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
body	B
weight	I
gain	I
.	O
	
5.7	O
Embryo-Fetal	O
Toxicity	O
JEVTANA	O
is	O
not	O
indicated	O
for	O
use	O
in	O
female	O
patients	O
.	O
	
On	O
average	O
,	O
pain	O
scores	O
returned	O
to	O
baseline	O
by	O
the	O
end	O
of	O
the	O
treatment	O
day	O
and	O
then	O
remained	O
at	O
or	O
below	O
baseline	O
levels	O
.	O
	
[	O
See	O
C	O
ontraindications	O
(	O
4	O
)	O
,	O
W	O
arnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Hypersensitivity	B
reactions	O
,	O
including	O
anaphylaxis	B
,	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
KALBITOR	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
median	O
dose	O
intensity	O
was	O
483	O
mg/day	O
,	O
and	O
500	O
mg/day	O
,	O
in	O
the	O
AP	O
CML	O
and	O
BP	O
CML	O
cohorts	O
,	O
respectively	O
.	O
	
Monitor	O
liver-related	O
laboratory	O
tests	O
.	O
	
Assessment	O
of	O
the	O
incidence	O
of	O
antibody	O
formation	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
Increases	B
in	I
creatinine	I
1.5	O
to	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
occurred	O
in	O
9	O
%	O
of	O
patients	O
.	O
	
The	O
adverse	O
reactions	O
presented	O
in	O
the	O
table	O
below	O
are	O
based	O
on	O
safety	O
information	O
from	O
769	O
patients	O
treated	O
with	O
TECFIDERA	O
240	O
mg	O
twice	O
a	O
day	O
and	O
771	O
placebo-treated	O
patients	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reaction	O
leading	O
to	O
treatment	O
discontinuation	O
was	O
subdural	B
hematoma	I
(	O
1.8	O
%	O
)	O
.	O
	
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=4	O
%	O
Patients	O
Treated	O
with	O
NESINA	O
25	O
mg	O
and	O
More	O
Frequently	O
Than	O
in	O
Patients	O
Given	O
Placebo	O
in	O
Pooled	O
Studies	O
Number	O
of	O
Patients	O
(	O
%	O
)	O
NESINA25	O
mg	O
Placebo	O
Active	O
Comparator	O
N=5902	O
N=2926	O
N=2257	O
Nasopharyngitis	B
257	O
(	O
4.4	O
)	O
89	O
(	O
3.0	O
)	O
113	O
(	O
5.0	O
)	O
Headache	B
247	O
(	O
4.2	O
)	O
72	O
(	O
2.5	O
)	O
121	O
(	O
5.4	O
)	O
Upper	B
Respiratory	I
Tract	I
Infection	I
247	O
(	O
4.2	O
)	O
61	O
(	O
2.1	O
)	O
113	O
(	O
5.0	O
)	O
Pancreatitis	O
In	O
the	O
clinical	O
trial	O
program	O
,	O
pancreatitis	B
was	O
reported	O
in	O
11	O
of	O
5902	O
(	O
0.2	O
%	O
)	O
patients	O
receiving	O
NESINA	O
25	O
mg	O
daily	O
compared	O
to	O
five	O
of	O
5183	O
(	O
<	O
0.1	O
%	O
)	O
patients	O
receiving	O
all	O
comparators	O
.	O
	
Anti-drug	O
antibody	O
titers	O
were	O
sustained	O
or	O
increased	O
for	O
the	O
duration	O
of	O
Vimizim	O
treatment	O
.	O
	
5.3	O
Lymphopenia	O
TECFIDERA	O
may	O
decrease	B
lymphocyte	I
counts	I
.	O
	
(	O
5.2	O
,	O
5.3	O
,	O
5.4	O
)	O
*	O
Hyponatremia	B
:	O
Monitor	O
sodium	O
levels	O
in	O
patients	O
at	O
risk	O
or	O
patients	O
experiencing	O
hyponatremia	O
symptoms	O
.	O
	
(	O
5.1	O
)	O
*	O
Infections	B
:	O
Monitor	O
for	O
fever	O
and	O
other	O
signs	O
of	O
infection	O
and	O
treat	O
promptly	O
.	O
	
*	O
Cytopenias	B
:	O
Check	O
complete	O
blood	O
counts	O
monthly	O
(	O
5.3	O
)	O
.	O
	
Therefore	O
,	O
a	O
lower	O
dose	O
of	O
insulin	O
or	O
insulin	O
secretagogue	O
may	O
be	O
required	O
to	O
minimize	O
the	O
risk	O
of	O
hypoglycemia	O
when	O
used	O
in	O
combination	O
with	O
INVOKANA	O
.	O
	
(	O
5.5	O
)	O
*	O
Other	O
Malignancies	B
:	O
malignant	B
diseases	I
have	O
been	O
reported	O
.	O
	
A	O
grade	O
of	O
0	O
represented	O
no	O
reaction	O
present	O
in	O
the	O
treated	O
area	O
,	O
and	O
a	O
grade	O
of	O
4	O
indicated	O
a	O
marked	O
and	O
severe	O
skin	O
reaction	O
that	O
extended	O
beyond	O
the	O
treated	O
area	O
.	O
	
[	O
See	O
Clinical	O
Studies	O
(	O
14	O
)	O
.	O
]	O
	
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
(	O
3.7	O
%	O
)	O
XIAFLEX-treated	O
patients	O
(	O
5.2	O
)	O
.	O
	
*	O
TRULICITY	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
and	O
in	O
patients	O
with	O
Multiple	O
Endocrine	O
Neoplasia	O
syndrome	O
type	O
2	O
(	O
MEN	O
2	O
)	O
.	O
	
Do	O
not	O
administer	O
COMETRIQ	O
to	O
patients	O
with	O
severe	O
hemorrhage	O
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Discontinuation	O
of	O
PRISTIQ	O
should	O
be	O
considered	O
in	O
patients	O
with	O
symptomatic	O
hyponatremia	O
and	O
appropriate	O
medical	O
intervention	O
should	O
be	O
instituted	O
.	O
	
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
reporting	O
severe	O
adverse	O
gastrointestinal	O
reactions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
Patients	O
were	O
treated	O
with	O
pemetrexed	O
500	O
mg/m2	O
followed	O
after	O
30	O
minutes	O
by	O
cisplatin	O
75	O
mg/m2	O
every	O
three	O
weeks	O
for	O
a	O
maximum	O
of	O
six	O
treatment	O
courses	O
.	O
	
These	O
adverse	O
reactions	O
occurred	O
more	O
frequently	O
among	O
patients	O
with	O
a	O
baseline	O
history	O
of	O
hypertension	O
and	O
among	O
patients	O
receiving	O
concomitant	O
corticosteroids	O
and	O
non-steroidal	O
anti-inflammatory	O
drugs	O
.	O
	
Episodes	O
of	O
sinus	B
tachycardia	I
,	O
associated	O
with	O
a	O
concomitant	O
increase	B
from	I
baseline	I
in	I
heart	I
rate	I
of	O
>	O
=15	O
beats	O
per	O
minute	O
,	O
were	O
reported	O
in	O
0.7	O
%	O
,	O
1.3	O
%	O
and	O
2.2	O
%	O
of	O
patient	O
treated	O
with	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
.	O
	
While	O
these	O
events	O
are	O
generally	O
self-limiting	O
,	O
there	O
have	O
been	O
reports	O
of	O
serious	O
discontinuation	O
symptoms	O
.	O
	
Cases	O
of	O
skin	B
laceration	I
requiring	O
skin	O
graft	O
after	O
finger	O
extension	O
procedures	O
have	O
been	O
reported	O
post-marketing	O
.	O
	
Table	O
1	O
:	O
Selected	O
Adverse	O
Reactions	O
in	O
Study	O
1	O
a	O
Incidences	O
presented	O
in	O
this	O
table	O
are	O
based	O
on	O
reports	O
of	O
adverse	O
events	O
regardless	O
of	O
causality	O
.	O
	
However	O
,	O
the	O
development	O
of	O
neutralizing	O
antibodies	O
may	O
be	O
underreported	O
due	O
to	O
lack	O
of	O
assay	O
sensitivity	O
.	O
	
POTIGA	O
causes	O
mucous	B
membrane	I
discoloration	I
and	O
it	O
is	O
not	O
clear	O
whether	O
this	O
discoloration	B
is	O
related	O
to	O
retinal	B
abnormalities	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
In	O
healthy	O
subjects	O
,	O
large	O
doses	O
of	O
inhaled	O
fluticasone	O
furoate/vilanterol	O
(	O
4	O
times	O
the	O
recommended	O
dose	O
of	O
vilanterol	O
,	O
representing	O
a	O
12-	O
or	O
10-fold	O
higher	O
systemic	O
exposure	O
than	O
seen	O
in	O
subjects	O
with	O
COPD	O
or	O
asthma	O
,	O
respectively	O
)	O
have	O
been	O
associated	O
with	O
clinically	O
significant	O
prolongation	B
of	I
the	I
QTc	I
interval	I
,	O
which	O
has	O
the	O
potential	O
for	O
producing	O
ventricular	B
arrhythmias	I
.	O
	
Placebo-Controlled	O
Experience	O
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
those	O
occurring	O
at	O
an	O
incidence	O
of	O
greater	O
than	O
5	O
%	O
in	O
the	O
NORTHERA	O
group	O
and	O
with	O
at	O
least	O
a	O
3	O
%	O
greater	O
incidence	O
in	O
the	O
NORTHERA	O
group	O
than	O
in	O
the	O
placebo	O
group	O
)	O
in	O
NORTHERA-treated	O
patients	O
during	O
the	O
three	O
placebo-controlled	O
trials	O
were	O
headache	B
,	O
dizziness	B
,	O
nausea	B
,	O
hypertension	B
.	O
	
Chronic	O
antipsychotic	O
treatment	O
should	O
generally	O
be	O
reserved	O
for	O
patients	O
who	O
suffer	O
from	O
a	O
chronic	O
illness	O
that	O
(	O
1	O
)	O
is	O
known	O
to	O
respond	O
to	O
antipsychotic	O
drugs	O
,	O
and	O
(	O
2	O
)	O
for	O
whom	O
alternative	O
,	O
equally	O
effective	O
,	O
but	O
potentially	O
less	O
harmful	O
treatments	O
are	O
not	O
available	O
or	O
appropriate	O
.	O
	
The	O
population	O
in	O
these	O
studies	O
was	O
48	O
%	O
white	O
,	O
13	O
%	O
African/African	O
American	O
,	O
7	O
%	O
Asian	O
,	O
and	O
29	O
%	O
Hispanic/Latino	O
.	O
	
3.7	O
5.7	O
4.3	O
Back	B
pain	I
3.2	O
3.1	O
4.2	O
Increased	O
urinationIncreased	O
urination	B
includes	O
the	O
following	O
adverse	O
reactions	O
,	O
listed	O
in	O
order	O
of	O
frequency	O
reported	O
:	O
pollakiuria	B
,	O
polyuria	B
,	O
and	O
urine	B
output	I
increased	I
.	O
	
Patients	O
with	O
risk	O
factors	O
for	O
diabetes	O
mellitus	O
(	O
e.g.	O
,	O
obesity	O
,	O
family	O
history	O
of	O
diabetes	O
)	O
who	O
are	O
starting	O
treatment	O
with	O
atypical	O
antipsychotics	O
should	O
undergo	O
fasting	O
blood	O
glucose	O
testing	O
at	O
the	O
beginning	O
of	O
treatment	O
and	O
periodically	O
during	O
treatment	O
.	O
	
(	O
5.6	O
)	O
*	O
Monitor	O
for	O
suicidal	O
thoughts	O
or	O
behaviors	O
.	O
	
b	O
Includes	O
the	O
terms	O
injection	B
site	I
haemorrhage	I
,	O
injection	B
site	I
irritation	I
,	O
and	O
injection	B
site	I
pain	I
.	O
	
In	O
clinical	O
trials	O
evaluating	O
BREO	O
ELLIPTA	O
in	O
subjects	O
with	O
COPD	O
or	O
asthma	O
,	O
there	O
was	O
no	O
evidence	O
of	O
a	O
treatment	O
effect	O
on	O
serum	O
glucose	O
or	O
potassium	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Gastrointestinal	B
toxicity	I
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Eight	O
(	O
2	O
%	O
)	O
patients	O
developed	O
antibodies	O
during	O
treatment	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
.	O
	
As	O
appropriate	O
,	O
administer	O
prophylactic	O
antibiotics	O
and	O
employ	O
surveillance	O
testing	O
during	O
treatment	O
with	O
BLINCYTO	O
.	O
	
In	O
those	O
diseases	O
causing	O
thinning	O
of	O
the	O
cornea	O
or	O
sclera	O
,	O
perforations	B
have	O
been	O
known	O
to	O
occur	O
with	O
the	O
use	O
of	O
topical	O
steroids	O
.	O
	
5.6	O
Thyroid	O
Accumulation	O
Failure	O
to	O
block	O
thyroid	O
uptake	O
of	O
iodine	O
123	O
may	O
result	O
in	O
an	O
increased	O
long	O
term	O
risk	O
for	O
thyroid	O
neoplasia	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
TRULICITY	O
has	O
not	O
been	O
evaluated	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
pancreatitis	O
.	O
	
Monitor	O
for	O
the	O
development	O
of	O
severe	O
diarrhea	O
or	O
colitis	O
.	O
	
Table	O
2	O
reports	O
the	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
in	O
either	O
group	O
.	O
	
Most	O
adverse	B
reactions	I
were	I
local	I
events	I
of	I
the	I
penis	I
and	O
the	O
majority	O
of	O
these	O
events	O
were	O
of	O
mild	O
or	O
moderate	O
severity	O
,	O
and	O
most	O
(	O
79	O
%	O
)	O
resolved	O
within	O
14	O
days	O
of	O
the	O
injection	O
.	O
	
Particular	O
care	O
should	O
be	O
taken	O
in	O
observing	O
patients	O
postoperatively	O
or	O
during	O
periods	O
of	O
stress	O
for	O
evidence	O
of	O
inadequate	O
adrenal	O
response	O
.	O
	
Delay	O
in	O
stopping	O
INTELENCE	O
(	O
r	O
)	O
treatment	O
after	O
the	O
onset	O
of	O
severe	O
rash	O
may	O
result	O
in	O
a	O
life-threatening	O
reaction	O
.	O
	
In	O
the	O
Dupuytren	O
's	O
contracture	O
clinical	O
studies	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
at	O
30	O
days	O
post	O
the	O
first	O
injection	O
of	O
XIAFLEX	O
0.58	O
mg	O
,	O
92	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-I	O
detected	O
and	O
86	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-II	O
detected	O
.	O
	
Hepatobiliary	O
disorders	O
:	O
jaundice	B
,	O
hepatomegaly	B
.	O
	
Clinical	O
correlation	O
,	O
including	O
histopathological	O
evaluation	O
of	O
the	O
suspected	O
recurrence	O
site	O
,	O
is	O
essential	O
to	O
proper	O
use	O
of	O
the	O
PET	O
imaging	O
information	O
.	O
	
Grade	O
3-4	O
low	B
serum	I
phosphorus	I
(	O
7	O
%	O
)	O
and	O
low	B
potassium	I
(	O
5	O
%	O
)	O
occurred	O
at	O
a	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
rate	O
in	O
the	O
ZYTIGA	O
arm	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
AGRANULOCYTOSIS/NEUTROPENIA	O
WARNING	O
:	O
AGRANULOCYTOSIS/NEUTROPENIA	O
*	O
Ferriprox	O
can	O
cause	O
agranulocytosis	B
that	O
can	O
lead	O
to	O
serious	O
infections	B
and	O
death	B
.	O
	
Monitor	O
fasting	O
glucose	O
prior	O
to	O
treatment	O
and	O
periodically	O
thereafter	O
as	O
clinically	O
indicated	O
.	O
	
Start	O
Natazia	O
no	O
earlier	O
than	O
4	O
weeks	O
after	O
delivery	O
,	O
in	O
women	O
who	O
are	O
not	O
breastfeeding	O
.	O
	
Patients	O
with	O
unstable	O
cardiac	O
disease	O
,	O
narrow-angle	O
glaucoma	O
,	O
or	O
symptomatic	O
prostatic	O
hypertrophy	O
or	O
bladder	O
outlet	O
obstruction	O
were	O
excluded	O
from	O
these	O
trials	O
.	O
	
There	O
was	O
fatal	B
pneumonia	B
in	O
1	O
subject	O
receiving	O
BREO	O
ELLIPTA	O
100/25	O
and	O
in	O
7	O
subjects	O
receiving	O
BREO	O
ELLIPTA	O
200/25	O
(	O
less	O
than	O
1	O
%	O
for	O
each	O
treatment	O
group	O
)	O
.	O
	
Half	O
of	O
the	O
patients	O
in	O
the	O
controlled	O
trials	O
who	O
discontinued	O
POTIGA	O
due	O
to	O
hallucinations	B
or	O
psychosis	B
required	O
hospitalization	O
.	O
	
During	O
this	O
period	O
of	O
HPA	O
suppression	O
,	O
patients	O
may	O
exhibit	O
signs	O
and	O
symptoms	O
of	O
adrenal	O
insufficiency	O
when	O
exposed	O
to	O
trauma	O
,	O
surgery	O
,	O
or	O
infection	O
(	O
particularly	O
gastroenteritis	O
)	O
or	O
other	O
conditions	O
associated	O
with	O
severe	O
electrolyte	O
loss	O
.	O
	
Event	O
PRADAXA	O
150	O
mgN	O
=	O
6059n	O
(	O
%	O
/year	O
b	O
)	O
WarfarinN	O
=	O
5998n	O
(	O
%	O
/year	O
b	O
)	O
PRADAXA	O
150	O
mgvs	O
.	O
	
Information	O
on	O
the	O
consequences	O
,	O
reversibility	O
,	O
time	O
to	O
onset	O
,	O
and	O
pathophysiology	O
of	O
the	O
skin	B
abnormalities	I
remains	O
incomplete	O
.	O
	
(	O
2.2	O
,	O
5.6	O
)	O
*	O
Pancreatitis	B
:	O
Elevations	B
of	I
lipase	I
and	O
pancreatitis	B
can	O
occur	O
.	O
	
Data	O
from	O
this	O
safety	O
study	O
indicate	O
that	O
the	O
greatest	O
risk	O
of	O
VTE	B
is	O
present	O
after	O
initially	O
starting	O
a	O
COC	O
or	O
restarting	O
(	O
following	O
a	O
4	O
week	O
or	O
greater	O
pill-free	O
interval	O
)	O
the	O
same	O
or	O
a	O
different	O
COC	O
.	O
	
Treatment	O
discontinuation	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
35/1300	O
(	O
2.7	O
%	O
)	O
of	O
patients	O
receiving	O
Teflaro	O
and	O
48/1297	O
(	O
3.7	O
%	O
)	O
of	O
patients	O
receiving	O
comparator	O
drugs	O
with	O
the	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
being	O
hypersensitivity	B
for	O
both	O
treatment	O
groups	O
at	O
a	O
rate	O
of	O
0.3	O
%	O
in	O
the	O
Teflaro	O
group	O
and	O
0.5	O
%	O
in	O
comparator	O
group	O
.	O
	
Nervous	O
system	O
disorders	O
:	O
cerebellar	B
syndrome	I
,	O
cerebral	B
hemorrhage	I
,	O
convulsion	B
,	O
gait	B
disturbance	I
,	O
intracranial	B
pressure	I
increased	I
,	O
psychomotor	B
skills	I
impaired	I
,	O
pyramidal	B
tract	I
syndrome	I
,	O
somnolence	B
.	O
	
One	O
published	O
report	O
of	O
18	O
F-methylcholine	O
PET	O
imaging	O
indicated	O
that	O
discontinuation	O
of	O
colchicine	O
for	O
two	O
weeks	O
resolved	O
the	O
colchicine	O
effect	O
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TRULICITY	O
.	O
	
Reports	O
of	O
penile	O
``	O
popping	O
''	O
sounds	O
or	O
sensations	O
A	O
popping	B
sensation	I
in	I
the	I
penis	I
''	O
,	O
and	O
sometimes	O
accompanied	O
by	O
detumescence	B
,	O
hematoma	B
and/or	O
pain	B
,	O
were	O
reported	O
in	O
73/551	O
(	O
13.2	O
%	O
)	O
XIAFLEX-treated	O
patients	O
and	O
1/281	O
(	O
0.3	O
%	O
)	O
placebo-treated	O
patients	O
.	O
	
Interrupt	O
and	O
then	O
reduce	O
or	O
discontinue	O
Zydelig	O
.	O
	
(	O
6.1	O
)	O
*	O
In	O
pediatric	O
patients	O
age	O
6	O
years	O
and	O
older	O
with	O
ITP	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nasopharyngitis	B
,	O
and	O
rhinitis	B
.	O
	
A	O
total	O
of	O
741	O
patients	O
have	O
been	O
treated	O
with	O
AMPYRA	O
for	O
over	O
six	O
months	O
,	O
501	O
for	O
over	O
one	O
year	O
and	O
352	O
for	O
over	O
two	O
years	O
.	O
	
If	O
such	O
effects	O
occur	O
,	O
BREO	O
ELLIPTA	O
may	O
need	O
to	O
be	O
discontinued	O
.	O
	
Patients	O
were	O
ineligible	O
if	O
AST	O
and/or	O
ALT	O
>	O
=2.5*	O
ULN	O
and	O
patients	O
were	O
excluded	O
if	O
they	O
had	O
liver	O
metastases	O
.	O
	
The	O
adverse	O
reactions	O
described	O
in	O
Table	O
2	O
were	O
identified	O
in	O
750	O
patients	O
treated	O
in	O
Study	O
1	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Serum	O
chemistry	O
abnormalities	O
ALT	B
increased	I
73	O
(	O
50	O
)	O
20	O
(	O
14	O
)	O
7	O
(	O
5	O
)	O
AST	B
increased	I
60	O
(	O
41	O
)	O
12	O
(	O
8	O
)	O
6	O
(	O
4	O
)	O
Hematology	O
abnormalities	O
neutrophils	B
decreased	I
78	O
(	O
53	O
)	O
20	O
(	O
14	O
)	O
16	O
(	O
11	O
)	O
hemoglobin	B
decreased	I
41	O
(	O
28	O
)	O
3	O
(	O
2	O
)	O
0	O
platelets	B
decreased	I
38	O
(	O
26	O
)	O
4	O
(	O
3	O
)	O
5	O
(	O
3	O
)	O
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
FATAL	B
AND	O
SERIOUS	O
TOXICITIES	B
,	O
SEVERE	O
DIARRHEA	B
,	O
COLITIS	B
,	O
PNEUMONITIS	B
,	O
and	O
INTESTINAL	B
PERFORATION	I
WARNING	O
:	O
FATAL	B
AND	O
SERIOUS	O
TOXICITIES	B
,	O
SEVERE	O
DIARRHEA	B
,	O
COLITIS	B
,	O
PNEUMONITIS	B
,	O
and	O
INTESTINAL	B
PERFORATION	I
*	O
Fatal	B
and/or	O
serious	O
hepatotoxicity	B
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
.	O
	
(	O
4	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Vascular	B
risks	I
:	I
Stop	I
Natazia	I
if	I
a	I
thrombotic	I
event	O
occurs	O
.	O
	
An	O
analyses	O
of	O
adjudicated	O
events	O
revealed	O
5	O
cases	O
of	O
confirmed	O
pancreatitis	B
in	O
patients	O
exposed	O
to	O
TRULICITY	O
(	O
1.4	O
cases	O
per	O
1000	O
patient	O
years	O
)	O
versus	O
1	O
case	O
in	O
non-incretin	O
comparators	O
(	O
0.88	O
cases	O
per	O
1000	O
patient	O
years	O
)	O
.	O
	
Delayed	O
AdreView	O
clearance	O
may	O
also	O
reduce	O
the	O
target	O
to	O
background	O
ratios	O
and	O
decrease	O
the	O
quality	O
of	O
scintigraphic	O
images	O
.	O
	
Brentuximab	O
vedotin	O
caused	O
embryo-fetal	B
toxicities	I
,	O
including	O
significantly	O
decreased	B
embryo	I
viability	I
and	O
fetal	B
malformations	I
,	O
in	O
animals	O
at	O
maternal	O
exposures	O
that	O
were	O
similar	O
to	O
human	O
exposures	O
at	O
the	O
recommended	O
doses	O
for	O
patients	O
with	O
classical	O
HL	O
and	O
sALCL	O
.	O
	
Delay	O
administration	O
of	O
HALAVEN	O
and	O
reduce	O
subsequent	O
doses	O
in	O
patients	O
who	O
experience	O
febrile	O
neutropenia	O
or	O
Grade	O
4	O
neutropenia	O
lasting	O
longer	O
than	O
7	O
days	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
I	O
nfections	O
and	O
infestations	O
:	O
cryptococcal	B
cutaneous	I
infection	I
,	O
enteroviral	B
encephalitis	I
,	O
pharyngitis	B
,	O
pneumonia	B
,	O
sepsis	B
,	O
furuncle	B
,	O
infectious	B
hepatitis	I
,	O
rash	B
pustular	I
,	O
subcutaneous	B
abscess	I
.	O
	
However	O
,	O
pregnancy	O
increases	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
as	O
much	O
or	O
more	O
than	O
the	O
use	O
of	O
COCs	O
.	O
	
(	O
5.8	O
,	O
8.1	O
,	O
8.7	O
)	O
5.1	O
Severe	O
or	O
Persistent	O
Gastrointestinal	O
Toxicity	O
Diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
or	O
abdominal	B
pain	I
occurred	O
in	O
96	O
%	O
of	O
255	O
patients	O
including	O
severe	O
cases	O
in	O
14	O
%	O
of	O
patients	O
treated	O
with	O
ZYKADIA	O
in	O
Study	O
1	O
.	O
	
It	O
is	O
predominantly	O
on	O
or	O
around	O
the	O
lips	O
or	O
in	O
the	O
nail	O
beds	O
of	O
the	O
fingers	O
or	O
toes	O
,	O
but	O
more	O
widespread	O
involvement	O
of	O
the	O
face	O
and	O
legs	O
has	O
also	O
been	O
reported	O
.	O
	
Inhaled	O
corticosteroids	O
should	O
be	O
used	O
with	O
caution	O
,	O
if	O
at	O
all	O
,	O
in	O
patients	O
with	O
active	O
or	O
quiescent	O
tuberculosis	O
infections	O
of	O
the	O
respiratory	O
tract	O
;	O
systemic	O
fungal	O
,	O
bacterial	O
,	O
viral	O
,	O
or	O
parasitic	O
infections	O
;	O
or	O
ocular	O
herpes	O
simplex	O
.	O
	
Three	O
of	O
these	O
trials	O
were	O
active-controlled	O
(	O
warfarin	O
)	O
(	O
RE-COVER	O
,	O
RE-COVER	O
II	O
,	O
and	O
RE-MEDY	O
)	O
,	O
and	O
one	O
study	O
(	O
RE-SONATE	O
)	O
was	O
placebo-controlled	O
.	O
	
How	O
the	O
dose	O
,	O
route	O
,	O
and	O
duration	O
of	O
corticosteroid	O
administration	O
affect	O
the	O
risk	O
of	O
developing	O
a	O
disseminated	O
infection	O
is	O
not	O
known	O
.	O
	
Consider	O
an	O
alternate	O
contraceptive	O
method	O
for	O
women	O
with	O
uncontrolled	O
dyslipidemia	O
.	O
	
Monitor	O
liver	O
enzymes	O
and	O
bilirubin	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Interrupt	O
Ferriprox	O
if	O
infection	O
develops	O
,	O
and	O
monitor	O
the	O
ANC	O
more	O
frequently	O
.	O
	
Therefore	O
,	O
XIAFLEX	O
should	O
be	O
injected	O
only	O
into	O
the	O
collagen	O
cord	O
with	O
a	O
MP	O
or	O
PIP	O
joint	O
contracture	O
,	O
and	O
care	O
should	O
be	O
taken	O
to	O
avoid	O
injecting	O
into	O
tendons	O
,	O
nerves	O
,	O
blood	O
vessels	O
,	O
or	O
other	O
collagen-containing	O
structures	O
of	O
the	O
hand	O
.	O
	
Subsequently	O
,	O
the	O
physician	O
may	O
continue	O
decreasing	O
the	O
dose	O
,	O
but	O
at	O
a	O
more	O
gradual	O
rate	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Discontinue	O
COMETRIQ	O
for	O
hypertensive	O
crisis	O
.	O
	
The	O
most	O
frequent	O
(	O
>	O
=2	O
%	O
)	O
serious	O
adverse	O
reactions	O
reported	O
for	O
subjects	O
treated	O
with	O
Zydelig	O
were	O
pneumonia	B
(	O
17	O
%	O
)	O
,	O
pyrexia	B
(	O
9	O
%	O
)	O
,	O
sepsis	B
(	O
8	O
%	O
)	O
,	O
febrile	B
neutropenia	I
(	O
5	O
%	O
)	O
and	O
diarrhea	B
(	O
5	O
%	O
)	O
.	O
	
Reproductive	O
system	O
and	O
breast	O
disorders	O
:	O
Menstrual	B
disorder	I
.	O
	
Upper	B
respiratory	I
tract	I
infection	I
was	O
the	O
most	O
common	O
adverse	O
reaction	O
reported	O
in	O
the	O
trial	O
through	O
Week	O
24	O
occurring	O
in	O
6.5	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
as	O
compared	O
with	O
7.6	O
%	O
of	O
control-treated	O
patients	O
,	O
respectively	O
.	O
	
The	O
safety	O
evaluation	O
of	O
GILOTRIF	O
is	O
based	O
on	O
the	O
data	O
from	O
more	O
than	O
3800	O
patients	O
,	O
including	O
2135	O
NSCLC	O
patients	O
receiving	O
GILOTRIF	O
monotherapy	O
at	O
or	O
above	O
the	O
recommended	O
dose	O
.	O
	
5.5	O
Renal	O
Impairment	O
In	O
patients	O
treated	O
with	O
GLP-1	O
receptor	O
agonists	O
,	O
there	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
renal	I
failure	I
and	O
worsening	O
of	O
chronic	B
renal	I
failure	I
,	O
which	O
may	O
sometimes	O
require	O
hemodialysis	O
.	O
	
The	O
most	O
common	O
adverse	O
event	O
leading	O
to	O
discontinuation	O
,	O
hypotension/orthostatic	O
hypotension	B
,	O
was	O
reported	O
by	O
0.4	O
%	O
(	O
8/2146	O
)	O
patients	O
randomized	O
to	O
Edarbi	O
40	O
mg	O
or	O
80	O
mg	O
compared	O
to	O
0	O
%	O
(	O
0/801	O
)	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
In	O
many	O
cases	O
,	O
this	O
hyponatremia	B
appears	O
to	O
be	O
the	O
result	O
of	O
the	O
syndrome	B
of	I
inappropriate	I
antidiuretic	I
hormone	I
secretion	I
(	O
SIADH	B
)	O
.	O
	
On	O
electrocardiograms	O
,	O
a	O
PR	B
interval	I
increase	I
to	O
at	O
least	O
220	O
milliseconds	O
was	O
observed	O
in	O
0.7	O
%	O
,	O
2.5	O
%	O
and	O
3.2	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
TRULICITY	O
0.75	O
mg	O
and	O
TRULICITY	O
1.5	O
mg	O
,	O
respectively	O
.	O
	
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Infections	B
:	O
Monitor	O
patients	O
for	O
signs	O
or	O
symptoms	O
and	O
treat	O
appropriately	O
.	O
	
(	O
5.1	O
)	O
*	O
Corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
or	O
other	O
serious	O
injury	B
to	I
the	I
penis	I
:	O
Avoid	O
injecting	O
into	O
the	O
urethra	O
,	O
nerves	O
,	O
blood	O
vessels	O
,	O
corpora	O
cavernosa	O
or	O
other	O
collagen-containing	O
structures	O
of	O
the	O
penis	O
.	O
	
In	O
general	O
,	O
discontinuation	O
events	O
occurred	O
more	O
frequently	O
with	O
longer	O
duration	O
of	O
therapy	O
.	O
	
If	O
signs	O
and	O
symptoms	O
fail	O
to	O
improve	O
after	O
2	O
days	O
,	O
the	O
patient	O
should	O
be	O
re-evaluated	O
.	O
	
Grade	O
3	O
or	O
higher	O
(	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
)	O
neurological	B
toxicities	I
following	O
initiation	O
of	O
BLINCYTO	O
administration	O
occurred	O
in	O
approximately	O
15	O
%	O
of	O
patients	O
and	O
included	O
encephalopathy	B
,	O
convulsions	B
,	O
speech	B
disorders	I
,	O
disturbances	B
in	I
consciousness	I
,	O
confusion	B
and	O
disorientation	B
,	O
and	O
balance	B
disorders	I
.	O
	
This	O
assay	O
has	O
substantial	O
limitations	O
in	O
detecting	O
anti-ipilimumab	O
antibodies	O
in	O
the	O
presence	O
of	O
ipilimumab	O
.	O
	
In	O
clinical	O
studies	O
,	O
555	O
patients	O
were	O
exposed	O
to	O
Amyvid	O
.	O
	
*	O
Renal	B
toxicity	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
If	O
a	O
patient	O
develops	O
skin	O
discoloration	O
,	O
serious	O
consideration	O
should	O
be	O
given	O
to	O
an	O
alternative	O
treatment	O
.	O
	
Table	O
1	O
shows	O
common	O
adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
FARXIGA	O
.	O
	
Given	O
these	O
confounders	O
,	O
the	O
relationship	O
between	O
atypical	O
antipsychotic	O
use	O
and	O
hyperglycemia-related	O
adverse	O
events	O
is	O
not	O
completely	O
understood	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
with	O
NORTHERA	O
are	O
included	O
in	O
more	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
of	O
the	O
label	O
:	O
*	O
Supine	B
Hypertension	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Hyperpyrexia	B
and	O
Confusion	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
May	O
exacerbate	B
existing	I
ischemic	I
heart	I
disease	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
EXCERPT	O
:	O
Headache	B
,	O
dizziness	B
,	O
nausea	B
,	O
hypertension	B
,	O
and	O
fatigue	B
(	O
greater	O
than	O
5	O
%	O
)	O
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Lundbeck	O
at	O
1-800-455-1141	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Pool	O
of	O
Placebo-Controlled	O
Trials	O
The	O
data	O
in	O
Table	O
1	O
are	O
derived	O
from	O
4	O
placebo-controlled	O
trials	O
.	O
	
FULYZAQ	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
infectious	O
diarrhea	O
.	O
	
However	O
,	O
some	O
patients	O
may	O
require	O
treatment	O
with	O
FANAPT	O
despite	O
the	O
presence	O
of	O
the	O
syndrome	O
.	O
	
Patients	O
with	O
major	O
risk	O
factors	O
for	O
decreased	O
bone	O
mineral	O
content	O
,	O
such	O
as	O
prolonged	O
immobilization	O
,	O
family	O
history	O
of	O
osteoporosis	O
,	O
postmenopausal	O
status	O
,	O
tobacco	O
use	O
,	O
advanced	O
age	O
,	O
poor	O
nutrition	O
,	O
or	O
chronic	O
use	O
of	O
drugs	O
that	O
can	O
reduce	O
bone	O
mass	O
(	O
e.g.	O
,	O
anticonvulsants	O
,	O
oral	O
corticosteroids	O
)	O
should	O
be	O
monitored	O
and	O
treated	O
with	O
established	O
standards	O
of	O
care	O
.	O
	
Two	O
patients	O
with	O
retinal	B
abnormalities	I
have	O
had	O
more	O
extensive	O
diagnostic	O
retinal	O
evaluations	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
belatacept	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Patients	O
in	O
the	O
study	O
received	O
a	O
median	O
of	O
4	O
doses	O
(	O
range	O
:	O
1-4	O
doses	O
)	O
.	O
	
Anaphylaxis	B
,	O
presenting	O
as	O
cough	B
,	O
erythema	B
,	O
throat	B
tightness	I
,	O
urticaria	B
,	O
flushing	B
,	O
cyanosis	B
,	O
hypotension	B
,	O
rash	B
,	O
dyspnea	B
,	O
chest	B
discomfort	I
,	O
and	O
gastrointestinal	B
symptoms	I
in	O
conjunction	O
with	O
urticaria	B
,	O
have	O
been	O
reported	O
to	O
occur	O
during	O
infusions	O
,	O
regardless	O
of	O
duration	O
of	O
the	O
course	O
of	O
treatment	O
.	O
	
Forty	O
percent	O
of	O
patients	O
had	O
elevated	B
uric	I
acid	I
levels	I
on	O
study	O
including	O
13	O
%	O
with	O
values	O
above	O
10	O
mg/dL	O
.	O
	
All	O
patients	O
treated	O
with	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
tested	O
positive	O
for	O
neutralizing	O
antibodies	O
capable	O
of	O
inhibiting	O
the	O
drug	O
from	O
binding	O
to	O
the	O
mannose-6-phosphate	O
receptor	O
at	O
least	O
once	O
during	O
the	O
trial	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
LEO	O
Pharma	O
Inc.	O
at	O
1-877-494-4536	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
AEDs	O
was	O
observed	O
as	O
early	O
as	O
one	O
week	O
after	O
starting	O
treatment	O
with	O
AEDs	O
and	O
persisted	O
for	O
the	O
duration	O
of	O
treatment	O
assessed	O
.	O
	
Signs	O
and	O
symptoms	O
have	O
included	O
difficulty	B
breathing	I
,	O
urticaria	B
,	O
and	O
swelling	B
of	I
the	I
throat	I
.	O
	
Table	O
5	O
:	O
Change	O
in	O
Body	O
Weight	O
in	O
Adult	O
Patients	O
from	O
Baseline	O
N*	O
=	O
Number	O
of	O
subjects	O
who	O
had	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
Adverse	O
events	O
leading	O
to	O
dose	O
reduction	O
occurred	O
in	O
11	O
%	O
of	O
patients	O
.	O
	
Patients	O
with	O
moderate	O
renal	O
impairment	O
who	O
are	O
taking	O
medications	O
that	O
interfere	O
with	O
potassium	O
excretion	O
,	O
such	O
as	O
potassium-sparing	O
diuretics	O
,	O
or	O
medications	O
that	O
interfere	O
with	O
the	O
renin-angiotensin-aldosterone	O
system	O
are	O
at	O
an	O
increased	O
risk	O
of	O
developing	O
hyperkalemia	B
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
elevations	B
in	I
triglycerides	I
>	O
=200	O
mg/dL	O
(	O
at	O
Endpoint	O
)	O
was	O
15.2	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
11.4	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
after	O
initiating	O
therapy	O
.	O
	
Skin	B
reactions	I
including	O
SJS	B
and	O
TEN	B
have	O
occurred	O
when	O
TREANDA	O
was	O
administered	O
concomitantly	O
with	O
allopurinol	O
and	O
other	O
medications	O
known	O
to	O
cause	O
these	O
syndromes	O
.	O
	
(	O
2.6	O
,	O
5.7	O
)	O
*	O
Drug	B
Induced	I
Liver	I
Injury	I
:	O
Discontinue	O
APTIOM	O
in	O
patients	O
with	O
jaundice	O
or	O
evidence	O
of	O
significant	O
liver	O
injury	O
.	O
	
In	O
a	O
pooled	O
analysis	O
of	O
these	O
14	O
controlled	O
clinical	O
trials	O
,	O
the	O
overall	O
incidence	O
of	O
adverse	O
events	O
was	O
66	O
%	O
in	O
patients	O
treated	O
with	O
NESINA	O
25	O
mg	O
compared	O
to	O
62	O
%	O
with	O
placebo	O
and	O
70	O
%	O
with	O
active	O
comparator	O
.	O
	
The	O
safety	O
and	O
efficacy	O
of	O
ARCAPTA	O
NEOHALER	O
in	O
patients	O
with	O
asthma	O
have	O
not	O
been	O
established	O
.	O
	
In	O
a	O
study	O
of	O
4550	O
postmenopausal	O
women	O
with	O
osteoporosis	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
in	O
serum	O
calcium	O
level	O
10	O
days	O
after	O
Prolia	O
dosing	O
was	O
-5.5	O
%	O
in	O
subjects	O
with	O
creatinine	O
clearance	O
<	O
30	O
mL/min	O
vs.	O
-3.1	O
%	O
in	O
subjects	O
with	O
creatinine	O
clearance	O
>	O
=	O
30	O
mL/min	O
.	O
	
Endocarditis	B
was	O
reported	O
in	O
no	O
placebo	O
patients	O
and	O
3	O
patients	O
receiving	O
Prolia	O
.	O
	
Five	O
of	O
the	O
9	O
SIRTURO	O
deaths	B
and	O
the	O
2	O
placebo	O
deaths	B
were	O
tuberculosis-related	O
.	O
	
The	O
safety	O
population	O
(	O
received	O
at	O
least	O
1	O
dose	O
of	O
BOSULIF	O
)	O
included	O
546	O
CML	O
patients	O
:	O
*	O
287	O
patients	O
with	O
CP	O
CML	O
previously	O
treated	O
with	O
imatinib	O
only	O
who	O
had	O
a	O
median	O
duration	O
of	O
BOSULIF	O
treatment	O
of	O
24	O
months	O
,	O
and	O
a	O
median	O
dose	O
intensity	O
of	O
484	O
mg/day	O
.	O
	
The	O
safety	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
KALBITOR	O
in	O
255	O
patients	O
with	O
HAE	O
treated	O
with	O
either	O
intravenous	O
or	O
subcutaneous	O
KALBITOR	O
.	O
	
In	O
the	O
pooled	O
analysis	O
of	O
8	O
controlled	O
trials	O
,	O
phimosis	B
was	O
reported	O
in	O
0.3	O
%	O
of	O
uncircumcised	O
male	O
patients	O
treated	O
with	O
INVOKANA	O
and	O
0.2	O
%	O
required	O
circumcision	O
to	O
treat	O
the	O
phimosis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
5.6	O
Use	O
in	O
Patients	O
with	O
Hepatic	O
Impairment	O
Cabazitaxel	O
is	O
extensively	O
metabolized	O
in	O
the	O
liver	O
.	O
	
Chemotherapy	O
was	O
given	O
by	O
intravenous	O
infusion	O
every	O
3	O
weeks	O
for	O
up	O
to	O
6	O
cycles	O
,	O
in	O
the	O
absence	O
of	O
dose-limiting	O
chemotherapy-related	O
toxicities	O
.	O
	
Some	O
events	O
occurred	O
when	O
TREANDA	O
was	O
given	O
in	O
combination	O
with	O
other	O
anticancer	O
agents	O
.	O
	
Female	B
patients	I
who	I
developed	I
genital	I
mycotic	I
infections	I
on	O
INVOKANA	O
were	O
more	O
likely	O
to	O
experience	O
recurrence	O
and	O
require	O
treatment	O
with	O
oral	O
or	O
topical	O
antifungal	O
agents	O
and	O
anti-microbial	O
agents	O
.	O
	
There	O
is	O
no	O
known	O
treatment	O
for	O
established	O
cases	O
of	O
TD	O
,	O
although	O
the	O
syndrome	O
may	O
remit	O
,	O
partially	O
or	O
completely	O
,	O
if	O
antipsychotic	O
treatment	O
is	O
withdrawn	O
.	O
	
Controlled	O
Clinical	O
Studies	O
Common	O
Adverse	O
Reactions	O
Adverse	O
reactions	O
occurring	O
in	O
>	O
=	O
5	O
%	O
of	O
patients	O
in	O
the	O
Qutenza	O
group	O
and	O
at	O
an	O
incidence	O
greater	O
than	O
in	O
the	O
control	O
group	O
were	O
application	B
site	I
erythema	I
,	O
application	B
site	I
pain	I
,	O
application	B
site	I
pruritus	I
and	O
application	B
site	I
papules	I
.	O
	
Discontinue	O
SIRTURO	O
if	O
significant	O
ventricular	O
arrhythmia	O
or	O
QTcF	O
interval	O
>	O
500	O
ms	O
develops	O
.	O
	
(	O
5.4	O
)	O
*	O
Life-threatening	O
paradoxical	B
bronchospasm	I
can	O
occur	O
.	O
	
Rare	O
post-marketing	O
cases	O
of	O
hepatosplenic	B
T-cell	I
lymphoma	I
(	O
HSTCL	B
)	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF-blocking	O
agents	O
.	O
	
There	O
is	O
a	O
risk	O
for	O
transmission	O
of	O
Creutzfeldt-Jakob	B
disease	I
(	O
CJD	B
)	O
however	O
,	O
no	O
cases	O
of	O
transmission	O
of	O
viral	B
diseases	I
or	O
CJD	B
have	O
ever	O
been	O
identified	O
for	O
albumin	O
(	O
5.6	O
)	O
5.1	O
Lack	O
of	O
Interchangeability	O
between	O
Botulinum	O
Toxin	O
Products	O
The	O
potency	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
are	O
specific	O
to	O
the	O
preparation	O
and	O
assay	O
method	O
utilized	O
.	O
	
The	O
safety	O
of	O
resuming	O
TNF-blockers	O
after	O
HBV	O
reactivation	O
has	O
been	O
controlled	O
is	O
not	O
known	O
.	O
	
Women	O
enrolled	O
in	O
Studies	O
1	O
and	O
2	O
received	O
calcium	O
(	O
600-1200	O
mg	O
)	O
and	O
vitamin	O
D	O
(	O
200-400	O
IU	O
)	O
daily	O
,	O
while	O
women	O
in	O
Studies	O
3	O
and	O
4	O
received	O
no	O
calcium	O
and	O
vitamin	O
D	O
supplementation	O
as	O
part	O
of	O
the	O
protocol	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
ENDOMETRIAL	B
CANCER	I
,	O
CARDIOVASCULAR	B
DISORDERS	I
,	O
AND	O
PROBABLE	O
DEMENTIA	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
Boxed	O
Warning	O
.	O
	
and	O
untreated	O
or	O
inadequately	O
treated	O
extrapyramidal	O
signs	O
and	O
symptoms	O
(	O
EPS	O
)	O
.	O
	
If	O
serious	O
and/or	O
immediate	O
hypersensitivity	O
reactions	O
occur	O
further	O
injection	O
of	O
XEOMIN	O
should	O
be	O
discontinued	O
and	O
appropriate	O
medical	O
therapy	O
immediately	O
instituted	O
.	O
	
Of	O
these	O
6	O
ADA	O
positive	O
patients	O
,	O
one	O
experienced	O
a	O
hypersensitivity	B
reaction	I
during	O
Study	O
1	O
(	O
2	O
%	O
,	O
1	O
of	O
56	O
)	O
.	O
	
The	O
other	O
patient	O
developed	O
probable	O
PML	B
after	O
taking	O
GILENYA	O
for	O
approximately	O
4	O
years	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
in	O
SAPHRIS-Treated	O
Patients	O
with	O
Schizophrenia	O
:	O
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
SAPHRIS	O
(	O
incidence	O
of	O
2	O
%	O
or	O
greater	O
,	O
rounded	O
to	O
the	O
nearest	O
percent	O
,	O
and	O
SAPHRIS	O
incidence	O
greater	O
than	O
placebo	O
)	O
that	O
occurred	O
during	O
acute	O
therapy	O
(	O
up	O
to	O
6-weeks	O
in	O
patients	O
with	O
schizophrenia	O
)	O
are	O
shown	O
in	O
Table	O
8	O
.	O
	
*	O
Using	O
estrogens	O
may	O
increase	O
your	O
chance	O
of	O
getting	O
cancer	O
of	O
the	O
uterus	O
(	O
womb	O
)	O
.	O
	
Ensure	O
that	O
patients	O
are	O
well	O
hydrated	O
before	O
administration	O
of	O
Kyprolis	O
in	O
Cycle	O
1	O
,	O
and	O
in	O
subsequent	O
cycles	O
as	O
needed	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
Most	O
patients	O
(	O
75	O
%	O
)	O
enrolled	O
in	O
the	O
cUTI	O
trial	O
were	O
female	O
,	O
and	O
most	O
patients	O
(	O
58	O
%	O
)	O
enrolled	O
in	O
the	O
cIAI	O
trial	O
were	O
male	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Because	O
adverse	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormality	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
was	O
hypophosphatemia	B
.	O
	
The	O
early	O
diagnosis	O
of	O
this	O
condition	O
is	O
important	O
for	O
the	O
appropriate	O
management	O
of	O
these	O
patients	O
.	O
	
If	O
an	O
anaphylactic	O
reaction	O
to	O
ZERBAXA	O
occurs	O
,	O
discontinue	O
the	O
drug	O
and	O
institute	O
appropriate	O
therapy	O
.	O
	
The	O
changes	O
in	O
mean	O
serum	O
creatinine	O
were	O
similar	O
to	O
those	O
observed	O
in	O
adults	O
.	O
	
(	O
5.4	O
)	O
*	O
*	O
Hyperglycemia	B
and	O
diabetes	B
mellitus	I
:	O
Monitor	O
patients	O
for	O
symptoms	O
of	O
hyperglycemia	O
including	O
polydipsia	O
,	O
polyuria	O
,	O
polyphagia	O
,	O
and	O
weakness	O
.	O
	
Delayed-onset	O
reactions	O
,	O
defined	O
as	O
adverse	O
reactions	O
occurring	O
2	O
-	O
48	O
hours	O
after	O
completion	O
of	O
alglucosidase	O
alfa	O
infusion	O
,	O
that	O
were	O
observed	O
in	O
>	O
=	O
3	O
%	O
more	O
patients	O
in	O
the	O
alglucosidase	O
alfa-treated	O
group	O
compared	O
to	O
patients	O
in	O
the	O
placebo-treated	O
group	O
in	O
the	O
controlled	O
trial	O
,	O
included	O
hyperhidrosis	B
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
who	O
are	O
treated	O
with	O
atypical	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
and	O
cerebrovascular-related	B
adverse	I
events	I
,	O
including	O
stroke	B
.	O
	
5.7	O
Hypertension	O
Hypertension	B
,	O
including	O
hypertensive	B
crisis	I
and	O
hypertensive	B
emergency	I
,	O
has	O
been	O
observed	O
with	O
Kyprolis	O
.	O
	
The	O
events	O
were	O
reported	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
receiving	O
TIVICAY	O
in	O
Phase	O
3	O
clinical	O
trials	O
.	O
	
b	O
Of	O
the	O
reported	O
adverse	O
drug	O
reactions	O
none	O
were	O
serious	O
.	O
	
The	O
safety	O
of	O
reinitiating	O
Kyprolis	O
therapy	O
in	O
patients	O
previously	O
experiencing	O
PRES	O
is	O
not	O
known	O
.	O
	
If	O
supine	O
hypertension	O
can	O
not	O
be	O
managed	O
by	O
elevation	O
of	O
the	O
head	O
of	O
the	O
bed	O
,	O
reduce	O
or	O
discontinue	O
NORTHERA	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Obtain	O
periodic	O
liver	O
testing	O
in	O
patients	O
during	O
treatment	O
with	O
GILOTRIF	O
.	O
	
The	O
causes	O
of	O
death	B
varied	O
and	O
included	O
complications	B
of	I
infection	I
,	O
surgery	O
and	O
underlying	O
conditions	O
.	O
	
*	O
Fatal	B
anaphylaxis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
5.8	O
Concomitant	O
Administration	O
with	O
CYP3A4	O
Inhibitors	O
*	O
Doses	O
of	O
Toviaz	O
greater	O
than	O
4	O
mg	O
are	O
not	O
recommended	O
in	O
patients	O
taking	O
a	O
potent	O
CYP3A4	O
inhibitor	O
(	O
e.g.	O
,	O
ketoconazole	O
,	O
itraconazole	O
,	O
clarithromycin	O
)	O
.	O
	
Adverse	O
reactions	O
observed	O
in	O
these	O
patients	O
were	O
similar	O
to	O
infantile-onset	O
Pompe	O
disease	O
patients	O
who	O
received	O
alglucosidase	O
alfa	O
in	O
other	O
clinical	O
trials	O
.	O
	
6.2	O
Clinical	O
Trials	O
Experience	O
in	O
Pediatric	O
Subjects	O
IMPAACT	O
P1093	O
is	O
an	O
ongoing	O
multicenter	O
,	O
open-label	O
,	O
non-comparative	O
trial	O
of	O
approximately	O
160	O
HIV-1-infected	O
pediatric	O
subjects	O
aged	O
6	O
weeks	O
to	O
less	O
than	O
18	O
years	O
,	O
of	O
which	O
23	O
treatment-experienced	O
,	O
INSTI-naive	O
subjects	O
aged	O
12	O
to	O
less	O
than	O
18	O
years	O
were	O
enrolled	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
,	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
5.7	O
Intradermal	O
Immune	O
Reaction	O
The	O
possibility	O
of	O
an	O
immune	O
reaction	O
when	O
injected	O
intradermally	O
is	O
unknown	O
.	O
	
The	O
average	O
age	O
was	O
53	O
years	O
(	O
range	O
from	O
0.1	O
to	O
97	O
years	O
)	O
.	O
	
Treatment	O
of	O
cervical	O
dystonia	O
with	O
botulinum	O
toxins	O
may	O
weaken	B
neck	I
muscles	I
that	O
serve	O
as	O
accessory	O
muscles	O
of	O
ventilation	O
.	O
	
Proteinuria	B
(	O
all	O
grades	O
)	O
occurred	O
in	O
52	O
%	O
of	O
subjects	O
receiving	O
STRIBILD	O
,	O
41	O
%	O
of	O
subjects	O
receiving	O
ATRIPLA	O
,	O
and	O
42	O
%	O
of	O
subjects	O
receiving	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
.	O
	
12-Month	O
Trials	O
Long-term	O
safety	O
data	O
is	O
based	O
on	O
two	O
12-month	O
trials	O
(	O
Trials	O
3	O
and	O
4	O
;	O
n	O
=	O
1,633	O
and	O
n	O
=	O
1,622	O
,	O
respectively	O
)	O
.	O
	
Hypokalemia	O
(	O
and/or	O
hypomagnesemia	O
)	O
may	O
increase	O
the	O
risk	O
of	O
QT	O
prolongation	O
and	O
arrhythmia	O
.	O
	
Within	O
each	O
MedDRA	O
system	O
organ	O
class	O
,	O
the	O
adverse	O
reactions	O
are	O
presented	O
in	O
order	O
of	O
decreasing	O
frequency	O
.	O
	
A	O
total	O
of	O
225	O
patients	O
were	O
treated	O
with	O
1,076	O
doses	O
of	O
30	O
mg	O
FIRAZYR	O
for	O
987	O
attacks	O
of	O
acute	O
HAE	O
.	O
	
Macular	B
edema	I
occurred	O
predominantly	O
during	O
the	O
first	O
3	O
to	O
4	O
months	O
of	O
therapy	O
.	O
	
If	O
PML	O
is	O
confirmed	O
,	O
consider	O
discontinuation	O
of	O
immunosuppressant	O
therapy	O
,	O
including	O
BENLYSTA	O
.	O
	
Since	O
all	O
CAPS	O
patients	O
received	O
ILARIS	O
in	O
Part	O
1	O
,	O
there	O
are	O
no	O
controlled	O
data	O
on	O
adverse	O
events	O
(	O
AEs	O
)	O
.	O
	
The	O
safety	O
data	O
described	O
in	O
this	O
section	O
reflect	O
exposure	O
to	O
BLINCYTO	O
in	O
clinical	O
trials	O
in	O
which	O
212	O
patients	O
with	O
relapsed	O
or	O
refractory	O
ALL	O
received	O
up	O
to	O
28	O
mcg/day	O
.	O
	
Before	O
initiating	O
JARDIANCE	O
,	O
assess	O
for	O
volume	O
contraction	O
and	O
correct	O
volume	O
status	O
if	O
indicated	O
.	O
	
Most	O
were	O
Grade	O
1	O
or	O
2	O
events	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
of	O
MTC	O
with	O
the	O
use	O
of	O
TANZEUM	O
and	O
inform	O
them	O
of	O
the	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g.	O
,	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
persistent	O
hoarseness	O
)	O
.	O
	
If	O
anaphylactic	O
or	O
other	O
clinically	O
significant	O
hypersensitivity	O
reactions	O
occur	O
,	O
discontinue	O
Picato	O
(	O
r	O
)	O
immediately	O
and	O
institute	O
appropriate	O
medical	O
therapy	O
.	O
	
(	O
4	O
)	O
Neutropenia	O
:	O
Neutropenic	B
deaths	B
have	O
been	O
reported	O
.	O
	
(	O
5.2	O
)	O
*	O
Angioedema	B
:	O
Patients	O
taking	O
concomitant	O
ACE	O
inhibitor	O
therapy	O
may	O
be	O
at	O
increased	O
risk	O
for	O
angioedema	O
.	O
	
Withhold	O
trametinib	O
if	O
RPED	O
is	O
diagnosed	O
.	O
	
Exercise	O
caution	O
in	O
the	O
peri-surgical	O
period	O
.	O
	
(	O
5.4	O
)	O
5.1	O
Increased	O
Risk	O
of	O
Thrombotic	O
Events	O
after	O
Premature	O
Discontinuation	O
Premature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
ELIQUIS	O
,	O
in	O
the	O
absence	O
of	O
adequate	O
alternative	O
anticoagulation	O
increases	O
the	O
risk	O
of	O
thrombotic	B
events	I
.	O
	
Mortality	B
related	O
to	O
diarrhea	B
has	O
been	O
reported	O
.	O
	
Renal	O
and	O
urinary	O
disorders	O
-	O
Urinary	B
retention	I
.	O
	
Physicians	O
prescribing	O
DIFICID	O
to	O
patients	O
with	O
a	O
known	O
macrolide	O
allergy	O
should	O
be	O
aware	O
of	O
the	O
possibility	O
of	O
hypersensitivity	O
reactions	O
.	O
	
(	O
5.3	O
)	O
*	O
Use	O
in	O
children	O
:	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
should	O
only	O
be	O
used	O
on	O
children	O
under	O
the	O
direct	O
supervision	O
of	O
an	O
adult	O
.	O
	
*	O
Hematologic	B
toxicities	I
:	O
Monitor	O
complete	O
blood	O
counts	O
prior	O
to	O
each	O
dose	O
of	O
ADCETRIS	O
.	O
	
Heart	O
Rate	O
Increase	O
In	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
,	O
mean	B
heart	I
rate	I
in	I
patients	I
treated	I
with	I
TANZEUM	I
was	I
higher	I
by	I
an	I
average	I
of	I
1	I
to	I
2	I
bpm	I
compared	O
with	O
mean	O
heart	O
rate	O
in	O
patients	O
treated	O
with	O
placebo	O
across	O
study	O
visits	O
.	O
	
Study	O
2	O
enrolled	O
patients	O
with	O
a	O
median	O
age	O
of	O
17	O
years	O
(	O
6	O
months	O
to	O
85	O
years	O
)	O
;	O
64	O
%	O
were	O
male	O
,	O
and	O
the	O
underlying	O
malignancies	O
were	O
osteogenic	O
sarcoma	O
in	O
32	O
%	O
,	O
and	O
leukemia	O
or	O
lymphoma	O
in	O
62	O
%	O
of	O
patients	O
.	O
	
5.6	O
Rebound	O
Hypertension	O
Patients	O
who	O
receive	O
prolonged	O
Cleviprex	O
infusions	O
and	O
are	O
not	O
transitioned	O
to	O
other	O
antihypertensive	O
therapies	O
should	O
be	O
monitored	O
for	O
the	O
possibility	O
of	O
rebound	O
hypertension	O
for	O
at	O
least	O
8	O
hours	O
after	O
the	O
infusion	O
is	O
stopped	O
.	O
	
To	O
aid	O
in	O
the	O
management	O
of	O
such	O
patients	O
,	O
consider	O
consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
diagnosis	O
and	O
treatment	O
of	O
invasive	O
fungal	O
infections	O
.	O
	
Some	O
of	O
these	O
infections	B
have	O
been	O
severe	O
(	O
e.g.	O
,	O
leading	O
to	O
sepsis	B
,	O
hepatic	B
failure	I
)	O
or	O
fatal	B
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
drug	O
reactions	O
were	O
infections	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rate	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Development	O
of	O
cardiomyopathy	B
resolved	O
in	O
all	O
five	O
patients	O
following	O
dose	O
reduction	O
(	O
4/55	O
)	O
and/or	O
dose	O
interruption	O
(	O
1/55	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
Reactions	I
Including	O
Anaphylaxis	B
:	O
Anaphylaxis	B
has	O
occurred	O
in	O
4	O
%	O
of	O
treated	O
patients	O
.	O
	
(	O
5.4	O
)	O
*	O
Other	O
serious	O
infections	B
:	O
increased	O
risk	O
of	O
protozoal	B
infections	I
,	O
including	O
opportunistic	B
infections	I
and	O
tuberculosis	B
.	O
	
One	O
subject	O
out	O
of	O
761	O
administered	O
Vizamyl	O
experienced	O
a	O
serious	O
hypersensitivity	B
reaction	I
with	O
flushing	B
,	O
dyspnea	B
and	O
chest	B
pressure	I
within	O
minutes	O
following	O
Vizamyl	O
administration	O
and	O
recovered	O
with	O
treatment	O
.	O
	
(	O
5.1	O
,	O
5.3	O
,	O
5.4	O
,	O
5.5	O
)	O
*	O
Use	O
in	O
liver	O
transplant	O
patients	O
is	O
not	O
recommended	O
due	O
to	O
an	O
increased	O
risk	O
of	O
graft	O
loss	O
and	O
death	O
.	O
	
In	O
the	O
postmarketing	O
experience	O
,	O
hypersensitivity	B
reactions	I
have	O
been	O
reported	O
.	O
	
Three	O
subjects	O
on	O
TANZEUM	O
and	O
one	O
subject	O
in	O
the	O
all-comparator	O
group	O
experienced	O
at	O
least	O
one	O
event	O
of	O
ALT	B
increase	I
of	O
10-fold	O
or	O
greater	O
above	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hepatotoxicity	B
:	O
Monitor	O
liver	O
function	O
before	O
and	O
during	O
therapy	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
:	O
febrile	B
neutropenia	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
*	O
Do	O
not	O
place	O
DUAVEE	O
in	O
pill	O
boxes	O
or	O
pill	O
organizers	O
.	O
	
Discontinue	O
SAPHRIS	O
in	O
patients	O
with	O
severe	O
neutropenia	O
(	O
absolute	O
neutrophil	O
count	O
<	O
1000/mm	O
3	O
)	O
and	O
follow	O
their	O
WBC	O
until	O
recovery	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
prostatic	O
hyperplasia	O
or	O
bladder-neck	O
obstruction	O
and	O
instruct	O
patients	O
to	O
consult	O
a	O
physician	O
immediately	O
if	O
this	O
occurs	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
.	O
	
Procedural	O
Complications	O
:	O
contusion	B
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
ribavirin	O
and	O
peginterferon	O
alfa	O
for	O
guidelines	O
for	O
discontinuation	O
of	O
therapy	O
based	O
on	O
laboratory	O
parameters	O
.	O
	
During	O
clinical	O
development	O
1346	O
patients	O
were	O
exposed	O
to	O
AdreView	O
,	O
251	O
patients	O
with	O
known	O
or	O
suspected	O
pheochromocytoma	O
or	O
neuroblastoma	O
,	O
985	O
patients	O
with	O
heart	O
failure	O
,	O
and	O
110	O
control	O
patients	O
.	O
	
A	O
randomized	O
,	O
parallel-arm	O
,	O
open-label	O
clinical	O
trial	O
was	O
conducted	O
in	O
previously	O
untreated	O
CHC	O
subjects	O
with	O
genotype	O
1	O
infection	O
to	O
compare	O
use	O
of	O
an	O
ESA	O
versus	O
ribavirin	O
dose	O
reduction	O
for	O
initial	O
management	O
of	O
anemia	O
during	O
therapy	O
with	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa-2b	O
and	O
ribavirin	O
.	O
	
Abdominal	O
pain	O
and	O
tenderness	O
,	O
fever	O
,	O
persistent	O
constipation	O
,	O
diarrhea	O
,	O
with	O
or	O
without	O
neutropenia	O
,	O
may	O
be	O
early	O
manifestations	O
of	O
serious	O
gastrointestinal	O
toxicity	O
and	O
should	O
be	O
evaluated	O
and	O
treated	O
promptly	O
.	O
	
Overall	O
,	O
a	O
higher	O
rate	O
of	O
APTC	O
events	O
was	O
observed	O
in	O
ULORIC	O
than	O
in	O
allopurinol-treated	O
patients	O
.	O
	
*	O
Perform	O
test	O
for	O
latent	O
TB	O
;	O
if	O
positive	O
,	O
start	O
treatment	O
for	O
TB	O
prior	O
to	O
starting	O
CIMZIA	O
(	O
5.1	O
)	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
Greater	O
Than	O
or	O
Equal	O
to	O
2	O
%	O
of	O
Patients	O
Treated	O
With	O
STENDRA	O
in	O
an	O
Open-Label	O
Extension	O
Trial	O
Adverse	O
Reaction	O
STENDRA	O
(	O
N	O
=	O
711	O
)	O
Headache	B
5.6	O
%	O
Flushing	B
3.5	O
%	O
Nasopharyngitis	B
3.4	O
%	O
Nasal	B
congestion	I
2.1	O
%	O
Adverse	O
reactions	O
reported	O
by	O
greater	O
than	O
or	O
equal	O
to	O
1	O
%	O
,	O
but	O
less	O
than	O
2	O
%	O
of	O
patients	O
in	O
the	O
open-label	O
extension	O
study	O
included	O
:	O
upper	B
respiratory	I
infection	I
(	O
URI	B
)	O
,	O
influenza	B
,	O
sinusitis	B
,	O
bronchitis	B
,	O
dizziness	B
,	O
back	B
pain	I
,	O
arthralgia	B
,	O
hypertension	B
,	O
and	O
diarrhea	B
.	O
	
SPRINT-1	O
(	O
subjects	O
who	O
were	O
previously	O
untreated	O
)	O
evaluated	O
the	O
use	O
of	O
VICTRELIS	O
in	O
combination	O
with	O
PegIntron/REBETOL	O
with	O
or	O
without	O
a	O
four-week	O
lead-in	O
period	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
PegIntron/REBETOL	O
alone	O
.	O
	
5.3	O
Worsening	O
of	O
Narrow-Angle	O
Glaucoma	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
narrow-angle	O
glaucoma	O
.	O
	
Discontinue	O
PROMACTA	O
if	O
antiviral	O
therapy	O
is	O
discontinued	O
.	O
	
Serious	O
adverse	O
reactions	O
In	O
Studies	O
1	O
and	O
2	O
,	O
serious	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
reported	O
in	O
31	O
%	O
of	O
patients	O
receiving	O
ADCETRIS	O
.	O
	
In	O
postmarketing	O
experience	O
with	O
TUDORZA	O
PRESSAIR	O
,	O
immediate	B
hypersensitivity	I
reactions	I
,	O
including	O
anaphylaxis	B
,	O
angioedema	B
(	O
including	O
swelling	B
of	I
the	I
lips	I
)	O
,	O
urticaria	B
,	O
rash	B
,	O
bronchospasm	B
,	O
or	O
itching	B
have	O
been	O
reported	O
.	O
	
Patients	O
with	O
abnormal	O
LVEF	O
,	O
history	O
of	O
acute	O
coronary	O
syndrome	O
within	O
6	O
months	O
,	O
current	O
evidence	O
of	O
Class	O
II	O
or	O
greater	O
congestive	O
heart	O
failure	O
(	O
New	O
York	O
Heart	O
Association	O
)	O
,	O
history	O
RVO	O
or	O
RPED	O
,	O
QTc	O
interval	O
>	O
=480	O
msec	O
,	O
treatment	O
refractory	O
hypertension	O
,	O
uncontrolled	O
arrhythmias	O
,	O
history	O
of	O
pneumonitis	O
or	O
interstitial	O
lung	O
disease	O
,	O
or	O
a	O
known	O
history	O
of	O
G6PD	O
deficiency	O
were	O
excluded	O
.	O
	
Patients	O
should	O
be	O
instructed	O
to	O
report	O
any	O
symptoms	O
suggestive	O
of	O
endophthalmitis	O
or	O
retinal	O
detachment	O
without	O
delay	O
and	O
should	O
be	O
managed	O
appropriately	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.7	O
)	O
andPatient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
There	O
is	O
neither	O
scientific	O
rationale	O
for	O
reversal	O
nor	O
experience	O
with	O
systemic	O
hemostatics	O
(	O
desmopressin	O
and	O
aprotinin	O
)	O
in	O
individuals	O
receiving	O
apixaban	O
.	O
	
Hypophosphatemia	O
and	O
osteomalacia	O
secondary	O
to	O
proximal	O
renal	O
tubulopathy	O
should	O
be	O
considered	O
in	O
patients	O
at	O
risk	O
of	O
renal	O
dysfunction	O
who	O
present	O
with	O
persistent	O
or	O
worsening	O
bone	O
or	O
muscle	O
symptoms	O
while	O
receiving	O
products	O
containing	O
tenofovir	O
DF	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Discontinue	O
ELIQUIS	O
in	O
patients	O
with	O
active	O
pathological	O
hemorrhage	O
.	O
	
If	O
CDAD	O
is	O
suspected	O
or	O
confirmed	O
,	O
ongoing	O
antibacterial	O
use	O
not	O
directed	O
against	O
C.	O
difficile	O
should	O
be	O
discontinued	O
,	O
if	O
possible	O
.	O
	
The	O
effects	O
of	O
tenofovir	O
DF-associated	O
changes	O
in	O
BMD	O
and	O
biochemical	O
markers	O
on	O
long-term	O
bone	O
health	O
and	O
future	O
fracture	O
risk	O
are	O
unknown	O
.	O
	
Treatment	O
of	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
therapy	O
with	O
TNF-blocking	O
agents	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
tuberculosis	O
reactivation	O
during	O
therapy	O
.	O
	
Discontinue	O
XALKORI	O
in	O
patients	O
with	O
new	O
onset	O
of	O
severe	O
visual	O
loss	O
(	O
best	O
corrected	O
vision	O
less	O
than	O
20/200	O
in	O
one	O
or	O
both	O
eyes	O
)	O
.	O
	
5.6	O
Pulmonary	O
Toxicity	O
Cases	O
of	O
interstitial	B
lung	I
disease	I
including	O
pneumonitis	B
and	O
pulmonary	B
fibrosis	I
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
MULTAQ	O
in	O
the	O
post-marketing	O
setting	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Immune	O
System	O
Disorders	O
:	O
Hypersensitivity	B
manifesting	O
as	O
bullous	B
rash	I
.	O
	
The	O
incidence	O
of	O
reported	O
thromboembolic	B
events	I
in	O
wet	O
AMD	O
studies	O
during	O
the	O
first	O
year	O
was	O
1.8	O
%	O
(	O
32	O
out	O
of	O
1824	O
)	O
in	O
the	O
combined	O
group	O
of	O
patients	O
treated	O
with	O
EYLEA	O
.	O
	
Patients	O
were	O
treated	O
with	O
alglucosidase	O
alfa	O
20	O
or	O
40	O
mg/kg	O
every	O
other	O
week	O
for	O
periods	O
ranging	O
from	O
1	O
to	O
106	O
weeks	O
(	O
mean	O
:	O
61	O
weeks	O
)	O
.	O
	
Do	O
not	O
restart	O
MULTAQ	O
in	O
patients	O
without	O
another	O
explanation	O
for	O
the	O
observed	O
liver	O
injury	O
.	O
	
Optic	B
atrophy	I
and	O
optic	B
nerve	I
disorder	I
have	O
been	O
reported	O
as	O
potential	O
causes	O
of	O
vision	B
loss	I
.	O
	
Assessment	O
of	O
BMD	O
should	O
be	O
considered	O
for	O
HIV-1	O
infected	O
patients	O
who	O
have	O
a	O
history	O
of	O
pathologic	O
bone	O
fracture	O
or	O
other	O
risk	O
factors	O
for	O
osteoporosis	O
or	O
bone	O
loss	O
.	O
	
5.6	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
trials	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TANZEUM	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Careful	O
medical	O
history	O
is	O
necessary	O
because	O
CDAD	O
has	O
been	O
reported	O
to	O
occur	O
more	O
than	O
2	O
months	O
after	O
the	O
administration	O
of	O
antibacterial	O
agents	O
.	O
	
There	O
is	O
no	O
established	O
way	O
to	O
reverse	O
the	O
anticoagulant	O
effect	O
of	O
apixaban	O
,	O
which	O
can	O
be	O
expected	O
to	O
persist	O
for	O
at	O
least	O
24	O
hours	O
after	O
the	O
last	O
dose	O
,	O
i.e.	O
,	O
for	O
about	O
two	O
drug	O
half-lives	O
.	O
	
Approximately	O
half	O
of	O
the	O
patients	O
(	O
54	O
%	O
)	O
were	O
male	O
.	O
	
SERIOUS	O
INFECTIONS	O
Patients	O
treated	O
with	O
SIMPONI	O
ARIA	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
ATEs	O
are	O
defined	O
as	O
nonfatal	O
stroke	O
,	O
nonfatal	O
myocardial	O
infarction	O
,	O
or	O
vascular	O
death	O
(	O
including	O
deaths	O
of	O
unknown	O
cause	O
)	O
.	O
	
Other	O
clinically	O
important	O
adverse	O
reactions	O
observed	O
in	O
<	O
10	O
%	O
of	O
patients	O
(	O
N	O
=	O
586	O
)	O
treated	O
with	O
TAFINLAR	O
were	O
:	O
Gastrointestinal	O
Disorders	O
:	O
Pancreatitis	B
.	O
	
Electrocardiogram	O
(	O
ECG	O
)	O
measurements	O
were	O
taken	O
at	O
various	O
time	O
points	O
during	O
the	O
SAPHRIS	O
clinical	O
trial	O
program	O
(	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
doses	O
)	O
.	O
	
Proper	O
aseptic	O
injection	O
technique	O
must	O
always	O
be	O
used	O
when	O
administering	O
EYLEA	O
.	O
	
Table	O
5	O
presents	O
adverse	O
reactions	O
from	O
Trial	O
2	O
,	O
a	O
multicenter	O
,	O
open-label	O
,	O
randomized	O
trial	O
of	O
162	O
patients	O
with	O
BRAF	O
V600E	O
or	O
V600K	O
mutation-positive	O
melanoma	O
receiving	O
TAFINLAR	O
150	O
mg	O
twice	O
daily	O
in	O
combination	O
with	O
trametinib	O
2	O
mg	O
orally	O
once	O
daily	O
(	O
n	O
=	O
55	O
)	O
,	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
in	O
combination	O
with	O
trametinib	O
1	O
mg	O
once	O
daily	O
(	O
n	O
=	O
54	O
)	O
,	O
and	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
150	O
mg	O
orally	O
twice	O
daily	O
(	O
n	O
=	O
53	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Initiate	O
treatment	O
for	O
latent	O
tuberculosis	O
prior	O
to	O
SIMPONI	O
ARIA	O
use	O
.	O
	
5.7	O
Fat	O
Redistribution	O
buffalo	B
hump	I
,	O
facial	B
wasting	I
,	O
breast	B
enlargement	I
,	O
and	O
``	O
cushingoid	B
appearance	I
''	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O
	
Use	O
of	O
procoagulant	O
reversal	O
agents	O
such	O
as	O
prothrombin	O
complex	O
concentrate	O
,	O
activated	O
prothrombin	O
complex	O
concentrate	O
,	O
or	O
recombinant	O
factor	O
VIIa	O
may	O
be	O
considered	O
but	O
has	O
not	O
been	O
evaluated	O
in	O
clinical	O
studies	O
.	O
	
Dronedarone	O
caused	O
fetal	B
harm	I
in	O
animal	O
studies	O
at	O
doses	O
equivalent	O
to	O
recommended	O
human	O
doses	O
.	O
	
*	O
CIMZIA	O
should	O
be	O
discontinued	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
or	O
sepsis	O
(	O
5.1	O
)	O
.	O
	
In	O
the	O
long-term	O
extension	O
studies	O
,	O
the	O
incidences	O
of	O
adjudicated	O
APTC	O
events	O
were	O
:	O
ULORIC	O
80	O
mg	O
0.97	O
(	O
95	O
%	O
CI	O
0.57-1.56	O
)	O
,	O
and	O
allopurinol	O
0.58	O
(	O
95	O
%	O
CI	O
0.02-3.24	O
)	O
.	O
	
Report	O
any	O
diagnosis	O
of	O
NSF	O
following	O
EOVIST	O
administration	O
to	O
Bayer	O
HealthCare	O
(	O
1-888-842-2937	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
)	O
.	O
	
JEVTANA	O
treatment	O
delay	O
or	O
discontinuation	O
may	O
be	O
necessary	O
.	O
	
Similar	O
SVR	O
rates	O
were	O
reported	O
in	O
subjects	O
who	O
were	O
randomized	O
to	O
receive	O
ribavirin	O
dose	O
reduction	O
compared	O
to	O
subjects	O
who	O
were	O
randomized	O
to	O
receive	O
an	O
ESA	O
.	O
	
*	O
If	O
you	O
have	O
high	O
blood	O
pressure	O
,	O
high	O
cholesterol	O
(	O
fat	O
in	O
the	O
blood	O
)	O
,	O
diabetes	O
,	O
are	O
overweight	O
,	O
or	O
if	O
you	O
use	O
tobacco	O
,	O
you	O
may	O
have	O
higher	O
chances	O
of	O
getting	O
heart	O
disease	O
.	O
	
A	O
causal	O
association	O
with	O
single-agent	O
ADCETRIS	O
has	O
not	O
been	O
established	O
.	O
	
5.2	O
Hepatotoxicity	O
PROMACTA	O
can	O
cause	O
liver	B
enzyme	I
elevations	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.5	O
Recrudescence	O
Food	O
enhances	O
absorption	O
of	O
artemether	O
and	O
lumefantrine	O
following	O
administration	O
of	O
Coartem	O
Tablets	O
.	O
	
The	O
safety	O
of	O
the	O
combination	O
of	O
VICTRELIS	O
800	O
mg	O
three	O
times	O
daily	O
with	O
PegIntron/REBETOL	O
was	O
assessed	O
in	O
2095	O
subjects	O
with	O
chronic	O
hepatitis	O
C	O
in	O
one	O
Phase	O
2	O
,	O
open-label	O
trial	O
and	O
two	O
Phase	O
3	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trials	O
.	O
	
Prescribers	O
and	O
patients	O
should	O
be	O
alert	O
for	O
signs	O
and	O
symptoms	O
of	O
acute	O
narrow-angle	O
glaucoma	O
(	O
e.g.	O
,	O
eye	O
pain	O
or	O
discomfort	O
,	O
blurred	O
vision	O
,	O
visual	O
halos	O
or	O
colored	O
images	O
in	O
association	O
with	O
red	O
eyes	O
from	O
conjunctival	O
congestion	O
and	O
corneal	O
edema	O
)	O
.	O
	
Discontinue	O
SIMPONI	O
ARIA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
,	O
an	O
opportunistic	O
infection	O
,	O
or	O
sepsis	O
.	O
	
In	O
total	O
,	O
536	O
(	O
approximately	O
75	O
%	O
)	O
patients	O
increased	O
their	O
dose	O
to	O
200	O
mg	O
and	O
5	O
(	O
less	O
than	O
1	O
%	O
)	O
patients	O
reduced	O
their	O
dose	O
to	O
50	O
mg.	O
Table	O
2	O
presents	O
the	O
adverse	O
reactions	O
reported	O
when	O
STENDRA	O
was	O
taken	O
as	O
recommended	O
(	O
on	O
an	O
as-needed	O
basis	O
)	O
in	O
this	O
open-label	O
extension	O
trial	O
.	O
	
(	O
5.4	O
)	O
*	O
Immediate	O
hypersensitivity	B
reactions	I
:	O
Discontinue	O
TUDORZA	O
PRESSAIR	O
at	O
once	O
and	O
consider	O
alternatives	O
if	O
immediate	O
hypersensitivity	O
reactions	O
,	O
including	O
angioedema	O
,	O
bronchospasm	O
,	O
or	O
anaphylaxis	O
,	O
occur	O
.	O
	
Monitor	O
patients	O
with	O
clinically	O
significant	O
neutropenia	O
for	O
fever	O
or	O
other	O
symptoms	O
or	O
signs	O
of	O
infection	O
and	O
treat	O
promptly	O
if	O
such	O
symptoms	O
or	O
signs	O
occur	O
.	O
	
*	O
After	O
opening	O
the	O
foil	O
pouch	O
the	O
DUAVEE	O
blisters	O
come	O
in	O
,	O
DUAVEE	O
must	O
be	O
used	O
within	O
60	O
days	O
.	O
	
In	O
three	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
lasting	O
up	O
to	O
3	O
months	O
in	O
duration	O
,	O
the	O
mean	O
age	O
of	O
patients	O
was	O
56.4	O
years	O
(	O
range	O
from	O
23	O
to	O
88	O
years	O
)	O
.	O
	
(	O
5.2	O
)	O
*	O
Thromboembolic	B
Complications	I
:	O
Portal	B
vein	I
thrombosis	I
has	O
been	O
reported	O
in	O
patients	O
with	O
chronic	O
liver	O
disease	O
receiving	O
PROMACTA	O
.	O
	
6.1	O
Clinical	O
Study	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.5	O
Hypersensitivity	O
Serious	O
acute	B
hypersensitivity	I
reactions	I
(	O
e.g.	O
,	O
urticaria	B
,	O
angioedema	B
)	O
have	O
been	O
observed	O
during	O
combination	O
therapy	O
with	O
VICTRELIS	O
,	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
Most	O
Common	O
Adverse	O
Reactions	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
DALVANCE	O
were	O
nausea	B
(	O
5.5	O
%	O
)	O
,	O
headache	B
(	O
4.7	O
%	O
)	O
,	O
and	O
diarrhea	B
(	O
4.4	O
%	O
)	O
.	O
	
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
EOVIST	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
from	O
the	O
body	O
prior	O
to	O
any	O
re-administration	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Increased	B
susceptibility	I
to	I
infection	I
and	O
the	O
possible	O
development	O
of	O
malignancies	B
may	O
result	O
from	O
immunosuppression	O
.	O
	
Permanently	O
discontinue	O
TAFINLAR	O
and	O
trametinib	O
for	O
all	O
Grade	O
4	O
hemorrhagic	O
events	O
and	O
for	O
any	O
Grade	O
3	O
hemorrhagic	O
events	O
that	O
do	O
not	O
improve	O
.	O
	
Most	O
adverse	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
intensity	O
and	O
resolved	O
spontaneously	O
.	O
	
In	O
one	O
of	O
the	O
3	O
cases	O
an	O
alternate	O
etiology	O
was	O
identified	O
to	O
explain	O
the	O
rise	B
in	I
liver	I
enzyme	I
(	O
acute	O
viral	O
hepatitis	O
)	O
.	O
	
Consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
is	O
recommended	O
to	O
aid	O
in	O
the	O
decision	O
whether	O
initiating	O
anti-tuberculosis	O
therapy	O
is	O
appropriate	O
for	O
an	O
individual	O
patient	O
.	O
	
Beta-blockers	O
should	O
be	O
withdrawn	O
only	O
after	O
a	O
gradual	O
reduction	O
in	O
dose	O
.	O
	
Recommended	O
doses	O
of	O
immunosuppressants	O
should	O
not	O
be	O
exceeded	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
administered	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
8	O
%	O
of	O
patients	O
developed	O
evidence	O
of	O
cardiomyopathy	B
(	O
decrease	B
in	I
LVEF	I
below	O
institutional	O
lower	O
limits	O
of	O
normal	O
with	O
an	O
absolute	B
decrease	I
in	I
LVEF	I
>	O
=10	O
%	O
below	O
baseline	O
)	O
.	O
	
In	O
the	O
AMPLIFY	O
study	O
,	O
ELIQUIS	O
was	O
statistically	O
superior	O
to	O
enoxaparin/warfarin	O
in	O
the	O
primary	O
safety	O
endpoint	O
of	O
major	O
bleeding	B
(	O
relative	O
risk	O
0.31	O
,	O
95	O
%	O
CI	O
[	O
0.17	O
,	O
0.55	O
]	O
,	O
P-value	O
<	O
0.0001	O
)	O
.	O
	
Administer	O
KALBITOR	O
in	O
a	O
setting	O
equipped	O
to	O
manage	O
anaphylaxis	O
and	O
hereditary	O
angioedema	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Piramal	O
at	O
1-855-545-5245	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
majority	O
of	O
the	O
events	O
were	O
mild	O
to	O
moderate	O
although	O
serious	O
infections	B
were	O
observed	O
.	O
	
Physicians	O
and	O
patients	O
should	O
be	O
aware	O
of	O
the	O
increased	O
risk	O
of	O
infection	O
with	O
AFINITOR	O
.	O
	
5.3	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
DIFICID	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
C.	O
difficile	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
increases	O
the	O
risk	O
of	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
(	O
4	O
)	O
(	O
5.2	O
)	O
*	O
Gastrointestinal	B
disorders	I
:	O
Nausea	B
,	O
vomiting	B
,	O
and	O
diarrhea	B
may	O
occur	O
.	O
	
Prosthetic	O
heart	O
valves	O
:	O
ELIQUIS	O
use	O
not	O
recommended	O
.	O
	
The	O
long-term	O
clinical	O
effects	O
of	O
the	O
increase	B
in	I
heart	I
rate	I
have	O
not	O
been	O
established	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
One	O
(	O
n=122	O
)	O
or	O
2	O
(	O
n=	O
18	O
)	O
doses	O
of	O
VORAXAZE	O
were	O
administered	O
intravenously	O
;	O
the	O
number	O
of	O
doses	O
was	O
not	O
specified	O
for	O
1	O
patient	O
.	O
	
Renal	O
function	O
should	O
be	O
evaluated	O
prior	O
to	O
initiating	O
JARDIANCE	O
and	O
periodically	O
thereafter	O
.	O
	
Closely	O
monitor	O
patients	O
for	O
fever	O
.	O
	
Keep	O
out	O
of	O
reach	O
of	O
children	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
and	O
allergic	B
contact	I
dermatitis	I
,	O
have	O
been	O
reported	O
post-marketing	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
monitoring	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TANZEUM	O
[	O
see	O
Contraindications	O
(	O
4.1	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
All	O
patients	O
were	O
treated	O
with	O
ILARIS	O
150	O
mg	O
subcutaneously	O
or	O
2	O
mg/kg	O
if	O
body	O
weight	O
was	O
greater	O
than	O
or	O
equal	O
to	O
15	O
kg	O
and	O
less	O
than	O
or	O
equal	O
to	O
40	O
kg	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
If	O
resolution	O
of	O
the	O
RPED	O
is	O
documented	O
on	O
repeat	O
ophthalmological	O
evaluation	O
within	O
3	O
weeks	O
,	O
resume	O
trametinib	O
at	O
a	O
lower	O
dose	O
level	O
.	O
	
(	O
5.3	O
)	O
*	O
Oral	B
ulceration	I
:	O
Mouth	B
ulcers	I
,	O
stomatitis	B
,	O
and	O
oral	B
mucositis	I
are	O
common	O
.	O
	
(	O
2.1	O
)	O
(	O
5.2	O
)	O
*	O
Contraindicated	O
if	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
JEVTANA	O
or	O
to	O
drugs	O
formulated	O
with	O
polysorbate	O
80	O
.	O
	
FANAPT	O
should	O
be	O
avoided	O
in	O
patients	O
with	O
histories	O
of	O
significant	O
cardiovascular	O
illness	O
,	O
e.g.	O
,	O
QT	O
prolongation	O
,	O
recent	O
acute	O
myocardial	O
infarction	O
,	O
uncompensated	O
heart	O
failure	O
,	O
or	O
cardiac	O
arrhythmia	O
.	O
	
These	O
findings	O
were	O
consistent	O
with	O
data	O
from	O
an	O
earlier	O
144-week	O
trial	O
of	O
treatment-naive	O
subjects	O
receiving	O
tenofovir	O
DF	O
+	O
lamivudine	O
+	O
efavirenz	O
.	O
	
Aspiration	B
may	O
result	O
from	O
severe	O
dysphagia	B
and	O
is	O
a	O
particular	O
risk	O
when	O
treating	O
patients	O
in	O
whom	O
swallowing	O
or	O
respiratory	O
function	O
is	O
already	O
compromised	O
.	O
	
(	O
5.2	O
)	O
*	O
Hypersensitivity	B
Reactions	I
,	O
including	O
Anaphylaxis	B
:	O
Serious	O
and	O
fatal	B
reactions	O
have	O
been	O
reported	O
.	O
	
These	O
clinical	O
trials	O
excluded	O
patients	O
with	O
diabetes	O
mellitus	O
,	O
a	O
known	O
risk	O
factor	O
for	O
macular	O
edema	O
(	O
see	O
below	O
Macular	O
Edema	O
in	O
Patients	O
with	O
History	O
of	O
Uveitis	O
or	O
Diabetes	O
Mellitus	O
)	O
.	O
	
For	O
patients	O
who	O
develop	O
prolonged	O
Grade	O
2	O
diarrhea	O
lasting	O
more	O
than	O
48	O
hours	O
or	O
greater	O
than	O
or	O
equal	O
to	O
Grade	O
3	O
diarrhea	O
,	O
withhold	O
GILOTRIF	O
until	O
diarrhea	O
resolves	O
to	O
Grade	O
1	O
or	O
less	O
,	O
and	O
resume	O
GILOTRIF	O
with	O
appropriate	O
dose	O
reduction	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
similar	O
in	O
nature	O
and	O
frequency	O
were	O
observed	O
to	O
those	O
seen	O
in	O
the	O
controlled	O
phase	O
of	O
the	O
trials	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Table	O
6	O
compares	O
the	O
incidence	O
of	O
treatment-emergent	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
10	O
mg	O
daily	O
versus	O
placebo	O
.	O
	
5.7	O
Renal	O
Impairment	O
Doses	O
of	O
Toviaz	O
greater	O
than	O
4	O
mg	O
are	O
not	O
recommended	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
[	O
see	O
Use	O
In	O
Specific	O
Populations	O
(	O
8.6	O
)	O
and	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Mortality	B
:	O
There	O
were	O
more	O
deaths	B
reported	O
with	O
BENLYSTA	O
than	O
with	O
placebo	O
during	O
the	O
controlled	O
period	O
of	O
clinical	O
trials	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
SUPINE	B
HYPERTENSION	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
In	O
clinical	O
trials	O
where	O
ethnicity	O
was	O
recorded	O
the	O
ethnic	O
distribution	O
was	O
74	O
%	O
Caucasian	O
,	O
12	O
%	O
Asian	O
,	O
4	O
%	O
Black	O
,	O
and	O
10	O
%	O
others	O
.	O
	
No	O
cases	O
of	O
transmission	O
of	O
viral	B
diseases	I
or	O
CJD	B
have	O
ever	O
been	O
reported	O
for	O
albumin	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
was	O
similar	O
to	O
that	O
for	O
adults	O
.	O
	
Additional	O
hypersensitivity	B
reactions	I
observed	O
in	O
infantile-onset	O
Pompe	O
disease	O
patients	O
treated	O
in	O
other	O
clinical	O
trials	O
and	O
expanded	O
access	O
programs	O
with	O
alglucosidase	O
alfa	O
included	O
livedo	B
reticularis	I
,	O
irritability	B
,	O
retching	B
,	O
increased	B
lacrimation	I
,	O
ventricular	B
extrasystoles	I
,	O
nodal	B
rhythm	I
,	O
rales	B
,	O
respiratory	B
tract	I
irritation	I
,	O
and	O
cold	B
sweat	I
.	O
	
(	O
all	O
grades	O
)	O
Reported	O
in	O
>	O
=	O
5	O
%	O
of	O
Subjects	O
in	O
Any	O
Treatment	O
Arm	O
in	O
Studies	O
102	O
and	O
103	O
(	O
Week	O
144	O
analysis	O
)	O
.	O
	
Consider	O
whether	O
to	O
restart	O
Kyprolis	O
based	O
on	O
a	O
benefit/risk	O
assessment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Warnings	O
and	O
Precautions	O
-	O
Cardiac	O
Toxicities	O
(	O
5.1	O
)	O
,	O
Pulmonary	O
Toxicity	O
(	O
5.4	O
)	O
,	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Discontinue	O
Kyprolis	O
if	O
PRES	O
is	O
suspected	O
and	O
evaluate	O
.	O
	
Dizziness	B
,	O
somnolence	B
,	O
fatigue	B
,	O
and	O
insomnia	B
appeared	O
to	O
show	O
a	O
dose	O
relationship	O
.	O
	
c	O
n	O
(	O
%	O
)	O
indicates	O
number	O
of	O
patients	O
and	O
percent	O
.	O
	
Table	O
7	O
:	O
Key	O
Laboratory	O
Abnormalities	O
Reported	O
in	O
Patients	O
with	O
RCC	O
at	O
a	O
Higher	O
Rate	O
in	O
the	O
AFINITOR	O
Arm	O
than	O
the	O
Placebo	O
Arm	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Reflects	O
corresponding	O
adverse	O
drug	O
reaction	O
reports	O
of	O
anemia	B
,	O
leukopenia	B
,	O
lymphopenia	B
,	O
neutropenia	B
,	O
and	O
thrombocytopenia	B
(	O
collectively	O
pancytopenia	B
)	O
,	O
which	O
occurred	O
at	O
lower	O
frequency	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
are	O
:	O
fatigue	B
,	O
headache	B
,	O
nausea	B
,	O
diarrhea	B
,	O
back	B
pain	I
,	O
pain	B
in	I
extremities	I
,	O
and	O
upper	B
abdominal	I
pain	I
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Genzyme	O
Corporation	O
at	O
1-800-745-4447	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.3	O
Clostridium	O
difficile	O
-associated	O
Diarrhea	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
for	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
ZERBAXA	O
,	O
and	O
may	O
range	O
in	O
severity	O
from	O
mild	O
diarrhea	B
to	O
fatal	B
colitis	B
.	O
	
5.3	O
Ischemic	O
Heart	O
Disease	O
,	O
Arrhythmias	O
,	O
and	O
Congestive	O
Heart	O
Failure	O
NORTHERA	O
may	O
exacerbate	B
existing	I
ischemic	I
heart	I
disease	I
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
hypercholesterolemia	B
,	O
hypertriglyceridemia	B
,	O
and	O
anemia	B
.	O
	
Additional	O
delayed-onset	O
reactions	O
occurring	O
in	O
alglucosidase	O
alfa-treated	O
patients	O
included	O
fatigue	B
,	O
myalgia	B
,	O
and	O
nausea	B
.	O
	
Monitor	O
glucose	O
regularly	O
in	O
patients	O
at	O
risk	O
for	O
diabetes	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
reactions	I
characterized	O
by	O
rash	B
,	O
constitutional	O
findings	O
,	O
and	O
sometimes	O
organ	B
dysfunction	I
,	O
including	O
liver	B
injury	I
,	O
have	O
been	O
reported	O
.	O
	
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
DYSPORT	O
(	O
r	O
)	O
:	O
vertigo	B
,	O
photophobia	B
,	O
influenza-like	B
illness	I
,	O
amyotrophy	B
,	O
burning	B
sensation	I
,	O
facial	B
paresis	I
,	O
hypoesthesia	B
,	O
erythema	B
,	O
and	O
excessive	B
granulation	I
tissue	I
.	O
	
In	O
both	O
indications	O
,	O
about	O
25	O
%	O
of	O
the	O
subjects	O
were	O
65	O
years	O
of	O
age	O
or	O
older	O
.	O
	
In	O
all	O
clinical	O
studies	O
,	O
including	O
uncontrolled	O
extension	O
studies	O
,	O
the	O
exposure	O
to	O
GILENYA	O
0.5	O
mg	O
was	O
approximately	O
4119	O
person-years	O
.	O
	
Consider	O
uric	O
acid	O
lowering	O
drugs	O
in	O
patients	O
at	O
risk	O
for	O
TLS	O
.	O
	
*	O
Do	O
not	O
take	O
additional	O
estrogen	O
products	O
while	O
you	O
are	O
taking	O
DUAVEE	O
.	O
	
Of	O
these	O
1368	O
patients	O
,	O
safety	O
data	O
were	O
received	O
for	O
940	O
patients	O
with	O
a	O
median	O
age	O
of	O
9	O
years	O
(	O
0	O
to	O
76	O
years	O
)	O
,	O
63	O
%	O
were	O
male	O
,	O
91	O
%	O
with	O
leukemia	O
,	O
3	O
%	O
with	O
lymphoma	O
,	O
and	O
6	O
%	O
with	O
unknown	O
disease	O
information	O
.	O
	
breathing	B
difficulties	I
can	O
be	O
life	O
threatening	O
and	O
there	O
have	O
been	O
reports	O
of	O
death	B
related	O
to	O
the	O
spread	B
of	I
toxin	I
effects	I
.	O
	
Extrapyramidal	B
symptoms	I
included	O
:	O
dystonia	B
,	O
blepharospasm	B
,	O
torticollis	B
,	O
dyskinesia	B
,	O
tardive	B
dyskinesia	I
,	O
muscle	B
rigidity	I
,	O
parkinsonism	B
,	O
gait	B
disturbance	I
,	O
masked	B
facies	I
,	O
and	O
tremor	B
(	O
excluding	O
akathisia	B
)	O
.	O
	
There	O
were	O
no	O
drug-related	O
adverse	O
reactions	O
associated	O
with	O
discontinuation	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
at	O
the	O
rate	O
of	O
at	O
least	O
1	O
%	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
.	O
	
While	O
adequate	O
hydration	O
is	O
required	O
prior	O
to	O
each	O
dose	O
in	O
Cycle	O
1	O
,	O
all	O
patients	O
should	O
also	O
be	O
monitored	O
for	O
evidence	O
of	O
volume	O
overload	O
,	O
especially	O
patients	O
at	O
risk	O
for	O
cardiac	O
failure	O
.	O
	
*	O
Using	O
estrogens	O
may	O
increase	O
your	O
chances	O
of	O
getting	O
strokes	O
or	O
blood	O
clots	O
.	O
	
In	O
arriving	O
at	O
a	O
diagnosis	O
,	O
it	O
is	O
important	O
to	O
identify	O
cases	O
in	O
which	O
the	O
clinical	O
presentation	O
includes	O
both	O
serious	O
medical	O
illness	O
(	O
e.g.	O
,	O
pneumonia	O
,	O
systemic	O
infection	O
,	O
etc	O
.	O
)	O
	
Estrogens	O
should	O
be	O
prescribed	O
at	O
the	O
lowest	O
effective	O
doses	O
and	O
for	O
the	O
shortest	O
duration	O
consistent	O
with	O
treatment	O
goals	O
and	O
risks	O
for	O
the	O
individual	O
woman	O
.	O
	
One	O
patient	O
developed	O
PML	B
after	O
taking	O
GILENYA	O
for	O
approximately	O
2.5	O
years	O
.	O
	
None	O
of	O
these	O
6	O
patients	O
had	O
neutralizing	O
antibodies.In	O
a	O
study	O
with	O
ERWINAZE	O
treatment	O
by	O
intravenous	O
administration	O
(	O
Study	O
2	O
)	O
,	O
4	O
of	O
30	O
(	O
13.3	O
%	O
)	O
patients	O
treated	O
with	O
ERWINAZE	O
developed	O
anti-ERWINAZE	O
antibodies	O
.	O
	
Deaths	B
as	O
a	O
complication	O
of	O
severe	O
dysphagia	B
have	O
been	O
reported	O
after	O
treatment	O
with	O
botulinum	O
toxin	O
.	O
	
Two	O
patients	O
died	B
of	O
herpetic	B
infections	I
during	O
controlled	O
trials	O
.	O
	
They	O
are	O
not	O
interchangeable	O
with	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
and	O
,	O
therefore	O
,	O
units	O
of	O
biological	O
activity	O
of	O
DYSPORT	O
(	O
r	O
)	O
can	O
not	O
be	O
compared	O
to	O
or	O
converted	O
into	O
units	O
of	O
any	O
other	O
botulinum	O
toxin	O
products	O
assessed	O
with	O
any	O
other	O
specific	O
assay	O
method	O
[	O
seeDescription	O
(	O
11	O
)	O
]	O
.	O
	
Even	O
in	O
the	O
absence	O
of	O
TNF-blocker	O
therapy	O
,	O
patients	O
with	O
rheumatoid	O
arthritis	O
may	O
be	O
at	O
a	O
higher	O
risk	O
(	O
approximately	O
2-fold	O
)	O
than	O
the	O
general	O
population	O
for	O
the	O
development	O
of	O
leukemia	O
.	O
	
The	O
patient	O
should	O
be	O
carefully	O
monitored	O
,	O
since	O
recurrences	O
of	O
NMS	O
have	O
been	O
reported	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
DALVANCE	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.5	O
Skin	O
Reactions	O
Skin	B
reactions	I
have	O
been	O
reported	O
with	O
TREANDA	O
treatment	O
in	O
clinical	O
trials	O
and	O
postmarketing	O
safety	O
reports	O
,	O
including	O
rash	B
,	O
toxic	B
skin	I
reactions	I
and	O
bullous	B
exanthema	I
.	O
	
After	O
6	O
cycles	O
,	O
patients	O
remained	O
on	O
study	O
with	O
no	O
additional	O
anticancer	O
treatment	O
,	O
and	O
tumor	O
assessments	O
continued	O
until	O
documented	O
disease	O
progression	O
.	O
	
Table	O
1	O
summarizes	O
all	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
occurring	O
in	O
>	O
=	O
1	O
%	O
of	O
patients	O
with	O
postherpetic	O
neuralgia	O
in	O
the	O
Qutenza	O
group	O
for	O
which	O
the	O
incidence	O
was	O
greater	O
than	O
in	O
the	O
control	O
group	O
.	O
	
(	O
5.1	O
)	O
*	O
Inhalation	O
of	O
airborne	O
capsaicin	O
can	O
result	O
in	O
coughing	B
or	O
sneezing	B
.	O
	
Single	O
intraperitoneal	O
doses	O
of	O
bendamustine	O
in	O
mice	O
and	O
rats	O
administered	O
during	O
organogenesis	O
caused	O
an	O
increase	B
in	I
resorptions	I
,	O
visceral	B
malformations	I
,	O
and	O
decreased	B
fetal	I
body	I
weights	I
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
(	O
total	O
bilirubin	O
>	O
3	O
*	O
ULN	O
)	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
At	O
2	O
years	O
,	O
patients	O
randomized	O
to	O
INVOKANA	O
100	O
mg	O
and	O
INVOKANA	O
300	O
mg	O
had	O
placebo-corrected	O
declines	B
in	I
BMD	I
at	I
the	I
total	I
hip	I
of	O
0.3	O
%	O
and	O
0.7	O
%	O
,	O
respectively	O
.	O
	
A	O
RCAPTA	O
NEOHALER	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
asthma	O
.	O
	
Serious	O
Infections	O
Receptor	O
activator	O
of	O
nuclear	O
factor	O
kappa-B	O
ligand	O
(	O
RANKL	O
)	O
is	O
expressed	O
on	O
activated	O
T	O
and	O
B	O
lymphocytes	O
and	O
in	O
lymph	O
nodes	O
.	O
	
XALKORI	O
was	O
discontinued	O
for	O
adverse	O
reactions	O
in	O
15	O
%	O
of	O
patients	O
.	O
	
5.2	O
Impairment	O
in	O
Renal	O
Function	O
INVOKANA	O
increases	B
serum	I
creatinine	I
and	O
decreases	B
eGFR	I
.	O
	
In	O
a	O
52-week	O
,	O
double-blind	O
,	O
comparator-controlled	O
trial	O
that	O
included	O
primarily	O
patients	O
with	O
schizophrenia	O
,	O
the	O
mean	O
decrease	O
from	O
baseline	O
of	O
total	O
cholesterol	O
was	O
6	O
mg/dL	O
and	O
the	O
mean	O
decrease	O
from	O
baseline	O
of	O
fasting	O
triglycerides	O
was	O
9.8	O
mg/dL	O
.	O
	
Monitor	O
serum	O
potassium	O
levels	O
periodically	O
after	O
initiating	O
INVOKANA	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
and	O
in	O
patients	O
predisposed	O
to	O
hyperkalemia	O
due	O
to	O
medications	O
or	O
other	O
medical	O
conditions	O
.	O
	
Six	O
percent	O
of	O
patients	O
receiving	O
IMBRUVICA	O
in	O
the	O
WM	O
trial	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
events	O
.	O
	
Patients	O
should	O
be	O
instructed	O
to	O
discontinue	O
TECFIDERA	O
and	O
seek	O
immediate	O
medical	O
care	O
should	O
they	O
experience	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
or	O
angioedema	O
.	O
	
There	O
were	O
four	O
suicides	B
in	O
drug-treated	O
patients	O
in	O
the	O
trials	O
and	O
none	O
in	O
placebo-treated	O
patients	O
,	O
but	O
the	O
number	O
of	O
events	O
is	O
too	O
small	O
to	O
allow	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	B
.	O
	
Three	O
patients	O
(	O
2	O
%	O
)	O
died	B
from	O
myelosuppression-related	B
adverse	I
reactions	I
;	O
one	O
each	O
from	O
neutropenic	B
sepsis	I
,	O
diffuse	B
alveolar	I
hemorrhage	I
with	O
Grade	O
3	O
thrombocytopenia	B
,	O
and	O
pneumonia	B
from	O
an	O
infection	B
(	I
CMV	I
)	O
.	O
	
Hepatic	O
Transaminases	O
An	O
increased	O
incidence	O
of	O
elevations	B
of	I
hepatic	I
transaminases	I
in	O
patients	O
treated	O
with	O
TECFIDERA	O
was	O
seen	O
primarily	O
during	O
the	O
first	O
six	O
months	O
of	O
treatment	O
,	O
and	O
most	O
patients	O
with	O
elevations	O
had	O
levels	O
<	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
However	O
,	O
some	O
of	O
these	O
cases	O
were	O
in	O
the	O
setting	O
of	O
disease	O
progression	O
.	O
	
The	O
results	O
of	O
these	O
evaluations	O
were	O
consistent	O
with	O
a	O
retinal	B
dystrophy	I
,	O
including	O
abnormalities	B
in	I
the	I
electroretinogram	I
of	O
both	O
patients	O
,	O
with	O
abnormal	B
fluorescein	I
angiography	I
and	O
diminished	B
sensitivity	I
on	I
visual	I
field	I
testing	O
in	O
one	O
patient	O
.	O
	
Since	O
patients	O
with	O
COPD	O
often	O
have	O
multiple	O
risk	O
factors	O
for	O
reduced	O
BMD	O
,	O
assessment	O
of	O
BMD	O
is	O
recommended	O
prior	O
to	O
initiating	O
BREO	O
ELLIPTA	O
and	O
periodically	O
thereafter	O
.	O
	
5.5	O
Metabolic	O
Changes	O
Atypical	O
antipsychotic	O
drugs	O
have	O
been	O
associated	O
with	O
metabolic	O
changes	O
that	O
may	O
increase	B
cardiovascular/cerebrovascular	I
risk	I
.	O
	
Before	O
starting	O
FULYZAQ	O
,	O
rule	O
out	O
infectious	O
etiologies	O
of	O
diarrhea	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
One	O
hundred	O
thirty-one	O
patients	O
(	O
median	O
age	O
57	O
years	O
,	O
60	O
%	O
male	O
)	O
received	O
YERVOY	O
as	O
a	O
single	O
agent	O
,	O
380	O
patients	O
(	O
median	O
age	O
56	O
years	O
,	O
61	O
%	O
male	O
)	O
received	O
YERVOY	O
with	O
an	O
investigational	O
gp100	O
peptide	O
vaccine	O
(	O
gp100	O
)	O
,	O
and	O
132	O
patients	O
(	O
median	O
age	O
57	O
years	O
,	O
54	O
%	O
male	O
)	O
received	O
gp100	O
peptide	O
vaccine	O
alone	O
.	O
	
The	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Drug	B
reaction	I
with	I
eosinophilia	I
and	I
systemic	I
symptoms	I
(	O
DRESS	B
syndrome	I
)	O
6.3	O
Immunogenicity	O
In	O
clinical	O
studies	O
,	O
1.1	O
%	O
of	O
1024	O
evaluable	O
patients	O
tested	O
positive	O
for	O
binding	O
antibodies	O
against	O
ipilimumab	O
in	O
an	O
electrochemiluminescent	O
(	O
ECL	O
)	O
based	O
assay	O
.	O
	
There	O
were	O
no	O
differences	O
in	O
the	O
occurrence	O
of	O
3+	O
proteinuria	B
(	O
<	O
4	O
%	O
in	O
both	O
studies	O
)	O
at	O
any	O
time	O
point	O
,	O
and	O
no	O
patients	O
experienced	O
4+	O
proteinuria	B
.	O
	
The	O
majority	O
of	O
events	O
resolved	O
following	O
interruption	O
of	O
BLINCYTO	O
,	O
but	O
some	O
resulted	O
in	O
treatment	O
discontinuation	O
.	O
	
In	O
acute	O
purulent	O
conditions	O
,	O
steroids	O
may	O
mask	O
infection	O
or	O
enhance	O
existing	O
infection	O
.	O
	
However	O
,	O
epidemiological	O
studies	O
suggest	O
an	O
increased	O
risk	O
of	O
treatment-emergent	O
hyperglycemia-related	B
adverse	I
events	I
in	O
patients	O
treated	O
with	O
the	O
atypical	O
antipsychotics	O
included	O
in	O
these	O
studies	O
.	O
	
(	O
5.3	O
)	O
*	O
Neuropsychiatric	B
symptoms	I
:	O
Monitor	O
for	O
confusional	O
state	O
,	O
psychotic	O
symptoms	O
,	O
and	O
hallucinations	O
.	O
	
*	O
Fluid	B
retention	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
5.16	O
Hypokalemia	O
and	O
Hyperglycemia	O
Beta-adrenergic	O
agonist	O
medicines	O
may	O
produce	O
significant	O
hypokalemia	B
in	O
some	O
patients	O
,	O
possibly	O
through	O
intracellular	O
shunting	O
,	O
which	O
has	O
the	O
potential	O
to	O
produce	O
adverse	O
cardiovascular	O
effects	O
.	O
	
Generally	O
,	O
adverse	O
reactions	O
were	O
mild	O
,	O
not	O
dose	O
related	O
,	O
and	O
similar	O
regardless	O
of	O
age	O
,	O
gender	O
,	O
and	O
race	O
.	O
	
Table	O
1	O
summarizes	O
the	O
reactions	O
reported	O
at	O
a	O
rate	O
of	O
at	O
least	O
3	O
%	O
in	O
patients	O
treated	O
with	O
CIMZIA	O
200	O
mg	O
every	O
other	O
week	O
compared	O
to	O
placebo	O
(	O
saline	O
formulation	O
)	O
,	O
given	O
concomitantly	O
with	O
methotrexate	O
.	O
	
Injection	O
into	O
these	O
structures	O
may	O
result	O
in	O
possible	O
permanent	O
injury	O
,	O
such	O
as	O
tendon	O
rupture	O
or	O
ligament	O
damage	O
,	O
or	O
skin	O
laceration	O
.	O
	
(	O
5.3	O
)	O
*	O
Effects	B
on	I
Ability	I
to	I
Drive	I
:	O
Advise	O
patients	O
to	O
refrain	O
from	O
driving	O
and	O
engaging	O
in	O
hazardous	O
occupations	O
or	O
activities	O
such	O
as	O
operating	O
heavy	O
or	O
potentially	O
dangerous	O
machinery	O
while	O
BLINCYTO	O
is	O
being	O
administered	O
.	O
	
Discontinue	O
COMETRIQ	O
for	O
perforation	O
or	O
for	O
fistula	O
formation	O
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
5.8	O
Seizure	O
Cases	O
of	O
seizure	B
have	O
been	O
reported	O
in	O
pre-marketing	O
clinical	O
studies	O
with	O
PRISTIQ	O
.	O
	
Injection	O
of	O
XIAFLEX	O
into	O
ligaments	B
of	I
the	I
hand	I
may	I
result	I
in	I
damage	I
to	O
those	O
structures	O
and	O
possible	O
permanent	B
injury	I
such	O
as	O
tendon	B
rupture	I
or	O
ligament	B
damage	I
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
in	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
through	O
Week	O
24	O
was	O
3.5	O
%	O
for	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
0.5	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
Contact	O
AstraZeneca	O
at	O
1-800-236-9933	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
In	O
such	O
children	O
or	O
adults	O
who	O
have	O
not	O
had	O
these	O
diseases	O
or	O
been	O
properly	O
immunized	O
,	O
particular	O
care	O
should	O
be	O
taken	O
to	O
avoid	O
exposure	O
.	O
	
The	O
demographic	O
characteristics	O
were	O
similar	O
among	O
the	O
4	O
pivotal	O
studies	O
and	O
between	O
the	O
treatment	O
groups	O
within	O
these	O
studies	O
.	O
	
Rapid	O
titration	O
at	O
greater	O
than	O
the	O
recommended	O
doses	O
appeared	O
to	O
increase	O
the	O
risk	O
of	O
psychosis	B
and	O
hallucinations	B
.	O
	
Interrupt	O
Ferriprox	O
therapy	O
if	O
neutropenia	O
develops	O
.	O
	
Patients	O
experiencing	O
new	O
,	O
worsening	O
,	O
or	O
recurrent	O
hepatotoxicity	O
may	O
require	O
a	O
delay	O
,	O
change	O
in	O
dose	O
,	O
or	O
discontinuation	O
of	O
ADCETRIS	O
.	O
	
Monitor	O
electrocardiograms	O
and	O
electrolytes	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
electrolyte	O
abnormalities	O
,	O
or	O
those	O
who	O
are	O
taking	O
medications	O
that	O
are	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
.	O
	
(	O
5.4	O
)	O
*	O
lipid	B
metabolic	I
effects	I
:	O
Monitor	O
prediabetic	O
and	O
diabetic	O
women	O
taking	O
Natazia	O
.	O
	
Immune	O
system	O
disorders	O
:	O
anaphylactic	B
shock	I
,	O
hypersensitivity	B
.	O
	
Monitor	O
complete	O
blood	O
counts	O
prior	O
to	O
each	O
dose	O
;	O
increase	O
the	O
frequency	O
of	O
monitoring	O
in	O
patients	O
who	O
develop	O
Grade	O
3	O
or	O
4	O
cytopenias	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
receiving	O
the	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
If	O
chickenpox	O
develops	O
,	O
treatment	O
with	O
antiviral	O
agents	O
may	O
be	O
considered	O
.	O
	
5.12	O
Cardiovascular	O
Effects	O
Vilanterol	O
,	O
like	O
other	O
beta2-agonists	O
,	O
can	O
produce	O
a	O
clinically	O
significant	O
cardiovascular	O
effect	O
in	O
some	O
patients	O
as	O
measured	O
by	O
increases	B
in	I
pulse	I
rate	I
,	O
and	O
also	O
cardiac	B
arrhythmias	I
,	O
such	O
as	O
supraventricular	B
tachycardia	I
and	O
extrasystoles	B
.	O
	
These	O
risks	O
importantly	O
may	O
limit	O
the	O
role	O
of	O
AdreView	O
in	O
the	O
diagnostic	O
evaluation	O
of	O
patients	O
with	O
severe	O
renal	O
impairment	O
.	O
	
Fifty	O
percent	O
(	O
50	O
%	O
)	O
of	O
the	O
population	O
were	O
male	O
;	O
81	O
%	O
were	O
White	O
,	O
14	O
%	O
were	O
Asian	O
,	O
and	O
3	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
After	O
initiation	O
of	O
TRULICITY	O
,	O
observe	O
patients	O
carefully	O
for	O
signs	O
and	O
symptoms	O
of	O
pancreatitis	O
,	O
including	O
persistent	O
severe	O
abdominal	O
pain	O
.	O
	
(	O
4	O
)	O
*	O
Cigarette	O
smoking	O
increases	O
the	O
risk	O
of	O
serious	O
cardiovascular	B
events	I
from	O
combination	O
oral	O
contraceptive	O
(	O
COC	O
)	O
use	O
.	O
	
Monitor	O
hepatic	O
function	O
prior	O
to	O
and	O
during	O
treatment	O
.	O
	
The	O
clinical	O
significance	O
of	O
the	O
lower	O
mean	O
triglyceride	O
values	O
in	O
NULOJIX-treated	O
patients	O
at	O
one	O
and	O
three	O
years	O
is	O
unknown	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=	O
1	O
%	O
of	O
XIAFLEX-Treated	O
Patients	O
with	O
Peyronie	O
's	O
disease	O
and	O
at	O
a	O
Greater	O
Incidence	O
than	O
Placebo	O
After	O
Up	O
to	O
Four	O
Treatment	O
Cycles	O
in	O
Studies	O
1	O
and	O
2	O
Combined	O
a	O
Includes	O
:	O
injection	B
site	I
hematoma	I
and	O
penile	B
hematoma	I
were	O
reported	O
with	O
the	O
verbatim	O
term	O
of	O
penile	B
bruising	I
or	O
injection	B
site	I
bruising	I
in	O
87	O
%	O
of	O
subjects	O
.	O
	
The	O
racial	O
and	O
ethnic	O
distribution	O
was	O
Caucasian	O
(	O
83	O
%	O
)	O
,	O
Black	O
(	O
5	O
%	O
)	O
,	O
Asian	O
(	O
2	O
%	O
)	O
,	O
and	O
other	O
(	O
5	O
%	O
)	O
.	O
	
Table	O
2	O
:	O
Laboratory	O
Abnormalities	O
of	O
Interest	O
in	O
Study	O
1	O
Abiraterone	O
(	O
N=791	O
)	O
Placebo	O
(	O
N=394	O
)	O
Laboratory	O
Abnormality	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3-4	O
(	O
%	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3-4	O
(	O
%	O
)	O
Hypertriglyceridemia	B
62.5	O
0.4	O
53.0	O
0	O
High	B
AST	I
30.6	O
2.1	O
36.3	O
1.5	O
Hypokalemia	B
28.3	O
5.3	O
19.8	O
1.0	O
Hypophosphatemia	B
23.8	O
7.2	O
15.7	O
5.8	O
High	B
ALT	I
11.1	O
1.4	O
10.4	O
0.8	O
High	B
Total	I
Bilirubin	I
6.6	O
0.1	O
4.6	O
0	O
Study	O
2	O
:	O
Metastatic	O
CRPC	O
Prior	O
to	O
Chemotherapy	O
Study	O
2	O
enrolled	O
1088	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
not	O
received	O
prior	O
cytotoxic	O
chemotherapy	O
.	O
	
(	O
5.1	O
)	O
*	O
Fatal	B
and/or	O
serious	O
and	O
severe	O
diarrhea	B
or	O
colitis	B
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
.	O
	
There	O
were	O
no	O
clinically	O
meaningful	O
differences	O
in	O
the	O
incidence	O
of	O
adverse	O
events	O
following	O
treatment	O
with	O
XIAFLEX	O
based	O
on	O
the	O
severity	O
of	O
baseline	O
erectile	O
dysfunction	O
or	O
concomitant	O
phosphodiesterase	O
type	O
5	O
(	O
PDE5	O
)	O
inhibitor	O
use	O
.	O
	
6.2	O
Post	O
Marketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
ZYTIGA	O
.	O
	
Such	O
monitoring	O
may	O
increase	O
the	O
risk	O
of	O
unnecessary	O
procedures	O
,	O
due	O
to	O
the	O
low	O
test	O
specificity	O
for	O
serum	O
calcitonin	O
and	O
a	O
high	O
background	O
incidence	O
of	O
thyroid	O
disease	O
.	O
	
The	O
impact	O
of	O
discontinuation	O
of	O
androgen-deprivation	O
therapy	O
upon	O
11	O
C-choline	O
PET	O
imaging	O
has	O
not	O
been	O
established	O
[	O
see	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
The	O
average	O
age	O
was	O
57	O
years	O
(	O
age	O
range	O
from	O
19	O
to	O
84	O
years	O
)	O
.	O
	
*	O
Hepatic	B
Decompensation	I
in	O
Patients	O
with	O
Chronic	O
Hepatitis	O
C	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Thromboembolic	B
Complications	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Cataracts	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
In	O
adult	O
patients	O
with	O
ITP	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
:	O
nausea	B
,	O
diarrhea	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
vomiting	B
,	O
increased	B
ALT	I
,	O
myalgia	B
,	O
and	O
urinary	B
tract	I
infection	I
.	O
	
Table	O
3	O
shows	O
adverse	O
reactions	O
on	O
the	O
ZYTIGA	O
arm	O
in	O
Study	O
2	O
that	O
occurred	O
with	O
a	O
>	O
=2	O
%	O
absolute	O
increase	O
in	O
frequency	O
compared	O
to	O
placebo	O
.	O
	
In	O
Study	O
1	O
,	O
patients	O
were	O
randomized	O
(	O
2:1	O
)	O
to	O
receive	O
either	O
HALAVEN	O
(	O
1.4	O
mg/m	O
2	O
on	O
Days	O
1	O
and	O
8	O
of	O
a	O
21-day	O
cycle	O
)	O
or	O
single	O
agent	O
treatment	O
chosen	O
by	O
their	O
physician	O
(	O
control	O
group	O
)	O
.	O
	
Table	O
5	O
shows	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
or	O
equal	O
to	O
1	O
%	O
of	O
XIAFLEX-treated	O
patients	O
and	O
at	O
a	O
frequency	O
greater	O
than	O
placebo-treated	O
patients	O
after	O
up	O
to	O
8	O
injections	O
in	O
the	O
pooled	O
placebo-controlled	O
trials	O
through	O
Day	O
365	O
.	O
	
eOn-treatment	O
analysis	O
based	O
on	O
the	O
safety	O
population	O
,	O
compared	O
to	O
ITT	O
analysis	O
presented	O
in	O
Section	O
14	O
Clinical	O
Studies	O
.	O
	
The	O
most	O
frequent	O
(	O
>	O
=	O
0.5	O
%	O
)	O
adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
EOVIST	O
were	O
nausea	B
,	O
headache	B
,	O
feeling	B
hot	I
,	O
dizziness	B
,	O
and	O
back	B
pain	I
.	O
	
Emergency	O
resuscitation	O
equipment	O
and	O
personnel	O
should	O
be	O
immediately	O
available	O
.	O
	
Respiratory	O
,	O
Thoracic	O
and	O
Mediastinal	O
Disorders	O
:	O
non-infectious	B
pneumonitis	I
.	O
	
(	O
5.6	O
)	O
*	O
Headache	B
:	O
Evaluate	O
significant	O
change	O
in	O
headaches	O
and	O
discontinue	O
Natazia	O
if	O
indicated	O
.	O
	
Permanently	O
discontinue	O
ZYKADIA	O
in	O
patients	O
diagnosed	O
with	O
treatment-related	O
ILD/pneumonitis	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Advise	O
patients	O
taking	O
Ferriprox	O
to	O
report	O
immediately	O
any	O
symptoms	O
indicative	O
of	O
infection	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
CORPORAL	B
RUPTURE	I
(	O
PENILE	B
FRACTURE	I
)	O
OR	O
OTHER	O
SERIOUS	O
PENILE	B
INJURY	I
IN	O
THE	O
TREATMENT	O
OF	O
PEYRONIE	O
'S	O
DISEASE	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
*	O
Corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX-treated	O
patients	O
in	O
clinical	O
studies	O
.	O
	
Preexisting	O
liver	O
disease	O
,	O
elevated	O
baseline	O
liver	O
enzymes	O
,	O
and	O
concomitant	O
medications	O
may	O
also	O
increase	O
the	O
risk	O
.	O
	
Adverse	O
reactions	O
during	O
exposure	O
were	O
obtained	O
by	O
general	O
inquiry	O
and	O
recorded	O
by	O
clinical	O
investigators	O
using	O
their	O
own	O
terminology	O
.	O
	
Major	O
Neuropsychiatric	B
Symptoms	I
in	O
Placebo-Controlled	O
Epilepsy	O
Trials	O
Adverse	O
Reaction	O
Number	O
(	O
%	O
)	O
with	O
Adverse	O
Reaction	O
Number	O
(	O
%	O
)	O
Discontinuing	O
POTIGA	O
(	O
n	O
=	O
813	O
)	O
Placebo	O
(	O
n	O
=	O
427	O
)	O
POTIGA	O
(	O
n	O
=	O
813	O
)	O
Placebo	O
(	O
n	O
=	O
427	O
)	O
Confusional	B
state	I
75	O
(	O
9	O
%	O
)	O
11	O
(	O
3	O
%	O
)	O
32	O
(	O
4	O
%	O
)	O
4	O
(	O
<	O
1	O
%	O
)	O
Psychosis	B
9	O
(	O
1	O
%	O
)	O
0	O
6	O
(	O
<	O
1	O
%	O
)	O
0	O
Hallucinationsa	O
14	O
(	O
2	O
%	O
)	O
2	O
(	O
<	O
1	O
%	O
)	O
6	O
(	O
<	O
1	O
%	O
)	O
0	O
a	O
Hallucinations	B
includes	O
mixed	B
hallucinations	I
.	O
	
The	O
contribution	O
of	O
the	O
underlying	O
disease	O
and/or	O
prior	O
corticosteroid	O
treatment	O
to	O
the	O
risk	O
is	O
also	O
not	O
known	O
.	O
	
Treatment	O
and	O
Reduction	O
in	O
the	O
Risk	O
of	O
Recurrence	O
of	O
Deep	O
Venous	O
Thrombosis	O
and	O
Pulmonary	O
Embolism	O
PRADAXA	O
was	O
studied	O
in	O
4387	O
patients	O
in	O
4	O
pivotal	O
,	O
parallel	O
,	O
randomized	O
,	O
double-blind	O
trials	O
.	O
	
Table	O
2	O
shows	O
treatment-emergent	O
adverse	O
reactions	O
and	O
the	O
category	O
of	O
``	O
any	O
common	O
adverse	O
event	O
''	O
in	O
ESCAPE-1	O
and	O
ESCAPE-2	O
where	O
the	O
rate	O
on	O
Cleviprex	O
exceeded	O
the	O
rate	O
on	O
placebo	O
by	O
at	O
least	O
5	O
%	O
(	O
common	O
adverse	O
reactions	O
)	O
.	O
	
Discoloration	B
of	I
the	I
palate	I
has	O
also	O
been	O
reported	O
.	O
	
Figure	O
1	O
Adjudicated	O
Major	O
Bleeding	B
by	O
Baseline	O
Characteristics	O
Including	O
Hemorrhagic	O
Stroke	O
Treated	O
Patients	O
Note	O
:	O
The	O
figure	O
above	O
presents	O
effects	O
in	O
various	O
subgroups	O
all	O
of	O
which	O
are	O
baseline	O
characteristics	O
and	O
all	O
of	O
which	O
were	O
pre-specified	O
.	O
	
Investigations	O
:	O
blood	B
bilirubin	I
increased	I
,	O
blood	B
creatinine	I
phosphokinase	I
increased	I
.	O
	
However	O
,	O
based	O
on	O
its	O
mechanism	O
of	O
action	O
and	O
findings	O
in	O
animals	O
,	O
ADCETRIS	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
The	O
risk	O
of	O
VTE	B
in	O
women	O
using	O
COCs	O
has	O
been	O
estimated	O
to	O
be	O
3	O
to	O
9	O
per	O
10,000	O
woman-years	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
Also	O
,	O
patients	O
taking	O
diuretics	O
or	O
who	O
are	O
otherwise	O
volume	O
depleted	O
can	O
be	O
at	O
greater	O
risk	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.6	O
)	O
]	O
.	O
	
Injection-site	O
Reactions	O
In	O
the	O
placebo-controlled	O
studies	O
,	O
injection-site	B
rash	I
)	O
were	O
reported	O
in	O
0.5	O
%	O
of	O
TRULICITY-treated	O
patients	O
and	O
in	O
0.0	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
All	O
infections	B
,	O
and	O
other	O
organisms	O
.	O
	
Injection	O
into	O
these	O
structures	O
may	O
result	O
in	O
possible	O
permanent	B
injury	I
such	O
as	O
corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
.	O
	
Urinary	B
retention	I
was	O
reported	O
as	O
an	O
adverse	O
event	O
in	O
29	O
of	O
1,365	O
(	O
approximately	O
2	O
%	O
)	O
patients	O
treated	O
with	O
POTIGA	O
in	O
the	O
open-label	O
and	O
placebo-controlled	O
epilepsy	O
database	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Because	O
these	O
reactions	O
may	O
worsen	O
renal	O
function	O
,	O
use	O
caution	O
when	O
initiating	O
or	O
escalating	O
doses	O
of	O
TRULICITY	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O
	
There	O
was	O
no	O
apparent	O
pattern	O
with	O
respect	O
to	O
the	O
anatomic	O
site	O
of	O
fracture	B
.	O
	
5.8	O
Leukopenia	O
,	O
Neutropenia	O
and	O
Agranulocytosis	O
In	O
clinical	O
trial	O
and	O
postmarketing	O
experience	O
,	O
events	O
of	O
leukopenia/neutropenia	O
have	O
been	O
reported	O
temporally	O
related	O
to	O
antipsychotic	O
agents	O
.	O
	
Renal	O
and	O
urinary	O
disorders	O
:	O
Nephrotic	B
syndrome	I
and	O
renal	B
failure	I
.	O
	
When	O
injecting	O
a	O
cord	O
affecting	O
a	O
PIP	O
joint	O
of	O
the	O
fifth	O
finger	O
,	O
the	O
needle	O
insertion	O
should	O
not	O
be	O
more	O
than	O
2	O
to	O
3	O
mm	O
in	O
depth	O
and	O
avoid	O
injecting	O
more	O
than	O
4	O
mm	O
distal	O
to	O
the	O
palmar	O
digital	O
crease	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
(	O
5.4	O
)	O
*	O
Hypertension	B
:	O
Monitor	O
blood	O
pressure	O
regularly	O
.	O
	
The	O
clinical	O
impact	O
of	O
anti-belatacept	O
antibodies	O
(	O
including	O
neutralizing	O
anti-belatacept	O
antibodies	O
)	O
could	O
not	O
be	O
determined	O
in	O
the	O
studies	O
.	O
	
For	O
these	O
events	O
,	O
the	O
median	O
time	O
to	O
onset	O
was	O
15	O
days	O
.	O
	
YERVOY	O
was	O
discontinued	O
for	O
adverse	O
reactions	O
in	O
10	O
%	O
of	O
patients	O
.	O
	
EXCERPT	O
:	O
Rule	O
out	O
infectious	O
etiologies	O
of	O
diarrhea	O
before	O
starting	O
crofelemer	O
.	O
	
If	O
signs	O
and	O
symptoms	O
of	O
tardive	O
dyskinesia	O
appear	O
in	O
a	O
patient	O
on	O
FANAPT	O
,	O
drug	O
discontinuation	O
should	O
be	O
considered	O
.	O
	
The	O
clinical	O
significance	O
of	O
small	O
changes	O
in	O
BMD	O
with	O
regard	O
to	O
long-term	O
consequences	O
such	O
as	O
fracture	O
is	O
unknown	O
.	O
	
Although	O
some	O
of	O
the	O
patients	O
with	O
retinal	B
abnormalities	I
have	O
been	O
found	O
to	O
have	O
abnormal	B
visual	I
acuity	I
,	O
it	O
is	O
not	O
possible	O
to	O
assess	O
whether	O
POTIGA	O
caused	O
their	O
decreased	B
visual	I
acuity	I
,	O
as	O
baseline	O
assessments	O
are	O
not	O
available	O
for	O
these	O
patients	O
.	O
	
5.15	O
Coexisting	O
Conditions	O
BREO	O
ELLIPTA	O
,	O
like	O
all	O
medicines	O
containing	O
sympathomimetic	O
amines	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
convulsive	O
disorders	O
or	O
thyrotoxicosis	O
and	O
in	O
those	O
who	O
are	O
unusually	O
responsive	O
to	O
sympathomimetic	O
amines	O
.	O
	
Cardiac	O
disorders	O
:	O
Angina	B
pectoris	I
,	O
arrhythmias	B
,	O
atrial	B
fibrillation	I
,	O
cardiac	B
failure	I
,	O
hypertensive	B
heart	I
disease	I
,	O
myocardial	B
infarction	I
,	O
myocardial	B
ischemia	I
,	O
pericardial	B
effusion	I
,	O
pericarditis	B
,	O
stroke	B
and	O
transient	B
ischemic	I
attack	I
.	O
	
(	O
5.2	O
)	O
*	O
POTIGA	O
can	O
cause	O
skin	B
discoloration	I
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
in	O
92	O
%	O
of	O
patients	O
and	O
moderately	O
impaired	O
in	O
8	O
%	O
of	O
patients	O
(	O
mean	O
eGFR	O
86	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
Assessment	O
of	O
the	O
relationship	O
between	O
atypical	O
antipsychotic	O
use	O
and	O
glucose	O
abnormalities	O
is	O
complicated	O
by	O
the	O
possibility	O
of	O
an	O
increased	O
background	O
risk	O
of	O
diabetes	O
mellitus	O
in	O
patients	O
with	O
schizophrenia	O
and	O
the	O
increasing	O
incidence	O
of	O
diabetes	O
mellitus	O
in	O
the	O
general	O
population	O
.	O
	
The	O
initial	O
prescription	O
and	O
renewal	O
of	O
the	O
medication	O
order	O
beyond	O
28	O
days	O
should	O
be	O
made	O
by	O
a	O
physician	O
only	O
after	O
examination	O
of	O
the	O
patient	O
with	O
the	O
aid	O
of	O
magnification	O
such	O
as	O
slit	O
lamp	O
biomicroscopy	O
and	O
,	O
where	O
appropriate	O
,	O
fluorescein	O
staining	O
.	O
	
One	O
case	O
of	O
MTC	B
was	O
reported	O
in	O
a	O
patient	O
treated	O
with	O
TRULICITY	O
.	O
	
Proteinuria	O
At	O
Month	O
1	O
after	O
transplantation	O
in	O
Studies	O
1	O
and	O
2	O
,	O
the	O
frequency	O
of	O
2+	O
proteinuria	B
on	O
urine	O
dipstick	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
was	O
33	O
%	O
(	O
130/390	O
)	O
and	O
28	O
%	O
(	O
107/384	O
)	O
in	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
5.3	O
Infections	O
In	O
patients	O
receiving	O
BLINCYTO	O
in	O
clinical	O
trials	O
,	O
serious	O
infections	B
such	O
as	O
sepsis	B
,	O
pneumonia	B
,	O
bacteremia	B
,	O
opportunistic	B
infections	I
,	O
and	O
catheter-site	B
infections	I
were	O
observed	O
in	O
approximately	O
25	O
%	O
of	O
patients	O
,	O
some	O
of	O
which	O
were	O
life-threatening	O
or	O
fatal	B
.	O
	
peri-infusional	B
reactions	I
consistent	O
with	O
hypersensitivity	B
or	O
anaphylaxis	B
were	O
not	O
reported	O
in	O
these	O
11	O
patients	O
nor	O
were	O
neutralizing	O
antibodies	O
against	O
ipilimumab	O
detected	O
.	O
	
Binding	O
to	O
this	O
receptor	O
is	O
required	O
for	O
Vimizim	O
to	O
be	O
taken	O
into	O
cells	O
where	O
it	O
is	O
active	O
.	O
	
Adverse	O
reaction	O
of	O
hyperuricemia	B
was	O
reported	O
for	O
15	O
%	O
of	O
patients	O
.	O
	
Monitor	O
clinically	O
and	O
discontinue	O
drug	O
for	O
severe	O
reactions	O
.	O
	
There	O
were	O
no	O
elevations	B
in	I
transaminases	I
>	O
=	O
3	O
times	O
the	O
ULN	O
with	O
concomitant	O
elevations	B
in	I
total	I
bilirubin	I
>	O
2	O
times	O
the	O
ULN	O
.	O
	
(	O
5.4	O
)	O
*	O
Arthralgia	B
:	O
Severe	O
and	O
disabling	O
arthralgia	B
has	O
been	O
reported	O
in	O
patients	O
taking	O
DPP-4	O
inhibitors	O
.	O
	
Three	O
active-controlled	O
trials	O
of	O
52	O
weeks	O
in	O
duration	O
were	O
conducted	O
in	O
patients	O
treated	O
with	O
pioglitazone	O
and	O
metformin	O
,	O
in	O
combination	O
with	O
metformin	O
and	O
as	O
monotherapy	O
compared	O
to	O
glipizide	O
.	O
	
Before	O
initiating	O
INVOKANA	O
in	O
patients	O
with	O
one	O
or	O
more	O
of	O
these	O
characteristics	O
,	O
volume	O
status	O
should	O
be	O
assessed	O
and	O
corrected	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
anaphylaxis	B
;	O
and	O
infusion	B
site	I
reactions	I
;	O
pneumocystis	B
jiroveci	I
pneumonia	I
and	O
pneumonitis	B
.	O
	
Women	O
should	O
be	O
advised	O
to	O
avoid	O
becoming	O
pregnant	O
when	O
receiving	O
TREANDA	O
.	O
	
Pooled	O
analyses	O
of	O
199	O
placebo-controlled	O
clinical	O
trials	O
(	O
mono-	O
and	O
adjunctive	O
therapy	O
)	O
of	O
11	O
different	O
AEDs	O
showed	O
that	O
patients	O
randomized	O
to	O
one	O
of	O
the	O
AEDs	O
had	O
approximately	O
twice	O
the	O
risk	O
(	O
adjusted	O
Relative	O
Risk	O
1.8	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.2	O
,	O
2.7	O
)	O
of	O
suicidal	B
thinking	I
compared	O
to	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
5.3	O
Hyperkalemia	O
INVOKANA	O
can	O
lead	O
to	O
hyperkalemia	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
more	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Ophthalmic	B
Adverse	I
Reaction	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Hypersensitivity	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
are	O
local	B
skin	I
reactions	I
,	O
application	B
site	I
pain	I
,	O
application	B
site	I
pruritus	I
,	O
application	B
site	I
irritation	I
,	O
application	B
site	I
infection	I
,	O
periorbital	B
edema	I
,	O
nasopharyngitis	B
and	O
headache	B
.	O
	
5.2	O
Myelosuppression	O
Thrombocytopenia	B
,	O
anemia	B
and	O
neutropenia	B
occur	O
with	O
BOSULIF	O
treatment	O
.	O
	
In	O
Phase	O
2	O
and	O
3	O
placebo-controlled	O
trials	O
combined	O
,	O
the	O
incidences	O
of	O
serious	O
adverse	O
events	O
in	O
patients	O
receiving	O
placebo	O
,	O
Toviaz	O
4	O
mg	O
,	O
and	O
Toviaz	O
8	O
mg	O
were	O
1.9	O
%	O
,	O
3.5	O
%	O
,	O
and	O
2.9	O
%	O
,	O
respectively	O
.	O
	
Hospitalizations	O
due	O
to	O
serious	O
infections	B
in	I
the	I
abdomen	I
(	O
0.0	O
%	O
placebo	O
vs.	O
0.1	O
%	O
Prolia	O
)	O
were	O
reported	O
.	O
	
TABLE	O
3	O
:	O
Changes	O
in	O
Lipids	O
in	O
Adult	O
Patients	O
N*	O
=	O
Number	O
of	O
subjects	O
who	O
had	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
Table	O
2	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=	O
0.1	O
%	O
subjects	O
who	O
received	O
Gadavist	O
.	O
	
Provide	O
supportive	O
medical	O
care	O
if	O
shortness	O
of	O
breath	O
develops	O
.	O
	
Adverse	O
reactions	O
are	O
events	O
that	O
occurred	O
after	O
the	O
first	O
dose	O
of	O
study	O
medication	O
treatment	O
and	O
within	O
7	O
days	O
of	O
the	O
last	O
dose	O
of	O
study	O
medication	O
or	O
events	O
present	O
at	O
baseline	O
that	O
increased	O
in	O
severity	O
after	O
the	O
start	O
of	O
study	O
medication	O
treatment	O
.	O
	
In	O
a	O
study	O
of	O
TREANDA	O
(	O
90	O
mg/m	O
2	O
)	O
in	O
combination	O
with	O
rituximab	O
,	O
one	O
case	O
of	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
occurred	O
.	O
	
(	O
5.2	O
)	O
Avoidance	O
of	O
Contact	O
Lenses	O
.	O
	
In	O
females	B
,	I
discontinuation	I
due	I
to	I
genital	I
mycotic	I
infections	I
occurred	O
in	O
0	O
%	O
and	O
0.7	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
and	O
INVOKANA	O
,	O
respectively	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Durata	O
Therapeutics	O
,	O
Inc.	O
at	O
1-855-387-2825	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov	O
/medwatch	O
.	O
	
Whether	O
antipsychotic	O
drug	O
products	O
differ	O
in	O
their	O
potential	O
to	O
cause	O
Tardive	B
Dyskinesia	I
(	O
TD	B
)	O
is	O
unknown	O
.	O
	
Hypoglycemia	O
In	O
all	O
clinical	O
trials	O
,	O
hypoglycemia	O
was	O
defined	O
as	O
any	O
event	O
regardless	O
of	O
symptoms	O
,	O
where	O
biochemical	O
hypoglycemia	O
was	O
documented	O
(	O
any	O
glucose	O
value	O
below	O
or	O
equal	O
to	O
70	O
mg/dL	O
)	O
.	O
	
Patients	O
>	O
=	O
65	O
years	O
of	O
age	O
are	O
more	O
likely	O
to	O
experience	O
certain	O
adverse	O
reactions	O
,	O
including	O
neutropenia	B
and	O
febrile	B
neutropenia	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
Given	O
these	O
considerations	O
,	O
SAPHRIS	O
should	O
be	O
prescribed	O
in	O
a	O
manner	O
that	O
is	O
most	O
likely	O
to	O
minimize	O
the	O
occurrence	O
of	O
TD	O
.	O
	
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Imatinib-Resistant	O
or	O
-Intolerant	O
Ph+	O
Chronic	O
Phase	O
(	O
CP	O
)	O
,	O
Accelerated	O
Phase	O
(	O
AP	O
)	O
,	O
and	O
Blast	O
Phase	O
(	O
BP	O
)	O
CML	O
The	O
single-arm	O
Phase	O
1/2	O
clinical	O
trial	O
(	O
Study	O
1	O
)	O
enrolled	O
patients	O
with	O
Ph+	O
chronic	O
,	O
accelerated	O
,	O
or	O
blast	O
phase	O
chronic	O
myelogenous	O
leukemia	O
(	O
CML	O
)	O
and	O
with	O
resistance	O
or	O
intolerance	O
to	O
prior	O
therapy	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Concomitant	O
short-acting	O
beta2-agonists	O
can	O
be	O
used	O
as	O
needed	O
for	O
acute	O
relief	O
(	O
5.2	O
)	O
*	O
Do	O
not	O
exceed	O
the	O
recommended	O
dose	O
.	O
	
Of	O
the	O
255	O
patients	O
,	O
66	O
%	O
of	O
patients	O
were	O
female	O
and	O
86	O
%	O
were	O
Caucasian	O
.	O
	
A	O
majority	O
of	O
Qutenza-treated	O
patients	O
in	O
clinical	O
studies	O
had	O
adverse	O
reactions	O
with	O
a	O
maximum	O
intensity	O
of	O
``	O
mild	O
''	O
or	O
``	O
moderate	O
''	O
.	O
	
5.4	O
Dysphagia	O
and	O
Breathing	O
Difficulties	O
in	O
Treatment	O
of	O
Cervical	O
Dystonia	O
Treatment	O
with	O
XEOMIN	O
and	O
other	O
botulinum	O
toxin	O
products	O
can	O
result	O
in	O
breathing	B
difficulties	I
.	O
	
(	O
5.11	O
)	O
*	O
The	O
starting	O
dose	O
of	O
INLYTA	O
should	O
be	O
decreased	O
if	O
used	O
in	O
patients	O
with	O
moderate	O
hepatic	O
impairment	O
.	O
	
5.3	O
Progressive	O
Multifocal	O
Leukoencephalopathy	O
A	O
case	O
of	O
progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
and	O
a	O
case	O
of	O
probable	O
PML	B
occurred	O
in	O
patients	O
with	O
MS	O
who	O
received	O
GILENYA	O
in	O
the	O
post	O
marketing	O
setting	O
.	O
	
The	O
incidence	O
of	O
all-cause	O
mortality	B
was	O
0.0	O
%	O
in	O
the	O
DUAVEE	O
group	O
and	O
0.2	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
Adequate	O
data	O
are	O
not	O
available	O
on	O
whether	O
anti-viral	O
therapy	O
can	O
reduce	O
the	O
risk	O
of	O
HBV	O
reactivation	O
in	O
HBV	O
carriers	O
who	O
are	O
treated	O
with	O
TNF-blockers	O
.	O
	
Additional	O
signs	O
may	O
include	O
elevated	B
creatine	I
phosphokinase	I
,	O
myoglobinuria	B
(	O
rhabdomyolysis	B
)	O
,	O
and	O
acute	B
renal	I
failure	I
.	O
	
(	O
5.8	O
)	O
*	O
Infusion	B
Reactions	I
:	O
Pre-medicate	O
with	O
dexamethasone	O
.	O
	
There	O
is	O
no	O
general	O
agreement	O
about	O
specific	O
pharmacological	O
treatment	O
regimens	O
for	O
NMS	O
.	O
	
Patients	O
with	O
RA	O
and	O
other	O
chronic	O
inflammatory	O
diseases	O
,	O
particularly	O
patients	O
with	O
highly	O
active	O
disease	O
and/or	O
chronic	O
exposure	O
to	O
immunosuppressant	O
therapies	O
,	O
may	O
be	O
at	O
higher	O
risk	O
(	O
up	O
to	O
several	O
fold	O
)	O
than	O
the	O
general	O
population	O
for	O
the	O
development	O
of	O
lymphoma	B
,	O
even	O
in	O
the	O
absence	O
of	O
TNF-blocking	O
therapy	O
.	O
	
Overall	O
,	O
3.9	O
%	O
of	O
patients	O
reported	O
at	O
least	O
one	O
adverse	O
reaction	O
,	O
primarily	O
occurring	O
immediately	O
or	O
several	O
days	O
following	O
DOTAREM	O
administration	O
.	O
	
Serious	O
infections	B
occurred	O
at	O
a	O
rate	O
of	O
2.3	O
%	O
in	O
the	O
GILENYA	O
group	O
versus	O
1.6	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
Aspiration	B
may	O
result	O
from	O
severe	O
dysphagia	B
and	O
is	O
a	O
particular	O
risk	O
when	O
treating	O
patients	O
in	O
whom	O
swallowing	O
or	O
respiratory	O
function	O
is	O
already	O
compromised	O
.	O
	
Isolated	O
delayed	O
onset	O
events	O
,	O
including	O
transient	O
asystole	B
and	O
unexplained	O
death	B
,	O
have	O
occurred	O
within	O
24	O
hours	O
of	O
the	O
first	O
dose	O
.	O
	
(	O
5.2	O
)	O
5.1	O
Nephrogenic	O
Systemic	O
Fibrosis	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
nephrogenic	B
systemic	I
fibrosis	I
(	O
NSF	B
)	O
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
These	O
exclusion	O
criteria	O
included	O
a	O
history	O
of	O
seizure	O
,	O
underlying	O
brain	O
injury	O
with	O
loss	O
of	O
consciousness	O
,	O
transient	O
ischemic	O
attack	O
within	O
the	O
past	O
12	O
months	O
,	O
cerebral	O
vascular	O
accident	O
,	O
brain	O
metastases	O
,	O
and	O
brain	O
arteriovenous	O
malformation	O
.	O
	
The	O
route	O
of	O
administration	O
was	O
intramuscular	O
n=852	O
,	O
intravenous	O
n=29	O
,	O
other	O
or	O
unknown	O
n=59	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
acute	B
pancreatitis	I
,	O
cholecystitis	B
,	O
cholelithiasis	B
,	O
arterial	B
thrombotic	I
events	I
and	O
reflex	B
sympathetic	I
dystrophy	I
.	O
	
*	O
Report	O
any	O
unusual	O
vaginal	O
bleeding	O
right	O
away	O
while	O
you	O
are	O
taking	O
DUAVEE	O
.	O
	
Patients	O
with	O
multiple	O
myeloma	O
and	O
a	O
high	O
tumor	O
burden	O
should	O
be	O
considered	O
to	O
be	O
at	O
greater	O
risk	O
for	O
TLS	O
.	O
	
The	O
overall	O
exposure	O
in	O
the	O
controlled	O
trials	O
was	O
equivalent	O
to	O
1716	O
person-years	O
.	O
	
ZERBAXA	O
was	O
evaluated	O
in	O
Phase	O
3	O
comparator-controlled	O
clinical	O
trials	O
of	O
cIAI	O
and	O
cUTI	O
,	O
which	O
included	O
a	O
total	O
of	O
1015	O
patients	O
treated	O
with	O
ZERBAXA	O
and	O
1032	O
patients	O
treated	O
with	O
comparator	O
(	O
levofloxacin	O
750	O
mg	O
daily	O
in	O
cUTI	O
or	O
meropenem	O
1	O
g	O
every	O
8	O
hours	O
in	O
cIAI	O
)	O
for	O
up	O
to	O
14	O
days	O
.	O
	
The	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
Postmarketing	O
reports	O
indicate	O
that	O
the	O
effects	O
of	O
DYSPORT	O
(	O
r	O
)	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	I
produce	I
symptoms	I
consistent	I
with	I
botulinum	I
toxin	I
effects	I
.	O
	
*	O
You	O
and	O
your	O
healthcare	O
provider	O
should	O
talk	O
regularly	O
about	O
whether	O
you	O
still	O
need	O
treatment	O
with	O
DUAVEE	O
.	O
	
Death	B
due	O
to	O
cardiac	B
arrest	I
has	O
occurred	O
within	O
a	O
day	O
of	O
Kyprolis	O
administration	O
.	O
	
The	O
most	O
common	O
(	O
>	O
=20	O
%	O
)	O
adverse	O
reactions	O
observed	O
following	O
treatment	O
with	O
INLYTA	O
were	O
diarrhea	B
,	O
hypertension	B
,	O
fatigue	B
,	O
decreased	B
appetite	I
,	O
nausea	B
,	O
dysphonia	B
,	O
hand-foot	B
)	I
syndrome	I
,	O
weight	B
decreased	I
,	O
vomiting	B
,	O
asthenia	B
,	O
and	O
constipation	B
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=2	O
%	O
of	O
Patients	O
on	O
OTEZLA	O
30	O
mg	O
Twice	O
Daily	O
and	O
>	O
=1	O
%	O
Than	O
That	O
Observed	O
in	O
Patients	O
on	O
Placebo	O
for	O
up	O
to	O
Day	O
112	O
(	O
Week	O
16	O
)	O
a	O
Of	O
the	O
reported	O
gastrointestinal	B
adverse	I
reactions	I
,	O
1	O
subject	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
nausea	B
and	O
vomiting	B
in	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
;	O
1	O
subject	O
treated	O
with	O
OTEZLA	O
20	O
mg	O
twice	O
daily	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
diarrhea	B
;	O
1	O
patient	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
headache	B
.	O
	
The	O
median	O
age	O
of	O
patients	O
was	O
31	O
years	O
(	O
range	O
18	O
to	O
61	O
years	O
)	O
,	O
89	O
%	O
were	O
Caucasian	O
,	O
and	O
34	O
%	O
were	O
male	O
.	O
	
Monitor	O
serum	O
potassium	O
and	O
magnesium	O
in	O
patients	O
at	O
risk	O
for	O
electrolyte	O
disturbances	O
.	O
	
Delay	O
in	O
stopping	O
treatment	O
with	O
TIVICAY	O
or	O
other	O
suspect	O
agents	O
after	O
the	O
onset	O
of	O
hypersensitivity	O
may	O
result	O
in	O
a	O
life-threatening	O
reaction	O
.	O
	
Additional	O
adverse	O
drug	O
reactions	O
observed	O
with	O
STRIBILD	O
included	O
suicidal	B
ideation	I
and	O
suicide	B
attempt	I
(	O
0.3	O
%	O
)	O
,	O
all	O
in	O
subjects	O
with	O
a	O
pre-existing	O
history	O
of	O
depression	O
or	O
psychiatric	O
illness	O
.	O
	
(	O
5.1	O
)	O
*	O
Patients	O
with	O
underlying	O
hepatitis	O
B	O
or	O
C	O
may	O
be	O
at	O
increased	O
risk	O
for	O
worsening	O
or	O
development	O
of	O
transaminase	B
elevations	I
with	O
use	O
of	O
TIVICAY	O
.	O
	
The	O
rate	O
of	O
adverse	O
reactions	O
resulting	O
in	O
permanent	O
discontinuation	O
was	O
3.8	O
%	O
in	O
the	O
AFINITOR-treated	O
patients	O
.	O
	
Three	O
patients	O
with	O
anti-belimumab	O
antibodies	O
experienced	O
mild	O
infusion	B
reactions	I
of	O
nausea	B
,	O
erythematous	B
rash	I
,	O
pruritus	B
,	O
eyelid	B
edema	I
,	O
headache	B
,	O
and	O
dyspnea	B
;	O
none	O
of	O
the	O
reactions	O
was	O
life-threatening	O
.	O
	
c	O
The	O
1,200-mg	O
dose	O
of	O
HORIZANT	O
was	O
a	O
treatment	O
arm	O
in	O
each	O
of	O
the	O
3	O
double-blind	O
,	O
placebo-controlled	O
,	O
12-week	O
clinical	O
trials	O
.	O
	
Patients	O
were	O
treated	O
with	O
FIRAZYR	O
30	O
mg	O
and	O
could	O
receive	O
up	O
to	O
3	O
doses	O
of	O
FIRAZYR	O
30	O
mg	O
administered	O
at	O
least	O
6	O
hours	O
apart	O
for	O
each	O
attack	O
.	O
	
In	O
Study	O
1	O
,	O
diarrhea	B
occurred	O
in	O
96	O
%	O
of	O
patients	O
treated	O
with	O
GILOTRIF	O
(	O
n=229	O
)	O
,	O
of	O
which	O
15	O
%	O
was	O
Grade	O
3	O
in	O
severity	O
and	O
occurred	O
within	O
the	O
first	O
6	O
weeks	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Progressive	B
Multifocal	I
Leukoencephalopathy	I
(	O
PML	B
)	O
:	O
Patients	O
presenting	O
with	O
new-onset	O
or	O
deteriorating	O
neurological	O
signs	O
and	O
symptoms	O
should	O
be	O
evaluated	O
for	O
PML	O
by	O
an	O
appropriate	O
specialist	O
.	O
	
5.6	O
Risk	O
of	O
Serious	O
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Complete	O
Gastrointestinal	O
Obstruction	O
No	O
studies	O
have	O
been	O
conducted	O
in	O
patients	O
with	O
complete	O
gastrointestinal	O
obstruction	O
or	O
in	O
patients	O
who	O
have	O
surgery	O
for	O
correction	O
of	O
complete	O
bowel	O
obstruction	O
.	O
	
Deaths	B
as	O
a	O
complication	O
of	O
severe	O
dysphagia	B
have	O
been	O
reported	O
after	O
treatment	O
with	O
botulinum	O
toxin	O
.	O
	
Trials	O
3	O
and	O
4	O
included	O
3,255	O
subjects	O
,	O
of	O
which	O
57	O
%	O
were	O
male	O
and	O
85	O
%	O
were	O
white	O
.	O
	
Trial	O
2	O
was	O
a	O
12-week	O
trial	O
that	O
evaluated	O
the	O
efficacy	O
of	O
BREO	O
ELLIPTA	O
100/25	O
,	O
BREO	O
ELLIPTA	O
200/25	O
,	O
and	O
fluticasone	O
furoate	O
100	O
mcg	O
in	O
adolescent	O
and	O
adult	O
subjects	O
with	O
asthma	O
.	O
	
Patients	O
were	O
aged	O
1	O
to	O
18	O
years	O
with	O
a	O
median	O
duration	O
of	O
treatment	O
of	O
437	O
days	O
(	O
range	O
13	O
to	O
466	O
days	O
)	O
.	O
	
Based	O
on	O
effective	O
donor	O
screening	O
and	O
product	O
manufacturing	O
processes	O
,	O
it	O
carries	O
an	O
extremely	O
remote	O
risk	O
for	O
transmission	O
of	O
viral	B
diseases	I
.	O
	
In	O
Study	O
1	O
,	O
liver	B
test	I
abnormalities	I
of	O
any	O
grade	O
occurred	O
in	O
17.5	O
%	O
of	O
the	O
patients	O
treated	O
with	O
GILOTRIF	O
.	O
	
(	O
5.1	O
)	O
*	O
Serious	O
anaphylactic	B
)	I
reactions	I
have	O
been	O
reported	O
with	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
Instances	O
of	O
suicidal	B
behavior	I
have	O
been	O
observed	O
in	O
0.1	O
%	O
(	O
1/1308	O
)	O
of	O
subjects	O
while	O
receiving	O
OTEZLA	O
,	O
compared	O
to	O
0.2	O
%	O
(	O
1/506	O
)	O
in	O
placebo-treated	O
subjects	O
.	O
	
If	O
a	O
patient	O
experiences	O
anticholinergic	O
CNS	O
effects	O
,	O
dose	O
reduction	O
or	O
drug	O
discontinuation	O
should	O
be	O
considered	O
.	O
	
The	O
risk	O
of	O
impaired	B
renal	I
function	I
with	O
JARDIANCE	O
is	O
increased	O
in	O
elderly	O
patients	O
and	O
patients	O
with	O
moderate	O
renal	O
impairment	O
.	O
	
Human	O
relevance	O
of	O
GLP-1	O
receptor	O
agonist	O
induced	O
C-cell	B
tumors	I
in	O
rodents	O
has	O
not	O
been	O
determined	O
.	O
	
Monitor	O
renal	O
function	O
,	O
blood	O
glucose	O
,	O
lipids	O
,	O
and	O
hematologic	O
parameters	O
prior	O
to	O
treatment	O
and	O
periodically	O
thereafter	O
.	O
	
5.4	O
Progressive	O
Multifocal	O
Leukoencephalopathy	O
Progressive	O
multifocal	O
leukoencephalopathy	O
(	O
PML	O
)	O
is	O
an	O
often	O
rapidly	O
progressive	O
and	O
fatal	O
opportunistic	O
infection	O
of	O
the	O
CNS	O
that	O
is	O
caused	O
by	O
the	O
JC	O
virus	O
,	O
a	O
human	O
polyoma	O
virus	O
.	O
	
Premedicate	O
with	O
corticosteroids	O
and	O
H2	O
antagonists	O
.	O
	
(	O
2.2	O
)	O
(	O
4	O
)	O
*	O
Severe	O
hypersensitivity	B
can	O
occur	O
and	O
may	O
include	O
generalized	B
rash/erythema	O
,	O
hypotension	B
and	O
bronchospasm	B
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
SUICIDAL	B
THOUGHTS	I
WARNING	O
:	O
SUICIDAL	B
THOUGHTS	I
Antidepressants	O
increased	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
children	O
,	O
adolescents	O
,	O
and	O
young	O
adults	O
in	O
short-term	O
studies	O
.	O
	
(	O
5.4	O
)	O
*	O
Renal	B
failure	I
:	O
Cases	O
of	O
renal	B
failure	I
(	O
including	O
acute	B
renal	I
failure	I
)	O
,	O
some	O
with	O
a	O
fatal	B
outcome	O
,	O
have	O
been	O
observed	O
.	O
	
EXCERPT	O
:	O
Advanced	O
HR+	O
BC	O
,	O
advanced	O
PNET	O
,	O
advanced	O
RCC	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=30	O
%	O
)	O
include	O
stomatitis	B
,	O
infections	B
,	O
rash	B
,	O
fatigue	B
,	O
diarrhea	B
,	O
edema	B
,	O
abdominal	B
pain	I
,	O
nausea	B
,	O
fever	B
,	O
asthenia	B
,	O
cough	B
,	O
headache	B
and	O
decreased	B
appetite	I
.	O
	
All	O
patients	O
received	O
at	O
least	O
one	O
dose	O
of	O
BLINCYTO	O
.	O
	
(	O
5.1	O
)	O
*	O
Impairment	B
in	I
renal	I
function	I
:	O
Monitor	O
renal	O
function	O
during	O
therapy	O
.	O
	
*	O
Carcinogenicity	O
of	O
albiglutide	O
could	O
not	O
be	O
assessed	O
in	O
rodents	O
,	O
but	O
other	O
glucagon-like	O
peptide-1	O
(	O
GLP-1	O
)	O
receptor	O
agonists	O
have	O
caused	O
thyroid	B
C-cell	I
tumors	I
in	O
rodents	O
at	O
clinically	O
relevant	O
exposures	O
.	O
	
Twenty-one	O
of	O
290	O
patients	O
(	O
7	O
%	O
)	O
experienced	O
adverse	O
reactions	O
that	O
were	O
assessed	O
as	O
related	O
to	O
VORAXAZE	O
.	O
	
Patients	O
experiencing	O
new	O
or	O
worsening	O
peripheral	O
neuropathy	O
may	O
require	O
a	O
delay	O
,	O
change	O
in	O
dose	O
,	O
or	O
discontinuation	O
of	O
ADCETRIS	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
To	O
avoid	O
transfer	O
of	O
the	O
drug	O
into	O
the	O
eyes	O
and	O
to	O
the	O
periocular	O
area	O
during	O
and	O
after	O
application	O
,	O
patients	O
should	O
wash	O
hands	O
well	O
after	O
applying	O
Picato	O
(	O
r	O
)	O
gel	O
.	O
	
The	O
reactions	O
generally	O
related	O
to	O
rash	B
and	O
pruritis	B
within	O
minutes	O
of	O
DaTscan	O
administration	O
.	O
	
Prior	O
to	O
initiating	O
SIMPONI	O
ARIA	O
,	O
assess	O
if	O
treatment	O
for	O
latent	O
tuberculosis	O
is	O
needed	O
;	O
An	O
induration	O
of	O
5	O
mm	O
or	O
greater	O
is	O
a	O
positive	O
tuberculin	O
skin	O
test	O
,	O
even	O
for	O
patients	O
previously	O
vaccinated	O
with	O
Bacille	O
Calmette-Guerin	O
(	O
BCG	O
)	O
.	O
	
One	O
(	O
n=106	O
)	O
or	O
2	O
(	O
n=	O
30	O
)	O
doses	O
of	O
VORAXAZE	O
were	O
administered	O
intravenously	O
;	O
the	O
number	O
of	O
doses	O
was	O
not	O
specified	O
in	O
13	O
patients	O
.	O
	
(	O
5.7	O
)	O
(	O
8.1	O
)	O
5.1	O
Bone	O
Marrow	O
Suppression	O
Bone	B
marrow	I
suppression	I
manifested	O
as	O
neutropenia	B
,	O
anemia	B
,	O
thrombocytopenia	B
and/or	O
pancytopenia	B
may	O
occur	O
.	O
	
Most	O
subjects	O
(	O
530	O
,	O
70	O
%	O
)	O
received	O
a	O
dose	O
of	O
185	O
MBq	O
(	O
5	O
mCi	O
)	O
.	O
	
Withhold	O
trametinib	O
for	O
up	O
to	O
3	O
weeks	O
for	O
Grade	O
3	O
hemorrhagic	O
events	O
;	O
if	O
improved	O
,	O
resume	O
at	O
a	O
lower	O
dose	O
level	O
.	O
	
Do	O
not	O
use	O
NULOJIX	O
in	O
transplant	O
recipients	O
who	O
are	O
EBV	O
seronegative	O
or	O
with	O
unknown	O
serostatus	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Three	O
hundred	O
ninety-five	O
patients	O
,	O
including	O
approximately	O
250	O
children	O
(	O
aged	O
2	O
to	O
17	O
years	O
)	O
have	O
been	O
treated	O
with	O
ILARIS	O
in	O
interventional	O
trials	O
in	O
CAPS	O
or	O
SJIA	O
.	O
	
Table	O
5	O
:	O
Bleeding	B
Results	O
in	O
the	O
AMPLIFY	O
Study	O
ELIQUISN=2676n	O
(	O
%	O
)	O
Enoxaparin/WarfarinN=2689n	O
(	O
%	O
)	O
Relative	O
Risk	O
(	O
95	O
%	O
CI	O
)	O
*	O
CRNM	B
=	O
clinically	B
relevant	I
nonmajor	I
bleeding.Events	O
associated	O
with	O
each	O
endpoint	O
were	O
counted	O
once	O
per	O
subject	O
,	O
but	O
subjects	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
endpoints	O
.	O
	
Avoid	O
prolonged	O
exposure	O
to	O
UV	O
light	O
and	O
sunlight	O
.	O
	
Avoid	O
accidental	O
transfer	O
of	O
the	O
drug	O
into	O
the	O
eyes	O
and	O
to	O
the	O
periocular	O
area	O
.	O
	
5.7	O
Pheochromocytoma	O
There	O
is	O
no	O
information	O
to	O
guide	O
use	O
of	O
Cleviprex	O
in	O
treating	O
hypertension	O
associated	O
with	O
pheochromocytoma	O
.	O
	
Overall	O
,	O
177	O
patients	O
were	O
enrolled	O
into	O
the	O
study	O
and	O
received	O
ILARIS	O
4	O
mg/kg	O
(	O
up	O
to	O
300	O
mg	O
maximum	O
)	O
in	O
Part	O
I	O
,	O
and	O
100	O
patients	O
received	O
ILARIS	O
4	O
mg/kg	O
(	O
up	O
to	O
300	O
mg	O
maximum	O
)	O
every	O
4	O
weeks	O
or	O
placebo	O
in	O
Part	O
II	O
.	O
	
Invasive	O
Fungal	O
Infections	O
If	O
patients	O
develop	O
a	O
serious	O
systemic	O
illness	O
and	O
they	O
reside	O
or	O
travel	O
in	O
regions	O
where	O
mycoses	O
are	O
endemic	O
,	O
consider	O
invasive	O
fungal	O
infection	O
in	O
the	O
differential	O
diagnosis	O
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
for	O
patients	O
treated	O
with	O
STENDRA	O
(	O
50	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
)	O
was	O
2.8	O
%	O
.	O
	
5.4	O
Worsening	O
of	O
Urinary	O
Retention	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
urinary	O
retention	O
.	O
	
In	O
the	O
event	O
of	O
recrudescent	O
P.	O
falciparum	O
infection	O
after	O
treatment	O
with	O
Coartem	O
Tablets	O
,	O
patients	O
should	O
be	O
treated	O
with	O
a	O
different	O
antimalarial	O
drug	O
.	O
	
Cases	O
of	O
pulmonary	B
toxicity	I
have	O
also	O
been	O
reported	O
in	O
patients	O
receiving	O
ADCETRIS	O
.	O
	
Patients	O
with	O
low	O
albumin	O
levels	O
(	O
less	O
than	O
3.5	O
g/dL	O
)	O
or	O
Model	O
for	O
End-Stage	O
Liver	O
Disease	O
(	O
MELD	O
)	O
score	O
greater	O
than	O
or	O
equal	O
to	O
10	O
at	O
baseline	O
had	O
a	O
greater	O
risk	O
for	O
hepatic	B
decompensation	I
on	O
the	O
arm	O
receiving	O
treatment	O
with	O
PROMACTA	O
plus	O
antivirals	O
.	O
	
No	O
definite	O
causality	O
assessment	O
or	O
benefit	O
risk	O
assessment	O
could	O
be	O
made	O
for	O
these	O
events	O
due	O
to	O
the	O
presence	O
of	O
confounding	O
factors	O
and	O
lack	O
of	O
randomization	O
of	O
ESA	O
use	O
.	O
	
Most	O
cases	O
occurred	O
in	O
association	O
with	O
sepsis	B
,	O
dehydration	B
,	O
or	O
obstructive	B
uropathy	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Cardiovascular	O
Safety	O
Cardiovascular	B
events	I
and	O
deaths	B
were	O
adjudicated	O
to	O
one	O
of	O
the	O
pre-defined	O
endpoints	O
from	O
the	O
Anti-Platelet	O
Trialists	O
'	O
Collaborations	O
(	O
APTC	O
)	O
(	O
cardiovascular	B
death	I
,	O
non-fatal	O
myocardial	B
infarction	I
,	O
and	O
non-fatal	O
stroke	B
)	O
in	O
the	O
randomized	O
controlled	O
and	O
long-term	O
extension	O
studies	O
.	O
	
*	O
Monitor	O
all	O
patients	O
for	O
active	O
TB	O
during	O
treatment	O
,	O
even	O
if	O
initial	O
latent	O
TB	O
test	O
is	O
negative	O
(	O
5.1	O
)	O
*	O
Lymphoma	B
and	O
other	O
malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
in	O
children	O
and	O
adolescent	O
patients	O
treated	O
with	O
TNF	O
blockers	O
,	O
of	O
which	O
CIMZIA	O
is	O
a	O
member	O
(	O
5.2	O
)	O
.	O
	
*	O
Adrenocortical	B
Insufficiency	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
The	O
most	O
common	O
cause	O
of	O
deaths	B
occurring	O
in	O
patients	O
(	O
%	O
)	O
in	O
the	O
two	O
arms	O
(	O
KRd	O
versus	O
Rd	O
)	O
included	O
renal	B
0	I
(	I
0	I
%	I
)	I
versus	I
1	I
(	I
<	I
1	I
%	I
)	I
,	I
and	I
other	I
adverse	I
events	I
9	O
(	O
2	O
%	O
)	O
versus	O
10	O
(	O
3	O
%	O
)	O
.	O
	
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
Table	O
1	O
lists	O
selected	O
adverse	O
reactions	O
occurring	O
in	O
more	O
than	O
2	O
%	O
of	O
patients	O
treated	O
with	O
DALVANCE	O
in	O
clinical	O
trials	O
.	O
	
Hepatobiliary	O
Disorders	O
:	O
cholelithiasis/cholecystitis	O
,	O
hepatic	B
steatosis	I
,	O
hepatitis	B
,	O
hepatomegaly	B
.	O
	
The	O
average	O
age	O
of	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
in	O
the	O
NULOJIX	O
recommended	O
dose	O
and	O
cyclosporine	O
control	O
regimens	O
was	O
49	O
years	O
,	O
ranging	O
from	O
18	O
to	O
79	O
years	O
.	O
	
All	O
patients	O
were	O
monitored	O
for	O
adverse	O
reactions	O
over	O
a	O
24	O
hour	O
period	O
following	O
AdreView	O
administration	O
.	O
	
Observe	O
patients	O
closely	O
for	O
hypersensitivity	O
reactions	O
,	O
especially	O
during	O
the	O
first	O
and	O
second	O
infusions	O
.	O
	
41.1	O
%	O
were	O
current	O
or	O
previous	O
smokers	O
.	O
	
*	O
Keep	O
DUAVEE	O
in	O
the	O
blister	O
until	O
you	O
are	O
ready	O
to	O
take	O
it	O
to	O
protect	O
the	O
tablet	O
from	O
moisture	O
.	O
	
(	O
5.5	O
)	O
5.1	O
Not	O
for	O
Acute	O
Use	O
TUDORZA	O
PRESSAIR	O
is	O
intended	O
as	O
a	O
twice-daily	O
maintenance	O
treatment	O
for	O
COPD	O
and	O
is	O
not	O
indicated	O
for	O
the	O
initial	O
treatment	O
of	O
acute	O
episodes	O
of	O
bronchospasm	O
(	O
i.e.	O
,	O
rescue	O
therapy	O
)	O
.	O
	
Intraocular	O
pressure	O
and	O
the	O
perfusion	O
of	O
the	O
optic	O
nerve	O
head	O
should	O
be	O
monitored	O
and	O
managed	O
appropriately	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.7	O
)	O
]	O
.	O
	
Should	O
a	O
stroke	O
occur	O
or	O
be	O
suspected	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
immediately	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Galactorrhea	B
,	O
amenorrhea	B
,	O
gynecomastia	B
,	O
and	O
impotence	B
have	O
been	O
reported	O
in	O
patients	O
receiving	O
prolactin-elevating	O
compounds	O
.	O
	
It	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
these	O
events	O
are	O
related	O
directly	O
to	O
the	O
use	O
of	O
PDE5	O
inhibitors	O
,	O
to	O
the	O
patient	O
's	O
underlying	O
vascular	O
risk	O
factors	O
or	O
anatomical	O
defects	O
,	O
to	O
a	O
combination	O
of	O
these	O
factors	O
,	O
or	O
to	O
other	O
factors	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
andPatient	O
Counseling	O
Information	O
(	O
17.6	O
)	O
]	O
.	O
	
Discontinue	O
SIMPONI	O
ARIA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
.	O
	
Such	O
monitoring	O
may	O
increase	O
the	O
risk	O
of	O
unnecessary	O
procedures	O
,	O
due	O
to	O
the	O
low	O
specificity	O
of	O
serum	O
calcitonin	O
testing	O
for	O
MTC	O
and	O
a	O
high	O
background	O
incidence	O
of	O
thyroid	O
disease	O
.	O
	
In	O
clinical	O
trials	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
5	O
%	O
)	O
following	O
alglucosidase	O
alfa	O
treatment	O
were	O
hypersensitivity	B
reactions	I
,	O
and	O
included	O
anaphylaxis	B
,	O
rash	B
,	O
pyrexia	B
,	O
flushing/feeling	O
hot	B
,	O
urticaria	B
,	O
headache	B
,	O
hyperhidrosis	B
,	O
nausea	B
,	O
cough	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
tachycardia	B
,	O
tachypnea	B
,	O
chest	B
discomfort	I
,	O
dizziness	B
,	O
muscle	B
twitching	I
,	O
agitation	B
,	O
cyanosis	B
,	O
erythema	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
pallor	B
,	O
rigors	B
,	O
tremor	B
,	O
vomiting	B
,	O
fatigue	B
,	O
and	O
myalgia	B
.	O
	
Advise	O
patients	O
of	O
signs	O
and	O
symptoms	O
of	O
blood	O
loss	O
and	O
to	O
report	O
them	O
immediately	O
or	O
go	O
to	O
an	O
emergency	O
room	O
.	O
	
If	O
bone	O
abnormalities	O
are	O
suspected	O
,	O
then	O
appropriate	O
consultation	O
should	O
be	O
obtained	O
.	O
	
Permanently	O
discontinue	O
for	O
life-threatening	O
bradycardia	O
due	O
to	O
XALKORI	O
;	O
however	O
,	O
if	O
associated	O
with	O
concomitant	O
medications	O
known	O
to	O
cause	O
bradycardia	O
or	O
hypotension	O
,	O
hold	O
XALKORI	O
until	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
and	O
if	O
concomitant	O
medications	O
can	O
be	O
adjusted	O
or	O
discontinued	O
,	O
restart	O
XALKORI	O
at	O
250	O
mg	O
once	O
daily	O
with	O
frequent	O
monitoring	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
If	O
hepatic	O
injury	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
MULTAQ	O
and	O
test	O
serum	O
enzymes	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
,	O
alanine	O
aminotransferase	O
(	O
ALT	O
)	O
and	O
alkaline	O
phosphatase	O
,	O
as	O
well	O
as	O
serum	O
bilirubin	O
,	O
to	O
establish	O
whether	O
there	O
is	O
liver	O
injury	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
ribavirin	O
for	O
additional	O
information	O
regarding	O
dose	O
reduction	O
and/or	O
discontinuation	O
.	O
	
The	O
elevation	O
has	O
a	O
rapid	O
onset	O
,	O
reaches	O
a	O
plateau	O
after	O
7	O
days	O
and	O
is	O
reversible	O
after	O
discontinuation	O
.	O
	
There	O
is	O
no	O
experience	O
with	O
antifibrinolytic	O
agents	O
(	O
tranexamic	O
acid	O
,	O
aminocaproic	O
acid	O
)	O
in	O
individuals	O
receiving	O
apixaban	O
.	O
	
Patients	O
with	O
histoplasmosis	O
or	O
other	O
invasive	O
fungal	O
infections	O
may	O
present	O
with	O
disseminated	O
,	O
rather	O
than	O
localized	O
,	O
disease	O
.	O
	
Perform	O
a	O
baseline	O
ocular	O
examination	O
prior	O
to	O
administration	O
of	O
PROMACTA	O
and	O
,	O
during	O
therapy	O
with	O
PROMACTA	O
,	O
regularly	O
monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
cataracts	O
.	O
	
Among	O
these	O
202	O
patients	O
,	O
66	O
(	O
33	O
%	O
)	O
were	O
exposed	O
to	O
TAFINLAR	O
and	O
68	O
(	O
34	O
%	O
)	O
were	O
exposed	O
to	O
trametinib	O
for	O
greater	O
than	O
6	O
to	O
12	O
months	O
while	O
40	O
(	O
20	O
%	O
)	O
were	O
exposed	O
to	O
TAFINLAR	O
and	O
36	O
(	O
18	O
%	O
)	O
were	O
exposed	O
to	O
trametinib	O
for	O
greater	O
than	O
one	O
year	O
.	O
	
Two	O
of	O
the	O
patients	O
(	O
1	O
%	O
)	O
with	O
persistently	O
positive	O
antibodies	O
experienced	O
adverse	O
reactions	O
consistent	O
with	O
infusion	B
reactions	I
that	O
led	O
to	O
discontinuation	O
of	O
treatment	O
.	O
	
There	O
were	O
no	O
reports	O
of	O
Torsade	B
de	I
Pointes	I
or	O
any	O
other	O
adverse	O
reactions	O
associated	O
with	O
delayed	B
ventricular	I
repolarization	I
.	O
	
The	O
mechanism	O
and	O
long-term	O
consequences	O
of	O
these	O
events	O
are	O
currently	O
unknown	O
.	O
	
Protamine	O
sulfate	O
and	O
vitamin	O
K	O
are	O
not	O
expected	O
to	O
affect	O
the	O
anticoagulant	O
activity	O
of	O
apixaban	O
.	O
	
Among	O
the	O
factors	O
that	O
may	O
increase	O
the	O
risk	O
for	O
NSF	O
are	O
repeated	O
or	O
higher	O
than	O
recommended	O
doses	O
of	O
a	O
GBCA	O
and	O
degree	O
of	O
renal	O
impairment	O
at	O
the	O
time	O
of	O
exposure	O
.	O
	
5.10	O
Women	O
of	O
Childbearing	O
Potential	O
Premenopausal	O
women	O
who	O
have	O
not	O
undergone	O
a	O
hysterectomy	O
or	O
oophorectomy	O
must	O
use	O
effective	O
contraception	O
while	O
using	O
MULTAQ	O
.	O
	
If	O
ribavirin	O
is	O
permanently	O
discontinued	O
for	O
management	O
of	O
anemia	O
,	O
then	O
peginterferon	O
alfa	O
and	O
VICTRELIS	O
must	O
also	O
be	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
use	O
of	O
SAPHRIS	O
should	O
be	O
avoided	O
in	O
combination	O
with	O
other	O
drugs	O
known	O
to	O
prolong	O
QTc	O
including	O
Class	O
1A	O
antiarrhythmics	O
(	O
e.g.	O
,	O
quinidine	O
,	O
procainamide	O
)	O
or	O
Class	O
3	O
antiarrhythmics	O
(	O
e.g.	O
,	O
amiodarone	O
,	O
sotalol	O
)	O
,	O
antipsychotic	O
medications	O
(	O
e.g.	O
,	O
ziprasidone	O
,	O
chlorpromazine	O
,	O
thioridazine	O
)	O
,	O
and	O
antibiotics	O
(	O
e.g.	O
,	O
gatifloxacin	O
,	O
moxifloxacin	O
)	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Endophthalmitis	O
and	O
Retinal	O
Detachments	O
Intravitreal	O
injections	O
,	O
including	O
those	O
with	O
EYLEA	O
,	O
have	O
been	O
associated	O
with	O
endophthalmitis	B
and	O
retinal	B
detachments	I
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Overall	O
,	O
a	O
higher	O
incidence	O
of	O
infusion	B
related	I
reactions	I
was	O
observed	O
in	O
patients	O
who	O
developed	O
persistently	O
positive	O
antibodies	O
.	O
	
The	O
median	O
age	O
was	O
54	O
years	O
,	O
57	O
%	O
were	O
male	O
,	O
and	O
>	O
99	O
%	O
were	O
white	O
.	O
	
Cataracts	B
were	O
observed	O
in	O
toxicology	O
studies	O
of	O
eltrombopag	O
in	O
rodents	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.2	O
)	O
]	O
.	O
	
*	O
Invasive	B
fungal	I
infections	I
,	O
including	O
histoplasmosis	B
,	O
coccidioidomycosis	B
,	O
candidiasis	B
,	O
aspergillosis	B
,	O
blastomycosis	B
and	O
pneumocystosis	B
.	O
	
Clinical	O
Trials	O
in	O
Infantile-Onset	O
and	O
Juvenile-Onset	O
Pompe	O
Disease	O
Two	O
multicenter	O
,	O
open-label	O
clinical	O
trials	O
were	O
conducted	O
in	O
39	O
infantile-onset	O
Pompe	O
disease	O
patients	O
,	O
ages	O
1	O
month	O
to	O
3.5	O
years	O
old	O
.	O
	
Significantly	O
elevated	O
serum	O
calcitonin	O
may	O
indicate	O
MTC	O
and	O
patients	O
with	O
MTC	O
usually	O
have	O
calcitonin	O
values	O
>	O
50	O
ng/L	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Evaluation	O
of	O
erectile	O
dysfunction	O
(	O
ED	O
)	O
should	O
include	O
an	O
appropriate	O
medical	O
assessment	O
to	O
identify	O
potential	O
underlying	O
causes	O
,	O
as	O
well	O
as	O
treatment	O
options	O
.	O
	
Subgroup	O
analyses	O
of	O
women	O
50	O
to	O
59	O
years	O
of	O
age	O
suggest	O
no	O
increased	O
risk	O
of	O
stroke	B
for	O
those	O
women	O
receiving	O
conjugated	O
estrogens	O
(	O
0.625	O
mg	O
)	O
-alone	O
versus	O
those	O
receiving	O
placebo	O
(	O
18	O
versus	O
21	O
per	O
10,000	O
women-years	O
)	O
.	O
	
5.3	O
Thromboembolic	O
Events	O
There	O
is	O
a	O
potential	O
risk	O
of	O
arterial	B
thromboembolic	I
events	I
(	O
ATEs	B
)	O
following	O
intravitreal	O
use	O
of	O
VEGF	O
inhibitors	O
,	O
including	O
EYLEA	O
.	O
	
Incidence	O
of	O
Laboratory	O
Abnormalities	O
Increased	O
From	O
Baseline	O
Occurring	O
at	O
a	O
Higher	O
Incidence	O
in	O
Patients	O
Treated	O
With	O
TAFINLAR	O
in	O
Trial	O
1	O
[	O
Between-Arm	O
Difference	O
of	O
>	O
=5	O
%	O
(	O
All	O
Grades	O
)	O
or	O
>	O
=2	O
%	O
(	O
Grades	O
3	O
or	O
4	O
)	O
]	O
Test	O
TAFINLAR	O
N	O
=	O
187	O
DTIC	O
N	O
=	O
59	O
All	O
Grades	O
(	O
%	O
)	O
Grades	O
3	O
and	O
4	O
(	O
%	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grades	O
3	O
and	O
4	O
(	O
%	O
)	O
Hyperglycemia	B
50	O
6	O
43	O
0	O
Hypophosphatemia	B
37	O
6a	O
14	O
2	O
Increased	B
alkaline	I
phosphatase	I
19	O
0	O
14	O
2	O
Hyponatremia	B
8	O
2	O
3	O
0	O
a	O
Grade	O
4	O
laboratory	O
abnormality	O
limited	O
to	O
hypophosphatemia	B
(	O
n	O
=	O
1	O
)	O
.	O
	
If	O
liver	O
injury	O
is	O
found	O
,	O
institute	O
appropriate	O
treatment	O
and	O
investigate	O
the	O
probable	O
cause	O
.	O
	
5.5	O
Severe	O
Visual	O
Loss	O
Across	O
all	O
clinical	O
trials	O
,	O
the	O
incidence	O
of	O
Grade	O
4	O
visual	B
field	I
defect	I
with	O
vision	B
loss	I
was	O
0.2	O
%	O
(	O
4/1669	O
)	O
.	O
	
Although	O
the	O
effect	O
of	O
supplementation	O
with	O
calcium	O
and	O
vitamin	O
D	O
was	O
not	O
studied	O
,	O
such	O
supplementation	O
may	O
be	O
beneficial	O
in	O
all	O
patients	O
.	O
	
Premedicate	O
all	O
patients	O
prior	O
to	O
the	O
initiation	O
of	O
the	O
infusion	O
of	O
JEVTANA	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
5.4	O
Pancytopenia	O
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
Serious	O
cases	O
of	O
pancytopenia	B
have	O
been	O
reported	O
postmarketing	O
in	O
patients	O
receiving	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
CNS	B
PTLD	I
,	O
PML	B
,	O
and	O
other	O
CNS	B
infections	I
were	O
more	O
frequently	O
observed	O
in	O
association	O
with	O
a	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
compared	O
to	O
the	O
recommended	O
regimen	O
;	O
therefore	O
,	O
administration	O
of	O
higher	O
than	O
the	O
recommended	O
doses	O
and/or	O
more	O
frequent	O
dosing	O
of	O
NULOJIX	O
is	O
not	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
Patients	O
with	O
histoplasmosis	B
,	O
rather	O
than	O
localized	O
disease	O
.	O
	
Immune	O
System	O
Disorder	O
:	O
hypersensitivity	B
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Table1	O
.	O
	
Deaths	B
due	O
to	O
adverse	O
events	O
within	O
30	O
days	O
of	O
the	O
last	O
dose	O
of	O
any	O
therapy	O
in	O
the	O
KRd	O
arm	O
occurred	O
in	O
27/392	O
(	O
7	O
%	O
)	O
patients	O
compared	O
with	O
27/389	O
(	O
7	O
%	O
)	O
patients	O
who	O
died	B
due	O
to	O
adverse	O
events	O
within	O
30	O
days	O
of	O
the	O
last	O
dose	O
of	O
any	O
Rd	O
therapy	O
.	O
	
*	O
Hepatotoxicity	B
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
*	O
Store	O
DUAVEE	O
at	O
room	O
temperature	O
between	O
68	O
degrees	O
F	O
to	O
77	O
degrees	O
F	O
(	O
20	O
degrees	O
C	O
to	O
25	O
degrees	O
C	O
)	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
RISK	O
FOR	O
HEPATIC	B
DECOMPENSATION	I
IN	O
PATIENTS	O
WITH	O
CHRONIC	O
HEPATITIS	O
C	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
6.2	O
Post	O
Marketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
ADCETRIS	O
.	O
	
*	O
See	O
you	O
healthcare	O
provider	O
right	O
away	O
if	O
you	O
get	O
vaginal	O
bleeding	O
while	O
taking	O
DUAVEE	O
.	O
	
In	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
and	O
thrombocytopenia	O
,	O
ascites	B
and	O
encephalopathy	B
occurred	O
more	O
frequently	O
on	O
the	O
arm	O
receiving	O
treatment	O
with	O
PROMACTA	O
plus	O
antivirals	O
(	O
7	O
%	O
)	O
than	O
the	O
placebo	O
plus	O
antivirals	O
arm	O
(	O
4	O
%	O
)	O
.	O
	
b	O
Grade	O
4	O
adverse	O
reactions	O
limited	O
to	O
hyperkeratosis	B
(	O
n	O
=	O
1	O
)	O
and	O
constipation	B
(	O
n	O
=	O
1	O
)	O
.	O
	
In	O
Study	O
3	O
,	O
pulmonary	B
toxicity	I
was	O
reported	O
in	O
8	O
patients	O
(	O
5	O
%	O
)	O
in	O
the	O
ADCETRIS-treated	O
arm	O
and	O
5	O
patients	O
(	O
3	O
%	O
)	O
in	O
the	O
placebo	O
arm	O
.	O
	
5.6	O
Hepatic	O
and	O
Renal	O
Impairment	O
Coartem	O
Tablets	O
have	O
not	O
been	O
studied	O
for	O
efficacy	O
and	O
safety	O
in	O
patients	O
with	O
severe	O
hepatic	O
and/or	O
renal	O
impairment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
]	O
.	O
	
The	O
following	O
serious	O
and	O
otherwise	O
important	O
adverse	O
drug	O
reactions	O
(	O
ADRs	O
)	O
are	O
discussed	O
in	O
detail	O
in	O
another	O
section	O
of	O
the	O
labeling	O
:	O
*	O
Anemia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Neutropenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Pancytopenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Hypersensitivity	B
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
more	O
than	O
35	O
%	O
of	O
subjects	O
regardless	O
of	O
investigator	O
's	O
causality	O
assessment	O
)	O
in	O
adult	O
subjects	O
were	O
fatigue	B
,	O
anemia	B
,	O
nausea	B
,	O
headache	B
,	O
and	O
dysgeusia	B
when	O
VICTRELIS	O
was	O
used	O
in	O
combination	O
with	O
PegIntron	O
and	O
REBETOL	O
.	O
	
In	O
this	O
extension	O
trial	O
,	O
all	O
eligible	O
patients	O
were	O
initially	O
assigned	O
to	O
STENDRA	O
100	O
mg.	O
At	O
any	O
point	O
during	O
the	O
trial	O
,	O
patients	O
could	O
request	O
to	O
have	O
their	O
dose	O
of	O
STENDRA	O
increased	O
to	O
200	O
mg	O
or	O
decreased	O
to	O
50	O
mg	O
based	O
on	O
their	O
individual	O
response	O
to	O
treatment	O
.	O
	
In	O
the	O
Phase	O
3	O
randomized	O
controlled	O
studies	O
,	O
the	O
incidences	O
of	O
adjudicated	O
APTC	O
events	O
per	O
100	O
patient-years	O
of	O
exposure	O
were	O
:	O
Placebo	O
0	O
(	O
95	O
%	O
CI	O
0.00-6.16	O
)	O
,	O
ULORIC	O
40	O
mg	O
0	O
(	O
95	O
%	O
CI	O
0.00-1.08	O
)	O
,	O
ULORIC	O
80	O
mg	O
1.09	O
(	O
95	O
%	O
CI	O
0.44-2.24	O
)	O
,	O
and	O
allopurinol	O
0.60	O
(	O
95	O
%	O
CI	O
0.16-1.53	O
)	O
.	O
	
5.4	O
Renal	O
Failure	O
In	O
the	O
randomized	O
clinical	O
trial	O
,	O
renal	B
failure	I
of	O
any	O
grade	O
occurred	O
in	O
4	O
%	O
of	O
the	O
patients	O
being	O
treated	O
with	O
JEVTANA	O
,	O
including	O
four	O
cases	O
with	O
fatal	B
outcome	O
.	O
	
Thromboembolic	B
events	I
were	O
reported	O
in	O
clinical	O
trials	O
with	O
VICTRELIS	O
among	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
,	O
and	O
among	O
those	O
receiving	O
PegIntron/REBETOL	O
alone	O
,	O
regardless	O
of	O
ESA	O
use	O
.	O
	
(	O
5.3	O
)	O
*	O
Progressive	B
Multifocal	I
Leukoencephalopathy	I
(	O
PML	B
)	O
:	O
increased	O
risk	O
;	O
consider	O
in	O
the	O
diagnosis	O
of	O
patients	O
reporting	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
and	O
symptoms	O
.	O
	
Given	O
the	O
similarity	O
in	O
hypersensitivity	O
symptoms	O
and	O
acute	O
HAE	O
symptoms	O
,	O
monitor	O
patients	O
closely	O
for	O
hypersensitivity	O
reactions	O
(	O
5	O
)	O
.	O
	
Two	O
percent	O
demonstrated	O
a	O
decrease	B
in	I
LVEF	I
below	O
institutional	O
lower	O
limits	O
of	O
normal	O
with	O
an	O
absolute	B
decrease	I
in	I
LVEF	I
of	O
>	O
=20	O
%	O
below	O
baseline	O
.	O
	
Major	O
15	O
(	O
0.6	O
)	O
49	O
(	O
1.8	O
)	O
0.31	O
(	O
0.17	O
,	O
0.55	O
)	O
p	O
<	O
0.0001	O
CRNM*	O
103	O
(	O
3.9	O
)	O
215	O
(	O
8.0	O
)	O
Major	O
+	O
CRNM	B
115	O
(	O
4.3	O
)	O
261	O
(	O
9.7	O
)	O
Minor	O
313	O
(	O
11.7	O
)	O
505	O
(	O
18.8	O
)	O
All	O
402	O
(	O
15.0	O
)	O
676	O
(	O
25.1	O
)	O
Adverse	O
reactions	O
occurring	O
in	O
>	O
=1	O
%	O
of	O
patients	O
in	O
the	O
AMPLIFY	O
study	O
are	O
listed	O
in	O
Table	O
6	O
.	O
	
Consider	O
appropriate	O
empiric	O
antifungal	O
therapy	O
and	O
take	O
into	O
account	O
both	O
the	O
risk	O
for	O
severe	O
fungal	O
infection	O
and	O
the	O
risks	O
of	O
antifungal	O
therapy	O
while	O
a	O
diagnostic	O
workup	O
is	O
being	O
performed	O
.	O
	
If	O
accidental	O
exposure	O
occurs	O
,	O
flush	O
eyes	O
with	O
water	O
and	O
seek	O
medical	O
care	O
.	O
	
The	O
Study	O
1	O
population	O
enrolled	O
patients	O
with	O
a	O
median	O
age	O
of	O
18	O
years	O
(	O
1	O
month	O
to	O
85	O
years	O
)	O
;	O
63	O
%	O
were	O
male	O
,	O
and	O
the	O
underlying	O
malignancies	O
were	O
osteosarcoma/sarcomas	O
in	O
32	O
%	O
,	O
and	O
leukemia	O
or	O
lymphoma	O
in	O
63	O
%	O
of	O
patients	O
.	O
	
Consider	O
anti-tuberculosis	O
therapy	O
prior	O
to	O
initiation	O
of	O
SIMPONI	O
ARIA	O
in	O
patients	O
with	O
a	O
past	O
history	O
of	O
latent	O
or	O
active	O
tuberculosis	O
in	O
whom	O
an	O
adequate	O
course	O
of	O
treatment	O
can	O
not	O
be	O
confirmed	O
,	O
and	O
for	O
patients	O
with	O
a	O
negative	O
test	O
for	O
latent	O
tuberculosis	O
but	O
having	O
risk	O
factors	O
for	O
tuberculosis	O
infection	O
.	O
	
(	O
4	O
,	O
5.1	O
)	O
*	O
Only	O
physicians	O
experienced	O
in	O
immunosuppressive	O
therapy	O
and	O
management	O
of	O
kidney	O
transplant	O
patients	O
should	O
prescribe	O
NULOJIX	O
.	O
	
AMPLIFY	O
Study	O
The	O
mean	O
duration	O
of	O
exposure	O
to	O
ELIQUIS	O
was	O
154	O
days	O
and	O
to	O
enoxaparin/warfarin	O
was	O
152	O
days	O
in	O
the	O
AMPLIFY	O
study	O
.	O
	
Withhold	O
TAFINLAR	O
for	O
Grade	O
3	O
hemorrhagic	O
events	O
;	O
if	O
improved	O
resume	O
at	O
a	O
lower	O
dose	O
level	O
.	O
	
In	O
clinical	O
trials	O
,	O
761	O
adults	O
(	O
367	O
men	O
and	O
394	O
women	O
,	O
91	O
%	O
Caucasian	O
)	O
with	O
a	O
mean	O
age	O
of	O
62	O
years	O
(	O
range	O
18-93	O
years	O
)	O
received	O
Vizamyl	O
.	O
	
Neutropenic	B
deaths	B
have	O
been	O
reported	O
.	O
	
Reduction	O
of	O
Risk	O
of	O
Stroke	O
and	O
Systemic	O
Embolism	O
in	O
Non-valvular	O
Atrial	O
Fibrillation	O
Reduce	O
the	O
dose	O
of	O
PRADAXA	O
to	O
75	O
mg	O
twice	O
daily	O
when	O
dronedarone	O
or	O
systemic	O
ketoconazole	O
is	O
coadministered	O
with	O
PRADAXA	O
in	O
patients	O
with	O
moderate	O
renal	O
impairment	O
(	O
CrCl	O
30-50	O
mL/min	O
)	O
.	O
	
Management	O
includes	O
mouthwashes	O
and	O
topical	O
treatments	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
-	O
Stevens-Johnson	B
syndrome	I
.	O
	
Discontinue	O
JEVTANA	O
immediately	O
if	O
severe	O
reactions	O
occur	O
and	O
administer	O
appropriate	O
therapy	O
.	O
	
Monitor	O
patients	O
for	O
symptoms	O
of	O
neuropathy	O
,	O
such	O
as	O
hypoesthesia	O
,	O
hyperesthesia	O
,	O
paresthesia	O
,	O
discomfort	O
,	O
a	O
burning	O
sensation	O
,	O
neuropathic	O
pain	O
,	O
or	O
weakness	O
.	O
	
If	O
accidental	O
exposure	O
occurs	O
,	O
the	O
area	O
should	O
be	O
flushed	O
with	O
water	O
and	O
the	O
patient	O
should	O
seek	O
medical	O
care	O
as	O
soon	O
as	O
possible	O
.	O
	
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Among	O
the	O
290	O
patients	O
included	O
in	O
the	O
safety	O
evaluation	O
of	O
VORAXAZE	O
,	O
there	O
were	O
8	O
deaths	B
within	O
30	O
days	O
of	O
VORAXAZE	O
exposure	O
that	O
were	O
not	O
related	O
to	O
progressive	O
disease	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
1	O
%	O
of	O
ULORIC-treated	O
patients	O
,	O
and	O
at	O
least	O
0.5	O
%	O
greater	O
than	O
placebo	O
,	O
are	O
liver	B
function	I
abnormalities	I
,	O
nausea	B
,	O
arthralgia	B
,	O
and	O
rash	B
.	O
	
CAPS	O
Study	O
1	O
investigated	O
the	O
safety	O
of	O
ILARIS	O
in	O
an	O
8-week	O
,	O
open-label	O
period	O
(	O
Part	O
1	O
)	O
,	O
followed	O
by	O
a	O
24-week	O
,	O
randomized	O
withdrawal	O
period	O
(	O
Part	O
2	O
)	O
,	O
followed	O
by	O
a	O
16-week	O
,	O
open-label	O
period	O
(	O
Part	O
3	O
)	O
.	O
	
The	O
criterion	O
for	O
allowing	O
patients	O
to	O
receive	O
a	O
second	O
glucarpidase	O
dose	O
was	O
not	O
specified	O
in	O
the	O
protocol	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
*	O
Carcinogenicity	O
of	O
albiglutide	O
could	O
not	O
be	O
assessed	O
in	O
rodents	O
,	O
but	O
other	O
glucagon-like	O
peptide-1	O
(	O
GLP-1	O
)	O
receptor	O
agonists	O
have	O
caused	O
thyroid	B
C-cell	I
tumors	I
in	O
rodents	O
at	O
clinically	O
relevant	O
exposures	O
.	O
	
More	O
frequent	O
monitoring	O
of	O
renal	O
function	O
is	O
recommended	O
in	O
these	O
patients	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
,	O
8.6	O
)	O
]	O
.	O
	
If	O
Grade	O
3	O
or	O
4	O
neutropenia	O
develops	O
,	O
consider	O
dose	O
delays	O
,	O
reductions	O
,	O
discontinuation	O
,	O
or	O
G-CSF	O
prophylaxis	O
with	O
subsequent	O
doses	O
(	O
5.3	O
)	O
.	O
	
(	O
5.4	O
)	O
5	O
.	O
	
In	O
clinical	O
studies	O
,	O
there	O
were	O
uncommon	O
reports	O
of	O
ischemic	B
cardiac	I
adverse	I
reactions	I
,	O
including	O
myocardial	B
ischemia	I
,	O
myocardial	B
infarction	I
,	O
and	O
coronary	B
occlusion	I
requiring	O
revascularization	O
;	O
these	O
patients	O
had	O
multiple	O
underlying	O
cardiac	O
risk	O
factors	O
.	O
	
Discontinue	O
infusion	O
immediately	O
if	O
hypersensitivity	O
is	O
observed	O
and	O
treat	O
as	O
indicated	O
.	O
	
In	O
clinical	O
trials	O
with	O
NULOJIX	O
,	O
two	O
cases	O
of	O
PML	B
were	O
reported	O
in	O
patients	O
receiving	O
NULOJIX	O
at	O
higher	O
cumulative	O
doses	O
and	O
more	O
frequently	O
than	O
the	O
recommended	O
regimen	O
,	O
along	O
with	O
mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
and	O
corticosteroids	O
;	O
one	O
case	O
occurred	O
in	O
a	O
kidney	O
transplant	O
recipient	O
and	O
the	O
second	O
case	O
occurred	O
in	O
a	O
liver	O
transplant	O
recipient	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
A	O
theoretical	O
risk	O
for	O
transmission	O
of	O
Creutzfeldt-Jakob	B
disease	I
(	O
CJD	B
)	O
is	O
also	O
considered	O
extremely	O
remote	O
.	O
	
Safety	O
was	O
also	O
evaluated	O
in	O
99	O
patients	O
(	O
51	O
male	O
,	O
48	O
females	O
)	O
with	O
Pompe	O
disease	O
in	O
an	O
ongoing	O
,	O
open-label	O
,	O
prospective	O
study	O
in	O
patients	O
12	O
months	O
of	O
age	O
and	O
older	O
who	O
were	O
previously	O
treated	O
with	O
the	O
160	O
L	O
scale	O
of	O
alglucosidase	O
alfa	O
and	O
switched	O
to	O
the	O
4000	O
L	O
scale	O
of	O
alglucosidase	O
alfa	O
.	O
	
5.6	O
Hepatic	O
Impairment	O
Toviaz	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
and	O
therefore	O
is	O
not	O
recommended	O
for	O
use	O
in	O
this	O
patient	O
population	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
and	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
Depression	B
was	O
reported	O
as	O
serious	O
in	O
0.1	O
%	O
(	O
1/1308	O
)	O
of	O
subjects	O
exposed	O
to	O
OTEZLA	O
,	O
compared	O
to	O
none	O
in	O
placebo-treated	O
subjects	O
(	O
0/506	O
)	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
BENLYSTA	O
.	O
	
5.4	O
Hepatic	O
Toxicity	O
In	O
3865	O
patients	O
who	O
received	O
GILOTRIF	O
across	O
clinical	O
trials	O
,	O
10.1	O
%	O
had	O
liver	B
test	I
abnormalities	I
,	O
of	O
which	O
7	O
(	O
0.18	O
%	O
)	O
were	O
fatal	B
.	O
	
Monitor	O
supine	O
blood	O
pressure	O
prior	O
to	O
and	O
during	O
treatment	O
and	O
more	O
frequently	O
when	O
increasing	O
doses	O
.	O
	
Consider	O
interrupting	O
therapy	O
with	O
BENLYSTA	O
if	O
patients	O
develop	O
a	O
new	O
infection	O
during	O
treatment	O
with	O
BENLYSTA	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Diarrhea	O
Diarrhea	B
has	O
resulted	O
in	O
dehydration	B
with	O
or	O
without	O
renal	B
impairment	I
;	O
some	O
of	O
these	O
cases	O
were	O
fatal	B
.	O
	
b	O
The	O
600-mg	O
dose	O
of	O
HORIZANT	O
was	O
a	O
treatment	O
arm	O
in	O
2	O
of	O
the	O
3	O
double-blind	O
,	O
placebo-controlled	O
,	O
12-week	O
clinical	O
trials	O
.	O
	
In	O
all	O
three	O
controlled	O
trials	O
,	O
patients	O
were	O
eligible	O
for	O
treatment	O
of	O
subsequent	O
attacks	O
in	O
an	O
open-label	O
extension	O
.	O
	
They	O
had	O
a	O
mean	O
age	O
of	O
64	O
years	O
and	O
an	O
average	O
smoking	O
history	O
of	O
46	O
pack-years	O
,	O
with	O
44	O
%	O
identified	O
as	O
current	O
smokers	O
.	O
	
Discontinue	O
TIVICAY	O
and	O
other	O
suspect	O
agents	O
immediately	O
if	O
signs	O
or	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
develop	O
,	O
as	O
a	O
delay	O
in	O
stopping	O
treatment	O
may	O
result	O
in	O
a	O
life-threatening	O
reaction	O
.	O
	
Neutralizing	O
antibodies	O
were	O
detected	O
in	O
3	O
patients	O
receiving	O
BENLYSTA	O
1	O
mg/kg	O
.	O
	
Adverse	O
reactions	O
leading	O
to	O
permanent	O
discontinuation	O
in	O
the	O
AFINITOR	O
arm	O
were	O
hypersensitivity/angioedema/bronchospasm	O
,	O
convulsion	B
,	O
and	O
hypophosphatemia	B
.	O
	
The	O
median	O
duration	O
of	O
blinded	O
study	O
treatment	O
was	O
48	O
weeks	O
(	O
range	O
2	O
to	O
115	O
weeks	O
)	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
45	O
weeks	O
(	O
range	O
9	O
to	O
115	O
weeks	O
)	O
for	O
those	O
receiving	O
placebo	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
psoriatic	O
arthritis	O
who	O
discontinued	O
treatment	O
due	O
to	O
any	O
adverse	O
reaction	O
was	O
4.6	O
%	O
for	O
patients	O
taking	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
and	O
1.2	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
In	O
Virologically-Suppressed	O
HIV-1-Infected	O
Subjects	O
No	O
new	O
adverse	O
reactions	O
to	O
STRIBILD	O
through	O
Week	O
48	O
were	O
identified	O
in	O
584	O
virologically	O
stably	O
suppressed	O
subjects	O
switching	O
to	O
STRIBILD	O
from	O
a	O
regimen	O
containing	O
a	O
RTV-boosted	O
protease	O
inhibitor	O
(	O
PI	O
)	O
or	O
a	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
(	O
NNRTI	O
)	O
.	O
	
Clinical	O
status	O
,	O
including	O
liver	O
aminotransferases	O
,	O
should	O
be	O
monitored	O
and	O
appropriate	O
therapy	O
initiated	O
.	O
	
Avoid	O
use	O
of	O
FANAPT	O
in	O
combination	O
with	O
other	O
drugs	O
that	O
are	O
known	O
to	O
prolong	O
QTc	O
;	O
use	O
caution	O
and	O
consider	O
dose	O
modification	O
when	O
prescribing	O
FANAPT	O
with	O
other	O
drugs	O
that	O
inhibit	O
FANAPT	O
metabolism	O
.	O
	
In	O
clinical	O
studies	O
with	O
Kyprolis	O
,	O
these	O
events	O
typically	O
occurred	O
early	O
in	O
the	O
course	O
of	O
Kyprolis	O
therapy	O
(	O
<	O
5	O
cycles	O
)	O
.	O
	
What	O
is	O
DUAVEE	O
?	O
	
In	O
the	O
presence	O
of	O
binding	O
and	O
neutralizing	O
antibodies	O
to	O
DYSPORT	O
(	O
r	O
)	O
some	O
patients	O
continue	O
to	O
experience	O
clinical	O
benefit	O
.	O
	
During	O
the	O
controlled	O
portion	O
of	O
the	O
Phase	O
3	O
trial	O
in	O
RA	O
for	O
SIMPONI	O
ARIA	O
,	O
the	O
incidence	O
of	O
malignancies	B
other	O
than	O
lymphoma	O
and	O
NMSC	O
per	O
100-patient-years	O
of	O
follow-up	O
was	O
0.56	O
(	O
95	O
%	O
CI	O
:	O
0.01	O
,	O
3.11	O
)	O
in	O
the	O
SIMPONI	O
ARIA	O
group	O
compared	O
with	O
an	O
incidence	O
of	O
0	O
(	O
95	O
%	O
CI	O
:	O
0.00	O
,	O
3.79	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
Table	O
1	O
presents	O
adverse	O
reactions	O
reported	O
in	O
>	O
=10	O
%	O
patients	O
who	O
received	O
INLYTA	O
or	O
sorafenib	O
.	O
	
6.6	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
AFINITOR	O
.	O
	
Patients	O
received	O
ERWINAZE	O
according	O
to	O
several	O
schedules	O
,	O
and	O
treatment	O
center	O
specifications	O
with	O
doses	O
that	O
ranged	O
from	O
20,000	O
to	O
25,000	O
International	O
Units/m	O
2	O
.	O
	
Table	O
9	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
2	O
%	O
or	O
More	O
of	O
Adult	O
Patients	O
in	O
Any	O
SAPHRIS	O
Dose	O
Group	O
and	O
Which	O
Occurred	O
at	O
Greater	O
Incidence	O
Than	O
in	O
the	O
Placebo	O
Group	O
in	O
3-Week	O
Bipolar	O
Mania	O
Trials	O
*	O
SAPHRIS	O
5	O
mg	O
to	O
10	O
mg	O
twice	O
daily	O
with	O
flexible	O
dosing	O
.	O
	
Study	O
1	O
excluded	O
the	O
use	O
of	O
concomitant	O
medications	O
that	O
may	O
lower	O
the	O
seizure	O
threshold	O
,	O
whereas	O
Study	O
2	O
permitted	O
the	O
use	O
of	O
these	O
medications	O
.	O
	
These	O
events	O
were	O
confounded	O
by	O
concomitant	O
medications	O
and/or	O
preexisting	O
disease	O
,	O
and	O
the	O
relationship	O
to	O
GILENYA	O
is	O
uncertain	O
.	O
	
Avoid	O
use	O
of	O
GBCAs	O
among	O
these	O
patients	O
unless	O
the	O
diagnostic	O
information	O
is	O
essential	O
and	O
not	O
available	O
with	O
non-contrast	O
MRI	O
or	O
other	O
modalities	O
.	O
	
6.3	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
a	O
potential	O
for	O
immunogenicity	O
.	O
	
The	O
mean	O
age	O
of	O
treated	O
patients	O
was	O
48	O
to	O
50	O
years	O
(	O
range	O
18	O
to	O
92	O
years	O
)	O
,	O
across	O
treatment	O
arms	O
and	O
indications	O
.	O
	
This	O
included	O
783	O
patients	O
who	O
received	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
2-year	O
placebo-controlled	O
trials	O
(	O
Studies	O
1	O
and	O
3	O
)	O
and	O
429	O
patients	O
who	O
received	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
1	O
year	O
active-controlled	O
trial	O
(	O
Study	O
2	O
)	O
.	O
	
5.3	O
Tumor	O
Lysis	O
Syndrome	O
Cases	O
of	O
tumor	B
lysis	I
syndrome	I
(	O
TLS	B
)	O
,	O
including	O
fatal	B
outcomes	O
,	O
have	O
been	O
reported	O
in	O
patients	O
who	O
received	O
Kyprolis	O
.	O
	
Vaginal	O
bleeding	O
after	O
menopause	O
may	O
be	O
a	O
warning	O
sign	O
of	O
cancer	O
of	O
the	O
uterus	O
(	O
womb	O
)	O
.	O
	
Cases	O
of	O
chronic	B
leukemia	I
have	O
been	O
reported	O
with	O
post-marketing	O
TNF-blocker	O
use	O
in	O
rheumatoid	O
arthritis	O
and	O
other	O
indications	O
.	O
	
Treatment	O
of	O
cervical	O
dystonia	O
with	O
botulinum	O
toxins	O
may	O
weaken	B
neck	I
muscles	I
that	O
serve	O
as	O
accessory	O
muscles	O
of	O
ventilation	O
.	O
	
Most	O
adverse	O
reactions	O
were	O
mild	O
or	O
moderate	O
in	O
severity	O
and	O
transient	O
in	O
nature	O
.	O
	
PML	B
is	O
an	O
opportunistic	B
viral	I
infection	I
of	I
the	I
brain	I
caused	O
by	O
the	O
JC	B
virus	I
(	O
JCV	B
)	O
that	O
typically	O
only	O
occurs	O
in	O
patients	O
who	O
are	O
immunocompromised	O
,	O
and	O
that	O
usually	O
leads	O
to	O
death	B
or	O
severe	O
disability	B
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
.	O
	
Patients	O
with	O
pre-existing	O
swallowing	O
or	O
breathing	O
difficulties	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
complications	O
.	O
	
Patients	O
who	O
are	O
carriers	O
of	O
HBV	O
and	O
require	O
treatment	O
with	O
TNF-blockers	O
should	O
be	O
closely	O
monitored	O
for	O
clinical	O
and	O
laboratory	O
signs	O
of	O
active	O
HBV	O
infection	O
throughout	O
therapy	O
and	O
for	O
several	O
months	O
following	O
termination	O
of	O
therapy	O
.	O
	
The	O
incidence	O
of	O
serious	O
adverse	O
reactions	O
was	O
3.5	O
%	O
in	O
the	O
DUAVEE	O
group	O
and	O
4.8	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
Adverse	O
reactions	O
reported	O
in	O
>	O
=	O
2	O
%	O
of	O
postmenopausal	O
women	O
with	O
osteoporosis	O
and	O
more	O
frequently	O
in	O
the	O
Prolia-treated	O
women	O
than	O
in	O
the	O
placebo-treated	O
women	O
are	O
shown	O
in	O
the	O
table	O
below	O
.	O
	
Severe	O
hypoglycemia	O
was	O
defined	O
as	O
an	O
event	O
consistent	O
with	O
hypoglycemia	O
where	O
the	O
patient	O
required	O
the	O
assistance	O
of	O
another	O
person	O
to	O
recover	O
,	O
lost	O
consciousness	O
,	O
or	O
experienced	O
a	O
seizure	O
(	O
regardless	O
of	O
whether	O
biochemical	O
documentation	O
of	O
a	O
low	O
glucose	O
value	O
was	O
obtained	O
)	O
.	O
	
(	O
4	O
,	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Do	O
not	O
initiate	O
in	O
acutely	O
deteriorating	O
COPD	O
patients	O
(	O
5.2	O
)	O
*	O
Do	O
not	O
use	O
for	O
relief	O
of	O
acute	O
symptoms	O
.	O
	
(	O
5.5	O
)	O
*	O
Use	O
with	O
caution	O
in	O
patients	O
with	O
cardiovascular	O
or	O
convulsive	O
disorders	O
,	O
thyrotoxicosis	O
or	O
sensitivity	O
to	O
sympathomimetic	O
drugs	O
.	O
	
The	O
majority	O
of	O
adult	O
patients	O
were	O
enrolled	O
in	O
studies	O
in	O
Thailand	O
,	O
while	O
the	O
majority	O
of	O
pediatric	O
patients	O
were	O
enrolled	O
in	O
Africa	O
.	O
	
The	O
risk	O
of	O
developing	O
TD	B
and	O
the	O
likelihood	O
that	O
it	O
will	O
become	O
irreversible	O
are	O
believed	O
to	O
increase	O
as	O
the	O
duration	O
of	O
treatment	O
and	O
the	O
total	O
cumulative	O
dose	O
of	O
antipsychotic	O
drugs	O
administered	O
to	O
the	O
patient	O
increase	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
DALVANCE	O
were	O
nausea	B
(	O
5.5	O
%	O
)	O
,	O
headache	B
(	O
4.7	O
%	O
)	O
,	O
and	O
diarrhea	B
(	O
4.4	O
%	O
)	O
.	O
	
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
clinical	O
trials	O
,	O
male	B
genital	I
mycotic	I
infections	I
(	O
e.g.	O
,	O
candidal	B
balanitis	I
,	O
balanoposthitis	B
)	O
occurred	O
in	O
0.6	O
%	O
,	O
4.2	O
%	O
,	O
and	O
3.7	O
%	O
of	O
males	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
The	O
median	O
duration	O
of	O
study	O
treatment	O
was	O
10.9	O
months	O
for	O
patients	O
in	O
the	O
XALKORI	O
arm	O
and	O
4.1	O
months	O
for	O
patients	O
in	O
the	O
chemotherapy	O
arm	O
.	O
	
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
Gadavist	O
were	O
usually	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
transient	O
in	O
nature	O
.	O
	
5.3	O
Unintended	O
Skin	O
Exposure	O
If	O
skin	O
not	O
intended	O
to	O
be	O
treated	O
comes	O
in	O
contact	O
with	O
Qutenza	O
,	O
apply	O
Cleansing	O
Gel	O
for	O
one	O
minute	O
and	O
wipe	O
off	O
with	O
dry	O
gauze	O
.	O
	
All	O
serious	O
adverse	O
events	O
were	O
judged	O
to	O
be	O
not	O
related	O
or	O
unlikely	O
to	O
be	O
related	O
to	O
study	O
medication	O
by	O
the	O
investigator	O
,	O
except	O
for	O
four	O
patients	O
receiving	O
Toviaz	O
who	O
reported	O
one	O
serious	O
adverse	O
event	O
each	O
:	O
angina	B
,	O
chest	B
pain	I
,	O
gastroenteritis	B
,	O
and	O
QT	B
prolongation	I
on	O
ECG	O
.	O
	
S	O
Includes	O
subjects	O
treated	O
with	O
flexible	O
dose	O
of	O
SAPHRIS	O
5	O
or	O
10	O
mg	O
twice	O
daily	O
(	O
N=90	O
)	O
.	O
	
However	O
,	O
the	O
incidence	O
of	O
nonfatal	O
serious	O
infections	B
was	O
3.3	O
%	O
in	O
the	O
placebo	O
and	O
4.0	O
%	O
in	O
the	O
Prolia	O
groups	O
.	O
	
More	O
frequent	O
renal	O
function	O
monitoring	O
is	O
recommended	O
in	O
patients	O
with	O
an	O
eGFR	O
below	O
60	O
mL/min/1.73	O
m	O
2	O
.	O
	
In	O
these	O
trials	O
,	O
which	O
had	O
a	O
median	O
treatment	O
duration	O
of	O
12	O
weeks	O
,	O
the	O
estimated	O
incidence	O
of	O
suicidal	B
behavior	I
among	O
27,863	O
AED-treated	O
patients	O
was	O
0.43	O
%	O
,	O
compared	O
to	O
0.24	O
%	O
among	O
16,029	O
placebo-treated	O
patients	O
,	O
representing	O
an	O
increase	O
of	O
approximately	O
one	O
case	O
of	O
suicidal	B
thinking	I
for	O
every	O
530	O
patients	O
treated	O
.	O
	
(	O
5.7	O
)	O
*	O
Embryo-fetal	B
toxicity	I
:	O
Fetal	B
harm	I
can	O
occur	O
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Four	O
placebo-controlled	O
and	O
one	O
active-controlled	O
trials	O
of	O
16	O
weeks	O
up	O
through	O
two	O
years	O
in	O
duration	O
were	O
conducted	O
in	O
combination	O
with	O
metformin	O
,	O
in	O
combination	O
with	O
pioglitazone	O
and	O
with	O
pioglitazone	O
added	O
to	O
a	O
background	O
of	O
metformin	O
therapy	O
.	O
	
Use	O
caution	O
when	O
driving	O
or	O
operating	O
machinery	O
.	O
	
Pediatric	O
Patients	O
:	O
Data	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
trial	O
are	O
presented	O
in	O
Table	O
4	O
.	O
	
Elevations	B
of	I
alanine	I
aminotransferase	I
to	O
>	O
=	O
3	O
times	O
the	O
ULN	O
occurred	O
in	O
a	O
small	O
number	O
of	O
patients	O
treated	O
with	O
both	O
TECFIDERA	O
and	O
placebo	O
and	O
were	O
balanced	O
between	O
groups	O
.	O
	
In	O
rare	O
instances	O
severe	O
anaphylactoid	B
reactions	I
have	O
occurred	O
,	O
particularly	O
in	O
the	O
second	O
and	O
subsequent	O
cycles	O
of	O
therapy	O
.	O
	
Chronic	O
Lymphocytic	O
Leukemia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
IMBRUVICA	O
in	O
an	O
open	O
label	O
clinical	O
trial	O
(	O
Study	O
1	O
)	O
that	O
included	O
48	O
patients	O
with	O
previously	O
treated	O
CLL	O
and	O
a	O
randomized	O
clinical	O
trial	O
(	O
Study	O
2	O
)	O
that	O
included	O
391	O
randomized	O
patients	O
with	O
previously	O
treated	O
CLL	O
or	O
SLL	O
.	O
	
Neutralizing	O
antibody	O
titers	O
were	O
not	O
determined	O
in	O
the	O
patients	O
.	O
	
Adverse	O
Reactions	O
Based	O
on	O
Gender	O
and	O
Race	O
No	O
significant	O
gender	O
differences	O
were	O
noted	O
in	O
the	O
incidence	O
of	O
adverse	O
reactions	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
6	O
years	O
,	O
had	O
a	O
mean	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
of	O
8.3	O
%	O
,	O
and	O
21	O
%	O
had	O
established	O
microvascular	O
complications	O
of	O
diabetes	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Urinary	B
retention	I
:	O
Patients	O
should	O
be	O
carefully	O
monitored	O
for	O
urologic	O
symptoms	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pfizer	O
Inc.	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
reported	O
adverse	O
reaction	O
was	O
headache	B
,	O
occurring	O
in	O
2	O
%	O
of	O
patients	O
,	O
followed	O
by	O
musculoskeletal	B
pain	I
,	O
blood	B
pressure	I
increased	I
,	O
fatigue	B
,	O
nausea	B
,	O
and	O
injection	B
site	I
reaction	I
,	O
all	O
occurring	O
in	O
<	O
1	O
%	O
of	O
patients	O
(	O
6	O
)	O
.	O
	
Therefore	O
,	O
close	O
monitoring	O
is	O
warranted	O
in	O
patients	O
with	O
a	O
change	O
in	O
vision	O
or	O
with	O
a	O
history	O
of	O
increased	O
intraocular	O
pressure	O
,	O
glaucoma	O
,	O
and/or	O
cataracts	O
.	O
	
Because	O
trough	O
levels	O
of	O
ipilimumab	O
interfere	O
with	O
the	O
ECL	O
assay	O
results	O
,	O
a	O
subset	O
analysis	O
was	O
performed	O
in	O
the	O
dose	O
cohort	O
with	O
the	O
lowest	O
trough	O
levels	O
.	O
	
Monitor	O
patients	O
receiving	O
BLINCYTO	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
toxicities	O
,	O
and	O
interrupt	O
or	O
discontinue	O
BLINCYTO	O
as	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
frequency	O
of	O
2+	O
proteinuria	B
was	O
similar	O
between	O
the	O
two	O
treatment	O
groups	O
between	O
one	O
and	O
three	O
years	O
after	O
transplantation	O
(	O
<	O
10	O
%	O
in	O
both	O
studies	O
)	O
.	O
	
This	O
patient	O
had	O
pretreatment	O
calcitonin	O
levels	O
approximately	O
8	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
Although	O
the	O
majority	O
of	O
these	O
events	O
were	O
observed	O
in	O
the	O
setting	O
of	O
CRS	B
,	O
some	O
were	O
observed	O
outside	O
of	O
this	O
setting	O
.	O
	
The	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
positive	O
for	O
antibodies	O
to	O
belatacept	O
in	O
specific	O
assays	O
.	O
	
5.13	O
Reduction	O
in	O
Bone	O
Mineral	O
Density	O
Decreases	B
in	I
bone	I
mineral	I
density	I
)	O
have	O
been	O
observed	O
with	O
long-term	O
administration	O
of	O
products	O
containing	O
inhaled	O
corticosteroids	O
.	O
	
The	O
safety	O
of	O
HORIZANT	O
in	O
doses	O
ranging	O
from	O
600	O
to	O
2,400	O
mg	O
has	O
been	O
evaluated	O
in	O
515	O
patients	O
with	O
RLS	O
in	O
3	O
double	O
blind	O
,	O
placebo-controlled	O
,	O
12	O
week	O
clinical	O
trials	O
.	O
	
The	O
need	O
for	O
continued	O
treatment	O
should	O
be	O
reassessed	O
periodically	O
.	O
	
The	O
safety	O
evaluation	O
of	O
NORTHERA	O
is	O
based	O
on	O
two	O
placebo-controlled	O
studies	O
1	O
to	O
2	O
weeks	O
in	O
duration	O
(	O
Studies	O
301	O
and	O
302	O
)	O
,	O
one	O
8-week	O
placebo-controlled	O
study	O
(	O
Study	O
306	O
)	O
,	O
and	O
two	O
long-term	O
,	O
open-label	O
extension	O
studies	O
(	O
Studies	O
303	O
and	O
304	O
)	O
.	O
	
Psychiatric	O
disorders	O
:	O
Anxiety	B
,	O
bipolar	B
disorder	I
,	O
and	O
suicide	B
attempt	I
.	O
	
(	O
5.3	O
)	O
*	O
Wound	B
Complications	I
:	O
Withhold	O
COMETRIQ	O
for	O
dehiscence	O
or	O
complications	O
requiring	O
medical	O
intervention	O
.	O
	
Of	O
the	O
64	O
dulaglutide-treated	O
patients	O
that	O
developed	O
dulaglutide	O
ADAs	O
,	O
34	O
patients	O
(	O
0.9	O
%	O
of	O
the	O
overall	O
population	O
)	O
had	O
dulaglutide-neutralizing	O
antibodies	O
,	O
and	O
36	O
patients	O
(	O
0.9	O
%	O
of	O
the	O
overall	O
population	O
)	O
developed	O
antibodies	O
against	O
native	O
GLP-1	O
.	O
	
Other	O
XIAFLEX-associated	O
serious	O
local	O
adverse	O
reactions	O
included	O
pulley	B
rupture	I
,	O
ligament	B
injury	I
,	O
complex	B
regional	I
pain	I
syndrome	I
(	O
CRPS	B
)	O
,	O
sensory	B
abnormality	I
of	I
the	I
hand	I
,	O
and	O
skin	B
laceration	I
)	O
.	O
	
(	O
5.2	O
)	O
*	O
Hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
:	O
Healthcare	O
providers	O
should	O
be	O
prepared	O
to	O
address	O
hypersensitivity	O
reactions	O
,	O
including	O
anaphylaxis	O
,	O
following	O
XIAFLEX	O
injections	O
.	O
	
For	O
infectious	B
adverse	I
reactions	I
,	O
the	O
causative	O
organism	O
is	O
reported	O
if	O
specified	O
by	O
the	O
physician	O
in	O
the	O
clinical	O
trials	O
.	O
	
PR	O
Interval	O
Prolongation	O
and	O
Adverse	O
Reactions	O
of	O
First	O
Degree	O
Atrioventricular	O
(	O
AV	O
)	O
Block	O
A	O
mean	O
increase	B
from	I
baseline	I
in	I
PR	I
interval	I
of	O
2-3	O
milliseconds	O
was	O
observed	O
in	O
TRULICITY-treated	O
patients	O
in	O
contrast	O
to	O
a	O
mean	O
decrease	O
of	O
0.9	O
millisecond	O
in	O
placebo-treated	O
patients	O
.	O
	
Elderly	O
patients	O
may	O
be	O
at	O
greater	O
risk	O
of	O
developing	O
hyponatremia	B
with	O
SSRIs	O
and	O
SNRIs	O
.	O
	
Monitoring	O
of	O
orthostatic	O
vital	O
signs	O
should	O
be	O
considered	O
in	O
patients	O
who	O
are	O
vulnerable	O
to	O
hypotension	O
.	O
	
Eleven	O
of	O
the	O
13	O
fractures	B
were	O
reported	O
within	O
the	O
first	O
52	O
weeks	O
.	O
	
A	O
majority	O
of	O
reported	O
events	O
occurred	O
in	O
patients	O
who	O
had	O
experienced	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
or	O
dehydration	B
.	O
	
Urinary	B
retention	I
was	O
generally	O
reported	O
within	O
the	O
first	O
6	O
months	O
of	O
treatment	O
,	O
but	O
was	O
also	O
observed	O
later	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
the	O
exposure	O
to	O
CIMZIA	O
in	O
2,367	O
RA	O
patients	O
,	O
including	O
2,030	O
exposed	O
for	O
at	O
least	O
6	O
months	O
,	O
1,663	O
exposed	O
for	O
at	O
least	O
one	O
year	O
and	O
282	O
for	O
at	O
least	O
2	O
years	O
;	O
and	O
1,774	O
in	O
adequate	O
and	O
well-controlled	O
studies	O
.	O
	
After	O
withdrawal	O
from	O
systemic	O
corticosteroids	O
,	O
a	O
number	O
of	O
months	O
are	O
required	O
for	O
recovery	O
of	O
hypothalamic-pituitary-adrenal	O
(	O
HPA	O
)	O
function	O
.	O
	
Approximately	O
10	O
%	O
of	O
patients	O
in	O
long-term	O
clinical	O
trials	O
developed	O
skin	B
discoloration	I
,	O
generally	O
after	O
2	O
or	O
more	O
years	O
of	O
treatment	O
and	O
at	O
higher	O
doses	O
(	O
900	O
mg	O
or	O
greater	O
)	O
of	O
POTIGA	O
.	O
	
Perioperative	O
Hypertension	O
The	O
placebo-controlled	O
experience	O
with	O
Cleviprex	O
in	O
the	O
perioperative	O
setting	O
was	O
both	O
small	O
and	O
brief	O
(	O
about	O
30	O
minutes	O
)	O
.	O
	
The	O
risk	O
of	O
VTE	B
is	O
highest	O
during	O
the	O
first	O
year	O
of	O
use	O
.	O
	
5.12	O
Embryo-Fetal	O
Toxicity	O
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
of	O
ADCETRIS	O
in	O
pregnant	O
women	O
.	O
	
Metabolism	O
and	O
nutrition	O
disorders	O
:	O
metabolic	B
acidosis	I
,	O
dehydration	B
.	O
	
Consequently	O
,	O
to	O
provide	O
a	O
meaningful	O
estimate	O
of	O
the	O
proportion	O
of	O
individuals	O
experiencing	O
adverse	O
reactions	O
,	O
reactions	O
were	O
grouped	O
in	O
standardized	O
categories	O
using	O
MedDRA	O
terminology	O
.	O
	
Cases	O
have	O
occurred	O
after	O
the	O
first	O
dose	O
of	O
ADCETRIS	O
or	O
after	O
ADCETRIS	O
rechallenge	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
AGRANULOCYTOSIS	B
/NEUTROPENIA	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Because	O
of	O
the	O
risks	O
of	O
corporal	B
rupture	I
or	O
other	O
serious	O
penile	B
injury	I
,	O
XIAFLEX	O
is	O
available	O
for	O
the	O
treatment	O
of	O
Peyronie	O
's	O
disease	O
only	O
through	O
a	O
restricted	O
program	O
under	O
a	O
Risk	O
Evaluation	O
and	O
Mitigation	O
Strategy	O
(	O
REMS	O
)	O
called	O
the	O
XIAFLEX	O
REMS	O
Program	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
(	O
2.2	O
,	O
5.2	O
)	O
*	O
Interstitial	B
Lung	I
Disease	I
(	O
ILD	B
)	O
/Pneumonitis	O
:	O
Occurred	O
in	O
4	O
%	O
of	O
patients	O
.	O
	
Hypersensitivity	O
Reactions	O
In	O
the	O
RE-LY	O
study	O
,	O
drug	O
hypersensitivity	B
(	O
including	O
urticaria	B
,	O
rash	B
,	O
and	O
pruritus	B
)	O
,	O
allergic	B
edema	I
,	O
anaphylactic	B
reaction	I
,	O
and	O
anaphylactic	B
shock	I
were	O
reported	O
in	O
<	O
0.1	O
%	O
of	O
patients	O
receiving	O
PRADAXA	O
.	O
	
If	O
a	O
patient	O
is	O
exposed	O
to	O
chickenpox	O
,	O
prophylaxis	O
with	O
varicella	O
zoster	O
immune	O
globulin	O
(	O
VZIG	O
)	O
may	O
be	O
indicated	O
.	O
	
5.5	O
Dizziness	O
and	O
Somnolence	O
POTIGA	O
causes	O
dose-related	O
increases	O
in	O
dizziness	B
and	O
somnolence	B
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Overall	O
,	O
4	O
%	O
of	O
subjects	O
reported	O
one	O
or	O
more	O
adverse	O
reactions	O
following	O
EOVIST	O
administration	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
associated	O
with	O
PROMACTA	O
are	O
described	O
in	O
other	O
sections	O
.	O
	
dIntracranial	O
bleed	B
included	O
subdural	B
bleeds	I
.	O
	
*	O
Fatal	B
and/or	O
serious	O
hepatotoxicity	B
occurred	O
in	O
14	O
%	O
of	O
Zydelig-treated	O
patients	O
.	O
	
d	O
Includes	O
:	O
contusion	B
,	O
ecchymoses	B
,	O
penile	B
hemorrhage	I
,	O
and	O
injection	B
site	I
hemorrhage	I
.	O
	
If	O
Grade	O
3	O
or	O
4	O
neutropenia	O
develops	O
,	O
consider	O
dose	O
delays	O
,	O
reductions	O
,	O
discontinuation	O
,	O
or	O
G-CSF	O
prophylaxis	O
with	O
subsequent	O
ADCETRIS	O
doses	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
myopathy	B
,	O
including	O
rhabdomyolysis	B
.	O
	
Significantly	O
elevated	O
serum	O
calcitonin	O
value	O
may	O
indicate	O
MTC	O
and	O
patients	O
with	O
MTC	O
usually	O
have	O
calcitonin	O
values	O
>	O
50	O
ng/L	O
.	O
	
5.2	O
Allergic	O
Reactions	O
As	O
with	O
any	O
injectable	O
drug	O
product	O
,	O
allergic	B
reactions	I
and	O
anaphylaxis	B
may	O
occur	O
.	O
	
5.4	O
Increased	O
Radiation	O
Exposure	O
in	O
Patients	O
with	O
Severe	O
Renal	O
Impairment	O
AdreView	O
is	O
cleared	O
by	O
glomerular	O
filtration	O
and	O
is	O
not	O
dialyzable	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
TRULICITY	O
.	O
	
Table	O
4	O
provides	O
the	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
10	O
%	O
of	O
subjects	O
receiving	O
Zydelig	O
monotherapy	O
,	O
and	O
Table	O
5	O
provides	O
the	O
treatment-emergent	O
laboratory	O
abnormalities	O
.	O
	
A	O
total	O
of	O
503	O
patients	O
received	O
HALAVEN	O
,	O
and	O
247	O
patients	O
in	O
the	O
control	O
group	O
received	O
therapy	O
consisting	O
of	O
chemotherapy	O
[	O
total	O
97	O
%	O
(	O
anthracyclines	O
10	O
%	O
,	O
capecitabine	O
18	O
%	O
,	O
gemcitabine	O
19	O
%	O
,	O
taxanes	O
15	O
%	O
,	O
vinorelbine	O
25	O
%	O
,	O
other	O
chemotherapies	O
10	O
%	O
)	O
]	O
or	O
hormonal	O
therapy	O
(	O
3	O
%	O
)	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
drug	O
reactions	O
(	O
>	O
=	O
25	O
%	O
)	O
in	O
the	O
XIAFLEX	O
clinical	O
trials	O
in	O
patients	O
with	O
Peyronie	O
's	O
disease	O
were	O
penile	B
hematoma	I
,	O
penile	B
swelling	I
,	O
and	O
penile	B
pain	I
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
with	O
ZYTIGA	O
was	O
13.8	O
months	O
.	O
	
HALAVEN	O
is	O
a	O
microtubule	O
inhibitor	O
;	O
therefore	O
,	O
it	O
is	O
expected	O
to	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Interrupt	O
Ferriprox	O
if	O
infection	O
develops	O
,	O
and	O
monitor	O
the	O
ANC	O
more	O
frequently	O
.	O
	
When	O
liver	O
function	O
tests	O
show	O
sustained	O
improvement	O
or	O
return	O
to	O
baseline	O
,	O
initiate	O
corticosteroid	O
tapering	O
and	O
continue	O
to	O
taper	O
over	O
1	O
month	O
.	O
	
In	O
Study	O
1	O
,	O
pneumonitis	B
was	O
reported	O
in	O
4	O
%	O
of	O
255	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
Blood	O
Disorders	O
:	O
Anemia	B
,	O
eosinophilia	B
,	O
leukopenia	B
,	O
thrombocytopenia	B
Eye	O
Disorders	O
:	O
Diplopia	B
,	O
vision	B
blurred	I
Gastrointestinal	O
Disorders	O
:	O
Abdominal	B
distention	I
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
Hypothermia	B
Investigations	O
:	O
Hepatic	B
enzyme	I
increased	I
Musculoskeletal	O
:	O
Muscle	B
spasms	I
Psychiatric	O
Disorders	O
:	O
Agitation	B
,	O
anxiety	B
,	O
apathy	B
,	O
confusional	B
state	I
,	O
depression	B
,	O
delirium	B
,	O
delusion	B
,	O
hallucination	B
Renal	O
and	O
Urinary	O
Disorders	O
:	O
Urinary	B
retention	I
Respiratory	O
Disorders	O
:	O
Aspiration	B
,	O
respiratory	B
depression	I
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Rash	B
,	O
urticaria	B
,	O
angioedema	B
,	O
and	O
lip	B
edema	I
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Somnolence	B
or	O
Sedation	B
:	O
Monitor	O
for	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
depression	O
.	O
	
Table	O
5	O
Bleeding	B
Events	O
in	O
RE-SONATE	O
Treated	O
Patients	O
Note	O
:	O
MBE	B
can	O
belong	O
to	O
more	O
than	O
one	O
criterion	O
.	O
	
For	O
COPD	O
,	O
increasing	O
the	O
daily	O
dose	O
of	O
BREO	O
ELLIPTA	O
100/25	O
is	O
not	O
appropriate	O
in	O
this	O
situation	O
.	O
	
The	O
incidence	O
of	O
rash	B
was	O
higher	O
in	O
women	O
compared	O
to	O
men	O
in	O
the	O
INTELENCE	O
(	O
r	O
)	O
arm	O
in	O
the	O
Phase	O
3	O
trials	O
(	O
rash	B
>	O
=	O
Grade	O
2	O
was	O
reported	O
in	O
9/60	O
[	O
15.0	O
%	O
]	O
women	O
versus	O
51/539	O
[	O
9.5	O
%	O
]	O
men	O
;	O
discontinuations	O
due	O
to	O
rash	B
were	O
reported	O
in	O
3/60	O
[	O
5.0	O
%	O
]	O
women	O
versus	O
10/539	O
[	O
1.9	O
%	O
]	O
men	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Hematologic	O
Toxicity	O
Beleodaq	O
can	O
cause	O
thrombocytopenia	B
,	O
leukopenia	B
(	O
neutropenia	B
and	O
lymphopenia	B
)	O
,	O
and/or	O
anemia	B
;	O
monitor	O
blood	O
counts	O
weekly	O
during	O
treatment	O
,	O
and	O
modify	O
dosage	O
as	O
necessary	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Patients	O
can	O
have	O
more	O
than	O
one	O
site	O
of	O
bleeding	B
.	O
	
Advise	O
the	O
patient	O
to	O
rinse	O
his/her	O
mouth	O
with	O
water	O
without	O
swallowing	O
following	O
inhalation	O
to	O
help	O
reduce	O
the	O
risk	O
of	O
oropharyngeal	O
candidiasis	O
.	O
	
5.3	O
Liver	O
Disease	O
Discontinue	O
Natazia	O
if	O
jaundice	O
develops	O
.	O
	
Three	O
percent	O
(	O
3	O
%	O
)	O
of	O
255	O
patients	O
experienced	O
a	O
QTc	B
interval	I
increase	I
over	O
baseline	O
greater	O
than	O
60	O
msec	O
in	O
Study	O
1	O
.	O
	
(	O
5.1	O
)	O
*	O
Ferriprox	O
can	O
cause	O
fetal	B
harm	I
.	O
	
One	O
(	O
0.2	O
%	O
)	O
patient	O
died	B
as	O
a	O
result	O
of	O
toxic	B
epidermal	I
necrolysis	I
and	O
one	O
additional	O
patient	O
required	O
hospitalization	O
for	O
severe	O
dermatitis	B
.	O
	
(	O
5.6	O
)	O
*	O
Neutropenia	B
:	O
monitor	O
blood	O
counts	O
.	O
	
Skin	O
:	O
case	O
of	O
severe	O
skin	B
reactions	I
,	O
including	O
Stevens-Johnson	B
syndrome	I
,	O
toxic	B
epidermal	I
necrolysis	I
,	O
erythema	B
multiforme	I
,	O
and	O
new	O
or	O
worsening	O
psoriasis	B
)	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
TNF	O
blockers	O
.	O
	
A	O
total	O
of	O
2711	O
patients	O
treated	O
with	O
EYLEA	O
constituted	O
the	O
safety	O
population	O
in	O
seven	O
phase	O
3	O
studies	O
.	O
	
The	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
AEDs	O
was	O
observed	O
as	O
early	O
as	O
one	O
week	O
after	O
starting	O
drug	O
treatment	O
with	O
AEDs	O
and	O
persisted	O
for	O
the	O
duration	O
of	O
treatment	O
assessed	O
.	O
	
Bladder	O
cancer	O
risk	O
factors	O
and	O
hematuria	O
(	O
a	O
potential	O
indicator	O
of	O
pre-existing	O
tumors	O
)	O
were	O
balanced	O
between	O
treatment	O
arms	O
at	O
baseline	O
.	O
	
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
in	O
at	O
least	O
2	O
%	O
of	O
pediatric	O
subjects	O
were	O
rash	B
and	O
diarrhea	B
.	O
	
In	O
these	O
trials	O
,	O
patients	O
were	O
given	O
up	O
to	O
4	O
treatment	O
cycles	O
of	O
XIAFLEX	O
or	O
placebo	O
.	O
	
After	O
resumption	O
of	O
treatment	O
at	O
a	O
lower	O
dose	O
,	O
26	O
%	O
of	O
patients	O
had	O
recurrence	B
of	I
ALT	I
and	I
AST	I
elevations	I
.	O
	
5.5	O
Gallbladder	O
Disease	O
Studies	O
suggest	O
a	O
small	O
increased	O
relative	O
risk	O
of	O
developing	O
gallbladder	B
disease	I
among	O
COC	O
users	O
.	O
	
In	O
the	O
non-Hodgkin	O
's	O
lymphoma	O
study	O
,	O
52	O
%	O
of	O
patients	O
were	O
male	O
,	O
the	O
median	O
age	O
was	O
55	O
years	O
,	O
and	O
88	O
%	O
of	O
patients	O
were	O
Caucasian	O
.	O
	
Based	O
on	O
patient	O
diaries	O
from	O
three	O
clinical	O
trials	O
evaluating	O
the	O
safety	O
and	O
efficacy	O
of	O
Natazia	O
for	O
contraception	O
,	O
10-23	O
%	O
of	O
women	O
experienced	O
intracyclic	B
bleeding	I
per	O
cycle	O
.	O
	
Adverse	O
reactions	O
of	O
Grade	O
3	O
or	O
higher	O
were	O
reported	O
in	O
80	O
%	O
of	O
patients	O
.	O
	
Protamine	O
sulfate	O
and	O
vitamin	O
K	O
are	O
not	O
expected	O
to	O
affect	O
the	O
anticoagulant	O
activity	O
of	O
dabigatran	O
.	O
	
(	O
5.1	O
)	O
*	O
Some	O
patients	O
with	O
retinal	O
abnormalities	O
have	O
been	O
found	O
to	O
have	O
abnormal	O
visual	O
acuity	O
.	O
	
(	O
5.1	O
,	O
6.1	O
)	O
*	O
Impairment	B
in	I
renal	I
function	I
:	O
Monitor	O
renal	O
function	O
during	O
therapy	O
.	O
	
Prescriptions	O
for	O
FANAPT	O
should	O
be	O
written	O
for	O
the	O
smallest	O
quantity	O
of	O
tablets	O
consistent	O
with	O
good	O
patient	O
management	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
overdose	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merz	O
Pharmaceuticals	O
,	O
LLC	O
at	O
888-493-6646	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Renal	O
function	O
should	O
be	O
evaluated	O
prior	O
to	O
initiation	O
of	O
FARXIGA	O
and	O
monitored	O
periodically	O
thereafter	O
.	O
	
(	O
B	O
)	O
SPINAL/EPIDURAL	O
HEMATOMA	O
:	O
spinal	B
hematomas	I
may	O
occur	O
in	O
patients	O
treated	O
with	O
PRADAXA	O
who	O
are	O
receiving	O
neuraxial	O
anesthesia	O
or	O
undergoing	O
spinal	O
puncture	O
.	O
	
All	O
patients	O
taking	O
POTIGA	O
should	O
have	O
baseline	O
and	O
periodic	O
(	O
every	O
6	O
months	O
)	O
systematic	O
visual	O
monitoring	O
by	O
an	O
ophthalmic	O
professional	O
.	O
	
Withhold	O
YERVOY	O
dosing	O
for	O
moderate	O
enterocolitis	O
;	O
administer	O
anti-diarrheal	O
treatment	O
and	O
,	O
if	O
persistent	O
for	O
more	O
than	O
1	O
week	O
,	O
initiate	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
0.5	O
mg/kg/day	O
prednisone	O
or	O
equivalent	O
.	O
	
In	O
this	O
study	O
,	O
76	O
%	O
(	O
44	O
of	O
58	O
)	O
completed	O
all	O
planned	O
therapy	O
.	O
	
Non-GI	B
fistulas	I
were	O
reported	O
in	O
4	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
Severe	O
hypoglycemia	B
occurred	O
in	O
2.4	O
%	O
and	O
3.4	O
%	O
of	O
patients	O
when	O
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
,	O
respectively	O
,	O
was	O
co-administered	O
with	O
prandial	O
insulin	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
TB	B
for	O
all	O
patients	O
exposed	O
to	O
CIMZIA	O
across	O
all	O
indications	O
was	O
345	O
days	O
.	O
	
Infections	O
The	O
incidence	O
of	O
infections	B
in	O
controlled	O
studies	O
in	O
Crohn	O
's	O
disease	O
was	O
38	O
%	O
for	O
CIMZIA-treated	O
patients	O
and	O
30	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Do	O
not	O
administer	O
COMETRIQ	O
to	O
patients	O
with	O
a	O
recent	O
history	O
of	O
hemorrhage	O
or	O
hemoptysis	O
.	O
	
Pool	O
of	O
Placebo-	O
and	O
Active-Controlled	O
Trials	O
The	O
occurrence	O
of	O
adverse	O
reactions	O
was	O
also	O
evaluated	O
in	O
a	O
larger	O
pool	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
participating	O
in	O
6	O
placebo-	O
and	O
active-controlled	O
trials	O
evaluating	O
the	O
use	O
of	O
TRULICITY	O
as	O
monotherapy	O
and	O
add-on	O
therapy	O
to	O
oral	O
medications	O
or	O
insulin	O
.	O
	
*	O
Neurological	B
toxicities	I
,	O
which	O
may	O
be	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
The	O
race	O
distribution	O
was	O
89	O
%	O
White	O
,	O
7	O
%	O
Black	O
,	O
3	O
%	O
Hispanic	O
,	O
1	O
%	O
other	O
,	O
and	O
<	O
1	O
%	O
Asian	O
.	O
	
Alternatively	O
,	O
administration	O
of	O
non-enteric	O
coated	O
aspirin	O
(	O
up	O
to	O
a	O
dose	O
of	O
325	O
mg	O
)	O
30	O
minutes	O
prior	O
to	O
TECFIDERA	O
dosing	O
may	O
reduce	O
the	O
incidence	O
or	O
severity	O
of	O
flushing	B
[	O
see	O
Dosing	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Monitor	O
complete	O
blood	O
counts	O
monthly	O
.	O
	
Hematologic	B
toxicities	I
,	O
based	O
on	O
laboratory	O
values	O
and	O
CTC	O
grade	O
,	O
in	O
NHL	O
patients	O
treated	O
in	O
both	O
single	O
arm	O
studies	O
combined	O
are	O
described	O
in	O
Table	O
4	O
.	O
	
It	O
is	O
important	O
to	O
note	O
that	O
early	O
manifestations	O
of	O
hypersensitivity	B
,	O
such	O
as	O
fever	B
or	O
lymphadenopathy	B
,	O
may	O
be	O
present	O
even	O
though	O
rash	B
is	O
not	O
evident	O
.	O
	
These	O
changes	O
were	O
not	O
associated	O
with	O
other	O
abnormal	B
thyroid	I
function	I
tests	O
suggesting	O
hypothyroidism	B
.	O
	
A	O
subset	O
of	O
patients	O
experienced	O
a	O
recurrence	O
of	O
symptoms	O
when	O
restarting	O
the	O
same	O
drug	O
or	O
a	O
different	O
DPP-4	O
inhibitor	O
.	O
	
Risk	O
of	O
Acute	B
Respiratory	I
Complications	I
:	O
Patients	O
with	O
acute	O
febrile	O
or	O
respiratory	O
illness	O
may	O
be	O
at	O
higher	O
risk	O
of	O
life-threatening	O
complications	O
from	O
hypersensitivity	B
reactions	I
.	O
	
The	O
most	O
frequent	O
second	B
primary	I
malignancy	I
was	O
non-melanoma	B
skin	I
cancer	I
(	O
range	O
,	O
4	O
to	O
11	O
%	O
)	O
.	O
	
5.2	O
Hypersensitivity	O
Clinically	O
significant	O
hypersensitivity	B
including	O
anaphylaxis	B
has	O
been	O
reported	O
with	O
Prolia	O
.	O
	
Reduced	B
fetal	I
weights	I
were	O
observed	O
at	O
lower	O
exposures	O
.	O
	
The	O
incidence	O
of	O
antibody	O
formation	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Vertex	O
Pharmaceuticals	O
Incorporated	O
at	O
1-877-634-8789	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Anaphylaxis	B
occurred	O
as	O
late	O
into	O
treatment	O
as	O
the	O
47	O
th	O
infusion	O
.	O
	
If	O
ARCAPTA	O
NEOHALER	O
no	O
longer	O
controls	O
the	O
symptoms	O
of	O
bronchoconstriction	O
,	O
or	O
the	O
patient	O
's	O
inhaled	O
,	O
short-acting	O
beta2-agonist	O
becomes	O
less	O
effective	O
or	O
the	O
patient	O
needs	O
more	O
inhalation	O
of	O
short-acting	O
beta2-agonist	O
than	O
usual	O
,	O
these	O
may	O
be	O
markers	O
of	O
deterioration	O
of	O
disease	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
11	O
years	O
,	O
had	O
a	O
mean	O
HbA1C	O
of	O
8.0	O
%	O
and	O
33	O
%	O
had	O
established	O
microvascular	O
complications	O
of	O
diabetes	O
.	O
	
(	O
5.14	O
)	O
5.1	O
Increased	O
Mortality	O
in	O
Elderly	O
Patients	O
with	O
Dementia-Related	O
Psychosis	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
.	O
	
Therefore	O
,	O
consider	O
dosage	O
modifications	O
of	O
both	O
APTIOM	O
and	O
carbamazepine	O
if	O
these	O
drugs	O
are	O
used	O
concomitantly	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
6.1	O
Retrospective	O
Case	O
Series	O
Experience	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
occurring	O
in	O
>	O
=	O
13	O
%	O
of	O
patients	O
)	O
,	O
regardless	O
of	O
causality	O
,	O
are	O
:	O
Infections	B
,	O
vomiting	B
,	O
abdominal	B
pain	I
,	O
pyrexia	B
,	O
tonsilitis	B
,	O
anemia	B
,	O
ear	B
infection	I
,	O
diarrhea	B
,	O
nasopharyngitis	B
,	O
and	O
headache	B
.	O
	
Events	O
related	O
to	O
visual	B
changes	I
were	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
Temporarily	O
suspend	O
,	O
dose	O
reduce	O
,	O
or	O
permanently	O
discontinue	O
XALKORI	O
.	O
	
Table	O
2	O
:	O
Proportion	O
of	O
Patients	O
With	O
at	O
Least	O
One	O
Volume	B
Depletion-Related	I
Adverse	I
Reaction	I
(	O
Pooled	O
Results	O
from	O
8	O
Clinical	O
Trials	O
)	O
Baseline	O
Characteristic	O
Comparator	O
Group	O
%	O
INVOKANA	O
100	O
mg	O
%	O
INVOKANA	O
300	O
mg	O
%	O
Overall	O
population	O
1.5	O
%	O
2.3	O
%	O
3.4	O
%	O
75	O
years	O
of	O
age	O
and	O
older	O
2.6	O
%	O
4.9	O
%	O
8.7	O
%	O
eGFR	B
less	I
than	I
60	I
mL/min/1.73	I
m	I
2	I
2.5	O
%	O
4.7	O
%	O
8.1	O
%	O
Use	O
of	O
loop	O
diuretic	O
4.7	O
%	O
3.2	O
%	O
8.8	O
%	O
Falls	O
In	O
a	O
pool	O
of	O
nine	O
clinical	O
trials	O
with	O
mean	O
duration	O
of	O
exposure	O
to	O
INVOKANA	O
of	O
85	O
weeks	O
,	O
the	O
proportion	O
of	O
patients	O
who	O
experienced	O
falls	B
was	O
1.3	O
%	O
,	O
1.5	O
%	O
,	O
and	O
2.1	O
%	O
with	O
comparator	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
Avoid	O
co-administration	O
of	O
strong	O
CYP3A4	O
inducers	O
,	O
such	O
as	O
rifamycins	O
(	O
i.e.	O
,	O
rifampin	O
,	O
rifapentine	O
and	O
rifabutin	O
)	O
,	O
or	O
moderate	O
CYP3A4	O
inducers	O
,	O
such	O
as	O
efavirenz	O
,	O
during	O
treatment	O
with	O
SIRTURO	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Risk	O
of	O
Suicidal	B
Thoughts	I
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
Placebo	O
Patients	O
with	O
Events	O
per	O
1,000	O
Patients	O
Drug	O
Patients	O
with	O
Events	O
per	O
1,000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Events	O
in	O
Drug	O
Patients/Incidence	O
in	O
Placebo	O
Patients	O
Risk	O
Difference	O
:	O
Additional	O
Drug	O
Patients	O
with	O
Events	O
per	O
1,000	O
Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
The	O
impact	O
of	O
treatment	O
with	O
CIMZIA	O
on	O
the	O
development	O
and	O
course	O
of	O
malignancies	O
,	O
as	O
well	O
as	O
active	O
and/or	O
chronic	O
infections	O
,	O
is	O
not	O
fully	O
understood	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
,	O
5.5	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Pancreatitis	O
Pancreatitis	B
was	O
reported	O
in	O
1	O
patient	O
(	O
0.8	O
%	O
)	O
in	O
the	O
placebo	O
group	O
and	O
1	O
patient	O
(	O
0.8	O
%	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
Monitor	O
ALT	O
,	O
aspartate	O
aminotransferase	O
(	O
AST	O
)	O
and	O
bilirubin	O
before	O
initiation	O
of	O
and	O
periodically	O
throughout	O
treatment	O
with	O
INLYTA	O
.	O
	
The	O
time	O
from	O
product	O
administration	O
to	O
event	O
occurrence	O
was	O
variable	O
.	O
	
Women	O
on	O
thyroid	O
replacement	O
therapy	O
may	O
require	O
higher	O
doses	O
of	O
thyroid	O
hormone	O
.	O
	
5.8	O
Withdrawal	O
Seizures	O
As	O
with	O
all	O
AEDs	O
,	O
when	O
POTIGA	O
is	O
discontinued	O
,	O
it	O
should	O
be	O
withdrawn	O
gradually	O
when	O
possible	O
to	O
minimize	O
the	O
potential	O
of	O
increased	O
seizure	O
frequency	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
In	O
studies	O
of	O
ACE	O
inhibitors	O
in	O
patients	O
with	O
unilateral	O
or	O
bilateral	O
renal	O
artery	O
stenosis	O
,	O
increases	B
in	I
serum	I
creatinine	I
have	O
been	O
reported	O
.	O
	
Fatal	B
pulmonary	B
embolism	I
was	O
reported	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
.	O
	
Therefore	O
,	O
use	O
of	O
BENLYSTA	O
is	O
not	O
recommended	O
in	O
combination	O
with	O
biologic	O
therapies	O
or	O
intravenous	O
cyclophosphamide	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
associated	O
with	O
discontinuation	O
in	O
subjects	O
treated	O
with	O
SAPHRIS	O
(	O
rates	O
at	O
least	O
1	O
%	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
)	O
were	O
depression	B
(	O
2.5	O
%	O
)	O
,	O
suicidal	B
ideation	I
(	O
2.5	O
%	O
)	O
,	O
bipolar	B
I	I
disorder	I
(	O
1.9	O
%	O
)	O
,	O
insomnia	B
(	O
1.9	O
%	O
)	O
and	O
depressive	B
symptoms	I
(	O
1.3	O
%	O
)	O
.	O
	
Electrocardiographic	O
Findings	O
ECG	O
measurements	O
were	O
only	O
recorded	O
in	O
a	O
limited	O
number	O
of	O
patients	O
in	O
an	O
open-label	O
study	O
without	O
a	O
placebo	O
or	O
active	O
control	O
.	O
	
In	O
most	O
cases	O
the	O
reactions	O
were	O
of	O
mild	O
or	O
moderate	O
intensity	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
with	O
Prolia	O
in	O
men	O
with	O
osteoporosis	O
are	O
back	B
pain	I
,	O
arthralgia	B
,	O
and	O
nasopharyngitis	B
.	O
	
Adverse	O
events	O
leading	O
to	O
discontinuation	O
of	O
Kyprolis	O
occurred	O
in	O
12	O
%	O
of	O
patients	O
and	O
the	O
most	O
common	O
events	O
included	O
pneumonia	B
(	O
1	O
%	O
)	O
,	O
myocardial	B
infarction	I
(	O
0.8	O
%	O
)	O
,	O
and	O
upper	B
respiratory	I
tract	I
infection	I
(	O
0.8	O
%	O
)	O
.	O
	
The	O
sudden	O
drop	O
in	O
estrogen	O
levels	O
causes	O
``	O
surgical	O
menopause	O
.	O
	
Monitor	O
patients	O
periodically	O
.	O
	
*	O
currently	O
have	O
or	O
have	O
had	O
certain	O
cancers	O
.	O
	
More	O
serious	O
or	O
even	O
fatal	B
course	O
of	O
chickenpox	B
or	O
measles	B
can	O
occur	O
in	O
susceptible	O
patients	O
.	O
	
The	O
most	O
frequently	O
reported	O
of	O
these	O
adverse	O
reactions	O
were	O
headache	B
,	O
nasopharyngitis	B
,	O
injection	B
site	I
pain	I
,	O
sinusitis	B
,	O
URI	B
,	O
injection	B
site	I
bruising	I
,	O
and	O
injection	B
site	I
reaction	I
)	O
.	O
	
BENLYSTA	O
should	O
be	O
administered	O
by	O
healthcare	O
providers	O
prepared	O
to	O
manage	O
infusion	O
reactions	O
.	O
	
3Includes	O
the	O
preferred	O
terms	O
abdominal	B
pain	I
,	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
lower	I
,	O
and	O
abdominal	B
discomfort	I
.	O
	
6.2	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
a	O
potential	O
for	O
immunogenicity	O
.	O
	
Adverse	O
reactions	O
with	O
GILENYA	O
0.5	O
mg	O
in	O
Study	O
2	O
,	O
the	O
1-year	O
active-controlled	O
(	O
versus	O
interferon	O
beta-1a	O
)	O
study	O
were	O
generally	O
similar	O
to	O
those	O
in	O
Studies	O
1	O
and	O
3	O
.	O
	
Screen	O
all	O
patients	O
for	O
renal	O
impairment	O
by	O
obtaining	O
a	O
history	O
and/or	O
laboratory	O
tests	O
.	O
	
Grade	O
3	O
and	O
higher	O
adverse	O
reactions	O
were	O
reported	O
among	O
47	O
%	O
of	O
XTANDI-treated	O
patients	O
and	O
53	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
Breathing	O
Difficulty	O
Breathing	B
difficulties	I
were	O
reported	O
by	O
approximately	O
3	O
%	O
of	O
patients	O
following	O
DYSPORT	O
(	O
r	O
)	O
administration	O
and	O
in	O
1	O
%	O
of	O
placebo	O
patients	O
in	O
clinical	O
trials	O
during	O
the	O
double-blind	O
phase	O
.	O
	
Amyvid	O
scan	O
results	O
are	O
indicative	O
of	O
the	O
brain	O
neuritic	O
amyloid	O
plaque	O
content	O
only	O
at	O
the	O
time	O
of	O
image	O
acquisition	O
and	O
a	O
negative	O
scan	O
result	O
does	O
not	O
preclude	O
the	O
development	O
of	O
brain	O
amyloid	O
in	O
the	O
future	O
.	O
	
*	O
Fat	B
Redistribution	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Your	O
healthcare	O
provider	O
may	O
need	O
to	O
check	O
you	O
more	O
carefully	O
if	O
you	O
have	O
certain	O
conditions	O
,	O
such	O
as	O
asthma	O
(	O
wheezing	O
)	O
,	O
epilepsy	O
(	O
seizures	O
)	O
,	O
diabetes	O
,	O
migraine	O
,	O
endometriosis	O
,	O
lupus	O
,	O
or	O
problems	O
with	O
your	O
heart	O
,	O
liver	O
,	O
thyroid	O
,	O
kidneys	O
,	O
or	O
have	O
high	O
calcium	O
levels	O
in	O
your	O
blood	O
.	O
	
The	O
adverse	O
events	O
occurring	O
in	O
>	O
=5	O
%	O
of	O
XEOMIN-treated	O
patients	O
and	O
greater	O
than	O
placebo	O
in	O
the	O
Phase	O
3	O
study	O
were	O
eyelid	B
ptosis	I
,	O
dry	B
eye	I
,	O
dry	B
mouth	I
,	O
diarrhea	B
,	O
headache	B
,	O
visual	B
impairment	I
,	O
dyspnea	B
,	O
nasopharyngitis	B
,	O
and	O
respiratory	B
tract	I
infection	I
.	O
	
*	O
Hypersensitivity	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
In	O
addition	O
to	O
the	O
reactions	O
shown	O
in	O
Tables	O
2	O
and	O
3	O
,	O
adverse	O
reactions	O
occurring	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
of	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
200/25	O
included	O
viral	B
respiratory	I
tract	I
infection	I
,	O
pharyngitis	B
,	O
pyrexia	B
,	O
and	O
arthralgia	B
.	O
	
The	O
majority	O
of	O
patients	O
were	O
able	O
to	O
be	O
rechallenged	O
with	O
alglucosidase	O
alfa	O
using	O
lower	O
doses	O
and/or	O
pretreatment	O
with	O
anti-inflammatory	O
drugs	O
and/or	O
corticosteroids	O
and	O
were	O
able	O
to	O
continue	O
treatment	O
under	O
close	O
clinical	O
supervision	O
.	O
	
Six	O
of	O
the	O
9	O
patients	O
were	O
hospitalized	O
for	O
severe	O
endocrinopathies	B
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
Observed	O
in	O
Treatment-naive	O
and	O
Treatment-experienced	O
Trials	O
The	O
following	O
ADRs	O
occurred	O
in	O
less	O
than	O
2	O
%	O
of	O
treatment-naive	O
or	O
treatment-experienced	O
subjects	O
receiving	O
TIVICAY	O
in	O
a	O
combination	O
regimen	O
in	O
any	O
one	O
trial	O
.	O
	
Among	O
these	O
patients	O
,	O
63	O
%	O
had	O
a	O
history	O
of	O
hypertension	O
,	O
51	O
%	O
had	O
a	O
history	O
of	O
dyslipidemia	O
,	O
25	O
%	O
had	O
a	O
history	O
of	O
myocardial	O
infarction	O
,	O
8	O
%	O
had	O
a	O
history	O
of	O
unstable	O
angina	O
and	O
7	O
%	O
had	O
a	O
history	O
of	O
congestive	O
heart	O
failure	O
.	O
	
Do	O
not	O
administer	O
in	O
combination	O
with	O
HEPSERA	O
.	O
	
Subjects	O
participating	O
in	O
this	O
trial	O
had	O
a	O
history	O
of	O
one	O
or	O
more	O
asthma	O
exacerbations	O
that	O
required	O
treatment	O
with	O
oral/systemic	O
corticosteroids	O
or	O
emergency	O
department	O
visit	O
or	O
in-patient	O
hospitalization	O
for	O
the	O
treatment	O
of	O
asthma	O
in	O
the	O
year	O
prior	O
to	O
trial	O
entry	O
.	O
	
(	O
5.2	O
)	O
*	O
Toviaz	O
,	O
like	O
other	O
antimuscarinic	O
drugs	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
decreased	O
gastrointestinal	O
motility	O
,	O
such	O
as	O
those	O
with	O
severe	O
constipation	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
were	O
stomatitis	B
,	O
rash	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
edema	B
,	O
abdominal	B
pain	I
,	O
nausea	B
,	O
fever	B
,	O
and	O
headache	B
.	O
	
AEDs	O
increase	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
patients	O
taking	O
these	O
drugs	O
for	O
any	O
indication	O
.	O
	
There	O
were	O
no	O
reports	O
of	O
prolactin	B
elevations	I
>	O
=4	O
times	O
ULN	O
(	O
at	O
Endpoint	O
)	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
or	O
placebo	O
.	O
	
5.2	O
Serious	O
Infections	O
Serious	O
and	O
sometimes	O
fatal	B
infections	B
have	O
been	O
reported	O
in	O
patients	O
receiving	O
immunosuppressive	O
agents	O
,	O
including	O
BENLYSTA	O
.	O
	
(	O
5.1	O
)	O
*	O
When	O
treating	O
patients	O
with	O
asthma	O
,	O
only	O
prescribe	O
BREO	O
ELLIPTA	O
for	O
patients	O
not	O
adequately	O
controlled	O
on	O
a	O
long-term	O
asthma	O
control	O
medication	O
,	O
such	O
as	O
an	O
ICS	O
,	O
or	O
whose	O
disease	O
severity	O
clearly	O
warrants	O
initiation	O
of	O
treatment	O
with	O
both	O
an	O
ICS	O
and	O
a	O
LABA	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
alglucosidase	O
alfa	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Table	O
8	O
:	O
Percentage	O
of	O
EPS	B
Compared	O
to	O
Placebo	O
Placebo	O
(	O
%	O
)	O
FANAPT	O
10-16	O
mg/day	O
(	O
%	O
)	O
FANAPT	O
20-24	O
mg/day	O
(	O
%	O
)	O
Adverse	O
Event	O
Term	O
(	O
N=587	O
)	O
(	O
N=483	O
)	O
(	O
N=391	O
)	O
All	O
EPS	O
events	O
11.6	O
13.5	O
15.1	O
Akathisia	B
2.7	O
1.7	O
2.3	O
Bradykinesia	B
0	O
0.6	O
0.5	O
Dyskinesia	B
1.5	O
1.7	O
1.0	O
Dystonia	B
0.7	O
1.0	O
0.8	O
Parkinsonism	B
0	O
0.2	O
0.3	O
Tremor	B
1.9	O
2.5	O
3.1	O
Adverse	O
Reactions	O
Associated	O
with	O
Discontinuation	O
of	O
Treatment	O
in	O
Clinical	O
Trials	O
Based	O
on	O
the	O
pooled	O
data	O
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
,	O
there	O
was	O
no	O
difference	O
in	O
the	O
incidence	O
of	O
discontinuation	O
due	O
to	O
adverse	O
events	O
between	O
FANAPT-treated	O
(	O
5	O
%	O
)	O
and	O
placebo-treated	O
(	O
5	O
%	O
)	O
patients	O
.	O
	
Unless	O
an	O
alternate	O
etiology	O
has	O
been	O
identified	O
,	O
signs	O
or	O
symptoms	O
of	O
endocrinopathies	O
should	O
be	O
considered	O
immune-mediated	O
.	O
	
Of	O
the	O
353	O
patients	O
included	O
in	O
the	O
pooled	O
analyses	O
of	O
patients	O
with	O
CF	O
who	O
had	O
either	O
a	O
G551D	O
mutation	O
or	O
were	O
homozygous	O
for	O
the	O
F508del	O
mutation	O
in	O
the	O
CFTR	O
gene	O
,	O
50	O
%	O
of	O
patients	O
were	O
female	O
and	O
97	O
%	O
were	O
Caucasian	O
;	O
221	O
received	O
KALYDECO	O
,	O
and	O
132	O
received	O
placebo	O
from	O
16	O
to	O
48	O
weeks	O
.	O
	
Analysis	O
of	O
seventeen	O
placebo-controlled	O
trials	O
(	O
modal	O
duration	O
10	O
weeks	O
)	O
,	O
largely	O
in	O
patients	O
taking	O
atypical	O
antipsychotic	O
drugs	O
,	O
revealed	O
a	O
risk	O
of	O
death	B
in	O
the	O
drug-treated	O
patients	O
of	O
between	O
1.6	O
to	O
1.7	O
times	O
the	O
risk	O
of	O
death	O
in	O
placebo-treated	O
patients	O
.	O
	
5.6	O
Other	O
Immune-mediated	O
Adverse	O
Reactions	O
,	O
Including	O
Ocular	O
Manifestations	O
The	O
following	O
clinically	O
significant	O
immune-mediated	B
adverse	I
reactions	I
were	O
seen	O
in	O
less	O
than	O
1	O
%	O
of	O
YERVOY-treated	O
patients	O
in	O
Study	O
1	O
:	O
nephritis	B
,	O
pneumonitis	B
,	O
meningitis	B
,	O
pericarditis	B
,	O
uveitis	B
,	O
iritis	B
,	O
and	O
hemolytic	B
anemia	I
.	O
	
In	O
these	O
studies	O
,	O
a	O
total	O
of	O
6285	O
patients	O
were	O
randomized	O
and	O
treated	O
,	O
3282	O
patients	O
with	O
MULTAQ	O
400	O
mg	O
twice	O
daily	O
,	O
and	O
2875	O
with	O
placebo	O
.	O
	
There	O
were	O
two	O
additional	O
reports	O
of	O
RPLS	B
in	O
other	O
clinical	O
trials	O
with	O
INLYTA	O
.	O
	
The	O
population	O
was	O
45-77	O
years	O
of	O
age	O
,	O
63	O
%	O
male	O
,	O
100	O
%	O
white	O
,	O
and	O
were	O
treatment	O
naive	O
.	O
	
Dizziness	B
led	O
to	O
withdrawal	O
in	O
2	O
%	O
of	O
patients	O
receiving	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
3	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
The	O
majority	O
of	O
the	O
most	O
common	O
adverse	O
reactions	O
presented	O
inTable	O
2occurred	O
within	O
the	O
first	O
2	O
weeks	O
of	O
treatment	O
and	O
tended	O
to	O
resolve	O
over	O
time	O
with	O
continued	O
dosing	O
.	O
	
5.2	O
Hypotension	O
and	O
Reflex	O
Tachycardia	O
Cleviprex	O
may	O
produce	O
systemic	B
hypotension	I
and	O
reflex	B
tachycardia	I
.	O
	
Grade	O
3	O
or	O
4	O
stomatitis	B
was	O
reported	O
in	O
4	O
%	O
-9	O
%	O
of	O
patients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
5.7	O
Acute	O
Rejection	O
and	O
Graft	B
Loss	I
with	I
Corticosteroid	I
Minimization	I
occurred	O
in	O
patients	O
with	O
4	O
to	O
6	O
HLA	O
mismatches	O
.	O
	
S	O
On-treatment	O
analysis	O
based	O
on	O
the	O
safety	O
population	O
,	O
compared	O
to	O
ITT	O
analysis	O
presented	O
in	O
Section	O
14	O
.	O
	
Because	O
these	O
events	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
frequency	O
or	O
to	O
establish	O
a	O
causal	O
relationship	O
with	O
drug	O
exposure	O
.	O
	
Several	O
patients	O
discontinued	O
GILENYA	O
because	O
of	O
unexplained	O
dyspnea	B
during	O
the	O
extension	O
(	O
uncontrolled	O
)	O
studies	O
.	O
	
Good	O
oral	O
hygiene	O
practices	O
should	O
be	O
maintained	O
during	O
treatment	O
with	O
Prolia	O
.	O
	
Although	O
a	O
causal	O
link	O
between	O
the	O
emergence	O
of	O
such	O
symptoms	O
and	O
either	O
the	O
worsening	B
of	I
depression	I
and/or	O
the	O
emergence	O
of	O
suicidal	B
impulses	I
has	O
not	O
been	O
established	O
,	O
there	O
is	O
concern	O
that	O
such	O
symptoms	O
may	O
represent	O
precursors	O
to	O
emerging	O
suicidality	B
.	O
	
In	O
the	O
combined	O
clinical	O
trial	O
experience	O
with	O
all	O
doses	O
of	O
fingolimod	O
,	O
the	O
rate	O
of	O
macular	B
edema	I
was	O
approximately	O
20	O
%	O
in	O
MS	O
patients	O
with	O
a	O
history	O
of	O
uveitis	O
versus	O
0.6	O
%	O
in	O
those	O
without	O
a	O
history	O
of	O
uveitis	O
.	O
	
ONJ	B
has	O
been	O
reported	O
in	O
patients	O
receiving	O
denosumab	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
the	O
post-marketing	O
period	O
seizures	B
have	O
been	O
reported	O
.	O
	
EXCERPT	O
:	O
In	O
clinical	O
trials	O
,	O
the	O
most	O
common	O
related	O
adverse	O
events	O
(	O
occurring	O
in	O
>	O
1	O
%	O
of	O
patients	O
)	O
were	O
paraesthesia	B
,	O
flushing	B
,	O
nausea	B
and/or	O
vomiting	B
,	O
hypotension	B
and	O
headache	B
.	O
	
Advise	O
patients	O
to	O
contact	O
their	O
healthcare	O
provider	O
if	O
they	O
become	O
pregnant	O
,	O
or	O
if	O
pregnancy	O
is	O
suspected	O
,	O
while	O
taking	O
TAFINLAR	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Bleeding	B
was	O
assessed	O
in	O
each	O
study	O
beginning	O
with	O
the	O
first	O
dose	O
of	O
double-blind	O
study	O
drug	O
.	O
	
For	O
patients	O
receiving	O
Cleviprex	O
and	O
all	O
active	O
comparators	O
the	O
incidence	O
of	O
serious	O
adverse	O
events	O
within	O
one	O
hour	O
of	O
drug	O
infusion	O
discontinuation	O
was	O
similar	O
.	O
	
The	O
mean	O
age	O
of	O
patients	O
treated	O
with	O
TANZEUM	O
was	O
55	O
years	O
,	O
1.5	O
%	O
of	O
the	O
population	O
in	O
these	O
studies	O
was	O
75	O
years	O
or	O
older	O
and	O
51	O
%	O
of	O
participants	O
were	O
male	O
.	O
	
5.11	O
Fluid	O
Retention	O
Estrogens	O
may	O
cause	O
some	O
degree	O
of	O
fluid	B
retention	I
.	O
	
Isolated	O
cases	O
of	O
aspergillosis	B
,	O
herpes	B
zoster	I
)	O
were	O
reported	O
during	O
ILARIS	O
treatment	O
.	O
	
The	O
incidence	O
of	O
urinary	B
tract	I
infections	I
in	O
male	O
patients	O
randomized	O
to	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
was	O
3.2	O
%	O
,	O
3.6	O
%	O
,	O
and	O
4.1	O
%	O
,	O
respectively	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
Because	O
GILENYA	O
exposure	O
is	O
doubled	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
,	O
these	O
patients	O
should	O
be	O
closely	O
monitored	O
,	O
as	O
the	O
risk	O
of	O
adverse	O
reactions	O
is	O
greater	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
,	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
For	O
patients	O
with	O
SEGA	O
and	O
severe	O
hepatic	O
impairment	O
,	O
reduce	O
the	O
starting	O
dose	O
of	O
AFINITOR	O
Tablets	O
or	O
AFINITOR	O
DISPERZ	O
by	O
approximately	O
50	O
%	O
and	O
adjust	O
subsequent	O
doses	O
based	O
on	O
therapeutic	O
drug	O
monitoring	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
,	O
2.5	O
)	O
]	O
.	O
	
Currently	O
available	O
data	O
are	O
inadequate	O
to	O
determine	O
whether	O
concurrent	O
use	O
of	O
inhaled	O
corticosteroids	O
or	O
other	O
long-term	O
asthma	O
control	O
drugs	O
mitigates	O
the	O
increased	O
risk	O
of	O
asthma-related	O
death	B
from	O
LABA	O
.	O
	
5.9	O
Hyperglycemia	O
Hyperglycemia	B
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Renal	O
function	O
of	O
patients	O
should	O
be	O
monitored	O
particularly	O
where	O
patients	O
have	O
additional	O
risk	O
factors	O
that	O
may	O
further	O
impair	O
renal	O
function	O
.	O
	
Rates	O
of	O
seroconversion	O
increased	O
with	O
exposure	O
to	O
KALBITOR	O
over	O
time	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
the	O
JEVTANA	O
group	O
was	O
neutropenia	B
(	O
2	O
%	O
)	O
.	O
	
It	O
is	O
possible	O
that	O
use	O
of	O
IL-1	O
inhibitors	O
such	O
as	O
ILARIS	O
increases	O
the	O
risk	O
of	O
reactivation	B
of	I
tuberculosis	I
or	O
of	O
opportunistic	B
infections	I
.	O
	
*	O
b	O
See	O
below	O
for	O
other	O
events	O
of	O
injection	B
site	I
reactions	I
reported	O
.	O
	
Due	O
to	O
the	O
long	O
half-life	O
of	O
DAMPA	O
(	O
t1/2of	O
approximately	O
9	O
hours	O
)	O
,	O
measurement	O
of	O
methotrexate	O
using	O
immunoassays	O
is	O
unreliable	O
for	O
samples	O
collected	O
within	O
48	O
hours	O
following	O
VORAXAZE	O
administration	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.1	O
)	O
]	O
.	O
	
Specifically	O
,	O
nocturia	B
was	O
reported	O
by	O
0.4	O
%	O
,	O
0.3	O
%	O
,	O
and	O
0.8	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
.	O
	
Since	O
many	O
of	O
the	O
patients	O
in	O
the	O
Phase	O
3	O
trial	O
were	O
also	O
taking	O
medications	O
that	O
cause	O
liver	O
enzyme	O
elevations	O
(	O
e.g.	O
,	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
[	O
NSAIDs	O
]	O
,	O
methotrexate	O
[	O
MTX	O
]	O
,	O
or	O
isoniazid	O
prophylaxis	O
)	O
,	O
the	O
relationship	O
between	O
SIMPONI	O
ARIA	O
and	O
liver	O
enzyme	O
elevation	O
is	O
not	O
clear	O
.	O
	
d	O
Includes	O
the	O
following	O
terms	O
:	O
abdominal	B
pain	I
,	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
lower	I
,	O
and	O
abdominal	B
discomfort	I
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
(	O
2.1	O
,	O
5.3	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
such	O
as	O
flushing	B
and	O
dyspnea	B
have	O
been	O
observed	O
within	O
minutes	O
following	O
Vizamyl	O
administration	O
.	O
	
During	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
the	O
incidence	O
of	O
adverse	O
reactions	O
suggestive	O
of	O
body	B
temperature	I
increases	I
(	O
pyrexia	B
and	O
feeling	B
hot	I
)	O
was	O
<	O
=1	O
%	O
.	O
	
These	O
patients	O
may	O
have	O
an	O
increased	O
risk	O
for	O
a	O
hypersensitivity	O
reaction	O
to	O
Gadavist	O
.	O
	
MULTAQ	O
should	O
only	O
be	O
initiated	O
in	O
patients	O
in	O
sinus	O
rhythm	O
who	O
are	O
receiving	O
appropriate	O
antithrombotic	O
therapy	O
[	O
see	O
Drug	O
interactions	O
(	O
7.3	O
)	O
]	O
.	O
	
The	O
QTcF	B
was	I
increased	I
more	O
than	O
60	O
msec	O
from	O
baseline	O
in	O
13	O
%	O
(	O
7/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
Other	O
Adverse	O
Reactions	O
Table	O
1	O
summarizes	O
the	O
adverse	O
drug	O
reactions	O
that	O
occurred	O
at	O
a	O
rate	O
of	O
at	O
least	O
1	O
%	O
in	O
the	O
SIMPONI	O
ARIA	O
+	O
MTX	O
group	O
with	O
a	O
higher	O
incidence	O
than	O
in	O
the	O
placebo	O
+	O
MTX	O
group	O
during	O
the	O
controlled	O
period	O
of	O
Trial	O
1	O
through	O
Week	O
24	O
.	O
	
Table	O
8	O
.	O
	
The	O
median	O
time	O
from	O
onset	O
to	O
resolution	O
or	O
improvement	O
of	O
any	O
grade	O
was	O
23	O
weeks	O
(	O
range	O
,	O
0.1-138	O
)	O
,	O
of	O
Grade	O
2	O
was	O
24	O
weeks	O
(	O
range	O
,	O
1-108	O
)	O
and	O
of	O
Grade	O
3	O
was	O
25	O
weeks	O
(	O
range	O
,	O
2-98	O
)	O
.	O
	
In	O
addition	O
,	O
mammography	O
examinations	O
should	O
be	O
scheduled	O
based	O
on	O
patient	O
age	O
,	O
risk	O
factors	O
,	O
and	O
prior	O
mammogram	O
results	O
.	O
	
When	O
vasodilators	O
are	O
taken	O
in	O
combination	O
,	O
blood-pressure-lowering	O
effects	O
of	O
each	O
individual	O
compound	O
may	O
be	O
increased	O
.	O
	
Because	O
this	O
adverse	O
reaction	O
was	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
possible	O
to	O
estimate	O
its	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Avoid	O
use	O
in	O
patients	O
with	O
known	O
QT	O
prolongation	O
,	O
those	O
with	O
hypokalemia	O
or	O
hypomagnesemia	O
,	O
and	O
those	O
taking	O
other	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
.	O
	
Therefore	O
,	O
caution	O
should	O
be	O
used	O
when	O
administering	O
general	O
anesthesia	O
.	O
	
Observe	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
during	O
and	O
following	O
EOVIST	O
administration	O
.	O
	
Exercise	O
caution	O
in	O
patients	O
with	O
heart	O
failure	O
and	O
monitor	O
them	O
carefully	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
the	O
emergence	O
of	O
serotonin	O
syndrome	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
hypersensitivity	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
,	O
including	O
shock	B
have	O
uncommonly	O
occurred	O
following	O
EOVIST	O
administration	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
The	O
potential	O
risk	O
of	O
using	O
a	O
TNF	O
blocker	O
in	O
combination	O
with	O
azathioprine	O
or	O
6-MP	O
should	O
be	O
carefully	O
considered	O
.	O
	
Renal	O
and	O
Urinary	O
Disorders	O
:	O
tubulointerstitial	B
nephritis	I
.	O
	
Patients	O
who	O
demonstrate	O
hemodynamic	O
instability	O
on	O
alpha-blocker	O
therapy	O
alone	O
are	O
at	O
increased	O
risk	O
of	O
symptomatic	B
hypotension	I
with	O
concomitant	O
use	O
of	O
PDE5	O
inhibitors	O
.	O
	
If	O
mefloquine	O
is	O
administered	O
immediately	O
prior	O
to	O
Coartem	O
Tablets	O
there	O
may	O
be	O
a	O
decreased	O
exposure	O
to	O
lumefantrine	O
,	O
possibly	O
due	O
to	O
a	O
mefloquine-induced	O
decrease	O
in	O
bile	O
production	O
.	O
	
Skin	O
biopsy	O
in	O
one	O
patient	O
demonstrated	O
deposition	B
of	I
anti-rhGAA	I
antibodies	I
in	O
the	O
lesion	O
.	O
	
In	O
a	O
placebo-controlled	O
trial	O
of	O
PROMACTA	O
in	O
patients	O
with	O
chronic	O
liver	O
diseaseand	O
thrombocytopenia	O
not	O
related	O
to	O
ITP	O
,	O
six	O
patients	O
treated	O
with	O
PROMACTA	O
and	O
one	O
patient	O
in	O
the	O
placebo	O
group	O
developed	O
portal	B
vein	I
thromboses	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Grade	O
3	O
events	O
were	O
reported	O
in	O
3	O
of	O
the	O
25	O
patients	O
treated	O
with	O
ADCETRIS	O
who	O
experienced	O
infusion-related	B
reactions	I
.	O
	
5.8	O
Hypertriglyceridemia	O
In	O
women	O
with	O
pre-existing	O
hypertriglyceridemia	O
,	O
treatment	O
with	O
estrogens	O
may	O
be	O
associated	O
with	O
elevations	B
of	I
plasma	I
triglycerides	I
leading	O
to	O
pancreatitis	B
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
generalized	B
rash	I
,	O
Stevens	B
Johnson	I
Syndrome	I
,	O
hypersensitivity	B
skin	I
reactions	I
.	O
	
Cases	O
of	O
chronic	B
leukemia	I
have	O
been	O
reported	O
in	O
association	O
with	O
post-marketing	O
TNF-blocker	O
use	O
in	O
RA	O
and	O
other	O
indications	O
.	O
	
The	O
concomitant	O
use	O
of	O
PRISTIQ	O
with	O
MAOIs	O
intended	O
to	O
treat	O
psychiatric	O
disorders	O
is	O
contraindicated	O
.	O
	
Events	O
resulting	O
in	O
discontinuation	O
were	O
similar	O
to	O
those	O
seen	O
in	O
previous	O
studies	O
with	O
PegIntron/REBETOL	O
.	O
	
No	O
Grade	O
4	O
infusion-related	B
reactions	I
were	O
reported	O
.	O
	
In	O
the	O
extension	O
chronic	O
ITP	O
trial	O
,	O
one	O
additional	O
patient	O
had	O
PROMACTA	O
discontinued	O
due	O
to	O
liver	B
test	I
abnormalities	I
(	O
less	O
than	O
or	O
equal	O
to	O
Grade	O
3	O
)	O
.	O
	
Another	O
patient	O
developed	O
severe	O
inflammatory	B
arthropathy	I
in	O
association	O
with	O
pyrexia	B
and	O
elevated	B
erythrocyte	I
sedimentation	I
rate	I
.	O
	
Therefore	O
,	O
patients	O
should	O
be	O
monitored	O
for	O
decreased	O
efficacy	O
and	O
food	O
consumption	O
should	O
be	O
encouraged	O
while	O
taking	O
Coartem	O
Tablets	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.4	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
*	O
In	O
those	O
patients	O
who	O
are	O
stable	O
on	O
alpha-blocker	O
therapy	O
,	O
PDE5	O
inhibitors	O
should	O
be	O
initiated	O
at	O
the	O
lowest	O
dose	O
(	O
STENDRA	O
50	O
mg	O
)	O
.	O
	
Ventricular	B
arrhythmias	I
and	O
bradycardia	B
,	O
resulting	O
in	O
cardiac	B
arrest	I
or	O
death	B
,	O
or	O
requiring	O
cardiac	O
resuscitation	O
or	O
defibrillation	O
have	O
been	O
observed	O
in	O
infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
cardiac	O
hypertrophy	O
during	O
general	O
anesthesia	O
for	O
central	O
venous	O
catheter	O
placement	O
.	O
	
(	O
5.1,12.6	O
)	O
*	O
Halofantrine	O
and	O
Coartem	O
Tablets	O
should	O
not	O
be	O
administered	O
within	O
one	O
month	O
of	O
each	O
other	O
due	O
to	O
potential	O
additive	O
effects	O
on	O
the	O
QT	O
interval	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
:	O
Agranulocytosis	B
.	O
	
Therefore	O
,	O
physicians	O
should	O
inform	O
patients	O
that	O
substantial	O
consumption	O
of	O
alcohol	O
(	O
e.g.	O
,	O
greater	O
than	O
3	O
units	O
)	O
in	O
combination	O
with	O
STENDRA	O
may	O
increase	O
the	O
potential	O
for	O
orthostatic	O
signs	O
and	O
symptoms	O
,	O
including	O
increase	O
in	O
heart	O
rate	O
,	O
decrease	O
in	O
standing	O
blood	O
pressure	O
,	O
dizziness	O
,	O
and	O
headache	O
[	O
seeDrug	O
Interactions	O
(	O
7.1	O
)	O
andClinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
All	O
women	O
should	O
receive	O
yearly	O
breast	O
examinations	O
by	O
a	O
healthcare	O
provider	O
and	O
perform	O
monthly	O
breast	O
self-examinations	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
greater	O
than	O
or	O
equal	O
to	O
20	O
%	O
)	O
were	O
nausea	B
,	O
fatigue	B
,	O
cough	B
,	O
diarrhea	B
,	O
and	O
headache	B
.	O
	
Whether	O
any	O
of	O
the	O
symptoms	O
described	O
above	O
represent	O
such	O
a	O
conversion	O
is	O
unknown	O
.	O
	
(	O
5.2	O
)	O
*	O
Hepatic	B
Effects	I
:	O
Postmarketing	O
reports	O
of	O
hepatic	B
failure	I
,	O
sometimes	O
fatal	B
.	O
	
Delayed	O
reactions	O
can	O
occur	O
up	O
to	O
several	O
days	O
after	O
EOVIST	O
administration	O
.	O
	
5.4	O
New	O
Onset	O
or	O
Worsening	O
Heart	O
Failure	O
worsening	B
of	I
heart	I
failure	I
has	O
been	O
reported	O
during	O
treatment	O
with	O
MULTAQ	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reaction	O
occurring	O
in	O
approximately	O
25	O
%	O
of	O
patients	O
was	O
a	O
mild	O
taste	B
following	I
instillation	I
.	O
	
5.4	O
Extravasation	O
and	O
Injection	O
Site	O
Reactions	O
Ensure	O
catheter	O
and	O
venous	O
patency	O
before	O
the	O
injection	O
of	O
Gadavist	O
.	O
	
The	O
potential	O
role	O
of	O
TNF	O
blocker	O
therapy	O
in	O
the	O
development	O
of	O
malignancies	O
in	O
adults	O
is	O
not	O
known	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
SIMPONI	O
ARIA	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
Review	O
the	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
prior	O
to	O
initiation	O
of	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
These	O
reactions	O
may	O
occur	O
in	O
patients	O
with	O
no	O
history	O
of	O
prior	O
exposure	O
to	O
Vizamyl	O
.	O
	
e	O
Includes	O
the	O
following	O
terms	O
:	O
brain	B
stem	I
hemorrhage	I
,	O
cerebral	B
hemorrhage	I
,	O
gastric	B
hemorrhage	I
,	O
epistaxis	B
,	O
gingival	B
hemorrhage	I
,	O
hematuria	B
,	O
vaginal	B
hemorrhage	I
,	O
hemorrhage	B
intracranial	I
,	O
eye	B
hemorrhage	I
,	O
and	O
vitreous	B
hemorrhage	I
.	O
	
In	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
,	O
through	O
Week	O
24	O
,	O
ALT	B
elevations	I
>	O
=	O
5	O
*	O
ULN	O
occurred	O
in	O
0.8	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
0	O
%	O
of	O
control-treated	O
patients	O
and	O
ALT	B
elevations	I
>	O
=	O
3	O
*	O
ULN	O
occurred	O
in	O
2.3	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
2.5	O
%	O
of	O
control-treated	O
patients	O
.	O
	
5.2	O
Cardiovascular	O
Death	O
and	O
Heart	O
Failure	O
in	O
Permanent	O
AF	O
MULTAQ	O
doubles	O
the	O
risk	O
of	O
cardiovascular	B
death	I
)	O
and	O
heart	B
failure	I
events	I
in	O
patients	O
with	O
permanent	O
AF	O
.	O
	
*	O
Administer	O
Gadavist	O
only	O
in	O
situations	O
where	O
trained	O
personnel	O
and	O
therapies	O
are	O
promptly	O
available	O
for	O
the	O
treatment	O
of	O
hypersensitivity	O
reactions	O
,	O
including	O
personnel	O
trained	O
in	O
resuscitation	O
.	O
	
*	O
Elevated	B
Blood	I
Pressure	I
:	O
Control	O
hypertension	O
before	O
initiating	O
treatment	O
.	O
	
Hematuria	O
:	O
Adverse	O
events	O
of	O
hematuria	B
,	O
including	O
those	O
requiring	O
medical	O
intervention	O
,	O
were	O
more	O
common	O
in	O
JEVTANA-treated	O
patients	O
.	O
	
6.2	O
Immunogenicity	O
In	O
the	O
KALBITOR	O
HAE	O
program	O
,	O
patients	O
developed	O
antibodies	O
to	O
KALBITOR	O
.	O
	
Monitoring	O
of	O
renal	O
function	O
,	O
including	O
measurement	O
of	O
blood	O
urea	O
nitrogen	O
(	O
BUN	O
)	O
,	O
urinary	O
protein	O
,	O
or	O
serum	O
creatinine	O
,	O
is	O
recommended	O
prior	O
to	O
the	O
start	O
of	O
AFINITOR	O
therapy	O
and	O
periodically	O
thereafter	O
.	O
	
Impairment	B
in	I
Renal	I
Function	I
Use	O
of	O
JARDIANCE	O
was	O
associated	O
with	O
increases	B
in	I
serum	I
creatinine	I
and	O
decreases	B
in	I
eGFR	I
(	O
see	O
Table	O
2	O
)	O
.	O
	
Adverse	O
Reactions	O
in	O
Placebo-controlled	O
Trials	O
Reported	O
in	O
>	O
=5	O
%	O
of	O
Patients	O
Treated	O
with	O
TANZEUM	O
a	O
Adverse	O
Reaction	O
Placebo	O
(	O
N	O
=	O
468	O
)	O
%	O
TANZEUM	O
(	O
N	O
=	O
923	O
)	O
%	O
Upper	B
respiratory	I
tract	I
infection	I
13.0	O
14.2	O
Diarrhea	B
10.5	O
13.1	O
Nausea	B
9.6	O
11.1	O
Injection	B
site	I
reactionb	O
2.1	O
10.5	O
Cough	B
6.2	O
6.9	O
Back	B
pain	I
5.8	O
6.7	O
Arthralgia	B
6.4	O
6.6	O
Sinusitis	B
5.8	O
6.2	O
Influenza	B
3.2	O
5.2	O
*	O
a	O
Adverse	O
reactions	O
reported	O
includes	O
adverse	O
reactions	O
occurring	O
with	O
the	O
use	O
of	O
glycemic	O
rescue	O
medications	O
which	O
included	O
metformin	O
(	O
17	O
%	O
for	O
placebo	O
and	O
10	O
%	O
for	O
TANZEUM	O
)	O
and	O
insulin	O
(	O
24	O
%	O
for	O
placebo	O
and	O
14	O
%	O
for	O
TANZEUM	O
)	O
.	O
	
Prior	O
to	O
initiating	O
immunomodulatory	O
therapies	O
,	O
including	O
ILARIS	O
,	O
patients	O
should	O
be	O
evaluated	O
for	O
active	O
and	O
latent	O
tuberculosis	O
infection	O
.	O
	
Eight	O
of	O
these	O
11	O
patients	O
had	O
received	O
a	O
single	O
dose	O
of	O
VORAXAZE	O
.	O
	
A	O
causal	O
relationship	O
of	O
ILARIS	O
to	O
these	O
events	O
can	O
not	O
be	O
excluded	O
.	O
	
For	O
patients	O
with	O
SEGA	O
and	O
mild	O
or	O
moderate	O
hepatic	O
impairment	O
,	O
adjust	O
the	O
dose	O
of	O
AFINITOR	O
Tablets	O
or	O
AFINITOR	O
DISPERZ	O
based	O
on	O
therapeutic	O
drug	O
monitoring	O
.	O
	
Available	O
data	O
from	O
controlled	O
clinical	O
trials	O
suggest	O
that	O
LABA	O
increase	O
the	O
risk	O
of	O
asthma-related	O
hospitalization	O
in	O
pediatric	O
and	O
adolescent	O
patients	O
.	O
	
*	O
Monitor	O
for	O
worsening	O
and	O
emergence	O
of	O
suicidal	O
thoughts	O
and	O
behaviors	O
(	O
5.1	O
)	O
.	O
	
5.8	O
Fetal	O
Risk	O
Based	O
on	O
animal	O
studies	O
,	O
GILENYA	O
may	O
cause	O
fetal	B
harm	I
.	O
	
Discontinue	O
GRANIX	O
in	O
patients	O
with	O
ARDS	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
from	O
clinical	O
trials	O
and/or	O
post-marketing	O
surveillance	O
.	O
	
The	O
long-term	O
effects	O
of	O
antibodies	O
to	O
KALBITOR	O
are	O
not	O
known	O
.	O
	
Table	O
3	O
:	O
Bleeding	B
During	O
the	O
Treatment	O
Period	O
in	O
Patients	O
Undergoing	O
Elective	O
Hip	O
or	O
Knee	O
Replacement	O
Surgery	O
Bleeding	O
Endpoint*	O
ADVANCE-3Hip	O
Replacement	O
Surgery	O
ADVANCE-2Knee	O
Replacement	O
Surgery	O
ADVANCE-1Knee	O
Replacement	O
Surgery	O
*	O
All	O
bleeding	B
criteria	O
included	O
surgical	B
site	I
bleeding	I
.	O
	
Advise	O
female	O
patients	O
of	O
reproductive	O
potential	O
to	O
use	O
a	O
highly	O
effective	O
non-hormonal	O
method	O
of	O
contraception	O
since	O
TAFINLAR	O
can	O
render	O
hormonal	O
contraceptives	O
ineffective	O
,	O
during	O
treatment	O
and	O
for	O
at	O
least	O
2	O
weeks	O
after	O
treatment	O
with	O
TAFINLAR	O
or	O
for	O
4	O
months	O
after	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
1	O
%	O
)	O
with	O
VORAXAZE	O
are	O
paraesthesias	B
,	O
flushing	B
,	O
nausea	B
and/or	O
vomiting	B
,	O
hypotension	B
,	O
and	O
headache	B
.	O
	
The	O
majority	O
of	O
seizures	B
occurred	O
at	O
the	O
recommended	O
dose	O
and	O
in	O
patients	O
without	O
a	O
history	O
of	O
seizures	O
,	O
and	O
generally	O
within	O
days	O
to	O
weeks	O
of	O
starting	O
therapy	O
.	O
	
A	O
routine	O
oral	O
exam	O
should	O
be	O
performed	O
by	O
the	O
prescriber	O
prior	O
to	O
initiation	O
of	O
Prolia	O
treatment	O
.	O
	
GILENYA	O
has	O
not	O
been	O
tested	O
in	O
MS	O
patients	O
with	O
diabetes	O
mellitus	O
.	O
	
If	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
no	O
dose	O
modification	O
of	O
trametinib	O
is	O
required	O
for	O
patients	O
who	O
develop	O
non-cutaneous	O
malignancies	O
.	O
	
Because	O
of	O
this	O
,	O
patients	O
who	O
have	O
conditions	O
that	O
might	O
be	O
influenced	O
by	O
this	O
factor	O
,	O
such	O
as	O
cardiac	O
dysfunction	O
or	O
renal	O
impairment	O
,	O
warrant	O
careful	O
observation	O
when	O
estrogens	O
are	O
prescribed	O
.	O
	
In	O
this	O
pool	O
,	O
a	O
total	O
of	O
2,116	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
treated	O
with	O
TANZEUM	O
for	O
a	O
mean	O
duration	O
of	O
75	O
weeks	O
.	O
	
Severe	O
Hypertension	O
The	O
adverse	O
events	O
for	O
patients	O
with	O
severe	O
hypertension	O
are	O
based	O
on	O
an	O
uncontrolled	O
study	O
in	O
patients	O
with	O
severe	O
hypertension	O
(	O
VELOCITY	O
,	O
n=126	O
)	O
.	O
	
If	O
either	O
occurs	O
,	O
decrease	O
the	O
dose	O
of	O
Cleviprex	O
.	O
	
Of	O
those	O
patients	O
who	O
developed	O
new	O
cuSCC	B
,	O
approximately	O
33	O
%	O
developed	O
one	O
or	O
more	O
cuSCC	B
with	O
continued	O
administration	O
of	O
TAFINLAR	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Exclusive	O
of	O
an	O
uncommon	O
,	O
mild	O
injection	B
site	I
reaction	I
,	O
no	O
adverse	O
reactions	O
to	O
11	O
C-choline	O
have	O
been	O
reported	O
.	O
	
Concomitant	O
administration	O
of	O
drugs	O
associated	O
with	O
ONJ	O
may	O
increase	O
the	O
risk	O
of	O
developing	O
ONJ	O
.	O
	
Advise	O
patients	O
to	O
report	O
symptoms	O
of	O
severe	O
hyperglycemia	O
such	O
as	O
excessive	O
thirst	O
or	O
any	O
increase	O
in	O
the	O
volume	O
or	O
frequency	O
of	O
urination	O
.	O
	
GI	B
bleed	I
includes	O
rectal	B
bleeding	I
.	O
	
Graft	B
loss	I
in	O
some	O
patients	O
.	O
	
5.4	O
Oral	O
Ulceration	O
Mouth	B
ulcers	I
,	O
stomatitis	B
,	O
and	O
oral	B
mucositis	I
have	O
occurred	O
in	O
patients	O
treated	O
with	O
AFINITOR	O
at	O
an	O
incidence	O
ranging	O
from	O
44	O
%	O
-78	O
%	O
across	O
the	O
clinical	O
trial	O
experience	O
.	O
	
Obesity	O
and	O
prolonged	O
nucleoside	O
exposure	O
may	O
be	O
risk	O
factors	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
INCREASED	O
MORTALITY	B
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
WARNING	O
:	O
INCREASED	O
MORTALITY	B
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
prematurely	O
discontinued	O
study	O
drug	O
due	O
to	O
adverse	O
reactions	O
was	O
2	O
%	O
for	O
KALYDECO-treated	O
patients	O
and	O
5	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Patients	O
ranged	O
in	O
age	O
from	O
18	O
to	O
83	O
years	O
,	O
with	O
an	O
overall	O
median	O
age	O
of	O
51	O
years	O
.	O
	
All	O
patients	O
started	O
the	O
study	O
at	O
a	O
dose	O
of	O
100	O
mg/m	O
2	O
intravenously	O
over	O
30	O
minutes	O
on	O
Days	O
1	O
and	O
2	O
every	O
28	O
days	O
.	O
	
Somnolence	B
led	O
to	O
withdrawal	O
in	O
<	O
1	O
%	O
of	O
patients	O
receiving	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
2	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
were	O
stomatitis	B
,	O
infections	B
,	O
rash	B
,	O
fatigue	B
,	O
diarrhea	B
,	O
and	O
decreased	B
appetite	I
.	O
	
5.9	O
Reversible	O
Posterior	O
Leukoencephalopathy	O
Syndrome	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
reversible	B
posterior	I
leukoencephalopathy	I
syndrome	I
(	O
RPLS	B
)	O
was	O
reported	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
mean	O
exposure	O
across	O
studies	O
was	O
12	O
months	O
.	O
	
Patients	O
may	O
present	O
with	O
fatigue	O
,	O
headache	O
,	O
mental	O
status	O
changes	O
,	O
abdominal	O
pain	O
,	O
unusual	O
bowel	O
habits	O
,	O
and	O
hypotension	O
,	O
or	O
nonspecific	O
symptoms	O
which	O
may	O
resemble	O
other	O
causes	O
such	O
as	O
brain	O
metastasis	O
or	O
underlying	O
disease	O
.	O
	
Adverse	O
event	O
data	O
collected	O
from	O
those	O
trials	O
showed	O
the	O
following	O
rates	O
of	O
EPS-related	B
adverse	I
events	I
as	O
shown	O
in	O
Table	O
8	O
.	O
	
Once	O
asthma	O
control	O
is	O
achieved	O
and	O
maintained	O
,	O
assess	O
the	O
patient	O
at	O
regular	O
intervals	O
and	O
step	O
down	O
therapy	O
(	O
e.g.	O
,	O
discontinue	O
BREO	O
ELLIPTA	O
)	O
if	O
possible	O
without	O
loss	O
of	O
asthma	O
control	O
and	O
maintain	O
the	O
patient	O
on	O
a	O
long-term	O
asthma	O
control	O
medication	O
,	O
such	O
as	O
an	O
ICS	O
.	O
	
In	O
some	O
patients	O
infected	O
with	O
HBV	O
and	O
treated	O
with	O
EMTRIVA	O
,	O
the	O
exacerbations	B
of	I
hepatitis	I
B	I
were	O
associated	O
with	O
liver	B
decompensation	I
and	O
liver	B
failure	I
.	O
	
Side-by-side	O
tabulation	O
is	O
to	O
simplify	O
presentation	O
;	O
direct	O
comparisons	O
across	O
trials	O
should	O
not	O
be	O
made	O
due	O
to	O
differing	O
trial	O
designs	O
.	O
	
Immune-mediated	B
reactions	I
presenting	O
as	O
proteinuria	B
,	O
nephrotic	B
syndrome	I
,	O
and	O
necrotizing	B
skin	I
lesions	I
have	O
occurred	O
in	O
some	O
patients	O
following	O
alglucosidase	O
alfa	O
treatment	O
.	O
	
Overall	O
,	O
67	O
%	O
were	O
female	O
and	O
73	O
%	O
were	O
white	O
;	O
the	O
mean	O
age	O
was	O
42	O
years	O
(	O
adolescents	O
aged	O
12	O
to	O
17	O
years	O
made	O
up	O
14	O
%	O
of	O
the	O
population	O
)	O
.	O
	
(	O
5.4	O
)	O
*	O
Risk	O
of	O
adverse	O
reactions	O
or	O
loss	O
of	O
virologic	O
response	O
due	O
to	O
drug	O
interactions	O
:	O
The	O
concomitant	O
use	O
of	O
STRIBILD	O
and	O
other	O
drugs	O
may	O
result	O
in	O
known	O
or	O
potentially	O
significant	O
drug	O
interactions	O
,	O
some	O
of	O
which	O
may	O
lead	O
to	O
loss	O
of	O
therapeutic	O
effect	O
of	O
STRIBILD	O
and	O
possible	O
development	O
of	O
resistance	O
;	O
and	O
possible	O
clinically	O
significant	O
adverse	O
reactions	O
from	O
greater	O
exposures	O
of	O
concomitant	O
drugs	O
.	O
	
The	O
mean	O
duration	O
of	O
diabetes	O
was	O
seven	O
years	O
,	O
the	O
mean	O
body	O
mass	O
index	O
(	O
BMI	O
)	O
was	O
31	O
kg/m	O
2	O
(	O
51	O
%	O
of	O
patients	O
had	O
a	O
BMI	O
>	O
=30	O
kg/m	O
2	O
)	O
,	O
and	O
the	O
mean	O
age	O
was	O
57	O
years	O
(	O
24	O
%	O
of	O
patients	O
>	O
=65	O
years	O
of	O
age	O
)	O
.	O
	
In	O
a	O
3-week	O
,	O
placebo-controlled	O
pediatric	O
trial	O
with	O
bipolar	O
I	O
disorder	O
,	O
the	O
mean	O
increases	B
(	I
at	I
Endpoint	I
)	I
in	I
prolactin	I
levels	I
were	O
3.2	O
ng/mL	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
2.1	O
ng/mL	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
6.4	O
ng/mL	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
compared	O
to	O
an	O
increase	O
of	O
2.5	O
ng/mL	O
for	O
placebo-treated	O
patients	O
.	O
	
(	O
2.3,5.3	O
)	O
*	O
Hepatic	B
toxicity	I
:	O
Fatal	B
hepatic	B
impairment	I
occurs	O
in	O
0.18	O
%	O
of	O
patients	O
.	O
	
5.4	O
Suicidal	O
Behavior	O
and	O
Ideation	O
HORIZANT	O
(	O
gabapentin	O
enacarbil	O
)	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
,	O
an	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
5	O
%	O
)	O
were	O
stomatitis	B
and	O
diarrhea	B
.	O
	
(	O
5.3	O
)	O
*	O
Toviaz	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
being	O
treated	O
for	O
narrow-angle	O
glaucoma	O
,	O
and	O
only	O
where	O
the	O
potential	O
benefits	O
outweigh	O
the	O
risks	O
(	O
5.4	O
)	O
*	O
Central	B
Nervous	I
System	I
Effects	I
:	O
Somnolence	B
has	O
been	O
reported	O
with	O
Toviaz	O
.	O
	
There	O
were	O
4	O
suicides	B
in	O
drug-treated	O
patients	O
in	O
the	O
trials	O
and	O
none	O
in	O
placebo-treated	O
patients	O
,	O
but	O
the	O
number	O
is	O
too	O
small	O
to	O
allow	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	B
.	O
	
5.2	O
Bladder	O
Outlet	O
Obstruction	O
Toviaz	O
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
with	O
clinically	O
significant	O
bladder	O
outlet	O
obstruction	O
because	O
of	O
the	O
risk	O
of	O
urinary	O
retention	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
In	O
patients	O
with	O
confirmed	O
PML	O
,	O
consider	O
stopping	O
immunosuppressant	O
therapy	O
,	O
including	O
BENLYSTA	O
.	O
	
(	O
2.3,5.1	O
)	O
*	O
Bullous	O
and	O
Exfoliative	O
Skin	B
Disorders	I
:	I
Severe	I
bullous	I
,	I
blistering	I
,	I
and	I
exfoliating	I
lesions	I
occurred	O
in	O
0.15	O
%	O
of	O
patients	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
CK	B
elevations	I
>	O
=3	O
times	O
ULN	O
during	O
a	O
3-week	O
trial	O
in	O
pediatric	O
bipolar	O
I	O
disorder	O
at	O
any	O
time	O
were	O
1	O
%	O
,	O
0	O
%	O
,	O
and	O
1	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
,	O
versus	O
3	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Treatment-emergent	O
ADRs	O
in	O
VIKING-3	O
were	O
generally	O
similar	O
compared	O
with	O
observations	O
with	O
the	O
50-mg	O
once-daily	O
dose	O
in	O
adult	O
Phase	O
3	O
trials	O
.	O
	
*	O
Take	O
1	O
DUAVEE	O
tablet	O
at	O
the	O
same	O
time	O
each	O
day	O
.	O
	
All	O
9	O
patients	O
had	O
hypopituitarism	B
and	O
some	O
had	O
additional	O
concomitant	O
endocrinopathies	B
such	O
as	O
adrenal	B
insufficiency	I
,	O
hypogonadism	B
,	O
and	O
hypothyroidism	B
.	O
	
Recurrent	O
reactions	O
consisting	O
of	O
flu-like	B
illness	I
or	O
a	O
combination	O
of	O
events	O
such	O
as	O
pyrexia	B
,	O
chills	B
,	O
myalgia	B
,	O
arthralgia	B
,	O
pain	B
,	O
or	O
fatigue	B
occurring	O
after	O
completion	O
of	O
infusions	O
and	O
lasting	O
usually	O
for	O
1	O
-	O
3	O
days	O
have	O
been	O
observed	O
in	O
some	O
patients	O
treated	O
with	O
alglucosidase	O
alfa	O
.	O
	
Following	O
resolution	O
of	O
transaminase	O
elevations	O
,	O
consider	O
the	O
benefits	O
and	O
risks	O
of	O
resuming	O
KALYDECO	O
dosing	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
12-Month	O
Trial	O
Long-term	O
safety	O
data	O
is	O
based	O
on	O
a	O
12-month	O
trial	O
that	O
evaluated	O
the	O
safety	O
of	O
BREO	O
ELLIPTA	O
100/25	O
once	O
daily	O
(	O
n	O
=	O
201	O
)	O
,	O
BREO	O
ELLIPTA	O
200/25	O
once	O
daily	O
(	O
n	O
=	O
202	O
)	O
,	O
and	O
fluticasone	O
propionate	O
500	O
mcg	O
twice	O
daily	O
(	O
n	O
=	O
100	O
)	O
in	O
adolescent	O
and	O
adult	O
subjects	O
with	O
asthma	O
(	O
Trial	O
4	O
)	O
.	O
	
*	O
are	O
going	O
to	O
have	O
surgery	O
or	O
will	O
be	O
on	O
bed	O
rest	O
.	O
	
*	O
Effects	O
on	O
serum	O
liver	O
biochemistries	O
in	O
patients	O
with	O
hepatitis	O
B	O
or	O
C	O
co-infection	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Other	O
errors	O
may	O
be	O
due	O
to	O
extensive	O
brain	O
atrophy	O
that	O
limits	O
the	O
ability	O
to	O
distinguish	O
gray	O
and	O
white	O
matter	O
on	O
the	O
Amyvid	O
scan	O
as	O
well	O
as	O
motion	O
artifacts	O
that	O
distort	O
the	O
image	O
.	O
	
Other	O
adverse	O
reactions	O
with	O
a	O
plausible	O
relationship	O
to	O
treatment	O
that	O
have	O
been	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=0.3	O
%	O
and	O
greater	O
than	O
placebo	O
in	O
more	O
than	O
3300	O
patients	O
treated	O
with	O
Edarbi	O
in	O
controlled	O
trials	O
are	O
listed	O
below	O
:	O
Gastrointestinal	O
Disorders	O
:	O
nausea	B
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
asthenia	B
,	O
fatigue	B
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
muscle	B
spasm	I
Nervous	O
System	O
Disorders	O
:	O
dizziness	B
,	O
dizziness	B
postural	I
Respiratory	O
,	O
Thoracic	O
,	O
and	O
Mediastinal	O
Disorders	O
:	O
cough	B
6.2	O
Clinical	O
Laboratory	O
Findings	O
In	O
controlled	O
clinical	O
trials	O
,	O
clinically	O
relevant	O
changes	O
in	O
standard	O
laboratory	O
parameters	O
were	O
uncommon	O
with	O
administration	O
of	O
Edarbi	O
.	O
	
No	O
serious	O
adverse	O
events	O
occurred	O
in	O
patients	O
who	O
received	O
XEOMIN	O
;	O
one	O
placebo-treated	O
patient	O
experienced	O
a	O
serious	O
adverse	O
event	O
(	O
dyspnea	B
)	O
.	O
	
Vascular	O
Events	O
Vascular	B
events	I
,	O
including	O
hemorrhagic	B
strokes	I
,	O
and	O
peripheral	B
arterial	I
occlusive	I
disease	I
were	O
reported	O
in	O
premarketing	O
clinical	O
trials	O
in	O
patients	O
who	O
received	O
GILENYA	O
doses	O
(	O
1.25-5	O
mg	O
)	O
higher	O
than	O
recommended	O
for	O
use	O
in	O
MS	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
less	O
frequently	O
(	O
<	O
5	O
%	O
)	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
these	O
infections	O
.	O
	
Estrogens	O
may	O
increase	O
the	O
chances	O
of	O
getting	O
certain	O
types	O
of	O
cancers	O
,	O
including	O
cancer	O
of	O
the	O
breast	O
or	O
uterus	O
.	O
	
In	O
clinical	O
trials	O
with	O
INLYTA	O
,	O
gastrointestinal	B
perforation	I
was	O
reported	O
in	O
5/715	O
patients	O
(	O
1	O
%	O
)	O
,	O
including	O
one	O
death	B
.	O
	
The	O
infusion	O
rate	O
may	O
be	O
slowed	O
or	O
interrupted	O
if	O
the	O
patient	O
develops	O
an	O
infusion	O
reaction	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
Among	O
SAPHRIS-Treated	O
(	O
Adjunctive	O
)	O
Bipolar	O
Patients	O
:	O
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
SAPHRIS	O
(	O
incidence	O
of	O
2	O
%	O
or	O
greater	O
,	O
rounded	O
to	O
the	O
nearest	O
percent	O
,	O
and	O
SAPHRIS	O
incidence	O
greater	O
than	O
placebo	O
)	O
that	O
occurred	O
during	O
acute	O
adjunctive	O
therapy	O
at	O
3	O
weeks	O
,	O
a	O
time	O
when	O
most	O
of	O
the	O
patients	O
were	O
still	O
participating	O
in	O
the	O
trial	O
,	O
are	O
shown	O
in	O
Table	O
11	O
.	O
	
(	O
5.3	O
)	O
*	O
Candida	B
albicans	I
infection	I
of	I
the	I
mouth	I
may	O
occur	O
.	O
	
``	O
When	O
the	O
estrogen	O
levels	O
begin	O
dropping	O
,	O
some	O
women	O
get	O
very	O
uncomfortable	O
symptoms	O
,	O
such	O
as	O
feelings	O
of	O
warmth	O
in	O
the	O
face	O
,	O
neck	O
,	O
and	O
chest	O
,	O
or	O
sudden	O
intense	O
episodes	O
of	O
heat	O
and	O
sweating	O
(	O
``	O
hot	O
flashes	O
''	O
or	O
``	O
hot	O
flushes	O
''	O
)	O
.	O
	
Adverse	O
Reactions	O
Most	O
Commonly	O
Leading	O
to	O
Discontinuation	O
of	O
Treatment	O
in	O
Premarketing	O
Controlled	O
Trials	O
The	O
proportion	O
of	O
patients	O
with	O
Crohn	O
's	O
disease	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
in	O
the	O
controlled	O
clinical	O
studies	O
was	O
8	O
%	O
for	O
CIMZIA	O
and	O
7	O
%	O
for	O
placebo	O
.	O
	
Discontinuation	O
due	O
to	O
any	O
adverse	O
event	O
occurred	O
in	O
26	O
%	O
in	O
the	O
KRd	O
arm	O
versus	O
25	O
%	O
in	O
the	O
Rd	O
arm	O
.	O
	
Several	O
patients	O
had	O
a	O
prior	O
history	O
of	O
pancreatitis	O
.	O
	
The	O
dosage	O
of	O
POTIGA	O
should	O
be	O
reduced	O
over	O
a	O
period	O
of	O
at	O
least	O
3	O
weeks	O
,	O
unless	O
safety	O
concerns	O
require	O
abrupt	O
withdrawal	O
.	O
	
5.7	O
Coexisting	O
Conditions	O
ARCAPTA	O
NEOHALER	O
,	O
like	O
other	O
sympathomimetic	O
amines	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
convulsive	O
disorders	O
or	O
thyrotoxicosis	O
,	O
and	O
in	O
patients	O
who	O
are	O
unusually	O
responsive	O
to	O
sympathomimetic	O
amines	O
.	O
	
The	O
safety	O
and	O
efficacy	O
of	O
CIMZIA	O
in	O
patients	O
with	O
immunosuppression	O
has	O
not	O
been	O
formally	O
evaluated	O
.	O
	
5.12	O
Hepatic	O
Impairment	O
The	O
systemic	O
exposure	O
to	O
axitinib	O
was	O
higher	O
in	O
subjects	O
with	O
moderate	O
hepatic	O
impairment	O
(	O
Child-Pugh	O
class	O
B	O
)	O
compared	O
to	O
subjects	O
with	O
normal	O
hepatic	O
function	O
.	O
	
Osteonecrosis	O
of	O
the	O
Jaw	O
No	O
cases	O
of	O
ONJ	B
were	O
reported	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
observed	O
across	O
pre-marketing	O
clinical	O
trials	O
were	O
similar	O
in	O
type	O
and	O
frequency	O
as	O
those	O
observed	O
in	O
the	O
placebo-controlled	O
trial	O
(	O
see	O
Table1	O
)	O
.	O
	
The	O
higher	O
risk	O
of	O
falls	B
for	O
patients	O
treated	O
with	O
INVOKANA	O
was	O
observed	O
within	O
the	O
first	O
few	O
weeks	O
of	O
treatment	O
.	O
	
Monitor	O
with	O
periodic	O
liver	O
testing	O
.	O
	
The	O
incidence	O
of	O
diplopia	B
was	O
greater	O
with	O
the	O
concomitant	O
use	O
of	O
APTIOM	O
and	O
carbamazepine	O
compared	O
to	O
the	O
use	O
of	O
APTIOM	O
without	O
carbamazepine	O
(	O
up	O
to	O
16	O
%	O
vs.	O
6	O
%	O
,	O
respectively	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Anyone	O
considering	O
prescribing	O
POTIGA	O
or	O
any	O
other	O
AED	O
must	O
balance	O
this	O
risk	O
with	O
the	O
risk	O
of	O
untreated	O
illness	O
.	O
	
Co-administration	O
of	O
SIRTURO	O
with	O
strong	O
CYP3A4	O
inhibitors	O
may	O
increase	O
the	O
systemic	O
exposure	O
to	O
bedaquiline	O
,	O
which	O
could	O
potentially	O
increase	O
the	O
risk	O
of	O
adverse	O
reactions	O
.	O
	
Baseline	O
Follow	O
Up	O
Renal	O
Function	O
Status	O
n	O
Normaln	O
(	O
%	O
)	O
Mildn	O
(	O
%	O
)	O
Mild	O
to	O
Moderaten	O
(	O
%	O
)	O
Moderate	O
to	O
Severen	O
(	O
%	O
)	O
Severen	O
(	O
%	O
)	O
Kidney	B
Failuren	O
(	O
%	O
)	O
Notes	O
:	O
Grading	O
is	O
based	O
on	O
Modification	O
in	O
Diet	O
in	O
Renal	O
Disease	O
method	O
(	O
MDRD	O
)	O
.KDIGO	O
Classification	O
by	O
eGFR	O
:	O
Normal	O
:	O
greater	O
than	O
or	O
equal	O
to	O
90	O
,	O
Mild	O
:	O
60	O
to	O
less	O
than	O
90	O
,	O
Mild	O
to	O
Moderate	O
:	O
45	O
to	O
less	O
than	O
60	O
,	O
Moderate	O
to	O
Severe	O
:	O
30	O
to	O
less	O
than	O
45	O
,	O
Severe	O
:	O
15	O
to	O
less	O
than	O
30	O
,	O
Kidney	O
Failure	O
:	O
less	O
than	O
15	O
ml/min/1.73	O
m	O
2	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Accredo	O
Health	O
Group	O
Inc.	O
at	O
1-888-454-8860	O
,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
and	O
use	O
of	O
effective	O
contraception	O
.	O
	
The	O
incidence	O
of	O
dizziness	B
was	O
greater	O
with	O
the	O
concomitant	O
use	O
of	O
APTIOM	O
and	O
carbamazepine	O
compared	O
to	O
the	O
use	O
of	O
APTIOM	O
without	O
carbamazepine	O
(	O
up	O
to	O
37	O
%	O
vs.	O
19	O
%	O
,	O
respectively	O
)	O
.	O
	
Analyses	O
of	O
17	O
placebo-controlled	O
trials	O
(	O
modal	O
duration	O
of	O
10	O
weeks	O
)	O
,	O
largely	O
in	O
patients	O
taking	O
atypical	O
antipsychotic	O
drugs	O
,	O
revealed	O
a	O
risk	O
of	O
death	B
in	O
the	O
drug-treated	O
patients	O
of	O
between	O
1.6	O
to	O
1.7	O
times	O
that	O
seen	O
in	O
placebo-treated	O
patients	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
mean	O
eGFR	O
81	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
a	O
positive	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
test	O
result	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
,	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Advise	O
women	O
to	O
avoid	O
becoming	O
pregnant	O
while	O
taking	O
IMBRUVICA	O
.	O
	
In	O
clinical	O
trials	O
with	O
Vimizim	O
,	O
44	O
of	O
235	O
(	O
18.7	O
%	O
)	O
patients	O
experienced	O
hypersensitivity	B
reactions	O
,	O
including	O
anaphylaxis	B
.	O
	
Careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
patient	O
's	O
clinical	O
status	O
prior	O
to	O
administration	O
of	O
Vimizim	O
and	O
consider	O
delaying	O
the	O
Vimizim	O
infusion	O
(	O
5.2	O
)	O
.	O
	
Symptoms	O
have	O
included	O
hypotension	B
,	O
dyspnea	B
,	O
throat	B
tightness	I
,	O
upper	B
airway	I
edema	I
,	O
pruritus	B
,	O
and	O
urticaria	B
.	O
	
5.6	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
has	O
been	O
reported	O
with	O
IMBRUVICA	O
therapy	O
.	O
	
Patients	O
experienced	O
relief	O
of	O
symptoms	O
upon	O
discontinuation	O
of	O
the	O
medication	O
.	O
	
5.4	O
Atrial	O
Fibrillation	O
Atrial	B
fibrillation	I
and	O
atrial	B
flutter	I
(	O
range	O
,	O
6	O
to	O
9	O
%	O
)	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
,	O
particularly	O
in	O
patients	O
with	O
cardiac	O
risk	O
factors	O
,	O
acute	O
infections	O
,	O
and	O
a	O
previous	O
history	O
of	O
atrial	O
fibrillation	O
.	O
	
Administration	O
of	O
TECFIDERA	O
with	O
food	O
may	O
reduce	O
the	O
incidence	O
of	O
flushing	B
.	O
	
The	O
population	O
was	O
31-84	O
years	O
of	O
age	O
,	O
60	O
%	O
male	O
,	O
and	O
40	O
%	O
female	O
.	O
	
The	O
safety	O
profile	O
for	O
patients	O
in	O
study	O
AS-1	O
treated	O
with	O
CIMZIA	O
was	O
similar	O
to	O
the	O
safety	O
profile	O
seen	O
in	O
patients	O
with	O
RA	O
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
Grade	O
>	O
=3	O
hemorrhagic	B
events	I
was	O
higher	O
in	O
COMETRIQ-treated	O
patients	O
compared	O
with	O
placebo	O
(	O
3	O
%	O
vs.	O
1	O
%	O
)	O
.	O
	
Heart	O
Rate	O
Increase	O
and	O
Tachycardia	O
Related	O
Adverse	O
Reactions	O
.	O
	
All	O
were	O
serious	O
and	O
one	O
GI	B
fistula	I
was	O
fatal	B
(	O
<	O
1	O
%	O
)	O
.	O
	
In	O
Study	O
1	O
,	O
the	O
number	O
of	O
ERWINAZE	O
courses	O
ranged	O
from	O
1	O
to	O
9	O
.	O
	
Reports	O
include	O
cases	O
of	O
pulmonary	B
TB	I
.	O
	
Patients	O
who	O
fail	O
to	O
show	O
substantial	O
clinical	O
benefit	O
after	O
adequate	O
titration	O
should	O
be	O
discontinued	O
from	O
POTIGA	O
.	O
	
These	O
hematomas	B
may	O
result	O
in	O
permanent	B
paralysis	I
(	O
5.3	O
)	O
.	O
	
Adverse	B
reactions	I
related	I
to	I
renal	I
function	I
can	O
occur	O
after	O
initiating	O
FARXIGA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Women	O
with	O
a	O
tendency	O
to	O
chloasma	O
should	O
avoid	O
exposure	O
to	O
the	O
sun	O
or	O
ultraviolet	O
radiation	O
while	O
taking	O
COCs	O
.	O
	
Patients	O
with	O
abnormal	O
coagulation	O
(	O
except	O
for	O
patients	O
taking	O
low-dose	O
aspirin	O
,	O
e.g.	O
,	O
up	O
to	O
150	O
mg	O
per	O
day	O
)	O
were	O
excluded	O
from	O
participating	O
in	O
these	O
studies	O
.	O
	
The	O
majority	O
of	O
these	O
immune-mediated	B
reactions	I
initially	O
manifested	O
during	O
treatment	O
;	O
however	O
,	O
a	O
minority	O
occurred	O
weeks	O
to	O
months	O
after	O
discontinuation	O
of	O
YERVOY	O
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
.	O
]	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=20	O
%	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
dose	O
and	O
frequency	O
of	O
NULOJIX	O
were	O
anemia	B
,	O
diarrhea	B
,	O
urinary	B
tract	I
infection	I
,	O
peripheral	B
edema	I
,	O
constipation	B
,	O
hypertension	B
,	O
pyrexia	B
,	O
graft	B
dysfunction	I
,	O
cough	B
,	O
nausea	B
,	O
vomiting	B
,	O
headache	B
,	O
hypokalemia	B
,	O
hyperkalemia	B
,	O
and	O
leukopenia	B
.	O
	
Some	O
women	O
may	O
encounter	O
amenorrhea	B
or	O
oligomenorrhea	B
after	O
stopping	O
COCs	O
,	O
especially	O
when	O
such	O
a	O
condition	O
was	O
pre-existent	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
,	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.12	O
Suicide	O
The	O
possibility	O
of	O
a	O
suicide	O
attempt	O
is	O
inherent	O
in	O
psychotic	O
illness	O
,	O
and	O
close	O
supervision	O
of	O
high-risk	O
patients	O
should	O
accompany	O
drug	O
therapy	O
.	O
	
*	O
POTIGA	O
can	O
cause	O
retinal	B
abnormalities	I
,	O
which	O
are	O
known	O
to	O
result	O
in	O
damage	B
to	I
the	I
photoreceptors	I
and	O
vision	B
loss	I
.	O
	
Consider	O
administration	O
of	O
platelet	O
concentrates	O
in	O
cases	O
where	O
thrombocytopenia	O
is	O
present	O
or	O
long-acting	O
antiplatelet	O
drugs	O
have	O
been	O
used	O
.	O
	
Do	O
not	O
use	O
BREO	O
ELLIPTA	O
for	O
patients	O
whose	O
asthma	O
is	O
adequately	O
controlled	O
on	O
low-	O
or	O
medium-dose	O
inhaled	O
corticosteroids	O
.	O
	
Antibody	O
formation	O
was	O
associated	O
with	O
lowered	O
drug	O
plasma	O
concentration	O
and	O
reduced	O
efficacy	O
.	O
	
(	O
5.2	O
)	O
*	O
Hepatotoxicity	B
:	O
Beleodaq	O
may	O
cause	O
hepatic	B
toxicity	I
and	O
liver	B
function	I
test	I
abnormalities	I
.	O
	
Rash	B
was	O
reported	O
more	O
frequently	O
in	O
female	O
subjects	O
than	O
in	O
male	O
subjects	O
(	O
rash	B
>	O
=	O
Grade	O
2	O
was	O
reported	O
in	O
13/64	O
[	O
20.3	O
%	O
]	O
females	O
versus	O
2/37	O
[	O
5.4	O
%	O
]	O
males	O
;	O
discontinuations	O
due	O
to	O
rash	B
were	O
reported	O
in	O
4/64	O
[	O
6.3	O
%	O
]	O
females	O
versus	O
0/37	O
[	O
0	O
%	O
]	O
males	O
)	O
.	O
	
There	O
were	O
too	O
few	O
cases	O
to	O
determine	O
whether	O
the	O
emergence	O
of	O
these	O
events	O
is	O
related	O
to	O
FARXIGA	O
.	O
	
There	O
were	O
four	O
suicides	B
in	O
drug	O
treated	O
patients	O
in	O
the	O
trials	O
and	O
none	O
in	O
placebo	O
treated	O
patients	O
,	O
but	O
the	O
number	O
is	O
too	O
small	O
to	O
allow	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	B
.	O
	
AdreView	O
imaging	O
should	O
not	O
be	O
performed	O
if	O
discontinuation	O
of	O
these	O
medications	O
would	O
involve	O
risks	O
which	O
outweigh	O
the	O
value	O
of	O
AdreView	O
imaging	O
.	O
	
5.6	O
Carbohydrate	O
and	O
Lipid	O
Metabolic	O
Effects	O
Carefully	O
monitor	O
prediabetic	O
and	O
diabetic	O
women	O
who	O
are	O
taking	O
Natazia	O
.	O
	
In	O
the	O
lung	O
cancer	O
study	O
,	O
80	O
%	O
of	O
patients	O
were	O
male	O
,	O
the	O
median	O
age	O
was	O
58	O
years	O
,	O
and	O
95	O
%	O
of	O
patients	O
were	O
Caucasian	O
.	O
	
These	O
findings	O
were	O
generally	O
observed	O
within	O
the	O
first	O
12	O
weeks	O
of	O
treatment	O
and	O
were	O
reversible	O
with	O
dose	O
interruption	O
.	O
	
The	O
safety	O
of	O
ZYTIGA	O
in	O
patients	O
with	O
left	O
ventricular	O
ejection	O
fraction	O
<	O
50	O
%	O
or	O
New	O
York	O
Heart	O
Association	O
(	O
NYHA	O
)	O
Class	O
III	O
or	O
IV	O
heart	O
failure	O
(	O
in	O
Study	O
1	O
)	O
or	O
NYHA	O
Class	O
II	O
to	O
IV	O
heart	O
failure	O
(	O
in	O
Study	O
2	O
)	O
was	O
not	O
established	O
because	O
these	O
patients	O
were	O
excluded	O
from	O
these	O
randomized	O
clinical	O
trials	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
These	O
trials	O
included	O
832	O
patients	O
of	O
whom	O
551	O
and	O
281	O
received	O
XIAFLEX	O
and	O
placebo	O
,	O
respectively	O
.	O
	
(	O
5.5	O
)	O
*	O
Anaphylaxis	B
:	O
Monitor	O
patients	O
for	O
anaphylaxis	O
and	O
discontinue	O
Zydelig	O
.	O
	
Monitor	O
liver	O
function	O
and	O
modify	O
,	O
interrupt	O
,	O
or	O
discontinue	O
ZYTIGA	O
dosing	O
as	O
recommended	O
.	O
	
The	O
patient	O
demographics	O
were	O
similar	O
to	O
Studies	O
1	O
and	O
2	O
.	O
	
5.2	O
Imaging	O
Errors	O
due	O
to	O
Concomitant	O
Medications	O
and	O
Risks	O
Associated	O
with	O
Withdrawal	O
of	O
Medications	O
Many	O
medications	O
have	O
the	O
potential	O
to	O
interfere	O
with	O
AdreView	O
imaging	O
and	O
review	O
of	O
the	O
patient	O
's	O
medications	O
is	O
required	O
prior	O
to	O
AdreView	O
dosing	O
due	O
to	O
the	O
risk	O
for	O
unreliable	O
imaging	O
results	O
.	O
	
5.5	O
Pneumonia	O
An	O
increase	O
in	O
the	O
incidence	O
of	O
pneumonia	B
has	O
been	O
observed	O
in	O
subjects	O
with	O
COPD	O
receiving	O
BREO	O
ELLIPTA	O
100/25	O
in	O
clinical	O
trials	O
.	O
	
b	O
Bleeding	B
site	O
based	O
on	O
investigator	O
assessment	O
.	O
	
5.2	O
Infections	O
Serious	O
and	O
sometimes	O
fatal	B
infections	B
,	O
including	O
pneumonia	B
and	O
sepsis	B
,	O
have	O
occurred	O
with	O
Beleodaq	O
.	O
	
5.3	O
Immune-mediated	O
Dermatitis	O
In	O
Study	O
1	O
,	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
immune-mediated	B
dermatitis	I
(	O
eg	O
,	O
Stevens-Johnson	B
syndrome	I
,	O
toxic	B
epidermal	I
necrolysis	I
,	O
or	O
rash	B
complicated	O
by	O
full	O
thickness	O
dermal	B
ulceration	I
;	O
Grade	O
3-5	O
)	O
occurred	O
in	O
13	O
(	O
2.5	O
%	O
)	O
YERVOY-treated	O
patients	O
.	O
	
Women	O
should	O
be	O
advised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
and	O
to	O
avoid	O
pregnancy	O
while	O
on	O
this	O
drug	O
.	O
	
5.4	O
QT	O
Interval	O
Prolongation	O
QTc	B
interval	I
prolongation	I
,	O
which	O
may	O
lead	O
to	O
an	O
increased	O
risk	O
for	O
ventricular	B
tachyarrhythmias	I
(	O
e.g.	O
,	O
Torsade	B
de	I
pointes	I
)	O
or	O
sudden	B
death	I
,	O
occurred	O
in	O
patients	O
treated	O
with	O
ZYKADIA	O
in	O
clinical	O
trials	O
.	O
	
Steroid	O
hormones	O
may	O
be	O
poorly	O
metabolized	O
in	O
patients	O
with	O
impaired	O
liver	O
function	O
.	O
	
COCs	O
have	O
been	O
shown	O
to	O
increase	O
both	O
the	O
relative	O
and	O
attributable	O
risks	O
of	O
cerebrovascular	B
events	I
(	O
hemorrhagic	B
strokes	I
)	O
,	O
although	O
,	O
in	O
general	O
,	O
the	O
risk	O
is	O
greatest	O
among	O
older	O
(	O
>	O
35	O
years	O
of	O
age	O
)	O
,	O
hypertensive	O
women	O
who	O
also	O
smoke	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
in	O
patients	O
with	O
Grade	O
3-5	O
hepatotoxicity	O
and	O
administer	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
of	O
prednisone	O
or	O
equivalent	O
.	O
	
Advise	O
patients	O
taking	O
Ferriprox	O
to	O
immediately	O
interrupt	O
therapy	O
and	O
report	O
to	O
their	O
physician	O
if	O
they	O
experience	O
any	O
symptoms	O
indicative	O
of	O
infection	O
.	O
	
Embryo-fetal	B
toxicity	I
and	O
teratogenicity	B
occurred	O
in	O
rats	O
that	O
received	O
eribulin	O
mesylate	O
at	O
approximately	O
half	O
of	O
the	O
recommended	O
human	O
dose	O
based	O
on	O
body	O
surface	O
area	O
.	O
	
Increasing	O
use	O
of	O
inhaled	O
,	O
short-acting	O
beta2-agonists	O
is	O
a	O
marker	O
of	O
deteriorating	O
asthma	O
.	O
	
5.4	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
has	O
occurred	O
in	O
Beleodaq-treated	O
patients	O
in	O
the	O
clinical	O
trial	O
of	O
patients	O
with	O
relapsed	O
or	O
refractory	O
PTCL	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
are	O
categorized	O
by	O
system	O
organ	O
class	O
.	O
	
Hepatic	B
adenomas	I
are	O
associated	O
with	O
COC	O
use	O
.	O
	
Ferriprox	O
can	O
also	O
cause	O
neutropenia	B
,	O
which	O
may	O
foreshadow	O
agranulocytosis	B
.	O
	
Laboratory	O
abnormalities	O
considered	O
ADRs	O
are	O
included	O
in	O
Table	O
2	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
extensive	O
or	O
intensive	O
chemotherapy	O
may	O
be	O
at	O
higher	O
risk	O
of	O
life	O
threatening	O
infections	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
some	O
incidences	O
these	O
pneumonia	B
events	O
were	O
fatal	B
.	O
	
Table	O
3	O
Bleeding	B
Events	O
in	O
RE-COVER	O
and	O
RE-COVER	O
II	O
Treated	O
Patients	O
Note	O
:	O
MBE	B
can	O
belong	O
to	O
more	O
than	O
one	O
criterion	O
.	O
	
5.2	O
Radiation	O
Risk	O
Neuraceq	O
,	O
similar	O
to	O
other	O
radiopharmaceuticals	O
,	O
contributes	O
to	O
a	O
patient	O
's	O
overall	O
long-term	B
cumulative	I
radiation	I
exposure	I
.	O
	
Risk	O
may	O
be	O
increased	O
with	O
concomitant	O
use	O
of	O
other	O
CNS	O
depressants	O
.	O
	
5.5	O
Gastrointestinal	O
Toxicity	O
Nausea	B
,	O
vomiting	B
and	O
diarrhea	B
occur	O
with	O
Beleodaq	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
and	O
may	O
require	O
the	O
use	O
of	O
antiemetic	O
and	O
antidiarrheal	O
medications	O
.	O
	
Patients	O
should	O
not	O
use	O
more	O
than	O
1	O
inhalation	O
once	O
daily	O
of	O
BREO	O
ELLIPTA	O
.	O
	
RE-SONATE	O
was	O
a	O
placebo-controlled	O
study	O
in	O
which	O
684	O
patients	O
received	O
PRADAXA	O
150	O
mg	O
twice	O
daily	O
following	O
6	O
to	O
18	O
months	O
of	O
oral	O
anticoagulant	O
regimen	O
.	O
	
Monitor	O
liver	O
function	O
tests	O
(	O
hepatic	O
transaminase	O
and	O
bilirubin	O
levels	O
)	O
and	O
assess	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
hepatotoxicity	O
before	O
each	O
dose	O
of	O
YERVOY	O
.	O
	
Monitor	O
blood	O
counts	O
at	O
least	O
every	O
two	O
weeks	O
for	O
the	O
first	O
3	O
months	O
of	O
therapy	O
,	O
and	O
at	O
least	O
weekly	O
in	O
patients	O
while	O
neutrophil	O
counts	O
are	O
less	O
than	O
1.0	O
Gi/L	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Oral	O
contraceptives	O
must	O
be	O
used	O
with	O
caution	O
in	O
women	O
with	O
cardiovascular	O
disease	O
risk	O
factors	O
.	O
	
When	O
medically	O
feasible	O
,	O
stop	O
these	O
drugs	O
before	O
AdreView	O
administration	O
and	O
monitor	O
patients	O
for	O
withdrawal	O
signs	O
and	O
symptoms	O
.	O
	
*	O
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
patients	O
(	O
3.7	O
%	O
)	O
in	O
the	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials	O
in	O
Peyronie	O
's	O
disease	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Control	O
hypertension	O
and	O
correct	O
hypokalemia	O
before	O
and	O
during	O
treatment	O
with	O
ZYTIGA	O
.	O
	
(	O
5.8	O
)	O
5.1	O
Hepatotoxicity	O
Fatal	B
and/or	O
serious	O
hepatotoxicity	B
occurred	O
in	O
14	O
%	O
of	O
patients	O
treated	O
with	O
Zydelig	O
.	O
	
GRANIX	O
clinical	O
trials	O
safety	O
data	O
are	O
based	O
upon	O
the	O
results	O
of	O
three	O
randomized	O
clinical	O
trials	O
in	O
patients	O
receiving	O
myeloablative	O
chemotherapy	O
for	O
breast	O
cancer	O
(	O
N=348	O
)	O
,	O
lung	O
cancer	O
(	O
N=240	O
)	O
and	O
non-Hodgkin	O
's	O
lymphoma	O
(	O
N=92	O
)	O
.	O
	
When	O
medically	O
feasible	O
,	O
stop	O
these	O
drugs	O
before	O
AdreView	O
administration	O
and	O
monitor	O
patients	O
for	O
the	O
occurrence	O
of	O
clinically	O
significant	O
withdrawal	O
symptoms	O
,	O
especially	O
patients	O
with	O
elevated	O
levels	O
of	O
circulating	O
catecholamines	O
and	O
their	O
metabolites	O
.	O
	
Neovascular	O
(	O
Wet	O
)	O
Age-Related	O
Macular	O
Degeneration	O
(	O
AMD	O
)	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
EYLEA	O
in	O
1824	O
patients	O
with	O
wet	O
AMD	O
,	O
including	O
1223	O
patients	O
treated	O
with	O
the	O
2-mg	O
dose	O
,	O
in	O
2	O
double-masked	O
,	O
active-controlled	O
clinical	O
studies	O
(	O
VIEW1	O
and	O
VIEW2	O
)	O
for	O
12	O
months	O
[	O
seeClinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
In	O
Study	O
RA-III	O
,	O
too	O
few	O
patients	O
developed	O
antibodies	O
to	O
allow	O
for	O
meaningful	O
analysis	O
of	O
ACR20	O
response	O
by	O
antibody	O
status	O
.	O
	
CIMZIA	O
should	O
be	O
discontinued	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
or	O
sepsis	O
.	O
	
If	O
the	O
patient	O
is	O
known	O
or	O
strongly	O
suspected	O
to	O
have	O
hypersensitivity	O
to	O
iodine	O
,	O
an	O
iodine-containing	O
contrast	O
agent	O
or	O
other	O
products	O
containing	O
iodine	O
,	O
the	O
decision	O
to	O
administer	O
AdreView	O
should	O
be	O
based	O
upon	O
an	O
assessment	O
of	O
the	O
expected	O
benefits	O
compared	O
to	O
the	O
potential	O
hypersensitivity	O
risks	O
.	O
	
The	O
safety	O
of	O
two	O
concurrent	O
injections	O
of	O
XIAFLEX	O
0.58	O
mg	O
into	O
Dupuytren	O
's	O
cords	O
in	O
the	O
same	O
hand	O
was	O
evaluated	O
in	O
a	O
historically-controlled	O
,	O
open-label	O
multi-center	O
trial	O
in	O
715	O
adult	O
subjects	O
with	O
Dupuytren	O
's	O
contracture	O
(	O
Study	O
3	O
)	O
.	O
	
In	O
the	O
two	O
randomized	O
clinical	O
trials	O
,	O
grade	O
3	O
to	O
4	O
hypertension	B
occurred	O
in	O
2	O
%	O
of	O
patients	O
,	O
grade	O
3	O
to	O
4	O
hypokalemia	B
in	O
4	O
%	O
of	O
patients	O
,	O
and	O
grade	O
3	O
to	O
4	O
edema	B
in	O
1	O
%	O
of	O
patients	O
treated	O
with	O
ZYTIGA	O
[	O
seeAdverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Discontinue	O
Zydelig	O
if	O
intestinal	O
perforation	O
is	O
suspected	O
.	O
	
5.14	O
Other	O
Conditions	O
In	O
women	O
with	O
hereditary	O
angioedema	O
,	O
exogenous	O
estrogens	O
may	O
induce	O
or	O
exacerbate	O
symptoms	O
of	O
angioedema	B
.	O
	
5.2	O
Impairment	O
in	O
Renal	O
Function	O
FARXIGA	O
increases	B
serum	I
creatinine	I
and	O
decreases	B
eGFR	I
.	O
	
Consider	O
the	O
benefits	O
and	O
risks	O
before	O
neuraxial	O
intervention	O
in	O
patients	O
who	O
are	O
or	O
who	O
need	O
to	O
be	O
anticoagulated	O
(	O
5.3	O
)	O
.	O
	
The	O
rate	O
of	O
progression	O
of	O
retinal	B
abnormalities	I
and	O
their	O
reversibility	O
are	O
unknown	O
.	O
	
In	O
clinical	O
trials	O
of	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
,	O
in	O
patients	O
with	O
RA	O
,	O
some	O
patients	O
have	O
developed	O
ANA	B
.	O
	
To	O
reduce	O
the	O
potential	O
risk	O
of	O
bleeding	O
associated	O
with	O
the	O
concurrent	O
use	O
of	O
dabigatran	O
and	O
epidural	O
or	O
spinal	O
anesthesia/analgesia	O
or	O
spinal	O
puncture	O
,	O
consider	O
the	O
pharmacokinetic	O
profile	O
of	O
dabigatran	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
If	O
retinal	O
pigmentary	O
abnormalities	O
or	O
vision	O
changes	O
are	O
detected	O
,	O
POTIGA	O
should	O
be	O
discontinued	O
unless	O
no	O
other	O
suitable	O
treatment	O
options	O
are	O
available	O
and	O
the	O
benefits	O
of	O
treatment	O
outweigh	O
the	O
potential	O
risk	O
of	O
vision	O
loss	O
.	O
	
Aspiration	O
pneumonia	O
is	O
a	O
common	O
cause	O
of	O
morbidity	O
and	O
mortality	O
in	O
elderly	O
patients	O
,	O
in	O
particular	O
those	O
with	O
advanced	O
Alzheimer	O
's	O
dementia	O
.	O
	
In	O
this	O
study	O
,	O
159	O
patients	O
received	O
XEOMIN	O
(	O
78	O
were	O
randomized	O
to	O
receive	O
a	O
total	O
dose	O
of	O
120	O
Units	O
,	O
and	O
81	O
were	O
randomized	O
to	O
receive	O
a	O
total	O
dose	O
of	O
240	O
Units	O
)	O
.	O
	
About	O
25	O
%	O
of	O
patients	O
were	O
from	O
the	O
United	O
States	O
and	O
75	O
%	O
from	O
other	O
countries	O
.	O
	
Discontinuation	O
of	O
therapy	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
18	O
%	O
of	O
patients	O
treated	O
with	O
BLINCYTO	O
.	O
	
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
,	O
5.3	O
,	O
5.4	O
,	O
5.5	O
)	O
.	O
]	O
	
Adverse	O
reactions	O
which	O
occurred	O
in	O
>	O
=	O
25	O
%	O
of	O
COMETRIQ-treated	O
patients	O
occurring	O
more	O
frequently	O
in	O
the	O
COMETRIQ	O
arm	O
with	O
a	O
between-arm	O
difference	O
of	O
>	O
=	O
5	O
%	O
included	O
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
:	O
diarrhea	B
,	O
stomatitis	B
,	O
palmar-plantar	B
erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
,	O
decreased	B
weight	I
,	O
decreased	B
appetite	I
,	O
nausea	B
,	O
fatigue	B
,	O
oral	B
pain	I
,	O
hair	B
color	I
changes	I
,	O
dysgeusia	B
,	O
hypertension	B
,	O
abdominal	B
pain	I
,	O
and	O
constipation	B
.	O
	
Discontinue	O
COMETRIQ	O
in	O
patients	O
who	O
experience	O
a	O
perforation	O
or	O
a	O
fistula	O
.	O
	
Approximately	O
86	O
%	O
of	O
the	O
population	O
studied	O
was	O
Caucasian	O
,	O
and	O
0.8	O
%	O
of	O
the	O
population	O
was	O
aged	O
65	O
years	O
or	O
older	O
.	O
	
Infections	B
were	O
more	O
frequently	O
reported	O
in	O
females	O
than	O
in	O
males	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
Tuberculosis	O
and	O
Opportunistic	O
Infections	O
In	O
completed	O
and	O
ongoing	O
global	O
clinical	O
studies	O
in	O
all	O
indications	O
including	O
5,118	O
CIMZIA-treated	O
patients	O
,	O
the	O
overall	O
rate	O
of	O
tuberculosis	B
is	O
approximately	O
0.61	O
per	O
100	O
patient-years	O
across	O
all	O
indications	O
.	O
	
Documented	O
symptomatic	B
hypoglycemia	I
occurred	O
in	O
85	O
%	O
and	O
80	O
%	O
of	O
patients	O
when	O
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
,	O
respectively	O
,	O
was	O
co-administered	O
with	O
prandial	O
insulin	O
.	O
	
Advise	O
women	O
of	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
The	O
combination	O
of	O
transaminase	B
elevations	I
and	O
elevated	B
bilirubin	I
without	O
evidence	O
of	O
obstruction	O
is	O
generally	O
recognized	O
as	O
an	O
important	O
predictor	O
of	O
severe	O
liver	B
injury	I
.	O
	
5.5	O
Severe	O
and	O
Disabling	O
Arthralgia	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
severe	O
and	O
disabling	O
arthralgia	B
in	O
patients	O
taking	O
DPP-4	O
inhibitors	O
.	O
	
The	O
most	O
common	O
non-hematologic	O
adverse	O
reactions	O
(	O
>	O
=30	O
%	O
)	O
were	O
nausea	B
(	O
75	O
%	O
)	O
,	O
fatigue	B
(	O
57	O
%	O
)	O
,	O
vomiting	B
(	O
40	O
%	O
)	O
,	O
diarrhea	B
(	O
37	O
%	O
)	O
and	O
pyrexia	B
(	O
34	O
%	O
)	O
.	O
	
If	O
abnormalities	O
are	O
detected	O
,	O
monitoring	O
of	O
these	O
parameters	O
should	O
be	O
continued	O
to	O
ensure	O
that	O
further	O
deterioration	O
does	O
not	O
occur	O
.	O
	
Epilepsy	O
and	O
many	O
other	O
illnesses	O
for	O
which	O
AEDs	O
are	O
prescribed	O
are	O
themselves	O
associated	O
with	O
morbidity	B
and	O
mortality	B
and	O
an	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reaction	O
is	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
:	O
*	O
Transaminase	B
Elevations	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
to	O
KALYDECO	O
(	O
occurring	O
in	O
>	O
=8	O
%	O
of	O
patients	O
with	O
CF	O
who	O
have	O
a	O
G551D	O
mutation	O
in	O
the	O
CFTR	O
gene	O
)	O
were	O
headache	B
,	O
oropharyngeal	B
pain	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nasal	B
congestion	I
,	O
abdominal	B
pain	I
,	O
nasopharyngitis	B
,	O
diarrhea	B
,	O
rash	B
,	O
nausea	B
,	O
and	O
dizziness	B
.	O
	
Frequent	O
symptoms	O
of	O
hypersensitivity	B
reactions	O
(	O
occurring	O
in	O
more	O
than	O
2	O
patients	O
)	O
included	O
anaphylactic	B
reactions	I
,	O
urticaria	B
,	O
peripheral	B
edema	I
,	O
cough	B
,	O
dyspnea	B
,	O
and	O
flushing	B
.	O
	
Some	O
patients	O
required	O
hospitalization	O
and	O
discontinuation	O
of	O
APTIOM	O
.	O
	
BEPREVE	O
should	O
not	O
be	O
used	O
to	O
treat	O
contact	O
lens-related	O
irritation	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Same	O
Active	O
Ingredient	O
:	O
Patients	O
receiving	O
Prolia	O
should	O
not	O
receive	O
XGEVA	O
(	O
r	O
)	O
(	O
5.1	O
)	O
*	O
Hypersensitivity	B
including	O
anaphylactic	B
reactions	I
may	O
occur	O
.	O
	
5.3	O
Hypocalcemia	O
and	O
Mineral	O
Metabolism	O
Hypocalcemia	B
may	I
be	I
exacerbated	I
by	O
the	O
use	O
of	O
Prolia	O
.	O
	
These	O
findings	O
confirm	O
the	O
myelosuppressive	B
effects	I
seen	O
in	O
patients	O
treated	O
with	O
TREANDA	O
.	O
	
Avoid	O
use	O
of	O
XALKORI	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
.	O
	
In	O
premarketing	O
clinical	O
trials	O
,	O
18	O
of	O
235	O
(	O
7.7	O
%	O
)	O
patients	O
treated	O
with	O
Vimizim	O
experienced	O
signs	O
and	O
symptoms	O
consistent	O
with	O
anaphylaxis	B
.	O
	
If	O
a	O
serious	O
hypersensitivity	O
reaction	O
is	O
suspected	O
,	O
discontinue	O
NESINA	O
,	O
assess	O
for	O
other	O
potential	O
causes	O
for	O
the	O
event	O
and	O
institute	O
alternative	O
treatment	O
for	O
diabetes	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
*	O
Interstitial	B
Lung	I
Disease	I
(	O
ILD	B
)	O
/Pneumonitis	O
:	O
Occurred	O
in	O
2.9	O
%	O
of	O
patients	O
.	O
	
It	O
is	O
important	O
to	O
exclude	O
cases	O
where	O
the	O
clinical	O
presentation	O
includes	O
both	O
serious	O
medical	O
illness	O
(	O
e.g	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
in	O
Vimizim	O
patients	O
and	O
occurring	O
at	O
a	O
higher	O
incidence	O
than	O
placebo-treated	O
patients	O
)	O
were	O
pyrexia	B
,	O
vomiting	B
,	O
headache	B
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
chills	B
,	O
and	O
fatigue	B
(	O
6.1	O
)	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
4.2	O
%	O
and	O
0.8	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
In	O
this	O
pool	O
,	O
INVOKANA	O
was	O
also	O
associated	O
with	O
the	O
adverse	O
reactions	O
of	O
fatigue	B
(	O
1.7	O
%	O
with	O
comparator	O
,	O
2.2	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
2.0	O
%	O
with	O
INVOKANA	O
300	O
mg	O
)	O
and	O
loss	B
of	I
strength	I
(	O
i.e.	O
,	O
asthenia	B
)	O
(	O
0.6	O
%	O
with	O
comparator	O
,	O
0.7	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
1.1	O
%	O
with	O
INVOKANA	O
300	O
mg	O
)	O
.	O
	
Somnolence	O
and	O
Fatigue	O
APTIOM	O
causes	O
dose-dependent	O
increases	O
in	O
somnolence	B
and	O
fatigue-related	O
adverse	O
reactions	O
(	O
fatigue	B
,	O
asthenia	B
,	O
malaise	B
,	O
hypersomnia	B
,	O
sedation	B
,	O
and	O
lethargy	B
)	O
.	O
	
In	O
this	O
setting	O
,	O
a	O
re-evaluation	O
of	O
the	O
patient	O
and	O
the	O
COPD	O
treatment	O
regimen	O
should	O
be	O
undertaken	O
at	O
once	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
increased	B
ALT	I
was	O
30	O
and	O
33	O
days	O
,	O
respectively	O
,	O
and	O
the	O
median	O
duration	O
for	O
each	O
was	O
21	O
days	O
.	O
	
Pancreatitis	O
Pancreatitis	B
was	O
reported	O
in	O
4	O
patients	O
(	O
0.1	O
%	O
)	O
in	O
the	O
placebo	O
and	O
8	O
patients	O
(	O
0.2	O
%	O
)	O
in	O
the	O
Prolia	O
groups	O
.	O
	
(	O
5.3	O
)	O
*	O
Tardive	B
Dyskinesia	I
:	O
Discontinue	O
if	O
clinically	O
appropriate	O
.	O
	
Other	O
binding	O
proteins	O
may	O
be	O
elevated	B
in	I
serum	I
,	I
for	I
example	I
,	I
corticosteroid	I
binding	I
globulin	I
)	O
,	O
leading	O
to	O
increased	B
total	I
circulating	I
corticosteroids	I
,	O
respectively	O
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
(	O
Child-Pugh	O
class	O
C	O
)	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
,	O
andClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
5.11	O
Immunosuppression	O
Since	O
TNF	O
mediates	O
inflammation	O
and	O
modulates	O
cellular	O
immune	O
responses	O
,	O
the	O
possibility	O
exists	O
for	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
,	O
to	O
affect	O
host	O
defenses	O
against	O
infections	O
and	O
malignancies	O
.	O
	
5.6	O
Depression	O
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
psychiatric	B
events	I
were	O
reported	O
more	O
frequently	O
with	O
BENLYSTA	O
(	O
16	O
%	O
)	O
than	O
with	O
placebo	O
(	O
12	O
%	O
)	O
,	O
related	O
primarily	O
to	O
depression-related	O
events	O
(	O
6.3	O
%	O
BENLYSTA	O
and	O
4.7	O
%	O
placebo	O
)	O
,	O
insomnia	B
(	O
6.0	O
%	O
BENLYSTA	O
and	O
5.3	O
%	O
placebo	O
)	O
,	O
and	O
anxiety	B
(	O
3.9	O
%	O
BENLYSTA	O
and	O
2.8	O
%	O
placebo	O
)	O
.	O
	
Following	O
the	O
second	O
dose	O
,	O
a	O
further	O
decrease	B
in	I
heart	I
rate	I
may	O
occur	O
when	O
compared	O
to	O
the	O
heart	O
rate	O
prior	O
to	O
the	O
second	O
dose	O
,	O
but	O
this	O
change	O
is	O
of	O
a	O
smaller	O
magnitude	O
than	O
that	O
observed	O
following	O
the	O
first	O
dose	O
.	O
	
Record	O
the	O
specific	O
GBCA	O
and	O
the	O
dose	O
administered	O
to	O
a	O
patient	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Seizure	B
occurred	O
in	O
0.9	O
%	O
of	O
patients	O
receiving	O
XTANDI	O
who	O
previously	O
received	O
docetaxel	O
and	O
in	O
0.1	O
%	O
of	O
patients	O
who	O
were	O
chemotherapy-naive	O
.	O
	
2Includes	O
the	O
preferred	O
terms	O
oral	B
hypoesthesia	I
,	O
oral	B
paresthesia	I
,	O
and	O
oral	B
dysesthesia	I
.	O
	
Management	O
of	O
cardiac	O
failure	O
may	O
require	O
permanent	O
discontinuation	O
of	O
INLYTA	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
pneumonia	O
.	O
	
Adverse	O
reactions	O
that	O
occurred	O
after	O
repeated	O
injections	O
in	O
2-3	O
%	O
of	O
the	O
population	O
included	O
bronchitis	B
,	O
influenza	B
,	O
pharyngolaryngeal	B
pain	I
,	O
cough	B
,	O
contact	B
dermatitis	I
,	O
injection	B
site	I
swelling	I
,	O
and	O
injection	B
site	I
discomfort	I
.	O
	
This	O
study	O
showed	O
a	O
statistically	O
significant	O
reduction	B
in	I
heart	I
rate	I
compared	O
to	O
baseline	O
,	O
averaging	O
about	O
three	O
beats	O
per	O
minute	O
,	O
observed	O
thirty	O
minutes	O
after	O
injection	O
.	O
	
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
60	O
%	O
of	O
the	O
patients	O
in	O
the	O
KRd	O
arm	O
and	O
54	O
%	O
of	O
the	O
patients	O
in	O
the	O
Rd	O
arm	O
.	O
	
In	O
other	O
women	O
,	O
symptoms	O
can	O
be	O
more	O
severe	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
in	O
the	O
controlled	O
clinical	O
studies	O
was	O
5	O
%	O
for	O
CIMZIA	O
and	O
2.5	O
%	O
for	O
placebo	O
.	O
	
Grade	O
3/4	O
venous	B
thromboembolic	I
events	I
were	O
reported	O
in	O
9/359	O
patients	O
(	O
3	O
%	O
)	O
receiving	O
INLYTA	O
(	O
including	O
pulmonary	B
embolism	I
,	O
deep	B
vein	I
thrombosis	I
,	O
retinal	B
vein	I
occlusion	I
and	O
retinal	B
vein	I
thrombosis	I
)	O
and	O
2/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Adverse	O
Reactions	O
Associated	O
with	O
Discontinuation	O
of	O
Treatment	O
:	O
Approximately	O
16	O
%	O
(	O
25/158	O
)	O
of	O
SAPHRIS-treated	O
patients	O
discontinued	O
treatment	O
due	O
to	O
an	O
adverse	O
reaction	O
,	O
compared	O
with	O
about	O
11	O
%	O
(	O
18/166	O
)	O
on	O
placebo	O
.	O
	
Without	O
knowledge	O
of	O
the	O
background	O
incidence	O
and	O
recurrence	O
in	O
a	O
similar	O
population	O
not	O
treated	O
with	O
gabapentin	O
,	O
it	O
is	O
impossible	O
to	O
know	O
whether	O
the	O
incidence	O
reported	O
in	O
this	O
cohort	O
is	O
or	O
is	O
not	O
affected	O
by	O
treatment	O
.	O
	
The	O
increase	O
may	O
be	O
larger	O
when	O
coadministered	O
with	O
chlorthalidone	O
or	O
hydrochlorothiazide	O
.	O
	
Immune-mediated	B
dermatitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
XEOMIN	O
treated	O
subjects	O
were	O
24	O
to	O
74	O
years	O
old	O
,	O
and	O
were	O
predominantly	O
female	O
(	O
88	O
%	O
)	O
.	O
	
Prolactin	O
:	O
In	O
short-term	O
,	O
placebo-controlled	O
adult	O
schizophrenia	O
trials	O
,	O
the	O
mean	O
decreases	B
in	I
prolactin	I
levels	I
were	O
6.5	O
ng/mL	O
for	O
SAPHRIS-treated	O
patients	O
compared	O
to	O
10.7	O
ng/mL	O
for	O
placebo-treated	O
patients	O
.	O
	
Laboratory	O
Abnormalities	O
Table	O
8	O
describes	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
reported	O
at	O
a	O
rate	O
of	O
>	O
10	O
%	O
for	O
patients	O
who	O
received	O
Kyprolis	O
monotherapy	O
.	O
	
5.2	O
Immune-Mediated	O
Reactions	O
Immune-mediated	B
cutaneous	I
reactions	I
have	O
been	O
reported	O
with	O
alglucosidase	O
alfa	O
including	O
necrotizing	B
skin	I
lesions	I
[	O
seeAdverse	O
Reactions	O
(	O
6.3	O
)	O
]	O
.	O
	
The	O
risk	O
of	O
acute	O
kidney	O
injury	O
may	O
increase	O
with	O
increasing	O
dose	O
of	O
the	O
contrast	O
agent	O
;	O
administer	O
the	O
lowest	O
dose	O
necessary	O
for	O
adequate	O
imaging	O
.	O
	
During	O
the	O
trial	O
,	O
48	O
%	O
of	O
patients	O
on	O
the	O
XTANDI	O
arm	O
and	O
46	O
%	O
of	O
patients	O
on	O
the	O
placebo	O
arm	O
received	O
glucocorticoids	O
.	O
	
*	O
Toviaz	O
should	O
be	O
administered	O
with	O
caution	O
to	O
patients	O
with	O
clinically	O
significant	O
bladder	O
outlet	O
obstruction	O
because	O
of	O
the	O
risk	O
of	O
urinary	O
retention	O
.	O
	
Because	O
HORIZANT	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
,	O
HORIZANT	O
also	O
increases	O
this	O
risk	O
.	O
	
Withhold	O
GILOTRIF	O
for	O
acute	O
onset	O
or	O
worsening	O
of	O
pulmonary	O
symptoms	O
.	O
	
Out	O
of	O
2,133	O
patients	O
in	O
3	O
clinical	O
trials	O
,	O
a	O
total	O
of	O
14	O
deaths	B
occurred	O
during	O
the	O
placebo-controlled	O
,	O
double-blind	O
treatment	O
periods	O
:	O
3/675	O
(	O
0.4	O
%	O
)	O
,	O
5/673	O
(	O
0.7	O
%	O
)	O
,	O
0/111	O
(	O
0	O
%	O
)	O
,	O
and	O
6/674	O
(	O
0.9	O
%	O
)	O
deaths	B
in	O
the	O
groups	O
receiving	O
placebo	O
,	O
BENLYSTA	O
1	O
mg/kg	O
,	O
BENLYSTA	O
4	O
mg/kg	O
,	O
and	O
BENLYSTA	O
10	O
mg/kg	O
,	O
respectively	O
.	O
	
5.3	O
Gastrointestinal-Related	O
Adverse	O
Reactions	O
in	O
Opioid-Tolerant	O
Patients	O
Patients	O
recently	O
exposed	O
to	O
opioids	O
are	O
expected	O
to	O
be	O
more	O
sensitive	O
to	O
the	O
effects	O
of	O
mu-opioid	O
receptor	O
antagonists	O
,	O
such	O
as	O
ENTEREG	O
.	O
	
Asthma-related	O
hospitalizations	O
occurred	O
in	O
10	O
subjects	O
(	O
1	O
%	O
)	O
treated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
compared	O
with	O
7	O
subjects	O
(	O
0.7	O
%	O
)	O
treated	O
with	O
fluticasone	O
furoate	O
100	O
mcg	O
.	O
	
Inform	O
patients	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
,	O
hypersensitivity	O
reactions	O
,	O
and	O
immune-mediated	O
reactions	O
and	O
have	O
them	O
seek	O
immediate	O
medical	O
care	O
should	O
signs	O
and	O
symptoms	O
occur	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
)	O
]	O
.	O
	
*	O
If	O
you	O
take	O
too	O
much	O
DUAVEE	O
,	O
call	O
your	O
healthcare	O
provider	O
.	O
	
The	O
mean	O
age	O
was	O
39	O
years	O
;	O
adolescents	O
(	O
aged	O
12	O
to	O
17	O
years	O
)	O
made	O
up	O
16	O
%	O
of	O
the	O
population	O
.	O
	
In	O
addition	O
to	O
the	O
hypersensitivity	B
reactions	I
reported	O
in	O
clinical	O
trials	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
,	O
the	O
following	O
hypersensitivity	B
reactions	I
have	O
been	O
reported	O
in	O
at	O
least	O
2	O
patients	O
and	O
included	O
:	O
anaphylactic	B
shock	I
,	O
respiratory	B
failure	I
,	O
respiratory	B
arrest	I
,	O
cardiac	B
arrest	I
,	O
hypoxia	B
,	O
dyspnea	B
,	O
wheezing	B
,	O
convulsions	B
,	O
peripheral	B
coldness	I
,	O
restlessness	B
,	O
nervousness	B
,	O
back	B
pain	I
,	O
stridor	B
,	O
pharyngeal	B
edema	I
,	O
abdominal	B
pain	I
,	O
apnea	B
,	O
muscle	B
spasm	I
,	O
and	O
conjunctivitis	B
.	O
	
Do	O
not	O
use	O
if	O
the	O
blister	O
package	O
has	O
been	O
open	O
for	O
more	O
than	O
60	O
days	O
.	O
	
The	O
reactions	O
listed	O
are	O
those	O
that	O
could	O
be	O
of	O
clinical	O
importance	O
,	O
as	O
well	O
as	O
reactions	O
that	O
are	O
plausibly	O
drug-related	O
on	O
pharmacologic	O
or	O
other	O
grounds	O
.	O
	
Risk	O
factors	O
for	O
PML	O
include	O
treatment	O
with	O
immunosuppressant	O
therapies	O
and	O
impairment	O
of	O
immune	O
function	O
.	O
	
Angioedema	B
associated	O
with	O
upper	B
airway	I
swelling	I
may	O
be	O
life-threatening	O
.	O
	
The	O
adverse	O
events	O
observed	O
during	O
long-term	O
,	O
open-label	O
studies	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
12-week	O
,	O
placebo-controlled	O
studies	O
,	O
and	O
included	O
dry	B
mouth	I
,	O
constipation	B
,	O
dry	B
eyes	I
,	O
dyspepsia	B
,	O
and	O
abdominal	B
pain	I
.	O
	
Titration	O
was	O
used	O
over	O
the	O
first	O
5	O
days	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
Across	O
the	O
clinical	O
development	O
program	O
for	O
YERVOY	O
,	O
the	O
following	O
likely	O
immune-mediated	B
adverse	I
reactions	I
were	O
also	O
reported	O
with	O
less	O
than	O
1	O
%	O
incidence	O
:	O
myocarditis	B
,	O
angiopathy	B
,	O
temporal	B
arteritis	I
,	O
vasculitis	B
,	O
polymyalgia	B
rheumatica	I
,	O
conjunctivitis	B
,	O
blepharitis	B
,	O
episcleritis	B
,	O
scleritis	B
,	O
leukocytoclastic	B
vasculitis	I
,	O
erythema	B
multiforme	I
,	O
psoriasis	B
,	O
pancreatitis	B
,	O
arthritis	B
,	O
autoimmune	B
thyroiditis	I
,	O
sarcoidosis	B
,	O
neurosensory	B
hypoacusis	I
,	O
autoimmune	B
central	I
neuropathy	I
(	O
encephalitis	B
)	O
,	O
myositis	B
,	O
polymyositis	B
,	O
and	O
ocular	B
myositis	I
.	O
	
Over	O
the	O
course	O
of	O
a	O
typical	O
10-week	O
controlled	O
trial	O
,	O
the	O
rate	O
of	O
death	B
in	O
drug-treated	O
patients	O
was	O
about	O
4.5	O
%	O
,	O
compared	O
to	O
a	O
rate	O
of	O
about	O
2.6	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
Treatment	O
with	O
STRIBILD	O
should	O
be	O
suspended	O
in	O
any	O
patient	O
who	O
develops	O
clinical	O
or	O
laboratory	O
findings	O
suggestive	O
of	O
lactic	O
acidosis	O
or	O
pronounced	O
hepatotoxicity	O
(	O
which	O
may	O
include	O
hepatomegaly	O
and	O
steatosis	O
even	O
in	O
the	O
absence	O
of	O
marked	O
transaminase	O
elevations	O
)	O
.	O
	
In	O
short-term	O
trials	O
with	O
ENTEREG	O
(	O
r	O
)	O
,	O
no	O
increased	O
risk	O
of	O
myocardial	B
infarction	I
was	O
observed	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Monitor	O
thyroid	O
function	O
tests	O
and	O
clinical	O
chemistries	O
at	O
the	O
start	O
of	O
treatment	O
,	O
before	O
each	O
dose	O
,	O
and	O
as	O
clinically	O
indicated	O
based	O
on	O
symptoms	O
.	O
	
The	O
types	O
of	O
adverse	O
events	O
that	O
led	O
to	O
discontinuation	O
were	O
similar	O
for	O
the	O
FANAPT-	O
and	O
placebo-treated	O
patients	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
discontinuation	O
in	O
GILOTRIF-treated	O
patients	O
were	O
diarrhea	B
(	O
1.3	O
%	O
)	O
,	O
ILD	B
(	O
0.9	O
%	O
)	O
,	O
and	O
paronychia	B
(	O
0.9	O
%	O
)	O
.	O
	
Manifestations	O
included	O
hypotension	B
,	O
angioedema	B
,	O
urticaria	B
or	O
other	O
rash	B
,	O
pruritus	B
,	O
and	O
dyspnea	B
.	O
	
The	O
incidence	O
of	O
adverse	O
events	O
leading	O
to	O
study	O
drug	O
discontinuation	O
for	O
Cleviprex	O
in	O
severe	O
hypertension	O
was	O
4.8	O
%	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
treatment	O
discontinuation	O
in	O
the	O
JEVTANA	O
group	O
were	O
neutropenia	B
and	O
renal	B
failure	I
.	O
	
5.5	O
Posterior	O
Reversible	O
Encephalopathy	O
Syndrome	O
There	O
have	O
been	O
rare	O
cases	O
of	O
posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
reported	O
in	O
patients	O
receiving	O
GILENYA	O
.	O
	
5.4	O
Osteonecrosis	O
of	O
the	O
Jaw	O
Osteonecrosis	O
of	O
the	O
jaw	O
(	O
ONJ	O
)	O
,	O
which	O
can	O
occur	O
spontaneously	O
,	O
is	O
generally	O
associated	O
with	O
tooth	O
extraction	O
and/or	O
local	O
infection	O
with	O
delayed	O
healing	O
.	O
	
5.9	O
Autoimmunity	O
Treatment	O
with	O
CIMZIA	O
may	O
result	O
in	O
the	O
formation	B
of	I
autoantibodies	I
and	O
rarely	O
,	O
in	O
the	O
development	O
of	O
a	O
lupus-like	B
syndrome	I
.	O
	
In	O
open	O
label	O
extension	O
trials	O
in	O
MS	O
patients	O
,	O
the	O
incidence	O
of	O
seizures	B
during	O
treatment	O
with	O
dalfampridine	O
15	O
mg	O
twice	O
daily	O
(	O
1.7/100PY	O
)	O
was	O
over	O
4	O
times	O
higher	O
than	O
the	O
incidence	O
during	O
treatment	O
with	O
10	O
mg	O
twice	O
daily	O
(	O
0.4/100PY	O
)	O
.	O
	
The	O
fatal	B
case	O
of	O
PML	B
was	O
reported	O
in	O
a	O
patient	O
receiving	O
higher	O
than	O
recommended	O
doses	O
of	O
NULOJIX	O
and	O
MMF	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ANAPHYLAXIS	B
WARNING	O
:	O
ANAPHYLAXIS	B
Anaphylaxis	B
has	O
been	O
reported	O
after	O
administration	O
of	O
KALBITOR	O
.	O
	
Major	O
327	O
(	O
2.13	O
)	O
462	O
(	O
3.09	O
)	O
0.69	O
(	O
0.60	O
,	O
0.80	O
)	O
<	O
0.0001	O
Intracranial	O
(	O
ICH	B
)	O
?	O
	
Closely	O
observe	O
patients	O
with	O
G6PD	O
deficiency	O
for	O
signs	O
of	O
hemolytic	O
anemia	O
.	O
	
5.7	O
Liver	O
Injury	O
Elevations	B
of	I
liver	I
enzymes	I
may	O
occur	O
in	O
patients	O
receiving	O
GILENYA	O
.	O
	
periodontal	O
and/or	O
other	O
pre-existing	O
dental	O
disease	O
,	O
anemia	O
,	O
coagulopathy	O
,	O
infection	O
,	O
ill-fitting	O
dentures	O
)	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Division	O
of	O
Nuclear	O
Medicine	O
,	O
Department	O
of	O
Radiology	O
,	O
Mayo	O
Clinic	O
at	O
507-284-2511	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Imaging	O
errors	O
have	O
been	O
reported	O
;	O
blood	O
PSA	O
levels	O
<	O
2	O
ng/mL	O
have	O
been	O
associated	O
with	O
poor	O
imaging	O
performance	O
(	O
5.1	O
)	O
.	O
	
Prior	O
to	O
initiation	O
of	O
therapy	O
with	O
ILARIS	O
,	O
patients	O
should	O
receive	O
all	O
recommended	O
vaccinations	O
.	O
	
Beta-blocker	O
use	O
for	O
this	O
purpose	O
is	O
not	O
recommended	O
.	O
	
Drugs	O
that	O
affect	O
the	O
immune	O
system	O
by	O
blocking	O
TNF	O
have	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
new	O
tuberculosis	O
and	O
reactivation	O
of	O
latent	O
tuberculosis	O
(	O
TB	O
)	O
.	O
	
5.2	O
Monitoring	O
Methotrexate	O
Concentration/Interference	O
with	O
Assay	O
Methotrexate	O
concentrations	O
within	O
48	O
hours	O
following	O
administration	O
of	O
VORAXAZE	O
can	O
only	O
be	O
reliably	O
measured	O
by	O
a	O
chromatographic	O
method	O
.	O
	
Gastrointestinal	O
Adverse	O
Reactions	O
In	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
,	O
gastrointestinal	B
complaints	I
occurred	O
more	O
frequently	O
among	O
patients	O
receiving	O
TANZEUM	O
(	O
39	O
%	O
)	O
than	O
patients	O
receiving	O
placebo	O
(	O
33	O
%	O
)	O
.	O
	
Increased	B
Urination	I
In	O
the	O
pool	O
of	O
five	O
placebo-controlled	O
clinical	O
trials	O
,	O
adverse	O
reactions	O
of	O
increased	B
urination	I
(	O
e.g.	O
,	O
polyuria	B
,	O
pollakiuria	B
,	O
and	O
nocturia	B
)	O
occurred	O
more	O
frequently	O
on	O
JARDIANCE	O
than	O
on	O
placebo	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
Blood	O
Glucose	O
and	O
Lipids	O
Hyperglycemia	B
,	O
hyperlipidemia	B
,	O
and	O
hypertriglyceridemia	B
have	O
been	O
reported	O
in	O
patients	O
taking	O
AFINITOR	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
Patients	O
should	O
be	O
informed	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
and	O
instructed	O
to	O
discontinue	O
AMPYRA	O
and	O
seek	O
immediate	O
medical	O
care	O
should	O
these	O
signs	O
and	O
symptoms	O
occur	O
(	O
17.3	O
)	O
.	O
	
5.6	O
Potential	O
for	O
Tumor	O
Growth	O
Stimulatory	O
Effects	O
on	O
Malignant	O
Cells	O
The	O
granulocyte	O
colony-stimulating	O
factor	O
(	O
G-CSF	O
)	O
receptor	O
through	O
which	O
GRANIX	O
acts	O
has	O
been	O
found	O
on	O
tumor	O
cell	O
lines	O
.	O
	
Twenty-two	O
(	O
6	O
%	O
)	O
patients	O
discontinued	O
JEVTANA	O
treatment	O
due	O
to	O
neutropenia	B
,	O
febrile	B
neutropenia	I
,	O
infection	B
,	O
or	O
sepsis	B
.	O
	
Consider	O
discontinuing	O
Prolia	O
if	O
severe	O
symptoms	O
develop	O
.	O
	
5.2	O
Acute	O
Respiratory	O
Distress	O
Syndrome	O
(	O
ARDS	O
)	O
Acute	B
respiratory	I
distress	I
syndrome	I
(	O
ARDS	B
)	O
can	O
occur	O
in	O
patients	O
receiving	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
.	O
	
Elderly	O
Population	O
:	O
The	O
following	O
grade	O
1-4	O
adverse	O
reactions	O
were	O
reported	O
at	O
rates	O
>	O
=	O
5	O
%	O
higher	O
in	O
patients	O
65	O
years	O
of	O
age	O
or	O
greater	O
compared	O
to	O
younger	O
patients	O
:	O
fatigue	B
(	O
40	O
%	O
vs.	O
30	O
%	O
)	O
,	O
neutropenia	B
(	O
97	O
%	O
vs.	O
89	O
%	O
)	O
,	O
asthenia	B
(	O
24	O
%	O
vs.	O
15	O
%	O
)	O
,	O
pyrexia	B
(	O
15	O
%	O
vs.	O
8	O
%	O
)	O
,	O
dizziness	B
(	O
10	O
%	O
vs.	O
5	O
%	O
)	O
,	O
urinary	B
tract	I
infection	I
(	O
10	O
%	O
vs.	O
3	O
%	O
)	O
and	O
dehydration	B
(	O
7	O
%	O
vs.	O
2	O
%	O
)	O
,	O
respectively	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Clinical	B
Worsening/Suicide	O
Risk	B
:	O
Monitor	O
for	O
clinical	O
worsening	O
and	O
suicide	O
risk	O
(	O
5.1	O
)	O
.	O
	
Because	O
CERDELGA	O
is	O
predicted	O
to	O
cause	O
increases	B
in	I
ECG	I
intervals	I
(	I
PR	I
)	O
at	O
substantially	O
elevated	O
eliglustat	O
plasma	O
concentrations	O
,	O
use	O
of	O
CERDELGA	O
is	O
not	O
recommended	O
in	O
patients	O
with	O
pre-existing	O
cardiac	O
disease	O
(	O
congestive	O
heart	O
failure	O
,	O
recent	O
acute	O
myocardial	O
infarction	O
,	O
bradycardia	O
,	O
heart	O
block	O
,	O
ventricular	O
arrhythmia	O
)	O
,	O
long	O
QT	O
syndrome	O
,	O
and	O
in	O
combination	O
with	O
Class	O
IA	O
(	O
e.g.	O
,	O
quinidine	O
,	O
procainamide	O
)	O
and	O
Class	O
III	O
(	O
e.g.	O
,	O
amiodarone	O
,	O
sotalol	O
)	O
antiarrhythmic	O
medications	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
LABA	O
,	O
such	O
as	O
vilanterol	O
,	O
one	O
of	O
the	O
active	O
ingredients	O
in	O
BREO	O
ELLIPTA	O
,	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
Generally	O
,	O
the	O
observed	O
infections	B
responded	O
to	O
standard	O
therapy	O
.	O
	
Antibody	O
titers	O
were	O
determined	O
using	O
a	O
bridging	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
for	O
anti-glucarpidase	O
antibodies	O
.	O
	
The	O
incidence	O
of	O
urinary	B
tract	I
infections	I
in	O
female	O
patients	O
randomized	O
to	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
was	O
16.6	O
%	O
,	O
18.4	O
%	O
,	O
and	O
17.0	O
%	O
,	O
respectively	O
.	O
	
QT	O
Prolongation	O
:	O
In	O
Trial	O
2	O
,	O
QTcF	B
prolongation	I
to	O
>	O
500	O
msec	O
occurred	O
in	O
4	O
%	O
(	O
2/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
in	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
5.12	O
Potential	O
for	O
Cognitive	O
and	O
Motor	O
Impairment	O
Somnolence	B
was	O
reported	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
The	O
reported	O
endometrial	B
cancer	I
risk	O
among	O
unopposed	O
estrogen	O
users	O
is	O
about	O
2	O
to	O
12	O
times	O
greater	O
than	O
in	O
non-users	O
,	O
and	O
appears	O
dependent	O
on	O
duration	O
of	O
treatment	O
and	O
on	O
estrogen	O
dose	O
.	O
	
Patients	O
experiencing	O
these	O
symptoms	O
should	O
be	O
advised	O
to	O
stop	O
taking	O
STENDRA	O
and	O
seek	O
prompt	O
medical	O
attention	O
.	O
	
5.3	O
Increased	O
Risk	O
of	O
Stroke	O
in	O
Permanent	O
AF	O
In	O
a	O
placebo-controlled	O
study	O
in	O
patients	O
with	O
permanent	O
atrial	O
fibrillation	O
,	O
dronedarone	O
was	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
stroke	B
,	O
particularly	O
in	O
the	O
first	O
two	O
weeks	O
of	O
therapy	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.4	O
)	O
]	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bausch	O
&	O
Lomb	O
Incorporated	O
.	O
	
Ribavirin	O
therapy	O
should	O
not	O
be	O
started	O
unless	O
a	O
report	O
of	O
a	O
negative	O
pregnancy	O
test	O
has	O
been	O
obtained	O
immediately	O
prior	O
to	O
initiation	O
of	O
therapy	O
.	O
	
Delayed	O
reactions	O
can	O
occur	O
up	O
to	O
several	O
days	O
after	O
administration	O
.	O
	
Autoimmune	O
Disorders	O
and	O
Autoantibodies	O
The	O
use	O
of	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
the	O
formation	B
of	I
autoantibodies	I
and	O
,	O
rarely	O
,	O
with	O
the	O
development	O
of	O
a	O
lupus-like	B
syndrome	I
.	O
	
c	O
Includes	O
the	O
following	O
terms	O
:	O
rash	B
,	O
rash	B
generalized	I
,	O
rash	B
pruritic	I
,	O
rash	B
erythematous	I
,	O
rash	B
papular	I
,	O
rash	B
vesicular	I
,	O
rash	B
macular	I
,	O
and	O
rash	B
maculo-papular	I
.	O
	
Prescriptions	O
for	O
SAPHRIS	O
should	O
be	O
written	O
for	O
the	O
smallest	O
quantity	O
of	O
tablets	O
consistent	O
with	O
good	O
patient	O
management	O
in	O
order	O
to	O
reduce	O
the	O
risk	O
of	O
overdose	O
.	O
	
Consideration	O
should	O
be	O
given	O
to	O
the	O
following	O
:	O
*	O
Patients	O
should	O
be	O
stable	O
on	O
alpha-blocker	O
therapy	O
prior	O
to	O
initiating	O
treatment	O
with	O
a	O
PDE5	O
inhibitor	O
.	O
	
In	O
Study	O
3	O
,	O
infusion-related	B
reactions	I
were	O
reported	O
in	O
25	O
patients	O
(	O
15	O
%	O
)	O
in	O
the	O
ADCETRIS-treated	O
arm	O
and	O
3	O
patients	O
(	O
2	O
%	O
)	O
in	O
the	O
placebo	O
arm	O
.	O
	
(	O
5.8	O
,	O
2.3	O
)	O
*	O
Hyperglycemia	B
:	O
Monitor	O
serum	O
glucose	O
levels	O
in	O
patients	O
with	O
pre-existing	O
diabetes	O
or	O
hyperglycemia	O
.	O
	
Seven	O
of	O
the	O
patients	O
treated	O
with	O
PROMACTA	O
in	O
the	O
controlled	O
trials	O
with	O
hepatobiliary	B
laboratory	I
abnormalities	I
were	O
re-exposed	O
to	O
PROMACTA	O
in	O
the	O
extension	O
trial	O
.	O
	
If	O
examination	O
reveals	O
papilledema	O
or	O
retinal	O
vascular	O
lesions	O
,	O
DUAVEE	O
should	O
be	O
permanently	O
discontinued	O
.	O
	
During	O
the	O
four	O
week	O
lead-in	O
period	O
with	O
PegIntron/REBETOL	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
,	O
28/1263	O
(	O
2	O
%	O
)	O
subjects	O
experienced	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
of	O
treatment	O
.	O
	
Periodic	O
skin	O
examinations	O
are	O
recommended	O
for	O
all	O
patients	O
,	O
particularly	O
those	O
with	O
risk	O
factors	O
for	O
skin	O
cancer	O
.	O
	
Psychiatric	O
Disorders	O
:	O
psychotic	B
behavior	I
including	O
aggressive	B
thoughts	I
.	O
	
Increased	O
risk	O
of	O
thrombotic	B
events	I
after	O
premature	O
discontinuation	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
?	O
	
5.3	O
Acute	O
Kidney	O
Injury	O
In	O
patients	O
with	O
chronic	O
renal	O
impairment	O
,	O
acute	B
kidney	I
injury	I
sometimes	O
requiring	O
dialysis	O
has	O
been	O
observed	O
with	O
the	O
use	O
of	O
some	O
GBCAs	O
.	O
	
If	O
such	O
reactions	O
occur	O
,	O
discontinue	O
further	O
administration	O
of	O
CIMZIA	O
and	O
institute	O
appropriate	O
therapy	O
.	O
	
(	O
2.4	O
,	O
5.1	O
)	O
*	O
Cardiovascular	B
Events	I
:	O
A	O
higher	O
rate	O
of	O
cardiovascular	B
thromboembolic	I
events	I
was	O
observed	O
in	O
patients	O
treated	O
with	O
ULORIC	O
than	O
allopurinol	O
in	O
clinical	O
trials	O
.	O
	
*	O
Immune	B
Reconstitution	I
Syndrome	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)	O
]	O
.	O
	
Screening	O
patients	O
for	O
bipolar	O
disorder	O
A	O
major	O
depressive	O
episode	O
may	O
be	O
the	O
initial	O
presentation	O
of	O
bipolar	O
disorder	O
.	O
	
(	O
14.4	O
)	O
.	O
	
The	O
median	O
time	O
to	O
first	O
onset	O
of	O
any	O
grade	O
was	O
14	O
weeks	O
(	O
range	O
,	O
0.1-47	O
)	O
,	O
of	O
Grade	O
2	O
was	O
27	O
weeks	O
(	O
range	O
,	O
0.4-52	O
)	O
and	O
of	O
Grade	O
3	O
was	O
34	O
weeks	O
(	O
range	O
,	O
7-106	O
)	O
.	O
	
5.7	O
Alcohol	O
Patients	O
should	O
be	O
made	O
aware	O
that	O
both	O
alcohol	O
and	O
PDE5	O
inhibitors	O
including	O
STENDRA	O
act	O
as	O
vasodilators	O
.	O
	
(	O
5.2	O
)	O
*	O
QT	O
prolonging	O
drugs	O
,	O
including	O
quinine	O
and	O
quinidine	O
,	O
should	O
be	O
used	O
cautiously	O
following	O
Coartem	O
Tablets	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
-	O
Anemia	B
,	O
Eosinophilia	B
,	O
Neutropenia	B
,	O
Thrombocytopenia	B
Cardiac	O
disorders	O
-	O
Bradycardia	B
,	O
Palpitations	B
Gastrointestinal	O
disorders	O
-	O
Abdominal	B
pain	I
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
-	O
Pyrexia	B
Hepatobiliary	O
disorders	O
-	O
Hepatitis	B
Immune	O
system	O
disorders	O
-	O
Hypersensitivity	B
,	O
Anaphylaxis	B
Infections	O
and	O
infestations	O
-	O
Clostridium	B
difficile	I
colitis	I
Metabolism	O
and	O
nutrition	O
disorders	O
-	O
Hyperglycemia	B
,	O
Hyperkalemia	B
Nervous	O
system	O
disorders	O
-	O
Dizziness	B
,	O
Convulsion	B
Renal	O
and	O
urinary	O
disorders	O
-	O
Renal	B
failure	I
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
-	O
Urticaria	B
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reaction	O
has	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
Teflaro	O
.	O
	
5.4	O
Risk	O
of	O
Cardiac	O
Arrhythmia	O
and	O
Sudden	O
Cardiac	O
Death	O
During	O
General	O
Anesthesia	O
for	O
Central	O
Venous	O
Catheter	O
Placement	O
Administration	O
of	O
general	O
anesthesia	O
can	O
be	O
complicated	O
by	O
the	O
presence	O
of	O
severe	O
cardiac	O
and	O
skeletal	O
(	O
including	O
respiratory	O
)	O
muscle	O
weakness	O
.	O
	
(	O
4	O
,	O
5.1	O
)	O
In	O
patients	O
with	O
permanent	O
atrial	O
fibrillation	O
,	O
MULTAQ	O
doubles	O
the	O
risk	O
of	O
death	B
,	O
stroke	B
and	O
hospitalization	O
for	O
heart	B
failure	I
.	O
	
*	O
Bone	B
Effects	I
of	O
Tenofovir	O
DF	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Prophylactic	O
therapy	O
(	O
i.e.	O
,	O
non-steroidal	O
anti-inflammatory	O
drug	O
[	O
NSAID	O
]	O
or	O
colchicine	O
upon	O
initiation	O
of	O
treatment	O
)	O
may	O
be	O
beneficial	O
for	O
up	O
to	O
six	O
months	O
.	O
	
Some	O
of	O
these	O
reactions	O
occurred	O
after	O
the	O
first	O
administration	O
of	O
CIMZIA	O
.	O
	
The	O
risk	O
of	O
acute	B
kidney	I
injury	I
might	O
be	O
lower	O
with	O
EOVIST	O
due	O
to	O
its	O
dual	O
excretory	O
pathways	O
.	O
	
*	O
?	O
	
Acute	B
cardiorespiratory	I
failure	I
has	O
been	O
observed	O
in	O
infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
underlying	O
cardiac	O
hypertrophy	O
,	O
possibly	O
associated	O
with	O
fluid	B
overload	I
with	O
intravenous	O
administration	O
of	O
alglucosidase	O
alfa	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Adverse	O
Reactions	O
Pooled	O
Phase	O
3	O
Clinical	O
Trials	O
(	O
four	O
trials	O
,	O
two	O
in	O
ABSSSI	O
and	O
two	O
in	O
CABP	O
)	O
Teflaro	O
(	O
N=1300	O
)	O
Pooled	O
Comparators	O
a	O
(	O
N=1297	O
)	O
Gastrointestinal	O
Disorders	O
Diarrhea	B
5	O
%	O
3	O
%	O
Nausea	B
4	O
%	O
4	O
%	O
Constipation	B
2	O
%	O
2	O
%	O
Vomiting	B
2	O
%	O
2	O
%	O
Laboratory	O
Investigations	O
Increased	B
transaminases	I
2	O
%	O
3	O
%	O
Metabolism	O
and	O
Nutrition	O
disorders	O
Hypokalemia	B
2	O
%	O
3	O
%	O
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
Rash	B
3	O
%	O
2	O
%	O
Vascular	O
Disorders	O
Phlebitis	B
2	O
%	O
1	O
%	O
Other	O
Adverse	O
Reactions	O
Observed	O
During	O
Clinical	O
Trials	O
of	O
Teflaro	O
Following	O
is	O
a	O
list	O
of	O
additional	O
adverse	O
reactions	O
reported	O
by	O
the	O
1740	O
patients	O
who	O
received	O
Teflaro	O
in	O
any	O
clinical	O
trial	O
with	O
incidences	O
less	O
than	O
2	O
%	O
.	O
	
(	O
5.1,5.2,12.3	O
)	O
*	O
Antimalarials	O
should	O
not	O
be	O
given	O
concomitantly	O
,	O
unless	O
there	O
is	O
no	O
other	O
treatment	O
option	O
,	O
due	O
to	O
limited	O
safety	O
data	O
.	O
	
The	O
effect	O
of	O
treatment	O
with	O
DUAVEE	O
on	O
the	O
risk	O
of	O
breast	O
cancer	O
is	O
unknown	O
.	O
	
Eleven	O
patients	O
(	O
26	O
%	O
)	O
were	O
treated	O
for	O
greater	O
than	O
6	O
months	O
and	O
7	O
patients	O
(	O
16	O
%	O
)	O
were	O
treated	O
for	O
greater	O
than	O
1	O
year	O
.	O
	
In	O
Study	O
3	O
,	O
67	O
%	O
of	O
patients	O
treated	O
with	O
ADCETRIS	O
experienced	O
any	O
grade	O
of	O
neuropathy	B
.	O
	
5.7	O
Elevated	O
Blood	O
Pressure	O
In	O
a	O
small	O
number	O
of	O
case	O
reports	O
in	O
women	O
receiving	O
estrogens	O
,	O
substantial	O
increases	B
in	I
blood	I
pressure	I
have	O
been	O
attributed	O
to	O
idiosyncratic	O
reactions	O
to	O
estrogens	O
.	O
	
Discontinue	O
for	O
intolerable	O
Grade	O
2	O
,	O
or	O
Grade	O
3	O
or	O
4	O
rash	O
not	O
improving	O
within	O
3	O
weeks	O
despite	O
interruption	O
of	O
TAFINLAR	O
.	O
	
In	O
Studies	O
1	O
and	O
2	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
associated	O
with	O
infusion-related	B
reactions	I
were	O
chills	B
(	O
4	O
%	O
)	O
,	O
nausea	B
(	O
3	O
%	O
)	O
,	O
dyspnea	B
(	O
3	O
%	O
)	O
,	O
pruritus	B
(	O
3	O
%	O
)	O
,	O
pyrexia	B
(	O
2	O
%	O
)	O
,	O
and	O
cough	B
(	O
2	O
%	O
)	O
.	O
	
Systemic	B
immune-mediated	I
reactions	I
,	O
including	O
possible	O
type	B
III	I
immune-mediated	I
reactions	I
have	O
been	O
observed	O
with	O
alglucosidase	O
alfa	O
.	O
	
In	O
some	O
patients	O
,	O
concomitant	O
use	O
of	O
these	O
two	O
drug	O
classes	O
can	O
lower	O
blood	O
pressure	O
significantly	O
leading	O
to	O
symptomatic	B
hypotension	I
(	O
e.g.	O
,	O
dizziness	B
,	O
lightheadedness	B
,	O
fainting	B
)	O
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
rhabdomyolysis	B
.	O
	
Even	O
in	O
the	O
absence	O
of	O
TNF-blocker	O
therapy	O
,	O
patients	O
with	O
RA	O
may	O
be	O
at	O
a	O
higher	O
risk	O
(	O
approximately	O
2-fold	O
)	O
than	O
the	O
general	O
population	O
for	O
the	O
development	O
of	O
leukemia	O
.	O
	
These	O
patients	O
may	O
have	O
an	O
increased	O
risk	O
for	O
a	O
hypersensitivity	B
reaction	I
to	O
EOVIST	O
.	O
	
5.2	O
Serotonin	O
Syndrome	O
The	O
development	O
of	O
a	O
potentially	O
life-threatening	O
serotonin	B
syndrome	I
has	O
been	O
reported	O
with	O
SNRIs	O
and	O
SSRIs	O
,	O
including	O
PRISTIQ	O
,	O
alone	O
but	O
particularly	O
with	O
concomitant	O
use	O
of	O
other	O
serotonergic	O
drugs	O
(	O
including	O
triptans	O
,	O
tricyclic	O
antidepressants	O
,	O
fentanyl	O
,	O
lithium	O
,	O
tramadol	O
,	O
tryptophan	O
,	O
buspirone	O
,	O
and	O
St.	O
John	O
's	O
Wort	O
)	O
,	O
and	O
with	O
drugs	O
that	O
impair	O
metabolism	O
of	O
serotonin	O
(	O
in	O
particular	O
,	O
MAOIs	O
,	O
both	O
those	O
intended	O
to	O
treat	O
psychiatric	O
disorders	O
and	O
also	O
others	O
,	O
such	O
as	O
linezolid	O
and	O
intravenous	O
methylene	O
blue	O
)	O
.	O
	
During	O
the	O
entire	O
course	O
of	O
treatment	O
,	O
the	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
was	O
13	O
%	O
for	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
and	O
12	O
%	O
for	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
Most	O
hypersensitivity	O
reactions	O
to	O
Gadavist	O
have	O
occurred	O
within	O
half	O
an	O
hour	O
after	O
administration	O
.	O
	
In	O
patients	O
with	O
permanent	O
AF	O
,	O
MULTAQ	O
doubles	O
the	O
risk	O
of	O
death	B
,	O
stroke	B
,	O
and	O
hospitalization	O
for	O
heart	B
failure	I
.	O
	
Observe	O
for	O
hypersensitivity	O
signs	O
and	O
symptoms	O
following	O
Vizamyl	O
administration	O
.	O
	
Experience	O
in	O
Systemic	O
Anaplastic	O
Large	O
Cell	O
Lymphoma	O
Summary	O
of	O
Clinical	O
Trial	O
Experience	O
in	O
Relapsed	O
sALCL	O
(	O
Study	O
2	O
)	O
ADCETRIS	O
was	O
studied	O
in	O
58	O
patients	O
with	O
sALCL	O
in	O
a	O
single	O
arm	O
clinical	O
trial	O
in	O
which	O
the	O
recommended	O
starting	O
dose	O
and	O
schedule	O
was	O
1.8	O
mg/kg	O
intravenously	O
every	O
3	O
weeks	O
.	O
	
At	O
Week	O
20	O
in	O
Trial	O
1	O
,	O
17	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
13	O
%	O
of	O
control	O
patients	O
were	O
newly	B
ANA-positive	I
(	O
at	O
titers	O
of	O
1:160	O
or	O
greater	O
)	O
.	O
	
It	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
these	O
events	O
are	O
related	O
directly	O
to	O
the	O
use	O
of	O
PDE5	O
inhibitors	O
or	O
to	O
other	O
factors	O
[	O
seeAdverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Most	O
studies	O
show	O
no	O
significant	O
increased	O
risk	O
associated	O
with	O
use	O
of	O
estrogens	O
for	O
less	O
than	O
1	O
year	O
.	O
	
Extravasation	O
into	O
tissues	O
during	O
Gadavist	O
administration	B
may	I
result	I
in	I
moderate	I
irritation	I
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.2	O
)	O
]	O
.	O
	
MULTAQ	O
offers	O
no	O
benefit	O
in	O
subjects	O
in	O
permanent	O
AF	O
.	O
	
5.2	O
ECG	O
Changes	O
and	O
Potential	O
for	O
Cardiac	O
Arrhythmias	O
Use	O
of	O
CERDELGA	O
in	O
patients	O
with	O
pre-existing	O
cardiac	O
conditions	O
has	O
not	O
been	O
studied	O
during	O
clinical	O
trials	O
.	O
	
For	O
pediatric	O
patients	O
with	O
SEGA	O
that	O
do	O
not	O
require	O
immediate	O
treatment	O
,	O
complete	O
the	O
recommended	O
childhood	O
series	O
of	O
live	O
virus	O
vaccinations	O
according	O
to	O
American	O
Council	O
on	O
Immunization	O
Practices	O
(	O
ACIP	O
)	O
guidelines	O
prior	O
to	O
the	O
start	O
of	O
therapy	O
.	O
	
*	O
Serotonin	B
Syndrome	I
:	O
Serotonin	B
syndrome	I
has	O
been	O
reported	O
with	O
SSRIs	O
and	O
SNRIs	O
,	O
including	O
with	O
PRISTIQ	O
,	O
both	O
when	O
taken	O
alone	O
,	O
but	O
especially	O
when	O
co-administered	O
with	O
other	O
serotonergic	O
agents	O
(	O
including	O
triptans	O
,	O
tricyclic	O
antidepressants	O
,	O
fentanyl	O
,	O
lithium	O
,	O
tramadol	O
,	O
tryptophan	O
,	O
buspirone	O
,	O
and	O
St.	O
John	O
's	O
Wort	O
)	O
.	O
	
Hepatic	O
Laboratory	O
Abnormalities	O
:	O
The	O
incidences	O
of	O
grade	O
3-4	O
increased	B
AST	I
,	O
increased	B
ALT	I
,	O
and	O
increased	B
bilirubin	I
were	O
each	O
<	O
=	O
1	O
%	O
.	O
	
In	O
patients	O
who	O
report	O
upper	O
abdominal	O
or	O
shoulder	O
pain	O
after	O
receiving	O
GRANIX	O
,	O
discontinue	O
GRANIX	O
and	O
evaluate	O
for	O
an	O
enlarged	O
spleen	O
or	O
splenic	O
rupture	O
.	O
	
Urinary	B
tract	I
infections	I
occurred	O
more	O
frequently	O
in	O
female	O
patients	O
.	O
	
Neutralizing	O
antibodies	O
were	O
detected	O
in	O
11	O
of	O
the	O
25	O
patients	O
who	O
tested	O
positive	O
for	O
anti-glucarpidase	O
binding	O
antibodies	O
.	O
	
Infections	B
,	O
in	O
some	O
instances	O
serious	O
,	O
have	O
been	O
reported	O
with	O
ILARIS	O
.	O
	
JARDIANCE	O
may	O
increase	O
the	O
risk	O
of	O
hypotension	B
in	O
patients	O
at	O
risk	O
for	O
volume	O
contraction	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
,	O
8.6	O
)	O
]	O
.	O
	
DAMPA	O
(	O
4-deoxy-4-amino-N	O
10	O
-methylpteroic	O
acid	O
)	O
is	O
an	O
inactive	O
metabolite	O
of	O
methotrexate	O
resulting	O
from	O
treatment	O
with	O
VORAXAZE	O
.	O
	
In	O
addition	O
to	O
diarrhea	B
and	O
nausea	B
(	O
see	O
Table	O
1	O
)	O
,	O
the	O
following	O
gastrointestinal	B
adverse	I
reactions	I
also	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
TANZEUM	O
:	O
vomiting	B
(	O
2.6	O
%	O
versus	O
4.2	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
gastroesophageal	B
reflux	I
disease	I
(	O
1.9	O
%	O
versus	O
3.5	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
and	O
dyspepsia	B
(	O
2.8	O
%	O
versus	O
3.4	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
.	O
	
Coadministration	O
of	O
ILARIS	O
with	O
TNF	O
inhibitors	O
is	O
not	O
recommended	O
because	O
this	O
may	O
increase	O
the	O
risk	O
of	O
serious	O
infections	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Caution	O
patients	O
about	O
risk	O
of	O
bleeding	O
associated	O
with	O
concomitant	O
use	O
of	O
PRISTIQ	O
and	O
NSAIDs	O
,	O
aspirin	O
,	O
or	O
other	O
drugs	O
that	O
affect	O
coagulation	O
(	O
5.4	O
)	O
.	O
	
Most	O
of	O
these	O
events	O
were	O
not	O
specific	O
to	O
the	O
injection	O
site	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Patients	O
who	O
develop	O
symptoms	O
of	O
capillary	O
leak	O
syndrome	O
should	O
be	O
closely	O
monitored	O
and	O
receive	O
standard	O
symptomatic	O
treatment	O
,	O
which	O
may	O
include	O
a	O
need	O
for	O
intensive	O
care	O
.	O
	
Prophylaxis	O
for	O
Pneumocystis	O
jiroveci	O
is	O
recommended	O
after	O
transplantation	O
.	O
	
Signs	O
and	O
symptoms	O
have	O
included	O
respiratory	B
compromise	I
,	O
urticaria	B
,	O
and	O
angioedema	B
of	I
the	I
throat	I
.	O
	
Monitoring	O
of	O
fasting	O
serum	O
glucose	O
and	O
lipid	O
profile	O
is	O
recommended	O
prior	O
to	O
the	O
start	O
of	O
AFINITOR	O
therapy	O
and	O
periodically	O
thereafter	O
as	O
well	O
as	O
management	O
with	O
appropriate	O
medical	O
therapy	O
.	O
	
chemotherapy	O
,	O
corticosteroids	O
,	O
angiogenesis	O
inhibitors	O
)	O
,	O
poor	O
oral	O
hygiene	O
,	O
and	O
co-morbid	O
disorders	O
(	O
e.g	O
.	O
	
5.11	O
Embryofetal	O
Toxicity	O
Based	O
on	O
its	O
mechanism	O
of	O
action	O
,	O
TAFINLAR	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
**	O
Fatal	B
bleeding	B
is	O
an	O
adjudicated	O
death	B
with	O
the	O
primary	O
cause	O
of	O
death	B
as	O
intracranial	B
bleeding	I
or	O
non-intracranial	B
bleeding	I
during	O
the	O
on-treatment	O
period	O
.	O
	
The	O
two	O
cases	O
of	O
PTLD	B
were	O
reported	O
among	O
the	O
140	O
EBV	O
seropositive	O
patients	O
(	O
1.4	O
%	O
)	O
.	O
	
There	O
is	O
limited	O
experience	O
with	O
short-duration	O
therapy	O
with	O
beta-blockers	O
as	O
a	O
treatment	O
for	O
Cleviprex-induced	O
tachycardia	O
.	O
	
(	O
5.1	O
)	O
*	O
Live	O
vaccines	O
should	O
not	O
be	O
given	O
concurrently	O
with	O
ILARIS	O
.	O
	
In	O
Trial	O
2	O
,	O
the	O
incidence	O
of	O
basal	B
cell	I
carcinoma	I
was	O
increased	O
in	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
:	O
9	O
%	O
(	O
5/55	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
5.3	O
Hemorrhage	O
Hemorrhages	B
,	O
including	O
major	O
hemorrhages	B
defined	O
as	O
symptomatic	B
bleeding	I
in	O
a	O
critical	O
area	O
or	O
organ	O
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
common	O
adverse	O
reactions	O
for	O
Cleviprex	O
in	O
severe	O
hypertension	O
included	O
headache	B
(	O
6.3	O
%	O
)	O
,	O
nausea	B
(	O
4.8	O
%	O
)	O
,	O
and	O
vomiting	B
(	O
3.2	O
%	O
)	O
.	O
	
Includes	O
13	O
subjects	O
with	O
major	O
bleeding	B
events	O
that	O
occurred	O
before	O
the	O
first	O
dose	O
of	O
apixaban	O
(	O
administered	O
12	O
to	O
24	O
hours	O
post	O
surgery	O
)	O
.	O
	
Increased	O
incidence	O
of	O
seizures	B
has	O
been	O
observed	O
at	O
20	O
mg	O
twice	O
daily	O
in	O
controlled	O
clinical	O
studies	O
of	O
9-14	O
weeks	O
duration	O
with	O
dalfampridine	O
in	O
patients	O
with	O
MS	O
.	O
	
If	O
a	O
patient	O
develops	O
symptoms	O
suggestive	O
of	O
a	O
lupus-like	O
syndrome	O
following	O
treatment	O
with	O
CIMZIA	O
,	O
discontinue	O
treatment	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Adequately	O
supplement	O
all	O
patients	O
with	O
calcium	O
and	O
vitamin	O
D	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
,	O
Contraindications	O
(	O
4.1	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
,	O
and	O
Patient	O
Counseling	O
Information	O
(	O
17.3	O
)	O
]	O
.	O
	
In	O
addition	O
to	O
the	O
examination	O
of	O
the	O
fundus	O
including	O
the	O
macula	O
prior	O
to	O
treatment	O
and	O
at	O
3-4	O
months	O
after	O
starting	O
treatment	O
,	O
MS	O
patients	O
with	O
diabetes	O
mellitus	O
or	O
a	O
history	O
of	O
uveitis	O
should	O
have	O
regular	O
follow-up	O
examinations	O
.	O
	
Treatment	O
discontinuations	O
due	O
to	O
adverse	O
drug	O
reactions	O
occurred	O
in	O
18	O
%	O
of	O
patients	O
who	O
received	O
JEVTANA	O
and	O
8	O
%	O
of	O
patients	O
who	O
received	O
mitoxantrone	O
.	O
	
Demographic	O
Differences	O
in	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
An	O
examination	O
of	O
population	O
subgroups	O
in	O
the	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
did	O
not	O
reveal	O
any	O
evidence	O
of	O
differences	O
in	O
safety	O
on	O
the	O
basis	O
of	O
age	O
,	O
gender	O
or	O
race	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
In	O
a	O
limited	O
number	O
of	O
patients	O
,	O
hypophysitis	B
was	O
diagnosed	O
by	O
imaging	O
studies	O
through	O
enlargement	O
of	O
the	O
pituitary	O
gland	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
POTENTIAL	O
RISK	O
OF	O
MYOCARDIAL	B
INFARCTION	I
WITH	O
LONG-TERM	O
USE	O
:	O
FOR	O
SHORT-TERM	O
HOSPITAL	O
USE	O
ONLY	O
WARNING	O
:	O
POTENTIAL	O
RISK	O
OF	O
MYOCARDIAL	B
INFARCTION	I
WITH	O
LONG-TERM	O
USE	O
:	O
FOR	O
SHORT-TERM	O
HOSPITAL	O
USE	O
ONLY	O
There	O
was	O
a	O
greater	O
incidence	O
of	O
myocardial	B
infarction	I
in	O
alvimopan-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients	O
in	O
a	O
12-month	O
clinical	O
trial	O
,	O
although	O
a	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
.	O
	
In	O
addition	O
,	O
Grade	O
1	O
insomnia	B
was	O
reported	O
by	O
1	O
%	O
and	O
less	O
than	O
1	O
%	O
of	O
subjects	O
receiving	O
TIVICAY	O
and	O
raltegravir	O
,	O
respectively	O
,	O
in	O
SPRING-2	O
;	O
whereas	O
in	O
SINGLE	O
the	O
rates	O
were	O
7	O
%	O
and	O
4	O
%	O
for	O
TIVICAY	O
and	O
ATRIPLA	O
,	O
respectively	O
.	O
	
Due	O
to	O
overlap	O
in	O
signs	O
and	O
symptoms	O
,	O
it	O
was	O
not	O
possible	O
to	O
distinguish	O
between	O
hypersensitivity	B
reactions	I
and	O
infusion	B
reactions	I
in	O
all	O
cases	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Clinical	O
trials	O
of	O
GILOTRIF	O
excluded	O
patients	O
with	O
an	O
abnormal	O
left	O
ventricular	O
ejection	O
fraction	O
(	O
LVEF	O
)	O
,	O
i.e.	O
,	O
below	O
the	O
institutional	O
lower	O
limit	O
of	O
normal	O
.	O
	
Placebo	O
patients	O
whose	O
tender	O
and	O
swollen	O
joint	O
counts	O
had	O
not	O
improved	O
by	O
at	O
least	O
20	O
%	O
were	O
re-randomized	O
1:1	O
in	O
a	O
blinded	O
fashion	O
to	O
either	O
OTEZLA	O
20	O
mg	O
twice	O
daily	O
or	O
30	O
mg	O
twice	O
daily	O
at	O
week	O
16	O
while	O
OTEZLA	O
patients	O
remained	O
on	O
their	O
initial	O
treatment	O
.	O
	
The	O
most	O
common	O
Grade	O
3/4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
2	O
%	O
)	O
were	O
stomatitis	B
,	O
infections	B
,	O
hyperglycemia	B
,	O
fatigue	B
,	O
dyspnea	B
,	O
pneumonitis	B
,	O
and	O
diarrhea	B
.	O
	
Particular	O
caution	O
should	O
be	O
exercised	O
when	O
administering	O
nucleoside	O
analogs	O
to	O
any	O
patient	O
with	O
known	O
risk	O
factors	O
for	O
liver	O
disease	O
;	O
however	O
,	O
cases	O
have	O
also	O
been	O
reported	O
in	O
patients	O
with	O
no	O
known	O
risk	O
factors	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
for	O
clinically	O
significant	O
or	O
severe	O
immune-mediated	O
adverse	O
reactions	O
.	O
	
*	O
Take	O
DUAVEE	O
exactly	O
as	O
your	O
healthcare	O
provider	O
tells	O
you	O
to	O
take	O
it	O
.	O
	
In	O
addition	O
,	O
one	O
case	O
of	O
hyperparathyroidism	B
has	O
been	O
reported	O
.	O
	
Overall	O
,	O
63	O
%	O
were	O
female	O
and	O
67	O
%	O
were	O
white	O
.	O
	
In	O
some	O
cases	O
angioedema	O
occurred	O
after	O
the	O
first	O
dose	O
.	O
	
Consider	O
the	O
diagnosis	O
of	O
PML	O
in	O
any	O
patient	O
presenting	O
with	O
new-onset	O
or	O
deteriorating	O
neurological	O
signs	O
and	O
symptoms	O
and	O
consult	O
with	O
a	O
neurologist	O
or	O
other	O
appropriate	O
specialist	O
as	O
clinically	O
indicated	O
.	O
	
Reactions	O
already	O
listed	O
for	O
either	O
adults	O
or	O
pediatric	O
patients	O
in	O
other	O
parts	O
of	O
Adverse	O
Reactions	O
(	O
6	O
)	O
,	O
or	O
those	O
considered	O
in	O
Contraindications	O
(	O
4	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
or	O
Overdosage	O
(	O
10	O
)	O
are	O
not	O
included	O
.	O
	
Withhold	O
GILOTRIF	O
for	O
severe	O
and	O
prolonged	O
diarrhea	O
not	O
responsive	O
to	O
anti-diarrheal	O
agents	O
.	O
	
No	O
single	O
cause	O
of	O
death	B
predominated	O
.	O
	
Discontinue	O
GILOTRIF	O
if	O
ILD	O
is	O
diagnosed	O
.	O
	
(	O
5.1	O
)	O
.	O
	
Infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
compromised	O
cardiac	O
or	O
respiratory	O
function	O
may	O
be	O
at	O
risk	O
of	O
serious	O
acute	B
exacerbation	I
of	I
their	I
cardiac	I
or	I
respiratory	I
compromise	I
due	O
to	O
fluid	B
overload	I
,	O
and	O
require	O
additional	O
monitoring	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
While	O
subjects	O
aged	O
12	O
to	O
17	O
years	O
were	O
included	O
in	O
this	O
trial	O
,	O
BREO	O
ELLIPTA	O
is	O
not	O
approved	O
for	O
use	O
in	O
this	O
age-group	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
]	O
.	O
	
Further	O
information	O
is	O
available	O
at	O
www.ENTEREGREMS.com	O
or	O
1-800-278-0340	O
.	O
	
Extreme	O
care	O
should	O
be	O
exercised	O
,	O
with	O
appropriate	O
resuscitation	O
measures	O
available	O
,	O
if	O
the	O
decision	O
is	O
made	O
to	O
re-administer	O
the	O
product	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
5.3	O
Acute	O
Kidney	O
Injury	O
In	O
patients	O
with	O
chronically	O
reduced	O
renal	O
function	O
,	O
acute	B
kidney	I
injury	I
requiring	O
dialysis	O
has	O
occurred	O
with	O
the	O
use	O
of	O
GBCAs	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=	O
1	O
%	O
of	O
GILENYA-treated	O
patients	O
and	O
>	O
=	O
1	O
%	O
higher	O
rate	O
than	O
for	O
placebo	O
.	O
	
The	O
proportion	O
of	O
pediatric	O
patients	O
with	O
ALT	B
elevations	I
>	O
=3	O
times	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
was	O
2.4	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
versus	O
none	O
for	O
the	O
other	O
SAPHRIS	O
dose	O
groups	O
and	O
placebo-treated	O
patients	O
.	O
	
Serum	O
creatinine	O
Small	O
reversible	O
increases	B
in	I
serum	I
creatinine	I
are	O
seen	O
in	O
patients	O
receiving	O
80	O
mg	O
of	O
Edarbi	O
.	O
	
*	O
Classical	O
HL	O
post-auto-HSCT	O
consolidation	O
:	O
neutropenia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
thrombocytopenia	B
,	O
anemia	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
fatigue	B
,	O
peripheral	B
motor	I
neuropathy	I
,	O
nausea	B
,	O
cough	B
,	O
and	O
diarrhea	B
(	O
6.1	O
)	O
.	O
	
Table	O
8	O
:	O
Grade	O
3-4	O
Laboratory	O
Abnormalities	O
(	O
>	O
10	O
%	O
)	O
(	O
Monotherapy	O
)	O
Adverse	O
Reaction	O
Kyprolis	O
(	O
N	O
=	O
598	O
)	O
Decreased	B
Platelets	I
184	O
(	O
31	O
%	O
)	O
Decreased	B
Lymphocytes	I
151	O
(	O
25	O
%	O
)	O
Decreased	B
Hemoglobin	I
132	O
(	O
22	O
%	O
)	O
Decreased	B
Total	I
White	I
Blood	I
Cell	I
Count	I
71	O
(	O
12	O
%	O
)	O
Decreased	B
Sodium	I
69	O
(	O
12	O
%	O
)	O
Decreased	B
Absolute	I
Neutrophil	I
Count	I
67	O
(	O
11	O
%	O
)	O
6.2	O
Post-marketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
were	O
reported	O
in	O
the	O
post-marketing	O
experience	O
with	O
Kyprolis	O
.	O
	
The	O
use	O
of	O
clinical	O
information	O
in	O
the	O
interpretation	O
of	O
Amyvid	O
images	O
has	O
not	O
been	O
evaluated	O
and	O
may	O
lead	O
to	O
errors	O
.	O
	
(	O
5.2	O
)	O
*	O
Do	O
not	O
use	O
in	O
combination	O
with	O
an	O
additional	O
medicine	O
containing	O
a	O
LABA	O
because	O
of	O
risk	O
of	O
overdose	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
of	O
CIMZIA	O
were	O
tuberculosis	B
infections	I
(	O
0.5	O
%	O
)	O
;	O
and	O
pyrexia	B
,	O
urticaria	B
,	O
pneumonia	B
,	O
and	O
rash	B
(	O
0.3	O
%	O
)	O
.	O
	
In	O
some	O
women	O
,	O
the	O
symptoms	O
are	O
mild	O
,	O
and	O
they	O
will	O
not	O
need	O
to	O
take	O
medicines	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
events	O
reported	O
in	O
the	O
KRd	O
arm	O
as	O
compared	O
with	O
the	O
Rd	O
arm	O
were	O
pneumonia	B
(	O
14	O
%	O
versus	O
11	O
%	O
)	O
,	O
respiratory	B
tract	I
infection	I
(	O
4	O
%	O
versus	O
1.5	O
%	O
)	O
,	O
pyrexia	B
(	O
4	O
%	O
versus	O
2	O
%	O
)	O
,	O
and	O
pulmonary	B
embolism	I
(	O
3	O
%	O
versus	O
2	O
%	O
)	O
.	O
	
Glabellar	O
Lines	O
In	O
placebo-controlled	O
clinical	O
trials	O
of	O
DYSPORT	O
(	O
r	O
)	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
following	O
injection	O
of	O
DYSPORT	O
(	O
r	O
)	O
were	O
nasopharyngitis	B
,	O
headache	B
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
reaction	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
sinusitis	B
,	O
and	O
nausea	B
.	O
	
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
venous	B
thromboembolic	I
events	I
were	O
reported	O
in	O
11/359	O
patients	O
(	O
3	O
%	O
)	O
receiving	O
INLYTA	O
and	O
2/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Table	O
10	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
2	O
%	O
or	O
More	O
of	O
Pediatric	O
Patients	O
(	O
Ages	O
10	O
to	O
17	O
Years	O
)	O
in	O
Any	O
SAPHRIS	O
Dose	O
Group	O
and	O
Which	O
Occurred	O
at	O
Greater	O
Incidence	O
Than	O
in	O
the	O
Placebo	O
Group	O
in	O
a	O
3-Week	O
Bipolar	O
Mania	O
Trial	O
1Includes	O
the	O
preferred	O
terms	O
tachycardia	B
and	O
heart	B
rate	I
increased	I
.	O
	
Hypertension	B
led	O
to	O
study	O
discontinuation	O
in	O
<	O
1	O
%	O
of	O
patients	O
in	O
each	O
arm	O
.	O
	
Among	O
the	O
factors	O
that	O
may	O
increase	O
the	O
risk	O
for	O
NSF	O
are	O
repeated	O
or	O
higher	O
than	O
recommended	O
doses	O
of	O
a	O
GBCA	O
and	O
the	O
degree	O
of	O
renal	O
impairment	O
at	O
the	O
time	O
of	O
exposure	O
.	O
	
See	O
Table	O
6	O
for	O
steps	O
to	O
prevent	O
or	O
manage	O
these	O
possible	O
and	O
known	O
significant	O
drug	O
interactions	O
,	O
including	O
dosing	O
recommendations	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.5	O
)	O
]	O
.	O
	
(	O
5.5	O
)	O
*	O
Potential	O
worsening	B
of	I
infections	I
)	O
.	O
	
If	O
you	O
have	O
or	O
have	O
had	O
cancer	O
,	O
talk	O
with	O
your	O
healthcare	O
provider	O
about	O
whether	O
you	O
should	O
use	O
DUAVEE	O
.	O
	
A	O
dose	O
decrease	O
is	O
recommended	O
when	O
administering	O
INLYTA	O
to	O
patients	O
with	O
moderate	O
hepatic	O
impairment	O
(	O
Child-Pugh	O
class	O
B	O
)	O
.	O
	
Dermatologic	O
Reactions	O
dermal	B
adverse	I
events	I
(	O
such	O
as	O
dermatitis	B
,	O
eczema	B
,	O
and	O
rashes	B
)	O
were	O
reported	O
in	O
4	O
patients	O
(	O
3.3	O
%	O
)	O
in	O
the	O
placebo	O
group	O
and	O
5	O
patients	O
(	O
4.2	O
%	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
The	O
clinical	O
significance	O
of	O
this	O
is	O
unknown	O
.	O
	
estradiol	B
,	I
may	I
be	I
decreased	I
.	O
	
(	O
5.2	O
)	O
*	O
Neuroleptic	B
Malignant	I
Syndrome	I
:	O
Manage	O
with	O
immediate	O
discontinuation	O
and	O
close	O
monitoring	O
.	O
	
Of	O
these	O
reports	O
,	O
1	O
patient	O
in	O
the	O
placebo	O
group	O
and	O
all	O
8	O
patients	O
in	O
the	O
Prolia	O
group	O
had	O
serious	O
events	O
,	O
including	O
one	O
death	B
in	O
the	O
Prolia	O
group	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
>	O
=13	O
%	O
of	O
patients	O
are	O
:	O
Infections	B
,	O
vomiting	B
,	O
abdominal	B
pain	I
,	O
pyrexia	B
,	O
tonsilitis	B
,	O
anemia	B
,	O
ear	B
infection	I
,	O
diarrhea	B
,	O
nasopharyngitis	B
,	O
and	O
headache	B
.	O
	
Additionally	O
,	O
elevations	B
in	I
ALT	I
greater	O
than	O
five	O
times	O
the	O
ULN	O
occurred	O
in	O
184	O
(	O
11	O
%	O
)	O
and	O
93	O
(	O
5.7	O
%	O
)	O
patients	O
,	O
respectively	O
.	O
	
In	O
the	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
these	O
events	O
were	O
reported	O
in	O
13	O
%	O
of	O
placebo	O
patients	O
,	O
16	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
800	O
mg/day	O
APTIOM	O
,	O
and	O
28	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
1200	O
mg/day	O
APTIOM	O
.	O
	
(	O
5.12	O
)	O
*	O
Suicide	B
:	O
The	O
possibility	O
of	O
a	O
suicide	O
attempt	O
is	O
inherent	O
in	O
schizophrenia	O
and	O
bipolar	O
disorder	O
.	O
	
The	O
types	O
and	O
frequency	O
of	O
common	O
adverse	O
reactions	O
observed	O
in	O
the	O
pool	O
of	O
eight	O
clinical	O
trials	O
were	O
consistent	O
with	O
those	O
listed	O
in	O
Table	O
1	O
.	O
	
Adverse	O
reactions	O
reported	O
in	O
>	O
=	O
10	O
%	O
of	O
Prolia-treated	O
patients	O
receiving	O
ADT	O
for	O
prostate	O
cancer	O
or	O
adjuvant	O
AI	O
therapy	O
for	O
breast	O
cancer	O
,	O
and	O
more	O
frequently	O
than	O
in	O
the	O
placebo-treated	O
patients	O
were	O
:	O
arthralgia	B
(	O
13.0	O
%	O
placebo	O
vs.	O
14.3	O
%	O
Prolia	O
)	O
and	O
back	B
pain	I
(	O
10.5	O
%	O
placebo	O
vs.	O
11.5	O
%	O
Prolia	O
)	O
.	O
	
Pool	O
of	O
Placebo-Controlled	O
Trials	O
evaluating	O
JARDIANCE	O
10	O
and	O
25	O
mg	O
The	O
data	O
in	O
Table	O
1	O
are	O
derived	O
from	O
a	O
pool	O
of	O
four	O
24-week	O
placebo-controlled	O
trials	O
and	O
18-week	O
data	O
from	O
a	O
placebo-controlled	O
trial	O
with	O
insulin	O
.	O
	
Increasing	O
the	O
daily	O
dosage	O
of	O
ARCAPTA	O
NEOHALER	O
beyond	O
the	O
recommended	O
dose	O
is	O
not	O
appropriate	O
in	O
this	O
situation	O
.	O
	
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
BioMarin	O
at	O
1-866-906-6100	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Impairment	O
in	O
Renal	O
Function	O
INVOKANA	O
is	O
associated	O
with	O
a	O
dose-dependent	O
increase	B
in	I
serum	I
creatinine	I
and	O
a	O
concomitant	O
fall	B
in	I
estimated	I
GFR	I
(	O
Table	O
3	O
)	O
.	O
	
Permanently	O
discontinue	O
in	O
patients	O
with	O
ILD/pneumonitis	O
.	O
	
5.7	O
Withdrawal	O
of	O
AEDs	O
As	O
with	O
all	O
antiepileptic	O
drugs	O
,	O
APTIOM	O
should	O
be	O
withdrawn	O
gradually	O
because	O
of	O
the	O
risk	O
of	O
increased	O
seizure	O
frequency	O
and	O
status	O
epilepticus	O
.	O
	
Across	O
clinical	O
trials	O
,	O
32	O
of	O
1560	O
patients	O
(	O
2.1	O
%	O
)	O
had	O
QTcF	B
(	I
corrected	I
QT	I
by	I
the	I
Fridericia	I
method	I
)	I
greater	I
than	I
or	I
equal	I
to	I
500	I
ms	I
and	O
76	O
of	O
1520	O
patients	O
(	O
5.0	O
%	O
)	O
had	O
an	O
increase	B
from	I
baseline	I
QTcF	I
greater	O
than	O
or	O
equal	O
to	O
60	O
ms	O
by	O
automated	O
machine-read	O
evaluation	O
of	O
ECG	O
.	O
	
Red	O
blood	O
cell	O
transfusions	O
were	O
administered	O
to	O
20	O
%	O
of	O
patients	O
receiving	O
TREANDA	O
compared	O
with	O
6	O
%	O
of	O
patients	O
receiving	O
chlorambucil	O
.	O
	
If	O
an	O
anaphylactic	O
or	O
other	O
clinically	O
significant	O
allergic	O
reaction	O
occurs	O
,	O
initiate	O
appropriate	O
therapy	O
and	O
discontinue	O
further	O
use	O
of	O
Prolia	O
[	O
see	O
Contraindications	O
(	O
4.3	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Monitor	O
patients	O
closely	O
and	O
take	O
appropriate	O
precautions	O
in	O
patients	O
at	O
risk	O
for	O
tumor	O
lysis	O
syndrome	O
(	O
e.g	O
.	O
	
Hypersensitivity	B
reactions	O
have	O
occurred	O
as	O
early	O
as	O
30	O
minutes	O
from	O
the	O
start	O
of	O
infusion	O
but	O
as	O
late	O
as	O
six	O
days	O
after	O
infusion	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
antibodies	O
to	O
denosumab	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
BEPREVE	O
should	O
not	O
be	O
instilled	O
while	O
wearing	O
contact	O
lenses	O
.	O
	
Serious	O
,	O
life-threatening	O
complications	O
were	O
reported	O
with	O
APTIOM-associated	O
hyponatremia	B
(	O
as	O
low	O
as	O
112	O
mEq/L	O
)	O
including	O
seizures	B
,	O
severe	O
nausea/vomiting	O
leading	O
to	O
dehydration	B
,	O
severe	O
gait	B
instability	I
,	O
and	O
injury	B
.	O
	
Non-Hodgkin	O
Lymphoma	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
TREANDA	O
in	O
176	O
patients	O
with	O
indolent	O
B-cell	O
NHL	O
treated	O
in	O
two	O
single-arm	O
studies	O
.	O
	
The	O
time	O
to	O
onset	O
of	O
symptoms	O
following	O
initiation	O
of	O
drug	O
therapy	O
varied	O
from	O
one	O
day	O
to	O
years	O
.	O
	
APTIOM	O
should	O
be	O
discontinued	O
in	O
patients	O
with	O
jaundice	O
or	O
other	O
evidence	O
of	O
significant	O
liver	O
injury	O
(	O
e.g.	O
,	O
laboratory	O
evidence	O
)	O
.	O
	
The	O
most	O
common	O
non-hematologic	O
Grade	O
3	O
or	O
4	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
were	O
fatigue	B
(	O
11	O
%	O
)	O
,	O
febrile	B
neutropenia	I
(	O
6	O
%	O
)	O
,	O
and	O
pneumonia	B
,	O
hypokalemia	B
and	O
dehydration	B
,	O
each	O
reported	O
in	O
5	O
%	O
of	O
patients	O
.	O
	
The	O
majority	O
of	O
cases	O
occurred	O
in	O
countries	O
with	O
high	O
endemic	O
rates	O
of	O
TB	B
.	O
	
Severe	O
hypoglycemia	B
occurred	O
in	O
0	O
%	O
and	O
0.7	O
%	O
of	O
patients	O
when	O
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
,	O
respectively	O
,	O
was	O
co-administered	O
with	O
a	O
sulfonylurea	O
.	O
	
The	O
kidney	O
transplant	O
recipient	O
was	O
treated	O
with	O
the	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
,	O
mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
,	O
and	O
corticosteroids	O
for	O
2	O
years	O
.	O
	
5.2	O
Hemorrhage	O
Serious	O
and	O
sometimes	O
fatal	B
hemorrhage	B
occurred	O
with	O
COMETRIQ	O
.	O
	
Investigators	O
graded	O
the	O
severity	O
of	O
gastrointestinal	B
adverse	I
reactions	I
occurring	O
on	O
0.75	O
mg	O
and	O
1.5	O
mg	O
of	O
TRULICITY	O
as	O
``	O
mild	O
''	O
in	B
58	O
%	O
and	O
48	O
%	O
of	O
cases	O
,	O
respectively	O
,	O
``	O
moderate	O
''	O
in	B
35	O
%	O
and	O
42	O
%	O
of	O
cases	O
,	O
respectively	O
,	O
or	O
``	O
severe	O
''	O
in	B
7	O
%	O
and	O
11	O
%	O
of	O
cases	O
,	O
respectively	O
.	O
	
The	O
population	O
exposed	O
to	O
COMETRIQ	O
was	O
70	O
%	O
male	O
,	O
90	O
%	O
white	O
,	O
and	O
had	O
a	O
median	O
age	O
of	O
55	O
years	O
.	O
	
Long-standing	B
hyperprolactinemia	I
when	O
associated	O
with	O
hypogonadism	B
may	O
lead	O
to	O
decreased	B
bone	I
density	I
in	O
both	O
female	O
and	O
male	O
patients	O
.	O
	
The	O
most	O
frequently	O
reported	O
genital	B
mycotic	I
infections	I
were	O
vulvovaginal	B
mycotic	I
infections	I
in	O
females	O
and	O
balanitis	B
in	O
males	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RETINAL	B
ABNORMALITIES	I
AND	O
POTENTIAL	O
VISION	B
LOSS	I
WARNING	O
:	O
RETINAL	B
ABNORMALITIES	I
AND	O
POTENTIAL	O
VISION	B
LOSS	I
POTIGA	O
can	O
cause	O
retinal	B
abnormalities	I
,	O
which	O
are	O
known	O
to	O
result	O
in	O
damage	B
to	I
the	I
photoreceptors	I
and	O
vision	B
loss	I
.	O
	
Ankylosing	O
Spondylitis	O
Clinical	O
Study	O
CIMZIA	O
has	O
been	O
studied	O
in	O
325	O
patients	O
with	O
axial	O
spondyloarthritis	O
of	O
whom	O
the	O
majority	O
had	O
ankylosing	O
spondylitis	O
(	O
AS	O
)	O
in	O
a	O
placebo-controlled	O
study	O
(	O
AS-1	O
)	O
.	O
	
Cervical	O
Dystonia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
a	O
single	O
intramuscular	O
dose	O
of	O
XEOMIN	O
in	O
a	O
placebo-controlled	O
,	O
Phase	O
3	O
trial	O
in	O
patients	O
with	O
cervical	O
dystonia	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
FANAPT	O
and	O
other	O
antipsychotic	O
drugs	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
at	O
risk	O
for	O
aspiration	O
pneumonia	O
[	O
see	O
Boxed	O
Warning	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypotension	B
:	O
Before	O
initiating	O
FARXIGA	O
,	O
assess	O
volume	O
status	O
and	O
correct	O
hypovolemia	O
in	O
the	O
elderly	O
,	O
in	O
patients	O
with	O
renal	O
impairment	O
or	O
low	O
systolic	O
blood	O
pressure	O
,	O
and	O
in	O
patients	O
on	O
diuretics	O
.	O
	
Four	O
patients	O
out	O
of	O
2,367	O
patients	O
treated	O
with	O
CIMZIA	O
in	O
RA	O
clinical	O
studies	O
developed	O
clinical	O
signs	O
suggestive	O
of	O
a	O
lupus-like	B
syndrome	I
.	O
	
The	O
adverse	O
reactions	O
reported	O
most	O
frequently	O
as	O
the	O
reason	O
for	O
discontinuation	O
of	O
treatment	O
included	O
encephalopathy	B
and	O
sepsis	B
.	O
	
Approximately	O
70	O
%	O
of	O
patients	O
were	O
male	O
;	O
67	O
%	O
were	O
white	O
,	O
11	O
%	O
were	O
black	O
,	O
and	O
22	O
%	O
other	O
races	O
.	O
	
5.12	O
Embryo-fetal	O
Toxicity	O
COMETRIQ	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Pregnancy	O
should	O
be	O
ruled	O
out	O
in	O
the	O
event	O
of	O
amenorrhea	O
occurring	O
in	O
two	O
or	O
more	O
consecutive	O
cycles	O
.	O
	
Chloasma	B
may	O
occasionally	O
occur	O
,	O
especially	O
in	O
women	O
with	O
a	O
history	O
of	O
chloasma	O
gravidarum	O
.	O
	
POTIGA	O
should	O
only	O
be	O
used	O
in	O
patients	O
who	O
have	O
responded	O
inadequately	O
to	O
several	O
alternative	O
treatments	O
and	O
for	O
whom	O
the	O
benefits	O
outweigh	O
the	O
potential	O
risk	O
of	O
vision	O
loss	O
.	O
	
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
and	O
if	O
observed	O
,	O
treat	O
urgently	O
.	O
	
Elderly	O
patients	O
and	O
patients	O
with	O
impaired	O
renal	O
function	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
changes	O
.	O
	
Most	O
patients	O
who	O
developed	O
these	O
infections	B
were	O
taking	O
concomitant	O
immunosuppressants	O
such	O
as	O
methotrexate	O
or	O
corticosteroids	O
.	O
	
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
PRADAXA	O
:	O
angioedema	B
,	O
thrombocytopenia	B
,	O
esophageal	B
ulcer	I
.	O
	
(	O
5.4	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Severe	O
cutaneous	B
reactions	I
:	O
Monitor	O
patients	O
for	O
the	O
development	O
of	O
severe	O
cutaneous	O
reactions	O
and	O
discontinue	O
Zydelig	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Hypertension	O
,	O
Hypokalemia	O
and	O
Fluid	O
Retention	O
Due	O
to	O
Mineralocorticoid	O
Excess	O
ZYTIGA	O
may	O
cause	O
hypertension	B
,	O
hypokalemia	B
,	O
and	O
fluid	B
retention	I
as	O
a	O
consequence	O
of	O
increased	B
mineralocorticoid	I
levels	I
resulting	O
from	O
CYP17	O
inhibition	O
[	O
seeClinical	O
Pharmacology	O
(	O
12.1	O
)	O
]	O
.	O
	
In	O
Study	O
3	O
,	O
finger	O
extension	O
procedures	O
were	O
performed	O
approximately	O
24	O
to	O
72	O
hours	O
after	O
injection	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
AdreView	O
administration	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
In	O
animal	O
studies	O
,	O
administration	O
of	O
ceritinib	O
to	O
rats	O
and	O
rabbits	O
during	O
organogenesis	O
at	O
maternal	O
plasma	O
exposures	O
below	O
the	O
recommended	O
human	O
dose	O
of	O
750	O
mg	O
daily	O
caused	O
increases	B
in	I
skeletal	I
anomalies	I
in	O
rats	O
and	O
rabbits	O
.	O
	
Congestive	O
Heart	O
Failure	O
Many	O
commonly	O
used	O
cardiovascular	O
,	O
pulmonary	O
,	O
and	O
neuropsychiatric	O
medications	O
interfere	O
with	O
AdreView	O
imaging	O
(	O
see	O
above	O
)	O
.	O
	
In	O
the	O
breast	O
cancer	O
study	O
,	O
99	O
%	O
of	O
patients	O
were	O
female	O
,	O
the	O
median	O
age	O
was	O
50	O
years	O
,	O
and	O
86	O
%	O
of	O
patients	O
were	O
Caucasian	O
.	O
	
Elevations	B
in	I
ALT	I
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
have	O
occurred	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
data	O
described	O
below	O
are	O
based	O
on	O
two	O
identical	O
,	O
pooled	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multi-center	O
trials	O
through	O
Day	O
365	O
in	O
patients	O
with	O
Peyronie	O
's	O
disease	O
(	O
Studies	O
1	O
and	O
2	O
)	O
.	O
	
In	O
patients	O
receiving	O
the	O
recommended	O
CIMZIA	O
dosage	O
of	O
200	O
mg	O
every	O
other	O
week	O
with	O
concomitant	O
MTX	O
,	O
the	O
ACR20	O
response	O
was	O
lower	O
among	O
antibody	O
positive	O
patients	O
than	O
among	O
antibody-negative	O
patients	O
(	O
Study	O
RA-I	O
,	O
48	O
%	O
versus	O
60	O
%	O
;	O
Study	O
RA-II	O
35	O
%	O
versus	O
59	O
%	O
,	O
respectively	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
reported	O
in	O
patients	O
receiving	O
EYLEA	O
were	O
conjunctival	B
hemorrhage	I
,	O
eye	B
pain	I
,	O
cataract	B
,	O
vitreous	B
floaters	I
,	O
intraocular	B
pressure	I
increased	I
,	O
and	O
vitreous	B
detachment	I
.	O
	
Patients	O
in	O
the	O
treatment	O
studies	O
who	O
rolled	O
over	O
into	O
the	O
RE-SONATE	O
study	O
had	O
combined	O
treatment	O
duration	O
up	O
to	O
9	O
months	O
,	O
with	O
mean	O
exposure	O
of	O
165	O
days	O
.	O
	
Monitor	O
patients	O
with	O
advanced	O
stage	O
disease	O
and/or	O
high	O
tumor	O
burden	O
and	O
take	O
appropriate	O
precautions	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
5.1	O
,	O
5.2	O
)	O
*	O
Withdrawal	O
:	O
Symptoms	O
may	O
occur	O
with	O
rapid	O
dose	O
reduction	O
or	O
discontinuation	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
adverse	O
drug	O
reaction	O
,	O
withhold	O
ZYKADIA	O
with	O
resumption	O
at	O
a	O
reduced	O
dose	O
,	O
or	O
permanently	O
discontinue	O
ZYKADIA	O
as	O
described	O
in	O
Table	O
1	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
AdreView	O
contains	O
benzyl	O
alcohol	O
(	O
10.3	O
mg/mL	O
)	O
which	O
may	O
cause	O
serious	O
reactions	O
in	O
premature	O
or	O
low	O
birth-weight	O
infants	O
.	O
	
COCs	O
also	O
increase	O
the	O
risk	O
for	O
stroke	B
in	O
women	O
with	O
other	O
underlying	O
risk	O
factors	O
.	O
	
5.8	O
Embryo-fetal	O
Toxicity	O
Based	O
on	O
findings	O
in	O
animals	O
,	O
Zydelig	O
may	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
In	O
pooled	O
clinical	O
trials	O
,	O
the	O
incidence	O
of	O
agranulocytosis	B
was	O
1.7	O
%	O
of	O
patients	O
.	O
	
Concurrent	O
Administration	O
with	O
Vemurafenib	O
In	O
a	O
dose-finding	O
trial	O
,	O
Grade	O
3	O
increases	B
in	I
transaminases	I
with	O
or	O
without	O
concomitant	O
increases	B
in	I
total	I
bilirubin	I
occurred	O
in	O
6	O
of	O
10	O
patients	O
who	O
received	O
concurrent	O
YERVOY	O
(	O
3	O
mg/kg	O
)	O
and	O
vemurafenib	O
(	O
960	O
mg	O
BID	O
or	O
720	O
mg	O
BID	O
)	O
.	O
	
(	O
5.2	O
)	O
5.1	O
Agranulocytosis/Neutropenia	O
Fatal	B
agranulocytosis	B
can	O
occur	O
with	O
Ferriprox	O
use	O
.	O
	
Exclude	O
other	O
potential	O
causes	O
of	O
ILD/pneumonitis	O
,	O
and	O
permanently	O
discontinue	O
ZYKADIA	O
in	O
patients	O
diagnosed	O
with	O
treatment-related	O
ILD/pneumonitis	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Acute	O
or	O
chronic	O
disturbances	O
of	O
liver	O
function	O
may	O
necessitate	O
the	O
discontinuation	O
of	O
COC	O
use	O
until	O
markers	O
of	O
liver	O
function	O
return	O
to	O
normal	O
and	O
COC	O
causation	O
has	O
been	O
excluded	O
.	O
	
Long-term	B
cumulative	I
radiation	I
exposure	I
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cancer	B
.	O
	
a	O
Patients	O
with	O
at	O
least	O
one	O
MBE	B
.	O
	
There	O
was	O
also	O
an	O
increased	O
incidence	O
of	O
pneumonias	B
resulting	O
in	O
hospitalization	O
.	O
	
Do	O
not	O
administer	O
Beleodaq	O
to	O
patients	O
with	O
an	O
active	O
infection	O
.	O
	
Common	O
Adverse	O
Reactions	O
Clinical	O
ADRs	O
of	O
moderate	O
intensity	O
or	O
greater	O
(	O
greater	O
than	O
or	O
equal	O
to	O
Grade	O
2	O
)	O
and	O
reported	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
treated	O
with	O
INTELENCE	O
(	O
r	O
)	O
and	O
occurring	O
at	O
a	O
higher	O
rate	O
compared	O
to	O
placebo	O
(	O
excess	O
of	O
1	O
%	O
)	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Regeneron	O
at	O
1-855-395-3248	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
To	O
reduce	O
this	O
risk	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
if	O
PRADAXA	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
(	O
2.4	O
,	O
2.5	O
,	O
2.6	O
,	O
5.1	O
)	O
.	O
	
No	O
association	O
was	O
seen	O
between	O
antibody	O
development	O
and	O
the	O
development	O
of	O
adverse	O
events	O
.	O
	
Use	O
caution	O
and	O
monitor	O
for	O
symptoms	O
and	O
signs	O
of	O
adrenocortical	O
insufficiency	O
,	O
particularly	O
if	O
patients	O
are	O
withdrawn	O
from	O
prednisone	O
,	O
have	O
prednisone	O
dose	O
reductions	O
,	O
or	O
experience	O
unusual	O
stress	O
.	O
	
Corporal	O
Rupture	O
and	O
Other	O
Serious	O
Penile	O
Injury	O
*	O
Corporal	B
rupture	I
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
after	O
XIAFLEX	O
injections	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX	O
treated	O
patients	O
.	O
	
Avoid	O
concurrent	O
use	O
of	O
Zydelig	O
with	O
other	O
drugs	O
that	O
may	O
cause	O
liver	O
toxicity	O
.	O
	
Benzyl	O
alcohol	O
has	O
been	O
associated	O
with	O
a	O
fatal	B
``	O
Gasping	B
Syndrome	I
''	O
in	B
premature	O
infants	O
and	O
infants	O
of	O
low	O
birth	O
weight	O
.	O
	
(	O
5.1	O
)	O
*	O
Adrenocortical	B
insufficiency	I
:	O
Monitor	O
for	O
symptoms	O
and	O
signs	O
of	O
adrenocortical	O
insufficiency	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
In	O
general	O
,	O
in	O
clinical	O
trials	O
,	O
rash	B
was	O
mild	O
to	O
moderate	O
,	O
occurred	O
primarily	O
in	O
the	O
second	O
week	O
of	O
therapy	O
,	O
and	O
was	O
infrequent	O
after	O
Week	O
4	O
.	O
	
5.4	O
Local	O
Effects	O
of	O
Inhaled	O
Corticosteroids	O
In	O
clinical	O
trials	O
,	O
the	O
development	O
of	O
localized	O
infections	B
of	I
the	I
mouth	I
and	I
pharynx	I
with	I
Candida	I
albicans	I
has	O
occurred	O
in	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
.	O
	
The	O
RE-MEDY	O
and	O
RE-SONATE	O
studies	O
provided	O
safety	O
information	O
on	O
the	O
use	O
of	O
PRADAXA	O
for	O
the	O
reduction	O
in	O
the	O
risk	O
of	O
recurrence	O
of	O
deep	O
vein	O
thrombosis	O
and	O
pulmonary	O
embolism	O
.	O
	
Endometrial	O
biopsies	O
performed	O
in	O
a	O
subset	O
of	O
subjects	O
in	O
a	O
Phase	O
3	O
Natazia	O
clinical	O
trial	O
did	O
not	O
reveal	O
any	O
unexpected	O
or	O
concerning	O
findings	O
for	O
subjects	O
taking	O
COCs	O
.	O
	
A	O
pharmacokinetic	O
analysis	O
suggested	O
that	O
ZYKADIA	O
causes	O
concentration-dependent	O
increases	B
in	I
the	I
QTc	I
interval	I
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
moderate	O
,	O
severe	O
,	O
or	O
life-threatening	O
immune-mediated	B
dermatitis	I
was	O
3.1	O
weeks	O
and	O
ranged	O
up	O
to	O
17.3	O
weeks	O
from	O
the	O
initiation	O
of	O
YERVOY	O
.	O
	
(	O
5.1	O
)	O
*	O
Advise	O
patients	O
taking	O
Ferriprox	O
to	O
report	O
immediately	O
any	O
symptoms	O
indicative	O
of	O
infection	O
.	O
	
An	O
additional	O
13	O
(	O
2.5	O
%	O
)	O
patients	O
experienced	O
moderate	O
hepatotoxicity	B
manifested	O
by	O
liver	B
function	I
test	I
abnormalities	I
(	O
ALT	B
elevations	I
of	O
more	O
than	O
2.5	O
times	O
but	O
not	O
more	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
total	B
bilirubin	I
elevation	I
of	O
more	O
than	O
1.5	O
times	O
but	O
not	O
more	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
;	O
Grade	O
2	O
)	O
.	O
	
For	O
neutropenia	O
(	O
ANC	O
<	O
1.5	O
x	O
10	O
9	O
/L	O
and	O
>	O
0.5	O
x	O
10	O
9	O
/L	O
)	O
:	O
Instruct	O
the	O
patient	O
to	O
immediately	O
discontinue	O
Ferriprox	O
and	O
all	O
other	O
medications	O
with	O
a	O
potential	O
to	O
cause	O
neutropenia	O
.	O
	
The	O
majority	O
of	O
the	O
1,222	O
patients	O
were	O
women	O
(	O
82	O
%	O
)	O
with	O
a	O
median	O
age	O
of	O
58	O
years	O
(	O
range	O
:	O
26	O
to	O
91	O
years	O
)	O
.	O
	
[	O
See	O
Adverse	O
Reactions	O
(	O
6	O
)	O
.	O
]	O
	
Elevations	B
in	I
alanine	I
aminotransferase	I
(	O
ALT	O
)	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
occurred	O
in	O
27	O
%	O
of	O
255	O
patients	O
in	O
Study	O
1	O
.	O
	
In	O
clinical	O
trials	O
,	O
somnolence	B
or	O
sedation	B
was	O
reported	O
at	O
all	O
effective	O
doses	O
and	O
was	O
dose-related	O
.	O
	
Women	O
of	O
childbearing	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
pregnancy	O
while	O
receiving	O
Beleodaq	O
.	O
	
Acute	O
symptoms	O
should	O
be	O
treated	O
with	O
an	O
inhaled	O
,	O
short-acting	O
beta2-agonist	O
.	O
	
The	O
incidence	O
of	O
serious	O
infections	B
during	O
the	O
controlled	O
clinical	O
studies	O
was	O
3	O
%	O
per	O
patient-year	O
for	O
CIMZIA-treated	O
patients	O
and	O
1	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
In	O
this	O
pool	O
,	O
a	O
total	O
of	O
3342	O
patients	O
with	O
type	O
2	O
diabetes	O
were	O
treated	O
with	O
TRULICITY	O
for	O
a	O
mean	O
duration	O
of	O
52	O
weeks	O
.	O
	
Discontinue	O
COMETRIQ	O
in	O
patients	O
who	O
develop	O
an	O
acute	O
myocardial	O
infarction	O
or	O
any	O
other	O
clinically	O
significant	O
arterial	O
thromboembolic	O
complication	O
.	O
	
Therefore	O
NULOJIX	O
is	O
recommended	O
for	O
use	O
only	O
in	O
patients	O
who	O
are	O
EBV	O
seropositive	O
[	O
see	O
Boxed	O
Warning	O
and	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
the	O
types	O
and	O
frequency	O
of	O
common	O
adverse	O
reactions	O
,	O
excluding	O
hypoglycemia	B
,	O
were	O
similar	O
to	O
those	O
listed	O
in	O
Table	O
1	O
.	O
	
Discontinue	O
for	O
nephrotic	O
syndrome	O
.	O
	
Increase	O
in	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
In	O
the	O
pool	O
of	O
13	O
placebo-controlled	O
studies	O
,	O
changes	B
from	I
baseline	I
in	I
mean	I
lipid	I
values	I
were	O
reported	O
in	O
FARXIGA-treated	O
patients	O
compared	O
to	O
placebo-treated	O
patients	O
.	O
	
5.11	O
Dysphagia	O
Esophageal	B
dysmotility	I
and	O
aspiration	B
have	O
been	O
associated	O
with	O
antipsychotic	O
drug	O
use	O
.	O
	
Serious	O
infections	B
included	O
tuberculosis	B
,	O
pneumonia	B
,	O
cellulitis	B
,	O
and	O
pyelonephritis	B
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
8.0	O
years	O
and	O
had	O
a	O
mean	O
HbA1c	O
of	O
8.0	O
%	O
.	O
	
Table	O
1	O
Adverse	O
reactions	O
observed	O
in	O
>	O
1	O
%	O
of	O
patients	O
with	O
acute	O
attacks	O
of	O
HAE	O
and	O
at	O
a	O
higher	O
rate	O
with	O
FIRAZYR	O
versus	O
placebo	O
in	O
the	O
placebo-controlled	O
trialsEvents	O
occurring	O
within	O
14	O
days	O
of	O
study	O
drug	O
administration	O
FIRAZYR	O
(	O
N	O
=77	O
)	O
Placebo	O
(	O
N	O
=	O
75	O
)	O
System	O
Organ	O
ClassPreferred	O
Term	O
Subjects	O
(	O
%	O
)	O
Subjects	O
(	O
%	O
)	O
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
Injection	B
site	I
reaction	I
75	O
(	O
97	O
)	O
25	O
(	O
33	O
)	O
Pyrexia	B
3	O
(	O
4	O
)	O
0	O
Investigations	O
Transaminase	B
increased	I
3	O
(	O
4	O
)	O
0	O
Nervous	O
system	O
disorders	O
Dizziness	B
2	O
(	O
3	O
)	O
1	O
(	O
1	O
)	O
The	O
third	O
trial	O
was	O
active-controlled	O
and	O
was	O
comprised	O
of	O
35	O
patients	O
who	O
received	O
FIRAZYR	O
30	O
mg	O
and	O
38	O
patients	O
who	O
received	O
the	O
comparator	O
.	O
	
Symptomatic	B
hypotension	I
can	O
occur	O
after	O
initiating	O
FARXIGA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
particularly	O
in	O
patients	O
with	O
impaired	O
renal	O
function	O
(	O
eGFR	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
elderly	O
patients	O
,	O
or	O
patients	O
on	O
loop	O
diuretics	O
.	O
	
5.2	O
Risk	O
of	O
Bleeding	O
PRADAXA	O
increases	O
the	O
risk	O
of	O
bleeding	B
and	O
can	O
cause	O
significant	O
and	O
,	O
sometimes	O
,	O
fatal	B
bleeding	B
.	O
	
It	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
POTIGA	O
caused	O
this	O
decreased	B
visual	I
acuity	I
,	O
as	O
baseline	O
assessments	O
are	O
not	O
available	O
for	O
these	O
patients	O
.	O
	
EXCERPT	O
:	O
Immune-mediated	B
adverse	I
reactions	I
:	O
Permanently	O
discontinue	O
for	O
severe	O
reactions	O
.	O
	
5.7	O
Palmar-Plantar	O
Erythrodysesthesia	O
Syndrome	O
Palmar-plantar	B
erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
occurred	O
in	O
50	O
%	O
of	O
patients	O
treated	O
with	O
COMETRIQ	O
and	O
was	O
severe	O
(	O
>	O
=	O
Grade	O
3	O
)	O
in	O
13	O
%	O
of	O
patients	O
.	O
	
5.12	O
Monitoring	O
A	O
woman	O
who	O
is	O
taking	O
COCs	O
should	O
have	O
a	O
yearly	O
visit	O
with	O
her	O
healthcare	O
provider	O
for	O
a	O
blood	O
pressure	O
check	O
and	O
for	O
other	O
indicated	O
healthcare	O
.	O
	
Studies	O
also	O
do	O
not	O
suggest	O
a	O
teratogenic	B
effect	I
,	O
particularly	O
in	O
so	O
far	O
as	O
cardiac	B
anomalies	I
and	O
limb-reduction	B
defects	I
are	O
concerned	O
,	O
when	O
taken	O
inadvertently	O
during	O
early	O
pregnancy	O
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
was	O
13	O
%	O
for	O
the	O
recommended	O
NULOJIX	O
regimen	O
and	O
19	O
%	O
for	O
the	O
cyclosporine	O
control	O
arm	O
through	O
three	O
years	O
of	O
treatment	O
.	O
	
Hemodialysis	O
can	O
remove	O
dabigatran	O
;	O
however	O
the	O
clinical	O
experience	O
supporting	O
the	O
use	O
of	O
hemodialysis	O
as	O
a	O
treatment	O
for	O
bleeding	O
is	O
limited	O
[	O
see	O
Overdosage	O
(	O
10	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
*	O
The	O
rate	O
of	O
progression	O
of	O
retinal	O
abnormalities	O
and	O
their	O
reversibility	O
are	O
unknown	O
.	O
	
Drugs	O
with	O
alpha-adrenergic	O
blocking	O
effects	O
have	O
been	O
reported	O
to	O
induce	O
priapism	B
.	O
	
(	O
5.3	O
)	O
*	O
Genital	B
mycotic	I
infections	I
:	O
Monitor	O
and	O
treat	O
if	O
indicated	O
.	O
	
Blepharospasm	O
:	O
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
of	O
patients	O
and	O
>	O
placebo	O
)	O
are	O
eyelid	B
ptosis	I
,	O
dry	B
eye	I
,	O
dry	B
mouth	I
,	O
diarrhea	B
,	O
headache	B
,	O
visual	B
impairment	I
,	O
dyspnea	B
,	O
nasopharyngitis	B
,	O
and	O
respiratory	B
tract	I
infection	I
(	O
6.1	O
)	O
.	O
	
Common	O
Adverse	O
Reactions	O
(	O
>	O
=	O
2	O
%	O
)	O
:	O
headache	B
(	O
including	O
migraines	B
)	O
(	O
12.7	O
%	O
)	O
,	O
breast	B
pain	I
(	O
7.0	O
%	O
)	O
,	O
menstrual	B
disorders	I
(	O
metrorrhagia	B
,	O
menstruation	B
irregular	I
,	O
menorrhagia	B
,	O
vaginal	B
hemorrhage	I
,	O
dysfunctional	B
uterine	I
bleeding	I
,	O
genital	B
hemorrhage	I
,	O
abnormal	B
withdrawal	I
bleeding	I
,	O
uterine	B
hemorrhage	I
)	O
(	O
6.9	O
%	O
)	O
,	O
nausea	B
or	O
vomiting	B
(	O
6.0	O
%	O
)	O
,	O
acne	B
(	O
3.9	O
%	O
)	O
,	O
mood	B
changes	I
(	O
depression	B
,	O
mood	B
swings	I
,	O
depressed	B
mood	I
,	O
mood	B
altered	I
,	O
affect	B
lability	I
,	O
dysthymic	B
disorder	I
,	O
crying	B
)	O
(	O
3.0	O
%	O
)	O
and	O
increased	B
weight	I
(	O
2.9	O
%	O
)	O
.	O
	
The	O
overall	O
safety	O
profile	O
of	O
KALYDECO	O
is	O
based	O
on	O
pooled	O
data	O
from	O
three	O
placebo-controlled	O
clinical	O
trials	O
conducted	O
in	O
353	O
patients	O
6	O
years	O
of	O
age	O
and	O
older	O
with	O
CF	O
who	O
had	O
a	O
G551D	O
mutation	O
in	O
the	O
CFTR	O
gene	O
(	O
Trials	O
1	O
and	O
2	O
)	O
or	O
were	O
homozygous	O
for	O
the	O
F508del	O
mutation	O
(	O
Trial	O
3	O
)	O
.	O
	
Inform	O
patients	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
anaphylaxis	O
,	O
and	O
instruct	O
them	O
to	O
seek	O
immediate	O
medical	O
care	O
should	O
signs	O
and	O
symptoms	O
occur	O
.	O
	
Pre-treatment	O
with	O
antihistamines	O
with	O
or	O
without	O
antipyretics	O
is	O
recommended	O
prior	O
to	O
the	O
start	O
of	O
infusion	O
(	O
5.1	O
)	O
.	O
	
If	O
atrial	O
fibrillation	O
persists	O
,	O
consider	O
the	O
risks	O
and	O
benefits	O
of	O
IMBRUVICA	O
treatment	O
and	O
dose	O
modification	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Monitor	O
for	O
consequences	O
of	O
bone	O
oversuppression	O
(	O
5.9	O
)	O
5.1	O
Drug	O
Products	O
with	O
Same	O
Active	O
Ingredient	O
Prolia	O
contains	O
the	O
same	O
active	O
ingredient	O
(	O
denosumab	O
)	O
found	O
in	O
Xgeva	O
.	O
	
Nausea	B
and	O
vomiting	B
also	O
occurred	O
with	O
these	O
events	O
.	O
	
The	O
preservative	O
in	O
BEPREVE	O
,	O
benzalkonium	O
chloride	O
,	O
may	O
be	O
absorbed	O
by	O
soft	O
contact	O
lenses	O
.	O
	
Patients	O
with	O
a	O
prior	O
dermatologic	O
reaction	O
with	O
either	O
oxcarbazepine	O
or	O
APTIOM	O
should	O
not	O
be	O
treated	O
with	O
APTIOM	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Grade	O
3	O
or	O
4	O
increased	B
bilirubin	I
occurred	O
in	O
3	O
%	O
of	O
patients	O
.	O
	
New	O
malignancies	B
related	I
to	I
the	I
breast	I
(	O
0.6	O
%	O
placebo	O
vs.	O
0.9	O
%	O
Prolia	O
)	O
were	O
reported	O
.	O
	
Patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
should	O
be	O
informed	O
that	O
AEDs	O
increase	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
and	O
should	O
be	O
advised	O
of	O
the	O
need	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
depression	O
;	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
;	O
or	O
the	O
emergence	O
of	O
suicidal	O
thoughts	O
,	O
behavior	O
,	O
or	O
thoughts	O
about	O
self-harm	O
.	O
	
The	O
median	O
duration	O
of	O
therapy	O
with	O
BOSULIF	O
was	O
approximately	O
17	O
months	O
(	O
range	O
,	O
0.03	O
to	O
95	O
)	O
for	O
patients	O
in	O
these	O
studies	O
.	O
	
5.10	O
Immunizations	O
Patients	O
treated	O
with	O
CIMZIA	O
may	O
receive	O
vaccinations	O
,	O
except	O
for	O
live	O
or	O
live	O
attenuated	O
vaccines	O
.	O
	
In	O
developmental	O
toxicity	O
studies	O
in	O
mice	O
,	O
axitinib	O
was	O
teratogenic	B
,	O
embryotoxic	B
and	O
fetotoxic	B
at	O
maternal	O
exposures	O
that	O
were	O
lower	O
than	O
human	O
exposures	O
at	O
the	O
recommended	O
clinical	O
dose	O
.	O
	
(	O
5.9	O
)	O
*	O
Seizures	B
:	O
Use	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
conditions	O
that	O
lower	O
the	O
seizure	O
threshold	O
.	O
	
(	O
5.3	O
)	O
*	O
Bradycardia	B
:	O
XALKORI	O
can	O
cause	O
bradycardia	B
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
(	O
>	O
2	O
%	O
)	O
were	O
pneumonia	B
,	O
pyrexia	B
,	O
infection	B
,	O
anemia	B
,	O
increased	B
creatinine	I
,	O
thrombocytopenia	B
,	O
and	O
multi-organ	B
failure	I
.	O
	
There	O
was	O
an	O
increased	O
risk	O
of	O
these	O
adverse	O
reactions	O
during	O
the	O
titration	O
period	O
(	O
compared	O
to	O
the	O
maintenance	O
period	O
)	O
and	O
also	O
in	O
patients	O
60	O
years	O
of	O
age	O
and	O
older	O
(	O
compared	O
to	O
younger	O
adults	O
)	O
.	O
	
No	O
evidence	O
of	O
altered	O
pharmacokinetic	O
profile	O
,	O
toxicity	B
profile	O
,	O
or	O
clinical	O
response	O
was	O
associated	O
with	O
binding	O
antibody	O
development	O
.	O
	
Anaphylaxis	B
and	O
hypersensitivity	B
reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
SAPHRIS	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
see	O
alsoBoxed	O
Warningand	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
ARCAPTA	O
NEOHALER	O
should	O
not	O
be	O
used	O
for	O
the	O
relief	O
of	O
acute	O
symptoms	O
,	O
i.e	O
.	O
	
5.6	O
Embryofetal	O
Toxicity	O
There	O
are	O
no	O
adequate	O
and	O
well	O
controlled	O
studies	O
of	O
BOSULIF	O
in	O
pregnant	O
women	O
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
56	O
years	O
and	O
3	O
%	O
were	O
older	O
than	O
75	O
years	O
of	O
age	O
.	O
	
(	O
5.5	O
)	O
*	O
Embryofetal	B
Toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
Adverse	O
reactions	O
occurring	O
in	O
2-5	O
%	O
of	O
subjects	O
included	O
anterior	B
chamber	I
flare	I
,	O
corneal	B
edema	I
,	O
dry	B
eye	I
,	O
iridocyclitis	B
,	O
photophobia	B
,	O
and	O
reduced	B
visual	I
acuity	I
.	O
	
In	O
the	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
these	O
events	O
were	O
reported	O
in	O
1	O
%	O
of	O
placebo	O
patients	O
,	O
4	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
800	O
mg/day	O
APTIOM	O
,	O
and	O
7	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
1200	O
mg/day	O
APTIOM	O
.	O
	
Because	O
these	O
reactions	O
were	O
reported	O
retrospectively	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
In	O
Studies	O
1	O
and	O
2	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
neutropenia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
fatigue	B
,	O
nausea	B
,	O
anemia	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
diarrhea	B
,	O
pyrexia	B
,	O
rash	B
,	O
thrombocytopenia	B
,	O
cough	B
,	O
and	O
vomiting	B
.	O
	
5.1	O
Anaphylaxis	O
and	O
Hypersensitivity	O
Reactions	O
Anaphylaxis	B
and	O
hypersensitivity	B
reactions	I
have	O
been	O
observed	O
in	O
patients	O
during	O
and	O
up	O
to	O
3	O
hours	O
after	O
alglucosidase	O
alfa	O
infusion	O
.	O
	
Similar	O
events	O
have	O
been	O
reported	O
with	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
postmarketing	O
setting	O
although	O
a	O
causal	O
relationship	O
has	O
not	O
been	O
established	O
.	O
	
EPS-related	B
events	I
include	O
:	O
bradykinesia	B
,	O
dyskinesia	B
,	O
dystonia	B
,	O
oromandibular	B
dystonia	I
,	O
muscle	B
contractions	I
involuntary	I
,	O
muscle	B
twitching	I
,	O
musculoskeletal	B
stiffness	I
,	O
parkinsonism	B
,	O
protrusion	B
tongue	I
,	O
resting	B
tremor	I
,	O
and	O
tremor	B
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
treatment	O
discontinuation	O
was	O
seizure	B
,	O
which	O
occurred	O
in	O
0.9	O
%	O
of	O
the	O
XTANDI-treated	O
patients	O
compared	O
to	O
none	O
(	O
0	O
%	O
)	O
of	O
the	O
placebo-treated	O
patients	O
.	O
	
Eosinophilia	B
is	O
often	O
present	O
.	O
	
These	O
adverse	O
events	O
were	O
related	O
to	O
cardiac	B
disorders	I
in	O
10	O
(	O
2	O
%	O
)	O
patients	O
,	O
infections	B
in	O
8	O
(	O
1	O
%	O
)	O
patients	O
,	O
renal	B
disorders	I
in	O
4	O
(	O
<	O
1	O
%	O
)	O
patients	O
,	O
and	O
other	O
adverse	O
events	O
in	O
8	O
(	O
1	O
%	O
)	O
patients	O
.	O
	
Taper	O
patients	O
slowly	O
from	O
systemic	O
corticosteroids	O
if	O
transferring	O
to	O
BREO	O
ELLIPTA	O
.	O
	
6	O
24	O
Psychiatric	O
disorders	O
Anxiety	B
2	O
4	O
Depression	B
1	O
2	O
Insomnia	B
5	O
6	O
Monotherapy	O
in	O
Pediatric	O
Patients	O
with	O
Bipolar	O
Mania	O
:	O
The	O
following	O
findings	O
are	O
based	O
on	O
a	O
3-week	O
,	O
placebo-controlled	O
trial	O
for	O
bipolar	O
mania	O
in	O
which	O
SAPHRIS	O
was	O
administered	O
at	O
doses	O
of	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
or	O
10	O
mg	O
twice	O
daily	O
.	O
	
If	O
any	O
bleeding	O
requires	O
medical	O
intervention	O
,	O
temporarily	O
interrupt	O
the	O
INLYTA	O
dose	O
.	O
	
*	O
Administer	O
DOTAREM	O
only	O
in	O
situations	O
where	O
trained	O
personnel	O
and	O
therapies	O
are	O
promptly	O
available	O
for	O
the	O
treatment	O
of	O
hypersensitivity	O
reactions	O
,	O
including	O
personnel	O
trained	O
in	O
resuscitation	O
.	O
	
Because	O
of	O
its	O
mechanism	O
of	O
action	O
,	O
BENLYSTA	O
may	O
interfere	O
with	O
the	O
response	O
to	O
immunizations	O
.	O
	
Table	O
11	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
2	O
%	O
or	O
More	O
of	O
Adult	O
Patients	O
In	O
Any	O
SAPHRIS-Dose	O
Group	O
and	O
Which	O
Occurred	O
at	O
Greater	O
Incidence	O
Than	O
in	O
the	O
Placebo	O
Group	O
at	O
3	O
Weeks	O
in	O
Adjunctive	O
Bipolar	O
Mania	O
Trials	O
*	O
SAPHRIS	O
5	O
mg	O
to	O
10	O
mg	O
twice	O
daily	O
with	O
flexible	O
dosing	O
.	O
	
Grade	O
1-4	O
elevations	B
in	I
ALT	I
occurred	O
in	O
10	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
(	O
0.2	O
%	O
Grade	O
3-4	O
)	O
and	O
16	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
(	O
0.2	O
%	O
Grade	O
3-4	O
)	O
.	O
	
Estimated	O
creatinine	O
clearance	O
,	O
urine	O
glucose	O
and	O
urine	O
protein	O
should	O
be	O
documented	O
in	O
all	O
patients	O
prior	O
to	O
initiating	O
therapy	O
.	O
	
Laboratory	O
Findings	O
Patients	O
treated	O
with	O
DYSPORT	O
(	O
r	O
)	O
exhibited	O
a	O
small	O
increase	B
from	I
baseline	I
(	I
0.23	I
mol/L	I
)	I
in	I
mean	I
blood	I
glucose	I
relative	O
to	O
placebo-	O
treated	O
patients	O
.	O
	
DUAVEE	O
is	O
not	O
for	O
use	O
in	O
children	O
.	O
	
Table	O
5	O
:	O
Common	O
Adverse	O
Events	O
(	O
>	O
=	O
10	O
%	O
in	O
the	O
KRd	O
Arm	O
)	O
Occurring	O
in	O
Cycles	O
1-12	O
(	O
Combination	O
Therapy	O
)	O
KRd	O
=	O
Kyprolis	O
,	O
lenalidomide	O
,	O
and	O
low-dose	O
dexamethasone	O
;	O
Rd	O
=	O
lenalidomide	O
and	O
low-dose	O
dexamethasone	O
a	O
Pneumonia	B
includes	O
preferred	O
terms	O
of	O
pneumonia	B
,	O
bronchopneumonia	B
b	O
Peripheral	B
neuropathies	I
NEC	I
includes	O
preferred	O
terms	O
under	O
HLT	O
peripheral	B
neuropathies	I
NEC	I
c	O
Dyspnea	B
includes	O
preferred	O
terms	O
of	O
dyspnea	B
,	O
dyspnea	B
exertional	I
d	O
Embolic	B
and	I
thrombotic	I
events	I
,	I
venous	I
include	O
preferred	O
terms	O
in	O
MedDRA	O
SMQ	O
narrow	O
scope	O
search	O
of	O
embolic	B
and	I
thrombotic	I
events	I
,	I
venous	I
.	O
	
Pain	B
in	I
extremity	I
and	O
musculoskeletal	B
pain	I
have	O
also	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O
	
(	O
1.2	O
,	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
LABA	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
and	O
asthma-related	O
hospitalizations	O
.	O
	
Because	O
these	O
reactions	O
were	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Serious	O
adverse	O
drug	O
reactions	O
reported	O
in	O
2	O
%	O
or	O
more	O
of	O
patients	O
in	O
Study	O
1	O
were	O
convulsion	B
,	O
pneumonia	B
,	O
ILD/pneumonitis	O
,	O
dyspnea	B
,	O
dehydration	B
,	O
hyperglycemia	B
,	O
and	O
nausea	B
.	O
	
(	O
5.7	O
)	O
*	O
Immune	B
reconstitution	I
syndrome	I
:	O
May	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
Some	O
patients	O
(	O
13	O
%	O
)	O
received	O
premedication	O
,	O
which	O
may	O
have	O
mitigated	O
or	O
masked	O
an	O
infusion	O
reaction	O
;	O
however	O
,	O
there	O
is	O
insufficient	O
evidence	O
to	O
determine	O
whether	O
premedication	O
diminishes	O
the	O
frequency	O
or	O
severity	O
of	O
infusion	O
reactions	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
ATHENA	O
,	O
the	O
maximum	O
follow-up	O
was	O
30	O
months	O
.	O
	
6.1	O
Clinical	O
Study	O
Experience	O
in	O
Advanced	O
Hormone	O
Receptor-Positive	O
,	O
HER2-Negative	O
Breast	O
Cancer	O
The	O
efficacy	O
and	O
safety	O
of	O
AFINITOR	O
(	O
10	O
mg/day	O
)	O
plus	O
exemestane	O
(	O
25	O
mg/day	O
)	O
(	O
n=485	O
)	O
versus	O
placebo	O
plus	O
exemestane	O
(	O
25	O
mg/day	O
)	O
(	O
n=239	O
)	O
was	O
evaluated	O
in	O
a	O
randomized	O
,	O
controlled	O
trial	O
in	O
patients	O
with	O
advanced	O
or	O
metastatic	O
hormone	O
receptor-positive	O
,	O
HER2-negative	O
breast	O
cancer	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
*	O
Psoriatic	O
Arthritis	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
are	O
diarrhea	B
,	O
nausea	B
,	O
and	O
headache	B
(	O
6.1	O
)	O
*	O
Psoriasis	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
are	O
diarrhea	B
,	O
nausea	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
and	O
headache	B
,	O
including	O
tension	B
headache	I
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Celgene	O
Corporation	O
at	O
1-888-423-5436	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trial	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
WARNING	O
:	O
POTENTIAL	O
RISK	O
OF	O
MYOCARDIAL	B
INFARCTION	I
WITH	O
LONG-TERM	O
USE	O
:	O
FOR	O
SHORT-TERM	O
HOSPITAL	O
USE	O
ONLY	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Treatment-emergent	O
ADRs	O
of	O
moderate	O
to	O
severe	O
intensity	O
observed	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
in	O
either	O
treatment	O
arm	O
in	O
SPRING-2	O
and	O
SINGLE	O
trials	O
are	O
provided	O
in	O
Table	O
2	O
.	O
	
Of	O
these	O
discontinuations	O
,	O
8	O
in	O
the	O
STRIBILD	O
group	O
and	O
1	O
in	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
occurred	O
during	O
the	O
first	O
48	O
weeks	O
.	O
	
Monitor	O
patients	O
for	O
clinical	O
signs	O
and	O
symptoms	O
of	O
hypophysitis	O
,	O
adrenal	O
insufficiency	O
(	O
including	O
adrenal	O
crisis	O
)	O
,	O
and	O
hyper-	O
or	O
hypothyroidism	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
In	O
addition	O
to	O
adverse	O
reactions	O
reported	O
from	O
clinical	O
trials	O
,	O
the	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
BREO	O
ELLIPTA	O
.	O
	
Similar	O
to	O
the	O
controlled	O
studies	O
,	O
most	O
adverse	O
events	O
of	O
dry	B
mouth	I
and	O
constipation	B
were	O
mild	O
to	O
moderate	O
in	O
intensity	O
.	O
	
The	O
safety	O
and	O
effectiveness	O
of	O
HORIZANT	O
in	O
patients	O
with	O
epilepsy	O
have	O
not	O
been	O
studied	O
.	O
	
In	O
a	O
long-term	O
(	O
52-week	O
)	O
,	O
double-blind	O
,	O
comparator-controlled	O
adult	O
trial	O
that	O
included	O
primarily	O
patients	O
with	O
schizophrenia	O
,	O
the	O
mean	O
decrease	B
in	I
prolactin	I
from	O
baseline	O
for	O
SAPHRIS-treated	O
patients	O
was	O
26.9	O
ng/mL	O
.	O
	
(	O
2.3,5.4	O
)	O
*	O
Keratitis	B
:	O
Occurs	O
in	O
0.8	O
%	O
of	O
patients	O
.	O
	
Patients	O
receiving	O
any	O
therapy	O
for	O
chronic	O
infection	O
should	O
not	O
begin	O
therapy	O
with	O
BENLYSTA	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Infections	B
leading	O
to	O
discontinuation	O
of	O
treatment	O
occurred	O
in	O
0.7	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
1.0	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
5.3	O
Decreased	O
Gastrointestinal	O
Motility	O
Toviaz	O
,	O
like	O
other	O
antimuscarinic	O
drugs	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
decreased	O
gastrointestinal	O
motility	O
,	O
such	O
as	O
those	O
with	O
severe	O
constipation	O
.	O
	
*	O
Renal	B
Failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Of	O
the	O
586	O
subjects	O
,	O
59	O
%	O
were	O
female	O
and	O
84	O
%	O
were	O
white	O
;	O
the	O
mean	O
age	O
was	O
46	O
years	O
.	O
	
*	O
You	O
should	O
not	O
remove	O
DUAVEE	O
from	O
the	O
blister	O
until	O
right	O
before	O
you	O
are	O
ready	O
to	O
take	O
it	O
.	O
	
Acute	B
cardiorespiratory	I
failure	I
,	O
possibly	O
associated	O
with	O
fluid	B
overload	I
,	O
has	O
been	O
reported	O
in	O
infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
pre-existing	O
hypertrophic	O
cardiomyopathy	O
[	O
seeBoxed	O
WarningandWarning	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
ENTEREG	O
is	O
available	O
only	O
through	O
a	O
program	O
under	O
a	O
REMS	O
that	O
restricts	O
use	O
to	O
enrolled	O
hospitals	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Monitoring	O
of	O
complete	O
blood	O
count	O
is	O
recommended	O
prior	O
to	O
the	O
start	O
of	O
AFINITOR	O
therapy	O
and	O
periodically	O
thereafter	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
10	O
%	O
)	O
that	O
occurred	O
more	O
commonly	O
(	O
>	O
=	O
2	O
%	O
over	O
placebo	O
)	O
in	O
the	O
XTANDI-treated	O
patients	O
from	O
the	O
two	O
randomized	O
clinical	O
trials	O
were	O
asthenia/fatigue	O
,	O
back	B
pain	I
,	O
decreased	B
appetite	I
,	O
constipation	B
,	O
arthralgia	B
,	O
diarrhea	B
,	O
hot	B
flush	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
peripheral	B
edema	I
,	O
dyspnea	B
,	O
musculoskeletal	B
pain	I
,	O
weight	B
decreased	I
,	O
headache	B
,	O
hypertension	B
,	O
and	O
dizziness/vertigo	O
.	O
	
Consider	O
the	O
potential	O
risks	O
and	O
benefits	O
prior	O
to	O
the	O
administration	O
of	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
.	O
	
*	O
Discontinuation	B
Syndrome	I
:	O
Taper	O
dose	O
when	O
possible	O
and	O
monitor	O
for	O
discontinuation	O
symptoms	O
(	O
5.7	O
)	O
.	O
	
Patients	O
with	O
moderate	O
renal	O
impairment	O
at	O
baseline	O
had	O
larger	O
mean	O
changes	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
,	O
8.6	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
*	O
For	O
48	O
hours	O
after	O
VORAXAZE	O
administration	O
,	O
determine	O
the	O
leucovorin	O
dose	O
based	O
on	O
the	O
patient	O
's	O
pre-VORAXAZE	O
methotrexate	O
concentration	O
.	O
	
(	O
5.4	O
)	O
5.1	O
Serious	O
Infections	O
ILARIS	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	B
.	O
	
Phimosis	B
occurred	O
more	O
frequently	O
in	O
male	O
patients	O
treated	O
with	O
JARDIANCE	O
10	O
mg	O
(	O
less	O
than	O
0.1	O
%	O
)	O
and	O
JARDIANCE	O
25	O
mg	O
(	O
0.1	O
%	O
)	O
than	O
placebo	O
(	O
0	O
%	O
)	O
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
,	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Interruption	O
of	O
Prolia	O
therapy	O
should	O
be	O
considered	O
,	O
pending	O
a	O
risk/benefit	O
assessment	O
,	O
on	O
an	O
individual	O
basis	O
.	O
	
Because	O
they	O
are	O
reported	O
from	O
a	O
population	O
of	O
unknown	O
size	O
,	O
precise	O
estimates	O
of	O
frequency	O
can	O
not	O
be	O
made	O
.	O
	
*	O
Increased	O
risk	O
of	O
suicidal	B
thinking	I
in	O
children	O
,	O
adolescents	O
and	O
young	O
adults	O
taking	O
antidepressants	O
(	O
5.1	O
)	O
.	O
	
For	O
patients	O
with	O
mild	O
(	O
Child-Pugh	O
class	O
A	O
)	O
or	O
moderate	O
(	O
Child-Pugh	O
class	O
B	O
)	O
hepatic	O
impairment	O
,	O
a	O
dose	O
reduction	O
is	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
In	O
a	O
clinical	O
trial	O
of	O
liver	O
transplant	O
patients	O
,	O
use	O
of	O
NULOJIX	O
regimens	O
with	O
more	O
frequent	O
administration	O
of	O
belatacept	O
than	O
any	O
of	O
those	O
studied	O
in	O
kidney	O
transplant	O
,	O
along	O
with	O
mycophenolate	O
mofetil	O
(	O
MMF	O
)	O
and	O
corticosteroids	O
,	O
was	O
associated	O
with	O
a	O
higher	O
rate	O
of	O
graft	B
loss	I
and	O
death	B
compared	O
to	O
the	O
tacrolimus	O
control	O
arms	O
.	O
	
history	O
of	O
hypoparathyroidism	O
,	O
thyroid	O
surgery	O
,	O
parathyroid	O
surgery	O
,	O
malabsorption	O
syndromes	O
,	O
excision	O
of	O
small	O
intestine	O
,	O
severe	O
renal	O
impairment	O
[	O
creatinine	O
clearance	O
<	O
30	O
mL/min	O
]	O
or	O
receiving	O
dialysis	O
)	O
,	O
clinical	O
monitoring	O
of	O
calcium	O
and	O
mineral	O
levels	O
(	O
phosphorus	O
and	O
magnesium	O
)	O
is	O
highly	O
recommended	O
within	O
14	O
days	O
of	O
Prolia	O
injection	O
.	O
	
Delay	O
in	O
diagnosis	O
and	O
treatment	O
may	O
lead	O
to	O
permanent	O
neurological	O
sequelae	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
controlled	O
but	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
VORAXAZE	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
other	O
drugs	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
The	O
experience	O
in	O
open-label	O
clinical	O
trials	O
is	O
consistent	O
with	O
the	O
safety	O
profile	O
observed	O
in	O
the	O
placebo-controlled	O
clinical	O
trials	O
.	O
	
Patients	O
who	O
seroconvert	O
may	O
be	O
at	O
a	O
higher	O
risk	O
of	O
a	O
hypersensitivity	O
reaction	O
.	O
	
In	O
total	O
,	O
11	O
%	O
of	O
the	O
patients	O
treated	O
with	O
ELIQUIS	O
2.5	O
mg	O
twice	O
daily	O
experienced	O
adverse	O
reactions	O
.	O
	
Hepatic	O
Transaminases	O
Elevations	B
of	I
transaminases	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
ILARIS	O
.	O
	
Permanently	O
discontinue	O
TAFINLAR	O
for	O
RAS	O
mutation-positive	O
non-cutaneous	O
malignancies	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
the	O
patient	O
and	O
health	O
care	O
worker	O
(	O
5.3	O
)	O
.	O
	
New	O
primary	B
melanoma	I
occurred	O
in	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
and	O
in	O
none	O
of	O
the	O
55	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Adverse	B
reactions	I
of	I
the	I
hematologic	I
system	I
,	O
including	O
medically	O
significant	O
cytopenia	B
(	O
e.g.	O
,	O
leukopenia	B
,	O
pancytopenia	B
,	O
thrombocytopenia	B
)	O
have	O
been	O
infrequently	O
reported	O
with	O
CIMZIA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Figure	O
1	O
:	O
Major	O
Bleeding	B
Hazard	O
Ratios	O
by	O
Baseline	O
Characteristics	O
-	O
ARISTOTLE	O
Study	O
Note	O
:	O
The	O
figure	O
above	O
presents	O
effects	O
in	O
various	O
subgroups	O
,	O
all	O
of	O
which	O
are	O
baseline	O
characteristics	O
and	O
all	O
of	O
which	O
were	O
pre-specified	O
,	O
if	O
not	O
the	O
groupings	O
.	O
	
Monitor	O
serum	O
glucose	O
levels	O
as	O
clinically	O
appropriate	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
in	O
patients	O
with	O
pre-existing	O
diabetes	O
or	O
hyperglycemia	O
.	O
	
Corticosteroid	O
utilization	O
should	O
be	O
consistent	O
with	O
the	O
NULOJIX	O
clinical	O
trial	O
experience	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
For	O
patients	O
requiring	O
invasive	O
dental	O
procedures	O
,	O
clinical	O
judgment	O
of	O
the	O
treating	O
physician	O
and/or	O
oral	O
surgeon	O
should	O
guide	O
the	O
management	O
plan	O
of	O
each	O
patient	O
based	O
on	O
individual	O
benefit-risk	O
assessment	O
.	O
	
Discontinue	O
GRANIX	O
if	O
suspected	O
(	O
5.2	O
)	O
*	O
Allergic	B
reactions	I
(	O
angioneurotic	B
edema	I
,	O
dermatitis	B
allergic	I
,	O
drug	B
hypersensitivity	I
,	O
hypersensitivity	B
,	O
rash	B
,	O
pruritic	B
rash	I
and	O
urticaria	B
)	O
(	O
5.3	O
)	O
*	O
Sickle	B
cell	I
crisis	I
:	O
Severe	O
and	O
sometimes	O
fatal	B
crisis	O
can	O
occur	O
.	O
	
The	O
most	O
common	O
reason	O
for	O
dose	O
reduction	O
was	O
anemia	B
,	O
which	O
occurred	O
more	O
frequently	O
in	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
than	O
in	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
For	O
patients	O
receiving	O
hemodialysis	O
,	O
physicians	O
may	O
consider	O
the	O
prompt	O
initiation	O
of	O
hemodialysis	O
following	O
the	O
administration	O
of	O
a	O
GBCA	O
in	O
order	O
to	O
enhance	O
the	O
contrast	O
agent	O
's	O
elimination	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
ULORIC	O
.	O
	
Almost	O
all	O
of	O
these	O
patients	O
had	O
received	O
treatment	O
with	O
the	O
immunosuppressants	O
azathioprine	O
and/or	O
6-mercaptopurine	O
(	O
6-MP	O
)	O
concomitantly	O
with	O
a	O
TNF	O
blocker	O
at	O
or	O
prior	O
to	O
diagnosis	O
.	O
	
5.6	O
Alpha-Blockers	O
and	O
Other	O
Antihypertensives	O
Physicians	O
should	O
discuss	O
with	O
patients	O
the	O
potential	O
for	O
STENDRA	O
to	O
augment	O
the	O
blood	O
pressure-lowering	O
effect	O
of	O
alpha-blockers	O
and	O
other	O
antihypertensive	O
medications	O
[	O
seeDrug	O
Interactions	O
(	O
7.1	O
)	O
andClinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Nephrotic	B
syndrome	I
secondary	O
to	O
membranous	B
glomerulonephritis	I
was	O
observed	O
in	O
some	O
Pompe	O
disease	O
patients	O
treated	O
with	O
alglucosidase	O
alfa	O
who	O
had	O
persistently	O
positive	B
anti-rhGAA	I
IgG	I
antibody	I
titers	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
associated	O
with	O
infusion-related	B
reactions	I
were	O
nausea	B
(	O
4	O
%	O
)	O
,	O
chills	B
(	O
4	O
%	O
)	O
,	O
dyspnea	B
(	O
2	O
%	O
)	O
,	O
headache	B
(	O
2	O
%	O
)	O
,	O
pruritus	B
(	O
2	O
%	O
)	O
,	O
rash	B
(	O
2	O
%	O
)	O
,	O
back	B
pain	I
(	O
2	O
%	O
)	O
,	O
and	O
vomiting	B
(	O
2	O
%	O
)	O
.	O
	
Table	O
6	O
presents	O
the	O
most	O
common	O
adverse	O
drug	O
reactions	O
(	O
experienced	O
by	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
of	O
pediatric	O
patients	O
6	O
years	O
and	O
older	O
receiving	O
PROMACTA	O
)	O
across	O
the	O
two	O
placebo-controlled	O
trials	O
,	O
with	O
a	O
higher	O
incidence	O
for	O
PROMACTA	O
versus	O
placebo	O
.	O
	
5.5	O
Gallbladder	O
Disease	O
A	O
2-	O
to	O
4-fold	O
increase	O
in	O
the	O
risk	O
of	O
gallbladder	B
disease	I
requiring	O
surgery	O
in	O
postmenopausal	O
women	O
receiving	O
estrogens	O
has	O
been	O
reported	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
(	O
N	O
=	O
586	O
)	O
,	O
the	O
incidence	O
of	O
cuSCC	B
was	O
11	O
%	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
neutropenia	B
,	O
anemia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
fatigue	B
,	O
nausea	B
,	O
pyrexia	B
,	O
rash	B
,	O
diarrhea	B
,	O
and	O
pain	B
.	O
	
However	O
,	O
the	O
duration	O
of	O
exposure	O
associated	O
with	O
increased	O
risk	O
is	O
not	O
consistent	O
across	O
all	O
epidemiologic	O
studies	O
,	O
and	O
some	O
report	O
no	O
association	O
.	O
	
5.8	O
Combination	O
with	O
Other	O
PDE5	O
Inhibitors	O
or	O
Erectile	O
Dysfunction	O
Therapies	O
The	O
safety	O
and	O
efficacy	O
of	O
combinations	O
of	O
STENDRA	O
with	O
other	O
treatments	O
for	O
ED	O
has	O
not	O
been	O
studied	O
.	O
	
Coartem	O
Tablets	O
should	O
be	O
avoided	O
in	O
patients	O
:	O
*	O
with	O
congenital	O
prolongation	O
of	O
the	O
QT	O
interval	O
(	O
e.g.	O
,	O
long	O
QT	O
syndrome	O
)	O
or	O
any	O
other	O
clinical	O
condition	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
such	O
as	O
patients	O
with	O
a	O
history	O
of	O
symptomatic	O
cardiac	O
arrhythmias	O
,	O
with	O
clinically	O
relevant	O
bradycardia	O
or	O
with	O
severe	O
cardiac	O
disease	O
.	O
	
Most	O
Common	O
Adverse	O
Reactions	O
No	O
adverse	O
reactions	O
occurred	O
in	O
greater	O
than	O
5	O
%	O
of	O
patients	O
receiving	O
Teflaro	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bristol-Myers	O
Squibb	O
at	O
1-800-721-5072	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
5.5	O
Interference	O
with	O
Laboratory	O
Tests	O
Serum	O
iron	O
determination	O
using	O
complexometric	O
methods	O
(	O
for	O
example	O
,	O
ferrocene	O
complexation	O
method	O
)	O
may	O
result	O
in	O
falsely	O
high	O
or	O
low	O
values	O
for	O
up	O
to	O
24	O
hours	O
after	O
the	O
examination	O
with	O
EOVIST	O
because	O
of	O
the	O
caloxetate	O
trisodium	O
excipients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
some	O
instances	O
,	O
HBV	B
reactivation	I
occurring	O
in	O
conjunction	O
with	O
TNF	O
blocker	O
therapy	O
has	O
been	O
fatal	B
.	O
	
Consideration	O
should	O
be	O
given	O
to	O
changing	O
the	O
therapeutic	O
regimen	O
,	O
including	O
possibly	O
discontinuing	O
the	O
medication	O
,	O
in	O
patients	O
whose	O
depression	O
is	O
persistently	O
worse	O
,	O
or	O
who	O
are	O
experiencing	O
emergent	O
suicidality	O
or	O
symptoms	O
that	O
might	O
be	O
precursors	O
to	O
worsening	O
depression	O
or	O
suicidality	O
,	O
especially	O
if	O
these	O
symptoms	O
are	O
severe	O
,	O
abrupt	O
in	O
onset	O
,	O
or	O
were	O
not	O
part	O
of	O
the	O
patient	O
's	O
presenting	O
symptoms	O
.	O
	
Table	O
4	O
Selected	O
Hematological	O
Parameters	O
Previously	O
Untreated	O
(	O
SPRINT-1	O
and	O
SPRINT-2	O
)	O
Previous	O
Treatment	O
Failures	O
(	O
RESPOND-2	O
)	O
Percentage	O
of	O
Subjects	O
Reporting	O
Selected	O
Hematological	O
Parameters	O
Percentage	O
of	O
Subjects	O
Reporting	O
Selected	O
Hematological	O
Parameters	O
Hematological	O
Parameters	O
VICTRELIS	O
+	O
PegIntron	O
+	O
REBETOL	O
(	O
n=1225	O
)	O
PegIntron	O
+	O
REBETOL	O
(	O
n=467	O
)	O
VICTRELIS	O
+	O
PegIntron	O
+	O
REBETOL	O
(	O
n=323	O
)	O
PegIntron	O
+	O
REBETOL	O
(	O
n=80	O
)	O
Hemoglobin	B
(	I
g/dL	I
)	I
6	O
3	O
10	O
1	O
Neutrophils	B
(	I
*	I
10	I
9	I
/L	I
)	I
8	O
4	O
7	O
4	O
Platelets	B
(	I
*	I
10	I
9	I
/L	I
)	I
<	O
1	O
0	O
0	O
0	O
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
The	O
most	O
common	O
reported	O
adverse	O
reaction	O
occurring	O
in	O
approximately	O
25	O
%	O
of	O
subjects	O
was	O
a	O
mild	O
taste	B
following	I
instillation	I
.	O
	
Four	O
patients	O
(	O
1	O
%	O
)	O
treated	O
with	O
PROMACTA	O
and	O
three	O
patients	O
in	O
the	O
placebo	O
group	O
(	O
2	O
%	O
)	O
discontinued	O
treatment	O
due	O
to	O
hepatobiliary	B
laboratory	I
abnormalities	I
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Palmar-plantar	B
erythrodysesthesia	I
syndrome	I
,	O
hyperkeratosis	B
,	O
hyperhidrosis	B
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
adult	O
trials	O
of	O
therapeutic	O
doses	O
(	O
5-10	O
mg	O
twice	O
daily	O
)	O
,	O
somnolence	B
was	O
reported	O
in	O
24	O
%	O
(	O
90/379	O
)	O
of	O
patients	O
on	O
SAPHRIS	O
compared	O
to	O
6	O
%	O
(	O
13/203	O
)	O
of	O
placebo	O
patients	O
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
including	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
In	O
the	O
pooled	O
Phase	O
3	O
CABP	O
trials	O
,	O
51/520	O
(	O
9.8	O
%	O
)	O
of	O
Teflaro-treated	O
patients	O
compared	O
to	O
24/534	O
(	O
4.5	O
%	O
)	O
of	O
ceftriaxone-treated	O
patients	O
seroconverted	B
from	I
a	I
negative	I
to	I
a	I
positive	I
direct	I
Coombs	I
'	I
test	I
result	I
.	O
	
Such	O
an	O
event	O
may	O
be	O
a	O
sign	O
of	O
non-arteritic	B
anterior	I
ischemic	I
optic	I
neuropathy	I
(	O
NAION	B
)	O
,	O
a	O
rare	O
condition	O
and	O
a	O
cause	O
of	O
decreased	B
vision	I
including	O
permanent	B
loss	I
of	I
vision	I
that	O
has	O
been	O
reported	O
rarely	O
postmarketing	O
in	O
temporal	O
association	O
with	O
the	O
use	O
of	O
all	O
PDE5	O
inhibitors	O
.	O
	
No	O
serious	O
infusion	B
reactions	I
were	O
reported	O
.	O
	
f	O
Includes	O
the	O
following	O
terms	O
:	O
renal	B
failure	I
and	O
renal	B
failure	I
acute	I
.	O
	
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
after	O
an	O
average	O
follow-up	O
of	O
7.1	O
years	O
,	O
daily	O
conjugated	O
estrogen	O
(	O
0.625	O
mg	O
)	O
-alone	O
was	O
not	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
invasive	B
breast	I
cancer	I
(	O
relative	O
risk	O
[	O
RR	O
]	O
0.80	O
)	O
.	O
	
5.13	O
Body	O
Temperature	O
Regulation	O
Disruption	B
of	I
the	I
body	I
's	I
ability	I
to	I
reduce	I
core	I
body	I
temperature	I
has	O
been	O
attributed	O
to	O
antipsychotic	O
agents	O
.	O
	
Before	O
administering	O
Vizamyl	O
,	O
ask	O
patients	O
about	O
prior	O
reactions	O
to	O
drugs	O
,	O
especially	O
those	O
containing	O
polysorbate	O
80	O
.	O
	
MULTAQ	O
is	O
contraindicated	O
in	O
patients	O
in	O
atrial	O
fibrillation	O
(	O
AF	O
)	O
who	O
will	O
not	O
or	O
can	O
not	O
be	O
cardioverted	O
into	O
normal	O
sinus	O
rhythm	O
.	O
	
In	O
this	O
clinical	O
context	O
,	O
if	O
the	O
patient	O
is	O
found	O
to	O
have	O
abnormal	O
liver	O
tests	O
(	O
ALT	O
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
the	O
reference	O
range	O
)	O
,	O
ULORIC	O
treatment	O
should	O
be	O
interrupted	O
and	O
investigation	O
done	O
to	O
establish	O
the	O
probable	O
cause	O
.	O
	
Have	O
resuscitation	O
equipment	O
and	O
trained	O
personnel	O
immediately	O
available	O
at	O
the	O
time	O
of	O
Vizamyl	O
administration	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
In	O
the	O
short-term	O
placebo-controlled	O
trials	O
for	O
both	O
schizophrenia	O
and	O
acute	O
bipolar	O
disorder	O
,	O
the	O
incidence	O
of	O
adverse	O
reactions	O
suggestive	O
of	O
body	B
temperature	I
increases	I
was	O
low	O
(	O
<	O
=1	O
%	O
)	O
and	O
comparable	O
to	O
placebo	O
(	O
0	O
%	O
)	O
.	O
	
Breast	O
Cancer	O
The	O
most	O
important	O
randomized	O
clinical	O
study	O
providing	O
information	O
about	O
breast	O
cancer	O
in	O
estrogen-alone	O
users	O
is	O
the	O
WHI	O
substudy	O
of	O
daily	O
conjugated	O
estrogens	O
(	O
0.625	O
mg	O
)	O
-alone	O
.	O
	
Other	O
clinically	O
important	O
adverse	O
reactions	O
(	O
N	O
=	O
202	O
)	O
observed	O
in	O
<	O
10	O
%	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
were	O
:	O
Eye	O
Disorders	O
:	O
Vision	B
blurred	I
,	O
transient	B
blindness	I
.	O
	
ULORIC	O
should	O
not	O
be	O
restarted	O
in	O
these	O
patients	O
without	O
another	O
explanation	O
for	O
the	O
liver	O
test	O
abnormalities	O
.	O
	
*	O
Before	O
Gadavist	O
administration	O
,	O
assess	O
all	O
patients	O
for	O
any	O
history	O
of	O
a	O
reaction	O
to	O
contrast	O
media	O
,	O
bronchial	O
asthma	O
and/or	O
allergic	O
disorders	O
.	O
	
(	O
4	O
,	O
5.2	O
)	O
EXCERPT	O
:	O
WARNING	O
:	O
INCREASED	O
RISK	O
OF	O
DEATH	B
,	O
STROKE	B
AND	O
HEART	B
FAILURE	I
IN	O
PATIENTS	O
WITH	O
DECOMPENSATED	O
HEART	O
FAILURE	O
OR	O
PERMANENT	O
ATRIAL	O
FIBRILLATION	O
MULTAQ	O
is	O
contraindicated	O
in	O
patients	O
with	O
symptomatic	O
heart	O
failure	O
with	O
recent	O
decompensation	O
requiring	O
hospitalization	O
or	O
NYHA	O
Class	O
IV	O
heart	O
failure	O
.	O
	
Other	O
adverse	O
reactions	O
occurring	O
in	O
2-5	O
%	O
of	O
subjects	O
were	O
eye	B
irritation	I
,	O
headache	B
,	O
and	O
nasopharyngitis	B
.	O
	
If	O
peginterferon	O
alfa	O
is	O
permanently	O
discontinued	O
,	O
then	O
ribavirin	O
and	O
VICTRELIS	O
must	O
also	O
be	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
No	O
adverse	O
reactions	O
representing	O
hemolytic	B
anemia	I
were	O
reported	O
in	O
any	O
treatment	O
group	O
.	O
	
During	O
adult	O
pre-marketing	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
somnolence	B
was	O
reported	O
in	O
18	O
%	O
(	O
358/1953	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
Vascular	O
Disorders	O
:	O
Hypertension	B
.	O
	
Treatment-related	O
Adverse	O
Reactions	O
(	O
>	O
=3	O
%	O
)	O
from	O
Extension	O
Trial	O
in	O
Adults	O
with	O
Chronic	O
Immune	O
(	O
Idiopathic	O
)	O
Thrombocytopenia	O
Adverse	O
Reaction	O
PROMACTA	O
50	O
mg	O
n	O
=	O
299	O
(	O
%	O
)	O
Headache	B
10	O
Hyperbilirubinemia	B
6	O
ALT	B
increased	I
6	O
Cataract	B
5	O
AST	B
increased	I
4	O
Fatigue	B
4	O
Nausea	B
4	O
In	O
the	O
three	O
controlled	O
chronic	O
ITP	O
trials	O
,	O
serum	B
liver	I
test	I
abnormalities	I
(	O
predominantly	O
Grade	O
2	O
or	O
less	O
in	O
severity	O
)	O
were	O
reported	O
in	O
11	O
%	O
and	O
7	O
%	O
of	O
patients	O
for	O
PROMACTA	O
and	O
placebo	O
,	O
respectively	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
>	O
2	O
%	O
of	O
patients	O
receiving	O
Teflaro	O
in	O
the	O
pooled	O
phase	O
3	O
clinical	O
trials	O
were	O
diarrhea	B
,	O
nausea	B
,	O
and	O
rash	B
.	O
	
*	O
with	O
a	O
family	O
history	O
of	O
congenital	O
prolongation	O
of	O
the	O
QT	O
interval	O
or	O
sudden	O
death	O
.	O
	
Some	O
patients	O
have	O
been	O
able	O
to	O
be	O
rechallenged	O
and	O
have	O
continued	O
to	O
receive	O
alglucosidase	O
alfa	O
under	O
close	O
clinical	O
supervision	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
such	O
combinations	O
is	O
not	O
recommended	O
.	O
	
Ovarian	O
Cancer	O
In	O
some	O
epidemiological	O
studies	O
,	O
the	O
use	O
of	O
estrogen-only	O
products	O
,	O
in	O
particular	O
for	O
5	O
or	O
more	O
years	O
,	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
ovarian	B
cancer	I
.	O
	
Table	O
7	O
.	O
	
The	O
median	O
time	O
to	O
first	O
cuSCC	B
was	O
9	O
weeks	O
(	O
range	O
:	O
1	O
to	O
53	O
weeks	O
)	O
.	O
	
If	O
the	O
decision	O
has	O
been	O
made	O
to	O
discontinue	O
treatment	O
,	O
medication	O
should	O
be	O
tapered	O
,	O
as	O
rapidly	O
as	O
is	O
feasible	O
,	O
but	O
with	O
recognition	O
that	O
abrupt	O
discontinuation	O
can	O
be	O
associated	O
with	O
certain	O
symptoms	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
for	O
a	O
description	O
of	O
the	O
risks	O
of	O
discontinuation	O
of	O
PRISTIQ	O
]	O
.	O
	
The	O
majority	O
of	O
reports	O
have	O
occurred	O
in	O
patients	O
concomitantly	O
receiving	O
other	O
medications	O
that	O
suppress	O
the	O
immune	O
system	O
,	O
which	O
may	O
also	O
contribute	O
to	O
HBV	B
reactivation	I
.	O
	
If	O
liver	O
injury	O
is	O
detected	O
,	O
promptly	O
interrupt	O
ULORIC	O
and	O
assess	O
patient	O
for	O
probable	O
cause	O
,	O
then	O
treat	O
cause	O
if	O
possible	O
,	O
to	O
resolution	O
or	O
stabilization	O
.	O
	
It	O
is	O
uncertain	O
whether	O
the	O
occurrence	O
of	O
HSTCL	O
is	O
related	O
to	O
use	O
of	O
a	O
TNF	O
blocker	O
or	O
a	O
TNF	O
blocker	O
in	O
combination	O
with	O
these	O
other	O
immunosuppressants	O
.	O
	
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
EOVIST	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
prior	O
to	O
any	O
re-administration	O
.	O
	
Adverse	O
reactions	O
that	O
led	O
to	O
dose	O
modifications	O
of	O
any	O
drug	O
(	O
primarily	O
PegIntron	O
and	O
REBETOL	O
)	O
occurred	O
in	O
39	O
%	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
24	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
Pediatric	O
Patients	O
:	O
The	O
data	O
described	O
below	O
reflect	O
median	O
exposure	O
to	O
PROMACTA	O
of	O
91	O
days	O
for	O
82	O
pediatric	O
patients	O
(	O
aged	O
6	O
to	O
17	O
years	O
)	O
with	O
chronic	O
ITP	O
,	O
of	O
whom	O
52	O
%	O
were	O
female	O
,	O
across	O
the	O
randomized	O
phase	O
of	O
two	O
placebo-controlled	O
trials	O
.	O
	
Drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
,	O
including	O
antimalarials	O
such	O
as	O
quinine	O
and	O
quinidine	O
,	O
should	O
be	O
used	O
cautiously	O
following	O
Coartem	O
Tablets	O
,	O
due	O
to	O
the	O
long	O
elimination	O
half-life	O
of	O
lumefantrine	O
(	O
3	O
to	O
6	O
days	O
)	O
and	O
the	O
potential	O
for	O
additive	O
effects	O
on	O
the	O
QT	O
interval	O
;	O
ECG	O
monitoring	O
is	O
advised	O
if	O
use	O
of	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
is	O
medically	O
required	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.7	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
In	O
these	O
patients	O
,	O
renal	O
biopsy	O
was	O
consistent	O
with	O
immune	B
complex	I
deposition	I
.	O
	
Caution	O
is	O
advised	O
when	O
PDE5	O
inhibitors	O
are	O
co-administered	O
with	O
alpha-blockers	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Need	O
for	O
Aseptic	O
Technique	O
Use	O
aseptic	O
technique	O
and	O
discard	O
any	O
unused	O
product	O
within	O
12	O
hours	O
of	O
stopper	O
puncture	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
range	O
of	O
time	O
to	O
diagnosis	O
of	O
cuSCC	B
was	O
136	O
to197	O
days	O
in	O
the	O
combination	O
arm	O
and	O
was	O
9	O
to	O
197	O
days	O
in	O
the	O
arm	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
5.1	O
Imaging	O
Errors	O
Imaging	O
errors	O
have	O
been	O
reported	O
with	O
11	O
C-choline	O
PET	O
and	O
PET/CT	O
imaging	O
.	O
	
Discontinue	O
GRANIX	O
if	O
suspected	O
(	O
5.4	O
)	O
*	O
Capillary	B
Leak	I
Syndrome	I
:	O
Monitor	O
if	O
symptoms	O
develop	O
and	O
administer	O
standard	O
symptomatic	O
treatment	O
(	O
5.5	O
)	O
5.1	O
Splenic	O
Rupture	O
Splenic	B
rupture	I
,	O
including	O
fatal	B
cases	O
,	O
can	O
occur	O
following	O
administration	O
of	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
.	O
	
Patients	O
who	O
are	O
suspected	O
of	O
having	O
or	O
who	O
develop	O
ONJ	O
while	O
on	O
Prolia	O
should	O
receive	O
care	O
by	O
a	O
dentist	O
or	O
an	O
oral	O
surgeon	O
.	O
	
5.8	O
Immunizations	O
The	O
use	O
of	O
live	O
vaccines	O
should	O
be	O
avoided	O
during	O
treatment	O
with	O
NULOJIX	O
,	O
including	O
but	O
not	O
limited	O
to	O
the	O
following	O
:	O
intranasal	O
influenza	O
,	O
measles	O
,	O
mumps	O
,	O
rubella	O
,	O
oral	O
polio	O
,	O
BCG	O
,	O
yellow	O
fever	O
,	O
varicella	O
,	O
and	O
TY21a	O
typhoid	O
vaccines	O
.	O
	
In	O
Trial	O
2	O
,	O
the	O
incidence	O
of	O
Grade	O
3	O
hyperglycemia	B
based	O
on	O
laboratory	O
values	O
was	O
5	O
%	O
(	O
3/55	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
2	O
%	O
(	O
1/53	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
[	O
see	O
Contraindications	O
(	O
4	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
ANAPHYLAXIS	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
Anaphylaxis	B
has	O
been	O
reported	O
after	O
administration	O
of	O
KALBITOR	O
(	O
r	O
)	O
.	O
	
5.7	O
Hematological	O
Reactions	O
Rare	O
reports	O
of	O
pancytopenia	B
,	O
including	O
aplastic	B
anemia	I
,	O
have	O
been	O
reported	O
with	O
TNF	O
blockers	O
.	O
	
Anti-ecallantide	O
IgE	O
antibodies	O
were	O
detected	O
at	O
a	O
rate	O
of	O
4.7	O
%	O
for	O
tested	O
patients	O
,	O
and	O
anti-	O
P.	O
pastoris	O
IgE	O
antibodies	O
were	O
also	O
detected	O
at	O
a	O
rate	O
of	O
20.2	O
%	O
.	O
	
Bleeding	B
results	O
during	O
the	O
treatment	O
period	O
in	O
the	O
Phase	O
III	O
studies	O
are	O
shown	O
in	O
Table	O
3	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
call	O
877-377-3784	O
or	O
contact	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
If	O
PRES	O
is	O
suspected	O
,	O
GILENYA	O
should	O
be	O
discontinued	O
.	O
	
Monitor	O
patients	O
receiving	O
the	O
combination	O
closely	O
for	O
signs	O
or	O
symptoms	O
of	O
non-cutaneous	O
malignancies	O
.	O
	
In	O
the	O
pool	O
of	O
five	O
placebo-controlled	O
clinical	O
trials	O
,	O
adverse	O
reactions	O
related	O
to	O
volume	B
depletion	I
(	O
e.g.	O
,	O
blood	B
pressure	I
(	I
ambulatory	I
)	I
decreased	I
,	O
blood	B
pressure	I
systolic	I
decreased	I
,	O
dehydration	B
,	O
hypotension	B
,	O
hypovolemia	B
,	O
orthostatic	B
hypotension	I
,	O
and	O
syncope	B
)	O
were	O
reported	O
by	O
0.3	O
%	O
,	O
0.5	O
%	O
,	O
and	O
0.3	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
respectively	O
.	O
	
In	O
the	O
randomized	O
,	O
placebo-controlled	O
portion	O
of	O
SJIA	O
Study	O
2	O
,	O
high	B
ALT	I
greater	O
than	O
or	O
equal	O
to	O
3	O
times	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
were	O
reported	O
in	O
2	O
(	O
4.1	O
%	O
)	O
ILARIS-treated	O
patients	O
and	O
1	O
(	O
2.0	O
%	O
)	O
placebo	O
patient	O
.	O
	
Discard	O
unused	O
portion	O
12	O
hours	O
after	O
stopper	O
puncture	O
.	O
	
In	O
addition	O
,	O
two	O
cases	O
of	O
PTLD	B
involving	O
the	O
liver	O
allograft	O
(	O
one	O
fatal	B
)	O
and	O
one	O
fatal	B
case	O
of	O
PML	B
were	O
observed	O
among	O
the	O
147	O
patients	O
randomized	O
to	O
NULOJIX	O
.	O
	
For	O
advanced	O
HR+	O
BC	O
,	O
advanced	O
PNET	O
,	O
advanced	O
RCC	O
,	O
and	O
renal	O
angiomyolipoma	O
with	O
TSC	O
patients	O
with	O
severe	O
hepatic	B
impairment	I
(	O
Child-Pugh	O
class	O
C	O
)	O
,	O
AFINITOR	O
may	O
be	O
used	O
at	O
a	O
reduced	O
dose	O
if	O
the	O
desired	O
benefit	O
outweighs	O
the	O
risk	O
.	O
	
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
.	O
]	O
	
Drugs	O
that	O
inhibit	O
CYP2D6	O
and	O
CYP3A	O
metabolism	O
pathways	O
may	O
significantly	O
increase	O
the	O
exposure	O
to	O
eliglustat	O
and	O
result	O
in	O
prolongation	B
of	I
the	I
PR	I
,	I
QTc	I
,	I
and/or	I
QRS	I
cardiac	I
intervals	I
that	O
could	O
result	O
in	O
cardiac	B
arrhythmias	I
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
SUICIDAL	B
THOUGHTS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Gastrointestinal	O
:	O
Gastritis	B
,	O
intestinal	B
obstruction	I
.	O
	
Reactions	O
can	O
occur	O
on	O
initial	O
exposure	O
.	O
	
5.6	O
Serious	O
Infections	O
In	O
a	O
clinical	O
trial	O
of	O
over	O
7800	O
women	O
with	O
postmenopausal	O
osteoporosis	O
,	O
serious	O
infections	B
leading	O
to	O
hospitalization	O
were	O
reported	O
more	O
frequently	O
in	O
the	O
Prolia	O
group	O
than	O
in	O
the	O
placebo	O
group	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Dose	O
delays	O
were	O
reported	O
in	O
28	O
%	O
of	O
JEVTANA-treated	O
patients	O
and	O
15	O
%	O
of	O
mitoxantrone-treated	O
patients	O
.	O
	
Discontinue	O
GRANIX	O
in	O
patients	O
undergoing	O
a	O
sickle	O
cell	O
crisis	O
.	O
	
Study	O
1	O
:	O
Metastatic	O
Castration-Resistant	O
Prostate	O
Cancer	O
Following	O
Chemotherapy	O
Study	O
1	O
enrolled	O
1199	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
previously	O
received	O
docetaxel	O
.	O
	
Hematologic	O
Parameters	O
Decreased	B
hemoglobin	I
have	O
been	O
reported	O
in	O
patients	O
taking	O
AFINITOR	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
These	O
adverse	O
reactions	O
were	O
not	O
present	O
at	O
baseline	O
,	O
occurred	O
more	O
commonly	O
on	O
TANZEUM	O
than	O
on	O
placebo	O
,	O
and	O
occurred	O
in	O
at	O
least	O
5	O
%	O
of	O
patients	O
treated	O
with	O
TANZEUM	O
.	O
	
(	O
5.3	O
)	O
*	O
Do	O
not	O
administer	O
leucovorin	O
within	O
2	O
hours	O
before	O
or	O
after	O
a	O
dose	O
of	O
VORAXAZE	O
.	O
	
ILARIS	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
a	O
positive	O
tuberculosis	O
screen	O
,	O
and	O
the	O
safety	O
of	O
ILARIS	O
in	O
individuals	O
with	O
latent	O
tuberculosis	O
infection	O
is	O
unknown	O
.	O
	
In	O
Study	O
1	O
,	O
all	O
patients	O
were	O
evaluated	O
for	O
LVEF	O
at	O
screening	O
and	O
every	O
9	O
weeks	O
thereafter	O
in	O
the	O
GILOTRIF-treated	O
group	O
and	O
as	O
needed	O
in	O
the	O
pemetrexed/cisplatin	O
group	O
.	O
	
*	O
Eye	O
disorders	O
:	O
infrequent	O
:	O
diplopia	B
,	O
vision	B
blurred	I
*	O
Gastrointestinal	O
disorders	O
:	O
infrequent	O
:	O
gastroesophageal	B
reflux	I
disease	I
*	O
Injury	O
,	O
Poisoning	O
,	O
and	O
Procedural	O
Complications	O
:	O
infrequent	O
:	O
fall	B
*	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
infrequent	O
:	O
photosensitivity	B
reaction	I
*	O
Renal	O
and	O
urinary	O
disorders	O
:	O
infrequent	O
:	O
enuresis	B
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
SAPHRIS	O
.	O
	
5.2	O
E.A.S.E	O
.	O
	
In	O
postmarketing	O
experience	O
with	O
alglucosidase	O
alfa	O
,	O
serious	O
adverse	O
reactions	O
have	O
been	O
reported	O
,	O
including	O
anaphylaxis	B
[	O
seeBoxed	O
WarningandWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Take	O
the	O
next	O
dose	O
at	O
your	O
regular	O
time	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Common	O
adverse	O
reactions	O
(	O
reported	O
in	O
>	O
=4	O
%	O
of	O
patients	O
treated	O
with	O
NESINA	O
25	O
mg	O
and	O
more	O
frequently	O
than	O
in	O
patients	O
who	O
received	O
placebo	O
)	O
are	O
:	O
nasopharyngitis	B
,	O
headache	B
and	O
upper	B
respiratory	I
tract	I
infection	I
.	O
	
Physicians	O
should	O
exercise	O
caution	O
when	O
considering	O
the	O
use	O
of	O
BENLYSTA	O
in	O
patients	O
with	O
chronic	O
infections	O
.	O
	
Withhold	O
or	O
discontinue	O
GILOTRIF	O
for	O
severe	O
or	O
worsening	O
liver	O
tests	O
.	O
	
[	O
See	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
.	O
]	O
	
Serious	O
adverse	O
events	O
,	O
judged	O
to	O
be	O
at	O
least	O
possibly	O
related	O
to	O
study	O
medication	O
by	O
the	O
investigator	O
and	O
reported	O
more	O
than	O
once	O
during	O
the	O
open-label	O
treatment	O
period	O
of	O
up	O
to	O
3	O
years	O
,	O
included	O
urinary	B
retention	I
(	O
3	O
cases	O
)	O
,	O
diverticulitis	B
(	O
3	O
cases	O
)	O
,	O
constipation	B
(	O
2	O
cases	O
)	O
,	O
irritable	B
bowel	I
syndrome	I
(	O
2	O
cases	O
)	O
,	O
and	O
electrocardiogram	O
QT	B
corrected	I
interval	I
prolongation	I
(	O
2	O
cases	O
)	O
.	O
	
Of	O
the	O
21	O
patients	O
with	O
moderate	O
to	O
life-threatening	O
endocrinopathy	B
,	O
17	O
patients	O
required	O
long-term	O
hormone	O
replacement	O
therapy	O
including	O
,	O
most	O
commonly	O
,	O
adrenal	O
hormones	O
(	O
n=10	O
)	O
and	O
thyroid	O
hormones	O
(	O
n=13	O
)	O
.	O
	
Four	O
(	O
0.6	O
%	O
)	O
subjects	O
who	O
received	O
STRIBILD	O
developed	O
laboratory	O
findings	O
consistent	O
with	O
proximal	B
renal	I
tubular	I
dysfunction	I
leading	O
to	O
discontinuation	O
of	O
STRIBILD	O
during	O
the	O
first	O
48	O
weeks	O
of	O
treatment	O
.	O
	
Through	O
96	O
weeks	O
,	O
the	O
rates	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
3	O
%	O
in	O
subjects	O
receiving	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
+	O
EPZICOM	O
and	O
12	O
%	O
in	O
subjects	O
receiving	O
ATRIPLA	O
once	O
daily	O
.	O
	
*	O
Increased	O
incidence	O
of	O
myocardial	B
infarction	I
was	O
seen	O
in	O
a	O
clinical	O
trial	O
of	O
patients	O
taking	O
alvimopan	O
for	O
long-term	O
use	O
.	O
	
(	O
5.8	O
)	O
5.1	O
Lactic	O
Acidosis/Severe	O
Hepatomegaly	O
with	O
Steatosis	O
Lactic	B
acidosis	I
and	O
severe	O
hepatomegaly	B
with	O
steatosis	B
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
nucleoside	O
analogs	O
,	O
including	O
tenofovir	O
DF	O
,	O
a	O
component	O
of	O
STRIBILD	O
,	O
in	O
combination	O
with	O
other	O
antiretrovirals	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
,	O
reported	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
,	O
that	O
led	O
to	O
dose	O
reductions	O
or	O
interruptions	O
were	O
:	O
increased	B
ALT	I
(	O
29	O
%	O
)	O
,	O
nausea	B
(	O
20	O
%	O
)	O
,	O
increased	B
AST	I
(	O
16	O
%	O
)	O
,	O
diarrhea	B
(	O
16	O
%	O
)	O
,	O
and	O
vomiting	B
(	O
16	O
%	O
)	O
.	O
	
Laboratory	O
Abnormalities	O
Transaminase	O
Elevations	O
:	O
In	O
Trials	O
1	O
,	O
2	O
,	O
and	O
3	O
the	O
incidence	O
of	O
maximum	O
AST	B
)	I
>	I
8	I
,	I
>	I
5	I
,	I
or	I
>	I
3	I
*	I
ULN	I
was	O
2	O
%	O
,	O
2	O
%	O
,	O
and	O
6	O
%	O
in	O
KALYDECO-treated	O
patients	O
and	O
2	O
%	O
,	O
2	O
%	O
,	O
and	O
8	O
%	O
in	O
placebo-treated	O
patients	O
,	O
respectively	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
was	O
61	O
years	O
(	O
range	O
28-93	O
years	O
)	O
,	O
and	O
75	O
%	O
were	O
Caucasian	O
.	O
	
Due	O
to	O
overlap	O
in	O
signs	O
and	O
symptoms	O
,	O
it	O
was	O
not	O
possible	O
to	O
distinguish	O
between	O
hypersensitivity	B
reactions	I
and	O
infusion	B
reactions	I
in	O
all	O
cases	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Grade	O
1-4	O
elevations	B
in	I
bilirubin	I
occurred	O
in	O
3	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
(	O
0.1	O
%	O
Grade	O
3-4	O
)	O
and	O
2	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
(	O
no	O
Grade	O
3-4	O
)	O
.	O
	
5.8	O
Concomitant	O
Use	O
with	O
Other	O
Biologic	O
Therapies	O
or	O
Intravenous	O
Cyclophosphamide	O
BENLYSTA	O
has	O
not	O
been	O
studied	O
in	O
combination	O
with	O
other	O
biologic	O
therapies	O
,	O
including	O
B-cell	O
targeted	O
therapies	O
,	O
or	O
intravenous	O
cyclophosphamide	O
.	O
	
(	O
5.7	O
)	O
*	O
Women	O
of	O
childbearing	O
potential	O
should	O
use	O
effective	O
contraception	O
during	O
and	O
for	O
2	O
months	O
after	O
stopping	O
GILENYA	O
.	O
	
*	O
During	O
and	O
following	O
DOTAREM	O
administration	O
,	O
observe	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
who	O
had	O
a	O
venous	O
thromboembolic	O
event	O
within	O
the	O
previous	O
6	O
months	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
of	O
Prolia	O
in	O
patients	O
with	O
postmenopausal	O
osteoporosis	O
are	O
back	B
pain	I
and	O
constipation	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
most	O
serious	O
adverse	O
reactions	O
were	O
:	O
*	O
Serious	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Malignancies	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Heart	B
Failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
and	O
controlled	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
,	O
and	O
may	O
not	O
predict	O
the	O
rates	O
observed	O
in	O
a	O
broader	O
patient	O
population	O
in	O
clinical	O
practice	O
.	O
	
It	O
is	O
not	O
known	O
if	O
DUAVEE	O
is	O
safe	O
and	O
effective	O
in	O
people	O
with	O
kidney	O
problems	O
.	O
	
Other	O
adverse	O
reactions	O
with	O
incidences	O
of	O
less	O
than	O
5	O
%	O
in	O
the	O
DYSPORT	O
(	O
r	O
)	O
500	O
Units	O
group	O
in	O
the	O
double-blind	O
phase	O
of	O
clinical	O
trials	O
included	O
dizziness	B
in	O
3.5	O
%	O
of	O
DYSPORT	O
(	O
r	O
)	O
-treated	O
patients	O
and	O
1	O
%	O
of	O
placebo-treated	O
patients	O
,	O
and	O
muscle	B
atrophy	I
in	O
1	O
%	O
of	O
DYSPORT	O
(	O
r	O
)	O
-treated	O
patients	O
and	O
in	O
none	O
of	O
the	O
placebo-treated	O
patients	O
.	O
	
Upper	O
Limb	O
Spasticity	O
Table	O
6	O
lists	O
the	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
in	O
any	O
DYSPORT	O
(	O
r	O
)	O
dose	O
group	O
and	O
more	O
frequent	O
than	O
placebo	O
in	O
double	O
blind	O
studies	O
evaluating	O
the	O
treatment	O
of	O
upper	O
limb	O
spasticity	O
in	O
adults	O
with	O
DYSPORT	O
(	O
r	O
)	O
.	O
	
Therapeutic	O
Infectious	O
Agents	O
Other	O
uses	O
of	O
therapeutic	O
infectious	O
agents	O
such	O
as	O
live	O
attenuated	O
bacteria	O
(	O
e.g.	O
,	O
BCG	O
bladder	O
instillation	O
for	O
the	O
treatment	O
of	O
cancer	O
)	O
could	O
result	O
in	O
clinical	O
infections	O
,	O
including	O
disseminated	O
infections	O
.	O
	
(	O
5.6	O
)	O
*	O
Risk	O
of	O
impaired	B
adrenal	I
function	I
when	O
transferring	O
from	O
systemic	O
corticosteroids	O
.	O
	
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
of	O
Treatment	O
:	O
A	O
total	O
of	O
6.7	O
%	O
(	O
7/104	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
5.1	O
%	O
(	O
5/99	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
5.1	O
%	O
(	O
5/99	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
discontinued	O
treatment	O
due	O
to	O
adverse	O
reactions	O
compared	O
to	O
4	O
%	O
(	O
4/101	O
)	O
on	O
placebo	O
.	O
	
The	O
majority	O
of	O
patients	O
who	O
reported	O
serious	O
depression	B
or	O
suicidal	B
behavior	I
had	O
a	O
history	O
of	O
depression	O
or	O
other	O
serious	O
psychiatric	O
disorders	O
and	O
most	O
were	O
receiving	O
psychoactive	O
medications	O
.	O
	
5.3	O
Venous	O
Thromboembolic	O
Events	O
In	O
clinical	O
trials	O
,	O
venous	B
thromboembolic	I
events	I
have	O
been	O
reported	O
,	O
including	O
deaths	B
.	O
	
Table	O
1	O
shows	O
adverse	O
reactions	O
reported	O
in	O
Study	O
1	O
that	O
occurred	O
at	O
a	O
>	O
=	O
2	O
%	O
higher	O
frequency	O
in	O
the	O
XTANDI	O
arm	O
compared	O
to	O
the	O
placebo	O
arm	O
.	O
	
For	O
events	O
of	O
akathisia	B
,	O
incidences	O
were	O
2	O
%	O
,	O
2	O
%	O
,	O
and	O
1	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
,	O
as	O
compared	O
to	O
0	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Lymphomas	O
Cases	O
of	O
lymphoma	B
have	O
occurred	O
in	O
premarketing	O
clinical	O
trials	O
and	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
Extravasation	O
into	O
tissues	O
during	O
DOTAREM	O
administration	B
may	I
result	I
in	I
tissue	I
irritation	I
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.2	O
)	O
]	O
.	O
	
Deaths	B
due	O
to	O
adverse	O
events	O
within	O
30	O
days	O
of	O
the	O
last	O
dose	O
of	O
Kyprolis	O
occurred	O
in	O
30/598	O
(	O
5	O
%	O
)	O
patients	O
receiving	O
Kyprolis	O
monotherapy	O
.	O
	
Some	O
of	O
the	O
reactions	O
were	O
life-threatening	O
and	O
included	O
anaphylactic	B
shock	I
,	O
cardiac	B
arrest	I
,	O
respiratory	B
arrest	I
,	O
respiratory	B
distress	I
,	O
hypoxia	B
,	O
apnea	B
,	O
dyspnea	B
,	O
bradycardia	B
,	O
tachycardia	B
,	O
bronchospasm	B
,	O
throat	B
tightness	I
,	O
hypotension	B
,	O
angioedema	B
(	O
including	O
lip	B
swelling	I
,	O
periorbital	B
edema	I
,	O
and	O
face	B
edema	I
)	O
,	O
and	O
urticaria	B
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
in	O
either	O
Study	O
1	O
or	O
2	O
,	O
regardless	O
of	O
causality	O
,	O
using	O
the	O
NCI	O
Common	O
Toxicity	O
Criteria	O
(	O
CTC	O
)	O
Version	O
3.0	O
,	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
*	O
Immune	B
Reconstitution	I
Syndrome	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Image	O
interpretation	O
errors	O
(	O
especially	O
false	O
negatives	O
)	O
have	O
been	O
observed	O
(	O
5.1	O
)	O
.	O
	
XEOMIN-treated	O
patients	O
were	O
22	O
to	O
79	O
years	O
of	O
age	O
(	O
mean	O
62	O
years	O
)	O
,	O
predominantly	O
female	O
(	O
65	O
%	O
)	O
,	O
Caucasian	O
(	O
79	O
%	O
)	O
,	O
and	O
had	O
a	O
mean	O
time	O
since	O
diagnosis	O
of	O
approximately	O
5	O
years	O
.	O
	
Immune-mediated	B
enterocolitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Patients	O
received	O
placebo	O
(	O
N=995	O
)	O
,	O
JARDIANCE	O
10	O
mg	O
(	O
N=999	O
)	O
,	O
or	O
JARDIANCE	O
25	O
mg	O
(	O
N=977	O
)	O
once	O
daily	O
.	O
	
When	O
prescribing	O
ARCAPTA	O
NEOHALER	O
,	O
the	O
healthcare	O
provider	O
should	O
also	O
prescribe	O
an	O
inhaled	O
,	O
short-acting	O
beta2-	O
agonist	O
and	O
instruct	O
the	O
patient	O
on	O
how	O
it	O
should	O
be	O
used	O
.	O
	
Table	O
1	O
summarizes	O
adverse	O
reactions	O
occurring	O
in	O
2	O
or	O
more	O
patients	O
treated	O
with	O
Carbaglu	O
in	O
the	O
retrospective	O
case	O
series	O
.	O
	
Cognitive	O
Dysfunction	O
APTIOM	O
causes	O
dose-dependent	O
increases	O
in	O
cognitive	B
dysfunction-related	O
events	O
(	O
memory	B
impairment	I
,	O
disturbance	B
in	I
attention	I
,	O
amnesia	B
,	O
confusional	B
state	I
,	O
aphasia	B
,	O
speech	B
disorder	I
,	O
slowness	B
of	I
thought	I
,	O
disorientation	B
,	O
and	O
psychomotor	B
retardation	I
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
IOP	B
)	I
increase-	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
result	O
in	O
glaucoma	B
with	O
damage	B
to	I
the	I
optic	I
nerve	I
,	O
defects	B
in	I
visual	I
acuity	I
.	O
	
Among	O
these	O
patients	O
,	O
2	O
patients	O
discontinued	O
INVOKANA	O
.	O
	
5.3	O
Neuroleptic	O
Malignant	O
Syndrome	O
A	O
potentially	O
fatal	B
symptom	O
complex	O
sometimes	O
referred	O
to	O
as	O
Neuroleptic	B
Malignant	I
Syndrome	I
(	O
NMS	B
)	O
has	O
been	O
reported	O
in	O
association	O
with	O
administration	O
of	O
antipsychotic	O
drugs	O
,	O
including	O
SAPHRIS	O
.	O
	
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
below	O
and	O
elsewhere	O
in	O
the	O
labeling	O
:	O
.	O
	
None	O
of	O
the	O
patients	O
tested	O
positive	O
for	O
neutralizing	O
antibodies	O
,	O
as	O
was	O
assessed	O
using	O
a	O
chemiluminescent	O
cell-based	O
in	O
vitro	O
biological	O
assay	O
.	O
	
The	O
three	O
factors	O
associated	O
with	O
the	O
largest	O
increase	O
in	O
volume	B
depletion-related	I
adverse	I
reactions	I
were	O
the	O
use	O
of	O
loop	O
diuretics	O
,	O
moderate	O
renal	O
impairment	O
(	O
eGFR	O
30	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
and	O
age	O
75	O
years	O
and	O
older	O
(	O
Table	O
2	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
and	O
8.6	O
)	O
]	O
.	O
	
Eye	B
events	I
were	O
serious	O
in	O
0.7	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0	O
placebo	O
patients	O
)	O
and	O
led	O
to	O
discontinuation	O
in	O
4	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0.2	O
%	O
of	O
placebo-treated	O
patients	O
)	O
.	O
	
The	O
use	O
of	O
ARCAPTA	O
NEOHALER	O
in	O
this	O
setting	O
is	O
inappropriate	O
.	O
	
No	O
data	O
are	O
available	O
on	O
the	O
response	O
to	O
live	O
vaccinations	O
or	O
the	O
secondary	O
transmission	O
of	O
infection	O
by	O
live	O
vaccines	O
in	O
patients	O
receiving	O
CIMZIA	O
.	O
	
Table	O
2	O
identifies	O
the	O
shift	O
from	O
baseline	O
to	O
lowest	O
observed	O
estimated	O
glomerular	O
filtration	O
rate	O
(	O
eGFR	O
)	O
during	O
BOSULIF	O
therapy	O
for	O
patients	O
in	O
the	O
global	O
Ph+	O
Leukemia	O
studies	O
.	O
	
Bleeding	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
Table	O
2	O
shows	O
the	O
number	O
of	O
adjudicated	O
major	O
bleeding	B
events	O
during	O
the	O
treatment	O
period	O
in	O
the	O
RE-LY	O
study	O
,	O
with	O
the	O
bleeding	B
rate	O
per	O
100	O
subject-years	O
(	O
%	O
)	O
.	O
	
(	O
5.11	O
)	O
*	O
Potential	O
for	O
Motor	B
Impairment	I
:	O
Use	O
caution	O
when	O
operating	O
machinery	O
.	O
	
The	O
incidence	O
of	O
all-cause	O
mortality	B
was	O
0.8	O
%	O
(	O
n	O
=	O
1	O
)	O
in	O
the	O
placebo	O
group	O
and	O
0.8	O
%	O
(	O
n	O
=	O
1	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
Women	O
of	O
childbearing	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
becoming	O
pregnant	O
while	O
receiving	O
INLYTA	O
.	O
	
Impaired	B
glucose	I
tolerance	I
.	O
	
New	O
Malignancies	O
The	O
overall	O
incidence	O
of	O
new	O
malignancies	B
was	O
4.3	O
%	O
in	O
the	O
placebo	O
and	O
4.8	O
%	O
in	O
the	O
Prolia	O
groups	O
.	O
	
5.2	O
Serious	O
Dermatologic	O
Reactions	O
Serious	O
dermatologic	B
reactions	I
including	O
Stevens-Johnson	B
Syndrome	I
(	O
SJS	B
)	O
have	O
been	O
reported	O
in	O
association	O
with	O
APTIOM	O
use	O
.	O
	
5.3	O
Drug	O
Reaction	O
with	O
Eosinophilia	O
and	O
Systemic	O
Symptoms	O
(	O
DRESS	O
)	O
/Multiorgan	O
Hypersensitivity	O
Drug	B
Reaction	I
with	I
Eosinophilia	I
and	I
Systemic	I
Symptoms	I
(	O
DRESS	B
)	O
,	O
also	O
known	O
as	O
Multiorgan	B
Hypersensitivity	I
,	O
has	O
been	O
reported	O
in	O
patients	O
taking	O
APTIOM	O
.	O
	
Clinically	O
important	O
chemistry	O
laboratory	O
values	O
that	O
were	O
new	O
or	O
worsened	O
from	O
baseline	O
and	O
occurred	O
in	O
>	O
1	O
%	O
of	O
patients	O
at	O
Grade	O
3	O
or	O
4	O
,	O
in	O
NHL	O
patients	O
treated	O
in	O
both	O
single	O
arm	O
studies	O
combined	O
were	O
hyperglycemia	B
(	O
3	O
%	O
)	O
,	O
elevated	B
creatinine	I
(	O
2	O
%	O
)	O
,	O
hyponatremia	B
(	O
2	O
%	O
)	O
,	O
and	O
hypocalcemia	B
(	O
2	O
%	O
)	O
.	O
	
Remove	O
contact	O
lenses	O
prior	O
to	O
instillation	O
of	O
BEPREVE	O
.	O
	
Consider	O
DPP-4	O
inhibitors	O
as	O
a	O
possible	O
cause	O
for	O
severe	O
joint	O
pain	O
and	O
discontinue	O
drug	O
if	O
appropriate	O
.	O
	
Abnormal	O
thyroid	O
function	O
tests	O
should	O
be	O
clinically	O
evaluated	O
.	O
	
.	O
	
Dizziness	B
and	O
disturbance	B
in	I
gait	I
were	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
Patients	O
receiving	O
Prolia	O
should	O
not	O
receive	O
Xgeva	O
.	O
	
5.5	O
Second	O
Primary	O
Malignancies	O
Other	O
malignancies	B
(	O
range	O
,	O
5	O
to	O
14	O
%	O
)	O
including	O
non-skin	B
carcinomas	I
(	O
range	O
,	O
1	O
to	O
3	O
%	O
)	O
have	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
Monitor	O
for	O
symptoms	O
(	O
5.4	O
)	O
*	O
Atypical	B
femoral	I
fractures	I
:	O
Have	O
been	O
reported	O
.	O
	
Serious	O
Adverse	O
Reactions	O
:	O
myocardial	B
infarction	I
(	O
2	O
cases	O
)	O
,	O
ruptured	B
ovarian	I
cyst	I
(	O
2	O
cases	O
)	O
,	O
deep	B
vein	I
thrombosis	I
,	O
focal	B
nodular	I
hyperplasia	I
of	I
the	I
liver	I
,	O
uterine	B
leiomyoma	I
,	O
acute	B
cholecystitis	I
,	O
and	O
chronic	B
acalculous	I
cholecystitis	I
.	O
	
In	O
cases	O
of	O
symptomatic	O
bradycardia	O
that	O
is	O
not	O
life-threatening	O
,	O
hold	O
XALKORI	O
until	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
re-evaluate	O
the	O
use	O
of	O
concomitant	O
medications	O
,	O
and	O
adjust	O
the	O
dose	O
of	O
XALKORI	O
.	O
	
Because	O
of	O
the	O
potential	O
for	O
hypersensitivity	O
reactions	O
,	O
administer	O
antihistamines	O
with	O
or	O
without	O
antipyretics	O
prior	O
to	O
infusion	O
.	O
	
In	O
addition	O
,	O
the	O
following	O
clinical	O
trials	O
have	O
also	O
been	O
conducted	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12	O
)	O
and	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
:	O
*	O
An	O
8-week	O
crossover	O
design	O
trial	O
(	O
Trial	O
4	O
)	O
involving	O
39	O
patients	O
between	O
the	O
ages	O
of	O
6	O
and	O
57	O
years	O
with	O
a	O
G1244E	O
,	O
G1349D	O
,	O
G178R	O
,	O
G551S	O
,	O
G970R	O
,	O
S1251N	O
,	O
S1255P	O
,	O
S549N	O
,	O
or	O
S549R	O
mutation	O
in	O
the	O
CFTR	O
gene	O
.	O
	
5.4	O
Use	O
with	O
Medications	O
Known	O
to	O
Cause	O
Hypoglycemia	O
Insulin	O
and	O
insulin	O
secretagogues	O
,	O
such	O
as	O
sulfonylureas	O
,	O
are	O
known	O
to	O
cause	O
hypoglycemia	O
.	O
	
The	O
majority	O
of	O
these	O
immune-mediated	O
reactions	O
initially	O
manifested	O
during	O
treatment	O
;	O
however	O
,	O
a	O
minority	O
occurred	O
weeks	O
to	O
months	O
after	O
discontinuation	O
of	O
YERVOY	O
.	O
	
No	O
fatal	B
adverse	O
events	O
occurred	O
on	O
treatment	O
among	O
patients	O
in	O
remission	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
in	O
NULOJIX-treated	O
patients	O
were	O
cytomegalovirus	B
infection	I
(	O
1.5	O
%	O
)	O
and	O
complications	B
of	I
transplanted	I
kidney	I
(	O
1.5	O
%	O
)	O
.	O
	
5.9	O
COC	O
Use	O
Before	O
or	O
During	O
Early	O
Pregnancy	O
Extensive	O
epidemiological	O
studies	O
have	O
revealed	O
no	O
increased	O
risk	O
of	O
birth	B
defects	I
in	O
women	O
who	O
have	O
used	O
oral	O
contraceptives	O
prior	O
to	O
pregnancy	O
.	O
	
Glabellar	O
Lines	O
:	O
The	O
most	O
commonly	O
observed	O
adverse	O
reaction	O
(	O
>	O
1	O
%	O
of	O
patients	O
and	O
>	O
placebo	O
)	O
is	O
headache	B
(	O
6.1	O
)	O
.	O
	
It	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
POTIGA	O
caused	O
this	O
decreased	B
visual	I
acuity	I
.	O
	
Activated	O
prothrombin	O
complex	O
concentrates	O
(	O
aPCCs	O
,	O
e.g.	O
,	O
FEIBA	O
)	O
,	O
or	O
recombinant	O
Factor	O
VIIa	O
,	O
or	O
concentrates	O
of	O
coagulation	O
factors	O
II	O
,	O
IX	O
or	O
X	O
may	O
be	O
considered	O
but	O
their	O
use	O
has	O
not	O
been	O
evaluated	O
in	O
clinical	O
trials	O
.	O
	
Some	O
patients	O
with	O
retinal	B
abnormalities	I
have	O
been	O
found	O
to	O
have	O
abnormal	B
visual	I
acuity	I
.	O
	
Promptly	O
evaluate	O
any	O
signs	O
or	O
symptoms	O
of	O
blood	O
loss	O
(	O
e.g.	O
,	O
a	O
drop	O
in	O
hemoglobin	O
and/or	O
hematocrit	O
or	O
hypotension	O
)	O
.	O
	
Patients	O
treated	O
with	O
concomitant	O
immunosuppressants	O
(	O
MTX	O
)	O
had	O
a	O
lower	O
rate	O
of	O
antibody	O
development	O
than	O
patients	O
not	O
taking	O
immunosuppressants	O
at	O
baseline	O
.	O
	
Patients	O
should	O
be	O
cautioned	O
about	O
operating	O
hazardous	O
machinery	O
,	O
including	O
automobiles	O
,	O
until	O
they	O
are	O
reasonably	O
certain	O
that	O
therapy	O
with	O
FANAPT	O
does	O
not	O
affect	O
them	O
adversely	O
.	O
	
(	O
5.7	O
)	O
5.1	O
Hypotension	O
FARXIGA	O
causes	O
intravascular	B
volume	I
contraction	I
.	O
	
More	O
patients	O
receiving	O
TRULICITY	O
0.75	O
mg	O
(	O
1.3	O
%	O
)	O
and	O
TRULICITY	O
1.5	O
mg	O
(	O
3.5	O
%	O
)	O
discontinued	O
treatment	O
due	O
to	O
gastrointestinal	B
adverse	I
reactions	I
than	O
patients	O
receiving	O
placebo	O
(	O
0.2	O
%	O
)	O
.	O
	
For	O
invasive	O
dental	O
procedures	O
,	O
withhold	O
COMETRIQ	O
treatment	O
for	O
at	O
least	O
28	O
days	O
prior	O
to	O
scheduled	O
surgery	O
,	O
if	O
possible	O
.	O
	
Women	O
on	O
thyroid	O
hormone	O
replacement	O
therapy	O
may	O
need	O
increased	O
doses	O
of	O
thyroid	O
hormone	O
because	O
serum	O
concentrations	O
of	O
thyroid-binding	B
globulin	I
increase	I
with	O
use	O
of	O
COCs	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Withhold	O
dose	O
for	O
moderate	O
immune-mediated	O
adverse	O
reactions	O
until	O
return	O
to	O
baseline	O
,	O
improvement	O
to	O
mild	O
severity	O
,	O
or	O
complete	O
resolution	O
,	O
and	O
patient	O
is	O
receiving	O
less	O
than	O
7.5	O
mg	O
prednisone	O
or	O
equivalent	O
per	O
day	O
.	O
	
(	O
5.7	O
)	O
*	O
Proteinuria	B
:	O
Monitor	O
urine	O
protein	O
.	O
	
If	O
contraceptive	O
methods	O
are	O
being	O
considered	O
,	O
use	O
effective	O
contraception	O
during	O
treatment	O
,	O
and	O
for	O
at	O
least	O
1	O
month	O
after	O
the	O
last	O
dose	O
of	O
Zydelig	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Table	O
2	O
:	O
Summary	O
of	O
PTLD	B
Reported	O
in	O
Studies	O
1	O
,	O
2	O
,	O
and	O
3	O
Through	O
Three	O
Years	O
of	O
Treatment	O
NULOJIX	O
Non-Recommended	O
Regimen*	O
(	O
N=477	O
)	O
NULOJIX	O
Recommended	O
Regimen	O
(	O
N=472	O
)	O
Cyclosporine	O
(	O
N=476	O
)	O
Trial	O
EBV	O
Positive	O
(	O
n=406	O
)	O
EBV	O
Negative	O
(	O
n=43	O
)	O
EBV	O
Unknown	O
(	O
n=28	O
)	O
EBV	O
Positive	O
(	O
n=404	O
)	O
EBV	O
Negative	O
(	O
n=48	O
)	O
EBV	O
Unknown	O
(	O
n=20	O
)	O
EBV	O
Positive	O
(	O
n=399	O
)	O
EBV	O
Negative	O
(	O
n=57	O
)	O
EBV	O
Unknown	O
(	O
n=20	O
)	O
*	O
Regimen	O
with	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
the	O
recommended	O
NULOJIX	O
regimen	O
.	O
	
Adverse	O
reactions	O
for	O
FIRAZYR	O
were	O
similar	O
in	O
nature	O
and	O
frequency	O
to	O
those	O
reported	O
in	O
Table	O
1	O
.	O
	
At	O
baseline	O
,	O
2.5	O
%	O
of	O
the	O
population	O
reported	O
retinopathy	O
.	O
	
Higher	O
proportions	O
of	O
patients	O
with	O
marked	O
laboratory	O
abnormalities	O
of	O
hyperphosphatemia	B
(	O
>	O
=5.6	O
mg/dL	O
for	O
age	O
17-65	O
years	O
or	O
>	O
=5.1	O
mg/dL	O
for	O
age	O
>	O
=66	O
years	O
)	O
were	O
reported	O
on	O
FARXIGA	O
at	O
Week	O
24	O
(	O
0.9	O
%	O
versus	O
1.7	O
%	O
for	O
placebo	O
and	O
FARXIGA	O
10	O
mg	O
,	O
respectively	O
)	O
.	O
	
The	O
infections	B
consisted	O
primarily	O
of	O
upper	B
respiratory	I
infections	I
(	O
20	O
%	O
for	O
CIMZIA	O
,	O
13	O
%	O
for	O
placebo	O
)	O
.	O
	
5.3	O
Thrombotic	O
Events	O
COMETRIQ	O
treatment	O
results	O
in	O
an	O
increased	O
incidence	O
of	O
thrombotic	B
events	I
(	O
venous	B
thromboembolism	I
:	O
6	O
%	O
vs.	O
3	O
%	O
and	O
arterial	B
thromboembolism	I
:	O
2	O
%	O
vs.	O
0	O
%	O
in	O
COMETRIQ-treated	O
and	O
placebo-treated	O
patients	O
,	O
respectively	O
)	O
.	O
	
The	O
mean	O
age	O
of	O
patients	O
was	O
56	O
years	O
,	O
2	O
%	O
were	O
75	O
years	O
or	O
older	O
and	O
51	O
%	O
were	O
male	O
.	O
	
5.2	O
Hepatotoxicity	O
Drug-induced	O
hepatotoxicity	B
occurred	O
in	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
In	O
clinical	O
trials	O
,	O
HALAVEN	O
has	O
been	O
administered	O
to	O
1,222	O
patients	O
with	O
multiple	O
tumor	O
types	O
,	O
including	O
240	O
patients	O
exposed	O
to	O
HALAVEN	O
for	O
6	O
months	O
or	O
longer	O
.	O
	
5.2	O
Carcinoma	O
of	O
the	O
Breasts	O
and	O
Reproductive	O
Organs	O
Women	O
who	O
currently	O
have	O
or	O
have	O
had	O
breast	O
cancer	O
should	O
not	O
use	O
Natazia	O
because	O
breast	O
cancer	O
is	O
a	O
hormonally-sensitive	O
tumor	O
.	O
	
Obtain	O
a	O
complete	O
blood	O
cell	O
(	O
CBC	O
)	O
count	O
,	O
including	O
a	O
white	O
blood	O
cell	O
(	O
WBC	O
)	O
count	O
corrected	O
for	O
the	O
presence	O
of	O
nucleated	O
red	O
blood	O
cells	O
,	O
an	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
,	O
and	O
a	O
platelet	O
count	O
daily	O
until	O
recovery	O
(	O
ANC	O
>	O
=	O
1.5	O
x	O
10	O
9	O
/L	O
)	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=	O
5	O
%	O
of	O
XIAFLEX-Treated	O
Patients	O
with	O
Dupuytren	O
's	O
Contracture	O
and	O
at	O
a	O
Greater	O
Incidence	O
than	O
Placebo	O
in	O
the	O
Placebo-Controlled	O
Trials	O
Through	O
Day	O
90	O
After	O
Up	O
to	O
3	O
Injections	O
a	O
Most	O
of	O
these	O
events	O
were	O
swelling	B
of	I
the	I
injected	I
hand	I
.	O
	
5.2	O
Immune-mediated	O
Hepatitis	O
In	O
Study	O
1	O
,	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
hepatotoxicity	B
(	O
ALT	B
elevations	I
of	O
more	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
total	B
bilirubin	I
elevations	I
more	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
;	O
Grade	O
3-5	O
)	O
occurred	O
in	O
8	O
(	O
2	O
%	O
)	O
YERVOY-treated	O
patients	O
,	O
with	O
fatal	B
hepatic	B
failure	I
in	O
0.2	O
%	O
and	O
hospitalization	O
in	O
0.4	O
%	O
of	O
YERVOY-treated	O
patients	O
.	O
	
When	O
beginning	O
treatment	O
with	O
BREO	O
ELLIPTA	O
,	O
patients	O
who	O
have	O
been	O
taking	O
oral	O
or	O
inhaled	O
,	O
short-acting	O
beta2-agonists	O
on	O
a	O
regular	O
basis	O
(	O
e.g.	O
,	O
4	O
times	O
a	O
day	O
)	O
should	O
be	O
instructed	O
to	O
discontinue	O
the	O
regular	O
use	O
of	O
these	O
drugs	O
and	O
to	O
use	O
them	O
only	O
for	O
symptomatic	O
relief	O
of	O
acute	O
respiratory	O
symptoms	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Advise	O
women	O
of	O
potential	O
harm	O
to	O
the	O
fetus	O
and	O
to	O
avoid	O
pregnancy	O
while	O
receiving	O
Beleodaq	O
.	O
	
5.4	O
Intestinal	O
Perforation	O
Fatal	B
and	O
serious	O
intestinal	B
perforation	I
occurred	O
in	O
Zydelig-treated	O
patients	O
.	O
	
(	O
5.2	O
)	O
*	O
Fatal	B
and	O
serious	O
pneumonitis	B
can	O
occur	O
in	O
Zydelig-treated	O
patients	O
.	O
	
Table	O
4	O
shows	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
of	O
XIAFLEX-treated	O
patients	O
after	O
two	O
concurrent	O
injections	O
of	O
XIAFLEX	O
in	O
the	O
same	O
hand	O
through	O
Day	O
60	O
in	O
Study	O
3	O
.	O
	
Increased	O
dosage	O
of	O
corticosteroids	O
may	O
be	O
indicated	O
before	O
,	O
during	O
and	O
after	O
stressful	O
situations	O
.	O
	
The	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
considered	O
positive	O
for	O
antibodies	O
to	O
certolizumab	O
pegol	O
in	O
an	O
ELISA	O
,	O
and	O
are	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTS	O
,	O
and	O
(	O
B	O
)	O
EPIDURAL	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTS	O
:	O
Premature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
PRADAXA	O
,	O
increases	O
the	O
risk	O
of	O
thrombotic	O
events	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
other	O
clinical	O
trials	O
of	O
the	O
same	O
or	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.3	O
Risks	O
for	O
Benzyl	O
Alcohol	O
Toxicity	O
in	O
Infants	O
AdreView	O
contains	O
benzyl	O
alcohol	O
at	O
a	O
concentration	O
of	O
10.3	O
mg/mL	O
.	O
	
In	O
Study	O
1	O
,	O
sinus	B
bradycardia	I
,	O
defined	O
as	O
a	O
heart	B
rate	I
of	I
less	I
than	I
50	I
beats	I
per	I
minute	I
,	O
was	O
noted	O
as	O
a	O
new	O
finding	O
in	O
1	O
%	O
of	O
255	O
patients	O
.	O
	
Discontinue	O
Zydelig	O
for	O
recurrent	O
hepatotoxicity	O
.	O
	
In	O
the	O
controlled	O
and	O
uncontrolled	O
clinical	O
studies	O
of	O
XIAFLEX	O
in	O
Peyronie	O
's	O
disease	O
,	O
1044	O
patients	O
received	O
a	O
total	O
of	O
7466	O
XIAFLEX	O
injections	O
.	O
	
5.3	O
Nutritional	O
Management	O
Since	O
hyperammonemia	O
is	O
the	O
result	O
of	O
protein	O
catabolism	O
,	O
complete	O
protein	O
restriction	O
is	O
recommended	O
to	O
be	O
maintained	O
for	O
24	O
to	O
48	O
hours	O
and	O
caloric	O
supplementation	O
should	O
be	O
maximized	O
to	O
reverse	O
catabolism	O
and	O
nitrogen	O
turnover	O
.	O
	
This	O
includes	O
cases	O
of	O
Stevens-Johnson	B
syndrome	I
,	O
hypersensitivity	B
reaction	I
,	O
toxic	B
epidermal	I
necrolysis	I
and	O
erythema	B
multiforme	I
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
CIMZIA	O
.	O
	
Generally	O
milder	O
withdrawal	O
symptoms	O
(	O
e.g.	O
,	O
dysphoria	O
,	O
anxiety	O
,	O
and	O
insomnia	O
)	O
have	O
been	O
reported	O
following	O
abrupt	O
discontinuance	O
of	O
benzodiazepines	O
taken	O
continuously	O
at	O
therapeutic	O
doses	O
for	O
several	O
months	O
.	O
	
Women	O
who	O
are	O
not	O
pregnant	O
and	O
use	O
Natazia	O
,	O
may	O
experience	O
amenorrhea	B
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
See	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
AdreView	O
administration	O
.	O
	
Monitor	O
blood	O
pressure	O
,	O
serum	O
potassium	O
and	O
symptoms	O
of	O
fluid	O
retention	O
at	O
least	O
monthly	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=5.0	O
%	O
of	O
Subjects	O
Who	O
Received	O
Two	O
Concurrent	O
Injections	O
of	O
XIAFLEX	O
in	O
Study	O
3	O
Adverse	O
Reaction	O
XIAFLEXN=715	O
Subjects	O
with	O
>	O
=1	O
adverse	O
reaction	O
95	O
%	O
Edema	B
peripheral	I
77	O
%	O
Contusion	B
59	O
%	O
Pain	B
in	I
extremity	I
51	O
%	O
Laceration	B
22	O
%	O
Pruritus	B
15	O
%	O
Injection	B
site	I
pain	I
14	O
%	O
Lymphadenopathy	B
13	O
%	O
Blood	B
blister	I
12	O
%	O
Injection	B
site	I
hematoma	I
8	O
%	O
Axillary	B
pain	I
7	O
%	O
Injection	B
site	I
hemorrhage	I
6	O
%	O
Injection	B
site	I
swelling	I
5	O
%	O
Ecchymosis	B
5	O
%	O
Safety	O
of	O
Retreatment	O
of	O
Recurrent	O
Contractures	O
An	O
observational	O
,	O
open	O
label	O
study	O
was	O
conducted	O
in	O
subjects	O
who	O
had	O
participated	O
in	O
XIAFLEX	O
clinical	O
trials	O
for	O
Dupuytren	O
's	O
contracture	O
(	O
Study	O
4	O
)	O
.	O
	
Monitor	O
plasma	O
zinc	O
,	O
and	O
supplement	O
in	O
the	O
event	O
of	O
a	O
deficiency	O
.	O
	
Interrupt	O
or	O
discontinue	O
Zydelig	O
.	O
	
Adrenocortical	B
insufficiency	I
was	O
reported	O
in	O
patients	O
receiving	O
ZYTIGA	O
in	O
combination	O
with	O
prednisone	O
,	O
following	O
interruption	O
of	O
daily	O
steroids	O
and/or	O
with	O
concurrent	O
infection	O
or	O
stress	O
.	O
	
*	O
In	O
other	O
XIAFLEX-treated	O
patients	O
(	O
9	O
of	O
1044	O
;	O
0.9	O
%	O
)	O
,	O
a	O
combination	O
of	O
penile	B
ecchymoses	I
,	O
sudden	O
penile	B
detumescence	I
,	O
and/or	O
a	O
penile	B
``	O
popping	B
''	O
sound	B
was	O
reported	O
,	O
and	O
in	O
these	O
cases	O
,	O
a	O
diagnosis	O
of	O
corporal	B
rupture	I
can	O
not	O
be	O
excluded	O
.	O
	
Monitor	O
ALT	O
and	O
AST	O
in	O
all	O
patients	O
every	O
2	O
weeks	O
for	O
the	O
first	O
3	O
months	O
of	O
treatment	O
,	O
every	O
4	O
weeks	O
for	O
the	O
next	O
3	O
months	O
,	O
then	O
every	O
1	O
to	O
3	O
months	O
thereafter	O
.	O
	
EXCERPT	O
:	O
*	O
Most	O
common	O
adverse	O
reaction	O
to	O
GRANIX	O
is	O
bone	B
pain	I
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
TEVA	O
at	O
1-866-832-8537	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
section	O
of	O
the	O
labeling	O
:	O
*	O
Endophthalmitis	B
and	O
retinal	B
detachments	I
*	O
Increased	B
intraocular	I
pressure	I
*	O
Thromboembolic	B
events	I
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
reported	O
in	O
patients	O
receiving	O
EYLEA	O
were	O
conjunctival	B
hemorrhage	I
,	O
eye	B
pain	I
,	O
cataract	B
,	O
vitreous	B
floaters	I
,	O
intraocular	B
pressure	I
increased	I
,	O
and	O
vitreous	B
detachment	I
.	O
	
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
The	O
underlying	O
pathology	O
was	O
not	O
ascertained	O
in	O
all	O
patients	O
but	O
in	O
some	O
instances	O
included	O
immune-mediated	B
hepatitis	I
.	O
	
Implement	O
a	O
plan	O
to	O
monitor	O
for	O
and	O
to	O
manage	O
agranulocytosis/neutropenia	O
prior	O
to	O
initiating	O
Ferriprox	O
treatment	O
.	O
	
Evaluate	O
for	O
retinal	O
vein	O
thrombosis	O
immediately	O
.	O
	
One	O
patient	O
(	O
0.4	O
%	O
)	O
required	O
permanent	O
discontinuation	O
due	O
to	O
elevated	B
transaminases	I
,	O
and	O
jaundice	B
.	O
	
When	O
possible	O
,	O
avoid	O
use	O
of	O
ZYKADIA	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
.	O
	
(	O
5.1	O
)	O
*	O
Interrupt	O
Ferriprox	O
if	O
infection	O
develops	O
and	O
monitor	O
the	O
ANC	O
more	O
frequently	O
.	O
	
(	O
2.2	O
,	O
5.3	O
)	O
*	O
Tumor	B
lysis	I
syndrome	I
:	O
Monitor	O
patients	O
with	O
advanced	O
stage	O
disease	O
and/or	O
high	O
tumor	O
burden	O
and	O
take	O
appropriate	O
precautions	O
.	O
	
RE-MEDY	O
was	O
an	O
active-controlled	O
study	O
(	O
warfarin	O
)	O
in	O
which	O
1430	O
patients	O
received	O
PRADAXA	O
150	O
mg	O
twice	O
daily	O
following	O
3	O
to	O
12	O
months	O
of	O
oral	O
anticoagulant	O
regimen	O
.	O
	
Patients	O
using	O
BREO	O
ELLIPTA	O
should	O
not	O
use	O
another	O
medicine	O
containing	O
a	O
LABA	O
(	O
e.g.	O
,	O
salmeterol	O
,	O
formoterol	O
fumarate	O
,	O
arformoterol	O
tartrate	O
,	O
indacaterol	O
)	O
for	O
any	O
reason	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
(	O
5.8	O
)	O
*	O
Reversible	B
posterior	I
leukoencephalopathy	I
syndrome	I
(	O
RPLS	B
)	O
:	O
Discontinue	O
COMETRIQ	O
.	O
	
Documented	O
symptomatic	B
hypoglycemia	I
occurred	O
in	O
39	O
%	O
and	O
40	O
%	O
of	O
patients	O
when	O
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
,	O
respectively	O
,	O
was	O
co-administered	O
with	O
a	O
sulfonylurea	O
.	O
	
In	O
addition	O
,	O
it	O
is	O
recommended	O
to	O
avoid	O
use	O
of	O
XIAFLEX	O
in	O
patients	O
with	O
coagulation	O
disorders	O
,	O
including	O
patients	O
receiving	O
concomitant	O
anticoagulants	O
(	O
except	O
for	O
low-dose	O
aspirin	O
)	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
8.2	O
years	O
and	O
had	O
a	O
mean	O
HbA1c	O
of	O
7.6-8.5	O
%	O
.	O
	
Serious	O
infections	B
observed	O
included	O
viral	B
infections	I
,	O
pneumonia	B
,	O
and	O
pyelonephritis	B
.	O
	
Reversal	O
of	O
Anticoagulant	O
Effect	O
:	O
A	O
specific	O
reversal	O
agent	O
for	O
dabigatran	O
is	O
not	O
available	O
.	O
	
(	O
5.1	O
)	O
*	O
Patients	O
who	O
fail	O
to	O
show	O
substantial	O
clinical	O
benefit	O
after	O
adequate	O
titration	O
should	O
be	O
discontinued	O
from	O
POTIGA	O
.	O
	
FANAPT	O
shares	O
this	O
pharmacologic	O
activity	O
.	O
	
(	O
5.4	O
)	O
*	O
Increased	B
LDL-C	I
:	O
Monitor	O
and	O
treat	O
per	O
standard	O
of	O
care	O
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
,	O
Including	O
Anaphylaxis	O
In	O
the	O
controlled	O
portions	O
of	O
the	O
clinical	O
trials	O
in	O
Dupuytren	O
's	O
contracture	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
a	O
greater	O
proportion	O
of	O
XIAFLEX-treated	O
patients	O
(	O
15	O
%	O
)	O
compared	O
to	O
placebo-treated	O
patients	O
(	O
1	O
%	O
)	O
had	O
mild	O
allergic	B
reactions	I
(	O
pruritus	B
)	O
after	O
up	O
to	O
3	O
injections	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	O
during	O
treatment	O
with	O
ZYKADIA	O
and	O
for	O
at	O
least	O
2	O
weeks	O
following	O
completion	O
of	O
therapy	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
Oral	O
contraceptive	O
use	O
should	O
be	O
discontinued	O
if	O
pregnancy	O
is	O
confirmed	O
.	O
	
Post-Transplant	O
Lymphoproliferative	O
Disorder	O
Reported	O
cases	O
of	O
post-transplant	B
lymphoproliferative	I
disorder	I
(	O
PTLD	B
)	O
up	O
to	O
36	O
months	O
post	O
transplant	O
were	O
obtained	O
for	O
NULOJIX	O
by	O
pooling	O
both	O
dosage	O
regimens	O
of	O
NULOJIX	O
in	O
Studies	O
1	O
and	O
2	O
(	O
804	O
patients	O
)	O
with	O
data	O
from	O
a	O
third	O
study	O
in	O
kidney	O
transplantation	O
(	O
Study	O
3	O
,	O
145	O
patients	O
)	O
which	O
evaluated	O
two	O
NULOJIX	O
dosage	O
regimens	O
similar	O
,	O
but	O
slightly	O
different	O
,	O
from	O
those	O
of	O
Studies	O
1	O
and	O
2	O
(	O
see	O
Table	O
2	O
)	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
IMMUNE-MEDIATED	B
ADVERSE	I
REACTIONS	I
WARNING	O
:	O
IMMUNE-MEDIATED	B
ADVERSE	I
REACTIONS	I
YERVOY	O
can	O
result	O
in	O
severe	O
and	O
fatal	B
immune-mediated	B
adverse	I
reactions	I
due	O
to	O
T-cell	O
activation	O
and	O
proliferation	O
.	O
	
5.13	O
Drug	O
Interactions	O
Women	O
who	O
take	O
medications	O
that	O
are	O
strong	O
cytochrome	O
P450	O
3A4	O
(	O
CYP3A4	O
)	O
inducers	O
(	O
for	O
example	O
,	O
carbamazepine	O
,	O
phenytoin	O
,	O
rifampicin	O
,	O
and	O
St.	O
John	O
's	O
wort	O
)	O
should	O
not	O
choose	O
Natazia	O
as	O
their	O
oral	O
contraceptive	O
while	O
using	O
these	O
inducers	O
and	O
for	O
at	O
least	O
28	O
days	O
after	O
discontinuation	O
of	O
these	O
inducers	O
due	O
to	O
the	O
possibility	O
of	O
decreased	O
contraceptive	O
efficacy	O
.	O
	
Before	O
initiating	O
FARXIGA	O
in	O
patients	O
with	O
one	O
or	O
more	O
of	O
these	O
characteristics	O
,	O
volume	O
status	O
should	O
be	O
assessed	O
and	O
corrected	O
.	O
	
If	O
PRADAXA	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
,	O
2.5	O
,	O
2.6	O
)	O
]	O
.	O
	
Approximately	O
one	O
third	O
of	O
the	O
patients	O
who	O
had	O
eye	O
examinations	O
performed	O
after	O
approximately	O
4	O
years	O
of	O
treatment	O
were	O
found	O
to	O
have	O
retinal	B
pigmentary	I
abnormalities	I
.	O
	
Patients	O
who	O
develop	O
arrhythmic	O
symptoms	O
(	O
e.g.	O
,	O
palpitations	O
,	O
lightheadedness	O
)	O
or	O
new	O
onset	O
dyspnea	O
should	O
have	O
an	O
ECG	O
performed	O
.	O
	
For	O
the	O
100	O
mg	O
dose	O
of	O
PRISTIQ	O
the	O
discontinuation	O
rate	O
due	O
to	O
an	O
adverse	O
reaction	O
was	O
8.7	O
%	O
.	O
	
If	O
anaphylaxis	O
or	O
severe	O
hypersensitivity	O
reactions	O
occur	O
,	O
immediately	O
stop	O
the	O
infusion	O
and	O
initiate	O
appropriate	O
medical	O
treatment	O
.	O
	
*	O
A	O
24-week	O
open-label	O
trial	O
(	O
Trial	O
6	O
)	O
in	O
34	O
patients	O
2	O
to	O
less	O
than	O
6	O
years	O
of	O
age	O
.	O
	
May	O
worsen	O
,	O
especially	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O
	
Increases	B
in	I
AST	I
of	O
Grade	O
3	O
or	O
4	O
were	O
limited	O
to	O
1	O
%	O
and	O
3	O
%	O
of	O
patients	O
,	O
respectively	O
.	O
	
The	O
reporting	O
rate	O
of	O
these	O
reactions	O
associated	O
with	O
oxcarbazepine	O
use	O
exceeds	O
the	O
background	O
incidence	O
rate	O
estimates	O
by	O
a	O
factor	O
of	O
3-	O
to	O
10-fold	O
.	O
	
Lenses	O
may	O
be	O
reinserted	O
after	O
10	O
minutes	O
following	O
administration	O
of	O
BEPREVE	O
.	O
	
DRESS	B
typically	O
,	O
although	O
not	O
exclusively	O
,	O
presents	O
with	O
fever	B
,	O
rash	B
,	O
and/or	O
lymphadenopathy	B
,	O
in	O
association	O
with	O
other	O
organ	O
system	O
involvement	O
,	O
such	O
as	O
hepatitis	B
,	O
nephritis	B
,	O
hematological	B
abnormalities	I
,	O
myocarditis	B
,	O
or	O
myositis	B
sometimes	O
resembling	O
an	O
acute	O
viral	O
infection	O
.	O
	
A	O
CBC	O
including	O
lymphocyte	O
count	O
should	O
also	O
be	O
obtained	O
after	O
6	O
months	O
of	O
treatment	O
,	O
every	O
6	O
to	O
12	O
months	O
thereafter	O
,	O
and	O
as	O
clinically	O
indicated	O
.	O
	
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
in	O
pregnant	O
women	O
using	O
INLYTA	O
.	O
	
Fifty-eight	O
percent	O
(	O
58	O
%	O
)	O
of	O
the	O
population	O
was	O
male	O
and	O
73	O
%	O
were	O
Caucasian	O
,	O
16	O
%	O
were	O
Asian	O
,	O
and	O
4	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
0	O
%	O
and	O
2.5	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
Similar	O
proportions	O
of	O
patients	O
developed	O
protective	O
levels	O
of	O
anti-vaccine	O
antibodies	O
between	O
CIMZIA	O
and	O
placebo	O
treatment	O
groups	O
;	O
however	O
patients	O
receiving	O
CIMZIA	O
and	O
concomitant	O
methotrexate	O
had	O
a	O
lower	O
humoral	O
response	O
compared	O
with	O
patients	O
receiving	O
CIMZIA	O
alone	O
.	O
	
Appropriate	O
clinical	O
monitoring	O
for	O
SIRTURO-related	O
adverse	O
reactions	O
is	O
recommended	O
.	O
	
A	O
causal	O
relationship	O
to	O
drug	O
exposure	O
has	O
not	O
been	O
established	O
.	O
	
However	O
,	O
across	O
clinical	O
trials	O
no	O
renal	B
abscesses	I
were	O
confirmed	O
by	O
microbiology	O
tests	O
.	O
	
In	O
the	O
pool	O
of	O
eight	O
clinical	O
trials	O
,	O
hypersensitivity-related	B
adverse	I
reactions	I
(	O
including	O
erythema	B
,	O
rash	B
,	O
pruritus	B
,	O
urticaria	B
,	O
and	O
angioedema	B
)	O
occurred	O
in	O
3.0	O
%	O
,	O
3.8	O
%	O
,	O
and	O
4.2	O
%	O
of	O
patients	O
receiving	O
comparator	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
(	O
5.4	O
)	O
*	O
Severe	O
Visual	B
Loss	I
:	O
Reported	O
in	O
0.2	O
%	O
of	O
patients	O
.	O
	
Somnolence	B
and	O
fatigue-related	B
events	I
were	O
serious	O
in	O
0.3	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0	O
placebo	O
patients	O
)	O
and	O
led	O
to	O
discontinuation	O
in	O
3	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0.7	O
%	O
of	O
placebo-treated	O
patients	O
)	O
.	O
	
In	O
these	O
trials	O
,	O
which	O
had	O
a	O
median	O
treatment	O
duration	O
of	O
12	O
weeks	O
,	O
the	O
estimated	O
incidence	O
of	O
suicidal	B
behavior	I
among	O
27,863	O
AED-treated	O
patients	O
was	O
0.43	O
%	O
compared	O
with	O
0.24	O
%	O
among	O
16,029	O
placebo-treated	O
patients	O
,	O
representing	O
an	O
increase	O
of	O
approximately	O
1	O
case	O
of	O
suicidal	B
thinking	I
for	O
every	O
530	O
patients	O
treated	O
.	O
	
BOSULIF	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Monitor	O
electrolytes	O
if	O
QT	O
prolongation	O
is	O
detected	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.4	O
)	O
]	O
.	O
	
Acute	O
symptoms	O
should	O
be	O
treated	O
with	O
an	O
inhaled	O
short-acting	O
beta2-agonist	O
.	O
	
JARDIANCE	O
was	O
used	O
as	O
monotherapy	O
in	O
one	O
trial	O
and	O
as	O
add-on	O
therapy	O
in	O
four	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
5.2	O
Deterioration	O
of	O
Disease	O
and	O
Acute	O
Episodes	O
ARCAPTA	O
NEOHALER	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
with	O
acutely	O
deteriorating	O
COPD	O
,	O
which	O
may	O
be	O
a	O
life-threatening	O
condition	O
.	O
	
Visual	O
Changes	O
APTIOM	O
causes	O
dose-dependent	O
increases	O
in	O
events	O
related	O
to	O
visual	B
changes	I
including	O
diplopia	B
,	O
blurred	B
vision	I
,	O
and	O
impaired	B
vision	I
.	O
	
In	O
clinical	O
studies	O
,	O
treatment	O
with	O
INVOKANA	O
was	O
associated	O
with	O
a	O
dose-dependent	O
increase	O
in	O
the	O
incidence	O
of	O
volume	B
depletion-related	I
adverse	I
reactions	I
(	O
e.g.	O
,	O
hypotension	B
,	O
postural	B
dizziness	I
,	O
orthostatic	B
hypotension	I
,	O
syncope	B
,	O
and	O
dehydration	B
)	O
.	O
	
Additional	O
signs	O
may	O
include	O
elevated	B
creatine	I
phosphokinase	I
,	O
myoglobinuria	B
(	O
rhabdomyolysis	B
)	O
,	O
and	O
acute	B
renal	I
failure	I
.	O
	
*	O
Record	O
the	O
date	O
you	O
open	O
the	O
foil	O
pouch	O
in	O
the	O
space	O
provided	O
on	O
the	O
blister	O
package	O
label	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
.	O
	
Common	O
adverse	O
events	O
(	O
>	O
=5	O
%	O
in	O
any	O
XEOMIN	O
treatment	O
group	O
)	O
observed	O
in	O
patients	O
who	O
received	O
XEOMIN	O
(	O
120	O
Units	O
or	O
240	O
Units	O
)	O
included	O
dysphagia	B
,	O
neck	B
pain	I
,	O
muscle	B
weakness	I
,	O
injection	B
site	I
pain	I
,	O
and	O
musculoskeletal	B
pain	I
.	O
	
Hemoglobin/Hematocrit	O
Low	B
hemoglobin	I
were	O
observed	O
in	O
0.2	O
%	O
,	O
0.4	O
%	O
,	O
and	O
0.3	O
%	O
of	O
Edarbi-treated	O
subjects	O
,	O
respectively	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
(	O
2.1	O
,	O
5.2	O
)	O
.	O
	
Other	O
adverse	O
reactions	O
occurred	O
at	O
a	O
rate	O
of	O
1	O
%	O
or	O
less	O
and	O
the	O
reported	O
events	O
consisted	O
of	O
headache	B
,	O
nausea	B
,	O
vertigo	B
,	O
dry	B
mouth	I
or	O
dizziness	B
.	O
	
The	O
data	O
below	O
reflect	O
exposure	O
to	O
ADCETRIS	O
as	O
monotherapy	O
in	O
327	O
patients	O
with	O
classical	O
Hodgkin	O
lymphoma	O
(	O
HL	O
)	O
and	O
systemic	O
anaplastic	O
large	O
cell	O
lymphoma	O
(	O
sALCL	O
)	O
,	O
including	O
160	O
patients	O
in	O
two	O
uncontrolled	O
single-arm	O
trials	O
(	O
Studies	O
1	O
and	O
2	O
)	O
and	O
167	O
patients	O
in	O
one	O
placebo-controlled	O
randomized	O
trial	O
(	O
Study	O
3	O
)	O
.	O
	
These	O
consisted	O
mainly	O
of	O
dyspnea	B
.	O
	
You	O
and	O
your	O
healthcare	O
provider	O
should	O
talk	O
regularly	O
about	O
whether	O
you	O
still	O
need	O
treatment	O
with	O
DUAVEE	O
.	O
	
Please	O
see	O
www.proliasafety.com	O
or	O
call	O
1-800-772-6436	O
for	O
more	O
information	O
about	O
this	O
program	O
.	O
	
Prescribe	O
only	O
for	O
recommended	O
patient	O
populations	O
.	O
	
Grade	O
3/4	O
hemorrhagic	B
events	I
were	O
reported	O
in	O
5/359	O
(	O
1	O
%	O
)	O
patients	O
receiving	O
INLYTA	O
(	O
including	O
cerebral	B
hemorrhage	I
,	O
hematuria	B
,	O
hemoptysis	B
,	O
lower	B
gastrointestinal	I
hemorrhage	I
,	O
and	O
melena	B
)	O
and	O
11/355	O
(	O
3	O
%	O
)	O
patients	O
receiving	O
sorafenib	O
.	O
	
No	O
data	O
are	O
available	O
on	O
the	O
secondary	O
transmission	O
of	O
infection	O
from	O
persons	O
receiving	O
live	O
vaccines	O
to	O
patients	O
receiving	O
BENLYSTA	O
or	O
the	O
effect	O
of	O
BENLYSTA	O
on	O
new	O
immunizations	O
.	O
	
Somnolence	B
includes	O
the	O
following	O
events	O
:	O
somnolence	B
and	O
sedation	B
.	O
	
Serious	O
depression	B
was	O
reported	O
in	O
0.4	O
%	O
(	O
6/1,458	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
0.1	O
%	O
(	O
1/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
with	O
SAPHRIS	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
in	O
SAPHRIS-treated	O
Bipolar	O
Patients	O
:	O
Adverse	O
reactions	O
associated	O
with	O
the	O
use	O
of	O
SAPHRIS	O
(	O
incidence	O
of	O
>	O
=2	O
%	O
in	O
any	O
SAPHRIS	O
dose	O
group	O
and	O
greater	O
than	O
placebo	O
)	O
that	O
occurred	O
during	O
acute	O
therapy	O
are	O
shown	O
in	O
Table	O
10	O
.	O
	
Fatal	B
cardiac	B
failure	I
was	O
reported	O
in	O
2/359	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
1/355	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
*	O
have	O
unusual	O
vaginal	O
bleeding	O
.	O
	
(	O
5.7	O
)	O
*	O
Hypercorticism	B
and	O
adrenal	B
suppression	I
may	O
occur	O
with	O
very	O
high	O
dosages	O
or	O
at	O
the	O
regular	O
dosage	O
in	O
susceptible	O
individuals	O
.	O
	
The	O
majority	O
of	O
the	O
reports	O
of	O
eyelid	B
ptosis	I
were	O
mild	O
to	O
moderate	O
in	O
severity	O
and	O
resolved	O
over	O
several	O
weeks	O
.	O
	
(	O
r	O
)	O
)	O
Program	O
.	O
	
Through	O
96	O
weeks	O
,	O
the	O
rate	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
was	O
2	O
%	O
in	O
both	O
treatment	O
arms	O
.	O
	
In	O
the	O
clinical	O
trials	O
of	O
STRIBILD	O
over	O
144	O
weeks	O
,	O
13	O
(	O
1.9	O
%	O
)	O
subjects	O
in	O
the	O
STRIBILD	O
group	O
(	O
N=701	O
)	O
,	O
8	O
(	O
2.3	O
%	O
)	O
subjects	O
in	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
(	O
N=355	O
)	O
and	O
no	O
subjects	O
in	O
the	O
ATRIPLA	O
group	O
(	O
N	O
=	O
352	O
)	O
discontinued	O
study	O
drug	O
due	O
to	O
a	O
renal	B
adverse	I
reaction	I
.	O
	
Moderate	O
endocrinopathy	B
(	O
requiring	O
hormone	O
replacement	O
or	O
medical	O
intervention	O
;	O
Grade	O
2	O
)	O
occurred	O
in	O
12	O
(	O
2.3	O
%	O
)	O
patients	O
and	O
consisted	O
of	O
hypothyroidism	B
,	O
adrenal	B
insufficiency	I
,	O
hypopituitarism	B
,	O
and	O
1	O
case	O
each	O
of	O
hyperthyroidism	B
and	O
Cushing	B
's	I
syndrome	I
.	O
	
In	O
those	O
patients	O
treated	O
with	O
HORIZANT	O
who	O
reported	O
dizziness	B
,	O
symptoms	O
persisted	O
during	O
treatment	O
in	O
about	O
20	O
%	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
observed	O
with	O
MULTAQ	O
400	O
mg	O
twice	O
daily	O
in	O
the	O
5	O
studies	O
were	O
diarrhea	B
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
vomiting	B
,	O
and	O
asthenia	B
.	O
	
(	O
6.5	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Therefore	O
,	O
when	O
treating	O
patients	O
with	O
asthma	O
,	O
physicians	O
should	O
only	O
prescribe	O
BREO	O
ELLIPTA	O
for	O
patients	O
not	O
adequately	O
controlled	O
on	O
a	O
long-term	O
asthma	O
control	O
medication	O
,	O
such	O
as	O
an	O
inhaled	O
corticosteroid	O
,	O
or	O
whose	O
disease	O
severity	O
clearly	O
warrants	O
initiation	O
of	O
treatment	O
with	O
both	O
an	O
inhaled	O
corticosteroid	O
and	O
a	O
LABA	O
.	O
	
Initiate	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
prednisone	O
or	O
equivalent	O
for	O
severe	O
immune-mediated	O
adverse	O
reactions	O
.	O
	
(	O
5.6	O
)	O
*	O
accumulation	B
of	I
body	I
fat	I
:	O
Observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O
	
Dizziness	B
,	O
tachycardia	B
,	O
and	O
weight	B
increased	I
were	O
at	O
least	O
twice	O
as	O
common	O
on	O
20	O
to	O
24	O
mg/day	O
as	O
on	O
10	O
to	O
16	O
mg/day	O
.	O
	
Remove	O
1	O
tablet	O
at	O
a	O
time	O
from	O
the	O
blister	O
package	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
alglucosidase	O
alfa	O
.	O
	
Severe	O
acute	B
exacerbations	I
of	I
hepatitis	I
B	I
have	O
been	O
reported	O
in	O
patients	O
coinfected	O
with	O
HIV-1	O
and	O
HBV	O
who	O
have	O
discontinued	O
EMTRIVA	O
or	O
VIREAD	O
,	O
two	O
of	O
the	O
components	O
of	O
STRIBILD	O
.	O
	
Reactions	O
are	O
further	O
categorized	O
by	O
MedDRA	O
system	O
organ	O
class	O
and	O
listed	O
in	O
order	O
of	O
decreasing	O
frequency	O
according	O
to	O
the	O
following	O
definitions	O
:	O
those	O
occurring	O
in	O
at	O
least	O
1/100	O
patients	O
(	O
frequent	O
)	O
(	O
only	O
those	O
not	O
already	O
listed	O
in	O
the	O
tabulated	O
results	O
from	O
placebo-controlled	O
trials	O
appear	O
in	O
this	O
listing	O
)	O
;	O
those	O
occurring	O
in	O
1/100	O
to	O
1/1000	O
patients	O
(	O
infrequent	O
)	O
;	O
and	O
those	O
occurring	O
in	O
fewer	O
than	O
1/1000	O
patients	O
(	O
rare	O
)	O
.	O
	
Infections	B
resulting	O
in	O
death	B
occurred	O
in	O
0.3	O
%	O
(	O
4/1,458	O
)	O
of	O
patients	O
treated	O
with	O
BENLYSTA	O
and	O
in	O
0.1	O
%	O
(	O
1/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
A	O
variety	O
of	O
CNS	B
anticholinergic	I
effects	I
have	O
been	O
reported	O
,	O
including	O
headache	B
,	O
dizziness	B
,	O
and	O
somnolence	B
.	O
	
Thrombotic	B
events	I
included	O
five	O
patients	O
with	O
pulmonary	B
embolus	I
in	O
the	O
everolimus	O
arm	O
and	O
one	O
in	O
the	O
placebo	O
arm	O
as	O
well	O
as	O
three	O
patients	O
with	O
thrombosis	B
in	O
the	O
everolimus	O
arm	O
and	O
two	O
in	O
the	O
placebo	O
arm	O
.	O
	
*	O
Embryo-Fetal	B
Toxicity	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Angioedema	B
of	I
the	I
face	I
has	O
been	O
reported	O
with	O
fesoterodine	O
.	O
	
5.3	O
Lack	O
of	O
Interchangeability	O
With	O
Gabapentin	O
HORIZANT	O
is	O
not	O
interchangeable	O
with	O
other	O
gabapentin	O
products	O
because	O
of	O
differing	O
pharmacokinetic	O
profiles	O
.	O
	
Withhold	O
GILOTRIF	O
for	O
keratitis	O
evaluation	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
prolactin	B
elevations	I
>	O
=4	O
times	O
ULN	O
(	O
at	O
Endpoint	O
)	O
were	O
2.6	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
0.6	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
Consider	O
interrupting	O
therapy	O
with	O
BENLYSTA	O
in	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
while	O
undergoing	O
treatment	O
with	O
BENLYSTA	O
and	O
monitor	O
these	O
patients	O
closely	O
.	O
	
Laboratory	O
Abnormalities	O
Treatment-naive	O
Subjects	O
:	O
Selected	O
laboratory	O
abnormalities	O
(	O
Grades	O
2	O
to	O
4	O
)	O
with	O
a	O
worsening	O
grade	O
from	O
baseline	O
and	O
representing	O
the	O
worst-grade	O
toxicity	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Administer	O
topical	O
or	O
systemic	O
corticosteroids	O
if	O
there	O
is	O
no	O
improvement	O
of	O
symptoms	O
within	O
1	O
week	O
.	O
	
Following	O
resolution	O
of	O
transaminase	O
elevations	O
,	O
consider	O
the	O
benefits	O
and	O
risks	O
of	O
resuming	O
KALYDECO	O
dosing	O
.	O
	
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
,	O
HYPERSENSITIVITY	B
AND	O
IMMUNE-MEDIATED	B
REACTIONS	I
,	O
and	O
RISK	O
OF	O
CARDIORESPIRATORY	B
FAILURE	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
*	O
Neutropenic	B
deaths	B
have	O
been	O
reported	O
.	O
	
Permanently	O
discontinue	O
GRANIX	O
in	O
patients	O
with	O
serious	O
allergic	O
reactions	O
.	O
	
Advise	O
families	O
and	O
caregivers	O
of	O
the	O
need	O
for	O
close	O
observation	O
and	O
communication	O
with	O
the	O
prescriber	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
See	O
Table	O
3	O
and	O
Table	O
4	O
for	O
other	O
potentially	O
significant	O
drug	O
interactions	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
An	O
increase	O
in	O
the	O
AFINITOR	O
dose	O
is	O
recommended	O
when	O
co-administered	O
with	O
a	O
strong	O
CYP3A4/PgP	O
inducer	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
,	O
2.5	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
The	O
mean	O
age	O
was	O
63	O
years	O
,	O
80	O
%	O
were	O
male	O
and	O
20	O
%	O
were	O
female	O
,	O
and	O
100	O
%	O
were	O
white	O
.	O
	
The	O
population	O
had	O
a	O
mean	O
age	O
of	O
39	O
(	O
range	O
:	O
18	O
to	O
75	O
)	O
,	O
94	O
%	O
were	O
female	O
,	O
and	O
52	O
%	O
were	O
Caucasian	O
.	O
	
Administration	O
of	O
ILARIS	O
should	O
be	O
discontinued	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
.	O
	
The	O
rate	O
of	O
treatment	O
discontinuation	O
due	O
to	O
urinary	B
tract	I
infections	I
was	O
0.1	O
%	O
,	O
0.2	O
%	O
,	O
and	O
0.1	O
%	O
for	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
VORAXAZE	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Serious	O
Adverse	O
Events	O
and	O
Discontinuation	O
-	O
Perioperative	O
Hypertension	O
Studies	O
The	O
incidence	O
of	O
adverse	O
events	O
leading	O
to	O
study	O
drug	O
discontinuation	O
in	O
patients	O
with	O
perioperative	O
hypertension	O
receiving	O
Cleviprex	O
was	O
5.9	O
%	O
versus	O
3.2	O
%	O
for	O
all	O
active	O
comparators	O
.	O
	
All	O
patients	O
should	O
be	O
instructed	O
to	O
seek	O
medical	O
advice	O
if	O
signs	O
,	O
symptoms	O
,	O
or	O
high	O
risk	O
exposure	O
suggestive	O
of	O
tuberculosis	O
(	O
e.g.	O
,	O
persistent	O
cough	O
,	O
weight	O
loss	O
,	O
subfebrile	O
temperature	O
)	O
appear	O
during	O
or	O
after	O
ILARIS	O
therapy	O
.	O
	
(	O
5.3	O
)	O
*	O
Continue	O
hydration	O
and	O
alkalinization	O
of	O
the	O
urine	O
as	O
indicated	O
.	O
	
Baseline	O
estimated	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
eGFR	O
>	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
in	O
91	O
%	O
of	O
the	O
study	O
population	O
and	O
moderately	O
impaired	O
(	O
eGFR	O
30	O
to	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
in	O
9	O
%	O
.	O
	
Withhold	O
trametinib	O
for	O
any	O
fever	O
higher	O
than	O
104oF	O
.	O
	
All	O
had	O
grade	O
4	O
neutropenia	B
and	O
one	O
had	O
febrile	B
neutropenia	I
.	O
	
Episodes	O
vary	O
in	O
frequency	O
,	O
severity	O
and	O
may	O
be	O
life-threatening	O
if	O
treatment	O
is	O
delayed	O
.	O
	
*	O
Angle	B
Closure	I
Glaucoma	I
:	O
Angle	B
closure	I
glaucoma	I
has	O
occurred	O
in	O
patients	O
with	O
untreated	O
anatomically	O
narrow	O
angles	O
treated	O
with	O
antidepressants	O
.	O
	
Healthcare	O
professionals	O
should	O
be	O
aware	O
of	O
the	O
similarity	O
of	O
symptoms	O
between	O
hypersensitivity	O
reactions	O
and	O
hereditary	O
angioedema	O
and	O
patients	O
should	O
be	O
monitored	O
closely	O
.	O
	
Subjects	O
treated	O
with	O
apixaban	O
with	O
diabetes	O
bled	B
more	O
(	O
3.0	O
%	O
per	O
year	O
)	O
than	O
did	O
subjects	O
without	O
diabetes	O
(	O
1.9	O
%	O
per	O
year	O
)	O
.	O
	
In	O
Trial	O
1	O
,	O
5	O
of	O
12	O
patients	O
with	O
a	O
history	O
of	O
diabetes	O
required	O
more	O
intensive	O
hypoglycemic	O
therapy	O
while	O
taking	O
TAFINLAR	O
.	O
	
Discontinuation	O
of	O
Prolia	O
therapy	O
should	O
be	O
considered	O
based	O
on	O
individual	O
benefit-risk	O
assessment	O
.	O
	
The	O
changes	B
in	I
FEV1	I
appear	O
to	O
be	O
reversible	O
after	O
treatment	O
discontinuation	O
.	O
	
T3	B
resin	I
uptake	I
is	I
decreased	I
,	O
reflecting	O
the	O
elevated	B
TBG	I
.	O
	
The	O
range	O
of	O
time	O
to	O
diagnosis	O
of	O
basal	B
cell	I
carcinoma	I
was	O
28	O
to	O
249	O
days	O
in	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
was	O
197	O
days	O
for	O
the	O
patient	O
receiving	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
(	O
5.4	O
)	O
*	O
Cleviprex	O
gives	O
no	O
protection	O
against	O
the	O
effects	O
of	O
abrupt	O
beta-blocker	O
withdrawal	O
.	O
	
Symptoms	O
of	O
PRES	B
are	O
usually	O
reversible	O
but	O
may	O
evolve	O
into	O
ischemic	B
stroke	I
or	O
cerebral	B
hemorrhage	I
.	O
	
The	O
pooled	O
analyses	O
of	O
placebo-controlled	O
studies	O
in	O
adults	O
with	O
MDD	O
or	O
other	O
psychiatric	O
disorders	O
included	O
a	O
total	O
of	O
295	O
short-term	O
studies	O
(	O
median	O
duration	O
of	O
2	O
months	O
)	O
of	O
11	O
antidepressant	O
drugs	O
in	O
over	O
77,000	O
patients	O
.	O
	
Careful	O
monitoring	O
and	O
appropriate	O
dose	O
adjustments	O
for	O
adverse	O
reactions	O
are	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
Discontinue	O
and	O
do	O
not	O
restart	O
AMPYRA	O
if	O
this	O
occurs	O
(	O
5.4	O
)	O
5.1	O
Seizures	O
AMPYRA	O
can	O
cause	O
seizures	B
.	O
	
The	O
evaluation	O
of	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
VORAXAZE	O
is	O
confounded	O
by	O
the	O
population	O
in	O
which	O
it	O
was	O
studied	O
,	O
patients	O
with	O
toxic	O
plasma	O
methotrexate	O
levels	O
due	O
to	O
impaired	O
renal	O
function	O
.	O
	
Prophylaxis	O
of	O
Deep	O
Vein	O
Thrombosis	O
Following	O
Hip	O
or	O
Knee	O
Replacement	O
Surgery	O
The	O
safety	O
of	O
ELIQUIS	O
has	O
been	O
evaluated	O
in	O
1	O
Phase	O
II	O
and	O
3	O
Phase	O
III	O
studies	O
including	O
5924	O
patients	O
exposed	O
to	O
ELIQUIS	O
2.5	O
mg	O
twice	O
daily	O
undergoing	O
major	O
orthopedic	O
surgery	O
of	O
the	O
lower	O
limbs	O
(	O
elective	O
hip	O
replacement	O
or	O
elective	O
knee	O
replacement	O
)	O
treated	O
for	O
up	O
to	O
38	O
days	O
.	O
	
Overall	O
,	O
20.2	O
%	O
of	O
patients	O
seroconverted	O
to	O
anti-ecallantide	O
antibodies	O
.	O
	
Do	O
not	O
exceed	O
the	O
recommended	O
dose	O
;	O
the	O
risk	O
of	O
acute	O
kidney	O
injury	O
may	O
increase	O
with	O
higher	O
than	O
recommended	O
doses	O
.	O
	
Spinal/epidural	O
anesthesia	O
or	O
puncture	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
1	O
%	O
)	O
are	O
related	O
to	O
bleeding	B
.	O
	
5.5	O
Hepatitis	O
B	O
Virus	O
Reactivation	O
Use	O
of	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
,	O
has	O
been	O
associated	O
with	O
reactivation	B
of	I
hepatitis	I
B	I
virus	I
)	O
in	O
patients	O
who	O
are	O
chronic	O
carriers	O
of	O
this	O
virus	O
.	O
	
*	O
Worsening	B
Renal	I
Impairment	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Total	B
bilirubin	I
greater	I
than	I
or	I
equal	I
to	I
1.5	I
x	I
ULN	I
was	O
reported	O
in	O
76	O
%	O
and	O
50	O
%	O
of	O
patients	O
receiving	O
PROMACTA	O
and	O
placebo	O
,	O
respectively	O
.	O
	
The	O
effect	O
of	O
treatment	O
with	O
DUAVEE	O
on	O
the	O
risk	O
of	O
ovarian	O
cancer	O
is	O
unknown	O
.	O
	
In	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
through	O
approximately	O
92	O
weeks	O
,	O
the	O
incidence	O
of	O
malignancies	B
per	O
100	O
patient-years	O
,	O
other	O
than	O
lymphoma	B
and	O
NMSC	B
,	O
in	O
SIMPONI	O
ARIA-treated	O
patients	O
was	O
0.31	O
(	O
CI	O
:	O
0.06	O
,	O
0.92	O
)	O
and	O
the	O
incidence	O
of	O
NMSC	B
was	O
0.1	O
(	O
95	O
%	O
CI	O
:	O
0.00	O
,	O
0.58	O
)	O
.	O
	
In	O
vitro	O
studies	O
with	O
human	O
platelets	O
indicate	O
that	O
STENDRA	O
potentiates	B
the	I
anti-aggregatory	I
effect	I
of	I
sodium	I
nitroprusside	I
(	O
a	O
nitric	O
oxide	O
[	O
NO	O
]	O
donor	O
)	O
.	O
	
Appropriate	O
medical	O
support	O
and	O
monitoring	O
measures	O
should	O
be	O
readily	O
available	O
during	O
alglucosidase	O
alfa	O
infusion	O
,	O
and	O
some	O
patients	O
may	O
require	O
prolonged	O
observation	O
times	O
that	O
should	O
be	O
individualized	O
based	O
on	O
the	O
needs	O
of	O
the	O
patient	O
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=	O
2	O
%	O
of	O
Patients	O
Receiving	O
Teflaro	O
in	O
the	O
Pooled	O
Phase	O
3	O
Clinical	O
Trials	O
a	O
Comparators	O
included	O
vancomycin	O
1	O
gram	O
IV	O
every	O
12h	O
plus	O
aztreonam	O
1	O
gram	O
IV	O
every	O
12h	O
in	O
the	O
Phase	O
3	O
ABSSSI	O
trials	O
,	O
and	O
ceftriaxone	O
1	O
gram	O
IV	O
every	O
24h	O
in	O
the	O
Phase	O
3	O
CABP	O
trials	O
.	O
	
(	O
5.3,7.2,7.3	O
)	O
5.1	O
Prolongation	O
of	O
the	O
QT	O
Interval	O
Some	O
antimalarials	O
(	O
e.g.	O
,	O
halofantrine	O
,	O
quinine	O
,	O
quinidine	O
)	O
including	O
Coartem	O
Tablets	O
have	O
been	O
associated	O
with	O
prolongation	B
of	I
the	I
QT	I
interval	I
on	O
the	O
electrocardiogram	O
.	O
	
When	O
vasodilators	O
are	O
used	O
in	O
combination	O
,	O
an	O
additive	O
effect	O
on	O
blood	O
pressure	O
may	O
be	O
anticipated	O
.	O
	
Therefore	O
,	O
patients	O
receiving	O
alglucosidase	O
alfa	O
should	O
undergo	O
periodic	O
urinalysis	O
[	O
seeAdverse	O
Reactions	O
(	O
6.3	O
)	O
]	O
.	O
	
5.2	O
Use	O
of	O
QT	O
Prolonging	O
Drugs	O
and	O
Other	O
Antimalarials	O
Halofantrine	O
and	O
Coartem	O
Tablets	O
should	O
not	O
be	O
administered	O
within	O
1	O
month	O
of	O
each	O
other	O
due	O
to	O
the	O
long	O
elimination	O
half-life	O
of	O
lumefantrine	O
(	O
3	O
to	O
6	O
days	O
)	O
and	O
potential	O
additive	O
effects	O
on	O
the	O
QT	O
interval	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Interstitial	B
infiltration	I
and/or	I
inflammation	I
were	I
observed	I
on	I
radiographs	I
and	I
computed	I
tomographic	I
imaging	I
of	I
the	I
chest	I
.	O
	
5.6	O
Visual	O
Abnormalities	O
Retinal	B
vascular	I
thrombosis	I
has	O
been	O
reported	O
in	O
patients	O
receiving	O
estrogens	O
.	O
	
There	O
may	O
be	O
circumstances	O
when	O
it	O
is	O
necessary	O
to	O
initiate	O
treatment	O
with	O
a	O
MAOI	O
such	O
as	O
linezolid	O
or	O
intravenous	O
methylene	O
blue	O
in	O
a	O
patient	O
taking	O
PRISTIQ	O
.	O
	
Serious	O
adverse	O
events	O
were	O
reported	O
in	O
11	O
%	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
and	O
in	O
8	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
.	O
	
Immune	O
System	O
Disorders	O
:	O
anaphylaxis	B
,	O
anaphylactic	B
reaction	I
.	O
	
The	O
majority	O
of	O
reported	O
TNF	O
blocker	O
cases	O
occurred	O
in	O
adolescent	O
and	O
young	O
adult	O
males	O
with	O
Crohn	O
's	O
disease	O
or	O
ulcerative	O
colitis	O
.	O
	
The	O
usefulness	O
of	O
hemodialysis	O
in	O
the	O
prevention	O
of	O
NSF	O
is	O
unknown	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
*	O
Hypersensitivity	O
reactions	O
:	O
anaphylaxis	B
,	O
urticaria	B
,	O
angioedema	B
,	O
and	O
serious	O
skin	B
reactions	I
(	O
bullous	B
eruption	I
)	O
have	O
been	O
reported	O
.	O
	
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
Asthenia	B
.	O
	
In	O
short-term	O
,	O
fixed-dose	O
,	O
placebo-controlled	O
schizophrenia	O
adult	O
trials	O
,	O
somnolence	B
was	O
reported	O
in	O
15	O
%	O
(	O
41/274	O
)	O
of	O
patients	O
on	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
and	O
in	O
13	O
%	O
(	O
26/208	O
)	O
of	O
patients	O
on	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
compared	O
to	O
7	O
%	O
(	O
26/378	O
)	O
of	O
placebo	O
patients	O
.	O
	
The	O
small	O
number	O
of	O
patients	O
positive	O
for	O
antibodies	O
to	O
SIMPONI	O
ARIA	O
limits	O
the	O
ability	O
to	O
draw	O
definitive	O
conclusions	O
regarding	O
the	O
relationship	O
between	O
antibodies	O
to	O
golimumab	O
and	O
clinical	O
efficacy	O
or	O
safety	O
measures	O
.	O
	
5.5	O
Liver	O
Injury	O
*	O
Hepatocellular	B
liver	I
injury	I
,	O
including	O
acute	B
liver	I
failure	I
requiring	O
transplant	O
,	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
MULTAQ	O
in	O
the	O
postmarketing	O
setting	O
.	O
	
Because	O
IL-1	O
blockade	O
may	O
interfere	O
with	O
immune	O
response	O
to	O
infections	O
,	O
it	O
is	O
recommended	O
that	O
prior	O
to	O
initiation	O
of	O
therapy	O
with	O
ILARIS	O
,	O
adult	O
and	O
pediatric	O
patients	O
receive	O
all	O
recommended	O
vaccinations	O
,	O
as	O
appropriate	O
,	O
including	O
pneumococcal	O
vaccine	O
and	O
inactivated	O
influenza	O
vaccine	O
.	O
	
The	O
data	O
above	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
considered	O
positive	O
for	O
antibodies	O
to	O
SIMPONI	O
ARIA	O
in	O
an	O
ELISA	O
assay	O
.	O
	
at	O
1-800-323-0000	O
,	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
malignancies	B
occurred	O
after	O
a	O
median	O
of	O
30	O
months	O
of	O
therapy	O
(	O
range	O
1	O
to	O
84	O
months	O
)	O
.	O
	
MULTAQ	O
doubles	O
the	O
risk	O
of	O
death	B
in	O
these	O
patients	O
(	O
4	O
,	O
5.1	O
,	O
14.3	O
)	O
.	O
	
5.2	O
Risk	O
for	O
Image	O
Misinterpretation	O
and	O
Other	O
Errors	O
Errors	O
may	O
occur	O
while	O
using	O
Vizamyl	O
PET	O
images	O
to	O
estimate	O
brain	O
neuritic	O
plaque	O
density	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Somnolence	B
led	O
to	O
discontinuation	O
in	O
0	O
%	O
,	O
3	O
%	O
,	O
1	O
%	O
,	O
and	O
2	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
and	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
.	O
	
Gastrointestinal	O
Disorders	O
:	O
Stomatitis	B
,	O
pancreatitis	B
.	O
	
Because	O
these	O
events	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Administration	O
Reactions	O
In	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
through	O
Week	O
24	O
,	O
1.1	O
%	O
of	O
SIMPONI	O
ARIA	O
infusions	O
were	O
associated	O
with	O
an	O
infusion	B
reaction	I
compared	O
with	O
0.2	O
%	O
of	O
infusions	O
in	O
the	O
control	O
group	O
.	O
	
Discontinue	O
medication	O
pending	O
examination	O
if	O
there	O
is	O
sudden	O
partial	O
or	O
complete	O
loss	O
of	O
vision	O
,	O
or	O
a	O
sudden	O
onset	O
of	O
proptosis	O
,	O
diplopia	O
,	O
or	O
migraine	O
.	O
	
Patients	O
typically	O
reported	O
cough	B
and	O
dyspnea	B
.	O
	
Adverse	O
Reactions	O
(	O
>	O
=3	O
%	O
)	O
with	O
a	O
Higher	O
Incidence	O
for	O
PROMACTA	O
versus	O
Placebo	O
from	O
Two	O
Placebo-controlled	O
Trials	O
in	O
Pediatric	O
Patients	O
6	O
Years	O
and	O
Older	O
with	O
Chronic	O
Immune	O
(	O
Idiopathic	O
)	O
Thrombocytopenia	O
PROMACTA	O
Placebo	O
n	O
=	O
82	O
n	O
=	O
40	O
Adverse	O
Reaction	O
(	O
%	O
)	O
(	O
%	O
)	O
Upper	B
respiratory	I
tract	I
infection	I
16	O
5	O
Nasopharyngitis	B
12	O
5	O
Rhinitis	B
11	O
8	O
Abdominal	B
pain	I
9	O
5	O
Cough	B
9	O
0	O
Oropharyngeal	B
pain	I
9	O
3	O
Toothache	B
6	O
0	O
AST	B
increased	I
5	O
0	O
Diarrhea	B
5	O
3	O
Rash	B
5	O
3	O
ALT	B
increaseda	O
6	O
0	O
Vitamin	B
D	I
deficiency	I
4	O
0	O
*	O
a	O
Includes	O
adverse	O
reactions	O
or	O
laboratory	O
abnormalities	O
>	O
3	O
x	O
ULN	O
.	O
	
*	O
receiving	O
medications	O
that	O
are	O
metabolized	O
by	O
the	O
cytochrome	O
enzyme	O
CYP2D6	O
which	O
also	O
have	O
cardiac	O
effects	O
(	O
e.g.	O
,	O
flecainide	O
,	O
imipramine	O
,	O
amitriptyline	O
,	O
clomipramine	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
,	O
Drug	O
Interactions	O
(	O
7.6	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Patients	O
improved	O
following	O
treatment	O
interruption	O
.	O
	
Phosphodiesterase	O
type	O
5	O
inhibitors	O
,	O
including	O
STENDRA	O
,	O
and	O
alpha-adrenergic	O
blocking	O
agents	O
are	O
both	O
vasodilators	O
with	O
blood	O
pressure-lowering	O
effects	O
.	O
	
Postmarketing	O
cases	O
of	O
hepatosplenic	B
T-cell	I
lymphoma	I
(	O
HSTCL	B
)	O
,	O
a	O
rare	O
type	O
of	O
T-cell	O
lymphoma	O
that	O
has	O
a	O
very	O
aggressive	O
disease	O
course	O
and	O
is	O
usually	O
fatal	B
,	O
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF	O
blockers	O
,	O
including	O
CIMZIA	O
.	O
	
Hepatobiliary	O
Disorders	O
:	O
hepatic	B
failure	I
(	O
some	O
fatal	B
)	O
,	O
jaundice	B
,	O
serious	O
cases	O
of	O
abnormal	B
liver	I
function	I
test	O
results	O
,	O
liver	B
disorder	I
.	O
	
Record	O
the	O
specific	O
GBCA	O
and	O
the	O
dose	O
administrated	O
to	O
a	O
patient	O
.	O
	
No	O
reports	O
involved	O
the	O
administration	O
of	O
methylene	O
blue	O
by	O
other	O
routes	O
(	O
such	O
as	O
oral	O
tablets	O
or	O
local	O
tissue	O
injection	O
)	O
or	O
at	O
lower	O
doses	O
.	O
	
Families	O
and	O
caregivers	O
of	O
patients	O
being	O
treated	O
with	O
antidepressants	O
for	O
major	O
depressive	O
disorder	O
or	O
other	O
indications	O
,	O
both	O
psychiatric	O
and	O
nonpsychiatric	O
,	O
should	O
be	O
alerted	O
about	O
the	O
need	O
to	O
monitor	O
patients	O
for	O
the	O
emergence	O
of	O
agitation	O
,	O
irritability	O
,	O
unusual	O
changes	O
in	O
behavior	O
,	O
and	O
the	O
other	O
symptoms	O
described	O
above	O
,	O
as	O
well	O
as	O
the	O
emergence	O
of	O
suicidality	O
,	O
and	O
to	O
report	O
such	O
symptoms	O
immediately	O
to	O
healthcare	O
providers	O
.	O
	
There	O
are	O
no	O
data	O
on	O
the	O
risks	O
of	O
using	O
CIMZIA	O
in	O
patients	O
who	O
have	O
experienced	O
a	O
severe	O
hypersensitivity	O
reaction	O
towards	O
another	O
TNF	O
blocker	O
;	O
in	O
these	O
patients	O
caution	O
is	O
needed	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Do	O
not	O
restart	O
ULORIC	O
if	O
liver	O
injury	O
is	O
confirmed	O
and	O
no	O
alternate	O
etiology	O
can	O
be	O
found	O
.	O
	
Bleeding	B
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
?	O
	
5.4	O
Extravasation	O
and	O
Injection	B
Site	I
Reactions	I
.	O
	
(	O
5.1,5.2,7.7,12.3	O
)	O
*	O
Substrates	O
,	O
inhibitors	O
,	O
or	O
inducers	O
of	O
CYP3A4	O
,	O
including	O
antiretroviral	O
medications	O
,	O
should	O
be	O
used	O
cautiously	O
with	O
Coartem	O
Tablets	O
,	O
due	O
to	O
a	O
potential	O
loss	O
of	O
efficacy	O
of	O
the	O
concomitant	O
drug	O
or	O
additive	O
QT	O
prolongation	O
.	O
	
Table	O
4	O
lists	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=	O
2	O
%	O
of	O
patients	O
receiving	O
Teflaro	O
in	O
the	O
pooled	O
Phase	O
3	O
clinical	O
trials	O
.	O
	
5.3	O
Risk	O
of	O
Acute	O
Cardiorespiratory	O
Failure	O
Patients	O
with	O
acute	O
underlying	O
respiratory	O
illness	O
or	O
compromised	O
cardiac	O
and/or	O
respiratory	O
function	O
may	O
be	O
at	O
risk	O
of	O
serious	O
exacerbation	B
of	I
their	I
cardiac	I
or	I
respiratory	I
compromise	I
during	O
infusions	O
.	O
	
5.9	O
Effects	O
on	O
Bleeding	O
The	O
safety	O
of	O
STENDRA	O
is	O
unknown	O
in	O
patients	O
with	O
bleeding	O
disorders	O
and	O
patients	O
with	O
active	O
peptic	O
ulceration	O
.	O
	
AST	B
greater	I
than	I
or	I
equal	I
to	I
3	I
x	I
ULN	I
was	O
reported	O
in	O
34	O
%	O
and	O
38	O
%	O
of	O
patients	O
for	O
PROMACTA	O
and	O
placebo	O
,	O
respectively	O
.	O
	
In	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
four	O
cases	O
of	O
non-cutaneous	B
malignancies	I
were	O
identified	O
:	O
KRAS	B
mutation-positive	I
pancreatic	I
adenocarcinoma	I
(	O
n	O
=	O
1	O
)	O
,	O
recurrent	B
NRAS	I
mutation-positive	I
colorectal	I
carcinoma	I
(	O
n	O
=	O
1	O
)	O
,	O
head	B
and	I
neck	I
carcinoma	I
(	O
n	O
=	O
1	O
)	O
,	O
and	O
glioblastoma	B
(	O
n	O
=	O
1	O
)	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Severe	O
or	O
Essential	O
Hypertension	O
Adverse	O
reactions	O
that	O
were	O
reported	O
in	O
<	O
1	O
%	O
of	O
patients	O
with	O
severe	O
or	O
essential	O
hypertension	O
included	O
:	O
Cardiac	O
:	O
myocardial	B
infarction	I
,	O
cardiac	B
arrestNervous	O
system	O
:	O
syncopeRespiratory	O
:	O
dyspnea	B
6.2	O
Post-Marketing	O
and	O
Other	O
Clinical	O
Experience	O
Because	O
adverse	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
estimate	O
reliably	O
their	O
frequency	O
or	O
to	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Major	O
45	O
(	O
1.41	O
)	O
29	O
(	O
0.92	O
)	O
1.54	O
(	O
0.96	O
,	O
2.45	O
)	O
0.07	O
Fatal	B
5	O
(	O
0.16	O
)	O
5	O
(	O
0.16	O
)	O
0.99	O
(	O
0.23	O
,	O
4.29	O
)	O
-	O
Intracranial	O
11	O
(	O
0.34	O
)	O
11	O
(	O
0.35	O
)	O
0.99	O
(	O
0.39	O
,	O
2.51	O
)	O
-	O
ARISTOTLE	O
Major	O
Bleeding	B
Forest	O
Plot	O
Other	O
Adverse	O
Reactions	O
Hypersensitivity	B
reactions	I
(	O
including	O
drug	B
hypersensitivity	I
,	O
such	O
as	O
skin	B
rash	I
,	O
and	O
anaphylactic	B
reactions	I
,	O
such	O
as	O
allergic	B
edema	I
)	O
and	O
syncope	B
were	O
reported	O
in	O
<	O
1	O
%	O
of	O
patients	O
receiving	O
ELIQUIS	O
.	O
	
Neutralizing	O
antibodies	O
to	O
ecallantide	O
were	O
determined	O
in	O
vitro	O
to	O
be	O
present	O
in	O
8.8	O
%	O
of	O
patients	O
and	O
were	O
not	O
associated	O
with	O
loss	O
of	O
efficacy	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
toxic	O
methotrexate	O
levels	O
due	O
to	O
prolonged	O
methotrexate	O
clearance	O
include	O
myelosuppression	O
,	O
mucositis	O
,	O
acute	O
hepatitis	O
,	O
and	O
renal	O
dysfunction	O
and	O
failure	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
AMPYRA	O
can	O
cause	O
seizures	B
;	O
the	O
risk	O
of	O
seizures	B
increases	O
with	O
increasing	O
AMPYRA	O
doses	O
;	O
discontinue	O
AMPYRA	O
and	O
do	O
not	O
restart	O
if	O
a	O
seizure	O
occurs	O
(	O
5.1	O
)	O
*	O
AMPYRA	O
should	O
not	O
be	O
taken	O
with	O
other	O
forms	O
of	O
4-aminopyridine	O
(	O
4-AP	O
,	O
fampridine	O
)	O
,	O
since	O
the	O
active	O
ingredient	O
is	O
the	O
same	O
(	O
5.3	O
)	O
*	O
AMPYRA	O
can	O
cause	O
anaphylaxis	B
.	O
	
There	O
was	O
considerable	O
variation	O
in	O
risk	O
of	O
suicidality	B
among	O
drugs	O
,	O
but	O
a	O
tendency	O
toward	O
an	O
increase	O
in	O
the	O
younger	O
patients	O
for	O
almost	O
all	O
drugs	O
studied	O
.	O
	
Symptoms	O
reported	O
included	O
sudden	O
onset	O
of	O
severe	O
headache	B
,	O
altered	B
mental	I
status	I
,	O
visual	B
disturbances	I
,	O
and	O
seizure	B
.	O
	
These	O
patients	O
may	O
also	O
develop	O
marked	O
elevations	B
of	I
serum	I
parathyroid	I
hormone	I
(	O
PTH	O
)	O
.	O
	
In	O
these	O
patients	O
,	O
extensive	O
dental	O
surgery	O
to	O
treat	O
ONJ	O
may	O
exacerbate	O
the	O
condition	O
.	O
	
The	O
incidence	O
of	O
Grade	O
3	O
hyperglycemia	B
based	O
on	O
laboratory	O
values	O
was	O
6	O
%	O
(	O
12/187	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
compared	O
with	O
none	O
of	O
the	O
dacarbazine-treated	O
patients	O
.	O
	
Monitor	O
heart	O
failure	O
patients	O
carefully	O
.	O
	
Increased	B
thyroid-binding	I
globulin	I
)	O
leading	O
to	O
increased	B
circulating	I
total	I
thyroid	I
hormone	I
by	O
radioimmunoassay	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Serious	O
Allergic	O
Reactions	O
Serious	O
allergic	B
reactions	I
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Table	O
1	O
shows	O
common	O
adverse	O
reactions	O
excluding	O
hypoglycemia	B
associated	O
with	O
the	O
use	O
of	O
TANZEUM	O
in	O
the	O
pool	O
of	O
placebo-controlled	O
trials	O
.	O
	
The	O
incidence	O
of	O
hypoglycemia	B
increased	O
when	O
JARDIANCE	O
was	O
administered	O
with	O
insulin	O
or	O
sulfonylurea	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
There	O
was	O
no	O
adverse	O
reaction	O
that	O
was	O
more	O
than	O
2	O
%	O
more	O
common	O
on	O
Cleviprex	O
than	O
on	O
the	O
average	O
of	O
all	O
comparators	O
.	O
	
(	O
5.5	O
)	O
*	O
Activation	B
of	I
Mania	I
:	O
Use	O
cautiously	O
in	O
patients	O
with	O
Bipolar	O
Disorder	O
.	O
	
5.5	O
Capillary	O
Leak	O
Syndrome	O
Capillary	B
leak	I
syndrome	I
(	O
CLS	B
)	O
can	O
occur	O
in	O
patients	O
receiving	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
and	O
is	O
characterized	O
by	O
hypotension	B
,	O
hypoalbuminemia	B
,	O
edema	B
and	O
hemoconcentration	B
.	O
	
Withhold	O
TAFINLAR	O
,	O
and	O
trametinib	O
if	O
used	O
in	O
combination	O
,	O
for	O
any	O
serious	O
febrile	O
reaction	O
or	O
fever	O
complicated	O
by	O
hypotension	O
,	O
rigors	O
or	O
chills	O
,	O
dehydration	O
,	O
or	O
renal	O
failure	O
and	O
evaluate	O
for	O
signs	O
and	O
symptoms	O
of	O
infection	O
.	O
	
When	O
possible	O
,	O
optimal	O
glucose	O
and	O
lipid	O
control	O
should	O
be	O
achieved	O
before	O
starting	O
a	O
patient	O
on	O
AFINITOR	O
.	O
	
In	O
these	O
trials	O
,	O
93	O
%	O
of	O
patients	O
treated	O
with	O
BENLYSTA	O
reported	O
an	O
adverse	O
reaction	O
compared	O
with	O
92	O
%	O
treated	O
with	O
placebo	O
.	O
	
These	O
trials	O
were	O
comprised	O
of	O
374	O
patients	O
of	O
whom	O
249	O
and	O
125	O
received	O
0.58	O
mg	O
of	O
XIAFLEX	O
and	O
placebo	O
,	O
respectively	O
.	O
	
Intracranial	B
bleed	I
includes	O
subarachnoid	B
bleeding	I
.	O
	
Systemic	O
and	O
local	O
corticosteroid	O
use	O
may	O
result	O
in	O
the	O
following	O
:	O
*	O
Candida	B
albicans	I
infection	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Increased	O
risk	O
of	O
pneumonia	B
in	O
COPD	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Immunosuppression	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Hypercorticism	B
and	O
adrenal	B
suppression	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)	O
]	O
*	O
Reduction	B
in	I
bone	I
mineral	I
density	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.13	O
)	O
]	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Some	O
drugs	O
that	O
are	O
inhibitors	O
of	O
CYP2D6	O
and	O
CYP3A	O
are	O
contraindicated	O
with	O
CERDELGA	O
depending	O
on	O
the	O
patient	O
's	O
CYP2D6	O
metabolizer	O
status	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
PRISTIQ	O
is	O
not	O
approved	O
for	O
use	O
in	O
pediatric	O
patients	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
]	O
.	O
	
The	O
administration	O
of	O
antihistamines	O
,	O
steroids	O
,	O
bronchodilators	O
,	O
and/or	O
epinephrine	O
may	O
reduce	O
the	O
severity	O
of	O
the	O
reactions	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEUTROPENIA	B
AND	O
HYPERSENSITIVITY	B
WARNING	O
:	O
NEUTROPENIA	B
AND	O
HYPERSENSITIVITY	B
EXCERPT	O
:	O
WARNING	O
:	O
NEUTROPENIA	B
AND	O
HYPERSENSITIVITY	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
chronic	O
or	O
recurrent	O
urinary	O
tract	O
infections	O
were	O
more	O
likely	O
to	O
experience	O
a	O
urinary	B
tract	I
infection	I
.	O
	
ILARIS	O
should	O
not	O
be	O
administered	O
to	O
patients	O
during	O
an	O
active	O
infection	O
requiring	O
medical	O
intervention	O
.	O
	
Withhold	O
or	O
discontinue	O
GILOTRIF	O
for	O
confirmed	O
ulcerative	O
keratitis	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
mania	O
adult	O
trials	O
,	O
the	O
mean	O
increase	B
in	I
prolactin	I
levels	I
was	O
4.9	O
ng/mL	O
for	O
SAPHRIS-treated	O
patients	O
compared	O
to	O
a	O
decrease	O
of	O
0.2	O
ng/mL	O
for	O
placebo-treated	O
patients	O
.	O
	
The	O
same	O
dose	O
of	O
HORIZANT	O
results	O
in	O
different	O
plasma	O
concentrations	O
of	O
gabapentin	O
relative	O
to	O
other	O
gabapentin	O
products	O
.	O
	
6.2	O
Post-marketing	O
Experience	O
The	O
following	O
events	O
have	O
been	O
reported	O
in	O
association	O
with	O
fesoterodine	O
use	O
in	O
worldwide	O
post-marketing	O
experience	O
:	O
Eye	O
disorders	O
:	O
Blurred	B
vision	I
;	O
Cardiac	O
disorders	O
:	O
Palpitations	B
;	O
General	O
disorders	O
and	O
administrative	O
site	O
conditions	O
:	O
Hypersensitivity	B
reactions	I
,	O
including	O
angioedema	B
with	O
airway	B
obstruction	I
,	O
face	B
edema	I
;	O
Central	O
nervous	O
system	O
disorders	O
:	O
Dizziness	B
,	O
headache	B
,	O
somnolence	B
;	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
Urticaria	B
,	O
pruritus	B
Because	O
these	O
spontaneously	O
reported	O
events	O
are	O
from	O
the	O
worldwide	O
post-marketing	O
experience	O
,	O
the	O
frequency	O
of	O
events	O
and	O
the	O
role	O
of	O
fesoterodine	O
in	O
their	O
causation	O
can	O
not	O
be	O
reliably	O
determined	O
.	O
	
*	O
Life-threatening	O
anaphylactic	B
reactions	I
and	O
severe	O
hypersensitivity	B
reactions	I
have	O
occurred	O
in	O
some	O
patients	O
during	O
and	O
after	O
alglucosidase	O
alfa	O
infusions	O
.	O
	
Dosing	O
should	O
be	O
interrupted	O
in	O
patients	O
with	O
ALT	O
or	O
AST	O
of	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
5.4	O
Immune-mediated	O
Neuropathies	O
In	O
Study	O
1	O
,	O
1	O
case	O
of	O
fatal	B
Guillain-Barre	B
syndrome	I
and	O
1	O
case	O
of	O
severe	O
(	O
Grade	O
3	O
)	O
peripheral	B
motor	I
neuropathy	I
were	O
reported	O
.	O
	
Among	O
subjects	O
aged	O
12	O
to	O
17	O
years	O
,	O
asthma-related	O
hospitalizations	O
occurred	O
in	O
4	O
subjects	O
(	O
2.6	O
%	O
)	O
treated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
(	O
n	O
=	O
151	O
)	O
compared	O
with	O
0	O
subjects	O
treated	O
with	O
fluticasone	O
furoate	O
100	O
mcg	O
(	O
n	O
=	O
130	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Takeda	O
Pharmaceuticals	O
at	O
1-877-TAKEDA-7	O
(	O
1-877-825-3327	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
mean	O
change	O
from	O
baseline	O
observed	O
for	O
selected	O
lipid	O
values	O
is	O
presented	O
in	O
Table	O
4	O
.	O
	
(	O
5.1	O
)	O
*	O
STRIBILD	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
chronic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
.	O
	
Do	O
not	O
place	O
DUAVEE	O
in	O
pill	O
boxes	O
or	O
pill	O
organizers	O
.	O
	
Extrapyramidal	O
Symptoms	O
(	O
EPS	O
)	O
in	O
Clinical	O
Trials	O
Pooled	O
data	O
from	O
the	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
provided	O
information	O
regarding	O
treatment-emergent	O
EPS	B
.	O
	
*	O
Use	O
in	O
Patients	O
with	O
Hepatic	O
Impairment	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Grade	O
3-4	O
renal	B
failure	I
occurred	O
in	O
six	O
patients	O
in	O
the	O
everolimus	O
arm	O
and	O
three	O
patients	O
in	O
the	O
placebo	O
arm	O
.	O
	
5.5	O
Central	O
Nervous	O
System	O
Effects	O
Toviaz	O
is	O
associated	O
with	O
anticholinergic	B
central	I
nervous	I
sytem	I
(	I
CNS	I
)	I
effects	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Progressive	O
Multifocal	O
Leukoencephalopathy	O
(	O
PML	O
)	O
Cases	O
of	O
JC	B
virus-associated	O
PML	B
resulting	O
in	O
neurological	B
deficits	I
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
in	O
patients	O
with	O
SLE	O
receiving	O
immunosuppressants	O
,	O
including	O
BENLYSTA	O
.	O
	
Across	O
the	O
3	O
studies	O
,	O
there	O
were	O
1493	O
patients	O
randomized	O
equally	O
to	O
placebo	O
,	O
OTEZLA	O
20	O
mg	O
twice	O
daily	O
or	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
.	O
	
(	O
6.4	O
)	O
SEGA	O
with	O
TSC	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
are	O
stomatitis	B
and	O
respiratory	B
tract	I
infection	I
.	O
	
The	O
most	O
common	O
reasons	O
for	O
discontinuation	O
of	O
therapy	O
with	O
MULTAQ	O
were	O
gastrointestinal	B
disorders	I
(	O
3.2	O
%	O
versus	O
1.8	O
%	O
in	O
the	O
placebo	O
group	O
)	O
and	O
QT	B
prolongation	I
(	O
1.5	O
%	O
versus	O
0.5	O
%	O
in	O
the	O
placebo	O
group	O
)	O
.	O
	
(	O
5.5	O
)	O
*	O
Decreases	B
in	I
bone	I
mineral	I
density	I
)	O
:	O
Consider	O
monitoring	O
BMD	O
in	O
patients	O
with	O
a	O
history	O
of	O
pathologic	O
fracture	O
or	O
other	O
risk	O
factors	O
of	O
osteoporosis	O
or	O
bone	O
loss	O
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
below	O
is	O
based	O
upon	O
two	O
double-blind	O
,	O
placebo-controlled	O
,	O
48-week	O
clinical	O
trials	O
(	O
Trials	O
1	O
and	O
2	O
)	O
in	O
a	O
total	O
of	O
213	O
patients	O
with	O
CF	O
ages	O
6	O
to	O
53	O
who	O
have	O
a	O
G551D	O
mutation	O
in	O
the	O
CFTR	O
gene	O
and	O
who	O
were	O
treated	O
with	O
KALYDECO	O
150	O
mg	O
orally	O
or	O
placebo	O
twice	O
daily	O
.	O
	
Among	O
the	O
32	O
patients	O
with	O
evaluable	O
pharmacokinetic	O
(	O
PK	O
)	O
samples	O
,	O
5	O
patients	O
tested	O
positive	O
for	O
uptake	O
inhibition	O
.	O
	
Administer	O
corticosteroid	O
eye	O
drops	O
to	O
patients	O
who	O
develop	O
uveitis	O
,	O
iritis	O
,	O
or	O
episcleritis	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
moderate	O
to	O
severe	O
immune-mediated	B
endocrinopathy	I
was	O
11	O
weeks	O
and	O
ranged	O
up	O
to	O
19.3	O
weeks	O
after	O
the	O
initiation	O
of	O
YERVOY	O
.	O
	
In	O
short-term	O
placebo-controlled	O
trials	O
(	O
4-	O
to	O
6-weeks	O
)	O
,	O
there	O
were	O
1.0	O
%	O
(	O
13/1342	O
)	O
iloperidone-treated	O
patients	O
with	O
hematocrit	B
at	I
least	I
one	I
time	I
below	I
the	I
extended	I
normal	I
range	I
during	O
post-randomization	O
treatment	O
,	O
compared	O
to	O
0.3	O
%	O
(	O
2/585	O
)	O
on	O
placebo	O
.	O
	
5.3	O
New	O
Onset	O
or	O
Worsening	O
Renal	O
Impairment	O
Renal	B
impairment	I
,	O
including	O
cases	O
of	O
acute	B
renal	I
failure	I
and	O
Fanconi	B
syndrome	I
(	O
renal	B
tubular	I
injury	I
with	O
severe	O
hypophosphatemia	B
)	O
,	O
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
tenofovir	O
DF	O
,	O
a	O
component	O
of	O
STRIBILD	O
,	O
and	O
with	O
the	O
use	O
of	O
STRIBILD	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
In	O
SINGLE	O
,	O
833	O
subjects	O
were	O
randomized	O
and	O
received	O
at	O
least	O
1	O
dose	O
of	O
either	O
TIVICAY	O
50	O
mg	O
with	O
fixed-dose	O
abacavir	O
sulfate	O
and	O
lamivudine	O
(	O
EPZICOM	O
)	O
once	O
daily	O
or	O
fixed-dose	O
efavirenz/emtricitabine/tenofovir	O
(	O
ATRIPLA	O
(	O
r	O
)	O
)	O
once	O
daily	O
.	O
	
(	O
5.1	O
)	O
*	O
ENTEREG	O
is	O
available	O
only	O
through	O
a	O
restricted	O
program	O
for	O
short-term	O
use	O
(	O
15	O
doses	O
)	O
called	O
the	O
ENTEREG	O
Access	O
Support	O
and	O
Education	O
(	O
E.A.S.E	O
.	O
	
Somnolence/sedation	O
led	O
to	O
withdrawal	O
in	O
2	O
%	O
of	O
patients	O
receiving	O
600	O
mg	O
of	O
HORIZANT	O
per	O
day	O
.	O
	
5.11	O
Elevation	O
of	O
Liver	O
Enzymes	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
ALT	B
)	I
elevations	I
of	O
all	O
grades	O
occurred	O
in	O
22	O
%	O
of	O
patients	O
on	O
both	O
arms	O
,	O
with	O
Grade	O
3/4	O
events	O
in	O
<	O
1	O
%	O
of	O
patients	O
on	O
the	O
INLYTA	O
arm	O
and	O
2	O
%	O
of	O
patients	O
on	O
the	O
sorafenib	O
arm	O
.	O
	
Grade	O
3/4	O
cardiac	B
failure	I
was	O
observed	O
in	O
2/359	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
1/355	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Resulting	O
oligohydramnios	B
can	O
be	O
associated	O
with	O
fetal	B
lung	I
hypoplasia	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
that	O
led	O
to	O
discontinuation	O
in	O
pediatric	O
patients	O
treated	O
with	O
SAPHRIS	O
(	O
rates	O
at	O
least	O
2	O
%	O
in	O
any	O
SAPHRIS	O
arm	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
)	O
were	O
somnolence	B
(	O
3	O
%	O
in	O
the	O
2.5mg	O
twice	O
daily	O
group	O
,	O
1	O
%	O
in	O
the	O
5mg	O
twice	O
daily	O
group	O
,	O
and	O
2	O
%	O
in	O
the	O
10mg	O
twice	O
daily	O
group	O
)	O
,	O
abdominal	B
pain	I
(	O
2	O
%	O
in	O
the	O
10mg	O
twice	O
daily	O
group	O
)	O
,	O
and	O
nausea	B
(	O
2	O
%	O
in	O
the	O
10mg	O
twice	O
daily	O
group	O
)	O
No	O
placebo-treated	O
patients	O
dropped	O
out	O
for	O
these	O
events	O
.	O
	
Serious	O
psychiatric	B
events	I
were	O
reported	O
in	O
0.8	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
(	O
0.6	O
%	O
and	O
1.2	O
%	O
with	O
1	O
and	O
10	O
mg/kg	O
,	O
respectively	O
)	O
and	O
0.4	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
[	O
seeDosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
If	O
such	O
changes	O
occur	O
,	O
discontinue	O
BREO	O
ELLIPTA	O
slowly	O
.	O
	
(	O
5.1	O
)	O
*	O
Do	O
not	O
initiate	O
in	O
acutely	O
deteriorating	O
COPD	O
or	O
asthma	O
.	O
	
There	O
were	O
no	O
new	O
clinically	O
relevant	O
AEs	O
that	O
emerged	O
in	O
the	O
later	O
treatment	O
cycles	O
.	O
	
The	O
Prolia	O
Postmarketing	O
Active	O
Safety	O
Surveillance	O
Program	O
is	O
available	O
to	O
collect	O
information	O
from	O
prescribers	O
on	O
specific	O
adverse	O
events	O
.	O
	
*	O
help	O
reduce	O
your	O
chances	O
of	O
developing	O
osteoporosis	O
(	O
thin	O
,	O
weak	O
bones	O
)	O
If	O
you	O
use	O
DUAVEE	O
only	O
to	O
prevent	O
osteoporosis	O
due	O
to	O
menopause	O
,	O
talk	O
with	O
your	O
healthcare	O
provider	O
about	O
whether	O
a	O
different	O
treatment	O
or	O
medicine	O
without	O
estrogens	O
might	O
be	O
better	O
for	O
you.DUAVEE	O
should	O
be	O
taken	O
for	O
the	O
shortest	O
time	O
possible	O
and	O
only	O
for	O
as	O
long	O
as	O
treatment	O
is	O
needed	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=7	O
%	O
and	O
higher	O
than	O
placebo	O
)	O
:	O
upper	B
respiratory	I
tract	I
infection	I
,	O
rash	B
,	O
and	O
urinary	B
tract	I
infection	I
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
UCB	O
,	O
Inc.	O
at	O
1-866-822-0068	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
from	O
last	O
dose	O
of	O
DYSPORT	O
(	O
r	O
)	O
was	O
approximately	O
one	O
week	O
,	O
and	O
the	O
median	O
duration	O
was	O
approximately	O
three	O
weeks	O
.	O
	
5.7	O
Immunization	O
Live	O
vaccines	O
should	O
not	O
be	O
given	O
for	O
30	O
days	O
before	O
or	O
concurrently	O
with	O
BENLYSTA	O
as	O
clinical	O
safety	O
has	O
not	O
been	O
established	O
.	O
	
The	O
risk	O
of	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
also	O
occur	O
in	O
adults	O
treated	O
for	O
spasticity	O
and	O
other	O
conditions	O
,	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
In	O
addition	O
,	O
patients	O
taking	O
Edarbi	O
who	O
had	O
moderate	O
to	O
severe	O
renal	O
impairment	O
at	O
baseline	O
or	O
who	O
were	O
>	O
75	O
years	O
of	O
age	O
were	O
more	O
likely	O
to	O
report	O
serum	B
creatinine	I
increases	I
.	O
	
Approximately	O
61	O
%	O
of	O
XEOMIN-treated	O
patients	O
had	O
previously	O
received	O
another	O
botulinum	O
toxin	O
type	O
A	O
product	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
These	O
reactions	O
were	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O
	
*	O
DUAVEE	O
comes	O
in	O
a	O
blister	O
package	O
.	O
	
Discontinue	O
ERWINAZE	O
for	O
a	O
thrombotic	O
or	O
hemorrhagic	O
event	O
until	O
symptoms	O
resolve	O
;	O
after	O
resolution	O
,	O
treatment	O
with	O
ERWINAZE	O
may	O
be	O
resumed	O
.	O
	
The	O
relationship	O
to	O
GILENYA	O
remains	O
uncertain	O
.	O
	
ARCAPTA	O
NEOHALER	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
acutely	O
deteriorating	O
COPD	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Other	O
adverse	O
reactions	O
occurring	O
more	O
frequently	O
on	O
INVOKANA	O
than	O
on	O
comparator	O
were	O
:	O
Volume	O
Depletion-Related	O
Adverse	O
Reactions	O
INVOKANA	O
results	O
in	O
an	O
osmotic	B
diuresis	I
,	O
which	O
may	O
lead	O
to	O
reductions	B
in	I
intravascular	I
volume	I
.	O
	
In	O
the	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
these	O
events	O
were	O
reported	O
in	O
16	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
APTIOM	O
compared	O
to	O
6	O
%	O
of	O
placebo	O
patients	O
.	O
	
Monitor	O
with	O
electrocardiograms	O
and	O
electrolytes	O
in	O
patients	O
who	O
have	O
a	O
history	O
of	O
or	O
predisposition	O
for	O
QTc	O
prolongation	O
,	O
or	O
who	O
are	O
taking	O
medications	O
that	O
prolong	O
QT	O
.	O
	
Somnolence	B
and	O
fatigue	B
were	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
Discontinue	O
XALKORI	O
in	O
patients	O
with	O
severe	O
visual	O
loss	O
.	O
	
In	O
the	O
pool	O
of	O
eight	O
clinical	O
trials	O
,	O
the	O
incidence	O
rate	O
of	O
pancreatitis	B
(	I
acute	I
)	O
was	O
0.9	O
,	O
2.7	O
,	O
and	O
0.9	O
per	O
1000	O
patient-years	O
of	O
exposure	O
to	O
comparator	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
1976	O
patients	O
to	O
JARDIANCE	O
with	O
a	O
mean	O
exposure	O
duration	O
of	O
approximately	O
23	O
weeks	O
.	O
	
When	O
beginning	O
ARCAPTA	O
NEOHALER	O
,	O
patients	O
who	O
have	O
been	O
taking	O
inhaled	O
,	O
short-acting	O
beta2-agonists	O
on	O
a	O
regular	O
basis	O
(	O
e.g.	O
,	O
four	O
times	O
a	O
day	O
)	O
should	O
be	O
instructed	O
to	O
discontinue	O
the	O
regular	O
use	O
of	O
these	O
drugs	O
and	O
use	O
them	O
only	O
for	O
symptomatic	O
relief	O
of	O
acute	O
respiratory	O
symptoms	O
.	O
	
Obtain	O
serum	O
potassium	O
,	O
calcium	O
,	O
and	O
magnesium	O
at	O
baseline	O
and	O
correct	O
if	O
abnormal	O
.	O
	
Bosutinib	O
caused	O
embryofetal	B
toxicities	I
in	O
rabbits	O
at	O
maternal	O
exposures	O
that	O
were	O
greater	O
than	O
the	O
clinical	O
exposure	O
at	O
the	O
recommended	O
bosutinib	O
dose	O
of	O
500	O
mg/day	O
.	O
	
Pooled	O
analyses	O
of	O
199	O
placebo-controlled	O
clinical	O
trials	O
(	O
mono-	O
and	O
adjunctive-therapy	O
)	O
of	O
11	O
different	O
AEDs	O
showed	O
that	O
patients	O
randomized	O
to	O
one	O
of	O
the	O
AEDs	O
had	O
approximately	O
twice	O
the	O
risk	O
(	O
adjusted	O
relative	O
risk	O
1.8	O
,	O
95	O
%	O
confidence	O
interval	O
[	O
CI	O
]	O
:	O
1.2	O
,	O
2.7	O
)	O
of	O
suicidal	B
thinking	I
compared	O
with	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
Therefore	O
,	O
avoid	O
the	O
use	O
of	O
strong	O
CYP3A4	O
inhibitors	O
for	O
more	O
than	O
14	O
consecutive	O
days	O
while	O
on	O
SIRTURO	O
,	O
unless	O
the	O
benefit	O
of	O
treatment	O
with	O
the	O
drug	O
combination	O
outweighs	O
the	O
risk	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Epilepsy	O
and	O
many	O
other	O
illnesses	O
for	O
which	O
AEDs	O
are	O
prescribed	O
are	O
themselves	O
associated	O
with	O
morbidity	O
and	O
mortality	O
and	O
an	O
increased	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hepatotoxicity	B
:	O
Fatal	B
hepatotoxicity	B
occurred	O
in	O
0.1	O
%	O
of	O
patients	O
.	O
	
Increased	B
plasma	I
high-density	I
lipoprotein	I
,	O
reduced	B
low-density	I
lipoprotein	I
(	I
LDL	I
)	I
cholesterol	I
concentrations	I
,	O
increased	B
triglyceride	I
levels	I
.	O
	
Treatment	O
to	O
Increase	O
Bone	O
Mass	O
in	O
Men	O
with	O
Osteoporosis	O
The	O
safety	O
of	O
Prolia	O
in	O
the	O
treatment	O
of	O
men	O
with	O
osteoporosis	O
was	O
assessed	O
in	O
a	O
1-year	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
60	O
years	O
and	O
5	O
%	O
were	O
older	O
than	O
75	O
years	O
of	O
age	O
.	O
	
In	O
a	O
placebo-controlled	O
clinical	O
trial	O
of	O
patients	O
with	O
rheumatoid	O
arthritis	O
,	O
no	O
difference	O
was	O
detected	O
in	O
antibody	O
response	O
to	O
vaccine	O
between	O
CIMZIA	O
and	O
placebo	O
treatment	O
groups	O
when	O
the	O
pneumococcal	O
polysaccharide	O
vaccine	O
and	O
influenza	O
vaccine	O
were	O
administered	O
concurrently	O
with	O
CIMZIA	O
.	O
	
Patients	O
with	O
MPS	O
IVA	O
should	O
be	O
monitored	O
for	O
signs	O
and	O
symptoms	O
of	O
SCC	O
(	O
including	O
back	O
pain	O
,	O
paralysis	O
of	O
limbs	O
below	O
the	O
level	O
of	O
compression	O
,	O
urinary	O
and	O
fecal	O
incontinence	O
)	O
and	O
given	O
appropriate	O
clinical	O
care	O
.	O
	
Consider	O
interruption	O
of	O
TECFIDERA	O
in	O
patients	O
with	O
lymphocyte	O
counts	O
<	O
0.5	O
x	O
10	O
9	O
/L	O
persisting	O
for	O
more	O
than	O
six	O
months	O
.	O
	
DRESS	B
may	O
be	O
fatal	B
or	O
life-threatening	O
.	O
	
Other	O
important	O
serious	O
adverse	O
reactions	O
reported	O
in	O
clinical	O
trials	O
and/or	O
postmarketing	O
experience	O
were	O
acute	B
renal	I
failure	I
,	O
cardiac	B
failure	I
,	O
hypersensitivity	B
,	O
skin	B
reactions	I
,	O
pulmonary	B
fibrosis	I
,	O
and	O
myelodysplastic	B
syndrome	I
.	O
	
Bleeding	B
events	O
of	O
any	O
grade	O
,	O
including	O
bruising	B
and	O
petechiae	B
,	O
occurred	O
in	O
approximately	O
half	O
of	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
Serious	O
and	O
sometimes	O
fatal	B
dermatologic	B
reactions	I
,	O
including	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
and	O
SJS	B
,	O
have	O
been	O
reported	O
in	O
patients	O
using	O
oxcarbazepine	O
or	O
carbamazepine	O
which	O
are	O
chemically	O
related	O
to	O
APTIOM	O
.	O
	
Patients	O
treated	O
with	O
TREANDA	O
may	O
also	O
have	O
changes	B
in	I
their	I
creatinine	I
levels	I
.	O
	
Due	O
to	O
the	O
potential	O
for	O
anaphylaxis	O
,	O
appropriate	O
medical	O
support	O
should	O
be	O
readily	O
available	O
when	O
Vimizim	O
is	O
administered	O
.	O
	
*	O
A	O
24-week	O
placebo-controlled	O
trial	O
(	O
Trial	O
5	O
)	O
involving	O
69	O
patients	O
between	O
the	O
ages	O
of	O
6	O
and	O
68	O
years	O
with	O
an	O
R117H	O
mutation	O
in	O
the	O
CFTR	O
gene	O
.	O
	
Consider	O
discontinuing	O
Prolia	O
if	O
severe	O
symptoms	O
develop	O
(	O
5.7	O
)	O
*	O
Severe	O
Muscle	B
Pain	I
may	O
occur	O
.	O
	
Anaphylaxis	B
and	O
Hypersensitivity	B
Reactions	I
:	O
Life-threatening	O
anaphylaxis	B
and	O
hypersensitivity	B
reactions	O
have	O
been	O
observed	O
in	O
some	O
patients	O
during	O
treatment	O
with	O
Vimizim	O
.	O
	
At	O
the	O
recommended	O
dose	O
of	O
50	O
mg	O
,	O
the	O
discontinuation	O
rate	O
due	O
to	O
an	O
adverse	O
reaction	O
for	O
PRISTIQ	O
(	O
4.1	O
%	O
)	O
was	O
similar	O
to	O
the	O
rate	O
for	O
placebo	O
(	O
3.8	O
%	O
)	O
.	O
	
[	O
See	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
.	O
]	O
	
(	O
5.1	O
,	O
5.2	O
,	O
5.3	O
,	O
5.4	O
,	O
5.5	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
YERVOY	O
can	O
result	O
in	O
severe	O
and	O
fatal	B
immune-mediated	B
reactions	I
due	O
to	O
T-cell	O
activation	O
and	O
proliferation	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Bleeding	B
:	O
PRADAXA	O
can	O
cause	O
serious	O
and	O
fatal	B
bleeding	B
(	O
5.2	O
)	O
*	O
Bioprosthetic	O
heart	O
valves	O
:	O
PRADAXA	O
use	O
not	O
recommended	O
(	O
5.4	O
)	O
5.1	O
Increased	O
Risk	O
of	O
Thrombotic	O
Events	O
after	O
Premature	O
Discontinuation	O
Premature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
PRADAXA	O
,	O
in	O
the	O
absence	O
of	O
adequate	O
alternative	O
anticoagulation	O
increases	O
the	O
risk	O
of	O
thrombotic	O
events	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
hypotension	O
after	O
initiating	O
therapy	O
.	O
	
(	O
5.5	O
)	O
*	O
Bladder	B
Cancer	I
:	O
An	O
imbalance	O
in	O
bladder	B
cancers	I
was	O
observed	O
in	O
clinical	O
trials	O
.	O
	
Severe	O
priapism	B
may	O
require	O
surgical	O
intervention	O
.	O
	
(	O
5.1	O
)	O
*	O
All	O
patients	O
taking	O
POTIGA	O
should	O
have	O
baseline	O
and	O
periodic	O
(	O
every	O
6	O
months	O
)	O
systematic	O
visual	O
monitoring	O
by	O
an	O
ophthalmic	O
professional	O
.	O
	
PRADAXA	O
's	O
anticoagulant	O
activity	O
and	O
half-life	O
are	O
increased	O
in	O
patients	O
with	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
YERVOY	O
with	O
the	O
incidences	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Information	O
on	O
selected	O
significant	O
adverse	O
reactions	O
observed	O
during	O
clinical	O
trials	O
is	O
summarized	O
below	O
.	O
	
The	O
majority	O
of	O
these	O
events	O
were	O
infections	B
.	O
	
The	O
administration	O
of	O
oral	O
contraceptives	O
to	O
induce	O
withdrawal	O
bleeding	O
should	O
not	O
be	O
used	O
as	O
a	O
test	O
for	O
pregnancy	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Apprise	O
women	O
of	O
reproductive	O
potential	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
XIAFLEX-associated	O
pruritus	B
increased	O
after	O
more	O
XIAFLEX	O
injections	O
in	O
patients	O
with	O
Dupuytren	O
's	O
contracture	O
.	O
	
Twenty-nine	O
patients	O
(	O
85	O
%	O
)	O
with	O
Grade	O
3-5	O
enterocolitis	B
were	O
treated	O
with	O
high-dose	O
(	O
>	O
=40	O
mg	O
prednisone	O
equivalent	O
per	O
day	O
)	O
corticosteroids	O
,	O
with	O
a	O
median	O
dose	O
of	O
80	O
mg/day	O
of	O
prednisone	O
or	O
equivalent	O
;	O
the	O
median	O
duration	O
of	O
treatment	O
was	O
2.3	O
weeks	O
(	O
ranging	O
up	O
to	O
13.9	O
weeks	O
)	O
followed	O
by	O
corticosteroid	O
taper	O
.	O
	
The	O
population	O
in	O
these	O
studies	O
was	O
71	O
%	O
White	O
,	O
7	O
%	O
Black	O
or	O
African	O
American	O
,	O
11	O
%	O
Asian	O
;	O
32	O
%	O
were	O
of	O
Hispanic	O
or	O
Latino	O
ethnicity	O
.	O
	
The	O
incidence	O
of	O
new	O
cases	O
of	O
infections	B
in	O
controlled	O
clinical	O
studies	O
in	O
rheumatoid	O
arthritis	O
was	O
0.91	O
per	O
patient-year	O
for	O
all	O
CIMZIA-treated	O
patients	O
and	O
0.72	O
per	O
patient-year	O
for	O
placebo-treated	O
patients	O
.	O
	
There	O
is	O
no	O
evidence	O
of	O
increased	O
risk	O
of	O
infections	O
with	O
continued	O
exposure	O
over	O
time	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.9	O
)	O
*	O
Embryofetal	B
toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
Idelalisib	O
is	O
teratogenic	B
in	O
rats	O
,	O
at	O
systemic	O
exposures	O
12	O
times	O
those	O
reported	O
in	O
patients	O
at	O
the	O
recommended	O
dose	O
of	O
150	O
mg	O
twice	O
daily	O
.	O
	
Eight	O
of	O
79	O
(	O
10.1	O
%	O
)	O
patients	O
in	O
the	O
SIRTURO	O
group	O
and	O
16	O
of	O
81	O
(	O
19.8	O
%	O
)	O
patients	O
in	O
the	O
placebo	O
treatment	O
group	O
were	O
HIV-infected	O
.	O
	
All	O
patients	O
who	O
tested	O
positive	O
for	O
binding	O
antibodies	O
also	O
tested	O
positive	O
for	O
neutralizing	O
anti-blinatumomab	O
antibodies	O
.	O
	
(	O
5.1	O
)	O
*	O
Measure	O
the	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
before	O
starting	O
Ferriprox	O
and	O
monitor	O
the	O
ANC	O
weekly	O
on	O
therapy	O
.	O
	
Of	O
these	O
7	O
patients	O
,	O
6	O
had	O
complete	O
resolution	O
;	O
time	O
to	O
resolution	O
ranged	O
up	O
to	O
15.6	O
weeks	O
.	O
	
If	O
at	O
any	O
time	O
AST	O
or	O
ALT	O
rise	O
above	O
five	O
times	O
the	O
ULN	O
,	O
or	O
the	O
bilirubin	O
rises	O
above	O
three	O
times	O
the	O
ULN	O
,	O
interrupt	O
ZYTIGA	O
treatment	O
and	O
closely	O
monitor	O
liver	O
function	O
.	O
	
Conduct	O
periodic	O
monitoring	O
with	O
electrocardiograms	O
(	O
ECGs	O
)	O
and	O
electrolytes	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
electrolyte	O
abnormalities	O
,	O
or	O
those	O
who	O
are	O
taking	O
medications	O
that	O
are	O
known	O
to	O
prolong	O
the	O
QTc	O
interval	O
.	O
	
Some	O
studies	O
suggest	O
that	O
COCs	O
are	O
associated	O
with	O
an	O
increase	O
in	O
the	O
risk	O
of	O
cervical	B
cancer	I
.	O
	
Clinically	O
significant	O
cardiovascular	O
effects	O
and	O
fatalities	B
have	O
been	O
reported	O
in	O
association	O
with	O
excessive	O
use	O
of	O
inhaled	O
sympathomimetic	O
drugs	O
.	O
	
Monitor	O
liver	O
function	O
tests	O
and	O
omit	O
or	O
modify	O
dosage	O
for	O
hepatic	O
toxicities	O
.	O
	
BREO	O
ELLIPTA	O
should	O
not	O
be	O
used	O
for	O
the	O
relief	O
of	O
acute	O
symptoms	O
,	O
i.e.	O
,	O
as	O
rescue	O
therapy	O
for	O
the	O
treatment	O
of	O
acute	O
episodes	O
of	O
bronchospasm	O
.	O
	
c	O
Confidence	O
interval	O
Patients	O
Major	O
bleeding	B
event	O
a	O
Bleeding	B
sites	O
for	O
MBE	B
b	O
Clinically	O
relevant	O
non-major	O
bleeding	B
Any	O
bleeding	B
In	O
the	O
RE-MEDY	O
study	O
,	O
the	O
rate	O
of	O
any	O
gastrointestinal	B
bleeds	I
in	O
patients	O
receiving	O
PRADAXA	O
150	O
mg	O
was	O
3.1	O
%	O
(	O
2.2	O
%	O
on	O
warfarin	O
)	O
.	O
	
(	O
5.3	O
)	O
*	O
Serious	O
Dermatological	B
Reactions	I
(	O
including	O
Stevens-Johnson	B
syndrome	I
and	O
toxic	B
epidermal	I
necrolysis	I
)	O
:	O
Discontinue	O
ONFI	O
at	O
first	O
sign	O
of	O
rash	O
unless	O
the	O
rash	O
is	O
clearly	O
not	O
drug-related	O
.	O
	
Concurrent	O
elevations	B
in	I
ALT	I
greater	O
than	O
3	O
times	O
the	O
ULN	O
and	O
total	B
bilirubin	I
greater	I
than	I
2	I
times	I
the	I
ULN	I
,	O
with	O
normal	O
alkaline	O
phosphatase	O
,	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
in	O
clinical	O
studies	O
.	O
	
Stop	O
Natazia	O
if	O
there	O
is	O
unexplained	O
loss	O
of	O
vision	O
,	O
proptosis	O
,	O
diplopia	O
,	O
papilledema	O
,	O
or	O
retinal	O
vascular	O
lesions	O
.	O
	
Agranulocytosis	B
and	O
neutropenia	B
usually	O
resolve	O
upon	O
discontinuation	O
of	O
Ferriprox	O
,	O
but	O
there	O
have	O
been	O
reports	O
of	O
agranulocytosis	B
leading	O
to	O
death	B
.	O
	
There	O
were	O
insufficient	O
numbers	O
of	O
patients	O
with	O
biopsy-proven	O
hepatitis	O
to	O
characterize	O
the	O
clinical	O
course	O
of	O
this	O
event	O
.	O
	
There	O
have	O
been	O
rare	O
reports	O
of	O
deaths	O
,	O
primarily	O
in	O
preterm	O
infants	O
,	O
associated	O
with	O
exposure	O
to	O
excessive	O
amounts	O
of	O
benzyl	O
alcohol	O
[	O
see	O
Description	O
(	O
11	O
)	O
]	O
.	O
	
Monitor	O
weekly	O
for	O
liver	O
toxicity	O
if	O
the	O
ALT	O
or	O
AST	O
rises	O
above	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
until	O
resolved	O
.	O
	
These	O
patients	O
were	O
managed	O
without	O
surgical	O
intervention	O
,	O
but	O
the	O
long-term	O
consequences	O
are	O
unknown	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Severe	O
,	O
potentially	O
life	O
threatening	O
and	O
fatal	B
skin	B
reactions	I
have	O
been	O
reported	O
.	O
	
(	O
5.3	O
)	O
*	O
Fatal	B
and	O
serious	O
intestinal	B
perforation	I
can	O
occur	O
in	O
Zydelig-treated	O
patients	O
across	O
clinical	O
trials	O
.	O
	
Plasma	O
Zinc	O
Concentration	O
Decreased	B
plasma	I
zinc	I
concentrations	I
have	O
been	O
observed	O
on	O
Ferriprox	O
therapy	O
.	O
	
Control	O
hypertension	O
and	O
correct	O
hypokalemia	O
before	O
treatment	O
.	O
	
Prior	O
to	O
administration	O
,	O
question	O
the	O
patient	O
for	O
a	O
history	O
of	O
prior	O
reactions	O
to	O
iodine	O
,	O
an	O
iodine-containing	O
contrast	O
agent	O
or	O
other	O
products	O
containing	O
iodine	O
.	O
	
If	O
pathology	O
and	O
pregnancy	O
are	O
excluded	O
,	O
bleeding	O
irregularities	O
may	O
resolve	O
over	O
time	O
or	O
with	O
a	O
change	O
to	O
a	O
different	O
COC	O
.	O
	
Cabozantinib	O
was	O
embryolethal	B
in	O
rats	O
at	O
exposures	O
below	O
the	O
recommended	O
human	O
dose	O
,	O
with	O
increased	O
incidences	O
of	O
skeletal	B
variations	I
in	O
rats	O
and	O
visceral	B
variations	I
in	O
rabbits	O
.	O
	
If	O
adequate	O
hyperglycemic	O
control	O
can	O
not	O
be	O
achieved	O
with	O
optimal	O
medical	O
management	O
,	O
permanently	O
discontinue	O
ZYKADIA	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Increased	O
dosage	O
of	O
corticosteroids	O
may	O
be	O
indicated	O
before	O
,	O
during	O
and	O
after	O
stressful	O
situations	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Laboratory	O
Abnormalities	O
in	O
Treatment-Experienced	O
Patients	O
Selected	O
Grade	O
2	O
to	O
Grade	O
4	O
laboratory	O
abnormalities	O
that	O
represent	O
a	O
worsening	O
from	O
baseline	O
observed	O
in	O
adult	O
subjects	O
treated	O
with	O
INTELENCE	O
(	O
r	O
)	O
are	O
presented	O
in	O
Table	O
2	O
.	O
	
One	O
patient	O
with	O
baseline	O
hyperuricemia	O
and	O
bulky	O
disease	O
experienced	O
Grade	O
4	O
tumor	B
lysis	I
syndrome	I
during	O
the	O
first	O
cycle	O
of	O
treatment	O
and	O
died	B
due	O
to	O
multi-organ	B
failure	I
.	O
	
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
.	O
	
(	O
5.13	O
)	O
*	O
Close	O
monitoring	O
for	O
glaucoma	O
and	O
cataracts	O
is	O
warranted	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
signs	O
or	O
symptoms	O
of	O
SJS/TEN	O
,	O
especially	O
during	O
the	O
first	O
8	O
weeks	O
of	O
treatment	O
initiation	O
or	O
when	O
re-introducing	O
therapy	O
.	O
	
5.4	O
Genital	O
Mycotic	O
Infections	O
FARXIGA	O
increases	O
the	O
risk	O
of	O
genital	B
mycotic	I
infections	I
.	O
	
Withdrawal	O
symptoms	O
occurred	O
following	O
abrupt	O
discontinuation	O
of	O
ONFI	O
;	O
the	O
risk	O
of	O
withdrawal	O
symptoms	O
is	O
greater	O
with	O
higher	O
doses	O
.	O
	
Because	O
these	O
events	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Uncontrolled	O
hyperammonemia	O
can	O
rapidly	O
result	O
in	O
brain	O
injury/damage	O
or	O
death	O
,	O
and	O
prompt	O
use	O
of	O
all	O
therapies	O
necessary	O
to	O
reduce	O
plasma	O
ammonia	O
levels	O
is	O
essential	O
.	O
	
Clinical	O
Myocardial	O
Infarction	O
Events	O
In	O
the	O
active-controlled	O
VTE	O
studies	O
,	O
a	O
higher	O
rate	O
of	O
clinical	O
myocardial	B
infarction	I
was	O
reported	O
in	O
patients	O
who	O
received	O
PRADAXA	O
[	O
20	O
(	O
0.66	O
per	O
100	O
patient-years	O
)	O
]	O
than	O
in	O
those	O
who	O
received	O
warfarin	O
[	O
5	O
(	O
0.17	O
per	O
100	O
patient-years	O
)	O
]	O
.	O
	
BREO	O
ELLIPTA	O
has	O
not	O
been	O
studied	O
in	O
subjects	O
with	O
acutely	O
deteriorating	O
COPD	O
or	O
asthma	O
.	O
	
5.3	O
Laboratory	O
Tests	O
Serum	O
Liver	O
Enzyme	O
Activities	O
In	O
clinical	O
studies	O
,	O
7.5	O
%	O
of	O
642	O
subjects	O
treated	O
with	O
Ferriprox	O
developed	O
increased	B
ALT	I
values	I
.	O
	
An	O
increase	O
in	O
frequency	O
or	O
severity	O
of	O
migraine	B
during	O
COC	O
use	O
(	O
which	O
may	O
be	O
prodromal	O
of	O
a	O
cerebrovascular	B
event	I
)	O
may	O
be	O
a	O
reason	O
for	O
immediate	O
discontinuation	O
of	O
the	O
COC	O
.	O
	
In	O
cases	O
of	O
symptomatic	O
bradycardia	O
that	O
is	O
not	O
life-threatening	O
,	O
withhold	O
ZYKADIA	O
until	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
evaluate	O
the	O
use	O
of	O
concomitant	O
medications	O
,	O
and	O
adjust	O
the	O
dose	O
of	O
ZYKADIA	O
.	O
	
In	O
patients	O
with	O
baseline	O
moderate	O
hepatic	O
impairment	O
receiving	O
a	O
reduced	O
ZYTIGA	O
dose	O
of	O
250	O
mg	O
,	O
measure	O
ALT	O
,	O
AST	O
,	O
and	O
bilirubin	O
prior	O
to	O
the	O
start	O
of	O
treatment	O
,	O
every	O
week	O
for	O
the	O
first	O
month	O
,	O
every	O
two	O
weeks	O
for	O
the	O
following	O
two	O
months	O
of	O
treatment	O
and	O
monthly	O
thereafter	O
.	O
	
If	O
pneumonitis	O
is	O
suspected	O
,	O
interrupt	O
Zydelig	O
until	O
the	O
etiology	O
of	O
the	O
pulmonary	O
symptoms	O
has	O
been	O
determined	O
.	O
	
5.1	O
Risk	O
for	O
Image	O
Misinterpretation	O
and	O
Other	O
Errors	O
Errors	O
may	O
occur	O
in	O
the	O
Neuraceq	O
estimation	O
of	O
brain	O
neuritic	O
beta-amyloid	O
plaque	O
density	O
during	O
image	O
interpretation	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
5.3	O
Excessive	O
Use	O
of	O
BREO	O
ELLIPTA	O
and	O
Use	O
with	O
Other	O
Long-Acting	O
Beta2-Agonists	O
BREO	O
ELLIPTA	O
should	O
not	O
be	O
used	O
more	O
often	O
than	O
recommended	O
,	O
at	O
higher	O
doses	O
than	O
recommended	O
,	O
or	O
in	O
conjunction	O
with	O
other	O
medicines	O
containing	O
LABA	O
,	O
as	O
an	O
overdose	O
may	O
result	O
.	O
	
In	O
general	O
,	O
somnolence	B
and	O
sedation	B
begin	O
within	O
the	O
first	O
month	O
of	O
treatment	O
and	O
may	O
diminish	O
with	O
continued	O
treatment	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
reported	O
in	O
patients	O
receiving	O
HALAVEN	O
were	O
febrile	B
neutropenia	I
(	O
4	O
%	O
)	O
and	O
neutropenia	B
(	O
2	O
%	O
)	O
.	O
	
Although	O
some	O
past	O
studies	O
have	O
suggested	O
that	O
COCs	O
might	O
increase	O
the	O
incidence	O
of	O
breast	B
cancer	I
,	O
more	O
recent	O
studies	O
have	O
not	O
confirmed	O
such	O
findings	O
.	O
	
The	O
adverse	O
reactions	O
were	O
predominantly	O
of	O
mild	O
to	O
moderate	O
intensity	O
.	O
	
Do	O
not	O
resume	O
Ferriprox	O
in	O
patients	O
who	O
have	O
developed	O
agranulocytosis	O
unless	O
potential	O
benefits	O
outweigh	O
potential	O
risks	O
.	O
	
Table	O
3	O
shows	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
or	O
equal	O
to	O
5	O
%	O
of	O
XIAFLEX-treated	O
patients	O
and	O
at	O
a	O
frequency	O
greater	O
than	O
placebo-treated	O
patients	O
after	O
up	O
to	O
3	O
injections	O
in	O
the	O
pooled	O
placebo-controlled	O
trials	O
through	O
Day	O
90	O
(	O
Studies	O
1	O
and	O
2	O
)	O
.	O
	
5.5	O
Severe	O
Cutaneous	O
Reactions	O
One	O
case	O
of	O
toxic	B
epidermal	I
necrolysis	I
(	O
TEN	B
)	O
occurred	O
in	O
a	O
study	O
of	O
Zydelig	O
in	O
combination	O
with	O
rituximab	O
and	O
bendamustine	O
.	O
	
Anti-blinatumomab	O
antibody	O
formation	O
may	O
affect	O
pharmacokinetics	O
of	O
BLINCYTO	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Exelixis	O
,	O
Inc.	O
at	O
1-855-500-3935	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Table	O
5	O
:	O
Incidence	O
of	O
MajorMajor	O
episodes	O
of	O
hypoglycemia	B
were	O
defined	O
as	O
symptomatic	O
episodes	O
requiring	O
external	O
(	O
third	O
party	O
)	O
assistance	O
due	O
to	O
severe	O
impairment	B
in	I
consciousness	I
with	O
a	O
plasma	B
glucose	I
value	I
<	I
54	I
mg/dL	I
and	O
prompt	O
recovery	O
after	O
glucose	O
or	O
glucagon	O
administration	O
.	O
	
Patients	O
with	O
a	O
pre-existing	O
low	O
WBC	O
or	O
a	O
history	O
of	O
drug	O
induced	O
leukopenia/neutropenia	O
should	O
have	O
their	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
monitored	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
and	O
should	O
discontinue	O
FANAPT	O
at	O
the	O
first	O
sign	O
of	O
a	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
The	O
population	O
in	O
these	O
studies	O
was	O
69	O
%	O
White	O
,	O
7	O
%	O
Black	O
or	O
African	O
American	O
,	O
13	O
%	O
Asian	O
;	O
30	O
%	O
were	O
of	O
Hispanic	O
or	O
Latino	O
ethnicity	O
.	O
	
In	O
pooled	O
analysis	O
from	O
clinical	O
studies	O
including	O
longer	O
term	O
trials	O
,	O
in	O
3210	O
adults	O
treated	O
with	O
iloperidone	O
,	O
gynecomastia	B
was	O
reported	O
in	O
2	O
male	O
subjects	O
(	O
0.1	O
%	O
)	O
compared	O
to	O
0	O
%	O
in	O
placebo-treated	O
patients	O
,	O
and	O
galactorrhea	B
was	O
reported	O
in	O
8	O
female	O
subjects	O
(	O
0.2	O
%	O
)	O
compared	O
to	O
3	O
female	O
subjects	O
(	O
0.5	O
%	O
)	O
in	O
placebo-treated	O
patients	O
.	O
	
Adverse	O
drug	O
reactions	O
for	O
SIRTURO	O
were	O
identified	O
from	O
the	O
pooled	O
safety	O
data	O
from	O
335	O
SIRTURO-exposed	O
patients	O
who	O
received	O
8	O
weeks	O
(	O
Study	O
2	O
)	O
and	O
24	O
weeks	O
(	O
Studies	O
1	O
and	O
3	O
)	O
at	O
the	O
proposed	O
dose	O
.	O
	
Hypersensitivity	B
reactions	I
related	O
to	O
BLINCYTO	O
treatment	O
were	O
hypersensitivity	B
(	O
1	O
%	O
)	O
and	O
bronchospasm	B
(	O
<	O
1	O
%	O
)	O
.	O
	
Overall	O
,	O
the	O
rate	O
of	O
PTLD	B
in	O
949	O
patients	O
treated	O
with	O
any	O
of	O
the	O
NULOJIX	O
regimens	O
was	O
9-fold	O
higher	O
in	O
those	O
who	O
were	O
EBV	O
seronegative	O
or	O
EBV	O
serostatus	O
unknown	O
(	O
8/139	O
)	O
compared	O
to	O
those	O
who	O
were	O
EBV	O
seropositive	O
(	O
5/810	O
patients	O
)	O
.	O
	
Of	O
the	O
34	O
patients	O
with	O
Grade	O
3-5	O
enterocolitis	B
,	O
74	O
%	O
experienced	O
complete	O
resolution	O
,	O
3	O
%	O
experienced	O
improvement	O
to	O
Grade	O
2	O
severity	O
,	O
and	O
24	O
%	O
did	O
not	O
improve	O
.	O
	
In	O
the	O
double-blind	O
,	O
placebo-controlled	O
portions	O
of	O
the	O
clinical	O
trials	O
in	O
Peyronie	O
's	O
disease	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
a	O
greater	O
proportion	O
of	O
XIAFLEX-treated	O
patients	O
(	O
4	O
%	O
)	O
compared	O
to	O
placebo-treated	O
patients	O
(	O
1	O
%	O
)	O
had	O
localized	B
pruritus	I
after	O
up	O
to	O
4	O
treatment	O
cycles	O
(	O
involving	O
up	O
to	O
8	O
XIAFLEX	O
injection	O
procedures	O
)	O
.	O
	
Perform	O
an	O
oral	O
examination	O
prior	O
to	O
initiation	O
of	O
COMETRIQ	O
and	O
periodically	O
during	O
COMETRIQ	O
therapy	O
.	O
	
The	O
overall	O
percentage	O
of	O
patients	O
with	O
antibodies	O
to	O
certolizumab	O
pegol	O
detectable	O
on	O
at	O
least	O
one	O
occasion	O
was	O
7	O
%	O
(	O
105	O
of	O
1,509	O
)	O
in	O
the	O
rheumatoid	O
arthritis	O
placebo-controlled	O
trials	O
.	O
	
Risk	O
factors	O
for	O
bleeding	O
include	O
the	O
concomitant	O
use	O
of	O
other	O
drugs	O
that	O
increase	O
the	O
risk	O
of	O
bleeding	O
(	O
e.g.	O
,	O
anti-platelet	O
agents	O
,	O
heparin	O
,	O
fibrinolytic	O
therapy	O
,	O
and	O
chronic	O
use	O
of	O
NSAIDs	O
)	O
.	O
	
For	O
some	O
TNF	O
blockers	O
,	O
more	O
cases	O
of	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
those	O
TNF	O
blockers	O
compared	O
to	O
control	O
patients	O
.	O
	
5.3	O
XIAFLEX	O
REMS	O
Program	O
Because	O
of	O
the	O
risks	O
of	O
corporal	O
rupture	O
(	O
penile	O
fracture	O
)	O
or	O
other	O
serious	O
penile	O
injury	O
in	O
the	O
treatment	O
of	O
Peyronie	O
's	O
disease	O
,	O
XIAFLEX	O
is	O
available	O
only	O
through	O
the	O
XIAFLEX	O
REMS	O
Program	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
However	O
,	O
if	O
severe	O
hypersensitivity	O
reactions	O
occur	O
,	O
immediately	O
stop	O
the	O
infusion	O
of	O
Vimizim	O
and	O
initiate	O
appropriate	O
treatment	O
.	O
	
In	O
this	O
clinical	O
context	O
,	O
if	O
the	O
patient	O
is	O
found	O
to	O
have	O
clinically	O
significant	O
liver	O
enzyme	O
elevations	O
and	O
if	O
abnormal	O
liver	O
tests	O
persist	O
or	O
worsen	O
,	O
NESINA	O
should	O
be	O
interrupted	O
and	O
investigation	O
done	O
to	O
establish	O
the	O
probable	O
cause	O
.	O
	
Keep	O
bottle	O
tightly	O
closed	O
when	O
not	O
in	O
use	O
.	O
	
Adverse	O
Reactions	O
Leading	O
to	O
Study	O
Discontinuation	O
:	O
11.4	O
%	O
of	O
the	O
women	O
discontinued	O
from	O
the	O
clinical	O
trials	O
due	O
to	O
an	O
adverse	O
reaction	O
;	O
the	O
most	O
frequent	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
were	O
menstrual	B
disorder	I
(	O
metrorrhagia	B
,	O
menorrhagia	B
,	O
menstruation	B
irregular	I
,	O
genital	B
hemorrhage	I
,	O
vaginal	B
hemorrhage	I
,	O
dysfunctional	B
uterine	I
bleeding	I
)	O
(	O
2.3	O
%	O
)	O
;	O
mood	B
changes	I
(	O
depression	B
,	O
mood	B
swings	I
,	O
mood	B
altered	I
,	O
depressed	B
mood	I
,	O
dysthymic	B
disorder	I
,	O
crying	B
)	O
(	O
1.2	O
%	O
)	O
;	O
acne	B
(	O
1.1	O
%	O
)	O
,	O
headache	B
(	O
including	O
migraines	B
)	O
(	O
1.1	O
%	O
)	O
,	O
and	O
weight	B
increased	I
(	O
0.7	O
%	O
)	O
.	O
	
Patients	O
with	O
a	O
prior	O
anaphylactic-type	O
reaction	O
with	O
either	O
oxcarbazepine	O
or	O
APTIOM	O
should	O
not	O
be	O
treated	O
with	O
APTIOM	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Avoid	O
using	O
XALKORI	O
in	O
combination	O
with	O
other	O
agents	O
known	O
to	O
cause	O
bradycardia	O
(	O
e.g.	O
,	O
beta-blockers	O
,	O
non-dihydropyridine	O
calcium	O
channel	O
blockers	O
,	O
clonidine	O
and	O
digoxin	O
)	O
to	O
the	O
extent	O
possible	O
.	O
	
Other	O
adverse	O
reactions	O
seen	O
frequently	O
in	O
one	O
or	O
more	O
studies	O
included	O
asthenia	B
,	O
fatigue	B
,	O
malaise	B
,	O
and	O
weakness	B
;	O
dry	B
mouth	I
;	O
somnolence	B
;	O
cough	B
;	O
constipation	B
;	O
headache	B
;	O
mucosal	B
inflammation	I
and	O
stomatitis	B
.	O
	
There	O
was	O
an	O
increased	O
risk	O
of	O
these	O
adverse	O
reactions	O
during	O
the	O
titration	O
period	O
(	O
compared	O
to	O
the	O
maintenance	O
period	O
)	O
and	O
there	O
also	O
may	O
be	O
an	O
increased	O
risk	O
of	O
these	O
adverse	O
reactions	O
in	O
patients	O
60	O
years	O
of	O
age	O
and	O
older	O
compared	O
to	O
younger	O
adults	O
.	O
	
Across	O
clinical	O
trials	O
(	O
n=1669	O
)	O
,	O
49	O
XALKORI-treated	O
patients	O
(	O
2.9	O
%	O
)	O
had	O
ILD	B
of	O
any	O
grade	O
,	O
18	O
patients	O
(	O
1.1	O
%	O
)	O
had	O
Grade	O
3	O
or	O
4	O
ILD	B
,	O
and	O
8	O
patients	O
(	O
0.5	O
%	O
)	O
had	O
fatal	B
ILD	B
.	O
	
(	O
5.6	O
)	O
5.1	O
Pancreatitis	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
pancreatitis	I
in	O
patients	O
taking	O
NESINA	O
.	O
	
Of	O
the	O
total	O
8,394	O
patients	O
exposed	O
to	O
at	O
least	O
one	O
dose	O
of	O
PRISTIQ	O
;	O
2,116	O
were	O
exposed	O
to	O
PRISTIQ	O
for	O
6	O
months	O
,	O
representing	O
1,658	O
patient-years	O
of	O
exposure	O
,	O
and	O
421	O
were	O
exposed	O
for	O
one	O
year	O
,	O
representing	O
416	O
patient-years	O
of	O
exposure	O
.	O
	
Patients	O
using	O
supplemental	O
oxygen	O
or	O
continuous	O
positive	O
airway	O
pressure	O
(	O
CPAP	O
)	O
during	O
sleep	O
should	O
have	O
these	O
treatments	O
readily	O
available	O
during	O
infusion	O
in	O
the	O
event	O
of	O
an	O
acute	O
reaction	O
,	O
or	O
extreme	O
drowsiness/sleep	O
induced	O
by	O
antihistamine	O
use	O
.	O
	
In	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials	O
,	O
2	O
%	O
of	O
patients	O
experienced	O
lymphocyte	B
counts	I
<	I
0.5	I
x	I
10	I
9	I
/L	I
for	O
at	O
least	O
six	O
months	O
.	O
	
Advise	O
women	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
and	O
to	O
avoid	O
pregnancy	O
while	O
taking	O
the	O
drug	O
(	O
5.7	O
)	O
.	O
	
Consider	O
the	O
benefit-risk	O
of	O
withholding	O
IMBRUVICA	O
for	O
at	O
least	O
3	O
to	O
7	O
days	O
pre	O
and	O
post-surgery	O
depending	O
upon	O
the	O
type	O
of	O
surgery	O
and	O
the	O
risk	O
of	O
bleeding	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Given	O
the	O
potential	O
for	O
delay	O
in	O
lymphocyte	O
recovery	O
after	O
discontinuation	O
of	O
TECFIDERA	O
,	O
consider	O
following	O
lymphocyte	O
counts	O
until	O
lymphopenia	O
is	O
resolved	O
.	O
	
5.3	O
Hepatic	O
Toxicity	O
One	O
case	O
consistent	O
with	O
drug	B
induced	I
liver	I
injury	I
(	O
defined	O
as	O
concurrent	O
elevations	B
in	I
ALT	I
greater	O
than	O
or	O
equal	O
to	O
3*ULN	O
with	O
total	B
bilirubin	I
greater	I
than	I
2*ULN	I
and	O
alkaline	B
phosphatase	I
less	I
than	I
2*ULN	I
)	O
occurred	O
in	O
a	O
trial	O
of	O
BOSULIF	O
in	O
combination	O
with	O
letrozole	O
.	O
	
ARCAPTA	O
NEOHALER	O
has	O
not	O
been	O
investigated	O
in	O
patients	O
whose	O
diabetes	O
mellitus	O
is	O
not	O
well	O
controlled	O
.	O
	
Renal	B
cysts	I
occurred	O
in	O
8	O
(	O
5	O
%	O
)	O
patients	O
treated	O
with	O
XALKORI	O
and	O
1	O
(	O
1	O
%	O
)	O
patient	O
treated	O
with	O
chemotherapy	O
in	O
Study	O
1	O
.	O
	
SAPHRIS	O
(	O
r	O
)	O
(	O
asenapine	O
)	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.2	O
)	O
]	O
.	O
	
The	O
data	O
combined	O
eight	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
and	O
reflect	O
exposure	O
of	O
6177	O
patients	O
to	O
INVOKANA	O
.	O
	
(	O
5.8	O
)	O
*	O
QT	B
Prolongation	I
:	O
Increases	B
in	I
QT	I
interval	I
;	O
avoid	O
use	O
with	O
drugs	O
that	O
also	O
increase	O
the	O
QT	O
interval	O
and	O
in	O
patients	O
with	O
risk	O
factors	O
for	O
prolonged	O
QT	O
interval	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
discontinuation	O
of	O
XALKORI	O
were	O
ILD	B
(	O
1.7	O
%	O
)	O
,	O
AST	B
elevation	I
(	O
1.2	O
%	O
)	O
,	O
dyspnea	B
(	O
1.2	O
%	O
)	O
,	O
and	O
pulmonary	B
embolism	I
(	O
1.2	O
%	O
)	O
.	O
	
Interrupt	O
,	O
dose	O
reduce	O
or	O
discontinue	O
BOSULIF	O
as	O
necessary	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.4	O
Immediate	O
Hypersensitivity	O
Reactions	O
Immediate	O
hypersensitivity	B
reactions	I
may	O
occur	O
after	O
administration	O
of	O
ARCAPTA	O
NEOHALER	O
.	O
	
Table	O
1	O
Summary	O
of	O
Treatment	O
Exposure	O
in	O
RE-LY	O
PRADAXA	O
110	O
mg	O
twice	O
daily	O
PRADAXA	O
150	O
mg	O
twice	O
daily	O
Warfarin	O
Total	O
number	O
treated	O
5983	O
6059	O
5998	O
Exposure	O
>	O
12	O
months	O
4936	O
4939	O
5193	O
>	O
24	O
months	O
2387	O
2405	O
2470	O
Mean	O
exposure	O
(	O
months	O
)	O
20.5	O
20.3	O
21.3	O
Total	O
patient-years	O
10,242	O
10,261	O
10,659	O
Drug	O
Discontinuation	O
in	O
RE-LY	O
The	O
rates	O
of	O
adverse	O
reactions	O
leading	O
to	O
treatment	O
discontinuation	O
were	O
21	O
%	O
for	O
PRADAXA	O
150	O
mg	O
and	O
16	O
%	O
for	O
warfarin	O
.	O
	
The	O
following	O
may	O
increase	O
the	O
risk	O
for	O
QT	B
prolongation	I
when	O
patients	O
are	O
receiving	O
SIRTURO	O
:	O
*	O
use	O
with	O
other	O
QT	O
prolonging	O
drugs	O
including	O
fluoroquinolones	O
and	O
macrolide	O
antibacterial	O
drugs	O
and	O
the	O
antimycobacterial	O
drug	O
,	O
clofazimine	O
*	O
a	O
history	O
of	O
Torsade	O
de	O
Pointes	O
*	O
a	O
history	O
of	O
congenital	O
long	O
QT	O
syndrome	O
*	O
a	O
history	O
of	O
or	O
ongoing	O
hypothyroidism	O
*	O
a	O
history	O
of	O
or	O
ongoing	O
bradyarrhythmias	O
*	O
a	O
history	O
of	O
uncompensated	O
heart	O
failure	O
*	O
serum	O
calcium	O
,	O
magnesium	O
,	O
or	O
potassium	O
levels	O
below	O
the	O
lower	O
limits	O
of	O
normal	O
If	O
necessary	O
,	O
bedaquiline	O
treatment	O
initiation	O
could	O
be	O
considered	O
in	O
these	O
patients	O
after	O
a	O
favorable	O
benefit	O
risk	O
assessment	O
and	O
with	O
frequent	O
ECG	O
monitoring	O
.	O
	
The	O
increased	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
AEDs	O
was	O
observed	O
as	O
early	O
as	O
1	O
week	O
after	O
starting	O
treatment	O
with	O
AEDs	O
and	O
persisted	O
for	O
the	O
duration	O
of	O
treatment	O
assessed	O
.	O
	
as	O
rescue	O
therapy	O
for	O
the	O
treatment	O
of	O
acute	O
episodes	O
of	O
bronchospasm	O
.	O
	
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
potential	O
for	O
immunogenicity	O
.	O
	
Cognitive	B
dysfunction-related	O
events	O
were	O
serious	O
in	O
0.2	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0.2	O
%	O
of	O
placebo	O
patients	O
)	O
and	O
led	O
to	O
discontinuation	O
in	O
1	O
%	O
of	O
APTIOM-treated	O
patients	O
(	O
and	O
0.5	O
%	O
of	O
placebo-treated	O
patients	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
of	O
those	O
exposed	O
to	O
DUREZOL	O
occurring	O
in	O
5-10	O
%	O
of	O
subjects	O
included	O
blurred	B
vision	I
,	O
eye	B
irritation	I
,	O
eye	B
pain	I
,	O
headache	B
,	O
increased	B
IOP	I
,	O
iritis	B
,	O
conjunctival	B
hyperemia	I
,	O
punctate	B
keratitis	I
,	O
and	O
uveitis	B
.	O
	
The	O
incidence	O
of	O
serious	O
adverse	O
events	O
was	O
30.6	O
%	O
in	O
the	O
placebo	O
group	O
and	O
34.6	O
%	O
in	O
the	O
Prolia	O
group	O
.	O
	
More	O
than	O
half	O
(	O
55	O
%	O
)	O
of	O
the	O
population	O
was	O
male	O
;	O
46	O
%	O
were	O
White	O
,	O
50	O
%	O
were	O
Asian	O
,	O
and	O
3	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
Only	O
use	O
SIRTURO	O
when	O
an	O
effective	O
treatment	O
regimen	O
can	O
not	O
otherwise	O
be	O
provided	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
The	O
QT	O
interval	O
should	O
be	O
monitored	O
when	O
POTIGA	O
is	O
prescribed	O
with	O
medicines	O
known	O
to	O
increase	O
QT	O
interval	O
and	O
in	O
patients	O
with	O
known	O
prolonged	O
QT	O
interval	O
,	O
congestive	O
heart	O
failure	O
,	O
ventricular	O
hypertrophy	O
,	O
hypokalemia	O
,	O
or	O
hypomagnesemia	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
transaminase	B
elevations	I
>	O
=3	O
times	O
ULN	O
(	O
at	O
Endpoint	O
)	O
was	O
0.9	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
1.3	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
5.6	O
Discontinuation	O
of	O
HORIZANT	O
When	O
discontinuing	O
HORIZANT	O
,	O
patients	O
with	O
RLS	O
receiving	O
600	O
mg	O
or	O
less	O
once	O
daily	O
can	O
discontinue	O
the	O
drug	O
without	O
tapering	O
.	O
	
Grade	O
3/4	O
hypertension	B
was	O
observed	O
in	O
56/359	O
patients	O
(	O
16	O
%	O
)	O
receiving	O
INLYTA	O
and	O
39/355	O
patients	O
(	O
11	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
*	O
Risk	O
of	O
Cardiac	B
Arrhythmia	I
and	O
Sudden	B
Cardiac	I
Death	I
during	O
General	O
Anesthesia	O
for	O
Central	O
Venous	O
Catheter	O
Placement	O
:	O
Caution	O
should	O
be	O
used	O
when	O
administering	O
general	O
anesthesia	O
for	O
the	O
placement	O
of	O
a	O
central	O
venous	O
catheter	O
intended	O
for	O
alglucosidase	O
alfa	O
infusion	O
(	O
5.4	O
)	O
.	O
	
The	O
common	O
adverse	O
events	O
occurring	O
at	O
a	O
rate	O
of	O
10	O
%	O
or	O
greater	O
with	O
Kyprolis	O
monotherapy	O
are	O
presented	O
in	O
Table	O
7	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
occurring	O
in	O
at	O
least	O
10	O
%	O
of	O
patients	O
,	O
using	O
the	O
NCI	O
CTC	O
Version	O
4	O
,	O
are	O
shown	O
in	O
Table	O
3	O
.	O
	
6.1	O
Clinical	O
Study	O
Experience	O
The	O
data	O
from	O
clinical	O
studies	O
reflect	O
exposure	O
to	O
DaTscan	O
in	O
942	O
subjects	O
with	O
a	O
mean	O
age	O
of	O
66	O
years	O
(	O
range	O
25	O
to	O
90	O
years	O
)	O
.	O
	
Common	O
Adverse	O
Reactions	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
more	O
than	O
5	O
%	O
of	O
patients	O
who	O
received	O
500	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
in	O
the	O
placebo	O
controlled	O
clinical	O
trials	O
)	O
in	O
cervical	O
dystonia	O
patients	O
were	O
:	O
muscular	B
weakness	I
,	O
dysphagia	B
,	O
dry	B
mouth	I
,	O
injection	B
site	I
discomfort	I
,	O
fatigue	B
,	O
headache	B
,	O
neck	B
pain	I
,	O
musculoskeletal	B
pain	I
,	O
dysphonia	B
,	O
injection	B
site	I
pain	I
,	O
and	O
eye	B
disorders	I
(	O
consisting	O
of	O
blurred	B
vision	I
,	O
diplopia	B
,	O
and	O
reduced	B
visual	I
acuity	I
)	O
.	O
	
Severe	O
reactions	O
are	O
generally	O
managed	O
with	O
infusion	O
interruption	O
,	O
administration	O
of	O
antihistamines	O
,	O
corticosteroids	O
,	O
intravenous	O
fluids	O
,	O
and/or	O
oxygen	O
,	O
when	O
clinically	O
indicated	O
.	O
	
DUAVEE	O
may	O
also	O
affect	O
how	O
your	O
other	O
medicines	O
work	O
.	O
	
DRESS	B
typically	O
,	O
although	O
not	O
exclusively	O
,	O
presents	O
with	O
fever	B
,	O
rash	B
,	O
and/or	O
lymphadenopathy	B
,	O
in	O
association	O
with	O
other	O
organ	O
system	O
involvement	O
,	O
such	O
as	O
hepatitis	B
,	O
nephritis	B
,	O
hematological	B
abnormalities	I
,	O
myocarditis	B
,	O
or	O
myositis	B
sometimes	O
resembling	O
an	O
acute	O
viral	O
infection	O
.	O
	
Use	O
INLYTA	O
with	O
caution	O
in	O
patients	O
who	O
are	O
at	O
risk	O
for	O
,	O
or	O
who	O
have	O
a	O
history	O
of	O
,	O
these	O
events	O
.	O
	
In	O
a	O
3-week	O
,	O
placebo-controlled	O
pediatric	O
trial	O
with	O
bipolar	O
I	O
disorder	O
,	O
the	O
incidences	O
of	O
EPS-related	B
events	I
,	O
excluding	O
events	O
related	O
to	O
akathisia	B
,	O
were	O
4	O
%	O
,	O
3	O
%	O
,	O
and	O
5	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
,	O
as	O
compared	O
to	O
3	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
All	O
serious	O
adverse	O
events	O
were	O
assessed	O
as	O
unrelated	O
to	O
study	O
drug	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Correct	O
volume	O
or	O
salt	O
depletion	O
prior	O
to	O
administration	O
of	O
Edarbi	O
.	O
	
Patients	O
receiving	O
BENLYSTA	O
should	O
be	O
instructed	O
to	O
contact	O
their	O
healthcare	O
provider	O
if	O
they	O
experience	O
new	O
or	O
worsening	O
depression	O
,	O
suicidal	O
thoughts	O
,	O
or	O
other	O
mood	O
changes	O
.	O
	
Report	O
any	O
diagnosis	O
of	O
NSF	O
following	O
DOTAREM	O
administration	O
to	O
Guerbet	O
LLC	O
(	O
1-877-729-6679	O
)	O
or	O
FDA	O
(	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
)	O
.	O
	
On	O
Day	O
1	O
,	O
the	O
maximum	O
decline	B
in	I
heart	I
rate	I
generally	O
occurs	O
within	O
6	O
hours	O
and	O
recovers	O
,	O
although	O
not	O
to	O
baseline	O
levels	O
,	O
by	O
8	O
to	O
10	O
hours	O
postdose	O
.	O
	
Falls	B
were	O
not	O
associated	O
with	O
loss	B
of	I
consciousness	I
or	O
seizure	B
.	O
	
In	O
patients	O
receiving	O
anti-TNF	O
therapy	O
,	O
limited	O
data	O
are	O
available	O
on	O
the	O
response	O
to	O
live	O
vaccination	O
,	O
or	O
on	O
the	O
secondary	O
transmission	O
of	O
infection	O
by	O
live	O
vaccines	O
.	O
	
Additionally	O
,	O
serum	O
phosphorus	O
should	O
be	O
measured	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
impairment	O
.	O
	
have	O
occurred	O
following	O
administration	O
of	O
DYSPORT	O
(	O
r	O
)	O
.	O
	
Do	O
not	O
take	O
DUAVEE	O
if	O
you	O
:	O
*	O
currently	O
have	O
or	O
have	O
had	O
blood	O
clots	O
*	O
are	O
allergic	O
to	O
estrogens	O
or	O
bazedoxifene	O
,	O
the	O
active	O
ingredients	O
in	O
DUAVEE	O
,	O
or	O
any	O
of	O
its	O
ingredients	O
.	O
	
If	O
an	O
anaphylactic	O
or	O
other	O
serious	O
allergic	O
reaction	O
occurs	O
,	O
administration	O
of	O
SIMPONI	O
ARIA	O
should	O
be	O
discontinued	O
immediately	O
and	O
appropriate	O
therapy	O
instituted	O
.	O
	
Some	O
patients	O
required	O
hospitalization	O
and	O
renal	O
replacement	O
therapy	O
.	O
	
(	O
5.6	O
)	O
*	O
Liver	B
injury	I
:	O
liver	O
enzyme	O
results	O
should	O
be	O
available	O
before	O
initiation	O
.	O
	
These	O
patients	O
may	O
have	O
an	O
increased	O
risk	O
for	O
a	O
hypersensitivity	B
reaction	I
to	O
DOTAREM	O
.	O
	
The	O
incidence	O
of	O
Grade	O
1-4	O
thrombocytopenia	B
was	O
6	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
(	O
0.3	O
%	O
Grade	O
3-4	O
)	O
and	O
5	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
(	O
0.5	O
%	O
Grade	O
3-4	O
)	O
.	O
	
These	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
and	O
breathing	B
difficulties	I
.	O
	
5.2	O
Hypotension	O
in	O
Volume-	O
or	O
Salt-Depleted	O
Patients	O
In	O
patients	O
with	O
an	O
activated	O
renin-angiotensin	O
system	O
,	O
such	O
as	O
volume-	O
and/or	O
salt-depleted	O
patients	O
(	O
e.g.	O
,	O
those	O
being	O
treated	O
with	O
high	O
doses	O
of	O
diuretics	O
)	O
,	O
symptomatic	B
hypotension	I
may	O
occur	O
after	O
initiation	O
of	O
treatment	O
with	O
Edarbi	O
.	O
	
5.7	O
Thyroid	O
Dysfunction	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
hypothyroidism	B
was	O
reported	O
in	O
69/359	O
patients	O
(	O
19	O
%	O
)	O
receiving	O
INLYTA	O
and	O
29/355	O
patients	O
(	O
8	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
For	O
those	O
patients	O
who	O
reported	O
dry	B
mouth	I
,	O
most	O
had	O
their	O
first	O
occurrence	O
of	O
the	O
event	O
within	O
the	O
first	O
month	O
of	O
treatment	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
have	O
been	O
associated	O
with	O
TREANDA	O
in	O
clinical	O
trials	O
and	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
.	O
	
Dizziness	B
led	O
to	O
withdrawal	O
in	O
1	O
%	O
of	O
patients	O
receiving	O
600	O
mg	O
of	O
HORIZANT	O
per	O
day	O
.	O
	
Serious	O
infusion	B
reactions	I
(	O
excluding	O
hypersensitivity	B
reactions	I
)	O
were	O
reported	O
in	O
0.5	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
0.4	O
%	O
of	O
patients	O
receiving	O
placebo	O
and	O
included	O
bradycardia	B
,	O
myalgia	B
,	O
headache	B
,	O
rash	B
,	O
urticaria	B
,	O
and	O
hypotension	B
.	O
	
The	O
study	O
population	O
characteristics	O
were	O
:	O
median	O
age	O
53	O
years	O
,	O
age	O
less	O
than	O
65	O
(	O
84	O
%	O
)	O
,	O
female	O
(	O
53	O
%	O
)	O
,	O
Caucasian	O
(	O
63	O
%	O
)	O
,	O
Asian	O
(	O
34	O
%	O
)	O
,	O
NSCLC	O
adenocarcinoma	O
histology	O
(	O
90	O
%	O
)	O
,	O
never	O
or	O
former	O
smoker	O
(	O
97	O
%	O
)	O
,	O
ECOG	O
PS	O
0	O
or	O
1	O
(	O
89	O
%	O
)	O
,	O
brain	O
metastasis	O
(	O
49	O
%	O
)	O
,	O
and	O
number	O
of	O
prior	O
therapies	O
2	O
or	O
more	O
(	O
67	O
%	O
)	O
.	O
	
Data	O
from	O
a	O
large	O
placebo-controlled	O
US	O
trial	O
that	O
compared	O
the	O
safety	O
of	O
another	O
LABA	O
(	O
salmeterol	O
)	O
with	O
placebo	O
added	O
to	O
usual	O
asthma	O
therapy	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
subjects	O
receiving	O
salmeterol	O
.	O
	
Two	O
patients	O
treated	O
with	O
KALYDECO	O
were	O
reported	O
to	O
have	O
serious	O
adverse	O
reactions	O
of	O
elevated	B
liver	I
transaminases	I
compared	O
to	O
none	O
on	O
placebo	O
.	O
	
There	O
was	O
no	O
apparent	O
association	O
between	O
mean	O
or	O
peak	O
IgG	O
antibody	O
titers	O
and	O
the	O
occurrence	O
of	O
adverse	O
reactions	O
.	O
	
Do	O
not	O
use	O
BREO	O
ELLIPTA	O
for	O
patients	O
whose	O
asthma	O
is	O
adequately	O
controlled	O
on	O
low-	O
or	O
medium-dose	O
inhaled	O
corticosteroids	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
clinical	O
relevance	O
of	O
this	O
in	O
vitro	O
inhibition	O
is	O
not	O
fully	O
understood	O
.	O
	
All	O
reported	O
reactions	O
are	O
included	O
except	O
those	O
already	O
listed	O
in	O
Table	O
7	O
,	O
or	O
other	O
parts	O
of	O
the	O
Adverse	O
Reactions	O
(	O
6	O
)	O
section	O
,	O
those	O
considered	O
in	O
the	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
,	O
those	O
reaction	O
terms	O
which	O
were	O
so	O
general	O
as	O
to	O
be	O
uninformative	O
,	O
reactions	O
reported	O
in	O
fewer	O
than	O
3	O
patients	O
and	O
which	O
were	O
neither	O
serious	O
nor	O
life-threatening	O
,	O
reactions	O
that	O
are	O
otherwise	O
common	O
as	O
background	O
reactions	O
,	O
and	O
reactions	O
considered	O
unlikely	O
to	O
be	O
drug	O
related	O
.	O
	
The	O
safety	O
of	O
reinitiating	O
INLYTA	O
therapy	O
in	O
patients	O
previously	O
experiencing	O
RPLS	O
is	O
not	O
known	O
.	O
	
During	O
the	O
controlled	O
trials	O
in	O
patients	O
with	O
RLS	O
,	O
somnolence/sedation	O
was	O
reported	O
in	O
20	O
%	O
of	O
patients	O
treated	O
with	O
600	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
6	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Dose	O
adjustments	O
(	O
interruptions	O
or	O
reductions	O
)	O
were	O
more	O
frequent	O
among	O
patients	O
in	O
the	O
AFINITOR	O
plus	O
exemestane	O
arm	O
than	O
in	O
the	O
placebo	O
plus	O
exemestane	O
arm	O
(	O
63	O
%	O
versus	O
14	O
%	O
)	O
.	O
	
Cardiac	O
Disorders	O
Palpitations	B
,	O
tachycardia	B
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Elevated	B
transaminases	I
)	O
:	O
Transaminases	O
(	O
ALT	O
and	O
AST	O
)	O
should	O
be	O
assessed	O
prior	O
to	O
initiating	O
KALYDECO	O
,	O
every	O
3	O
months	O
during	O
the	O
first	O
year	O
of	O
treatment	O
,	O
and	O
annually	O
thereafter	O
.	O
	
When	O
dermatitis	O
is	O
controlled	O
,	O
corticosteroid	O
tapering	O
should	O
occur	O
over	O
a	O
period	O
of	O
at	O
least	O
1	O
month	O
.	O
	
Psychiatric	O
Disorders	O
:	O
Suicidal	B
ideation	I
.	O
	
Program	O
include	O
the	O
following	O
:	O
ENTEREG	O
is	O
available	O
only	O
for	O
short-term	O
(	O
15	O
doses	O
)	O
use	O
in	O
hospitalized	O
patients	O
.	O
	
If	O
appropriate	O
,	O
initiation	O
of	O
anti-hepatitis	O
B	O
therapy	O
may	O
be	O
warranted	O
.	O
	
There	O
were	O
484	O
subjects	O
included	O
in	O
the	O
efficacy	O
and	O
safety	O
analyses	O
.	O
	
A	O
causal	O
relationship	O
with	O
alvimopan	O
with	O
long-term	O
use	O
has	O
not	O
been	O
established	O
.	O
	
If	O
appropriate	O
,	O
initiation	O
of	O
anti-hepatitis	O
B	O
therapy	O
may	O
be	O
warranted	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Therefore	O
,	O
co-administration	O
is	O
not	O
recommended	O
.	O
	
Across	O
the	O
clinical	O
development	O
program	O
of	O
YERVOY	O
,	O
myasthenia	B
gravis	I
and	O
additional	O
cases	O
of	O
Guillain-Barre	B
syndrome	I
have	O
been	O
reported	O
.	O
	
During	O
the	O
controlled	O
period	O
of	O
the	O
trials	O
in	O
psoriasis	O
,	O
weight	B
decrease	I
between	O
5	O
%	O
-10	O
%	O
of	O
body	O
weight	O
occurred	O
in	O
12	O
%	O
(	O
96/784	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
compared	O
to	O
5	O
%	O
(	O
19/382	O
)	O
treated	O
with	O
placebo	O
.	O
	
Risk	O
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
PlaceboPatients	O
WithEvents	O
Per1,000	O
Patients	O
Drug	O
PatientsWith	O
Events	O
Per1,000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Eventsin	O
DrugPatients/Incidencein	O
Placebo	O
Patients	O
Risk	O
Difference	O
:	O
Additional	O
DrugPatients	O
WithEvents	O
Per	O
1,000Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
for	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
for	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
the	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
In	O
many	O
cases	O
,	O
the	O
occurrence	O
of	O
these	O
adverse	O
reactions	O
led	O
to	O
discontinuation	O
of	O
therapy	O
.	O
	
There	O
were	O
many	O
adverse	O
events	O
associated	O
with	O
the	O
operative	O
procedure	O
in	O
the	O
clinical	O
studies	O
of	O
Cleviprex	O
and	O
relatively	O
few	O
plausibly	O
related	O
to	O
the	O
drugs	O
used	O
to	O
lower	O
blood	O
pressure	O
.	O
	
Lymphocyte	O
counts	O
generally	O
return	O
to	O
the	O
normal	O
range	O
within	O
1-2	O
months	O
of	O
stopping	O
therapy	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Advise	O
patients	O
to	O
seek	O
prompt	O
medical	O
attention	O
if	O
they	O
develop	O
signs	O
or	O
symptoms	O
of	O
severe	O
infection	O
,	O
including	O
cellulitis	O
.	O
	
*	O
Seizure	B
:	O
Can	O
occur	O
.	O
	
5.9	O
Drug-drug	O
Interactions	O
Due	O
to	O
significant	O
increases	O
in	O
exposure	O
of	O
everolimus	O
,	O
co-administration	O
with	O
strong	O
CYP3A4/PgP	O
inhibitors	O
should	O
be	O
avoided	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
,	O
2.5	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Because	O
patients	O
with	O
moderate	O
to	O
severe	O
renal	O
impairment	O
(	O
CrCl	O
<	O
=50mL/min	O
)	O
would	O
require	O
a	O
dose	O
lower	O
than	O
10	O
mg	O
twice	O
daily	O
and	O
no	O
strength	O
smaller	O
than	O
10	O
mg	O
is	O
available	O
,	O
AMPYRA	O
is	O
contraindicated	O
in	O
these	O
patients	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Consultation	O
with	O
a	O
specialist	O
(	O
e.g.	O
,	O
neurologist	O
and/or	O
infectious	O
disease	O
)	O
should	O
be	O
considered	O
for	O
any	O
suspected	O
or	O
confirmed	O
cases	O
of	O
PML	O
.	O
	
Injection	B
site	I
reactions	I
.	O
	
Patients	O
were	O
allowed	O
,	O
but	O
not	O
required	O
,	O
to	O
take	O
glucocorticoids	O
.	O
	
5.6	O
Liver	O
Transplant	O
Use	O
of	O
NULOJIX	O
in	O
liver	O
transplant	O
patients	O
is	O
not	O
recommended	O
[	O
see	O
Boxed	O
Warning	O
]	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
BENLYSTA	O
plus	O
standard	O
of	O
care	O
compared	O
with	O
placebo	O
plus	O
standard	O
of	O
care	O
in	O
2,133	O
patients	O
in	O
3	O
controlled	O
trials	O
.	O
	
Bleeding	B
events	O
were	O
counted	O
during	O
treatment	O
or	O
within	O
2	O
days	O
of	O
stopping	O
study	O
treatment	O
(	O
on-treatment	O
period	O
)	O
.	O
	
Refer	O
to	O
Table	O
2	O
for	O
recommended	O
dose	O
modifications	O
for	O
adverse	O
reactions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
majority	O
of	O
elevations	O
occurred	O
within	O
6	O
to	O
9	O
months	O
.	O
	
Only	O
Study	O
1	O
included	O
a	O
placebo	O
group	O
,	O
allowing	O
comparison	O
of	O
adverse	O
reaction	O
rates	O
on	O
ONFI	O
at	O
several	O
doses	O
to	O
placebo	O
.	O
	
(	O
5.2	O
)	O
*	O
Dihydropyridine	O
calcium	O
channel	O
blockers	O
can	O
produce	O
negative	B
inotropic	I
effects	I
and	O
exacerbate	B
heart	I
failure	I
.	O
	
Discontinuation	O
due	O
to	O
GI	B
adverse	I
reactions	I
occurred	O
in	O
2	O
%	O
of	O
individuals	O
on	O
TANZEUM	O
or	O
placebo	O
.	O
	
Do	O
not	O
discontinue	O
therapy	O
with	O
leucovorin	O
based	O
on	O
the	O
determination	O
of	O
a	O
single	O
methotrexate	O
concentration	O
below	O
the	O
leucovorin	O
treatment	O
threshold	O
.	O
	
Number	O
(	O
%	O
)	O
of	O
Patients	O
PlaceboN=995	O
JARDIANCE	O
10	O
mgN=999	O
JARDIANCE	O
25	O
mgN=977	O
Urinary	B
tract	I
infection	I
a	O
7.6	O
%	O
9.3	O
%	O
7.6	O
%	O
Female	B
genital	I
mycotic	I
infections	I
b	O
1.5	O
%	O
5.4	O
%	O
6.4	O
%	O
Upper	B
respiratory	I
tract	I
infection	I
3.8	O
%	O
3.1	O
%	O
4.0	O
%	O
Increased	B
urination	I
c	O
1.0	O
%	O
3.4	O
%	O
3.2	O
%	O
Dyslipidemia	B
3.4	O
%	O
3.9	O
%	O
2.9	O
%	O
Arthralgia	B
2.2	O
%	O
2.4	O
%	O
2.3	O
%	O
Male	B
genital	I
mycotic	I
infections	I
d	O
0.4	O
%	O
3.1	O
%	O
1.6	O
%	O
Nausea	B
1.4	O
%	O
2.3	O
%	O
1.1	O
%	O
Thirst	B
(	O
including	O
polydipsia	B
)	O
was	O
reported	O
in	O
0	O
%	O
,	O
1.7	O
%	O
,	O
and	O
1.5	O
%	O
for	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
.	O
	
Advise	O
all	O
patients	O
to	O
seek	O
immediate	O
medical	O
attention	O
if	O
they	O
develop	O
signs	O
and	O
symptoms	O
suggestive	O
of	O
blood	O
dyscrasias	O
or	O
infection	O
(	O
e.g.	O
,	O
persistent	O
fever	O
,	O
bruising	O
,	O
bleeding	O
,	O
pallor	O
)	O
while	O
on	O
CIMZIA	O
.	O
	
These	O
wound-related	O
complications	O
may	O
require	O
surgical	O
intervention	O
.	O
	
The	O
most	O
common	O
fatal	B
adverse	O
reactions	O
in	O
JEVTANA-treated	O
patients	O
were	O
infections	B
(	O
n=5	O
)	O
and	O
renal	B
failure	I
(	O
n=4	O
)	O
.	O
	
There	O
has	O
been	O
a	O
long-standing	O
concern	O
,	O
however	O
,	O
that	O
antidepressants	O
may	O
have	O
a	O
role	O
in	O
inducing	O
worsening	B
of	I
depression	I
and	O
the	O
emergence	O
of	O
suicidality	B
in	O
certain	O
patients	O
during	O
the	O
early	O
phases	O
of	O
treatment	O
.	O
	
There	O
were	O
differences	O
in	O
absolute	O
risk	O
of	O
suicidality	B
across	O
the	O
different	O
indications	O
,	O
with	O
the	O
highest	O
incidence	O
in	O
MDD	O
.	O
	
Complete	O
treatment	O
of	O
pre-existing	O
invasive	O
fungal	O
infections	O
prior	O
to	O
starting	O
treatment	O
with	O
AFINITOR	O
.	O
	
Treatment	O
with	O
medications	O
that	O
work	O
through	O
inhibition	O
of	O
IL-1	O
has	O
been	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
serious	O
infections	B
.	O
	
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
the	O
types	O
and	O
frequency	O
of	O
common	O
adverse	O
reactions	O
excluding	O
hypoglycemia	B
were	O
similar	O
to	O
those	O
listed	O
in	O
Table	O
1	O
.	O
	
Perform	O
dermatologic	O
evaluations	O
prior	O
to	O
initiation	O
of	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
or	O
in	O
combination	O
with	O
trametinib	O
,	O
every	O
2	O
months	O
while	O
on	O
therapy	O
,	O
and	O
for	O
up	O
to	O
6	O
months	O
following	O
discontinuation	O
of	O
TAFINLAR	O
.	O
	
(	O
5.3	O
)	O
*	O
Venous	B
Thromboembolism	I
:	O
Deep	B
vein	I
thrombosis	I
and	O
pulmonary	B
embolism	I
can	O
occur	O
in	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
duration	O
of	O
ELIQUIS	O
exposure	O
was	O
>	O
=12	O
months	O
for	O
9375	O
patients	O
and	O
>	O
=24	O
months	O
for	O
3369	O
patients	O
in	O
the	O
two	O
studies	O
.	O
	
5.6	O
Interference	O
with	O
Visualization	O
of	O
Liver	O
Lesions	O
Severe	O
renal	O
or	O
hepatic	O
failure	O
may	O
impair	O
EOVIST	O
imaging	O
performance	O
.	O
	
For	O
patients	O
who	O
test	O
positive	O
for	O
HBV	O
infection	O
,	O
consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
hepatitis	O
B	O
is	O
recommended	O
.	O
	
Through	O
Week	O
24	O
,	O
the	O
incidence	O
of	O
serious	O
infections	B
per	O
100	O
patient-years	O
of	O
follow-up	O
was	O
2.2	O
(	O
95	O
%	O
CI	O
0.61	O
,	O
5.71	O
)	O
for	O
the	O
SIMPONI	O
ARIA	O
group	O
,	O
and	O
0	O
(	O
0.00	O
,	O
3.79	O
)	O
for	O
the	O
placebo	O
group	O
.	O
	
The	O
types	O
of	O
AR	O
resulting	O
in	O
withdrawal	O
from	O
the	O
study	O
varied	O
considerably	O
.	O
	
In	O
Trial	O
1	O
,	O
cutaneous	B
squamous	I
cell	I
carcinomas	I
and	O
keratoacanthomas	B
(	O
cuSCC	B
)	O
occurred	O
in	O
7	O
%	O
(	O
14/187	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
and	O
in	O
none	O
of	O
the	O
patients	O
treated	O
with	O
dacarbazine	O
.	O
	
Physicians	O
should	O
consider	O
whether	O
their	O
patients	O
with	O
underlying	O
NAION	O
risk	O
factors	O
could	O
be	O
adversely	O
affected	O
by	O
use	O
of	O
PDE5	O
inhibitors	O
.	O
	
Table	O
5	O
presents	O
the	O
most	O
common	O
treatment-related	O
adverse	O
reactions	O
(	O
experienced	O
by	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
of	O
patients	O
receiving	O
PROMACTA	O
)	O
from	O
the	O
extension	O
trial	O
.	O
	
In	O
a	O
3-week	O
,	O
placebo-controlled	O
,	O
bipolar	O
I	O
pediatric	O
trial	O
,	O
the	O
incidence	O
of	O
somnolence	B
(	O
including	O
sedation	B
and	O
hypersomnia	B
)	O
for	O
placebo	O
,	O
SAPHRIS	O
2.5	O
mg	O
twice	O
daily	O
,	O
5	O
mg	O
twice	O
daily	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
was	O
12	O
%	O
(	O
12/101	O
)	O
,	O
46	O
%	O
(	O
48/104	O
)	O
,	O
53	O
%	O
(	O
52/99	O
)	O
,	O
and	O
49	O
%	O
(	O
49/99	O
)	O
,	O
respectively	O
.	O
	
Venous	O
Thromboembolism	O
(	O
VTE	O
)	O
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
the	O
risk	O
of	O
VTE	B
[	O
DVT	B
and	O
pulmonary	B
embolism	I
(	O
PE	B
)	O
]	O
was	O
increased	O
for	O
women	O
receiving	O
daily	O
conjugated	O
estrogens	O
(	O
0.625	O
mg	O
)	O
-alone	O
compared	O
to	O
placebo	O
(	O
30	O
versus	O
22	O
per	O
10,000	O
women-years	O
)	O
,	O
although	O
only	O
the	O
increased	O
risk	O
of	O
DVT	B
reached	O
statistical	O
significance	O
(	O
23	O
versus	O
15	O
per	O
10,000	O
women-years	O
)	O
.	O
	
Three	O
percent	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
had	O
platelet	B
counts	I
of	I
less	I
than	I
50	I
*	I
10	I
9	I
per	I
L	I
compared	O
to	O
1	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
unknown	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
casual	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
5.5	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
DALVANCE	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
bacterial	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
increases	O
the	O
risk	O
of	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
Malignancies	B
,	O
some	O
fatal	B
,	O
have	O
been	O
reported	O
among	O
children	O
,	O
adolescents	O
,	O
and	O
young	O
adults	O
who	O
received	O
treatment	O
with	O
TNF-blocking	O
agents	O
(	O
initiation	O
of	O
therapy	O
<	O
=	O
18	O
years	O
of	O
age	O
)	O
,	O
of	O
which	O
CIMZIA	O
is	O
a	O
member	O
.	O
	
Patients	O
must	O
have	O
a	O
negative	O
pregnancy	O
test	O
prior	O
to	O
therapy	O
;	O
use	O
two	O
or	O
more	O
forms	O
of	O
contraception	O
,	O
and	O
have	O
monthly	O
pregnancy	O
tests	O
.	O
	
Summary	O
of	O
Clinical	O
Trial	O
Experience	O
in	O
Classical	O
HL	O
Post-auto-HSCT	O
Consolidation	O
(	O
Study	O
3	O
)	O
ADCETRIS	O
was	O
studied	O
in	O
329	O
patients	O
with	O
classical	O
HL	O
at	O
high	O
risk	O
of	O
relapse	O
or	O
progression	O
post-auto-HSCT	O
in	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
in	O
which	O
the	O
recommended	O
starting	O
dose	O
and	O
schedule	O
was	O
1.8	O
mg/kg	O
of	O
ADCETRIS	O
administered	O
intravenously	O
over	O
30	O
minutes	O
every	O
3	O
weeks	O
or	O
placebo	O
for	O
up	O
to	O
16	O
cycles	O
.	O
	
Clinical	O
surveillance	O
of	O
all	O
women	O
taking	O
DUAVEE	O
is	O
important	O
.	O
	
5.4	O
Effects	O
on	O
Eye	O
Physicians	O
should	O
advise	O
patients	O
to	O
stop	O
use	O
of	O
all	O
PDE5	O
inhibitors	O
,	O
including	O
STENDRA	O
,	O
and	O
seek	O
medical	O
attention	O
in	O
the	O
event	O
of	O
a	O
sudden	O
loss	O
of	O
vision	O
in	O
one	O
or	O
both	O
eyes	O
.	O
	
Immunogenicity	O
Antibodies	O
to	O
SIMPONI	O
ARIA	O
were	O
detected	O
in	O
13	O
(	O
3	O
%	O
)	O
golimumab-treated	O
patients	O
following	O
IV	O
administration	O
of	O
SIMPONI	O
ARIA	O
in	O
combination	O
with	O
MTX	O
through	O
Week	O
24	O
of	O
Trial	O
1	O
.	O
	
(	O
5.2	O
)	O
*	O
Direct	B
Coombs	I
'	I
test	I
seroconversion	I
has	O
been	O
reported	O
with	O
Teflaro	O
.	O
	
In	O
limited	O
comparative	O
studies	O
,	O
the	O
adverse	O
reaction	O
profile	O
of	O
Coartem	O
Tablets	O
appeared	O
similar	O
to	O
that	O
of	O
another	O
antimalarial	O
regimen	O
.	O
	
Testing	O
for	O
IgG	O
titers	O
may	O
also	O
be	O
considered	O
if	O
patients	O
develop	O
hypersensitivity	O
reactions	O
,	O
other	O
immune-mediated	O
reactions	O
,	O
or	O
lose	O
clinical	O
response	O
.	O
	
(	O
5.1	O
)	O
*	O
Anemia	B
-	O
The	O
addition	O
of	O
VICTRELIS	O
to	O
peginterferon	O
alfa	O
and	O
ribavirin	O
is	O
associated	O
with	O
an	O
additional	O
decrease	B
in	I
hemoglobin	I
concentrations	I
compared	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
alone	O
.	O
	
Obtain	O
a	O
liver	O
test	O
panel	O
(	O
serum	O
alanine	O
aminotransferase	O
[	O
ALT	O
]	O
,	O
aspartate	O
aminotransferase	O
[	O
AST	O
]	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
total	O
bilirubin	O
)	O
as	O
a	O
baseline	O
before	O
initiating	O
ULORIC	O
.	O
	
Advise	O
female	O
patients	O
of	O
reproductive	O
potential	O
to	O
avoid	O
becoming	O
pregnant	O
and	O
to	O
use	O
highly	O
effective	O
contraception	O
while	O
using	O
AFINITOR	O
and	O
for	O
up	O
to	O
8	O
weeks	O
after	O
ending	O
treatment	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
The	O
size	O
of	O
the	O
control	O
group	O
and	O
limited	O
duration	O
of	O
the	O
controlled	O
portions	O
of	O
the	O
studies	O
precludes	O
the	O
ability	O
to	O
draw	O
firm	O
conclusions	O
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
IgG	O
antibody	O
formation	O
every	O
3	O
months	O
for	O
2	O
years	O
and	O
then	O
annually	O
thereafter	O
.	O
	
Most	O
adverse	O
reactions	O
were	O
mild	O
,	O
did	O
not	O
lead	O
to	O
discontinuation	O
of	O
study	O
medication	O
,	O
and	O
resolved	O
.	O
	
5.5	O
Macrophage	O
Activation	O
Syndrome	O
Macrophage	O
activation	O
syndrome	O
(	O
MAS	O
)	O
is	O
a	O
known	O
,	O
life-threatening	O
disorder	O
that	O
may	O
develop	O
in	O
patients	O
with	O
rheumatic	O
conditions	O
,	O
in	O
particular	O
SJIA	O
,	O
and	O
should	O
be	O
aggressively	O
treated	O
.	O
	
STENDRA	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
anatomical	O
deformation	O
of	O
the	O
penis	O
(	O
such	O
as	O
angulation	O
,	O
cavernosal	O
fibrosis	O
,	O
or	O
Peyronie	O
's	O
disease	O
)	O
,	O
or	O
in	O
patients	O
who	O
have	O
conditions	O
which	O
may	O
predispose	O
them	O
to	O
priapism	O
(	O
such	O
as	O
sickle	O
cell	O
anemia	O
,	O
multiple	O
myeloma	O
,	O
or	O
leukemia	O
)	O
.	O
	
Adequate	O
diagnostic	O
measures	O
,	O
including	O
directed	O
or	O
random	O
endometrial	O
sampling	O
when	O
indicated	O
,	O
should	O
be	O
undertaken	O
to	O
rule	O
out	O
malignancy	O
in	O
postmenopausal	O
women	O
with	O
undiagnosed	O
persistent	O
or	O
recurring	O
abnormal	O
genital	O
bleeding	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
,	O
regardless	O
of	O
causality	O
,	O
were	O
neutropenia	B
,	O
peripheral	B
sensory	I
neuropathy	I
,	O
fatigue	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nausea	B
,	O
diarrhea	B
,	O
anemia	B
,	O
pyrexia	B
,	O
thrombocytopenia	B
,	O
rash	B
,	O
abdominal	B
pain	I
,	O
cough	B
,	O
and	O
vomiting	B
.	O
	
The	O
increase	O
in	O
VTE	B
risk	O
was	O
demonstrated	O
during	O
the	O
first	O
2	O
years	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.5	O
)	O
]	O
.	O
	
Somnolence	B
(	O
including	O
sedation	B
)	O
led	O
to	O
discontinuation	O
in	O
0.6	O
%	O
(	O
12/1953	O
)	O
of	O
patients	O
in	O
short-term	O
,	O
placebo-controlled	O
trials	O
.	O
	
5.4	O
Immunizations	O
Live	O
vaccines	O
should	O
not	O
be	O
given	O
concurrently	O
with	O
ILARIS	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Appropriate	O
fluid	O
and	O
electrolyte	O
management	O
,	O
protein	O
supplementation	O
,	O
antibiotic	O
treatment	O
of	O
C.	O
difficile	O
,	O
and	O
surgical	O
evaluation	O
should	O
be	O
instituted	O
as	O
clinically	O
indicated	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
From	O
this	O
information	O
,	O
it	O
is	O
not	O
possible	O
to	O
determine	O
whether	O
these	O
events	O
are	O
related	O
directly	O
to	O
the	O
use	O
of	O
PDE5	O
inhibitors	O
or	O
to	O
other	O
factors	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
These	O
cases	O
were	O
reported	O
post-marketing	O
and	O
are	O
derived	O
from	O
a	O
variety	O
of	O
sources	O
including	O
registries	O
and	O
spontaneous	O
post-marketing	O
reports	O
.	O
	
Appropriate	O
measures	O
such	O
as	O
fluid	O
and	O
electrolyte	O
management	O
,	O
protein	O
supplementation	O
,	O
antibacterial	O
treatment	O
of	O
C.	O
difficile	O
,	O
and	O
surgical	O
evaluation	O
should	O
be	O
instituted	O
as	O
clinically	O
indicated	O
.	O
	
6.2	O
Post	O
Marketing	O
Experience	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
rarely	O
during	O
the	O
post-marketing	O
use	O
of	O
BEPREVE	O
.	O
	
Test	O
patients	O
for	O
HBV	O
infection	O
before	O
initiating	O
treatment	O
with	O
CIMZIA	O
.	O
	
In	O
patients	O
with	O
end-stage	O
renal	O
failure	O
,	O
hepatic	O
contrast	O
was	O
markedly	O
reduced	O
and	O
was	O
attributed	O
to	O
elevated	O
serum	O
ferritin	O
levels	O
.	O
	
Reduction	O
of	O
Risk	O
of	O
Stroke	O
and	O
Systemic	O
Embolism	O
in	O
Patients	O
with	O
Nonvalvular	O
Atrial	O
Fibrillation	O
The	O
safety	O
of	O
ELIQUIS	O
was	O
evaluated	O
in	O
the	O
ARISTOTLE	O
and	O
AVERROES	O
studies	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
including	O
11,284	O
patients	O
exposed	O
to	O
ELIQUIS	O
5	O
mg	O
twice	O
daily	O
and	O
602	O
patients	O
exposed	O
to	O
ELIQUIS	O
2.5	O
mg	O
twice	O
daily	O
.	O
	
TAFINLAR	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
results	O
in	O
an	O
increased	O
incidence	O
of	O
basal	B
cell	I
carcinoma	I
.	O
	
*	O
with	O
known	O
disturbances	O
of	O
electrolyte	O
balance	O
,	O
e.g.	O
,	O
hypokalemia	O
or	O
hypomagnesemia	O
.	O
	
Vomiting	B
was	O
the	O
primary	O
adverse	O
reaction	O
leading	O
to	O
discontinuation	O
of	O
dosing	O
;	O
this	O
occurred	O
at	O
an	O
incidence	O
of	O
0.5	O
%	O
in	O
both	O
the	O
fidaxomicin	O
and	O
vancomycin	O
patients	O
in	O
Phase	O
3	O
studies	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
bleeding	O
.	O
	
While	O
taking	O
AFINITOR	O
,	O
be	O
vigilant	O
for	O
signs	O
and	O
symptoms	O
of	O
infection	O
;	O
if	O
a	O
diagnosis	O
of	O
an	O
infection	O
is	O
made	O
,	O
institute	O
appropriate	O
treatment	O
promptly	O
and	O
consider	O
interruption	O
or	O
discontinuation	O
of	O
AFINITOR	O
.	O
	
Rare	O
cases	O
of	O
neurological	B
disorders	I
,	O
including	O
seizure	B
disorder	I
,	O
optic	B
neuritis	I
,	O
and	O
peripheral	B
neuropathy	I
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
CIMZIA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
risk	O
differences	O
(	O
drug	O
vs.	O
placebo	O
)	O
,	O
however	O
,	O
were	O
relatively	O
stable	O
within	O
age	O
strata	O
and	O
across	O
indications	O
.	O
	
The	O
incidence	O
of	O
antibody	O
development	O
in	O
patients	O
receiving	O
GRANIX	O
has	O
not	O
been	O
adequately	O
determined	O
.	O
	
A	O
negative	O
image	O
does	O
not	O
rule	O
out	O
the	O
presence	O
of	O
recurrent	O
prostate	O
cancer	O
and	O
a	O
positive	O
image	O
does	O
not	O
confirm	O
the	O
presence	O
of	O
recurrent	O
cancer	O
.	O
	
Other	O
Adverse	O
Reactions	O
Hypoglycemia	O
The	O
proportion	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
documented	O
symptomatic	O
hypoglycemic	B
episode	I
on	O
TANZEUM	O
and	O
the	O
proportion	O
of	O
patients	O
experiencing	O
at	O
least	O
one	O
severe	O
hypoglycemic	B
episode	I
on	O
TANZEUM	O
in	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
is	O
shown	O
in	O
Table	O
2	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Interleukin-1	O
blockade	O
may	O
interfere	O
with	O
immune	O
response	O
to	O
infections	O
.	O
	
Percentages	O
calculated	O
with	O
the	O
number	O
of	O
male	O
subjects	O
in	O
each	O
group	O
as	O
denominator	O
:	O
placebo	O
(	O
N=514	O
)	O
,	O
JARDIANCE	O
10	O
mg	O
(	O
N=556	O
)	O
,	O
JARDIANCE	O
25	O
mg	O
(	O
N=557	O
)	O
.	O
	
One	O
case	O
of	O
ANC	B
less	I
than	I
0.5x10	I
9	I
/L	I
was	O
observed	O
in	O
the	O
ILARIS	O
group	O
and	O
none	O
in	O
the	O
placebo	O
group	O
.	O
	
Estrogens	O
may	O
be	O
poorly	O
metabolized	O
in	O
women	O
with	O
impaired	O
liver	O
function	O
.	O
	
Pooled	O
analyses	O
of	O
short-term	O
placebo-controlled	O
studies	O
of	O
antidepressant	O
drugs	O
(	O
SSRIs	O
and	O
others	O
)	O
showed	O
that	O
these	O
drugs	O
increase	O
the	O
risk	O
of	O
suicidal	B
thinking	I
(	O
suicidality	B
)	O
in	O
children	O
,	O
adolescents	O
,	O
and	O
young	O
adults	O
(	O
ages	O
18	O
to	O
24	O
)	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
and	O
other	O
psychiatric	O
disorders	O
.	O
	
5.6	O
Respiratory	O
Effects	O
Dose-dependent	O
reductions	B
in	I
forced	I
expiratory	I
volume	I
over	I
1	I
second	I
)	O
were	O
observed	O
in	O
patients	O
treated	O
with	O
GILENYA	O
as	O
early	O
as	O
1	O
month	O
after	O
treatment	O
initiation	O
.	O
	
Consider	O
discontinuation	O
of	O
CIMZIA	O
therapy	O
in	O
patients	O
with	O
confirmed	O
significant	O
hematologic	O
abnormalities	O
.	O
	
Elevations	O
5-fold	O
the	O
ULN	O
or	O
greater	O
occurred	O
in	O
4.5	O
%	O
of	O
patients	O
on	O
GILENYA	O
and	O
1	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
Prophylaxis	O
with	O
antipyretics	O
may	O
be	O
required	O
when	O
resuming	O
TAFINLAR	O
or	O
trametinib	O
.	O
	
Table	O
1	O
:	O
Bleeding	B
Events	O
in	O
Patients	O
with	O
Nonvalvular	O
Atrial	O
Fibrillation	O
in	O
ARISTOTLE*	O
ELIQUISN=9088n	O
(	O
per	O
100	O
pt-year	O
)	O
WarfarinN=9052n	O
(	O
per	O
100	O
pt-year	O
)	O
Hazard	O
Ratio	O
(	O
95	O
%	O
CI	O
)	O
P-value	O
*	O
Bleeding	B
events	O
within	O
each	O
subcategory	O
were	O
counted	O
once	O
per	O
subject	O
,	O
but	O
subjects	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
endpoints	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
in	O
Patients	O
with	O
Dupuytren	O
's	O
Contracture	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Patients	O
received	O
BENLYSTA	O
at	O
doses	O
of	O
1	O
mg/kg	O
(	O
N	O
=	O
673	O
)	O
,	O
4	O
mg/kg	O
(	O
N	O
=	O
111	O
;	O
Trial	O
1	O
only	O
)	O
,	O
or	O
10	O
mg/kg	O
(	O
N	O
=	O
674	O
)	O
or	O
placebo	O
(	O
N	O
=	O
675	O
)	O
intravenously	O
over	O
a	O
1-hour	O
period	O
on	O
Days	O
0	O
,	O
14	O
,	O
28	O
,	O
and	O
then	O
every	O
28	O
days	O
.	O
	
Physicians	O
should	O
also	O
consider	O
the	O
risk	O
that	O
reduced	O
immunosuppression	O
represents	O
to	O
the	O
functioning	O
allograft	O
.	O
	
The	O
conditions	O
and	O
duration	O
of	O
exposure	O
varied	O
greatly	O
and	O
included	O
single-	O
and	O
multiple-dose	O
clinical	O
pharmacology	O
studies	O
in	O
healthy	O
volunteers	O
and	O
two	O
double-blind	O
studies	O
in	O
patients	O
with	O
LGS	O
(	O
Study	O
1	O
and	O
2	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
The	O
pooled	O
mean	O
maximum	O
dose	O
in	O
these	O
studies	O
was	O
10	O
mg/hour	O
and	O
the	O
mean	O
duration	O
of	O
treatment	O
was	O
8	O
hours	O
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
below	O
is	O
based	O
upon	O
2	O
placebo-controlled	O
,	O
clinical	O
trials	O
(	O
EDEMA3	O
(	O
r	O
)	O
and	O
EDEMA4	O
(	O
r	O
)	O
)	O
in	O
a	O
total	O
of	O
143	O
unique	O
patients	O
with	O
HAE	O
.	O
	
In	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
,	O
the	O
median	O
time	O
to	O
initial	O
onset	O
of	O
fever	B
was	O
30	O
days	O
compared	O
with	O
19	O
days	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
;	O
the	O
median	O
duration	O
of	O
fever	B
was	O
6	O
days	O
with	O
the	O
combination	O
compared	O
with	O
4	O
days	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
PML	O
is	O
usually	O
diagnosed	O
by	O
brain	O
imaging	O
,	O
cerebrospinal	O
fluid	O
(	O
CSF	O
)	O
testing	O
for	O
JC	O
viral	O
DNA	O
by	O
polymerase	O
chain	O
reaction	O
(	O
PCR	O
)	O
,	O
and/or	O
brain	O
biopsy	O
.	O
	
5.2	O
Renal	O
Impairment	O
AMPYRA	O
is	O
eliminated	O
through	O
the	O
kidneys	O
primarily	O
as	O
unchanged	O
drug	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.4	O
)	O
]	O
.	O
	
A	O
reduction	O
of	O
the	O
AFINITOR	O
dose	O
is	O
recommended	O
when	O
co-administered	O
with	O
a	O
moderate	O
CYP3A4/PgP	O
inhibitor	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
,	O
2.5	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Use	O
cautiously	O
in	O
patients	O
with	O
seizure	O
disorder	O
(	O
5.8	O
)	O
.	O
	
The	O
incidence	O
of	O
opportunistic	B
infections	I
was	O
similar	O
between	O
placebo	O
and	O
Prolia	O
groups	O
,	O
and	O
the	O
overall	O
incidence	O
of	O
infections	B
was	O
similar	O
between	O
the	O
treatment	O
groups	O
.	O
	
5.10	O
Immune	O
System	O
Effects	O
Following	O
GILENYA	O
Discontinuation	O
Fingolimod	O
remains	O
in	O
the	O
blood	O
and	O
has	O
pharmacodynamic	O
effects	O
,	O
including	O
decreased	B
lymphocyte	I
counts	I
,	O
for	O
up	O
to	O
2	O
months	O
following	O
the	O
last	O
dose	O
of	O
GILENYA	O
.	O
	
Monitor	O
for	O
symptoms	O
of	O
motor	O
or	O
sensory	O
neuropathy	O
such	O
as	O
unilateral	O
or	O
bilateral	O
weakness	O
,	O
sensory	O
alterations	O
,	O
or	O
paresthesia	O
.	O
	
(	O
5.1	O
,	O
6	O
)	O
*	O
Use	O
with	O
CYP3A	O
inducers	O
:	O
Concomitant	O
use	O
with	O
strong	O
CYP3A	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
St.	O
John	O
's	O
wort	O
)	O
substantially	O
decreases	O
exposure	O
of	O
ivacaftor	O
,	O
which	O
may	O
diminish	O
effectiveness	O
.	O
	
Hepatic	O
function	O
should	O
be	O
monitored	O
closely	O
with	O
both	O
clinical	O
and	O
laboratory	O
follow-up	O
for	O
at	O
least	O
several	O
months	O
in	O
patients	O
who	O
are	O
coinfected	O
with	O
HIV-1	O
and	O
HBV	O
and	O
discontinue	O
STRIBILD	O
.	O
	
Through	O
48	O
weeks	O
,	O
the	O
rates	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
were	O
2	O
%	O
in	O
subjects	O
receiving	O
TIVICAY	O
and	O
4	O
%	O
in	O
subjects	O
receiving	O
darunavir/ritonavir	O
.	O
	
*	O
Application	B
site	I
reactions	I
,	O
have	O
been	O
reported	O
.	O
	
Anyone	O
considering	O
prescribing	O
HORIZANT	O
must	O
balance	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
or	O
behavior	O
with	O
the	O
risk	O
of	O
untreated	O
illness	O
.	O
	
Weight	B
decrease	I
of	O
>	O
=10	O
%	O
of	O
body	O
weight	O
occurred	O
in	O
2	O
%	O
(	O
16/784	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
compared	O
to	O
1	O
%	O
(	O
3/382	O
)	O
subjects	O
treated	O
with	O
placebo	O
.	O
	
There	O
was	O
one	O
death	B
due	O
to	O
pulmonary	B
embolism	I
on	O
the	O
placebo	O
arm	O
.	O
	
The	O
rates	O
of	O
treatment-emergent	O
adverse	O
events	O
resulting	O
in	O
permanent	O
discontinuation	O
were	O
24	O
%	O
and	O
5	O
%	O
for	O
the	O
AFINITOR	O
plus	O
exemestane	O
and	O
placebo	O
plus	O
exemestane	O
treatment	O
groups	O
,	O
respectively	O
.	O
	
Hepatic	O
function	O
should	O
be	O
monitored	O
closely	O
in	O
these	O
patients	O
.	O
	
These	O
events	O
were	O
observed	O
primarily	O
in	O
subjects	O
with	O
a	O
pre-existing	O
history	O
of	O
depression	O
or	O
other	O
psychiatric	O
illness	O
.	O
	
Withhold	O
YERVOY	O
dosing	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
signs	O
and	O
symptoms	O
.	O
	
KALYDECO	O
was	O
permanently	O
discontinued	O
in	O
one	O
patient	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
*	O
Infantile-onset	O
Pompe	O
disease	O
patients	O
with	O
compromised	O
cardiac	O
or	O
respiratory	O
function	O
may	O
be	O
at	O
risk	O
of	O
serious	O
acute	B
exacerbation	I
of	I
their	I
cardiac	I
or	I
respiratory	I
compromise	I
due	O
to	O
fluid	B
overload	I
,	O
and	O
require	O
additional	O
monitoring	O
(	O
5.3	O
)	O
.	O
	
These	O
events	O
have	O
been	O
chosen	O
for	O
inclusion	O
due	O
to	O
either	O
their	O
seriousness	O
,	O
frequency	O
of	O
reporting	O
,	O
or	O
causal	O
connection	O
to	O
BREO	O
ELLIPTA	O
or	O
a	O
combination	O
of	O
these	O
factors	O
.	O
	
Two	O
of	O
the	O
four	O
subjects	O
had	O
renal	O
impairment	O
(	O
i.e	O
.	O
	
It	O
is	O
important	O
to	O
emphasize	O
that	O
,	O
although	O
the	O
reactions	O
reported	O
occurred	O
during	O
treatment	O
with	O
FANAPT	O
,	O
they	O
were	O
not	O
necessarily	O
caused	O
by	O
it	O
.	O
	
The	O
clearance	O
values	O
for	O
4	O
of	O
these	O
5	O
patients	O
were	O
approximately	O
1.2-	O
to	O
1.8-fold	O
greater	O
in	O
the	O
presence	O
of	O
inhibitory	O
antibodies	O
(	O
Week	O
52	O
)	O
as	O
compared	O
to	O
in	O
the	O
absence	O
of	O
inhibitory	O
antibodies	O
(	O
Week	O
0	O
)	O
[	O
seeClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Once	O
asthma	O
control	O
is	O
achieved	O
and	O
maintained	O
,	O
assess	O
the	O
patient	O
at	O
regular	O
intervals	O
and	O
step	O
down	O
therapy	O
(	O
e.g.	O
,	O
discontinue	O
BREO	O
ELLIPTA	O
)	O
if	O
possible	O
without	O
loss	O
of	O
asthma	O
control	O
and	O
maintain	O
the	O
patient	O
on	O
a	O
long-term	O
asthma	O
control	O
medication	O
,	O
such	O
as	O
an	O
inhaled	O
corticosteroid	O
.	O
	
In	O
those	O
patients	O
treated	O
with	O
HORIZANT	O
who	O
reported	O
somnolence	B
,	O
the	O
somnolence	B
persisted	O
during	O
treatment	O
in	O
about	O
30	O
%	O
.	O
	
5.10	O
Proteinuria	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
proteinuria	B
was	O
reported	O
in	O
39/359	O
patients	O
(	O
11	O
%	O
)	O
receiving	O
INLYTA	O
and	O
26/355	O
patients	O
(	O
7	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Non-acute	O
hypersensitivity	B
reactions	I
including	O
rash	B
,	O
nausea	B
,	O
fatigue	B
,	O
myalgia	B
,	O
headache	B
,	O
and	O
facial	B
edema	I
,	O
have	O
been	O
reported	O
and	O
typically	O
occurred	O
up	O
to	O
a	O
week	O
following	O
the	O
most	O
recent	O
infusion	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
reactions	O
reported	O
in	O
patients	O
treated	O
with	O
GILOTRIF	O
were	O
diarrhea	B
(	O
6.6	O
%	O
)	O
;	O
vomiting	B
(	O
4.8	O
%	O
)	O
;	O
and	O
dyspnea	B
,	O
fatigue	B
,	O
and	O
hypokalemia	B
(	O
1.7	O
%	O
each	O
)	O
.	O
	
The	O
most	O
common	O
infusion	B
reactions	I
(	O
>	O
=3	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
)	O
were	O
headache	B
,	O
nausea	B
,	O
and	O
skin	B
reactions	I
.	O
	
The	O
incidence	O
of	O
these	O
adverse	O
reactions	O
was	O
greater	O
in	O
the	O
patients	O
receiving	O
1,200	O
mg	O
per	O
day	O
.	O
	
Dry	B
mouth	I
led	O
to	O
discontinuation	O
in	O
0.4	O
%	O
,	O
0.4	O
%	O
,	O
and	O
0.8	O
%	O
of	O
patients	O
receiving	O
placebo	O
,	O
Toviaz	O
4	O
mg	O
,	O
and	O
Toviaz	O
8	O
mg	O
,	O
respectively	O
.	O
	
Hyperthyroidism	B
was	O
reported	O
in	O
4/359	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
4/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
Two	O
patients	O
(	O
2	O
%	O
)	O
on	O
placebo	O
and	O
1	O
patient	O
(	O
0.5	O
%	O
)	O
on	O
KALYDECO	O
permanently	O
discontinued	O
treatment	O
for	O
elevated	B
transaminases	I
,	O
all	O
>	O
8	O
*	O
ULN	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
59	O
%	O
of	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
Alternatives	O
to	O
NSAIDs	O
should	O
be	O
considered	O
,	O
if	O
needed	O
,	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
dysfunction	O
.	O
	
Some	O
of	O
these	O
reactions	O
occurred	O
after	O
the	O
first	O
administration	O
of	O
golimumab	O
.	O
	
Who	O
should	O
not	O
take	O
DUAVEE	O
?	O
	
When	O
pregnancy	O
is	O
detected	O
,	O
discontinue	O
Edarbi	O
as	O
soon	O
as	O
possible	O
[	O
seeUse	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
Postmarketing	O
reports	O
indicate	O
that	O
the	O
effects	O
of	O
XEOMIN	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	O
produce	O
symptoms	O
consistent	O
with	O
botulinum	O
toxin	B
effects	I
.	O
	
(	O
5.5	O
)	O
*	O
Decrease	B
in	I
pulmonary	I
function	I
tests	I
)	O
:	O
Obtain	O
PFT	O
when	O
clinically	O
indicated	O
.	O
	
Falls	O
and	O
Fall-related	O
Injuries	O
In	O
the	O
two	O
randomized	O
clinical	O
trials	O
,	O
falls	B
including	O
fall-related	B
injuries	I
,	O
occurred	O
in	O
9	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
compared	O
to	O
4	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
Reduction	O
in	O
Heart	O
Rate	O
After	O
the	O
first	O
dose	O
of	O
GILENYA	O
,	O
the	O
heart	B
rate	I
decrease	I
starts	O
within	O
an	O
hour	O
.	O
	
It	O
is	O
unknown	O
if	O
treatment	O
with	O
BENLYSTA	O
is	O
associated	O
with	O
increased	O
risk	O
for	O
these	O
events	O
.	O
	
(	O
5.1	O
)	O
*	O
Drugs	O
that	O
act	O
directly	O
on	O
the	O
renin-angiotensin	O
system	O
can	O
cause	O
death	B
to	I
the	I
developing	I
fetus	I
.	O
	
Six	O
XEOMIN	O
treated	O
subjects	O
experienced	O
six	O
serious	O
adverse	O
events	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
In	O
a	O
pooled	O
analysis	O
of	O
clinical	O
studies	O
,	O
adverse	O
reactions	O
with	O
an	O
incidence	O
of	O
less	O
than	O
2	O
%	O
reported	O
in	O
DYSPORT	O
(	O
r	O
)	O
treatment	O
groups	O
included	O
dysphagia	B
0.5	O
%	O
,	O
gait	B
disturbance	I
0.5	O
%	O
,	O
hypertonia	B
0.5	O
%	O
,	O
and	O
sensation	B
of	I
heaviness	I
0.3	O
%	O
.	O
	
Although	O
cobicistat	O
(	O
a	O
component	O
of	O
STRIBILD	O
)	O
may	O
cause	O
modest	O
increases	B
in	I
serum	I
creatinine	I
and	O
modest	O
declines	B
in	I
estimated	I
creatinine	I
clearance	I
without	O
affecting	O
renal	O
glomerular	O
function	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
,	O
patients	O
who	O
experience	O
a	O
confirmed	O
increase	O
in	O
serum	O
creatinine	O
of	O
greater	O
than	O
0.4	O
mg	O
per	O
dL	O
from	O
baseline	O
should	O
be	O
closely	O
monitored	O
for	O
renal	O
safety	O
.	O
	
Some	O
medicines	O
may	O
affect	O
how	O
DUAVEE	O
works	O
.	O
	
In	O
patients	O
treated	O
with	O
Kyprolis	O
,	O
the	O
incidence	O
of	O
serious	O
adverse	O
events	O
was	O
higher	O
in	O
those	O
>	O
=	O
65	O
years	O
old	O
and	O
in	O
those	O
>	O
=	O
75	O
years	O
old	O
[	O
see	O
Geriatric	O
Use	O
(	O
8.5	O
)	O
]	O
.	O
	
If	O
anaphylaxis	O
or	O
severe	O
hypersensitivity	O
reactions	O
occur	O
,	O
immediately	O
discontinue	O
administration	O
of	O
alglucosidase	O
alfa	O
,	O
and	O
initiate	O
appropriate	O
medical	O
treatment	O
.	O
	
Other	O
than	O
injection	B
site	I
reactions	I
,	O
most	O
adverse	O
reactions	O
became	O
noticeable	O
about	O
one	O
week	O
after	O
treatment	O
and	O
lasted	O
several	O
weeks	O
.	O
	
In	O
short-term	O
placebo-controlled	O
bipolar	O
mania	O
adult	O
trials	O
,	O
the	O
incidence	O
of	O
EPS-related	B
events	I
,	O
excluding	O
events	O
related	O
to	O
akathisia	B
,	O
for	O
SAPHRIS-treated	O
patients	O
was	O
7	O
%	O
versus	O
2	O
%	O
for	O
placebo	O
;	O
and	O
the	O
incidence	O
of	O
akathisia-related	O
events	O
for	O
SAPHRIS-treated	O
patients	O
was	O
4	O
%	O
versus	O
2	O
%	O
for	O
placebo	O
.	O
	
In	O
clinical	O
trials	O
with	O
INLYTA	O
,	O
arterial	B
thromboembolic	I
events	I
(	O
including	O
transient	B
ischemic	I
attack	I
,	O
cerebrovascular	B
accident	I
,	O
myocardial	B
infarction	I
,	O
and	O
retinal	B
artery	I
occlusion	I
)	O
were	O
reported	O
in	O
17/715	O
patients	O
(	O
2	O
%	O
)	O
,	O
with	O
two	O
deaths	B
secondary	O
to	O
cerebrovascular	B
accident	I
.	O
	
Monitor	O
glucose	O
levels	O
in	O
patients	O
at	O
baseline	O
and	O
periodically	O
during	O
treatment	O
.	O
	
Some	O
of	O
these	O
events	O
have	O
been	O
fatal	B
or	O
life-threatening	O
.	O
	
(	O
5.13,8.1	O
)	O
5.1	O
Hypertension	O
and	O
Hypertensive	O
Crisis	O
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
hypertension	B
was	O
reported	O
in	O
145/359	O
patients	O
(	O
40	O
%	O
)	O
receiving	O
INLYTA	O
and	O
103/355	O
patients	O
(	O
29	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
the	O
postmarketing	O
use	O
of	O
EDARBI	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
adult	O
trials	O
,	O
the	O
mean	O
increase	B
in	I
transaminase	I
levels	I
for	O
SAPHRIS-treated	O
patients	O
was	O
1.6	O
units/L	O
compared	O
to	O
a	O
decrease	O
of	O
0.4	O
units/L	O
for	O
placebo-treated	O
patients	O
.	O
	
Do	O
not	O
take	O
DUAVEE	O
if	O
the	O
test	O
is	O
positive	O
and	O
talk	O
to	O
your	O
healthcare	O
provider	O
.	O
	
Appropriate	O
medical	O
support	O
and	O
monitoring	O
measures	O
should	O
be	O
available	O
during	O
infusion	O
(	O
5.3	O
)	O
.	O
	
Table	O
7	O
:	O
Most	O
Commonly	O
Reported	O
Adverse	O
Events	O
(	O
>	O
=	O
10	O
%	O
)	O
with	O
Kyprolis	O
Monotherapy	O
a	O
Pneumonia	B
includes	O
the	O
preferred	O
terms	O
of	O
pneumonia	B
,	O
bronchopneumonia	B
.	O
	
One	O
patient	O
with	O
urticaria	B
had	O
recurrence	O
when	O
INVOKANA	O
was	O
re-initiated	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
6.1	O
%	O
and	O
7.0	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
6.2	O
Endogenous	O
Anterior	O
Uveitis	O
A	O
total	O
of	O
200	O
subjects	O
participated	O
in	O
the	O
clinical	O
trials	O
for	O
endogenous	O
anterior	O
uveitis	O
,	O
of	O
which	O
106	O
were	O
exposed	O
to	O
DUREZOL	O
.	O
	
Cognitive	B
dysfunction	I
events	O
were	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
The	O
QT-prolonging	B
effect	O
occurred	O
within	O
3	O
hours	O
.	O
	
No	O
discernible	O
pattern	O
between	O
death	B
and	O
sputum	O
culture	O
conversion	O
,	O
relapse	O
,	O
sensitivity	O
to	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
,	O
HIV	O
status	O
,	O
or	O
severity	O
of	O
disease	O
could	O
be	O
observed	O
.	O
	
At	O
baseline	O
,	O
57	O
%	O
of	O
the	O
population	O
had	O
diabetes	O
more	O
than	O
5	O
years	O
and	O
had	O
a	O
mean	O
hemoglobin	O
A1c	O
(	O
HbA1c	O
)	O
of	O
8	O
%	O
.	O
	
There	O
were	O
4	O
suicides	B
in	O
drug-treated	O
patients	O
in	O
the	O
trials	O
and	O
none	O
in	O
placebo-treated	O
patients	O
,	O
but	O
the	O
number	O
is	O
too	O
small	O
to	O
allow	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	B
.	O
	
SIRTURO	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
ventricular	O
arrhythmias	O
or	O
recent	O
myocardial	O
infarction	O
.	O
	
Table	O
2	O
summarizes	O
the	O
adverse	O
reactions	O
regardless	O
of	O
causality	O
from	O
the	O
trial	O
in	O
patients	O
with	O
relapsed	O
or	O
refractory	O
PTCL	O
.	O
	
Using	O
an	O
electrochemiluminescent	O
bridging	O
immunoassay	O
,	O
less	O
than	O
1	O
%	O
(	O
55	O
out	O
of	O
8113	O
)	O
of	O
patients	O
treated	O
with	O
Prolia	O
for	O
up	O
to	O
5	O
years	O
tested	O
positive	O
for	O
binding	O
antibodies	O
(	O
including	O
pre-existing	O
,	O
transient	O
,	O
and	O
developing	O
antibodies	O
)	O
.	O
	
Prior	O
to	O
neuraxial	O
intervention	O
the	O
physician	O
should	O
consider	O
the	O
potential	O
benefit	O
versus	O
the	O
risk	O
in	O
anticoagulated	O
patients	O
or	O
in	O
patients	O
to	O
be	O
anticoagulated	O
for	O
thromboprophylaxis	O
.	O
	
Tables	O
5	O
and	O
6	O
summarize	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
in	O
XALKORI-treated	O
patients	O
.	O
	
Patients	O
with	O
a	O
pre-existing	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
or	O
a	O
history	O
of	O
leukopenia/neutropenia	O
should	O
have	O
their	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
monitored	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
and	O
SAPHRIS	O
should	O
be	O
discontinued	O
at	O
the	O
first	O
sign	O
of	O
a	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
a	O
patient	O
becomes	O
pregnant	O
while	O
receiving	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
seeUse	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Limited	O
information	O
is	O
presented	O
on	O
the	O
110	O
mg	O
dosing	O
arm	O
because	O
this	O
dose	O
is	O
not	O
approved	O
.	O
	
If	O
signs	O
suggesting	O
allergic	O
reactions	O
(	O
in	O
particular	O
,	O
difficulties	O
in	O
breathing	O
or	O
swallowing	O
,	O
swelling	O
of	O
tongue	O
,	O
lips	O
and	O
face	O
,	O
urticaria	O
,	O
skin	O
rash	O
)	O
occur	O
,	O
ARCAPTA	O
NEOHALER	O
should	O
be	O
discontinued	O
immediately	O
and	O
alternative	O
therapy	O
instituted	O
.	O
	
5.5	O
Renal	O
Toxicity	O
An	O
on-treatment	O
decline	B
in	I
estimated	I
glomerular	I
filtration	I
rate	I
(	O
eGFR	O
)	O
has	O
occurred	O
in	O
patients	O
treated	O
with	O
BOSULIF	O
.	O
	
The	O
patient	O
recovered	O
fully	O
following	O
discontinuation	O
of	O
BOSULIF	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
INCREASED	B
MORTALITY	I
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
WARNING	O
:	O
INCREASED	B
MORTALITY	I
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
.	O
	
Renal	B
cysts	I
occurred	O
in	O
8	O
(	O
5	O
%	O
)	O
patients	O
treated	O
with	O
XALKORI	O
and	O
1	O
(	O
1	O
%	O
)	O
patient	O
treated	O
with	O
chemotherapy	O
in	O
Study	O
2	O
.	O
	
Withholding	O
treatment	O
should	O
be	O
considered	O
in	O
patients	O
with	O
serious	O
infections	O
until	O
the	O
infection	O
(	O
s	O
)	O
is	O
resolved	O
.	O
	
IMBRUVICA	O
may	O
increase	O
the	O
risk	O
of	O
hemorrhage	B
in	O
patients	O
receiving	O
antiplatelet	O
or	O
anticoagulant	O
therapies	O
.	O
	
Evaluation	O
of	O
airway	O
patency	O
should	O
be	O
considered	O
prior	O
to	O
initiation	O
of	O
treatment	O
with	O
Vimizim	O
.	O
	
*	O
Embryo-Fetal	B
Toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
Events	O
related	O
to	O
dizziness	B
and	O
disturbance	B
in	I
gait	I
were	O
more	O
often	O
serious	O
in	O
APTIOM-treated	O
patients	O
than	O
in	O
placebo-treated	O
patients	O
(	O
2	O
%	O
vs.	O
0	O
%	O
)	O
,	O
and	O
more	O
often	O
led	O
to	O
study	O
withdrawal	O
in	O
APTIOM-treated	O
patients	O
than	O
in	O
placebo-treated	O
patients	O
(	O
9	O
%	O
vs.	O
0.7	O
%	O
)	O
.	O
	
Patient	O
exposure	O
PRISTIQ	O
was	O
evaluated	O
for	O
safety	O
in	O
8,394	O
patients	O
diagnosed	O
with	O
major	O
depressive	O
disorder	O
who	O
participated	O
in	O
multiple-dose	O
pre-marketing	O
studies	O
,	O
representing	O
2,784	O
patient-years	O
of	O
exposure	O
.	O
	
After	O
initiation	O
of	O
NESINA	O
,	O
patients	O
should	O
be	O
observed	O
carefully	O
for	O
signs	O
and	O
symptoms	O
of	O
pancreatitis	O
.	O
	
NESINA	O
should	O
not	O
be	O
restarted	O
in	O
these	O
patients	O
without	O
another	O
explanation	O
for	O
the	O
liver	O
test	O
abnormalities	O
.	O
	
Management	O
of	O
hypersensitivity	O
reactions	O
should	O
be	O
based	O
on	O
the	O
severity	O
of	O
the	O
reaction	O
and	O
include	O
slowing	O
or	O
temporary	O
interruption	O
of	O
the	O
infusion	O
and/or	O
administration	O
of	O
additional	O
antihistamines	O
,	O
antipyretics	O
,	O
and/or	O
corticosteroids	O
for	O
mild	O
reactions	O
.	O
	
In	O
Studies	O
1	O
and	O
2	O
,	O
Grade	O
3	O
syncope	B
occurred	O
in	O
2.0	O
%	O
of	O
XALKORI-treated	O
patients	O
and	O
in	O
0.6	O
%	O
of	O
the	O
chemotherapy-treated	O
patients	O
.	O
	
If	O
a	O
patient	O
develops	O
any	O
of	O
these	O
reactions	O
after	O
treatment	O
with	O
APTIOM	O
,	O
the	O
drug	O
should	O
be	O
discontinued	O
.	O
	
Evaluate	O
patients	O
with	O
thigh	O
or	O
groin	O
pain	O
to	O
rule	O
out	O
a	O
femoral	O
fracture	O
(	O
5.5	O
)	O
*	O
Serious	O
infections	B
including	O
skin	B
infections	I
:	O
May	O
occur	O
,	O
including	O
those	O
leading	O
to	O
hospitalization	O
.	O
	
[	O
See	O
Clinical	O
Studies	O
(	O
14.1	O
,	O
14.2	O
.	O
)	O
]	O
	
(	O
5.1	O
)	O
*	O
BEPREVE	O
should	O
not	O
be	O
used	O
to	O
treat	O
contact	O
lens-related	O
irritation	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
Heart	O
Failure	O
In	O
placebo-controlled	O
and	O
open-label	O
rheumatoid	O
arthritis	O
studies	O
,	O
cases	O
of	O
worsening	B
heart	I
failure	I
have	O
been	O
reported	O
for	O
CIMZIA-treated	O
patients	O
.	O
	
Discontinue	O
COMETRIQ	O
in	O
patients	O
who	O
develop	O
nephrotic	O
syndrome	O
.	O
	
Required	O
components	O
of	O
the	O
XIAFLEX	O
REMS	O
Program	O
include	O
the	O
following	O
:	O
*	O
Prescribers	O
must	O
be	O
certified	O
with	O
the	O
program	O
by	O
enrolling	O
and	O
completing	O
training	O
in	O
the	O
administration	O
of	O
XIAFLEX	O
treatment	O
for	O
Peyronie	O
's	O
disease	O
.	O
	
Adverse	O
Reactions	O
With	O
>	O
=	O
10	O
%	O
Incidence	O
for	O
Any	O
Grade	O
or	O
>	O
=	O
5	O
%	O
Incidence	O
for	O
Grade	O
3	O
or	O
Higher	O
(	O
N	O
=	O
212	O
)	O
Adverse	O
Reaction	O
Any	O
GradeGrading	O
based	O
on	O
NCI	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
(	O
CTCAE	O
)	O
version	O
4.0	O
(	O
%	O
)	O
Grade	O
3	O
or	O
Higher	O
(	O
%	O
)	O
Blood	O
and	O
lymphatic	O
system	O
disorders	O
Febrile	B
neutropenia	I
Anemia	B
Neutropenia	B
Thrombocytopenia	B
Leukopenia	B
251816119	O
23131588	O
Gastrointestinal	O
disorders	O
Nausea	B
Constipation	B
DiarrheaDiarrhea	O
includes	O
the	O
following	O
terms	O
:	O
colitis	B
,	O
diarrhea	B
,	O
enteritis	B
,	O
and	O
neutropenic	B
colitis	I
.	O
	
Administer	O
systemic	O
high-dose	O
corticosteroids	O
for	O
severe	O
,	O
persistent	O
,	O
or	O
recurring	O
immune-mediated	O
reactions	O
.	O
	
d	O
Includes	O
fatigue	B
,	O
asthenia	B
,	O
malaise	B
.	O
	
Advise	O
patients	O
regarding	O
good	O
oral	O
hygiene	O
practices	O
.	O
	
The	O
incidence	O
of	O
XIAFLEX-associated	O
pruritus	B
was	O
similar	O
after	O
each	O
injection	O
regardless	O
of	O
the	O
number	O
of	O
injections	O
administered	O
.	O
	
Discontinue	O
PRADAXA	O
in	O
patients	O
with	O
active	O
pathological	O
bleeding	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Approximately	O
one	O
third	O
(	O
3	O
%	O
,	O
39	O
of	O
1,509	O
)	O
of	O
these	O
patients	O
had	O
antibodies	O
with	O
neutralizing	O
activity	O
in	O
vitro	O
.	O
	
Increase	O
in	O
Serum	O
Inorganic	O
Phosphorus	O
In	O
the	O
pool	O
of	O
13	O
placebo-controlled	O
studies	O
,	O
increases	B
from	I
baseline	I
in	I
mean	I
serum	I
phosphorus	I
levels	I
were	O
reported	O
at	O
Week	O
24	O
in	O
FARXIGA-treated	O
patients	O
compared	O
with	O
placebo-treated	O
patients	O
(	O
mean	O
increase	O
of	O
0.13	O
versus	O
-0.04	O
mg/dL	O
,	O
respectively	O
)	O
.	O
	
Across	O
the	O
treatment	O
arms	O
,	O
the	O
mean	O
age	O
of	O
patients	O
was	O
56	O
years	O
,	O
1	O
%	O
were	O
75	O
years	O
or	O
older	O
and	O
53	O
%	O
were	O
male	O
.	O
	
Infliximab	O
was	O
administered	O
to	O
5	O
of	O
the	O
62	O
patients	O
(	O
8	O
%	O
)	O
with	O
moderate	O
,	O
severe	O
,	O
or	O
life-threatening	O
immune-mediated	B
enterocolitis	I
following	O
inadequate	O
response	O
to	O
corticosteroids	O
.	O
	
Studies	O
1	O
and	O
2	O
were	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
in	O
newly	O
diagnosed	O
patients	O
with	O
pulmonary	O
MDR-TB	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
:	O
*	O
Hypersensitivity	B
reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Pancreatitis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Glucose	B
intolerance	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Thrombosis	B
and	O
hemorrhage	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
1	O
%	O
or	O
greater	O
)	O
with	O
ERWINAZE	O
treatment	O
are	O
systemic	B
hypersensitivity	I
,	O
hyperglycemia	B
,	O
transaminases	B
abnormal	I
,	O
fever	B
,	O
pancreatitis	B
,	O
local	B
reactions	I
,	O
vomiting	B
,	O
nausea	B
,	O
thrombosis	B
,	O
hyperbilirubinemia	B
,	O
abdominal	B
pain	I
,	O
and	O
diarrhea	B
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
=25	O
%	O
)	O
are	O
increased	B
AST	I
,	O
increased	B
ALT	I
,	O
lymphopenia	B
,	O
increased	B
alkaline	I
phosphatase	I
,	O
hypocalcemia	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
hypophosphatemia	B
,	O
and	O
hyperbilirubinemia	B
.	O
	
Institute	O
hormone	O
replacement	O
therapy	O
as	O
needed	O
.	O
	
No	O
association	O
was	O
seen	O
between	O
antibody	O
development	O
and	O
development	O
of	O
adverse	O
events	O
.	O
	
5.3	O
Avoidance	O
of	O
Contact	O
Lenses	O
Patients	O
should	O
not	O
wear	O
contact	O
lenses	O
if	O
they	O
have	O
signs	O
or	O
symptoms	O
of	O
bacterial	O
conjunctivitis	O
or	O
during	O
the	O
course	O
of	O
therapy	O
with	O
Besivance	O
.	O
	
Most	O
of	O
the	O
adverse	O
reactions	O
appear	O
to	O
be	O
dose	O
related	O
(	O
especially	O
those	O
classified	O
as	O
psychiatric	O
and	O
nervous	O
system	O
symptoms	O
)	O
,	O
including	O
dizziness	B
,	O
somnolence	B
,	O
confusional	B
state	I
,	O
tremor	B
,	O
abnormal	B
coordination	I
,	O
memory	B
impairment	I
,	O
blurred	B
vision	I
,	O
gait	B
disturbance	I
,	O
aphasia	B
,	O
balance	B
disorder	I
,	O
constipation	B
,	O
dysuria	B
,	O
and	O
chromaturia	B
.	O
	
Prescribers	O
should	O
monitor	O
patients	O
for	O
somnolence	O
and	O
sedation	O
,	O
particularly	O
with	O
concomitant	O
use	O
of	O
other	O
central	O
nervous	O
system	O
depressants	O
.	O
	
When	O
prescribing	O
BREO	O
ELLIPTA	O
,	O
the	O
healthcare	O
provider	O
should	O
also	O
prescribe	O
an	O
inhaled	O
,	O
short-acting	O
beta2-agonist	O
and	O
instruct	O
the	O
patient	O
on	O
how	O
it	O
should	O
be	O
used	O
.	O
	
Other	O
severe	O
or	O
life-threatening	O
(	O
Grade	O
>	O
=3	O
)	O
cutaneous	B
reactions	I
,	O
including	O
dermatitis	B
exfoliative	I
,	O
rash	B
,	O
rash	B
erythematous	I
,	O
rash	B
generalized	I
,	O
rash	B
macular	I
,	O
rash	B
maculo-papular	I
,	O
rash	B
papular	I
,	O
rash	B
pruritic	I
,	O
exfoliative	B
rash	I
,	O
and	O
skin	B
disorder	I
,	O
have	O
been	O
reported	O
in	O
Zydelig-treated	O
patients	O
.	O
	
The	O
safety	O
of	O
ZYTIGA	O
re-treatment	O
of	O
patients	O
who	O
develop	O
AST	O
or	O
ALT	O
greater	O
than	O
or	O
equal	O
to	O
20*	O
ULN	O
and/or	O
bilirubin	O
greater	O
than	O
or	O
equal	O
to	O
10*	O
ULN	O
is	O
unknown	O
.	O
	
For	O
agranulocytosis	O
(	O
ANC	O
<	O
0.5	O
x	O
10	O
9	O
/L	O
)	O
:	O
Consider	O
hospitalization	O
and	O
other	O
management	O
as	O
clinically	O
appropriate	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
resulting	O
in	O
discontinuation	O
of	O
HALAVEN	O
was	O
peripheral	B
neuropathy	I
(	O
5	O
%	O
)	O
.	O
	
There	O
is	O
substantial	O
evidence	O
that	O
COCs	O
do	O
not	O
increase	O
the	O
incidence	O
of	O
breast	B
cancer	I
.	O
	
Patients	O
with	O
pneumonitis	O
thought	O
to	O
be	O
caused	O
by	O
Zydelig	O
have	O
been	O
treated	O
with	O
discontinuation	O
of	O
Zydelig	O
and	O
administration	O
of	O
corticosteroids	O
.	O
	
Measure	O
serum	O
transaminases	O
(	O
ALT	O
and	O
AST	O
)	O
and	O
bilirubin	O
levels	O
prior	O
to	O
starting	O
treatment	O
with	O
ZYTIGA	O
,	O
every	O
two	O
weeks	O
for	O
the	O
first	O
three	O
months	O
of	O
treatment	O
and	O
monthly	O
thereafter	O
.	O
	
Image	O
interpretation	O
should	O
be	O
performed	O
independently	O
of	O
the	O
patient	O
's	O
clinical	O
information	O
.	O
	
5.2	O
Deterioration	O
of	O
Disease	O
and	O
Acute	O
Episodes	O
BREO	O
ELLIPTA	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
during	O
rapidly	O
deteriorating	O
or	O
potentially	O
life-threatening	O
episodes	O
of	O
COPD	O
or	O
asthma	O
.	O
	
In	O
the	O
placebo-controlled	O
study	O
,	O
a	O
similar	O
rate	O
of	O
non-fatal	O
and	O
fatal	B
clinical	O
myocardial	B
infarction	I
was	O
reported	O
in	O
patients	O
who	O
received	O
PRADAXA	O
[	O
1	O
(	O
0.32	O
per	O
100	O
patient-years	O
)	O
]	O
and	O
in	O
those	O
who	O
received	O
placebo	O
[	O
1	O
(	O
0.34	O
per	O
100	O
patient-years	O
)	O
]	O
.	O
	
Management	O
of	O
hyperammonemia	O
due	O
to	O
NAGS	O
deficiency	O
should	O
be	O
done	O
in	O
coordination	O
with	O
medical	O
personnel	O
experienced	O
in	O
metabolic	O
disorders	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
The	O
following	O
events	O
have	O
been	O
identified	O
during	O
postmarketing	O
use	O
of	O
INTELENCE	O
(	O
r	O
)	O
.	O
	
As	O
with	O
all	O
antiepileptic	O
drugs	O
,	O
ONFI	O
should	O
be	O
withdrawn	O
gradually	O
to	O
minimize	O
the	O
risk	O
of	O
precipitating	O
seizures	O
,	O
seizure	O
exacerbation	O
,	O
or	O
status	O
epilepticus	O
.	O
	
Permanently	O
discontinue	O
ZYKADIA	O
for	O
life-threatening	O
bradycardia	O
if	O
no	O
contributing	O
concomitant	O
medication	O
is	O
identified	O
;	O
however	O
,	O
if	O
associated	O
with	O
a	O
concomitant	O
medication	O
known	O
to	O
cause	O
bradycardia	O
or	O
hypotension	O
,	O
withhold	O
ZYKADIA	O
until	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
and	O
if	O
the	O
concomitant	O
medication	O
can	O
be	O
adjusted	O
or	O
discontinued	O
,	O
resume	O
ZYKADIA	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
upon	O
recovery	O
to	O
asymptomatic	O
bradycardia	O
or	O
to	O
a	O
heart	O
rate	O
of	O
60	O
bpm	O
or	O
above	O
,	O
with	O
frequent	O
monitoring	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.7	O
Headache	O
If	O
a	O
woman	O
taking	O
Natazia	O
develops	O
new	O
headaches	B
that	I
are	I
recurrent	I
,	O
or	O
severe	O
,	O
evaluate	O
the	O
cause	O
and	O
discontinue	O
Natazia	O
if	O
indicated	O
.	O
	
Women	O
of	O
reproductive	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
pregnancy	O
when	O
taking	O
Ferriprox	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
and	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
5.6	O
Bradycardia	O
Bradycardia	B
can	O
occur	O
in	O
patients	O
receiving	O
ZYKADIA	O
.	O
	
Studies	O
have	O
shown	O
an	O
increased	O
risk	O
of	O
developing	O
hepatocellular	B
carcinoma	I
in	O
long-term	O
(	O
>	O
8	O
years	O
)	O
COC	O
users	O
.	O
	
The	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
is	O
highly	O
dependent	O
on	O
several	O
factors	O
,	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
(	O
5.12	O
)	O
*	O
Assess	O
for	O
decrease	O
in	O
bone	O
mineral	O
density	O
initially	O
and	O
periodically	O
thereafter	O
.	O
	
If	O
neurological	O
compromise	O
is	O
noted	O
,	O
urgent	O
treatment	O
is	O
necessary	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.Consider	O
the	O
benefits	O
and	O
risks	O
before	O
neuraxial	O
intervention	O
in	O
patients	O
anticoagulated	O
or	O
to	O
be	O
anticoagulated	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
One	O
treatment-related	O
death	B
associated	O
with	O
hepatic	B
failure	I
was	O
reported	O
in	O
the	O
trial	O
.	O
	
6.2	O
Clinical	O
Studies	O
Experience	O
in	O
Patients	O
with	O
Peyronie	O
's	O
Disease	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Four	O
(	O
0.62	O
%	O
)	O
Ferriprox-treated	O
subjects	O
discontinued	O
the	O
drug	O
due	O
to	O
increased	B
serum	I
ALT	I
levels	O
and	O
1	O
(	O
0.16	O
%	O
)	O
due	O
to	O
an	O
increase	B
in	I
both	I
ALT	I
.	O
	
5.8	O
Bleeding	O
Irregularities	O
Breakthrough	B
bleeding	I
and	O
spotting	B
sometimes	O
occur	O
in	O
patients	O
on	O
COCs	O
,	O
especially	O
during	O
the	O
first	O
three	O
months	O
of	O
use	O
.	O
	
The	O
more	O
severe	O
withdrawal	O
symptoms	O
have	O
usually	O
been	O
limited	O
to	O
patients	O
who	O
received	O
excessive	O
doses	O
over	O
an	O
extended	O
period	O
of	O
time	O
,	O
followed	O
by	O
an	O
abrupt	O
discontinuation	O
.	O
	
Immune	O
System	O
Disorders	O
:	O
Severe	O
hypersensitivity	B
reactions	O
including	O
DRESS	B
and	O
cases	O
of	O
hepatic	B
failure	I
have	O
been	O
reported	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
5.2	O
Therapeutic	O
Monitoring	O
Plasma	O
ammonia	O
levels	O
should	O
be	O
maintained	O
within	O
normal	O
range	O
for	O
age	O
via	O
individual	O
dose	O
adjustment	O
.	O
	
The	O
initiation	O
of	O
BREO	O
ELLIPTA	O
in	O
this	O
setting	O
is	O
not	O
appropriate	O
.	O
	
c	O
Confidence	O
interval	O
Patients	O
Major	O
bleeding	B
event	O
a	O
Clinically	O
relevant	O
non-major	O
bleeding	B
Any	O
bleeding	B
In	O
the	O
RE-SONATE	O
study	O
,	O
the	O
rate	O
of	O
any	O
gastrointestinal	B
bleeds	I
in	O
patients	O
receiving	O
PRADAXA	O
150	O
mg	O
was	O
0.7	O
%	O
(	O
0.3	O
%	O
on	O
placebo	O
)	O
.	O
	
A	O
treatment-related	O
death	B
from	O
ventricular	B
fibrillation	I
was	O
reported	O
in	O
another	O
monotherapy	O
clinical	O
trial	O
with	O
Beleodaq	O
.	O
	
(	O
5.14	O
)	O
*	O
Use	O
with	O
caution	O
in	O
patients	O
with	O
convulsive	O
disorders	O
,	O
thyrotoxicosis	O
,	O
diabetes	O
mellitus	O
,	O
and	O
ketoacidosis	O
.	O
	
Factors	O
that	O
can	O
increase	O
the	O
risk	O
of	O
developing	O
epidural	O
or	O
spinal	O
hematomas	O
in	O
these	O
patients	O
include	O
:	O
use	O
of	O
indwelling	O
epidural	O
catheters	O
concomitant	O
use	O
of	O
other	O
drugs	O
that	O
affect	O
hemostasis	O
,	O
such	O
as	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
platelet	O
inhibitors	O
,	O
other	O
anticoagulants	O
a	O
history	O
of	O
traumatic	O
or	O
repeated	O
epidural	O
or	O
spinal	O
punctures	O
a	O
history	O
of	O
spinal	O
deformity	O
or	O
spinal	O
surgery	O
optimal	O
timing	O
between	O
the	O
administration	O
of	O
PRADAXA	O
and	O
neuraxial	O
procedures	O
is	O
not	O
known	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
5.5	O
Physical	O
and	O
Psychological	O
Dependence	O
Patients	O
with	O
a	O
history	O
of	O
substance	O
abuse	O
should	O
be	O
under	O
careful	O
surveillance	O
when	O
receiving	O
ONFI	O
or	O
other	O
psychotropic	O
agents	O
because	O
of	O
the	O
predisposition	O
of	O
such	O
patients	O
to	O
habituation	O
and	O
dependence	O
[	O
see	O
Drug	O
Abuse	O
and	O
Dependence	O
(	O
9	O
)	O
]	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
genital	O
mycotic	O
infections	O
were	O
more	O
likely	O
to	O
develop	O
genital	B
mycotic	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Oral	O
contraceptive-related	O
cholestasis	B
may	O
occur	O
in	O
women	O
with	O
a	O
history	O
of	O
pregnancy-related	O
cholestasis	O
.	O
	
AdreView	O
safety	O
and	O
effectiveness	O
have	O
not	O
been	O
established	O
in	O
neonates	O
(	O
pediatric	O
patients	O
below	O
the	O
age	O
of	O
1	O
month	O
)	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
adverse	O
drug	O
reaction	O
,	O
withhold	O
ZYKADIA	O
until	O
hyperglycemia	O
is	O
adequately	O
controlled	O
,	O
then	O
resume	O
ZYKADIA	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
reported	O
in	O
patients	O
receiving	O
HALAVEN	O
were	O
neutropenia	B
,	O
anemia	B
,	O
asthenia/fatigue	O
,	O
alopecia	B
,	O
peripheral	B
neuropathy	I
,	O
nausea	B
,	O
and	O
constipation	B
.	O
	
The	O
other	O
most	O
common	O
reactions	O
were	O
flushing	B
(	O
0.3	O
%	O
)	O
and	O
headache	B
(	O
0.4	O
%	O
)	O
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
drug	O
reactions	O
(	O
>	O
=	O
25	O
%	O
)	O
in	O
the	O
XIAFLEX	O
clinical	O
trials	O
in	O
patients	O
with	O
Dupuytren	O
's	O
contracture	O
included	O
edema	B
peripheral	I
(	O
mostly	O
swelling	B
of	I
the	I
injected	I
hand	I
)	O
,	O
contusion	B
,	O
injection	B
site	I
hemorrhage	I
,	O
injection	B
site	I
reaction	I
,	O
and	O
pain	B
in	I
the	I
treated	I
extremity	I
.	O
	
Peripheral	B
neuropathy	I
was	O
the	O
most	O
common	O
toxicity	O
leading	O
to	O
discontinuation	O
of	O
HALAVEN	O
(	O
5	O
%	O
of	O
patients	O
;	O
24/503	O
)	O
.	O
	
Discontinue	O
Zydelig	O
permanently	O
in	O
patients	O
who	O
experience	O
intestinal	O
perforation	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
(	O
5.2	O
)	O
.	O
	
Table	O
4	O
Bleeding	B
Events	O
in	O
RE-MEDY	O
Treated	O
Patients	O
Note	O
:	O
MBE	B
can	O
belong	O
to	O
more	O
than	O
one	O
criterion	O
.	O
	
Forty-four	O
(	O
70	O
%	O
)	O
patients	O
with	O
moderate	O
dermatitis	B
were	O
reported	O
to	O
have	O
complete	O
resolution	O
,	O
7	O
(	O
11	O
%	O
)	O
improved	O
to	O
mild	O
(	O
Grade	O
1	O
)	O
severity	O
,	O
and	O
12	O
(	O
19	O
%	O
)	O
had	O
no	O
reported	O
improvement	O
.	O
	
Promptly	O
measure	O
serum	O
total	O
bilirubin	O
,	O
AST	O
,	O
and	O
ALT	O
if	O
clinical	O
symptoms	O
or	O
signs	O
suggestive	O
of	O
hepatotoxicity	O
develop	O
.	O
	
Patients	O
taking	O
Zydelig	O
who	O
present	O
with	O
pulmonary	O
symptoms	O
such	O
as	O
cough	O
,	O
dyspnea	O
,	O
hypoxia	O
,	O
interstitial	O
infiltrates	O
on	O
a	O
radiologic	O
exam	O
,	O
or	O
a	O
decline	O
by	O
more	O
than	O
5	O
%	O
in	O
oxygen	O
saturation	O
should	O
be	O
evaluated	O
for	O
pneumonitis	O
.	O
	
Permanently	O
discontinue	O
ZYKADIA	O
in	O
patients	O
who	O
develop	O
QTc	O
interval	O
prolongation	O
in	O
combination	O
with	O
Torsade	O
de	O
pointes	O
or	O
polymorphic	O
ventricular	O
tachycardia	O
or	O
signs/symptoms	O
of	O
serious	O
arrhythmia	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
Study	O
3	O
was	O
an	O
open-label	O
,	O
noncomparative	O
study	O
with	O
SIRTURO	O
administered	O
as	O
part	O
of	O
an	O
individualized	O
pulmonary	O
MDR-TB	O
treatment	O
regimen	O
in	O
previously	O
treated	O
patients	O
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
.	O
]	O
	
For	O
patients	O
whose	O
sera	O
tested	O
positive	O
in	O
the	O
screening	O
immunoassay	O
,	O
an	O
in	O
vitro	O
biological	O
assay	O
was	O
performed	O
to	O
detect	O
neutralizing	O
antibodies	O
.	O
	
Among	O
the	O
28	O
patients	O
with	O
Grade	O
2	O
enterocolitis	B
,	O
79	O
%	O
experienced	O
complete	O
resolution	O
,	O
11	O
%	O
improved	O
,	O
and	O
11	O
%	O
did	O
not	O
improve	O
.	O
	
The	O
mean	O
age	O
at	O
study	O
entry	O
was	O
38	O
years	O
(	O
range	O
18	O
to	O
83	O
years	O
)	O
,	O
64	O
%	O
were	O
female	O
,	O
and	O
95	O
%	O
were	O
white	O
.	O
	
In	O
the	O
short-term	O
trials	O
,	O
FANAPT	O
was	O
associated	O
with	O
modest	O
levels	O
of	O
prolactin	B
elevation	I
compared	O
to	O
greater	O
prolactin	B
elevations	I
observed	O
with	O
some	O
other	O
antipsychotic	O
agents	O
.	O
	
Hypoglycemia	B
was	O
more	O
frequent	O
when	O
FARXIGA	O
was	O
added	O
to	O
sulfonylurea	O
or	O
insulin	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Possible	O
risk	O
factors	O
for	O
leukopenia/neutropenia	O
include	O
preexisting	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
and	O
history	O
of	O
drug	O
induced	O
leukopenia/neutropenia	O
.	O
	
In	O
the	O
controlled	O
rheumatoid	O
arthritis	O
studies	O
,	O
there	O
were	O
more	O
new	O
cases	O
of	O
serious	O
infection	B
adverse	O
reactions	O
in	O
the	O
CIMZIA	O
treatment	O
groups	O
,	O
compared	O
to	O
the	O
placebo	O
groups	O
(	O
0.06	O
per	O
patient-year	O
for	O
all	O
CIMZIA	O
doses	O
vs.	O
0.02	O
per	O
patient-year	O
for	O
placebo	O
)	O
.	O
	
Adverse	O
Reactions	O
Incidence	O
in	O
Placebo-Controlled	O
Adjunctive	O
Trials	O
in	O
Adult	O
Patients	O
with	O
Partial-Onset	O
Seizures	O
(	O
Adverse	O
reactions	O
in	O
at	O
least	O
2	O
%	O
of	O
patients	O
treated	O
with	O
POTIGA	O
in	O
any	O
treatment	O
group	O
and	O
numerically	O
more	O
frequent	O
than	O
in	O
the	O
placebo	O
group	O
.	O
)	O
	
In	O
Studies	O
1	O
and	O
2	O
the	O
NULOJIX	O
regimen	O
is	O
identical	O
to	O
the	O
recommended	O
regimen	O
,	O
but	O
is	O
slightly	O
different	O
in	O
Study	O
3	O
.	O
	
The	O
detection	O
of	O
anti-blinatumomab	O
antibody	O
formation	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
Across	O
all	O
YERVOY-treated	O
patients	O
(	O
n=511	O
)	O
,	O
5	O
(	O
1	O
%	O
)	O
patients	O
developed	O
intestinal	B
perforation	I
,	O
4	O
(	O
0.8	O
%	O
)	O
patients	O
died	B
as	O
a	O
result	O
of	O
complications	O
,	O
and	O
26	O
(	O
5	O
%	O
)	O
patients	O
were	O
hospitalized	O
for	O
severe	O
enterocolitis	B
.	O
	
Withhold	O
COMETRIQ	O
in	O
patients	O
with	O
dehiscence	O
or	O
wound	O
healing	O
complications	O
requiring	O
medical	O
intervention	O
.	O
	
At	O
baseline	O
,	O
5.2	O
%	O
of	O
the	O
population	O
reported	O
retinopathy	O
.	O
	
The	O
total	O
number	O
of	O
NULOJIX	O
patients	O
from	O
these	O
three	O
studies	O
(	O
949	O
)	O
was	O
compared	O
to	O
the	O
pooled	O
cyclosporine	O
control	O
groups	O
from	O
all	O
three	O
studies	O
(	O
476	O
patients	O
)	O
.	O
	
Further	O
information	O
is	O
available	O
at	O
www.XIAFLEXREMS.com	O
or	O
1-877-313-1235	O
.	O
	
5.11	O
Interference	O
with	O
Laboratory	O
Tests	O
The	O
use	O
of	O
COCs	O
may	O
change	O
the	O
results	O
of	O
some	O
laboratory	O
tests	O
,	O
such	O
as	O
coagulation	O
factors	O
,	O
lipids	O
,	O
glucose	O
tolerance	O
,	O
and	O
binding	O
proteins	O
.	O
	
(	O
5.6	O
)	O
*	O
Macrovascular	O
outcomes	O
:	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
FARXIGA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
trials	O
,	O
somnolence	B
(	O
including	O
sedation	B
)	O
was	O
reported	O
in	O
11.9	O
%	O
(	O
104/874	O
)	O
of	O
adult	O
patients	O
treated	O
with	O
FANAPT	O
at	O
doses	O
of	O
10	O
mg/day	O
or	O
greater	O
versus	O
5.3	O
%	O
(	O
31/587	O
)	O
treated	O
with	O
placebo	O
.	O
	
Malignancies	O
In	O
clinical	O
studies	O
of	O
CIMZIA	O
,	O
the	O
overall	O
incidence	O
rate	O
of	O
malignancies	B
was	O
similar	O
for	O
CIMZIA-treated	O
and	O
control	O
patients	O
.	O
	
The	O
following	O
adverse	O
events	O
were	O
reported	O
in	O
Crohn	O
's	O
disease	O
patients	O
who	O
were	O
antibody-positive	O
(	O
N	O
=	O
100	O
)	O
at	O
an	O
incidence	O
at	O
least	O
3	O
%	O
higher	O
compared	O
to	O
antibody-negative	O
patients	O
(	O
N	O
=	O
1,242	O
)	O
:	O
abdominal	B
pain	I
,	O
arthralgia	B
,	O
edema	B
peripheral	I
,	O
erythema	B
nodosum	I
,	O
injection	B
site	I
erythema	I
,	O
injection	B
site	I
pain	I
,	O
pain	B
in	I
extremity	I
,	O
and	O
upper	B
respiratory	I
tract	I
infection	I
.	O
	
Anaphylaxis	B
was	O
reported	O
in	O
a	O
post-marketing	O
clinical	O
trial	O
(	O
Study	O
3	O
)	O
in	O
one	O
patient	O
who	O
had	O
previous	O
exposure	O
to	O
XIAFLEX	O
for	O
the	O
treatment	O
of	O
Dupuytren	O
's	O
contracture	O
.	O
	
ONJ	B
can	O
manifest	O
as	O
jaw	B
pain	I
,	O
osteomyelitis	B
,	O
osteitis	B
,	O
bone	B
erosion	I
,	O
periodontal	B
infection	I
,	O
toothache	B
,	O
gingival	B
ulceration	I
,	O
persistent	B
jaw	I
pain	I
or	O
slow	B
healing	I
of	I
the	I
mouth	I
or	I
jaw	I
after	I
dental	I
surgery	I
.	O
	
(	O
5.5	O
)	O
*	O
Macrovascular	O
outcomes	O
:	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
NESINA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Adverse	O
reactions	O
reported	O
as	O
reasons	O
for	O
discontinuation	O
of	O
treatment	O
In	O
the	O
pre-marketing	O
pooled	O
8-week	O
placebo-controlled	O
studies	O
in	O
patients	O
with	O
MDD	O
,	O
1,834	O
patients	O
were	O
exposed	O
to	O
PRISTIQ	O
(	O
50	O
to	O
400	O
mg	O
)	O
.	O
	
Non-hematologic	O
adverse	O
reactions	O
(	O
any	O
grade	O
)	O
in	O
the	O
TREANDA	O
group	O
that	O
occurred	O
with	O
a	O
frequency	O
greater	O
than	O
15	O
%	O
were	O
pyrexia	B
(	O
24	O
%	O
)	O
,	O
nausea	B
(	O
20	O
%	O
)	O
,	O
and	O
vomiting	B
(	O
16	O
%	O
)	O
.	O
	
5.6	O
Neurological	O
Adverse	O
Reactions	O
Dizziness	O
and	O
Disturbance	O
in	O
Gait	O
and	O
Coordination	O
APTIOM	O
causes	O
dose-related	O
increases	O
in	O
adverse	O
reactions	O
related	O
to	O
dizziness	B
and	O
disturbance	B
in	I
gait	I
(	O
dizziness	B
,	O
ataxia	B
,	O
vertigo	B
,	O
balance	B
disorder	I
,	O
gait	B
disturbance	I
,	O
nystagmus	B
,	O
and	O
abnormal	B
coordination	I
)	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Monitor	O
with	O
liver	O
function	O
tests	O
including	O
ALT	O
and	O
total	O
bilirubin	O
every	O
2	O
weeks	O
during	O
the	O
first	O
2	O
months	O
of	O
treatment	O
,	O
then	O
once	O
a	O
month	O
and	O
as	O
clinically	O
indicated	O
,	O
with	O
more	O
frequent	O
repeat	O
testing	O
for	O
increased	O
liver	O
transaminases	O
,	O
alkaline	O
phosphatase	O
,	O
or	O
total	O
bilirubin	O
in	O
patients	O
who	O
develop	O
transaminase	O
elevations	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
To	O
minimize	O
the	O
risk	O
of	O
contamination	O
,	O
do	O
not	O
touch	O
dropper	O
tip	O
to	O
any	O
surface	O
.	O
	
5.4	O
Anaphylactic	O
Reactions	O
and	O
Angioedema	O
Rare	O
cases	O
of	O
anaphylaxis	B
and	O
angioedema	B
have	O
been	O
reported	O
in	O
patients	O
taking	O
APTIOM	O
.	O
	
Across	O
clinical	O
trials	O
,	O
bradycardia	B
occurred	O
in	O
205	O
(	O
12.3	O
%	O
)	O
of	O
1669	O
patients	O
treated	O
with	O
XALKORI	O
.	O
	
Patients	O
eligible	O
for	O
Trial	O
6	O
were	O
those	O
with	O
the	O
G551D	O
,	O
G1244E	O
,	O
G1349D	O
,	O
G178R	O
,	O
G551S	O
,	O
G970R	O
,	O
S1251N	O
,	O
S1255P	O
,	O
S549N	O
,	O
or	O
S549R	O
mutation	O
in	O
the	O
CFTR	O
gene	O
.	O
	
Measure	O
liver	O
tests	O
promptly	O
in	O
patients	O
who	O
report	O
symptoms	O
that	O
may	O
indicate	O
liver	O
injury	O
,	O
including	O
fatigue	O
,	O
anorexia	O
,	O
right	O
upper	O
abdominal	O
discomfort	O
,	O
dark	O
urine	O
or	O
jaundice	O
.	O
	
Risk	O
factors	O
for	O
development	O
of	O
serious	O
dermatologic	B
reactions	I
with	O
APTIOM	O
use	O
have	O
not	O
been	O
identified	O
.	O
	
5.4	O
Flushing	O
TECFIDERA	O
may	O
cause	O
flushing	B
(	O
e.g.	O
,	O
warmth	B
,	O
redness	B
,	O
itching	B
,	O
and/or	O
burning	B
sensation	I
)	O
.	O
	
Before	O
initiating	O
treatment	O
with	O
TECFIDERA	O
,	O
a	O
CBC	O
including	O
lymphocyte	O
count	O
should	O
be	O
obtained	O
.	O
	
5.1	O
Hemorrhage	O
Fatal	B
bleeding	B
events	I
have	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
5.3	O
Spinal	O
or	O
Cervical	O
Cord	O
Compression	O
Spinal	O
or	O
cervical	O
cord	O
compression	O
(	O
SCC	O
)	O
is	O
a	O
known	O
and	O
serious	O
complication	O
of	O
MPS	O
IVA	O
and	O
may	O
occur	O
as	O
part	O
of	O
the	O
natural	O
history	O
of	O
the	O
disease	O
.	O
	
Monitor	O
and	O
manage	O
patients	O
using	O
standards	O
of	O
care	O
.	O
	
If	O
paradoxical	O
bronchospasm	O
occurs	O
,	O
ARCAPTA	O
NEOHALER	O
should	O
be	O
discontinued	O
immediately	O
and	O
alternative	O
therapy	O
instituted	O
.	O
	
Reduction	O
of	O
Risk	O
of	O
Stroke	O
and	O
Systemic	O
Embolism	O
in	O
Non-valvular	O
Atrial	O
Fibrillation	O
The	O
RE-LY	O
(	O
Randomized	O
Evaluation	O
of	O
Long-term	O
Anticoagulant	O
Therapy	O
)	O
study	O
provided	O
safety	O
information	O
on	O
the	O
use	O
of	O
two	O
doses	O
of	O
PRADAXA	O
and	O
warfarin	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
The	O
mean	O
duration	O
of	O
exposure	O
to	O
INVOKANA	O
was	O
38	O
weeks	O
with	O
1832	O
individuals	O
exposed	O
to	O
INVOKANA	O
for	O
greater	O
than	O
50	O
weeks	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
known	O
cardiovascular	O
or	O
cerebrovascular	O
disease	O
,	O
and	O
in	O
antipsychotic-naive	O
patients	O
.	O
	
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
(	O
e.g.	O
,	O
numbness	O
or	O
weakness	O
of	O
the	O
legs	O
,	O
bowel	O
,	O
or	O
bladder	O
dysfunction	O
)	O
.	O
	
Local	B
cystic	I
invasion	I
beyond	I
the	I
kidney	I
occurred	O
,	O
in	O
some	O
cases	O
with	O
imaging	O
characteristics	O
suggestive	O
of	O
abscess	B
formation	O
.	O
	
All	O
men	O
were	O
instructed	O
to	O
take	O
at	O
least	O
1000	O
mg	O
of	O
calcium	O
and	O
800	O
IU	O
of	O
vitamin	O
D	O
supplementation	O
per	O
day	O
.	O
	
These	O
application	B
site	I
reactions	I
.	O
	
5.7	O
Suicidal	O
Behavior	O
and	O
Ideation	O
Antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
including	O
POTIGA	O
,	O
increase	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
patients	O
taking	O
these	O
drugs	O
for	O
any	O
indication	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
Therapeutic	O
Monitoring	O
:	O
Plasma	O
ammonia	O
levels	O
should	O
be	O
maintained	O
within	O
normal	O
range	O
for	O
age	O
via	O
individual	O
dose	O
adjustment	O
.	O
	
SAPHRIS	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
seeBoxed	O
Warningand	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
6.3	O
Immunogenicity	O
Denosumab	O
is	O
a	O
human	O
monoclonal	O
antibody	O
.	O
	
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Peripheral	O
T-Cell	O
Lymphoma	O
The	O
safety	O
of	O
Beleodaq	O
was	O
evaluated	O
in	O
129	O
patients	O
with	O
relapsed	O
or	O
refractory	O
PTCL	O
in	O
the	O
single	O
arm	O
clinical	O
trial	O
in	O
which	O
patients	O
were	O
administered	O
Beleodaq	O
at	O
a	O
dosage	O
of	O
1,000	O
mg/m2	O
administered	O
over	O
30	O
minutes	O
by	O
IV	O
infusion	O
once	O
daily	O
on	O
Days	O
1-5	O
of	O
a	O
21-day	O
cycle	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Discontinue	O
SIRTURO	O
and	O
all	O
other	O
QT	O
prolonging	O
drugs	O
if	O
the	O
patient	O
develops	O
:	O
*	O
Clinically	O
significant	O
ventricular	O
arrhythmia	O
*	O
A	O
QTcF	O
interval	O
of	O
greater	O
than	O
500	O
ms	O
(	O
confirmed	O
by	O
repeat	O
ECG	O
)	O
If	O
syncope	O
occurs	O
,	O
obtain	O
an	O
ECG	O
to	O
detect	O
QT	O
prolongation	O
.	O
	
Because	O
most	O
trials	O
included	O
in	O
the	O
analysis	O
did	O
not	O
extend	O
beyond	O
24	O
weeks	O
,	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
or	O
behavior	O
beyond	O
24	O
weeks	O
could	O
not	O
be	O
assessed	O
.	O
	
5.5	O
Drug	O
Reaction	O
With	O
Eosinophilia	O
and	O
Systemic	O
Symptoms	O
(	O
DRESS	O
)	O
/Multiorgan	O
Hypersensitivity	O
Drug	B
Reaction	I
with	I
Eosinophilia	I
and	I
Systemic	I
Symptoms	I
(	O
DRESS	B
)	O
,	O
also	O
known	O
as	O
multiorgan	B
hypersensitivity	I
,	O
has	O
been	O
reported	O
in	O
patients	O
taking	O
antiepileptic	O
drugs	O
,	O
including	O
gabapentin	O
.	O
	
5.4	O
Thrombosis	O
and	O
Hemorrhage	O
Serious	O
thrombotic	B
events	I
,	O
including	O
sagittal	B
sinus	I
thrombosis	I
and	O
pulmonary	B
embolism	I
have	O
been	O
reported	O
with	O
both	O
E.	O
coli	O
and	O
Erwinia	O
-derived	O
L-asparaginase	O
therapy	O
.	O
	
In	O
a	O
controlled	O
clinical	O
study	O
with	O
INLYTA	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
RCC	O
,	O
Grade	O
3/4	O
arterial	B
thromboembolic	I
events	I
were	O
reported	O
in	O
4/359	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
4/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
(	O
2	O
,	O
5.1	O
)	O
*	O
Infections	B
:	O
GILENYA	O
may	O
increase	O
the	O
risk	O
of	O
infections	B
.	O
	
Study	O
2	O
:	O
Chemotherapy-naive	O
Metastatic	O
Castration-Resistant	O
Prostate	O
Cancer	O
Study	O
2	O
enrolled	O
1717	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
not	O
received	O
prior	O
cytotoxic	O
chemotherapy	O
,	O
of	O
whom	O
1715	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
drug	O
.	O
	
The	O
mean	O
change	O
from	O
baseline	O
for	O
the	O
all-SAPHRIS	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
treated	O
group	O
was	O
comparable	O
to	O
placebo	O
in	O
each	O
of	O
the	O
rating	O
scale	O
scores	O
.	O
	
During	O
the	O
clinical	O
studies	O
,	O
two	O
patients	O
(	O
<	O
1	O
%	O
)	O
experienced	O
adverse	O
reactions	O
leading	O
to	O
withdrawal	O
.	O
	
Other	O
accompanying	O
reactions	O
included	O
chest	B
discomfort	I
,	O
wheezing	B
,	O
tachypnea	B
,	O
cyanosis	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
convulsions	B
,	O
pruritus	B
,	O
rash	B
,	O
hyperhidrosis	B
,	O
nausea	B
,	O
dizziness	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
flushing/feeling	O
hot	B
,	O
erythema	B
,	O
pyrexia	B
,	O
pallor	B
,	O
peripheral	B
coldness	I
,	O
restlessness	B
,	O
nervousness	B
,	O
headache	B
,	O
back	B
pain	I
,	O
and	O
paresthesia	B
.	O
	
Keep	O
a	O
list	O
of	O
your	O
medicines	O
and	O
show	O
it	O
to	O
your	O
healthcare	O
provider	O
and	O
pharmacist	O
when	O
you	O
get	O
a	O
new	O
medicine	O
.	O
	
The	O
most	O
common	O
cause	O
of	O
discontinuation	O
due	O
to	O
an	O
adverse	O
event	O
was	O
acute	B
renal	I
failure	I
(	O
2	O
%	O
)	O
.	O
	
*	O
Risk	O
of	O
Acute	B
Cardiorespiratory	I
Failure	I
:	O
Patients	O
with	O
compromised	O
cardiac	O
or	O
respiratory	O
function	O
may	O
be	O
at	O
risk	O
of	O
acute	B
cardiorespiratory	I
failure	I
.	O
	
It	O
is	O
not	O
known	O
if	O
DUAVEE	O
passes	O
into	O
your	O
breast	O
milk	O
.	O
	
In	O
clinical	O
trials	O
,	O
no	O
serious	O
adverse	O
reactions	O
were	O
reported	O
.	O
	
There	O
were	O
808	O
subjects	O
included	O
in	O
the	O
efficacy	O
and	O
safety	O
analyses	O
.	O
	
Other	O
Findings	O
:	O
Oral	B
hypoesthesia	I
and/or	O
oral	B
paresthesia	I
may	O
occur	O
directly	O
after	O
administration	O
of	O
SAPHRIS	O
and	O
usually	O
resolves	O
within	O
1	O
hour	O
.	O
	
It	O
is	O
important	O
to	O
note	O
that	O
early	O
manifestations	O
of	O
hypersensitivity	B
,	O
such	O
as	O
fever	B
or	O
lymphadenopathy	B
,	O
may	O
be	O
present	O
even	O
though	O
rash	B
is	O
not	O
evident	O
.	O
	
System	O
Organ	O
Class/Preferred	O
Term	O
Placebo	O
N=166	O
%	O
SAPHRIS	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily*	O
N=158	O
%	O
Gastrointestinal	O
disorders	O
Dyspepsia	B
2	O
3	O
Oral	B
hypoesthesia	I
0	O
5	O
General	O
disorders	O
Fatigue	B
2	O
4	O
Edema	B
peripheral	I
<	O
1	O
3	O
Investigations	O
Increased	B
weight	I
0	O
3	O
Nervous	O
system	O
disorders	O
Dizziness	B
2	O
4	O
Other	O
extrapyramidal	B
symptoms	I
(	O
excluding	O
akathisia	B
)	O
5	O
6	O
Somnolence	B
?	O
	
Correct	O
volume	O
or	O
salt	O
depletion	O
prior	O
to	O
administration	O
of	O
Edarbi	O
,	O
or	O
start	O
treatment	O
at	O
40	O
mg	O
.	O
	
Fatal	B
hemorrhage	B
was	O
reported	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
(	O
gastric	B
hemorrhage	I
)	O
and	O
3/355	O
patients	O
(	O
1	O
%	O
)	O
receiving	O
sorafenib	O
.	O
	
EXCERPT	O
:	O
*	O
Postmenopausal	O
osteoporosis	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
5	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
were	O
:	O
back	B
pain	I
,	O
pain	B
in	I
extremity	I
,	O
hypercholesterolemia	B
,	O
musculoskeletal	B
pain	I
,	O
and	O
cystitis	B
.	O
	
Laboratory	O
Abnormalities	O
Table	O
6	O
describes	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
reported	O
at	O
a	O
rate	O
of	O
>	O
=10	O
%	O
in	O
the	O
KRd	O
arm	O
for	O
patients	O
who	O
received	O
combination	O
therapy	O
.	O
	
It	O
is	O
recommended	O
that	O
therapeutic	O
infectious	O
agents	O
not	O
be	O
given	O
concurrently	O
with	O
SIMPONI	O
ARIA	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Routine	O
monitoring	O
of	O
estimated	O
creatinine	O
clearance	O
,	O
urine	O
glucose	O
,	O
and	O
urine	O
protein	O
should	O
be	O
performed	O
during	O
STRIBILD	O
therapy	O
in	O
all	O
patients	O
.	O
	
(	O
5.10	O
)	O
*	O
Use	O
with	O
caution	O
in	O
patients	O
with	O
cardiovascular	O
disorders	O
because	O
of	O
beta-adrenergic	O
stimulation	O
.	O
	
(	O
5.2	O
)	O
*	O
Monitor	O
for	O
worsening	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
.	O
	
The	O
adverse	O
reactions	O
below	O
reflect	O
exposure	O
to	O
XEOMIN	O
with	O
glabellar	O
lines	O
in	O
placebo-controlled	O
studies	O
.	O
	
(	O
5.8	O
)	O
*	O
Blood	O
pressure	O
(	O
BP	O
)	O
:	O
Monitor	O
BP	O
during	O
treatment	O
.	O
	
The	O
GBCA-associated	O
NSF	B
risk	O
appears	O
highest	O
for	O
patients	O
with	O
chronic	O
,	O
severe	O
kidney	O
disease	O
(	O
GFR	O
<	O
30	O
mL/min/1.73m	O
2	O
)	O
as	O
well	O
as	O
patients	O
with	O
acute	O
kidney	O
injury	O
.	O
	
Infections	O
In	O
Study	O
1	O
,	O
1	O
%	O
of	O
patients	O
treated	O
with	O
XTANDI	O
compared	O
to	O
0.3	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
died	B
from	O
infections	B
or	O
sepsis	B
.	O
	
More	O
than	O
two-thirds	O
of	O
patients	O
were	O
from	O
Asia	O
(	O
GILOTRIF	O
70	O
%	O
;	O
pemetrexed/cisplatin	O
72	O
%	O
)	O
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
,	O
including	O
Anaphylaxis	O
Acute	B
hypersensitivity	I
reactions	I
,	O
including	O
anaphylaxis	B
and	O
death	B
,	O
have	O
been	O
reported	O
in	O
association	O
with	O
BENLYSTA	O
.	O
	
Monitoring	O
for	O
proteinuria	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
is	O
recommended	O
.	O
	
Dizziness	B
was	O
reported	O
in	O
13	O
%	O
of	O
patients	O
receiving	O
600	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
4	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Testing	O
was	O
performed	O
in	O
patients	O
who	O
experienced	O
moderate	O
to	O
severe	O
or	O
hypersensitivity	B
reactions	I
,	O
for	O
which	O
mast-cell	O
activation	O
was	O
suspected	O
.	O
	
The	O
median	O
duration	O
of	O
exposure	O
to	O
ZYKADIA	O
was	O
6	O
months	O
.	O
	
This	O
finding	O
with	O
salmeterol	O
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
event	O
in	O
patients	O
treated	O
with	O
Toviaz	O
was	O
dry	B
mouth	I
.	O
	
Fatigue/asthenia	O
was	O
reported	O
in	O
6	O
%	O
of	O
patients	O
treated	O
with	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
1	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
*	O
Myelosuppression	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Anaphylaxis	B
and	O
Infusion	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Tumor	B
Lysis	I
Syndrome	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Skin	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Other	O
Malignancies	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Extravasation	B
injury	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
*	O
*	O
Most	O
common	O
non-hematologic	O
adverse	O
reactions	O
for	O
CLL	O
(	O
frequency	O
>	O
=	O
15	O
%	O
)	O
are	O
pyrexia	B
,	O
nausea	B
,	O
and	O
vomiting	B
.	O
	
5.5	O
Infusion	O
Reactions	O
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
adverse	B
events	I
associated	I
with	I
the	I
infusion	I
(	O
occurring	O
on	O
the	O
same	O
day	O
of	O
the	O
infusion	O
)	O
were	O
reported	O
in	O
17	O
%	O
(	O
251/1,458	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
15	O
%	O
(	O
99/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
all	O
grades	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
are	O
neutropenia	B
,	O
anemia	B
,	O
leukopenia	B
,	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
asthenia	B
,	O
abdominal	B
pain	I
,	O
hematuria	B
,	O
back	B
pain	I
,	O
anorexia	B
,	O
peripheral	B
neuropathy	I
,	O
pyrexia	B
,	O
dyspnea	B
,	O
dysgeusia	B
,	O
cough	B
,	O
arthralgia	B
,	O
and	O
alopecia	B
.	O
	
Patients	O
should	O
be	O
monitored	O
for	O
signs	O
of	O
anticholinergic	O
CNS	O
effects	O
,	O
particularly	O
after	O
beginning	O
treatment	O
or	O
increasing	O
the	O
dose	O
.	O
	
5.2	O
Weight	O
Decrease	O
During	O
the	O
controlled	O
period	O
of	O
the	O
studies	O
in	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
,	O
weight	B
decrease	I
between	O
5	O
%	O
-10	O
%	O
of	O
body	O
weight	O
was	O
reported	O
in	O
10	O
%	O
(	O
49/497	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
compared	O
to	O
3.3	O
%	O
(	O
16/495	O
)	O
treated	O
with	O
placebo	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
rates	O
of	O
treatment-emergent	O
adverse	O
events	O
resulting	O
in	O
permanent	O
discontinuation	O
were	O
20	O
%	O
and	O
6	O
%	O
for	O
the	O
AFINITOR	O
and	O
placebo	O
treatment	O
groups	O
,	O
respectively	O
.	O
	
Treatment-experienced	O
,	O
Integrase	O
Strand	O
Transfer	O
Inhibitor-naive	O
Subjects	O
:	O
In	O
an	O
international	O
,	O
multicenter	O
,	O
double-blind	O
trial	O
(	O
ING111762	O
,	O
SAILING	O
)	O
,	O
719	O
HIV-1-infected	O
,	O
antiretroviral	O
treatment-experienced	O
adults	O
were	O
randomized	O
and	O
received	O
either	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
or	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
with	O
investigator-selected	O
background	O
regimen	O
consisting	O
of	O
up	O
to	O
2	O
agents	O
,	O
including	O
at	O
least	O
one	O
fully	O
active	O
agent	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
LACTIC	B
ACIDOSIS/SEVERE	O
HEPATOMEGALY	B
WITH	O
STEATOSIS	B
and	O
POST	O
TREATMENT	O
ACUTE	B
EXACERBATION	I
OF	I
HEPATITIS	I
B	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
(	O
5.2	O
,	O
7.2	O
,	O
12.3	O
)	O
*	O
Cataracts	B
:	O
Non-congenital	B
lens	I
opacities	I
have	O
been	O
reported	O
in	O
pediatric	O
patients	O
treated	O
with	O
KALYDECO	O
.	O
	
Institute	O
medical	O
intervention	O
as	O
appropriate	O
for	O
management	O
of	O
severe	O
neuropathy	O
.	O
	
Common	O
and	O
Drug-Related	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
Based	O
on	O
the	O
pooled	O
data	O
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
,	O
the	O
following	O
adverse	O
reactions	O
occurred	O
in	O
>	O
=5	O
%	O
incidence	O
in	O
the	O
patients	O
treated	O
with	O
FANAPT	O
and	O
at	O
least	O
twice	O
the	O
placebo	O
rate	O
for	O
at	O
least	O
1	O
dose	O
:	O
dizziness	B
,	O
dry	B
mouth	I
,	O
fatigue	B
,	O
nasal	B
congestion	I
,	O
somnolence	B
,	O
tachycardia	B
,	O
orthostatic	B
hypotension	I
,	O
and	O
weight	B
increased	I
.	O
	
In	O
patients	O
with	O
a	O
history	O
of	O
transaminase	O
elevations	O
,	O
more	O
frequent	O
monitoring	O
of	O
liver	O
function	O
tests	O
should	O
be	O
considered	O
.	O
	
For	O
mild	O
to	O
moderate	O
dermatitis	O
,	O
such	O
as	O
localized	O
rash	O
and	O
pruritus	O
,	O
treat	O
symptomatically	O
.	O
	
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Pruritus	B
.	O
	
ENTEREG	O
REMS	O
Program	O
ENTEREG	O
is	O
available	O
only	O
through	O
a	O
program	O
called	O
the	O
ENTEREG	O
Access	O
Support	O
and	O
Education	O
(	O
E.A.S.E	O
.	O
)	O
	
(	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
worsening	B
renal	I
impairment	I
:	O
Can	O
include	O
acute	B
renal	I
failure	I
and	O
Fanconi	B
syndrome	I
.	O
	
Advise	O
females	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
and	O
to	O
use	O
highly	O
effective	O
contraception	O
.	O
	
Serious	O
infections	B
occurred	O
in	O
6.0	O
%	O
of	O
patients	O
treated	O
with	O
BENLYSTA	O
and	O
in	O
5.2	O
%	O
of	O
patients	O
who	O
received	O
placebo	O
.	O
	
Table	O
2	O
compares	O
the	O
incidence	O
of	O
treatment-emergent	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
10	O
mg	O
daily	O
versus	O
placebo	O
.	O
	
(	O
5.2	O
)	O
*	O
Continue	O
therapy	O
with	O
leucovorin	O
until	O
the	O
methotrexate	O
concentration	O
has	O
been	O
maintained	O
below	O
the	O
leucovorin	O
treatment	O
threshold	O
for	O
a	O
minimum	O
of	O
3	O
days	O
.	O
	
(	O
6.1	O
)	O
*	O
Asthma	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
)	O
are	O
nasopharyngitis	B
,	O
oral	B
candidiasis	I
,	O
headache	B
,	O
influenza	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
bronchitis	B
,	O
sinusitis	B
,	O
oropharyngeal	B
pain	I
,	O
dysphonia	B
,	O
and	O
cough	B
.	O
	
Patient	O
monitoring	O
may	O
help	O
detect	O
patients	O
at	O
risk	O
for	O
PVAN	O
.	O
	
The	O
data	O
described	O
below	O
are	O
based	O
on	O
two	O
pooled	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trials	O
through	O
Day	O
90	O
in	O
patients	O
with	O
Dupuytren	O
's	O
contracture	O
(	O
Studies	O
1	O
and	O
2	O
)	O
.	O
	
Defined	O
as	O
clinically	O
overt	O
bleeding	B
accompanied	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
a	O
decrease	B
in	I
hemoglobin	I
of	O
>	O
=2	O
g/dL	O
,	O
a	O
transfusion	O
of	O
2	O
or	O
more	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
compartment	B
syndrome	I
or	O
with	O
fatal	B
outcome	I
.	O
	
Because	O
there	O
was	O
no	O
apparent	O
dose-related	O
increase	O
in	O
the	O
majority	O
of	O
adverse	O
events	O
observed	O
with	O
BENLYSTA	O
,	O
the	O
safety	O
data	O
summarized	O
below	O
are	O
presented	O
for	O
the	O
3	O
doses	O
pooled	O
,	O
unless	O
otherwise	O
indicated	O
;	O
the	O
adverse	O
reaction	O
table	O
displays	O
the	O
results	O
for	O
the	O
recommended	O
dose	O
of	O
10	O
mg/kg	O
compared	O
with	O
placebo	O
.	O
	
Obtain	O
frequent	O
blood	O
counts	O
to	O
monitor	O
for	O
neutropenia	O
.	O
	
Do	O
not	O
administer	O
GRANIX	O
to	O
patients	O
with	O
a	O
history	O
of	O
serious	O
allergic	O
reactions	O
to	O
filgrastim	O
or	O
pegfilgrastim	O
.	O
	
In	O
clinical	O
trials	O
,	O
GILENYA	O
was	O
discontinued	O
if	O
the	O
elevation	O
exceeded	O
5	O
times	O
the	O
ULN	O
.	O
	
prednisone	O
)	O
at	O
the	O
time	O
of	O
fracture	O
.	O
	
Serious	O
skin	B
infections	I
,	O
as	O
well	O
as	O
infections	B
of	I
the	I
abdomen	I
,	O
were	O
more	O
frequent	O
in	O
patients	O
treated	O
with	O
Prolia	O
.	O
	
As	O
PML	O
has	O
been	O
associated	O
with	O
high	O
levels	O
of	O
overall	O
immunosuppression	O
,	O
the	O
recommended	O
doses	O
and	O
frequency	O
of	O
NULOJIX	O
and	O
concomitant	O
immunosuppressives	O
,	O
including	O
MMF	O
,	O
should	O
not	O
be	O
exceeded	O
.	O
	
Withhold	O
TAFINLAR	O
for	O
fever	O
of	O
101.3oF	O
or	O
higher	O
.	O
	
Two	O
randomized	O
clinical	O
trials	O
enrolled	O
patients	O
with	O
metastatic	O
prostate	O
cancer	O
that	O
has	O
progressed	O
on	O
androgen	O
deprivation	O
therapy	O
(	O
GnRH	O
therapy	O
or	O
bilateral	O
orchiectomy	O
)	O
,	O
a	O
disease	O
setting	O
that	O
is	O
also	O
defined	O
as	O
metastatic	O
CRPC	O
.	O
	
Patients	O
were	O
permitted	O
to	O
participate	O
sequentially	O
in	O
both	O
placebo-controlled	O
trials	O
;	O
safety	O
data	O
collected	O
during	O
exposure	O
to	O
KALBITOR	O
was	O
attributed	O
to	O
treatment	O
with	O
KALBITOR	O
,	O
and	O
safety	O
data	O
collected	O
during	O
exposure	O
to	O
placebo	O
was	O
attributed	O
to	O
treatment	O
with	O
placebo	O
.	O
	
Healthcare	O
providers	O
should	O
follow	O
current	O
CDC	O
guidelines	O
both	O
to	O
evaluate	O
for	O
and	O
to	O
treat	O
possible	O
latent	O
tuberculosis	O
infections	O
before	O
initiating	O
therapy	O
with	O
ILARIS	O
.	O
	
Thus	O
,	O
the	O
ability	O
to	O
differentiate	O
the	O
adverse	O
event	O
profile	O
between	O
treatments	O
is	O
limited	O
.	O
	
Discontinuation	O
from	O
study	O
due	O
to	O
genital	B
infection	I
occurred	O
in	O
0	O
%	O
of	O
placebo-treated	O
patients	O
and	O
0.2	O
%	O
of	O
patients	O
treated	O
with	O
either	O
JARDIANCE	O
10	O
or	O
25	O
mg	O
.	O
	
5.16	O
Laboratory	O
Tests	O
Serum	O
follicle	O
stimulating	O
hormone	O
(	O
FSH	O
)	O
and	O
estradiol	O
levels	O
have	O
not	O
been	O
shown	O
to	O
be	O
useful	O
in	O
the	O
management	O
of	O
moderate	O
to	O
severe	O
vasomotor	O
symptoms	O
.	O
	
Additional	O
Adverse	O
Reactions	O
Other	O
adverse	O
reactions	O
known	O
to	O
occur	O
following	O
administration	O
of	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
include	O
myalgia	B
,	O
headache	B
,	O
vomiting	B
,	O
Sweet	B
's	I
syndrome	I
(	O
acute	B
febrile	I
neutrophilic	I
dermatosis	I
)	O
,	O
cutaneous	B
vasculitis	I
and	O
thrombocytopenia	B
.	O
	
5.5	O
Atypical	O
Subtrochanteric	O
and	O
Diaphyseal	O
Femoral	B
Fractures	I
have	O
been	O
reported	O
in	O
patients	O
receiving	O
Prolia	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Table	O
1	O
Age	O
Range	O
Drug-Placebo	O
Difference	O
in	O
Number	O
of	O
Cases	O
of	O
Suicidality	B
per	O
1,000	O
Patients	O
Treated	O
Increases	O
Compared	O
to	O
Placebo	O
<	O
18	O
14	O
additional	O
cases	O
18	O
to	O
24	O
5	O
additional	O
cases	O
Decreases	O
Compared	O
to	O
Placebo	O
25	O
to	O
64	O
1	O
fewer	O
case	O
>	O
=65	O
6	O
fewer	O
cases	O
No	O
suicides	B
occurred	O
in	O
any	O
of	O
the	O
pediatric	O
studies	O
.	O
	
5.6	O
Neurologic	O
Reactions	O
Use	O
of	O
TNF	O
blockers	O
,	O
of	O
which	O
CIMZIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
rare	O
cases	O
of	O
new	O
onset	O
or	O
exacerbation	O
of	O
clinical	O
symptoms	O
and/or	O
radiographic	O
evidence	O
of	O
central	B
nervous	I
system	I
demyelinating	I
disease	I
,	O
including	O
multiple	B
sclerosis	I
,	O
and	O
with	O
peripheral	B
demyelinating	I
disease	I
,	O
including	O
Guillain-Barre	B
syndrome	I
.	O
	
Pneumocystis	B
jiroveci	I
pneumonia	I
,	O
some	O
with	O
a	O
fatal	B
outcome	O
,	O
has	O
been	O
reported	O
in	O
patients	O
who	O
received	O
everolimus	O
.	O
	
Although	O
no	O
high	O
risk	O
group	O
has	O
been	O
identified	O
,	O
exercise	O
caution	O
in	O
patients	O
being	O
treated	O
with	O
CIMZIA	O
who	O
have	O
ongoing	O
,	O
or	O
a	O
history	O
of	O
,	O
significant	O
hematologic	O
abnormalities	O
.	O
	
Adverse	O
reactions	O
leading	O
to	O
permanent	O
treatment	O
discontinuation	O
occurred	O
in	O
33	O
%	O
of	O
patients	O
>	O
=	O
65	O
years	O
of	O
age	O
compared	O
to	O
17	O
%	O
in	O
patients	O
<	O
65	O
years	O
of	O
age	O
.	O
	
Patients	O
with	O
osteosarcoma	O
were	O
eligible	O
for	O
these	O
studies	O
if	O
the	O
plasma	O
methotrexate	O
concentration	O
was	O
greater	O
than	O
50	O
mumol/L	O
at	O
24	O
hours	O
,	O
greater	O
that	O
5	O
mumol/L	O
at	O
48	O
hours	O
,	O
or	O
greater	O
than	O
2	O
standard	O
deviations	O
above	O
the	O
mean	O
methotrexate	O
elimination	O
curve	O
at	O
least	O
12	O
hours	O
after	O
methotrexate	O
administration	O
and	O
there	O
was	O
a	O
2-fold	O
or	O
greater	O
increase	O
in	O
serum	O
creatinine	O
above	O
baseline	O
.	O
	
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
the	O
adverse	O
reaction	O
rates	O
observed	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
other	O
trials	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
For	O
women	O
with	O
a	O
history	O
of	O
cholestatic	O
jaundice	O
associated	O
with	O
past	O
estrogen	O
use	O
or	O
with	O
pregnancy	O
,	O
caution	O
should	O
be	O
exercised	O
;	O
and	O
in	O
the	O
case	O
of	O
recurrence	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
.	O
	
In	O
the	O
randomized	O
,	O
placebo-controlled	O
portion	O
of	O
SJIA	O
Study	O
2	O
decreased	B
white	I
blood	I
cell	I
counts	I
)	O
less	O
than	O
or	O
equal	O
to	O
0.8	O
times	O
lower	O
limit	O
of	O
normal	O
(	O
LLN	O
)	O
were	O
reported	O
in	O
5	O
patients	O
(	O
10.4	O
%	O
)	O
in	O
the	O
ILARIS	O
group	O
compared	O
to	O
2	O
(	O
4.0	O
%	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
Injection	B
site	I
pruritus	I
also	O
contributed	O
to	O
the	O
frequently	O
reported	O
reactions	O
.	O
	
Percentages	O
calculated	O
with	O
the	O
number	O
of	O
female	O
subjects	O
in	O
each	O
group	O
as	O
denominator	O
:	O
placebo	O
(	O
N=481	O
)	O
,	O
JARDIANCE	O
10	O
mg	O
(	O
N=443	O
)	O
,	O
JARDIANCE	O
25	O
mg	O
(	O
N=420	O
)	O
.	O
	
Thirty-three	O
patients	O
receiving	O
DIFICID	O
(	O
5.9	O
%	O
)	O
withdrew	O
from	O
trials	O
as	O
a	O
result	O
of	O
adverse	O
reactions	O
(	O
AR	O
)	O
.	O
	
Malignancies	O
One	O
case	O
of	O
malignancy	B
other	O
than	O
lymphoma	B
and	O
NMSC	B
with	O
SIMPONI	O
ARIA	O
was	O
reported	O
through	O
Week	O
24	O
during	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
.	O
	
(	O
5.11	O
,	O
8.1	O
)	O
EXCERPT	O
:	O
5.1	O
New	O
Primary	O
Malignancies	O
New	O
primary	B
malignancies	I
,	I
cutaneous	I
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
SAPHRIS	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
dementia-related	O
psychosis	O
,	O
and	O
should	O
not	O
be	O
used	O
in	O
patients	O
at	O
risk	O
for	O
aspiration	O
pneumonia	O
[	O
see	O
also	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
These	O
events	O
are	O
notable	O
because	O
of	O
their	O
seriousness	O
,	O
severity	O
,	O
or	O
increased	O
frequency	O
in	O
subjects	O
who	O
received	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
compared	O
with	O
subjects	O
who	O
received	O
only	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
PRISTIQ	O
should	O
be	O
discontinued	O
before	O
initiating	O
treatment	O
with	O
the	O
MAOI	O
[	O
see	O
Contraindications	O
(	O
4.2	O
)	O
and	O
Dosage	O
and	O
Administration	O
(	O
2.6	O
)	O
]	O
.	O
	
(	O
5.1	O
,	O
2.3	O
)	O
*	O
Tumor	B
Promotion	I
in	I
BRAF	I
Wild-Type	I
Melanoma	I
:	O
Increased	B
cell	I
proliferation	I
can	O
occur	O
with	O
BRAF	O
inhibitors	O
.	O
	
Most	O
patients	O
responded	O
to	O
corticosteroids	O
.	O
	
Experience	O
in	O
Classical	O
Hodgkin	O
Lymphoma	O
Summary	O
of	O
Clinical	O
Trial	O
Experience	O
in	O
Relapsed	O
Classical	O
HL	O
(	O
Study	O
1	O
)	O
ADCETRIS	O
was	O
studied	O
in	O
102	O
patients	O
with	O
classical	O
HL	O
in	O
a	O
single	O
arm	O
clinical	O
trial	O
in	O
which	O
the	O
recommended	O
starting	O
dose	O
and	O
schedule	O
was	O
1.8	O
mg/kg	O
intravenously	O
every	O
3	O
weeks	O
.	O
	
Infections	O
and	O
Infestations	O
:	O
Cellulitis	B
,	O
folliculitis	B
,	O
paronychia	B
,	O
rash	B
pustular	I
.	O
	
Women	O
taking	O
DUAVEE	O
should	O
not	O
take	O
additional	O
estrogens	O
as	O
this	O
may	O
increase	O
the	O
risk	O
of	O
endometrial	O
hyperplasia	O
.	O
	
In	O
the	O
event	O
of	O
an	O
erection	O
that	O
persists	O
longer	O
than	O
4	O
hours	O
,	O
the	O
patient	O
should	O
seek	O
immediate	O
medical	O
assistance	O
.	O
	
Discontinuation	O
of	O
Coartem	O
Tablets	O
due	O
to	O
adverse	O
drug	O
reactions	O
occurred	O
in	O
1.1	O
%	O
of	O
patients	O
treated	O
with	O
the	O
6-dose	O
regimen	O
overall	O
:	O
0.2	O
%	O
(	O
1/647	O
)	O
in	O
adults	O
and	O
1.6	O
%	O
(	O
21/1,332	O
)	O
in	O
children	O
.	O
	
If	O
a	O
hypersensitivity	O
reaction	O
occurs	O
,	O
discontinue	O
Teflaro	O
.	O
	
There	O
is	O
evidence	O
to	O
suggest	O
that	O
some	O
patients	O
who	O
develop	O
high	O
and	O
sustained	O
IgG	O
antibody	O
titers	O
may	O
experience	O
reduced	B
clinical	I
efficacy	I
to	O
alglucosidase	O
alfa	O
treatment	O
,	O
such	O
as	O
loss	B
of	I
motor	I
function	I
,	O
ventilator	O
dependence	O
,	O
or	O
death	B
.	O
	
Approximately	O
half	O
the	O
cases	O
were	O
lymphomas	B
,	O
including	O
non-Hodgkin	B
's	I
lymphoma	I
.	O
	
During	O
randomized	O
controlled	O
studies	O
,	O
transaminase	B
elevations	I
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
were	O
observed	O
(	O
AST	O
:	O
2	O
%	O
,	O
2	O
%	O
,	O
and	O
ALT	O
:	O
3	O
%	O
,	O
2	O
%	O
in	O
ULORIC	O
and	O
allopurinol-treated	O
patients	O
,	O
respectively	O
)	O
.	O
	
Neutrophils	O
and	O
Platelets	O
The	O
proportion	O
of	O
subjects	O
with	O
decreased	B
neutrophil	I
and	I
platelet	I
counts	I
was	O
higher	O
in	O
subjects	O
treated	O
with	O
VICTRELIS	O
in	O
combination	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
.	O
	
Advise	O
patients	O
treated	O
with	O
MULTAQ	O
to	O
report	O
immediately	O
symptoms	O
suggesting	O
hepatic	O
injury	O
(	O
such	O
as	O
anorexia	O
,	O
nausea	O
,	O
vomiting	O
,	O
fever	O
,	O
malaise	O
,	O
fatigue	O
,	O
right	O
upper	O
quadrant	O
pain	O
,	O
jaundice	O
,	O
dark	O
urine	O
,	O
or	O
itching	O
)	O
.	O
	
In	O
the	O
controlled	O
portions	O
of	O
clinical	O
trials	O
of	O
all	O
the	O
TNF	O
blockers	O
,	O
more	O
cases	O
of	O
lymphoma	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF	O
blockers	O
compared	O
to	O
control	O
patients	O
.	O
	
Patients	O
who	O
have	O
serum	O
ALT	O
greater	O
than	O
three	O
times	O
the	O
reference	O
range	O
with	O
serum	O
total	O
bilirubin	O
greater	O
than	O
two	O
times	O
the	O
reference	O
range	O
without	O
alternative	O
etiologies	O
are	O
at	O
risk	O
for	O
severe	O
drug-induced	O
liver	O
injury	O
and	O
should	O
not	O
be	O
restarted	O
on	O
ULORIC	O
.	O
	
An	O
observational	O
study	O
evaluated	O
whether	O
recent	O
use	O
of	O
PDE5	O
inhibitors	O
,	O
as	O
a	O
class	O
,	O
was	O
associated	O
with	O
acute	O
onset	O
of	O
NAION	B
.	O
	
In	O
addition	O
,	O
because	O
ILARIS	O
may	O
interfere	B
with	I
normal	I
immune	I
response	I
to	O
new	O
antigens	O
,	O
vaccinations	O
may	O
not	O
be	O
effective	O
in	O
patients	O
receiving	O
ILARIS	O
.	O
	
Among	O
299	O
patients	O
with	O
chronic	O
ITP	O
who	O
received	O
PROMACTA	O
in	O
the	O
single-arm	O
extension	O
trial	O
,	O
the	O
adverse	O
reactions	O
occurred	O
in	O
a	O
pattern	O
similar	O
to	O
that	O
seen	O
in	O
the	O
placebo-controlled	O
trials	O
.	O
	
Subgroup	O
analyses	O
of	O
women	O
50	O
to	O
59	O
years	O
of	O
age	O
suggest	O
a	O
statistically	O
non-significant	O
reduction	O
in	O
CHD	B
events	O
(	O
CE	O
[	O
0.625	O
mg	O
]	O
-alone	O
compared	O
to	O
placebo	O
)	O
in	O
women	O
with	O
less	O
than	O
10	O
years	O
since	O
menopause	O
(	O
8	O
versus	O
16	O
per	O
10,000	O
women-years	O
)	O
.	O
	
For	O
patients	O
with	O
lesser	O
elevations	O
of	O
serum	O
ALT	O
or	O
bilirubin	O
and	O
with	O
an	O
alternate	O
probable	O
cause	O
,	O
treatment	O
with	O
ULORIC	O
can	O
be	O
used	O
with	O
caution	O
.	O
	
In	O
controlled	O
studies	O
of	O
CIMZIA	O
for	O
Crohn	O
's	O
disease	O
and	O
other	O
investigational	O
uses	O
,	O
there	O
was	O
one	O
case	O
of	O
lymphoma	B
among	O
2,657	O
Cimzia-treated	O
patients	O
and	O
one	O
case	O
of	O
Hodgkin	B
's	I
lymphoma	I
among	O
1,319	O
placebo-treated	O
patients	O
.	O
	
Coronary	O
Heart	O
Disease	O
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
no	O
overall	O
effect	O
on	O
coronary	B
heart	I
disease	I
(	O
CHD	B
)	O
events	O
(	O
defined	O
as	O
nonfatal	O
myocardial	B
infarction	I
,	O
silent	B
myocardial	I
infarction	I
,	O
or	O
CHD	B
death	I
)	O
was	O
reported	O
in	O
women	O
receiving	O
estrogen-alone	O
compared	O
to	O
placebo	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.5	O
)	O
]	O
.	O
	
If	O
CDAD	O
is	O
suspected	O
or	O
confirmed	O
,	O
antibacterials	O
not	O
directed	O
against	O
C.	O
difficile	O
should	O
be	O
discontinued	O
,	O
if	O
possible	O
.	O
	
Since	O
no	O
data	O
are	O
available	O
on	O
either	O
the	O
efficacy	O
or	O
on	O
the	O
risks	O
of	O
secondary	O
transmission	O
of	O
infection	O
by	O
live	O
vaccines	O
in	O
patients	O
receiving	O
ILARIS	O
,	O
live	O
vaccines	O
should	O
not	O
be	O
given	O
concurrently	O
with	O
ILARIS	O
.	O
	
The	O
results	O
suggest	O
an	O
approximate	O
2-fold	O
increase	O
in	O
the	O
risk	O
of	O
NAION	B
within	O
5	O
half-lives	O
of	O
PDE5	O
inhibitor	O
use	O
.	O
	
The	O
effect	O
of	O
antibody	O
development	O
on	O
the	O
long	O
term	O
efficacy	O
of	O
alglucosidase	O
alfa	O
is	O
not	O
fully	O
understood	O
.	O
	
(	O
5.1	O
)	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
with	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
Teflaro	O
.	O
	
Physicians	O
should	O
be	O
attentive	O
to	O
symptoms	O
of	O
infection	O
or	O
worsening	O
of	O
SJIA	O
,	O
as	O
these	O
are	O
known	O
triggers	O
for	O
MAS	O
.	O
	
If	O
not	O
treated	O
immediately	O
,	O
penile	O
tissue	O
damage	O
and	O
permanent	O
loss	O
of	O
potency	O
could	O
result	O
.	O
	
Extensive	O
brain	O
atrophy	O
may	O
limit	O
the	O
ability	O
to	O
distinguish	O
grey	O
and	O
white	O
matter	O
on	O
a	O
Vizamyl	O
scan	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.5	O
)	O
]	O
.	O
	
Neoplasms	O
Benign	O
,	O
Malignant	O
,	O
and	O
Unspecified	O
(	O
including	O
cysts	O
and	O
polyps	O
)	O
:	O
Skin	B
papilloma	I
.	O
	
Median	O
duration	O
of	O
treatment	O
was	O
9	O
cycles	O
(	O
range	O
,	O
1-16	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
No	O
dose-effect	O
relationship	O
for	O
these	O
transaminase	O
elevations	O
was	O
noted	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
If	O
concomitant	O
use	O
of	O
PRISTIQ	O
with	O
other	O
serotonergic	O
drugs	O
,	O
including	O
triptans	O
,	O
tricyclic	O
antidepressants	O
,	O
fentanyl	O
,	O
lithium	O
,	O
tramadol	O
,	O
buspirone	O
,	O
tryptophan	O
,	O
and	O
St.	O
John	O
's	O
Wort	O
is	O
clinically	O
warranted	O
,	O
patients	O
should	O
be	O
made	O
aware	O
of	O
a	O
potential	O
increased	O
risk	O
for	O
serotonin	O
syndrome	O
,	O
particularly	O
during	O
treatment	O
initiation	O
and	O
dose	O
increases	O
.	O
	
The	O
concomitant	O
use	O
of	O
ADCETRIS	O
with	O
bleomycin	O
is	O
contraindicated	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Hemorrhage	B
:	O
Major	O
hemorrhagic	B
events	I
can	O
occur	O
in	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Chronic	O
Hepatitis	O
C-associated	O
Thrombocytopenia	O
:	O
In	O
the	O
two	O
placebo-controlled	O
trials	O
,	O
955	O
patients	O
with	O
chronic	O
hepatitis	O
C-associated	O
thrombocytopenia	O
received	O
PROMACTA	O
.	O
	
After	O
an	O
average	O
follow-up	O
of	O
5.2	O
years	O
,	O
28	O
women	O
in	O
the	O
estrogen-alone	O
group	O
and	O
19	O
women	O
in	O
the	O
placebo	O
group	O
were	O
diagnosed	O
with	O
probable	O
dementia	B
.	O
	
In	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
of	O
Trial	O
1	O
,	O
in	O
SIMPONI	O
ARIA	O
treated	O
patients	O
,	O
the	O
incidence	O
of	O
active	B
TB	I
per	O
100	O
patient-years	O
was	O
0.31	O
(	O
95	O
%	O
CI	O
:	O
0.06	O
;	O
0.92	O
)	O
and	O
the	O
incidence	O
of	O
other	O
opportunistic	B
infections	I
per	O
100	O
patient-years	O
was	O
0.42	O
(	O
95	O
%	O
CI	O
:	O
0.11	O
,	O
1.07	O
)	O
.	O
	
Counseling	O
patients	O
about	O
the	O
protective	O
measures	O
necessary	O
to	O
guard	O
against	O
sexually	O
transmitted	O
diseases	O
,	O
including	O
Human	O
Immunodeficiency	O
Virus	O
(	O
HIV	O
)	O
,	O
should	O
be	O
considered	O
.	O
	
The	O
safety	O
of	O
DIFICID	O
200	O
mg	O
tablets	O
taken	O
twice	O
a	O
day	O
for	O
10	O
days	O
was	O
evaluated	O
in	O
564	O
patients	O
with	O
CDAD	O
in	O
two	O
active-comparator	O
controlled	O
trials	O
with	O
86.7	O
%	O
of	O
patients	O
receiving	O
a	O
full	O
course	O
of	O
treatment	O
.	O
	
Short-term	O
studies	O
did	O
not	O
show	O
an	O
increase	O
in	O
the	O
risk	O
of	O
suicidality	B
with	O
antidepressants	O
compared	O
to	O
placebo	O
in	O
adults	O
beyond	O
age	O
24	O
;	O
there	O
was	O
a	O
reduction	O
with	O
antidepressants	O
compared	O
to	O
placebo	O
in	O
adults	O
aged	O
65	O
and	O
older	O
.	O
	
The	O
safety	O
of	O
JEVTANA	O
in	O
combination	O
with	O
prednisone	O
was	O
evaluated	O
in	O
371	O
patients	O
with	O
hormone-refractory	O
metastatic	O
prostate	O
cancer	O
treated	O
in	O
a	O
single	O
randomized	O
trial	O
,	O
compared	O
to	O
mitoxantrone	O
plus	O
prednisone	O
.	O
	
The	O
safety	O
of	O
VORAXAZE	O
is	O
based	O
on	O
data	O
from	O
290	O
patients	O
who	O
were	O
treated	O
in	O
2	O
single-arm	O
,	O
open-label	O
,	O
multicenter	O
trials	O
enrolling	O
patients	O
who	O
had	O
markedly	O
delayed	O
methotrexate	O
clearance	O
secondary	O
to	O
renal	O
dysfunction	O
.	O
	
5.7	O
Geriatric	O
Patients	O
In	O
the	O
randomized	O
advanced	O
hormone	O
receptor-positive	O
,	O
HER2-negative	O
breast	O
cancer	O
study	O
,	O
the	O
incidence	O
of	O
deaths	B
due	O
to	O
any	O
cause	O
within	O
28	O
days	O
of	O
the	O
last	O
AFINITOR	O
dose	O
was	O
6	O
%	O
in	O
patients	O
>	O
=	O
65	O
years	O
of	O
age	O
compared	O
to	O
2	O
%	O
in	O
patients	O
<	O
65	O
years	O
of	O
age	O
.	O
	
The	O
causal	O
relationship	O
of	O
these	O
events	O
to	O
CIMZIA	O
remains	O
unclear	O
.	O
	
c	O
Predefined	O
adverse	O
event	O
grouping	O
,	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
polyuria	B
,	O
pollakiuria	B
,	O
and	O
nocturia	B
d	O
Male	O
genital	O
mycotic	O
infections	O
include	O
the	O
following	O
adverse	O
reactions	O
:	O
balanoposthitis	B
,	O
balanitis	B
,	O
genital	B
infections	I
fungal	I
,	O
genitourinary	B
tract	I
infection	I
,	O
balanitis	B
candida	I
,	O
scrotal	B
abscess	I
,	O
penile	B
infection	I
.	O
	
In	O
addition	O
to	O
the	O
term	O
injection	B
site	I
reaction	I
(	O
see	O
Table	O
1	O
)	O
,	O
the	O
following	O
other	O
types	O
of	O
injection	B
site	I
reactions	I
also	O
occurred	O
more	O
frequently	O
on	O
TANZEUM	O
:	O
injection	B
site	I
hematoma	I
(	O
1.9	O
%	O
versus	O
2.1	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
injection	B
site	I
erythema	I
(	O
0.4	O
%	O
versus	O
1.7	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
injection	B
site	I
rash	I
(	O
0	O
%	O
versus	O
1.4	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
injection	B
site	I
hypersensitivity	I
(	O
0	O
%	O
versus	O
0.8	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
,	O
and	O
injection	B
site	I
hemorrhage	I
(	O
0.6	O
%	O
versus	O
0.7	O
%	O
for	O
placebo	O
versus	O
TANZEUM	O
)	O
.	O
	
Transient	O
decreases	B
in	I
absolute	I
neutrophil	I
count	I
)	O
to	O
less	O
than	O
1x10	O
9	O
/L	O
were	O
reported	O
in	O
3	O
patients	O
(	O
6.0	O
%	O
)	O
in	O
the	O
ILARIS	O
group	O
compared	O
to1	O
patient	O
(	O
2.0	O
%	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
Use	O
of	O
DUAVEE	O
in	O
patients	O
with	O
hepatic	O
impairment	O
is	O
contraindicated	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
5.17	O
Drug-Laboratory	O
Test	O
Interactions	O
Accelerated	B
prothrombin	I
time	I
;	O
increased	B
platelet	I
count	I
;	O
increased	B
factors	I
II	I
;	O
decreased	B
levels	I
of	I
antifactor	I
Xa	I
,	O
decreased	B
antithrombin	I
III	I
activity	I
;	O
increased	B
levels	I
of	I
fibrinogen	I
;	O
increased	B
plasminogen	I
antigen	I
.	O
	
Hypoglycemia	B
was	O
more	O
frequent	O
when	O
TANZEUM	O
was	O
added	O
to	O
sulfonylurea	O
or	O
insulin	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Bilirubin	O
Asymptomatic	O
and	O
mild	O
elevations	B
of	I
serum	I
bilirubin	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
ILARIS	O
without	O
concomitant	O
elevations	B
of	I
transaminases	I
.	O
	
If	O
a	O
diagnosis	O
of	O
invasive	O
systemic	O
fungal	O
infection	O
is	O
made	O
,	O
discontinue	O
AFINITOR	O
and	O
treat	O
with	O
appropriate	O
antifungal	O
therapy	O
.	O
	
Therefore	O
,	O
exercise	O
caution	O
when	O
considering	O
resumption	O
of	O
CIMZIA	O
therapy	O
in	O
this	O
situation	O
and	O
monitor	O
patients	O
closely	O
.	O
	
These	O
risk	O
differences	O
(	O
drug-placebo	O
difference	O
in	O
the	O
number	O
of	O
cases	O
of	O
suicidality	B
per	O
1,000	O
patients	O
treated	O
)	O
are	O
provided	O
in	O
Table	O
1	O
.	O
	
In	O
both	O
studies	O
,	O
patients	O
received	O
XTANDI	O
160	O
mg	O
orally	O
once	O
daily	O
in	O
the	O
active	O
treatment	O
arm	O
or	O
placebo	O
in	O
the	O
control	O
arm	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
administered	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
the	O
incidence	O
of	O
pyrexia	B
was	O
57	O
%	O
(	O
116/202	O
)	O
.	O
	
Patients	O
were	O
treated	O
with	O
KALBITOR	O
30	O
mg	O
subcutaneous	O
or	O
placebo	O
.	O
	
Physicians	O
should	O
consider	O
PML	O
in	O
the	O
differential	O
diagnosis	O
in	O
patients	O
with	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
or	O
symptoms	O
.	O
	
AMPYRA	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Genital	B
mycotic	I
infections	I
occurred	O
more	O
frequently	O
in	O
female	O
than	O
male	O
patients	O
(	O
see	O
Table	O
1	O
)	O
.	O
	
The	O
adverse	O
events	O
observed	O
within	O
one	O
hour	O
of	O
the	O
end	O
of	O
the	O
infusion	O
were	O
similar	O
in	O
patients	O
who	O
received	O
Cleviprex	O
and	O
in	O
those	O
who	O
received	O
comparator	O
agents	O
.	O
	
5.2	O
Immunosuppression	O
The	O
impact	O
of	O
treatment	O
with	O
anti-interleukin-1	O
(	O
IL-1	O
)	O
therapy	O
on	O
the	O
development	O
of	O
malignancies	O
is	O
not	O
known	O
.	O
	
(	O
5.1	O
)	O
*	O
Measurement	O
of	O
methotrexate	O
using	O
immunoassays	O
is	O
unreliable	O
for	O
samples	O
collected	O
within	O
48	O
hours	O
following	O
VORAXAZE	O
administration	O
.	O
	
Most	O
Common	O
Adverse	O
Reactions	O
in	O
an	O
LGS	O
Placebo	O
Controlled	O
Clinical	O
Trial	O
(	O
Study	O
1	O
)	O
Table	O
3	O
lists	O
the	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=5	O
%	O
of	O
ONFI	O
treated	O
patients	O
(	O
at	O
any	O
dose	O
)	O
,	O
and	O
at	O
a	O
rate	O
greater	O
than	O
placebo	O
treated	O
patients	O
,	O
in	O
the	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
parallel	O
group	O
clinical	O
study	O
of	O
adjunctive	O
AED	O
therapy	O
for	O
15	O
weeks	O
(	O
Study	O
1	O
)	O
.	O
	
During	O
Prolia	O
treatment	O
,	O
patients	O
should	O
be	O
advised	O
to	O
report	O
new	O
or	O
unusual	O
thigh	O
,	O
hip	O
,	O
or	O
groin	O
pain	O
.	O
	
Serum	O
transaminase	O
levels	O
returned	O
to	O
normal	O
within	O
approximately	O
2	O
months	O
after	O
discontinuation	O
of	O
GILENYA	O
.	O
	
5.4	O
Use	O
in	O
Patients	O
with	O
Sickle	O
Cell	O
Disease	O
Severe	O
and	O
sometimes	O
fatal	B
sickle	B
cell	I
crises	I
can	O
occur	O
in	O
patients	O
with	O
sickle	O
cell	O
disease	O
receiving	O
human	O
granulocyte	O
colony-stimulating	O
factors	O
.	O
	
Do	O
not	O
give	O
JEVTANA	O
if	O
neutrophil	O
counts	O
are	O
<	O
=1,500	O
cells/mm3	O
.	O
	
In	O
2	O
of	O
the	O
trials	O
(	O
Trial	O
1	O
and	O
Trial	O
3	O
)	O
,	O
treatment	O
was	O
given	O
for	O
48	O
weeks	O
,	O
while	O
in	O
the	O
other	O
trial	O
(	O
Trial	O
2	O
)	O
treatment	O
was	O
given	O
for	O
72	O
weeks	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
In	O
these	O
trials	O
,	O
patients	O
were	O
treated	O
with	O
up	O
to	O
3	O
injections	O
of	O
0.58	O
mg	O
of	O
XIAFLEX	O
or	O
placebo	O
with	O
approximately	O
4-week	O
intervals	O
between	O
injections	O
and	O
the	O
patients	O
had	O
finger	O
extension	O
procedures	O
the	O
day	O
after	O
injection	O
,	O
if	O
needed	O
,	O
to	O
facilitate	O
disruption	O
of	O
the	O
cord	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
5.8	O
Serious	O
Skin	O
Toxicity	O
Serious	O
skin	B
toxicity	I
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
and	O
with	O
trametinib	O
as	O
a	O
single	O
agent	O
[	O
refer	O
to	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
]	O
.	O
	
?	O
	
(	O
6.2	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
ENTEREG	O
REMS	O
Program	O
that	O
restricts	O
use	O
to	O
enrolled	O
hospitals	O
because	O
of	O
the	O
potential	O
risk	O
of	O
myocardial	O
infarction	O
with	O
long-term	O
use	O
of	O
ENTEREG	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Patients	O
who	O
develop	O
increased	O
transaminase	O
levels	O
should	O
be	O
closely	O
monitored	O
until	O
the	O
abnormalities	O
resolve	O
.	O
	
(	O
2.3,5.5	O
)	O
*	O
Embryofetal	B
toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
Dose	O
delay	O
or	O
reduction	O
was	O
necessary	O
in	O
61	O
%	O
of	O
everolimus	O
patients	O
and	O
29	O
%	O
of	O
placebo	O
patients	O
.	O
	
In	O
the	O
clinical	O
trials	O
,	O
one	O
subject	O
treated	O
with	O
OTEZLA	O
attempted	B
suicide	I
while	O
one	O
who	O
received	O
placebo	O
committed	O
suicide	B
.	O
	
Dose-Related	O
Adverse	O
Reactions	O
in	O
Clinical	O
Trials	O
Based	O
on	O
the	O
pooled	O
data	O
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
,	O
adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
greater	O
than	O
2	O
%	O
incidence	O
in	O
the	O
patients	O
treated	O
with	O
FANAPT	O
,	O
and	O
for	O
which	O
the	O
incidence	O
in	O
patients	O
treated	O
with	O
FANAPT	O
20	O
to	O
24	O
mg/day	O
were	O
twice	O
than	O
the	O
incidence	O
in	O
patients	O
treated	O
with	O
FANAPT	O
10	O
to	O
16	O
mg/day	O
were	O
:	O
abdominal	B
discomfort	I
,	O
dizziness	B
,	O
hypotension	B
,	O
musculoskeletal	B
stiffness	I
,	O
tachycardia	B
,	O
and	O
weight	B
increased	I
.	O
	
*	O
If	O
you	O
miss	O
a	O
dose	O
of	O
DUAVEE	O
,	O
take	O
it	O
as	O
soon	O
as	O
you	O
remember	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
in	O
patients	O
with	O
severe	O
neuropathy	O
(	O
interfering	O
with	O
daily	O
activities	O
)	O
such	O
as	O
Guillain-Barre-like	O
syndromes	O
.	O
	
Baseline	O
and	O
follow-up	O
examinations	O
are	O
recommended	O
in	O
pediatric	O
patients	O
initiating	O
KALYDECO	O
treatment	O
.	O
	
*	O
Lactic	B
acidosis	I
and	O
severe	O
hepatomegaly	B
with	O
steatosis	B
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
with	O
the	O
use	O
of	O
nucleoside	O
analogs	O
,	O
including	O
tenofovir	O
disoproxil	O
fumarate	O
(	O
DF	O
)	O
,	O
a	O
component	O
of	O
STRIBILD	O
.	O
	
In	O
this	O
study	O
,	O
the	O
majority	O
of	O
myocardial	B
infarctions	I
occurred	O
between	O
1	O
and	O
4	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O
	
The	O
ADRs	O
observed	O
in	O
FLAMINGO	O
were	O
generally	O
consistent	O
with	O
those	O
seen	O
in	O
SPRING-2	O
and	O
SINGLE	O
.	O
	
Antibody	O
titers	O
for	O
cellular	O
uptake	O
inhibition	O
were	O
present	O
in	O
18	O
of	O
59	O
(	O
31	O
%	O
)	O
patients	O
by	O
Week	O
78	O
.	O
	
Currently	O
available	O
data	O
are	O
inadequate	O
to	O
determine	O
whether	O
concurrent	O
use	O
of	O
inhaled	O
corticosteroids	O
(	O
ICS	O
)	O
or	O
other	O
long-term	O
asthma	O
control	O
drugs	O
mitigates	O
the	O
increased	O
risk	O
of	O
asthma-related	O
death	B
from	O
LABA	O
.	O
	
The	O
safety	O
evaluation	O
of	O
ZYKADIA	O
is	O
based	O
on	O
255	O
ALK-positive	O
patients	O
in	O
Study	O
1	O
(	O
246	O
patients	O
with	O
NSCLC	O
and	O
9	O
patients	O
with	O
other	O
cancers	O
who	O
received	O
ZYKADIA	O
at	O
a	O
dose	O
of	O
750	O
mg	O
daily	O
)	O
.	O
	
Patients	O
should	O
be	O
informed	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
an	O
acute	O
hypersensitivity	O
reaction	O
and	O
be	O
instructed	O
to	O
seek	O
immediate	O
medical	O
care	O
should	O
a	O
reaction	O
occur	O
.	O
	
Adverse	O
laboratory	O
and	O
ECG	O
effects	O
are	O
presented	O
separately	O
in	O
Table	O
2	O
.	O
	
(	O
6.1	O
)	O
*	O
Most	O
common	O
non-hematologic	O
adverse	O
reactions	O
for	O
NHL	O
(	O
frequency	O
>	O
=	O
15	O
%	O
)	O
are	O
nausea	B
,	O
fatigue	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
pyrexia	B
,	O
constipation	B
,	O
anorexia	B
,	O
cough	B
,	O
headache	B
,	O
weight	B
decreased	I
,	O
dyspnea	B
,	O
rash	B
,	O
and	O
stomatitis	B
.	O
	
In	O
patients	O
who	O
had	O
thyroid	O
stimulating	O
hormone	O
(	O
TSH	O
)	O
<	O
5	O
muU/mL	O
before	O
treatment	O
,	O
elevations	B
of	I
TSH	I
to	O
>	O
=10	O
muU/mL	O
occurred	O
in	O
79/245	O
patients	O
(	O
32	O
%	O
)	O
receiving	O
INLYTA	O
and	O
25/232	O
patients	O
(	O
11	O
%	O
)	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
the	O
remaining	O
patients	O
,	O
symptoms	O
resolved	O
within	O
3	O
to	O
4	O
weeks	O
.	O
	
Grade	O
3	O
proteinuria	B
was	O
reported	O
in	O
11/359	O
patients	O
(	O
3	O
%	O
)	O
receiving	O
INLYTA	O
and	O
6/355	O
patients	O
(	O
2	O
%	O
)	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
mechanism	O
of	O
action	O
of	O
BENLYSTA	O
could	O
increase	O
the	O
risk	O
for	O
the	O
development	O
of	O
malignancies	B
.	O
	
A	O
total	O
of	O
64	O
%	O
of	O
patients	O
on	O
GILOTRIF	O
and	O
67	O
%	O
of	O
pemetrexed/cisplatin	O
patients	O
were	O
female	O
.	O
	
Some	O
patients	O
in	O
the	O
clinical	O
studies	O
or	O
in	O
the	O
postmarketing	O
setting	O
have	O
undergone	O
testing	O
for	O
alglucosidase	O
alfa-specific	O
IgE	O
antibodies	O
.	O
	
(	O
5.8	O
)	O
*	O
If	O
paradoxical	O
bronchospasm	O
occurs	O
,	O
discontinue	O
BREO	O
ELLIPTA	O
and	O
institute	O
alternative	O
therapy	O
.	O
	
Caution	O
should	O
be	O
exercised	O
when	O
using	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
in	O
patients	O
who	O
have	O
or	O
have	O
had	O
significant	O
cytopenias	O
.	O
	
Ensure	O
safe	O
handling	O
to	O
protect	O
patients	O
and	O
health	O
care	O
workers	O
from	O
unintentional	O
radiation	O
exposure	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
.	O
	
In	O
Study	O
2	O
,	O
1	O
patient	O
in	O
each	O
treatment	O
group	O
(	O
0.1	O
%	O
)	O
had	O
an	O
infection	B
resulting	O
in	O
death	B
.	O
	
Adverse	O
reactions	O
are	O
adverse	O
events	O
in	O
which	O
there	O
is	O
some	O
basis	O
to	O
believe	O
there	O
is	O
a	O
causal	O
relationship	O
between	O
the	O
drug	O
and	O
the	O
occurrence	O
of	O
the	O
adverse	O
event	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Fetal	O
Toxicity	O
Use	O
of	O
drugs	O
that	O
act	O
on	O
the	O
renin-angiotensin	O
system	O
during	O
the	O
second	O
and	O
third	O
trimesters	O
of	O
pregnancy	O
reduces	B
fetal	I
renal	I
function	I
and	O
increases	O
neonatal	B
morbidity	I
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
who	O
have	O
evidence	O
of	O
untreated	O
brain	O
metastasis	O
or	O
recent	O
active	O
gastrointestinal	O
bleeding	O
and	O
should	O
not	O
be	O
used	O
in	O
those	O
patients	O
.	O
	
If	O
hypotension	O
does	O
occur	O
,	O
the	O
patient	O
should	O
be	O
placed	O
in	O
the	O
supine	O
position	O
and	O
,	O
if	O
necessary	O
,	O
given	O
an	O
intravenous	O
infusion	O
of	O
normal	O
saline	O
.	O
	
10	O
22	O
Psychiatric	O
disorders	O
Insomnia	B
8	O
10	O
Vascular	O
disorders	O
Hypertension	B
<	O
1	O
3	O
Dystonia	O
:	O
Symptoms	O
of	O
dystonia	B
,	O
prolonged	B
abnormal	I
contractions	I
of	I
muscle	I
groups	I
,	O
may	O
occur	O
in	O
susceptible	O
individuals	O
during	O
the	O
first	O
few	O
days	O
of	O
treatment	O
.	O
	
In	O
most	O
cases	O
,	O
initial	O
symptoms	O
occurred	O
within	O
minutes	O
of	O
DOTAREM	O
administration	O
and	O
resolved	O
with	O
prompt	O
emergency	O
treatment	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
(	O
5.4	O
)	O
*	O
Posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
:	O
If	O
suspected	O
,	O
discontinue	O
GILENYA	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
5.10	O
Hypersensitivity	O
Reactions	O
In	O
post-marketing	O
experience	O
,	O
serious	O
systemic	O
hypersensitivity	B
reactions	I
(	O
including	O
anaphylactic	B
reaction	I
)	O
have	O
been	O
reported	O
following	O
administration	O
of	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
(	O
e.g.	O
,	O
high-dose	O
or	O
multiple	O
non-steroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
)	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.4	O
)	O
]	O
.	O
	
Pancreatitis	B
has	O
been	O
reported	O
in	O
clinical	O
trials	O
(	O
6.1	O
)	O
*	O
Male	O
Osteoporosis	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
5	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
were	O
:	O
back	B
pain	I
,	O
arthralgia	B
,	O
and	O
nasopharyngitis	B
(	O
6.1	O
)	O
*	O
Bone	O
loss	O
due	O
to	O
hormone	O
ablation	O
for	O
cancer	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
10	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
were	O
:	O
arthralgia	B
and	O
back	B
pain	I
.	O
	
In	O
SPRING-2	O
,	O
822	O
subjects	O
were	O
randomized	O
and	O
received	O
at	O
least	O
1	O
dose	O
of	O
either	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
or	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
,	O
both	O
in	O
combination	O
with	O
fixed-dose	O
dual	O
nucleoside	O
reverse	O
transcriptase	O
inhibitor	O
(	O
NRTI	O
)	O
treatment	O
(	O
either	O
abacavir	O
sulfate	O
and	O
lamivudine	O
[	O
EPZICOM	O
(	O
r	O
)	O
]	O
or	O
emtricitabine/tenofovir	O
[	O
TRUVADA	O
(	O
r	O
)	O
]	O
)	O
.	O
	
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
DaTscan	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
In	O
a	O
randomized	O
trial	O
comparing	O
Kyprolis	O
as	O
a	O
single	O
agent	O
versus	O
corticosteroids	O
with	O
optional	O
oral	O
cyclophosphamide	O
for	O
patients	O
with	O
relapsed	O
and	O
refractory	O
multiple	O
myeloma	O
,	O
mortality	B
was	O
higher	O
in	O
the	O
patients	O
treated	O
with	O
Kyprolis	O
in	O
comparison	O
to	O
the	O
control	O
arm	O
in	O
the	O
subgroup	O
of	O
48	O
patients	O
>	O
=75	O
years	O
of	O
age	O
.	O
	
Caution	O
should	O
be	O
exercised	O
when	O
administering	O
alglucosidase	O
alfa	O
to	O
patients	O
susceptible	O
to	O
fluid	O
volume	O
overload	O
.	O
	
In	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
adult	O
trials	O
,	O
the	O
incidence	O
of	O
reported	O
EPS-related	B
events	I
,	O
excluding	O
events	O
related	O
to	O
akathisia	B
,	O
for	O
SAPHRIS-treated	O
patients	O
was	O
10	O
%	O
versus	O
7	O
%	O
for	O
placebo	O
;	O
and	O
the	O
incidence	O
of	O
akathisia-related	O
events	O
for	O
SAPHRIS-treated	O
patients	O
was	O
6	O
%	O
versus	O
3	O
%	O
for	O
placebo	O
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
was	O
17.5	O
months	O
with	O
XTANDI	O
and	O
4.6	O
months	O
with	O
placebo	O
.	O
	
A	O
recent	O
CBC	O
should	O
be	O
available	O
before	O
initiating	O
treatment	O
.	O
	
Administer	O
insulin	O
therapy	O
as	O
necessary	O
in	O
patients	O
with	O
hyperglycemia	O
.	O
	
HORIZANT	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
.	O
	
How	O
should	O
I	O
take	O
DUAVEE	O
?	O
	
Some	O
of	O
these	O
reactions	O
were	O
IgE-mediated	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
initiated	O
was	O
4	O
(	O
range	O
1-35	O
)	O
.	O
	
The	O
rates	O
of	O
adverse	O
reactions	O
were	O
higher	O
in	O
the	O
combined	O
controlled	O
and	O
open-label	O
experience	O
than	O
in	O
the	O
placebo-controlled	O
trials	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Spectrum	O
Pharmaceuticals	O
,	O
Inc.	O
at	O
1-888-292-9617	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
Beleodaq	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
Prolia	O
:	O
*	O
Drug-related	O
hypersensitivity	B
reactions	I
:	O
anaphylaxis	B
,	O
rash	B
,	O
urticaria	B
,	O
facial	B
swelling	I
,	O
and	O
erythema	B
*	O
Hypocalcemia	B
:	O
severe	O
hypocalcemia	B
*	O
Musculoskeletal	B
pain	I
,	O
including	O
severe	O
cases	O
*	O
Parathyroid	O
Hormone	O
(	O
PTH	O
)	O
:	O
Marked	O
elevation	B
in	I
serum	I
PTH	I
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
(	O
creatinine	O
clearance	O
<	O
30	O
mL/min	O
)	O
or	O
receiving	O
dialysis	O
.	O
	
The	O
risk	O
of	O
suicidal	B
thoughts	I
was	O
generally	O
consistent	O
among	O
drugs	O
in	O
the	O
data	O
analyzed	O
.	O
	
5.3	O
Hepatotoxicity	O
More	O
hepatic-related	B
adverse	I
reactions	I
were	O
reported	O
with	O
the	O
use	O
of	O
SIRTURO	O
plus	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
compared	O
to	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
without	O
the	O
addition	O
of	O
SIRTURO	O
.	O
	
Females	O
of	O
reproductive	O
potential	O
should	O
be	O
advised	O
to	O
avoid	O
pregnancy	O
while	O
being	O
treated	O
with	O
BOSULIF	O
.	O
	
Patients	O
treated	O
with	O
any	O
AED	O
for	O
any	O
indication	O
should	O
be	O
monitored	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
depression	O
,	O
suicidal	O
thoughts	O
or	O
behavior	O
,	O
and/or	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
.	O
	
Obtain	O
an	O
ECG	O
before	O
initiation	O
of	O
treatment	O
,	O
and	O
at	O
least	O
2	O
,	O
12	O
,	O
and	O
24	O
weeks	O
after	O
starting	O
treatment	O
with	O
SIRTURO	O
.	O
	
A	O
total	O
of	O
725	O
men	O
were	O
exposed	O
to	O
placebo	O
and	O
731	O
men	O
were	O
exposed	O
to	O
Prolia	O
administered	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
subcutaneous	O
dose	O
.	O
	
Prompt	O
use	O
of	O
all	O
therapies	O
necessary	O
to	O
reduce	O
plasma	O
ammonia	O
levels	O
is	O
essential	O
.	O
	
Most	O
of	O
these	O
reactions	O
may	O
have	O
been	O
the	O
consequence	O
of	O
the	O
surgical	O
procedure	O
.	O
	
*	O
Choking	B
has	O
been	O
reported	O
by	O
patients	O
,	O
some	O
of	O
whom	O
may	O
have	O
also	O
experienced	O
oropharyngeal	B
muscular	I
dysfunction	I
or	O
hypoesthesia	B
.	O
	
A	O
total	O
of	O
120	O
men	O
were	O
exposed	O
to	O
placebo	O
and	O
120	O
men	O
were	O
exposed	O
to	O
Prolia	O
administered	O
subcutaneously	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
dose	O
.	O
	
The	O
majority	O
of	O
renal	B
cysts	I
.	O
	
Perform	O
complete	O
blood	O
counts	O
weekly	O
for	O
the	O
first	O
month	O
of	O
therapy	O
and	O
then	O
monthly	O
thereafter	O
,	O
or	O
as	O
clinically	O
indicated	O
.	O
	
The	O
numbers	O
of	O
patients	O
and	O
their	O
exposures	O
are	O
described	O
in	O
Table	O
1	O
.	O
	
5.5	O
Paradoxical	O
Bronchospasm	O
As	O
with	O
other	O
inhaled	O
beta2-agonists	O
,	O
ARCAPTA	O
NEOHALER	O
may	O
produce	O
paradoxical	B
bronchospasm	I
that	O
may	O
be	O
life-threatening	O
.	O
	
Table	O
5	O
.	O
	
If	O
traumatic	O
puncture	O
occurs	O
,	O
delay	O
the	O
administration	O
of	O
ELIQUIS	O
for	O
48	O
hours	O
.	O
	
Patients	O
received	O
INVOKANA	O
100	O
mg	O
(	O
N=3092	O
)	O
,	O
INVOKANA	O
300	O
mg	O
(	O
N=3085	O
)	O
or	O
comparator	O
(	O
N=3262	O
)	O
once	O
daily	O
.	O
	
TECFIDERA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
pre-existing	O
low	O
lymphocyte	O
counts	O
.	O
	
In	O
clinical	O
trials	O
,	O
SCC	O
was	O
observed	O
both	O
in	O
patients	O
receiving	O
Vimizim	O
and	O
patients	O
receiving	O
placebo	O
.	O
	
If	O
a	O
patient	O
develops	O
a	O
dermatologic	O
reaction	O
while	O
taking	O
APTIOM	O
,	O
discontinue	O
APTIOM	O
use	O
,	O
unless	O
the	O
reaction	O
is	O
clearly	O
not	O
drug-related	O
.	O
	
Grade	O
3	O
or	O
greater	O
infections	B
occurred	O
in	O
14	O
%	O
to	O
26	O
%	O
of	O
patients	O
.	O
	
Anaphylaxis	B
and	O
angioedema	B
associated	O
with	O
laryngeal	B
edema	I
can	O
be	O
fatal	B
.	O
	
A	O
total	O
of	O
1,867	O
subjects	O
were	O
included	O
in	O
two	O
clinical	O
phase	O
3	O
studies	O
with	O
a	O
treatment	O
duration	O
up	O
to	O
28	O
cycles	O
with	O
Natazia	O
as	O
an	O
oral	O
contraceptive	O
and	O
264	O
subjects	O
in	O
the	O
two	O
phase	O
3	O
clinical	O
trials	O
with	O
a	O
treatment	O
duration	O
of	O
7	O
cycles	O
evaluating	O
Natazia	O
in	O
the	O
treatment	O
of	O
heavy	O
,	O
prolonged	O
,	O
and/or	O
frequent	O
menstrual	O
bleeding	O
in	O
women	O
without	O
organic	O
pathology	O
.	O
	
The	O
hypersensitivity	B
reactions	I
include	O
itching	B
,	O
body	B
rash	I
,	O
and	O
swelling	B
of	I
lips	I
.	O
	
Of	O
34	O
patients	O
enrolled	O
,	O
32	O
had	O
the	O
G551D	O
mutation	O
and	O
2	O
had	O
the	O
S549N	O
mutation	O
.	O
	
Consider	O
as	O
a	O
possible	O
cause	O
for	O
severe	O
joint	O
pain	O
and	O
discontinue	O
drug	O
if	O
appropriate	O
.	O
	
Temporarily	O
suspend	O
,	O
dose	O
reduce	O
,	O
or	O
permanently	O
discontinue	O
XALKORI	O
as	O
described	O
in	O
Table	O
2	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
In	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
these	O
events	O
were	O
reported	O
in	O
26	O
%	O
and	O
38	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
APTIOM	O
at	O
doses	O
of	O
800	O
mg	O
and	O
1200	O
mg/day	O
,	O
respectively	O
,	O
compared	O
to	O
12	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
Adverse	O
reactions	O
were	O
reported	O
according	O
to	O
NCI	O
CTC	O
v.2.0	O
.	O
	
Patients	O
treated	O
with	O
concomitant	O
immunosuppressants	O
had	O
a	O
lower	O
rate	O
of	O
antibody	O
development	O
than	O
patients	O
not	O
taking	O
immunosuppressants	O
at	O
baseline	O
(	O
3	O
%	O
and	O
11	O
%	O
,	O
respectively	O
)	O
.	O
	
5.6	O
Osteonecrosis	O
of	O
the	O
Jaw	O
Osteonecrosis	B
of	I
the	I
jaw	I
(	O
ONJ	B
)	O
occurred	O
in	O
1	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
c	O
Includes	O
abdominal	B
discomfort	I
,	O
abdominal	B
pain	I
,	O
abdominal	B
pain	I
lower	I
,	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
tenderness	I
,	O
gastrointestinal	B
pain	I
.	O
	
Because	O
XIAFLEX	O
contains	O
foreign	O
proteins	O
,	O
severe	O
allergic	B
reactions	I
to	O
XIAFLEX	O
can	O
occur	O
.	O
	
Withhold	O
COMETRIQ	O
in	O
patients	O
who	O
develop	O
intolerable	O
Grade	O
2	O
PPES	O
or	O
Grade	O
3-4	O
PPES	O
until	O
improvement	O
to	O
Grade	O
1	O
;	O
resume	O
COMETRIQ	O
at	O
a	O
reduced	O
dose	O
.	O
	
5.10	O
Depression	O
Women	O
with	O
a	O
history	O
of	O
depression	O
should	O
be	O
carefully	O
observed	O
and	O
Natazia	O
discontinued	O
if	O
depression	O
recurs	O
to	O
a	O
serious	O
degree	O
.	O
	
*	O
Healthcare	O
sites	O
must	O
be	O
certified	O
with	O
the	O
program	O
and	O
ensure	O
that	O
XIAFLEX	O
is	O
only	O
dispensed	O
for	O
use	O
by	O
certified	O
prescribers	O
.	O
	
Among	O
401	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
treated	O
with	O
the	O
recommended	O
regimen	O
of	O
NULOJIX	O
and	O
the	O
71	O
patients	O
in	O
Study	O
3	O
treated	O
with	O
a	O
very	O
similar	O
(	O
but	O
non-identical	O
)	O
NULOJIX	O
regimen	O
,	O
there	O
were	O
5	O
cases	O
of	O
PTLD	B
:	O
3	O
in	O
EBV	O
seropositive	O
patients	O
and	O
2	O
in	O
EBV	O
seronegative	O
patients	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
5.14	O
Potential	O
for	O
Cognitive	O
and	O
Motor	O
Impairment	O
FANAPT	O
,	O
like	O
other	O
antipsychotics	O
,	O
has	O
the	O
potential	O
to	O
impair	B
judgment	I
.	O
	
FARXIGA	O
should	O
not	O
be	O
used	O
in	O
patients	O
with	O
active	O
bladder	O
cancer	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
prior	O
history	O
of	O
bladder	O
cancer	O
.	O
	
Table	O
4	O
.	O
	
The	O
infections	B
consisted	O
primarily	O
of	O
upper	B
respiratory	I
tract	I
infections	I
,	O
herpes	B
infections	I
,	O
urinary	B
tract	I
infections	I
,	O
and	O
lower	B
respiratory	I
tract	I
infections	I
.	O
	
Hypoglycemia	O
The	O
frequency	O
of	O
hypoglycemia	B
by	O
study	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
is	O
shown	O
in	O
Table	O
5	O
.	O
	
Baseline	O
estimated	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
eGFR	O
>	O
=60	O
ml/min/1.73	O
m2	O
)	O
in	O
95.7	O
%	O
of	O
the	O
TRULICITY	O
population	O
.	O
	
Resume	O
COMETRIQ	O
therapy	O
after	O
surgery	O
based	O
on	O
clinical	O
judgment	O
of	O
adequate	O
wound	O
healing	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
was	O
7.4	O
weeks	O
(	O
range	O
:	O
1.6-13.4	O
)	O
and	O
6.3	O
weeks	O
(	O
range	O
:	O
0.3-18.9	O
)	O
after	O
the	O
initiation	O
of	O
YERVOY	O
for	O
patients	O
with	O
Grade	O
3-5	O
enterocolitis	B
and	O
with	O
Grade	O
2	O
enterocolitis	B
,	O
respectively	O
.	O
	
If	O
formation	O
of	O
anti-blinatumomab	O
antibodies	O
with	O
a	O
clinically	O
significant	O
effect	O
is	O
suspected	O
,	O
contact	O
Amgen	O
at	O
1-800-77-AMGEN	O
(	O
1-800-772-6436	O
)	O
to	O
discuss	O
antibody	O
testing	O
.	O
	
The	O
immunogenicity	O
of	O
BLINCYTO	O
has	O
been	O
evaluated	O
using	O
either	O
an	O
electrochemiluminescence	O
detection	O
technology	O
(	O
ECL	O
)	O
or	O
an	O
enzyme-linked	O
immunosorbent	O
assay	O
(	O
ELISA	O
)	O
screening	O
immunoassay	O
for	O
the	O
detection	O
of	O
binding	O
anti-blinatumomab	O
antibodies	O
.	O
	
One	O
of	O
the	O
476	O
patients	O
treated	O
with	O
cyclosporine	O
developed	O
PTLD	B
,	O
without	O
CNS	O
involvement	O
.	O
	
In	O
both	O
treatment	O
arms	O
,	O
patients	O
received	O
SIRTURO	O
or	O
placebo	O
in	O
combination	O
with	O
other	O
drugs	O
used	O
to	O
treat	O
MDR-TB	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
1	O
%	O
or	O
greater	O
)	O
are	O
:	O
systemic	B
hypersensitivity	I
,	O
hyperglycemia	B
,	O
transaminases	B
abnormal	I
,	O
fever	B
,	O
pancreatitis	B
,	O
local	B
reactions	I
,	O
vomiting	B
,	O
nausea	B
,	O
thrombosis	B
,	O
hyperbilirubinemia	B
,	O
abdominal	B
pain	I
,	O
and	O
diarrhea	B
.	O
	
Laboratory	O
Tests	O
Increase	O
in	O
Hematocrit	O
In	O
the	O
pool	O
of	O
13	O
placebo-controlled	O
studies	O
,	O
increases	B
from	I
baseline	I
in	I
mean	I
hematocrit	I
values	I
were	O
observed	O
in	O
FARXIGA-treated	O
patients	O
starting	O
at	O
Week	O
1	O
and	O
continuing	O
up	O
to	O
Week	O
16	O
,	O
when	O
the	O
maximum	O
mean	O
difference	O
from	O
baseline	O
was	O
observed	O
.	O
	
In	O
this	O
trial	O
,	O
elevated	B
plasma	I
prolactin	I
levels	I
were	O
observed	O
in	O
26	O
%	O
of	O
adults	O
treated	O
with	O
FANAPT	O
compared	O
to	O
12	O
%	O
in	O
the	O
placebo-group	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
1670	O
patients	O
to	O
TRULICITY	O
and	O
a	O
mean	O
duration	O
of	O
exposure	O
to	O
TRULICITY	O
of	O
23.8	O
weeks	O
.	O
	
The	O
data	O
described	O
below	O
represent	O
adverse	O
reactions	O
observed	O
from	O
the	O
two	O
placebo-controlled	O
trials	O
,	O
consisting	O
of	O
77	O
patients	O
who	O
received	O
FIRAZYR	O
at	O
a	O
dose	O
of	O
30	O
mg	O
SC	O
,	O
and	O
75	O
who	O
received	O
placebo	O
.	O
	
Table	O
4	O
shows	O
the	O
number	O
of	O
patients	O
experiencing	O
bleeding	B
events	O
in	O
the	O
study	O
.	O
	
Neuraceq	O
,	O
like	O
all	O
radiopharmaceuticals	O
,	O
contributes	O
to	O
a	O
patient	O
's	O
long-term	B
cumulative	I
radiation	I
exposure	I
.	O
	
Withhold	O
ZYKADIA	O
in	O
patients	O
who	O
develop	O
a	O
QTc	O
interval	O
greater	O
than	O
500	O
msec	O
on	O
at	O
least	O
2	O
separate	O
ECGs	O
until	O
the	O
QTc	O
interval	O
is	O
less	O
than	O
481	O
msec	O
or	O
recovery	O
to	O
baseline	O
if	O
the	O
QTc	O
interval	O
is	O
greater	O
than	O
or	O
equal	O
to	O
481	O
msec	O
,	O
then	O
resume	O
ZYKADIA	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
.	O
	
Elevations	O
of	O
AST	O
,	O
ALT	O
,	O
or	O
bilirubin	O
from	O
the	O
patient	O
's	O
baseline	O
should	O
prompt	O
more	O
frequent	O
monitoring	O
.	O
	
However	O
,	O
the	O
incidence	O
of	O
pruritus	B
increased	O
with	O
more	O
injections	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Neuropathy	B
lasting	O
more	O
than	O
one	O
year	O
occurred	O
in	O
5	O
%	O
(	O
26/503	O
)	O
of	O
patients	O
.	O
	
Adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
>	O
1	O
%	O
were	O
associated	O
with	O
the	O
injection	B
site	I
(	I
1.3	I
%	I
)	I
,	I
problems	I
.	O
	
If	O
signs	O
or	O
symptoms	O
suggest	O
SJS/TEN	O
,	O
use	O
of	O
this	O
drug	O
should	O
not	O
be	O
resumed	O
and	O
alternative	O
therapy	O
should	O
be	O
considered	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
(	O
5.15	O
)	O
*	O
Be	O
alert	O
to	O
hypokalemia	O
and	O
hyperglycemia	O
.	O
	
ECG	O
analysis	O
did	O
not	O
identify	O
QTc	B
prolongation	I
.	O
	
Withhold	O
Zydelig	O
if	O
the	O
ALT	O
or	O
AST	O
is	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
,	O
and	O
continue	O
to	O
monitor	O
AST	O
,	O
ALT	O
and	O
total	O
bilirubin	O
weekly	O
until	O
the	O
abnormality	O
is	O
resolved	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Observe	O
infants	O
for	O
signs	O
or	O
symptoms	O
of	O
benzyl	O
alcohol	O
toxicity	O
following	O
AdreView	O
administration	O
.	O
	
Women	O
with	O
a	O
history	O
of	O
COC-related	O
cholestasis	B
may	O
have	O
the	O
condition	O
recur	O
with	O
subsequent	O
COC	O
use	O
.	O
	
Avoid	O
using	O
ZYKADIA	O
in	O
combination	O
with	O
other	O
agents	O
known	O
to	O
cause	O
bradycardia	O
(	O
e.g.	O
,	O
beta-blockers	O
,	O
non-dihydropyridine	O
calcium	O
channel	O
blockers	O
,	O
clonidine	O
,	O
and	O
digoxin	O
)	O
to	O
the	O
extent	O
possible	O
.	O
	
No	O
new	O
safety	O
signals	O
were	O
identified	O
among	O
subjects	O
who	O
were	O
retreated	O
with	O
XIAFLEX	O
.	O
	
Monitor	O
serum	O
ALT	O
values	O
monthly	O
during	O
therapy	O
with	O
Ferriprox	O
,	O
and	O
consider	O
interruption	O
of	O
therapy	O
if	O
there	O
is	O
a	O
persistent	O
increase	O
in	O
the	O
serum	O
transaminase	O
levels	O
.	O
	
COPD	O
may	O
deteriorate	O
acutely	O
over	O
a	O
period	O
of	O
hours	O
or	O
chronically	O
over	O
several	O
days	O
or	O
longer	O
.	O
	
Ongoing	O
monitoring	O
of	O
plasma	O
ammonia	O
levels	O
,	O
neurological	O
status	O
,	O
laboratory	O
tests	O
and	O
clinical	O
responses	O
in	O
patients	O
receiving	O
Carbaglu	O
is	O
crucial	O
to	O
assess	O
patient	O
response	O
to	O
treatment	O
.	O
	
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
rhabdomyolysis	B
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
Fatal	B
cases	O
of	O
toxic	B
epidermal	I
necrolysis	I
have	O
been	O
reported	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Withdrawal	O
symptoms	O
(	O
e.g.	O
,	O
convulsions	O
,	O
psychosis	O
,	O
hallucinations	O
,	O
behavioral	O
disorder	O
,	O
tremor	O
,	O
and	O
anxiety	O
)	O
have	O
been	O
reported	O
following	O
abrupt	O
discontinuance	O
of	O
benzodiazepines	O
.	O
	
CTCAE	O
Grade	O
3	O
or	O
4	O
ILD/pneumonitis	O
was	O
reported	O
in	O
3	O
%	O
of	O
patients	O
,	O
and	O
fatal	B
ILD/pneumonitis	O
was	O
reported	O
in	O
1	O
patient	O
(	O
0.4	O
%	O
)	O
in	O
Study	O
1	O
.	O
	
Hypersensitivity	B
reactions	I
have	O
uncommonly	O
been	O
reported	O
during	O
the	O
postmarketing	O
use	O
of	O
AdreView	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Across	O
the	O
clinical	O
development	O
program	O
for	O
YERVOY	O
,	O
mycophenolate	O
treatment	O
has	O
been	O
administered	O
in	O
patients	O
who	O
have	O
persistent	O
severe	O
hepatitis	O
despite	O
high-dose	O
corticosteroids	O
.	O
	
Monitor	O
patients	O
for	O
the	O
development	O
of	O
severe	O
cutaneous	O
reactions	O
and	O
discontinue	O
Zydelig	O
.	O
	
No	O
deaths	B
clearly	O
related	O
to	O
ZYTIGA	O
were	O
reported	O
due	O
to	O
hepatotoxicity	B
events	O
.	O
	
Correct	O
hypokalemia	O
or	O
hypomagnesemia	O
prior	O
to	O
initiating	O
HALAVEN	O
and	O
monitor	O
these	O
electrolytes	O
periodically	O
during	O
therapy	O
.	O
	
Diarrhea	B
can	O
occur	O
at	O
any	O
time	O
.	O
	
The	O
use	O
of	O
clinical	O
information	O
in	O
the	O
interpretation	O
of	O
Neuraceq	O
images	O
has	O
not	O
been	O
evaluated	O
and	O
may	O
lead	O
to	O
errors	O
.	O
	
5.3	O
Withdrawal	O
Symptoms	O
Abrupt	O
discontinuation	O
of	O
ONFI	O
should	O
be	O
avoided	O
.	O
	
5.7	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
FARXIGA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
(	O
5.3	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
5.1	O
Hyperammonemia	O
Any	O
episode	O
of	O
acute	O
symptomatic	O
hyperammonemia	O
should	O
be	O
treated	O
as	O
a	O
life-threatening	O
emergency	O
.	O
	
The	O
safety	O
profile	O
for	O
subjects	O
who	O
completed	O
48	O
weeks	O
of	O
treatment	O
was	O
similar	O
to	O
the	O
safety	O
profile	O
for	O
subjects	O
who	O
completed	O
24	O
weeks	O
of	O
treatment	O
.	O
	
Data	O
are	O
not	O
available	O
to	O
determine	O
whether	O
the	O
rate	O
of	O
death	B
in	O
patients	O
with	O
COPD	O
is	O
increased	O
by	O
LABA	O
.	O
	
Gastrointestinal	O
Adverse	O
Reactions	O
In	O
the	O
four	O
pivotal	O
studies	O
,	O
patients	O
on	O
PRADAXA	O
150	O
mg	O
had	O
a	O
similar	O
incidence	O
of	O
gastrointestinal	B
adverse	I
reactions	I
(	O
24.7	O
%	O
vs.	O
22.7	O
%	O
on	O
warfarin	O
)	O
.	O
	
(	O
5.7	O
)	O
*	O
Embryo-fetal	B
toxicity	I
:	O
may	O
cause	O
fetal	B
harm	I
.	O
	
Women	O
with	O
hypertriglyceridemia	O
,	O
or	O
a	O
family	O
history	O
thereof	O
,	O
may	O
be	O
at	O
an	O
increased	O
risk	O
of	O
pancreatitis	B
when	O
using	O
COCs	O
.	O
	
The	O
period	O
of	O
time	O
necessary	O
to	O
discontinue	O
any	O
specific	O
medication	O
prior	O
to	O
AdreView	O
dosing	O
has	O
not	O
been	O
established	O
[	O
see	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
hypertension	B
increases	O
with	O
increasing	O
concentration	O
of	O
progestin	O
.	O
	
In	O
all	O
three	O
studies	O
a	O
placebo	O
(	O
Cycle	O
1	O
of	O
the	O
breast	O
cancer	O
study	O
only	O
)	O
or	O
a	O
non-US-approved	O
filgrastim	O
product	O
were	O
used	O
as	O
controls	O
.	O
	
5.5	O
Hyperglycemia	O
Hyperglycemia	B
can	O
occur	O
in	O
patients	O
receiving	O
ZYKADIA	O
.	O
	
In	O
each	O
cycle	O
,	O
two	O
injections	O
of	O
XIAFLEX	O
or	O
two	O
injections	O
of	O
placebo	O
were	O
administered	O
1	O
to	O
3	O
days	O
apart	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Thrombocytopenia	B
,	O
leukopenia	B
(	O
neutropenia	B
and	O
lymphopenia	B
)	O
,	O
and	O
anemia	B
:	O
Monitor	O
blood	O
counts	O
and	O
modify	O
dosage	O
for	O
hematologic	O
toxicities	O
.	O
	
The	O
frequency	O
,	O
type	O
and	O
severity	O
of	O
adverse	O
drug	O
reactions	O
in	O
pediatric	O
subjects	O
were	O
comparable	O
to	O
those	O
observed	O
in	O
adult	O
subjects	O
,	O
except	O
for	O
rash	B
which	O
was	O
observed	O
more	O
frequently	O
in	O
pediatric	O
subjects	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTS	O
,	O
(	O
B	O
)	O
EPIDURAL	B
HEMATOMA	I
WARNING	O
:	O
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTS	O
,	O
(	O
B	O
)	O
EPIDURAL	B
HEMATOMA	I
(	O
A	O
)	O
PREMATURE	O
DISCONTINUATION	O
OF	O
PRADAXA	O
INCREASES	O
THE	O
RISK	O
OF	O
THROMBOTIC	O
EVENTSPremature	O
discontinuation	O
of	O
any	O
oral	O
anticoagulant	O
,	O
including	O
PRADAXA	O
,	O
increases	O
the	O
risk	O
of	O
thrombotic	O
events	O
.	O
	
The	O
majority	O
of	O
these	O
cases	O
were	O
mild	O
to	O
moderate	O
and	O
occurred	O
during	O
the	O
first	O
year	O
of	O
exposure	O
.	O
	
Injection	O
of	O
XIAFLEX	O
into	O
corpora	B
cavernosa	I
of	I
the	I
penis	I
may	I
result	I
in	I
damage	I
to	O
those	O
structures	O
and	O
possible	O
injury	O
such	O
as	O
corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
.	O
	
5.9	O
Reversible	O
Posterior	O
Leukoencephalopathy	O
Syndrome	O
Reversible	B
Posterior	I
Leukoencephalopathy	I
Syndrome	I
(	O
RPLS	B
)	O
,	O
a	O
syndrome	O
of	O
subcortical	B
vasogenic	I
edema	I
diagnosed	O
by	O
characteristic	O
finding	O
on	O
MRI	O
,	O
occurred	O
in	O
one	O
(	O
<	O
1	O
%	O
)	O
patient	O
.	O
	
5.5	O
Risk	O
of	O
bleeding	O
in	O
Patients	O
with	O
Abnormal	O
Coagulation	O
In	O
the	O
XIAFLEX	O
trials	O
in	O
Dupuytren	O
's	O
contracture	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
70	O
%	O
and	O
38	O
%	O
of	O
XIAFLEX-treated	O
patients	O
developed	O
an	O
ecchymosis/contusion	O
or	O
an	O
injection	B
site	I
hemorrhage	I
,	O
respectively	O
(	O
see	O
Table	O
3	O
)	O
.	O
	
Testing	O
should	O
include	O
visual	O
acuity	O
and	O
dilated	O
fundus	O
photography	O
.	O
	
5.3	O
Hypoglycemia	O
with	O
Concomitant	O
Use	O
with	O
Insulin	O
and	O
Insulin	O
Secretagogues	O
Insulin	O
and	O
insulin	O
secretagogues	O
are	O
known	O
to	O
cause	O
hypoglycemia	O
.	O
	
In	O
the	O
studies	O
with	O
CIMZIA	O
in	O
RA	O
,	O
there	O
were	O
36	O
cases	O
of	O
TB	B
among	O
2,367	O
exposed	O
patients	O
,	O
including	O
some	O
fatal	B
cases	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
were	O
injection	B
site	I
reactions	I
,	O
which	O
occurred	O
in	O
almost	O
all	O
patients	O
(	O
97	O
%	O
)	O
in	O
clinical	O
trials	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
genital	O
mycotic	O
infections	O
were	O
more	O
likely	O
to	O
have	O
a	O
genital	B
mycotic	I
infection	I
during	O
the	O
study	O
than	O
those	O
with	O
no	O
prior	O
history	O
(	O
10.0	O
%	O
,	O
23.1	O
%	O
,	O
and	O
25.0	O
%	O
versus	O
0.8	O
%	O
,	O
5.9	O
%	O
,	O
and	O
5.0	O
%	O
on	O
placebo	O
,	O
FARXIGA	O
5	O
mg	O
,	O
and	O
FARXIGA	O
10	O
mg	O
,	O
respectively	O
)	O
.	O
	
Tissue	O
culture	O
experiments	O
indicate	O
that	O
approximately	O
one-third	O
of	O
human	O
breast	O
cancers	O
are	O
prolactin-dependent	O
in	O
vitro	O
,	O
a	O
factor	O
of	O
potential	O
importance	O
if	O
the	O
prescription	O
of	O
these	O
drugs	O
is	O
contemplated	O
in	O
a	O
patient	O
with	O
previously	O
detected	O
breast	O
cancer	O
.	O
	
The	O
Study	O
1	O
population	O
included	O
patients	O
with	O
a	O
median	O
age	O
of	O
11	O
years	O
(	O
2	O
to	O
18	O
years	O
)	O
;	O
59	O
%	O
were	O
male	O
,	O
78	O
%	O
were	O
White	O
,	O
10	O
%	O
were	O
Black/African	O
American	O
,	O
5	O
%	O
were	O
Asian	O
,	O
and	O
7	O
%	O
were	O
other	O
or	O
unknown	O
.	O
	
Two	O
(	O
1	O
%	O
)	O
of	O
these	O
were	O
fatal	B
.	O
	
The	O
long-term	O
clinical	O
effects	O
of	O
the	O
increase	B
in	I
HR	I
have	O
not	O
been	O
established	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
.	O
	
Among	O
the	O
477	O
patients	O
in	O
Studies	O
1	O
,	O
2	O
,	O
and	O
3	O
treated	O
with	O
the	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
,	O
there	O
were	O
8	O
cases	O
of	O
PTLD	B
:	O
2	O
in	O
EBV	O
seropositive	O
patients	O
and	O
6	O
in	O
EBV	O
seronegative	O
or	O
serostatus	O
unknown	O
patients	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Janssen	O
Therapeutics	O
,	O
Division	O
of	O
Janssen	O
Products	O
,	O
LP	O
at	O
1-800-JANSSEN	O
(	O
1-800-526-7736	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
In	O
clinical	O
trials	O
,	O
rapid	O
corticosteroid	O
tapering	O
resulted	O
in	O
recurrence	O
or	O
worsening	O
symptoms	O
of	O
enterocolitis	O
in	O
some	O
patients	O
.	O
	
Non-melanoma	B
skin	I
cancer	I
was	O
reported	O
in	O
1.5	O
%	O
(	O
6/401	O
)	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
NULOJIX	O
regimen	O
and	O
in	O
3.7	O
%	O
(	O
15/405	O
)	O
of	O
patients	O
treated	O
with	O
cyclosporine	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
CYTOKINE	B
RELEASE	I
SYNDROME	I
and	O
NEUROLOGICAL	B
TOXICITIES	I
WARNING	O
:	O
CYTOKINE	B
RELEASE	I
SYNDROME	I
and	O
NEUROLOGICAL	B
TOXICITIES	I
*	O
Cytokine	B
Release	I
Syndrome	I
(	O
CRS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
Evaluate	O
at	O
each	O
visit	O
for	O
signs	O
and	O
symptoms	O
of	O
endocrinopathy	O
.	O
	
The	O
safety	O
of	O
COMETRIQ	O
was	O
evaluated	O
in	O
330	O
patients	O
with	O
progressive	O
metastatic	O
medullary	O
thyroid	O
cancer	O
randomized	O
to	O
receive	O
140	O
mg	O
COMETRIQ	O
(	O
n	O
=	O
214	O
)	O
or	O
placebo	O
(	O
n	O
=	O
109	O
)	O
administered	O
daily	O
until	O
disease	O
progression	O
or	O
intolerable	O
toxicity	O
in	O
a	O
randomized	O
,	O
doubleblind	O
,	O
controlled	O
trial	O
.	O
	
The	O
preservative	O
in	O
DUREZOL	O
may	O
be	O
absorbed	O
by	O
soft	O
contact	O
lenses	O
.	O
	
Patients	O
with	O
severe	O
neutropenia	O
(	O
absolute	O
neutrophil	O
count	O
<	O
1000/mm	O
3	O
)	O
should	O
discontinue	O
FANAPT	O
and	O
have	O
their	O
WBC	O
followed	O
until	O
recovery	O
.	O
	
POTIGA	O
was	O
associated	O
with	O
dose-related	O
weight	B
gain	I
,	O
with	O
mean	O
weight	B
increasing	I
by	O
0.2	O
kg	O
,	O
1.2	O
kg	O
,	O
1.6	O
kg	O
,	O
and	O
2.7	O
kg	O
in	O
the	O
placebo	O
,	O
600	O
mg	O
per	O
day	O
,	O
900	O
mg	O
per	O
day	O
,	O
and	O
1,200	O
mg	O
per	O
day	O
groups	O
,	O
respectively	O
.	O
	
5.3	O
Cytopenias	O
Treatment-emergent	O
Grade	O
3	O
or	O
4	O
cytopenias	B
including	O
neutropenia	B
(	O
range	O
,	O
19	O
to	O
29	O
%	O
)	O
,	O
thrombocytopenia	B
(	O
range	O
,	O
5	O
to	O
17	O
%	O
)	O
,	O
and	O
anemia	B
(	O
range	O
,	O
0	O
to	O
9	O
%	O
)	O
occurred	O
in	O
patients	O
treated	O
with	O
IMBRUVICA	O
.	O
	
These	O
patients	O
received	O
TREANDA	O
at	O
a	O
dose	O
of	O
120	O
mg/m	O
2	O
intravenously	O
on	O
Days	O
1	O
and	O
2	O
for	O
up	O
to	O
eight	O
21-day	O
cycles	O
.	O
	
In	O
the	O
majority	O
of	O
patients	O
who	O
experienced	O
flushing	B
,	O
it	O
was	O
mild	O
or	O
moderate	O
in	O
severity	O
.	O
	
Sleep	O
apnea	O
is	O
common	O
in	O
MPS	O
IVA	O
patients	O
.	O
	
Patients	O
with	O
a	O
prior	O
DRESS	O
reaction	O
with	O
either	O
oxcarbazepine	O
or	O
APTIOM	O
should	O
not	O
be	O
treated	O
with	O
APTIOM	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
high	O
tumor	O
burden	O
)	O
(	O
5.6	O
)	O
.	O
	
Monitor	O
patients	O
for	O
pulmonary	O
symptoms	O
indicative	O
of	O
ILD/pneumonitis	O
.	O
	
Depending	O
on	O
the	O
severity	O
of	O
hyponatremia	O
,	O
the	O
dose	O
of	O
APTIOM	O
may	O
need	O
to	O
be	O
reduced	O
or	O
discontinued	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
NESINA	O
should	O
promptly	O
be	O
discontinued	O
and	O
appropriate	O
management	O
should	O
be	O
initiated	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Wyeth	O
Pharmaceuticals	O
Inc.	O
,	O
a	O
subsidiary	O
of	O
Pfizer	O
Inc.	O
,	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
5.3	O
Hepatic	O
Effects	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
fatal	B
and	O
nonfatal	O
hepatic	B
failure	I
in	O
patients	O
taking	O
NESINA	O
,	O
although	O
some	O
of	O
the	O
reports	O
contain	O
insufficient	O
information	O
necessary	O
to	O
establish	O
the	O
probable	O
cause	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Remove	O
contact	O
lenses	O
prior	O
to	O
instillation	O
of	O
BEPREVE	O
.	O
	
Permanently	O
discontinue	O
XALKORI	O
in	O
patients	O
who	O
develop	O
QTc	O
greater	O
than	O
500	O
ms	O
or	O
greater	O
than	O
or	O
equal	O
to	O
60	O
ms	O
change	O
from	O
baseline	O
with	O
Torsade	O
de	O
pointes	O
or	O
polymorphic	O
ventricular	O
tachycardia	O
or	O
signs/symptoms	O
of	O
serious	O
arrhythmia	O
.	O
	
In	O
the	O
controlled	O
adjunctive	O
epilepsy	O
trials	O
,	O
4/415	O
patients	O
(	O
1.0	O
%	O
)	O
treated	O
with	O
800	O
mg	O
and	O
6/410	O
(	O
1.5	O
%	O
)	O
patients	O
treated	O
with	O
1200	O
mg	O
of	O
APTIOM	O
had	O
at	O
least	O
one	O
serum	O
sodium	O
value	O
less	O
than	O
125	O
mEq/L	O
,	O
compared	O
to	O
none	O
of	O
the	O
patients	O
assigned	O
to	O
placebo	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Adverse	O
reactions	O
associated	O
with	O
ophthalmic	O
steroids	O
include	O
elevated	B
intraocular	I
pressure	I
,	O
which	O
may	O
be	O
associated	O
with	O
optic	B
nerve	I
damage	I
,	O
visual	B
acuity	I
and	I
field	I
defects	I
,	O
posterior	B
subcapsular	I
cataract	I
formation	I
;	O
secondary	B
ocular	I
infection	I
,	O
and	O
perforation	B
of	I
the	I
globe	I
where	O
there	O
is	O
thinning	O
of	O
the	O
cornea	O
or	O
sclera	O
.	O
	
The	O
safety	O
of	O
Prolia	O
in	O
the	O
treatment	O
of	O
bone	O
loss	O
in	O
women	O
with	O
nonmetastatic	O
breast	O
cancer	O
receiving	O
aromatase	O
inhibitor	O
(	O
AI	O
)	O
therapy	O
was	O
assessed	O
in	O
a	O
2-year	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multinational	O
study	O
of	O
252	O
postmenopausal	O
women	O
aged	O
35	O
to	O
84	O
years	O
.	O
	
Table	O
3	O
.	O
	
Pain	B
in	I
extremity	I
(	O
7.7	O
%	O
placebo	O
vs.	O
9.9	O
%	O
Prolia	O
)	O
and	O
musculoskeletal	B
pain	I
(	O
3.8	O
%	O
placebo	O
vs.	O
6.0	O
%	O
Prolia	O
)	O
have	O
also	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O
	
Adverse	O
Reaction	O
PlaceboN=646	O
INVOKANA	O
100	O
mgN=833	O
INVOKANA	O
300	O
mgN=834	O
Female	B
genital	I
mycotic	I
infections	I
3.2	O
%	O
10.4	O
%	O
11.4	O
%	O
Urinary	B
tract	I
infections	I
4.0	O
%	O
5.9	O
%	O
4.3	O
%	O
Increased	B
urination	I
0.8	O
%	O
5.3	O
%	O
4.6	O
%	O
Male	B
genital	I
mycotic	I
infections	I
0.6	O
%	O
4.2	O
%	O
3.7	O
%	O
Vulvovaginal	B
pruritus	I
0.0	O
%	O
1.6	O
%	O
3.0	O
%	O
Thirst	B
0.2	O
%	O
2.8	O
%	O
2.3	O
%	O
Constipation	B
0.9	O
%	O
1.8	O
%	O
2.3	O
%	O
Nausea	B
1.5	O
%	O
2.2	O
%	O
2.3	O
%	O
Abdominal	B
pain	I
was	O
also	O
more	O
commonly	O
reported	O
in	O
patients	O
taking	O
INVOKANA	O
100	O
mg	O
(	O
1.8	O
%	O
)	O
,	O
300	O
mg	O
(	O
1.7	O
%	O
)	O
than	O
in	O
patients	O
taking	O
placebo	O
(	O
0.8	O
%	O
)	O
.	O
	
These	O
metabolic	B
changes	I
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
weight	B
gain	I
.	O
	
The	O
majority	O
(	O
95	O
%	O
)	O
of	O
these	O
patients	O
had	O
Grade	O
1	O
visual	B
adverse	I
reactions	I
.	O
	
In	O
patients	O
with	O
transaminase	O
elevations	O
,	O
monitor	O
liver	O
enzymes	O
more	O
frequently	O
.	O
	
In	O
addition	O
,	O
beta-agonists	O
have	O
been	O
reported	O
to	O
produce	O
ECG	B
changes	I
,	O
such	O
as	O
flattening	B
of	I
the	I
T	I
wave	I
,	O
prolongation	B
of	I
the	I
QTc	I
interval	I
,	O
and	O
ST	B
segment	I
depression	I
,	O
although	O
the	O
clinical	O
significance	O
of	O
these	O
findings	O
is	O
unknown	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
serious	O
adverse	O
reactions	O
reported	O
with	O
PRADAXA	O
were	O
related	O
to	O
bleeding	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
This	O
case	O
represented	O
1	O
out	O
of	O
1209	O
patients	O
in	O
BOSULIF	O
clinical	O
trials	O
.	O
	
Inhalation	O
of	O
high	O
doses	O
of	O
beta2-adrenergic	O
agonists	O
may	O
produce	O
increases	B
in	I
plasma	I
glucose	I
.	O
	
Advise	O
the	O
patient	O
to	O
rinse	O
his/her	O
mouth	O
with	O
water	O
without	O
swallowing	O
after	O
inhalation	O
to	O
help	O
reduce	O
the	O
risk	O
.	O
	
The	O
laboratory	O
findings	O
in	O
these	O
4	O
subjects	O
improved	O
but	O
did	O
not	O
completely	O
resolve	O
in	O
all	O
subjects	O
upon	O
discontinuation	O
of	O
STRIBILD	O
.	O
	
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
in	O
All	O
Controlled	O
Clinical	O
Studies	O
In	O
the	O
3	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
studies	O
,	O
199	O
of	O
813	O
patients	O
(	O
25	O
%	O
)	O
receiving	O
POTIGA	O
and	O
45	O
of	O
427	O
patients	O
(	O
11	O
%	O
)	O
receiving	O
placebo	O
discontinued	O
treatment	O
because	O
of	O
adverse	O
reactions	O
.	O
	
Do	O
not	O
start	O
in	O
patients	O
with	O
active	O
infections	O
.	O
	
Discontinuations	O
due	O
to	O
adverse	O
events	O
were	O
reported	O
for	O
6	O
%	O
of	O
XTANDI-treated	O
patients	O
and	O
6	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
Similar	O
results	O
may	O
be	O
anticipated	O
in	O
patients	O
treated	O
with	O
Edarbi	O
[	O
seeDrug	O
Interactions	O
(	O
7	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
,	O
andClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
eye	B
swelling	I
,	O
eyelid	B
edema	I
,	O
dysphagia	B
,	O
nausea	B
,	O
flu-like	B
symptoms	I
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
reaction	I
,	O
allergic	B
dermatitis	I
,	O
localized	B
allergic	I
reactions	I
,	O
herpes	B
zoster	I
,	O
muscular	B
weakness	I
,	O
muscle	B
spasm	I
,	O
dysarthria	B
,	O
myalgia	B
and	O
hypersensitivity	B
.	O
	
*	O
When	O
pregnancy	O
is	O
detected	O
,	O
discontinue	O
Edarbi	O
as	O
soon	O
as	O
possible	O
.	O
	
Adverse	O
reactions	O
reported	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
were	O
:	O
facial	B
paresis	I
(	O
brow	B
ptosis	I
)	O
,	O
muscle	B
disorder	I
(	O
elevation	B
of	I
eyebrow	I
)	O
,	O
injection	B
site	I
pain	I
,	O
and	O
eyelid	B
edema	I
.	O
	
Monitor	O
for	O
symptoms	O
of	O
gastrointestinal	O
perforation	O
or	O
fistula	O
periodically	O
throughout	O
treatment	O
with	O
INLYTA	O
.	O
	
In	O
some	O
patients	O
,	O
heart	B
rate	I
decrease	I
during	O
the	O
second	O
period	O
is	O
more	O
pronounced	O
than	O
the	O
decrease	O
observed	O
in	O
the	O
first	O
6	O
hours	O
.	O
	
6Includes	O
the	O
preferred	O
terms	O
somnolence	B
,	O
sedation	B
,	O
and	O
hypersomnia	B
.	O
	
Hypertension	B
In	O
the	O
two	O
randomized	O
trials	O
,	O
hypertension	B
was	O
reported	O
in	O
11	O
%	O
of	O
patients	O
receiving	O
XTANDI	O
and	O
4	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
The	O
emtricitabine	O
and	O
tenofovir	O
DF	O
components	O
of	O
STRIBILD	O
are	O
primarily	O
excreted	O
by	O
the	O
kidney	O
.	O
	
Therefore	O
,	O
the	O
combination	O
of	O
anakinra	O
with	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Ask	O
your	O
healthcare	O
provider	O
if	O
you	O
do	O
not	O
know	O
if	O
you	O
take	O
any	O
of	O
these	O
medicines	O
.	O
	
Appropriate	O
medical	O
support	O
,	O
including	O
cardiopulmonary	O
resuscitation	O
equipment	O
,	O
should	O
be	O
readily	O
available	O
when	O
alglucosidase	O
alfa	O
is	O
administered	O
.	O
	
Discontinue	O
INLYTA	O
if	O
hypertension	O
is	O
severe	O
and	O
persistent	O
despite	O
anti-hypertensive	O
therapy	O
and	O
dose	O
reduction	O
of	O
INLYTA	O
,	O
and	O
discontinuation	O
should	O
be	O
considered	O
if	O
there	O
is	O
evidence	O
of	O
hypertensive	O
crisis	O
.	O
	
While	O
these	O
symptoms	O
can	O
occur	O
at	O
low	O
doses	O
,	O
they	O
occur	O
more	O
frequently	O
and	O
with	O
greater	O
severity	O
with	O
high	O
potency	O
and	O
at	O
higher	O
doses	O
of	O
first	O
generation	O
antipsychotic	O
drugs	O
.	O
	
The	O
proportion	O
of	O
patients	O
with	O
transaminase	B
elevations	I
>	O
=3	O
times	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
(	O
at	O
Endpoint	O
)	O
was	O
2.5	O
%	O
for	O
SAPHRIS-treated	O
patients	O
versus	O
0.6	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
In	O
patients	O
with	O
PHN	O
receiving	O
HORIZANT	O
twice	O
daily	O
,	O
the	O
dose	O
should	O
be	O
reduced	O
to	O
once	O
daily	O
for	O
1	O
week	O
prior	O
to	O
discontinuation	O
to	O
minimize	O
the	O
potential	O
of	O
withdrawal	O
seizure	O
,	O
see	O
Table	O
2	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
median	O
onset	O
time	O
for	O
hypertension	B
(	O
systolic	B
blood	I
pressure	I
>	I
150	I
mmHg	I
or	O
diastolic	B
blood	I
pressure	I
>	I
100	I
mmHg	I
)	O
was	O
within	O
the	O
first	O
month	O
of	O
the	O
start	O
of	O
INLYTA	O
treatment	O
and	O
blood	B
pressure	I
increases	I
have	O
been	O
observed	O
as	O
early	O
as	O
4	O
days	O
after	O
starting	O
INLYTA	O
.	O
	
*	O
have	O
any	O
other	O
medical	O
conditions	O
.	O
	
b	O
Peripheral	B
neuropathies	I
NEC	I
includes	O
the	O
preferred	O
terms	O
under	O
HLT	O
peripheral	B
neuropathies	I
NEC	I
.	O
	
(	O
6.2	O
)	O
In	O
clinical	O
trials	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
,	O
headache	B
,	O
nausea	B
,	O
vertigo	B
,	O
dry	B
mouth	I
or	O
dizziness	B
occurred	O
in	O
<	O
1	O
%	O
of	O
subjects	O
.	O
	
Treatment-experienced	O
,	O
Integrase	O
Strand	O
Transfer	O
Inhibitor-experienced	O
Subjects	O
:	O
In	O
a	O
multicenter	O
,	O
open-label	O
,	O
single-arm	O
trial	O
(	O
ING112574	O
,	O
VIKING-3	O
)	O
,	O
183	O
HIV-1-infected	O
,	O
antiretroviral	O
treatment-experienced	O
adults	O
with	O
virological	O
failure	O
and	O
current	O
or	O
historical	O
evidence	O
of	O
raltegravir	O
and/or	O
elvitegravir	O
resistance	O
received	O
TIVICAY	O
50	O
mg	O
twice	O
daily	O
with	O
the	O
current	O
failing	O
background	O
regimen	O
for	O
7	O
days	O
and	O
with	O
optimized	O
background	O
therapy	O
from	O
Day	O
8	O
.	O
	
Severe	O
acute	B
exacerbations	I
of	I
hepatitis	I
B	I
have	O
been	O
reported	O
in	O
patients	O
who	O
are	O
coinfected	O
with	O
HBV	O
and	O
human	O
immunodeficiency	O
virus-1	O
(	O
HIV-1	O
)	O
and	O
have	O
discontinued	O
EMTRIVA	O
or	O
VIREAD	O
,	O
which	O
are	O
components	O
of	O
STRIBILD	O
.	O
	
The	O
information	O
presented	O
in	O
these	O
sections	O
was	O
derived	O
from	O
pooled	O
data	O
from	O
4	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
in	O
patients	O
who	O
received	O
FANAPT	O
at	O
daily	O
doses	O
within	O
a	O
range	O
of	O
10	O
to	O
24	O
mg	O
(	O
n=874	O
)	O
.	O
	
Patients	O
treated	O
with	O
OTEZLA	O
should	O
have	O
their	O
weight	O
monitored	O
regularly	O
.	O
	
Causes	O
of	O
death	B
on	O
the	O
AFINITOR	O
arm	O
included	O
one	O
case	O
of	O
each	O
of	O
the	O
following	O
:	O
acute	B
renal	I
failure	I
,	O
acute	B
respiratory	I
distress	I
,	O
cardiac	B
arrest	I
,	O
death	B
(	O
cause	O
unknown	O
)	O
,	O
hepatic	B
failure	I
,	O
pneumonia	B
,	O
and	O
sepsis	B
.	O
	
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
malignancies	B
(	O
including	O
non-melanoma	B
skin	I
cancers	I
)	O
were	O
reported	O
in	O
0.4	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
0.4	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
(	O
5.9	O
)	O
5.1	O
Angioedema	O
Angioedema	B
of	I
the	I
face	I
has	O
been	O
reported	O
with	O
fesoterodine	O
.	O
	
Patients	O
on	O
the	O
placebo	O
arm	O
could	O
cross	O
over	O
to	O
open-label	O
AFINITOR	O
upon	O
disease	O
progression	O
.	O
	
Permanently	O
discontinue	O
YERVOY	O
in	O
patients	O
with	O
Stevens-Johnson	O
syndrome	O
,	O
toxic	O
epidermal	O
necrolysis	O
,	O
or	O
rash	O
complicated	O
by	O
full	O
thickness	O
dermal	O
ulceration	O
,	O
or	O
necrotic	O
,	O
bullous	O
,	O
or	O
hemorrhagic	O
manifestations	O
.	O
	
Transaminase	O
elevations	O
were	O
more	O
common	O
in	O
patients	O
who	O
had	O
abnormal	O
transaminases	O
at	O
baseline	O
.	O
	
(	O
5.3	O
)	O
*	O
Avoid	O
coadministration	O
with	O
other	O
anti-retroviral	O
products	O
:	O
Do	O
not	O
use	O
with	O
products	O
containing	O
any	O
of	O
the	O
components	O
of	O
STRIBILD	O
(	O
cobicistat	O
,	O
elvitegravir	O
,	O
emtricitabine	O
,	O
and	O
tenofovir	O
disoproxil	O
fumarate	O
)	O
,	O
including	O
ATRIPLA	O
,	O
COMPLERA	O
,	O
EMTRIVA	O
,	O
TRUVADA	O
,	O
TYBOST	O
,	O
VIREAD	O
,	O
or	O
VITEKTA	O
;	O
with	O
drugs	O
containing	O
lamivudine	O
;	O
or	O
with	O
drugs	O
or	O
regimens	O
containing	O
ritonavir	O
.	O
	
Four	O
placebo-controlled	O
add-on	O
combination	O
therapy	O
trials	O
of	O
26	O
weeks	O
duration	O
were	O
also	O
conducted	O
:	O
with	O
metformin	O
,	O
with	O
a	O
sulfonylurea	O
,	O
with	O
a	O
thiazolidinedione	O
and	O
with	O
insulin	O
.	O
	
Since	O
patients	O
who	O
develop	O
IgE	O
antibodies	O
to	O
alglucosidase	O
alfa	O
appear	O
to	O
be	O
at	O
a	O
higher	O
risk	O
for	O
developing	O
anaphylaxis	O
and	O
hypersensitivity	O
reactions	O
,	O
these	O
patients	O
should	O
be	O
monitored	O
more	O
closely	O
during	O
administration	O
of	O
alglucosidase	O
alfa	O
.	O
	
Fatal	B
adverse	O
reactions	O
in	O
GILOTRIF-treated	O
patients	O
in	O
Study	O
1	O
included	O
pulmonary	B
toxicity/ILD-like	O
adverse	B
reactions	I
(	O
1.3	O
%	O
)	O
,	O
sepsis	B
(	O
0.43	O
%	O
)	O
,	O
and	O
pneumonia	B
(	O
0.43	O
%	O
)	O
.	O
	
Magnetic	O
resonance	O
imaging	O
is	O
necessary	O
to	O
confirm	O
the	O
diagnosis	O
of	O
RPLS	O
.	O
	
5.2	O
Somnolence/Sedation	O
and	O
Dizziness	O
HORIZANT	O
causes	O
somnolence/sedation	O
and	O
dizziness	B
(	O
see	O
Tables	O
4	O
and	O
5	O
)	O
.	O
	
The	O
incidence	O
of	O
constipation	B
was	O
2	O
%	O
in	O
those	O
taking	O
placebo	O
,	O
4	O
%	O
in	O
those	O
taking	O
4	O
mg/day	O
,	O
and	O
6	O
%	O
in	O
those	O
taking	O
8	O
mg/day	O
.	O
	
Stop	O
treatment	O
with	O
INLYTA	O
at	O
least	O
24	O
hours	O
prior	O
to	O
scheduled	O
surgery	O
.	O
	
Diarrhea	B
,	O
headache	B
,	O
and	O
nausea	B
were	O
the	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
.	O
	
Chronic	O
Lymphocytic	O
Leukemia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
TREANDA	O
in	O
153	O
patients	O
with	O
CLL	O
studied	O
in	O
an	O
active-controlled	O
,	O
randomized	O
trial	O
.	O
	
Dizziness	B
was	O
reported	O
in	O
17	O
%	O
of	O
patients	O
receiving	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
compared	O
with	O
15	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Some	O
patients	O
(	O
13	O
%	O
)	O
received	O
premedication	O
,	O
which	O
may	O
have	O
mitigated	O
or	O
masked	O
a	O
hypersensitivity	O
response	O
;	O
however	O
,	O
there	O
is	O
insufficient	O
evidence	O
to	O
determine	O
whether	O
premedication	O
diminishes	O
the	O
frequency	O
or	O
severity	O
of	O
hypersensitivity	O
reactions	O
.	O
	
In	O
the	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
trial	O
in	O
late-onset	O
patients	O
,	O
all	O
alglucosidase	O
alfa-treated	O
patients	O
with	O
available	O
samples	O
(	O
N=59	O
,	O
100	O
%	O
)	O
developed	O
IgG	O
antibodies	O
to	O
alglucosidase	O
alfa	O
.	O
	
The	O
overall	O
incidence	O
of	O
bone	B
pain	I
in	O
Cycle	O
1	O
of	O
treatment	O
was	O
3.4	O
%	O
(	O
3.4	O
%	O
GRANIX	O
,	O
1.4	O
%	O
placebo	O
,	O
7.5	O
%	O
non-US-approved	O
filgrastim	O
product	O
)	O
.	O
	
However	O
,	O
there	O
is	O
substantial	O
evidence	O
from	O
placebo-controlled	O
maintenance	O
studies	O
in	O
adults	O
with	O
depression	O
that	O
the	O
use	O
of	O
antidepressants	O
can	O
delay	O
the	O
recurrence	O
of	O
depression	O
.	O
	
5.3	O
Angioedema	O
with	O
Concomitant	O
Use	O
of	O
Angiotensin-Converting	O
Enzyme	O
(	O
ACE	O
)	O
Inhibitors	O
Patients	O
taking	O
concomitant	O
ACE	O
inhibitor	O
therapy	O
may	O
be	O
at	O
increased	O
risk	O
for	O
angioedema	B
(	O
e.g.	O
,	O
swelling	B
of	I
the	I
airways	I
,	O
with	O
or	O
without	O
respiratory	B
impairment	I
)	O
.	O
	
Adequate	O
data	O
are	O
not	O
available	O
on	O
the	O
safety	O
or	O
efficacy	O
of	O
treating	O
patients	O
who	O
are	O
carriers	O
of	O
HBV	O
with	O
anti-viral	O
therapy	O
in	O
conjunction	O
with	O
TNF	O
blocker	O
therapy	O
to	O
prevent	O
HBV	O
reactivation	O
.	O
	
Physicians	O
should	O
exercise	O
caution	O
when	O
administering	O
ILARIS	O
to	O
patients	O
with	O
infections	O
,	O
a	O
history	O
of	O
recurring	O
infections	O
or	O
underlying	O
conditions	O
which	O
may	O
predispose	O
them	O
to	O
infections	O
.	O
	
At	O
baseline	O
,	O
21	O
%	O
of	O
the	O
population	O
reported	O
peripheral	O
neuropathy	O
and	O
5	O
%	O
reported	O
retinopathy	O
.	O
	
5.14	O
Exacerbation	O
of	O
Other	O
Conditions	O
Estrogens	O
may	O
cause	O
an	O
exacerbation	O
of	O
asthma	O
,	O
diabetes	O
mellitus	O
,	O
epilepsy	O
,	O
migraine	O
or	O
porphyria	O
,	O
systemic	O
lupus	O
erythematosus	O
,	O
and	O
hepatic	O
hemangiomas	O
and	O
should	O
be	O
used	O
with	O
caution	O
in	O
women	O
with	O
these	O
conditions	O
.	O
	
The	O
data	O
obtained	O
in	O
an	O
assay	O
are	O
highly	O
dependent	O
on	O
several	O
factors	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
underlying	O
disease	O
,	O
and	O
the	O
number	O
of	O
patients	O
tested	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
in	O
91	O
%	O
of	O
patients	O
and	O
moderately	O
impaired	O
in	O
9	O
%	O
of	O
patients	O
(	O
mean	O
eGFR	O
86.8	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
Pool	O
of	O
Placebo-	O
and	O
Active-controlled	O
Trials	O
The	O
occurrence	O
of	O
adverse	O
reactions	O
was	O
also	O
evaluated	O
in	O
a	O
larger	O
pool	O
of	O
patients	O
with	O
type	O
2	O
diabetes	O
participating	O
in	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
.	O
	
The	O
risk	O
of	O
seizures	O
in	O
patients	O
with	O
epileptiform	O
activity	O
on	O
an	O
EEG	O
is	O
unknown	O
,	O
and	O
could	O
be	O
substantially	O
higher	O
than	O
that	O
observed	O
in	O
AMPYRA	O
clinical	O
studies	O
.	O
	
5.8	O
Use	O
with	O
Biological	O
Disease-Modifying	O
Antirheumatic	O
Drugs	O
(	O
Biological	O
DMARDs	O
)	O
Serious	O
infections	B
were	O
seen	O
in	O
clinical	O
studies	O
with	O
concurrent	O
use	O
of	O
anakinra	O
(	O
an	O
interleukin-1	O
antagonist	O
)	O
and	O
another	O
TNF	O
blocker	O
,	O
etanercept	O
,	O
with	O
no	O
added	O
benefit	O
compared	O
to	O
etanercept	O
alone	O
.	O
	
tooth	O
extraction	O
,	O
dental	O
implants	O
,	O
oral	O
surgery	O
)	O
,	O
diagnosis	O
of	O
cancer	O
,	O
concomitant	O
therapies	O
(	O
e.g	O
.	O
	
5.1	O
Suicidal	O
Thoughts	O
and	O
Behaviors	O
in	O
Children	O
,	O
Adolescents	O
and	O
Young	O
Adults	O
Patients	O
with	O
major	O
depressive	O
disorder	O
(	O
MDD	O
)	O
,	O
both	O
adult	O
and	O
pediatric	O
,	O
may	O
experience	O
worsening	O
of	O
their	O
depression	O
and/or	O
the	O
emergence	O
of	O
suicidal	O
ideation	O
and	O
behavior	O
(	O
suicidality	O
)	O
or	O
unusual	O
changes	O
in	O
behavior	O
,	O
whether	O
or	O
not	O
they	O
are	O
taking	O
antidepressant	O
medications	O
,	O
and	O
this	O
risk	O
may	O
persist	O
until	O
significant	O
remission	O
occurs	O
.	O
	
Bleeding	O
in	O
Patients	O
with	O
Nonvalvular	O
Atrial	O
Fibrillation	O
in	O
ARISTOTLE	O
and	O
AVERROES	O
Tables	O
1	O
and	O
2	O
show	O
the	O
number	O
of	O
patients	O
experiencing	O
major	O
bleeding	B
during	O
the	O
treatment	O
period	O
and	O
the	O
bleeding	B
rate	O
(	O
percentage	O
of	O
subjects	O
with	O
at	O
least	O
one	O
bleeding	B
event	O
per	O
100	O
patient-years	O
)	O
in	O
ARISTOTLE	O
and	O
AVERROES	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
severe	O
skin	B
toxicity	I
and	O
secondary	B
infections	I
of	I
the	I
skin	I
requiring	O
hospitalization	O
occurred	O
in	O
2.5	O
%	O
(	O
5/202	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Auxilium	O
Pharmaceuticals	O
,	O
Inc.	O
at	O
1-877-663-0412	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Treatment	O
of	O
latent	O
tuberculosis	O
infection	O
should	O
be	O
initiated	O
prior	O
to	O
NULOJIX	O
use	O
.	O
	
Atypical	B
femoral	I
fractures	I
most	O
commonly	O
occur	O
with	O
minimal	O
or	O
no	O
trauma	O
to	O
the	O
affected	O
area	O
.	O
	
Patients	O
with	O
preexisting	O
liver	O
disease	O
may	O
be	O
at	O
increased	O
risk	O
of	O
developing	O
elevated	B
liver	I
enzymes	I
when	O
taking	O
GILENYA	O
.	O
	
During	O
its	O
development	O
for	O
the	O
adjunctive	O
treatment	O
of	O
seizures	O
associated	O
with	O
LGS	O
,	O
ONFI	O
was	O
administered	O
to	O
333	O
healthy	O
volunteers	O
and	O
300	O
patients	O
with	O
a	O
current	O
or	O
prior	O
diagnosis	O
of	O
LGS	O
,	O
including	O
197	O
patients	O
treated	O
for	O
12	O
months	O
or	O
more	O
.	O
	
An	O
increased	O
incidence	O
of	O
serious	O
infections	B
has	O
been	O
associated	O
with	O
administration	O
of	O
another	O
IL-1	O
blocker	O
in	O
combination	O
with	O
TNF	O
inhibitors	O
.	O
	
The	O
range	O
of	O
mean	O
baseline	O
LDL-C	O
levels	O
was	O
90.3	O
to	O
90.6	O
mg/dL	O
across	O
treatment	O
groups	O
.	O
	
Each	O
ECLIPSE	O
study	O
compared	O
Cleviprex	O
(	O
n=752	O
)	O
to	O
an	O
active	O
comparator	O
:	O
nitroglycerin	O
(	O
NTG	O
,	O
n=278	O
)	O
,	O
sodium	O
nitroprusside	O
(	O
SNP	O
,	O
n=283	O
)	O
,	O
or	O
nicardipine	O
(	O
NIC	O
,	O
n=193	O
)	O
.	O
	
5.3	O
Continuation	O
and	O
Timing	O
of	O
Leucovorin	O
Rescue	O
Continue	O
to	O
administer	O
leucovorin	O
after	O
VORAXAZE	O
.	O
	
Other	O
factors	O
associated	O
with	O
hematuria	B
were	O
well-balanced	O
between	O
arms	O
and	O
do	O
not	O
account	O
for	O
the	O
increased	O
rate	O
of	O
hematuria	B
on	O
the	O
JEVTANA	O
arm	O
.	O
	
Blood	O
pressure	O
should	O
be	O
monitored	O
during	O
treatment	O
with	O
GILENYA	O
.	O
	
5.3	O
Concurrent	O
Treatment	O
with	O
Other	O
Forms	O
of	O
4-Aminopyridine	O
AMPYRA	O
should	O
not	O
be	O
taken	O
with	O
other	O
forms	O
of	O
4-aminopyridine	O
(	O
4-AP	O
,	O
fampridine	O
)	O
since	O
the	O
active	O
ingredient	O
is	O
the	O
same	O
.	O
	
KALIBITORN=100	O
PlaceboN=81	O
Adverse	O
Reactions	O
n	O
(	O
%	O
)	O
a	O
n	O
(	O
%	O
)	O
a	O
Headache	B
8	O
(	O
8	O
%	O
)	O
6	O
(	O
7	O
%	O
)	O
Nausea	B
5	O
(	O
5	O
%	O
)	O
1	O
(	O
1	O
%	O
)	O
Diarrhea	B
4	O
(	O
4	O
%	O
)	O
3	O
(	O
4	O
%	O
)	O
Pyrexia	B
4	O
(	O
4	O
%	O
)	O
0	O
Injection	B
site	I
reactions	I
3	O
(	O
3	O
%	O
)	O
1	O
(	O
1	O
%	O
)	O
Nasopharyngitis	B
3	O
(	O
3	O
%	O
)	O
0	O
Some	O
patients	O
in	O
EDEMA3	O
and	O
EDEMA4	O
received	O
a	O
second	O
,	O
open-label	O
30	O
mg	O
subcutaneous	O
dose	O
of	O
KALBITOR	O
within	O
24	O
hours	O
following	O
the	O
initial	O
dose	O
.	O
	
In	O
Trial	O
2	O
,	O
the	O
incidence	O
of	O
fever	B
(	O
serious	O
and	O
non-serious	O
)	O
was	O
71	O
%	O
(	O
39/55	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
and	O
26	O
%	O
(	O
14/53	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
5.5	O
Other	O
Serious	O
Infections	O
Patients	O
receiving	O
immunosuppressants	O
,	O
including	O
NULOJIX	O
,	O
are	O
at	O
increased	O
risk	O
of	O
developing	O
protozoal	B
infections	I
,	O
including	O
opportunistic	B
infections	I
.	O
	
During	O
controlled	O
and	O
open-labeled	O
portions	O
of	O
CIMZIA	O
studies	O
of	O
Crohn	O
's	O
disease	O
and	O
other	O
diseases	O
,	O
malignancies	B
(	O
excluding	O
non-melanoma	B
skin	I
cancer	I
)	O
were	O
observed	O
at	O
a	O
rate	O
(	O
95	O
%	O
confidence	O
interval	O
)	O
of	O
0.5	O
(	O
0.4	O
,	O
0.7	O
)	O
per	O
100	O
patient-years	O
among	O
4,650	O
CIMZIA-treated	O
patients	O
versus	O
a	O
rate	O
of	O
0.6	O
(	O
0.1	O
,	O
1.7	O
)	O
per	O
100	O
patient-years	O
among	O
1,319	O
placebo-treated	O
patients	O
.	O
	
(	O
5.2	O
)	O
*	O
Neutropenia	B
-	O
The	O
addition	O
of	O
VICTRELIS	O
to	O
peginterferon	O
alfa	O
and	O
ribavirin	O
may	O
result	O
in	O
worsening	B
of	I
neutropenia	I
associated	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
therapy	O
alone	O
.	O
	
Cardiovert	O
patients	O
who	O
are	O
in	O
atrial	O
fibrillation	O
(	O
if	O
clinically	O
indicated	O
)	O
or	O
discontinue	O
MULTAQ	O
.	O
	
The	O
greatest	O
risk	O
appears	O
associated	O
with	O
prolonged	O
use	O
,	O
with	O
increased	O
risks	O
of	O
15-	O
to	O
24-fold	O
for	O
5	O
to	O
10	O
years	O
or	O
more	O
of	O
treatment	O
.	O
	
For	O
patients	O
taking	O
concomitant	O
strong	O
CYP3A4	O
inhibitors	O
(	O
including	O
ketoconazole	O
,	O
ritonavir	O
,	O
atazanavir	O
,	O
clarithromycin	O
,	O
indinavir	O
,	O
itraconazole	O
,	O
nefazodone	O
,	O
nelfinavir	O
,	O
saquinavir	O
,	O
and	O
telithromycin	O
)	O
,	O
do	O
not	O
use	O
STENDRA	O
[	O
seeDrug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Patients	O
who	O
experience	O
anaphylactic	O
or	O
hypersensitivity	O
reactions	O
may	O
also	O
be	O
tested	O
for	O
IgE	O
antibodies	O
to	O
alglucosidase	O
alfa	O
and	O
other	O
mediators	O
of	O
anaphylaxis	O
[	O
seeAdverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
In	O
children	O
,	O
the	O
adverse	O
reactions	O
were	O
pyrexia	B
,	O
cough	B
,	O
vomiting	B
,	O
anorexia	B
,	O
and	O
headache	B
.	O
	
(	O
5.3	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Serious	O
and	O
occasionally	O
fatal	B
anaphylactic	B
)	I
reactions	I
and	O
serious	O
skin	B
reactions	I
have	O
been	O
reported	O
in	O
patients	O
receiving	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
Therefore	O
,	O
PDE5	O
inhibitors	O
,	O
including	O
STENDRA	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
these	O
patients	O
and	O
only	O
when	O
the	O
anticipated	O
benefits	O
outweigh	O
the	O
risks	O
.	O
	
During	O
clinical	O
trials	O
,	O
no	O
anaphylactic	B
reactions	I
have	O
been	O
reported	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
of	O
PROMACTA	O
to	O
446	O
patients	O
with	O
chronic	O
ITP	O
aged	O
18	O
to	O
85	O
years	O
,	O
of	O
whom	O
65	O
%	O
were	O
female	O
,	O
across	O
the	O
ITP	O
clinical	O
development	O
program	O
including	O
three	O
placebo-controlled	O
trials	O
.	O
	
If	O
feasible	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
at	O
least	O
4	O
to	O
6	O
weeks	O
before	O
surgery	O
of	O
the	O
type	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
thromboembolism	O
,	O
or	O
during	O
periods	O
of	O
prolonged	O
immobilization	O
.	O
	
Gastrointestinal	O
Disorders	O
Dysgeusia	B
(	O
alteration	B
of	I
taste	I
)	O
was	O
an	O
adverse	O
event	O
reported	O
at	O
an	O
increased	O
frequency	O
in	O
subjects	O
receiving	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
compared	O
with	O
subjects	O
receiving	O
peginterferon	O
alfa	O
and	O
ribavirin	O
alone	O
(	O
Table	O
3	O
)	O
.	O
	
Rates	O
in	O
clinical	O
studies	O
for	O
CIMZIA	O
can	O
not	O
be	O
compared	O
to	O
the	O
rates	O
of	O
clinical	O
trials	O
of	O
other	O
TNF	O
blockers	O
and	O
may	O
not	O
predict	O
the	O
rates	O
observed	O
when	O
CIMZIA	O
is	O
used	O
in	O
a	O
broader	O
patient	O
population	O
.	O
	
It	O
should	O
be	O
noted	O
that	O
PRISTIQ	O
is	O
not	O
approved	O
for	O
use	O
in	O
treating	O
bipolar	O
depression	O
.	O
	
In	O
HIV-1-Infected	O
Subjects	O
With	O
No	O
Antiretroviral	O
Treatment	O
History	O
The	O
safety	O
assessment	O
of	O
STRIBILD	O
is	O
based	O
on	O
the	O
Week	O
144	O
pooled	O
data	O
from	O
1408	O
subjects	O
in	O
two	O
randomized	O
,	O
double-blind	O
,	O
active-controlled	O
clinical	O
trials	O
,	O
Study	O
102	O
and	O
Study	O
103	O
,	O
in	O
antiretroviral	O
treatment-naive	O
HIV-1	O
infected	O
adult	O
subjects	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
The	O
majority	O
of	O
the	O
TB	B
cases	O
occurred	O
in	O
countries	O
with	O
a	O
high	O
incidence	O
rate	O
of	O
TB	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
anaphylactic	B
)	I
reactions	I
have	O
been	O
reported	O
with	O
beta-lactam	O
antibacterial	O
drugs	O
,	O
including	O
Teflaro	O
.	O
	
There	O
were	O
no	O
Grade	O
3	O
or	O
4	O
infusion-related	B
reactions	I
reported	O
in	O
Studies	O
1	O
and	O
2	O
;	O
however	O
,	O
Grade	O
1	O
or	O
2	O
infusion-related	B
reactions	I
were	O
reported	O
for	O
19	O
patients	O
(	O
12	O
%	O
)	O
.	O
	
(	O
5.10	O
)	O
*	O
Embryofetal	B
Toxicity	I
:	O
Can	O
cause	O
fetal	B
harm	I
.	O
	
Vizamyl	O
scan	O
results	O
are	O
indicative	O
of	O
the	O
brain	O
neuritic	O
amyloid	O
plaque	O
content	O
only	O
at	O
the	O
time	O
of	O
image	O
acquisition	O
and	O
a	O
negative	O
scan	O
result	O
does	O
not	O
preclude	O
the	O
development	O
of	O
brain	O
amyloid	O
in	O
the	O
future	O
.	O
	
(	O
5.5	O
,	O
2.3	O
)	O
*	O
Ocular	B
Toxicities	I
:	O
Perform	O
ophthalmologic	O
evaluation	O
for	O
any	O
visual	O
disturbances	O
.	O
	
Consider	O
discontinuation	O
of	O
DUAVEE	O
if	O
pancreatitis	O
occurs	O
.	O
	
Stepwise	O
increase	O
in	O
alpha-blocker	O
dose	O
may	O
be	O
associated	O
with	O
further	O
lowering	O
of	O
blood	O
pressure	O
when	O
taking	O
a	O
PDE5	O
inhibitor	O
.	O
	
If	O
a	O
gout	O
flare	O
occurs	O
during	O
treatment	O
,	O
ULORIC	O
need	O
not	O
be	O
discontinued	O
.	O
	
*	O
In	O
those	O
patients	O
already	O
taking	O
an	O
optimized	O
dose	O
of	O
a	O
PDE5	O
inhibitor	O
,	O
alpha-blocker	O
therapy	O
should	O
be	O
initiated	O
at	O
the	O
lowest	O
dose	O
.	O
	
5.9	O
Hepatic	O
Impairment	O
and	O
Past	O
History	O
of	O
Cholestatic	O
Jaundice	O
DUAVEE	O
has	O
not	O
been	O
studied	O
in	O
women	O
with	O
impaired	O
liver	O
function	O
or	O
past	O
history	O
of	O
cholestatic	O
jaundice	O
.	O
	
(	O
5.4	O
,	O
2.3	O
)	O
*	O
Cardiomyopathy	B
:	O
Assess	O
LVEF	O
before	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
,	O
after	O
one	O
month	O
of	O
treatment	O
,	O
then	O
every	O
2	O
to	O
3	O
months	O
thereafter	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Gout	B
Flare	I
:	O
An	O
increase	O
in	O
gout	B
flares	I
is	O
frequently	O
observed	O
during	O
initiation	O
of	O
anti-hyperuricemic	O
agents	O
,	O
including	O
ULORIC	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
an	O
unknown	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
6.1	O
Adverse	O
Reactions	O
from	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
However	O
,	O
prior	O
to	O
initiating	O
treatment	O
with	O
an	O
antidepressant	O
,	O
patients	O
with	O
depressive	O
symptoms	O
should	O
be	O
adequately	O
screened	O
to	O
determine	O
if	O
they	O
are	O
at	O
risk	O
for	O
bipolar	O
disorder	O
;	O
such	O
screening	O
should	O
include	O
a	O
detailed	O
psychiatric	O
history	O
,	O
including	O
a	O
family	O
history	O
of	O
suicide	O
,	O
bipolar	O
disorder	O
,	O
and	O
depression	O
.	O
	
Motion	O
artifacts	O
may	O
distort	O
the	O
image	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
(	O
5.9	O
)	O
*	O
Glucose-6-Phosphate	B
Dehydrogenase	I
Deficiency	I
:	O
Closely	O
monitor	O
for	O
hemolytic	O
anemia	O
.	O
	
Infusion	O
reactions	O
Two	O
cases	O
of	O
anaphylaxis	B
were	O
reported	O
in	O
the	O
dose-finding	O
trials	O
.	O
	
Eight	O
patients	O
had	O
a	O
new	O
cytogenetic	B
abnormality	I
reported	O
on	O
therapy	O
,	O
including	O
5	O
patients	O
who	O
had	O
complex	O
changes	B
in	I
chromosome	I
7	I
.	O
	
5.5	O
Risk	O
of	O
Antibody	O
Development	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
potential	O
for	O
immunogenicity	O
.	O
	
In	O
the	O
controlled	O
phase	O
of	O
Trial	O
1	O
through	O
Week	O
24	O
,	O
infections	B
were	O
observed	O
in	O
27	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
compared	O
with	O
24	O
%	O
of	O
control-treated	O
patients	O
,	O
and	O
serious	O
infections	B
were	O
observed	O
in	O
0.9	O
%	O
of	O
SIMPONI	O
ARIA-treated	O
patients	O
and	O
0.0	O
%	O
of	O
control-treated	O
patients	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
are	O
nausea	B
(	O
11	O
%	O
)	O
,	O
vomiting	B
(	O
7	O
%	O
)	O
,	O
abdominal	B
pain	I
(	O
6	O
%	O
)	O
,	O
gastrointestinal	B
hemorrhage	I
(	O
4	O
%	O
)	O
,	O
anemia	B
(	O
2	O
%	O
)	O
,	O
and	O
neutropenia	B
(	O
2	O
%	O
)	O
(	O
6	O
)	O
.	O
	
Because	O
immobilization	O
increases	O
the	O
risk	O
for	O
venous	O
thromboembolic	O
events	O
independent	O
of	O
therapy	O
,	O
DUAVEE	O
should	O
be	O
discontinued	O
prior	O
to	O
and	O
during	O
prolonged	O
immobilization	O
(	O
e.g.	O
,	O
post-surgical	O
recovery	O
,	O
prolonged	O
bed	O
rest	O
)	O
and	O
DUAVEE	O
therapy	O
should	O
be	O
resumed	O
only	O
after	O
the	O
patient	O
is	O
fully	O
ambulatory	O
.	O
	
The	O
following	O
serious	O
adverse	O
reactions	O
of	O
trametinib	O
as	O
a	O
single	O
agent	O
,	O
which	O
may	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
are	O
not	O
described	O
in	O
the	O
Full	O
Prescribing	O
Information	O
for	O
TAFINLAR	O
:	O
*	O
Retinal	B
vein	I
occlusion	I
*	O
Interstitial	B
lung	I
disease	I
*	O
New	O
primary	B
malignancies	I
,	I
cutaneous	I
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Treatment	O
with	O
antibacterial	O
agents	O
alters	O
the	O
normal	O
flora	O
of	O
the	O
colon	O
and	O
may	O
permit	O
overgrowth	O
of	O
C.	O
difficile	O
.	O
	
It	O
should	O
be	O
recognized	O
that	O
symptoms	O
of	O
the	O
underlying	O
disease	O
being	O
treated	O
may	O
be	O
similar	O
to	O
symptoms	O
of	O
hypersensitivity	O
.	O
	
Individuals	O
who	O
have	O
already	O
experienced	O
NAION	O
are	O
at	O
increased	O
risk	O
of	O
NAION	O
recurrence	O
.	O
	
Patients	O
with	O
RA	O
,	O
particularly	O
those	O
with	O
highly	O
active	O
disease	O
,	O
are	O
at	O
a	O
higher	O
risk	O
for	O
the	O
development	O
of	O
lymphoma	O
.	O
	
Adverse	O
events	O
such	O
as	O
dry	B
mouth	I
,	O
nausea	B
,	O
vomiting	B
and	O
diarrhea	B
were	O
also	O
reported	O
at	O
an	O
increased	O
frequency	O
in	O
subjects	O
receiving	O
VICTRELIS	O
in	O
combination	O
with	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
Patients	O
treated	O
with	O
dronedarone	O
should	O
undergo	O
monitoring	O
of	O
cardiac	O
rhythm	O
no	O
less	O
often	O
than	O
every	O
3	O
months	O
.	O
	
(	O
5.3	O
)	O
*	O
Hypersensitivity	B
-	O
Serious	O
acute	B
hypersensitivity	I
reactions	I
(	O
e.g.	O
,	O
urticaria	B
,	O
angioedema	B
)	O
have	O
been	O
observed	O
during	O
combination	O
therapy	O
with	O
VICTRELIS	O
,	O
peginterferon	O
alfa	O
and	O
ribavirin	O
.	O
	
5.2	O
Malignancies	O
In	O
the	O
controlled	O
portions	O
of	O
clinical	O
studies	O
of	O
some	O
TNF	O
blockers	O
,	O
more	O
cases	O
of	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF	O
blockers	O
compared	O
to	O
control	O
patients	O
.	O
	
5.2	O
Cardiovascular	O
Events	O
In	O
the	O
randomized	O
controlled	O
studies	O
,	O
there	O
was	O
a	O
higher	O
rate	O
of	O
cardiovascular	B
thromboembolic	I
events	I
(	O
cardiovascular	B
deaths	I
,	O
non-fatal	O
myocardial	B
infarctions	I
,	O
and	O
non-fatal	O
strokes	B
)	O
in	O
patients	O
treated	O
with	O
ULORIC	O
(	O
0.74	O
per	O
100	O
P-Y	O
[	O
95	O
%	O
Confidence	O
Interval	O
(	O
CI	O
)	O
0.36-1.37	O
]	O
)	O
than	O
allopurinol	O
(	O
0.60	O
per	O
100	O
P-Y	O
[	O
95	O
%	O
CI	O
0.16-1.53	O
]	O
)	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
adults	O
,	O
the	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
were	O
headache	B
,	O
anorexia	B
,	O
dizziness	B
,	O
and	O
asthenia	B
.	O
	
Patients	O
who	O
experience	O
reduced	O
clinical	O
response	O
may	O
also	O
be	O
tested	O
for	O
inhibitory	O
antibody	O
activity	O
.	O
	
Inhibitors	O
of	O
CYP3A4	O
may	O
reduce	O
STENDRA	O
clearance	O
and	O
increase	O
plasma	O
concentrations	O
of	O
avanafil	O
.	O
	
This	O
risk	O
has	O
been	O
shown	O
to	O
persist	O
for	O
at	O
least	O
8	O
to	O
15	O
years	O
after	O
estrogen	O
therapy	O
is	O
discontinued	O
.	O
	
Of	O
the	O
329	O
enrolled	O
patients	O
,	O
327	O
(	O
167	O
brentuximab	O
vedotin	O
,	O
160	O
placebo	O
)	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
treatment	O
.	O
	
Do	O
not	O
administer	O
leucovorin	O
within	O
2	O
hours	O
before	O
or	O
after	O
a	O
dose	O
of	O
VORAXAZE	O
because	O
leucovorin	O
is	O
a	O
substrate	O
for	O
VORAXAZE	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
ESCAPE-1	O
ESCAPE-2	O
CLVN=53	O
(	O
%	O
)	O
PBON=51	O
(	O
%	O
)	O
CLVN=61	O
(	O
%	O
)	O
PBON=49	O
(	O
%	O
)	O
Any	O
common	O
adverse	O
event	O
27	O
(	O
51	O
%	O
)	O
21	O
(	O
41	O
%	O
)	O
32	O
(	O
53	O
%	O
)	O
24	O
(	O
49	O
%	O
)	O
Acute	B
renal	I
failure	I
5	O
(	O
9	O
%	O
)	O
1	O
(	O
2	O
%	O
)	O
--	O
--	O
Atrial	B
fibrillation	I
--	O
--	O
13	O
(	O
21	O
%	O
)	O
6	O
(	O
12	O
%	O
)	O
Nausea	B
--	O
--	O
13	O
(	O
21	O
%	O
)	O
6	O
(	O
12	O
%	O
)	O
Three	O
randomized	O
,	O
parallel	O
,	O
open-label	O
studies	O
called	O
ECLIPSE	O
,	O
with	O
longer	O
exposure	O
in	O
cardiac	O
surgery	O
patients	O
define	O
the	O
adverse	O
reactions	O
for	O
patients	O
with	O
perioperative	O
hypertension	O
.	O
	
If	O
PML	O
is	O
diagnosed	O
,	O
consideration	O
should	O
be	O
given	O
to	O
reduction	O
or	O
withdrawal	O
of	O
immunosuppression	O
taking	O
into	O
account	O
the	O
risk	O
to	O
the	O
allograft	O
.	O
	
In	O
patients	O
with	O
mild	O
renal	O
impairment	O
(	O
CrCl	O
51-80	O
mL/min	O
)	O
,	O
AMPYRA	O
plasma	O
levels	O
may	O
approach	O
those	O
seen	O
at	O
a	O
dose	O
of	O
15	O
mg	O
twice	O
daily	O
,	O
a	O
dose	O
that	O
may	O
be	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
seizures	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Hypertension	B
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
8	O
%	O
of	O
patients	O
on	O
GILENYA	O
0.5	O
mg	O
and	O
in	O
4	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
The	O
incidence	O
of	O
grade	O
>	O
=	O
2	O
hematuria	B
was	O
6	O
%	O
in	O
JEVTANA-treated	O
patients	O
and	O
2	O
%	O
in	O
mitoxantrone-treated	O
patients	O
.	O
	
Patients	O
on	O
concomitant	O
immunosuppressant	O
agents	O
or	O
with	O
impaired	O
immune	O
systems	O
may	O
be	O
at	O
increased	O
risk	O
for	O
serious	O
infections	B
.	O
	
Patients	O
should	O
be	O
evaluated	O
for	O
tuberculosis	O
and	O
tested	O
for	O
latent	O
infection	O
prior	O
to	O
initiating	O
NULOJIX	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-877-423-6597	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Withhold	O
TAFINLAR	O
,	O
and	O
trametinib	O
if	O
used	O
in	O
combination	O
,	O
for	O
intolerable	O
or	O
severe	O
skin	O
toxicity	O
.	O
	
The	O
most	O
common	O
reason	O
for	O
treatment	O
discontinuation	O
in	O
both	O
studies	O
was	O
for	O
bleeding-related	B
adverse	I
reactions	I
;	O
in	O
ARISTOTLE	O
this	O
occurred	O
in	O
1.7	O
%	O
and	O
2.5	O
%	O
of	O
patients	O
treated	O
with	O
ELIQUIS	O
and	O
warfarin	O
,	O
respectively	O
,	O
and	O
in	O
AVERROES	O
,	O
in	O
1.5	O
%	O
and	O
1.3	O
%	O
on	O
ELIQUIS	O
and	O
aspirin	O
,	O
respectively	O
.	O
	
Peyronie	O
's	O
Disease	O
(	O
6.2	O
)	O
The	O
most	O
frequently	O
reported	O
adverse	O
drug	O
reactions	O
reported	O
with	O
>	O
=	O
25	O
%	O
of	O
patients	O
treated	O
with	O
XIAFLEX	O
and	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
were	O
penile	B
hematoma	I
,	O
penile	B
swelling	I
and	O
penile	B
pain	I
.	O
	
5.5	O
Urinary	O
Tract	O
Infections	O
Urinary	B
tract	I
infections	I
(	O
UTIs	B
)	O
were	O
reported	O
more	O
frequently	O
as	O
adverse	O
reactions	O
in	O
controlled	O
studies	O
in	O
patients	O
receiving	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
(	O
12	O
%	O
)	O
as	O
compared	O
to	O
placebo	O
(	O
8	O
%	O
)	O
.	O
	
LDL-C	B
increased	I
by	O
2.3	O
%	O
,	O
4.6	O
%	O
,	O
and	O
6.5	O
%	O
in	O
patients	O
treated	O
with	O
placebo	O
,	O
JARDIANCE	O
10	O
mg	O
,	O
and	O
JARDIANCE	O
25	O
mg	O
,	O
respectively	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
These	O
trials	O
evaluated	O
the	O
use	O
of	O
TANZEUM	O
as	O
monotherapy	O
,	O
and	O
as	O
add-on	O
therapy	O
to	O
oral	O
antidiabetic	O
agents	O
,	O
and	O
as	O
add-on	O
therapy	O
to	O
basal	O
insulin	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Established	O
microvascular	O
complications	O
of	O
diabetes	O
at	O
baseline	O
included	O
diabetic	O
nephropathy	O
(	O
7	O
%	O
)	O
,	O
retinopathy	O
(	O
8	O
%	O
)	O
,	O
or	O
neuropathy	O
(	O
16	O
%	O
)	O
.	O
	
The	O
CAPS	O
clinical	O
studies	O
employed	O
the	O
biosensor	O
binding	O
assay	O
,	O
and	O
most	O
of	O
the	O
SJIA	O
clinical	O
studies	O
employed	O
the	O
bridging	O
assay	O
.	O
	
Women	O
dependent	O
on	O
thyroid	O
hormone	O
replacement	O
therapy	O
who	O
are	O
also	O
receiving	O
estrogens	O
may	O
require	O
increased	O
doses	O
of	O
their	O
thyroid	O
replacement	O
therapy	O
.	O
	
Suicide	O
is	O
a	O
known	O
risk	O
of	O
depression	O
and	O
certain	O
other	O
psychiatric	O
disorders	O
,	O
and	O
these	O
disorders	O
themselves	O
are	O
the	O
strongest	O
predictors	O
of	O
suicide	O
.	O
	
The	O
majority	O
(	O
4	O
of	O
5	O
patients	O
)	O
of	O
fatal	B
infection-related	B
adverse	I
reactions	I
occurred	O
after	O
a	O
single	O
dose	O
of	O
JEVTANA	O
.	O
	
A	O
dental	O
examination	O
with	O
appropriate	O
preventive	O
dentistry	O
is	O
recommended	O
prior	O
to	O
treatment	O
with	O
Prolia	O
in	O
patients	O
with	O
risk	O
factors	O
for	O
ONJ	O
such	O
as	O
invasive	O
dental	O
procedures	O
(	O
e.g	O
.	O
	
A	O
higher	O
risk	O
of	O
serious	O
infections	B
was	O
also	O
observed	O
in	O
combination	O
use	O
of	O
TNF	O
blockers	O
with	O
abatacept	O
and	O
rituximab	O
.	O
	
AMPYRA	O
has	O
not	O
been	O
evaluated	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
evidence	O
of	O
epileptiform	O
activity	O
on	O
an	O
EEG	O
,	O
as	O
these	O
patients	O
were	O
excluded	O
from	O
clinical	O
trials	O
.	O
	
5.6	O
Impaired	O
Wound	O
Healing	O
Everolimus	O
delays	B
wound	I
healing	I
and	O
increases	O
the	O
occurrence	O
of	O
wound-related	B
complications	I
like	O
wound	B
dehiscence	I
,	O
wound	B
infection	I
,	O
incisional	B
hernia	I
,	O
lymphocele	B
,	O
and	O
seroma	B
.	O
	
Patients	O
who	O
are	O
carriers	O
of	O
HBV	O
and	O
require	O
treatment	O
with	O
CIMZIA	O
should	O
be	O
closely	O
monitored	O
for	O
clinical	O
and	O
laboratory	O
signs	O
of	O
active	O
HBV	O
infection	O
throughout	O
therapy	O
and	O
for	O
several	O
months	O
following	O
termination	O
of	O
therapy	O
.	O
	
In	O
a	O
pooled	O
analysis	O
of	O
randomized	O
double-blind	O
oncology	O
clinical	O
trials	O
,	O
the	O
incidence	O
of	O
angioedema	B
in	O
patients	O
taking	O
everolimus	O
with	O
an	O
ACE	O
inhibitor	O
was	O
6.8	O
%	O
compared	O
to	O
1.3	O
%	O
in	O
the	O
control	O
arm	O
with	O
an	O
ACE	O
inhibitor	O
.	O
	
All	O
patients	O
being	O
treated	O
with	O
antidepressants	O
for	O
any	O
indication	O
should	O
be	O
monitored	O
appropriately	O
and	O
observed	O
closely	O
for	O
clinical	O
worsening	O
,	O
suicidality	O
,	O
and	O
unusual	O
changes	O
in	O
behavior	O
,	O
especially	O
during	O
the	O
initial	O
few	O
months	O
of	O
a	O
course	O
of	O
drug	O
therapy	O
,	O
or	O
at	O
times	O
of	O
dose	O
changes	O
,	O
either	O
increases	O
or	O
decreases	O
.	O
	
Bone	B
pain	I
was	O
the	O
most	O
frequent	O
treatment-emergent	O
adverse	O
reaction	O
that	O
occurred	O
in	O
at	O
least	O
1	O
%	O
or	O
greater	O
in	O
patients	O
treated	O
with	O
GRANIX	O
at	O
the	O
recommended	O
dose	O
and	O
was	O
numerically	O
two	O
times	O
more	O
frequent	O
than	O
in	O
the	O
placebo	O
group	O
.	O
	
5.13	O
Hereditary	O
Angioedema	O
Exogenous	O
estrogens	O
may	O
exacerbate	B
symptoms	I
of	I
angioedema	I
in	O
women	O
with	O
hereditary	O
angioedema	O
.	O
	
Baseline	O
estimated	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
eGFR	O
>	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
in	O
92	O
%	O
of	O
the	O
population	O
and	O
moderately	O
impaired	O
(	O
eGFR	O
30	O
to	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
in	O
8	O
%	O
of	O
the	O
population	O
.	O
	
ILARIS	O
has	O
been	O
associated	O
with	O
an	O
increased	O
incidence	O
of	O
serious	O
infections	B
.	O
	
In	O
those	O
patients	O
treated	O
with	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
who	O
reported	O
dizziness	B
,	O
symptoms	O
persisted	O
during	O
treatment	O
in	O
about	O
6	O
%	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
for	O
patients	O
taking	O
OTEZLA	O
were	O
nausea	B
(	O
1.8	O
%	O
)	O
,	O
diarrhea	B
(	O
1.8	O
%	O
)	O
,	O
and	O
headache	B
(	O
1.2	O
%	O
)	O
.	O
	
The	O
decision	O
to	O
resume	O
INLYTA	O
therapy	O
after	O
surgery	O
should	O
be	O
based	O
on	O
clinical	O
judgment	O
of	O
adequate	O
wound	O
healing	O
.	O
	
Most	O
patients	O
who	O
developed	O
IgG	O
antibodies	O
did	O
so	O
within	O
the	O
first	O
3	O
months	O
of	O
exposure	O
(	O
median	O
time	O
to	O
seroconversion	O
was	O
4	O
weeks	O
)	O
.	O
	
Nervous	O
System	O
Disorders	O
Tremor	B
.	O
	
The	O
detection	O
of	O
antibody	O
formation	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assay	O
.	O
	
Patients	O
should	O
be	O
advised	O
not	O
to	O
drive	O
a	O
car	O
or	O
operate	O
other	O
complex	O
machinery	O
until	O
they	O
have	O
gained	O
sufficient	O
experience	O
on	O
HORIZANT	O
to	O
assess	O
whether	O
HORIZANT	O
impairs	O
their	O
ability	O
to	O
perform	O
these	O
tasks	O
.	O
	
Limited	O
data	O
suggest	O
that	O
patients	O
with	O
a	O
history	O
of	O
multiple	O
drug	O
allergies	O
or	O
significant	O
hypersensitivity	O
may	O
be	O
at	O
increased	O
risk	O
.	O
	
Advise	O
patients	O
not	O
to	O
drive	O
or	O
operate	O
heavy	O
machinery	O
until	O
they	O
know	O
how	O
Toviaz	O
affects	O
them	O
(	O
5.5	O
)	O
*	O
Toviaz	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
myasthenia	O
gravis	O
,	O
a	O
disease	O
characterized	O
by	O
decreased	O
cholinergic	O
activity	O
at	O
the	O
neuromuscular	O
junction	O
.	O
	
Two	O
placebo-controlled	O
monotherapy	O
trials	O
of	O
12	O
and	O
26	O
weeks	O
of	O
duration	O
were	O
conducted	O
in	O
patients	O
treated	O
with	O
NESINA	O
12.5	O
mg	O
daily	O
,	O
NESINA	O
25	O
mg	O
daily	O
and	O
placebo	O
.	O
	
Musculoskeletal	O
Disorders	O
:	O
Myositis	B
.	O
	
All	O
5	O
patients	O
had	O
maximum	O
AST	B
levels	I
>	I
8	I
*	I
ULN	I
,	O
which	O
returned	O
to	O
baseline	O
levels	O
following	O
interruption	O
of	O
KALYDECO	O
dosing	O
.	O
	
Tell	O
your	O
healthcare	O
provider	O
if	O
you	O
have	O
any	O
side	O
effects	O
that	O
bother	O
you	O
or	O
do	O
not	O
go	O
away	O
.	O
	
Administer	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
of	O
prednisone	O
or	O
equivalent	O
.	O
	
For	O
patients	O
with	O
a	O
history	O
of	O
transaminase	O
elevations	O
,	O
more	O
frequent	O
monitoring	O
of	O
liver	O
function	O
tests	O
should	O
be	O
considered	O
.	O
	
Adverse	O
Reactions	O
Occurring	O
at	O
an	O
Incidence	O
of	O
2	O
%	O
or	O
More	O
among	O
FANAPT	O
-Treated	O
Patients	O
and	O
More	O
Frequent	O
than	O
Placebo	O
Table	O
7	O
enumerates	O
the	O
pooled	O
incidences	O
of	O
treatment-emergent	O
adverse	O
reactions	O
that	O
were	O
spontaneously	O
reported	O
in	O
four	O
placebo-controlled	O
,	O
4-	O
or	O
6-week	O
,	O
fixed-	O
or	O
flexible-dose	O
studies	O
,	O
listing	O
those	O
reactions	O
that	O
occurred	O
in	O
2	O
%	O
or	O
more	O
of	O
patients	O
treated	O
with	O
FANAPT	O
in	O
any	O
of	O
the	O
dose	O
groups	O
,	O
and	O
for	O
which	O
the	O
incidence	O
in	O
FANAPT-treated	O
patients	O
in	O
any	O
dose	O
group	O
was	O
greater	O
than	O
the	O
incidence	O
in	O
patients	O
treated	O
with	O
placebo	O
.	O
	
STRIBILD	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
chronic	O
hepatitis	O
B	O
virus	O
(	O
HBV	O
)	O
infection	O
and	O
the	O
safety	O
and	O
efficacy	O
of	O
STRIBILD	O
have	O
not	O
been	O
established	O
in	O
patients	O
coinfected	O
with	O
HBV	O
and	O
HIV-1	O
.	O
	
The	O
rate	O
of	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
was	O
4	O
%	O
of	O
subjects	O
at	O
Week	O
48	O
.	O
	
(	O
5.3	O
)	O
*	O
Not	O
recommended	O
in	O
patients	O
with	O
severe	O
hepatic	O
impairment	O
.	O
	
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
malignancies	B
,	O
excluding	O
non-melanoma	O
skin	O
cancers	O
,	O
were	O
observed	O
in	O
0.2	O
%	O
(	O
3/1,458	O
)	O
and	O
0.3	O
%	O
(	O
2/675	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
placebo	O
,	O
respectively	O
.	O
	
(	O
2.3,5.2	O
)	O
*	O
Interstitial	B
lung	I
disease	I
(	O
ILD	B
)	O
:	O
Occurs	O
in	O
1.5	O
%	O
of	O
patients	O
.	O
	
Deaths	B
during	O
double-blind	O
treatment	O
where	O
an	O
adverse	O
event	O
was	O
the	O
primary	O
cause	O
occurred	O
in	O
seven	O
patients	O
on	O
AFINITOR	O
and	O
one	O
patient	O
on	O
placebo	O
.	O
	
If	O
unexplained	O
or	O
clinically	O
significant	O
weight	O
loss	O
occurs	O
,	O
weight	O
loss	O
should	O
be	O
evaluated	O
,	O
and	O
discontinuation	O
of	O
OTEZLA	O
should	O
be	O
considered	O
.	O
	
If	O
the	O
recommended	O
dose	O
is	O
exceeded	O
,	O
the	O
dose	O
should	O
be	O
reduced	O
to	O
600	O
mg	O
daily	O
for	O
1	O
week	O
prior	O
to	O
discontinuation	O
to	O
minimize	O
the	O
potential	O
of	O
withdrawal	O
seizure	O
.	O
	
In	O
short-term	O
,	O
placebo-controlled	O
bipolar	O
adult	O
mania	O
trials	O
,	O
the	O
mean	O
increase	B
in	I
transaminase	I
levels	I
for	O
SAPHRIS-treated	O
patients	O
was	O
8.9	O
units/L	O
compared	O
to	O
a	O
decrease	O
of	O
4.9	O
units/L	O
in	O
placebo-treated	O
patients	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GE	O
Healthcare	O
at	O
1-800-654-0118	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Long-term	B
cumulative	I
radiation	I
exposure	I
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cancer	B
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Anaphylaxis	B
and	O
Hypersensitivity	B
Reactions	I
:	O
Life-threatening	O
anaphylaxis	B
and	O
hypersensitivity	B
reactions	I
have	O
been	O
observed	O
in	O
some	O
patients	O
during	O
and	O
after	O
treatment	O
with	O
alglucosidase	O
alfa	O
.	O
	
c	O
Dyspnea	B
includes	O
the	O
preferred	O
terms	O
of	O
dyspnea	B
,	O
dyspnea	B
exertional	I
.	O
	
The	O
median	O
age	O
of	O
these	O
patients	O
was	O
64	O
years	O
(	O
range	O
32-87	O
)	O
.	O
	
In	O
some	O
cases	O
of	O
anaphylaxis	O
,	O
epinephrine	O
has	O
been	O
administered	O
.	O
	
Especially	O
tell	O
your	O
healthcare	O
provider	O
if	O
you	O
take	O
other	O
hormonal	O
medicines	O
,	O
including	O
progestins	O
or	O
other	O
medicines	O
like	O
DUAVEE	O
.	O
	
Dystonic	B
symptoms	I
include	O
:	O
spasm	B
of	I
the	I
neck	I
muscles	I
,	O
sometimes	O
progressing	O
to	O
tightness	B
of	I
the	I
throat	I
,	O
swallowing	B
difficulty	I
,	O
difficulty	B
breathing	I
,	O
and/or	O
protrusion	B
of	I
the	I
tongue	I
.	O
	
Fall-related	B
injuries	I
were	O
more	O
severe	O
in	O
patients	O
treated	O
with	O
XTANDI	O
and	O
included	O
non-pathologic	B
fractures	I
,	O
joint	B
injuries	I
,	O
and	O
hematomas	B
.	O
	
Screen	O
patients	O
for	O
acute	O
kidney	O
injury	O
and	O
other	O
conditions	O
that	O
may	O
reduce	O
renal	O
function	O
.	O
	
Because	O
of	O
physiological	O
diurnal	O
variation	O
,	O
there	O
is	O
a	O
second	O
period	O
of	O
heart	B
rate	I
decrease	I
within	O
24	O
hours	O
after	O
the	O
first	O
dose	O
.	O
	
In	O
addition	O
to	O
cases	O
of	O
gastrointestinal	B
perforation	I
were	O
reported	O
in	O
4/715	O
patients	O
(	O
1	O
%	O
)	O
.	O
	
Headache	B
was	O
the	O
most	O
common	O
adverse	O
reaction	O
,	O
reported	O
for	O
57	O
subjects	O
(	O
7.1	O
%	O
)	O
,	O
followed	O
by	O
injection	B
site	I
hematoma	I
in	O
8	O
subjects	O
(	O
1.0	O
%	O
)	O
.	O
	
WARNING	O
:	O
FETAL	B
TOXICITY	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
5.6	O
Use	O
with	O
Anakinra	O
Concurrent	O
administration	O
of	O
anakinra	O
(	O
an	O
interleukin-1	O
antagonist	O
)	O
and	O
another	O
TNF-blocker	O
,	O
was	O
associated	O
with	O
a	O
greater	O
portion	O
of	O
serious	O
infections	O
and	O
neutropenia	O
and	O
no	O
additional	O
benefits	O
compared	O
with	O
the	O
TNF-blocker	O
alone	O
.	O
	
STRIBILD	O
should	O
be	O
discontinued	O
if	O
estimated	O
creatinine	O
clearance	O
declines	O
below	O
50	O
mL	O
per	O
minute	O
as	O
dose	O
interval	O
adjustment	O
required	O
for	O
emtricitabine	O
and	O
tenofovir	O
DF	O
can	O
not	O
be	O
achieved	O
with	O
the	O
fixed-dose	O
combination	O
tablet	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
withdrawal	O
in	O
patients	O
receiving	O
POTIGA	O
were	O
dizziness	B
(	O
6	O
%	O
)	O
,	O
confusional	B
state	I
(	O
4	O
%	O
)	O
,	O
fatigue	B
(	O
3	O
%	O
)	O
,	O
and	O
somnolence	B
(	O
3	O
%	O
)	O
.	O
	
In	O
patients	O
whose	O
renal	O
function	O
may	O
depend	O
on	O
the	O
activity	O
of	O
the	O
renin-angiotensin	O
system	O
(	O
e.g.	O
,	O
patients	O
with	O
severe	O
congestive	O
heart	O
failure	O
,	O
renal	O
artery	O
stenosis	O
,	O
or	O
volume	O
depletion	O
)	O
,	O
treatment	O
with	O
angiotensin-converting	O
enzyme	O
inhibitors	O
and	O
angiotensin	O
receptor	O
blockers	O
has	O
been	O
associated	O
with	O
oliguria	B
or	O
progressive	B
azotemia	I
and	O
rarely	O
with	O
acute	B
renal	I
failure	I
and	O
death	B
.	O
	
Grade	O
3-4	O
adverse	O
reactions	O
were	O
reported	O
in	O
44	O
%	O
of	O
XTANDI-treated	O
patients	O
and	O
37	O
%	O
of	O
placebo-treated	O
patients	O
.	O
	
Monitor	O
for	O
infection	O
during	O
treatment	O
and	O
for	O
2	O
months	O
after	O
discontinuation	O
.	O
	
In	O
the	O
546	O
patients	O
from	O
the	O
safety	O
population	O
,	O
the	O
incidence	O
of	O
ALT	B
elevation	I
was	O
17	O
%	O
and	O
AST	B
elevation	I
was	O
14	O
%	O
.	O
	
WARNING	O
:	O
INCREASED	B
MORTALITY	I
IN	O
ELDERLY	O
PATIENTS	O
WITH	O
DEMENTIA-RELATED	O
PSYCHOSIS	O
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Renal	O
Cysts	O
Renal	B
cysts	I
were	O
experienced	O
by	O
50	O
(	O
3	O
%	O
)	O
of	O
1669	O
patients	O
.	O
	
There	O
were	O
13	O
(	O
0.8	O
%	O
)	O
patients	O
with	O
Grade	O
3	O
and	O
4	O
(	O
0.2	O
%	O
)	O
patients	O
with	O
Grade	O
4	O
visual	B
impairment	I
.	O
	
Therefore	O
,	O
use	O
of	O
ELIQUIS	O
is	O
not	O
recommended	O
in	O
these	O
patients	O
.	O
	
Treatment	O
of	O
Bone	O
Loss	O
in	O
Patients	O
Receiving	O
Androgen	O
Deprivation	O
Therapy	O
for	O
Prostate	O
Cancer	O
or	O
Adjuvant	O
Aromatase	O
Inhibitor	O
Therapy	O
for	O
Breast	O
Cancer	O
The	O
safety	O
of	O
Prolia	O
in	O
the	O
treatment	O
of	O
bone	O
loss	O
in	O
men	O
with	O
nonmetastatic	O
prostate	O
cancer	O
receiving	O
androgen	O
deprivation	O
therapy	O
(	O
ADT	O
)	O
was	O
assessed	O
in	O
a	O
3-year	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
multinational	O
study	O
of	O
1468	O
men	O
aged	O
48	O
to	O
97	O
years	O
.	O
	
These	O
adverse	O
reactions	O
were	O
not	O
present	O
at	O
baseline	O
,	O
occurred	O
more	O
commonly	O
on	O
INVOKANA	O
than	O
on	O
placebo	O
,	O
and	O
occurred	O
in	O
at	O
least	O
2	O
%	O
of	O
patients	O
treated	O
with	O
either	O
INVOKANA	O
100	O
mg	O
or	O
INVOKANA	O
300	O
mg.	O
Table	O
1	O
:	O
Adverse	O
Reactions	O
From	O
Pool	O
of	O
Four	O
26-Week	O
Placebo-Controlled	O
Studies	O
Reported	O
in	O
>	O
=	O
2	O
%	O
of	O
INVOKANA-Treated	O
PatientsThe	O
four	O
placebo-controlled	O
trials	O
included	O
one	O
monotherapy	O
trial	O
and	O
three	O
add-on	O
combination	O
trials	O
with	O
metformin	O
,	O
metformin	O
and	O
sulfonylurea	O
,	O
or	O
metformin	O
and	O
pioglitazone	O
.	O
	
Therefore	O
,	O
ARCAPTA	O
NEOHALER	O
,	O
like	O
other	O
sympathomimetic	O
amines	O
,	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
cardiovascular	O
disorders	O
,	O
especially	O
coronary	O
insufficiency	O
,	O
cardiac	O
arrhythmias	O
,	O
and	O
hypertension	O
.	O
	
Test	O
for	O
viral	O
hepatitis	O
and	O
discontinue	O
other	O
hepatotoxic	O
medications	O
if	O
evidence	O
of	O
new	O
or	O
worsening	O
liver	O
dysfunction	O
occurs	O
.	O
	
Table	O
3	O
shows	O
absolute	O
and	O
relative	O
risk	O
by	O
indication	O
for	O
all	O
evaluated	O
AEDs	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
described	O
in	O
more	O
detail	O
in	O
other	O
sections	O
of	O
the	O
prescribing	O
information	O
.	O
	
The	O
management	O
of	O
NMS	O
should	O
include	O
:	O
1	O
)	O
immediate	O
discontinuation	O
of	O
antipsychotic	O
drugs	O
and	O
other	O
drugs	O
not	O
essential	O
to	O
concurrent	O
therapy	O
;	O
2	O
)	O
intensive	O
symptomatic	O
treatment	O
and	O
medical	O
monitoring	O
;	O
and	O
3	O
)	O
treatment	O
of	O
any	O
concomitant	O
serious	O
medical	O
problems	O
for	O
which	O
specific	O
treatments	O
are	O
available	O
.	O
	
Additionally	O
in	O
Prolia-treated	O
men	O
with	O
nonmetastatic	O
prostate	O
cancer	O
receiving	O
ADT	O
,	O
a	O
greater	O
incidence	O
of	O
cataracts	B
was	O
observed	O
(	O
1.2	O
%	O
placebo	O
vs.	O
4.7	O
%	O
Prolia	O
)	O
.	O
	
A	O
total	O
of	O
120	O
women	O
were	O
exposed	O
to	O
placebo	O
and	O
129	O
women	O
were	O
exposed	O
to	O
Prolia	O
administered	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
subcutaneous	O
dose	O
.	O
	
One	O
death	B
occurred	O
during	O
the	O
24	O
weeks	O
of	O
administration	O
of	O
SIRTURO	O
.	O
	
In	O
randomized	O
controlled	O
studies	O
,	O
ALT	B
)	I
elevations	I
greater	O
than	O
three	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
were	O
observed	O
:	O
1.3	O
%	O
in	O
alogliptin-treated	O
patients	O
and	O
1.5	O
%	O
in	O
all	O
comparator-treated	O
patients	O
.	O
	
5.5	O
Hyponatremia	O
Clinically	O
significant	O
hyponatremia	B
(	O
sodium	O
<	O
125	O
mEq/L	O
)	O
can	O
develop	O
in	O
patients	O
taking	O
APTIOM	O
.	O
	
Consider	O
periodic	O
monitoring	O
with	O
electrocardiograms	O
(	O
ECGs	O
)	O
and	O
electrolytes	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
electrolyte	O
abnormalities	O
,	O
or	O
who	O
are	O
taking	O
medications	O
that	O
are	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
.	O
	
(	O
5.2	O
)	O
5.1	O
Contamination	O
of	O
Tip	O
and	O
Solution	O
To	O
minimize	O
contaminating	O
the	O
dropper	O
tip	O
and	O
solution	O
,	O
care	O
should	O
be	O
taken	O
not	O
to	O
touch	O
the	O
eyelids	O
or	O
surrounding	O
areas	O
with	O
the	O
dropper	O
tip	O
of	O
the	O
bottle	O
.	O
	
These	O
cases	O
generally	O
occurred	O
within	O
3	O
months	O
after	O
the	O
initiation	O
of	O
XALKORI	O
.	O
	
Careful	O
consideration	O
should	O
be	O
given	O
to	O
the	O
patient	O
's	O
clinical	O
status	O
prior	O
to	O
administration	O
of	O
Vimizim	O
and	O
consider	O
delaying	O
the	O
Vimizim	O
infusion	O
.	O
	
*	O
Tumor	B
Lysis	I
Syndrome	I
(	O
TLS	B
)	O
:	O
Monitor	O
patients	O
at	O
risk	O
for	O
TLS	O
(	O
e.g	O
.	O
	
APTIOM	O
should	O
be	O
discontinued	O
and	O
not	O
be	O
resumed	O
if	O
an	O
alternative	O
etiology	O
for	O
the	O
signs	O
or	O
symptoms	O
can	O
not	O
be	O
established	O
.	O
	
Monitor	O
patients	O
for	O
fever	O
and	O
infections	O
and	O
evaluate	O
promptly	O
.	O
	
Immune-mediated	B
endocrinopathies	I
:	O
Monitor	O
thyroid	O
function	O
tests	O
and	O
clinical	O
chemistries	O
prior	O
to	O
each	O
dose	O
.	O
	
Interrupt	O
or	O
discontinue	O
BLINCYTO	O
as	O
recommended	O
.	O
	
Other	O
Malignancies	O
Malignancies	B
,	O
excluding	O
non-melanoma	B
skin	I
cancer	I
and	O
PTLD	B
,	O
were	O
reported	O
in	O
Study	O
1	O
and	O
Study	O
2	O
in	O
3.5	O
%	O
(	O
14/401	O
)	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
NULOJIX	O
regimen	O
and	O
3.7	O
%	O
(	O
15/405	O
)	O
of	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
Additional	O
Adverse	O
Reactions	O
Observed	O
during	O
All	O
Phase	O
2	O
and	O
3	O
Clinical	O
Trials	O
Following	O
is	O
a	O
list	O
of	O
adverse	O
reactions	O
reported	O
by	O
patients	O
treated	O
with	O
POTIGA	O
during	O
all	O
clinical	O
trials	O
:	O
rash	B
,	O
nystagmus	B
,	O
dyspnea	B
,	O
leukopenia	B
,	O
muscle	B
spasms	I
,	O
alopecia	B
,	O
nephrolithiasis	B
,	O
syncope	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
euphoric	B
mood	I
,	O
renal	B
colic	I
,	O
coma	B
,	O
encephalopathy	B
.	O
	
If	O
super-infection	O
occurs	O
,	O
discontinue	O
use	O
and	O
institute	O
alternative	O
therapy	O
.	O
	
(	O
24	O
weeks	O
)	O
N=197	O
N=212	O
N=196	O
Major	O
[	O
n	O
(	O
%	O
)	O
]	O
1	O
(	O
0.5	O
)	O
1	O
(	O
0.5	O
)	O
1	O
(	O
0.5	O
)	O
Minor	O
[	O
n	O
(	O
%	O
)	O
]	O
67	O
(	O
34.0	O
)	O
92	O
(	O
43.4	O
)	O
79	O
(	O
40.3	O
)	O
Genital	O
Mycotic	O
Infections	O
Genital	B
mycotic	I
infections	I
were	O
more	O
frequent	O
with	O
FARXIGA	O
treatment	O
.	O
	
5.9	O
Hyperprolactinemia	O
As	O
with	O
other	O
drugs	O
that	O
antagonize	O
dopamine	O
D2	O
receptors	O
,	O
FANAPT	O
elevates	B
prolactin	I
levels	I
.	O
	
Mammary	B
gland	I
proliferative	I
changes	I
and	O
increases	B
in	I
serum	I
prolactin	I
were	O
seen	O
in	O
mice	O
and	O
rats	O
treated	O
with	O
FANAPT	O
[	O
see	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
Rare	O
cases	O
of	O
opportunistic	B
infections	I
have	O
also	O
been	O
reported	O
in	O
these	O
clinical	O
trials	O
.	O
	
Upon	O
improvement	O
to	O
Grade	O
1	O
or	O
less	O
,	O
initiate	O
corticosteroid	O
taper	O
and	O
continue	O
to	O
taper	O
over	O
at	O
least	O
1	O
month	O
.	O
	
TRULICITY	O
0.75	O
mg	O
and	O
1.5	O
mg	O
resulted	O
in	O
a	O
mean	O
increase	B
in	I
heart	I
rate	I
)	O
of	O
2-4	O
beats	O
per	O
minute	O
(	O
bpm	O
)	O
.	O
	
Monitor	O
patients	O
for	O
symptoms	O
of	O
perforations	O
and	O
fistulas	O
.	O
	
Monitor	O
blood	O
pressure	O
prior	O
to	O
initiation	O
and	O
regularly	O
during	O
COMETRIQ	O
treatment	O
.	O
	
Baseline	O
estimated	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
eGFR	O
>	O
=60mL/min/1.73	O
m	O
2	O
)	O
in	O
96.0	O
%	O
of	O
the	O
pooled	O
study	O
populations	O
.	O
	
In	O
the	O
XIAFLEX	O
controlled	O
trials	O
in	O
Peyronie	O
's	O
disease	O
(	O
Studies	O
1	O
and	O
2	O
)	O
,	O
65.5	O
%	O
of	O
XIAFLEX-treated	O
patients	O
developed	O
penile	B
hematoma	I
,	O
and	O
14.5	O
%	O
developed	O
penile	B
ecchymosis	I
(	O
see	O
Table	O
4	O
)	O
.	O
	
FARXIGA	O
can	O
increase	O
the	O
risk	O
of	O
hypoglycemia	B
when	O
combined	O
with	O
insulin	O
or	O
an	O
insulin	O
secretagogue	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Immunogenicity	O
Patients	O
were	O
tested	O
at	O
multiple	O
time	O
points	O
for	O
antibodies	O
to	O
certolizumab	O
pegol	O
during	O
Studies	O
CD1	O
and	O
CD2	O
.	O
	
A	O
penile	O
modeling	O
procedure	O
was	O
performed	O
at	O
the	O
study	O
site	O
on	O
patients	O
1	O
to	O
3	O
days	O
after	O
the	O
second	O
injection	O
of	O
the	O
cycle	O
.	O
	
In	O
Study	O
1	O
,	O
CTCAE	O
Grade	O
3-4	O
hyperglycemia	B
,	O
based	O
on	O
laboratory	O
values	O
,	O
occurred	O
in	O
13	O
%	O
of	O
255	O
patients	O
.	O
	
An	O
increase	B
in	I
blood	I
pressure	I
has	O
been	O
reported	O
in	O
women	O
taking	O
COCs	O
,	O
and	O
this	O
increase	O
is	O
more	O
likely	O
in	O
older	O
women	O
and	O
with	O
extended	O
duration	O
of	O
use	O
.	O
	
In	O
these	O
trials	O
,	O
which	O
had	O
a	O
median	O
treatment	O
duration	O
of	O
12	O
weeks	O
,	O
the	O
estimated	O
incidence	O
rate	O
of	O
suicidal	B
behavior	I
among	O
27,863	O
AED	O
treated	O
patients	O
was	O
0.43	O
%	O
,	O
compared	O
to	O
0.24	O
%	O
among	O
16,029	O
placebo	O
treated	O
patients	O
,	O
representing	O
an	O
increase	O
of	O
approximately	O
one	O
case	O
of	O
suicidal	B
thinking	I
for	O
every	O
530	O
patients	O
treated	O
.	O
	
5.6	O
Bladder	O
Cancer	O
Across	O
22	O
clinical	O
studies	O
,	O
newly	O
diagnosed	O
cases	O
of	O
bladder	B
cancer	I
were	O
reported	O
in	O
10/6045	O
patients	O
(	O
0.17	O
%	O
)	O
treated	O
with	O
FARXIGA	O
and	O
1/3512	O
patient	O
(	O
0.03	O
%	O
)	O
treated	O
with	O
placebo/comparator	O
.	O
	
If	O
anticoagulation	O
with	O
PRADAXA	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
,	O
2.5	O
,	O
2.6	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Dosage	O
Modifications	O
due	O
to	O
Adverse	O
Reactions	O
In	O
the	O
trial	O
,	O
dosage	O
adjustments	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
12	O
%	O
of	O
Beleodaq-treated	O
patients	O
.	O
	
Dyspepsia	B
(	O
including	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
,	O
abdominal	B
discomfort	I
,	O
and	O
epigastric	B
discomfort	I
)	O
occurred	O
in	O
patients	O
on	O
PRADAXA	O
in	O
7.5	O
%	O
vs.	O
5.5	O
%	O
on	O
warfarin	O
,	O
and	O
gastritis-like	O
symptoms	O
(	O
including	O
gastritis	B
,	O
GERD	B
,	O
esophagitis	B
,	O
erosive	B
gastritis	I
and	O
gastric	B
hemorrhage	I
)	O
occurred	O
at	O
3.0	O
%	O
vs.	O
1.7	O
%	O
,	O
respectively	O
.	O
	
No	O
trial	O
adequate	O
to	O
determine	O
whether	O
the	O
rate	O
of	O
asthma-related	O
death	B
is	O
increased	O
in	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
has	O
been	O
conducted	O
.	O
	
Rash	B
was	O
self-limiting	O
and	O
generally	O
resolved	O
within	O
1	O
week	O
on	O
continued	O
therapy	O
.	O
	
Treatment	O
of	O
hyperammonemia	O
may	O
require	O
dialysis	O
,	O
preferably	O
hemodialysis	O
,	O
to	O
remove	O
a	O
large	O
burden	O
of	O
ammonia	O
.	O
	
In	O
patients	O
with	O
prior	O
history	O
of	O
bladder	O
cancer	O
,	O
the	O
benefits	O
of	O
glycemic	O
control	O
versus	O
unknown	O
risks	O
for	O
cancer	O
recurrence	O
with	O
FARXIGA	O
should	O
be	O
considered	O
.	O
	
ONFI	O
should	O
be	O
tapered	O
by	O
decreasing	O
the	O
dose	O
every	O
week	O
by	O
5-10	O
mg/day	O
until	O
discontinuation	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
CTCAE	O
Grade	O
3-4	O
elevations	B
of	I
lipase	I
occurred	O
in	O
15	O
%	O
of	O
patients	O
receiving	O
ZYKADIA	O
in	O
Study	O
1	O
.	O
	
Pheochromocytoma	O
and	O
Neuroblastoma	O
Drugs	O
which	O
interfere	O
with	O
norepinephrine	O
uptake	O
in	O
neuroendocrine	O
tumors	O
may	O
lead	O
to	O
false	O
negative	O
imaging	O
results	O
.	O
	
A	O
small	O
proportion	O
of	O
women	O
will	O
have	O
adverse	B
lipid	I
changes	I
while	O
on	O
COCs	O
.	O
	
Advise	O
women	O
of	O
potential	O
risk	O
to	O
a	O
fetus	O
and	O
to	O
avoid	O
pregnancy	O
while	O
taking	O
Zydelig	O
.	O
	
In	O
animal	O
studies	O
,	O
administration	O
of	O
deferiprone	O
during	O
the	O
period	O
of	O
organogenesis	O
resulted	O
in	O
embryofetal	B
death	I
at	O
doses	O
lower	O
than	O
equivalent	O
human	O
clinical	O
doses	O
.	O
	
Avoid	O
concurrent	O
use	O
of	O
Zydelig	O
and	O
other	O
drugs	O
that	O
cause	O
diarrhea	O
.	O
	
ECG	O
monitoring	O
is	O
recommended	O
if	O
therapy	O
is	O
initiated	O
in	O
patients	O
with	O
congestive	O
heart	O
failure	O
,	O
bradyarrhythmias	O
,	O
drugs	O
known	O
to	O
prolong	O
the	O
QT	O
interval	O
,	O
including	O
Class	O
Ia	O
and	O
III	O
antiarrhythmics	O
,	O
and	O
electrolyte	O
abnormalities	O
.	O
	
Errors	O
may	O
also	O
occur	O
in	O
cases	O
with	O
severe	O
brain	O
atrophy	O
that	O
limits	O
the	O
ability	O
to	O
distinguish	O
gray	O
and	O
white	O
matter	O
on	O
the	O
Neuraceq	O
scan	O
.	O
	
5.6	O
Anaphylaxis	O
Serious	O
allergic	B
reactions	I
,	O
including	O
anaphylaxis	B
,	O
have	O
been	O
reported	O
in	O
patients	O
on	O
Zydelig	O
.	O
	
Withhold	O
HALAVEN	O
in	O
patients	O
who	O
experience	O
Grade	O
3	O
or	O
4	O
peripheral	O
neuropathy	O
until	O
resolution	O
to	O
Grade	O
2	O
or	O
less	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Over	O
95	O
%	O
of	O
XIAFLEX-treated	O
patients	O
had	O
an	O
adverse	B
reaction	I
of	I
the	I
injected	I
extremity	I
after	O
up	O
to	O
3	O
injections	O
.	O
	
One	O
percent	O
(	O
1	O
%	O
)	O
of	O
patients	O
discontinued	O
ZYKADIA	O
in	O
Study	O
1	O
due	O
to	O
ILD/pneumonitis	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=25	O
%	O
)	O
were	O
neutropenia	B
,	O
anemia	B
,	O
asthenia/fatigue	O
,	O
alopecia	B
,	O
peripheral	B
neuropathy	I
,	O
nausea	B
,	O
and	O
constipation	B
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Eisai	O
Inc.	O
at	O
(	O
1-877-873-4724	O
)	O
or	O
contact	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
the	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
other	O
clinical	O
trials	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Neuraceq	O
scan	O
results	O
are	O
indicative	O
of	O
the	O
presence	O
of	O
brain	O
neuritic	O
beta-amyloid	O
plaques	O
only	O
at	O
the	O
time	O
of	O
image	O
acquisition	O
and	O
a	O
negative	O
scan	O
result	O
does	O
not	O
preclude	O
the	O
development	O
of	O
brain	O
neuritic	O
beta-amyloid	O
plaques	O
in	O
the	O
future	O
.	O
	
5.3	O
Hepatotoxicity	O
Beleodaq	O
can	O
cause	O
fatal	B
hepatotoxicity	B
and	O
liver	B
function	I
test	I
abnormalities	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Table	O
1	O
:	O
Treatment-Emergent	O
Adverse	O
ReactionsIncludes	O
adverse	O
reactions	O
at	O
least	O
possibly	O
,	O
probably	O
,	O
or	O
very	O
likely	O
related	O
to	O
the	O
drug	O
.	O
	
5.3	O
Hepatotoxicity	O
In	O
the	O
two	O
randomized	O
clinical	O
trials	O
,	O
grade	O
3	O
or	O
4	O
AST	B
increases	I
(	O
at	O
least	O
5*	O
ULN	O
)	O
were	O
reported	O
in	O
4	O
%	O
of	O
patients	O
who	O
received	O
ZYTIGA	O
,	O
typically	O
during	O
the	O
first	O
3	O
months	O
after	O
starting	O
treatment	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
a	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
she	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
Measure	O
the	O
absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
before	O
starting	O
Ferriprox	O
therapy	O
and	O
monitor	O
the	O
ANC	O
weekly	O
on	O
therapy	O
.	O
	
Median	O
time	O
to	O
resolution	O
ranged	O
between	O
1	O
week	O
and	O
1	O
month	O
across	O
trials	O
,	O
following	O
interruption	O
of	O
Zydelig	O
therapy	O
and	O
in	O
some	O
instances	O
,	O
use	O
of	O
corticosteroids	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
An	O
estimate	O
of	O
the	O
attributable	O
risk	O
is	O
3.3	O
cases/100,000	O
COC	O
users	O
.	O
	
(	O
5.1	O
)	O
*	O
Drugs	O
which	O
block	O
norepinephrine	O
uptake	O
or	O
deplete	O
norepinephrine	O
stores	O
may	O
decrease	O
AdreView	O
uptake	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
was	O
similar	O
for	O
each	O
injection	O
,	O
regardless	O
of	O
the	O
number	O
of	O
injections	O
administered	O
.	O
	
5.7	O
Neutropenia	O
Treatment-emergent	O
Grade	O
3	O
or	O
4	O
neutropenia	B
occurred	O
in	O
31	O
%	O
of	O
Zydelig-treated	O
patients	O
across	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Discontinuations	O
due	O
to	O
Adverse	O
Reactions	O
Twenty-five	O
patients	O
(	O
19.4	O
%	O
)	O
discontinued	O
treatment	O
with	O
Beleodaq	O
due	O
to	O
adverse	O
reactions	O
.	O
	
Grade	O
2	O
or	O
higher	O
laboratory	O
abnormalities	B
that	I
represent	I
a	I
worsening	I
from	I
baseline	I
of	I
AST	I
occurred	O
in	O
27.8	O
%	O
,	O
25.0	O
%	O
and	O
7.1	O
%	O
respectively	O
,	O
of	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
co-infected	O
subjects	O
as	O
compared	O
to	O
6.7	O
%	O
,	O
7.5	O
%	O
and	O
1.8	O
%	O
of	O
non-co-infected	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
subjects	O
.	O
	
These	O
hematomas	B
may	O
result	O
in	O
permanent	B
.	O
	
5.5	O
Increases	O
in	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
(	O
LDL-C	O
)	O
Increases	B
in	I
LDL-C	I
occur	O
with	O
FARXIGA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.4	O
High	O
Blood	O
Pressure	O
For	O
women	O
with	O
well-controlled	O
hypertension	O
,	O
monitor	O
blood	O
pressure	O
and	O
stop	O
Natazia	O
if	O
blood	O
pressure	O
rises	O
significantly	O
.	O
	
Monitor	O
fasting	O
serum	O
glucose	O
prior	O
to	O
the	O
start	O
of	O
ZYKADIA	O
treatment	O
and	O
periodically	O
thereafter	O
as	O
clinically	O
indicated	O
.	O
	
Co-administration	O
of	O
a	O
corticosteroid	O
suppresses	O
adrenocorticotropic	O
hormone	O
(	O
ACTH	O
)	O
drive	O
,	O
resulting	O
in	O
a	O
reduction	O
in	O
the	O
incidence	O
and	O
severity	O
of	O
these	O
adverse	O
reactions	O
.	O
	
Do	O
not	O
rechallenge	O
patients	O
who	O
develop	O
neutropenia	O
with	O
Ferriprox	O
unless	O
potential	O
benefits	O
outweigh	O
potential	O
risks	O
.	O
	
COCs	O
may	O
decrease	B
glucose	I
tolerance	I
in	O
a	O
dose-related	O
fashion	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
laboratory	O
abnormalities	O
,	O
withhold	O
ZYKADIA	O
with	O
resumption	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
5.2	O
Potentiation	O
of	O
Sedation	O
from	O
Concomitant	O
Use	O
with	O
Central	O
Nervous	O
System	O
Depressants	O
Since	O
ONFI	O
has	O
a	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
depressant	O
effect	O
,	O
patients	O
or	O
their	O
caregivers	O
should	O
be	O
cautioned	O
against	O
simultaneous	O
use	O
with	O
other	O
CNS	O
depressant	O
drugs	O
or	O
alcohol	O
,	O
and	O
cautioned	O
that	O
the	O
effects	O
of	O
other	O
CNS	O
depressant	O
drugs	O
or	O
alcohol	O
may	O
be	O
potentiated	O
.	O
	
There	O
are	O
insufficient	O
data	O
to	O
determine	O
whether	O
FARXIGA	O
has	O
an	O
effect	O
on	O
pre-existing	O
bladder	O
tumors	O
.	O
	
When	O
plasma	O
ammonia	O
level	O
is	O
normalized	O
,	O
dietary	O
protein	O
intake	O
can	O
usually	O
be	O
reintroduced	O
.	O
	
Rash	B
(	O
greater	O
than	O
or	O
equal	O
to	O
Grade	O
2	O
)	O
occurred	O
in	O
15	O
%	O
of	O
pediatric	O
subjects	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post	O
approval	O
use	O
of	O
PRADAXA	O
.	O
	
Reported	O
infections	O
include	O
:	O
*	O
Active	B
tuberculosis	I
,	O
including	O
reactivation	B
of	I
latent	I
tuberculosis	I
.	O
	
A	O
28-week	O
,	O
placebo-controlled	O
,	O
US	O
trial	O
that	O
compared	O
the	O
safety	O
of	O
another	O
LABA	O
(	O
salmeterol	O
)	O
with	O
placebo	O
,	O
each	O
added	O
to	O
usual	O
asthma	O
therapy	O
,	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
subjects	O
receiving	O
salmeterol	O
(	O
13/13,176	O
in	O
subjects	O
treated	O
with	O
salmeterol	O
vs.	O
3/13,179	O
in	O
subjects	O
treated	O
with	O
placebo	O
;	O
relative	O
risk	O
:	O
4.37	O
[	O
95	O
%	O
CI	O
:	O
1.25	O
,	O
15.34	O
]	O
)	O
.	O
	
Discontinue	O
COMETRIQ	O
for	O
severe	O
hypertension	O
that	O
can	O
not	O
be	O
controlled	O
with	O
anti-hypertensive	O
therapy	O
.	O
	
These	O
adverse	O
reactions	O
were	O
not	O
present	O
at	O
baseline	O
,	O
occurred	O
more	O
commonly	O
on	O
TRULICITY	O
than	O
on	O
placebo	O
,	O
and	O
occurred	O
in	O
at	O
least	O
5	O
%	O
of	O
patients	O
treated	O
with	O
TRULICITY	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
IMMUNE-MEDIATED	B
ADVERSE	I
REACTIONS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
5.10	O
Drug	O
Interactions	O
Avoid	O
administration	O
of	O
COMETRIQ	O
with	O
agents	O
that	O
are	O
strong	O
CYP3A4	O
inducers	O
or	O
inhibitors	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.1	O
,	O
7.2	O
)	O
]	O
.	O
	
XEOMIN-treated	O
patients	O
were	O
18	O
to	O
79	O
years	O
old	O
(	O
mean	O
53	O
years	O
)	O
,	O
and	O
were	O
predominantly	O
female	O
(	O
66	O
%	O
)	O
and	O
Caucasian	O
(	O
91	O
%	O
)	O
.	O
	
This	O
,	O
in	O
turn	O
,	O
may	O
inhibit	B
reproductive	I
function	I
by	O
impairing	B
gonadalsteroidogenesis	I
in	O
both	O
female	O
and	O
male	O
patients	O
.	O
	
Discontinuation	O
from	O
study	O
due	O
to	O
genital	B
infection	I
occurred	O
in	O
0	O
%	O
of	O
placebo-treated	O
patients	O
and	O
0.2	O
%	O
of	O
patients	O
treated	O
with	O
FARXIGA	O
10	O
mg	O
.	O
	
Besivance	O
is	O
for	O
topical	O
ophthalmic	O
use	O
only	O
,	O
and	O
should	O
not	O
be	O
injected	O
subconjunctivally	O
,	O
nor	O
should	O
it	O
be	O
introduced	O
directly	O
into	O
the	O
anterior	O
chamber	O
of	O
the	O
eye	O
.	O
	
Immune-mediated	B
hepatitis	I
:	O
Evaluate	O
liver	O
function	O
tests	O
before	O
each	O
dose	O
of	O
YERVOY	O
.	O
	
[	O
See	O
Clinical	O
Studies	O
(	O
14	O
)	O
.	O
]	O
	
Lenses	O
may	O
be	O
reinserted	O
after	O
10	O
minutes	O
following	O
administration	O
of	O
DUREZOL	O
.	O
	
Patients	O
received	O
6	O
doses	O
of	O
ERWINAZE	O
25,000	O
International	O
Units/m	O
2	O
intramuscularly	O
on	O
a	O
Monday	O
,	O
Wednesday	O
,	O
and	O
Friday	O
schedule	O
as	O
a	O
replacement	O
for	O
each	O
scheduled	O
dose	O
of	O
pegaspargase	O
remaining	O
on	O
their	O
original	O
treatment	O
protocol	O
.	O
	
Dizziness	B
362014	O
31	O
<	O
1	O
Psychiatric	O
disorders	O
Insomnia	B
15	O
0	O
Respiratory	O
,	O
thoracic	O
,	O
and	O
mediastinal	O
disorders	O
Cough	B
DyspneaDyspnea	O
includes	O
the	O
following	O
terms	O
:	O
acute	B
respiratory	I
failure	I
,	O
bronchial	B
hyperactivity	I
,	O
bronchospasm	B
,	O
dyspnea	B
,	O
dyspnea	B
exertional	I
,	O
respiratory	B
distress	I
,	O
respiratory	B
failure	I
,	O
and	O
wheezing	B
.	O
	
Six	O
of	O
the	O
8	O
cases	O
presented	O
with	O
CNS	O
involvement	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
the	O
labeling	O
:	O
*	O
Increased	B
mortality	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
QT	B
Prolongation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Drug	O
Interactions	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
in	O
10	O
%	O
or	O
more	O
of	O
patients	O
treated	O
with	O
SIRTURO	O
were	O
nausea	B
,	O
arthralgia	B
,	O
headache	B
,	O
hemoptysis	B
and	O
chest	B
pain	I
.	O
	
In	O
symptomatic	O
patients	O
,	O
rule	O
out	O
infectious	O
etiologies	O
and	O
consider	O
endoscopic	O
evaluation	O
for	O
persistent	O
or	O
severe	O
symptoms	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Eli	O
Lilly	O
and	O
Company	O
at	O
1-800-LillyRx	O
(	O
1-800-545-5979	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
If	O
hypersensitivity	O
reactions	O
occur	O
,	O
discontinue	O
use	O
of	O
FARXIGA	O
;	O
treat	O
per	O
standard	O
of	O
care	O
and	O
monitor	O
until	O
signs	O
and	O
symptoms	O
resolve	O
.	O
	
In	O
a	O
short-term	O
placebo-controlled	O
trial	O
(	O
4-weeks	O
)	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
to	O
endpoint	O
in	O
plasma	B
prolactin	I
levels	I
for	I
the	I
FANAPT	I
24	I
mg/day-treated	I
group	I
was	I
an	I
increase	I
of	O
2.6	O
ng/mL	O
compared	O
to	O
a	O
decrease	O
of	O
6.3	O
ng/mL	O
in	O
the	O
placebo-group	O
.	O
	
Six	O
percent	O
(	O
6	O
%	O
)	O
of	O
TECFIDERA	O
patients	O
and	O
<	O
1	O
%	O
of	O
placebo	O
patients	O
experienced	O
lymphocyte	B
counts	I
<	I
0.5x10	I
9	I
/L	I
(	O
lower	O
limit	O
of	O
normal	O
0.91x10	O
9	O
/L	O
)	O
.	O
	
*	O
Atrial	B
Fibrillation	I
:	O
Monitor	O
patients	O
for	O
atrial	O
fibrillation	O
(	O
5.4	O
)	O
.	O
	
Consider	O
the	O
risks	O
and	O
benefits	O
of	O
re-administering	O
Vimizim	O
following	O
a	O
severe	O
reaction	O
.	O
	
[	O
See	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Flushing	B
symptoms	O
generally	O
began	O
soon	O
after	O
initiating	O
TECFIDERA	O
and	O
usually	O
improved	O
or	O
resolved	O
over	O
time	O
.	O
	
3	O
%	O
.	O
	
5.2	O
Contact	O
Lens	O
Use	O
Patients	O
should	O
be	O
advised	O
not	O
to	O
wear	O
a	O
contact	O
lens	O
if	O
their	O
eye	O
is	O
red	O
.	O
	
Withhold	O
XALKORI	O
in	O
patients	O
who	O
develop	O
QTc	O
greater	O
than	O
500	O
ms	O
on	O
at	O
least	O
2	O
separate	O
ECGs	O
until	O
recovery	O
to	O
a	O
QTc	O
less	O
than	O
or	O
equal	O
to	O
480	O
ms	O
,	O
then	O
resume	O
XALKORI	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
2	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
A	O
higher	O
percentage	O
of	O
APTIOM-treated	O
patients	O
(	O
5.1	O
%	O
)	O
than	O
placebo-treated	O
patients	O
(	O
0.7	O
%	O
)	O
experienced	O
decreases	B
in	I
sodium	I
values	I
of	O
more	O
than	O
10	O
mEq/L	O
.	O
	
Therefore	O
,	O
obtaining	O
a	O
liver	O
test	O
panel	O
and	O
assessing	O
the	O
patient	O
before	O
initiating	O
NESINA	O
therapy	O
is	O
recommended	O
.	O
	
These	O
18	O
patients	O
experienced	O
26	O
anaphylactic	B
reactions	I
during	O
infusion	O
with	O
signs	O
and	O
symptoms	O
including	O
cough	B
,	O
erythema	B
,	O
throat	B
tightness	I
,	O
urticaria	B
,	O
flushing	B
,	O
cyanosis	B
,	O
hypotension	B
,	O
rash	B
,	O
dyspnea	B
,	O
chest	B
discomfort	I
,	O
and	O
gastrointestinal	B
symptoms	I
(	O
e.g.	O
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
retching	B
,	O
and	O
vomiting	B
)	O
in	O
conjunction	O
with	O
urticaria	B
.	O
	
Exclude	O
other	O
potential	O
causes	O
of	O
ILD/pneumonitis	O
,	O
and	O
permanently	O
discontinue	O
XALKORI	O
in	O
patients	O
diagnosed	O
with	O
drug-related	O
ILD/pneumonitis	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Hyponatremia	B
was	O
also	O
observed	O
in	O
monotherapy	O
trials	O
.	O
	
5.7	O
Embryo-Fetal	O
Toxicity	O
Based	O
on	O
findings	O
in	O
animals	O
,	O
IMBRUVICA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Pre-existing	O
hypocalcemia	O
must	O
be	O
corrected	O
prior	O
to	O
initiating	O
therapy	O
with	O
Prolia	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Because	O
postmarketing	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Approximately	O
half	O
of	O
the	O
patients	O
(	O
49	O
%	O
)	O
were	O
male	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
25	O
%	O
)	O
are	O
nausea	B
,	O
fatigue	B
,	O
pyrexia	B
,	O
anemia	B
,	O
and	O
vomiting	B
.	O
	
Baseline	O
evaluations	O
of	O
liver	O
laboratory	O
tests	O
are	O
recommended	O
.	O
	
The	O
finding	O
of	O
increased	O
risk	O
with	O
AEDs	O
of	O
varying	O
mechanism	O
of	O
action	O
and	O
across	O
a	O
range	O
of	O
indications	O
suggests	O
that	O
the	O
risk	O
applies	O
to	O
all	O
AEDs	O
used	O
for	O
any	O
indication	O
.	O
	
Alcohol	O
and	O
other	O
hepatotoxic	O
drugs	O
should	O
be	O
avoided	O
while	O
on	O
SIRTURO	O
,	O
especially	O
in	O
patients	O
with	O
impaired	O
hepatic	O
function	O
.	O
	
In	O
these	O
trials	O
6	O
%	O
of	O
patients	O
on	O
POTIGA	O
and	O
1.2	O
%	O
on	O
placebo	O
discontinued	O
treatment	O
because	O
of	O
dizziness	B
;	O
3	O
%	O
of	O
patients	O
on	O
POTIGA	O
and	O
<	O
1.0	O
%	O
on	O
placebo	O
discontinued	O
because	O
of	O
somnolence	B
.	O
	
Discontinue	O
if	O
evidence	O
of	O
liver	O
injury	O
.	O
	
Transaminase	B
elevations	I
generally	O
occurred	O
within	O
the	O
first	O
2	O
months	O
of	O
treatment	O
.	O
	
6.1	O
Ocular	O
Surgery	O
Ocular	B
adverse	I
reactions	I
occurring	O
in	O
5-15	O
%	O
of	O
subjects	O
in	O
clinical	O
studies	O
with	O
DUREZOL	O
included	O
corneal	B
edema	I
,	O
conjunctival	B
hyperemia	I
,	O
eye	B
pain	I
,	O
photophobia	B
,	O
posterior	B
capsule	I
opacification	I
,	O
anterior	B
chamber	I
cells	I
,	O
anterior	B
chamber	I
flare	I
,	O
conjunctival	B
edema	I
,	O
and	O
blepharitis	B
.	O
	
The	O
incidence	O
of	O
serious	O
adverse	O
events	O
was	O
9.2	O
%	O
in	O
the	O
placebo	O
group	O
and	O
14.7	O
%	O
in	O
the	O
Prolia	O
group	O
.	O
	
Neuropathy	O
Neuropathy	B
in	O
nature	O
,	O
occurred	O
in	O
419	O
(	O
25	O
%	O
)	O
of	O
1669	O
patients	O
.	O
	
SAPHRIS	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
.	O
	
Most	O
cases	O
of	O
transaminase	B
elevations	I
occurred	O
early	O
in	O
treatment	O
;	O
of	O
patients	O
who	O
experienced	O
transaminase	B
elevations	I
of	O
any	O
grade	O
,	O
more	O
than	O
80	O
%	O
experienced	O
their	O
first	O
event	O
within	O
the	O
first	O
3	O
months	O
.	O
	
The	O
decrease	B
in	I
serum	I
potassium	I
is	O
usually	O
transient	O
,	O
not	O
requiring	O
supplementation	O
.	O
	
In	O
the	O
single-arm	O
Phase	O
1/2	O
clinical	O
trial	O
in	O
546	O
patients	O
with	O
CML	O
treated	O
with	O
prior	O
therapy	O
,	O
severe	O
fluid	B
retention	I
was	O
reported	O
in	O
14	O
patients	O
(	O
3	O
%	O
)	O
.	O
	
If	O
such	O
effects	O
occur	O
,	O
ARCAPTA	O
NEOHALER	O
may	O
need	O
to	O
be	O
discontinued	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
15	O
%	O
)	O
are	O
gastritis-like	O
symptoms	O
and	O
bleeding	B
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Boehringer	O
Ingelheim	O
Pharmaceuticals	O
,	O
Inc.	O
at	O
(	O
800	O
)	O
542-6257	O
or	O
(	O
800	O
)	O
459-9906	O
TTY	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
(	O
mean	O
eGFR	O
88	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
(	O
5.5	O
)	O
*	O
Hypersensitivity	B
Reactions	I
:	O
Hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
and	O
angioedema	B
,	O
have	O
been	O
observed	O
.	O
	
DUAVEE	O
is	O
not	O
for	O
pregnant	O
women	O
.	O
	
Heart	B
rates	I
below	I
40	I
beats	I
per	I
minute	I
were	O
rarely	O
observed	O
.	O
	
Serum	O
creatinine	O
levels	O
and	O
estimated	O
GFR	O
may	O
not	O
reliably	O
assess	O
renal	O
function	O
in	O
the	O
setting	O
of	O
acute	O
kidney	O
injury	O
.	O
	
No	O
patients	O
experienced	O
hypertensive	B
crisis	I
.	O
	
The	O
usefulness	O
of	O
hemodialysis	O
in	O
the	O
prevention	O
of	O
NSF	O
is	O
unknown	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
Progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
;	O
Withhold	O
GILENYA	O
at	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
treatment	O
discontinuation	O
was	O
fatigue/asthenia	O
,	O
which	O
occurred	O
in	O
1	O
%	O
of	O
patients	O
on	O
each	O
treatment	O
arm	O
.	O
	
In	O
addition	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
A	O
transient	O
hypotensive	O
response	O
is	O
not	O
a	O
contraindication	O
to	O
further	O
treatment	O
,	O
which	O
usually	O
can	O
be	O
continued	O
without	O
difficulty	O
once	O
the	O
blood	O
pressure	O
has	O
stabilized	O
.	O
	
A	O
total	O
of	O
801	O
patients	O
were	O
treated	O
for	O
at	O
least	O
6	O
months	O
,	O
585	O
patients	O
were	O
treated	O
for	O
1	O
year	O
or	O
longer	O
,	O
and	O
311	O
patients	O
were	O
treated	O
for	O
at	O
least	O
2	O
years	O
.	O
	
You	O
should	O
not	O
do	O
both	O
.	O
	
If	O
anaphylaxis	O
or	O
severe	O
hypersensitivity	O
reactions	O
occur	O
,	O
immediately	O
discontinue	O
infusion	O
and	O
initiate	O
appropriate	O
medical	O
treatment	O
(	O
5.1	O
)	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Hypersensitivity	B
and	O
injection	B
site	I
reactions	I
have	O
been	O
reported	O
following	O
DaTscan	O
administration	O
.	O
	
In	O
a	O
52-week	O
,	O
double-blind	O
,	O
comparator-controlled	O
trial	O
that	O
included	O
primarily	O
adult	O
patients	O
with	O
schizophrenia	O
,	O
the	O
mean	O
increase	B
from	I
baseline	I
of	I
ALT	I
was	O
1.7	O
units/L	O
.	O
	
Hypertension	B
was	O
managed	O
with	O
standard	O
antihypertensive	O
therapy	O
.	O
	
Patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
should	O
be	O
informed	O
that	O
HORIZANT	O
increases	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
and	O
should	O
be	O
advised	O
of	O
the	O
need	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
depression	O
,	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
,	O
or	O
the	O
emergence	O
of	O
suicidal	O
thoughts	O
,	O
behavior	O
,	O
or	O
thoughts	O
about	O
self-harm	O
.	O
	
In	O
the	O
case	O
of	O
mild	O
pancreatitis	O
,	O
hold	O
ERWINAZE	O
until	O
the	O
signs	O
and	O
symptoms	O
subside	O
and	O
amylase	O
levels	O
return	O
to	O
normal	O
.	O
	
If	O
INLYTA	O
is	O
interrupted	O
,	O
patients	O
receiving	O
antihypertensive	O
medications	O
should	O
be	O
monitored	O
for	O
hypotension	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
An	O
elevated	O
risk	O
of	O
acute	B
dystonia	I
is	O
observed	O
in	O
males	O
and	O
younger	O
age	O
groups	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
,	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Table	O
3	O
compares	O
the	O
incidence	O
of	O
the	O
most	O
frequent	O
adverse	O
reactions	O
from	O
a	O
single	O
treatment	O
cycle	O
of	O
500	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
compared	O
to	O
placebo	O
[	O
seeClinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
Your	O
healthcare	O
provider	O
will	O
let	O
you	O
know	O
if	O
you	O
need	O
to	O
stop	O
taking	O
DUAVEE	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
re-administering	O
alglucosidase	O
alfa	O
following	O
an	O
anaphylactic	O
or	O
hypersensitivity	O
reaction	O
should	O
be	O
considered	O
.	O
	
Approximately	O
57	O
%	O
of	O
the	O
patients	O
were	O
male	O
.	O
	
Transaminase	O
elevations	O
were	O
more	O
common	O
in	O
patients	O
with	O
a	O
history	O
of	O
transaminase	O
elevations	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
To	O
enroll	O
in	O
the	O
E.A.S.E	O
.	O
	
Gastrointestinal	O
Disorders	O
:	O
Abdominal	B
pain	I
,	O
abdominal	B
discomfort	I
,	O
flatulence	B
,	O
upper	B
abdominal	I
pain	I
,	O
vomiting	B
.	O
	
Monitor	O
CLcr	O
,	O
urine	O
glucose	O
,	O
and	O
urine	O
protein	O
in	O
all	O
patients	O
.	O
	
In	O
these	O
trials	O
,	O
which	O
had	O
a	O
median	O
treatment	O
duration	O
of	O
12	O
weeks	O
,	O
the	O
estimated	O
incidence	O
rate	O
of	O
suicidal	B
behavior	I
among	O
27,863	O
AED-treated	O
patients	O
was	O
0.43	O
%	O
,	O
compared	O
with	O
0.24	O
%	O
among	O
16,029	O
placebo-treated	O
patients	O
,	O
representing	O
an	O
increase	O
of	O
approximately	O
1	O
case	O
of	O
suicidal	B
thinking	I
for	O
every	O
530	O
patients	O
treated	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
decreased	B
hemoglobin	I
,	O
hyperglycemia	B
,	O
alkaline	B
phosphatase	I
increased	I
,	O
hypercholesterolemia	B
,	O
bicarbonate	B
decreased	I
,	O
and	O
increased	B
aspartate	I
transaminase	I
)	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
cytochrome	O
P450	O
enzyme	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
phenobarbital	O
,	O
carbamazepine	O
,	O
phenytoin	O
)	O
with	O
OTEZLA	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.5	O
)	O
*	O
Not	O
recommended	O
in	O
patients	O
with	O
complete	O
gastrointestinal	O
obstruction	O
or	O
in	O
patients	O
who	O
have	O
surgery	O
for	O
correction	O
of	O
complete	O
bowel	O
obstruction	O
.	O
	
The	O
only	O
treatment-emergent	O
ADR	O
of	O
moderate	O
to	O
severe	O
intensity	O
with	O
at	O
least	O
2	O
%	O
frequency	O
in	O
either	O
treatment	O
group	O
was	O
diarrhea	B
,	O
2	O
%	O
(	O
6	O
of	O
354	O
)	O
in	O
subjects	O
receiving	O
TIVICAY	O
50	O
mg	O
once	O
daily	O
+	O
background	O
regimen	O
and	O
1	O
%	O
(	O
5	O
of	O
361	O
)	O
in	O
subjects	O
receiving	O
raltegravir	O
400	O
mg	O
twice	O
daily	O
+	O
background	O
regimen	O
.	O
	
In	O
addition	O
to	O
the	O
reactions	O
shown	O
in	O
Tables	O
2	O
and	O
3	O
,	O
adverse	O
reactions	O
occurring	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
of	O
the	O
subjects	O
treated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
or	O
BREO	O
ELLIPTA	O
200/25	O
for	O
12	O
months	O
included	O
pyrexia	B
,	O
back	B
pain	I
,	O
extrasystoles	B
,	O
upper	B
abdominal	I
pain	I
,	O
respiratory	B
tract	I
infection	I
,	O
allergic	B
rhinitis	I
,	O
pharyngitis	B
,	O
rhinitis	B
,	O
arthralgia	B
,	O
supraventricular	B
extrasystoles	I
,	O
ventricular	B
extrasystoles	I
,	O
acute	B
sinusitis	I
,	O
and	O
pneumonia	B
.	O
	
A	O
reaction	O
was	O
considered	O
treatment-emergent	O
if	O
it	O
occurred	O
for	O
the	O
first	O
time	O
or	O
worsened	O
while	O
receiving	O
therapy	O
following	O
baseline	O
evaluation	O
.	O
	
Withhold	O
YERVOY	O
dosing	O
in	O
patients	O
with	O
moderate	O
neuropathy	O
(	O
not	O
interfering	O
with	O
daily	O
activities	O
)	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
,	O
HYPERSENSITIVITY	B
AND	O
IMMUNE-MEDIATED	B
REACTIONS	I
,	O
AND	O
RISK	O
OF	O
CARDIORESPIRATORY	B
FAILURE	I
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
,	O
HYPERSENSITIVITY	B
AND	O
IMMUNE-MEDIATED	B
REACTIONS	I
,	O
AND	O
RISK	O
OF	O
CARDIORESPIRATORY	B
FAILURE	I
Life-threatening	O
anaphylactic	B
reactions	I
and	O
severe	O
hypersensitivity	B
reactions	I
,	O
presenting	O
as	O
respiratory	B
distress	I
,	O
hypoxia	B
,	O
apnea	B
,	O
dyspnea	B
,	O
bradycardia	B
,	O
tachycardia	B
,	O
bronchospasm	B
,	O
throat	B
tightness	I
,	O
hypotension	B
,	O
angioedema	B
(	O
including	O
lip	B
swelling	I
,	O
periorbital	B
edema	I
,	O
and	O
face	B
edema	I
)	O
,	O
and	O
urticaria	B
,	O
have	O
occurred	O
in	O
some	O
patients	O
during	O
and	O
after	O
alglucosidase	O
alfa	O
infusions	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Transaminase	O
(	O
ALT	O
or	O
AST	O
)	O
Elevations	O
Elevated	B
transaminases	I
have	O
been	O
reported	O
in	O
patients	O
with	O
CF	O
receiving	O
KALYDECO	O
.	O
	
Immune	O
System	O
Disorders	O
Hypersensitivity	B
reactions	I
,	O
including	O
anaphylaxis	B
,	O
angioedema	B
,	O
rash	B
,	O
and	O
urticaria	B
.	O
	
The	O
extent	O
to	O
which	O
the	O
findings	O
of	O
increased	O
mortality	O
in	O
observational	O
studies	O
may	O
be	O
attributed	O
to	O
the	O
antipsychotic	O
drug	O
as	O
opposed	O
to	O
some	O
characteristic	O
(	O
s	O
)	O
of	O
the	O
patients	O
is	O
not	O
clear	O
.	O
	
Alglucosidase	O
alfa-treated	O
patients	O
who	O
experience	O
a	O
decrease	O
in	O
motor	O
function	O
should	O
be	O
tested	O
for	O
the	O
presence	O
of	O
inhibitory	O
antibodies	O
that	O
neutralize	O
enzyme	O
uptake	O
or	O
activity	O
.	O
	
Table	O
1	O
lists	O
adverse	O
events	O
,	O
regardless	O
of	O
causality	O
,	O
that	O
were	O
reported	O
in	O
the	O
combined	O
Phase	O
3	O
,	O
randomized	O
,	O
placebo-controlled	O
trials	O
at	O
an	O
incidence	O
greater	O
than	O
placebo	O
and	O
in	O
1	O
%	O
or	O
more	O
of	O
patients	O
treated	O
with	O
Toviaz	O
4	O
or	O
8	O
mg	O
once	O
daily	O
for	O
up	O
to	O
12	O
weeks	O
.	O
	
(	O
6.1	O
)	O
*	O
Most	O
common	O
hematologic	B
abnormalities	I
for	O
both	O
indications	O
(	O
frequency	O
>	O
=	O
15	O
%	O
)	O
are	O
lymphopenia	B
,	O
anemia	B
,	O
leukopenia	B
,	O
thrombocytopenia	B
,	O
and	O
neutropenia	B
.	O
	
Patients	O
should	O
be	O
monitored	O
during	O
and	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
after	O
administration	O
of	O
BENLYSTA	O
.	O
	
Discontinuation	O
of	O
therapy	O
in	O
GILOTRIF-treated	O
patients	O
for	O
adverse	O
reactions	O
was	O
14.0	O
%	O
.	O
	
Anaphylaxis	B
was	O
observed	O
in	O
0.6	O
%	O
(	O
9/1,458	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
0.4	O
%	O
(	O
3/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Whether	O
the	O
impairment	O
is	O
related	O
to	O
somnolence	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
or	O
other	O
effects	O
of	O
HORIZANT	O
is	O
unknown	O
.	O
	
A	O
placebo-controlled	O
trial	O
with	O
another	O
LABA	O
(	O
salmeterol	O
)	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
.	O
	
Some	O
patients	O
who	O
tested	O
positive	O
for	O
alglucosidase	O
alfa-specific	O
IgE	O
antibodies	O
and	O
experienced	O
hypersensitivity	B
reactions	I
were	O
able	O
to	O
be	O
rechallenged	O
with	O
alglucosidase	O
alfa	O
using	O
a	O
slower	O
infusion	O
rate	O
at	O
lower	O
starting	O
doses	O
and	O
have	O
continued	O
to	O
receive	O
treatment	O
under	O
close	O
clinical	O
supervision	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Antifungal	O
agents	O
should	O
not	O
be	O
used	O
unless	O
fungal	O
infection	O
has	O
been	O
diagnosed	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
CIMZIA	O
in	O
combination	O
with	O
other	O
biological	O
DMARDs	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
Includes	O
5	O
subjects	O
with	O
major	O
bleeding	B
events	O
that	O
occurred	O
before	O
the	O
first	O
dose	O
of	O
apixaban	O
(	O
administered	O
12	O
to	O
24	O
hours	O
post	O
surgery	O
)	O
.	O
	
The	O
most	O
common	O
(	O
>	O
=	O
10	O
%	O
)	O
grade	O
1-4	O
adverse	O
reactions	O
were	O
anemia	B
,	O
leukopenia	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
asthenia	B
,	O
abdominal	B
pain	I
,	O
hematuria	B
,	O
back	B
pain	I
,	O
anorexia	B
,	O
peripheral	B
neuropathy	I
,	O
pyrexia	B
,	O
dyspnea	B
,	O
dysguesia	B
,	O
cough	B
,	O
arthralgia	B
,	O
and	O
alopecia	B
.	O
	
*	O
Interstitial	B
Lung	I
Disease	I
and	O
Eosinophilic	B
Pneumonia	I
:	O
Can	O
occur	O
(	O
5.10	O
)	O
.	O
	
The	O
major	O
hemorrhagic	B
events	I
of	O
gastric	B
hemorrhage	I
occurred	O
in	O
5	O
%	O
(	O
3/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
none	O
of	O
the	O
53	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
canakinumab	O
between	O
the	O
CAPS	O
and	O
SJIA	O
clinical	O
studies	O
or	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Table	O
1	O
shows	O
common	O
adverse	O
reactions	O
(	O
excluding	O
hypoglycemia	B
)	O
associated	O
with	O
the	O
use	O
of	O
JARDIANCE	O
.	O
	
More	O
patients	O
on	O
TANZEUM	O
than	O
on	O
placebo	O
:	O
discontinued	O
due	O
to	O
an	O
injection	B
site	I
reaction	I
(	O
2	O
%	O
versus	O
0.2	O
%	O
)	O
,	O
experienced	O
more	O
than	O
2	O
reactions	O
(	O
38	O
%	O
versus	O
20	O
%	O
)	O
,	O
had	O
a	O
reaction	O
judged	O
by	O
investigators	O
to	O
be	O
``	O
moderate	O
''	O
or	O
``	O
severe	O
''	O
(	O
27	O
%	O
versus	O
6	O
%	O
)	O
and	O
required	O
local	O
or	O
systemic	O
treatment	O
for	O
the	O
reactions	O
(	O
36	O
%	O
versus	O
11	O
%	O
)	O
.	O
	
5.3	O
Lipid	O
Intake	O
Cleviprex	O
contains	O
approximately	O
0.2	O
g	O
of	O
lipid	O
per	O
mL	O
(	O
2.0	O
kcal	O
)	O
.	O
	
At	O
baseline	O
,	O
the	O
population	O
had	O
diabetes	O
for	O
an	O
average	O
of	O
8	O
years	O
and	O
had	O
a	O
mean	O
HbA1c	O
of	O
8.2	O
%	O
.	O
	
Use	O
of	O
DUAVEE	O
in	O
patients	O
with	O
renal	O
impairment	O
is	O
not	O
recommended	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Leukocytosis	O
In	O
clinical	O
studies	O
,	O
leukocytosis	B
(	O
WBC	B
counts	I
>	I
100,000	I
x	I
10	I
6	I
/L	I
)	O
was	O
observed	O
in	O
less	O
than	O
1	O
%	O
patients	O
with	O
non-myeloid	O
malignancies	O
receiving	O
GRANIX	O
.	O
	
Recent	O
(	O
i.e.	O
,	O
within	O
last	O
6	O
months	O
)	O
transaminase	O
and	O
bilirubin	O
levels	O
should	O
be	O
available	O
before	O
initiation	O
of	O
GILENYA	O
therapy	O
.	O
	
It	O
is	O
unknown	O
whether	O
the	O
suicidality	B
risk	O
extends	O
to	O
longer-term	O
use	O
,	O
i.e.	O
,	O
beyond	O
several	O
months	O
.	O
	
Prophylaxis	O
for	O
PJP	O
should	O
be	O
considered	O
when	O
concomitant	O
use	O
of	O
corticosteroids	O
or	O
other	O
immunosuppressive	O
agents	O
are	O
required	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
a	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
In	O
patients	O
who	O
develop	O
serious	O
infections	O
while	O
on	O
Prolia	O
,	O
prescribers	O
should	O
assess	O
the	O
need	O
for	O
continued	O
Prolia	O
therapy	O
.	O
	
Because	O
it	O
takes	O
approximately	O
2	O
months	O
to	O
eliminate	O
GILENYA	O
from	O
the	O
body	O
,	O
women	O
of	O
childbearing	O
potential	O
should	O
use	O
effective	O
contraception	O
to	O
avoid	O
pregnancy	O
during	O
and	O
for	O
2	O
months	O
after	O
stopping	O
GILENYA	O
treatment	O
.	O
	
Patients	O
should	O
discontinue	O
use	O
of	O
any	O
product	O
containing	O
4-aminopyridine	O
prior	O
to	O
initiating	O
treatment	O
with	O
AMPYRA	O
in	O
order	O
to	O
reduce	O
the	O
potential	O
for	O
dose-related	O
adverse	O
reactions	O
.	O
	
Serious	O
febrile	B
reactions	I
and	O
fever	B
of	O
any	O
severity	O
complicated	O
by	O
hypotension	B
,	O
rigors	B
or	O
chills	B
occurred	O
in	O
3.7	O
%	O
(	O
7/187	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
and	O
in	O
none	O
of	O
the	O
59	O
patients	O
treated	O
with	O
dacarbazine	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Astellas	O
Pharma	O
US	O
,	O
Inc.	O
at	O
1-800-727-7003	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
Occurring	O
at	O
>	O
=3	O
%	O
and	O
Higher	O
than	O
Placebo	O
in	O
2	O
Placebo	O
Controlled	O
Clinical	O
Trials	O
in	O
Patients	O
with	O
HAE	O
Treated	O
with	O
KALBITOR	O
a	O
Patients	O
experiencing	O
more	O
than	O
1	O
event	O
with	O
the	O
same	O
preferred	O
term	O
are	O
counted	O
only	O
once	O
for	O
that	O
preferred	O
term	O
.	O
	
These	O
infections	B
may	O
lead	O
to	O
serious	O
,	O
including	O
fatal	B
,	O
outcomes	O
[	O
see	O
Boxed	O
Warning	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
the	O
group	O
treated	O
with	O
TANZEUM	O
,	O
investigators	O
graded	O
the	O
severity	O
of	O
GI	B
reactions	I
as	O
``	O
mild	O
''	O
in	O
56	O
%	O
of	O
cases	O
,	O
``	O
moderate	O
''	O
in	O
37	O
%	O
of	O
cases	O
,	O
and	O
``	O
severe	O
''	O
in	O
7	O
%	O
of	O
cases	O
.	O
	
5.12	O
Embryo-fetal	O
Toxicity	O
Based	O
on	O
the	O
mechanism	O
of	O
action	O
,	O
AFINITOR	O
can	O
cause	O
fetal	B
harm	I
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
No	O
patient	O
required	O
dose	O
reduction	O
or	O
permanent	O
discontinuation	O
of	O
TAFINLAR	O
or	O
trametinib	O
for	O
skin	O
toxicity	O
.	O
	
Polyoma	O
Virus	O
Nephropathy	O
In	O
addition	O
to	O
cases	O
of	O
JC	B
virus-associated	O
PML	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
,	O
cases	O
of	O
polyoma	B
virus-associated	I
nephropathy	I
(	O
PVAN	B
)	O
,	O
mostly	O
due	O
to	O
BK	B
virus	I
infection	I
,	O
have	O
been	O
reported	O
.	O
	
They	O
may	O
be	O
bilateral	O
and	O
many	O
patients	O
report	O
prodromal	O
pain	O
in	O
the	O
affected	O
area	O
,	O
usually	O
presenting	O
as	O
dull	O
,	O
aching	O
thigh	B
pain	I
,	O
weeks	O
to	O
months	O
before	O
a	O
complete	O
fracture	O
occurs	O
.	O
	
Recurrence	O
of	O
liver	B
transaminase	I
elevations	I
occurred	O
with	O
rechallenge	O
in	O
some	O
patients	O
.	O
	
If	O
concomitant	O
use	O
of	O
PRISTIQ	O
with	O
other	O
serotonergic	O
drugs	O
is	O
clinically	O
warranted	O
,	O
patients	O
should	O
be	O
made	O
aware	O
of	O
a	O
potential	O
increased	O
risk	O
for	O
serotonin	O
syndrome	O
,	O
particularly	O
during	O
treatment	O
initiation	O
and	O
dose	O
increases	O
(	O
5.2	O
)	O
.	O
	
In	O
the	O
CIMZIA	O
RA	O
clinical	O
trials	O
(	O
placebo-controlled	O
and	O
open	O
label	O
)	O
a	O
total	O
of	O
three	O
cases	O
of	O
lymphoma	B
were	O
observed	O
among	O
2,367	O
patients	O
.	O
	
Individuals	O
with	O
``	O
crowded	O
''	O
optic	O
disc	O
are	O
also	O
considered	O
at	O
greater	O
risk	O
for	O
NAION	O
compared	O
to	O
the	O
general	O
population	O
,	O
however	O
,	O
evidence	O
is	O
insufficient	O
to	O
support	O
screening	O
of	O
prospective	O
users	O
of	O
PDE5	O
inhibitors	O
,	O
including	O
STENDRA	O
,	O
for	O
this	O
uncommon	O
condition	O
.	O
	
Hypertoxin-producing	O
strains	O
of	O
C.	O
difficile	O
cause	O
increased	O
morbidity	O
and	O
mortality	O
,	O
as	O
these	O
infections	O
can	O
be	O
refractory	O
to	O
antimicrobial	O
therapy	O
and	O
may	O
require	O
colectomy	O
.	O
	
5.3	O
Malignant	O
Neoplasms	O
Endometrial	O
Cancer	O
An	O
increased	O
risk	O
of	O
endometrial	B
cancer	I
has	O
been	O
reported	O
with	O
the	O
use	O
of	O
unopposed	O
estrogen	O
therapy	O
in	O
women	O
with	O
a	O
uterus	O
.	O
	
Standard	O
international	O
guidelines	O
were	O
followed	O
for	O
infection	O
prophylaxis	O
for	O
herpes	O
simplex	O
virus	O
(	O
HSV	O
)	O
,	O
varicella-zoster	O
virus	O
(	O
VZV	O
)	O
,	O
and	O
Pneumocystis	O
jiroveci	O
pneumonia	O
(	O
PCP	O
)	O
post-auto-HSCT	O
.	O
	
This	O
component	O
reduces	O
the	O
risk	O
of	O
endometrial	O
hyperplasia	O
that	O
can	O
occur	O
with	O
the	O
conjugated	O
estrogens	O
component	O
.	O
	
5.15	O
Dysphagia	O
Esophageal	B
dysmotility	I
and	O
aspiration	B
have	O
been	O
associated	O
with	O
antipsychotic	O
drug	O
use	O
.	O
	
For	O
patients	O
taking	O
concomitant	O
moderate	O
CYP3A4	O
inhibitors	O
(	O
including	O
erythromycin	O
,	O
amprenavir	O
,	O
aprepitant	O
,	O
diltiazem	O
,	O
fluconazole	O
,	O
fosamprenavir	O
,	O
and	O
verapamil	O
)	O
,	O
the	O
maximum	O
recommended	O
dose	O
of	O
STENDRA	O
is	O
50	O
mg	O
,	O
not	O
to	O
exceed	O
once	O
every	O
24	O
hours	O
[	O
seeDrug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
Before	O
therapy	O
with	O
Teflaro	O
is	O
instituted	O
,	O
careful	O
inquiry	O
about	O
previous	O
hypersensitivity	O
reactions	O
to	O
other	O
cephalosporins	O
,	O
penicillins	O
,	O
or	O
carbapenems	O
should	O
be	O
made	O
.	O
	
Tables	O
1	O
and	O
2	O
show	O
the	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=3	O
%	O
)	O
in	O
adults	O
and	O
children	O
respectively	O
who	O
received	O
the	O
6-dose	O
regimen	O
of	O
Coartem	O
Tablets	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
myocardial	O
infarction	O
(	O
MI	O
)	O
and	O
stroke	O
.	O
	
Extreme	O
care	O
must	O
be	O
taken	O
to	O
avoid	O
pregnancy	O
in	O
female	O
patients	O
and	O
in	O
female	O
partners	O
of	O
male	O
patients	O
.	O
	
Observe	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
hypersensitivity	O
reactions	O
during	O
and	O
following	O
Gadavist	O
administration	O
.	O
	
Most	O
hypersensitivity	O
reactions	O
to	O
EOVIST	O
have	O
occurred	O
within	O
half	O
an	O
hour	O
after	O
administration	O
.	O
	
(	O
5.6	O
,	O
2.3	O
)	O
*	O
Serious	O
Febrile	B
Reactions	I
:	O
Incidence	O
and	O
severity	O
of	O
pyrexia	B
are	O
increased	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
When	O
Coartem	O
Tablets	O
are	O
coadministered	O
with	O
inducers	O
of	O
CYP3A4	O
it	O
may	O
result	O
in	O
decreased	O
concentrations	O
of	O
artemether	O
and/or	O
lumefantrine	O
and	O
loss	O
of	O
antimalarial	O
efficacy	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
Cases	O
of	O
TB	B
included	O
extrapulmonary	B
TB	I
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
of	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
SAPHRIS	O
has	O
not	O
been	O
evaluated	O
in	O
patients	O
with	O
a	O
recent	O
history	O
of	O
myocardial	O
infarction	O
or	O
unstable	O
heart	O
disease	O
.	O
	
Hepatic	O
:	O
Liver	B
Injury	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
Respiratory	O
:	O
Interstitial	B
lung	I
disease	I
including	O
pneumonitis	B
and	O
pulmonary	B
fibrosis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
Immune	O
:	O
Anaphylactic	B
reactions	I
including	O
angioedema	B
Vascular	O
:	O
Vasculitis	B
,	O
including	O
leukocytoclastic	B
vasculitis	I
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
INCREASED	O
RISK	O
OF	O
DEATH	B
,	O
STROKE	B
AND	O
HEART	B
FAILURE	I
IN	O
PATIENTS	O
WITH	O
DECOMPENSATED	O
HEART	O
FAILURE	O
OR	O
PERMANENT	O
ATRIAL	O
FIBRILLATION	O
WARNING	O
:	O
INCREASED	O
RISK	O
OF	O
DEATH	B
,	O
STROKE	B
AND	O
HEART	B
FAILURE	I
IN	O
PATIENTS	O
WITH	O
DECOMPENSATED	O
HEART	O
FAILURE	O
OR	O
PERMANENT	O
ATRIAL	O
FIBRILLATION	O
In	O
patients	O
with	O
symptomatic	O
heart	O
failure	O
and	O
recent	O
decompensation	O
requiring	O
hospitalization	O
or	O
NYHA	O
Class	O
IV	O
heart	O
failure	O
;	O
MULTAQ	O
doubles	O
the	O
risk	O
of	O
death	B
.	O
	
Patients	O
with	O
these	O
diagnoses	O
were	O
excluded	O
from	O
pre-marketing	O
clinical	O
trials	O
.	O
	
Long-term	B
cumulative	I
radiation	I
exposure	I
is	O
associated	O
with	O
an	O
increased	O
risk	O
of	O
cancer	B
.	O
	
TAFINLAR	O
may	O
render	O
hormonal	O
contraceptives	O
less	O
effective	O
and	O
an	O
alternative	O
method	O
of	O
contraception	O
should	O
be	O
used	O
.	O
	
CIMZIA	O
has	O
not	O
been	O
formally	O
studied	O
in	O
patients	O
with	O
CHF	O
;	O
however	O
,	O
in	O
clinical	O
studies	O
in	O
patients	O
with	O
CHF	O
with	O
another	O
TNF	O
blocker	O
,	O
worsening	B
congestive	I
heart	I
failure	I
)	O
and	O
increased	B
mortality	I
due	O
to	O
CHF	B
were	O
observed	O
.	O
	
Drugs	O
that	O
have	O
a	O
mixed	O
effect	O
on	O
CYP3A4	O
,	O
especially	O
antiretroviral	O
drugs	O
such	O
as	O
HIV	O
protease	O
inhibitors	O
and	O
non-nucleoside	O
reverse	O
transcriptase	O
inhibitors	O
,	O
and	O
those	O
that	O
have	O
an	O
effect	O
on	O
the	O
QT	O
interval	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
taking	O
Coartem	O
Tablets	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.3	O
,	O
7.7	O
)	O
]	O
.	O
	
Based	O
on	O
the	O
clinical	O
trial	O
experience	O
,	O
ILARIS	O
does	O
not	O
appear	O
to	O
increase	O
the	O
incidence	O
of	O
MAS	B
in	O
SJIA	O
patients	O
,	O
but	O
no	O
definitive	O
conclusion	O
can	O
be	O
made	O
.	O
	
Maintain	O
clinical	O
supervision	O
if	O
this	O
product	O
is	O
to	O
be	O
given	O
to	O
a	O
penicillin-	O
or	O
other	O
beta-lactam-allergic	O
patient	O
,	O
because	O
cross	O
sensitivity	O
among	O
beta-lactam	O
antibacterial	O
agents	O
has	O
been	O
clearly	O
established	O
.	O
	
Contact	O
your	O
local	O
Genzyme	O
representative	O
or	O
Genzyme	O
Corporation	O
at	O
1-800-745-4447	O
for	O
information	O
on	O
testing	O
and	O
to	O
obtain	O
a	O
sample	O
collection	O
box	O
.	O
	
5.3	O
Prolonged	O
Erection	O
Prolonged	B
erection	I
greater	O
than	O
4	O
hours	O
and	O
priapism	B
(	O
painful	B
erections	I
greater	O
than	O
6	O
hours	O
in	O
duration	O
)	O
have	O
been	O
reported	O
with	O
other	O
PDE5	O
inhibitors	O
.	O
	
Dysphagia	B
was	O
reported	O
in	O
0.2	O
%	O
and	O
0	O
%	O
(	O
1/572	O
,	O
0/379	O
)	O
of	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
(	O
5-10	O
mg	O
twice	O
daily	O
)	O
of	O
SAPHRIS	O
as	O
compared	O
to	O
0	O
%	O
(	O
0/378	O
,	O
0/203	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
in	O
short-term	O
schizophrenia	O
and	O
bipolar	O
mania	O
adult	O
trials	O
,	O
respectively	O
.	O
	
Overall	O
,	O
312	O
patients	O
(	O
95	O
%	O
)	O
received	O
HSV	O
and	O
VZV	O
prophylaxis	O
with	O
a	O
median	O
duration	O
of	O
11.1	O
months	O
(	O
range	O
,	O
0-20	O
)	O
and	O
319	O
patients	O
(	O
98	O
%	O
)	O
received	O
PCP	O
prophylaxis	O
with	O
a	O
median	O
duration	O
of	O
6.5	O
months	O
(	O
range	O
,	O
0-20	O
)	O
.	O
	
5.3	O
Acute	O
Kidney	O
Injury	O
In	O
patients	O
with	O
chronic	O
renal	O
impairment	O
,	O
acute	B
kidney	I
injury	I
sometimes	O
requiring	O
dialysis	O
has	O
been	O
observed	O
with	O
the	O
use	O
of	O
some	O
GBCAs	O
.	O
	
(	O
5.5	O
)	O
5.1	O
Embryofetal	O
Toxicity	O
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
Ribavirin	O
may	O
cause	O
birth	B
defects	I
and/or	O
death	B
of	I
the	I
exposed	I
fetus	I
.	O
	
5.3	O
Hepatic	O
Effects	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
fatal	B
and	O
non-fatal	O
hepatic	B
failure	I
in	O
patients	O
taking	O
ULORIC	O
,	O
although	O
the	O
reports	O
contain	O
insufficient	O
information	O
necessary	O
to	O
establish	O
the	O
probable	O
cause	O
.	O
	
In	O
patients	O
with	O
abnormally	O
high	O
(	O
>	O
3	O
mg/dL	O
)	O
serum	O
bilirubin	O
,	O
reduced	O
hepatic	O
contrast	O
was	O
observed	O
.	O
	
This	O
is	O
approximately	O
2-fold	O
higher	O
than	O
expected	O
in	O
the	O
general	O
population	O
.	O
	
Laboratory	O
Values	O
Changes	O
in	O
selected	O
hematological	O
parameters	O
during	O
treatment	O
of	O
adult	O
subjects	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron	O
and	O
REBETOL	O
are	O
described	O
in	O
Table	O
4	O
.	O
	
In	O
addition	O
,	O
women	O
taking	O
DUAVEE	O
should	O
be	O
advised	O
to	O
move	O
about	O
periodically	O
during	O
travel	O
involving	O
prolonged	O
immobilization	O
.	O
	
Table	O
4	O
presents	O
the	O
most	O
common	O
adverse	O
drug	O
reactions	O
(	O
experienced	O
by	O
greater	O
than	O
or	O
equal	O
to	O
3	O
%	O
of	O
patients	O
receiving	O
PROMACTA	O
)	O
from	O
the	O
three	O
placebo-controlled	O
trials	O
,	O
with	O
a	O
higher	O
incidence	O
in	O
PROMACTA	O
versus	O
placebo	O
.	O
	
However	O
,	O
treatment	O
with	O
immunosuppressants	O
,	O
including	O
ILARIS	O
,	O
may	O
result	O
in	O
an	O
increase	O
in	O
the	O
risk	O
of	O
malignancies	B
.	O
	
CDAD	O
must	O
be	O
considered	O
in	O
all	O
patients	O
who	O
present	O
with	O
diarrhea	O
following	O
antibiotic	O
use	O
.	O
	
5.5	O
Sudden	O
Hearing	O
Loss	O
Use	O
of	O
PDE5	O
inhibitors	O
has	O
been	O
associated	O
with	O
loss	B
of	I
hearing	I
,	O
which	O
may	O
be	O
accompanied	O
by	O
tinnitus	B
or	O
dizziness	B
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
golimumab	O
exposure	O
.	O
	
Liver	O
enzymes	O
should	O
be	O
monitored	O
in	O
patients	O
who	O
develop	O
symptoms	O
suggestive	O
of	O
hepatic	O
dysfunction	O
,	O
such	O
as	O
unexplained	O
nausea	O
,	O
vomiting	O
,	O
abdominal	O
pain	O
,	O
fatigue	O
,	O
anorexia	O
,	O
or	O
jaundice	O
and/or	O
dark	O
urine	O
.	O
	
A	O
number	O
of	O
reports	O
note	O
that	O
patients	O
were	O
also	O
receiving	O
treatment	O
with	O
glucocorticoids	O
(	O
e.g	O
.	O
	
PVAN	B
is	O
associated	O
with	O
serious	O
outcomes	O
;	O
including	O
deteriorating	B
renal	I
function	I
and	O
kidney	B
graft	I
loss	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
median	O
time	O
to	O
onset	O
of	O
skin	B
toxicity	I
in	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
was	O
37	O
days	O
(	O
range	O
:	O
1	O
to	O
225	O
days	O
)	O
and	O
median	O
time	O
to	O
resolution	O
of	O
skin	B
toxicity	I
was	O
33	O
days	O
(	O
range	O
:	O
3	O
to	O
421	O
days	O
)	O
.	O
	
In	O
AVERROES	O
,	O
the	O
mean	O
duration	O
of	O
exposure	O
was	O
approximately	O
59	O
weeks	O
(	O
>	O
3000	O
patient-years	O
)	O
.	O
	
An	O
accelerated	O
vaccination	O
schedule	O
may	O
be	O
appropriate	O
.	O
	
In	O
patients	O
treated	O
with	O
TAFINLAR	O
,	O
the	O
median	O
time	O
to	O
initial	O
onset	O
of	O
fever	B
(	O
any	O
severity	O
)	O
was	O
11	O
days	O
(	O
range	O
:	O
1	O
to	O
202	O
days	O
)	O
and	O
the	O
median	O
duration	O
of	O
fever	B
was	O
3	O
days	O
(	O
range	O
:	O
1	O
to	O
129	O
days	O
)	O
.	O
	
Table	O
1	O
shows	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=3	O
%	O
of	O
KALBITOR-treated	O
patients	O
that	O
also	O
occurred	O
at	O
a	O
higher	O
rate	O
than	O
in	O
the	O
placebo-treated	O
patients	O
in	O
the	O
two	O
controlled	O
trials	O
(	O
EDEMA3	O
and	O
EDEMA4	O
)	O
of	O
the	O
30	O
mg	O
subcutaneous	O
dose	O
.	O
	
5.4	O
Anaphylaxis	O
AMPYRA	O
can	O
cause	O
anaphylaxis	B
and	O
severe	O
allergic	B
reactions	I
.	O
	
5.9	O
Blood	O
Pressure	O
Effects	O
In	O
MS	O
controlled	O
clinical	O
trials	O
,	O
patients	O
treated	O
with	O
GILENYA	O
0.5	O
mg	O
had	O
an	O
average	O
increase	B
over	I
placebo	I
of	I
approximately	I
3	I
mmHg	I
in	I
systolic	I
pressure	I
,	O
first	O
detected	O
after	O
approximately	O
1	O
month	O
of	O
treatment	O
initiation	O
,	O
and	O
persisting	O
with	O
continued	O
treatment	O
.	O
	
Constipation	B
also	O
contributed	O
to	O
the	O
frequently	O
reported	O
reactions	O
.	O
	
5.12	O
Hypocalcemia	O
Estrogen	O
therapy	O
should	O
be	O
used	O
with	O
caution	O
in	O
women	O
with	O
hypoparathyroidism	O
as	O
estrogen-induced	O
hypocalcemia	O
may	O
occur	O
.	O
	
Forty-eight	O
percent	O
of	O
patients	O
were	O
white	O
,	O
15	O
%	O
African/African	O
American	O
,	O
9	O
%	O
Asian	O
,	O
and	O
26	O
%	O
were	O
Hispanic/Latino	O
.	O
	
Do	O
not	O
administer	O
ILARIS	O
to	O
patients	O
during	O
an	O
active	O
infection	O
requiring	O
medical	O
intervention	O
.	O
	
Lipid	O
intake	O
restrictions	O
may	O
be	O
necessary	O
for	O
patients	O
with	O
significant	O
disorders	O
of	O
lipid	O
metabolism	O
.	O
	
Dabrafenib	O
was	O
teratogenic	B
and	O
embryotoxic	B
in	O
rats	O
at	O
doses	O
three	O
times	O
greater	O
than	O
the	O
human	O
exposure	O
at	O
the	O
recommended	O
clinical	O
dose	O
.	O
	
This	O
may	O
be	O
associated	O
with	O
concomitant	O
use	O
of	O
corticosteroids	O
or	O
other	O
immunosuppressive	O
agents	O
.	O
	
There	O
were	O
suicides	B
in	O
the	O
adult	O
studies	O
,	O
but	O
the	O
number	O
was	O
not	O
sufficient	O
to	O
reach	O
any	O
conclusion	O
about	O
drug	O
effect	O
on	O
suicide	O
.	O
	
No	O
complications	O
attributable	O
to	O
leukocytosis	B
were	O
reported	O
in	O
clinical	O
studies	O
.	O
	
*	O
Hyponatremia	B
:	O
Can	O
occur	O
in	O
association	O
with	O
SIADH	O
(	O
5.9	O
)	O
.	O
	
The	O
most	O
common	O
(	O
>	O
=	O
5	O
%	O
)	O
grade	O
3-4	O
adverse	O
reactions	O
in	O
patients	O
who	O
received	O
JEVTANA	O
were	O
neutropenia	B
,	O
leukopenia	B
,	O
anemia	B
,	O
febrile	B
neutropenia	I
,	O
diarrhea	B
,	O
fatigue	B
,	O
and	O
asthenia	B
.	O
	
S	O
Intracranial	O
,	O
intraspinal	O
,	O
intraocular	O
,	O
pericardial	O
,	O
an	O
operated	O
joint	O
requiring	O
re-operation	O
or	O
intervention	O
,	O
intramuscular	O
with	O
compartment	O
syndrome	O
,	O
or	O
retroperitoneal	O
.	O
	
Because	O
of	O
the	O
nature	O
of	O
the	O
adverse	O
events	O
seen	O
with	O
this	O
combination	O
therapy	O
,	O
similar	O
toxicities	O
may	O
also	O
result	O
from	O
the	O
use	O
of	O
CIMZIA	O
in	O
this	O
combination	O
.	O
	
The	O
majority	O
of	O
injection	B
site	I
reactions	I
were	O
judged	O
as	O
``	O
mild	O
''	O
by	O
investigators	O
in	O
both	O
groups	O
(	O
73	O
%	O
for	O
TANZEUM	O
versus	O
94	O
%	O
for	O
placebo	O
)	O
.	O
	
6.4	O
Laboratory	O
Findings	O
Hematology	O
During	O
clinical	O
trials	O
with	O
ILARIS	O
,	O
mean	O
values	O
decreased	B
for	I
white	I
blood	I
cells	I
.	O
	
In	O
Trial	O
2	O
,	O
treatment	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
resulted	O
in	O
an	O
increased	O
incidence	O
and	O
severity	O
of	O
any	O
hemorrhagic	B
event	I
:	O
16	O
%	O
(	O
9/55	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
compared	O
with	O
2	O
%	O
(	O
1/53	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
.	O
	
However	O
,	O
prescribers	O
and	O
patients	O
should	O
be	O
aware	O
that	O
patients	O
'	O
ability	O
to	O
assess	O
their	O
own	O
driving	O
competence	O
,	O
as	O
well	O
as	O
their	O
ability	O
to	O
assess	O
the	O
degree	O
of	O
somnolence	O
caused	O
by	O
HORIZANT	O
,	O
can	O
be	O
imperfect	O
.	O
	
In	O
the	O
controlled	O
clinical	O
trials	O
,	O
hypersensitivity	B
reactions	I
(	O
occurring	O
on	O
the	O
same	O
day	O
of	O
infusion	O
)	O
were	O
reported	O
in	O
13	O
%	O
(	O
191/1,458	O
)	O
of	O
patients	O
receiving	O
BENLYSTA	O
and	O
11	O
%	O
(	O
76/675	O
)	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
dose	O
reduction	O
in	O
the	O
patients	O
treated	O
with	O
GILOTRIF	O
were	O
diarrhea	B
(	O
20	O
%	O
)	O
,	O
rash/acne	O
(	O
19	O
%	O
)	O
,	O
paronychia	B
(	O
14	O
%	O
)	O
,	O
and	O
stomatitis	B
(	O
10	O
%	O
)	O
.	O
	
Some	O
of	O
the	O
patients	O
who	O
tested	O
positive	O
for	O
alglucosidase	O
alfa-specific	O
IgE	O
antibodies	O
experienced	O
anaphylactic	B
reactions	I
[	O
seeBoxed	O
WarningandWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Withhold	O
YERVOY	O
dosing	O
in	O
symptomatic	O
patients	O
.	O
	
Observational	O
studies	O
suggest	O
that	O
,	O
similar	O
to	O
atypical	O
antipsychotic	O
drugs	O
,	O
treatment	O
with	O
conventional	O
antipsychotic	O
drugs	O
may	O
increase	O
mortality	O
.	O
	
STRIBILD	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
chronic	O
HBV	O
infection	O
and	O
the	O
safety	O
and	O
efficacy	O
of	O
STRIBILD	O
have	O
not	O
been	O
established	O
in	O
patients	O
coinfected	O
with	O
HBV	O
and	O
HIV-1	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
In	O
the	O
event	O
of	O
a	O
serious	O
reaction	O
,	O
administration	O
of	O
BENLYSTA	O
must	O
be	O
discontinued	O
immediately	O
and	O
appropriate	O
medical	O
therapy	O
administered	O
.	O
	
In	O
those	O
patients	O
treated	O
with	O
1,200	O
mg	O
of	O
HORIZANT	O
per	O
day	O
who	O
reported	O
somnolence	B
(	O
10	O
%	O
)	O
,	O
the	O
somnolence	B
persisted	O
during	O
treatment	O
in	O
about	O
27	O
%	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Teva	O
Pharmaceuticals	O
at	O
1-800-896-5855	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Treat	O
hypothyroidism	O
and	O
hyperthyroidism	O
according	O
to	O
standard	O
medical	O
practice	O
to	O
maintain	O
euthyroid	O
state	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
hyperglycemia	B
,	O
lymphopenia	B
,	O
decreased	B
hemoglobin	I
,	O
hypophosphatemia	B
,	O
increased	B
alkaline	I
phosphatase	I
,	O
neutropenia	B
,	O
increased	B
aspartate	I
transaminase	I
)	O
,	O
potassium	B
decreased	I
,	O
and	O
thrombocytopenia	B
.	O
	
It	O
is	O
recommended	O
that	O
ALT	O
and	O
AST	O
be	O
assessed	O
prior	O
to	O
initiating	O
KALYDECO	O
,	O
every	O
3	O
months	O
during	O
the	O
first	O
year	O
of	O
treatment	O
,	O
and	O
annually	O
thereafter	O
.	O
	
cutaneous	B
immune-mediated	I
reactions	I
,	O
including	O
proteinuria	B
and	O
nephrotic	B
syndrome	I
secondary	O
to	O
membranous	B
glomerulonephritis	I
,	O
and	O
necrotizing	B
skin	I
lesions	I
have	O
been	O
reported	O
in	O
postmarketing	O
safety	O
experience	O
with	O
alglucosidase	O
alfa	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Consider	O
initiation	O
of	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
prednisone	O
or	O
equivalent	O
for	O
severe	O
neuropathies	O
.	O
	
The	O
stated	O
frequencies	O
of	O
adverse	O
reactions	O
represent	O
the	O
proportions	O
of	O
individuals	O
who	O
experienced	O
a	O
treatment-emergent	O
adverse	O
reaction	O
of	O
the	O
type	O
listed	O
.	O
	
Exacerbation	O
Trial	O
In	O
a	O
24-	O
to	O
76-week	O
trial	O
,	O
subjects	O
received	O
BREO	O
ELLIPTA	O
100/25	O
(	O
n	O
=	O
1,009	O
)	O
or	O
fluticasone	O
furoate	O
100	O
mcg	O
(	O
n	O
=	O
1,010	O
)	O
(	O
Trial	O
5	O
)	O
.	O
	
(	O
5.6	O
)	O
*	O
Not	O
recommended	O
in	O
pancreatic	O
or	O
gastric	O
anastomosis	O
.	O
	
Monitor	O
serum	O
phosphorus	O
in	O
patients	O
at	O
risk	O
for	O
renal	O
impairment	O
.	O
	
These	O
events	O
have	O
been	O
included	O
because	O
of	O
their	O
seriousness	O
and	O
assessment	O
of	O
potential	O
causal	O
relationship	O
.	O
	
Program	O
,	O
an	O
authorized	O
hospital	O
representative	O
must	O
acknowledge	O
that	O
:	O
*	O
hospital	O
staff	O
who	O
prescribe	O
,	O
dispense	O
,	O
or	O
administer	O
ENTEREG	O
have	O
been	O
provided	O
the	O
educational	O
materials	O
on	O
the	O
need	O
to	O
limit	O
use	O
of	O
ENTEREG	O
to	O
short-term	O
,	O
inpatient	O
use	O
;	O
*	O
patients	O
will	O
not	O
receive	O
more	O
than	O
15	O
doses	O
of	O
ENTEREG	O
;	O
and	O
*	O
ENTEREG	O
will	O
not	O
be	O
dispensed	O
to	O
patients	O
after	O
they	O
have	O
been	O
discharged	O
from	O
the	O
hospital	O
.	O
	
During	O
the	O
24-week	O
,	O
open-label	O
,	O
clinical	O
trial	O
in	O
34	O
patients	O
ages	O
2	O
to	O
less	O
than	O
6	O
years	O
(	O
Trial	O
6	O
)	O
,	O
where	O
patients	O
received	O
either	O
50	O
mg	O
(	O
less	O
than	O
14	O
kg	O
)	O
or	O
75	O
mg	O
(	O
14	O
kg	O
or	O
greater	O
)	O
ivacaftor	O
granules	O
twice	O
daily	O
,	O
the	O
incidence	O
of	O
patients	O
experiencing	O
transaminase	B
elevations	I
(	O
AST	B
)	I
>	I
3	I
*	I
ULN	I
was	O
14.7	O
%	O
(	O
5/34	O
)	O
.	O
	
Monitor	O
patients	O
for	O
signs	O
and	O
symptoms	O
of	O
dermatitis	O
such	O
as	O
rash	O
and	O
pruritus	O
.	O
	
Pooled	O
analyses	O
of	O
199	O
placebo-controlled	O
clinical	O
trials	O
(	O
monotherapy	O
and	O
adjunctive	O
therapy	O
)	O
of	O
11	O
different	O
AEDs	O
showed	O
that	O
patients	O
randomized	O
to	O
1	O
of	O
the	O
AEDs	O
had	O
approximately	O
twice	O
the	O
risk	O
[	O
adjusted	O
relative	O
risk	O
1.8	O
,	O
95	O
%	O
confidence	O
interval	O
(	O
CI	O
)	O
:	O
1.2	O
,	O
2.7	O
]	O
of	O
suicidal	B
thinking	I
compared	O
with	O
patients	O
randomized	O
to	O
placebo	O
.	O
	
Table	O
3	O
:	O
Key	O
Laboratory	O
Abnormalities	O
Reported	O
in	O
>	O
=	O
10	O
%	O
of	O
Patients	O
with	O
Advanced	O
HR+	O
BC	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Exemestane	O
(	O
25	O
mg/day	O
)	O
b	O
Reflects	O
corresponding	O
adverse	O
drug	O
reaction	O
reports	O
of	O
anemia	B
,	O
leukopenia	B
,	O
lymphopenia	B
,	O
neutropenia	B
,	O
and	O
thrombocytopenia	B
(	O
collectively	O
as	O
pancytopenia	B
)	O
,	O
which	O
occurred	O
at	O
lower	O
frequency	O
.	O
	
Creatine	O
Kinase	O
(	O
CK	O
)	O
:	O
The	O
proportion	O
of	O
adult	O
patients	O
with	O
CK	B
elevations	I
>	O
3	O
times	O
ULN	O
at	O
any	O
time	O
were	O
6.4	O
%	O
and	O
11.1	O
%	O
for	O
patients	O
treated	O
with	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
respectively	O
,	O
as	O
compared	O
to	O
6.7	O
%	O
for	O
placebo-treated	O
patients	O
in	O
short-term	O
,	O
fixed-dose	O
trials	O
in	O
schizophrenia	O
and	O
bipolar	O
mania	O
.	O
	
Extrapyramidal	O
Symptoms	O
:	O
In	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
adult	O
trials	O
,	O
data	O
was	O
objectively	O
collected	O
on	O
the	O
Simpson	O
Angus	O
Rating	O
Scale	O
for	O
extrapyramidal	B
symptoms	I
(	O
EPS	B
)	O
,	O
the	O
Barnes	O
Akathisia	O
Scale	O
(	O
for	O
akathisia	B
)	O
and	O
the	O
Assessments	O
of	O
Involuntary	O
Movement	O
Scales	O
(	O
for	O
dyskinesias	B
)	O
.	O
	
5.2	O
Arterial	O
Thromboembolic	O
Events	O
In	O
clinical	O
trials	O
,	O
arterial	B
thromboembolic	I
events	I
have	O
been	O
reported	O
,	O
including	O
deaths	B
.	O
	
Severe	O
pancreatitis	O
is	O
a	O
contraindication	O
to	O
additional	O
asparaginase	O
administration	O
.	O
	
The	O
patients	O
received	O
a	O
median	O
of	O
5	O
(	O
range	O
1-20	O
)	O
prior	O
regimens	O
.	O
	
One	O
patient	O
experienced	O
disturbance	B
in	I
attention	I
,	O
eyelid	B
disorder	I
,	O
feeling	B
abnormal	I
and	O
headache	B
,	O
and	O
one	O
patient	O
experienced	O
dysphagia	B
.	O
	
What	O
should	O
I	O
tell	O
my	O
healthcare	O
provider	O
before	O
taking	O
DUAVEE	O
?	O
	
Discontinuation	O
of	O
INLYTA	O
treatment	O
due	O
to	O
hypertension	B
occurred	O
in	O
1/359	O
patients	O
(	O
<	O
1	O
%	O
)	O
receiving	O
INLYTA	O
and	O
none	O
of	O
the	O
patients	O
receiving	O
sorafenib	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
clinical	O
significance	O
of	O
this	O
finding	O
is	O
unknown	O
.	O
	
Immune-mediated	B
neuropathies	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Four	O
serious	O
adverse	O
events	O
occurred	O
in	O
two	O
placebo-treated	O
subjects	O
.	O
	
Table	O
2	O
includes	O
adverse	O
reactions	O
reported	O
in	O
Study	O
2	O
that	O
occurred	O
at	O
a	O
>	O
=	O
2	O
%	O
higher	O
frequency	O
in	O
the	O
XTANDI	O
arm	O
compared	O
to	O
the	O
placebo	O
arm	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
anaphylactoid	B
reactions	I
have	O
been	O
reported	O
with	O
DOTAREM	O
,	O
involving	O
cardiovascular	O
,	O
respiratory	O
,	O
and/or	O
cutaneous	O
manifestations	O
.	O
	
(	O
5.3	O
)	O
*	O
Macular	B
edema	I
:	O
Perform	O
an	O
examination	O
of	O
the	O
fundus	O
including	O
the	O
macula	O
before	O
and	O
3-4	O
months	O
after	O
treatment	O
initiation	O
.	O
	
Table	O
5	O
reflects	O
exposure	O
to	O
DYSPORT	O
(	O
r	O
)	O
in	O
398	O
patients	O
19	O
to	O
75	O
years	O
of	O
age	O
who	O
were	O
evaluated	O
in	O
the	O
randomized	O
,	O
placebo-	O
controlled	O
clinical	O
studies	O
that	O
assessed	O
the	O
use	O
of	O
DYSPORT	O
(	O
r	O
)	O
for	O
the	O
temporary	O
improvement	O
in	O
the	O
appearance	O
of	O
glabellar	O
lines	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
POTIGA	O
was	O
administered	O
as	O
adjunctive	O
therapy	O
to	O
1,365	O
patients	O
with	O
epilepsy	O
in	O
all	O
controlled	O
and	O
uncontrolled	O
clinical	O
studies	O
during	O
the	O
premarketing	O
development	O
.	O
	
One	O
(	O
0.3	O
%	O
)	O
subject	O
who	O
received	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
developed	O
laboratory	O
findings	O
consistent	O
with	O
proximal	B
renal	I
tubular	I
dysfunction	I
leading	O
to	O
discontinuation	O
of	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
after	O
Week	O
96	O
.	O
	
If	O
you	O
think	O
you	O
may	O
be	O
pregnant	O
,	O
you	O
should	O
have	O
a	O
pregnancy	O
test	O
and	O
know	O
the	O
results	O
.	O
	
5.4	O
Avoid	O
Use	O
with	O
Other	O
Antiretroviral	O
Products	O
STRIBILD	O
is	O
indicated	O
for	O
use	O
as	O
a	O
complete	O
regimen	O
for	O
the	O
treatment	O
of	O
HIV-1	O
infection	O
and	O
coadministration	O
with	O
other	O
antiretroviral	O
products	O
is	O
not	O
recommended	O
.	O
	
5.8	O
Hematologic	O
Cytopenias	O
There	O
have	O
been	O
post-marketing	O
reports	O
of	O
pancytopenia	B
,	O
leukopenia	B
,	O
neutropenia	B
,	O
aplastic	B
anemia	I
,	O
and	O
thrombocytopenia	B
in	O
patients	O
receiving	O
TNF-blockers	O
.	O
	
Medical	O
history	O
of	O
hypertension	O
was	O
balanced	O
between	O
arms	O
.	O
	
In	O
controlled	O
clinical	O
trials	O
,	O
adverse	O
reactions	O
of	O
symptomatic	B
bradycardia	I
following	O
the	O
first	O
dose	O
were	O
reported	O
in	O
0.6	O
%	O
of	O
patients	O
receiving	O
GILENYA	O
0.5	O
mg	O
and	O
in	O
0.1	O
%	O
of	O
patients	O
on	O
placebo	O
.	O
	
*	O
Drugs	O
that	O
act	O
directly	O
on	O
the	O
renin-angiotensin	O
system	O
can	O
cause	O
death	B
to	I
the	I
developing	I
fetus	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reactions	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.6	O
Cardiovascular	O
Effects	O
ARCAPTA	O
NEOHALER	O
,	O
like	O
other	O
beta2-agonists	O
,	O
can	O
produce	O
a	O
clinically	O
significant	O
cardiovascular	B
effect	I
in	O
some	O
patients	O
as	O
measured	O
by	O
increases	B
in	I
pulse	I
rate	I
,	O
or	O
symptoms	O
.	O
	
5.4	O
Fluid	O
Retention	O
Fluid	B
retention	I
occurs	O
with	O
BOSULIF	O
and	O
may	O
manifest	O
as	O
pericardial	B
effusion	I
,	O
pleural	B
effusion	I
,	O
pulmonary	B
edema	I
,	O
and/or	O
peripheral	B
edema	I
.	O
	
5.5	O
Acute	O
PE	O
in	O
Hemodynamically	O
Unstable	O
Patients	O
or	O
Patients	O
who	O
Require	O
Thrombolysis	O
or	O
Pulmonary	O
Embolectomy	O
Initiation	O
of	O
ELIQUIS	O
is	O
not	O
recommended	O
as	O
an	O
alternative	O
to	O
unfractionated	O
heparin	O
for	O
the	O
initial	O
treatment	O
of	O
patients	O
with	O
PE	O
who	O
present	O
with	O
hemodynamic	O
instability	O
or	O
who	O
may	O
receive	O
thrombolysis	O
or	O
pulmonary	O
embolectomy	O
.	O
	
Table	O
6	O
.	O
	
(	O
5.6	O
)	O
*	O
Orthostatic	B
Hypotension	I
,	O
Syncope	B
,	O
and	O
Other	O
Hemodynamic	B
Effects	I
:	O
Dizziness	B
,	O
tachycardia	B
or	O
bradycardia	B
,	O
and	O
syncope	B
may	O
occur	O
,	O
especially	O
early	O
in	O
treatment	O
.	O
	
(	O
5.1	O
,	O
5.2	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Cerebrovascular	B
Adverse	I
Events	I
:	O
An	O
increased	O
incidence	O
of	O
cerebrovascular	B
adverse	I
events	I
(	O
e.g.	O
,	O
stroke	B
,	O
transient	B
ischemic	I
attack	I
)	O
has	O
been	O
seen	O
in	O
elderly	O
patients	O
with	O
dementia-related	O
psychoses	O
treated	O
with	O
atypical	O
antipsychotic	O
drugs	O
.	O
	
5.3	O
Excessive	O
Use	O
of	O
ARCAPTA	O
NEOHALER	O
and	O
Use	O
with	O
Other	O
Long-Acting	O
Beta2-Agonists	O
As	O
with	O
other	O
inhaled	O
beta2-adrenergic	O
drugs	O
,	O
ARCAPTA	O
NEOHALER	O
should	O
not	O
be	O
used	O
more	O
often	O
,	O
at	O
higher	O
doses	O
than	O
recommended	O
,	O
or	O
in	O
conjunction	O
with	O
other	O
medications	O
containing	O
long-acting	O
beta2-agonists	O
,	O
as	O
an	O
overdose	O
may	O
result	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Increased	O
Mortality	O
An	O
increased	O
risk	O
of	O
death	B
was	O
seen	O
in	O
the	O
SIRTURO	O
treatment	O
group	O
(	O
9/79	O
,	O
11.4	O
%	O
)	O
compared	O
to	O
the	O
placebo	O
treatment	O
group	O
(	O
2/81	O
,	O
2.5	O
%	O
)	O
in	O
one	O
placebo-controlled	O
trial	O
(	O
based	O
on	O
the	O
120-week	O
visit	O
window	O
)	O
.	O
	
Most	O
of	O
these	O
adverse	O
reactions	O
were	O
mild	O
to	O
moderate	O
in	O
intensity	O
and	O
occurred	O
during	O
the	O
titration	O
phase	O
.	O
	
Seventeen	O
patients	O
(	O
1.0	O
%	O
)	O
required	O
permanent	O
discontinuation	O
due	O
to	O
elevated	B
transaminases	I
.	O
	
*	O
Hematologic	B
Toxicity	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Infection	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Tumor	B
Lysis	I
Syndrome	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Gastrointestinal	B
Toxicity	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
The	O
most	O
common	O
adverse	O
reactions	O
observed	O
in	O
the	O
trial	O
of	O
patients	O
with	O
relapsed	O
or	O
refractory	O
PTCL	O
treated	O
with	O
Beleodaq	O
were	O
nausea	B
,	O
fatigue	B
,	O
pyrexia	B
,	O
anemia	B
,	O
and	O
vomiting	B
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
A	O
24-week	O
,	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
clinical	O
trial	O
of	O
Vimizim	O
was	O
conducted	O
in	O
176	O
patients	O
with	O
MPS	O
IVA	O
,	O
ages	O
5	O
to	O
57	O
years	O
old	O
.	O
	
Hypocalcemia	B
(	O
serum	O
calcium	O
<	O
8.4	O
mg/dL	O
)	O
was	O
reported	O
only	O
in	O
Prolia-treated	O
patients	O
(	O
2.4	O
%	O
vs.	O
0	O
%	O
)	O
at	O
the	O
month	O
1	O
visit	O
.	O
	
In	O
a	O
trial	O
carried	O
out	O
in	O
patients	O
with	O
moderate	O
renal	O
impairment	O
with	O
a	O
baseline	O
eGFR	O
of	O
30	O
to	O
less	O
than	O
50	O
mL/min/1.73	O
m	O
2	O
(	O
mean	O
baseline	O
eGFR	O
39	O
mL/min/1.73	O
m	O
2	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
the	O
proportion	O
of	O
patients	O
who	O
experienced	O
at	O
least	O
one	O
event	O
of	O
significant	O
renal	B
function	I
decline	I
,	O
defined	O
as	O
an	O
eGFR	B
30	I
%	I
lower	I
than	I
baseline	I
,	O
was	O
6.9	O
%	O
with	O
placebo	O
,	O
18	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
22.5	O
%	O
with	O
INVOKANA	O
300	O
mg.	O
At	O
the	O
end	O
of	O
treatment	O
,	O
4.6	O
%	O
with	O
placebo	O
,	O
3.4	O
%	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
2.2	O
%	O
with	O
INVOKANA	O
300	O
mg	O
had	O
a	O
significant	O
renal	B
function	I
decline	I
.	O
	
Monitor	O
symptoms	O
(	O
such	O
as	O
fatigue	O
,	O
anorexia	O
,	O
nausea	O
,	O
jaundice	O
,	O
dark	O
urine	O
,	O
liver	O
tenderness	O
and	O
hepatomegaly	O
)	O
and	O
laboratory	O
tests	O
(	O
ALT	O
,	O
AST	O
,	O
alkaline	O
phosphatase	O
,	O
and	O
bilirubin	O
)	O
at	O
baseline	O
,	O
monthly	O
while	O
on	O
treatment	O
,	O
and	O
as	O
needed	O
.	O
	
The	O
risk	O
did	O
not	O
vary	O
substantially	O
by	O
age	O
(	O
5	O
to	O
100	O
years	O
)	O
in	O
the	O
clinical	O
trials	O
analyzed	O
.	O
	
These	O
cases	O
of	O
anaphylaxis	B
occurred	O
as	O
early	O
as	O
30	O
minutes	O
from	O
the	O
start	O
of	O
infusion	O
and	O
up	O
to	O
three	O
hours	O
after	O
infusion	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
serious	O
hypersensitivity	B
reactions	I
in	O
patients	O
treated	O
with	O
NESINA	O
.	O
	
In	O
patients	O
predisposed	O
to	O
hypocalcemia	O
and	O
disturbances	O
of	O
mineral	O
metabolism	O
(	O
e.g	O
.	O
	
Ibrutinib	O
caused	O
malformations	B
in	O
rats	O
at	O
exposures	O
14	O
times	O
those	O
reported	O
in	O
patients	O
with	O
MCL	O
and	O
20	O
times	O
those	O
reported	O
in	O
patients	O
with	O
CLL	O
or	O
WM	O
,	O
receiving	O
the	O
ibrutinib	O
dose	O
of	O
560	O
mg	O
per	O
day	O
and	O
420	O
mg	O
per	O
day	O
,	O
respectively	O
.	O
	
Measurement	O
of	O
serum	O
sodium	O
and	O
chloride	O
levels	O
should	O
be	O
considered	O
during	O
maintenance	O
treatment	O
with	O
APTIOM	O
,	O
particularly	O
if	O
the	O
patient	O
is	O
receiving	O
other	O
medications	O
known	O
to	O
decrease	O
serum	O
sodium	O
levels	O
and	O
should	O
be	O
performed	O
if	O
symptoms	O
of	O
hyponatremia	O
develop	O
(	O
e.g.	O
,	O
nausea/vomiting	O
,	O
malaise	O
,	O
headache	O
,	O
lethargy	O
,	O
confusion	O
,	O
irritability	O
,	O
muscle	O
weakness/spasms	O
,	O
obtundation	O
,	O
or	O
increase	O
in	O
seizure	O
frequency	O
or	O
severity	O
)	O
.	O
	
5.3	O
QT	O
Interval	O
Prolongation	O
QTc	B
prolongation	I
can	O
occur	O
in	O
patients	O
treated	O
with	O
XALKORI	O
.	O
	
Table	O
1	O
contains	O
the	O
treatment	O
emergent	O
adverse	O
reactions	O
,	O
regardless	O
of	O
attribution	O
,	O
that	O
were	O
reported	O
in	O
>	O
=	O
5	O
%	O
of	O
patients	O
in	O
either	O
treatment	O
group	O
in	O
the	O
randomized	O
CLL	O
clinical	O
study	O
.	O
	
These	O
effects	O
were	O
dose-related	O
and	O
generally	O
appeared	O
within	O
the	O
first	O
8	O
weeks	O
of	O
treatment	O
(	O
as	O
early	O
as	O
after	O
3	O
days	O
)	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bayer	O
HealthCare	O
Pharmaceuticals	O
Inc.	O
at	O
1-888-842-2937	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Four	O
weeks	O
after	O
stopping	O
TECFIDERA	O
,	O
mean	O
lymphocyte	O
counts	O
increased	O
but	O
did	O
not	O
return	O
to	O
baseline	O
.	O
	
5.2	O
Risk	O
of	O
Acute	O
Respiratory	O
Complications	O
Patients	O
with	O
acute	O
febrile	O
or	O
respiratory	O
illness	O
at	O
the	O
time	O
of	O
Vimizim	O
infusion	O
may	O
be	O
at	O
higher	O
risk	O
of	O
life-threatening	O
complications	O
from	O
hypersensitivity	B
reactions	I
.	O
	
Permanently	O
discontinue	O
YERVOY	O
in	O
patients	O
with	O
severe	O
enterocolitis	O
and	O
initiate	O
systemic	O
corticosteroids	O
at	O
a	O
dose	O
of	O
1	O
to	O
2	O
mg/kg/day	O
of	O
prednisone	O
or	O
equivalent	O
.	O
	
Abdominal	B
pain	I
Vomiting	B
2520201513	O
0	O
<	O
1120	O
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
Pyrexia	B
Peripheral	B
edema	I
Fatigue	B
Chills	B
Chest	B
pain	I
6225171511	O
7	O
<	O
1101	O
Immune	O
system	O
disorders	O
Cytokine	B
release	I
syndrome	I
11	O
1	O
Infections	O
and	O
infestations	O
Other	O
pathogen	O
infections	B
Bacterial	B
infections	I
Fungal	B
infections	I
Viral	B
infections	I
Pneumonia	B
Sepsis	B
4419151397	O
25127486	O
Investigations	O
Increased	B
alanine	I
aminotransferase	I
Increased	B
aspartate	I
aminotransferase	I
Increased	B
weight	I
121111	O
640	O
Metabolism	O
and	O
nutrition	O
disorders	O
Hypokalemia	B
Hypomagnesemia	B
Hyperglycemia	B
Decreased	B
appetite	I
Hypophosphatemia	B
231211106	O
60735	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Back	B
pain	I
Pain	B
in	I
extremity	I
Bone	B
pain	I
Arthralgia	B
14121110	O
2132	O
Nervous	O
system	O
disorders	O
Headache	B
TremorTremor	O
includes	O
the	O
following	O
terms	O
:	O
resting	B
tremor	I
and	O
tremor	B
.	O
	
The	O
data	O
presented	O
below	O
are	O
based	O
on	O
information	O
collected	O
from	O
Study	O
1	O
,	O
a	O
single-arm	O
,	O
multi-center	O
,	O
open-label	O
,	O
safety	O
and	O
clinical	O
pharmacology	O
trial	O
(	O
intramuscular	O
administration	O
)	O
,	O
the	O
ERWINAZE	O
Master	O
Treatment	O
Protocol	O
(	O
EMTP	O
)	O
,	O
an	O
expanded	O
access	O
program	O
(	O
both	O
intramuscular	O
,	O
intravenous	O
,	O
and	O
other	O
or	O
unknown	O
administration	O
)	O
,	O
and	O
Study	O
2	O
,	O
a	O
single-arm	O
,	O
multi-center	O
,	O
open-label	O
,	O
pharmacokinetic	O
(	O
PK	O
)	O
study	O
trial	O
of	O
intravenous	O
administration	O
of	O
ERWINAZE.Study	O
1	O
enrolled	O
58	O
patients	O
treated	O
on	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
-sponsored	O
cooperative	O
group	O
ALL	O
protocols	O
who	O
were	O
unable	O
to	O
continue	O
to	O
receive	O
pegaspargase	O
due	O
to	O
hypersensitivity	O
reactions	O
.	O
	
Neither	O
clinical	O
studies	O
nor	O
epidemiologic	O
studies	O
conducted	O
to	O
date	O
have	O
shown	O
an	O
association	O
between	O
chronic	O
administration	O
of	O
this	O
class	O
of	O
drugs	O
and	O
tumorigenesis	O
in	O
humans	O
;	O
the	O
available	O
evidence	O
is	O
considered	O
too	O
limited	O
to	O
be	O
conclusive	O
at	O
this	O
time	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Shire	O
Human	O
Genetic	O
Therapies	O
at	O
the	O
OnePath	O
(	O
r	O
)	O
phone	O
#	O
1-866-888-0660	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
safety	O
of	O
icatibant	O
was	O
evaluated	O
in	O
three	O
controlled	O
trials	O
that	O
included	O
223	O
patients	O
who	O
received	O
FIRAZYR	O
30	O
mg	O
(	O
n=113	O
)	O
,	O
placebo	O
(	O
n=75	O
)	O
,	O
or	O
comparator	O
(	O
n=38	O
)	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
5.2	O
Growth	O
of	O
Resistant	O
Organisms	O
with	O
Prolonged	O
Use	O
As	O
with	O
other	O
anti-infectives	O
,	O
prolonged	O
use	O
of	O
Besivance	O
(	O
besifloxacin	O
ophthalmic	O
suspension	O
)	O
0.6	O
%	O
may	O
result	O
in	O
overgrowth	B
of	I
non-susceptible	I
organisms	I
.	O
	
Genital	B
mycotic	I
infections	I
were	O
reported	O
in	O
0.9	O
%	O
of	O
patients	O
on	O
placebo	O
,	O
5.7	O
%	O
on	O
FARXIGA	O
5	O
mg	O
,	O
and	O
4.8	O
%	O
on	O
FARXIGA	O
10	O
mg	O
,	O
in	O
the	O
12-study	O
placebo-controlled	O
pool	O
.	O
	
Hyperprolactinemia	B
may	O
suppress	B
hypothalamic	I
GnRH	I
,	O
resulting	O
in	O
reduced	B
pituitary	I
gonadotropin	I
secretion	I
.	O
	
The	O
data	O
described	O
below	O
reflect	O
a	O
median	O
exposure	O
to	O
COMETRIQ	O
for	O
204	O
days	O
.	O
	
No	O
cases	O
of	O
PML	B
were	O
reported	O
in	O
patients	O
treated	O
with	O
the	O
recommended	O
NULOJIX	O
regimen	O
or	O
the	O
control	O
regimen	O
in	O
these	O
trials	O
.	O
	
Additionally	O
,	O
the	O
observed	O
incidence	O
of	O
antibody	O
(	O
including	O
neutralizing	O
antibody	O
)	O
positivity	O
in	O
an	O
assay	O
may	O
be	O
influenced	O
by	O
several	O
factors	O
,	O
including	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
patients	O
(	O
3.7	O
%	O
)	O
in	O
the	O
controlled	O
and	O
uncontrolled	O
clinical	O
trials	O
in	O
Peyronie	O
's	O
disease	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Should	O
the	O
physician	O
decide	O
to	O
administer	O
anticoagulation	O
in	O
the	O
context	O
of	O
epidural	O
or	O
spinal	O
anesthesia/analgesia	O
or	O
lumbar	O
puncture	O
,	O
monitor	O
frequently	O
to	O
detect	O
any	O
signs	O
or	O
symptoms	O
of	O
neurological	O
impairment	O
,	O
such	O
as	O
midline	O
back	O
pain	O
,	O
sensory	O
and	O
motor	O
deficits	O
(	O
numbness	O
,	O
tingling	O
,	O
or	O
weakness	O
in	O
lower	O
limbs	O
)	O
,	O
bowel	O
and/or	O
bladder	O
dysfunction	O
.	O
	
Autoantibodies	O
In	O
clinical	O
studies	O
in	O
Crohn	O
's	O
disease	O
,	O
4	O
%	O
of	O
patients	O
treated	O
with	O
CIMZIA	O
and	O
2	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
that	O
had	O
negative	O
baseline	O
ANA	B
titers	I
developed	I
positive	I
titers	O
during	O
the	O
studies	O
.	O
	
At	O
study	O
baseline	O
,	O
approximately	O
25	O
%	O
had	O
mild	O
,	O
50	O
%	O
had	O
moderate	O
,	O
and	O
25	O
%	O
had	O
severe	O
cervical	O
dystonia	O
.	O
	
The	O
overall	O
percentage	O
of	O
antibody	O
positive	O
patients	O
was	O
8	O
%	O
in	O
patients	O
continuously	O
exposed	O
to	O
CIMZIA	O
,	O
approximately	O
6	O
%	O
were	O
neutralizing	O
in	O
vitro	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
in	O
Placebo-Controlled	O
Trials	O
Reported	O
in	O
>	O
=5	O
%	O
of	O
TRULICITY-Treated	O
Patients	O
a	O
Includes	O
diarrhea	B
,	O
fecal	B
volume	I
increased	I
,	O
frequent	B
bowel	I
movements	I
.	O
	
Withhold	O
COMETRIQ	O
for	O
hypertension	O
that	O
is	O
not	O
adequately	O
controlled	O
with	O
medical	O
management	O
;	O
when	O
controlled	O
,	O
resume	O
COMETRIQ	O
at	O
a	O
reduced	O
dose	O
.	O
	
Some	O
patients	O
with	O
Dupuytren	O
's	O
contracture	O
developed	O
IgE-anti-drug	O
antibodies	O
in	O
greater	O
proportions	O
and	O
higher	O
titers	O
with	O
successive	O
XIAFLEX	O
injections	O
.	O
	
Monitor	O
lipase	O
and	O
amylase	O
prior	O
to	O
the	O
start	O
of	O
ZYKADIA	O
treatment	O
and	O
periodically	O
thereafter	O
as	O
clinically	O
indicated	O
.	O
	
Consider	O
alternative	O
contraception	O
for	O
women	O
with	O
uncontrolled	O
dyslipidemia	O
.	O
	
5.2	O
genotoxicity	B
in	O
animal	O
studies	O
,	O
Ferriprox	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
Use	O
caution	O
when	O
treating	O
patients	O
whose	O
underlying	O
medical	O
conditions	O
might	O
be	O
compromised	O
by	O
increases	O
in	O
blood	O
pressure	O
,	O
hypokalemia	O
or	O
fluid	O
retention	O
,	O
e.g.	O
,	O
those	O
with	O
heart	O
failure	O
,	O
recent	O
myocardial	O
infarction	O
or	O
ventricular	O
arrhythmia	O
.	O
	
The	O
increased	O
risk	O
of	O
asthma-related	O
death	B
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
,	O
including	O
vilanterol	O
,	O
one	O
of	O
the	O
active	O
ingredients	O
in	O
BREO	O
ELLIPTA	O
.	O
	
Patients	O
with	O
tuberculosis	B
have	I
frequently	I
presented	I
with	I
disseminated	I
disease	O
.	O
	
Hypersensitivity	O
Reactions	O
In	O
the	O
4	O
pivotal	O
studies	O
,	O
drug	O
hypersensitivity	B
(	O
including	O
urticaria	B
,	O
rash	B
,	O
and	O
pruritus	B
)	O
,	O
allergic	B
edema	I
,	O
anaphylactic	B
reaction	I
,	O
and	O
anaphylactic	B
shock	I
were	O
reported	O
in	O
0.1	O
%	O
of	O
patients	O
receiving	O
PRADAXA	O
.	O
	
In	O
the	O
majority	O
of	O
cases	O
,	O
rash	B
type	O
,	O
and	O
occurred	O
in	O
the	O
second	O
week	O
of	O
therapy	O
.	O
	
Consequently	O
,	O
FARXIGA	O
should	O
not	O
be	O
used	O
in	O
patients	O
with	O
active	O
bladder	O
cancer	O
.	O
	
Prescribers	O
should	O
caution	O
patients	O
against	O
engaging	O
in	O
hazardous	O
activities	O
requiring	O
mental	O
alertness	O
,	O
such	O
as	O
operating	O
dangerous	O
machinery	O
or	O
motor	O
vehicles	O
,	O
until	O
the	O
effect	O
of	O
ONFI	O
is	O
known	O
.	O
	
5.6	O
Suicidal	O
Behavior	O
and	O
Ideation	O
Antiepileptic	O
drugs	O
(	O
AEDs	O
)	O
,	O
including	O
ONFI	O
,	O
increase	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
in	O
patients	O
taking	O
these	O
drugs	O
for	O
any	O
indication	O
.	O
	
Monitor	O
LDL-C	O
and	O
treat	O
per	O
standard	O
of	O
care	O
after	O
initiating	O
FARXIGA	O
.	O
	
Macular	O
Edema	O
Following	O
Retinal	O
Vein	O
Occlusion	O
(	O
RVO	O
)	O
The	O
data	O
described	O
below	O
reflect	O
6	O
months	O
exposure	O
to	O
EYLEA	O
with	O
a	O
monthly	O
2	O
mg	O
dose	O
in	O
218	O
patients	O
following	O
CRVO	O
in	O
2	O
clinical	O
studies	O
(	O
COPERNICUS	O
and	O
GALILEO	O
)	O
and	O
91	O
patients	O
following	O
BRVO	O
in	O
one	O
clinical	O
study	O
(	O
VIBRANT	O
)	O
[	O
seeClinical	O
Studies	O
(	O
14.2	O
)	O
,	O
(	O
14.3	O
)	O
]	O
.	O
	
In	O
general	O
,	O
adverse	O
events	O
reported	O
by	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
hepatitis	O
C	O
virus	O
co-infection	O
were	O
similar	O
to	O
INTELENCE	O
(	O
r	O
)	O
-treated	O
subjects	O
without	O
hepatitis	O
B	O
and/or	O
hepatitis	O
C	O
virus	O
co-infection	O
.	O
	
There	O
was	O
a	O
6-fold	O
increase	O
in	O
the	O
risk	O
of	O
CTCAE	O
Grade	O
3-4	O
hyperglycemia	B
in	O
patients	O
with	O
diabetes	O
or	O
glucose	O
intolerance	O
and	O
a	O
2-fold	O
increase	O
in	O
patients	O
taking	O
corticosteroids	O
.	O
	
In	O
patients	O
who	O
develop	O
serious	O
allergic	O
reactions	O
,	O
discontinue	O
Zydelig	O
permanently	O
and	O
institute	O
appropriate	O
supportive	O
measures	O
.	O
	
Approximately	O
81	O
%	O
of	O
these	O
local	O
reactions	O
resolved	O
without	O
intervention	O
within	O
4	O
weeks	O
of	O
XIAFLEX	O
injections	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
signs	O
of	O
peripheral	O
motor	O
and	O
sensory	O
neuropathy	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
AdreView	O
administration	O
.	O
	
Monitor	O
liver	O
function	O
tests	O
before	O
treatment	O
and	O
before	O
the	O
start	O
of	O
each	O
cycle	O
.	O
	
Rupture	B
of	I
hepatic	I
adenomas	I
may	O
cause	O
death	B
through	O
intra-abdominal	B
hemorrhage	I
.	O
	
Diarrhea	B
due	O
to	O
Zydelig	O
responds	O
poorly	O
to	O
antimotility	O
agents	O
.	O
	
Interrupt	O
Ferriprox	O
therapy	O
if	O
neutropenia	O
develops	O
(	O
ANC	O
<	O
1.5	O
x	O
10	O
9	O
/L	O
)	O
.	O
	
5.4	O
QT	O
Prolongation	O
In	O
an	O
uncontrolled	O
open-label	O
ECG	O
study	O
in	O
26	O
patients	O
,	O
QT	B
prolongation	I
was	O
observed	O
on	O
Day	O
8	O
,	O
independent	O
of	O
eribulin	O
concentration	O
,	O
with	O
no	O
QT	B
prolongation	I
observed	O
on	O
Day	O
1	O
.	O
	
Patients	O
whose	O
baseline	O
ALT	O
or	O
AST	O
were	O
elevated	O
were	O
more	O
likely	O
to	O
experience	O
liver	B
test	I
elevation	I
than	O
those	O
beginning	O
with	O
normal	O
values	O
.	O
	
These	O
include	O
cases	O
of	O
Stevens-Johnson	B
syndrome	I
,	O
toxic	B
epidermal	I
necrolysis	I
and	O
erythema	B
multiforme	I
.	O
	
Subject-years	O
is	O
defined	O
as	O
cumulative	O
number	O
of	O
days	O
from	O
first	O
drug	O
intake	O
to	O
event	O
date	O
,	O
date	O
of	O
last	O
drug	O
intake	O
+	O
2	O
,	O
death	O
date	O
(	O
whatever	O
occurred	O
first	O
)	O
across	O
all	O
treated	O
subjects	O
divided	O
by	O
365.25	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
to	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
.	O
	
Febrile	B
neutropenia	I
has	O
been	O
reported	O
with	O
treatment	O
with	O
ADCETRIS	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
CIGARETTE	O
SMOKING	O
AND	O
SERIOUS	O
CARDIOVASCULAR	B
EVENTS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
Discontinuation	O
of	O
therapy	O
due	O
to	O
adverse	O
reactions	O
occurred	O
in	O
10	O
%	O
of	O
patients	O
treated	O
with	O
ZYKADIA	O
.	O
	
Patients	O
received	O
placebo	O
(	O
N=1393	O
)	O
,	O
FARXIGA	O
5	O
mg	O
(	O
N=1145	O
)	O
,	O
or	O
FARXIGA	O
10	O
mg	O
(	O
N=1193	O
)	O
once	O
daily	O
.	O
	
At	O
one	O
year	O
after	O
transplantation	O
these	O
values	O
were	O
183	O
mg/dL	O
,	O
50	O
mg/dL	O
,	O
102	O
mg/dL	O
,	O
and	O
151	O
mg/dL	O
,	O
respectively	O
,	O
in	O
401	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
and	O
196	O
mg/dL	O
,	O
48	O
mg/dL	O
,	O
108	O
mg/dL	O
,	O
and	O
195	O
mg/dL	O
,	O
respectively	O
,	O
in	O
405	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
Follow	O
instructions	O
for	O
preparation	O
(	O
including	O
admixing	O
)	O
and	O
administration	O
strictly	O
to	O
minimize	O
medication	O
errors	O
(	O
including	O
underdose	O
and	O
overdose	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
(	O
2.4	O
)	O
]	O
.	O
	
Anyone	O
considering	O
prescribing	O
ONFI	O
or	O
any	O
other	O
AED	O
must	O
balance	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
or	O
behavior	O
with	O
the	O
risk	O
of	O
untreated	O
illness	O
.	O
	
The	O
desired	O
therapeutic	O
response	O
was	O
achieved	O
at	O
doses	O
of	O
4-6	O
mg/hour	O
.	O
	
These	O
were	O
commonly	O
dyspepsia	B
(	O
including	O
abdominal	B
pain	I
upper	I
,	O
abdominal	B
pain	I
,	O
abdominal	B
discomfort	I
,	O
and	O
epigastric	B
discomfort	I
)	O
and	O
gastritis-like	O
symptoms	O
(	O
including	O
GERD	B
,	O
esophagitis	B
,	O
erosive	B
gastritis	I
,	O
gastric	B
hemorrhage	I
,	O
hemorrhagic	B
gastritis	I
,	O
hemorrhagic	B
erosive	I
gastritis	I
,	O
and	O
gastrointestinal	B
ulcer	I
)	O
.	O
	
Based	O
on	O
the	O
severity	O
of	O
the	O
adverse	O
drug	O
reaction	O
,	O
withhold	O
ZYKADIA	O
with	O
resumption	O
at	O
a	O
reduced	O
dose	O
as	O
described	O
in	O
Table	O
1	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Patients	O
with	O
alanine	O
aminotransferase	O
or	O
aspartate	O
aminotransferase	O
>	O
3	O
*	O
ULN	O
(	O
upper	O
limit	O
of	O
normal	O
)	O
experienced	O
a	O
higher	O
incidence	O
of	O
Grade	O
4	O
neutropenia	B
and	O
febrile	B
neutropenia	I
than	O
patients	O
with	O
normal	O
aminotransferase	O
levels	O
.	O
	
Among	O
patients	O
in	O
Study	O
3	O
who	O
reported	O
no	O
prior	O
exposure	O
to	O
XIAFLEX	O
,	O
97	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-I	O
and	O
AUX-II	O
after	O
two	O
concurrent	O
doses	O
of	O
XIAFLEX	O
0.58	O
mg	O
(	O
total	O
dose	O
of	O
1.16	O
mg	O
)	O
in	O
the	O
same	O
hand	O
.	O
	
In	O
other	O
XIAFLEX-treated	O
patients	O
(	O
9	O
of	O
1044	O
;	O
0.9	O
%	O
)	O
,	O
a	O
combination	O
of	O
penile	B
ecchymoses	I
,	O
sudden	O
penile	B
detumescence	I
,	O
and/or	O
a	O
penile	B
``	O
popping	B
''	O
sound	B
was	O
reported	O
,	O
and	O
in	O
these	O
cases	O
,	O
a	O
diagnosis	O
of	O
corporal	B
rupture	I
can	O
not	O
be	O
excluded	O
.	O
	
The	O
mean	O
time	O
to	O
nadir	O
was	O
13	O
days	O
and	O
the	O
mean	O
time	O
to	O
recovery	O
from	O
severe	O
neutropenia	B
(	O
<	O
500/mm	O
3	O
)	O
was	O
8	O
days	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
20	O
%	O
)	O
reported	O
in	O
the	O
two	O
randomized	O
clinical	O
trials	O
that	O
occurred	O
more	O
commonly	O
(	O
>	O
=2	O
%	O
)	O
in	O
the	O
abiraterone	O
acetate	O
arm	O
were	O
anemia	B
,	O
elevated	B
alkaline	I
phosphatase	I
,	O
hypertriglyceridemia	B
,	O
lymphopenia	B
,	O
hypercholesterolemia	B
,	O
hyperglycemia	B
,	O
elevated	B
AST	I
,	O
hypophosphatemia	B
,	O
elevated	B
ALT	I
and	O
hypokalemia	B
.	O
	
The	O
information	O
below	O
is	O
derived	O
from	O
a	O
clinical	O
trial	O
database	O
for	O
FANAPT	O
consisting	O
of	O
2070	O
patients	O
exposed	O
to	O
FANAPT	O
at	O
doses	O
of	O
10	O
mg/day	O
or	O
greater	O
,	O
for	O
the	O
treatment	O
of	O
schizophrenia	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
*	O
The	O
most	O
common	O
adverse	O
reactions	O
are	O
(	O
incidence	O
>	O
=	O
5	O
%	O
)	O
chromaturia	B
,	O
nausea	B
,	O
vomiting	B
and	O
abdominal	B
pain	I
,	O
alanine	B
aminotransferase	I
increased	I
,	O
arthralgia	B
and	O
neutropenia	B
.	O
	
Comparisons	O
between	O
placebo	O
and	O
SIMPONI	O
ARIA	O
were	O
based	O
on	O
the	O
first	O
24	O
weeks	O
of	O
exposure	O
.	O
	
Controlled	O
Studies	O
with	O
Rheumatoid	O
Arthritis	O
CIMZIA	O
was	O
studied	O
primarily	O
in	O
placebo-controlled	O
trials	O
and	O
in	O
long-term	O
follow-up	O
studies	O
.	O
	
POTIGA	O
was	O
discontinued	O
in	O
3	O
of	O
the	O
5	O
patients	O
who	O
required	O
catheterization	O
,	O
and	O
all	O
were	O
able	O
to	O
void	O
spontaneously	O
;	O
however	O
,	O
1	O
of	O
the	O
3	O
patients	O
continued	O
intermittent	O
self-catheterization	O
.	O
	
Table	O
1	O
:	O
Change	O
in	O
Fasting	O
Glucose	O
FANAPT	O
Placebo	O
24	O
mg/day	O
Mean	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
n=114	O
n=228	O
Serum	O
Glucose	O
Change	O
from	O
Baseline	O
-0.5	O
6.6	O
Proportion	O
of	O
Patients	O
with	O
Shifts	O
Serum	O
Glucose	O
Normal	O
to	O
High	O
2.5	O
%	O
10.7	O
%	O
(	O
<	O
100	O
mg/dL	O
to	O
>	O
=126	O
mg/dL	O
)	O
(	O
2/80	O
)	O
(	O
18/169	O
)	O
Pooled	O
analyses	O
of	O
glucose	O
data	O
from	O
clinical	O
studies	O
including	O
longer	O
term	O
trials	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
54	O
(	O
49	O
%	O
)	O
subjects	O
treated	O
with	O
Zydelig	O
+	O
rituximab	O
.	O
	
*	O
Palmar-plantar	B
Erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
:	O
Interrupt	O
COMETRIQ	O
,	O
decrease	O
dose	O
.	O
	
Steroids	O
should	O
be	O
used	O
with	O
caution	O
in	O
the	O
presence	O
of	O
glaucoma	O
.	O
	
S	O
A	O
medically	O
important	O
event	O
that	O
may	O
be	O
life-threatening	O
or	O
result	O
in	O
death	B
or	O
hospitalization	O
or	O
prolongation	O
of	O
existing	O
hospitalization	O
.	O
	
Serious	O
adverse	O
events	O
that	O
may	O
be	O
associated	O
with	O
CRS	B
included	O
pyrexia	B
,	O
headache	B
,	O
nausea	B
,	O
asthenia	B
,	O
hypotension	B
,	O
increased	B
alanine	I
aminotransferase	I
,	O
increased	B
aspartate	I
aminotransferase	I
,	O
and	O
increased	B
total	I
bilirubin	I
;	O
these	O
events	O
infrequently	O
led	O
to	O
BLINCYTO	O
discontinuation	O
.	O
	
Tuberculosis	B
and	O
herpes	B
infections	I
were	O
reported	O
more	O
frequently	O
in	O
patients	O
receiving	O
NULOJIX	O
than	O
cyclosporine	O
.	O
	
(	O
2.3	O
)	O
,	O
(	O
5.2	O
)	O
5	O
.	O
	
5.4	O
Bacterial	O
Infections	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
suppress	B
the	I
host	I
response	I
and	O
thus	O
increase	O
the	O
hazard	O
of	O
secondary	B
ocular	I
infections	I
.	O
	
Orthostatic	B
hypotension	I
was	O
reported	O
in	O
5	O
%	O
of	O
patients	O
given	O
20	O
to	O
24	O
mg/day	O
,	O
3	O
%	O
of	O
patients	O
given	O
10	O
to	O
16	O
mg/day	O
,	O
and	O
1	O
%	O
of	O
patients	O
given	O
placebo	O
.	O
	
In	O
this	O
study	O
13	O
patients	O
experienced	O
bone	B
fractures	I
for	O
treatment	O
durations	O
up	O
to	O
104	O
weeks	O
.	O
	
The	O
rate	O
of	O
withdrawals	O
due	O
to	O
adverse	O
events	O
in	O
placebo-controlled	O
monotherapy	O
and	O
combination	O
therapy	O
trials	O
was	O
2.4	O
%	O
(	O
19/801	O
)	O
for	O
placebo	O
,	O
2.2	O
%	O
(	O
24/1072	O
)	O
for	O
Edarbi	O
40	O
mg	O
,	O
and	O
2.7	O
%	O
(	O
29/1074	O
)	O
for	O
Edarbi	O
80	O
mg	O
.	O
	
Abrupt	O
discontinuation	O
or	O
dose	O
reduction	O
has	O
been	O
associated	O
with	O
the	O
appearance	O
of	O
new	O
symptoms	O
that	O
include	O
dizziness	B
,	O
nausea	B
,	O
headache	B
,	O
irritability	B
,	O
insomnia	B
,	O
diarrhea	B
,	O
anxiety	B
,	O
fatigue	B
,	O
abnormal	B
dreams	I
,	O
and	O
hyperhidrosis	B
.	O
	
*	O
Macrovascular	O
outcomes	O
:	O
There	O
have	O
been	O
no	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TRULICITY	O
or	O
any	O
other	O
antidiabetic	O
drug	O
(	O
5.7	O
)	O
.	O
	
(	O
5.4	O
)	O
item	O
{	O
Viral	O
infections-	O
Employment	O
of	O
a	O
corticosteroid	O
medication	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
a	O
history	O
of	O
herpes	O
simplex	O
requires	O
great	O
caution	O
.	O
	
Caution	O
should	O
be	O
exercised	O
in	O
treating	O
patients	O
with	O
pre-existing	O
hypertension	O
,	O
cardiovascular	O
,	O
or	O
cerebrovascular	O
conditions	O
that	O
might	O
be	O
compromised	O
by	O
increases	O
in	O
blood	O
pressure	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
RISK	O
OF	O
THYROID	B
C-CELL	I
TUMORS	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
New-Onset	O
Diabetes	O
After	O
Transplantation	O
The	O
incidence	O
of	O
new-onset	B
diabetes	I
after	I
transplantation	I
(	O
NODAT	B
)	O
was	O
defined	O
in	O
Studies	O
1	O
and	O
2	O
as	O
use	O
of	O
an	O
antidiabetic	O
agent	O
for	O
>	O
=30	O
days	O
or	O
>	O
=2	O
fasting	O
plasma	O
glucose	O
values	O
>	O
=126	O
mg/dL	O
(	O
7.0	O
mmol/L	O
)	O
post-transplantation	O
.	O
	
5.14	O
Glaucoma	O
and	O
Cataracts	O
Glaucoma	B
,	O
increased	B
intraocular	I
pressure	I
,	O
and	O
cataracts	B
have	O
been	O
reported	O
in	O
patients	O
with	O
COPD	O
or	O
asthma	O
following	O
the	O
long-term	O
administration	O
of	O
inhaled	O
corticosteroids	O
.	O
	
Because	O
of	O
the	O
observed	O
ophthalmologic	O
adverse	O
reactions	O
,	O
POTIGA	O
should	O
only	O
be	O
used	O
in	O
patients	O
who	O
have	O
responded	O
inadequately	O
to	O
several	O
alternative	O
treatments	O
and	O
for	O
whom	O
the	O
benefits	O
outweigh	O
the	O
risk	O
of	O
retinal	O
abnormalities	O
and	O
potential	O
vision	O
loss	O
.	O
	
While	O
all	O
atypical	O
antipsychotic	O
drugs	O
have	O
been	O
shown	O
to	O
produce	O
some	O
metabolic	O
changes	O
,	O
each	O
drug	O
in	O
the	O
class	O
has	O
its	O
own	O
specific	O
risk	O
profile	O
.	O
	
Advise	O
patients	O
with	O
myelosuppression	O
following	O
TREANDA	O
treatment	O
to	O
contact	O
a	O
physician	O
if	O
they	O
have	O
symptoms	O
or	O
signs	O
of	O
infection	O
.	O
	
Causality	O
can	O
not	O
be	O
excluded	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pharmacyclics	O
at	O
1-877-877-3536	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
In	O
a	O
monotherapy	O
study	O
comparing	O
NESINA	O
to	O
a	O
sulfonylurea	O
in	O
elderly	O
patients	O
,	O
the	O
incidence	O
of	O
hypoglycemia	B
was	O
5.4	O
%	O
with	O
NESINA	O
compared	O
to	O
26	O
%	O
with	O
glipizide	O
(	O
Table	O
2	O
)	O
.	O
	
Patients	O
who	O
experience	O
Grade	O
3	O
or	O
worse	O
allergic-type	O
reactions	O
should	O
not	O
be	O
rechallenged	O
.	O
	
Adjunctive	O
Therapy	O
Controlled	O
Trials	O
In	O
the	O
controlled	O
adjunctive	O
therapy	O
epilepsy	O
trials	O
(	O
Study	O
3	O
,	O
Study	O
4	O
,	O
and	O
Study	O
5	O
)	O
,	O
the	O
rate	O
of	O
discontinuation	O
as	O
a	O
result	O
of	O
any	O
adverse	O
reaction	O
was	O
14	O
%	O
for	O
the	O
800	O
mg	O
dose	O
,	O
25	O
%	O
for	O
the	O
1200	O
mg	O
dose	O
,	O
and	O
7	O
%	O
in	O
subjects	O
randomized	O
to	O
placebo	O
.	O
	
(	O
6.1	O
)	O
*	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
for	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
are	O
pyrexia	B
,	O
chills	B
,	O
fatigue	B
,	O
rash	B
,	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
abdominal	B
pain	I
,	O
peripheral	B
edema	I
,	O
cough	B
,	O
headache	B
,	O
arthralgia	B
,	O
night	B
sweats	I
,	O
decreased	B
appetite	I
,	O
constipation	B
,	O
and	O
myalgia	B
.	O
	
In	O
the	O
clinical	O
trials	O
,	O
blood	O
counts	O
were	O
monitored	O
every	O
week	O
initially	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Anaphylaxis	O
and	O
Angioedema	O
TECFIDERA	O
can	O
cause	O
anaphylaxis	B
and	O
angioedema	B
after	O
the	O
first	O
dose	O
or	O
at	O
any	O
time	O
during	O
treatment	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Valeant	O
Pharmaceuticals	O
North	O
America	O
LLC	O
at	O
1-800-321-4576	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Patients	O
were	O
randomized	O
to	O
three	O
treatment	O
groups	O
:	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
(	O
n=58	O
)	O
,	O
Vimizim	O
2	O
mg/kg	O
once	O
every	O
other	O
week	O
(	O
n=59	O
)	O
,	O
or	O
placebo	O
(	O
n=59	O
)	O
.	O
	
The	O
role	O
of	O
lymphopenia	B
in	O
this	O
case	O
is	O
unknown	O
.	O
	
Gastrointestinal	O
disorders	O
Diarrhea	B
37	O
0	O
Nausea	B
21	O
0	O
Stomatitis	B
16	O
0	O
Gastroesophageal	B
reflux	I
disease	I
13	O
0	O
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
Rash	B
22	O
0	O
Bruising	B
16	O
0	O
Pruritus	B
11	O
0	O
General	O
disorders	O
and	O
administrative	O
site	O
conditions	O
Fatigue	B
21	O
0	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Muscle	B
spasms	I
21	O
0	O
Arthropathy	B
13	O
0	O
Infections	O
and	O
infestations	O
Upper	B
respiratory	I
tract	I
infection	I
19	O
0	O
Sinusitis	B
19	O
0	O
Pneumonia	B
14	O
6	O
Skin	B
infection	I
14	O
2	O
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
Epistaxis	B
19	O
0	O
Cough	B
13	O
0	O
Nervous	O
system	O
disorders	O
Dizziness	B
14	O
0	O
Headache	B
13	O
0	O
Neoplasms	O
benign	O
,	O
malignant	O
,	O
and	O
unspecified	O
(	O
including	O
cysts	O
and	O
polyps	O
)	O
Skin	B
cancer	I
11	O
0	O
Table	O
8	O
:	O
Treatment-EmergentBased	O
on	O
laboratory	O
measurements	O
.	O
	
The	O
safety	O
of	O
INLYTA	O
has	O
been	O
evaluated	O
in	O
715	O
patients	O
in	O
monotherapy	O
studies	O
,	O
which	O
included	O
537	O
patients	O
with	O
advanced	O
RCC	O
.	O
	
Renal	B
function	I
abnormalities	I
can	O
occur	O
after	O
initiating	O
INVOKANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
the	O
clinical	O
study	O
of	O
7808	O
postmenopausal	O
women	O
with	O
osteoporosis	O
,	O
the	O
incidence	O
of	O
infections	B
resulting	O
in	O
death	B
was	O
0.2	O
%	O
in	O
both	O
placebo	O
and	O
Prolia	O
treatment	O
groups	O
.	O
	
Increases	O
in	O
Serum	O
Magnesium	O
Dose-related	O
increases	B
in	I
serum	I
magnesium	I
were	O
observed	O
early	O
after	O
initiation	O
of	O
INVOKANA	O
(	O
within	O
6	O
weeks	O
)	O
and	O
remained	O
elevated	O
throughout	O
treatment	O
.	O
	
Approximately	O
50	O
%	O
of	O
the	O
subjects	O
were	O
male	O
and	O
the	O
ethnic	O
distribution	O
was	O
60	O
%	O
Caucasian	O
,	O
30	O
%	O
Asian	O
,	O
6	O
%	O
Hispanic	O
,	O
2	O
%	O
Black	O
,	O
and	O
3	O
%	O
patients	O
of	O
other	O
ethnic	O
groups	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
were	O
required	O
in	O
16	O
%	O
of	O
XALKORI-treated	O
patients	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
ENTEREG	O
12	O
mg	O
in	O
1,793	O
patients	O
in	O
10	O
placebo-controlled	O
studies	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
the	O
rate	O
of	O
placebo	O
)	O
reported	O
with	O
acute	O
monotherapy	O
treatment	O
of	O
manic	O
or	O
mixed	O
episodes	O
associated	O
with	O
bipolar	O
I	O
disorder	O
in	O
adults	O
were	O
somnolence	B
,	O
dizziness	B
,	O
extrapyramidal	B
symptoms	I
other	O
than	O
akathisia	B
,	O
and	O
increased	B
weight	I
and	O
during	O
the	O
adjunctive	O
therapy	O
trial	O
in	O
bipolar	O
I	O
disorder	O
in	O
adults	O
were	O
somnolence	B
and	O
oral	B
hypoesthesia	I
.	O
	
This	O
finding	O
with	O
salmeterol	O
is	O
considered	O
a	O
class	O
effect	O
of	O
LABA	O
,	O
including	O
indacaterol	O
,	O
the	O
active	O
ingredient	O
in	O
ARCAPTA	O
NEOHALER	O
.	O
	
After	O
the	O
Cleansing	O
Gel	O
has	O
been	O
wiped	O
off	O
,	O
wash	O
the	O
area	O
with	O
soap	O
and	O
water	O
.	O
	
Monitor	O
and	O
manage	O
patients	O
using	O
standards	O
of	O
care	O
,	O
including	O
antidiarrheals	O
,	O
antiemetics	O
,	O
and	O
fluid	O
replacement	O
.	O
	
Tables	O
3	O
and	O
4	O
summarize	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
in	O
XALKORI-treated	O
patients	O
.	O
	
At	O
the	O
end	O
of	O
treatment	O
,	O
0.8	O
%	O
,	O
4.0	O
%	O
,	O
and	O
2.7	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
,	O
had	O
hemoglobin	B
above	I
the	I
upper	I
limit	I
of	I
normal	I
.	O
	
The	O
incidence	O
of	O
all-cause	O
mortality	B
was	O
2.3	O
%	O
(	O
n	O
=	O
90	O
)	O
in	O
the	O
placebo	O
group	O
and	O
1.8	O
%	O
(	O
n	O
=	O
70	O
)	O
in	O
the	O
Prolia	O
group	O
.	O
	
QT	O
Prolongation	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
(	O
5.1	O
)	O
QT	O
Prolongation	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
Antipsychotic	O
treatment	O
,	O
itself	O
,	O
however	O
,	O
may	O
suppress	O
(	O
or	O
partially	O
suppress	O
)	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
syndrome	O
and	O
thereby	O
may	O
possibly	O
mask	O
the	O
underlying	O
process	O
.	O
	
Other	O
adverse	O
reactions	O
reported	O
in	O
patients	O
receiving	O
Besivance	O
occurring	O
in	O
approximately	O
1-2	O
%	O
of	O
patients	O
included	O
:	O
blurred	B
vision	I
,	O
eye	B
pain	I
,	O
eye	B
irritation	I
,	O
eye	B
pruritus	I
and	O
headache	B
.	O
	
This	O
rare	B
type	I
of	I
T-cell	I
lymphoma	I
has	O
a	O
very	O
aggressive	O
disease	O
course	O
and	O
is	O
usually	O
fatal	B
.	O
	
Monitor	O
LDL-C	O
and	O
treat	O
if	O
appropriate	O
after	O
initiating	O
INVOKANA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
The	O
potency	O
Units	O
of	O
DYSPORT	O
(	O
r	O
)	O
are	O
not	O
interchangeable	O
with	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
and	O
,	O
therefore	O
,	O
units	O
of	O
biological	O
activity	O
of	O
DYSPORT	O
(	O
r	O
)	O
can	O
not	O
be	O
compared	O
to	O
or	O
converted	O
into	O
units	O
of	O
any	O
other	O
botulinum	O
toxin	O
products	O
(	O
5.1	O
)	O
*	O
Recommended	O
dose	O
and	O
frequency	O
of	O
administration	O
should	O
not	O
be	O
exceeded	O
(	O
5.4	O
)	O
*	O
Immediate	O
medical	O
attention	O
may	O
be	O
required	O
in	O
cases	O
of	O
swallowing	B
difficulties	I
(	O
5.3	O
)	O
*	O
Concomitant	O
neuromuscular	O
disorder	O
may	O
exacerbate	O
clinical	O
effects	O
of	O
treatment	O
(	O
5.5	O
)	O
*	O
DYSPORT	O
(	O
r	O
)	O
contains	O
human	O
albumin	O
.	O
	
(	O
2.4	O
,	O
5.10	O
)	O
*	O
Hepatic	B
Toxicity	I
and	O
Hepatic	B
Failure	I
:	O
Monitor	O
liver	O
enzymes	O
.	O
	
The	O
safety	O
of	O
SAPHRIS	O
was	O
evaluated	O
in	O
403	O
pediatric	O
patients	O
with	O
bipolar	O
I	O
disorder	O
who	O
participated	O
in	O
a	O
3-week	O
,	O
placebo-controlled	O
,	O
double-blind	O
trial	O
,	O
of	O
whom	O
302	O
patients	O
received	O
SAPHRIS	O
at	O
fixed	O
doses	O
ranging	O
from	O
2.5	O
mg	O
to	O
10	O
mg	O
twice	O
daily	O
.	O
	
Table	O
1	O
Table	O
2	O
6.2	O
Immunogenicity	O
As	O
with	O
most	O
therapeutic	O
proteins	O
,	O
patients	O
may	O
develop	O
anti-drug	O
antibodies	O
(	O
ADA	O
)	O
to	O
ERWINAZE.In	O
a	O
study	O
with	O
ERWINAZE	O
treatment	O
by	O
intramuscular	O
administration	O
(	O
Study	O
1	O
)	O
,	O
6	O
of	O
56	O
(	O
11	O
%	O
)	O
patients	O
treated	O
with	O
ERWINAZE	O
developed	O
antibodies	O
to	O
ERWINAZE	O
.	O
	
(	O
5.9	O
)	O
*	O
Monitor	O
for	O
proteinuria	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
Other	O
important	O
considerations	O
in	O
the	O
differential	O
diagnosis	O
include	O
central	O
anticholinergic	O
toxicity	O
,	O
heat	O
stroke	O
,	O
drug	O
fever	O
,	O
and	O
primary	O
central	O
nervous	O
system	O
(	O
CNS	O
)	O
pathology	O
.	O
	
Merkel	B
cell	I
carcinoma	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF-blocking	O
agents	O
.	O
	
Cases	O
of	O
syncope	B
were	O
also	O
reported	O
after	O
the	O
first	O
dose	O
of	O
GILENYA	O
.	O
	
Because	O
of	O
the	O
risk	O
of	O
seizure	O
associated	O
with	O
XTANDI	O
use	O
,	O
patients	O
should	O
be	O
advised	O
of	O
the	O
risk	O
of	O
engaging	O
in	O
any	O
activity	O
where	O
sudden	O
loss	O
of	O
consciousness	O
could	O
cause	O
serious	O
harm	O
to	O
themselves	O
or	O
others	O
.	O
	
The	O
following	O
additional	O
adverse	O
reactions	O
occurred	O
in	O
less	O
than	O
10	O
%	O
of	O
AFINITOR	O
-treated	O
patients	O
:	O
epistaxis	B
(	O
9	O
%	O
)	O
,	O
decreased	B
appetite	I
(	O
6	O
%	O
)	O
,	O
otitis	B
media	I
(	O
6	O
%	O
)	O
,	O
depression	B
(	O
5	O
%	O
)	O
,	O
abnormal	B
taste	I
(	O
5	O
%	O
)	O
,	O
increased	B
blood	I
luteinizing	I
hormone	I
(	I
LH	I
)	I
levels	I
(	O
4	O
%	O
)	O
,	O
increased	B
blood	I
follicle	I
stimulating	I
hormone	I
(	I
FSH	I
)	I
levels	I
(	O
3	O
%	O
)	O
,	O
hypersensitivity	B
(	O
3	O
%	O
)	O
,	O
ovarian	B
cyst	I
(	O
3	O
%	O
)	O
,	O
pneumonitis	B
(	O
1	O
%	O
)	O
,	O
and	O
angioedema	B
(	O
1	O
%	O
)	O
.	O
	
The	O
symptoms	O
are	O
consistent	O
with	O
the	O
mechanism	O
of	O
action	O
of	O
botulinum	O
toxin	O
and	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
,	O
and	O
breathing	B
difficulties	I
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
age	O
>	O
60	O
years	O
,	O
hypertension	O
or	O
diabetes	O
)	O
,	O
estimate	O
the	O
glomerular	O
filtration	O
rate	O
(	O
GFR	O
)	O
through	O
laboratory	O
testing	O
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
has	O
occurred	O
in	O
patients	O
with	O
impaired	O
elimination	O
of	O
GBCAs	O
.	O
	
Of	O
the	O
14	O
patients	O
receiving	O
GILENYA	O
,	O
7	O
patients	O
had	O
2:1	B
AV	I
block	I
(	O
5	O
patients	O
within	O
the	O
first	O
6	O
hours	O
postdose	O
and	O
2	O
patients	O
after	O
6	O
hours	O
postdose	O
)	O
.	O
	
Somnolence	B
includes	O
the	O
following	O
events	O
:	O
somnolence	B
,	O
sedation	B
,	O
and	O
hypersomnia	B
.	O
	
In	O
Study	O
2	O
,	O
1	O
of	O
871	O
(	O
0.1	O
%	O
)	O
chemotherapy-naive	O
patients	O
treated	O
with	O
XTANDI	O
and	O
1	O
of	O
844	O
(	O
0.1	O
%	O
)	O
patients	O
treated	O
with	O
placebo	O
experienced	O
a	O
seizure	B
.	O
	
Most	O
patients	O
(	O
>	O
70	O
%	O
)	O
in	O
both	O
trials	O
were	O
enrolled	O
in	O
Eastern	O
Europe	O
and	O
were	O
White	O
.	O
	
5.3	O
Congestive	O
Heart	O
Failure	O
Cases	O
of	O
worsening	B
congestive	I
heart	I
failure	I
)	O
and	O
new	B
onset	I
CHF	I
have	O
been	O
reported	O
with	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
.	O
	
Adverse	O
events	O
that	O
led	O
to	O
treatment	O
discontinuation	O
and	O
occurred	O
in	O
more	O
than	O
1	O
%	O
of	O
patients	O
taking	O
GILENYA	O
0.5	O
mg	O
were	O
serum	B
transaminase	I
elevations	I
(	O
4.7	O
%	O
compared	O
to	O
1	O
%	O
on	O
placebo	O
)	O
and	O
basal	B
cell	I
carcinoma	I
(	O
1	O
%	O
compared	O
to	O
0.5	O
%	O
on	O
placebo	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
3	O
%	O
;	O
2	O
or	O
more	O
patients	O
)	O
observed	O
in	O
alglucosidase	O
alfa-treated	O
patients	O
were	O
hypersensitivity	B
reactions	I
and	O
included	O
anaphylaxis	B
,	O
headache	B
,	O
nausea	B
,	O
urticaria	B
,	O
dizziness	B
,	O
chest	B
discomfort	I
,	O
vomiting	B
,	O
hyperhidrosis	B
,	O
flushing/feeling	O
hot	B
,	O
increased	B
blood	I
pressure	I
,	O
paresthesia	B
,	O
pyrexia	B
,	O
local	B
swelling	I
,	O
diarrhea	B
,	O
pruritus	B
,	O
rash	B
,	O
and	O
throat	B
tightness	I
.	O
	
If	O
hypertension	O
can	O
not	O
be	O
adequately	O
controlled	O
,	O
withhold	O
Kyprolis	O
and	O
evaluate	O
.	O
	
5.6	O
Embryofetal	O
Toxicity	O
Based	O
on	O
its	O
mechanism	O
of	O
action	O
,	O
GILOTRIF	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
NMS	B
is	O
an	O
uncommon	O
but	O
life-threatening	O
syndrome	O
characterized	O
by	O
fever	B
or	O
hyperthermia	B
,	O
muscle	B
rigidity	I
,	O
involuntary	B
movements	I
,	O
altered	B
consciousness	I
,	O
and	O
mental	B
status	I
changes	I
.	O
	
(	O
5.2	O
)	O
*	O
HORIZANT	O
is	O
not	O
interchangeable	O
with	O
other	O
gabapentin	O
products	O
.	O
	
Inform	O
patients	O
of	O
the	O
risk	O
and	O
of	O
symptoms	O
and	O
to	O
contact	O
a	O
physician	O
immediately	O
if	O
symptoms	O
of	O
an	O
infusion	O
reaction	O
occur	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
6.3	O
Postmarketing	O
Experience	O
Similar	O
adverse	O
reactions	O
have	O
been	O
observed	O
in	O
postmarketing	O
use	O
as	O
compared	O
to	O
the	O
clinical	O
trials	O
.	O
	
Although	O
the	O
overall	O
incidence	O
of	O
FD	O
&	O
C	O
Yellow	O
No	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
2	O
%	O
and	O
more	O
common	O
than	O
placebo	O
)	O
are	O
cough	B
,	O
oropharyngeal	B
pain	I
,	O
nasopharyngitis	B
,	O
headache	B
and	O
nausea	B
.	O
	
Evaluate	O
dyspnea	O
to	O
exclude	O
cardiopulmonary	O
conditions	O
including	O
cardiac	O
failure	O
and	O
pulmonary	O
syndromes	O
.	O
	
In	O
some	O
cases	O
of	O
anaphylactic	B
reactions	I
,	O
epinephrine	O
was	O
administered	O
.	O
	
The	O
safety	O
of	O
DYSPORT	O
(	O
r	O
)	O
for	O
the	O
treatment	O
of	O
hyperhidrosis	O
has	O
not	O
been	O
established	O
.	O
	
Creatinine	B
increases	I
were	O
comparable	O
by	O
background	O
NRTIs	O
and	O
were	O
similar	O
in	O
treatment-experienced	O
subjects	O
.	O
	
5.7	O
Risk	O
of	O
Serious	O
Adverse	O
Reactions	O
in	O
Pancreatic	O
and	O
Gastric	O
Anastomoses	O
ENTEREG	O
has	O
not	O
been	O
studied	O
in	O
patients	O
having	O
pancreatic	O
or	O
gastric	O
anastomosis	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
DOTAREM	O
exposure	O
in	O
2813	O
patients	O
,	O
representing	O
2672	O
adults	O
and	O
141	O
pediatric	O
patients	O
.	O
	
Table	O
4	O
displays	O
the	O
mean	O
changes	O
in	O
serum	O
creatinine	O
and	O
eGFR	O
levels	O
at	O
Week	O
144	O
and	O
the	O
percentage	O
of	O
subjects	O
with	O
elevations	B
in	I
serum	I
creatinine	I
(	O
All	O
Grades	O
)	O
.	O
	
(	O
5.13	O
)	O
*	O
Potential	O
for	O
motor	B
impairment	I
:	O
Use	O
caution	O
when	O
operating	O
machinery	O
.	O
	
In	O
the	O
clinical	O
trials	O
,	O
2	O
subjects	O
who	O
received	O
placebo	O
committed	O
suicide	B
compared	O
to	O
none	O
in	O
OTEZLA-treated	O
subjects	O
.	O
	
b	O
Includes	O
diarrhea	B
,	O
enteritis	B
,	O
enterocolitis	B
,	O
colitis	B
,	O
defecation	B
urgency	I
,	O
and	O
steatorrhea	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
1	O
%	O
and	O
more	O
common	O
than	O
with	O
placebo	O
)	O
:	O
ocular	B
irritation	I
,	O
application	B
site	I
irritation	I
,	O
and	O
application	B
site	I
anesthesia	I
.	O
	
Patients	O
with	O
neuromuscular	O
disorders	O
may	O
be	O
at	O
increased	O
risk	O
of	O
clinically	O
significant	O
effects	O
including	O
severe	O
dysphagia	B
and	O
respiratory	B
compromise	I
from	O
typical	O
doses	O
of	O
XEOMIN	O
[	O
See	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.5	O
Keratitis	O
Keratitis	B
,	O
characterized	O
as	O
worsening	B
eye	I
inflammation	I
,	O
lacrimation	B
,	O
light	B
sensitivity	I
,	O
blurred	B
vision	I
,	O
eye	B
pain	I
,	O
and/or	O
red	B
eye	I
occurred	O
in	O
0.8	O
%	O
of	O
patients	O
treated	O
with	O
GILOTRIF	O
among	O
3865	O
patients	O
across	O
clinical	O
trials	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
with	O
chronic	O
infections	O
.	O
	
Some	O
patients	O
had	O
residual	O
visual	B
acuity	I
loss	I
even	O
after	O
resolution	O
of	O
macular	B
edema	I
.	O
	
In	O
2-year	O
,	O
double-blind	O
,	O
placebo-controlled	O
studies	O
in	O
patients	O
with	O
multiple	O
sclerosis	O
,	O
macular	B
edema	I
with	O
or	O
without	O
visual	B
symptoms	I
occurred	O
in	O
1.5	O
%	O
of	O
patients	O
(	O
11/799	O
)	O
treated	O
with	O
fingolimod	O
1.25	O
mg	O
,	O
0.5	O
%	O
of	O
patients	O
(	O
4/783	O
)	O
treated	O
with	O
GILENYA	O
0.5	O
mg	O
and	O
0.4	O
%	O
of	O
patients	O
(	O
3/773	O
)	O
treated	O
with	O
placebo	O
.	O
	
The	O
proportion	O
of	O
subjects	O
with	O
psoriasis	O
who	O
discontinued	O
treatment	O
due	O
to	O
any	O
adverse	O
reaction	O
was	O
6.1	O
%	O
for	O
subjects	O
treated	O
with	O
OTEZLA	O
30	O
mg	O
twice	O
daily	O
and	O
4.1	O
%	O
for	O
placebo-treated	O
subjects	O
.	O
	
Infections	B
,	O
stomatitis	B
,	O
and	O
pneumonitis	B
were	O
the	O
most	O
common	O
reasons	O
for	O
treatment	O
delay	O
or	O
dose	O
reduction	O
.	O
	
No	O
cases	O
of	O
transmission	O
of	O
viral	O
diseases	O
or	O
CJD	O
have	O
ever	O
been	O
reported	O
for	O
albumin	O
.	O
	
It	O
is	O
recommended	O
that	O
patients	O
being	O
considered	O
for	O
FANAPT	O
treatment	O
who	O
are	O
at	O
risk	O
for	O
significant	O
electrolyte	O
disturbances	O
have	O
baseline	O
serum	O
potassium	O
and	O
magnesium	O
measurements	O
with	O
periodic	O
monitoring	O
.	O
	
5.4	O
Risk	O
of	O
Serious	O
Adverse	O
Reactions	O
in	O
Patients	O
with	O
Severe	O
Hepatic	O
Impairment	O
Patients	O
with	O
severe	O
hepatic	O
impairment	O
may	O
be	O
at	O
higher	O
risk	O
of	O
serious	O
adverse	O
reactions	O
(	O
including	O
dose-related	O
serious	O
adverse	O
reactions	O
)	O
because	O
up	O
to	O
10-fold	O
higher	O
plasma	O
levels	O
of	O
drug	O
have	O
been	O
observed	O
in	O
such	O
patients	O
compared	O
with	O
patients	O
with	O
normal	O
hepatic	O
function	O
.	O
	
Mean	O
percentage	O
decreases	B
in	I
BMD	I
from	O
baseline	O
to	O
Week	O
144	O
in	O
the	O
STRIBILD	O
group	O
were	O
comparable	O
to	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
at	O
the	O
lumbar	O
spine	O
(	O
-1.43	O
%	O
versus	O
-3.68	O
%	O
,	O
respectively	O
)	O
and	O
at	O
the	O
hip	O
(	O
-2.83	O
%	O
versus	O
-3.77	O
%	O
,	O
respectively	O
)	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
PRADAXA	O
is	O
contraindicated	O
in	O
patients	O
with	O
mechanical	O
prosthetic	O
valves	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
(	O
2.1	O
,	O
5.7	O
,	O
14.1	O
)	O
*	O
Immunizations	O
:	O
avoid	O
use	O
of	O
live	O
vaccines	O
during	O
treatment	O
.	O
	
If	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
do	O
not	O
modify	O
the	O
dose	O
of	O
TAFINLAR	O
.	O
	
5.3	O
Local	O
Skin	O
Reactions	O
Severe	O
skin	B
reactions	I
in	I
the	I
treated	I
area	I
,	O
can	O
occur	O
after	O
topical	O
application	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
*	O
Oral	B
ulceration	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
hypotension	O
after	O
initiating	O
therapy	O
and	O
increase	O
monitoring	O
in	O
clinical	O
situations	O
where	O
volume	O
contraction	O
is	O
expected	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.5	O
)	O
]	O
.	O
	
Have	O
anaphylactic	O
and	O
hypersensitivity	O
treatment	O
measures	O
available	O
prior	O
to	O
DaTscan	O
administration	O
and	O
,	O
following	O
administration	O
,	O
observe	O
patients	O
for	O
symptoms	O
or	O
signs	O
of	O
a	O
hypersensitivity	O
reaction	O
.	O
	
Rehydrate	O
and	O
treat	O
with	O
anti-emetics	O
and	O
anti-diarrheals	O
as	O
needed	O
.	O
	
Avoid	O
use	O
of	O
PRADAXA	O
and	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
(	O
CrCl	O
15-30	O
mL/min	O
)	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
Symptomatic	O
treatment	O
employed	O
in	O
clinical	O
trials	O
included	O
steroid	O
and	O
mydriatic	O
ophthalmic	O
drops	O
.	O
	
Promptly	O
evaluate	O
signs	O
and	O
symptoms	O
of	O
blood	O
loss	O
.	O
	
In	O
the	O
randomized	O
trial	O
,	O
five	O
patients	O
(	O
1.3	O
%	O
)	O
experienced	O
fatal	B
infectious	B
adverse	I
events	I
(	O
sepsis	B
or	O
septic	B
shock	I
)	O
.	O
	
Refer	O
to	O
the	O
prescribing	O
information	O
for	O
peginterferon	O
alfa	O
and	O
ribavirin	O
for	O
pre-treatment	O
,	O
on-treatment	O
and	O
post-treatment	O
laboratory	O
testing	O
recommendations	O
including	O
hematology	O
,	O
biochemistry	O
(	O
including	O
hepatic	O
function	O
tests	O
)	O
,	O
and	O
pregnancy	O
testing	O
requirements	O
.	O
	
Treatment	O
of	O
SJIA	O
A	O
total	O
of	O
201	O
SJIA	O
patients	O
aged	O
2	O
to	O
less	O
than	O
20	O
years	O
have	O
received	O
ILARIS	O
in	O
clinical	O
trials	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
important	O
adverse	O
reactions	O
are	O
described	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Anaphylaxis	B
and	O
Angioedema	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
*	O
e	O
Rate	O
of	O
documented	O
symptomatic	O
hypoglycemia	B
for	O
active	O
controls	O
18	O
%	O
(	O
glimepiride	O
)	O
and	O
2	O
%	O
(	O
sitagliptin	O
)	O
.	O
	
The	O
adverse	O
drug	O
reactions	O
associated	O
with	O
ILARIS	O
treatment	O
in	O
SJIA	O
patients	O
were	O
infections	B
,	O
abdominal	B
pain	I
,	O
and	O
injection	B
site	I
reactions	I
.	O
	
Liver	O
Enzyme	O
Abnormalities	O
In	O
the	O
pool	O
of	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
a	O
similar	O
proportion	O
of	O
patients	O
experienced	O
at	O
least	O
one	O
event	O
of	O
ALT	B
)	I
increase	I
of	O
3-fold	O
or	O
greater	O
above	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
0.9	O
%	O
and	O
0.9	O
%	O
for	O
all	O
comparators	O
versus	O
TANZEUM	O
)	O
.	O
	
In	O
Study	O
1	O
,	O
VORAXAZE-related	O
adverse	O
reactions	O
were	O
collected	O
on	O
a	O
flow	O
sheet	O
with	O
a	O
daily	O
log	O
of	O
adverse	O
reactions	O
characterized	O
as	O
``	O
glucarpidase	O
toxicity	O
.	O
''	O
	
Monitor	O
patients	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
tuberculosis	O
including	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
,	O
patients	O
who	O
are	O
on	O
treatment	O
for	O
latent	O
tuberculosis	O
,	O
or	O
patients	O
who	O
were	O
previously	O
treated	O
for	O
tuberculosis	O
infection	O
.	O
	
(	O
5.6	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Post-Transplant	B
Lymphoproliferative	I
Disorder	I
(	O
PTLD	B
)	O
:	O
increased	O
risk	O
,	O
predominantly	O
involving	O
the	O
CNS	O
;	O
monitor	O
for	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
and	O
symptoms	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
Clinical	O
Trials	O
of	O
Vizamyl	O
(	O
N	O
=	O
761	O
subjects	O
)	O
Adverse	O
Reaction	O
N	O
(	O
percent	O
of	O
patients	O
)	O
Flushing	B
16	O
(	O
2	O
%	O
)	O
Increased	B
blood	I
pressure	I
13	O
(	O
2	O
%	O
)	O
Headache	B
10	O
(	O
1	O
%	O
)	O
Nausea	B
8	O
(	O
1	O
%	O
)	O
Dizziness	B
8	O
(	O
1	O
%	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Hypersensitivity	B
reactions	I
:	O
Ask	O
patients	O
about	O
prior	O
reactions	O
to	O
Vizamyl	O
.	O
	
(	O
5.4	O
)	O
*	O
Elderly	O
patients	O
:	O
Patients	O
>	O
=	O
65	O
years	O
of	O
age	O
were	O
more	O
likely	O
to	O
experience	O
fatal	B
outcomes	O
not	O
related	O
to	O
disease	O
progression	O
and	O
certain	O
adverse	O
reactions	O
,	O
including	O
neutropenia	B
and	O
febrile	B
neutropenia	I
.	O
	
5.6	O
Drug	O
Interactions	O
See	O
Table	O
2	O
for	O
a	O
listing	O
of	O
drugs	O
that	O
are	O
contraindicated	O
for	O
use	O
with	O
VICTRELIS	O
due	O
to	O
potentially	O
life-threatening	O
adverse	O
events	O
,	O
significant	O
drug	O
interactions	O
or	O
loss	O
of	O
virologic	O
activity	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
These	O
two	O
trials	O
also	O
included	O
a	O
total	O
of	O
403	O
patients	O
treated	O
with	O
a	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
6.1.1	O
Safety	O
Experience	O
with	O
Kyprolis	O
in	O
Combination	O
with	O
Lenalidomide	O
and	O
Dexamethasone	O
in	O
Patients	O
with	O
Multiple	O
Myeloma	O
The	O
safety	O
of	O
Kyprolis	O
in	O
combination	O
with	O
lenalidomide	O
and	O
dexamethasone	O
(	O
KRd	O
)	O
was	O
evaluated	O
in	O
an	O
open-label	O
randomized	O
study	O
in	O
patients	O
with	O
relapsed	O
multiple	O
myeloma	O
.	O
	
*	O
Hepatitis	B
B	I
reactivation	I
-	O
Monitor	O
HBV	O
carriers	O
during	O
and	O
several	O
months	O
after	O
therapy	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Hepatic	O
Decompensation	O
in	O
Patients	O
with	O
Chronic	O
Hepatitis	O
C	O
In	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
,	O
PROMACTA	O
in	O
combination	O
with	O
interferon	O
and	O
ribavirin	O
may	O
increase	O
the	O
risk	O
of	O
hepatic	B
decompensation	I
.	O
	
Hepatobiliary	O
disorders	O
:	O
hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.8	O
)	O
]	O
.	O
	
In	O
patients	O
with	O
a	O
pre-existing	O
low	O
WBC/ANC	O
or	O
drug-induced	O
leukopenia/neutropenia	O
,	O
perform	O
a	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
)	O
in	O
patients	O
treated	O
with	O
TAFINLAR	O
were	O
,	O
in	O
order	O
of	O
decreasing	O
frequency	O
:	O
hyperkeratosis	B
,	O
headache	B
,	O
pyrexia	B
,	O
arthralgia	B
,	O
papilloma	B
,	O
alopecia	B
,	O
and	O
palmar-plantar	B
erythrodysesthesia	I
syndrome	I
(	O
PPES	B
)	O
.	O
	
In	O
several	O
cases	O
,	O
these	O
reactions	O
occurred	O
after	O
the	O
first	O
dose	O
.	O
	
How	O
do	O
I	O
store	O
DUAVEE	O
?	O
	
Consider	O
the	O
risks	O
and	O
benefits	O
of	O
treatment	O
prior	O
to	O
initiating	O
SIMPONI	O
ARIA	O
in	O
patients	O
:	O
*	O
with	O
chronic	O
or	O
recurrent	O
infection	O
;	O
*	O
who	O
have	O
been	O
exposed	O
to	O
tuberculosis	O
;	O
*	O
with	O
a	O
history	O
of	O
an	O
opportunistic	O
infection	O
;	O
*	O
who	O
have	O
resided	O
or	O
traveled	O
in	O
areas	O
of	O
endemic	O
tuberculosis	O
or	O
endemic	O
mycoses	O
,	O
such	O
as	O
histoplasmosis	O
,	O
coccidioidomycosis	O
,	O
or	O
blastomycosis	O
;	O
or	O
*	O
with	O
underlying	O
conditions	O
that	O
may	O
predispose	O
them	O
to	O
infection	O
.	O
	
The	O
following	O
events	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
in	O
the	O
three	O
placebo-controlled	O
3-month	O
clinical	O
trials	O
and/or	O
the	O
open-label	O
,	O
long-term	O
extension	O
study	O
lasting	O
12	O
months	O
.	O
	
SPRINT-2	O
(	O
subjects	O
who	O
were	O
previously	O
untreated	O
)	O
and	O
RESPOND-2	O
(	O
subjects	O
who	O
had	O
failed	O
previous	O
therapy	O
)	O
evaluated	O
the	O
use	O
of	O
VICTRELIS	O
800	O
mg	O
three	O
times	O
daily	O
in	O
combination	O
with	O
PegIntron/REBETOL	O
with	O
a	O
four-week	O
lead-in	O
period	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
PegIntron/REBETOL	O
alone	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
(	O
5.2	O
)	O
*	O
ALT	B
elevations	I
with	O
DALVANCE	O
treatment	O
were	O
reported	O
in	O
clinical	O
trials	O
.	O
	
Consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
tuberculosis	O
is	O
recommended	O
to	O
aid	O
in	O
the	O
decision	O
of	O
whether	O
initiating	O
anti-tuberculosis	O
therapy	O
is	O
appropriate	O
for	O
an	O
individual	O
patient	O
.	O
	
5.2	O
Acute	O
Pancreatitis	O
In	O
clinical	O
trials	O
,	O
acute	B
pancreatitis	I
has	O
been	O
reported	O
in	O
association	O
with	O
TANZEUM	O
.	O
	
(	O
N=134	O
)	O
40	O
mg	O
daily	O
(	O
N=757	O
)	O
80	O
mg	O
daily	O
(	O
N=1279	O
)	O
(	O
N=1277	O
)	O
Liver	B
Function	I
Abnormalities	I
0.7	O
%	O
6.6	O
%	O
4.6	O
%	O
4.2	O
%	O
Nausea	B
0.7	O
%	O
1.1	O
%	O
1.3	O
%	O
0.8	O
%	O
Arthralgia	B
0	O
%	O
1.1	O
%	O
0.7	O
%	O
0.7	O
%	O
Rash	B
0.7	O
%	O
0.5	O
%	O
1.6	O
%	O
1.6	O
%	O
The	O
most	O
common	O
adverse	O
reaction	O
leading	O
to	O
discontinuation	O
from	O
therapy	O
was	O
liver	B
function	I
abnormalities	I
in	O
1.8	O
%	O
of	O
ULORIC	O
40	O
mg	O
,	O
1.2	O
%	O
of	O
ULORIC	O
80	O
mg	O
,	O
and	O
in	O
0.9	O
%	O
of	O
allopurinol-treated	O
subjects	O
.	O
	
The	O
addition	O
of	O
VICTRELIS	O
to	O
peginterferon	O
alfa	O
and	O
ribavirin	O
is	O
associated	O
with	O
an	O
additional	B
decrease	I
in	I
hemoglobin	I
concentrations	I
.	O
	
5.2	O
Increase	O
in	O
Intraocular	O
Pressure	O
Acute	B
increases	I
in	I
intraocular	I
pressure	I
have	O
been	O
seen	O
within	O
60	O
minutes	O
of	O
intravitreal	O
injection	O
,	O
including	O
with	O
EYLEA	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Skin	O
and	O
subcutaneous	O
tissue	O
disorders	O
:	O
Toxic	B
epidermal	I
necrolysis	I
,	O
including	O
fatal	B
outcomes	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.11	O
)	O
]	O
.	O
	
5.4	O
Cataracts	O
In	O
the	O
three	O
controlled	O
clinical	O
trials	O
in	O
adults	O
with	O
chronic	O
ITP	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
15	O
(	O
7	O
%	O
)	O
patients	O
who	O
received	O
50	O
mg	O
of	O
PROMACTA	O
daily	O
and	O
8	O
(	O
7	O
%	O
)	O
placebo-group	O
patients	O
.	O
	
You	O
can	O
ask	O
your	O
pharmacist	O
or	O
healthcare	O
provider	O
for	O
information	O
about	O
DUAVEE	O
that	O
is	O
written	O
for	O
health	O
professionals	O
.	O
	
Do	O
not	O
restart	O
if	O
confirmed	O
.	O
	
Before	O
prescribing	O
STENDRA	O
,	O
it	O
is	O
important	O
to	O
note	O
the	O
following	O
:	O
EXCERPT	O
:	O
*	O
Patients	O
should	O
not	O
use	O
STENDRA	O
if	O
sexual	O
activity	O
is	O
inadvisable	O
due	O
to	O
cardiovascular	O
status	O
or	O
any	O
other	O
reason	O
(	O
5.1	O
)	O
*	O
Use	O
of	O
STENDRA	O
with	O
alpha-blockers	O
,	O
other	O
antihypertensives	O
,	O
or	O
substantial	O
amounts	O
of	O
alcohol	O
(	O
greater	O
than	O
3	O
units	O
)	O
may	O
lead	O
to	O
hypotension	B
(	O
2.3,5.6,5.7	O
)	O
*	O
Patients	O
should	O
seek	O
emergency	O
treatment	O
if	O
an	O
erection	O
lasts	O
greater	O
than	O
4	O
hours	O
(	O
5.3	O
)	O
*	O
Patients	O
should	O
stop	O
STENDRA	O
and	O
seek	O
medical	O
care	O
if	O
a	O
sudden	O
loss	O
of	O
vision	O
occurs	O
in	O
one	O
or	O
both	O
eyes	O
,	O
which	O
could	O
be	O
a	O
sign	O
of	O
Non	O
Arteritic	O
Ischemic	O
Optic	O
Neuropathy	O
(	O
NAION	O
)	O
.	O
	
Cases	O
of	O
MTC	B
in	O
patients	O
treated	O
with	O
liraglutide	O
,	O
another	O
GLP-1	O
receptor	O
agonist	O
,	O
have	O
been	O
reported	O
in	O
the	O
postmarketing	O
period	O
;	O
the	O
data	O
in	O
these	O
reports	O
are	O
insufficient	O
to	O
establish	O
or	O
exclude	O
a	O
causal	O
relationship	O
between	O
MTC	B
and	O
GLP-1	O
receptor	O
agonist	O
use	O
in	O
humans	O
.	O
	
Table	O
4	O
presents	O
the	O
adverse	O
reactions	O
occurring	O
in	O
>	O
=	O
2	O
%	O
of	O
subjects	O
treated	O
with	O
STENDRA	O
.	O
	
If	O
anemia	O
develops	O
during	O
or	O
after	O
treatment	O
with	O
Teflaro	O
,	O
drug-induced	O
hemolytic	O
anemia	O
should	O
be	O
considered	O
.	O
	
The	O
most	O
serious	O
adverse	O
reactions	O
reported	O
with	O
alglucosidase	O
alfa	O
treatment	O
included	O
anaphylaxis	B
and	O
acute	B
cardiorespiratory	I
failure	I
.	O
	
Renal	O
and	O
Urinary	O
Disorders	O
:	O
Interstitial	B
nephritis	I
.	O
	
Hepatotoxicity	B
may	O
reoccur	O
if	O
PROMACTA	O
is	O
reinitiated	O
.	O
	
Risk	O
factors	O
for	O
arterial	O
vascular	O
disease	O
(	O
for	O
example	O
,	O
hypertension	O
,	O
diabetes	O
mellitus	O
,	O
tobacco	O
use	O
,	O
hypercholesterolemia	O
,	O
and	O
obesity	O
)	O
and/or	O
VTE	O
(	O
for	O
example	O
,	O
personal	O
history	O
or	O
family	O
history	O
of	O
VTE	O
,	O
obesity	O
,	O
and	O
systemic	O
lupus	O
erythematosus	O
)	O
should	O
be	O
managed	O
appropriately	O
.	O
	
With	O
the	O
interventions	O
used	O
for	O
anemia	O
management	O
in	O
the	O
clinical	O
trials	O
,	O
the	O
average	O
additional	O
decrease	O
of	O
hemoglobin	O
was	O
approximately	O
1	O
g	O
per	O
dL	O
.	O
	
Hypertoxin-producing	O
strains	O
of	O
C.	O
difficile	O
cause	O
increased	O
morbidity	O
and	O
mortality	O
,	O
as	O
these	O
infections	O
can	O
be	O
refractory	O
to	O
antibacterial	O
therapy	O
and	O
may	O
require	O
colectomy	O
.	O
	
Hemodialysis	O
does	O
not	O
appear	O
to	O
have	O
a	O
substantial	O
impact	O
on	O
apixaban	O
exposure	O
[	O
seeClinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
corticosteroids	O
or	O
methotrexate	O
)	O
may	O
be	O
at	O
a	O
greater	O
risk	O
of	O
infection	B
.	O
	
In	O
a	O
trial	O
of	O
TANZEUM	O
in	O
patients	O
with	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
the	O
frequency	O
of	O
such	O
gastrointestinal	B
reactions	I
increased	O
as	O
renal	B
function	I
declined	I
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
If	O
the	O
potential	O
benefit	O
for	O
reinitiating	O
treatment	O
with	O
PROMACTA	O
is	O
considered	O
to	O
outweigh	O
the	O
risk	O
for	O
hepatotoxicity	O
,	O
then	O
consider	O
cautiously	O
reintroducing	O
PROMACTA	O
and	O
measure	O
serum	O
liver	O
tests	O
weekly	O
during	O
the	O
dose	O
adjustment	O
phase	O
.	O
	
Sixty-two	O
percent	O
of	O
these	O
patients	O
had	O
at	O
least	O
one	O
sample	O
that	O
was	O
positive	O
for	O
the	O
presence	O
of	O
neutralizing	O
antibodies	O
.	O
	
BRAF	O
V600E	O
or	O
V600K	O
Unresectable	O
or	O
Metastatic	O
Melanoma	O
:	O
The	O
safety	O
of	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
was	O
evaluated	O
in	O
Trial	O
2	O
and	O
other	O
trials	O
consisting	O
of	O
a	O
total	O
of	O
202	O
patients	O
with	O
BRAF	O
V600	O
mutation-positive	O
unresectable	O
or	O
metastatic	O
melanoma	O
who	O
received	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
in	O
combination	O
with	O
trametinib	O
2	O
mg	O
orally	O
once	O
daily	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
requiring	O
intervention	O
in	O
clinical	O
trials	O
were	O
hypersensitivity	B
reactions	I
,	O
occurring	O
in	O
20	O
of	O
39	O
(	O
51	O
%	O
)	O
patients	O
treated	O
with	O
alglucosidase	O
alfa	O
,	O
and	O
included	O
rash	B
,	O
pyrexia	B
,	O
urticaria	B
,	O
flushing	B
,	O
decreased	B
oxygen	I
saturation	I
,	O
cough	B
,	O
tachypnea	B
,	O
tachycardia	B
,	O
hypertension/increased	O
blood	B
pressure	I
,	O
pallor	B
,	O
rigors	B
,	O
vomiting	B
,	O
cyanosis	B
,	O
agitation	B
,	O
and	O
tremor	B
.	O
	
Diagnostic	O
studies	O
including	O
a	O
direct	O
Coombs	O
'	O
test	O
,	O
should	O
be	O
performed	O
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
>	O
=	O
2	O
%	O
of	O
Patients	O
Treated	O
with	O
STENDRA	O
in	O
a	O
Placebo-Controlled	O
Clinical	O
Trial	O
Lasting	O
2	O
Months	O
to	O
Determine	O
the	O
Time	O
to	O
Onset	O
of	O
Effect	O
(	O
Study	O
3	O
)	O
Adverse	O
Reaction	O
Placebon=143	O
STENDRA	O
100	O
mgn=146	O
STENDRA	O
200	O
mgn=146	O
Headache	B
0.7	O
%	O
1.4	O
%	O
8.9	O
%	O
Nasal	B
congestion	I
0.0	O
%	O
0.7	O
%	O
4.1	O
%	O
Gastroenteritis	B
viral	I
0.0	O
%	O
0.0	O
%	O
2.1	O
%	O
Across	O
all	O
trials	O
with	O
any	O
STENDRA	O
dose	O
,	O
1	O
subject	O
reported	O
a	O
change	B
in	I
color	I
vision	I
.	O
	
TANZEUM	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
or	O
in	O
patients	O
with	O
MEN	O
2	O
.	O
	
Because	O
these	O
reactions	O
may	O
worsen	O
renal	O
function	O
,	O
use	O
caution	O
when	O
initiating	O
or	O
escalating	O
doses	O
of	O
TANZEUM	O
in	O
patients	O
with	O
renal	O
impairment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
A	O
specific	O
antidote	O
for	O
ELIQUIS	O
is	O
not	O
available	O
.	O
	
In	O
clinical	O
trials	O
with	O
VICTRELIS	O
,	O
the	O
proportion	O
of	O
subjects	O
who	O
experienced	O
hemoglobin	B
values	I
less	I
than	I
10	I
g	I
per	I
dL	I
was	O
higher	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron	O
(	O
r	O
)	O
/REBETOL	O
(	O
r	O
)	O
than	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
pancreatitis	B
adjudicated	O
as	O
likely	O
related	O
to	O
therapy	O
occurred	O
more	O
frequently	O
in	O
patients	O
receiving	O
TANZEUM	O
(	O
6	O
of	O
2,365	O
[	O
0.3	O
%	O
]	O
)	O
than	O
in	O
patients	O
receiving	O
placebo	O
(	O
0	O
of	O
468	O
[	O
0	O
%	O
]	O
)	O
or	O
active	O
comparators	O
(	O
2	O
of	O
2,065	O
[	O
0.1	O
%	O
]	O
)	O
.	O
	
Tuberculosis	O
should	O
be	O
strongly	O
considered	O
in	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
during	O
CIMZIA	O
treatment	O
,	O
especially	O
in	O
patients	O
who	O
have	O
previously	O
or	O
recently	O
traveled	O
to	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
,	O
or	O
who	O
have	O
had	O
close	O
contact	O
with	O
a	O
person	O
with	O
active	O
tuberculosis	O
.	O
	
(	O
5.3	O
)	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
with	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
DALVANCE	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
postapproval	O
use	O
of	O
drug	O
TUDORZA	O
PRESSAIR	O
.	O
	
STENDRA	O
should	O
be	O
used	O
with	O
caution	O
,	O
and	O
only	O
when	O
the	O
anticipated	O
benefits	O
outweigh	O
the	O
risks	O
,	O
in	O
patients	O
with	O
a	O
history	O
of	O
NAION	O
.	O
	
Consider	O
other	O
antidiabetic	O
therapies	O
in	O
patients	O
with	O
a	O
history	O
of	O
pancreatitis	O
.	O
	
If	O
you	O
would	O
like	O
more	O
information	O
,	O
talk	O
with	O
your	O
healthcare	O
provider	O
.	O
	
6.3	O
Immunogenicity	O
Patients	O
with	O
classical	O
HL	O
and	O
sALCL	O
in	O
Studies	O
1	O
and	O
2	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
were	O
tested	O
for	O
antibodies	O
to	O
brentuximab	O
vedotin	O
every	O
3	O
weeks	O
using	O
a	O
sensitive	O
electrochemiluminescent	O
immunoassay	O
.	O
	
Sustained	B
increases	I
in	I
intraocular	I
pressure	I
have	O
also	O
been	O
reported	O
after	O
repeated	O
intravitreal	O
dosing	O
with	O
vascular	O
endothelial	O
growth	O
factor	O
(	O
VEGF	O
)	O
inhibitors	O
.	O
	
The	O
population	O
studied	O
had	O
a	O
mean	O
age	O
of	O
49	O
years	O
(	O
3	O
%	O
of	O
subjects	O
were	O
older	O
than	O
65	O
years	O
of	O
age	O
)	O
,	O
39	O
%	O
were	O
female	O
,	O
82	O
%	O
were	O
white	O
and	O
15	O
%	O
were	O
black	O
.	O
	
Patients	O
greater	O
than	O
65	O
years	O
of	O
age	O
,	O
patients	O
with	O
co-morbid	O
conditions	O
and/or	O
patients	O
taking	O
concomitant	O
immunosuppressants	O
such	O
as	O
corticosteroids	O
or	O
methotrexate	O
may	O
be	O
at	O
greater	O
risk	O
of	O
infection	O
.	O
	
A	O
causal	O
relationship	O
to	O
STENDRA	O
is	O
uncertain	O
.	O
	
Ask	O
your	O
healthcare	O
provider	O
for	O
ways	O
to	O
lower	O
your	O
chances	O
of	O
getting	O
heart	O
disease	O
.	O
	
These	O
hypersensitivity	B
reactions	I
included	O
:	O
anaphylaxis	B
,	O
angioedema	B
,	O
hypotension	B
,	O
tachycardia	B
,	O
swollen	B
tongue	I
,	O
dyspnea	B
,	O
wheezing	B
and	O
rash	B
.	O
	
*	O
Cardiac	B
arrest	I
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
(	O
NSF	B
)	O
*	O
Hypersensitivity	B
reactions	I
(	O
anaphylactic	B
shock	I
,	O
circulatory	B
collapse	I
,	O
respiratory	B
arrest	I
,	O
pulmonary	B
edema	I
,	O
bronchospasm	B
,	O
cyanosis	B
,	O
oropharyngeal	B
swelling	I
,	O
laryngeal	B
edema	I
,	O
blood	B
pressure	I
increased	I
,	O
chest	B
pain	I
,	O
angioedema	B
,	O
conjunctivitis	B
,	O
hyperhidrosis	B
,	O
cough	B
,	O
sneezing	B
,	O
burning	B
sensation	I
,	O
and	O
pallor	B
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
MI	O
and	O
stroke	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
,	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
medical	O
practice	O
.	O
	
In	O
Study	O
1	O
and	O
Study	O
2	O
,	O
NULOJIX	O
was	O
studied	O
at	O
the	O
recommended	O
dose	O
and	O
frequency	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
]	O
in	O
a	O
total	O
of	O
401	O
patients	O
compared	O
to	O
a	O
cyclosporine	O
control	O
regimen	O
in	O
a	O
total	O
of	O
405	O
patients	O
.	O
	
If	O
such	O
an	O
acute	O
reaction	O
occurs	O
,	O
combination	O
therapy	O
should	O
be	O
discontinued	O
and	O
appropriate	O
medical	O
therapy	O
immediately	O
instituted	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
In	O
such	O
patients	O
,	O
consider	O
discontinuation	O
of	O
SAPHRIS	O
at	O
the	O
first	O
sign	O
of	O
a	O
clinically	O
significant	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
Infections	O
:	O
PML	B
[	O
see	O
Boxed	O
Warning	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)	O
]	O
,	O
serious	O
infections	B
and	O
opportunistic	B
infections	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
Monitor	O
platelet	O
counts	O
regularly	O
.	O
	
The	O
immunogenicity	O
data	O
reflect	O
the	O
percentage	O
of	O
patients	O
whose	O
test	O
results	O
were	O
considered	O
positive	O
for	O
antibodies	O
to	O
EYLEA	O
in	O
immunoassays	O
.	O
	
*	O
Invasive	B
fungal	I
infections	I
-	O
For	O
patients	O
who	O
develop	O
a	O
systemic	O
illness	O
on	O
SIMPONI	O
ARIA	O
,	O
consider	O
empiric	O
antifungal	O
therapy	O
for	O
those	O
who	O
reside	O
in	O
or	O
travel	O
to	O
regions	O
where	O
mycoses	O
are	O
endemic	O
(	O
5.1	O
)	O
.	O
	
5.6	O
Increased	O
Low-Density	O
Lipoprotein	O
Cholesterol	O
(	O
LDL-C	O
)	O
Increases	B
in	I
LDL-C	I
can	O
occur	O
with	O
JARDIANCE	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Consider	O
tuberculosis	O
in	O
the	O
differential	O
diagnosis	O
in	O
patients	O
who	O
develop	O
a	O
new	O
infection	O
during	O
SIMPONI	O
ARIA	O
treatment	O
,	O
especially	O
in	O
patients	O
who	O
have	O
previously	O
or	O
recently	O
traveled	O
to	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
,	O
or	O
who	O
have	O
had	O
close	O
contact	O
with	O
a	O
person	O
with	O
active	O
tuberculosis	O
.	O
	
For	O
these	O
reasons	O
,	O
the	O
incidence	O
of	O
antibodies	O
to	O
albiglutide	O
can	O
not	O
be	O
directly	O
compared	O
with	O
the	O
incidence	O
of	O
antibodies	O
of	O
other	O
products	O
.	O
	
The	O
protocol	O
specified	O
that	O
patients	O
continue	O
receiving	O
intravenous	O
hydration	O
,	O
urinary	O
alkalinization	O
and	O
leucovorin	O
,	O
and	O
that	O
leucovorin	O
administration	O
be	O
adjusted	O
to	O
ensure	O
that	O
it	O
was	O
not	O
administered	O
within	O
two	O
hours	O
before	O
or	O
after	O
VORAXAZE	O
.	O
	
Monitor	O
closely	O
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
at	O
least	O
1	O
%	O
of	O
subjects	O
)	O
in	O
Vizamyl-treated	O
subjects	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
(	O
Boxed	O
Warning	O
,	O
4	O
,	O
5.1	O
,	O
5.6	O
)	O
*	O
Other	O
malignancies	B
:	O
increased	O
risk	O
with	O
all	O
immunosuppressants	O
;	O
appears	O
related	O
to	O
intensity	O
and	O
duration	O
of	O
use	O
.	O
	
*	O
d	O
Event	O
requiring	O
another	O
person	O
to	O
administer	O
a	O
resuscitative	O
action	O
.	O
	
The	O
safety	O
of	O
ILARIS	O
compared	O
to	O
placebo	O
was	O
investigated	O
in	O
two	O
phase	O
3	O
studies	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Doses	O
ranged	O
from	O
6	O
to	O
189	O
Units/kg	O
,	O
with	O
a	O
median	O
dose	O
of	O
50	O
Units/kg	O
.	O
	
5.2	O
Thyroid	O
Accumulation	O
The	O
DaTscan	O
injection	O
may	O
contain	O
up	O
to	O
6	O
%	O
of	O
free	O
iodide	O
(	O
iodine	O
123	O
)	O
.	O
	
(	O
5.2	O
)	O
*	O
?	O
	
Uveitis	B
(	O
including	O
iritis	B
)	O
occurred	O
in	O
1	O
%	O
(	O
6/586	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
and	O
uveitis	B
occurred	O
in	O
1	O
%	O
(	O
2/202	O
)	O
of	O
patients	O
treated	O
with	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
Treatment	O
and	O
Reduction	O
in	O
the	O
Risk	O
of	O
Recurrence	O
of	O
Deep	O
Venous	O
Thrombosis	O
and	O
Pulmonary	O
Embolism	O
Avoid	O
use	O
of	O
PRADAXA	O
and	O
concomitant	O
P-gp	O
inhibitors	O
in	O
patients	O
with	O
CrCl	O
<	O
50	O
mL/min	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
and	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.6	O
)	O
]	O
.	O
	
The	O
long-term	O
consequences	O
of	O
the	O
degree	O
of	O
suppression	B
of	I
bone	I
remodeling	I
observed	O
with	O
Prolia	O
may	O
contribute	O
to	O
adverse	O
outcomes	O
such	O
as	O
osteonecrosis	B
of	I
the	I
jaw	I
,	O
atypical	B
fractures	I
,	O
and	O
delayed	B
fracture	I
healing	I
.	O
	
If	O
experiencing	O
Grade	O
>	O
=	O
3	O
diarrhea	O
,	O
dosage	O
should	O
be	O
modified	O
.	O
	
Perform	O
ophthalmological	O
evaluation	O
at	O
any	O
time	O
a	O
patient	O
reports	O
visual	O
disturbances	O
and	O
compare	O
with	O
baseline	O
,	O
if	O
available	O
.	O
	
(	O
5.8	O
)	O
5.1	O
Post-Transplant	O
Lymphoproliferative	O
Disorder	O
NULOJIX-treated	O
patients	O
have	O
an	O
increased	O
risk	O
for	O
developing	O
post-transplant	B
lymphoproliferative	I
disorder	I
(	O
PTLD	B
)	O
,	O
predominantly	O
involving	O
the	O
CNS	O
,	O
compared	O
to	O
patients	O
on	O
a	O
cyclosporine-based	O
regimen	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
Table	O
2	O
]	O
.	O
	
The	O
use	O
of	O
PRADAXA	O
for	O
the	O
prophylaxis	O
of	O
thromboembolic	O
events	O
in	O
patients	O
with	O
atrial	O
fibrillation	O
in	O
the	O
setting	O
of	O
other	O
forms	O
of	O
valvular	O
heart	O
disease	O
,	O
including	O
the	O
presence	O
of	O
a	O
bioprosthetic	O
heart	O
valve	O
,	O
has	O
not	O
been	O
studied	O
and	O
is	O
not	O
recommended	O
.	O
	
*	O
Renal	B
failure	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
In	O
CAPS	O
Study	O
1	O
,	O
no	O
pattern	O
was	O
observed	O
for	O
any	O
type	O
or	O
frequency	O
of	O
adverse	O
events	O
throughout	O
the	O
three	O
study	O
periods	O
.	O
	
Administration	O
of	O
Picato	O
(	O
r	O
)	O
gel	O
is	O
not	O
recommended	O
until	O
the	O
skin	O
is	O
healed	O
from	O
any	O
previous	O
drug	O
or	O
surgical	O
treatment	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
A	O
theoretical	O
risk	O
for	O
transmission	O
of	O
Creutzfeldt-Jakob	B
disease	I
(	O
CJD	B
)	O
is	O
also	O
considered	O
extremely	O
remote	O
.	O
	
The	O
most	O
common	O
medical	O
interventions	O
required	O
during	O
AFINITOR	O
treatment	O
were	O
for	O
infections	B
,	O
anemia	B
,	O
and	O
stomatitis	B
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
for	O
subjects	O
taking	O
OTEZLA	O
were	O
nausea	B
(	O
1.6	O
%	O
)	O
,	O
diarrhea	B
(	O
1.0	O
%	O
)	O
,	O
and	O
headache	B
(	O
0.8	O
%	O
)	O
.	O
	
A	O
dose-dependent	O
increase	O
in	O
the	O
risk	O
of	O
macular	B
edema	I
occurred	O
in	O
the	O
GILENYA	O
clinical	O
development	O
program	O
.	O
	
In	O
Studies	O
102	O
and	O
103	O
,	O
bone	B
fractures	I
occurred	O
in	O
27	O
subjects	O
(	O
3.9	O
%	O
)	O
in	O
the	O
STRIBILD	O
group	O
,	O
8	O
subjects	O
(	O
2.3	O
%	O
)	O
in	O
the	O
ATRIPLA	O
group	O
,	O
and	O
19	O
subjects	O
(	O
5.4	O
%	O
)	O
in	O
the	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
group	O
.	O
	
Therefore	O
,	O
the	O
use	O
of	O
ENTEREG	O
is	O
not	O
recommended	O
in	O
this	O
population	O
.	O
	
Caution	O
is	O
warranted	O
when	O
prescribing	O
FANAPT	O
with	O
drugs	O
that	O
inhibit	O
FANAPT	O
metabolism	O
[	O
see	O
Drug	O
Interaction	O
s	O
(	O
7.1	O
)	O
]	O
,	O
and	O
in	O
patients	O
with	O
reduced	O
activity	O
of	O
CYP2D6	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.12	O
)	O
*	O
Priapism	B
:	O
Cases	O
have	O
been	O
reported	O
in	O
association	O
with	O
FANAPT	O
treatment	O
.	O
	
Overall	O
,	O
55	O
%	O
of	O
the	O
patients	O
were	O
men	O
.	O
	
Therefore	O
,	O
ENTEREG	O
is	O
not	O
recommended	O
for	O
use	O
in	O
these	O
patients	O
.	O
	
In	O
treatment-naive	O
subjects	O
,	O
a	O
mean	O
change	O
from	O
baseline	O
of	O
0.15	O
mg	O
per	O
dL	O
(	O
range	O
:	O
-0.32	O
mg	O
per	O
dL	O
to	O
0.65	O
mg	O
per	O
dL	O
)	O
was	O
observed	O
after	O
96	O
weeks	O
of	O
treatment	O
.	O
	
DYSPORT	O
(	O
r	O
)	O
is	O
approved	O
only	O
for	O
intramuscular	O
injection	O
.	O
	
(	O
5.1	O
)	O
*	O
Serious	O
Infections	B
:	O
Serious	O
and	O
sometimes	O
fatal	B
infections	B
have	O
been	O
reported	O
in	O
patients	O
receiving	O
immunosuppressive	O
agents	O
,	O
including	O
BENLYSTA	O
.	O
	
In	O
patients	O
who	O
develop	O
severe	O
hepatic	O
impairment	O
while	O
taking	O
GILOTRIF	O
,	O
treatment	O
should	O
be	O
discontinued	O
.	O
	
5.5	O
Pre-existing	O
Neuromuscular	O
Disorders	O
and	O
other	O
Special	O
Populations	O
Individuals	O
with	O
peripheral	O
motor	O
neuropathic	O
diseases	O
,	O
amyotrophic	O
lateral	O
sclerosis	O
,	O
or	O
neuromuscular	O
junctional	O
disorders	O
(	O
e.g.	O
,	O
myasthenia	O
gravis	O
or	O
Lambert-Eaton	O
syndrome	O
)	O
should	O
be	O
monitored	O
particularly	O
closely	O
when	O
given	O
botulinum	O
toxin	O
.	O
	
c	O
Includes	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
pulmonary	B
fibrosis	I
and	O
restrictive	B
pulmonary	I
disease	I
.	O
	
Instances	O
of	O
suicidal	B
ideation	I
have	O
been	O
observed	O
in	O
0.2	O
%	O
(	O
3/1441	O
)	O
of	O
subjects	O
while	O
receiving	O
OTEZLA	O
,	O
compared	O
to	O
none	O
in	O
placebo	O
treated	O
subjects	O
(	O
0/495	O
)	O
.	O
	
5	O
(	O
tartrazine	O
)	O
which	O
may	O
cause	O
allergic-type	B
reactions	I
(	O
including	O
bronchial	B
asthma	I
)	O
in	O
certain	O
susceptible	O
persons	O
.	O
	
Posterior	O
reversible	O
encephalopathy	O
syndrome	O
(	O
PRES	O
)	O
,	O
formerly	O
termed	O
Reversible	O
Posterior	O
Leukoencephalopathy	O
Syndrome	O
(	O
RPLS	O
)	O
,	O
is	O
a	O
neurological	O
disorder	O
which	O
can	O
present	O
with	O
seizure	O
,	O
headache	O
,	O
lethargy	O
,	O
confusion	O
,	O
blindness	O
,	O
altered	O
consciousness	O
,	O
and	O
other	O
visual	O
and	O
neurological	O
disturbances	O
,	O
along	O
with	O
hypertension	O
,	O
and	O
the	O
diagnosis	O
is	O
confirmed	O
by	O
neuro-radiological	O
imaging	O
(	O
MRI	O
)	O
.	O
	
No	O
association	O
between	O
anti-icatibant	O
antibodies	O
and	O
efficacy	O
was	O
observed	O
.	O
	
Table	O
5	O
lists	O
treatment-emergent	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
patients	O
with	O
PHN	O
treated	O
with	O
HORIZANT	O
1,200	O
mg/day	O
and	O
numerically	O
greater	O
than	O
placebo	O
.	O
	
Stop	O
Kyprolis	O
for	O
Grade	O
3	O
or	O
4	O
dyspnea	O
until	O
resolved	O
or	O
returned	O
to	O
baseline	O
.	O
	
ARCAPTA	O
NEOHALER	O
is	O
not	O
indicated	O
for	O
the	O
treatment	O
of	O
asthma	O
[	O
See	O
B	O
oxed	O
Warning	O
and	O
W	O
arning	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
observed	O
in	O
the	O
other	O
trials	O
were	O
similar	O
to	O
those	O
observed	O
in	O
the	O
confirmatory	O
trials	O
.	O
	
One	O
patient	O
with	O
a	O
history	O
of	O
Wolff-Parkinson-White	O
syndrome	O
experienced	O
a	O
serious	O
adverse	O
reaction	O
of	O
supraventricular	B
tachycardia	I
.	O
	
5.10	O
Thrombocytopenia	O
Kyprolis	O
causes	O
thrombocytopenia	B
with	O
platelet	B
nadirs	I
observed	O
between	O
Day	O
8	O
and	O
Day	O
15	O
of	O
each	O
28-day	O
cycle	O
with	O
recovery	O
to	O
baseline	O
platelet	O
count	O
usually	O
by	O
the	O
start	O
of	O
the	O
next	O
cycle	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
(	O
5.1	O
)	O
*	O
Somnolence/sedation	O
and	O
dizziness	B
:	O
May	O
impair	B
the	I
patient	I
's	I
ability	I
to	I
operate	I
complex	I
machinery	I
.	O
	
Before	O
initiating	O
therapy	O
with	O
ZERBAXA	O
,	O
make	O
careful	O
inquiry	O
about	O
previous	O
hypersensitivity	O
reactions	O
to	O
other	O
cephalosporins	O
,	O
penicillins	O
,	O
or	O
other	O
beta-lactams	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
,	O
regardless	O
of	O
causality	O
,	O
occurring	O
in	O
at	O
least	O
3	O
%	O
of	O
patients	O
with	O
SLE	O
who	O
received	O
BENLYSTA	O
10	O
mg/kg	O
and	O
at	O
an	O
incidence	O
at	O
least	O
1	O
%	O
greater	O
than	O
that	O
observed	O
with	O
placebo	O
in	O
the	O
3	O
controlled	O
studies	O
.	O
	
Contact	O
lens	O
use	O
is	O
also	O
a	O
risk	O
factor	O
for	O
keratitis	O
and	O
ulceration	O
.	O
	
Patients	O
experiencing	O
seizure	B
were	O
permanently	O
discontinued	O
from	O
therapy	O
and	O
all	O
seizure	O
events	O
resolved	O
.	O
	
System	O
Organ	O
Class/Preferred	O
Term	O
Placebo	O
N=203	O
%	O
SAPHRIS	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily*	O
N=379	O
%	O
Gastrointestinal	O
disorders	O
Dry	B
mouth	I
1	O
3	O
Dyspepsia	B
2	O
4	O
Oral	B
hypoesthesia	I
<	O
1	O
4	O
Toothache	B
2	O
3	O
General	O
disorders	O
Fatigue	B
2	O
4	O
Investigations	O
Increased	B
weight	I
<	O
1	O
5	O
Metabolism	O
disorders	O
Increased	B
appetite	I
1	O
4	O
Musculoskeletal	O
and	O
connective	O
tissue	O
disorders	O
Arthralgia	B
1	O
3	O
Pain	B
in	I
extremity	I
<	O
1	O
2	O
Nervous	O
system	O
disorders	O
Akathisia	B
2	O
4	O
Dizziness	B
3	O
11	O
Dysgeusia	B
<	O
1	O
3	O
Headache	B
11	O
12	O
Other	O
extrapyramidal	B
symptoms	I
(	O
excluding	O
akathisia	B
)	O
2	O
7	O
Somnolence	B
?	O
	
Higher	O
than	O
recommended	O
dosing	O
or	O
repeat	O
dosing	O
appear	O
to	O
increase	O
the	O
risk	O
.	O
	
All	O
second	B
degree	I
AV	I
blocks	I
on	I
placebo	I
were	I
Mobitz	I
Type	I
I	I
and	O
occurred	O
after	O
the	O
first	O
12	O
hours	O
postdose	O
.	O
	
In	O
placebo-controlled	O
trials	O
,	O
the	O
most	O
frequent	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=10	O
%	O
and	O
>	O
placebo	O
)	O
for	O
GILENYA	O
0.5	O
mg	O
were	O
headache	B
,	O
liver	B
transaminase	I
elevation	I
,	O
diarrhea	B
,	O
cough	B
,	O
influenza	B
,	O
sinusitis	B
,	O
back	B
pain	I
,	O
abdominal	B
pain	I
,	O
and	O
pain	B
in	I
extremity	I
.	O
	
Monitor	O
for	O
evidence	O
of	O
TLS	O
during	O
treatment	O
and	O
manage	O
promptly	O
including	O
interruption	O
of	O
Kyprolis	O
until	O
TLS	O
is	O
resolved	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
During	O
the	O
initial	O
phase	O
of	O
combination	O
antiretroviral	O
treatment	O
,	O
patients	O
whose	O
immune	O
systems	O
respond	O
may	O
develop	O
an	O
inflammatory	B
response	I
to	O
indolent	O
or	O
residual	B
opportunistic	I
infections	I
(	O
such	O
as	O
Mycobacterium	B
avium	I
infection	I
,	O
cytomegalovirus	B
,	O
Pneumocystis	B
jirovecii	I
pneumonia	I
[	O
PCP	B
]	O
,	O
or	O
tuberculosis	B
)	O
,	O
which	O
may	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
In	O
several	O
exploratory	O
trials	O
of	O
other	O
TNF-blockers	O
in	O
the	O
treatment	O
of	O
CHF	O
,	O
there	O
were	O
greater	O
proportions	O
of	O
TNF-blocker	O
treated	O
patients	O
who	O
had	O
CHF	B
exacerbations	I
requiring	O
hospitalization	O
or	O
increased	B
mortality	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
5	O
%	O
or	O
greater	O
in	O
either	O
indication	O
)	O
occurring	O
in	O
patients	O
receiving	O
ZERBAXA	O
were	O
nausea	B
,	O
diarrhea	B
,	O
headache	B
,	O
and	O
pyrexia	B
.	O
	
breathing	B
difficulties	I
can	O
be	O
life	O
threatening	O
and	O
there	O
have	O
been	O
reports	O
of	O
death	B
.	O
	
5.2	O
Infections	O
Risk	O
of	O
Infections	O
GILENYA	O
causes	O
a	O
dose-dependent	O
reduction	B
in	I
peripheral	I
lymphocyte	I
count	I
to	O
20	O
%	O
-30	O
%	O
of	O
baseline	O
values	O
because	O
of	O
reversible	O
sequestration	B
of	I
lymphocytes	I
in	I
lymphoid	I
tissues	I
.	O
	
No	O
unconfounded	O
cases	O
of	O
NSF	B
have	O
been	O
reported	O
with	O
DOTAREM	O
.	O
	
For	O
moderate	O
to	O
severe	O
proteinuria	O
,	O
reduce	O
the	O
dose	O
or	O
temporarily	O
interrupt	O
treatment	O
with	O
INLYTA	O
.	O
	
The	O
incidence	O
of	O
Grade	O
3	O
or	O
greater	O
non-hematologic	O
,	O
non-infectious	O
adverse	O
reactions	O
occurring	O
with	O
ERWINAZE	O
in	O
Study	O
1	O
,	O
Study	O
2	O
and	O
EMTP	O
trial	O
is	O
provided	O
in	O
Table	O
2	O
.	O
	
The	O
patients	O
had	O
no	O
other	O
identified	O
systemic	O
medical	O
conditions	O
resulting	O
in	O
compromised	B
immune	I
system	I
function	O
and	O
had	O
not	O
previously	O
been	O
treated	O
with	O
natalizumab	O
,	O
which	O
has	O
a	O
known	O
association	O
with	O
PML	B
.	O
	
It	O
is	O
unknown	O
whether	O
this	O
finding	O
applies	O
to	O
younger	O
postmenopausal	O
women	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
In	O
the	O
absence	O
of	O
comparable	O
data	O
,	O
these	O
risks	O
should	O
be	O
assumed	O
to	O
be	O
similar	O
for	O
other	O
doses	O
of	O
conjugated	O
estrogens	O
and	O
other	O
dosage	O
forms	O
of	O
estrogens	O
.	O
	
(	O
2.1	O
)	O
Monitor	O
for	O
TLS	O
,	O
including	O
uric	O
acid	O
levels	O
and	O
treat	O
promptly	O
.	O
	
Nearly	O
all	O
of	O
the	O
reported	O
TNF-blocker	O
associated	O
cases	O
have	O
occurred	O
in	O
patients	O
with	O
Crohn	O
's	O
disease	O
or	O
ulcerative	O
colitis	O
.	O
	
(	O
5.1	O
)	O
*	O
venous	B
thrombotic	I
events	I
have	O
been	O
observed	O
and	O
can	O
be	O
fatal	B
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
ERWINAZE	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
a	O
6-dose	O
regimen	O
of	O
Coartem	O
Tablets	O
in	O
1,979	O
patients	O
including	O
647	O
adults	O
(	O
older	O
than	O
16	O
years	O
)	O
and	O
1,332	O
children	O
(	O
16	O
years	O
and	O
younger	O
)	O
.	O
	
Use	O
with	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
may	O
cause	O
additive	O
QT	B
prolongation	I
.	O
	
In	O
controlled	O
clinical	O
studies	O
,	O
98	O
%	O
of	O
patients	O
completed	O
>	O
=	O
90	O
%	O
of	O
the	O
intended	O
patch	O
application	O
duration	O
.	O
	
Use	O
with	O
drugs	O
that	O
prolong	O
the	O
QT	O
interval	O
may	O
cause	O
additive	B
QT	I
prolongation	I
.	O
	
(	O
5.2	O
,	O
5.3	O
)	O
*	O
Transient	O
increases	B
in	I
blood	I
pressure	I
may	O
occur	O
in	O
patients	O
during	O
and	O
shortly	O
after	O
the	O
Qutenza	O
treatment	O
.	O
	
(	O
5.6	O
)	O
5.1	O
Gastrointestinal	O
Toxicity	O
Diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
and	O
abdominal	B
pain	I
occur	O
with	O
BOSULIF	O
treatment	O
.	O
	
Approximately	O
80	O
%	O
of	O
these	O
patients	O
had	O
>	O
10	O
weeks	O
exposure	O
to	O
Toviaz	O
in	O
these	O
trials	O
.	O
	
5.4	O
Application	O
Associated	O
Pain	O
Even	O
following	O
use	O
of	O
a	O
local	O
anesthetic	O
prior	O
to	O
administration	O
of	O
Qutenza	O
,	O
patients	O
may	O
experience	O
substantial	O
procedural	B
pain	I
.	O
	
Decreases	O
in	O
Bone	O
Mineral	O
Density	O
Bone	O
mineral	O
density	O
(	O
BMD	O
)	O
was	O
measured	O
by	O
dual-energy	O
X-ray	O
absorptiometry	O
in	O
a	O
clinical	O
trial	O
of	O
714	O
older	O
adults	O
(	O
mean	O
age	O
64	O
years	O
)	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
that	O
led	O
to	O
permanent	O
discontinuation	O
in	O
XALKORI-treated	O
patients	O
were	O
elevated	B
transaminases	I
(	O
1.2	O
%	O
)	O
,	O
hepatotoxicity	B
(	O
1.2	O
%	O
)	O
,	O
and	O
ILD	B
(	O
1.2	O
%	O
)	O
.	O
	
Fatal	B
adverse	O
reactions	O
in	O
XALKORI-treated	O
patients	O
in	O
Study	O
2	O
occurred	O
in	O
9	O
(	O
5	O
%	O
)	O
patients	O
,	O
consisting	O
of	O
:	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
arrhythmia	B
,	O
dyspnea	B
,	O
pneumonia	B
,	O
pneumonitis	B
,	O
pulmonary	B
embolism	I
,	O
ILD	B
,	O
respiratory	B
failure	I
and	O
sepsis	B
.	O
	
The	O
adverse	O
reactions	O
described	O
in	O
this	O
section	O
reflect	O
Gadavist	O
exposure	O
in	O
6,330	O
subjects	O
(	O
including	O
184	O
pediatric	O
patients	O
,	O
ages	O
0	O
to	O
17	O
years	O
)	O
with	O
the	O
majority	O
receiving	O
the	O
recommended	O
dose	O
.	O
	
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
trials	O
,	O
the	O
mean	O
percent	O
change	B
in	I
serum	I
magnesium	I
levels	I
was	O
8.1	O
%	O
and	O
9.3	O
%	O
with	O
INVOKANA	O
100	O
mg	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
,	O
compared	O
to	O
-0.6	O
%	O
with	O
placebo	O
.	O
	
Data	O
from	O
a	O
large	O
placebo-controlled	O
US	O
study	O
that	O
compared	O
the	O
safety	O
of	O
another	O
long-acting	O
beta	O
2	O
-adrenergic	O
agonist	O
(	O
salmeterol	O
)	O
or	O
placebo	O
added	O
to	O
usual	O
asthma	O
therapy	O
showed	O
an	O
increase	O
in	O
asthma-related	O
deaths	B
in	O
patients	O
receiving	O
salmeterol	O
.	O
	
The	O
safety	O
profile	O
of	O
SAPHRIS	O
in	O
the	O
maintenance	O
treatment	O
of	O
schizophrenia	O
in	O
adults	O
was	O
similar	O
to	O
that	O
seen	O
with	O
acute	O
treatment	O
.	O
	
Table	O
4	O
identifies	O
the	O
clinically	O
relevant	O
or	O
severe	O
Grade	O
3/4	O
laboratory	O
test	O
abnormalities	O
for	O
the	O
Phase	O
1/2	O
CML	O
safety	O
population	O
.	O
	
All	O
patients	O
were	O
treated	O
with	O
antihistamines	O
prior	O
to	O
each	O
infusion	O
.	O
	
Patients	O
with	O
hypovolemia	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
changes	O
.	O
	
The	O
data	O
described	O
[	O
seeAdverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
reflect	O
exposure	O
to	O
INLYTA	O
in	O
359	O
patients	O
with	O
advanced	O
RCC	O
who	O
participated	O
in	O
a	O
randomized	O
clinical	O
study	O
versus	O
sorafenib	O
[	O
seeClinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Decrease	B
of	I
Hemoglobin	I
in	O
Patients	O
with	O
WM	O
(	O
N=63	O
)	O
Percent	O
of	O
Patients	O
(	O
N=63	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
Platelets	B
Decreased	I
43	O
13	O
Neutrophils	B
Decreased	I
44	O
19	O
Hemoglobin	B
Decreased	I
13	O
8	O
6	O
.	O
	
During	O
the	O
clinical	O
trial	O
,	O
the	O
patient	O
experienced	O
prolonged	O
lymphopenia	B
(	O
lymphocyte	O
counts	O
predominantly	O
<	O
0.5x10	O
9	O
/L	O
for	O
3.5	O
years	O
)	O
while	O
taking	O
TECFIDERA	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
Consider	O
interruption	O
of	O
TECFIDERA	O
if	O
lymphocyte	O
counts	O
<	O
0.5	O
x	O
10	O
9	O
/L	O
persist	O
for	O
more	O
than	O
six	O
months	O
.	O
	
In	O
the	O
event	O
of	O
treatment-related	O
myelosuppression	O
,	O
monitor	O
leukocytes	O
,	O
platelets	O
,	O
hemoglobin	O
(	O
Hgb	O
)	O
,	O
and	O
neutrophils	O
frequently	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
the	O
WM	O
trial	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
rash	B
,	O
nausea	B
,	O
muscle	B
spasms	I
,	O
and	O
fatigue	B
.	O
	
The	O
use	O
of	O
NESINA	O
as	O
add-on	O
therapy	O
to	O
glyburide	O
or	O
insulin	O
did	O
not	O
increase	O
the	O
incidence	O
of	O
hypoglycemia	B
compared	O
to	O
placebo	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
in	O
patients	O
with	O
B-cell	O
malignancies	O
(	O
MCL	O
,	O
CLL	O
,	O
WM	O
)	O
were	O
thrombocytopenia	B
,	O
neutropenia	B
,	O
diarrhea	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
bruising	B
,	O
nausea	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
and	O
rash	B
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
GlaxoSmithKline	O
at	O
1-888-825-5249	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
adverse	O
reactions	O
most	O
commonly	O
(	O
>	O
=1	O
%	O
in	O
any	O
APTIOM	O
treatment	O
group	O
,	O
and	O
greater	O
than	O
placebo	O
)	O
leading	O
to	O
discontinuation	O
,	O
in	O
descending	O
order	O
of	O
frequency	O
,	O
were	O
dizziness	B
,	O
nausea	B
,	O
vomiting	B
,	O
ataxia	B
,	O
diplopia	B
,	O
somnolence	B
,	O
headache	B
,	O
blurred	B
vision	I
,	O
vertigo	B
,	O
asthenia	B
,	O
fatigue	B
,	O
rash	B
,	O
dysarthria	B
,	O
and	O
tremor	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
below	O
and	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Distant	B
Spread	I
of	I
Toxin	I
Effect	I
[	O
seeBoxed	O
Warning	O
]	O
*	O
Lack	O
of	O
Interchangeability	O
between	O
Botulinum	O
Toxin	O
Products	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Spread	B
of	I
Effects	I
from	I
Toxin	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Dysphagia	B
and	O
Breathing	B
Difficulties	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Facial	O
Anatomy	O
in	O
the	O
Treatment	O
of	O
Glabellar	O
Lines	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Pre-existing	O
Neuromuscular	O
Disorders	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Human	O
Albumin	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Intradermal	B
Immune	I
Reaction	I
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5	O
.	O
	
Patients	O
with	O
myelosuppression	B
following	O
treatment	O
with	O
TREANDA	O
are	O
more	O
susceptible	O
to	O
infections	B
.	O
	
Of	O
the	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
,	O
5	O
%	O
(	O
14/304	O
)	O
developed	O
NODAT	B
by	O
the	O
end	O
of	O
one	O
year	O
compared	O
to	O
10	O
%	O
(	O
27/280	O
)	O
of	O
patients	O
on	O
the	O
cyclosporine	O
control	O
regimen	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
>	O
25	O
%	O
)	O
were	O
increased	B
AST	I
,	O
increased	B
ALT	I
,	O
lymphopenia	B
,	O
increased	B
ALP	I
,	O
hypocalcemia	B
,	O
neutropenia	B
,	O
thrombocytopenia	B
,	O
hypophosphatemia	B
,	O
and	O
hyperbilirubinemia	B
.	O
	
*	O
Dulaglutide	O
causes	O
thyroid	B
C-cell	I
tumors	I
in	O
rats	O
.	O
	
Pre-existing	O
hypertension	O
should	O
be	O
controlled	O
before	O
initiating	O
treatment	O
with	O
PRISTIQ	O
.	O
	
In	O
all	O
controlled	O
and	O
uncontrolled	O
trials	O
across	O
various	O
patient	O
populations	O
,	O
more	O
than	O
2,300	O
patients	O
have	O
received	O
HORIZANT	O
orally	O
in	O
daily	O
doses	O
ranging	O
from	O
600	O
to	O
3,600	O
mg	O
.	O
	
These	O
metabolic	O
changes	O
include	O
hyperglycemia	B
,	O
dyslipidemia	B
,	O
and	O
body	B
weight	I
gain	I
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17.3	O
)	O
]	O
.	O
	
The	O
rate	O
of	O
progression	O
of	O
retinal	B
abnormalities	I
and	O
the	O
reversibility	O
after	O
drug	O
discontinuation	O
are	O
unknown	O
.	O
	
If	O
significant	O
reductions	O
in	O
BMD	O
are	O
seen	O
and	O
BREO	O
ELLIPTA	O
is	O
still	O
considered	O
medically	O
important	O
for	O
that	O
patient	O
's	O
COPD	O
therapy	O
,	O
use	O
of	O
medicine	O
to	O
treat	O
or	O
prevent	O
osteoporosis	O
should	O
be	O
strongly	O
considered	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
occurring	O
in	O
>	O
=	O
5	O
%	O
of	O
CIMZIA-treated	O
patients	O
,	O
and	O
with	O
a	O
higher	O
incidence	O
compared	O
to	O
placebo	O
)	O
in	O
controlled	O
clinical	O
studies	O
with	O
CIMZIA	O
were	O
upper	B
respiratory	I
infections	I
(	O
e.g	O
.	O
	
Use	O
of	O
ocular	O
steroids	O
may	O
prolong	O
the	O
course	O
and	O
may	O
exacerbate	B
the	I
severity	I
of	I
many	I
viral	I
infections	I
of	I
the	I
eye	I
)	O
.	O
	
5.7	O
Discontinuation	O
Syndrome	O
Discontinuation	O
symptoms	O
have	O
been	O
systematically	O
and	O
prospectively	O
evaluated	O
in	O
patients	O
treated	O
with	O
PRISTIQ	O
during	O
clinical	O
studies	O
in	O
Major	O
Depressive	O
Disorder	O
.	O
	
Other	O
immune-mediated	B
adverse	I
reactions	I
,	O
including	O
ocular	B
manifestations	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Of	O
the	O
patients	O
who	O
developed	O
tuberculosis	B
through	O
3	O
years	O
,	O
all	O
but	O
one	O
NULOJIX	O
patient	O
lived	O
in	O
countries	O
with	O
a	O
high	O
prevalence	O
of	O
tuberculosis	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
The	O
ophthalmologic	O
monitoring	O
program	O
should	O
include	O
visual	O
acuity	O
testing	O
and	O
dilated	O
fundus	O
photography	O
.	O
	
Treatment	O
with	O
Edarbi	O
was	O
well-tolerated	O
with	O
an	O
overall	O
incidence	O
of	O
adverse	O
reactions	O
similar	O
to	O
placebo	O
.	O
	
Of	O
these	O
29	O
patients	O
,	O
5	O
(	O
17	O
%	O
)	O
required	O
catheterization	O
,	O
with	O
post-voiding	O
residuals	O
of	O
up	O
to	O
1,500	O
mL	O
.	O
	
Vascular	O
disorders	O
:	O
Thrombophlebitis	B
,	O
vasculitis	B
.	O
	
Trial	O
1	O
included	O
197	O
control-treated	O
patients	O
and	O
463	O
SIMPONI	O
ARIA-treated	O
patients	O
(	O
which	O
includes	O
control-treated	O
patients	O
who	O
switched	O
to	O
SIMPONI	O
ARIA	O
at	O
Week	O
16	O
)	O
.	O
	
Infusion	B
reactions	I
have	O
occurred	O
with	O
the	O
BLINCYTO	O
infusion	O
and	O
may	O
be	O
clinically	O
indistinguishable	O
from	O
manifestations	O
of	O
CRS	O
.	O
	
If	O
this	O
product	O
is	O
used	O
for	O
10	O
days	O
or	O
longer	O
,	O
intraocular	O
pressure	O
should	O
be	O
monitored	O
.	O
	
Of	O
these	O
,	O
806	O
received	O
FANAPT	O
for	O
at	O
least	O
6	O
months	O
,	O
with	O
463	O
exposed	O
to	O
FANAPT	O
for	O
at	O
least	O
12	O
months	O
.	O
	
Study	O
1	O
:	O
Metastatic	O
CRPC	O
Following	O
Chemotherapy	O
Study	O
1	O
enrolled	O
1195	O
patients	O
with	O
metastatic	O
CRPC	O
who	O
had	O
received	O
prior	O
docetaxel	O
chemotherapy	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
CORPORAL	B
RUPTURE	I
(	O
PENILE	B
FRACTURE	I
)	O
OR	O
OTHER	O
SERIOUS	O
PENILE	B
INJURY	I
IN	O
THE	O
TREATMENT	O
OF	O
PEYRONIE	O
'S	O
DISEASE	O
WARNING	O
:	O
CORPORAL	B
RUPTURE	I
(	O
PENILE	B
FRACTURE	I
)	O
OR	O
OTHER	O
SERIOUS	O
PENILE	B
INJURY	I
IN	O
THE	O
TREATMENT	O
OF	O
PEYRONIE	O
'S	O
DISEASE	O
Corporal	B
rupture	I
(	O
penile	B
fracture	I
)	O
was	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
5	O
of	O
1044	O
(	O
0.5	O
%	O
)	O
XIAFLEX-treated	O
patients	O
in	O
clinical	O
studies	O
.	O
	
Grade	O
3	O
or	O
greater	O
thrombocytopenia	B
occurred	O
in	O
1	O
%	O
(	O
7/503	O
)	O
of	O
patients	O
.	O
	
Figure	O
1	O
Gastrointestinal	O
Adverse	O
Reactions	O
Patients	O
on	O
PRADAXA	O
150	O
mg	O
had	O
an	O
increased	O
incidence	O
of	O
gastrointestinal	B
adverse	I
reactions	I
(	O
35	O
%	O
vs.	O
24	O
%	O
on	O
warfarin	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Forest	O
Laboratories	O
,	O
LLC	O
,	O
at	O
1-800-678-1605	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Patients	O
with	O
bilirubin	O
>	O
1.5	O
*	O
ULN	O
also	O
had	O
a	O
higher	O
incidence	O
of	O
Grade	O
4	O
neutropenia	B
and	O
febrile	B
neutropenia	I
.	O
	
Neutralizing	O
antibodies	O
to	O
AUX-I	O
or	O
AUX-II	O
,	O
were	O
detected	O
in	O
10	O
%	O
and	O
21	O
%	O
,	O
respectively	O
,	O
of	O
patients	O
treated	O
with	O
XIAFLEX	O
.	O
	
Monitor	O
and	O
manage	O
patients	O
using	O
standards	O
of	O
care	O
,	O
including	O
anti-diarrheals	O
,	O
anti-emetics	O
,	O
or	O
fluid	O
replacement	O
,	O
as	O
indicated	O
.	O
	
Dyslipidemia	O
Mean	O
values	O
of	O
total	O
cholesterol	O
,	O
HDL	O
,	O
LDL	O
,	O
and	O
triglycerides	O
were	O
reported	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
during	O
treatment	O
for	O
the	O
emergence	O
of	O
possible	O
bacterial	O
,	O
fungal	O
,	O
or	O
viral	O
infections	O
.	O
	
These	O
data	O
reflect	O
exposure	O
of	O
2338	O
patients	O
to	O
FARXIGA	O
with	O
a	O
mean	O
exposure	O
duration	O
of	O
21	O
weeks	O
.	O
	
Fatal	B
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
ZYKADIA	O
occurred	O
in	O
5	O
%	O
of	O
patients	O
,	O
consisting	O
of	O
:	O
pneumonia	B
(	O
4	O
patients	O
)	O
,	O
respiratory	B
failure	I
,	O
ILD/pneumonitis	O
,	O
pneumothorax	B
,	O
gastric	B
hemorrhage	I
,	O
general	B
physical	I
health	I
deterioration	I
,	O
pulmonary	B
tuberculosis	I
,	O
cardiac	B
tamponade	I
,	O
and	O
sepsis	B
(	O
1	O
patient	O
each	O
)	O
.	O
	
*	O
Women	O
over	O
35	O
years	O
old	O
who	O
smoke	O
should	O
not	O
use	O
Natazia	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
patients	O
treated	O
with	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
,	O
and	O
more	O
frequently	O
than	O
in	O
placebo-treated	O
patients	O
,	O
in	O
controlled	O
clinical	O
trials	O
.	O
	
Risk	O
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
Placebo	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Drug	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Drug	O
Events	O
in	O
Drug	O
Patients/Incidencein	O
Placebo	O
Patients	O
Risk	O
Difference	O
:	O
Additional	O
Drug	O
Patients	O
with	O
Events	O
per	O
1000	O
Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
for	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
for	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
the	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
There	O
have	O
been	O
reports	O
of	O
anaphylactic	B
reactions	I
in	O
patients	O
with	O
severe	O
milk	O
protein	O
allergy	O
after	O
inhalation	O
of	O
other	O
powder	O
medications	O
containing	O
lactose	O
;	O
therefore	O
,	O
patients	O
with	O
severe	O
milk	O
protein	O
allergy	O
should	O
not	O
use	O
BREO	O
ELLIPTA	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
bAnnual	O
event	O
rate	O
per	O
100	O
pt-years	O
=	O
100	O
*	O
number	O
of	O
subjects	O
with	O
event/subject-years	O
.	O
	
Hypersensitivity	B
reactions	I
including	O
Drug	B
Rash	I
with	I
Eosinophilia	I
and	I
Systemic	I
Symptoms	I
(	O
DRESS	B
)	O
have	O
also	O
been	O
reported	O
and	O
were	O
characterized	O
by	O
rash	B
,	O
constitutional	O
findings	O
,	O
and	O
sometimes	O
organ	B
dysfunction	I
,	O
including	O
hepatic	B
failure	I
.	O
	
Studies	O
1	O
and	O
2	O
were	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
NULOJIX	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
5.3	O
Hematologic	O
Toxicities	O
Prolonged	O
(	O
>	O
=1	O
week	O
)	O
severe	O
neutropenia	B
and	O
Grade	O
3	O
or	O
Grade	O
4	O
thrombocytopenia	B
or	O
anemia	B
can	O
occur	O
with	O
ADCETRIS	O
.	O
	
Blood	O
and	O
lymphatic	O
system	O
disorders	O
:	O
thrombocytosis	B
,	O
pancytopenia	B
.	O
	
Autoimmune	B
disorders	I
(	O
such	O
as	O
Graves	B
'	I
disease	I
,	O
polymyositis	B
,	O
and	O
Guillain-Barre	B
syndrome	I
)	O
have	O
also	O
been	O
reported	O
to	O
occur	O
in	O
the	O
setting	O
of	O
immune	O
reconstitution	O
;	O
however	O
,	O
the	O
time	O
to	O
onset	O
is	O
more	O
variable	O
,	O
and	O
can	O
occur	O
many	O
months	O
after	O
initiation	O
of	O
treatment	O
.	O
	
5.11	O
Hypersensitivity	O
Reactions	O
,	O
Including	O
Anaphylaxis	O
Hypersensitivity	B
reactions	I
such	O
as	O
anaphylaxis	B
,	O
angioedema	B
,	O
rash	B
,	O
and	O
urticaria	B
may	O
occur	O
after	O
administration	O
of	O
BREO	O
ELLIPTA	O
.	O
	
6.1	O
Controlled	O
Clinical	O
Trials	O
Experience	O
In	O
three	O
placebo-controlled	O
clinical	O
trials	O
of	O
up	O
to	O
14	O
weeks	O
duration	O
,	O
4	O
%	O
(	O
15/400	O
)	O
of	O
patients	O
treated	O
with	O
AMPYRA	O
10	O
mg	O
twice	O
daily	O
experienced	O
one	O
or	O
more	O
treatment	O
emergent	O
adverse	O
events	O
leading	O
to	O
discontinuation	O
,	O
compared	O
to	O
2	O
%	O
(	O
5/238	O
)	O
of	O
placebo-treated	O
patients	O
.	O
	
Table	O
2	O
shows	O
absolute	O
and	O
relative	O
risk	O
by	O
indication	O
for	O
all	O
evaluated	O
AEDs	O
.	O
	
[	O
See	O
Contraindications	O
(	O
4	O
)	O
.	O
]	O
	
Monitor	O
closely	O
and	O
take	O
appropriate	O
measures	O
.	O
	
Complete	O
blood	O
counts	O
should	O
be	O
monitored	O
prior	O
to	O
each	O
dose	O
of	O
ADCETRIS	O
and	O
more	O
frequent	O
monitoring	O
should	O
be	O
considered	O
for	O
patients	O
with	O
Grade	O
3	O
or	O
4	O
neutropenia	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
Ferriprox	O
.	O
	
Other	O
Adverse	O
Reactions	O
Adverse	O
reactions	O
that	O
occurred	O
at	O
a	O
frequency	O
of	O
>	O
=10	O
%	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
or	O
cyclosporine	O
control	O
regimen	O
in	O
Studies	O
1	O
and	O
2	O
through	O
three	O
years	O
are	O
summarized	O
by	O
preferred	O
term	O
in	O
decreasing	O
order	O
of	O
frequency	O
within	O
Table	O
4	O
.	O
	
5.3	O
Radiation	O
Risks	O
Choline	O
C	O
11	O
Injection	O
contributes	O
to	O
a	O
patient	O
's	O
overall	O
long-term	O
cumulative	O
radiation	O
exposure	O
.	O
	
Adverse	O
reactions	O
were	O
predominantly	O
of	O
mild	O
to	O
moderate	O
severity	O
.	O
	
Patients	O
,	O
their	O
caregivers	O
,	O
and	O
families	O
should	O
be	O
informed	O
that	O
AEDs	O
increase	O
the	O
risk	O
of	O
suicidal	O
thoughts	O
and	O
behavior	O
and	O
should	O
be	O
advised	O
of	O
the	O
need	O
to	O
be	O
alert	O
for	O
the	O
emergence	O
or	O
worsening	O
of	O
the	O
signs	O
and	O
symptoms	O
of	O
depression	O
,	O
any	O
unusual	O
changes	O
in	O
mood	O
or	O
behavior	O
,	O
or	O
the	O
emergence	O
of	O
suicidal	O
thoughts	O
,	O
behavior	O
,	O
or	O
thoughts	O
about	O
self-harm	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Severe	O
Skin	O
and	O
Hypersensitivity	O
Reactions	O
Severe	O
,	O
potentially	O
life-threatening	O
,	O
and	O
fatal	B
skin	B
reactions	I
have	O
been	O
reported	O
.	O
	
In	O
case	O
of	O
recurrent	O
events	O
of	O
the	O
same	O
category	O
,	O
the	O
first	O
event	O
was	O
considered	O
.	O
	
Somnolence	B
was	O
reported	O
in	O
22	O
%	O
of	O
patients	O
treated	O
with	O
POTIGA	O
and	O
12	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
(	O
See	O
the	O
respective	O
package	O
inserts	O
for	O
complete	O
VZIG	O
and	O
IG	O
prescribing	O
information	O
.	O
)	O
	
Dose	O
reduction	O
due	O
to	O
neutropenia	B
was	O
required	O
in	O
12	O
%	O
(	O
62/503	O
)	O
of	O
patients	O
and	O
discontinuation	O
was	O
required	O
in	O
<	O
1	O
%	O
of	O
patients	O
.	O
	
Severe	O
penile	B
hematoma	I
was	O
also	O
reported	O
as	O
an	O
adverse	O
reaction	O
in	O
39	O
of	O
1044	O
(	O
3.7	O
%	O
)	O
XIAFLEX-treated	O
patients	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
drug	O
reactions	O
(	O
>	O
=10	O
%	O
)	O
reported	O
in	O
the	O
two	O
randomized	O
clinical	O
trials	O
that	O
occurred	O
more	O
commonly	O
(	O
>	O
2	O
%	O
)	O
in	O
the	O
abiraterone	O
acetate	O
arm	O
were	O
fatigue	B
,	O
joint	B
swelling	I
,	O
edema	B
,	O
hot	B
flush	I
,	O
diarrhea	B
,	O
vomiting	B
,	O
cough	B
,	O
hypertension	B
,	O
dyspnea	B
,	O
urinary	B
tract	I
infection	I
and	O
contusion	B
.	O
	
The	O
most	O
common	O
reasons	O
for	O
dose	O
reductions	O
were	O
elevated	B
transaminases	I
,	O
diarrhea	B
or	O
colitis	B
,	O
and	O
rash	B
.	O
	
The	O
conditions	O
and	O
duration	O
of	O
treatment	O
with	O
FANAPT	O
varied	O
greatly	O
and	O
included	O
(	O
in	O
overlapping	O
categories	O
)	O
,	O
open-label	O
and	O
double-blind	O
phases	O
of	O
studies	O
,	O
inpatients	O
and	O
outpatients	O
,	O
fixed-dose	O
and	O
flexible-dose	O
studies	O
,	O
and	O
short-term	O
and	O
longer-term	O
exposure	O
.	O
	
(	O
5.1	O
,	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
ApoPharma	O
Inc.	O
at	O
:	O
Telephone	O
:	O
1-866-949-0995	O
Email	O
:	O
medicalsafety	O
@	O
apopharma.com	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
}	O
}	O
6.1	O
Clinical	O
Trial	O
Experience	O
The	O
following	O
adverse	O
reactions	O
are	O
also	O
discussed	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
Agranulocytosis/Neutropenia	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.13	O
,	O
7.1	O
)	O
5.1	O
Thromboembolic	O
Disorders	O
and	O
Other	O
Vascular	O
Problems	O
Stop	O
Natazia	O
if	O
an	O
arterial	O
or	O
venous	O
thrombotic	O
event	O
(	O
VTE	O
)	O
occurs	O
.	O
	
In	O
Study	O
5	O
,	O
treatment	O
of	O
recurrent	O
contractures	O
with	O
XIAFLEX	O
resulted	O
in	O
similar	O
immunogenicity	O
results	O
as	O
seen	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
Avoid	O
in	O
patients	O
with	O
congenital	O
long	O
QT	O
syndrome	O
(	O
5.4	O
)	O
5.1	O
Neutropenia	O
Severe	O
neutropenia	B
(	O
ANC	O
<	O
500/mm	O
3	O
)	O
lasting	O
more	O
than	O
one	O
week	O
occurred	O
in	O
12	O
%	O
(	O
62/503	O
)	O
of	O
patients	O
in	O
Study	O
1	O
,	O
leading	O
to	O
discontinuation	O
in	O
<	O
1	O
%	O
of	O
patients	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Cleviprex	O
was	O
infused	O
for	O
<	O
24	O
hours	O
in	O
the	O
majority	O
of	O
patients	O
(	O
n=1199	O
)	O
;	O
it	O
was	O
infused	O
as	O
a	O
continuous	O
infusion	O
in	O
an	O
additional	O
93	O
patients	O
for	O
durations	O
between	O
24	O
and	O
72	O
hours	O
.	O
	
More	O
rapid	O
titration	O
would	O
be	O
expected	O
to	O
increase	O
the	O
rate	O
of	O
orthostatic	O
hypotension	O
and	O
syncope	O
.	O
	
Median	O
exposure	O
in	O
days	O
for	O
pooled	O
studies	O
:	O
1203	O
for	O
NULOJIX	O
recommended	O
regimen	O
and	O
1163	O
for	O
cyclosporine	O
in	O
Studies	O
1	O
and	O
2.	O
?	O
	
(	O
5.5	O
)	O
5.1	O
Tendon	O
Rupture	O
or	O
Other	O
Serious	O
Injury	O
to	O
the	O
Injected	O
Finger/Hand	O
in	O
the	O
Treatment	O
of	O
Dupuytren	O
's	O
Contracture	O
In	O
the	O
controlled	O
and	O
uncontrolled	O
portions	O
of	O
clinical	O
trials	O
in	O
Dupuytren	O
's	O
contracture	O
,	O
flexor	B
tendon	I
ruptures	I
occurred	O
after	O
XIAFLEX	O
injection	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Immune-mediated	B
endocrinopathies	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
5.5	O
Viral	O
Infections	O
Employment	O
of	O
a	O
corticosteroid	O
medication	O
in	O
the	O
treatment	O
of	O
patients	O
with	O
a	O
history	O
of	O
herpes	O
simplex	O
requires	O
great	O
caution	O
.	O
	
PRISTIQ	O
should	O
be	O
prescribed	O
with	O
caution	O
in	O
patients	O
with	O
a	O
seizure	O
disorder	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Gilead	O
Sciences	O
,	O
Inc.	O
at	O
1-800-GILEAD-5	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
(	O
5.6	O
)	O
*	O
Preparation	O
and	O
Administration	O
Errors	O
:	O
Strictly	O
follow	O
instructions	O
for	O
preparation	O
(	O
including	O
admixing	O
)	O
and	O
administration	O
.	O
	
#	O
Most	O
herpes	B
infections	I
were	O
non-serious	O
and	O
1	O
led	O
to	O
treatment	O
discontinuation	O
.	O
	
The	O
protocol	O
included	O
provisions	O
for	O
patients	O
taking	O
placebo	O
to	O
receive	O
treatment	O
with	O
SIMPONI	O
ARIA	O
at	O
Week	O
16	O
or	O
Week	O
24	O
either	O
by	O
patient	O
response	O
(	O
based	O
on	O
uncontrolled	O
disease	O
activity	O
)	O
or	O
by	O
design	O
,	O
so	O
that	O
adverse	O
events	O
can	O
not	O
always	O
be	O
unambiguously	O
attributed	O
to	O
a	O
given	O
treatment	O
.	O
	
Two	O
patients	O
continued	O
treatment	O
with	O
POTIGA	O
and	O
were	O
able	O
to	O
void	O
spontaneously	O
after	O
catheter	O
removal	O
.	O
	
The	O
mean	O
age	O
of	O
the	O
population	O
was	O
59	O
years	O
and	O
4	O
%	O
were	O
older	O
than	O
75	O
years	O
.	O
	
Table	O
2	O
:	O
Change	O
in	O
Glucose	O
Mean	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
3-6	O
months	O
6-12	O
months	O
>	O
12	O
months	O
FANAPT	O
10-16	O
mg/day	O
1.8	O
(	O
N=773	O
)	O
5.4	O
(	O
N=723	O
)	O
5.4	O
(	O
N=425	O
)	O
FANAPT	O
20-24	O
mg/day	O
-3.6	O
(	O
N=34	O
)	O
-9.0	O
(	O
N=31	O
)	O
-18.0	O
(	O
N=20	O
)	O
Dyslipidemia	O
Undesirable	B
alterations	I
in	I
lipids	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
HORIZANT	O
in	O
the	O
treatment	O
of	O
RLS	O
was	O
studied	O
primarily	O
in	O
placebo-controlled	O
trials	O
(	O
n	O
=	O
642	O
)	O
,	O
and	O
in	O
long-term	O
follow-up	O
studies	O
.	O
	
Treatment	O
with	O
PRISTIQ	O
and	O
any	O
concomitant	O
serotonergic	O
agents	O
should	O
be	O
discontinued	O
immediately	O
if	O
the	O
above	O
events	O
occur	O
and	O
supportive	O
symptomatic	O
treatment	O
should	O
be	O
initiated	O
.	O
	
Fatal	B
adverse	O
reactions	O
occurred	O
in	O
6	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
and	O
resulted	O
from	O
hemorrhage	B
,	O
pneumonia	B
,	O
septicemia	B
,	O
fistulas	B
,	O
cardiac	B
arrest	I
,	O
respiratory	B
failure	I
,	O
and	O
unspecified	O
death	B
.	O
	
In	O
patients	O
receiving	O
BLINCYTO	O
in	O
clinical	O
trials	O
,	O
Grade	O
3	O
or	O
greater	O
elevations	B
in	I
liver	I
enzymes	I
occurred	O
in	O
approximately	O
6	O
%	O
of	O
patients	O
outside	O
the	O
setting	O
of	O
CRS	B
and	O
resulted	O
in	O
treatment	O
discontinuation	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
.	O
	
Activation	B
of	I
mania	I
has	O
also	O
been	O
reported	O
in	O
a	O
small	O
proportion	O
of	O
patients	O
with	O
major	O
affective	O
disorder	O
who	O
were	O
treated	O
with	O
other	O
marketed	O
antidepressants	O
.	O
	
It	O
is	O
unknown	O
whether	O
TRULICITY	O
will	O
cause	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
,	O
as	O
the	O
human	O
relevance	O
of	O
dulaglutide-induced	O
rodent	O
thyroid	B
C-cell	I
tumors	I
has	O
not	O
been	O
determined	O
.	O
	
Serious	O
adverse	O
reactions	O
reported	O
include	O
anaphylactic	B
shock	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
,	O
myelosuppression	B
,	O
gastrointestinal	B
toxicity	I
(	O
diarrhea	B
)	O
,	O
fluid	B
retention	I
,	O
hepatotoxicity	B
and	O
rash	B
.	O
	
bladder	B
infection	I
,	O
bacteriuria	B
,	O
cystitis	B
)	O
in	O
7	O
%	O
of	O
CIMZIA-treated	O
patients	O
and	O
in	O
6	O
%	O
of	O
placebo-treated	O
patients	O
,	O
and	O
arthralgia	B
(	O
6	O
%	O
CIMZIA	O
,	O
4	O
%	O
placebo	O
)	O
.	O
	
Consider	O
measures	O
to	O
prevent	O
severe	O
reactions	O
,	O
including	O
antihistamines	O
,	O
antipyretics	O
and	O
corticosteroids	O
in	O
subsequent	O
cycles	O
in	O
patients	O
who	O
have	O
experienced	O
Grade	O
1	O
or	O
2	O
infusion	O
reactions	O
.	O
	
Table	O
3	O
gives	O
the	O
incidence	O
of	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=2	O
%	O
of	O
subjects	O
with	O
partial-onset	O
seizures	O
in	O
any	O
APTIOM	O
treatment	O
group	O
and	O
for	O
which	O
the	O
incidence	O
was	O
greater	O
than	O
placebo	O
during	O
the	O
controlled	O
clinical	O
trials	O
.	O
	
If	O
liver	O
injury	O
is	O
detected	O
,	O
promptly	O
interrupt	O
NESINA	O
and	O
assess	O
patient	O
for	O
probable	O
cause	O
,	O
then	O
treat	O
cause	O
if	O
possible	O
,	O
to	O
resolution	O
or	O
stabilization	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
.	O
	
(	O
6.1	O
)	O
Glabellar	O
Lines	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
are	O
:	O
nasopharyngitis	B
,	O
headache	B
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
reaction	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
sinusitis	B
,	O
and	O
nausea	B
.	O
	
5.3	O
Anaphylaxis	O
and	O
Infusion	O
Reactions	O
Infusion	B
reactions	I
to	O
TREANDA	O
have	O
occurred	O
commonly	O
in	O
clinical	O
trials	O
.	O
	
Table	O
7	O
:	O
Non-Hematologic	O
Adverse	O
Reactions	O
in	O
>	O
=	O
10	O
%	O
of	O
Patients	O
with	O
Waldenstrom	O
's	O
Macroglobulinemia	O
(	O
N=63	O
)	O
System	O
Organ	O
Class	O
Preferred	O
Term	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
The	O
system	O
organ	O
class	O
and	O
individual	O
ADR	O
terms	O
are	O
sorted	O
in	O
descending	O
frequency	O
order	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
1	O
%	O
)	O
were	O
ingrown	B
toenails	I
,	O
application	B
site	I
dermatitis	I
,	O
application	B
site	I
vesicles	I
,	O
and	O
application	B
site	I
pain	I
.	O
	
The	O
system	O
organ	O
class	O
and	O
individual	O
ADR	O
terms	O
are	O
sorted	O
in	O
descending	O
frequency	O
order	O
in	O
the	O
IMBRUVICA	O
arm	O
.	O
	
(	O
5.1	O
)	O
*	O
Progressive	B
multifocal	I
leukoencephalopathy	I
(	O
PML	B
)	O
:	O
Withhold	O
TECFIDERA	O
at	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
.	O
	
The	O
mean	O
baseline	O
hemoglobin	O
value	O
was	O
approximately	O
14.1	O
g/dL	O
across	O
treatment	O
groups	O
.	O
	
Adult	O
Patients	O
:	O
Pooled	O
data	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
In	O
these	O
two	O
studies	O
combined	O
,	O
554	O
patients	O
received	O
Toviaz	O
4	O
mg/day	O
and	O
566	O
patients	O
received	O
Toviaz	O
8	O
mg/day	O
.	O
	
In	O
the	O
single-arm	O
Phase	O
1/2	O
clinical	O
trial	O
,	O
the	O
median	O
time	O
to	O
onset	O
for	O
diarrhea	O
(	O
all	O
grades	O
)	O
was	O
2	O
days	O
and	O
the	O
median	O
duration	O
per	O
event	O
was	O
1	O
day	O
.	O
	
The	O
population	O
was	O
19	O
to	O
97	O
years	O
old	O
,	O
64	O
%	O
were	O
female	O
,	O
and	O
84	O
%	O
were	O
Caucasian	O
;	O
64	O
%	O
were	O
undergoing	O
a	O
surgery	O
that	O
included	O
bowel	O
resection	O
.	O
	
They	O
represent	O
an	O
evaluation	O
of	O
the	O
adverse	O
reaction	O
data	O
from	O
870	O
patients	O
with	O
Ph+	O
leukemia	O
who	O
received	O
at	O
least	O
1	O
dose	O
of	O
single-agent	O
BOSULIF	O
.	O
	
These	O
adverse	O
reactions	O
are	O
:	O
hypersensitivity	B
reactions	I
,	O
paradoxical	B
bronchospasm	I
,	O
tachycardia/heart	O
rate	B
increase/palpitations	O
,	O
pruritus/rash	O
and	O
dizziness	B
.	O
	
Inhalation	O
of	O
airborne	O
capsaicin	O
can	O
result	O
in	O
coughing	B
or	O
sneezing	B
.	O
	
The	O
average	O
age	O
was	O
55	O
years	O
(	O
range	O
from1	O
week	O
to	O
93	O
years	O
)	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
64	O
patients	O
(	O
37.2	O
%	O
)	O
treated	O
with	O
XALKORI	O
and	O
40	O
patients	O
(	O
23.4	O
%	O
)	O
in	O
the	O
chemotherapy	O
arm	O
.	O
	
Male	B
patients	I
who	I
developed	I
genital	I
mycotic	I
infections	I
on	O
INVOKANA	O
were	O
more	O
likely	O
to	O
experience	O
recurrent	O
infections	O
(	O
22	O
%	O
on	O
INVOKANA	O
versus	O
none	O
on	O
placebo	O
)	O
,	O
and	O
require	O
treatment	O
with	O
oral	O
or	O
topical	O
antifungal	O
agents	O
and	O
anti-microbial	O
agents	O
than	O
patients	O
on	O
comparators	O
.	O
	
(	O
5.1	O
)	O
Growth	O
of	O
Resistant	O
Organisms	O
with	O
Prolonged	O
Use	O
.	O
	
Only	O
use	O
SIRTURO	O
when	O
an	O
effective	O
treatment	O
regimen	O
can	O
not	O
otherwise	O
be	O
provided	O
.	O
	
Across	O
all	O
controlled	O
and	O
uncontrolled	O
trials	O
,	O
more	O
than	O
1,600	O
patients	O
have	O
received	O
Qutenza	O
.	O
	
The	O
6-dose	O
Coartem	O
Tablets	O
population	O
was	O
patients	O
with	O
malaria	O
between	O
ages	O
2	O
months	O
and	O
71	O
years	O
:	O
67	O
%	O
(	O
1,332	O
)	O
were	O
16	O
years	O
and	O
younger	O
and	O
33	O
%	O
(	O
647	O
)	O
were	O
older	O
than	O
16	O
years	O
.	O
	
Only	O
use	O
SIRTURO	O
when	O
an	O
effective	O
treatment	O
regimen	O
can	O
not	O
otherwise	O
be	O
provided	O
[	O
see	O
Indications	O
and	O
Usage	O
(	O
1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Excessive	O
use	O
or	O
use	O
in	O
conjunction	O
with	O
other	O
medications	O
containing	O
LABA	O
can	O
result	O
in	O
clinically	O
significant	O
cardiovascular	B
effects	I
and	O
may	O
be	O
fatal	B
(	O
5.3	O
)	O
*	O
Immediate	O
hypersensitivity	B
reactions	I
may	O
occur	O
.	O
	
Anaphylaxis	B
was	O
reported	O
in	O
4	O
%	O
of	O
patients	O
with	O
HAE	O
.	O
	
The	O
incidence	O
of	O
nonfatal	O
serious	O
adverse	O
events	O
was	O
24.2	O
%	O
in	O
the	O
placebo	O
group	O
and	O
25.0	O
%	O
in	O
the	O
Prolia	O
group	O
.	O
	
DUAVEE	O
has	O
been	O
shown	O
to	O
reduce	O
the	O
risk	O
of	O
endometrial	B
hyperplasia	I
,	O
which	O
may	O
be	O
a	O
precursor	O
to	O
endometrial	O
cancer	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
leading	O
to	O
discontinuation	O
were	O
hot	B
flush	I
,	O
abdominal	B
pain	I
upper	I
,	O
and	O
nausea	B
.	O
	
5.2	O
Spread	O
of	O
Toxin	O
Effect	O
Post-marketing	O
safety	O
data	O
from	O
DYSPORT	O
(	O
r	O
)	O
and	O
other	O
approved	O
botulinum	O
toxins	O
suggest	O
that	O
botulinum	O
toxin	B
effects	I
may	I
,	I
in	I
some	I
cases	I
,	I
be	I
observed	I
beyond	I
the	I
site	I
of	I
local	I
injection	I
.	O
	
The	O
forms	O
specifically	O
requested	O
information	O
on	O
occurrence	O
of	O
allergic	B
reactions	I
,	O
thrombotic	B
events	I
,	O
hemorrhagic	B
events	I
,	O
hepatobiliary	B
disorders	I
,	O
pancreatic	B
disorders	I
,	O
and	O
hyperglycemia	B
.	O
	
When	O
distant	O
effects	O
occur	O
,	O
additional	O
respiratory	O
muscles	O
may	O
be	O
involved	O
[	O
See	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Monitor	O
ALT	O
,	O
AST	O
and	O
bilirubin	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
Of	O
these	O
4	O
patients	O
who	O
developed	O
anti-ERWINAZE	O
antibodies	O
,	O
3	O
experienced	O
hypersensitivity	B
reactions	I
(	O
10	O
%	O
,	O
3	O
of	O
30	O
)	O
during	O
the	O
study	O
.	O
	
EXCERPT	O
:	O
Commonly	O
observed	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
that	O
for	O
placebo	O
)	O
were	O
(	O
6.1	O
)	O
:	O
*	O
Schizophrenia	O
Adults	O
:	O
akathisia	B
,	O
oral	B
hypoesthesia	I
,	O
somnolence	B
.	O
	
5.9	O
Macrovascular	O
Outcomes	O
There	O
have	O
been	O
no	O
clinical	O
studies	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
INVOKANA	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
If	O
a	O
decision	O
is	O
made	O
to	O
administer	O
SIMPONI	O
ARIA	O
to	O
RA	O
patients	O
with	O
CHF	O
,	O
these	O
patients	O
should	O
be	O
closely	O
monitored	O
during	O
therapy	O
,	O
and	O
SIMPONI	O
ARIA	O
should	O
be	O
discontinued	O
if	O
new	O
or	O
worsening	O
symptoms	O
of	O
CHF	O
appear	O
.	O
	
*	O
Do	O
not	O
use	O
estrogens	O
to	O
prevent	O
heart	O
disease	O
,	O
heart	O
attacks	O
,	O
strokes	O
or	O
dementia	O
(	O
decline	O
in	O
brain	O
function	O
)	O
.	O
	
In	O
the	O
EMTP	O
trial	O
,	O
the	O
planned	O
number	O
of	O
doses	O
of	O
ERWINAZE	O
ranged	O
from	O
3	O
to	O
48	O
doses	O
.	O
	
5.1	O
Spread	O
of	O
Toxin	O
Effect	O
Postmarketing	O
safety	O
data	O
from	O
XEOMIN	O
and	O
other	O
approved	O
botulinum	O
toxins	O
suggest	O
that	O
botulinum	O
toxin	B
effects	I
may	I
,	I
in	I
some	I
cases	I
,	I
be	I
observed	I
beyond	I
the	I
site	I
of	I
local	I
injection	I
.	O
	
Postmarketing	O
Experience	O
In	O
the	O
postmarketing	O
setting	O
,	O
third-degree	B
AV	I
block	I
and	O
AV	B
block	I
with	O
junctional	B
escape	I
have	O
been	O
observed	O
during	O
the	O
first-dose	O
6-hour	O
observation	O
period	O
with	O
GILENYA	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
need	O
of	O
emergency	O
cardiorespiratory	O
support	O
.	O
	
Limited	O
safety	O
data	O
are	O
available	O
in	O
patients	O
with	O
predisposing	O
factors	O
for	O
seizure	O
because	O
these	O
patients	O
were	O
generally	O
excluded	O
from	O
the	O
trials	O
.	O
	
Avoid	O
use	O
of	O
GBCAs	O
in	O
these	O
patients	O
unless	O
the	O
diagnostic	O
information	O
is	O
essential	O
and	O
not	O
available	O
with	O
non-contrasted	O
MRI	O
or	O
other	O
modalities	O
.	O
	
Before	O
initiating	O
treatment	O
with	O
GILENYA	O
,	O
a	O
recent	O
CBC	O
(	O
i.e.	O
,	O
within	O
6	O
months	O
or	O
after	O
discontinuation	O
of	O
prior	O
therapy	O
)	O
should	O
be	O
available	O
.	O
	
The	O
effects	O
of	O
XEOMIN	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	O
produce	O
symptoms	O
consistent	O
with	O
botulinum	O
toxin	B
effects	I
.	O
	
In	O
an	O
exploratory	O
clinical	O
trial	O
evaluating	O
the	O
use	O
of	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
in	O
patients	O
with	O
severe	O
persistent	O
asthma	O
,	O
more	O
patients	O
treated	O
with	O
golimumab	O
reported	O
malignancies	B
compared	O
with	O
control	O
patients	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
the	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
greater	O
than	O
or	O
equal	O
to	O
2	O
%	O
of	O
subjects	O
switching	O
to	O
STRIBILD	O
were	O
nausea	B
(	O
4	O
%	O
)	O
,	O
flatulence	B
(	O
2	O
%	O
)	O
,	O
and	O
headache	B
(	O
2	O
%	O
)	O
.	O
	
A	O
total	O
of	O
2,034	O
subjects	O
with	O
COPD	O
received	O
at	O
least	O
1	O
dose	O
of	O
BREO	O
ELLIPTA	O
100/25	O
,	O
and	O
1,087	O
subjects	O
received	O
a	O
higher	O
strength	O
of	O
fluticasone	O
furoate/vilanterol	O
.	O
	
Patients	O
should	O
be	O
counseled	O
about	O
the	O
possibility	O
of	O
delayed-onset	O
hypersensitivity	O
reactions	O
and	O
given	O
proper	O
follow-up	O
instructions	O
.	O
	
5.6	O
Dyspnea	O
Dyspnea	B
was	O
reported	O
in	O
28	O
%	O
of	O
patients	O
treated	O
with	O
Kyprolis	O
and	O
was	O
Grade	O
3	O
or	O
greater	O
in	O
4	O
%	O
of	O
patients	O
.	O
	
(	O
1	O
,	O
5.2	O
,	O
7.1	O
,	O
7.3	O
,	O
12.3	O
)	O
*	O
Neuroleptic	B
Malignant	I
Syndrome	I
:	O
Manage	O
with	O
immediate	O
discontinuation	O
of	O
drug	O
and	O
close	O
monitoring	O
.	O
	
The	O
safety	O
of	O
reinitiating	O
Kyprolis	O
therapy	O
in	O
patients	O
previously	O
experiencing	O
TTP/HUS	O
is	O
not	O
known	O
.	O
	
Careful	O
consideration	O
should	O
be	O
given	O
to	O
this	O
potential	O
risk	O
prior	O
to	O
initiating	O
therapy	O
in	O
patients	O
with	O
these	O
conditions	O
.	O
	
Treatment	O
with	O
antibacterial	O
agents	O
alters	O
the	O
normal	O
flora	O
of	O
the	O
colon	O
and	O
may	O
permit	O
overgrowth	O
of	O
C	O
.	O
	
Afatinib	O
was	O
embryotoxic	B
and	O
,	O
in	O
animals	O
with	O
maternal	O
toxicity	O
,	O
led	O
to	O
abortions	B
at	I
late	I
gestational	I
stages	I
in	O
rabbits	O
at	O
doses	O
of	O
5	O
mg/kg	O
(	O
approximately	O
0.2	O
times	O
the	O
human	O
exposure	O
at	O
the	O
recommended	O
dose	O
of	O
40	O
mg	O
daily	O
)	O
or	O
greater	O
.	O
	
If	O
supine	O
hypertension	O
is	O
not	O
well-managed	O
,	O
NORTHERA	O
may	O
increase	O
the	O
risk	O
of	O
cardiovascular	O
events	O
.	O
	
Monitor	O
CrCl	O
at	O
least	O
daily	O
in	O
patients	O
with	O
changing	O
renal	O
function	O
and	O
adjust	O
the	O
dosage	O
of	O
ZERBAXA	O
accordingly	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Administer	O
dexamethasone	O
prior	O
to	O
Kyprolis	O
to	O
reduce	O
the	O
incidence	O
and	O
severity	O
of	O
infusion	O
reactions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
6.2	O
Adverse	O
Events	O
Associated	O
With	O
Gabapentin	O
The	O
following	O
adverse	O
events	O
have	O
been	O
reported	O
in	O
patients	O
receiving	O
gabapentin	O
,	O
either	O
in	O
clinical	O
trials	O
or	O
postmarketing	O
:	O
breast	B
enlargement	I
,	O
gynecomastia	B
,	O
and	O
elevated	B
creatine	I
kinase	I
.	O
	
Monitor	O
blood	O
pressure	O
regularly	O
in	O
all	O
patients	O
.	O
	
Two	O
patients	O
receiving	O
alglucosidase	O
alfa	O
discontinued	O
the	O
trial	O
due	O
to	O
anaphylactic	B
reactions	I
.	O
	
Appropriate	O
laboratory	O
testing	O
prior	O
to	O
initiating	O
therapy	O
and	O
monitoring	O
for	O
hepatotoxicity	O
during	O
therapy	O
with	O
TIVICAY	O
is	O
recommended	O
in	O
patients	O
with	O
underlying	O
hepatic	O
disease	O
such	O
as	O
hepatitis	O
B	O
or	O
C.	O
(	O
5.2	O
)	O
*	O
accumulation	B
of	I
body	I
fat	I
and	O
immune	B
reconstitution	I
syndrome	I
have	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
.	O
	
ENTEREG	O
is	O
not	O
recommended	O
for	O
use	O
in	O
these	O
patients	O
.	O
	
5.4	O
Macular	O
Edema	O
Fingolimod	O
increases	O
the	O
risk	O
of	O
macular	B
edema	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
irrespective	O
of	O
causality	O
)	O
leading	O
to	O
treatment	O
discontinuation	O
were	O
pneumonitis	B
and	O
dyspnea	B
.	O
	
Table	O
3	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=1	O
%	O
of	O
Subjects	O
on	O
OTEZLA	O
and	O
With	O
Greater	O
Frequency	O
Than	O
in	O
Subjects	O
on	O
Placebo	O
;	O
up	O
to	O
Day	O
112	O
(	O
Week	O
16	O
)	O
*	O
Two	O
subjects	O
treated	O
with	O
OTEZLA	O
experienced	O
serious	O
adverse	O
reaction	O
of	O
abdominal	B
pain	I
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
>	O
=	O
10	O
%	O
of	O
Patients	O
with	O
Advanced	O
PNET	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Includes	O
stomatitis	B
,	O
aphthous	B
stomatitis	I
,	O
gingival	B
pain	I
,	O
glossitis	B
,	O
glossodynia	B
,	O
lip	B
ulceration	I
,	O
mouth	B
ulceration	I
,	O
tongue	B
ulceration	I
,	O
and	O
mucosal	B
inflammation	I
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Zylera	O
Pharmaceuticals	O
,	O
LLC	O
.	O
	
5.6	O
Corneal	O
Exposure	O
,	O
Corneal	O
Ulceration	O
,	O
and	O
Ectropion	O
in	O
Patients	O
Treated	O
with	O
XEOMIN	O
for	O
Blepharospasm	O
Reduced	B
blinking	I
from	O
injection	O
of	O
botulinum	O
toxin	O
products	O
in	O
the	O
orbicularis	O
muscle	O
can	O
lead	O
to	O
corneal	B
exposure	I
and	O
corneal	B
ulceration	I
,	O
especially	O
in	O
patients	O
with	O
VII	O
nerve	O
disorders	O
.	O
	
Symptoms	O
of	O
macular	B
edema	I
included	O
blurred	B
vision	I
and	O
decreased	B
visual	I
acuity	I
.	O
	
Exercise	O
caution	O
in	O
patients	O
with	O
known	O
hypersensitivity	O
to	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
Changes	O
in	O
Serum	O
Creatinine	O
Dolutegravir	O
has	O
been	O
shown	O
to	O
increase	B
serum	I
creatinine	I
due	O
to	O
inhibition	O
of	O
tubular	O
secretion	O
of	O
creatinine	O
without	O
affecting	O
renal	O
glomerular	O
function	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
In	O
Studies	O
102	O
and	O
103	O
,	O
increases	B
in	I
serum	I
creatinine	I
and	O
decreases	B
in	I
estimated	I
creatinine	I
clearance	I
occurred	O
early	O
in	O
treatment	O
with	O
STRIBILD	O
,	O
after	O
which	O
they	O
stabilized	O
.	O
	
The	O
incidence	O
of	O
adverse	O
reactions	O
associated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
and	O
BREO	O
ELLIPTA	O
200/25	O
is	O
shown	O
in	O
Table	O
3	O
.	O
	
No	O
new	O
safety	O
findings	O
were	O
observed	O
following	O
the	O
switch	O
to	O
4000	O
L	O
scale	O
of	O
alglucosidase	O
alfa	O
.	O
	
Patients	O
with	O
a	O
pre-existing	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
or	O
a	O
history	O
of	O
leukopenia/neutropenia	O
should	O
have	O
their	O
complete	O
blood	O
count	O
(	O
CBC	O
)	O
monitored	O
frequently	O
during	O
the	O
first	O
few	O
months	O
of	O
therapy	O
and	O
should	O
discontinue	O
FANAPT	O
at	O
the	O
first	O
sign	O
of	O
a	O
decline	O
in	O
WBC	O
in	O
the	O
absence	O
of	O
other	O
causative	O
factors	O
.	O
	
Exposure	O
to	O
sunlight	O
and	O
ultraviolet	O
(	O
UV	O
)	O
light	O
should	O
be	O
limited	O
by	O
wearing	O
protective	O
clothing	O
and	O
using	O
a	O
sunscreen	O
with	O
a	O
high	O
protection	O
factor	O
.	O
	
Discontinue	O
trametinib	O
if	O
no	O
improvement	O
after	O
3	O
weeks	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
ELIQUIS	O
can	O
cause	O
serious	O
,	O
potentially	O
fatal	B
bleeding	B
.	O
	
If	O
the	O
patient	O
is	O
known	O
or	O
strongly	O
suspected	O
of	O
having	O
had	O
a	O
hypersensitivity	O
reaction	O
to	O
DaTscan	O
,	O
the	O
decision	O
to	O
administer	O
DaTscan	O
should	O
be	O
based	O
upon	O
an	O
assessment	O
of	O
the	O
expected	O
benefits	O
compared	O
to	O
the	O
potential	O
hypersensitivity	O
risks	O
.	O
	
It	O
is	O
unknown	O
whether	O
TANZEUM	O
(	O
r	O
)	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
Nonclinical	O
Toxicology	O
(	O
13.1	O
)	O
]	O
.	O
	
Of	O
the	O
total	O
population	O
across	O
the	O
three	O
trials	O
,	O
229	O
patients	O
received	O
a	O
dose	O
of	O
125	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
141	O
days	O
,	O
69	O
patients	O
received	O
a	O
dose	O
of	O
250	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
139	O
days	O
,	O
102	O
patients	O
received	O
a	O
dose	O
of	O
250	O
mg	O
four	O
times	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
14	O
days	O
,	O
54	O
patients	O
received	O
a	O
dose	O
of	O
500	O
mg	O
twice	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
146	O
days	O
,	O
and	O
242	O
patients	O
received	O
a	O
dose	O
of	O
500	O
mg	O
four	O
times	O
a	O
day	O
for	O
a	O
mean	O
duration	O
of	O
14	O
days	O
.	O
	
Neonates	O
(	O
i.e	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
:	O
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Interstitial	B
Lung	I
Disease/Pneumonitis	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
QT	B
Interval	I
Prolongation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Bradycardia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Severe	O
Visual	B
Loss	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
are	O
vision	B
disorders	I
,	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
edema	B
,	O
elevated	B
transaminases	I
,	O
upper	B
respiratory	I
infection	I
,	O
decreased	B
appetite	I
,	O
and	O
dysgeusia	B
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
65	O
%	O
of	O
patients	O
.	O
	
(	O
5.5	O
)	O
*	O
Impaired	B
wound	I
healing	I
:	O
Increased	O
risk	O
of	O
wound-related	B
complications	I
.	O
	
Physicians	O
should	O
consider	O
PTLD	O
in	O
patients	O
reporting	O
new	O
or	O
worsening	O
neurological	O
,	O
cognitive	O
,	O
or	O
behavioral	O
signs	O
or	O
symptoms	O
.	O
	
If	O
anticoagulation	O
with	O
ELIQUIS	O
is	O
discontinued	O
for	O
a	O
reason	O
other	O
than	O
pathological	O
bleeding	O
or	O
completion	O
of	O
a	O
course	O
of	O
therapy	O
,	O
consider	O
coverage	O
with	O
another	O
anticoagulant	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.4	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
,	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
RPED	B
occurred	O
in	O
2	O
%	O
(	O
1/55	O
)	O
of	O
patients	O
receiving	O
TAFINLAR	O
in	O
combination	O
with	O
trametinib	O
.	O
	
These	O
studies	O
did	O
not	O
show	O
an	O
increase	O
in	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
with	O
antidepressant	O
use	O
in	O
patients	O
over	O
age	O
24	O
;	O
there	O
was	O
a	O
reduction	O
in	O
risk	O
with	O
antidepressant	O
use	O
in	O
patients	O
aged	O
65	O
and	O
older	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Fatal	B
outcomes	O
have	O
been	O
observed	O
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
bleeding	B
events	O
was	O
0.7	O
%	O
in	O
the	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
1.7	O
%	O
in	O
enoxaparin/warfarin-treated	O
patients	O
in	O
the	O
AMPLIFY	O
study	O
.	O
	
(	O
2.3	O
)	O
*	O
JEVTANA	O
can	O
cause	O
fetal	B
harm	I
when	O
administered	O
to	O
a	O
pregnant	O
woman	O
.	O
	
As	O
such	O
,	O
reliability	O
in	O
estimating	O
their	O
frequency	O
or	O
in	O
establishing	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
is	O
not	O
always	O
possible	O
.	O
	
5	O
.	O
	
Additional	O
safety	O
information	O
was	O
collected	O
from	O
clinical	O
records	O
submitted	O
by	O
treating	O
physicians	O
.	O
	
*	O
Progressive	B
multifocal	I
leukoencephalopathy	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
SJIA	O
Study	O
2	O
was	O
a	O
two-part	O
study	O
with	O
an	O
open-label	O
,	O
single-arm	O
active	O
treatment	O
period	O
(	O
Part	O
I	O
)	O
followed	O
by	O
a	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
,	O
event-driven	O
withdrawal	O
design	O
(	O
Part	O
II	O
)	O
.	O
	
*	O
b	O
In	O
this	O
trial	O
,	O
no	O
documented	O
symptomatic	O
or	O
severe	O
hypoglycemia	B
were	O
reported	O
for	O
TANZEUM	O
50	O
mg	O
and	O
these	O
data	O
are	O
omitted	O
from	O
the	O
table	O
.	O
	
Eye	B
disorders	I
,	O
including	O
severe	O
eye	B
pain	I
,	O
chemical	B
conjunctivitis	I
,	O
corneal	B
burn	I
,	O
eyelid	B
edema	I
,	O
eyelid	B
ptosis	I
,	O
periorbital	B
edema	I
can	O
occur	O
after	O
exposure	O
.	O
	
Withhold	O
treatment	O
with	O
trametinib	O
and	O
continue	O
TAFINLAR	O
at	O
the	O
same	O
dose	O
if	O
absolute	O
LVEF	O
value	O
decreases	O
by	O
10	O
%	O
from	O
pretreatment	O
values	O
and	O
is	O
less	O
than	O
the	O
lower	O
limit	O
of	O
normal	O
.	O
	
If	O
an	O
infection	O
develops	O
,	O
monitor	O
carefully	O
,	O
and	O
stop	O
CIMZIA	O
if	O
infection	O
becomes	O
serious	O
(	O
5.1	O
)	O
*	O
Invasive	B
fungal	I
infections	I
-	O
for	O
patients	O
who	O
develop	O
a	O
systemic	O
illness	O
on	O
CIMZIA	O
,	O
consider	O
empiric	O
antifungal	O
therapy	O
for	O
those	O
who	O
reside	O
or	O
travel	O
to	O
regions	O
where	O
mycoses	O
are	O
endemic	O
(	O
5.1	O
)	O
*	O
Cases	O
of	O
lymphoma	B
and	O
other	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF	O
blockers	O
(	O
5.2	O
)	O
*	O
Heart	B
failure	I
,	I
worsening	I
may	O
occur	O
(	O
5.3	O
)	O
*	O
Anaphylaxis	B
or	O
serious	O
allergic	B
reactions	I
may	O
occur	O
(	O
5.4	O
)	O
*	O
Hepatitis	B
B	I
virus	I
reactivation	I
-	O
test	O
for	O
HBV	O
infection	O
before	O
starting	O
CIMZIA	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
additional	O
adverse	O
reactions	O
have	O
been	O
reported	O
during	O
postmarketing	O
use	O
of	O
Gadavist	O
.	O
	
Some	O
deaths	B
due	O
to	O
renal	B
failure	I
did	O
not	O
have	O
a	O
clear	O
etiology	O
.	O
	
Bipolar	O
I	O
Disorder	O
(	O
3-weeks	O
)	O
Placebo	O
SAPHRIS2.5	O
mgtwice	O
daily	O
SAPHRIS5	O
mgtwice	O
daily	O
SAPHRIS10	O
mgtwice	O
daily	O
Change	O
from	O
Baseline	O
(	O
kg	O
)	O
(	O
N*	O
)	O
0.5	O
(	O
89	O
)	O
1.7	O
(	O
92	O
)	O
1.6	O
(	O
90	O
)	O
1.4	O
(	O
87	O
)	O
Proportion	O
of	O
Subjects	O
with	O
a	O
>	O
=7	O
%	O
Increase	B
in	I
Body	I
Weight	I
%	O
with	O
>	O
=7	O
%	O
increase	B
in	I
body	I
weight	I
1.1	O
%	O
12.0	O
%	O
8.9	O
%	O
8.0	O
%	O
5.6	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
The	O
concomitant	O
use	O
of	O
a	O
TNF-blocker	O
and	O
abatacept	O
or	O
anakinra	O
was	O
associated	O
with	O
a	O
higher	O
risk	O
of	O
serious	O
infections	O
;	O
therefore	O
,	O
the	O
concomitant	O
use	O
of	O
SIMPONI	O
ARIA	O
and	O
these	O
biologic	O
products	O
is	O
not	O
recommended	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
,	O
5.6	O
)	O
and	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
]	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
infections	B
-	O
Do	O
not	O
start	O
SIMPONI	O
ARIA	O
during	O
an	O
active	O
infection	O
.	O
	
5.2	O
Paradoxical	O
Bronchospasm	O
Inhaled	O
medicines	O
,	O
including	O
TUDORZA	O
PRESSAIR	O
,	O
may	O
cause	O
paradoxical	B
bronchospasm	I
.	O
	
30.6	O
%	O
had	O
diabetes	O
mellitus	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
the	O
incidence	O
of	O
antibodies	O
to	O
EYLEA	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
Possible	O
risk	O
factors	O
for	O
leukopenia/neutropenia	O
include	O
pre-existing	O
low	O
white	O
blood	O
cell	O
count	O
(	O
WBC	O
)	O
/absolute	O
neutrophil	O
count	O
(	O
ANC	O
)	O
and	O
history	O
of	O
drug	O
induced	O
leukopenia/neutropenia	O
.	O
	
All	O
patients	O
also	O
received	O
basiliximab	O
induction	O
,	O
mycophenolate	O
mofetil	O
,	O
and	O
corticosteroids	O
.	O
	
Congestive	O
Heart	O
Failure	O
No	O
serious	O
adverse	O
reactions	O
to	O
AdreView	O
were	O
observed	O
in	O
clinical	O
studies	O
.	O
	
Details	O
of	O
the	O
study	O
treatment	O
are	O
described	O
in	O
Section	O
14.1	O
.	O
	
C.	O
difficile	O
produces	O
toxins	O
A	O
and	O
B	O
which	O
contribute	O
to	O
the	O
development	O
of	O
CDAD	O
.	O
	
Patients	O
greater	O
than	O
65	O
years	O
of	O
age	O
,	O
patients	O
with	O
co-morbid	O
conditions	O
,	O
and/or	O
patients	O
taking	O
concomitant	O
immunosuppressants	O
(	O
e.g	O
.	O
	
Mineralization	O
Defects	O
:	O
Cases	O
of	O
osteomalacia	B
associated	O
with	O
proximal	B
renal	I
tubulopathy	I
,	O
manifested	O
as	O
bone	B
pain	I
or	O
pain	B
in	I
extremities	I
and	O
which	O
may	O
contribute	O
to	O
fractures	B
,	O
have	O
been	O
reported	O
in	O
association	O
with	O
the	O
use	O
of	O
tenofovir	O
DF	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
A	O
majority	O
of	O
reported	O
events	O
occurred	O
in	O
patients	O
who	O
had	O
experienced	O
nausea	B
,	O
vomiting	B
,	O
diarrhea	B
,	O
or	O
dehydration	B
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TANZEUM	O
.	O
	
Most	O
,	O
but	O
not	O
all	O
,	O
of	O
these	O
patients	O
had	O
underlying	O
anatomic	O
or	O
vascular	O
risk	O
factors	O
for	O
developing	O
NAION	O
,	O
including	O
but	O
not	O
necessarily	O
limited	O
to	O
:	O
low	O
cup	O
to	O
disc	O
ratio	O
(	O
``	O
crowded	O
disc	O
''	O
)	O
,	O
age	O
over	O
50	O
,	O
diabetes	O
,	O
hypertension	O
,	O
coronary	O
artery	O
disease	O
,	O
hyperlipidemia	O
,	O
and	O
smoking	O
.	O
	
Reported	O
infections	O
with	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
include	O
:	O
*	O
Active	B
tuberculosis	I
,	O
including	O
reactivation	B
of	I
latent	I
tuberculosis	I
.	O
	
transfusion	O
)	O
if	O
clinically	O
indicated	O
.	O
	
Immunogenicity	O
assay	O
results	O
are	O
highly	O
dependent	O
on	O
several	O
factors	O
including	O
assay	O
sensitivity	O
and	O
specificity	O
,	O
assay	O
methodology	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
Stroke	O
In	O
the	O
WHI	O
estrogen-alone	O
substudy	O
,	O
a	O
statistically	O
significant	O
increased	O
risk	O
of	O
stroke	B
was	O
reported	O
in	O
women	O
50	O
to	O
79	O
years	O
of	O
age	O
receiving	O
daily	O
conjugated	O
estrogens	O
(	O
CE	O
)	O
(	O
0.625	O
mg	O
)	O
-alone	O
compared	O
to	O
women	O
in	O
the	O
same	O
age	O
group	O
receiving	O
placebo	O
(	O
45	O
versus	O
33	O
per	O
10,000	O
women-years	O
)	O
.	O
	
In	O
the	O
extension	O
trial	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
4	O
%	O
of	O
patients	O
who	O
underwent	O
ocular	O
examination	O
prior	O
to	O
therapy	O
with	O
PROMACTA	O
.	O
	
The	O
anti-brentuximab	O
antibodies	O
were	O
directed	O
against	O
the	O
antibody	O
component	O
of	O
brentuximab	O
vedotin	O
in	O
all	O
patients	O
with	O
transiently	O
or	O
persistently	O
positive	O
antibodies	O
.	O
	
5.10	O
Hyperprolactinemia	O
Like	O
other	O
drugs	O
that	O
antagonize	O
dopamine	O
D2receptors	O
,	O
SAPHRIS	O
can	O
elevate	B
prolactin	I
levels	I
,	O
and	O
the	O
elevation	O
can	O
persist	O
during	O
chronic	O
administration	O
.	O
	
For	O
more	O
information	O
,	O
go	O
to	O
www.DUAVEE.com	O
,	O
or	O
call	O
1-800-438-1985	O
.	O
	
Consider	O
lowering	O
sulfonylurea	O
or	O
insulin	O
dosage	O
when	O
starting	O
TANZEUM	O
.	O
	
The	O
adverse	O
events	O
reported	O
in	O
the	O
long	O
term	O
safety	O
trials	O
were	O
similar	O
to	O
those	O
occurring	O
in	O
the	O
placebo-controlled	O
trials	O
of	O
3	O
to	O
6	O
months	O
.	O
	
Table	O
1	O
Adverse	O
Reactions	O
Reaction	O
Rate	O
(	O
%	O
)	O
n	O
=	O
1581	O
Nausea	B
1.1	O
Headache	B
1.1	O
Feeling	B
hot	I
0.8	O
Dizziness	B
0.6	O
Back	B
pain	I
0.6	O
Vomiting	B
0.4	O
Blood	B
pressure	I
increased	I
0.4	O
Injection	B
site	I
reactions	I
)	O
0.4	O
Dysgeusia	B
0.4	O
Paresthesia	B
0.3	O
Flushing	B
0.3	O
Parosmia	B
0.3	O
Pruritus	B
(	I
generalized	I
)	O
0.3	O
Rash	B
0.3	O
Respiratory	B
disorders	I
(	O
dyspnea	B
,	O
respiratory	B
distress	I
)	O
0.2	O
Fatigue	B
0.2	O
Chest	B
pain	I
0.1	O
Vertigo	B
0.1	O
Dry	B
mouth	I
0.1	O
Chills	B
0.1	O
Feeling	B
abnormal	I
0.1	O
Adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
of	O
<	O
0.1	O
%	O
in	O
subjects	O
who	O
received	O
EOVIST	O
include	O
:	O
tremor	B
,	O
akathisia	B
,	O
bundle	B
branch	I
block	I
,	O
palpitation	B
,	O
oral	B
discomfort	I
,	O
salivary	B
hypersecretion	I
,	O
maculopapular	B
rash	I
,	O
hyperhidrosis	B
,	O
discomfort	B
,	O
and	O
malaise	B
.	O
	
(	O
5.1	O
)	O
*	O
Rapid	O
intravenous	O
infusion	B
of	I
glycopeptide	I
antibacterial	I
agents	I
can	I
cause	I
reactions	I
.	O
	
Anti-tuberculosis	O
therapy	O
should	O
also	O
be	O
considered	O
prior	O
to	O
initiation	O
of	O
CIMZIA	O
in	O
patients	O
with	O
a	O
past	O
history	O
of	O
latent	O
or	O
active	O
tuberculosis	O
in	O
whom	O
an	O
adequate	O
course	O
of	O
treatment	O
can	O
not	O
be	O
confirmed	O
,	O
and	O
for	O
patients	O
with	O
a	O
negative	O
test	O
for	O
latent	O
tuberculosis	O
but	O
having	O
risk	O
factors	O
for	O
tuberculosis	O
infection	O
.	O
	
This	O
list	O
also	O
includes	O
adverse	O
reactions	O
(	O
less	O
than	O
1	O
%	O
of	O
subjects	O
)	O
associated	O
with	O
organ	O
systems	O
from	O
Warnings	O
and	O
Precautions	O
.	O
	
Patients	O
with	O
thyroid	O
nodules	O
noted	O
on	O
physical	O
examination	O
or	O
neck	O
imaging	O
should	O
also	O
be	O
further	O
evaluated	O
.	O
	
For	O
patients	O
at	O
highest	O
risk	O
for	O
NSF	O
,	O
do	O
not	O
exceed	O
the	O
recommended	O
Gadavist	O
dose	O
and	O
allow	O
a	O
sufficient	O
period	O
of	O
time	O
for	O
elimination	O
of	O
the	O
drug	O
prior	O
to	O
re-administration	O
.	O
	
(	O
5.2	O
)	O
*	O
Hypoglycemia	B
:	O
Can	O
occur	O
when	O
used	O
in	O
combination	O
with	O
insulin	O
secretagogues	O
(	O
e.g.	O
,	O
sulfonylureas	O
)	O
or	O
insulin	O
.	O
	
SAPHRIS	O
should	O
also	O
be	O
avoided	O
in	O
patients	O
with	O
a	O
history	O
of	O
cardiac	O
arrhythmias	O
and	O
in	O
other	O
circumstances	O
that	O
may	O
increase	O
the	O
risk	O
of	O
the	O
occurrence	O
of	O
torsade	O
de	O
pointes	O
and/or	O
sudden	O
death	O
in	O
association	O
with	O
the	O
use	O
of	O
drugs	O
that	O
prolong	O
the	O
QTc	O
interval	O
,	O
including	O
bradycardia	O
;	O
hypokalemia	O
or	O
hypomagnesemia	O
;	O
and	O
presence	O
of	O
congenital	O
prolongation	O
of	O
the	O
QT	O
interval	O
.	O
	
In	O
the	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
and	O
thrombocytopenia	O
,	O
cataracts	B
developed	O
or	O
worsened	O
in	O
8	O
%	O
patients	O
treated	O
with	O
PROMACTA	O
and	O
5	O
%	O
patients	O
treated	O
with	O
placebo	O
.	O
	
If	O
hemoglobin	O
is	O
less	O
than	O
10	O
g	O
per	O
dL	O
,	O
a	O
decrease	O
in	O
dosage	O
of	O
ribavirin	O
is	O
recommended	O
;	O
and	O
if	O
hemoglobin	O
is	O
less	O
than	O
8.5	O
g	O
per	O
dL	O
,	O
discontinuation	O
of	O
ribavirin	O
is	O
recommended	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
and	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
studies	O
the	O
following	O
adverse	O
reactions	O
occurred	O
in	O
less	O
than	O
1	O
%	O
of	O
subjects	O
and	O
in	O
more	O
than	O
one	O
subject	O
treated	O
with	O
doses	O
ranging	O
from	O
40	O
mg	O
to	O
240	O
mg	O
of	O
ULORIC	O
.	O
	
If	O
serum	O
calcitonin	O
is	O
measured	O
and	O
found	O
to	O
be	O
elevated	O
,	O
the	O
patient	O
should	O
be	O
further	O
evaluated	O
.	O
	
Induration	O
of	O
5	O
mm	O
or	O
greater	O
with	O
tuberculin	O
skin	O
testing	O
should	O
be	O
considered	O
a	O
positive	O
test	O
result	O
when	O
assessing	O
if	O
treatment	O
for	O
latent	O
tuberculosis	O
is	O
needed	O
prior	O
to	O
initiating	O
CIMZIA	O
,	O
even	O
for	O
patients	O
previously	O
vaccinated	O
with	O
Bacille	O
Calmette-Guerin	O
(	O
BCG	O
)	O
.	O
	
Elevation	B
of	I
serum	I
iron	I
laboratory	O
values	O
were	O
reported	O
in	O
less	O
than	O
1	O
%	O
of	O
patients	O
after	O
administration	O
of	O
EOVIST	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
skin	B
reactions	I
have	O
been	O
reported	O
with	O
glycopeptide	O
antibacterial	O
agents	O
,	O
including	O
DALVANCE	O
;	O
exercise	O
caution	O
in	O
patients	O
with	O
known	O
hypersensitivity	O
to	O
glycopeptides	O
.	O
	
Some	O
of	O
these	O
events	O
were	O
reported	O
in	O
patients	O
without	O
known	O
underlying	O
renal	O
disease	O
.	O
	
Treatment	O
with	O
CIMZIA	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
with	O
an	O
active	O
infection	O
,	O
including	O
clinically	O
important	O
localized	O
infections	O
.	O
	
Arthralgias	B
and	O
muscle	B
pain	I
have	O
also	O
been	O
reported	O
in	O
cases	O
of	O
proximal	B
renal	I
tubulopathy	I
.	O
	
Treatment	O
with	O
antibacterial	O
agents	O
can	O
alter	O
the	O
normal	O
flora	O
of	O
the	O
colon	O
,	O
and	O
may	O
permit	O
overgrowth	O
of	O
C.	O
difficile	O
.	O
	
Certain	O
adverse	O
reactions	O
consistent	O
with	O
symptoms	O
of	O
anemia	B
,	O
such	O
as	O
dyspnea	B
,	O
exertional	B
dyspnea	I
,	O
dizziness	B
and	O
syncope	B
were	O
reported	O
more	O
frequently	O
in	O
subjects	O
who	O
received	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
than	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
increase	O
in	O
risk	O
was	O
demonstrated	O
in	O
year	O
1	O
and	O
persisted	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.5	O
)	O
]	O
.	O
	
The	O
effect	O
of	O
anti-brentuximab	O
vedotin	O
antibodies	O
on	O
safety	O
and	O
efficacy	O
is	O
not	O
known	O
.	O
	
5.3	O
Thrombotic/Thromboembolic	O
Complications	O
In	O
two	O
controlled	O
clinical	O
trials	O
in	O
patients	O
with	O
chronic	O
hepatitis	O
C	O
and	O
thrombocytopenia	O
,	O
3	O
%	O
(	O
31/955	O
)	O
treated	O
with	O
PROMACTA	O
experienced	O
a	O
thrombotic	B
event	I
(	O
1	O
%	O
in	O
patients	O
treated	O
with	O
PROMACTA	O
versus	O
less	O
than	O
1	O
%	O
for	O
placebo	O
)	O
.	O
	
If	O
drug-induced	O
hemolytic	O
anemia	O
is	O
suspected	O
,	O
discontinuation	O
of	O
Teflaro	O
should	O
be	O
considered	O
and	O
supportive	O
care	O
should	O
be	O
administered	O
to	O
the	O
patient	O
(	O
i.e	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
Ophthalmologic	O
:	O
Non-arteritic	B
anterior	I
ischemic	I
optic	I
neuropathy	I
(	O
NAION	B
)	O
,	O
a	O
cause	O
of	O
decreased	B
vision	I
including	O
permanent	B
loss	I
of	I
vision	I
,	O
has	O
been	O
reported	O
rarely	O
post-marketing	O
in	O
temporal	O
association	O
with	O
the	O
use	O
of	O
phosphodiesterase	O
type	O
5	O
(	O
PDE5	O
)	O
inhibitors	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
for	O
MTC	O
with	O
the	O
use	O
of	O
TANZEUM	O
and	O
inform	O
them	O
of	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g.	O
,	O
a	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
or	O
persistent	O
hoarseness	O
)	O
.	O
	
The	O
detection	O
of	O
an	O
immune	O
response	O
is	O
highly	O
dependent	O
on	O
the	O
sensitivity	O
and	O
specificity	O
of	O
the	O
assays	O
used	O
,	O
sample	O
handling	O
,	O
timing	O
of	O
sample	O
collection	O
,	O
concomitant	O
medications	O
,	O
and	O
underlying	O
disease	O
.	O
	
The	O
discontinuation	O
rate	O
due	O
to	O
adverse	O
reactions	O
for	O
patients	O
treated	O
with	O
STENDRA	O
50	O
mg	O
,	O
100	O
mg	O
,	O
or	O
200	O
mg	O
was	O
1.4	O
%	O
,	O
2.0	O
%	O
,	O
and	O
2.0	O
%	O
,	O
respectively	O
,	O
compared	O
to	O
1.7	O
%	O
for	O
placebo-treated	O
patients	O
.	O
	
If	O
this	O
occurs	O
,	O
treatment	O
with	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
stopped	O
and	O
other	O
treatments	O
considered	O
.	O
	
If	O
an	O
infection	O
develops	O
,	O
monitor	O
carefully	O
,	O
and	O
stop	O
SIMPONI	O
ARIA	O
if	O
infection	O
becomes	O
serious	O
(	O
5.1	O
)	O
.	O
	
The	O
median	O
number	O
of	O
cycles	O
initiated	O
was	O
22	O
cycles	O
for	O
the	O
KRd	O
arm	O
and	O
14	O
cycles	O
for	O
the	O
Rd	O
arm	O
.	O
	
Appropriate	O
measures	O
should	O
be	O
taken	O
to	O
identify	O
causes	O
of	O
renal	O
failure	O
and	O
treat	O
aggressively	O
.	O
	
(	O
8.4	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Serious	O
infections	B
-	O
do	O
not	O
start	O
CIMZIA	O
during	O
an	O
active	O
infection	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
for	O
example	O
,	O
age	O
>	O
60	O
years	O
,	O
diabetes	O
mellitus	O
or	O
chronic	O
hypertension	O
)	O
,	O
estimate	O
the	O
GFR	O
through	O
laboratory	O
testing	O
.	O
	
5.7	O
Plasmodium	O
vivax	O
Infection	O
Coartem	O
Tablets	O
have	O
been	O
shown	O
in	O
limited	O
data	O
(	O
43	O
patients	O
)	O
to	O
be	O
effective	O
in	O
treating	O
the	O
erythrocytic	O
stage	O
of	O
P.	O
vivax	O
infection	O
.	O
	
Treatment	O
with	O
SIMPONI	O
ARIA	O
should	O
not	O
be	O
initiated	O
in	O
patients	O
with	O
an	O
active	O
infection	O
,	O
including	O
clinically	O
important	O
localized	O
infections	O
.	O
	
The	O
most	O
frequent	O
(	O
>	O
=2	O
%	O
)	O
adverse	O
reactions	O
leading	O
to	O
dose	O
reduction	O
of	O
TAFINLAR	O
were	O
pyrexia	B
(	O
9	O
%	O
)	O
,	O
PPES	B
(	O
3	O
%	O
)	O
,	O
chills	B
(	O
3	O
%	O
)	O
,	O
fatigue	B
(	O
2	O
%	O
)	O
,	O
and	O
headache	B
(	O
2	O
%	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Avoid	O
treatment	O
in	O
the	O
periocular	O
area	O
.	O
	
Patients	O
in	O
SJIA	O
Study	O
1	O
received	O
a	O
single	O
dose	O
of	O
ILARIS	O
4	O
mg/kg	O
(	O
n=43	O
)	O
or	O
placebo	O
(	O
n=41	O
)	O
via	O
subcutaneous	O
injection	O
and	O
were	O
assessed	O
at	O
Day	O
15	O
for	O
the	O
efficacy	O
endpoints	O
and	O
had	O
a	O
safety	O
analysis	O
up	O
to	O
Day	O
29	O
.	O
	
*	O
Lymphopenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
For	O
symptomatic	O
cardiomyopathy	O
or	O
persistent	O
,	O
asymptomatic	O
LV	O
dysfunction	O
that	O
does	O
not	O
resolve	O
within	O
4	O
weeks	O
,	O
permanently	O
discontinue	O
trametinib	O
and	O
withhold	O
TAFINLAR	O
.	O
	
The	O
development	O
of	O
pneumonitis	B
has	O
been	O
reported	O
even	O
at	O
a	O
reduced	O
dose	O
.	O
	
For	O
the	O
purposes	O
of	O
assessing	O
Response-Guided	O
Therapy	O
milestones	O
,	O
a	O
confirmed	O
``	O
detectable	O
but	O
below	O
limit	O
of	O
quantification	O
''	O
HCV-RNA	O
result	O
should	O
not	O
be	O
considered	O
equivalent	O
to	O
an	O
``	O
undetectable	O
''	O
HCV-RNA	O
result	O
(	O
reported	O
as	O
``	O
Target	O
Not	O
Detected	O
''	O
or	O
``	O
HCV-RNA	O
Not	O
Detected	O
''	O
)	O
.	O
	
One	O
additional	O
patient	O
's	O
death	B
was	O
attributed	O
to	O
neutropenia	B
without	O
a	O
documented	O
infection	B
.	O
	
Hypersensitivity	B
reactions	I
(	O
dyspnea	B
,	O
angioedema	B
,	O
rash	B
,	O
and	O
pruritus	B
)	O
have	O
been	O
reported	O
.	O
	
(	O
5.5	O
)	O
(	O
6	O
)	O
(	O
8.5	O
)	O
*	O
Hepatic	B
impairment	I
:	O
Reduce	O
the	O
JEVTANA	O
dose	O
to	O
20	O
mg/m	O
2	O
in	O
patients	O
with	O
mild	O
hepatic	O
impairment	O
and	O
to	O
15	O
mg/m	O
2	O
in	O
patients	O
with	O
moderate	O
hepatic	O
impairment	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
bleeding	B
occurred	O
in	O
417	O
(	O
15.6	O
%	O
)	O
ELIQUIS-treated	O
patients	O
compared	O
to	O
661	O
(	O
24.6	O
%	O
)	O
enoxaparin/warfarin-treated	O
patients	O
.	O
	
Consider	O
a	O
diagnosis	O
of	O
non-infectious	O
pneumonitis	O
in	O
patients	O
presenting	O
with	O
non-specific	O
respiratory	O
signs	O
and	O
symptoms	O
such	O
as	O
hypoxia	O
,	O
pleural	O
effusion	O
,	O
cough	O
,	O
or	O
dyspnea	O
,	O
and	O
in	O
whom	O
infectious	O
,	O
neoplastic	O
,	O
and	O
other	O
causes	O
have	O
been	O
excluded	O
by	O
means	O
of	O
appropriate	O
investigations	O
.	O
	
This	O
information	O
was	O
abstracted	O
and	O
categorized	O
using	O
the	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
``	O
Common	O
Terminology	O
Criteria	O
for	O
Adverse	O
Events	O
''	O
(	O
CTCAE	O
)	O
version	O
3	O
scale	O
.	O
	
Adverse	O
reactions	O
are	O
listed	O
according	O
to	O
MedDRA	O
version	O
15.0	O
system	O
organ	O
class	O
.	O
	
*	O
Impaired	B
wound	I
healing	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
pyrexia	B
(	O
62	O
%	O
)	O
,	O
headache	B
(	O
36	O
%	O
)	O
,	O
peripheral	B
edema	I
(	O
25	O
%	O
)	O
,	O
febrile	B
neutropenia	I
(	O
25	O
%	O
)	O
,	O
nausea	B
(	O
25	O
%	O
)	O
,	O
hypokalemia	B
(	O
23	O
%	O
)	O
,	O
and	O
constipation	B
(	O
20	O
%	O
)	O
.	O
	
Across	O
clinical	O
trials	O
of	O
TAFINLAR	O
administered	O
in	O
combination	O
with	O
trametinib	O
(	O
N	O
=	O
202	O
)	O
,	O
the	O
incidence	O
of	O
RPED	B
was	O
1	O
%	O
(	O
2/202	O
)	O
.	O
	
As	O
the	O
total	O
burden	O
of	O
immunosuppression	O
is	O
a	O
risk	O
factor	O
for	O
PTLD	O
,	O
higher	O
than	O
the	O
recommended	O
doses	O
or	O
more	O
frequent	O
dosing	O
of	O
NULOJIX	O
and	O
higher	O
than	O
recommended	O
doses	O
of	O
concomitant	O
immunosuppressive	O
agents	O
are	O
not	O
recommended	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
.	O
	
Monitor	O
signs	O
and	O
symptoms	O
.	O
	
5.5	O
Effect	O
of	O
P-gp	O
Inducers	O
and	O
Inhibitors	O
on	O
Dabigatran	O
Exposure	O
The	O
concomitant	O
use	O
of	O
PRADAXA	O
with	O
P-gp	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
)	O
reduces	O
exposure	O
to	O
dabigatran	O
and	O
should	O
generally	O
be	O
avoided	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
?	O
	
Uveitis	O
and	O
Iritis	O
:	O
Uveitis	B
and	O
iritis	B
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
5.3	O
Other	O
Malignancies	O
Patients	O
receiving	O
immunosuppressants	O
,	O
including	O
NULOJIX	O
,	O
are	O
at	O
increased	O
risk	O
of	O
developing	O
PTLD	B
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
patients	O
less	O
than	O
1	O
month	O
of	O
age	O
or	O
preterm	O
infants	O
with	O
a	O
corrected	O
age	O
of	O
less	O
than	O
44	O
weeks	O
)	O
could	O
be	O
at	O
risk	O
for	O
gasping	B
syndrome	I
if	O
treated	O
with	O
ULESFIA	O
(	O
r	O
)	O
Lotion	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
]	O
.	O
	
A	O
total	O
of	O
696	O
HIV-positive	O
patients	O
in	O
three	O
placebo-controlled	O
trials	O
received	O
FULYZAQ	O
for	O
a	O
mean	O
duration	O
of	O
78	O
days	O
.	O
	
*	O
TANZEUM	O
is	O
contraindicated	O
in	O
patients	O
with	O
a	O
personal	O
or	O
family	O
history	O
of	O
MTC	O
or	O
in	O
patients	O
with	O
Multiple	O
Endocrine	O
Neoplasia	O
syndrome	O
type	O
2	O
(	O
MEN	O
2	O
)	O
.	O
	
Prior	O
to	O
administration	O
,	O
question	O
the	O
patient	O
for	O
a	O
history	O
of	O
prior	O
reactions	O
to	O
DaTscan	O
.	O
	
Routine	O
ophthalmological	O
examination	O
detected	O
macular	B
edema	I
in	O
some	O
patients	O
with	O
no	O
visual	B
symptoms	I
.	O
	
(	O
5.2	O
)	O
*	O
Clostridium	B
difficile	I
-associated	I
diarrhea	I
(	O
CDAD	B
)	O
has	O
been	O
reported	O
with	O
nearly	O
all	O
systemic	O
antibacterial	O
agents	O
,	O
including	O
ZERBAXA	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
NORTHERA	O
can	O
cause	O
supine	B
hypertension	I
and	O
may	O
increase	O
cardiovascular	B
risk	I
if	O
supine	B
hypertension	I
is	O
not	O
well-managed	O
(	O
5.1	O
)	O
.	O
	
Careful	O
testing	O
of	O
corneal	O
sensation	O
in	O
eyes	O
previously	O
operated	O
upon	O
,	O
avoidance	O
of	O
injection	O
into	O
the	O
lower	O
lid	O
area	O
to	O
avoid	O
ectropion	O
,	O
and	O
vigorous	O
treatment	O
of	O
any	O
epithelial	O
defect	O
should	O
be	O
employed	O
.	O
	
at	O
1-866-416-9637	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
During	O
the	O
clinical	O
trials	O
,	O
0.1	O
%	O
(	O
1/1308	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
discontinued	O
treatment	O
due	O
to	O
depression	B
compared	O
with	O
none	O
in	O
placebo-treated	O
subjects	O
(	O
0/506	O
)	O
.	O
	
Table	O
4	O
compares	O
the	O
incidence	O
of	O
treatment-emergent	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
10	O
mg	O
daily	O
versus	O
placebo	O
.	O
	
(	O
5.8	O
)	O
*	O
Suicide	B
:	O
Close	O
supervision	O
of	O
high	O
risk	O
patients	O
.	O
	
Of	O
the	O
1,039	O
subjects	O
,	O
60	O
%	O
were	O
female	O
and	O
88	O
%	O
were	O
white	O
;	O
the	O
mean	O
age	O
was	O
46	O
years	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
frequent	O
(	O
>	O
=	O
0.2	O
%	O
)	O
adverse	O
reactions	O
in	O
clinical	O
studies	O
were	O
nausea	B
,	O
headache	B
,	O
injection	B
site	I
pain	I
,	O
injection	B
site	I
coldness	I
,	O
and	O
burning	B
sensation	I
.	O
	
Increases	B
in	I
serum	I
creatinine	I
occurred	O
within	O
the	O
first	O
4	O
weeks	O
of	O
treatment	O
and	O
remained	O
stable	O
through	O
48	O
to	O
96	O
weeks	O
.	O
	
Laboratory	O
Abnormalities	O
The	O
frequency	O
of	O
laboratory	O
abnormalities	O
(	O
Grades	O
3-4	O
)	O
occurring	O
in	O
at	O
least	O
2	O
%	O
of	O
subjects	O
receiving	O
STRIBILD	O
in	O
Studies	O
102	O
and	O
103	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
5.5	O
End-Stage	O
Renal	O
Disease	O
No	O
studies	O
have	O
been	O
conducted	O
in	O
patients	O
with	O
end-stage	O
renal	O
disease	O
.	O
	
The	O
rates	O
of	O
treatment-emergent	O
adverse	O
events	O
(	O
irrespective	O
of	O
causality	O
)	O
resulting	O
in	O
permanent	O
discontinuation	O
were	O
14	O
%	O
and	O
3	O
%	O
for	O
the	O
AFINITOR	O
and	O
placebo	O
treatment	O
groups	O
,	O
respectively	O
.	O
	
Perform	O
an	O
examination	O
of	O
the	O
fundus	O
including	O
the	O
macula	O
in	O
all	O
patients	O
before	O
starting	O
treatment	O
,	O
again	O
3-4	O
months	O
after	O
starting	O
treatment	O
,	O
and	O
again	O
at	O
any	O
time	O
after	O
a	O
patient	O
reports	O
visual	O
disturbances	O
while	O
on	O
GILENYA	O
therapy	O
.	O
	
These	O
reactions	O
can	O
occur	O
immediately	O
following	O
or	O
up	O
to	O
24	O
hours	O
after	O
administration	O
of	O
Kyprolis	O
.	O
	
Table	O
4	O
:	O
Clinical	O
Cure	O
Rates	O
in	O
a	O
Phase	O
3	O
Trial	O
of	O
cIAI	O
by	O
Baseline	O
Renal	O
Function	O
(	O
MITT	O
Population	O
)	O
Baseline	O
Renal	O
Function	O
ZERBAXA	O
plus	O
metronidazolen/N	O
(	O
%	O
)	O
Meropenemn/N	O
(	O
%	O
)	O
Normal/mild	O
impairment	O
(	O
CrCl	O
>	O
=50	O
mL/min	O
)	O
312/366	O
(	O
85.2	O
)	O
355/404	O
(	O
87.9	O
)	O
Moderate	O
impairment	O
(	O
CrCl	O
30	O
to	O
<	O
=50	O
mL/min	O
)	O
11/23	O
(	O
47.8	O
)	O
9/13	O
(	O
69.2	O
)	O
5.2	O
Hypersensitivity	O
Reactions	O
Serious	O
and	O
occasionally	O
fatal	B
anaphylactic	B
)	I
reactions	I
have	O
been	O
reported	O
in	O
patients	O
receiving	O
beta-lactam	O
antibacterial	O
drugs	O
.	O
	
The	O
reported	O
frequency	O
for	O
the	O
group	O
receiving	O
10	O
mg/kg	O
may	O
underestimate	O
the	O
actual	O
frequency	O
due	O
to	O
lower	O
assay	O
sensitivity	O
in	O
the	O
presence	O
of	O
high	O
drug	O
concentrations	O
.	O
	
5.2	O
Hyperpyrexia	O
and	O
Confusion	O
Post-marketing	O
cases	O
of	O
a	O
symptom	O
complex	O
resembling	O
neuroleptic	B
malignant	I
syndrome	I
(	O
NMS	B
)	O
have	O
been	O
reported	O
with	O
NORTHERA	O
use	O
during	O
post-marketing	O
surveillance	O
in	O
Japan	O
.	O
	
If	O
this	O
drug	O
is	O
used	O
during	O
pregnancy	O
,	O
or	O
if	O
the	O
patient	O
becomes	O
pregnant	O
while	O
taking	O
this	O
drug	O
,	O
the	O
patient	O
should	O
be	O
apprised	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
)	O
]	O
.	O
	
(	O
5.3	O
,	O
5.4	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	O
have	O
been	O
reported	O
and	O
were	O
characterized	O
by	O
rash	B
,	O
constitutional	O
findings	O
,	O
and	O
sometimes	O
organ	B
dysfunction	I
,	O
including	O
liver	B
injury	I
.	O
	
Some	O
of	O
these	O
events	O
have	O
been	O
fatal	B
.	O
	
Serious	O
adverse	O
reactions	O
reported	O
with	O
alglucosidase	O
alfa	O
included	O
anaphylaxis	B
,	O
which	O
presented	O
as	O
angioedema	B
,	O
throat	B
tightness	I
and	O
chest	B
pain	I
.	O
	
(	O
5.3	O
)	O
*	O
Tardive	B
dyskinesia	I
:	O
Discontinue	O
if	O
clinically	O
appropriate	O
.	O
	
Table	O
3	O
summarizes	O
the	O
most	O
common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
at	O
least	O
3	O
%	O
of	O
alglucosidase	O
alfa-treated	O
patients	O
and	O
with	O
a	O
higher	O
incidence	O
than	O
the	O
placebo-treated	O
patients	O
during	O
the	O
randomized	O
,	O
double-blind	O
,	O
placebo-controlled	O
study	O
described	O
above	O
.	O
	
Withhold	O
Kyprolis	O
for	O
pulmonary	O
hypertension	O
until	O
resolved	O
or	O
returned	O
to	O
baseline	O
and	O
consider	O
whether	O
to	O
restart	O
Kyprolis	O
based	O
on	O
a	O
benefit/risk	O
assessment	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
L	O
ong	O
-	O
acting	O
beta	O
2	O
-adrenergic	O
agonists	O
,	O
such	O
as	O
A	O
RCAPTA	O
NEOHALER	O
,	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
in	O
Chronic	O
Obstructive	O
Pulmonary	O
Disease	O
The	O
clinical	O
program	O
for	O
BREO	O
ELLIPTA	O
included	O
7,700	O
subjects	O
with	O
COPD	O
in	O
two	O
6-month	O
lung	O
function	O
trials	O
,	O
two	O
12-month	O
exacerbation	O
trials	O
,	O
and	O
6	O
other	O
trials	O
of	O
shorter	O
duration	O
.	O
	
In	O
a	O
combined	O
analysis	O
of	O
Studies	O
115	O
and	O
121	O
,	O
the	O
frequency	O
of	O
adverse	O
reactions	O
(	O
all	O
grades	O
)	O
was	O
24	O
%	O
in	O
subjects	O
switching	O
to	O
STRIBILD	O
compared	O
to	O
6	O
%	O
of	O
subjects	O
in	O
either	O
group	O
who	O
stayed	O
on	O
their	O
baseline	O
antiretroviral	O
regimen	O
,	O
RTV-boosted	O
PI	O
+	O
TRUVADA	O
or	O
NNRTI	O
+	O
TRUVADA	O
.	O
	
Pool	O
of	O
Placebo-Controlled	O
Trials	O
The	O
data	O
in	O
Table	O
1	O
is	O
derived	O
from	O
four	O
26-week	O
placebo-controlled	O
trials	O
.	O
	
difficile	O
.	O
	
5.4	O
Allergic	O
Reactions	O
This	O
product	O
contains	O
FD	O
&	O
C	O
Yellow	O
No	O
.	O
	
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
in	O
this	O
trial	O
for	O
the	O
1,200	O
mg	O
dose	O
of	O
HORIZANT	O
were	O
dizziness	B
,	O
somnolence	B
,	O
and	O
headache	B
(	O
see	O
Table	O
5	O
)	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Laryngeal	O
attacks	O
:	O
Following	O
treatment	O
of	O
laryngeal	O
attacks	O
with	O
FIRAZYR	O
,	O
advise	O
patients	O
to	O
seek	O
immediate	O
medical	O
attention	O
.	O
	
If	O
the	O
diagnosis	O
of	O
TTP/HUS	O
is	O
excluded	O
,	O
Kyprolis	O
may	O
be	O
restarted	O
.	O
	
The	O
most	O
common	O
adverse	O
reaction	O
reported	O
for	O
AFINITOR	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
was	O
stomatitis	B
.	O
	
Vascular	O
Disorders	O
superficial	B
phlebitis	I
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
WARNING	O
:	O
NEPHROGENIC	B
SYSTEMIC	I
FIBROSIS	I
(	O
NSF	B
)	O
Gadolinium-based	O
contrast	O
agents	O
(	O
GBCAs	O
)	O
increase	O
the	O
risk	O
for	O
NSF	B
among	O
patients	O
with	O
impaired	O
elimination	O
of	O
the	O
drugs	O
.	O
	
GILENYA	O
may	O
therefore	O
increase	O
the	O
risk	O
of	O
infections	B
,	O
some	O
serious	O
in	O
nature	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
]	O
.	O
	
In	O
controlled	O
trials	O
of	O
other	O
TNF-blockers	O
in	O
patients	O
at	O
higher	O
risk	O
for	O
malignancies	O
(	O
e.g.	O
,	O
patients	O
with	O
COPD	O
,	O
patients	O
with	O
Wegener	O
's	O
granulomatosis	O
treated	O
with	O
concomitant	O
cyclophosphamide	O
)	O
a	O
greater	O
portion	O
of	O
malignancies	B
occurred	O
in	O
the	O
TNF-blocker	O
group	O
compared	O
to	O
the	O
controlled	O
group	O
.	O
	
Your	O
healthcare	O
provider	O
should	O
check	O
any	O
unusual	O
vaginal	O
bleeding	O
to	O
find	O
out	O
the	O
cause	O
.	O
	
SIMPONI	O
ARIA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
a	O
history	O
of	O
CHF	O
and	O
SIMPONI	O
ARIA	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
CHF	O
.	O
	
There	O
is	O
no	O
clinical	O
trial	O
experience	O
re-administering	O
XTANDI	O
to	O
patients	O
who	O
experienced	O
seizure	O
.	O
	
The	O
conduction	B
abnormalities	I
were	O
usually	O
transient	O
and	O
asymptomatic	O
,	O
and	O
resolved	O
within	O
the	O
first	O
24	O
hours	O
on	O
treatment	O
,	O
but	O
they	O
occasionally	O
required	O
treatment	O
with	O
atropine	O
or	O
isoproterenol	O
.	O
	
(	O
5.1	O
)	O
*	O
Hypersensitivity	B
:	O
anaphylactic	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
,	O
including	O
death	B
,	O
have	O
uncommonly	O
occurred	O
.	O
	
Glabellar	O
Lines	O
(	O
5.7	O
)	O
:	O
*	O
Risk	O
of	O
ptosis	B
(	O
5.7	O
)	O
.	O
	
Seventy-eight	O
percent	O
of	O
patients	O
(	O
693	O
of	O
893	O
)	O
were	O
able	O
to	O
receive	O
all	O
planned	O
doses	O
to	O
complete	O
their	O
prescribed	O
treatment	O
regimen	O
.	O
	
Use	O
with	O
caution	O
in	O
patients	O
who	O
are	O
at	O
increased	O
risk	O
for	O
these	O
events	O
.	O
	
(	O
5.11	O
)	O
*	O
Thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
.	O
	
The	O
symptoms	O
are	O
consistent	O
with	O
the	O
mechanism	O
of	O
action	O
of	O
botulinum	O
toxin	O
and	O
may	O
include	O
asthenia	B
,	O
generalized	B
muscle	I
weakness	I
,	O
diplopia	B
,	O
blurred	B
vision	I
,	O
ptosis	B
,	O
dysphagia	B
,	O
dysphonia	B
,	O
dysarthria	B
,	O
urinary	B
incontinence	I
and	O
breathing	B
difficulties	I
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
treatment	O
due	O
to	O
adverse	O
reactions	O
was	O
7.5	O
%	O
in	O
the	O
DUAVEE	O
group	O
and	O
10.0	O
%	O
in	O
the	O
placebo	O
group	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ENDOMETRIAL	B
CANCER	I
,	O
CARDIOVASCULAR	B
DISORDERS	I
,	O
AND	O
PROBABLE	O
DEMENTIA	B
WARNING	O
:	O
ENDOMETRIAL	B
CANCER	I
,	O
CARDIOVASCULAR	B
DISORDERS	I
,	O
AND	O
PROBABLE	O
DEMENTIA	B
*	O
Women	O
taking	O
DUAVEE	O
should	O
not	O
take	O
additional	O
estrogens	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
There	O
is	O
an	O
increased	O
risk	O
of	O
endometrial	B
cancer	I
in	O
a	O
woman	O
with	O
a	O
uterus	O
who	O
uses	O
unopposed	O
estrogens	O
.	O
	
If	O
hypertension	O
can	O
not	O
be	O
adequately	O
controlled	O
,	O
a	O
risk-benefit	O
decision	O
on	O
continued	O
Kyprolis	O
therapy	O
is	O
needed	O
.	O
	
(	O
5.10	O
)	O
*	O
Liver	B
enzyme	I
elevation	I
has	O
been	O
observed	O
during	O
treatment	O
with	O
INLYTA	O
.	O
	
In	O
most	O
cases	O
,	O
this	O
is	O
a	O
consequence	O
of	O
weakening	O
of	O
muscles	O
in	O
the	O
area	O
of	O
injection	O
that	O
are	O
involved	O
in	O
breathing	O
or	O
swallowing	O
.	O
	
The	O
incidence	O
of	O
non-hematologic	O
,	O
non-infectious	O
,	O
adverse	O
events	O
(	O
all	O
Grades	O
)	O
in	O
Study	O
1	O
,	O
Study	O
2	O
,	O
and	O
the	O
EMTP	O
trial	O
is	O
provided	O
in	O
Table	O
1	O
.	O
	
Discontinue	O
immediately	O
.	O
	
The	O
percentage	O
of	O
patients	O
who	O
withdrew	O
from	O
the	O
study	O
due	O
to	O
adverse	O
events	O
was	O
2.1	O
%	O
and	O
2.4	O
%	O
for	O
the	O
placebo	O
and	O
Prolia	O
groups	O
,	O
respectively	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Bausch	O
&	O
Lomb	O
Incorporated	O
at	O
1-800-323-0000	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Topical	O
Ophthalmic	O
Use	O
Only	O
.	O
	
Male	B
genital	I
mycotic	I
infections	I
occurred	O
more	O
commonly	O
in	O
uncircumcised	O
males	O
and	O
in	O
males	O
with	O
a	O
prior	O
history	O
of	O
balanitis	O
or	O
balanoposthitis	O
.	O
	
For	O
the	O
6-dose	O
regimen	O
,	O
Coartem	O
Tablets	O
was	O
studied	O
in	O
active-controlled	O
(	O
366	O
patients	O
)	O
and	O
non-controlled	O
,	O
open-label	O
trials	O
(	O
1,613	O
patients	O
)	O
.	O
	
A	O
total	O
of	O
394	O
patients	O
received	O
more	O
than	O
one	O
treatment	O
application	O
and	O
274	O
patients	O
were	O
followed	O
for	O
48	O
weeks	O
or	O
longer	O
.	O
	
Flush	O
eyes	O
and	O
mucous	O
membranes	O
with	O
cool	O
water	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
WARNING	O
:	O
ASTHMA-RELATED	O
DEATH	B
L	O
ong-acting	O
beta	O
2	O
-adrenergic	O
agonist	O
s	O
(	O
LABA	O
)	O
increase	O
the	O
risk	O
of	O
asthma-related	O
death	B
.	O
	
The	O
first	O
dose	O
of	O
ENTEREG	O
was	O
administered	O
30	O
minutes	O
to	O
5	O
hours	O
before	O
the	O
scheduled	O
start	O
of	O
surgery	O
and	O
then	O
twice	O
daily	O
until	O
hospital	O
discharge	O
(	O
or	O
for	O
a	O
maximum	O
of	O
7	O
days	O
of	O
postoperative	O
treatment	O
)	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
reactions	O
reported	O
in	O
patients	O
treated	O
with	O
XALKORI	O
were	O
pneumonia	B
(	O
4.1	O
%	O
)	O
,	O
pulmonary	B
embolism	I
(	O
3.5	O
%	O
)	O
,	O
dyspnea	B
(	O
2.3	O
%	O
)	O
,	O
and	O
ILD	B
(	O
2.9	O
%	O
)	O
.	O
	
However	O
,	O
epidemiological	O
studies	O
suggest	O
an	O
increased	O
risk	O
of	O
treatment-emergent	O
hyperglycemia-related	O
adverse	O
events	O
in	O
patients	O
treated	O
with	O
the	O
atypical	O
antipsychotics	O
included	O
in	O
these	O
studies	O
.	O
	
In	O
these	O
patients	O
,	O
increases	B
in	I
potassium	I
were	O
more	O
commonly	O
seen	O
in	O
those	O
with	O
elevated	O
potassium	O
at	O
baseline	O
.	O
	
TABLE	O
2	O
:	O
Changes	O
in	O
Fasting	O
Glucose	O
in	O
Pediatric	O
Subjects	O
Bipolar	O
I	O
Disorder	O
(	O
3-weeks	O
)	O
Placebo	O
SAPHRIS2.5	O
mgtwice	O
daily	O
SAPHRIS5	O
mgtwice	O
daily	O
SAPHRIS10	O
mgtwice	O
daily	O
Mean	O
Change	O
from	O
Baseline	O
in	O
Fasting	O
Glucose	O
at	O
Endpoint	O
Change	O
from	O
Baseline	O
(	O
mg/dL	O
)	O
(	O
N*	O
)	O
-2.24	O
(	O
56	O
)	O
1.43	O
(	O
51	O
)	O
-0.45	O
(	O
57	O
)	O
0.34	O
(	O
52	O
)	O
Proportion	O
of	O
Subjects	O
with	O
Shifts	O
from	O
Baseline	O
to	O
Endpoint	O
Normal	O
to	O
High	O
>	O
45	O
&	O
<	O
100	O
to	O
>	O
=126	O
mg/dL	O
0	O
%	O
0	O
%	O
1.8	O
%	O
0	O
%	O
(	O
n/N*	O
)	O
(	O
0/56	O
)	O
(	O
0/51	O
)	O
(	O
1/57	O
)	O
(	O
0/52	O
)	O
Dyslipidemia	B
Undesirable	B
alterations	I
in	I
lipids	I
have	O
been	O
observed	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
Increases	O
in	O
Hemoglobin	O
In	O
the	O
pool	O
of	O
four	O
placebo-controlled	O
trials	O
,	O
mean	O
changes	B
(	I
percent	I
changes	I
)	I
from	I
baseline	I
in	I
hemoglobin	I
were	O
-0.18	O
g/dL	O
(	O
-1.1	O
%	O
)	O
with	O
placebo	O
,	O
0.47	O
g/dL	O
(	O
3.5	O
%	O
)	O
with	O
INVOKANA	O
100	O
mg	O
,	O
and	O
0.51	O
g/dL	O
(	O
3.8	O
%	O
)	O
with	O
INVOKANA	O
300	O
mg	O
.	O
	
Permanent	O
discontinuation	O
of	O
XALKORI	O
treatment	O
for	O
adverse	O
reactions	O
was	O
8.2	O
%	O
.	O
	
Among	O
the	O
patients	O
who	O
experienced	O
diarrhea	O
,	O
the	O
median	O
number	O
of	O
episodes	O
of	O
diarrhea	O
per	O
patient	O
during	O
treatment	O
with	O
BOSULIF	O
was	O
3	O
(	O
range	O
1-221	O
)	O
.	O
	
A	O
total	O
of	O
1964	O
patients	O
participated	O
in	O
two	O
12-week	O
,	O
Phase	O
3	O
efficacy	O
and	O
safety	O
studies	O
and	O
subsequent	O
open-label	O
extension	O
studies	O
.	O
	
The	O
imbalance	O
in	O
deaths	B
is	O
unexplained	O
;	O
no	O
discernible	O
pattern	O
between	O
death	B
and	O
sputum	O
conversion	O
,	O
relapse	O
,	O
sensitivity	O
to	O
other	O
drugs	O
used	O
to	O
treat	O
tuberculosis	O
,	O
HIV	O
status	O
,	O
and	O
severity	O
of	O
disease	O
was	O
observed	O
.	O
	
(	O
5.2	O
)	O
*	O
Lymphopenia	B
:	O
Obtain	O
a	O
CBC	O
including	O
lymphocyte	O
count	O
before	O
initiating	O
TECFIDERA	O
,	O
after	O
6	O
months	O
,	O
and	O
every	O
6	O
to	O
12	O
months	O
thereafter	O
.	O
	
Table	O
5	O
:	O
Non-Hematologic	O
Adverse	O
Reactions	O
>	O
=	O
10	O
%	O
Reported	O
in	O
Study	O
2	O
IMBRUVICA	O
(	O
N=195	O
)	O
Ofatumumab	O
(	O
N=191	O
)	O
System	O
Organ	O
Class	O
ADR	O
Term	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
All	O
Grades	O
(	O
%	O
)	O
Grade	O
3	O
or	O
4	O
(	O
%	O
)	O
Subjects	O
with	O
multiple	O
events	O
for	O
a	O
given	O
ADR	O
term	O
are	O
counted	O
once	O
only	O
for	O
each	O
ADR	O
term	O
.	O
	
Adult	O
Patients	O
:	O
Pooled	O
data	O
on	O
mean	O
changes	O
in	O
body	O
weight	O
and	O
the	O
proportion	O
of	O
subjects	O
meeting	O
a	O
weight	B
gain	I
criterion	O
of	O
>	O
=7	O
%	O
of	O
body	O
weight	O
from	O
the	O
short-term	O
,	O
placebo-controlled	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
PML	O
is	O
an	O
opportunistic	O
viral	O
infection	O
of	O
the	O
brain	O
caused	O
by	O
the	O
JC	O
virus	O
(	O
JCV	O
)	O
that	O
typically	O
only	O
occurs	O
in	O
patients	O
who	O
are	O
immunocompromised	O
,	O
and	O
that	O
usually	O
leads	O
to	O
death	O
or	O
severe	O
disability	O
.	O
	
Of	O
the	O
176	O
patients	O
,	O
65	O
%	O
were	O
White	O
,	O
23	O
%	O
Asian	O
,	O
3	O
%	O
Black	O
,	O
and	O
10	O
%	O
Other	O
race	O
.	O
	
Do	O
not	O
restart	O
NESINA	O
if	O
liver	O
injury	O
is	O
confirmed	O
and	O
no	O
alternative	O
etiology	O
can	O
be	O
found	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
Study	O
1	O
and	O
Study	O
2	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
thrombocytopenia	B
,	O
neutropenia	B
,	O
diarrhea	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
rash	B
,	O
nausea	B
,	O
and	O
pyrexia	B
.	O
	
Eosinophilia	O
A	O
transient	O
increase	B
in	I
mean	I
eosinophil	I
counts	I
was	O
seen	O
during	O
the	O
first	O
2	O
months	O
of	O
therapy	O
.	O
	
Symptoms	O
include	O
fever	B
,	O
chills	B
,	O
pruritus	B
and	O
rash	B
.	O
	
7	O
)	O
]	O
EXCERPT	O
:	O
Cervical	O
Dystonia	O
Most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
>	O
5	O
%	O
of	O
patients	O
)	O
are	O
:	O
muscular	B
weakness	I
,	O
dysphagia	B
,	O
dry	B
mouth	I
,	O
injection	B
site	I
discomfort	I
,	O
fatigue	B
,	O
headache	B
,	O
neck	B
pain	I
,	O
musculoskeletal	B
pain	I
,	O
dysphonia	B
,	O
injection	B
site	I
pain	I
,	O
and	O
eye	B
disorders	I
.	O
	
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
in	O
patients	O
receiving	O
APTIOM	O
at	O
doses	O
of	O
800	O
mg	O
or	O
1200	O
mg	O
(	O
>	O
=4	O
%	O
and	O
>	O
=2	O
%	O
greater	O
than	O
placebo	O
)	O
were	O
dizziness	B
,	O
somnolence	B
,	O
nausea	B
,	O
headache	B
,	O
diplopia	B
,	O
vomiting	B
,	O
fatigue	B
,	O
vertigo	B
,	O
ataxia	B
,	O
blurred	B
vision	I
,	O
and	O
tremor	B
.	O
	
Discontinue	O
TREANDA	O
for	O
patients	O
with	O
Grade	O
4	O
infusion	O
reactions	O
.	O
	
Glucagon-like	O
peptide	O
(	O
GLP-1	O
)	O
receptor	O
agonists	O
have	O
induced	O
thyroid	B
C-cell	I
adenomas	I
in	O
mice	O
and	O
rats	O
at	O
clinically	O
relevant	O
exposures	O
.	O
	
As	O
with	O
all	O
antidepressants	O
,	O
PRISTIQ	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
or	O
family	O
history	O
of	O
mania	O
or	O
hypomania	O
.	O
	
Other	O
Adverse	O
Reactions	O
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
in	O
controlled	O
trials	O
of	O
Crohn	O
's	O
disease	O
were	O
described	O
above	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Restless	O
Legs	O
Syndrome	O
:	O
The	O
exposure	O
to	O
HORIZANT	O
in	O
1,201	O
patients	O
with	O
RLS	O
included	O
613	O
exposed	O
for	O
at	O
least	O
6	O
months	O
and	O
371	O
exposed	O
for	O
at	O
least	O
1	O
year	O
.	O
	
It	O
is	O
unknown	O
whether	O
TRULICITY	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
medullary	B
thyroid	I
carcinoma	I
(	O
MTC	B
)	O
,	O
in	O
humans	O
as	O
the	O
human	O
relevance	O
of	O
dulaglutide-induced	O
rodent	O
thyroid	B
C-cell	I
tumors	I
has	O
not	O
been	O
determined	O
(	O
5.1	O
,	O
13.1	O
)	O
.	O
	
BK	B
virus-associated	I
nephropathy	I
was	O
reported	O
in	O
6	O
NULOJIX	O
patients	O
(	O
4	O
of	O
which	O
resulted	O
in	O
graft	O
loss	O
)	O
and	O
6	O
cyclosporine	O
patients	O
(	O
none	O
of	O
which	O
resulted	O
in	O
graft	O
loss	O
)	O
by	O
Year	O
3	O
.	O
	
(	O
5.9	O
)	O
5.1	O
Cytokine	O
Release	O
Syndrome	O
Cytokine	B
Release	I
Syndrome	I
(	O
CRS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
5.2	O
Cataracts	O
Use	O
of	O
corticosteroids	O
may	O
result	O
in	O
posterior	B
subcapsular	I
cataract	I
formation	O
.	O
	
Summary	O
of	O
Clinical	O
Trials	O
in	O
Chronic	O
Lymphocytic	O
Leukemia	O
The	O
safety	O
data	O
reflect	O
subject	O
exposure	O
to	O
Zydelig	O
from	O
Study	O
1	O
,	O
in	O
which	O
218	O
subjects	O
with	O
relapsed	O
CLL	O
received	O
up	O
to	O
8	O
doses	O
of	O
rituximab	O
with	O
or	O
without	O
Zydelig	O
150	O
mg	O
twice	O
daily	O
.	O
	
5.9	O
Hyponatremia	O
Hyponatremia	B
may	O
occur	O
as	O
a	O
result	O
of	O
treatment	O
with	O
SSRIs	O
and	O
SNRIs	O
,	O
including	O
PRISTIQ	O
.	O
	
Data	O
from	O
a	O
placebo-controlled	O
,	O
4-week	O
,	O
fixed-dose	O
study	O
,	O
in	O
which	O
fasting	O
blood	O
samples	O
were	O
drawn	O
,	O
in	O
adult	O
subjects	O
with	O
schizophrenia	O
are	O
presented	O
in	O
Table	O
3	O
.	O
	
Fifty-eight	O
percent	O
(	O
58	O
%	O
)	O
of	O
the	O
population	O
were	O
male	O
;	O
84	O
%	O
were	O
White	O
,	O
9	O
%	O
were	O
Asian	O
,	O
and	O
3	O
%	O
were	O
Black	O
or	O
African	O
American	O
.	O
	
Hydronephrosis	B
occurred	O
in	O
2	O
patients	O
,	O
one	O
of	O
whom	O
had	O
associated	O
renal	B
function	I
impairment	I
that	O
resolved	O
upon	O
discontinuation	O
of	O
POTIGA	O
.	O
	
The	O
safety	O
data	O
described	O
below	O
are	O
based	O
on	O
one	O
,	O
randomized	O
,	O
double-blind	O
,	O
controlled	O
Phase	O
3	O
trial	O
in	O
patients	O
with	O
RA	O
receiving	O
SIMPONI	O
ARIA	O
by	O
intravenous	O
infusion	O
(	O
Trial	O
1	O
)	O
.	O
	
5.2	O
Urinary	O
Retention	O
POTIGA	O
caused	O
urinary	B
retention	I
in	O
clinical	O
trials	O
.	O
	
(	O
5.4	O
)	O
*	O
Patients	O
with	O
abnormal	O
coagulation	O
:	O
Use	O
with	O
caution	O
,	O
including	O
in	O
patients	O
who	O
have	O
received	O
anticoagulant	O
medications	O
other	O
than	O
low-dose	O
aspirin	O
within	O
7	O
days	O
of	O
the	O
injection	O
.	O
	
Table	O
3	O
:	O
Overall	O
Infections	B
and	O
Select	O
Infections	B
with	O
Identified	O
Etiology	O
by	O
Treatment	O
Group	O
following	O
One	O
and	O
Three	O
Years	O
of	O
Treatment	O
in	O
Studies	O
1	O
and	O
2*	O
Up	O
to	O
Year	O
1	O
Up	O
to	O
Year	O
3	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
n	O
(	O
%	O
)	O
Cyclosporine	O
N=405	O
n	O
(	O
%	O
)	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
n	O
(	O
%	O
)	O
Cyclosporine	O
N=405	O
n	O
(	O
%	O
)	O
*	O
Studies	O
1	O
and	O
2	O
were	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
NULOJIX	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
(	O
2.3	O
)	O
,	O
(	O
5.1	O
)	O
*	O
Neurological	B
toxicities	I
,	O
which	O
may	O
be	O
severe	O
,	O
life-threatening	O
,	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
In	O
the	O
Peyronie	O
's	O
disease	O
clinical	O
studies	O
,	O
at	O
6	O
weeks	O
after	O
the	O
first	O
treatment	O
cycle	O
of	O
XIAFLEX	O
0.58	O
mg	O
,	O
approximately	O
75	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-I	O
and	O
approximately	O
55	O
%	O
of	O
patients	O
had	O
antibodies	O
against	O
AUX-II	O
.	O
	
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
If	O
a	O
patient	O
is	O
exposed	O
to	O
measles	O
,	O
prophylaxis	O
with	O
pooled	O
intramuscular	O
immunoglobulin	O
(	O
IG	O
)	O
may	O
be	O
indicated	O
.	O
	
In	O
placebo-controlled	O
trials	O
in	O
patients	O
with	O
epilepsy	O
,	O
dizziness	B
was	O
reported	O
in	O
23	O
%	O
of	O
patients	O
treated	O
with	O
POTIGA	O
and	O
9	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
Elevated	B
ALT	I
(	O
5.3	O
)	O
,	O
Decreased	B
plasma	I
zinc	I
concentrations	I
(	O
5.3	O
)	O
.	O
	
All	O
of	O
these	O
patients	O
who	O
received	O
FANAPT	O
were	O
participating	O
in	O
multiple-dose	O
clinical	O
trials	O
.	O
	
Table	O
2	O
and	O
Table	O
3	O
summarize	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
reported	O
for	O
Zydelig	O
+	O
rituximab	O
and	O
placebo	O
+	O
rituximab	O
arms	O
.	O
	
Placebo	O
plus	O
prednisone	O
5	O
mg	O
twice	O
daily	O
was	O
given	O
to	O
control	O
patients	O
.	O
	
*	O
Ferriprox	O
can	O
cause	O
agranulocytosis	B
that	O
can	O
lead	O
to	O
serious	O
infections	B
and	O
death	B
.	O
	
Signs	O
or	O
symptoms	O
that	O
may	O
reflect	O
serious	O
penile	O
injury	O
should	O
be	O
promptly	O
evaluated	O
to	O
assess	O
for	O
corporal	O
rupture	O
or	O
severe	O
penile	O
hematoma	O
which	O
may	O
require	O
surgical	O
intervention	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Long-term	O
cumulative	O
radiation	O
exposure	O
is	O
associated	O
with	O
an	O
increased	O
risk	O
for	O
cancer	B
.	O
	
Table	O
4	O
:	O
Adverse	O
Reactions	O
Reported	O
by	O
>	O
=10	O
%	O
of	O
Patients	O
Treated	O
with	O
Either	O
the	O
NULOJIX	O
Recommended	O
Regimen	O
or	O
Control	O
in	O
Studies	O
1	O
and	O
2	O
Through	O
Three	O
Years*	O
,	O
Adverse	O
Reaction	O
NULOJIX	O
Recommended	O
Regimen	O
N=401	O
%	O
Cyclosporine	O
N=405	O
%	O
*	O
All	O
randomized	O
and	O
transplanted	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Mineralocorticoid	B
excess	I
:	O
Use	O
ZYTIGA	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
cardiovascular	O
disease	O
.	O
	
Chromaturia	B
(	O
reddish/brown	O
discoloration	O
of	O
the	O
urine	O
)	O
is	O
a	O
result	O
of	O
the	O
excretion	O
of	O
the	O
iron	O
in	O
the	O
urine	O
.	O
	
Prednisone	O
reduction	O
can	O
be	O
accomplished	O
by	O
reducing	O
the	O
daily	O
prednisone	O
dose	O
by	O
2.5	O
mg	O
on	O
a	O
weekly	O
basis	O
during	O
therapy	O
with	O
BREO	O
ELLIPTA	O
.	O
	
cDefined	O
as	O
bleeding	B
accompanied	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
a	O
decrease	B
in	I
hemoglobin	I
of	O
>	O
=2	O
g/dL	O
,	O
a	O
transfusion	O
of	O
2	O
or	O
more	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
bleeding	B
at	I
a	I
critical	I
site	I
or	O
with	O
fatal	B
outcome	O
.	O
	
Immediately	O
discontinue	O
treatment	O
if	O
severe	O
hypersensitivity	O
,	O
severe	O
rash	O
or	O
rash	O
with	O
systemic	O
symptoms	O
or	O
liver	O
transaminase	O
elevations	O
develops	O
and	O
monitor	O
clinical	O
status	O
,	O
including	O
liver	O
transaminases	O
closely	O
.	O
	
Table	O
1	O
lists	O
adverse	O
reactions	O
that	O
occurred	O
in	O
>	O
=	O
0.1	O
%	O
of	O
subjects	O
treated	O
with	O
EOVIST	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Acorda	O
Therapeutics	O
at	O
1-800-367-5109	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
If	O
paradoxical	O
bronchospasm	O
occurs	O
following	O
dosing	O
with	O
BREO	O
ELLIPTA	O
,	O
it	O
should	O
be	O
treated	O
immediately	O
with	O
an	O
inhaled	O
,	O
short-acting	O
bronchodilator	O
;	O
BREO	O
ELLIPTA	O
should	O
be	O
discontinued	O
immediately	O
;	O
and	O
alternative	O
therapy	O
should	O
be	O
instituted	O
.	O
	
During	O
the	O
initial	O
phase	O
of	O
combination	O
antiretroviral	O
treatment	O
,	O
patients	O
whose	O
immune	O
system	O
responds	O
may	O
develop	O
an	O
inflammatory	B
response	I
to	O
indolent	O
or	O
residual	O
opportunistic	B
infections	I
(	O
such	O
as	O
Mycobacterium	B
avium	I
infection	I
,	O
cytomegalovirus	B
,	O
Pneumocystis	B
jiroveci	I
pneumonia	I
(	O
PCP	B
)	O
or	O
tuberculosis	B
)	O
,	O
which	O
may	O
necessitate	O
further	O
evaluation	O
and	O
treatment	O
.	O
	
5.6	O
Increased	O
Toxicity	O
in	O
the	O
Presence	O
of	O
Severe	O
Renal	O
Impairment	O
The	O
frequency	O
of	O
>	O
=Grade	O
3	O
adverse	O
reactions	O
and	O
deaths	B
was	O
greater	O
in	O
patients	O
with	O
severe	O
renal	O
impairment	O
compared	O
to	O
patients	O
with	O
normal	O
renal	O
function	O
.	O
	
In	O
4	O
studies	O
FARXIGA	O
was	O
used	O
as	O
monotherapy	O
,	O
and	O
in	O
8	O
studies	O
FARXIGA	O
was	O
used	O
as	O
add-on	O
to	O
background	O
antidiabetic	O
therapy	O
or	O
as	O
combination	O
therapy	O
with	O
metformin	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
Tables	O
2	O
and	O
3	O
summarize	O
the	O
common	O
adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
observed	O
in	O
ZYKADIA-treated	O
patients	O
.	O
	
Patients	O
were	O
not	O
eligible	O
if	O
AST	O
and/or	O
ALT	O
>	O
=2.5*	O
ULN	O
in	O
the	O
absence	O
of	O
liver	O
metastases	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
collagenase	O
clostridium	O
histolyticum	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
most	O
frequent	O
serious	O
adverse	O
reactions	O
that	O
occurred	O
were	O
pneumonia	B
(	O
15	O
%	O
)	O
,	O
diarrhea	B
(	O
11	O
%	O
)	O
,	O
and	O
pyrexia	B
(	O
9	O
%	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
during	O
clinical	O
trials	O
were	O
chromaturia	B
,	O
nausea	B
,	O
vomiting	B
,	O
abdominal	B
pain	I
,	O
alanine	B
aminotransferase	I
increased	I
,	O
arthralgia	B
and	O
neutropenia	B
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Cleviprex	O
clinical	O
development	O
included	O
19	O
studies	O
,	O
with	O
99	O
healthy	O
subjects	O
and	O
1307	O
hypertensive	O
patients	O
who	O
received	O
at	O
least	O
one	O
dose	O
of	O
clevidipine	O
(	O
1406	O
total	O
exposures	O
)	O
.	O
	
5.4	O
Neuropsychiatric	O
Symptoms	O
Confusional	B
state	I
,	O
psychotic	B
symptoms	I
,	O
and	O
hallucinations	B
were	O
reported	O
more	O
frequently	O
as	O
adverse	O
reactions	O
in	O
patients	O
treated	O
with	O
POTIGA	O
than	O
in	O
those	O
treated	O
with	O
placebo	O
in	O
placebo-controlled	O
epilepsy	O
trials	O
(	O
see	O
Table	O
2	O
)	O
.	O
	
These	O
patients	O
should	O
also	O
be	O
instructed	O
to	O
carry	O
a	O
warning	O
card	O
indicating	O
that	O
they	O
may	O
need	O
supplementary	O
systemic	O
corticosteroids	O
during	O
periods	O
of	O
stress	O
,	O
a	O
severe	O
COPD	O
exacerbation	O
,	O
or	O
a	O
severe	O
asthma	O
attack	O
.	O
	
If	O
feasible	O
,	O
stop	O
Natazia	O
at	O
least	O
4	O
weeks	O
before	O
and	O
through	O
2	O
weeks	O
after	O
major	O
surgery	O
or	O
other	O
surgeries	O
known	O
to	O
have	O
an	O
elevated	O
risk	O
of	O
thromboembolism	O
.	O
	
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
:	O
acute	B
respiratory	I
distress	I
syndrome	I
,	O
epistaxis	B
,	O
hemoptysis	B
,	O
pulmonary	B
embolism	I
.	O
	
Less	O
Common	O
Adverse	O
Reactions	O
:	O
The	O
following	O
additional	O
adverse	O
reactions	O
were	O
reported	O
in	O
>	O
=5	O
%	O
to	O
<	O
10	O
%	O
of	O
the	O
HALAVEN-treated	O
group	O
:	O
*	O
Eye	O
Disorders	O
:	O
increased	B
lacrimation	I
*	O
Gastrointestinal	O
Disorders	O
:	O
dyspepsia	B
,	O
abdominal	B
pain	I
,	O
stomatitis	B
,	O
dry	B
mouth	I
*	O
General	O
Disorders	O
and	O
Administration	O
Site	O
Conditions	O
:	O
peripheral	B
edema	I
*	O
Infections	O
and	O
Infestations	O
:	O
upper	B
respiratory	I
tract	I
infection	I
*	O
Metabolism	O
and	O
Nutrition	O
Disorders	O
:	O
hypokalemia	B
*	O
Musculoskeletal	O
and	O
Connective	O
Tissue	O
Disorders	O
:	O
muscle	B
spasms	I
,	O
muscular	B
weakness	I
*	O
Nervous	O
System	O
Disorders	O
:	O
dysgeusia	B
,	O
dizziness	B
*	O
Psychiatric	O
Disorders	O
:	O
insomnia	B
,	O
depression	B
*	O
Skin	O
and	O
Subcutaneous	O
Tissue	O
Disorders	O
:	O
rash	B
6	O
.	O
	
Neutralizing	O
antibodies	O
to	O
AUX-I	O
or	O
AUX-II	O
,	O
were	O
detected	O
in	O
60	O
%	O
and	O
51.8	O
%	O
,	O
respectively	O
,	O
of	O
patients	O
tested	O
.	O
	
If	O
a	O
hypersensitivity	O
reaction	O
occurs	O
,	O
the	O
patient	O
should	O
discontinue	O
TRULICITY	O
and	O
promptly	O
seek	O
medical	O
advice	O
.	O
	
(	O
2.2	O
,	O
5.1	O
)	O
*	O
Hepatotoxicity	B
:	O
ZYKADIA	O
can	O
cause	O
hepatotoxicity	B
.	O
	
Grade	O
3-4	O
cardiac	B
failure	I
occurred	O
in	O
0.2	O
%	O
of	O
patients	O
taking	O
placebo	O
.	O
	
Avoid	O
the	O
use	O
of	O
ADCETRIS	O
in	O
patients	O
with	O
moderate	O
(	O
Child-Pugh	O
B	O
)	O
or	O
severe	O
(	O
Child-Pugh	O
C	O
)	O
hepatic	O
impairment	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.7	O
)	O
]	O
.	O
	
c	O
not	O
applicable	O
;	O
(	O
grading	O
system	O
does	O
not	O
specify	O
>	O
Grade	O
2	O
for	O
alopecia	B
)	O
.	O
	
Hypertension	O
Blood	O
pressure	O
and	O
use	O
of	O
antihypertensive	O
medications	O
were	O
reported	O
in	O
Studies	O
1	O
and	O
2	O
.	O
	
5.2	O
Fat	O
Redistribution	O
buffalo	B
hump	I
,	O
facial	B
wasting	I
,	O
breast	B
enlargement	I
,	O
and	O
``	O
cushingoid	B
appearance	I
''	O
have	O
been	O
observed	O
in	O
patients	O
receiving	O
antiretroviral	O
therapy	O
.	O
	
It	O
is	O
possible	O
that	O
systemic	O
corticosteroid	O
effects	O
such	O
as	O
hypercorticism	B
and	O
adrenal	B
suppression	I
(	O
including	O
adrenal	B
crisis	I
)	O
may	O
appear	O
in	O
a	O
small	O
number	O
of	O
patients	O
who	O
are	O
sensitive	O
to	O
these	O
effects	O
.	O
	
In	O
Phase	O
3	O
clinical	O
trials	O
,	O
Grade	O
3	O
and	O
4	O
rashes	B
were	O
reported	O
in	O
1.3	O
%	O
of	O
subjects	O
receiving	O
INTELENCE	O
(	O
r	O
)	O
compared	O
to	O
0.2	O
%	O
of	O
placebo	O
subjects	O
.	O
	
Major	O
bleeding	B
events	O
within	O
each	O
subcategory	O
were	O
counted	O
once	O
per	O
patient	O
,	O
but	O
patients	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
subcategories	O
.	O
	
During	O
withdrawal	O
from	O
oral	O
corticosteroids	O
,	O
some	O
patients	O
may	O
experience	O
symptoms	O
of	O
systemically	O
active	O
corticosteroid	O
withdrawal	O
(	O
e.g.	O
,	O
joint	O
and/or	O
muscular	O
pain	O
,	O
lassitude	O
,	O
depression	O
)	O
despite	O
maintenance	O
or	O
even	O
improvement	O
of	O
respiratory	O
function	O
.	O
	
Premedication	O
may	O
include	O
acetaminophen	O
,	O
an	O
antihistamine	O
,	O
and	O
a	O
corticosteroid	O
.	O
	
Cardiac	O
disorders	O
:	O
atrial	B
fibrillation	I
,	O
cardiac	B
failure	I
.	O
	
Do	O
not	O
use	O
NULOJIX	O
in	O
transplant	O
recipients	O
who	O
are	O
EBV	O
seronegative	O
or	O
with	O
unknown	O
EBV	O
serostatus	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Sustained	O
blood	B
pressure	I
increases	I
could	O
have	O
adverse	O
consequences	O
.	O
	
The	O
most	O
frequent	O
adverse	O
reactions	O
leading	O
to	O
permanent	O
discontinuation	O
in	O
patients	O
treated	O
with	O
COMETRIQ	O
were	O
:	O
hypocalcemia	B
,	O
increased	B
lipase	I
,	O
PPES	B
,	O
diarrhea	B
,	O
fatigue	B
,	O
hypertension	B
,	O
nausea	B
,	O
pancreatitis	B
,	O
tracheal	B
fistula	I
formation	I
and	O
vomiting	B
.	O
	
*	O
Pancreatitis	B
:	O
Has	O
been	O
reported	O
in	O
clinical	O
trials	O
.	O
	
(	O
6.1	O
)	O
*	O
PHN	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
greater	O
than	O
placebo	O
)	O
were	O
dizziness	B
,	O
somnolence	B
,	O
and	O
headache	B
.	O
	
During	O
controlled	O
clinical	O
studies	O
,	O
the	O
proportion	O
of	O
patients	O
with	O
serious	O
adverse	O
reactions	O
was	O
10	O
%	O
for	O
CIMZIA	O
and	O
9	O
%	O
for	O
placebo	O
.	O
	
Monitor	O
and	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
until	O
signs	O
and	O
symptoms	O
resolve	O
(	O
5.4	O
)	O
.	O
	
[	O
See	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
,	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
)	O
are	O
fatigue	B
,	O
diarrhea	B
,	O
pruritus	B
,	O
rash	B
,	O
and	O
colitis	B
.	O
	
Sustained	O
decreases	O
in	O
eGFR	O
were	O
seen	O
in	O
patients	O
with	O
moderate	O
renal	O
impairment	O
(	O
eGFR	O
30	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
This	O
reflects	O
its	O
alpha1-adrenergic	O
antagonist	O
properties	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reaction	O
in	O
adults	O
was	O
diarrhea	B
(	O
2	O
%	O
)	O
.	O
	
Patients	O
who	O
can	O
not	O
be	O
monitored	O
should	O
usually	O
not	O
be	O
treated	O
with	O
POTIGA	O
.	O
	
Across	O
all	O
short-	O
and	O
long-term	O
studies	O
,	O
the	O
overall	O
mean	O
change	O
from	O
baseline	O
at	O
endpoint	O
was	O
2.1	O
kg	O
.	O
	
Adverse	O
reactions	O
related	O
to	O
volume	B
depletion	I
(	O
including	O
reports	O
of	O
dehydration	B
,	O
hypovolemia	B
,	O
orthostatic	B
hypotension	I
,	O
or	O
hypotension	B
)	O
are	O
shown	O
in	O
Table	O
2	O
for	O
the	O
12-study	O
and	O
13-study	O
,	O
short-term	O
,	O
placebo-controlled	O
pools	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
(	O
5.6	O
)	O
}	O
}	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Alcon	O
Laboratories	O
,	O
Inc.	O
at	O
1-800-757-9195	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
have	O
been	O
associated	O
with	O
Zydelig	O
in	O
clinical	O
trials	O
and	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
prescribing	O
information	O
.	O
	
In	O
some	O
cases	O
,	O
disseminated	B
intravascular	I
coagulation	I
(	O
DIC	B
)	O
,	O
capillary	B
leak	I
syndrome	I
(	O
CLS	B
)	O
,	O
and	O
hemophagocytic	B
lymphohistiocytosis/macrophage	O
activation	B
syndrome	I
(	O
HLH/MAS	O
)	O
have	O
been	O
reported	O
in	O
the	O
setting	O
of	O
CRS	B
.	O
	
Infusion	O
Reactions	O
There	O
were	O
no	O
reports	O
of	O
anaphylaxis	B
or	O
drug	B
hypersensitivity	I
in	O
patients	O
treated	O
with	O
NULOJIX	O
in	O
Studies	O
1	O
and	O
2	O
through	O
three	O
years	O
.	O
	
Table	O
1	O
summarizes	O
the	O
most	O
common	O
adverse	O
reactions	O
that	O
occurred	O
in	O
the	O
placebo-controlled	O
trial	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
in	O
patients	O
treated	O
with	O
Vimizim	O
2	O
mg/kg	O
once	O
per	O
week	O
and	O
with	O
a	O
higher	O
incidence	O
than	O
in	O
the	O
placebo-treated	O
patients	O
.	O
	
Adverse	O
reactions	O
reported	O
within	O
48	O
weeks	O
of	O
treatment	O
and	O
in	O
at	O
least	O
1	O
%	O
of	O
subjects	O
treated	O
with	O
JUBLIA	O
and	O
those	O
reported	O
in	O
subjects	O
treated	O
with	O
the	O
vehicle	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
The	O
patient	O
was	O
also	O
not	O
taking	O
any	O
immunosuppressive	O
or	O
immunomodulatory	O
medications	O
concomitantly	O
.	O
	
2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
use	O
of	O
IMBRUVICA	O
.	O
	
The	O
following	O
risks	O
,	O
including	O
appropriate	O
action	O
to	O
be	O
taken	O
,	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
the	O
label	O
[	O
seeWarnings	O
and	O
Precautions	O
(	O
5.1-5.13	O
)	O
]	O
:	O
hypertension	B
,	O
arterial	B
thromboembolic	I
events	I
,	O
venous	B
thromboembolic	I
events	I
,	O
hemorrhage	B
,	O
cardiac	B
failure	I
,	O
gastrointestinal	B
perforation	I
and	O
fistula	B
formation	I
,	O
thyroid	B
dysfunction	I
,	O
wound	B
healing	I
complications	I
,	O
RPLS	B
,	O
proteinuria	B
,	O
elevation	B
of	I
liver	I
enzymes	I
,	O
hepatic	B
impairment	I
and	O
fetal	O
development	O
.	O
	
When	O
treating	O
pediatric	O
patients	O
,	O
weight	O
gain	O
should	O
be	O
monitored	O
and	O
assessed	O
against	O
that	O
expected	O
for	O
normal	O
growth	O
.	O
	
These	O
included	O
infections	B
,	O
subdural	B
hematomas	I
and	O
diarrhea	B
.	O
	
Approximately	O
1162	O
patients	O
have	O
received	O
more	O
than	O
2	O
years	O
of	O
treatment	O
with	O
TECFIDERA	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
WARNING	O
:	O
RISK	O
OF	O
ANAPHYLAXIS	B
Life-threatening	O
anaphylactic	B
reactions	I
have	O
occurred	O
in	O
some	O
patients	O
during	O
Vimizim	O
infusions	O
.	O
	
The	O
most	O
commonly	O
occurring	O
adverse	O
reactions	O
(	O
>	O
=	O
20	O
%	O
)	O
were	O
thrombocytopenia	B
,	O
diarrhea	B
,	O
neutropenia	B
,	O
anemia	B
,	O
fatigue	B
,	O
musculoskeletal	B
pain	I
,	O
peripheral	B
edema	I
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
nausea	B
,	O
bruising	B
,	O
dyspnea	B
,	O
constipation	B
,	O
rash	B
,	O
abdominal	B
pain	I
,	O
vomiting	B
and	O
decreased	B
appetite	I
(	O
see	O
Tables	O
1	O
and	O
2	O
)	O
.	O
	
6.2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
reactions	O
have	O
been	O
identified	O
during	O
the	O
postmarketing	O
use	O
of	O
NESINA	O
.	O
	
Preventive	O
measures	O
include	O
vigorous	O
hydration	O
and	O
close	O
monitoring	O
of	O
blood	O
chemistry	O
,	O
particularly	O
potassium	O
and	O
uric	O
acid	O
levels	O
.	O
	
Cervical	O
Dystonia	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
DYSPORT	O
(	O
r	O
)	O
in	O
357	O
cervical	O
dystonia	O
patients	O
in	O
6	O
studies	O
.	O
	
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
and	O
(	O
2.3	O
)	O
]	O
5.2	O
Infections	O
Infection	B
,	O
including	O
pneumonia	B
,	O
sepsis	B
,	O
septic	B
shock	I
,	O
and	O
death	B
have	O
occurred	O
in	O
adult	O
and	O
pediatric	O
patients	O
in	O
clinical	O
trials	O
and	O
in	O
postmarketing	O
reports	O
.	O
	
In	O
such	O
cases	O
,	O
promptly	O
discontinue	O
NESINA	O
,	O
assess	O
for	O
other	O
potential	O
causes	O
,	O
institute	O
appropriate	O
monitoring	O
and	O
treatment	O
and	O
initiate	O
alternative	O
treatment	O
for	O
diabetes	O
.	O
	
The	O
most	O
common	O
cause	O
of	O
death	B
as	O
reported	O
by	O
the	O
investigator	O
was	O
TB	O
(	O
9	O
subjects	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
in	O
children	O
(	O
>	O
12	O
%	O
)	O
are	O
pyrexia	B
,	O
cough	B
,	O
vomiting	B
,	O
anorexia	B
,	O
and	O
headache	B
.	O
	
DALVANCE	O
was	O
discontinued	O
due	O
to	O
an	O
adverse	O
reaction	O
in	O
53/1778	O
(	O
3	O
%	O
)	O
patients	O
and	O
the	O
comparator	O
was	O
discontinued	O
due	O
to	O
an	O
adverse	O
reaction	O
in	O
35/1224	O
(	O
2.8	O
%	O
)	O
patients	O
.	O
	
Dose	O
reductions	O
due	O
to	O
adverse	O
reactions	O
were	O
required	O
in	O
6.4	O
%	O
of	O
XALKORI-treated	O
patients	O
.	O
	
If	O
skin	O
reactions	O
are	O
severe	O
or	O
progressive	O
,	O
withhold	O
or	O
discontinue	O
TREANDA	O
.	O
	
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
Besivance	O
in	O
approximately	O
1,000	O
patients	O
between	O
1	O
and	O
98	O
years	O
old	O
with	O
clinical	O
signs	O
and	O
symptoms	O
of	O
bacterial	O
conjunctivitis	O
.	O
	
Laboratory	O
and	O
Imaging	O
Tests	O
Increases	O
in	O
Serum	O
Potassium	O
In	O
a	O
pooled	O
population	O
of	O
patients	O
(	O
N=723	O
)	O
with	O
moderate	O
renal	O
impairment	O
(	O
eGFR	O
45	O
to	O
less	O
than	O
60	O
mL/min/1.73	O
m	O
2	O
)	O
,	O
increases	B
in	I
serum	I
potassium	I
to	O
greater	O
than	O
5.4	O
mEq/L	O
and	O
15	O
%	O
above	O
baseline	O
occurred	O
in	O
5.3	O
%	O
,	O
5.0	O
%	O
,	O
and	O
8.8	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
A	O
total	O
of	O
3876	O
women	O
were	O
exposed	O
to	O
placebo	O
and	O
3886	O
women	O
were	O
exposed	O
to	O
Prolia	O
administered	O
subcutaneously	O
once	O
every	O
6	O
months	O
as	O
a	O
single	O
60	O
mg	O
dose	O
.	O
	
S	O
Includes	O
patients	O
treated	O
with	O
flexible	O
dose	O
of	O
SAPHRIS	O
5	O
or	O
10	O
mg	O
twice	O
daily	O
(	O
N=90	O
)	O
.	O
	
In	O
a	O
trial	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
serum	B
magnesium	I
levels	I
increased	I
by	O
0.2	O
%	O
,	O
9.2	O
%	O
,	O
and	O
14.8	O
%	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
The	O
median	O
duration	O
of	O
study	O
treatment	O
was	O
7.1	O
months	O
for	O
patients	O
who	O
received	O
XALKORI	O
and	O
2.8	O
months	O
for	O
patients	O
who	O
received	O
chemotherapy	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
compared	O
directly	O
with	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
No	O
deaths	B
,	O
intubations	O
,	O
or	O
serious	O
adverse	O
reactions	O
related	O
to	O
asthma	B
exacerbation	I
were	O
reported	O
in	O
this	O
trial	O
.	O
	
(	O
5.4	O
,	O
5.5	O
)	O
5.1	O
Eye	O
and	O
Mucous	O
Membrane	O
Exposure	O
Do	O
not	O
apply	O
Qutenza	O
to	O
the	O
face	O
or	O
scalp	O
to	O
avoid	O
risk	O
of	O
exposure	O
to	O
the	O
eyes	O
or	O
mucous	O
membranes	O
.	O
	
Laboratory	O
abnormalities	O
are	O
described	O
separately	O
in	O
Table	O
11	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Seizure	O
In	O
Study	O
1	O
,	O
which	O
enrolled	O
patients	O
who	O
previously	O
received	O
docetaxel	O
,	O
7	O
of	O
800	O
(	O
0.9	O
%	O
)	O
patients	O
treated	O
with	O
XTANDI	O
experienced	O
a	O
seizure	B
and	O
no	O
patients	O
treated	O
with	O
placebo	O
experienced	O
a	O
seizure	B
.	O
	
Prescribers	O
should	O
exercise	O
caution	O
in	O
considering	O
the	O
use	O
of	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
in	O
patients	O
with	O
central	O
or	O
peripheral	O
nervous	O
system	O
demyelinating	O
disorders	O
.	O
	
Three	O
additional	O
subjects	O
tested	O
positive	O
for	O
binding	O
antibodies	O
after	O
receiving	O
DYSPORT	O
(	O
r	O
)	O
treatment	O
.	O
	
This	O
drop	O
in	O
body	O
estrogen	O
levels	O
causes	O
the	O
``	O
change	O
of	O
life	O
''	O
or	O
menopause	O
(	O
the	O
end	O
of	O
monthly	O
menstrual	O
periods	O
)	O
.	O
	
A	O
risk	O
for	O
the	O
development	O
for	O
hepatosplenic	O
T-cell	O
lymphoma	O
in	O
patients	O
treated	O
with	O
TNF-blockers	O
can	O
not	O
be	O
excluded	O
.	O
	
Instruct	O
patients	O
receiving	O
GILENYA	O
to	O
report	O
symptoms	O
of	O
infections	O
to	O
a	O
physician	O
.	O
	
*	O
Screen	O
patients	O
for	O
acute	O
kidney	O
injury	O
and	O
other	O
conditions	O
that	O
may	O
reduce	O
renal	O
function	O
.	O
	
The	O
risk	O
of	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
also	O
occur	O
in	O
adults	O
,	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
The	O
most	O
common	O
key	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
50	O
%	O
)	O
were	O
hypercholesterolemia	B
and	O
elevated	B
partial	I
thromboplastin	I
time	I
.	O
	
In	O
Study	O
1	O
,	O
all	O
Grades	O
of	O
adverse	O
events	O
were	O
reported	O
for	O
the	O
following	O
adverse	O
events	O
of	O
special	O
interest	O
:	O
allergy	B
,	O
pancreatitis	B
,	O
coagulopathy	B
(	O
hemorrhage	B
,	O
thrombosis	B
or	O
infarct	B
)	O
,	O
hyperbilirubinemia	B
,	O
hyperglycemia	B
,	O
hyperlipidemia	B
,	O
ketoacidosis	B
,	O
and	O
CNS	B
events	I
,	O
and	O
cerebral	B
venous	I
thrombosis	I
)	O
and	O
only	O
Grade	O
3	O
and	O
4	O
events	O
were	O
reported	O
for	O
other	O
adverse	O
events	O
.	O
	
(	O
5.8	O
)	O
*	O
Reversible	B
Posterior	I
Leukoencephalopathy	I
Syndrome	I
(	O
RPLS	B
)	O
has	O
been	O
observed	O
.	O
	
The	O
most	O
commonly	O
observed	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
5	O
%	O
)	O
more	O
frequently	O
reported	O
in	O
women	O
treated	O
with	O
DUAVEE	O
than	O
placebo	O
are	O
presented	O
in	O
Table	O
1	O
.	O
	
(	O
5.1	O
)	O
*	O
Acute	B
Renal	I
Failure	I
:	O
Monitor	O
serum	O
creatinine	O
regularly	O
(	O
5.2	O
)	O
*	O
Tumor	B
Lysis	I
Syndrome	I
(	O
TLS	B
)	O
:	O
Administer	O
pre-treatment	O
hydration	O
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
and	O
in	O
approved	O
indications	O
,	O
symptoms	O
consistent	O
with	O
spread	B
of	I
toxin	I
effect	I
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
or	O
lower	O
than	O
the	O
maximum	O
recommended	O
total	O
dose	O
.	O
	
Consider	O
factors	O
that	O
contribute	O
to	O
fracture	O
risk	O
prior	O
to	O
initiating	O
INVOKANA	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
5.13	O
)	O
*	O
Embryo-fetal	B
Toxicity	I
:	O
Kyprolis	O
can	O
cause	O
fetal	B
harm	I
.	O
	
Patients	O
treated	O
with	O
botulinum	O
toxin	O
may	O
require	O
immediate	O
medical	O
attention	O
should	O
they	O
develop	O
problems	O
with	O
swallowing	O
,	O
speech	O
or	O
respiratory	O
disorders	O
.	O
	
Administer	O
this	O
product	O
in	O
a	O
setting	O
with	O
resuscitation	O
equipment	O
and	O
other	O
agents	O
necessary	O
to	O
treat	O
anaphylaxis	O
.	O
	
Monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
cardiac	O
failure	O
throughout	O
treatment	O
with	O
INLYTA	O
.	O
	
*	O
Bipolar	O
Disorder	O
Adults	O
(	O
Adjunctive	O
)	O
:	O
somnolence	B
,	O
oral	B
hypoesthesia	I
.	O
	
At	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
,	O
withhold	O
GILENYA	O
and	O
perform	O
an	O
appropriate	O
diagnostic	O
evaluation	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
infections	B
,	O
dyspnea	B
,	O
fatigue	B
,	O
stomatitis	B
,	O
dehydration	B
,	O
pneumonitis	B
,	O
abdominal	B
pain	I
,	O
and	O
asthenia	B
.	O
	
If	O
unexplained	O
or	O
clinically	O
significant	O
weight	O
loss	O
occurs	O
,	O
evaluate	O
weight	O
loss	O
and	O
consider	O
discontinuation	O
of	O
OTEZLA	O
(	O
5.2	O
)	O
*	O
Drug	O
Interactions	O
:	O
Use	O
with	O
strong	O
cytochrome	O
P450	O
enzyme	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
phenobarbital	O
,	O
carbamazepine	O
,	O
phenytoin	O
)	O
is	O
not	O
recommended	O
because	O
loss	O
of	O
efficacy	O
may	O
occur	O
(	O
5.3,7.1	O
)	O
5.1	O
Depression	O
Treatment	O
with	O
OTEZLA	O
is	O
associated	O
with	O
an	O
increase	O
in	O
adverse	O
reactions	O
of	O
depression	B
.	O
	
Based	O
on	O
effective	O
donor	O
screening	O
and	O
product	O
manufacturing	O
processes	O
,	O
it	O
carries	O
an	O
extremely	O
remote	O
risk	O
for	O
transmission	B
of	I
viral	I
diseases	I
.	O
	
BREO	O
ELLIPTA	O
100/25	O
was	O
studied	O
in	O
2,369	O
subjects	O
and	O
BREO	O
ELLIPTA	O
200/25	O
was	O
studied	O
in	O
956	O
subjects	O
.	O
	
Therefore	O
,	O
if	O
ENTEREG	O
is	O
administered	O
to	O
these	O
patients	O
,	O
they	O
should	O
be	O
monitored	O
for	O
gastrointestinal	O
adverse	O
reactions	O
.	O
	
Seventy-seven	O
subjects	O
initiated	O
a	O
lipid-lowering	O
agent	O
post-baseline	O
;	O
their	O
last	O
fasted	O
on-treatment	O
values	O
(	O
prior	O
to	O
starting	O
the	O
agent	O
)	O
were	O
used	O
regardless	O
if	O
they	O
discontinued	O
the	O
agent	O
(	O
SPRING-2	O
:	O
TIVICAY	O
n	O
=	O
9	O
,	O
raltegravir	O
n	O
=	O
13	O
;	O
SINGLE	O
:	O
TIVICAY	O
n	O
=	O
25	O
and	O
ATRIPLA	O
:	O
n	O
=	O
30	O
)	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
treatment	O
with	O
STRIBILD	O
,	O
the	O
RTV-boosted	O
PI	O
,	O
or	O
the	O
NNRTI	O
due	O
to	O
adverse	O
events	O
,	O
was	O
2	O
%	O
,	O
3	O
%	O
and	O
1	O
%	O
,	O
respectively	O
.	O
	
Overall	O
,	O
the	O
safety	O
profile	O
in	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
C	O
virus	O
co-infection	O
was	O
similar	O
to	O
that	O
observed	O
in	O
subjects	O
without	O
hepatitis	O
B	O
or	O
C	O
co-infection	O
,	O
although	O
the	O
rates	O
of	O
ALT	B
abnormalities	I
were	O
higher	O
in	O
the	O
subgroup	O
with	O
hepatitis	O
B	O
and/or	O
C	O
virus	O
co-infection	O
for	O
all	O
treatment	O
groups	O
.	O
	
Serum	O
Lipids	O
:	O
In	O
the	O
clinical	O
trials	O
of	O
STRIBILD	O
,	O
a	O
similar	O
percentage	O
of	O
subjects	O
receiving	O
STRIBILD	O
,	O
ATRIPLA	O
,	O
and	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
were	O
on	O
lipid	O
lowering	O
agents	O
at	O
baseline	O
(	O
12	O
%	O
,	O
12	O
%	O
,	O
and	O
13	O
%	O
,	O
respectively	O
)	O
.	O
	
5.1	O
Increased	O
Risks	O
in	O
Elderly	O
Patients	O
with	O
Dementia-Related	O
Psychosis	O
Increased	O
Mortality	O
Elderly	O
patients	O
with	O
dementia-related	O
psychosis	O
treated	O
with	O
atypical	O
antipsychotic	O
drugs	O
are	O
at	O
an	O
increased	O
risk	O
of	O
death	B
compared	O
to	O
placebo	O
.	O
	
5.2	O
Concomitant	O
Use	O
with	O
CYP3A	O
Inducers	O
Use	O
of	O
KALYDECO	O
with	O
strong	O
CYP3A	O
inducers	O
,	O
such	O
as	O
rifampin	O
,	O
substantially	O
decreases	O
the	O
exposure	O
of	O
ivacaftor	O
,	O
which	O
may	O
reduce	O
the	O
therapeutic	O
effectiveness	O
of	O
KALYDECO	O
.	O
	
Ecchymosis	O
easily	O
occurs	O
in	O
the	O
soft	O
tissues	O
of	O
the	O
eyelid	O
.	O
	
All	O
subjects	O
were	O
queried	O
about	O
the	O
presence	O
of	O
skin	O
and	O
scalp	O
symptoms	O
;	O
the	O
results	O
are	O
presented	O
in	O
Table	O
2	O
.	O
	
Continuation	O
of	O
GILENYA	O
in	O
patients	O
who	O
develop	O
macular	B
edema	I
has	O
not	O
been	O
evaluated	O
.	O
	
Reduce	O
or	O
withhold	O
dose	O
as	O
appropriate	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Overall	O
,	O
the	O
mean	O
age	O
of	O
patients	O
in	O
the	O
PHN	O
studies	O
ranged	O
from	O
61	O
to	O
64	O
years	O
of	O
age	O
across	O
dose	O
groups	O
;	O
the	O
majority	O
of	O
patients	O
were	O
male	O
(	O
45	O
%	O
to	O
61	O
%	O
)	O
and	O
Caucasian	O
(	O
80	O
%	O
to	O
98	O
%	O
)	O
.	O
	
If	O
CDAD	O
is	O
confirmed	O
,	O
discontinue	O
antibacterials	O
not	O
directed	O
against	O
C.	O
difficile	O
,	O
if	O
possible	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
in	O
COPD	B
or	O
loss	B
of	I
efficacy	I
.	O
	
6-Month	O
Trials	O
The	O
incidence	O
of	O
adverse	O
reactions	O
associated	O
with	O
BREO	O
ELLIPTA	O
100/25	O
in	O
Table	O
1	O
is	O
based	O
on	O
2	O
placebo-controlled	O
,	O
6-month	O
clinical	O
trials	O
(	O
Trials	O
1	O
and	O
2	O
;	O
n	O
=	O
1,224	O
and	O
n	O
=	O
1,030	O
,	O
respectively	O
)	O
.	O
	
Some	O
events	O
have	O
been	O
fatal	B
.	O
	
(	O
5.7	O
)	O
*	O
Leukopenia	B
,	O
Neutropenia	B
,	O
and	O
Agranulocytosis	B
have	O
been	O
reported	O
with	O
antipsychotics	O
.	O
	
5.8	O
Venous	O
Thrombosis	O
Venous	B
thromboembolic	I
events	I
(	O
including	O
deep	B
venous	I
thrombosis	I
and	O
pulmonary	B
embolism	I
)	O
have	O
been	O
observed	O
with	O
Kyprolis	O
.	O
	
Patients	O
should	O
be	O
advised	O
to	O
elevate	O
the	O
head	O
of	O
the	O
bed	O
when	O
resting	O
or	O
sleeping	O
.	O
	
GILOTRIF	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
keratitis	O
,	O
ulcerative	O
keratitis	O
,	O
or	O
severe	O
dry	O
eye	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
5.1	O
Decreased	O
Efficacy	O
in	O
Patients	O
with	O
Baseline	O
Creatinine	O
Clearance	O
of	O
30	O
to	O
<	O
=50	O
mL/min	O
In	O
a	O
subgroup	O
analysis	O
of	O
a	O
Phase	O
3	O
cIAI	O
trial	O
,	O
clinical	O
cure	O
rates	O
were	O
lower	O
in	O
patients	O
with	O
baseline	O
creatinine	O
clearance	O
(	O
CrCl	O
)	O
of	O
30	O
to	O
<	O
=50	O
mL/min	O
compared	O
to	O
those	O
with	O
CrCl	O
>	O
=50	O
mL/min	O
(	O
Table	O
4	O
)	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
resulting	O
in	O
discontinuation	O
of	O
treatment	O
(	O
>	O
=1	O
%	O
of	O
patients	O
receiving	O
BENLYSTA	O
or	O
placebo	O
)	O
were	O
infusion	B
reactions	I
(	O
1.6	O
%	O
BENLYSTA	O
and	O
0.9	O
%	O
placebo	O
)	O
,	O
lupus	B
nephritis	I
(	O
0.7	O
%	O
BENLYSTA	O
and	O
1.2	O
%	O
placebo	O
)	O
,	O
and	O
infections	B
(	O
0.7	O
%	O
BENLYSTA	O
and	O
1.0	O
%	O
placebo	O
)	O
.	O
	
Table	O
8	O
:	O
Adverse	O
Reactions	O
Reported	O
in	O
>	O
=	O
10	O
%	O
of	O
AFINITOR-treated	O
Patients	O
with	O
Renal	O
Angiomyolipoma	O
Grading	O
according	O
to	O
CTCAE	O
Version	O
3.0	O
a	O
Includes	O
stomatitis	B
,	O
aphthous	B
stomatitis	I
,	O
mouth	B
ulceration	I
,	O
gingival	B
pain	I
,	O
glossitis	B
,	O
and	O
glossodynia	B
.	O
	
Thrombocytopenia	B
was	O
reported	O
in	O
approximately	O
40	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
with	O
Kyprolis	O
.	O
	
ULESFIA	O
(	O
r	O
)	O
Lotion	O
may	O
cause	O
eye	B
irritation	I
.	O
	
(	O
5.2	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Hypersensitivity	B
reactions	I
have	O
been	O
reported	O
following	O
DaTscan	O
administration	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
6.3	O
Immunogenicity	O
A	O
biosensor	O
binding	O
assay	O
or	O
a	O
bridging	O
immunoassay	O
was	O
used	O
to	O
detect	O
antibodies	O
directed	O
against	O
canakinumab	O
in	O
patients	O
who	O
received	O
ILARIS	O
.	O
	
Presence	O
of	O
antibody	O
did	O
not	O
correlate	O
with	O
reduced	O
efficacy	O
as	O
measured	O
by	O
HbA1c	O
and	O
fasting	O
plasma	O
glucose	O
or	O
specific	O
adverse	O
reactions	O
.	O
	
Patients	O
with	O
pre-VORAXAZE	O
methotrexate	O
concentrations	O
>	O
100	O
mumol/L	O
were	O
to	O
receive	O
a	O
second	O
dose	O
of	O
VORAXAZE	O
48	O
hours	O
after	O
the	O
first	O
dose	O
.	O
	
Withhold	O
trametinib	O
and	O
continue	O
TAFINLAR	O
at	O
the	O
same	O
dose	O
for	O
uncomplicated	O
DVT	O
or	O
PE	O
;	O
if	O
improved	O
within	O
3	O
weeks	O
,	O
trametinib	O
may	O
be	O
resumed	O
at	O
a	O
lower	O
dose	O
level	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
(	O
5.3	O
)	O
*	O
Renal	B
failure	I
,	O
including	O
cases	O
with	O
fatal	B
outcomes	O
,	O
has	O
been	O
reported	O
.	O
	
General	O
disorders	O
and	O
administration	O
site	O
conditions	O
-	O
Asthenia	B
.	O
	
(	O
5.2	O
)	O
*	O
Development	O
of	O
drug-resistant	O
bacteria	O
:	O
Only	O
use	O
DIFICID	O
for	O
infection	O
proven	O
or	O
strongly	O
suspected	O
to	O
be	O
caused	O
by	O
C.	O
difficile	O
.	O
	
If	O
toxicity	O
recurs	O
at	O
Grade	O
3	O
,	O
consider	O
discontinuation	O
of	O
AFINITOR	O
.	O
	
Table	O
7	O
:	O
Bleeding	B
Results	O
in	O
the	O
AMPLIFY-EXT	O
Study	O
ELIQUIS	O
2.5	O
mg	O
bidN=840n	O
(	O
%	O
)	O
ELIQUIS	O
5	O
mg	O
bidN=811n	O
(	O
%	O
)	O
PlaceboN=826n	O
(	O
%	O
)	O
*	O
CRNM	B
=	O
clinically	B
relevant	I
nonmajor	I
bleeding.Events	O
associated	O
with	O
each	O
endpoint	O
were	O
counted	O
once	O
per	O
subject	O
,	O
but	O
subjects	O
may	O
have	O
contributed	O
events	O
to	O
multiple	O
endpoints	O
.	O
	
Patients	O
should	O
be	O
observed	O
for	O
an	O
appropriate	O
period	O
of	O
time	O
after	O
administration	O
of	O
KALBITOR	O
,	O
taking	O
into	O
account	O
the	O
time	O
to	O
onset	O
of	O
anaphylaxis	O
seen	O
in	O
clinical	O
trials	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
More	O
cases	O
of	O
pneumonia	B
in	O
the	O
group	O
receiving	O
TANZEUM	O
were	O
serious	O
(	O
0.4	O
%	O
for	O
TANZEUM	O
versus	O
0.1	O
%	O
for	O
all	O
comparators	O
)	O
.	O
	
A	O
total	O
of	O
108	O
subjects	O
treated	O
with	O
Picato	O
(	O
r	O
)	O
gel	O
on	O
the	O
face/scalp	O
and	O
38	O
subjects	O
treated	O
on	O
the	O
trunk/extremities	O
were	O
followed	O
for	O
12	O
months	O
.	O
	
To	O
decrease	O
thyroid	O
accumulation	O
of	O
iodine	O
123	O
,	O
block	O
the	O
thyroid	O
gland	O
before	O
administration	O
of	O
DaTscan	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
hazard	O
to	O
the	O
fetus	O
(	O
5.12	O
)	O
.	O
	
Consider	O
discontinuing	O
use	O
if	O
severe	O
symptoms	O
develop	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17.8	O
)	O
]	O
.	O
	
This	O
proteinuria	B
was	O
not	O
associated	O
with	O
increases	B
in	I
BUN	I
and	O
was	O
generally	O
transient	O
.	O
	
The	O
incidence	O
of	O
Common	O
Terminology	O
Criteria	O
(	O
CTC	O
)	O
Grade	O
3	O
and	O
4	O
non-infectious	B
pneumonitis	I
was	O
up	O
to	O
4.0	O
%	O
and	O
up	O
to	O
0.2	O
%	O
,	O
respectively	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
,	O
6.2	O
,	O
6.3	O
,	O
6.4	O
,	O
6.5	O
)	O
]	O
.	O
	
If	O
diagnosed	O
,	O
withhold	O
TAFINLAR	O
for	O
up	O
to	O
6	O
weeks	O
until	O
uveitis/iritis	O
resolves	O
to	O
Grade	O
0-1	O
.	O
	
Consider	O
these	O
risks	O
when	O
scheduling	O
patients	O
for	O
spinal	O
procedures	O
.	O
	
5.6	O
Ocular	O
Toxicities	O
Retinal	O
Pigment	O
Epithelial	O
Detachment	O
(	O
RPED	O
)	O
:	O
Retinal	B
pigment	I
epithelial	I
detachments	I
(	O
RPED	B
)	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
and	O
with	O
trametinib	O
as	O
a	O
single	O
agent	O
[	O
refer	O
to	O
Full	O
Prescribing	O
Information	O
for	O
trametinib	O
]	O
.	O
	
*	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Table	O
3	O
presents	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
study	O
.	O
	
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
MTC	B
was	O
diagnosed	O
in	O
1	O
patient	O
receiving	O
TANZEUM	O
and	O
1	O
patient	O
receiving	O
placebo	O
.	O
	
JC	B
virus	I
infection	I
resulting	O
in	O
PML	B
and	O
death	B
can	O
occur	O
in	O
patients	O
receiving	O
ADCETRIS	O
(	O
5.9	O
,	O
6.2	O
)	O
.	O
	
An	O
increased	O
risk	O
of	O
stroke	B
and	O
DVT	B
has	O
been	O
reported	O
with	O
estrogen-alone	O
therapy	O
.	O
	
5.11	O
Seizures	O
Seizures	B
were	O
reported	O
in	O
0	O
%	O
and	O
0.3	O
%	O
(	O
0/572	O
,	O
1/379	O
)	O
of	O
adult	O
patients	O
treated	O
with	O
doses	O
of	O
5	O
mg	O
and	O
10	O
mg	O
twice	O
daily	O
of	O
SAPHRIS	O
,	O
respectively	O
,	O
compared	O
to	O
0	O
%	O
(	O
0/503	O
,	O
0/203	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
in	O
short-term	O
schizophrenia	O
and	O
bipolar	O
mania	O
trials	O
,	O
respectively	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
received	O
an	O
ESA	O
was	O
43	O
%	O
in	O
those	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
compared	O
to	O
24	O
%	O
in	O
those	O
treated	O
with	O
PegIntron/REBETOL	O
alone	O
.	O
	
Stopping	O
or	O
slowing	O
the	O
infusion	O
may	O
result	O
in	O
cessation	O
of	O
these	O
reactions	O
.	O
	
Monitor	O
HBV	O
carriers	O
during	O
and	O
several	O
months	O
after	O
therapy	O
.	O
	
Evaluate	O
if	O
diarrhea	O
occurs	O
.	O
	
After	O
initiation	O
of	O
TANZEUM	O
,	O
observe	O
patients	O
carefully	O
for	O
signs	O
and	O
symptoms	O
of	O
pancreatitis	O
(	O
including	O
persistent	O
severe	O
abdominal	O
pain	O
,	O
sometimes	O
radiating	O
to	O
the	O
back	O
and	O
which	O
may	O
or	O
may	O
not	O
be	O
accompanied	O
by	O
vomiting	O
)	O
.	O
	
Ear	O
and	O
Labyrinth	O
Disorders	O
:	O
deafness	B
,	O
tinnitus	B
,	O
vertigo	B
.	O
	
Monitoring	O
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
CIMZIA	O
,	O
including	O
the	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
.	O
	
Routine	O
monthly	O
pregnancy	O
tests	O
must	O
be	O
performed	O
during	O
this	O
time	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Drug	O
Interactions	O
(	O
7	O
)	O
]	O
.	O
	
Five	O
of	O
the	O
six	O
patients	O
in	O
the	O
group	O
that	O
received	O
PROMACTA	O
experienced	O
a	O
thrombotic	B
complication	I
within	O
30	O
days	O
of	O
completing	O
treatment	O
with	O
PROMACTA	O
and	O
at	O
a	O
platelet	O
count	O
above	O
200	O
x	O
10	O
9	O
/L	O
.	O
	
Consider	O
the	O
diagnosis	O
of	O
pancreatitis	O
for	O
patients	O
presenting	O
with	O
severe	O
abdominal	O
pain	O
.	O
	
As	O
with	O
other	O
PDE5	O
inhibitors	O
STENDRA	O
has	O
systemic	O
vasodilatory	O
properties	O
and	O
may	O
augment	O
the	O
blood	O
pressure-lowering	O
effect	O
of	O
other	O
anti-hypertensive	O
medications	O
.	O
	
(	O
5.4	O
)	O
*	O
Renal	B
Impairment	I
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
reporting	O
severe	O
adverse	O
gastrointestinal	O
reactions	O
.	O
	
5.7	O
Orthostatic	O
Hypotension	O
,	O
Syncope	O
,	O
and	O
Other	O
Hemodynamic	O
Effects	O
SAPHRIS	O
may	O
induce	O
orthostatic	B
hypotension	I
and	O
syncope	B
in	O
some	O
patients	O
,	O
especially	O
early	O
in	O
treatment	O
,	O
because	O
of	O
its	O
alpha1-adrenergic	O
antagonist	O
activity	O
.	O
	
5.1	O
Serious	O
Infections	O
Patients	O
treated	O
with	O
SIMPONI	O
ARIA	O
are	O
at	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
involving	O
various	O
organ	O
systems	O
and	O
sites	O
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
.	O
	
In	O
addition	O
,	O
TUDORZA	O
PRESSAIR	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
with	O
severe	O
hypersensitivity	O
to	O
milk	O
proteins	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
The	O
data	O
described	O
below	O
primarily	O
derive	O
from	O
two	O
randomized	O
,	O
active-controlled	O
three-year	O
trials	O
of	O
NULOJIX	O
in	O
de	O
novo	O
kidney	O
transplant	O
patients	O
.	O
	
Antiemetic	O
prophylaxis	O
is	O
recommended	O
.	O
	
ALT	B
elevations	I
were	O
reversible	O
in	O
all	O
subjects	O
.	O
	
Higher	O
than	O
recommended	O
dosing	O
or	O
repeated	O
dosing	O
appears	O
to	O
increase	O
the	O
risk	O
(	O
5.1	O
)	O
*	O
Hypersensitivity	O
:	O
hypersensitivity	B
reactions	I
with	O
cutaneous	B
manifestations	I
,	O
ranging	O
from	O
mild	O
to	O
severe	O
reactions	O
including	O
shock	B
can	O
occur	O
.	O
	
Patients	O
should	O
be	O
closely	O
monitored	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
CIMZIA	O
,	O
including	O
the	O
possible	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
.	O
	
*	O
Malignancies	B
-	O
More	O
cases	O
of	O
lymphoma	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF-blockers	O
compared	O
with	O
patients	O
in	O
the	O
control	O
groups	O
.	O
	
SAPHRIS	O
should	O
be	O
used	O
with	O
caution	O
in	O
(	O
1	O
)	O
patients	O
with	O
known	O
cardiovascular	O
disease	O
(	O
history	O
of	O
myocardial	O
infarction	O
or	O
ischemic	O
heart	O
disease	O
,	O
heart	O
failure	O
or	O
conduction	O
abnormalities	O
)	O
,	O
cerebrovascular	O
disease	O
,	O
or	O
conditions	O
which	O
would	O
predispose	O
patients	O
to	O
hypotension	O
(	O
dehydration	O
,	O
hypovolemia	O
,	O
and	O
treatment	O
with	O
antihypertensive	O
medications	O
)	O
;	O
and	O
(	O
2	O
)	O
in	O
the	O
elderly	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
No	O
comparator-treated	O
subject	O
with	O
normal	O
baseline	O
transaminases	O
had	O
post-baseline	O
ALT	B
elevation	I
greater	O
than	O
10	O
times	O
ULN	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
has	O
occurred	O
in	O
patients	O
with	O
impaired	O
elimination	O
of	O
GBCAs	O
.	O
	
(	O
6	O
)	O
The	O
most	O
common	O
adverse	O
events	O
occurring	O
in	O
at	O
least	O
20	O
%	O
of	O
patients	O
treated	O
with	O
Kyprolis	O
in	O
the	O
combination	O
therapy	O
trial	O
:	O
decreased	B
lymphocytes	I
,	O
decreased	B
absolute	I
neutrophil	I
count	I
,	O
decreased	B
phosphorus	I
,	O
anemia	B
,	O
neutropenia	B
,	O
decreased	B
total	I
white	I
blood	I
cell	I
count	I
,	O
decreased	B
platelets	I
,	O
diarrhea	B
,	O
fatigue	B
,	O
thrombocytopenia	B
,	O
pyrexia	B
,	O
muscle	B
spasm	I
,	O
cough	B
,	O
upper	B
respiratory	I
tract	I
infection	I
,	O
decreased	B
hemoglobin	I
,	O
hypokalemia	B
.	O
	
Intensive	O
measures	O
may	O
be	O
required	O
for	O
severe	O
diarrhea	O
and	O
electrolyte	O
imbalance	O
.	O
	
SAPHRIS	O
should	O
be	O
used	O
cautiously	O
when	O
treating	O
patients	O
who	O
receive	O
treatment	O
with	O
other	O
drugs	O
that	O
can	O
induce	O
hypotension	O
,	O
bradycardia	O
,	O
respiratory	O
or	O
central	O
nervous	O
system	O
depression	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
]	O
.	O
	
6.2	O
Immunogenicity	O
As	O
with	O
all	O
therapeutic	O
proteins	O
,	O
there	O
is	O
a	O
potential	O
for	O
an	O
immune	O
response	O
in	O
patients	O
treated	O
with	O
EYLEA	O
.	O
	
If	O
reactivation	O
occurs	O
,	O
stop	O
SIMPONI	O
ARIA	O
and	O
begin	O
anti-viral	O
therapy	O
(	O
5.1	O
)	O
.	O
	
Given	O
the	O
similar	O
structural	O
formula	O
of	O
atropine	O
to	O
aclidinium	O
,	O
patients	O
with	O
a	O
history	O
of	O
hypersensitivity	O
reactions	O
to	O
atropine	O
should	O
be	O
closely	O
monitored	O
for	O
similar	O
hypersensitivity	O
reactions	O
to	O
TUDORZA	O
PRESSAIR	O
.	O
	
In	O
short-term	O
schizophrenia	O
adult	O
trials	O
,	O
syncope	B
was	O
reported	O
in	O
0.2	O
%	O
(	O
1/572	O
)	O
of	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
(	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
)	O
of	O
SAPHRIS	O
,	O
compared	O
to	O
0.3	O
%	O
(	O
1/378	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
The	O
population	O
exposed	O
to	O
TAFINLAR	O
was	O
60	O
%	O
male	O
,	O
99	O
%	O
white	O
,	O
and	O
had	O
a	O
median	O
age	O
of	O
53	O
years	O
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
Oral	O
contraceptives	O
containing	O
lower	O
doses	O
of	O
norethindrone	O
and	O
other	O
forms	O
of	O
hormonal	O
contraception	O
have	O
not	O
been	O
studied	O
or	O
are	O
contraindicated	O
.	O
	
Tests	O
for	O
latent	O
tuberculosis	O
infection	O
may	O
also	O
be	O
falsely	O
negative	O
while	O
on	O
therapy	O
with	O
CIMZIA	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
TANZEUM	O
.	O
	
Eye	O
Disorders	O
:	O
vision	B
blurred	I
.	O
	
Long-term	O
Safety	O
Trials	O
TUDORZA	O
PRESSAIR	O
was	O
studied	O
in	O
three	O
long	O
term	O
safety	O
trials	O
,	O
two	O
double	O
blind	O
and	O
one	O
open	O
label	O
,	O
ranging	O
from	O
40	O
to	O
52	O
weeks	O
in	O
patients	O
with	O
moderate	O
to	O
severe	O
COPD	O
.	O
	
(	O
5.5	O
)	O
*	O
Macrovascular	O
Outcomes	O
:	O
There	O
have	O
been	O
no	O
clinical	O
trials	O
establishing	O
conclusive	O
evidence	O
of	O
macrovascular	O
risk	O
reduction	O
with	O
TANZEUM	O
or	O
any	O
other	O
antidiabetic	O
drug	O
.	O
	
Monitor	O
patients	O
closely	O
for	O
the	O
development	O
of	O
signs	O
and	O
symptoms	O
of	O
infection	O
during	O
and	O
after	O
treatment	O
with	O
SIMPONI	O
ARIA	O
,	O
including	O
the	O
possible	O
development	O
of	O
tuberculosis	O
in	O
patients	O
who	O
tested	O
negative	O
for	O
latent	O
tuberculosis	O
infection	O
prior	O
to	O
initiating	O
therapy	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Inactive	O
Ingredients	O
:	O
calcium	O
phosphate	O
tribasic	O
,	O
hydroxypropyl	O
cellulose	O
,	O
microcrystalline	O
cellulose	O
,	O
powdered	O
cellulose	O
,	O
hypromellose	O
,	O
lactose	O
monohydrate	O
,	O
magnesium	O
stearate	O
,	O
polyethylene	O
glycol	O
,	O
sucrose	O
,	O
ascorbic	O
acid	O
,	O
sucrose	O
palmitic	O
acid	O
ester	O
,	O
hydroxyethylcellulose	O
,	O
titanium	O
dioxide	O
,	O
red	O
iron	O
oxide	O
,	O
yellow	O
iron	O
oxide	O
,	O
black	O
iron	O
oxide	O
,	O
povidone	O
,	O
polydextrose	O
,	O
maltitol	O
,	O
poloxamer	O
188	O
,	O
propylene	O
glycol	O
,	O
isopropyl	O
alcohol	O
.	O
	
Respiratory	O
,	O
thoracic	O
and	O
mediastinal	O
disorders	O
:	O
noninfectious	B
pulmonary	I
toxicity	I
including	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
and	O
ARDS	B
(	O
some	O
with	O
fatal	B
outcomes	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.10	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Symptoms	O
of	O
PVT	B
included	O
abdominal	B
pain	I
,	O
nausea	B
,	O
vomiting	B
,	O
and	O
diarrhea	B
.	O
	
During	O
adult	O
pre-marketing	O
clinical	O
trials	O
with	O
SAPHRIS	O
,	O
including	O
long-term	O
trials	O
without	O
comparison	O
to	O
placebo	O
,	O
seizures	B
were	O
reported	O
in	O
0.3	O
%	O
(	O
5/1953	O
)	O
of	O
patients	O
treated	O
with	O
SAPHRIS	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Peripheral	B
neuropathy	I
:	O
Monitor	O
patients	O
for	O
neuropathy	O
and	O
institute	O
dose	O
modifications	O
accordingly	O
(	O
5.1	O
)	O
.	O
	
Consider	O
the	O
potential	O
for	O
an	O
increased	O
risk	O
of	O
thromboembolism	O
when	O
administering	O
PROMACTA	O
to	O
patients	O
with	O
known	O
risk	O
factors	O
for	O
thromboembolism	O
(	O
e.g.	O
,	O
Factor	O
V	O
Leiden	O
,	O
ATIII	O
deficiency	O
,	O
antiphospholipid	O
syndrome	O
,	O
chronic	O
liver	O
disease	O
)	O
.	O
	
Both	O
patients	O
had	O
markedly	O
elevated	O
serum	O
calcitonin	O
levels	O
at	O
baseline	O
.	O
	
If	O
reactivation	O
occurs	O
,	O
stop	O
CIMZIA	O
and	O
begin	O
anti-viral	O
therapy	O
(	O
5.5	O
)	O
*	O
Demyelinating	B
disease	I
,	O
exacerbation	O
or	O
new	O
onset	O
,	O
may	O
occur	O
(	O
5.6	O
)	O
*	O
Cytopenias	B
,	O
pancytopenia	B
-	O
advise	O
patients	O
to	O
seek	O
immediate	O
medical	O
attention	O
if	O
symptoms	O
develop	O
,	O
and	O
consider	O
stopping	O
CIMZIA	O
(	O
5.7	O
)	O
*	O
Lupus-like	B
syndrome	I
-	O
stop	O
CIMZIA	O
if	O
syndrome	O
develops	O
(	O
5.9	O
)	O
5.1	O
Risk	O
of	O
Serious	O
Infections	O
[	O
see	O
Boxed	O
Warning	O
]	O
Patients	O
treated	O
with	O
CIMZIA	O
are	O
at	O
an	O
increased	O
risk	O
for	O
developing	O
serious	O
infections	B
involving	O
various	O
organ	O
systems	O
and	O
sites	O
that	O
may	O
lead	O
to	O
hospitalization	O
or	O
death	B
.	O
	
5.4	O
Hypersensitivity	O
Reactions	O
Across	O
8	O
Phase	O
III	O
clinical	O
trials	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
,	O
a	O
serious	O
hypersensitivity	B
reaction	I
with	O
pruritus	B
,	O
rash	B
,	O
and	O
dyspnea	B
occurred	O
in	O
a	O
patient	O
treated	O
with	O
TANZEUM	O
.	O
	
5.3	O
Hepatic	O
Effects	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
trials	O
,	O
more	O
DALVANCE-	O
than	O
comparator-treated	O
subjects	O
with	O
normal	O
baseline	O
transaminase	O
levels	O
had	O
post-baseline	O
ALT	B
)	I
elevation	I
greater	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
(	O
ULN	O
)	O
.	O
	
Transplant	O
recipients	O
who	O
are	O
EBV	O
seronegative	O
,	O
or	O
with	O
unknown	O
serostatus	O
,	O
should	O
not	O
receive	O
NULOJIX	O
[	O
see	O
Boxed	O
Warning	O
and	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
Factors	O
that	O
can	O
increase	O
the	O
risk	O
of	O
developing	O
spinal	B
hematomas	I
in	O
these	O
patients	O
include	O
:	O
*	O
?	O
use	O
of	O
indwelling	O
epidural	O
catheters	O
*	O
?	O
concomitant	O
use	O
of	O
other	O
drugs	O
that	O
affect	O
hemostasis	O
,	O
such	O
as	O
nonsteroidal	O
anti-inflammatory	O
drugs	O
(	O
NSAIDs	O
)	O
,	O
platelet	O
inhibitors	O
,	O
other	O
anticoagulants	O
*	O
?	O
a	O
history	O
of	O
traumatic	O
or	O
repeated	O
epidural	O
or	O
spinal	O
punctures	O
*	O
?	O
a	O
history	O
of	O
spinal	O
deformity	O
or	O
spinal	O
surgery	O
*	O
?	O
optimal	O
timing	O
between	O
the	O
administration	O
of	O
ELIQUIS	O
and	O
neuraxial	O
procedures	O
is	O
not	O
known	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
Monitor	O
patients	O
frequently	O
for	O
signs	O
and	O
symptoms	O
of	O
neurological	O
impairment	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Thyroid	B
C-cell	I
Tumors	I
:	O
See	O
Boxed	O
Warning	O
.	O
	
This	O
is	O
supplemented	O
with	O
information	O
on	O
adverse	O
drug	O
reactions	O
in	O
1326	O
patients	O
with	O
ALK-positive	O
metastatic	O
NSCLC	O
who	O
received	O
XALKORI	O
250	O
mg	O
twice	O
daily	O
across	O
clinical	O
trials	O
,	O
for	O
a	O
total	O
of	O
1669	O
patients	O
across	O
all	O
clinical	O
studies	O
.	O
	
*	O
Embryo-fetal	B
toxicity	I
:	O
Fetal	B
harm	I
can	O
occur	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
are	O
upper	B
respiratory	I
tract	I
infection	I
,	O
bronchitis	B
,	O
cough	B
,	O
flatulence	B
and	O
increased	B
bilirubin	I
.	O
	
Avoid	O
the	O
use	O
of	O
Potassium	O
Iodide	O
Oral	O
Solution	O
or	O
Lugol	O
's	O
Solution	O
in	O
patients	O
who	O
are	O
sensitive	O
to	O
such	O
products	O
.	O
	
5.2	O
Management	O
of	O
Immunosuppression	O
Only	O
physicians	O
experienced	O
in	O
management	O
of	O
systemic	O
immunosuppressant	O
therapy	O
in	O
transplantation	O
should	O
prescribe	O
NULOJIX	O
.	O
	
(	O
2.4	O
,	O
5.1	O
,	O
14.1	O
)	O
(	O
B	O
)	O
SPINAL/EPIDURAL	O
HEMATOMA	O
:	O
spinal	B
hematomas	I
may	O
occur	O
in	O
patients	O
treated	O
with	O
ELIQUIS	O
who	O
are	O
receiving	O
neuraxial	O
anesthesia	O
or	O
undergoing	O
spinal	O
puncture	O
.	O
	
Monitor	O
patients	O
for	O
visual	O
signs	O
and	O
symptoms	O
of	O
uveitis	O
(	O
e.g.	O
,	O
change	O
in	O
vision	O
,	O
photophobia	O
,	O
eye	O
pain	O
)	O
.	O
	
Non-infectious	B
pneumonitis	I
was	O
reported	O
in	O
up	O
to	O
19	O
%	O
of	O
patients	O
treated	O
with	O
AFINITOR	O
in	O
clinical	O
trials	O
.	O
	
Table	O
4	O
:	O
Incidence	O
(	O
%	O
)	O
of	O
Patients	O
With	O
Lipid	B
Abnormalities	I
of	O
Potential	O
Clinical	O
Significance*	O
PRISTIQ	O
Placebo	O
50	O
mg	O
100	O
mg	O
200	O
mg	O
400	O
mg	O
Total	B
Cholesterol*	I
(	I
Increase	I
of	I
>	I
=	I
50	I
mg/dl	I
and	I
an	I
absolute	I
value	I
of	I
>	I
=	I
261	I
mg/dl	I
)	O
2	O
3	O
4	O
4	O
10	O
LDL	B
Cholesterol*	I
(	I
Increase	I
>	I
=	I
50	I
mg/dl	I
and	I
an	I
absolute	I
value	I
of	I
>	I
=	I
190	I
mg/dl	I
)	O
0	O
1	O
0	O
1	O
2	O
Triglycerides	B
,	I
fasting*	I
(	I
Fasting	I
:	I
>	I
=	I
327	I
mg/dl	I
)	O
3	O
2	O
1	O
4	O
6	O
Proteinuria	O
Proteinuria	B
,	O
greater	O
than	O
or	O
equal	O
to	O
trace	O
,	O
was	O
observed	O
in	O
the	O
pre-marketing	O
fixed-dose	O
controlled	O
studies	O
(	O
see	O
Table	O
5	O
)	O
.	O
	
5.9	O
Suppression	O
of	O
Bone	O
Turnover	O
In	O
clinical	O
trials	O
in	O
women	O
with	O
postmenopausal	O
osteoporosis	O
,	O
treatment	O
with	O
Prolia	O
resulted	O
in	O
significant	O
suppression	B
of	I
bone	I
remodeling	I
as	O
evidenced	O
by	O
markers	O
of	O
bone	O
turnover	O
and	O
bone	O
histomorphometry	O
[	O
see	O
Clinical	O
Pharmacology	O
(	O
12.2	O
)	O
and	O
Clinical	O
Studies	O
(	O
14.1	O
)	O
]	O
.	O
	
Major	O
2	O
(	O
0.2	O
)	O
1	O
(	O
0.1	O
)	O
4	O
(	O
0.5	O
)	O
CRNM*	O
25	O
(	O
3.0	O
)	O
34	O
(	O
4.2	O
)	O
19	O
(	O
2.3	O
)	O
Major	O
+	O
CRNM	B
27	O
(	O
3.2	O
)	O
35	O
(	O
4.3	O
)	O
22	O
(	O
2.7	O
)	O
Minor	O
75	O
(	O
8.9	O
)	O
98	O
(	O
12.1	O
)	O
58	O
(	O
7.0	O
)	O
All	O
94	O
(	O
11.2	O
)	O
121	O
(	O
14.9	O
)	O
74	O
(	O
9.0	O
)	O
Adverse	O
reactions	O
occurring	O
in	O
>	O
=1	O
%	O
of	O
patients	O
in	O
the	O
AMPLIFY-EXT	O
study	O
are	O
listed	O
in	O
Table	O
8	O
.	O
	
Other	O
adverse	O
reactions	O
indicative	O
of	O
hypersensitivity	B
reactions	O
included	O
the	O
following	O
:	O
pruritus	B
(	O
5	O
%	O
)	O
,	O
rash	B
(	O
3	O
%	O
)	O
,	O
and	O
urticaria	B
(	O
2	O
%	O
)	O
.	O
	
AFINITOR	O
may	O
be	O
re-introduced	O
at	O
a	O
daily	O
dose	O
approximately	O
50	O
%	O
lower	O
than	O
the	O
dose	O
previously	O
administered	O
depending	O
on	O
the	O
individual	O
clinical	O
circumstances	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
5.7	O
Laboratory	O
Tests	O
HCV-RNA	O
levels	O
should	O
be	O
monitored	O
at	O
Treatment	O
Weeks	O
4	O
,	O
8	O
,	O
12	O
,	O
and	O
24	O
,	O
at	O
the	O
end	O
of	O
treatment	O
,	O
during	O
treatment	O
follow-up	O
,	O
and	O
for	O
other	O
time	O
points	O
as	O
clinically	O
indicated	O
.	O
	
Monitoring	O
of	O
complete	O
blood	O
counts	O
is	O
essential	O
on	O
a	O
weekly	O
basis	O
during	O
cycle	O
1	O
and	O
before	O
each	O
treatment	O
cycle	O
thereafter	O
so	O
that	O
the	O
dose	O
can	O
be	O
adjusted	O
,	O
if	O
needed	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Pneumonia	O
In	O
the	O
pool	O
of	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
the	O
adverse	O
reaction	O
of	O
pneumonia	B
was	O
reported	O
more	O
frequently	O
in	O
patients	O
receiving	O
TANZEUM	O
(	O
1.8	O
%	O
)	O
than	O
in	O
patients	O
in	O
the	O
all-comparators	O
group	O
(	O
0.8	O
%	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Biogen	O
at	O
1-800-456-2255	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
None	O
of	O
these	O
antibodies	O
were	O
shown	O
to	O
neutralize	O
the	O
activity	O
of	O
albiglutide	O
in	O
an	O
in	O
vitro	O
bioassay	O
.	O
	
VORAXAZE	O
was	O
given	O
at	O
a	O
dose	O
of	O
50	O
Units/kg	O
as	O
an	O
intravenous	O
injection	O
over	O
5	O
minutes	O
.	O
	
The	O
reactions	O
have	O
generally	O
consisted	O
of	O
skin	B
erythema	I
and	O
pruritis	B
and	O
have	O
either	O
resolved	O
spontaneously	O
or	O
following	O
the	O
administration	O
of	O
corticosteroids	O
and	O
anti-histamines	O
.	O
	
5.2	O
Eye	O
Irritation	O
Avoid	O
eye	O
exposure	O
.	O
	
In	O
the	O
event	O
of	O
a	O
severe	O
reaction	O
,	O
discontinue	O
DIFICID	O
.	O
	
Identify	O
cause	O
and	O
manage	O
aggressively	O
.	O
	
Permanently	O
discontinue	O
TAFINLAR	O
and	O
trametinib	O
for	O
life-threatening	O
PE	O
.	O
	
Patients	O
who	O
develop	O
radiological	O
changes	O
suggestive	O
of	O
non-infectious	O
pneumonitis	O
and	O
have	O
few	O
or	O
no	O
symptoms	O
may	O
continue	O
AFINITOR	O
therapy	O
without	O
dose	O
alteration	O
.	O
	
The	O
youngest	O
alglucosidase	O
alfa-treated	O
patient	O
was	O
16	O
years	O
of	O
age	O
,	O
and	O
the	O
youngest	O
placebo-treated	O
patient	O
was	O
10	O
years	O
of	O
age	O
.	O
	
In	O
the	O
combination	O
study	O
,	O
the	O
incidence	O
of	O
venous	B
thromboembolic	I
events	I
in	O
the	O
first	O
12	O
cycles	O
was	O
13	O
%	O
in	O
the	O
Kyprolis	O
combination	O
arm	O
versus	O
6	O
%	O
in	O
the	O
control	O
arm	O
.	O
	
(	O
5.6	O
)	O
*	O
Orthostatic	B
hypotension	I
:	O
Dizziness	B
,	O
tachycardia	B
,	O
and	O
syncope	B
can	O
occur	O
with	O
standing	O
.	O
	
(	O
5.3	O
)	O
*	O
Suicidal	B
thoughts	I
:	O
HORIZANT	O
is	O
a	O
prodrug	O
of	O
gabapentin	O
,	O
an	O
antiepileptic	O
drug	O
(	O
AED	O
)	O
.	O
	
Table	O
2	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=5	O
%	O
of	O
GD1	O
Patients	O
Switching	O
from	O
Enzyme	O
Replacement	O
Therapy	O
to	O
CERDELGA	O
and	O
More	O
Frequently	O
than	O
Imiglucerase	O
(	O
Trial	O
2	O
)	O
Trial	O
2	O
was	O
not	O
designed	O
to	O
support	O
comparative	O
claims	O
for	O
CERDELGA	O
for	O
the	O
adverse	O
reactions	O
reported	O
in	O
this	O
table	O
.	O
	
The	O
proportion	O
of	O
patients	O
who	O
discontinued	O
treatment	O
due	O
to	O
any	O
adverse	O
reaction	O
during	O
the	O
controlled	O
clinical	O
trials	O
was	O
6.2	O
%	O
for	O
patients	O
receiving	O
BENLYSTA	O
and	O
7.1	O
%	O
for	O
patients	O
receiving	O
placebo	O
.	O
	
If	O
keratitis	O
is	O
diagnosed	O
,	O
the	O
benefits	O
and	O
risks	O
of	O
continuing	O
treatment	O
should	O
be	O
carefully	O
considered	O
.	O
	
*	O
Hyperpyrexia	B
and	O
confusion	B
(	O
5.2	O
)	O
*	O
May	O
exacerbate	B
symptoms	I
in	I
patients	I
with	I
existing	I
ischemic	I
heart	I
disease	I
(	O
5.3	O
)	O
*	O
Allergic	B
reactions	I
(	O
5.4	O
)	O
5.1	O
Supine	O
Hypertension	O
NORTHERA	O
therapy	O
may	O
cause	O
or	O
exacerbate	O
supine	B
hypertension	I
in	O
patients	O
with	O
NOH	O
.	O
	
5	O
(	O
tartrazine	O
)	O
sensitivity	O
in	O
the	O
general	O
population	O
is	O
low	O
,	O
it	O
is	O
frequently	O
seen	O
in	O
patients	O
who	O
also	O
have	O
aspirin	O
hypersensitivity	O
.	O
	
Postherpetic	O
Neuralgia	O
:	O
The	O
exposure	O
to	O
HORIZANT	O
in	O
417	O
patients	O
with	O
PHN	O
included	O
207	O
patients	O
exposed	O
for	O
at	O
least	O
3	O
months	O
.	O
	
5.12	O
Thrombotic	O
Thrombocytopenic	O
Purpura/Hemolytic	O
Uremic	O
Syndrome	O
Cases	O
of	O
thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
including	O
fatal	B
outcome	O
have	O
been	O
reported	O
in	O
patients	O
who	O
received	O
Kyprolis	O
.	O
	
Patients	O
who	O
have	O
experienced	O
anaphylaxis	O
or	O
hypersensitivity	O
reactions	O
should	O
be	O
treated	O
with	O
caution	O
when	O
they	O
are	O
re-administered	O
alglucosidase	O
alfa	O
.	O
	
Of	O
the	O
2,254	O
subjects	O
,	O
70	O
%	O
were	O
male	O
and	O
84	O
%	O
were	O
white	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Patients	O
received	O
INVOKANA	O
100	O
mg	O
(	O
N=833	O
)	O
,	O
INVOKANA	O
300	O
mg	O
(	O
N=834	O
)	O
or	O
placebo	O
(	O
N=646	O
)	O
once	O
daily	O
.	O
	
Therefore	O
,	O
co-administration	O
of	O
KALYDECO	O
with	O
strong	O
CYP3A	O
inducers	O
(	O
e.g.	O
,	O
rifampin	O
,	O
St.	O
John	O
's	O
wort	O
)	O
is	O
not	O
recommended	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.2	O
)	O
and	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
GBCAs	O
have	O
been	O
associated	O
with	O
a	O
risk	O
for	O
NSF	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
While	O
receiving	O
study	O
drug	O
through	O
Week	O
144	O
,	O
an	O
additional	O
11	O
%	O
of	O
STRIBILD	O
subjects	O
were	O
started	O
on	O
lipid	O
lowering	O
agents	O
,	O
compared	O
to	O
13	O
%	O
of	O
ATRIPLA	O
and	O
12	O
%	O
of	O
ATV	O
+	O
RTV	O
+	O
TRUVADA	O
subjects	O
.	O
	
Macular	B
edema	I
has	O
also	O
been	O
reported	O
in	O
patients	O
taking	O
GILENYA	O
0.5	O
mg	O
in	O
the	O
postmarketing	O
setting	O
,	O
usually	O
within	O
the	O
first	O
6	O
months	O
of	O
treatment	O
.	O
	
To	O
prevent	O
ectropion	O
,	O
botulinum	O
toxin	O
products	O
should	O
not	O
be	O
injected	O
into	O
the	O
medial	O
lower	O
eyelid	O
area	O
.	O
	
During	O
the	O
clinical	O
trials	O
,	O
0.3	O
%	O
(	O
4/1441	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
discontinued	O
treatment	O
due	O
to	O
depression	B
or	O
depressed	B
mood	I
compared	O
with	O
none	O
in	O
placebo	O
treated	O
subjects	O
(	O
0/495	O
)	O
.	O
	
Key	O
observed	O
laboratory	O
abnormalities	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
5.8	O
Human	O
Albumin	O
and	O
Transmission	O
of	O
Viral	O
Diseases	O
This	O
product	O
contains	O
albumin	O
,	O
a	O
derivative	O
of	O
human	O
blood	O
.	O
	
The	O
patients	O
were	O
also	O
not	O
taking	O
any	O
immunosuppressive	O
or	O
immunomodulatory	O
medications	O
concomitantly	O
.	O
	
ENTEREG	O
is	O
contraindicated	O
in	O
patients	O
who	O
have	O
taken	O
therapeutic	O
doses	O
of	O
opioids	O
for	O
more	O
than	O
7	O
consecutive	O
days	O
immediately	O
prior	O
to	O
taking	O
ENTEREG	O
.	O
	
The	O
effect	O
of	O
FANAPT	O
on	O
the	O
QT	O
interval	O
was	O
augmented	O
by	O
the	O
presence	O
of	O
CYP450	O
2D6	O
or	O
3A4	O
metabolic	O
inhibition	O
(	O
paroxetine	O
20	O
mg	O
once	O
daily	O
and	O
ketoconazole	O
200	O
mg	O
twice	O
daily	O
,	O
respectively	O
)	O
.	O
	
(	O
5.12	O
)	O
*	O
Posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
:	O
Consider	O
neuro-radiological	O
imaging	O
(	O
MRI	O
)	O
for	O
onset	O
of	O
visual	O
or	O
neurological	O
symptoms	O
;	O
discontinue	O
Kyprolis	O
if	O
suspected	O
.	O
	
5.7	O
Bone	O
Fracture	O
An	O
increased	O
risk	O
of	O
bone	B
fracture	I
,	O
occurring	O
as	O
early	O
as	O
12	O
weeks	O
after	O
treatment	O
initiation	O
,	O
was	O
observed	O
in	O
patients	O
using	O
INVOKANA	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Forest	O
Laboratories	O
,	O
LLC	O
.	O
	
(	O
5.5	O
)	O
*	O
Gastrointestinal	B
perforation	I
,	O
including	O
death	B
,	O
have	O
occurred	O
.	O
	
Perform	O
appropriate	O
monitoring	O
and	O
treat	O
hyperglycemia	O
with	O
insulin	O
,	O
as	O
necessary	O
(	O
5.3	O
)	O
*	O
Thrombosis	B
,	O
hemorrhage	B
:	O
discontinue	O
ERWINAZE	O
until	O
resolved	O
(	O
5.4	O
)	O
5.1	O
Hypersensitivity	O
Reactions	O
Grade	O
3	O
and	O
4	O
hypersensitivity	B
reactions	I
after	O
the	O
use	O
of	O
ERWINAZE	O
have	O
occurred	O
in	O
5	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
In	O
Study	O
1	O
and	O
Study	O
2	O
,	O
safety	O
information	O
was	O
prospectively	O
and	O
systematically	O
collected	O
.	O
	
The	O
risk	O
of	O
the	O
symptoms	O
is	O
probably	O
greatest	O
in	O
children	O
treated	O
for	O
spasticity	O
but	O
symptoms	O
can	O
also	O
occur	O
in	O
adults	O
treated	O
for	O
spasticity	O
and	O
other	O
conditions	O
,	O
and	O
particularly	O
in	O
those	O
patients	O
who	O
have	O
underlying	O
conditions	O
that	O
would	O
predispose	O
them	O
to	O
these	O
symptoms	O
.	O
	
Withhold	O
Kyprolis	O
and	O
evaluate	O
promptly	O
.	O
	
Melanoma	B
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
TNF-blocking	O
agents	O
,	O
including	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
Sometimes	O
both	O
ovaries	O
are	O
removed	O
during	O
an	O
operation	O
before	O
natural	O
menopause	O
takes	O
place	O
.	O
	
(	O
5.1	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
For	O
All	O
Indications	O
:	O
*	O
The	O
potency	O
Units	O
of	O
XEOMIN	O
are	O
not	O
interchangeable	O
with	O
other	O
preparations	O
of	O
botulinum	O
toxin	O
products	O
.	O
	
For	O
patients	O
at	O
risk	O
for	O
chronically	O
reduced	O
renal	O
function	O
(	O
e.g	O
.	O
	
Seizure	B
occurred	O
from	O
31	O
to	O
603	O
days	O
after	O
initiation	O
of	O
XTANDI	O
.	O
	
Table	O
10	O
compares	O
the	O
incidence	O
of	O
adverse	O
reactions	O
reported	O
with	O
an	O
incidence	O
of	O
>	O
=	O
10	O
%	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
occurring	O
more	O
frequently	O
with	O
AFINITOR	O
than	O
with	O
placebo	O
.	O
	
*	O
Limiting	O
the	O
dose	O
injected	O
into	O
the	O
sternocleidomastoid	O
muscle	O
may	O
decrease	O
the	O
occurrence	O
of	O
dysphagia	O
.	O
	
Two	O
subjects	O
(	O
0.13	O
%	O
)	O
tested	O
positive	O
for	O
binding	O
antibodies	O
at	O
baseline	O
.	O
	
Discontinuation	O
of	O
SIMPONI	O
ARIA	O
should	O
be	O
considered	O
if	O
these	O
disorders	O
develop	O
.	O
	
Patients	O
in	O
the	O
chemotherapy	O
arm	O
received	O
pemetrexed	O
unless	O
they	O
had	O
received	O
pemetrexed	O
as	O
part	O
of	O
first-line	O
or	O
maintenance	O
treatment	O
.	O
	
Hypersensitivity	B
reactions	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Increases	O
in	O
Serum	O
Phosphate	O
Dose-related	O
increases	B
in	I
serum	I
phosphate	I
levels	O
were	O
observed	O
with	O
INVOKANA	O
.	O
	
5.2	O
Aerosolization	O
of	O
Capsaicin	O
Aerosolization	O
of	O
capsaicin	O
can	O
occur	O
upon	O
rapid	O
removal	O
of	O
Qutenza	O
patches	O
.	O
	
The	O
adult	O
information	O
below	O
is	O
derived	O
from	O
a	O
clinical	O
trial	O
database	O
for	O
SAPHRIS	O
consisting	O
of	O
over	O
4565	O
patients	O
and/or	O
healthy	O
subjects	O
exposed	O
to	O
one	O
or	O
more	O
sublingual	O
doses	O
of	O
SAPHRIS	O
.	O
	
In	O
addition	O
,	O
a	O
two-week	O
dose-ranging	O
trial	O
was	O
conducted	O
in	O
511	O
adult	O
patients	O
with	O
mild	O
persistent	O
asthma	O
taking	O
inhaled	O
corticosteroids	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Merck	O
Sharp	O
&	O
Dohme	O
Corp.	O
,	O
a	O
subsidiary	O
of	O
Merck	O
&	O
Co.	O
,	O
Inc.	O
,	O
at	O
1-877-888-4231	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Withhold	O
,	O
dose	O
reduce	O
,	O
or	O
discontinue	O
BOSULIF	O
.	O
	
Monitor	O
blood	O
pressure	O
periodically	O
during	O
the	O
treatment	O
and	O
provide	O
adequate	O
support	O
for	O
treatment	O
related	O
pain	O
.	O
	
Dose-related	O
increases	B
in	I
non-HDL-C	I
with	O
INVOKANA	O
were	O
observed	O
.	O
	
(	O
6.2	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Serious	O
Adverse	O
Reactions	O
The	O
following	O
serious	O
and	O
otherwise	O
important	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
other	O
sections	O
of	O
labeling	O
:	O
*	O
Hypersensitivity	B
Reactions	I
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Adverse	O
Reactions	O
(	O
6.3	O
)	O
]	O
.	O
	
All	O
but	O
one	O
subject	O
who	O
died	B
of	O
TB	O
had	O
not	O
converted	O
or	O
had	O
relapsed	O
.	O
	
5.6	O
Other	O
Malignancies	O
There	O
are	O
reports	O
of	O
malignant	B
diseases	I
that	O
have	O
developed	O
in	O
patients	O
who	O
have	O
been	O
treated	O
with	O
TREANDA	O
,	O
including	O
myelodysplastic	B
syndrome	I
,	O
myeloproliferative	B
disorders	I
,	O
acute	B
myeloid	I
leukemia	I
and	O
bronchial	B
carcinoma	I
.	O
	
Serious	O
Adverse	O
Reactions	O
and	O
Adverse	O
Reactions	O
Leading	O
to	O
Discontinuation	O
Serious	O
adverse	O
reactions	O
occurred	O
in	O
109/1778	O
(	O
6.1	O
%	O
)	O
of	O
patients	O
treated	O
with	O
DALVANCE	O
and	O
in	O
80/1224	O
(	O
6.5	O
%	O
)	O
of	O
patients	O
treated	O
with	O
comparator	O
.	O
	
Prior	O
to	O
the	O
initiation	O
of	O
the	O
next	O
cycle	O
of	O
therapy	O
,	O
the	O
ANC	O
should	O
be	O
>	O
=	O
1	O
x	O
10	O
9	O
/L	O
and	O
the	O
platelet	O
count	O
should	O
be	O
>	O
=	O
75	O
x	O
10	O
9	O
/L	O
.	O
	
Of	O
these	O
,	O
two	O
studies	O
were	O
randomized	O
,	O
double-blind	O
,	O
single	O
treatment	O
,	O
placebo	O
controlled	O
studies	O
with	O
subsequent	O
optional	O
open	O
label	O
treatment	O
in	O
which	O
dose	O
optimization	O
(	O
250	O
to	O
1000	O
Units	O
per	O
treatment	O
)	O
over	O
the	O
course	O
of	O
5	O
treatment	O
cycles	O
was	O
allowed	O
.	O
	
Laboratory	O
Tests	O
No	O
clinically	O
meaningful	O
changes	O
in	O
hematology	O
,	O
serum	O
chemistry	O
or	O
urinalysis	O
were	O
observed	O
in	O
patients	O
treated	O
with	O
NESINA	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Mantle	O
Cell	O
Lymphoma	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
IMBRUVICA	O
in	O
a	O
clinical	O
trial	O
that	O
included	O
111	O
patients	O
with	O
previously	O
treated	O
MCL	O
treated	O
with	O
560	O
mg	O
daily	O
with	O
a	O
median	O
treatment	O
duration	O
of	O
8.3	O
months	O
.	O
	
Anaphylaxis	B
,	O
presenting	O
as	O
cough	B
,	O
erythema	B
,	O
throat	B
tightness	I
,	O
urticaria	B
,	O
flushing	B
,	O
cyanosis	B
,	O
hypotension	B
,	O
rash	B
,	O
dyspnea	B
,	O
chest	B
discomfort	I
,	O
and	O
gastrointestinal	B
symptoms	I
(	O
e.g.	O
,	O
nausea	B
,	O
abdominal	B
pain	I
,	O
retching	B
,	O
and	O
vomiting	B
)	O
in	O
conjunction	O
with	O
urticaria	B
,	O
have	O
been	O
reported	O
to	O
occur	O
during	O
Vimizim	O
infusions	O
,	O
regardless	O
of	O
duration	O
of	O
the	O
course	O
of	O
treatment	O
.	O
	
Dizziness	B
,	O
nausea	B
,	O
somnolence	B
,	O
and	O
fatigue	B
were	O
all	O
reported	O
at	O
lower	O
incidences	O
during	O
the	O
AED	O
Withdrawal	O
Phase	O
and	O
Monotherapy	O
Phase	O
compared	O
with	O
the	O
Titration	O
Phase	O
.	O
	
The	O
data	O
described	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
and	O
below	O
reflect	O
exposure	O
to	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
and	O
in	O
combination	O
with	O
trametinib	O
.	O
	
The	O
onset	O
tends	O
to	O
be	O
within	O
the	O
first	O
treatment	O
cycle	O
of	O
TREANDA	O
and	O
,	O
without	O
intervention	O
,	O
may	O
lead	O
to	O
acute	B
renal	I
failure	I
and	O
death	B
.	O
	
Adverse	O
Reactions	O
in	O
Placebo-Controlled	O
and	O
Uncontrolled	O
Studies	O
In	O
placebo-controlled	O
and	O
uncontrolled	O
clinical	O
studies	O
,	O
a	O
total	O
of	O
2513	O
patients	O
have	O
received	O
TECFIDERA	O
and	O
been	O
followed	O
for	O
periods	O
up	O
to	O
4	O
years	O
with	O
an	O
overall	O
exposure	O
of	O
4603	O
person-years	O
.	O
	
After	O
adjusting	O
for	O
age	O
and	O
sex	O
,	O
the	O
mean	O
change	O
from	O
baseline	O
to	O
endpoint	O
in	O
weight	O
z-score	O
for	O
SAPHRS	O
2.5	O
mg	O
,	O
5	O
mg	O
,	O
and	O
10	O
mg	O
twice	O
daily	O
,	O
was	O
0.11	O
,	O
0.08	O
and	O
0.09	O
SD	O
versus	O
0.02	O
SD	O
for	O
placebo	O
,	O
respectively	O
.	O
	
The	O
patient	O
had	O
no	O
other	O
identified	O
systemic	O
medical	O
conditions	O
resulting	O
in	O
compromised	O
immune	O
system	O
function	O
and	O
had	O
not	O
previously	O
been	O
treated	O
with	O
natalizumab	O
,	O
which	O
has	O
a	O
known	O
association	O
with	O
PML	O
.	O
	
Volume	O
Depletion	O
FARXIGA	O
causes	O
an	O
osmotic	B
diuresis	I
,	O
which	O
may	O
lead	O
to	O
reductions	B
in	I
intravascular	I
volume	I
.	O
	
Clinical	O
monitoring	O
of	O
weight	O
is	O
recommended	O
.	O
	
Because	O
of	O
the	O
increased	O
risk	O
of	O
urinary	O
retention	O
on	O
POTIGA	O
,	O
urologic	O
symptoms	O
should	O
be	O
carefully	O
monitored	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
serious	O
adverse	O
reactions	O
were	O
:	O
*	O
Serious	O
Infections	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Malignancies	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=3	O
%	O
)	O
are	O
:	O
upper	B
respiratory	I
tract	I
infection	I
,	O
viral	B
infection	I
,	O
bronchitis	B
,	O
hypertension	B
,	O
and	O
rash	B
(	O
6.1	O
)	O
.	O
	
Infusion-related	B
reactions	I
within	O
one	O
hour	O
of	O
infusion	O
were	O
reported	O
in	O
5	O
%	O
of	O
patients	O
treated	O
with	O
the	O
recommended	O
dose	O
of	O
NULOJIX	O
,	O
similar	O
to	O
the	O
placebo	O
rate	O
.	O
	
Life-threatening	O
or	O
fatal	B
CRS	B
was	O
infrequently	O
reported	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
5.1	O
IOP	O
Increase	O
Prolonged	O
use	O
of	O
corticosteroids	O
may	O
result	O
in	O
glaucoma	B
with	O
damage	B
to	I
the	I
optic	I
nerve	I
,	O
defects	B
in	I
visual	I
acuity	I
.	O
	
Fungal	O
culture	O
should	O
be	O
taken	O
when	O
appropriate	O
.	O
	
Fungal	B
infections	I
were	O
reported	O
in	O
18	O
%	O
of	O
patients	O
receiving	O
NULOJIX	O
compared	O
to	O
22	O
%	O
receiving	O
cyclosporine	O
,	O
primarily	O
due	O
to	O
mucocutaneous	B
fungal	I
infections	I
.	O
	
The	O
best	O
method	O
of	O
detection	O
of	O
these	O
abnormalities	O
and	O
the	O
optimal	O
frequency	O
of	O
periodic	O
ophthalmologic	O
monitoring	O
are	O
unknown	O
.	O
	
5.7	O
Orthostatic	O
Hypotension	O
and	O
Syncope	O
FANAPT	O
can	O
induce	O
orthostatic	B
hypotension	I
associated	O
with	O
dizziness	B
,	O
tachycardia	B
,	O
and	O
syncope	B
.	O
	
Elderly	O
patients	O
and	O
patients	O
with	O
impaired	O
renal	O
function	O
were	O
more	O
susceptible	O
to	O
these	O
adverse	O
reactions	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
The	O
majority	O
of	O
patients	O
in	O
the	O
active	O
group	O
were	O
between	O
the	O
ages	O
of	O
18	O
and	O
64	O
.	O
	
*	O
Renal	B
Impairment	I
:	O
Monitor	O
renal	O
function	O
in	O
patients	O
with	O
renal	O
impairment	O
reporting	O
severe	O
adverse	O
gastrointestinal	O
reactions	O
(	O
5.5	O
)	O
.	O
	
Bleeding	B
events	O
related	O
to	O
SSRIs	O
and	O
SNRIs	O
have	O
ranged	O
from	O
ecchymosis	B
,	O
hematoma	B
,	O
epistaxis	B
,	O
and	O
petechiae	B
to	O
life-threatening	O
hemorrhages	B
.	O
	
Monitor	O
for	O
signs	O
or	O
symptoms	O
of	O
TLS	O
.	O
	
c	O
Underlying	O
etiology	O
not	O
established	O
.	O
	
Adverse	O
reactions	O
led	O
to	O
study	O
treatment	O
discontinuation	O
in	O
16	O
%	O
of	O
patients	O
receiving	O
COMETRIQ	O
and	O
in	O
8	O
%	O
of	O
patients	O
receiving	O
placebo	O
.	O
	
Cases	O
of	O
elevated	B
blood	I
pressure	I
requiring	O
immediate	O
treatment	O
have	O
been	O
reported	O
with	O
PRISTIQ	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
XenoPort	O
at	O
1-877-XENOPRT	O
(	O
1-877-936-6778	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Table	O
displays	O
adverse	O
reactions	O
that	O
were	O
reported	O
in	O
greater	O
than	O
5	O
%	O
of	O
patients	O
in	O
the	O
NORTHERA	O
group	O
and	O
with	O
at	O
least	O
a	O
3	O
%	O
greater	O
incidence	O
in	O
the	O
NORTHERA	O
group	O
than	O
in	O
the	O
placebo	O
group	O
.	O
	
5.8	O
Hypercorticism	O
and	O
Adrenal	O
Suppression	O
Inhaled	O
fluticasone	O
furoate	O
is	O
absorbed	O
into	O
the	O
circulation	O
and	O
can	O
be	O
systemically	O
active	O
.	O
	
Table	O
2	O
Adjudicated	O
Major	O
Bleeding	B
Events	O
in	O
Treated	O
Patientsa	O
aPatients	O
during	O
treatment	O
or	O
within	O
2	O
days	O
of	O
stopping	O
study	O
treatment	O
.	O
	
A	O
total	O
of	O
2.2	O
%	O
of	O
HIV-1-infected	O
subjects	O
receiving	O
INTELENCE	O
(	O
r	O
)	O
discontinued	O
from	O
Phase	O
3	O
trials	O
due	O
to	O
rash	B
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
.	O
	
Recipients	O
without	O
immunity	O
to	O
Epstein-Barr	O
virus	O
(	O
EBV	O
)	O
are	O
at	O
a	O
particularly	O
increased	O
risk	O
;	O
therefore	O
,	O
use	O
in	O
EBV	O
seropositive	O
patients	O
only	O
.	O
	
Congenital	O
,	O
familial	O
and	O
genetic	O
disorders	O
:	O
hypospadias	B
.	O
	
Patients	O
who	O
have	O
experienced	O
a	O
prior	O
infusion-related	O
reaction	O
should	O
be	O
premedicated	O
for	O
subsequent	O
infusions	O
.	O
	
However	O
,	O
by	O
the	O
end	O
of	O
the	O
third	O
year	O
,	O
the	O
cumulative	O
incidence	O
of	O
NODAT	B
was	O
8	O
%	O
(	O
24/304	O
)	O
in	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
and	O
10	O
%	O
(	O
29/280	O
)	O
in	O
patients	O
treated	O
with	O
the	O
cyclosporine	O
regimen	O
.	O
	
5.9	O
Preparation	O
and	O
Administration	O
Errors	O
Preparation	O
and	O
administration	O
errors	O
have	O
occurred	O
with	O
BLINCYTO	O
treatment	O
.	O
	
Cytopenias	O
:	O
Grade	O
3	O
neutropenia	B
occurred	O
in	O
28	O
%	O
(	O
143/503	O
)	O
of	O
patients	O
who	O
received	O
HALAVEN	O
in	O
Study	O
1	O
,	O
and	O
29	O
%	O
(	O
144/503	O
)	O
of	O
patients	O
experienced	O
Grade	O
4	O
neutropenia	B
.	O
	
5.7	O
Increased	O
Toxicity	O
in	O
the	O
Presence	O
of	O
Moderate	O
or	O
Severe	O
Hepatic	O
Impairment	O
The	O
frequency	O
of	O
>	O
=Grade	O
3	O
adverse	O
reactions	O
and	O
deaths	B
was	O
greater	O
in	O
patients	O
with	O
moderate	O
and	O
severe	O
hepatic	O
impairment	O
compared	O
to	O
patients	O
with	O
normal	O
hepatic	O
function	O
.	O
	
There	O
were	O
no	O
treatment	O
discontinuations	O
and	O
one	O
death	B
due	O
to	O
cardiac	B
failure	I
in	O
the	O
placebo	O
group	O
.	O
	
Withhold	O
if	O
not	O
responsive	O
to	O
anti-emetics	O
or	O
anti-diarrheals	O
,	O
then	O
dose	O
reduce	O
ZYKADIA	O
.	O
	
Because	O
most	O
trials	O
included	O
in	O
the	O
analysis	O
did	O
not	O
extend	O
beyond	O
24	O
weeks	O
,	O
the	O
risk	O
of	O
suicidal	B
thoughts	I
beyond	O
24	O
weeks	O
could	O
not	O
be	O
assessed	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Patients	O
requiring	O
oral	O
corticosteroids	O
should	O
be	O
weaned	O
slowly	O
from	O
systemic	O
corticosteroid	O
use	O
after	O
transferring	O
to	O
BREO	O
ELLIPTA	O
.	O
	
Discontinuations	O
resulting	O
from	O
these	O
reactions	O
were	O
more	O
common	O
in	O
the	O
drug-treated	O
group	O
(	O
see	O
Table	O
2	O
)	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
The	O
Medicines	O
Company	O
at	O
1-888-977-MDCO	O
(	O
6326	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Teflaro	O
was	O
evaluated	O
in	O
four	O
controlled	O
comparative	O
Phase	O
3	O
clinical	O
trials	O
(	O
two	O
in	O
ABSSSI	O
and	O
two	O
in	O
CABP	O
)	O
which	O
included	O
1300	O
adult	O
patients	O
treated	O
with	O
Teflaro	O
(	O
600	O
mg	O
administered	O
by	O
IV	O
over	O
1	O
hour	O
every	O
12h	O
)	O
and	O
1297	O
patients	O
treated	O
with	O
comparator	O
(	O
vancomycin	O
plus	O
aztreonam	O
or	O
ceftriaxone	O
)	O
for	O
a	O
treatment	O
period	O
up	O
to	O
21	O
days	O
.	O
	
2	O
Postmarketing	O
Experience	O
The	O
following	O
adverse	O
drug	O
reactions	O
have	O
been	O
identified	O
during	O
post-approval	O
of	O
HALAVEN	O
.	O
	
Skin	O
,	O
subcutaneous	O
tissue	O
disorders	O
:	O
hyperhidrosis	B
,	O
periorbital	B
edema	I
,	O
photosensitivity	B
reaction	I
,	O
pruritis	B
,	O
urticaria	B
,	O
rash	B
,	O
Henoch-Schonlein	B
purpura	I
.	O
	
For	O
each	O
subject	O
in	O
whom	O
a	O
Week	O
12	O
sample	O
was	O
selected	O
,	O
the	O
corresponding	O
Week	O
6	O
,	O
18	O
,	O
24	O
,	O
and	O
52	O
samples	O
were	O
assayed	O
if	O
they	O
were	O
also	O
binding	O
antibody	O
positive	O
.	O
	
Safe	O
handling	O
should	O
be	O
ensured	O
to	O
minimize	O
radiation	O
exposure	O
to	O
the	O
patient	O
and	O
health	O
care	O
workers	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2	O
.	O
	
The	O
most	O
serious	O
adverse	O
reaction	O
reported	O
in	O
clinical	O
trials	O
with	O
Ferriprox	O
was	O
agranulocytosis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Serious	O
adverse	O
reactions	O
were	O
reported	O
in	O
73	O
(	O
50	O
%	O
)	O
subjects	O
.	O
	
6.1	O
Clinical	O
Studies	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trial	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
Peripheral	O
Neuropathy	O
:	O
In	O
Study	O
1	O
,	O
17	O
%	O
of	O
enrolled	O
patients	O
had	O
Grade	O
1	O
peripheral	B
neuropathy	I
and	O
3	O
%	O
of	O
patients	O
had	O
Grade	O
2	O
peripheral	B
neuropathy	I
at	O
baseline	O
.	O
	
Patients	O
with	O
liver	O
metastases	O
were	O
excluded	O
if	O
AST	O
and/or	O
ALT	O
>	O
5*	O
ULN	O
.	O
	
Six	O
weeks	O
after	O
the	O
eighth	O
injection	O
(	O
fourth	O
treatment	O
cycle	O
)	O
of	O
XIAFLEX	O
,	O
>	O
99	O
%	O
of	O
XIAFLEX-treated	O
patients	O
developed	O
high	O
titers	O
of	O
antibodies	O
to	O
both	O
AUX-I	O
and	O
AUX-II	O
.	O
	
Patients	O
received	O
5-10	O
days	O
of	O
an	O
approved	O
parenteral	O
anticoagulant	O
therapy	O
followed	O
by	O
6	O
months	O
,	O
with	O
mean	O
exposure	O
of	O
164	O
days	O
,	O
of	O
oral	O
only	O
treatment	O
;	O
warfarin	O
was	O
overlapped	O
with	O
parenteral	O
therapy	O
.	O
	
The	O
median	O
duration	O
of	O
treatment	O
with	O
ZYTIGA	O
was	O
8	O
months	O
.	O
	
Hold	O
ADCETRIS	O
dosing	O
for	O
any	O
suspected	O
case	O
of	O
PML	O
and	O
discontinue	O
ADCETRIS	O
dosing	O
if	O
a	O
diagnosis	O
of	O
PML	O
is	O
confirmed	O
.	O
	
Four	O
percent	O
(	O
20/503	O
)	O
of	O
patients	O
experienced	O
peripheral	B
motor	I
neuropathy	I
of	O
any	O
grade	O
and	O
2	O
%	O
(	O
8/503	O
)	O
of	O
patients	O
developed	O
Grade	O
3	O
peripheral	B
motor	I
neuropathy	I
.	O
	
In	O
vitro	O
studies	O
showed	O
no	O
evidence	O
of	O
cross-reactivity	O
between	O
anti-drug-antibody	O
positive	O
patient	O
sera	O
and	O
a	O
series	O
of	O
relevant	O
MMPs	O
.	O
	
After	O
five	O
years	O
more	O
than	O
90	O
percent	O
of	O
patients	O
remained	O
seropositive	O
for	O
anti-AUX-I	O
and	O
anti-AUX-II	O
antibody	O
(	O
Study	O
4	O
)	O
.	O
	
Gastrointestinal	O
disorders	O
:	O
enterocolitis	B
,	O
rectal	B
hemorrhage	I
,	O
gastric	B
ulcer	I
,	O
pancreatitis	B
,	O
parotid	B
gland	I
enlargement	I
.	O
	
If	O
anaphylaxis	O
occurs	O
,	O
immediately	O
and	O
permanently	O
discontinue	O
administration	O
of	O
ADCETRIS	O
and	O
administer	O
appropriate	O
medical	O
therapy	O
.	O
	
Only	O
physicians	O
experienced	O
in	O
immunosuppressive	O
therapy	O
and	O
management	O
of	O
kidney	O
transplant	O
patients	O
should	O
prescribe	O
NULOJIX	O
.	O
	
Other	O
serious	O
adverse	O
reactions	O
included	O
thromboembolic	B
complications	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
The	O
incidence	O
of	O
rash	B
was	O
higher	O
in	O
females	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6	O
)	O
]	O
Discontinue	O
INTELENCE	O
(	O
r	O
)	O
immediately	O
if	O
signs	O
or	O
symptoms	O
of	O
severe	O
skin	O
reactions	O
or	O
hypersensitivity	O
reactions	O
develop	O
(	O
including	O
,	O
but	O
not	O
limited	O
to	O
,	O
severe	O
rash	O
or	O
rash	O
accompanied	O
by	O
fever	O
,	O
general	O
malaise	O
,	O
fatigue	O
,	O
muscle	O
or	O
joint	O
aches	O
,	O
blisters	O
,	O
oral	O
lesions	O
,	O
conjunctivitis	O
,	O
facial	O
edema	O
,	O
hepatitis	O
,	O
eosinophilia	O
,	O
angioedema	O
)	O
.	O
	
Major	O
bleeding	B
is	O
defined	O
as	O
bleeding	B
accompanied	O
by	O
one	O
or	O
more	O
of	O
the	O
following	O
:	O
a	O
decrease	B
in	I
hemoglobin	I
of	O
>	O
=2	O
g/dL	O
,	O
a	O
transfusion	O
of	O
>	O
=2	O
units	O
of	O
packed	O
red	O
blood	O
cells	O
,	O
bleeding	B
at	I
a	I
critical	I
site	I
or	O
with	O
a	O
fatal	B
outcome	O
.	O
	
5.3	O
Immune	O
Reconstitution	O
Syndrome	O
Immune	B
reconstitution	I
syndrome	I
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
combination	O
antiretroviral	O
therapy	O
,	O
including	O
INTELENCE	O
(	O
r	O
)	O
.	O
	
5.10	O
Paradoxical	O
Bronchospasm	O
As	O
with	O
other	O
inhaled	O
medicines	O
,	O
BREO	O
ELLIPTA	O
can	O
produce	O
paradoxical	B
bronchospasm	I
,	O
which	O
may	O
be	O
life	O
threatening	O
.	O
	
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
events	O
(	O
incidence	O
>	O
=2	O
%	O
and	O
at	O
a	O
rate	O
greater	O
than	O
the	O
placebo	O
rate	O
)	O
for	O
AMPYRA	O
were	O
urinary	B
tract	I
infection	I
,	O
insomnia	B
,	O
dizziness	B
,	O
headache	B
,	O
nausea	B
,	O
asthenia	B
,	O
back	B
pain	I
,	O
balance	B
disorder	I
,	O
multiple	B
sclerosis	I
relapse	I
,	O
paresthesia	B
,	O
nasopharyngitis	B
,	O
constipation	B
,	O
dyspepsia	B
,	O
and	O
pharyngolaryngeal	B
pain	I
(	O
6.1	O
)	O
.	O
	
This	O
risk	O
increases	O
with	O
age	O
,	O
particularly	O
in	O
women	O
over	O
35	O
years	O
of	O
age	O
,	O
and	O
with	O
the	O
number	O
of	O
cigarettes	O
smoked	O
.	O
	
(	O
6.1	O
)	O
EXCERPT	O
:	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
AstraZeneca	O
at	O
1-800-	O
236-9933	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
AdreView	O
may	O
increase	O
release	O
of	O
norepinephrine	O
from	O
chromaffin	O
granules	O
and	O
produce	O
a	O
transient	B
episode	I
of	I
hypertension	I
,	O
although	O
this	O
was	O
not	O
observed	O
in	O
the	O
clinical	O
studies	O
.	O
	
By	O
Year	O
3	O
,	O
one	O
or	O
more	O
antihypertensive	O
medications	O
were	O
used	O
in	O
85	O
%	O
of	O
NULOJIX-treated	O
patients	O
and	O
92	O
%	O
of	O
cyclosporine-treated	O
patients	O
.	O
	
5.8	O
Leukoencephalopathy	O
Cranial	O
magnetic	O
resonance	O
imaging	O
(	O
MRI	O
)	O
changes	O
showing	O
leukoencephalopathy	B
have	O
been	O
observed	O
in	O
patients	O
receiving	O
BLINCYTO	O
,	O
especially	O
in	O
patients	O
with	O
prior	O
treatment	O
with	O
cranial	O
irradiation	O
and	O
antileukemic	O
chemotherapy	O
(	O
including	O
systemic	O
high-dose	O
methotrexate	O
or	O
intrathecal	O
cytarabine	O
)	O
.	O
	
*	O
Fatal	B
and	O
serious	O
pneumonitis	B
can	O
occur	O
in	O
Zydelig-treated	O
patients	O
.	O
	
Of	O
56	O
patients	O
who	O
tested	O
negative	O
for	O
antibodies	O
during	O
treatment	O
and	O
reassessed	O
approximately	O
7	O
half-lives	O
after	O
discontinuation	O
of	O
NULOJIX	O
,	O
1	O
tested	O
antibody	O
positive	O
.	O
	
*	O
Hypersensitivity	B
Reactions	O
:	O
Discontinue	O
TRULICITY	O
if	O
suspected	O
.	O
	
(	O
N	O
for	O
males	O
:	O
Placebo=716	O
,	O
FARXIGA	O
5	O
mg=564	O
,	O
FARXIGA	O
10	O
mg=595	O
)	O
.	O
	
Patients	O
who	O
develop	O
symptoms	O
of	O
hyperglycemia	O
during	O
treatment	O
with	O
atypical	O
antipsychotics	O
should	O
undergo	O
fasting	O
blood	O
glucose	O
testing	O
.	O
	
Adverse	O
Reactions	O
N	O
(	O
Percent	O
of	O
patients	O
)	O
Headache	B
10	O
(	O
1.8	O
%	O
)	O
Musculoskeletal	B
pain	I
4	O
(	O
0.7	O
%	O
)	O
Blood	B
pressure	I
increased	I
a	O
4	O
(	O
0.7	O
%	O
)	O
Nausea	B
4	O
(	O
0.7	O
%	O
)	O
Fatigue	B
3	O
(	O
0.5	O
%	O
)	O
Injection	B
site	I
reaction	I
b	O
3	O
(	O
0.5	O
%	O
)	O
Anxiety	B
2	O
(	O
0.4	O
%	O
)	O
Back	B
pain	I
2	O
(	O
0.4	O
%	O
)	O
Claustrophobia	B
2	O
(	O
0.4	O
%	O
)	O
Dizziness	B
2	O
(	O
0.4	O
%	O
)	O
Feeling	B
cold	I
c	O
2	O
(	O
0.4	O
%	O
)	O
Insomnia	B
2	O
(	O
0.4	O
%	O
)	O
Neck	B
pain	I
2	O
(	O
0.4	O
%	O
)	O
Other	O
adverse	O
reactions	O
occurred	O
at	O
lower	O
frequencies	O
and	O
included	O
infusion	B
site	I
rash	I
,	O
dysgeusia	B
,	O
pruritis	B
,	O
urticaria	B
,	O
and	O
flushing	B
.	O
	
[	O
See	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.4	O
)	O
.	O
]	O
	
The	O
abnormalities	O
seen	O
in	O
patients	O
treated	O
with	O
POTIGA	O
have	O
funduscopic	B
features	I
similar	I
to	I
those	I
seen	I
in	I
retinal	I
pigment	I
dystrophies	I
that	O
are	O
known	O
to	O
result	O
in	O
damage	B
to	I
photoreceptors	I
and	O
vision	B
loss	I
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
adverse	O
reactions	O
are	O
described	O
in	O
more	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
of	O
the	O
label	O
:	O
*	O
Somnolence/sedation	O
and	O
dizziness	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
RLS	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=10	O
%	O
and	O
at	O
least	O
2	O
times	O
the	O
rate	O
of	O
placebo	O
)	O
were	O
somnolence/sedation	O
and	O
dizziness	B
.	O
	
For	O
patients	O
who	O
experience	O
a	O
sustained	O
increase	O
in	O
blood	O
pressure	O
while	O
receiving	O
PRISTIQ	O
,	O
either	O
dose	O
reduction	O
or	O
discontinuation	O
should	O
be	O
considered	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
*	O
Hepatotoxicity	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
*	O
Severe	O
Diarrhea	B
or	O
Colitis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
*	O
Pneumonitis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
*	O
Intestinal	B
Perforation	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
*	O
Severe	O
Cutaneous	B
Reactions	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
*	O
Anaphylaxis	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.6	O
)	O
]	O
*	O
Neutropenia	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.7	O
)	O
]	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=20	O
%	O
)	O
are	O
diarrhea	B
,	O
pyrexia	B
,	O
fatigue	B
,	O
nausea	B
,	O
cough	B
,	O
pneumonia	B
,	O
abdominal	B
pain	I
,	O
chills	B
,	O
and	O
rash	B
(	O
6.1	O
)	O
.	O
	
Six	O
patients	O
out	O
of	O
the	O
403	O
who	O
were	O
treated	O
with	O
the	O
NULOJIX	O
regimen	O
of	O
higher	O
cumulative	O
dose	O
and	O
more	O
frequent	O
dosing	O
than	O
recommended	O
in	O
Studies	O
1	O
and	O
2	O
(	O
1.5	O
%	O
)	O
were	O
reported	O
to	O
have	O
developed	O
CNS	B
infections	I
,	O
including	O
2	O
cases	O
of	O
cryptococcal	B
meningitis	I
,	O
one	O
case	O
of	O
Chagas	B
encephalitis	I
with	O
cryptococcal	B
meningitis	I
,	O
one	O
case	O
of	O
cerebral	B
aspergillosis	I
,	O
one	O
case	O
of	O
West	B
Nile	I
encephalitis	I
,	O
and	O
one	O
case	O
of	O
PML	B
(	O
discussed	O
above	O
)	O
.	O
	
Hydronephrosis	B
was	O
not	O
reported	O
in	O
placebo	O
patients	O
.	O
	
As	O
with	O
other	O
antipsychotics	O
,	O
FANAPT	O
should	O
be	O
used	O
cautiously	O
in	O
patients	O
with	O
a	O
history	O
of	O
seizures	O
or	O
with	O
conditions	O
that	O
potentially	O
lower	O
the	O
seizure	O
threshold	O
,	O
e.g.	O
,	O
Alzheimer	O
's	O
dementia	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Arbor	O
Pharmaceuticals	O
,	O
LLC	O
at	O
1-866-516-4950	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Other	O
Adverse	O
Reactions	O
Other	O
infrequent	O
adverse	O
reactions	O
(	O
occurring	O
in	O
less	O
than	O
3	O
%	O
of	O
RA	O
patients	O
)	O
were	O
similar	O
to	O
those	O
seen	O
in	O
Crohn	O
's	O
disease	O
patients	O
.	O
	
The	O
overall	O
trial	O
population	O
had	O
a	O
median	O
age	O
of	O
61	O
years	O
;	O
61	O
%	O
of	O
patients	O
in	O
the	O
GILOTRIF	O
arm	O
and	O
60	O
%	O
of	O
patients	O
in	O
the	O
pemetrexed/cisplatin	O
arm	O
were	O
younger	O
than	O
65	O
years	O
.	O
	
The	O
causative	O
organisms	O
for	O
these	O
reactions	O
are	O
identified	O
when	O
provided	O
by	O
the	O
physician	O
.	O
	
EXCERPT	O
:	O
WARNING	O
:	O
CYTOKINE	B
RELEASE	I
SYNDROME	I
and	O
NEUROLOGICAL	B
TOXICITIES	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
The	O
clinical	O
development	O
program	O
excluded	O
patients	O
with	O
active	O
autoimmune	O
disease	O
or	O
those	O
receiving	O
systemic	O
immunosuppression	O
for	O
organ	O
transplantation	O
.	O
	
5.6	O
Fungal	O
Infections	O
Fungal	B
infections	I
of	I
the	I
cornea	I
are	O
particularly	O
prone	O
to	O
develop	O
coincidentally	O
with	O
long-term	O
local	O
steroid	O
application	O
.	O
	
*	O
Perforations	B
and	O
Fistulas	B
:	O
Gastrointestinal	B
perforations	I
occurred	O
in	O
3	O
%	O
and	O
fistula	B
formation	I
in	O
1	O
%	O
of	O
COMETRIQ-treated	O
patients	O
.	O
	
Routine	O
monitoring	O
of	O
serum	O
calcitonin	O
or	O
using	O
thyroid	O
ultrasound	O
is	O
of	O
uncertain	O
value	O
for	O
early	O
detection	O
of	O
MTC	O
in	O
patients	O
treated	O
with	O
TRULICITY	O
[	O
see	O
Contraindications	O
(	O
4.1	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Table	O
2	O
Investigator	O
Assessment	O
of	O
Maximal	O
Local	B
Skin	I
Reactions	I
in	O
the	O
Treatment	O
Area	O
during	O
the	O
57	O
Days	O
Post	O
Treatment	O
Period	O
(	O
trunk/extremities	O
trials	O
)	O
Trunk	O
and	O
Extremities	O
(	O
n=457	O
)	O
Picato	O
(	O
r	O
)	O
gel	O
,	O
0.05	O
%	O
once	O
daily	O
for	O
2	O
days	O
Skin	B
reactions	I
Any	I
Gradea	I
>	I
Baseline	I
Grade	I
4	I
58	O
(	O
26	O
%	O
)	O
6	O
(	O
3	O
%	O
)	O
2	O
(	O
1	O
%	O
)	O
0	O
(	O
0	O
%	O
)	O
a	O
Mild	O
(	O
grade	O
1	O
)	O
,	O
Moderate	O
(	O
grade	O
2-3	O
)	O
or	O
Severe	O
(	O
grade	O
4	O
)	O
.	O
	
Patients	O
with	O
a	O
history	O
of	O
genital	O
mycotic	O
infections	O
and	O
uncircumcised	O
males	O
were	O
more	O
likely	O
to	O
develop	O
genital	B
mycotic	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Table	O
2	O
:	O
Risk	O
of	O
Suicidal	B
Thoughts	I
by	O
Indication	O
for	O
Antiepileptic	O
Drugs	O
in	O
the	O
Pooled	O
Analysis	O
Indication	O
Placebo	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Drug	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Relative	O
Risk	O
:	O
Incidence	O
of	O
Events	O
in	O
Drug	O
Patients/Incidence	O
in	O
Placebo	O
Patients	O
Risk	O
Differences	O
:	O
Additional	O
Drug	O
Patients	O
with	O
Events	O
Per	O
1000	O
Patients	O
Epilepsy	O
1.0	O
3.4	O
3.5	O
2.4	O
Psychiatric	O
5.7	O
8.5	O
1.5	O
2.9	O
Other	O
1.0	O
1.8	O
1.9	O
0.9	O
Total	O
2.4	O
4.3	O
1.8	O
1.9	O
The	O
relative	O
risk	O
for	O
suicidal	B
thoughts	I
was	O
higher	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
epilepsy	O
than	O
in	O
clinical	O
trials	O
in	O
patients	O
with	O
psychiatric	O
or	O
other	O
conditions	O
,	O
but	O
the	O
absolute	O
risk	O
differences	O
were	O
similar	O
for	O
epilepsy	O
and	O
psychiatric	O
indications	O
.	O
	
The	O
adverse	O
reaction	O
profile	O
of	O
TECFIDERA	O
in	O
the	O
uncontrolled	O
clinical	O
studies	O
was	O
consistent	O
with	O
the	O
experience	O
in	O
the	O
placebo-controlled	O
clinical	O
trials	O
.	O
	
Pre-medicate	O
in	O
subsequent	O
cycles	O
for	O
milder	O
reactions	O
.	O
	
At	O
the	O
first	O
sign	O
or	O
symptom	O
suggestive	O
of	O
PML	O
,	O
withhold	O
TECFIDERA	O
and	O
perform	O
an	O
appropriate	O
diagnostic	O
evaluation	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
The	O
median	O
duration	O
of	O
treatment	O
was	O
6.4	O
months	O
(	O
range	O
0.03	O
to	O
22.0	O
)	O
for	O
patients	O
who	O
received	O
INLYTA	O
and	O
5.0	O
months	O
(	O
range	O
0.03	O
to	O
20.1	O
)	O
for	O
patients	O
who	O
received	O
sorafenib	O
.	O
	
A	O
single	O
event	O
of	O
serum	B
sickness	I
was	O
reported	O
in	O
a	O
patient	O
treated	O
with	O
NESINA	O
25	O
mg.	O
Hypoglycemia	O
Hypoglycemic	B
events	I
were	O
documented	O
based	O
upon	O
a	O
blood	O
glucose	O
value	O
and/or	O
clinical	O
signs	O
and	O
symptoms	O
of	O
hypoglycemia	B
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Acute	B
pancreatitis	I
:	O
There	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
pancreatitis	I
.	O
	
Hematologic	O
nadirs	O
were	O
observed	O
predominantly	O
in	O
the	O
third	O
week	O
of	O
therapy	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Ipsen	O
Biopharmaceuticals	O
,	O
Inc.	O
at	O
877-397-7671	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Consider	O
discontinuation	O
for	O
Grade	O
3	O
infusions	O
reactions	O
as	O
clinically	O
appropriate	O
considering	O
individual	O
benefits	O
,	O
risks	O
,	O
and	O
supportive	O
care	O
.	O
	
TAFINLAR	O
was	O
studied	O
in	O
open-label	O
,	O
single-arm	O
trials	O
and	O
in	O
an	O
open-label	O
,	O
randomized	O
,	O
active-controlled	O
trial	O
.	O
	
Adverse	O
reactions	O
observed	O
in	O
these	O
studies	O
were	O
generally	O
similar	O
to	O
those	O
observed	O
and	O
attributed	O
to	O
drug	O
in	O
adjunctive	O
placebo-controlled	O
studies	O
.	O
	
in	O
Placebo	O
and	O
Active-Controlled	O
Studies	O
when	O
NESINA	O
Was	O
Used	O
as	O
Add-On	O
Therapy	O
to	O
Glyburide	O
,	O
Insulin	O
,	O
Metformin	O
,	O
Pioglitazone	O
or	O
Compared	O
to	O
Glipizide	O
Add-On	O
to	O
Glyburide	O
(	O
26	O
Weeks	O
)	O
NESINA	O
25	O
mg+	O
Glyburide	O
Placebo+	O
Glyburide	O
N=198	O
N=99	O
Overall	O
(	O
%	O
)	O
19	O
(	O
9.6	O
)	O
11	O
(	O
11.1	O
)	O
Severe	O
(	O
%	O
)	O
Severe	O
events	O
of	O
hypoglycemia	B
were	O
defined	O
as	O
those	O
events	O
requiring	O
medical	O
assistance	O
or	O
exhibiting	O
depressed	O
level	O
or	O
loss	O
of	O
consciousness	O
or	O
seizure	O
.	O
	
Monitor	O
ECGs	O
and	O
discontinue	O
SIRTURO	O
if	O
significant	O
ventricular	O
arrhythmia	O
or	O
QTcF	O
interval	O
>	O
500	O
ms	O
develops	O
.	O
	
In	O
non-clinical	O
studies	O
in	O
rats	O
and	O
rabbits	O
,	O
cabazitaxel	O
was	O
embryotoxic	B
,	O
fetotoxic	B
,	O
and	O
abortifacient	B
at	O
exposures	O
significantly	O
lower	O
than	O
those	O
expected	O
at	O
the	O
recommended	O
human	O
dose	O
level	O
.	O
	
Pain	B
in	I
extremity	I
and	O
musculoskeletal	B
pain	I
have	O
also	O
been	O
reported	O
in	O
clinical	O
trials	O
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Amgen	O
Inc.	O
at	O
1-800-77-AMGEN	O
(	O
1-800-772-6436	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Hyperglycemia	O
and	O
Diabetes	O
Mellitus	O
Hyperglycemia	B
,	O
in	O
some	O
cases	O
extreme	O
and	O
associated	O
with	O
ketoacidosis	B
or	O
hyperosmolar	B
coma	I
or	O
death	B
,	O
has	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
atypical	O
antipsychotics	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
one	O
clinical	O
trial	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
with	O
the	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
the	O
same	O
or	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Acorda	O
Therapeutics	O
at	O
1-877-900-6479	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
EXCERPT	O
:	O
WARNINGS	O
:	O
INCREASED	B
MORTALITY	I
;	O
QT	B
PROLONGATION	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
common	O
adverse	O
reactions	O
in	O
adults	O
(	O
>	O
30	O
%	O
)	O
are	O
headache	B
,	O
anorexia	B
,	O
dizziness	B
,	O
asthenia	B
,	O
arthralgia	B
and	O
myalgia	B
.	O
	
In	O
a	O
3-week	O
monotherapy	O
trial	O
,	O
the	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=5	O
%	O
and	O
at	O
least	O
twice	O
the	O
rate	O
of	O
placebo	O
)	O
reported	O
in	O
pediatric	O
patients	O
with	O
bipolar	O
I	O
disorder	O
treated	O
with	O
SAPHRIS	O
were	O
somnolence	B
,	O
dizziness	B
,	O
dysgeusia	B
,	O
oral	B
paresthesia	I
,	O
nausea	B
,	O
increased	B
appetite	I
,	O
fatigue	B
,	O
and	O
increased	B
weight	I
.	O
	
For	O
those	O
patients	O
who	O
require	O
the	O
use	O
of	O
opioids	O
to	O
treat	O
pain	O
during	O
or	O
following	O
the	O
procedure	O
,	O
their	O
ability	O
to	O
perform	O
potentially	O
hazardous	O
activities	O
such	O
as	O
driving	O
or	O
operating	O
machinery	O
may	O
be	O
affected	O
.	O
	
In	O
a	O
trial	O
of	O
patients	O
with	O
moderate	O
renal	O
impairment	O
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
,	O
the	O
mean	O
serum	B
phosphate	I
levels	I
increased	I
by	O
1.2	O
%	O
,	O
5.0	O
%	O
,	O
and	O
9.3	O
%	O
with	O
placebo	O
,	O
INVOKANA	O
100	O
mg	O
,	O
and	O
INVOKANA	O
300	O
mg	O
,	O
respectively	O
.	O
	
Across	O
the	O
347	O
patients	O
who	O
were	O
randomized	O
to	O
study	O
treatment	O
(	O
343	O
received	O
at	O
least	O
one	O
dose	O
of	O
study	O
treatment	O
)	O
,	O
the	O
median	O
age	O
was	O
50	O
years	O
;	O
14	O
%	O
of	O
patients	O
were	O
older	O
than	O
65	O
years	O
.	O
	
Atypical	O
Subtrochanteric	O
and	O
Diaphyseal	O
Fractures	O
In	O
the	O
osteoporosis	O
clinical	O
trial	O
program	O
,	O
atypical	B
femoral	I
fractures	I
were	O
reported	O
in	O
patients	O
treated	O
with	O
Prolia	O
.	O
	
N**	O
=	O
Number	O
of	O
patients	O
at	O
risk	O
at	O
Baseline	O
with	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
The	O
changes	O
averaged	O
less	O
than	O
10	O
mm	O
Hg	O
,	O
although	O
some	O
patients	O
had	O
greater	O
increases	O
and	O
these	O
changes	O
lasted	O
for	O
approximately	O
two	O
hours	O
after	O
patch	O
removal	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
EXCERPT	O
:	O
The	O
most	O
frequently	O
reported	O
adverse	O
events	O
(	O
>	O
=4	O
%	O
)	O
for	O
Toviaz	O
were	O
:	O
dry	B
mouth	I
(	O
placebo	O
,	O
7	O
%	O
;	O
Toviaz	O
4	O
mg	O
,	O
19	O
%	O
;	O
Toviaz	O
8	O
mg	O
,	O
35	O
%	O
)	O
and	O
constipation	B
(	O
placebo	O
,	O
2	O
%	O
;	O
Toviaz	O
4	O
mg	O
,	O
4	O
%	O
;	O
Toviaz	O
8	O
mg	O
,	O
6	O
%	O
)	O
.	O
	
(	O
2.3	O
,	O
5.3	O
)	O
*	O
Fluid	B
Retention	I
:	O
Monitor	O
patients	O
and	O
manage	O
using	O
standard	O
of	O
care	O
treatment	O
.	O
	
*	O
The	O
risk	O
for	O
NSF	B
appears	O
highest	O
among	O
patients	O
with	O
:	O
Chronic	O
,	O
severe	O
kidney	O
disease	O
(	O
GFR	O
<	O
30	O
mL/min/1.73	O
m2	O
)	O
,	O
orAcute	O
kidney	O
injury	O
.	O
	
Because	O
the	O
elimination	O
of	O
fingolimod	O
after	O
discontinuation	O
may	O
take	O
up	O
to	O
2	O
months	O
,	O
continue	O
monitoring	O
for	O
infections	O
throughout	O
this	O
period	O
.	O
	
System	O
Organ	O
Class/	O
Preferred	O
Term	O
Placebo	O
N=378	O
%	O
SAPHRIS	O
5	O
mg	O
twice	O
daily	O
N=274	O
%	O
SAPHRIS	O
10	O
mg	O
twice	O
daily	O
N=208	O
%	O
All	O
SAPHRIS	O
S	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
N=572	O
%	O
Gastrointestinal	O
disorders	O
Constipation	B
6	O
7	O
4	O
5	O
Dry	B
mouth	I
1	O
3	O
1	O
2	O
Oral	B
hypoesthesia	I
1	O
6	O
7	O
5	O
Salivary	B
hypersecretion	I
0	O
<	O
1	O
4	O
2	O
Stomach	B
discomfort	I
1	O
<	O
1	O
3	O
2	O
Vomiting	B
5	O
4	O
7	O
5	O
General	O
disorders	O
Fatigue	B
3	O
4	O
3	O
3	O
Irritability	B
<	O
1	O
2	O
1	O
2	O
Investigations	O
Increased	B
weight	I
<	O
1	O
2	O
2	O
3	O
Metabolism	O
disorders	O
Increased	B
appetite	I
<	O
1	O
3	O
0	O
2	O
Nervous	O
system	O
disorders	O
Akathisia*	O
3	O
4	O
11	O
6	O
Dizziness	B
4	O
7	O
3	O
5	O
Extrapyramidal	B
symptoms	I
(	O
excluding	O
akathisia	B
)	O
7	O
9	O
12	O
10	O
Somnolence	B
?	O
	
*	O
Immediate	O
medical	O
attention	O
may	O
be	O
required	O
in	O
cases	O
of	O
respiratory	O
,	O
speech	O
or	O
swallowing	O
difficulties	O
(	O
5.1	O
,	O
5.4	O
)	O
.	O
	
The	O
median	O
duration	O
of	O
blinded	O
study	O
treatment	O
was	O
52	O
weeks	O
(	O
range	O
24	O
to	O
89	O
weeks	O
)	O
for	O
patients	O
receiving	O
AFINITOR	O
and	O
47	O
weeks	O
(	O
range	O
14	O
to	O
88	O
weeks	O
)	O
for	O
those	O
receiving	O
placebo	O
.	O
	
Monitor	O
for	O
hypertension	O
and	O
treat	O
as	O
needed	O
.	O
	
5.2	O
Acute	O
Renal	O
Failure	O
Cases	O
of	O
acute	B
renal	I
failure	I
have	O
occurred	O
in	O
patients	O
receiving	O
Kyprolis	O
.	O
	
Almost	O
all	O
these	O
patients	O
had	O
received	O
treatment	O
with	O
azathioprine	O
(	O
AZA	O
)	O
or	O
6-mercaptopurine	O
(	O
6-MP	O
)	O
concomitantly	O
with	O
a	O
TNF-blocker	O
at	O
or	O
prior	O
to	O
diagnosis	O
.	O
	
Cases	O
of	O
central	B
demyelination	I
,	O
MS	B
,	O
optic	B
neuritis	I
,	O
and	O
peripheral	B
demyelinating	I
polyneuropathy	I
have	O
rarely	O
been	O
reported	O
in	O
patients	O
treated	O
with	O
the	O
subcutaneous	O
formulation	O
of	O
golimumab	O
.	O
	
*	O
Lower	O
lid	O
injections	O
should	O
not	O
be	O
repeated	O
if	O
diplopia	O
occurred	O
with	O
previous	O
botulinum	O
toxin	O
injections	O
.	O
	
Discontinuations	O
due	O
to	O
adverse	O
drug	O
reactions	O
(	O
ADRs	O
)	O
were	O
5.2	O
%	O
in	O
the	O
INTELENCE	O
(	O
r	O
)	O
arm	O
and	O
2.6	O
%	O
in	O
the	O
placebo	O
arm	O
.	O
	
Atrioventricular	O
Blocks	O
Initiation	O
of	O
GILENYA	O
treatment	O
has	O
resulted	O
in	O
transient	O
AV	B
conduction	I
delays	I
.	O
	
Permanently	O
discontinue	O
XTANDI	O
in	O
patients	O
who	O
develop	O
a	O
seizure	O
during	O
treatment	O
.	O
	
If	O
a	O
serious	O
hypersensitivity	O
reaction	O
occurs	O
,	O
discontinue	O
ERWINAZE	O
and	O
initiate	O
appropriate	O
therapy	O
.	O
	
(	O
5.4	O
)	O
*	O
Cardiac	B
failure	I
has	O
been	O
observed	O
and	O
can	O
be	O
fatal	B
.	O
	
*	O
Bipolar	O
Disorder	O
Pediatric	O
Patients	O
(	O
Monotherapy	O
)	O
:	O
somnolence	B
,	O
dizziness	B
,	O
dysgeusia	B
,	O
oral	B
paresthesia	I
,	O
nausea	B
,	O
increased	B
appetite	I
,	O
fatigue	B
,	O
increased	B
weight	I
.	O
	
In	O
unapproved	O
uses	O
,	O
including	O
spasticity	O
in	O
children	O
,	O
and	O
in	O
approved	O
indications	O
,	O
cases	O
of	O
spread	O
of	O
effect	O
have	O
been	O
reported	O
at	O
doses	O
comparable	O
to	O
or	O
lower	O
than	O
the	O
maximum	O
recommended	O
total	O
dose	O
.	O
	
Antipsychotic	O
treatment	O
itself	O
,	O
however	O
,	O
may	O
suppress	O
(	O
or	O
partially	O
suppress	O
)	O
the	O
signs	O
and	O
symptoms	O
of	O
the	O
syndrome	O
and	O
thereby	O
may	O
possibly	O
mask	O
the	O
underlying	O
process	O
.	O
	
Monitor	O
for	O
signs	O
and	O
symptoms	O
of	O
TTP/HUS	O
.	O
	
Due	O
to	O
the	O
low	O
rate	O
of	O
events	O
in	O
both	O
groups	O
,	O
it	O
is	O
not	O
possible	O
to	O
conclude	O
that	O
the	O
risk	O
of	O
venous	B
thromboembolism	I
with	O
DUAVEE	O
is	O
different	O
from	O
that	O
seen	O
with	O
other	O
estrogen	O
therapies	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Monotherapy	O
Historical	O
Control	O
Trials	O
In	O
the	O
monotherapy	O
epilepsy	O
trials	O
(	O
Study	O
1	O
and	O
Study	O
2	O
)	O
,	O
13	O
%	O
of	O
patients	O
randomized	O
to	O
receive	O
APTIOM	O
at	O
the	O
recommended	O
doses	O
of	O
1200	O
mg	O
and	O
1600	O
mg	O
once	O
daily	O
discontinued	O
from	O
the	O
trials	O
as	O
a	O
result	O
of	O
an	O
adverse	O
event	O
.	O
	
Because	O
these	O
reactions	O
are	O
reported	O
voluntarily	O
from	O
a	O
population	O
of	O
uncertain	O
size	O
,	O
it	O
is	O
not	O
always	O
possible	O
to	O
reliably	O
estimate	O
their	O
frequency	O
or	O
establish	O
a	O
causal	O
relationship	O
to	O
drug	O
exposure	O
:	O
dehydration	B
,	O
thrombotic	B
thrombocytopenic	I
purpura/hemolytic	O
uremic	B
syndrome	I
(	O
TTP/HUS	O
)	O
,	O
tumor	B
lysis	I
syndrome	I
including	O
fatal	B
outcomes	O
,	O
and	O
posterior	B
reversible	I
encephalopathy	I
syndrome	I
(	O
PRES	B
)	O
.	O
	
5.3	O
Dysphagia	O
and	O
Breathing	O
Difficulties	O
Treatment	O
with	O
DYSPORT	O
(	O
r	O
)	O
and	O
other	O
botulinum	O
toxin	O
products	O
can	O
result	O
in	O
breathing	B
difficulties	I
.	O
	
In	O
Study	O
2	O
all	O
adverse	O
events	O
of	O
all	O
Grades	O
were	O
prospectively	O
collected	O
.	O
	
(	O
5.7	O
)	O
*	O
Stop	O
INLYTA	O
at	O
least	O
24	O
hours	O
prior	O
to	O
scheduled	O
surgery	O
.	O
	
Prescribers	O
should	O
carefully	O
evaluate	O
the	O
risks	O
and	O
benefits	O
of	O
continuing	O
treatment	O
with	O
OTEZLA	O
if	O
such	O
events	O
occur	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
was	O
61	O
years	O
(	O
range	O
27-85	O
)	O
,	O
88	O
%	O
were	O
Caucasian	O
,	O
and	O
78	O
%	O
were	O
male	O
.	O
	
This	O
may	O
require	O
protective	O
drops	O
,	O
ointment	O
,	O
therapeutic	O
soft	O
contact	O
lenses	O
,	O
or	O
closure	O
of	O
the	O
eye	O
by	O
patching	O
or	O
other	O
means	O
.	O
	
Grades	O
2	O
to	O
4	O
ALT	B
abnormalities	I
in	O
hepatitis	O
B	O
and/or	O
C	O
co-infected	O
compared	O
with	O
HIV	O
mono-infected	O
subjects	O
receiving	O
TIVICAY	O
were	O
observed	O
in	O
18	O
%	O
vs.	O
3	O
%	O
with	O
the	O
50-mg	O
once-daily	O
dose	O
and	O
13	O
%	O
vs.	O
8	O
%	O
with	O
the	O
50-mg	O
twice-daily	O
dose	O
.	O
	
Hypersensitivity	B
reactions	I
and	O
acute	B
kidney	I
injury	I
are	O
described	O
in	O
other	O
sections	O
of	O
the	O
labeling	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
and	O
(	O
5.3	O
)	O
]	O
.	O
	
FANAPT	O
is	O
not	O
approved	O
for	O
the	O
treatment	O
of	O
patients	O
with	O
dementia-related	O
psychosis	O
[	O
s	O
ee	O
Boxed	O
Warning	O
]	O
.	O
	
Although	O
other	O
risk	O
factors	O
were	O
present	O
in	O
some	O
cases	O
(	O
such	O
as	O
corticosteroid	O
use	O
and/or	O
exposure	O
to	O
radiation	O
)	O
,	O
a	O
possible	O
risk	O
attributable	O
to	O
KALYDECO	O
can	O
not	O
be	O
excluded	O
.	O
	
Do	O
not	O
exceed	O
the	O
recommended	O
dosage	O
and	O
frequency	O
of	O
administration	O
of	O
DYSPORT	O
(	O
r	O
)	O
.	O
	
Laboratory	O
abnormalities	O
observed	O
in	O
the	O
FLAMINGO	O
trial	O
were	O
generally	O
consistent	O
with	O
observations	O
in	O
SPRING-2	O
and	O
SINGLE	O
.	O
	
The	O
mechanism	O
and	O
clinical	O
significance	O
are	O
unknown	O
.	O
	
Discontinue	O
GILOTRIF	O
in	O
patients	O
who	O
develop	O
life-threatening	O
bullous	O
,	O
blistering	O
,	O
or	O
exfoliating	O
lesions	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
MRI	O
signs	O
may	O
be	O
apparent	O
before	O
clinical	O
symptoms	O
.	O
	
In	O
order	O
to	O
reduce	O
the	O
complication	O
of	O
ptosis	O
the	O
following	O
steps	O
should	O
be	O
taken	O
:	O
*	O
Avoid	O
injection	O
near	O
the	O
levator	O
palpebrae	O
superioris	O
,	O
particularly	O
in	O
patients	O
with	O
larger	O
brow	O
depressor	O
complexes	O
.	O
	
Three	O
of	O
these	O
patients	O
had	O
subsequent	O
tests	O
which	O
were	O
negative	O
.	O
	
Keratitis	B
was	O
reported	O
in	O
5	O
(	O
2.2	O
%	O
)	O
patients	O
in	O
Study	O
1	O
,	O
with	O
Grade	O
3	O
in	O
1	O
(	O
0.4	O
%	O
)	O
.	O
	
The	O
reduction	O
in	O
clinical	O
cure	O
rates	O
was	O
more	O
marked	O
in	O
the	O
ZERBAXA	O
plus	O
metronidazole	O
arm	O
compared	O
to	O
the	O
meropenem	O
arm	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
were	O
serious	O
infections	B
(	O
6.0	O
%	O
and	O
5.2	O
%	O
in	O
the	O
groups	O
receiving	O
BENLYSTA	O
and	O
placebo	O
,	O
respectively	O
)	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Monitor	O
for	O
suicidal	O
thoughts	O
or	O
behaviors	O
.	O
	
5.11	O
Hepatic	O
Toxicity	O
and	O
Hepatic	O
Failure	O
Cases	O
of	O
hepatic	B
failure	I
,	O
including	O
fatal	B
cases	O
,	O
have	O
been	O
reported	O
(	O
<	O
1	O
%	O
)	O
during	O
treatment	O
with	O
Kyprolis	O
.	O
	
Thromboprophylaxis	O
is	O
recommended	O
and	O
should	O
be	O
based	O
on	O
an	O
assessment	O
of	O
the	O
patient	O
's	O
underlying	O
risks	O
,	O
treatment	O
regimen	O
,	O
and	O
clinical	O
status	O
.	O
	
Patients	O
were	O
randomized	O
in	O
a	O
2:1	O
ratio	O
and	O
received	O
alglucosidase	O
alfa	O
or	O
placebo	O
every	O
other	O
week	O
for	O
78	O
weeks	O
(	O
18	O
months	O
)	O
.	O
	
In	O
one	O
trial	O
INVOKANA	O
was	O
used	O
as	O
monotherapy	O
and	O
in	O
three	O
trials	O
INVOKANA	O
was	O
used	O
as	O
add-on	O
therapy	O
[	O
see	O
Clinical	O
Studies	O
(	O
14	O
)	O
]	O
.	O
	
At	O
screening	O
,	O
the	O
mean	O
postbronchodilator	O
percent	O
predicted	O
FEV1was	O
48	O
%	O
(	O
range	O
:	O
14	O
%	O
to	O
87	O
%	O
)	O
,	O
the	O
mean	O
postbronchodilator	O
FEV1/forced	O
vital	O
capacity	O
(	O
FVC	O
)	O
ratio	O
was	O
47	O
%	O
(	O
range	O
:	O
17	O
%	O
to	O
88	O
%	O
)	O
,	O
and	O
the	O
mean	O
percent	O
reversibility	O
was	O
14	O
%	O
(	O
range	O
:	O
-41	O
%	O
to	O
152	O
%	O
)	O
.	O
	
Evaluate	O
with	O
cardiac	O
imaging	O
and/or	O
other	O
tests	O
as	O
indicated	O
.	O
	
Subjects	O
ranged	O
in	O
age	O
from	O
18	O
to	O
83	O
years	O
,	O
with	O
an	O
overall	O
median	O
age	O
of	O
46	O
years	O
.	O
	
(	O
5.1	O
)	O
5.1	O
Laryngeal	O
Attacks	O
Given	O
the	O
potential	O
for	O
airway	O
obstruction	O
during	O
acute	O
laryngeal	O
HAE	O
attacks	O
,	O
patients	O
should	O
be	O
advised	O
to	O
seek	O
medical	O
attention	O
in	O
an	O
appropriate	O
healthcare	O
facility	O
immediately	O
in	O
addition	O
to	O
treatment	O
with	O
FIRAZYR	O
.	O
	
If	O
the	O
diagnosis	O
is	O
suspected	O
,	O
stop	O
Kyprolis	O
and	O
evaluate	O
.	O
	
All	O
events	O
resolved	O
with	O
continued	O
treatment	O
with	O
ILARIS	O
.	O
	
*	O
Flushing	B
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
)	O
]	O
.	O
	
The	O
risks	O
and	O
benefits	O
of	O
treatment	O
should	O
be	O
considered	O
prior	O
to	O
prescribing	O
TNF-blockers	O
,	O
including	O
SIMPONI	O
ARIA	O
,	O
to	O
patients	O
who	O
are	O
carriers	O
of	O
HBV	O
.	O
	
Atrial	O
Fibrillation/Flutte	O
r	O
In	O
the	O
pool	O
of	O
7	O
placebo-	O
and	O
active-controlled	O
trials	O
,	O
adverse	O
reactions	O
of	O
atrial	B
fibrillation	I
(	O
1.0	O
%	O
)	O
and	O
atrial	B
flutter	I
(	O
0.2	O
%	O
)	O
were	O
reported	O
more	O
frequently	O
for	O
TANZEUM	O
than	O
for	O
all	O
comparators	O
(	O
0.5	O
%	O
and	O
0	O
%	O
,	O
respectively	O
)	O
.	O
	
Primary	O
prophylaxis	O
with	O
G-CSF	O
should	O
be	O
considered	O
in	O
patients	O
with	O
high-risk	O
clinical	O
features	O
(	O
age	O
>	O
65	O
years	O
,	O
poor	O
performance	O
status	O
,	O
previous	O
episodes	O
of	O
febrile	O
neutropenia	O
,	O
extensive	O
prior	O
radiation	O
ports	O
,	O
poor	O
nutritional	O
status	O
,	O
or	O
other	O
serious	O
comorbidities	O
)	O
that	O
predispose	O
them	O
to	O
increased	O
complications	O
from	O
prolonged	O
neutropenia	O
.	O
	
The	O
assay	O
should	O
have	O
a	O
lower	O
limit	O
of	O
HCV-RNA	O
quantification	O
of	O
equal	O
to	O
or	O
less	O
than	O
25	O
IU	O
per	O
mL	O
,	O
and	O
a	O
limit	O
of	O
HCV-RNA	O
detection	O
of	O
approximately	O
10	O
to	O
15	O
IU	O
per	O
mL	O
.	O
	
For	O
cases	O
of	O
Grade	O
4	O
non-infectious	O
pneumonitis	O
,	O
discontinue	O
AFINITOR	O
.	O
	
(	O
6	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Novartis	O
Pharmaceuticals	O
Corporation	O
at	O
1-888-669-6682	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
6.1	O
Clinical	O
Trial	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
practice	O
.	O
	
Table	O
2	O
Adverse	O
Reactions	O
with	O
a	O
Frequency	O
>	O
=0.5	O
%	O
Reported	O
in	O
Clinical	O
Trials	O
(	O
n	O
=	O
978	O
Administrations	O
in	O
872	O
Subjects	O
)	O
Adverse	O
drug	O
reaction	O
n	O
(	O
%	O
)	O
application	B
site	I
erythema	I
17	O
(	O
1.7	O
)	O
Injection	B
site	I
irritation	I
12	O
(	O
1.2	O
)	O
Injection	B
site	I
pain	I
38	O
(	O
3.9	O
)	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
Image	O
interpretation	O
errors	O
(	O
especially	O
false	O
positives	O
)	O
have	O
been	O
observed	O
(	O
5.1	O
)	O
.	O
	
If	O
symptoms	O
are	O
moderate	O
,	O
consider	O
interrupting	O
therapy	O
until	O
symptoms	O
improve	O
.	O
	
Delay	O
or	O
discontinue	O
JEVTANA	O
.	O
	
Investigations	O
-	O
Weight	B
increased	I
,	O
liver	B
function	I
test	I
abnormal	I
,	O
blood	B
prolactin	I
increased	I
.	O
	
(	O
5.3	O
)	O
5.1	O
Not	O
for	O
Systemic	O
Infections	O
Since	O
there	O
is	O
minimal	O
systemic	O
absorption	O
of	O
fidaxomicin	O
,	O
DIFICID	O
is	O
not	O
effective	O
for	O
treatment	O
of	O
systemic	O
infections	O
.	O
	
ILARIS	O
should	O
not	O
be	O
administered	O
to	O
any	O
patients	O
with	O
known	O
clinical	O
hypersensitivity	O
to	O
ILARIS	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.3	O
)	O
]	O
.	O
	
All	O
other	O
patients	O
were	O
eligible	O
for	O
these	O
studies	O
if	O
the	O
plasma	O
methotrexate	O
level	O
was	O
greater	O
than	O
10	O
mumol/L	O
more	O
than	O
42	O
hours	O
after	O
the	O
start	O
of	O
the	O
methotrexate	O
or	O
the	O
plasma	O
level	O
was	O
greater	O
than	O
2	O
standard	O
deviations	O
above	O
the	O
mean	O
methotrexate	O
excretion	O
curve	O
at	O
least	O
12	O
hours	O
following	O
methotrexate	O
and	O
the	O
serum	O
creatinine	O
was	O
greater	O
than	O
1.5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
the	O
creatinine	O
clearance	O
was	O
less	O
than	O
60	O
mL/min	O
at	O
least	O
12	O
hours	O
following	O
methotrexate	O
administration	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
in	O
greater	O
detail	O
in	O
another	O
section	O
of	O
the	O
label	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5	O
)	O
]	O
:	O
*	O
Non-infectious	B
pneumonitis	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
Table	O
1	O
:	O
Adverse	O
Reactions	O
Occurring	O
in	O
>	O
=1	O
%	O
of	O
ULORIC-Treated	O
Patients	O
and	O
at	O
Least	O
0.5	O
%	O
Greater	O
than	O
Seen	O
in	O
Patients	O
Receiving	O
Placebo	O
in	O
Controlled	O
Studies	O
Adverse	O
Reactions	O
Placebo	O
ULORIC	O
allopurinolOf	O
the	O
subjects	O
who	O
received	O
allopurinol	O
,	O
10	O
received	O
100	O
mg	O
,	O
145	O
received	O
200	O
mg	O
,	O
and	O
1122	O
received	O
300	O
mg	O
,	O
based	O
on	O
level	O
of	O
renal	O
impairment	O
.	O
	
In	O
clinical	O
trials	O
,	O
121	O
patients	O
who	O
received	O
one	O
(	O
n=99	O
)	O
,	O
two	O
(	O
n=21	O
)	O
,	O
or	O
three	O
(	O
n=1	O
)	O
doses	O
of	O
VORAXAZE	O
were	O
evaluated	O
for	O
anti-glucarpidase	O
antibodies	O
.	O
	
If	O
signs	O
or	O
symptoms	O
of	O
spinal	O
hematoma	O
are	O
suspected	O
,	O
initiate	O
urgent	O
diagnosis	O
and	O
treatment	O
including	O
consideration	O
for	O
spinal	O
cord	O
decompression	O
even	O
though	O
such	O
treatment	O
may	O
not	O
prevent	O
or	O
reverse	O
neurological	O
sequelae	O
.	O
	
Retinal	B
detachments	I
resulting	O
from	O
trametinib	O
are	O
often	O
bilateral	O
and	O
multifocal	O
,	O
occurring	O
in	O
the	O
macular	O
region	O
of	O
the	O
retina	O
.	O
	
EBV	O
seropositive	O
patients	O
are	O
defined	O
as	O
having	O
evidence	O
of	O
acquired	O
immunity	O
shown	O
by	O
the	O
presence	O
of	O
IgG	O
antibodies	O
to	O
viral	O
capsid	O
antigen	O
(	O
VCA	O
)	O
and	O
EBV	O
nuclear	O
antigen	O
(	O
EBNA	O
)	O
.	O
	
JEVTANA	O
is	O
contraindicated	O
in	O
patients	O
who	O
have	O
a	O
history	O
of	O
severe	O
hypersensitivity	O
reactions	O
to	O
cabazitaxel	O
or	O
to	O
other	O
drugs	O
formulated	O
with	O
polysorbate	O
80	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.1	O
)	O
,	O
Contraindications	O
(	O
4	O
)	O
,	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
If	O
TAFINLAR	O
is	O
used	O
in	O
combination	O
with	O
trametinib	O
,	O
do	O
not	O
modify	O
the	O
dose	O
of	O
trametinib	O
.	O
	
Patients	O
who	O
are	O
EBV	O
seropositive	O
and	O
CMV	O
seronegative	O
may	O
be	O
at	O
increased	O
risk	O
for	O
PTLD	O
compared	O
to	O
patients	O
who	O
are	O
EBV	O
seropositive	O
and	O
CMV	O
seropositive	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
5.5	O
Urinary	O
Tract	O
Infections	O
JARDIANCE	O
increases	O
the	O
risk	O
for	O
urinary	B
tract	I
infections	I
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Gastrointestinal	O
disorders	O
:	O
Pancreatitis	B
(	O
including	O
fatal	B
outcomes	O
)	O
.	O
	
Monitor	O
and	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
until	O
signs	O
and	O
symptoms	O
resolve	O
.	O
	
In	O
these	O
trials	O
,	O
891	O
patients	O
were	O
treated	O
with	O
TUDORZA	O
PRESSAIR	O
at	O
the	O
recommended	O
dose	O
of	O
400	O
mcg	O
twice	O
daily	O
.	O
	
Before	O
using	O
DALVANCE	O
,	O
inquire	O
carefully	O
about	O
previous	O
hypersensitivity	O
reactions	O
to	O
glycopeptides	O
,	O
and	O
due	O
to	O
the	O
possibility	O
of	O
cross-sensitivity	O
,	O
exercise	O
caution	O
in	O
patients	O
with	O
a	O
history	O
of	O
glycopeptide	O
allergy	O
[	O
see	O
Patient	O
Counseling	O
Information	O
(	O
17	O
)	O
]	O
.	O
	
Cardiac	O
Disorders	O
:	O
angina	B
pectoris	I
,	O
atrial	B
fibrillation	I
,	O
cardiac	B
murmur	I
,	O
ECG	B
abnormal	I
,	O
palpitations	B
,	O
sinus	B
bradycardia	I
,	O
tachycardia	B
.	O
	
TANZEUM	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
a	O
history	O
of	O
pancreatitis	O
to	O
determine	O
whether	O
these	O
patients	O
are	O
at	O
increased	O
risk	O
for	O
pancreatitis	O
.	O
	
Women	O
of	O
childbearing	O
potential	O
and	O
men	O
must	O
use	O
at	O
least	O
two	O
forms	O
of	O
effective	O
contraception	O
during	O
treatment	O
and	O
for	O
at	O
least	O
6	O
months	O
after	O
treatment	O
has	O
concluded	O
.	O
	
Advise	O
females	O
of	O
reproductive	O
potential	O
to	O
use	O
effective	O
contraception	O
during	O
treatment	O
with	O
XALKORI	O
and	O
for	O
at	O
least	O
45	O
days	O
following	O
the	O
final	O
dose	O
[	O
see	O
Use	O
in	O
Specific	O
Populations	O
(	O
8.1	O
,	O
8.3	O
)	O
]	O
.	O
	
In	O
clinical	O
trials	O
with	O
VICTRELIS	O
,	O
dose	O
modifications	O
(	O
generally	O
of	O
PegIntron/REBETOL	O
)	O
due	O
to	O
anemia	B
occurred	O
twice	O
as	O
often	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
(	O
26	O
%	O
)	O
compared	O
to	O
PegIntron/REBETOL	O
(	O
13	O
%	O
)	O
.	O
	
If	O
the	O
QTc	O
Bazett	O
interval	O
is	O
>	O
=500	O
ms	O
,	O
discontinue	O
MULTAQ	O
[	O
see	O
Contraindications	O
(	O
4	O
)	O
]	O
.	O
	
5.5	O
Renal	O
Impairment	O
In	O
patients	O
treated	O
with	O
GLP-1	O
receptor	O
agonists	O
,	O
there	O
have	O
been	O
postmarketing	O
reports	O
of	O
acute	B
renal	I
failure	I
and	O
worsening	B
of	I
chronic	I
renal	I
failure	I
,	O
which	O
may	O
sometimes	O
require	O
hemodialysis	O
.	O
	
Patients	O
have	O
frequently	O
presented	O
with	O
disseminated	O
rather	O
than	O
localized	O
disease	O
.	O
	
It	O
is	O
unknown	O
whether	O
TANZEUM	O
causes	O
thyroid	B
C-cell	I
tumors	I
,	O
including	O
MTC	B
,	O
in	O
humans	O
[	O
see	O
Boxed	O
Warning	O
,	O
Contraindications	O
(	O
4.1	O
)	O
]	O
.	O
	
BOXED	O
WARNING	O
:	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
JC	B
virus	I
infection	I
resulting	O
in	O
PML	B
and	O
death	B
can	O
occur	O
in	O
patients	O
receiving	O
ADCETRIS	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.9	O
)	O
,	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
EXCERPT	O
:	O
WARNING	O
:	O
PROGRESSIVE	B
MULTIFOCAL	I
LEUKOENCEPHALOPATHY	I
(	O
PML	B
)	O
See	O
Full	O
Prescribing	O
Information	O
for	O
complete	O
boxed	O
warning	O
.	O
	
thromboembolic	B
complications	I
may	O
result	O
from	O
increases	B
in	I
platelet	I
counts	I
with	O
PROMACTA	O
.	O
	
Cases	O
of	O
other	O
malignancies	B
have	O
been	O
observed	O
among	O
patients	O
receiving	O
TNF-blockers	O
(	O
5.2	O
)	O
.	O
	
Diabetic	O
Macular	O
Edema	O
(	O
DME	O
)	O
The	O
data	O
described	O
below	O
reflect	O
exposure	O
to	O
EYLEA	O
in	O
578	O
patients	O
with	O
DME	O
treated	O
with	O
the	O
2-mg	O
dose	O
in	O
2	O
double-masked	O
,	O
controlled	O
clinical	O
studies	O
(	O
VIVID	O
and	O
VISTA	O
)	O
from	O
baseline	O
to	O
week	O
52	O
and	O
from	O
baseline	O
to	O
week	O
100	O
[	O
seeClinical	O
Studies	O
(	O
14.4	O
)	O
]	O
.	O
	
It	O
may	O
harm	O
them	O
.	O
	
5.8	O
Leukopenia	O
,	O
Neutropenia	O
,	O
and	O
Agranulocytosis	O
In	O
clinical	O
trial	O
and	O
postmarketing	O
experience	O
,	O
leukopenia	B
and	O
neutropenia	B
have	O
been	O
reported	O
temporally	O
related	O
to	O
antipsychotic	O
agents	O
,	O
including	O
SAPHRIS	O
.	O
	
Reproductive	O
System	O
and	O
Breast	O
Changes	O
:	O
breast	B
pain	I
,	O
erectile	B
dysfunction	I
,	O
gynecomastia	B
.	O
	
5.3	O
Neutropenia	O
(	O
Use	O
with	O
Ribavirin	O
and	O
Peginterferon	O
Alfa	O
)	O
In	O
Phase	O
2	O
and	O
3	O
clinical	O
trials	O
,	O
seven	O
percent	O
of	O
subjects	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
had	O
neutrophil	B
counts	I
of	I
less	I
than	I
0.5	I
*	I
10	I
9	I
per	I
L	I
compared	O
to	O
4	O
%	O
of	O
subjects	O
receiving	O
PegIntron/REBETOL	O
alone	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
If	O
the	O
abnormalities	O
are	O
confirmed	O
,	O
monitor	O
serum	O
liver	O
tests	O
weekly	O
until	O
resolved	O
or	O
stabilized	O
.	O
	
The	O
trial	O
excluded	O
patients	O
with	O
abnormal	O
left	O
ventricular	O
ejection	O
fraction	O
or	O
cardiac	O
valve	O
morphology	O
(	O
>	O
=Grade	O
2	O
)	O
,	O
corrected	O
QT	O
interval	O
>	O
=480	O
milliseconds	O
on	O
electrocardiogram	O
,	O
or	O
a	O
known	O
history	O
of	O
glucose-6-phosphate	O
dehydrogenase	O
deficiency	O
.	O
	
Dose	O
modifications	O
Adverse	O
reactions	O
that	O
led	O
to	O
dose	O
delays	O
in	O
more	O
than	O
5	O
%	O
of	O
patients	O
in	O
Studies	O
1	O
and	O
2	O
were	O
neutropenia	B
(	O
14	O
%	O
)	O
and	O
peripheral	B
sensory	I
neuropathy	I
(	O
11	O
%	O
)	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.2	O
)	O
]	O
.	O
	
Opportunistic	B
infections	I
organisms	O
including	O
aspergillosis	B
,	O
blastomycosis	B
,	O
candidiasis	B
,	O
coccidioidomycosis	B
,	O
histoplasmosis	B
,	O
legionellosis	B
,	O
listeriosis	B
,	O
pneumocystosis	B
,	O
and	O
tuberculosis	B
have	O
been	O
reported	O
with	O
TNF-blockers	O
.	O
	
Three	O
subjects	O
experienced	O
severe	O
or	O
life-threatening	O
infections	B
associated	O
with	O
neutropenia	B
,	O
and	O
two	O
subjects	O
experienced	O
life-threatening	O
neutropenia	B
while	O
receiving	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
.	O
	
In	O
short-term	O
bipolar	O
mania	O
adult	O
trials	O
,	O
syncope	B
was	O
reported	O
in	O
0.3	O
%	O
(	O
1/379	O
)	O
of	O
patients	O
treated	O
with	O
therapeutic	O
doses	O
(	O
5	O
mg	O
or	O
10	O
mg	O
twice	O
daily	O
)	O
of	O
SAPHRIS	O
,	O
compared	O
to	O
0	O
%	O
(	O
0/203	O
)	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
The	O
most	O
common	O
serious	O
adverse	O
reactions	O
were	O
pneumonia	B
(	O
4	O
%	O
)	O
,	O
pyrexia	B
(	O
4	O
%	O
)	O
,	O
vomiting	B
(	O
3	O
%	O
)	O
,	O
nausea	B
(	O
2	O
%	O
)	O
,	O
hepatotoxicity	B
(	O
2	O
%	O
)	O
and	O
peripheral	B
sensory	I
neuropathy	I
(	O
2	O
%	O
)	O
.	O
	
Discontinue	O
PROMACTA	O
if	O
ALT	O
levels	O
increase	O
to	O
greater	O
than	O
or	O
equal	O
to	O
3	O
x	O
ULN	O
in	O
patients	O
with	O
normal	O
liver	O
function	O
or	O
greater	O
than	O
or	O
equal	O
to	O
3	O
x	O
baseline	O
in	O
patients	O
with	O
pre-treatment	O
elevations	O
in	O
transaminases	O
and	O
are	O
:	O
*	O
progressively	O
increasing	O
,	O
or	O
*	O
persistent	O
for	O
greater	O
than	O
or	O
equal	O
to	O
4	O
weeks	O
,	O
or	O
*	O
accompanied	O
by	O
increased	O
direct	O
bilirubin	O
,	O
or	O
*	O
accompanied	O
by	O
clinical	O
symptoms	O
of	O
liver	O
injury	O
or	O
evidence	O
for	O
hepatic	O
decompensation	O
.	O
	
Monitoring	O
of	O
orthostatic	O
vital	O
signs	O
should	O
be	O
considered	O
in	O
all	O
such	O
patients	O
,	O
and	O
a	O
dose	O
reduction	O
should	O
be	O
considered	O
if	O
hypotension	O
occurs	O
.	O
	
This	O
Patient	O
Information	O
summarizes	O
the	O
most	O
important	O
information	O
about	O
DUAVEE	O
.	O
	
*	O
Heart	B
failure	I
,	O
may	O
occur	O
.	O
	
Renal	O
and	O
hematuria	B
.	O
	
6	O
ADVERSE	O
REACTIONS	O
The	O
most	O
serious	O
adverse	O
reactions	O
reported	O
with	O
NULOJIX	O
are	O
:	O
*	O
PTLD	B
,	O
predominantly	O
CNS	B
PTLD	I
,	O
and	O
other	O
malignancies	B
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
,	O
5.3	O
)	O
]	O
*	O
Serious	O
infections	B
,	O
including	O
JC	B
virus-associated	O
PML	B
and	O
polyoma	B
virus	I
nephropathy	I
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.4	O
,	O
5.5	O
,	O
5.6	O
)	O
]	O
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
>	O
=20	O
%	O
on	O
NULOJIX	O
treatment	O
)	O
are	O
anemia	B
,	O
diarrhea	B
,	O
urinary	B
tract	I
infection	I
,	O
peripheral	B
edema	I
,	O
constipation	B
,	O
hypertension	B
,	O
pyrexia	B
,	O
graft	B
dysfunction	I
,	O
cough	B
,	O
nausea	B
,	O
vomiting	B
,	O
headache	B
,	O
hypokalemia	B
,	O
hyperkalemia	B
,	O
and	O
leukopenia	B
.	O
	
Opportunistic	B
infections	I
,	O
or	O
other	O
opportunistic	O
pathogens	O
including	O
aspergillosis	B
,	O
blastomycosis	B
,	O
candidiasis	B
,	O
coccidioidomycosis	B
,	O
histoplasmosis	B
,	O
legionellosis	B
,	O
listeriosis	B
,	O
pneumocystosis	B
and	O
tuberculosis	B
have	O
been	O
reported	O
with	O
TNF	O
blockers	O
.	O
	
If	O
hypersensitivity	O
reactions	O
occur	O
,	O
discontinue	O
use	O
of	O
TANZEUM	O
;	O
treat	O
promptly	O
per	O
standard	O
of	O
care	O
and	O
monitor	O
until	O
signs	O
and	O
symptoms	O
resolve	O
[	O
see	O
Contraindications	O
(	O
4.2	O
)	O
]	O
.	O
	
Overall	O
,	O
abnormalities	B
in	I
liver	I
tests	I
(	I
ALT	I
)	O
were	O
reported	O
with	O
similar	O
frequency	O
in	O
the	O
DALVANCE	O
and	O
comparator	O
arms	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
The	O
proportion	O
of	O
subjects	O
who	O
discontinued	O
study	O
drug	O
due	O
to	O
anemia	B
was	O
1	O
%	O
in	O
subjects	O
treated	O
with	O
the	O
combination	O
of	O
VICTRELIS	O
with	O
PegIntron/REBETOL	O
and	O
1	O
%	O
in	O
subjects	O
who	O
received	O
PegIntron/REBETOL	O
.	O
	
Advise	O
pregnant	O
women	O
of	O
the	O
potential	O
risk	O
to	O
a	O
fetus	O
.	O
	
Women	O
taking	O
DUAVEE	O
should	O
not	O
take	O
progestins	O
,	O
additional	O
estrogens	O
or	O
additional	O
estrogen	O
agonist/antagonists	O
.	O
	
Reported	O
thromboembolic	B
complications	I
and	O
were	O
observed	O
at	O
low	O
and	O
at	O
normal	O
platelet	O
counts	O
.	O
	
For	O
these	O
reasons	O
,	O
comparison	O
of	O
incidence	O
of	O
antibodies	O
to	O
ADCETRIS	O
with	O
the	O
incidence	O
of	O
antibodies	O
to	O
other	O
products	O
may	O
be	O
misleading	O
.	O
	
5.4	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
Teflaro	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
bacterial	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
increases	O
the	O
risk	O
of	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
Excluded	O
from	O
this	O
list	O
are	O
those	O
events	O
that	O
were	O
minor	O
,	O
those	O
with	O
no	O
plausible	O
relation	O
to	O
drug	O
use	O
,	O
and	O
reports	O
too	O
imprecise	O
to	O
be	O
meaningful	O
.	O
	
The	O
demographic	O
and	O
baseline	O
characteristics	O
of	O
the	O
long	O
term	O
safety	O
trials	O
were	O
similar	O
to	O
those	O
of	O
the	O
placebo-controlled	O
trials	O
.	O
	
(	O
5.3	O
)	O
*	O
Hypersensitivity	B
Reactions	I
:	O
Discontinue	O
TANZEUM	O
if	O
suspected	O
.	O
	
Conjugated	O
estrogens	O
are	O
a	O
mixture	O
of	O
sodium	O
estrone	O
sulfate	O
and	O
sodium	O
equilin	O
sulfate	O
and	O
other	O
components	O
,	O
including	O
sodium	O
sulfate	O
conjugates	O
,	O
17alpha-dihydroequilin	O
,	O
17alpha-estradiol	O
,	O
and	O
17beta-dihydroequilin	O
.	O
	
Pyrexia	B
,	O
chills	B
,	O
and	O
nausea	B
were	O
the	O
most	O
common	O
reasons	O
cited	O
for	O
dose	O
reductions	O
and	O
pyrexia	B
,	O
chills	B
,	O
and	O
decreased	B
ejection	I
fraction	I
were	O
the	O
most	O
common	O
reasons	O
cited	O
for	O
dose	O
interruptions	O
of	O
TAFINLAR	O
and	O
trametinib	O
when	O
used	O
in	O
combination	O
.	O
	
One	O
of	O
these	O
forms	O
of	O
contraception	O
can	O
be	O
a	O
combined	O
oral	O
contraceptive	O
product	O
containing	O
at	O
least	O
1	O
mg	O
of	O
norethindrone	O
.	O
	
Blood	O
and	O
Lymphatic	O
System	O
Disorders	O
:	O
anemia	B
,	O
idiopathic	B
thrombocytopenic	I
purpura	I
,	O
leukocytosis/leukopenia	O
,	O
neutropenia	B
,	O
pancytopenia	B
,	O
splenomegaly	B
,	O
thrombocytopenia	B
.	O
	
If	O
pancreatitis	O
is	O
confirmed	O
,	O
TANZEUM	O
should	O
not	O
be	O
restarted	O
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
If	O
an	O
allergic	O
reaction	O
occurs	O
,	O
treatment	O
with	O
DALVANCE	O
should	O
be	O
discontinued	O
.	O
	
The	O
risk	O
may	O
also	O
be	O
increased	O
by	O
traumatic	O
or	O
repeated	O
epidural	O
or	O
spinal	O
puncture	O
.	O
	
CMV	O
prophylaxis	O
is	O
recommended	O
for	O
at	O
least	O
3	O
months	O
after	O
transplantation	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
These	O
hematomas	B
may	O
result	O
in	O
permanent	B
paralysis	I
.	O
	
5.7	O
Serious	O
Febrile	O
Reactions	O
Serious	O
febrile	B
reactions	I
and	O
fever	B
of	O
any	O
severity	O
complicated	O
by	O
hypotension	B
,	O
rigors	B
or	O
chills	B
,	O
dehydration	B
,	O
or	O
renal	B
failure	I
,	O
can	O
occur	O
when	O
TAFINLAR	O
is	O
administered	O
as	O
a	O
single	O
agent	O
or	O
when	O
used	O
in	O
combination	O
with	O
trametinib	O
.	O
	
5.8	O
Musculoskeletal	O
Pain	O
In	O
post-marketing	O
experience	O
,	O
severe	O
and	O
occasionally	O
incapacitating	O
muscle	B
pain	I
has	O
been	O
reported	O
in	O
patients	O
taking	O
Prolia	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.2	O
)	O
]	O
.	O
	
Adverse	O
reactions	O
for	O
FULYZAQ	O
that	O
occurred	O
in	O
at	O
least	O
2	O
%	O
of	O
patients	O
and	O
at	O
a	O
higher	O
incidence	O
than	O
placebo	O
are	O
provided	O
in	O
Table	O
1	O
.	O
	
Monitor	O
and	O
treat	O
as	O
appropriate	O
.	O
	
Failure	O
to	O
block	O
thyroid	O
uptake	O
of	O
iodine	O
123	O
may	O
result	O
in	O
an	O
increased	O
long	O
term	O
risk	O
for	O
thyroid	O
neoplasia	O
.	O
	
Twenty-five	O
of	O
these	O
121	O
patients	O
(	O
21	O
%	O
)	O
had	O
detectable	O
anti-glucarpidase	O
antibodies	O
following	O
VORAXAZE	O
administration	O
,	O
of	O
which	O
19	O
received	O
a	O
single	O
dose	O
of	O
VORAXAZE	O
and	O
6	O
received	O
two	O
doses	O
of	O
VORAXAZE	O
.	O
	
Table	O
1	O
summarizes	O
adverse	O
reactions	O
reported	O
at	O
a	O
rate	O
of	O
at	O
least	O
1	O
%	O
in	O
ULORIC	O
treatment	O
groups	O
and	O
at	O
least	O
0.5	O
%	O
greater	O
than	O
placebo	O
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
(	O
>	O
=25	O
%	O
)	O
of	O
XALKORI	O
in	O
Studies	O
1	O
and	O
2	O
are	O
vision	B
disorders	I
,	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
,	O
constipation	B
,	O
edema	B
,	O
elevated	B
transaminases	I
,	O
upper	B
respiratory	I
infection	I
,	O
decreased	B
appetite	I
,	O
and	O
dysgeusia	B
.	O
	
Patients	O
should	O
receive	O
premedication	O
.	O
	
EBV	O
Serostatus	O
The	O
risk	O
of	O
PTLD	B
was	O
higher	O
in	O
EBV	O
seronegative	O
patients	O
compared	O
to	O
EBV	O
seropositive	O
patients	O
.	O
	
5.2	O
Hypersensitivity	O
Reactions	O
Acute	B
hypersensitivity	I
reactions	I
,	O
including	O
dyspnea	B
,	O
rash	B
pruritus	B
,	O
and	O
angioedema	B
of	I
the	I
mouth	I
have	O
been	O
reported	O
with	O
fidaxomicin	O
.	O
	
The	O
use	O
of	O
corticosteroids	O
may	O
be	O
indicated	O
.	O
	
Study	O
1	O
,	O
conducted	O
by	O
the	O
National	O
Cancer	O
Institute	O
(	O
NCI	O
)	O
,	O
enrolled	O
184	O
patients	O
;	O
safety	O
information	O
is	O
available	O
for	O
149	O
patients	O
.	O
	
A	O
minority	O
of	O
patients	O
(	O
approximately	O
17	O
%	O
)	O
who	O
tested	O
positive	O
for	O
anti-albiglutide	O
antibodies	O
also	O
transiently	O
tested	O
positive	O
for	O
antibodies	O
to	O
human	O
albumin	O
.	O
	
If	O
irritation	O
persists	O
,	O
consult	O
a	O
physician	O
.	O
	
In	O
both	O
groups	O
,	O
patients	O
with	O
events	O
were	O
generally	O
male	O
,	O
older	O
,	O
and	O
had	O
underlying	O
renal	O
impairment	O
or	O
cardiac	O
disease	O
(	O
e.g.	O
,	O
history	O
of	O
arrhythmia	O
,	O
palpitations	O
,	O
congestive	O
heart	O
failure	O
,	O
cardiomyopathy	O
,	O
etc	O
.	O
	
)	O
.	O
	
For	O
patients	O
who	O
test	O
positive	O
for	O
hepatitis	O
B	O
surface	O
antigen	O
,	O
consultation	O
with	O
a	O
physician	O
with	O
expertise	O
in	O
the	O
treatment	O
of	O
hepatitis	O
B	O
is	O
recommended	O
before	O
initiating	O
TNF-blocker	O
therapy	O
.	O
	
EXCERPT	O
:	O
Most	O
common	O
adverse	O
reactions	O
(	O
incidence	O
>	O
=10	O
%	O
and	O
>	O
=2	O
%	O
placebo	O
)	O
were	O
flushing	B
,	O
abdominal	B
pain	I
,	O
diarrhea	B
,	O
and	O
nausea	B
.	O
	
The	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
(	O
occurring	O
in	O
at	O
least	O
0.5	O
%	O
of	O
subjects	O
)	O
during	O
Neuraceq	O
clinical	O
trials	O
are	O
shown	O
in	O
Table	O
2	O
.	O
	
Treatment	O
of	O
CAPS	O
The	O
data	O
described	O
herein	O
reflect	O
exposure	O
to	O
ILARIS	O
in	O
104	O
adult	O
and	O
pediatric	O
CAPS	O
patients	O
,	O
including	O
20	O
FCAS	O
,	O
72	O
MWS	O
,	O
10	O
MWS/NOMID	O
(	O
Neonatal	O
Onset	O
Multisystem	O
Inflammatory	O
Disorder	O
)	O
overlap	O
,	O
1	O
non-FCAS	O
non-MWS	O
,	O
and	O
1	O
misdiagnosed	O
in	O
placebo-controlled	O
(	O
35	O
patients	O
)	O
and	O
uncontrolled	O
trials	O
.	O
	
Corticosteroids	O
may	O
be	O
indicated	O
until	O
clinical	O
symptoms	O
resolve	O
.	O
	
Use	O
of	O
a	O
sensitive	O
real-time	O
reverse-transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT-PCR	O
)	O
assay	O
for	O
monitoring	O
HCV-RNA	O
levels	O
during	O
treatment	O
is	O
recommended	O
.	O
	
G-CSF	O
may	O
be	O
administered	O
to	O
reduce	O
the	O
risks	O
of	O
neutropenia	O
complications	O
associated	O
with	O
JEVTANA	O
use	O
.	O
	
In	O
the	O
two	O
clinical	O
trials	O
in	O
infantile-onset	O
patients	O
,	O
the	O
majority	O
of	O
patients	O
(	O
34	O
of	O
38	O
;	O
89	O
%	O
)	O
tested	O
positive	O
for	O
IgG	O
antibodies	O
to	O
alglucosidase	O
alfa	O
.	O
	
They	O
had	O
a	O
mean	O
age	O
of	O
62	O
years	O
and	O
an	O
average	O
smoking	O
history	O
of	O
44	O
pack-years	O
,	O
with	O
54	O
%	O
identified	O
as	O
current	O
smokers	O
.	O
	
Of	O
these	O
patients	O
,	O
there	O
were	O
2	O
respiratory-related	O
deaths	B
in	O
the	O
ARCAPTA	O
NEOHALER	O
300	O
mcg	O
dose	O
group	O
.	O
	
5.4	O
Development	O
of	O
Drug-Resistant	O
Bacteria	O
Prescribing	O
ZERBAXA	O
in	O
the	O
absence	O
of	O
a	O
proven	O
or	O
strongly	O
suspected	O
bacterial	O
infection	O
is	O
unlikely	O
to	O
provide	O
benefit	O
to	O
the	O
patient	O
and	O
risks	O
the	O
development	O
of	O
drug-resistant	O
bacteria	O
.	O
	
The	O
principal	O
efficacy	O
study	O
evaluating	O
the	O
efficacy	O
and	O
safety	O
of	O
HORIZANT	O
in	O
the	O
management	O
of	O
PHN	O
was	O
a	O
12-week	O
,	O
double-blind	O
,	O
multicenter	O
study	O
comparing	O
1,200	O
mg/day	O
,	O
2,400	O
mg/day	O
and	O
3,600	O
mg/day	O
to	O
placebo	O
.	O
	
Diarrhea	B
,	O
nausea	B
,	O
and	O
upper	B
respiratory	I
tract	I
infection	I
were	O
the	O
most	O
commonly	O
reported	O
adverse	O
reactions	O
.	O
	
(	O
5.4	O
)	O
5.1	O
Effects	O
on	O
Driving	O
HORIZANT	O
may	O
cause	O
significant	O
driving	B
impairment	I
[	O
see	O
Clinical	O
Studies	O
(	O
14.3	O
)	O
]	O
.	O
	
The	O
most	O
commonly-reported	O
adverse	O
reactions	O
,	O
occurring	O
in	O
>	O
=5	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
were	O
nausea	B
,	O
diarrhea	B
,	O
pyrexia	B
,	O
nasopharyngitis	B
,	O
bronchitis	B
,	O
insomnia	B
,	O
pain	B
in	I
extremity	I
,	O
depression	B
,	O
migraine	B
,	O
and	O
pharyngitis	B
.	O
	
A	O
similar	O
trend	O
was	O
also	O
seen	O
in	O
the	O
cUTI	O
trial	O
.	O
	
Withhold	O
GILOTRIF	O
during	O
evaluation	O
of	O
patients	O
with	O
suspected	O
keratitis	O
,	O
and	O
if	O
diagnosis	O
of	O
ulcerative	O
keratitis	O
is	O
confirmed	O
,	O
treatment	O
with	O
GILOTRIF	O
should	O
be	O
interrupted	O
or	O
discontinued	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
Reduce	O
or	O
discontinue	O
NORTHERA	O
if	O
supine	O
hypertension	O
persists	O
.	O
	
The	O
study	O
population	O
included	O
34	O
males	O
and	O
26	O
females	O
(	O
n=60	O
)	O
in	O
the	O
alglucosidase	O
alfa	O
group	O
and	O
11	O
males	O
and	O
19	O
females	O
(	O
n=30	O
)	O
in	O
the	O
placebo	O
group	O
.	O
	
Skin	B
discoloration	I
has	O
been	O
reported	O
with	O
higher	O
frequency	O
among	O
emtricitabine-treated	O
subjects	O
;	O
it	O
was	O
manifested	O
by	O
hyperpigmentation	B
on	I
the	I
palms	I
and	O
was	O
generally	O
mild	O
and	O
asymptomatic	O
.	O
	
5.4	O
Facial	O
Anatomy	O
in	O
the	O
Treatment	O
of	O
Glabellar	O
Lines	O
Caution	O
should	O
be	O
exercised	O
when	O
administering	O
DYSPORT	O
(	O
r	O
)	O
to	O
patients	O
with	O
surgical	O
alterations	O
to	O
the	O
facial	O
anatomy	O
,	O
excessive	O
weakness	O
or	O
atrophy	O
in	O
the	O
target	O
muscle	O
(	O
s	O
)	O
,	O
marked	O
facial	O
asymmetry	O
,	O
inflammation	O
at	O
the	O
injection	O
site	O
(	O
s	O
)	O
,	O
ptosis	O
,	O
excessive	O
dermatochalasis	O
,	O
deep	O
dermal	O
scarring	O
,	O
thick	O
sebaceous	O
skin	O
[	O
seeDosage	O
and	O
Administration	O
(	O
2.3	O
]	O
or	O
the	O
inability	O
to	O
substantially	O
lessen	O
glabellar	O
lines	O
by	O
physically	O
spreading	O
them	O
apart	O
[	O
seeClinical	O
Studies	O
(	O
14.2	O
)	O
]	O
.	O
	
Since	O
ENTEREG	O
acts	O
peripherally	O
,	O
clinical	O
signs	O
and	O
symptoms	O
of	O
increased	B
sensitivity	I
would	I
be	I
related	I
to	I
the	I
gastrointestinal	I
tract	I
(	O
e.g.	O
,	O
abdominal	B
pain	I
,	O
nausea	B
and	O
vomiting	B
,	O
diarrhea	B
)	O
.	O
	
No	O
hypersensitivity	B
or	O
anaphylactic	B
reactions	I
were	O
reported	O
with	O
FIRAZYR	O
.	O
	
*	O
Corrugator	O
injections	O
should	O
be	O
placed	O
at	O
least	O
1	O
cm	O
above	O
the	O
bony	O
supraorbital	O
ridge	O
.	O
	
The	O
most	O
common	O
Grade	O
3-4	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=	O
3	O
%	O
)	O
were	O
lymphopenia	B
,	O
hyperglycemia	B
,	O
anemia	B
,	O
hypophosphatemia	B
,	O
and	O
hypercholesterolemia	B
.	O
	
Carefully	O
weigh	O
risks	O
and	O
benefits	O
of	O
treatment	O
with	O
OTEZLA	O
in	O
patients	O
with	O
a	O
history	O
of	O
depression	O
and/or	O
suicidal	O
thoughts	O
or	O
behavior	O
.	O
	
(	O
5.7	O
)	O
5.1	O
Mortality	O
There	O
were	O
more	O
deaths	B
reported	O
with	O
BENLYSTA	O
than	O
with	O
placebo	O
during	O
the	O
controlled	O
period	O
of	O
the	O
clinical	O
trials	O
.	O
	
Typical	O
symptoms	O
associated	O
with	O
PML	B
are	O
diverse	O
,	O
progress	O
over	O
days	O
to	O
weeks	O
,	O
and	O
include	O
progressive	B
weakness	I
on	I
one	I
side	I
of	I
the	I
body	I
or	O
clumsiness	B
of	I
limbs	I
,	O
disturbance	B
of	I
vision	I
,	O
and	O
changes	B
in	I
thinking	I
leading	O
to	O
confusion	B
and	O
personality	B
changes	I
.	O
	
For	O
patients	O
who	O
develop	O
prolonged	O
Grade	O
2	O
cutaneous	O
adverse	O
reactions	O
lasting	O
more	O
than	O
7	O
days	O
,	O
intolerable	O
Grade	O
2	O
,	O
or	O
Grade	O
3	O
cutaneous	O
reactions	O
,	O
withhold	O
GILOTRIF	O
until	O
the	O
adverse	O
reaction	O
resolves	O
to	O
Grade	O
1	O
or	O
less	O
,	O
and	O
resume	O
GILOTRIF	O
with	O
appropriate	O
dose	O
reduction	O
[	O
see	O
Dosage	O
and	O
Administration	O
(	O
2.3	O
)	O
]	O
.	O
	
The	O
rates	O
of	O
adverse	O
reactions	O
below	O
were	O
derived	O
from	O
two	O
randomized	O
,	O
multi-center	O
,	O
vehicle-controlled	O
clinical	O
trials	O
and	O
one	O
open-label	O
study	O
in	O
subjects	O
with	O
head	O
lice	O
infestation	O
.	O
	
Because	O
of	O
its	O
anticholinergic	O
effects	O
,	O
XEOMIN	O
should	O
be	O
used	O
with	O
caution	O
in	O
patients	O
at	O
risk	O
of	O
developing	O
narrow	O
angle	O
glaucoma	O
.	O
	
Psoriatic	O
arthritis	O
:	O
During	O
the	O
0	O
to	O
16	O
week	O
placebo-controlled	O
period	O
of	O
the	O
3	O
controlled	O
clinical	O
trials	O
,	O
1.0	O
%	O
(	O
10/998	O
)	O
of	O
subjects	O
treated	O
with	O
OTEZLA	O
reported	O
depression	B
or	O
depressed	B
mood	I
compared	O
to	O
0.8	O
%	O
(	O
4/495	O
)	O
treated	O
with	O
placebo	O
.	O
	
Cerebrovascular	O
Adverse	O
Events	O
,	O
Including	O
Stroke	O
In	O
placebo-controlled	O
trials	O
with	O
risperidone	O
,	O
aripiprazole	O
,	O
and	O
olanzapine	O
in	O
elderly	O
patients	O
with	O
dementia	O
,	O
there	O
was	O
a	O
higher	O
incidence	O
of	O
cerebrovascular	B
adverse	I
events	I
(	O
cerebrovascular	B
accidents	I
and	O
transient	B
ischemic	I
attacks	I
)	O
including	O
fatalities	B
compared	O
to	O
placebo-treated	O
patients	O
.	O
	
Changes	O
from	O
baseline	O
in	O
total	O
cholesterol	O
,	O
HDL-cholesterol	O
,	O
LDL-cholesterol	O
,	O
and	O
triglycerides	O
are	O
presented	O
in	O
Table	O
5	O
.	O
	
Liver	B
chemistry	I
elevations	I
consistent	O
with	O
immune	B
reconstitution	I
syndrome	I
were	O
observed	O
in	O
some	O
subjects	O
with	O
hepatitis	O
B	O
and/or	O
C	O
at	O
the	O
start	O
of	O
therapy	O
with	O
TIVICAY	O
,	O
particularly	O
in	O
the	O
setting	O
where	O
anti-hepatitis	O
therapy	O
was	O
withdrawn	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
.	O
	
Patients	O
with	O
pre-	O
existing	O
swallowing	O
or	O
breathing	O
difficulties	O
may	O
be	O
more	O
susceptible	O
to	O
these	O
complications	O
.	O
	
The	O
malignancies	O
occurred	O
after	O
a	O
median	O
of	O
30	O
months	O
(	O
range	O
1	O
to	O
84	O
months	O
)	O
after	O
the	O
first	O
dose	O
of	O
TNF-blocker	O
therapy	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Cardiac	B
toxicities	I
include	O
cardiac	B
failure	I
and	O
myocardial	B
infarction	I
with	O
fatal	B
outcome	O
,	O
and	O
myocardial	B
ischemia	I
.	O
	
Of	O
the	O
patients	O
in	O
those	O
trials	O
,	O
approximately	O
95	O
%	O
were	O
between	O
18	O
and	O
60	O
years	O
old	O
,	O
approximately	O
50	O
%	O
were	O
male	O
,	O
and	O
approximately	O
80	O
%	O
were	O
Caucasian	O
.	O
	
Adverse	O
reactions	O
of	O
venous	B
thromboembolism	I
were	O
reported	O
in	O
0.0	O
%	O
of	O
patients	O
treated	O
with	O
DUAVEE	O
and	O
0.1	O
%	O
of	O
patients	O
treated	O
with	O
placebo	O
.	O
	
Monitor	O
thyroid	O
function	O
before	O
initiation	O
of	O
,	O
and	O
periodically	O
throughout	O
,	O
treatment	O
with	O
INLYTA	O
.	O
	
In	O
the	O
EMTP	O
trial	O
,	O
safety	O
data	O
were	O
derived	O
from	O
case	O
report	O
forms	O
that	O
collected	O
adverse	O
event	O
information	O
.	O
	
*	O
Bipolar	O
Disorder	O
Adults	O
(	O
Monotherapy	O
)	O
:	O
somnolence	B
,	O
dizziness	B
,	O
extrapyramidal	B
symptoms	I
other	O
than	O
akathisia	B
,	O
increased	B
weight	I
.	O
	
INLYTA	O
has	O
not	O
been	O
studied	O
in	O
patients	O
with	O
evidence	O
of	O
untreated	O
brain	O
metastasis	O
or	O
recent	O
active	O
gastrointestinal	O
bleeding	O
and	O
should	O
not	O
be	O
used	O
in	O
those	O
patients	O
.	O
	
5.2	O
Pancreatitis	O
Pancreatitis	B
has	O
been	O
reported	O
in	O
4	O
%	O
of	O
patients	O
in	O
clinical	O
trials	O
[	O
see	O
Adverse	O
Reactions	O
(	O
6.1	O
)	O
]	O
.	O
	
Discontinue	O
Kyprolis	O
if	O
suspected	O
.	O
	
There	O
is	O
no	O
known	O
treatment	O
for	O
established	O
cases	O
of	O
tardive	O
dyskinesia	O
,	O
although	O
the	O
syndrome	O
may	O
remit	O
,	O
partially	O
or	O
completely	O
,	O
if	O
antipsychotic	O
treatment	O
is	O
withdrawn	O
.	O
	
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.2	O
)	O
]	O
WARNING	O
:	O
DISTANT	B
SPREAD	I
OF	I
TOXIN	I
EFFECT	I
See	O
full	O
prescribing	O
information	O
for	O
complete	O
boxed	O
warning	O
The	O
effects	O
of	O
DYSPORT	O
(	O
r	O
)	O
and	O
all	O
botulinum	O
toxin	O
products	O
may	O
spread	B
from	I
the	I
area	I
of	I
injection	I
to	I
produce	I
symptoms	I
consistent	I
with	I
botulinum	I
toxin	I
effects	I
.	O
	
5.4	O
Demyelinating	O
Disorders	O
Use	O
of	O
TNF-blockers	O
,	O
of	O
which	O
SIMPONI	O
ARIA	O
is	O
a	O
member	O
,	O
has	O
been	O
associated	O
with	O
rare	O
cases	O
of	O
exacerbation	B
of	I
central	I
nervous	I
system	I
(	I
CNS	I
)	I
demyelinating	I
disorders	I
,	O
including	O
multiple	B
sclerosis	I
(	O
MS	B
)	O
and	O
peripheral	B
demyelinating	I
disorders	I
,	O
including	O
Guillain-Barre	B
syndrome	I
.	O
	
There	O
is	O
no	O
clinical	O
trial	O
experience	O
with	O
XTANDI	O
in	O
patients	O
who	O
have	O
had	O
a	O
seizure	O
.	O
	
The	O
most	O
frequently	O
reported	O
ADR	O
at	O
least	O
Grade	O
2	O
in	O
severity	O
was	O
rash	B
(	O
10.0	O
%	O
)	O
.	O
	
Blepharospasm	O
(	O
5.6	O
)	O
:	O
*	O
Corneal	B
exposure	I
*	O
Injection	O
of	O
XEOMIN	O
into	O
the	O
orbicularis	O
oculi	O
muscle	O
may	O
lead	O
to	O
reduced	B
blinking	I
and	O
corneal	B
exposure	I
.	O
	
The	O
most	O
common	O
adverse	O
reactions	O
reported	O
for	O
AFINITOR	O
(	O
incidence	O
>	O
=	O
30	O
%	O
)	O
were	O
stomatitis	B
and	O
respiratory	B
tract	I
infection	I
.	O
	
NSF	B
may	O
result	O
in	O
fatal	B
or	O
debilitating	O
fibrosis	B
affecting	O
the	O
skin	O
,	O
muscle	O
and	O
internal	O
organs	O
.	O
	
Consider	O
suspending	O
treatment	O
with	O
GILENYA	O
if	O
a	O
patient	O
develops	O
a	O
serious	O
infection	O
,	O
and	O
reassess	O
the	O
benefits	O
and	O
risks	O
prior	O
to	O
reinitiation	O
of	O
therapy	O
.	O
	
The	O
majority	O
were	O
in	O
adolescent	O
and	O
young	O
adult	O
males	O
.	O
	
Renal	B
insufficiency	I
adverse	I
events	I
(	O
renal	B
impairment	I
,	O
acute	B
renal	I
failure	I
,	O
renal	B
failure	I
)	O
have	O
occurred	O
with	O
an	O
incidence	O
of	O
approximately	O
8	O
%	O
in	O
a	O
randomized	O
controlled	O
trial	O
.	O
	
TABLE	O
1	O
:	O
Changes	O
in	O
Fasting	O
Glucose	O
in	O
Adult	O
Patients	O
N*	O
=	O
Number	O
of	O
patients	O
who	O
had	O
assessments	O
at	O
both	O
Baseline	O
and	O
Endpoint	O
.	O
	
The	O
duration	O
of	O
Prolia	O
exposure	O
to	O
time	O
of	O
atypical	B
femoral	I
fracture	I
diagnosis	O
was	O
as	O
early	O
as	O
21/2	O
years	O
[	O
see	O
Warnings	O
and	O
Precautions	O
(	O
5.5	O
)	O
]	O
.	O
	
Mean	O
changes	B
(	I
percent	I
changes	I
)	I
from	I
baseline	I
in	I
non-HDL-C	I
relative	O
to	O
placebo	O
were	O
2.1	O
mg/dL	O
(	O
1.5	O
%	O
)	O
and	O
5.1	O
mg/dL	O
(	O
3.6	O
%	O
)	O
with	O
INVOKANA	O
100	O
mg	O
and	O
300	O
mg	O
,	O
respectively	O
.	O
	
Monitor	O
blood	O
pressure	O
during	O
and	O
following	O
the	O
treatment	O
procedure	O
.	O
	
No	O
new	O
major	O
safety	O
findings	O
were	O
reported	O
from	O
a	O
50-week	O
,	O
open-label	O
,	O
uncontrolled	O
safety	O
trial	O
.	O
	
A	O
total	O
of	O
56	O
%	O
of	O
patients	O
were	O
female	O
and	O
45	O
%	O
of	O
patients	O
were	O
Asian	O
.	O
	
6	O
ADVERSE	O
REACTIONS	O
*	O
The	O
following	O
serious	O
adverse	O
reactions	O
are	O
discussed	O
elsewhere	O
in	O
labeling	O
:	O
*	O
Nephrogenic	B
Systemic	I
Fibrosis	I
(	O
NSF	B
)	O
[	O
see	O
Boxed	O
Warning	O
and	O
Warnings	O
and	O
Precautions	O
(	O
5.1	O
)	O
]	O
.	O
	
The	O
causes	O
of	O
death	B
in	O
the	O
remaining	O
subjects	O
varied	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
trials	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
trials	O
of	O
other	O
drugs	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
QT	B
prolongation	I
can	O
occur	O
with	O
SIRTURO	O
.	O
	
Patients	O
with	O
uncontrolled	O
or	O
significant	O
cardiovascular	O
disease	O
including	O
QT	O
interval	O
prolongation	O
were	O
excluded	O
by	O
protocol	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
studies	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
adverse	O
reaction	O
rates	O
observed	O
in	O
the	O
clinical	O
studies	O
of	O
a	O
drug	O
can	O
not	O
be	O
directly	O
compared	O
to	O
rates	O
in	O
the	O
clinical	O
studies	O
of	O
another	O
drug	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
There	O
are	O
no	O
adequate	O
and	O
well-controlled	O
studies	O
in	O
pregnant	O
women	O
using	O
JEVTANA	O
.	O
	
The	O
adverse	O
reaction	O
most	O
commonly	O
(	O
>	O
=1	O
%	O
on	O
APTIOM	O
)	O
leading	O
to	O
discontinuation	O
was	O
hyponatremia	B
.	O
	
BRAF	O
V600E	O
Unresectable	O
or	O
Metastatic	O
Melanoma	O
:	O
The	O
safety	O
of	O
TAFINLAR	O
as	O
a	O
single	O
agent	O
was	O
evaluated	O
in	O
586	O
patients	O
with	O
BRAF	O
V600	O
mutation-positive	O
unresectable	O
or	O
metastatic	O
melanoma	O
,	O
previously	O
treated	O
or	O
untreated	O
,	O
who	O
received	O
TAFINLAR	O
150	O
mg	O
orally	O
twice	O
daily	O
until	O
disease	O
progression	O
or	O
unacceptable	O
toxicity	O
,	O
including	O
181	O
patients	O
treated	O
for	O
at	O
least	O
6	O
months	O
and	O
86	O
additional	O
patients	O
treated	O
for	O
more	O
than	O
12	O
months	O
.	O
	
5.4	O
Tumor	O
Lysis	O
Syndrome	O
Tumor	B
lysis	I
syndrome	I
associated	O
with	O
TREANDA	O
treatment	O
has	O
occurred	O
in	O
patients	O
in	O
clinical	O
trials	O
and	O
in	O
postmarketing	O
reports	O
.	O
	
Fatal	B
and	O
serious	O
cases	O
of	O
renal	B
failure	I
have	O
occurred	O
with	O
IMBRUVICA	O
therapy	O
.	O
	
If	O
pancreatitis	O
is	O
suspected	O
,	O
promptly	O
discontinue	O
NESINA	O
.	O
	
(	O
6.1	O
)	O
Upper	O
Limb	O
Spasticity	O
The	O
most	O
frequently	O
reported	O
adverse	O
reactions	O
(	O
>	O
=2	O
%	O
)	O
are	O
:	O
urinary	B
tract	I
infection	I
,	O
nasopharyngitis	B
,	O
muscular	B
weakness	I
,	O
musculoskeletal	B
pain	I
,	O
dizziness	B
,	O
fall	B
and	O
depression	B
.	O
	
Myelosuppression	O
may	O
require	O
dose	O
delays	O
and/or	O
subsequent	O
dose	O
reductions	O
if	O
recovery	O
to	O
the	O
recommended	O
values	O
has	O
not	O
occurred	O
by	O
the	O
first	O
day	O
of	O
the	O
next	O
scheduled	O
cycle	O
.	O
	
(	O
6.1	O
)	O
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contact	O
Pfizer	O
,	O
Inc	O
at	O
1-800-438-1985	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
Hypersensitivity	B
reactions	I
including	O
anaphylactic	B
shock	I
(	O
fatal	B
)	O
,	O
urticaria	B
,	O
and	O
angioedema	B
have	O
been	O
reported	O
.	O
	
Typical	O
symptoms	O
associated	O
with	O
PML	O
are	O
diverse	O
,	O
progress	O
over	O
days	O
to	O
weeks	O
,	O
and	O
include	O
progressive	O
weakness	O
on	O
one	O
side	O
of	O
the	O
body	O
or	O
clumsiness	O
of	O
limbs	O
,	O
disturbance	O
of	O
vision	O
,	O
and	O
changes	O
in	O
thinking	O
,	O
memory	O
,	O
and	O
orientation	O
leading	O
to	O
confusion	O
and	O
personality	O
changes	O
.	O
	
(	O
5.3	O
)	O
*	O
Tumor	B
Lysis	I
Syndrome	I
:	O
Acute	B
renal	I
failure	I
and	O
death	B
;	O
anticipate	O
and	O
use	O
supportive	O
measures	O
.	O
	
No	O
new	O
adverse	O
reactions	O
were	O
reported	O
.	O
	
Local	B
skin	I
reactions	I
typically	O
occurred	O
within	O
1	O
day	O
of	O
treatment	O
initiation	O
,	O
peaked	O
in	O
intensity	O
up	O
to	O
1	O
week	O
following	O
completion	O
of	O
treatment	O
,	O
and	O
resolved	O
within	O
2	O
weeks	O
for	O
areas	O
treated	O
on	O
the	O
face	O
and	O
scalp	O
,	O
and	O
within	O
4	O
weeks	O
for	O
areas	O
treated	O
on	O
the	O
trunk	O
and	O
extremities	O
.	O
	
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Anaphylaxis	B
and	O
angioedema	B
:	O
Discontinue	O
and	O
do	O
not	O
restart	O
TECFIDERA	O
if	O
these	O
occur	O
.	O
	
Study	O
1	O
Adverse	O
reactions	O
and	O
laboratory	O
abnormalities	O
from	O
the	O
CLL	O
trial	O
(	O
N=48	O
)	O
using	O
single	O
agent	O
IMBRUVICA	O
420	O
mg	O
daily	O
occurring	O
at	O
a	O
rate	O
of	O
>	O
=	O
10	O
%	O
are	O
presented	O
in	O
Tables	O
3	O
and	O
4	O
.	O
	
Patients	O
should	O
have	O
baseline	O
ophthalmologic	O
testing	O
by	O
an	O
ophthalmic	O
professional	O
and	O
follow-up	O
testing	O
every	O
6	O
months	O
.	O
	
The	O
median	O
exposure	O
was	O
11.0	O
months	O
for	O
patients	O
treated	O
with	O
GILOTRIF	O
and	O
3.4	O
months	O
for	O
patients	O
treated	O
with	O
pemetrexed/cisplatin	O
.	O
	
Psoriatic	O
Arthritis	O
Clinical	O
Study	O
CIMZIA	O
has	O
been	O
studied	O
in	O
409	O
patients	O
with	O
psoriatic	O
arthritis	O
(	O
PsA	O
)	O
in	O
a	O
placebo-controlled	O
trial	O
.	O
	
Conditions	O
that	O
lower	O
the	O
seizure	O
threshold	O
may	O
be	O
more	O
prevalent	O
in	O
a	O
population	O
of	O
65	O
years	O
or	O
older	O
.	O
	
Renal-related	B
adverse	I
reactions	I
,	O
including	O
renal	B
failure	I
and	O
blood	B
creatinine	I
increase	I
,	O
were	O
more	O
frequent	O
in	O
patients	O
treated	O
with	O
FARXIGA	O
(	O
see	O
Table	O
4	O
)	O
.	O
	
Counsel	O
patients	O
regarding	O
the	O
potential	O
risk	O
of	O
MTC	O
with	O
use	O
of	O
TRULICITY	O
and	O
inform	O
them	O
of	O
symptoms	O
of	O
thyroid	O
tumors	O
(	O
e.g.	O
,	O
mass	O
in	O
the	O
neck	O
,	O
dysphagia	O
,	O
dyspnea	O
,	O
persistent	O
hoarseness	O
)	O
.	O
	
6.1	O
Clinical	O
Trials	O
Experience	O
Because	O
clinical	O
trials	O
are	O
conducted	O
under	O
widely	O
varying	O
conditions	O
,	O
the	O
adverse	O
reaction	O
rates	O
observed	O
can	O
not	O
be	O
directly	O
compared	O
with	O
rates	O
in	O
other	O
clinical	O
trials	O
or	O
experience	O
with	O
therapeutics	O
in	O
the	O
same	O
class	O
and	O
may	O
not	O
reflect	O
the	O
rates	O
observed	O
in	O
clinical	O
practice	O
.	O
	
*	O
Cytokine	B
Release	I
Syndrome	I
(	O
CRS	B
)	O
,	O
which	O
may	O
be	O
life-threatening	O
or	O
fatal	B
,	O
occurred	O
in	O
patients	O
receiving	O
BLINCYTO	O
.	O
	
Bacterial	O
,	O
Mycobacterial	O
,	O
Viral	O
,	O
and	O
Fungal	O
Infections	O
Adverse	O
reactions	O
of	O
infectious	B
etiology	I
were	O
reported	O
based	O
on	O
clinical	O
assessment	O
by	O
physicians	O
.	O
	
All	O
infections	B
#	O
27	O
(	O
7	O
)	O
26	O
(	O
6	O
)	O
55	O
(	O
14	O
)	O
46	O
(	O
11	O
)	O
Tuberculosis	B
2	O
(	O
1	O
)	O
1	O
(	O
<	O
1	O
)	O
6	O
(	O
2	O
)	O
1	O
(	O
<	O
1	O
)	O
Infections	O
Reported	O
in	O
the	O
CNS	O
Following	O
three	O
years	O
of	O
treatment	O
in	O
Studies	O
1	O
and	O
2	O
,	O
cryptococcal	B
meningitis	I
was	O
reported	O
in	O
one	O
patient	O
out	O
of	O
401	O
patients	O
treated	O
with	O
the	O
NULOJIX	O
recommended	O
regimen	O
(	O
0.2	O
%	O
)	O
and	O
one	O
patient	O
out	O
of	O
the	O
405	O
treated	O
with	O
the	O
cyclosporine	O
control	O
(	O
0.2	O
%	O
)	O
.	O
	
The	O
most	O
common	O
laboratory	O
abnormalities	O
(	O
incidence	O
>	O
=30	O
%	O
)	O
are	O
neutropenia	B
,	O
hypertriglyceridemia	B
,	O
hyperglycemia	B
,	O
ALT	B
elevations	I
,	O
and	O
AST	B
elevations	I
(	O
6.1	O
)	O
.	O
	
(	O
5.5	O
)	O
item	O
{	O
Fungal	O
infections-	O
Fungal	B
infections	I
of	I
the	I
cornea	I
are	O
particularly	O
prone	O
to	O
develop	O
coincidentally	O
with	O
long-term	O
local	O
steroid	O
application	O
.	O
	
Baseline	O
renal	O
function	O
was	O
normal	O
or	O
mildly	O
impaired	O
in	O
88	O
%	O
of	O
patients	O
and	O
moderately	O
impaired	O
in	O
11	O
%	O
of	O
patients	O
(	O
mean	O
eGFR	O
82	O
mL/min/1.73	O
m	O
2	O
)	O
.	O
	
To	O
report	O
SUSPECTED	O
ADVERSE	O
REACTIONS	O
,	O
contactJanssen	O
Biotech	O
,	O
Inc.	O
at	O
1-800-JANSSEN	O
(	O
1-800-526-7736	O
)	O
or	O
FDA	O
at	O
1-800-FDA-1088	O
or	O
www.fda.gov/medwatch	O
.	O
	
The	O
median	O
number	O
of	O
dosing	O
delays	O
was	O
one	O
in	O
patients	O
receiving	O
COMETRIQ	O
compared	O
to	O
none	O
in	O
patients	O
receiving	O
placebo	O
.	O
	
5.4	O
Abnormal	O
Bleeding	O
SSRIs	O
and	O
SNRIs	O
,	O
including	O
PRISTIQ	O
,	O
may	O
increase	O
the	O
risk	O
of	O
bleeding	B
events	O
.	O
	
5.6	O
Activation	O
of	O
Mania/Hypomania	O
During	O
all	O
MDD	O
phase	O
2	O
and	O
phase	O
3	O
studies	O
,	O
mania	B
was	O
reported	O
for	O
approximately	O
0.02	O
%	O
of	O
patients	O
treated	O
with	O
PRISTIQ	O
.	O
	
In	O
the	O
patients	O
who	O
developed	O
antibodies	O
during	O
treatment	O
,	O
the	O
median	O
titer	O
(	O
by	O
dilution	O
method	O
)	O
was	O
8	O
,	O
with	O
a	O
range	O
of	O
5	O
to	O
80	O
.	O
	
The	O
retinal	B
abnormalities	I
observed	O
with	O
POTIGA	O
have	O
been	O
reported	O
in	O
patients	O
who	O
were	O
originally	O
enrolled	O
in	O
clinical	O
trials	O
with	O
POTIGA	O
and	O
who	O
have	O
generally	O
taken	O
the	O
drug	O
for	O
a	O
long	O
period	O
of	O
time	O
in	O
2	O
ongoing	O
extension	O
trials	O
.	O
	
c	O
Includes	O
the	O
terms	O
feeling	B
cold	I
and	O
chills	B
.	O
	
0.3	O
2.8	O
2.7	O
Nausea	B
2.4	O
2.8	O
2.5	O
Influenza	B
2.3	O
2.7	O
2.3	O
Dyslipidemia	B
1.5	O
2.1	O
2.5	O
Constipation	B
1.5	O
2.2	O
1.9	O
Discomfort	B
with	I
urination	I
0.7	O
1.6	O
2.1	O
Pain	B
in	I
extremity	I
1.4	O
2.0	O
1.7	O
Pool	O
of	O
13	O
Placebo-Controlled	O
Studies	O
for	O
FARXIGA	O
10	O
mg	O
The	O
safety	O
and	O
tolerability	O
of	O
FARXIGA	O
10	O
mg	O
was	O
also	O
evaluated	O
in	O
a	O
larger	O
placebo-controlled	O
study	O
pool	O
.	O
	
The	O
following	O
adverse	O
reactions	O
are	O
described	O
in	O
more	O
detail	O
in	O
the	O
Warnings	O
and	O
Precautions	O
section	O
of	O
the	O
label	O
:	O
Seizures	B
,	O
Anaphylaxis	B
,	O
and	O
Urinary	B
Tract	I
Infections	I
.	O
	
The	O
risk	O
did	O
not	O
vary	O
substantially	O
by	O
age	O
(	O
5-100	O
years	O
)	O
in	O
the	O
clinical	O
trials	O
analyzed	O
.	O
	
5.9	O
Drug	O
Interactions	O
with	O
Strong	O
Cytochrome	O
P450	O
3A4	O
Inhibitors	O
Caution	O
should	O
be	O
exercised	O
when	O
considering	O
the	O
coadministration	O
of	O
BREO	O
ELLIPTA	O
with	O
long-term	O
ketoconazole	O
and	O
other	O
known	O
strong	O
CYP3A4	O
inhibitors	O
(	O
e.g.	O
,	O
ritonavir	O
,	O
clarithromycin	O
,	O
conivaptan	O
,	O
indinavir	O
,	O
itraconazole	O
,	O
lopinavir	O
,	O
nefazodone	O
,	O
nelfinavir	O
,	O
saquinavir	O
,	O
telithromycin	O
,	O
troleandomycin	O
,	O
voriconazole	O
)	O
because	O
increased	O
systemic	O
corticosteroid	O
and	O
increased	O
cardiovascular	O
adverse	O
effects	O
may	O
occur	O
[	O
see	O
Drug	O
Interactions	O
(	O
7.1	O
)	O
,	O
Clinical	O
Pharmacology	O
(	O
12.3	O
)	O
]	O
.	O
	
Monitor	O
for	O
pulmonary	O
symptoms	O
and	O
bilateral	O
interstitial	O
infiltrates	O
.	O
	
Interrupt	O
BLINCYTO	O
if	O
the	O
transaminases	O
rise	O
to	O
greater	O
than	O
5	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
or	O
if	O
bilirubin	O
rises	O
to	O
more	O
than	O
3	O
times	O
the	O
upper	O
limit	O
of	O
normal	O
.	O
	
Table	O
3	O
:	O
Key	O
Laboratory	O
Abnormalities	O
Occurring	O
in	O
>	O
10	O
%	O
(	O
All	O
NCI	O
CTCAE	O
Grades	O
)	O
of	O
ALK-Positive	O
Patients	O
Treated	O
with	O
ZYKADIA	O
in	O
Study	O
1	O
ZYKADIAN=255	O
All	O
Grades	O
Grade	O
3-4	O
%	O
%	O
Hemoglobin	B
decreased	I
84	O
5	O
ALT	B
)	I
increased	I
80	O
27	O
AST	B
)	I
increased	I
75	O
13	O
Creatinine	B
increased	I
58	O
2	O
Glucose	B
increased	I
49	O
13	O
Phosphate	B
decreased	I
36	O
7	O
Lipase	B
increased	I
28	O
10	O
Bilirubin	B
(	I
total	I
)	I
increased	I
15	O
1	O
5	O
WARNINGS	O
AND	O
PRECAUTIONS	O
EXCERPT	O
:	O
*	O
Severe	O
or	O
Persistent	O
Gastrointestinal	O
Toxicity	O
:	O
Dose	O
modification	O
due	O
to	O
diarrhea	B
,	O
nausea	B
,	O
vomiting	B
or	O
abdominal	B
pain	I
occurred	O
in	O
38	O
%	O
of	O
patients	O
.	O
	
Prior	O
to	O
AdreView	O
administration	O
,	O
ensure	O
emergency	O
cardiac	O
and	O
anti-hypertensive	O
treatments	O
are	O
readily	O
available	O
.	O
	
Patients	O
receiving	O
the	O
drug	O
should	O
be	O
managed	O
in	O
facilities	O
equipped	O
and	O
staffed	O
with	O
adequate	O
laboratory	O
and	O
supportive	O
medical	O
resources	O
.	O
	
If	O
an	O
infusion-related	O
reaction	O
occurs	O
,	O
the	O
infusion	O
should	O
be	O
interrupted	O
and	O
appropriate	O
medical	O
management	O
instituted	O
.	O
	
Intracranial	B
hemorrhage	I
included	O
subdural	B
bleeds	I
.	O
	
Effects	O
of	O
fluticasone	O
furoate	O
on	O
the	O
HPA	O
axis	O
are	O
not	O
observed	O
with	O
the	O
therapeutic	O
doses	O
of	O
BREO	O
ELLIPTA	O
.	O
	
Chronic	O
Immune	O
(	O
Idiopathic	O
)	O
Thrombocytopenia	O
:	O
Adults	O
:	O
In	O
clinical	O
trials	O
,	O
hemorrhage	B
was	O
the	O
most	O
common	O
serious	O
adverse	O
reaction	O
and	O
most	O
hemorrhagic	B
reactions	I
followed	O
discontinuation	O
of	O
PROMACTA	O
.	O
	
Table	O
3	O
shows	O
the	O
number	O
of	O
patients	O
experiencing	O
bleeding	B
events	O
in	O
the	O
pooled	O
analysis	O
of	O
RE-COVER	O
and	O
RE-COVER	O
II	O
studies	O
during	O
the	O
full	O
treatment	O
including	O
parenteral	O
and	O
oral	O
only	O
treatment	O
periods	O
after	O
randomization	O
.	O
	
Table	O
1shows	O
all	O
adverse	O
reactions	O
that	O
occurred	O
with	O
a	O
frequency	O
of	O
greater	O
than	O
or	O
equal	O
to	O
1	O
%	O
in	O
the	O
TUDORZA	O
PRESSAIR	O
group	O
in	O
the	O
two	O
3-month	O
and	O
one	O
6-month	O
placebo-controlled	O
trials	O
where	O
the	O
rates	O
in	O
the	O
TUDORZA	O
PRESSAIR	O
group	O
exceeded	O
placebo	O
.	O
	
Adverse	O
reaction	O
information	O
for	O
Ferriprox	O
represents	O
the	O
pooled	O
data	O
collected	O
from	O
642	O
patients	O
who	O
participated	O
in	O
single	O
arm	O
or	O
active-controlled	O
clinical	O
studies	O
.	O
	
The	O
median	O
duration	O
of	O
exposure	O
was	O
6.1	O
months	O
(	O
range	O
0.3	O
to	O
26.4	O
months	O
)	O
.	O
	
Dose	O
reduction	O
due	O
to	O
peripheral	B
neuropathy	I
was	O
required	O
by	O
3	O
%	O
(	O
14/503	O
)	O
of	O
patients	O
who	O
received	O
HALAVEN	O
.	O
	
In	O
addition	O
,	O
no	O
clinical	O
safety	O
concerns	O
related	O
to	O
the	O
inhibition	O
of	O
endogenous	O
MMPs	O
have	O
been	O
observed	O
.	O
	
5.10	O
Pulmonary	O
Toxicity	O
Events	O
of	O
noninfectious	B
pulmonary	I
toxicity	I
including	O
pneumonitis	B
,	O
interstitial	B
lung	I
disease	I
,	O
and	O
acute	B
respiratory	I
distress	I
syndrome	I
(	O
ARDS	B
)	O
,	O
some	O
with	O
fatal	B
outcomes	O
,	O
have	O
been	O
reported	O
.	O
	
Table	O
1	O
shows	O
adverse	O
reactions	O
on	O
the	O
ZYTIGA	O
arm	O
in	O
Study	O
1	O
that	O
occurred	O
with	O
a	O
>	O
=2	O
%	O
absolute	O
increase	O
in	O
frequency	O
compared	O
to	O
placebo	O
or	O
were	O
events	O
of	O
special	O
interest	O
.	O
	
The	O
median	O
age	O
of	O
patients	O
treated	O
with	O
Teflaro	O
was	O
54	O
years	O
,	O
ranging	O
between	O
18	O
and	O
99	O
years	O
old	O
.	O
	
Neutralizing	O
antibodies	O
were	O
assayed	O
for	O
a	O
subset	O
of	O
70	O
samples	O
selected	O
to	O
be	O
representative	O
of	O
high	O
and	O
low	O
titer	O
binding	O
antibody	O
responses	O
at	O
week	O
12	O
of	O
treatment	O
.	O
